{"title": "PDF", "author": "PDF", "url": "https://seimc.org/contenidos/gruposdeestudio/gesida/dcientificos/documentos/2010/gesidadcyrc2010_DocconsensoTARGESIDA-PNS-verpc.pdf", "hostname": "PDF", "description": "PDF", "sitename": "PDF", "date": "PDF", "id": "PDF", "license": "PDF", "body": "PDF", "comments": "PDF", "commentsbody": "PDF", "raw_text": "PDF", "text": "\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a0\nDocumento \u00a0de\u00a0consenso \u00a0de\u00a0Gesida/Plan \u00a0Nacional\u00a0sobre\u00a0el\u00a0Sida\u00a0\nrespecto\u00a0al\u00a0tratamiento \u00a0antirretroviral \u00a0en\u00a0adultos\u00a0infectados \u00a0\npor\u00a0el\u00a0virus\u00a0de\u00a0la\u00a0inmunodeficiencia \u00a0humana\u00a0\u00a0\n(Actualizaci\u00f3n \u00a0enero\u00a02010)\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nPanel\u00a0de\u00a0expertos\u00a0de\u00a0Gesida\u00a0y\u00a0Plan\u00a0Nacional\u00a0sobre\u00a0el\u00a0Sida\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0Documento \u00a0de\u00a0consenso \u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010) \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 2 \n Panel:\u00a0\nCoordinadores: \u00a0\u00a0\nFernando \u00a0Lozano\u00a0\nHospital\u00a0de\u00a0Valme.\u00a0Sevilla\u00a0\nPere\u00a0Domingo \u00a0Pedrol\u00a0\nHospital\u00a0de\u00a0la\u00a0Santa\u00a0Creu\u00a0i\u00a0Sant\u00a0Pau.\u00a0Barcelona \u00a0\nRosa\u00a0Polo\u00a0\nSecretar\u00eda \u00a0Plan\u00a0Nacional\u00a0sobre\u00a0 el\u00a0Sida.\u00a0 Ministerio \u00a0de\u00a0Sanidad\u00a0y\u00a0Pol\u00edtica\u00a0Social.\u00a0Madrid\u00a0\n\u00a0\nRedactores: \u00a0\nPere\u00a0Domingo \u00a0Pedrol\u00a0\nHospital\u00a0de\u00a0la\u00a0Santa\u00a0Creu\u00a0i\u00a0Sant\u00a0Pau.\u00a0Barcelona \u00a0Joaqu\u00edn\u00a0Portilla\u00a0\nHospital\u00a0General,\u00a0Alicante\u00a0\nM\u00aa\u00a0Jos\u00e9\u00a0 Galindo\u00a0\nHospital\u00a0Cl\u00ednico\u00a0Universitario, \u00a0Valencia\u00a0\u00a0Esteban\u00a0Ribera\u00a0\nHospital\u00a0Universitari \u00a0Vall\u00a0d\u2019Hebr\u00f3n, \u00a0Barcelona\u00a0\nJos\u00e9\u00a0 Antonio\u00a0Iribarren\u00a0\nHospital\u00a0Donostia, \u00a0San\u00a0Sebasti\u00e1n\u00a0Melcior\u00a0Riera\u00a0\nHospital\u00a0de\u00a0Son\u00a0Dureta,\u00a0Palma\u00a0de\u00a0Mallorca\u00a0\nHernando \u00a0Knobel\u00a0\nHospital\u00a0del\u00a0Mar,\u00a0Barcelona\u00a0\u00a0Antonio\u00a0Rivero\u00a0\nHospital\u00a0Reina\u00a0Sof\u00eda,\u00a0C\u00f3rdoba\u00a0\nJose\u00a0 L\u00f3pez\u00a0Aldeguer \u00a0\nHospital\u00a0Universitari \u00a0La\u00a0Fe,\u00a0Valencia\u00a0Jes\u00fas\u00a0Santos\u00a0\nHospital\u00a0Univ.\u00a0Virgen\u00a0 de\u00a0la\u00a0Victoria.\u00a0M\u00e1laga\u00a0\nFernando \u00a0Lozano\u00a0\nHospital\u00a0Universitario \u00a0de\u00a0Valme,\u00a0Sevilla\u00a0Jes\u00fas\u00a0Sanz\u00a0\nHospital\u00a0de\u00a0la\u00a0Princesa,\u00a0Madrid\u00a0\nDaniel\u00a0Podzamczer \u00a0\nHospital\u00a0Univ.\u00a0de\u00a0Belvitge,\u00a0L\u00b4Hospitalet. \u00a0\u00a0BarcelonaMontserrat \u00a0Tuset\u00a0\nHospital\u00a0Cl\u00ednic,\u00a0Barcelona \u00a0\n\u00a0\nConsultores: \u00a0\nAntonio\u00a0Antela\u00a0\nComplejo \u00a0Universitario \u00a0Hospitalario, \u00a0SantiagoJose\u00a0 R.\u00a0Arribas\u00a0\nHospital\u00a0La\u00a0Paz,\u00a0Madrid\nJulio\u00a0Arrizabalaga \u00a0\nHospital\u00a0Donostia, \u00a0San\u00a0Sebasti\u00e1n\u00a0\u00a0Juan\u00a0Berenguer\u00a0\nHospital\u00a0Gregorio\u00a0Mara\u00f1\u00f3n, \u00a0Madrid\u00a0\nBonaventura \u00a0Clotet\u00a0\nHospital\u00a0Germans\u00a0 Trias\u00a0i\u00a0Pujol,\u00a0BadalonaJos\u00e9\u00a0 M\u00aa\u00a0Gatell\u00a0\nHospital\u00a0Cl\u00ednic,\u00a0Barcelona\nJuan\u00a0Gonz\u00e1lez \u00a0Garc\u00eda\u00a0\nHospital\u00a0La\u00a0Paz,\u00a0MadridJos\u00e9\u00a0 Mar\u00eda\u00a0 Kindel\u00e1n\u00a0\nHospital\u00a0Reina\u00a0Sof\u00eda,\u00a0C\u00f3rdoba\u00a0\nPablo\u00a0Labarga\u00a0\nHospital\u00a0Carlos\u00a0III,\u00a0Madrid\u00a0Jaime\u00a0Locutura\u00a0\nHospital\u00a0General\u00a0Yag\u00fce,\u00a0 Burgos\u00a0\u00a0\nJuan\u00a0Carlos\u00a0L\u00f3pez\u00a0Bernaldo \u00a0\nHospital\u00a0Gregorio\u00a0Mara\u00f1\u00f3n, \u00a0Madrid\u00a0\u00a0Josep\u00a0Mallolas\u00a0\nHospital\u00a0Cl\u00ednic,\u00a0Barcelona\n\u00a0\n\u00a0\u00a0\u00a0Documento \u00a0de\u00a0consenso \u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010) \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 3 \n \u00a0\n\u00a0\u00a0\nEsteban\u00a0Mart\u00ednez\u00a0\nHospital\u00a0Cl\u00ednic,\u00a0Barcelona\u00a0Celia\u00a0Miralles,\u00a0\u00a0\nHospital\u00a0Xeral,\u00a0Vigo\nJos\u00e9\u00a0 M\u00aa\u00a0Mir\u00f3\u00a0\nHospital\u00a0Cl\u00ednic,\u00a0Barcelona\u00a0Santiago\u00a0Moreno\u00a0\nHospital\u00a0Ram\u00f3n\u00a0 y\u00a0Cajal,\u00a0Madrid\u00a0\nRosario\u00a0Palacios\u00a0\nHospital\u00a0Universit. \u00a0Virgen\u00a0de\u00a0la\u00a0Victoria.\u00a0M\u00e1lagaFrancisco \u00a0Pasquau\u00a0\nHospital\u00a0Marina\u00a0Baixa,\u00a0La\u00a0Vila\u00a0Joiosa,\u00a0Alicante\u00a0\nMaria\u00a0 Jes\u00fas\u00a0P\u00e9rez\u00a0El\u00edas\u00a0\nHospital\u00a0Ram\u00f3n\u00a0 y\u00a0Cajal,\u00a0Madrid\u00a0Juan\u00a0A.\u00a0Pineda\u00a0\nHospital\u00a0de\u00a0Valme,\u00a0Sevilla\nRosa\u00a0Polo\u00a0\nPlan\u00a0 Nacional\u00a0sobre\u00a0el\u00a0Sida,\u00a0MSPS.\u00a0MadridFederico\u00a0Pulido\u00a0\nHospital\u00a0Doce\u00a0de\u00a0Octubre,\u00a0Madrid\u00a0\nRafael\u00a0Rubio\u00a0\nHospital\u00a0Doce\u00a0de\u00a0Octubre,\u00a0Madrid\u00a0\u00a0Juan\u00a0Miguel\u00a0Santamar\u00eda \u00a0\nHospital\u00a0de\u00a0Basurto,\u00a0Bilbao\u00a0\u00a0\nFerran\u00a0Segura\u00a0\nConsorci\u00a0Hospitalari \u00a0Parc\u00a0Taul\u00ed,\u00a0SabadellVicente\u00a0Soriano\u00a0\nHospital\u00a0Carlos\u00a0III,\u00a0Madrid\nPompeyo \u00a0Viciana\u00a0\nHospital\u00a0Virgen\u00a0del\u00a0Roc\u00edo,\u00a0Sevilla\u00a0Miguel\u00a0A.\u00a0Von\u00a0Wichmann \u00a0\nHospital\u00a0Donostia, \u00a0San\u00a0Sebasti\u00e1n\u00a0\n\u00a0\n\u00a0\nRedactor \u00a0General:\u00a0\nJos\u00e9\u00a0 L\u00f3pez\u00a0Aldeguer \u00a0\nHospital\u00a0Universitario \u00a0La\u00a0Fe\u00a0,\u00a0Valencia\u00a0\n\u00a0\nAgradecimientos: \u00a0\nLa\u00a0Junta\u00a0Directiva\u00a0de\u00a0Gesida\u00a0y\u00a0la\u00a0Secretar\u00eda \u00a0del\u00a0Plan\u00a0Nacional\u00a0sobre\u00a0el\u00a0Sida\u00a0agradecen \u00a0las\u00a0apor\u2010\ntaciones\u00a0y\u00a0opiniones \u00a0de\u00a0los\u00a0doctores\u00a0Marisa\u00a0Alvarez,\u00a0Pablo\u00a0Bachiller, \u00a0Angel\u00a0 Burgos,\u00a0Bonaventu \u2010\nra\u00a0Clotet,\u00a0Mar\u00eda\u00a0Coronado, \u00a0Manuel\u00a0Cotarelo,\u00a0Carlos\u00a0 Due\u00f1as,\u00a0Pedro\u00a0Ferrer,\u00a0Emilio\u00a0Fumero,\u00a0Bea\u2010\ntriz\u00a0Hern\u00e1ndez \u00a0Novoa,\u00a0Maria\u00a0Olatz\u00a0Ibarra,\u00a0 Francisco \u00a0Ledesma, \u00a0Josep\u00a0Maria\u00a0Llibre,\u00a0Juan\u00a0E.\u00a0Losa\u00a0 y\u00a0\nOscar\u00a0 Serrano\u00a0que\u00a0han\u00a0contribuido \u00a0a\u00a0mejorar\u00a0la\u00a0redacci\u00f3n \u00a0y\u00a0enriquecer \u00a0el\u00a0contenido \u00a0del\u00a0docu\u2010\nmento\u00a0Documento \u00a0de\u00a0consenso \u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010) \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 4 \n \u00cdndice\u00a0\nResumen \u00a0\u00a0\u00a0 8\u00a0\n1.\u00a0Introducci\u00f3n \u00a0 \u00a0\n1.1.\u00a0Metodolog\u00eda \u00a0\u00a0\u00a0\u00a0\u00a0 9\u00a0\n1.2.\u00a0Principios \u00a0generales \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 10\u00a0\n2.\u00a0Par\u00e1metros\u00a0 para\u00a0guiar\u00a0 el\u00a0tratamiento \u00a0antirretroviral \u00a0 \u00a0\n2.1.\u00a0Linfocitos \u00a0CD4\u00a0 11\u00a0\n2.2.\u00a0Carga\u00a0 viral\u00a0plasm\u00e1tica \u00a0del\u00a0VIH\u00a0 12\u00a0\n2.3.\u00a0Niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0f\u00e1rmacos\u00a0 13\u00a0\n2.4.\u00a0Resistencia \u00a0del\u00a0VIH\u00a0a\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0 14\u00a0\n2.5.\u00a0Determinaci\u00f3n\u00a0 del\u00a0HLAB5701 \u00a0 16\u00a0\n2.6.\u00a0Determinaci\u00f3n\u00a0 del\u00a0tropismo\u00a0 17\u00a0\n3.\u00a0Infecci\u00f3n\u00a0aguda\u00a0por\u00a0VIH\u00a0 18\u00a0\n4.\u00a0Tratamiento \u00a0antirretroviral \u00a0inicial\u00a0 \u00a0\n4.1.\u00a0Cu\u00e1ndo\u00a0iniciar\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0 21\u00a0\n4.2.\u00a0\u00bfQu\u00e9\u00a0combinaci\u00f3n \u00a0de\u00a0antirretrovirales \u00a0debe\u00a0utilizarse? \u00a0 25\u00a0\n4.3.\u00a0Inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3sido \u00a0 26\u00a0\n4.4.\u00a0Inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0nucle\u00f3sidos \u00a0(NN)\u00a0\u00a0 35\u00a0\n4.5.\u00a0Inhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0 39\u00a0\n4.6.\u00a0Antagonistas \u00a0del\u00a0correceptor \u00a0CCR5\u00a0 43\u00a0\n4.7.\u00a0Inhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0 44\u00a0\n5.\u00a0Modificaci\u00f3n \u00a0del\u00a0tratamiento \u00a0antirretroviral \u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 5.1.\u00a0Fracaso\u00a0del\u00a0TARV\u00a0 45\u00a0\n5.1.1.\u00a0Cambio\u00a0de\u00a0TARV\u00a0tras\u00a0fracaso\u00a0precoz\u00a0 48\u00a0\n5.1.2.\u00a0Cambio\u00a0de\u00a0TARV\u00a0en\u00a0el\u00a0fracaso\u00a0avanzado \u00a0(TARV\u00a0 de\u00a0rescate)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 49\u00a0\n5.2.\u00a0Simplificaci\u00f3n \u00a0del\u00a0TARV\u00a0\u00a0 \u00a0\nReducci\u00f3n\u00a0 del\u00a0n\u00famero\u00a0de\u00a0f\u00e1rmacos\u00a0 62\u00a0\nReducci\u00f3n\u00a0 del\u00a0n\u00famero\u00a0de\u00a0comprimidos \u00a0y/o\u00a0de\u00a0dosis\u00a0 65\u00a0\nSimplificaci\u00f3n \u00a0a\u00a0reg\u00edmenes \u00a0de\u00a0administraci\u00f3n \u00a0una\u00a0vez\u00a0al\u00a0d\u00eda\u00a0 69\u00a0\n\u00a0\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 5 \n \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n6.\u00a0Adherencia\u00a0 73\u00a0\n7.\u00a0Efectos\u00a0adversos\u00a0del\u00a0tratamiento \u00a0antirretroviral \u00a0 76\u00a0\n8.\u00a0Interacciones \u00a0farmacocin\u00e9ticas \u00a0y\u00a0farmacodin\u00e1micas \u00a0 80\u00a0\n9.\u00a0Hepatopat\u00eda \u00a0cr\u00f3nica\u00a0y\u00a0tratamiento \u00a0antirretroviral \u00a0\u00a0\u00a0 83\u00a0\n10.\u00a0TARV\u00a0en\u00a0el\u00a0embarazo \u00a0y\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0materno\u00a0fetal\u00a0 87\u00a0\n11.\u00a0Profilaxis\u00a0postexposici\u00f3n \u00a0 90\u00a0\n12.\u00a0Nuevas\u00a0estrategias \u00a0terap\u00e9uticas \u00a0 93\u00a0\n13.\u00a0Coste\u00a0comparativo \u00a0de\u00a0combinaciones \u00a0de\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0\u00a0\u00a0\u00a0 97\u00a0\n14.\u00a0Bibliograf\u00eda \u00a0 98\u00a0\n15.\u00a0Tablas\u00a0 162\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 6 \n Abreviaturas \u00a0usadas:\u00a0\n\u00a0\n3TC\u00a0 Lamivudina \u00a0\nABC\u00a0 Abacavir\u00a0\nAN\u00a0 Inhibidores \u00a0transcriptasa \u00a0inversa\u00a0an\u00e1logos\u00a0nucle\u00f3sido \u00a0o\u00a0nucle\u00f3tido \u00a0\nAPV\u00a0 Amprenavir \u00a0\nATV\u00a0 Atazanavir \u00a0\nBID\u00a0 Pauta\u00a0de\u00a0tratamiento \u00a0administrada \u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda\u00a0\nCVP\u00a0 Carga\u00a0viral\u00a0plasm\u00e1tica \u00a0\nd4T\u00a0 Estavudina \u00a0\nddI\u00a0 Didanosina \u00a0\nDRV\u00a0 Darunavir \u00a0\nEFV\u00a0 Efavirenz\u00a0\nENF\u00a0 Enfuvirtida \u00a0\nETR\u00a0 Etravirina \u00a0\nFAR\u00a0 F\u00e1rmacos \u00a0antirretrovirales \u00a0\nFPV\u00a0 Fosamprenavir \u00a0\nFTC\u00a0 Emtricitabina \u00a0\nIDV\u00a0 Indinavir\u00a0\nIF\u00a0 Inhibidores \u00a0de\u00a0la\u00a0fusi\u00f3n\u00a0\nIInt\u00a0 Inhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0\nIP\u00a0 Inhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0\nIP/r\u00a0 Inhibidor\u00a0de\u00a0la\u00a0proteasa\u00a0(IP)\u00a0potenciado \u00a0con\u00a0ritonavir\u00a0\nIST\u00a0 Interrupci\u00f3n \u00a0estructurada \u00a0del\u00a0tratamiento \u00a0\nITT\u00a0 An\u00e1lisis\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0tratamiento \u00a0\nLPV\u00a0 Lopinavir\u00a0\nMVC\u00a0 Maraviroc \u00a0\nNFV\u00a0 Nelfinavir \u00a0\nNN\u00a0 Inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0nucle\u00f3sidos \u00a0\nNVP\u00a0 Nevirapina \u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 7 \n OT\u00a0 An\u00e1lisis\u00a0\u201cen\u00a0tratamiento\u201d \u00a0\nQD\u00a0 Pauta\u00a0de\u00a0tratamiento \u00a0administrada \u00a0una\u00a0vez\u00a0al\u00a0d\u00eda\u00a0\nRHS\u00a0 Reacci\u00f3n\u00a0de\u00a0hipersensibilidad \u00a0\nRAL\u00a0 Raltegravir \u00a0\nRTV\u00a0 Ritonavir\u00a0\nSQV\u00a0 Saquinavir \u00a0\nTARV\u00a0 Tratamiento \u00a0antirretroviral; \u00a0\u00eddem.\u00a0de\u00a0alta\u00a0eficacia\u00a0\nTDF\u00a0 Tenofovir \u00a0DF\u00a0\nTLOVR\u00a0 Tiempo\u00a0hasta\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0la\u00a0eficacia\u00a0virol\u00f3gica \u00a0\nTPV\u00a0 Tipranavir \u00a0\nZDV,\u00a0AZT\u00a0Zidovudina \u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 8 \n Resumen \u00a0\n\u00a0\nObjetivo: \u00a0Actualizar \u00a0las\u00a0recomendaciones \u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0(TARV)\u00a0\npara\u00a0los\u00a0adultos\u00a0infectados \u00a0por\u00a0el\u00a0VIH.\u00a0\nM\u00e9todos: \u00a0Estas\u00a0recomendaciones \u00a0se\u00a0han\u00a0consensuado \u00a0por\u00a0un\u00a0panel\u00a0de\u00a0expertos\u00a0del\u00a0\nGrupo\u00a0de\u00a0Estudio\u00a0de\u00a0Sida\u00a0(Gesida)\u00a0y\u00a0del\u00a0Plan\u00a0Nacional\u00a0sobre\u00a0el\u00a0Sida\u00a0(PNS).\u00a0Para\u00a0ello\u00a0se\u00a0\nhan\u00a0revisado\u00a0los\u00a0avances\u00a0en\u00a0la\u00a0fisiopatolog\u00eda \u00a0del\u00a0VIH,\u00a0los\u00a0resultados \u00a0de\u00a0eficacia\u00a0y\u00a0segu\u2010\nridad\u00a0de\u00a0ensayos\u00a0cl\u00ednicos,\u00a0estudios\u00a0de\u00a0cohortes\u00a0y\u00a0de\u00a0farmacocin\u00e9tica \u00a0publicados \u00a0en\u00a0\nrevistas\u00a0biom\u00e9dicas \u00a0o\u00a0presentados \u00a0en\u00a0congresos. \u00a0Se\u00a0han\u00a0definido\u00a0tres\u00a0niveles\u00a0de\u00a0evi\u2010\ndencia\u00a0seg\u00fan\u00a0la\u00a0procedencia \u00a0de\u00a0los\u00a0datos:\u00a0estudios\u00a0aleatorizados \u00a0(nivel\u00a0A),\u00a0de\u00a0cohortes\u00a0\no\u00a0de\u00a0caso\u2010control\u00a0(nivel\u00a0B),\u00a0u\u00a0opini\u00f3n\u00a0de\u00a0expertos\u00a0(nivel\u00a0C).\u00a0En\u00a0cada\u00a0una\u00a0de\u00a0las\u00a0situa\u2010\nciones\u00a0se\u00a0ha\u00a0establecido \u00a0recomendar, \u00a0considerar \u00a0o\u00a0no\u00a0recomendar \u00a0el\u00a0TARV.\u00a0\nResultados: \u00a0El\u00a0TARV\u00a0con\u00a0combinaciones \u00a0de\u00a0tres\u00a0f\u00e1rmacos\u00a0constituye \u00a0el\u00a0tratamiento \u00a0de\u00a0\ninicio\u00a0de\u00a0elecci\u00f3n\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0cr\u00f3nica\u00a0por\u00a0el\u00a0VIH.\u00a0Estas\u00a0pautas\u00a0deben\u00a0incluir\u00a02\u00a0inhibi\u2010\ndores\u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3sido \u00a0o\u00a0nucle\u00f3tido \u00a0(AN)\u00a0y\u00a01\u00a0inhibi\u2010\ndor\u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0an\u00e1logo\u00a0(NN)\u00a0o\u00a02\u00a0AN\u00a0y\u00a01\u00a0inhibidor\u00a0de\u00a0la\u00a0proteasa\u00a0po\u2010\ntenciado\u00a0con\u00a0ritonavir\u00a0(IP/r),\u00a0aunque\u00a0son\u00a0posibles\u00a0otras\u00a0combinaciones. \u00a0Se\u00a0recomienda \u00a0\niniciar\u00a0el\u00a0TARV\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0sintom\u00e1tica. \u00a0En\u00a0los\u00a0pacientes \u00a0\nasintom\u00e1ticos \u00a0el\u00a0inicio\u00a0de\u00a0TARV\u00a0se\u00a0basar\u00e1\u00a0en\u00a0los\u00a0resultados \u00a0de\u00a0determinaci\u00f3n \u00a0de\u00a0linfo\u2010\ncitos\u00a0CD4\u00a0(CD4/\u00b5L), \u00a0en\u00a0la\u00a0carga\u00a0viral\u00a0plasm\u00e1tica \u00a0(CVP)\u00a0y\u00a0en\u00a0las\u00a0comorbilidades \u00a0del\u00a0pa\u2010\nciente:\u00a01)\u00a0Si\u00a0los\u00a0linfocitos\u00a0CD4\u00a0son\u00a0inferiores \u00a0a\u00a0350\u00a0c\u00e9lulas/\u00b5L \u00a0se\u00a0recomienda \u00a0iniciar\u00a0el\u00a0\nTARV;\u00a0\u00a02)\u00a0En\u00a0caso\u00a0de\u00a0que\u00a0los\u00a0linfocitos\u00a0CD4\u00a0se\u00a0encuentren \u00a0entre\u00a0350\u00a0y\u00a0500\u00a0c\u00e9lulas/\u00b5L \u00a0se\u00a0\nrecomienda \u00a0el\u00a0tratamiento \u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0cirrosis\u00a0hep\u00e1tica,\u00a0hepatitis\u00a0cr\u00f3nica\u00a0por\u00a0\nvirus\u00a0C,\u00a0riesgo\u00a0cardiovascular \u00a0elevado,\u00a0nefropat\u00eda \u00a0VIH,\u00a0CVP\u00a0superior\u00a0a\u00a0100000\u00a0co\u2010\npias/mL,\u00a0proporci\u00f3n \u00a0de\u00a0CD4\u00a0inferior\u00a0a\u00a014%\u00a0o\u00a0en\u00a0pacientes \u00a0mayores\u00a0de\u00a055\u00a0a\u00f1os;\u00a03)\u00a0Si\u00a0los\u00a0\nlinfocitos\u00a0CD4\u00a0son\u00a0superiores \u00a0a\u00a0500\u00a0c\u00e9lulas/\u00b5L \u00a0en\u00a0general\u00a0se\u00a0puede\u00a0diferir\u00a0el\u00a0tratamien \u2010\nto,\u00a0pero\u00a0puede\u00a0considerarse \u00a0el\u00a0mismo\u00a0si\u00a0se\u00a0da\u00a0cualquiera \u00a0de\u00a0las\u00a0circunstancias \u00a0citadas\u00a0\nantes.\u00a0Se\u00a0recomienda \u00a0iniciar\u00a0el\u00a0tratamiento \u00a0en\u00a0caso\u00a0de\u00a0hepatitis\u00a0B\u00a0con\u00a0criterios\u00a0de\u00a0tra\u2010\ntamiento\u00a0y\u00a0se\u00a0puede\u00a0considerar \u00a0el\u00a0mismo\u00a0en\u00a0caso\u00a0de\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0sexual.\u00a0El\u00a0\nobjetivo\u00a0del\u00a0TARV\u00a0es\u00a0lograr\u00a0una\u00a0CVP\u00a0indetectable. \u00a0La\u00a0adherencia \u00a0al\u00a0TARV\u00a0juega\u00a0un\u00a0pa\u2010\npel\u00a0fundamental \u00a0en\u00a0la\u00a0duraci\u00f3n\u00a0de\u00a0la\u00a0respuesta \u00a0antiviral.\u00a0Las\u00a0opciones\u00a0terap\u00e9uticas \u00a0tras\u00a0\nlos\u00a0fracasos\u00a0del\u00a0TARV\u00a0son\u00a0limitadas\u00a0pero\u00a0los\u00a0nuevos\u00a0f\u00e1rmacos \u00a0posibilitan \u00a0la\u00a0consecu\u2010\nci\u00f3n\u00a0de\u00a0CVP\u00a0indetectable \u00a0en\u00a0pacientes \u00a0multitratados. \u00a0Los\u00a0estudios\u00a0genot\u00edpicos \u00a0son\u00a0de\u00a0\nutilidad.\u00a0La\u00a0toxicidad\u00a0es\u00a0un\u00a0factor\u00a0cada\u00a0vez\u00a0menos\u00a0limitante\u00a0del\u00a0TARV\u00a0cuyos\u00a0beneficios \u00a0\nsuperan\u00a0los\u00a0posibles\u00a0perjuicios. \u00a0Tambi\u00e9n\u00a0se\u00a0comentan \u00a0los\u00a0criterios\u00a0de\u00a0TARV\u00a0en\u00a0la\u00a0infec\u2010\nci\u00f3n\u00a0aguda,\u00a0embarazo \u00a0y\u00a0profilaxis\u00a0postexposici\u00f3n \u00a0as\u00ed\u00a0como\u00a0el\u00a0manejo\u00a0de\u00a0la\u00a0coinfecci\u00f3n \u00a0\npor\u00a0el\u00a0VIH\u00a0y\u00a0los\u00a0VHC\u00a0y\u00a0VHB.\u00a0\nConclusiones: \u00a0La\u00a0cifra\u00a0de\u00a0linfocitos\u00a0CD4,\u00a0la\u00a0CVP\u00a0y\u00a0las\u00a0comorbilidades \u00a0del\u00a0paciente\u00a0son\u00a0\nlos\u00a0factores\u00a0de\u00a0referencia \u00a0m\u00e1s\u00a0importantes \u00a0para\u00a0iniciar\u00a0el\u00a0TARV\u00a0en\u00a0pacientes \u00a0asintom\u00e1 \u2010\nticos.\u00a0Por\u00a0otra\u00a0parte,\u00a0el\u00a0n\u00famero\u00a0considerable \u00a0de\u00a0f\u00e1rmacos\u00a0disponibles, \u00a0los\u00a0m\u00e9todos\u00a0\nm\u00e1s\u00a0sensibles\u00a0de\u00a0monitorizaci\u00f3n \u00a0de\u00a0la\u00a0CVP,\u00a0y\u00a0la\u00a0posibilidad \u00a0de\u00a0determinar \u00a0las\u00a0resisten\u2010\ncias\u00a0hacen\u00a0que\u00a0las\u00a0estrategias \u00a0terap\u00e9uticas \u00a0deban\u00a0ser\u00a0mucho\u00a0m\u00e1s\u00a0individualizadas \u00a0para\u00a0\nconseguir \u00a0en\u00a0cualquier \u00a0circunstancia \u00a0el\u00a0objetivo\u00a0de\u00a0CVP\u00a0indetectable. \u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 9 \n \u00a0\n1.\u00a0INTRODUCCION \u00a0\nEl\u00a0tratamiento \u00a0antirretroviral \u00a0(TARV)\u00a0evoluciona \u00a0con\u00a0tal\u00a0rapidez\u00a0que\u00a0exige\u00a0una\u00a0frecuen\u2010\nte\u00a0actualizaci\u00f3n \u00a0de\u00a0sus\u00a0recomendaciones. \u00a0Desde\u00a0que\u00a0en\u00a01995\u00a0el\u00a0Plan\u00a0Nacional\u00a0Sobre\u00a0el\u00a0\nSida\u00a0(PNS)\u00a0y\u00a0su\u00a0Consejo\u00a0Asesor\u00a0Cl\u00ednico\u00a0editaran\u00a0las\u00a0primeras\u00a0\u201cRecomendaciones \u00a0de\u00a0tra\u2010\ntamiento\u00a0antirretroviral \u00a0en\u00a0el\u00a0adulto\u201d1,\u00a0este\u00a0organismo \u00a0junto\u00a0al\u00a0Grupo\u00a0de\u00a0Estudio\u00a0de\u00a0\nSida\u00a0(Gesida)\u00a0de\u00a0la\u00a0SEIMC\u00a0han\u00a0actualizado \u00a0estas\u00a0recomendaciones \u00a0con\u00a0periodicidad \u00a0\nanual,\u00a0public\u00e1ndolas \u00a0en\u00a0la\u00a0revista\u00a0Enfermedades \u00a0Infecciosas \u00a0y\u00a0Microbiolog\u00eda \u00a0Cl\u00ednica\u00a0o\u00a0\nen\u00a0sus\u00a0respectivas \u00a0p\u00e1ginas\u00a0web.\u00a0Otras\u00a0instituciones \u00a0y\u00a0sociedades \u00a0cient\u00edficas \u00a0elaboran\u00a0y\u00a0\nactualizan \u00a0sus\u00a0propias\u00a0recomendaciones \u00a0sobre\u00a0el\u00a0empleo\u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0antirretrovi \u2010\nrales\u00a0(FAR)2,\u00a03.\u00a0\u00a0\nEl\u00a0objetivo\u00a0de\u00a0este\u00a0documento \u00a0es\u00a0dar\u00a0a\u00a0conocer\u00a0a\u00a0la\u00a0comunidad \u00a0cient\u00edfica\u00a0y\u00a0a\u00a0los\u00a0profe\u2010\nsionales\u00a0que\u00a0tratan\u00a0a\u00a0pacientes \u00a0infectados \u00a0por\u00a0el\u00a0VIH\u00a0el\u00a0estado\u00a0del\u00a0arte\u00a0del\u00a0TARV\u00a0en\u00a0el\u00a0\nmomento \u00a0de\u00a0su\u00a0actualizaci\u00f3n. \u00a0Se\u00a0incluyen\u00a0algunos\u00a0aspectos\u00a0del\u00a0tratamiento \u00a0que\u00a0tanto\u00a0\nGesida\u00a0y\u00a0el\u00a0PNS,\u00a0en\u00a0colaboraci\u00f3n \u00a0con\u00a0otras\u00a0sociedades \u00a0cient\u00edficas \u00a0han\u00a0elaborado \u00a0in\u00a0ex\u2010\ntenso,\u00a0a\u00a0las\u00a0que\u00a0se\u00a0remite\u00a0al\u00a0lector\u00a0interesado \u00a0en\u00a0el\u00a0tema.\u00a0\u00a0\u00a0\u00a0\n\u00a01.1.\u00a0Metodolog\u00eda \u00a0\nEl\u00a0Panel\u00a0est\u00e1\u00a0formado\u00a0por\u00a0un\u00a0grupo\u00a0de\u00a0cl\u00ednicos\u00a0expertos\u00a0en\u00a0el\u00a0tratamiento \u00a0de\u00a0pacientes \u00a0\ninfectados \u00a0por\u00a0el\u00a0VIH\u00a0y\u00a0en\u00a0el\u00a0uso\u00a0de\u00a0los\u00a0FAR.\u00a0\nEstos\u00a0profesionales \u00a0han\u00a0sido\u00a0designados \u00a0\npor\u00a0la\u00a0Junta\u00a0Directiva\u00a0de\u00a0Gesida\u00a0y\u00a0la\u00a0Secretar\u00eda \u00a0del\u00a0PNS\u00a0y\u00a0aceptado \u00a0voluntariamente. \u00a0\nLos\u00a0miembros \u00a0se\u00a0han\u00a0dividido\u00a0en\u00a0grupos\u00a0formados \u00a0por\u00a0un\u00a0redactor\u00a0y\u00a0varios\u00a0consultores \u00a0\npara\u00a0actualizar \u00a0cada\u00a0cap\u00edtulo\u00a0de\u00a0las\u00a0recomendaciones. \u00a0Tres\u00a0miembros \u00a0del\u00a0panel\u00a0act\u00faan\u00a0\ncomo\u00a0Coordinadores \u00a0y\u00a0uno\u00a0como\u00a0Redactor\u00a0General.\u00a0\nPara\u00a0la\u00a0actualizaci\u00f3n \u00a0de\u00a0estas\u00a0gu\u00edas\u00a0se\u00a0han\u00a0revisado\u00a0los\u00a0datos\u00a0m\u00e1s\u00a0relevantes \u00a0de\u00a0las\u00a0\npublicaciones \u00a0cient\u00edficas \u00a0o\u00a0comunicaciones \u00a0a\u00a0congresos. \u00a0Con\u00a0esta\u00a0recopilaci\u00f3n \u00a0el\u00a0redac\u2010\ntor\u00a0de\u00a0cada\u00a0grupo\u00a0actualiza\u00a0su\u00a0cap\u00edtulo,\u00a0somete\u00a0sus\u00a0aportaciones \u00a0a\u00a0los\u00a0consultores \u00a0que,\u00a0\na\u00a0su\u00a0vez,\u00a0sugieren\u00a0cambios\u00a0en\u00a0el\u00a0mismo.\u00a0Cada\u00a0cap\u00edtulo\u00a0se\u00a0remite\u00a0a\u00a0los\u00a0coordinadores \u00a0y\u00a0\nfinalmente \u00a0se\u00a0ensamblan \u00a0en\u00a0el\u00a0documento \u00a0final\u00a0en\u00a0el\u00a0que\u00a0se\u00a0resaltan\u00a0las\u00a0novedades. \u00a0\nCon\u00a0posterioridad \u00a0el\u00a0documento \u00a0se\u00a0discute\u00a0y\u00a0consensua \u00a0en\u00a0una\u00a0reuni\u00f3n\u00a0presencial \u00a0de\u00a0\nlos\u00a0coordinadores \u00a0y\u00a0redactores \u00a0y,\u00a0finalmente, \u00a0si\u00a0queda\u00a0alg\u00fan\u00a0aspecto\u00a0pendiente \u00a0se\u00a0\nconcluye\u00a0en\u00a0la\u00a0Red.\u00a0Tras\u00a0ello\u00a0se\u00a0expone\u00a0durante\u00a0un\u00a0periodo\u00a0de\u00a0tiempo\u00a0en\u00a0la\u00a0web\u00a0de\u00a0las\u00a0\nentidades \u00a0promotoras \u00a0para\u00a0que\u00a0los\u00a0profesionales \u00a0a\u00a0los\u00a0que\u00a0va\u00a0dirigido\u00a0y\u00a0quien\u00a0est\u00e9\u00a0in\u2010\nteresado\u00a0pueda\u00a0sugerir\u00a0matices\u00a0o\u00a0cambios\u00a0que\u00a0el\u00a0Panel\u00a0puede\u00a0aceptar\u00a0a\u00a0posteriori .\u00a0\nEl\u00a0grado\u00a0de\u00a0evidencia \u00a0cient\u00edfica\u00a0aportado\u00a0por\u00a0un\u00a0estudio\u00a0de\u00a0investigaci\u00f3n \u00a0es\u00a0esencial\u00a0si\u00a0\nsus\u00a0resultados \u00a0van\u00a0a\u00a0matizar\u00a0una\u00a0recomendaci\u00f3n \u00a0de\u00a0pr\u00e1ctica\u00a0cl\u00ednica.\u00a0La\u00a0jerarquizaci\u00f3n \u00a0\nde\u00a0la\u00a0evidencia \u00a0est\u00e1\u00a0ligada\u00a0a\u00a0la\u00a0solidez\u00a0del\u00a0dise\u00f1o\u00a0de\u00a0cada\u00a0estudio\u00a0y\u00a0es\u00a0un\u00a0concepto \u00a0epi\u2010\ndemiol\u00f3gico \u00a0y\u00a0bioestad\u00edstico \u00a0incorporado \u00a0en\u00a0este\u00a0tipo\u00a0de\u00a0documentos \u00a0y\u00a0a\u00a0la\u00a0Medicina \u00a0\nBasada\u00a0en\u00a0la\u00a0Evidencia4,\u00a05.\u00a0\nPara\u00a0la\u00a0elaboraci\u00f3n \u00a0de\u00a0estas\u00a0recomendaciones \u00a0es\u00a0fundamental \u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0ensayos\u00a0\ncl\u00ednicos\u00a0controlados \u00a0que\u00a0demuestren \u00a0de\u00a0modo\u00a0claro\u00a0los\u00a0resultados \u00a0de\u00a0cada\u00a0interven\u2010\nci\u00f3n\u00a0terap\u00e9utica, \u00a0pero\u00a0aprovechamos \u00a0la\u00a0informaci\u00f3n \u00a0procedente \u00a0de\u00a0otro\u00a0tipo\u00a0de\u00a0estu\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 10 \n dios\u00a0como\u00a0los\u00a0de\u00a0cohortes\u00a0y\u00a0los\u00a0de\u00a0caso\u2010control.\u00a0Por\u00a0ello\u00a0se\u00a0han\u00a0seguido\u00a0los\u00a0niveles\u00a0de\u00a0\nrecomendaci\u00f3n \u00a0utilizados \u00a0en\u00a0versiones \u00a0anteriores \u00a0que,\u00a0seg\u00fan\u00a0la\u00a0procedencia \u00a0de\u00a0los\u00a0\ndatos,\u00a0son:\u00a0nivel\u00a0A:\u00a0estudios\u00a0aleatorizados \u00a0y\u00a0controlados, \u00a0nivel\u00a0B:\u00a0estudios\u00a0de\u00a0cohortes\u00a0\no\u00a0de\u00a0casos\u00a0y\u00a0controles, \u00a0y\u00a0nivel\u00a0C:\u00a0estudios\u00a0descriptivos \u00a0u\u00a0opini\u00f3n\u00a0de\u00a0expertos. \u00a0\u00a0\nSe\u00a0debe\u00a0recordar\u00a0que\u00a0los\u00a0datos\u00a0sobre\u00a0TARV\u00a0cambian\u00a0frecuentemente, \u00a0por\u00a0lo\u00a0que\u00a0los\u00a0\nlectores\u00a0deben\u00a0consultar \u00a0con\u00a0regularidad \u00a0otras\u00a0fuentes\u00a0de\u00a0informaci\u00f3n. \u00a0\u00a0\n\u00a01.2.\u00a0Principios \u00a0generales \u00a0\nTras\u00a0m\u00e1s\u00a0de\u00a020\u00a0a\u00f1os\u00a0de\u00a0estudios\u00a0cl\u00ednicos\u00a0con\u00a0FAR\u00a0efectuados \u00a0en\u00a0todos\u00a0los\u00a0estadios\u00a0evo\u2010\nlutivos\u00a0de\n\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0y\u00a0utilizando \u00a0los\u00a0f\u00e1rmacos \u00a0en\u00a0distintas\u00a0combinaciones \u00a0\npueden\u00a0establecerse \u00a0los\u00a0siguientes \u00a0principios: \u00a0\n1.\u00a0El\u00a0TARV\u00a0se\u00a0basa\u00a0en\u00a0combinaciones \u00a0de\u00a0al\u00a0menos\u00a0tres\u00a0f\u00e1rmacos \u00a0lo\u00a0que\u00a0retrasa\u00a0la\u00a0pro\u2010\ngresi\u00f3n\u00a0cl\u00ednica\u00a0(morbilidad \u00a0e\u00a0ingresos\u00a0hospitalarios), \u00a0reduce\u00a0\u00a0los\u00a0costes\u00a0y\u00a0aumenta\u00a0la\u00a0\nsupervivencia6,\u00a07.\u00a0Se\u00a0han\u00a0establecido \u00a0pautas\u00a0eficaces\u00a0con\u00a0menos\u00a0n\u00famero\u00a0de\u00a0f\u00e1rmacos \u00a0\nen\u00a0esquemas \u00a0de\u00a0simplificaci\u00f3n \u00a0y\u00a0rescate\u00a0alguna\u00a0de\u00a0las\u00a0cuales\u00a0no\u00a0est\u00e1n\u00a0autorizadas \u00a0por\u00a0\nlas\u00a0autoridades \u00a0sanitarias. \u00a0\n2.\u00a0La\u00a0adherencia \u00a0al\u00a0TARV\u00a0desempe\u00f1a \u00a0un\u00a0papel\u00a0primordial \u00a0en\u00a0el\u00a0grado\u00a0y\u00a0duraci\u00f3n\u00a0de\u00a0la\u00a0\nrespuesta \u00a0antiviral8.\u00a0Por\u00a0ello\u00a0es\u00a0imprescindible \u00a0que\u00a0cada\u00a0centro\u00a0hospitalario \u00a0tenga\u00a0una\u00a0\nestrategia \u00a0para\u00a0mejorar\u00a0el\u00a0cumplimiento \u00a0del\u00a0TARV\u00a0mediante \u00a0una\u00a0estrecha\u00a0colaboraci\u00f3n \u00a0\nentre\u00a0todos\u00a0los\u00a0profesionales \u00a0implicados. \u00a0\n3.\u00a0La\u00a0situaci\u00f3n\u00a0cl\u00ednica,\u00a0la\u00a0cifra\u00a0de\u00a0linfocitos\u00a0CD4\u00a0y\u00a0la\u00a0CVP\u00a0son\u00a0los\u00a0elementos \u00a0b\u00e1sicos\u00a0para\u00a0\nestablecer \u00a0las\u00a0decisiones \u00a0terap\u00e9uticas \u00a0y\u00a0monitorizar \u00a0la\u00a0efectividad \u00a0del\u00a0TARV.\u00a0Los\u00a0linfoci\u2010\ntos\u00a0CD4\u00a0y\u00a0la\u00a0CVP\u00a0son\u00a0los\u00a0par\u00e1metros \u00a0imprescindibles \u00a0para\u00a0la\u00a0toma\u00a0de\u00a0decisiones. \u00a0Am\u2010\nbos\u00a0son\u00a0factores\u00a0predictivos \u00a0independientes \u00a0de\u00a0la\u00a0progresi\u00f3n \u00a0de\u00a0la\u00a0enfermedad. \u00a0\nAdem\u00e1s,\u00a0la\u00a0primera\u00a0indica\u00a0el\u00a0riesgo\u00a0de\u00a0padecer\u00a0eventos\u00a0oportunistas \u00a0y\u00a0se\u00f1ala\u00a0el\u00a0mo\u2010\nmento\u00a0de\u00a0iniciar\u00a0las\u00a0profilaxis\u00a0de\u00a0las\u00a0infecciones \u00a0oportunistas. \u00a0Existe\u00a0una\u00a0buena\u00a0corre\u2010\nlaci\u00f3n\u00a0entre\u00a0las\u00a0respuestas \u00a0virol\u00f3gica, \u00a0inmunol\u00f3gica \u00a0y\u00a0cl\u00ednica\u00a0(restauraci\u00f3n \u00a0de\u00a0la\u00a0inmu\u2010\nnidad\u00a0celular,\u00a0retraso\u00a0en\u00a0la\u00a0progresi\u00f3n \u00a0y\u00a0aumento\u00a0de\u00a0supervivencia)9,\u00a010.\u00a0\n4.\u00a0El\u00a0objetivo\u00a0del\u00a0tratamiento \u00a0es\u00a0reducir\u00a0la\u00a0CVP\u00a0por\u00a0debajo\u00a0de\u00a0los\u00a0l\u00edmites\u00a0de\u00a0detecci\u00f3n \u00a0\n(<50\u00a0copias/mL) \u00a0y\u00a0mantenerla \u00a0suprimida \u00a0el\u00a0mayor\u00a0tiempo\u00a0posible.\u00a0\u00a0\n5.\u00a0La\u00a0aparici\u00f3n \u00a0de\u00a0resistencias \u00a0es\u00a0un\u00a0fen\u00f3meno \u00a0inevitable \u00a0cuando\u00a0el\u00a0VIH\u00a0se\u00a0expone\u00a0a\u00a0la\u00a0\npresi\u00f3n\u00a0selectiva\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0y\u00a0contin\u00faa\u00a0su\u00a0replicaci\u00f3n. \u00a0La\u00a0detecci\u00f3n \u00a0de\u00a0resisten\u2010\ncias\u00a0por\u00a0m\u00e9todos\u00a0genot\u00edpicos \u00a0es\u00a0muy\u00a0\u00fatil\u00a0en\u00a0el\u00a0fracaso\u00a0virol\u00f3gico. \u00a0Asimismo, \u00a0puede\u00a0ser\u00a0\n\u00fatil\u00a0medir\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0f\u00e1rmacos \u00a0en\u00a0determinadas \u00a0situaciones \u00a0cl\u00ednicas.\u00a0\n6.\u00a0Con\u00a0las\u00a0pautas\u00a0actuales\u00a0de\u00a0TARV\u00a0es\u00a0posible\u00a0la\u00a0restauraci\u00f3n \u00a0del\u00a0sistema\u00a0inmune\u00a0cuan\u2010\ntitativa\u00a0y\u00a0cualitativamente \u00a0independientemente \u00a0de\u00a0la\u00a0inmunodepresi\u00f3n \u00a0de\u00a0partida11,\u00a012.\u00a0\nLa\u00a0recuperaci\u00f3n \u00a0es\u00a0lenta\u00a0y\u00a0constante \u00a0mientras\u00a0el\u00a0TARV\u00a0sea\u00a0efectivo\u00a0y\u00a0es\u00a0m\u00e1s\u00a0dif\u00edcil\u00a0a\u00a0\npartir\u00a0de\u00a0un\u00a0determinado \u00a0grado\u00a0de\u00a0deterioro \u00a0y\u00a0en\u00a0la\u00a0edad\u00a0avanzada. \u00a0\n7.\u00a0En\u00a0diciembre \u00a0de\u00a02009\u00a0disponemos \u00a0de\u00a023\u00a0FAR\u00a0comercializados \u00a0que\u00a0pertenecen \u00a0a\u00a0seis\u00a0\nfamilias\u00a0lo\u00a0que\u00a0posibilita\u00a0estrategias \u00a0terap\u00e9uticas \u00a0individualizadas. \u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 11 \n 8.\u00a0La\u00a0toxicidad\u00a0de\u00a0los\u00a0FAR\u00a0a\u00a0medio\u00a0y\u00a0largo\u00a0plazo\u00a0es\u00a0un\u00a0factor\u00a0limitante\u00a0que\u00a0obliga\u00a0a\u00a0bus\u2010\ncar\u00a0nuevas\u00a0opciones\u00a0terap\u00e9uticas \u00a0manteniendo \u00a0la\u00a0potencia\u00a0antiviral13.\u00a0\n9.\u00a0Hay\u00a0diversas\u00a0pautas\u00a0de\u00a0TARV\u00a0que\u00a0son\u00a0similares\u00a0en\u00a0cuanto\u00a0a\u00a0potencia\u00a0antirretroviral. \u00a0\nLa\u00a0elecci\u00f3n\u00a0depender\u00e1 \u00a0de\u00a0las\u00a0preferencias \u00a0del\u00a0m\u00e9dico\u00a0o\u00a0paciente, \u00a0de\u00a0los\u00a0efectos\u00a0secun\u2010\ndarios,\u00a0adherencia, \u00a0tratamientos \u00a0previos\u00a0y\u00a0resistencias \u00a0cruzadas, \u00a0interacciones \u00a0farma\u2010\ncol\u00f3gicas, \u00a0disponibilidad \u00a0y\u00a0costes.\u00a0\u00a0\n10.\u00a0La\u00a0recomendaci\u00f3n \u00a0de\u00a0iniciar\u00a0el\u00a0TARV\u00a0s\u00f3lo\u00a0cuando\u00a0los\u00a0CD4\u00a0son\u00a0inferiores \u00a0a\u00a0350\u00a0se\u00a0\ndebe,\u00a0fundamentalmente \u00a0al\u00a0temor\u00a0a\u00a0los\u00a0efectos\u00a0secundarios14,\u00a0a\u00a0las\u00a0dificultades \u00a0de\u00a0\nadherencia8\u00a0y\u00a0el\u00a0riesgo\u00a0de\u00a0desarrollo \u00a0de\u00a0resistencias15.\u00a0Tambi\u00e9n\u00a0ha\u00a0influido\u00a0en\u00a0esta\u00a0ac\u2010\ntitud\u00a0la\u00a0imposibilidad \u00a0de\u00a0erradicar\u00a0el\u00a0VIH16\u00a0y\u00a0de\u00a0restaurar \u00a0la\u00a0respuesta \u00a0inmunoespec\u00edfica \u00a0\nfrente\u00a0al\u00a0mismo11,\u00a017.\u00a0Sin\u00a0embargo, \u00a0la\u00a0mejor\u00eda\u00a0gradual\u00a0de\u00a0las\u00a0pautas\u00a0de\u00a0inicio\u00a0en\u00a0cuanto\u00a0\na\u00a0tolerancia \u00a0y\u00a0simplicidad, \u00a0la\u00a0evidencia \u00a0de\u00a0un\u00a0efecto\u00a0negativo\u00a0directo\u00a0del\u00a0VIH\u00a0\u00a0per\u00a0se\u00a0\nsobre\u00a0la\u00a0salud,\u00a0as\u00ed\u00a0como\u00a0el\u00a0incremento \u00a0de\u00a0opciones\u00a0de\u00a0rescate\u00a0tras\u00a0un\u00a0fracaso\u00a0virol\u00f3gi\u2010\nco\u00a0ha\u00a0reabierto \u00a0el\u00a0debate\u00a0sobre\u00a0este\u00a0tema\u00a0y\u00a0algunos\u00a0expertos\u00a0abogan\u00a0por\u00a0recomenda \u2010\nciones\u00a0menos\u00a0restrictivas \u00a0para\u00a0iniciar\u00a0el\u00a0tratamiento. \u00a0\n11.\u00a0La\u00a0complejidad \u00a0creciente \u00a0del\u00a0TARV\u00a0implica\u00a0que\u00a0el\u00a0cuidado\u00a0de\u00a0los\u00a0pacientes \u00a0debe\u00a0\nefectuarse \u00a0por\u00a0personal\u00a0especializado \u00a0que\u00a0tenga\u00a0los\u00a0conocimientos \u00a0y\u00a0los\u00a0medios\u00a0ade\u2010\ncuados18.\u00a0\n12.\u00a0La\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0es\u00a0un\u00a0aspecto\u00a0fundamental \u00a0que\u00a0no\u00a0debe\u00a0\nolvidarse\u00a0nunca\u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0cl\u00ednica\u00a0diaria\u00a0y\u00a0que\u00a0debe\u00a0introducirse \u00a0de\u00a0forma\u00a0sistem\u00e1\u2010\ntica\u00a0en\u00a0la\u00a0educaci\u00f3n \u00a0sanitaria\u00a0de\u00a0los\u00a0pacientes \u00a0y\u00a0las\u00a0personas\u00a0de\u00a0su\u00a0entorno.\u00a0\n\u00a0\n2.\u00a0PARAMETROS \u00a0PARA\u00a0GUIAR\u00a0EL\u00a0TRATAMIENTO \u00a0ANTIRRETROVIRAL \u00a0\nEl\u00a0recuento\u00a0de\u00a0linfocitos\u00a0CD4\u00a0y\u00a0la\u00a0CVP\u00a0son\u00a0los\u00a0par\u00e1metros \u00a0que\u00a0se\u00a0utilizan\u00a0para\u00a0indicar\u00a0el\u00a0\nTARV,\u00a0monitorizar \u00a0su\u00a0eficacia\u00a0y\u00a0tomar\u00a0decisiones \u00a0respecto\u00a0a\u00a0cambios.\u00a0\u00a0\nExisten\u00a0otros\u00a0par\u00e1metros \u00a0que,\u00a0aunque\u00a0no\u00a0intervienen \u00a0directamente \u00a0en\u00a0el\u00a0inicio\u00a0del\u00a0\nTARV,\u00a0se\u00a0deben\u00a0realizar\u00a0igualmente \u00a0en\u00a0la\u00a0evaluaci\u00f3n \u00a0inicial\u00a0o\u00a0en\u00a0el\u00a0seguimiento \u00a0ya\u00a0que\u00a0\npueden\u00a0matizar\u00a0las\u00a0decisiones \u00a0terap\u00e9uticas \u00a0(Tabla\u00a01).\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n2.1.\u00a0Linfocitos \u00a0CD4\u00a0\nEl\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0CD4\u00a0es\u00a0el\u00a0marcador \u00a0principal\u00a0de\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0cl\u00ednica\u00a0de\u00a0\nla\u00a0infecci\u00f3n\u00a0VIH\u00a0y\u00a0necesidad \u00a0de\u00a0TARV.\u00a0Un\u00a0objetivo\u00a0del\u00a0TARV\u00a0es\u00a0la\u00a0restauraci\u00f3n \u00a0inmu\u2010\nnol\u00f3gica\u00a0y\u00a0la\u00a0forma\u00a0m\u00e1s\u00a0pr\u00e1ctica\u00a0de\u00a0valorarlo\u00a0es\u00a0midiendo \u00a0el\u00a0incremento \u00a0de\u00a0los\u00a0CD4,\u00a0\nque\u00a0es\u00a0evidente\u00a0en\u00a0las\u00a0primeras\u00a0semanas\u00a0de\u00a0tratamiento11,\u00a012,\u00a019\u201021.\u00a0Adem\u00e1s\u00a0del\u00a0n\u00famero\u00a0\nde\u00a0linfocitos\u00a0CD4\u00a0se\u00a0restaura\u00a0la\u00a0respuesta \u00a0proliferativa \u00a0frente\u00a0a\u00a0mit\u00f3genos \u00a0y\u00a0ant\u00edgenos \u00a0\nmemoria\u00a0pudiendo \u00a0retirar\u00a0las\u00a0profilaxis\u00a0de\u00a0infecciones \u00a0oportunistas19\u201022.\u00a0Paralelamente \u00a0\nal\u00a0aumento\u00a0de\u00a0los\u00a0linfocitos\u00a0CD4,\u00a0hay\u00a0una\u00a0disminuci\u00f3n \u00a0de\u00a0los\u00a0CD8\u00a0y\u00a0otros\u00a0marcadores \u00a0\nde\u00a0activaci\u00f3n \u00a0del\u00a0sistema\u00a0inmune19,\u00a020.\u00a0\nEl\u00a0aumento\u00a0de\u00a0la\u00a0cifra\u00a0de\u00a0CD4\u00a0es\u00a0lento\u00a0pero\u00a0constante \u00a0en\u00a0el\u00a0tiempo.\u00a0No\u00a0hay\u00a0datos\u00a0que\u00a0\ndefinan\u00a0cu\u00e1l\u00a0es\u00a0la\u00a0respuesta \u00a0inmunol\u00f3gica \u00a0adecuada. \u00a0Se\u00a0admite,\u00a0seg\u00fan\u00a0estudios\u00a0de\u00a0\ncin\u00e9tica\u00a0celular,\u00a0que\u00a0durante\u00a0el\u00a0primer\u00a0a\u00f1o\u00a0deber\u00eda\u00a0existir\u00a0un\u00a0aumento\u00a0m\u00ednimo\u00a0de\u00a050\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 12 \n 100\u00a0CD4/\u03bcL23.\u00a0No\u00a0es\u00a0raro\u00a0observar\u00a0una\u00a0discordancia \u00a0entre\u00a0respuesta \u00a0virol\u00f3gica \u00a0e\u00a0inmu\u2010\nnol\u00f3gica:\u00a0pacientes \u00a0que\u00a0mantienen \u00a0una\u00a0cifra\u00a0de\u00a0CD4\u00a0estable\u00a0o\u00a0que\u00a0disminuye \u00a0a\u00a0pesar\u00a0\nde\u00a0tener\u00a0una\u00a0CVP\u00a0no\u00a0detectable24\u201027.\u00a0En\u00a0esta\u00a0situaci\u00f3n\u00a0puede\u00a0existir\u00a0carga\u00a0viral\u00a0detec\u2010\ntable\u00a0en\u00a0tejido\u00a0linf\u00e1tico\u00a0por\u00a0un\u00a0TARV\u00a0sub\u00f3ptimo26.\u00a0Sin\u00a0embargo, \u00a0esta\u00a0linfopenia \u00a0puede\u00a0\ndeberse\u00a0a\u00a0otras\u00a0causas\u00a0como\u00a0hipertensi\u00f3n \u00a0portal,\u00a0toxicidad\u00a0farmacol\u00f3gica, \u00a0etc.\u00a0En\u00a0este\u00a0\nsentido,\u00a0se\u00a0ha\u00a0sugerido\u00a0que\u00a0en\u00a0cirr\u00f3ticos \u00a0se\u00a0pueda\u00a0usar\u00a0el\u00a0porcentaje \u00a0de\u00a0CD4\u00a0para\u00a0la\u00a0\ntoma\u00a0de\u00a0decisiones28,\u00a029,\u00a0aunque\u00a0tambi\u00e9n\u00a0en\u00a0estos\u00a0pacientes \u00a0el\u00a0n\u00famero\u00a0de\u00a0CD4\u00a0ha\u00a0de\u2010\nmostrado \u00a0ser\u00a0el\u00a0mejor\u00a0predictor \u00a0de\u00a0riesgo30.\u00a0Por\u00a0otra\u00a0parte,\u00a0se\u00a0ha\u00a0comunicado \u00a0la\u00a0posi\u2010\nbilidad\u00a0de\u00a0suspender \u00a0la\u00a0profilaxis\u00a0frente\u00a0a\u00a0\u00a0Pneumocystis \u00a0jirovecii ,\u00a0en\u00a0pacientes \u00a0con\u00a0\n<200\u00a0CD4/\u03bcL\u00a0si\u00a0la\u00a0CVP\u00a0est\u00e1\u00a0suprimida \u00a0lo\u00a0que\u00a0orienta\u00a0a\u00a0que\u00a0la\u00a0supresi\u00f3n \u00a0viral\u00a0continuada \u00a0\ndebe\u00a0ser\u00a0necesaria \u00a0para\u00a0la\u00a0reconstituci\u00f3n \u00a0de\u00a0la\u00a0funci\u00f3n\u00a0inmune31.\u00a0\nEn\u00a0los\u00a0pacientes \u00a0asintom\u00e1ticos \u00a0deben\u00a0medirse\u00a0los\u00a0linfocitos\u00a0CD4\u00a0cada\u00a03\u20106\u00a0meses\u00a0y\u00a0ante\u00a0\nun\u00a0hallazgo\u00a0que\u00a0oriente\u00a0a\u00a0tomar\u00a0una\u00a0decisi\u00f3n\u00a0terap\u00e9utica, \u00a0debe\u00a0repetirse\u00a0en\u00a03\u20104\u00a0sema\u2010\nnas32,\u00a033.\u00a0Se\u00a0aconseja\u00a0la\u00a0repetici\u00f3n \u00a0del\u00a0recuento\u00a0de\u00a0linfocitos\u00a0CD4\u00a0antes\u00a0de\u00a0tomar\u00a0la\u00a0de\u2010\ncisi\u00f3n\u00a0de\u00a0iniciar\u00a0el\u00a0TARV.\u00a0\u00a0\nLinfocitos \u00a0CD4.\u00a0Recomendaci\u00f3n \u00a0\n\u0083 Se\u00a0debe\u00a0controlar\u00a0el\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0CD4\u00a0ya\u00a0que\u00a0es\u00a0el\u00a0par\u00e1metro \u00a0m\u00e1s\u00a0impor\u2010\ntante\u00a0para\u00a0decidir\u00a0el\u00a0inicio\u00a0del\u00a0TARV\u00a0(nivel\u00a0B).\u00a0\u00a0\n\u00a0\n2.2.\u00a0Carga\u00a0viral\u00a0plasm\u00e1tica \u00a0del\u00a0VIH\u00a0\nEl\u00a0objetivo\u00a0del\u00a0TARV\u00a0es\u00a0suprimir\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0de\u00a0modo\u00a0r\u00e1pido\u00a0y\u00a0duradero. \u00a0La\u00a0CVP\u00a0\ndesciende \u00a0r\u00e1pidamente \u00a0(1\u20102\u00a0log 10)\u00a0al\u00a0inicio\u00a0del\u00a0TARV\u00a0y\u00a0el\u00a0nadir,\u00a0que\u00a0se\u00a0alcanza\u00a0a\u00a0las\u00a04\u20108\u00a0\nsemanas, \u00a0se\u00a0correlaciona \u00a0con\u00a0la\u00a0duraci\u00f3n\u00a0de\u00a0la\u00a0respuesta34\u201037.\u00a0Los\u00a0pacientes \u00a0con\u00a0CVP\u00a0\nmuy\u00a0elevadas\u00a0pueden\u00a0tardar\u00a0hasta\u00a024\u00a0semanas\u00a0en\u00a0conseguir \u00a0niveles\u00a0<50\u00a0copias/mL38.\u00a0\nEl\u00a0objetivo\u00a0de\u00a0supresi\u00f3n \u00a0de\u00a0la\u00a0CVP\u00a0es\u00a0llegar\u00a0a\u00a0una\u00a0cifra\u00a0inferior\u00a0a\u00a050\u00a0copias/mL, \u00a0cifra\u00a0con\u00a0\nla\u00a0que\u00a0se\u00a0ha\u00a0comprobado \u00a0que\u00a0no\u00a0se\u00a0seleccionan \u00a0mutaciones39,\u00a040\u00a0y\u00a0la\u00a0duraci\u00f3n\u00a0de\u00a0la\u00a0\nrespuesta \u00a0virol\u00f3gica \u00a0es\u00a0mucho\u00a0mayor\u00a0(frente\u00a0a\u00a0los\u00a0mantienen \u00a0CVP\u00a0entre\u00a050\u00a0y\u00a0500\u00a0co\u2010\npias/mL)35.\u00a0En\u00a0los\u00a0pacientes \u00a0con\u00a0CVP\u00a0controlada \u00a0se\u00a0ha\u00a0observado \u00a0ocasionalmente \u00a0bro\u2010\ntes\u00a0transitorios \u00a0de\u00a0viremia\u00a0de\u00a0bajo\u00a0nivel\u00a0(blips )41\u00a0que\u00a0vuelve\u00a0espont\u00e1neamente \u00a0a\u00a0ser\u00a0\nindetectable \u00a0sin\u00a0ning\u00fan\u00a0cambio\u00a0en\u00a0el\u00a0tratamiento. \u00a0La\u00a0patogenia \u00a0de\u00a0los\u00a0blips\u00a0no\u00a0est\u00e1\u00a0\nclara\u00a0y\u00a0se\u00a0ha\u00a0sugerido\u00a0que\u00a0la\u00a0activaci\u00f3n \u00a0inmune\u00a0por\u00a0infecciones \u00a0intercurrentes \u00a0estimu\u2010\nlar\u00edan\u00a0las\u00a0c\u00e9lulas\u00a0cr\u00f3nicamente \u00a0infectadas \u00a0(reservorios) \u00a0con\u00a0aparici\u00f3n \u00a0transitoria \u00a0de\u00a0\nCVP42.\u00a0La\u00a0mayor\u00eda\u00a0de\u00a0estudios\u00a0no\u00a0relacionan \u00a0los\u00a0blips\u00a0con\u00a0fracaso\u00a0virol\u00f3gico43\u201046,\u00a0aun\u2010\nque\u00a0un\u00a0peque\u00f1o\u00a0porcentaje \u00a0pueden\u00a0desarrollar \u00a0fracaso\u00a0virol\u00f3gico \u00a0con\u00a0aparici\u00f3n \u00a0de\u00a0\nmutaciones \u00a0de\u00a0resistencia47,\u00a048.\u00a0\u00a0\nLos\u00a0criterios\u00a0de\u00a0respuesta \u00a0y\u00a0fracaso\u00a0virol\u00f3gicos \u00a0son:\u00a0\nRespuesta \u00a0virol\u00f3gica :\u00a0Descenso \u00a0de\u00a0la\u00a0CVP\u00a0>1\u00a0log\u00a0a\u00a0las\u00a04\u00a0semanas\u00a0de\u00a0TARV\u00a0y\u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a0a\u00a0las\u00a016\u201024\u00a0semanas. \u00a0\nFracaso\u00a0virol\u00f3gico :\u00a0Cualquiera \u00a0de\u00a0las\u00a0siguientes \u00a0situaciones \u00a0a)\u00a0CVP\u00a0detectable \u00a0a\u00a0las\u00a024\u00a0\nsemanas\u00a0de\u00a0TARV,\u00a0o\u00a0b)\u00a0si\u00a0tras\u00a0alcanzar\u00a0una\u00a0CVP\u00a0indetectable \u00a0(<50\u00a0copias/mL), \u00a0\u00e9sta\u00a0\nvuelve\u00a0a\u00a0ser\u00a0detectable \u00a0en\u00a0dos\u00a0determinaciones \u00a0consecutivas. \u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 13 \n Es\u00a0conveniente \u00a0medir\u00a0la\u00a0CVP\u00a0a\u00a0las\u00a04\u00a0semanas\u00a0de\u00a0inicio\u00a0del\u00a0TARV\u00a0para\u00a0comprobar \u00a0la\u00a0res\u2010\npuesta\u00a0virol\u00f3gica \u00a0y\u00a0como\u00a0medida\u00a0indirecta\u00a0de\u00a0adherencia. \u00a0Posteriormente \u00a0la\u00a0determi\u2010\nnaci\u00f3n\u00a0se\u00a0har\u00e1\u00a0cada\u00a03\u20106\u00a0meses.\u00a0Si\u00a0la\u00a0medida\u00a0de\u00a0la\u00a0CVP\u00a0se\u00a0efect\u00faa\u00a0tras\u00a0un\u00a0proceso\u00a0viral\u00a0\nintercurrente \u00a0o\u00a0vacunaci\u00f3n \u00a0puede\u00a0haber\u00a0brotes\u00a0transitorios \u00a0de\u00a0la\u00a0CVP49.\u00a0\nCarga\u00a0viral.\u00a0Recomendaciones \u00a0\n\u0083 Se\u00a0debe\u00a0conocer\u00a0la\u00a0CVP\u00a0ya\u00a0que\u00a0es\u00a0un\u00a0criterio\u00a0secundario \u00a0para\u00a0el\u00a0inicio\u00a0del\u00a0TARV,\u00a0\ncomplementario \u00a0al\u00a0n\u00famero\u00a0de\u00a0CD4\u00a0(nivel\u00a0A).\u00a0\u00a0\n\u0083 Se\u00a0debe\u00a0controlar\u00a0la\u00a0eficacia\u00a0del\u00a0TARV\u00a0mediante \u00a0la\u00a0CVP\u00a0que\u00a0es\u00a0el\u00a0par\u00e1metro \u00a0princi\u2010\npal\u00a0para\u00a0evaluar\u00a0la\u00a0misma,\u00a0definir\u00a0su\u00a0fracaso\u00a0y\u00a0para\u00a0tomar\u00a0decisiones \u00a0de\u00a0cambio\u00a0\n(nivel\u00a0B).\u00a0\u00a0\n\u0083 Debe\u00a0utilizarse\u00a0una\u00a0t\u00e9cnica\u00a0de\u00a0determinaci\u00f3n \u00a0de\u00a0CVP\u00a0cuyo\u00a0dintel\u00a0de\u00a0detecci\u00f3n \u00a0sea\u00a0\n<50\u00a0copias/mL \u00a0y\u00a0usar\u00a0siempre\u00a0la\u00a0misma\u00a0t\u00e9cnica\u00a0(nivel\u00a0B).\u00a0\n\u0083 Si\u00a0se\u00a0van\u00a0a\u00a0tomar\u00a0decisiones \u00a0terap\u00e9uticas \u00a0en\u00a0funci\u00f3n\u00a0de\u00a0un\u00a0resultado, \u00a0se\u00a0debe\u00a0con\u2010\nfirmar\u00a0la\u00a0CVP\u00a0con\u00a0una\u00a0segunda\u00a0determinaci\u00f3n \u00a0(nivel\u00a0B).\u00a0\n\u00a0\n2.3.\u00a0Niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0f\u00e1rmacos \u00a0\nLas\u00a0concentraciones \u00a0plasm\u00e1ticas \u00a0de\u00a0algunos\u00a0FAR\u00a0se\u00a0correlacionan \u00a0con\u00a0su\u00a0eficacia\u00a0o\u00a0\ntoxicidad\u00a0por\u00a0lo\u00a0que\u00a0se\u00a0ha\u00a0sugerido\u00a0que\u00a0la\u00a0determinaci\u00f3n \u00a0de\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0\npodr\u00eda\u00a0ser\u00a0\u00fatil\u00a0para\u00a0optimizar \u00a0su\u00a0uso50.\u00a0\nSe\u00a0conocen\u00a0determinadas \u00a0situaciones \u00a0cl\u00ednicas\u00a0o\u00a0factores\u00a0que\u00a0pueden\u00a0inducir\u00a0variacio\u2010\nnes\u00a0importantes \u00a0en\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0los\u00a0FAR\u00a0lo\u00a0que\u00a0justificar\u00eda \u00a0su\u00a0determina \u2010\nci\u00f3n51.\u00a0Entre\u00a0ellos\u00a0est\u00e1n\u00a0el\u00a0sexo,\u00a0edad,\u00a0peso\u00a0y\u00a0superficie \u00a0corporal,\u00a0los\u00a0niveles\u00a0de\u00a0alfa1\u2010\nglucoprote\u00edna \u00a0y\u00a0variaciones \u00a0en\u00a0las\u00a0isoformas \u00a0del\u00a0citocromo \u00a0P450,\u00a0las\u00a0interacciones \u00a0me\u2010\ndicamentosas, \u00a0el\u00a0embarazo, \u00a0la\u00a0insuficiencia \u00a0hep\u00e1tica\u00a0o\u00a0renal.\u00a0\u00a0\nLa\u00a0monitorizaci\u00f3n \u00a0de\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0se\u00a0limita\u00a0a\u00a0NN\u00a0e\u00a0IP\u00a0ya\u00a0que\u00a0la\u00a0determina \u2010\nci\u00f3n\u00a0de\u00a0la\u00a0forma\u00a0activa\u00a0de\u00a0los\u00a0AN\u00a0(intracelular) \u00a0presenta\u00a0una\u00a0variabilidad \u00a0inter\u00a0e\u00a0intra\u2010\npaciente\u00a0tan\u00a0amplia\u00a0que\u00a0dificulta\u00a0su\u00a0uso\u00a0cl\u00ednico.\u00a0\u00a0\nEl\u00a0valor\u00a0de\u00a0los\u00a0niveles\u00a0de\u00a0IP\u00a0con\u00a0respecto\u00a0a\u00a0su\u00a0eficacia\u00a0ha\u00a0perdido\u00a0vigencia\u00a0desde\u00a0que\u00a0se\u00a0\nutilizan\u00a0potenciados \u00a0aunque\u00a0ha\u00a0aumentado \u00a0su\u00a0valor\u00a0para\u00a0reducir\u00a0toxicidad. \u00a0Los\u00a0datos\u00a0\nque\u00a0relacionaban \u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0IP\u00a0y\u00a0eficacia\u00a0se\u00a0obtuvieron \u00a0en\u00a0los\u00a0estudios\u00a0de\u00a0\ndesarrollo \u00a0donde\u00a0se\u00a0utilizaron \u00a0en\u00a0monoterapia52.\u00a0Los\u00a0estudios\u00a0en\u00a0reg\u00edmenes \u00a0de\u00a0combi\u2010\nnaci\u00f3n\u00a0han\u00a0mostrado \u00a0resultados \u00a0dispares,\u00a0variando\u00a0seg\u00fan\u00a0l\u00ednea\u00a0de\u00a0tratamiento \u00a0(sin\u00a0\nterapia\u00a0previa\u00a0frente\u00a0a\u00a0pretratados), \u00a0f\u00e1rmacos \u00a0acompa\u00f1antes \u00a0(otros\u00a0IP\u00a0o\u00a0NN)\u00a0o\u00a0poten\u2010\nciaci\u00f3n\u00a0con\u00a0RTV53\u201059.\u00a0En\u00a0cuanto\u00a0a\u00a0toxicidad, \u00a0se\u00a0ha\u00a0demostrado \u00a0una\u00a0relaci\u00f3n\u00a0entre\u00a0nive\u2010\nles\u00a0plasm\u00e1ticos \u00a0y\u00a0algunos\u00a0efectos\u00a0secundarios \u00a0como\u00a0alteraciones \u00a0gastrointestinales, \u00a0\nhipertrigliceridemia \u00a0y\u00a0parestesias \u00a0(RTV),\u00a0alteraciones \u00a0renales\u00a0(IDV),\u00a0hepatotoxicidad \u00a0\n(NVP),\u00a0colesterol \u00a0total\u00a0y\u00a0triglic\u00e9ridos \u00a0(LPV/r)60\u201064.\u00a0Igualmente \u00a0hay\u00a0datos\u00a0que\u00a0sugieren\u00a0\nque\u00a0los\u00a0pacientes \u00a0que\u00a0alcanzan\u00a0concentraciones \u00a0m\u00e1s\u00a0elevadas\u00a0de\u00a0EFV\u00a0tienen\u00a0mayor\u00a0\nriesgo\u00a0de\u00a0s\u00edntomas\u00a0neuropsiqui\u00e1tricos65,\u00a066.\u00a0\nLas\u00a0limitaciones \u00a0del\u00a0uso\u00a0rutinario\u00a0de\u00a0niveles\u00a0plasm\u00e1ticos \u00a0en\u00a0la\u00a0cl\u00ednica\u00a0diaria\u00a0son\u00a0m\u00falti\u2010\nples,\u00a0por\u00a0una\u00a0parte\u00a0no\u00a0existen\u00a0estudios\u00a0prospectivos \u00a0que\u00a0demuestren \u00a0su\u00a0utilidad\u00a0en\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 14 \n mejorar\u00a0la\u00a0eficacia\u00a0y\u00a0por\u00a0otra,\u00a0la\u00a0ausencia\u00a0de\u00a0rangos\u00a0terap\u00e9uticos \u00a0asociados \u00a0a\u00a0respuesta \u00a0\nterap\u00e9utica \u00a0o\u00a0la\u00a0posibilidad \u00a0de\u00a0reducir\u00a0reacciones \u00a0adversas. \u00a0Otra\u00a0limitaci\u00f3n \u00a0es\u00a0la\u00a0no\u00a0\ndisponibilidad \u00a0de\u00a0la\u00a0t\u00e9cnica\u00a0en\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0laboratorios. \u00a0\n\u00a0\nNiveles\u00a0de\u00a0f\u00e1rmac.\u00a0Recomendaci\u00f3n \u00a0\n\u0083 La\u00a0medici\u00f3n \u00a0de\u00a0niveles\u00a0podr\u00eda\u00a0ser\u00a0de\u00a0ayuda\u00a0en\u00a0el\u00a0manejo\u00a0de\u00a0situaciones \u00a0cl\u00ednicas\u00a0\nconcretas \u00a0(interacciones \u00a0farmacol\u00f3gicas, \u00a0TARV\u00a0en\u00a0trasplante \u00a0de\u00a0\u00f3rgano,\u00a0delgadez\u00a0u\u00a0\nobesidad\u00a0m\u00f3rbidas, \u00a0insuficiencia \u00a0hep\u00e1tica\u00a0o\u00a0renal)\u00a0(nivel\u00a0C).\u00a0\n\u00a02.4.\u00a0Resistencia \u00a0del\u00a0VIH\u00a0a\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0\nLa\u00a0tasa\u00a0de\u00a0mutaci\u00f3n \u00a0espont\u00e1nea \u00a0de\u00a0los\u00a0retrovirus \u00a0se\u00a0estima\u00a0en\u00a0un\u00a0nucle\u00f3tido \u00a0por\u00a0cada\u00a0\n10\n4\u00a0\u00f3\u00a0105\u00a0nucle\u00f3tidos \u00a0y\u00a0copia\u00a0de\u00a0la\u00a0cadena\u00a0del\u00a0ARN67\u201069.\u00a0Por\u00a0otro\u00a0lado,\u00a0la\u00a0vida\u00a0media\u00a0de\u00a0\nlos\u00a0linfocitos\u00a0CD4\u00a0infectados \u00a0que\u00a0replican\u00a0activamente \u00a0es\u00a0de\u00a0un\u00a0d\u00eda\u00a0y\u00a0se\u00a0estima\u00a0que\u00a0la\u00a0\nvida\u00a0media\u00a0del\u00a0virus\u00a0en\u00a0plasma\u00a0es\u00a0de\u00a06\u00a0horas70\u201073.\u00a0La\u00a0conjunci\u00f3n \u00a0de\u00a0esta\u00a0alta\u00a0tasa\u00a0de\u00a0\nerror\u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0y\u00a0de\u00a0la\u00a0r\u00e1pida\u00a0renovaci\u00f3n \u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0viral\u00a0produce\u00a0\nun\u00a0ac\u00famulo\u00a0de\u00a0gran\u00a0cantidad\u00a0de\u00a0variantes\u00a0virales,\u00a0que\u00a0reciben\u00a0el\u00a0nombre\u00a0de\u00a0cuasi\u00a0es\u2010\npecies.\u00a0El\u00a0n\u00famero\u00a0de\u00a0variantes\u00a0gen\u00e9ticas \u00a0distintas\u00a0presentes \u00a0en\u00a0un\u00a0momento \u00a0dado\u00a0en\u00a0\nun\u00a0individuo \u00a0infectado \u00a0se\u00a0estima\u00a0entre\u00a05\u00a0x105\u00a0y\u00a05\u00a0x1010.\u00a0\nLas\u00a0mutaciones \u00a0que\u00a0confieren \u00a0resistencia \u00a0pueden\u00a0existir\u00a0en\u00a0estas\u00a0cuasi\u00a0especies,\u00a0pero\u00a0\nrepresentan \u00a0una\u00a0proporci\u00f3n \u00a0m\u00ednima\u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0viral\u00a0hasta\u00a0que\u00a0se\u00a0ve\u00a0sometida \u00a0a\u00a0la\u00a0\npresi\u00f3n\u00a0selectiva\u00a0del\u00a0TARV72.\u00a0As\u00ed\u00a0pues,\u00a0el\u00a0tratamiento \u00a0conllevar\u00e1 \u00a0que\u00a0las\u00a0variantes\u00a0resis\u2010\ntentes\u00a0se\u00a0conviertan \u00a0en\u00a0poblaci\u00f3n \u00a0dominante \u00a0al\u00a0cabo\u00a0de\u00a0semanas\u00a0o\u00a0meses\u00a0si\u00a0no\u00a0se\u00a0su\u2010\nprime\u00a0la\u00a0replicaci\u00f3n \u00a0viral74\u201076.\u00a0\nNo\u00a0todas\u00a0las\u00a0mutaciones \u00a0tienen\u00a0la\u00a0misma\u00a0importancia. \u00a0Para\u00a0cada\u00a0FAR\u00a0existen\u00a0unas\u00a0lla\u2010\nmadas\u00a0\u201cprincipales\u201d, \u00a0cuya\u00a0presencia \u00a0est\u00e1\u00a0estrechamente \u00a0ligada\u00a0a\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0resis\u2010\ntencia\u00a0y\u00a0que\u00a0reducen\u00a0la\u00a0eficiencia \u00a0biol\u00f3gica\u00a0del\u00a0virus\u00a0(fitness)\u00a0y\u00a0otras\u00a0\u201csecundarias\u201d \u00a0que,\u00a0\nen\u00a0menor\u00a0medida,\u00a0tambi\u00e9n\u00a0contribuyen \u00a0a\u00a0la\u00a0resistencia \u00a0y\u00a0que,\u00a0en\u00a0general,\u00a0act\u00faan\u00a0mo\u2010\ndificando \u00a0la\u00a0capacidad \u00a0replicativa \u00a0viral.\u00a0\n\u00a0\nDetecci\u00f3n \u00a0de\u00a0resistencias \u00a0del\u00a0VIH\u00a0a\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0\nLas\u00a0variantes\u00a0resistentes \u00a0pueden\u00a0detectarse \u00a0mediante \u00a0t\u00e9cnicas\u00a0genot\u00edpicas \u00a0o\u00a0fenot\u00edpi\u2010\ncas15.\u00a0Las\u00a0genot\u00edpicas \u00a0detectan\u00a0cambios\u00a0espec\u00edficos \u00a0en\u00a0los\u00a0genomas\u00a0de\u00a0las\u00a0enzimas\u00a0dia\u2010\nna\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0(transcriptasa \u00a0inversa,\u00a0proteasa, \u00a0integrasa, \u00a0envuelta), \u00a0mientras\u00a0que\u00a0\nlas\u00a0t\u00e9cnicas\u00a0fenot\u00edpicas \u00a0determinan \u00a0la\u00a0respuesta \u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0viral\u00a0mayoritaria \u00a0a\u00a0\nconcentraciones \u00a0crecientes \u00a0de\u00a0los\u00a0distintos\u00a0f\u00e1rmacos. \u00a0Ambas\u00a0comparten \u00a0limitaciones \u00a0\ncomo\u00a0la\u00a0dificultad \u00a0de\u00a0detecci\u00f3n \u00a0cuando\u00a0la\u00a0poblaci\u00f3n \u00a0mutada\u00a0es\u00a0<20%\u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0\nviral\u00a0o\u00a0la\u00a0CVP\u00a0es\u00a0<1000\u00a0copias/mL15,\u00a0aunque\u00a0t\u00e9cnicas\u00a0recientes\u00a0van\u00a0reduciendo \u00a0ambas\u00a0\nlimitaciones. \u00a0Las\u00a0pruebas\u00a0de\u00a0resistencias \u00a0deben\u00a0realizarse \u00a0durante\u00a0el\u00a0TARV77\u00a0activo\u00a0ya\u00a0\nque\u00a0la\u00a0poblaci\u00f3n \u00a0viral\u00a0resistente \u00a0ser\u00e1\u00a0sustituida \u00a0por\u00a0otra\u00a0sensible\u00a0a\u00a0las\u00a0pocas\u00a0semanas\u00a0\nde\u00a0retirar\u00a0los\u00a0f\u00e1rmacos. \u00a0Los\u00a0resultados \u00a0de\u00a0estas\u00a0pruebas\u00a0se\u00a0deben\u00a0interpretar \u00a0teniendo\u00a0\npresente\u00a0los\u00a0estudios\u00a0previos\u00a0de\u00a0resistencia, \u00a0\u00a0la\u00a0historia\u00a0terap\u00e9utica \u00a0y\u00a0la\u00a0adherencia. \u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 15 \n Las\u00a0t\u00e9cnicas\u00a0genot\u00edpicas \u00a0y\u00a0fenot\u00edpicas \u00a0tienen\u00a0ventajas\u00a0y\u00a0desventajas \u00a0que\u00a0las\u00a0hacen\u00a0\ncomplementarias \u00a0entre\u00a0s\u00ed15.\u00a0Las\u00a0t\u00e9cnicas\u00a0genot\u00edpicas \u00a0son\u00a0m\u00e1s\u00a0sencillas,\u00a0r\u00e1pidas\u00a0y\u00a0acce\u2010\nsibles\u00a0para\u00a0la\u00a0mayor\u00a0parte\u00a0de\u00a0laboratorios \u00a0y\u00a0permiten \u00a0la\u00a0detecci\u00f3n \u00a0de\u00a0mutaciones \u00a0cen\u2010\ntinela\u00a0antes\u00a0de\u00a0que\u00a0se\u00a0detecten\u00a0cambios\u00a0de\u00a0susceptibilidad \u00a0en\u00a0las\u00a0pruebas\u00a0fenot\u00edpicas. \u00a0\nSu\u00a0mayor\u00a0limitaci\u00f3n \u00a0estriba\u00a0en\u00a0la\u00a0dificultad \u00a0de\u00a0establecer \u00a0una\u00a0correlaci\u00f3n \u00a0genot\u00edpica \u2010\nfenot\u00edpica \u00a0y,\u00a0sobre\u00a0todo,\u00a0en\u00a0las\u00a0dificultades \u00a0de\u00a0interpretaci\u00f3n \u00a0para\u00a0algunos\u00a0f\u00e1rmacos. \u00a0\nAdem\u00e1s,\u00a0su\u00a0aplicaci\u00f3n \u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0diaria\u00a0requiere\u00a0el\u00a0conocimiento \u00a0previo\u00a0por\u00a0parte\u00a0\ndel\u00a0cl\u00ednico\u00a0de\u00a0la\u00a0influencia \u00a0que\u00a0tiene\u00a0cada\u00a0mutaci\u00f3n \u00a0detectada \u00a0en\u00a0la\u00a0eficacia\u00a0de\u00a0cada\u00a0\nf\u00e1rmaco.\u00a0Las\u00a0t\u00e9cnicas\u00a0fenot\u00edpicas \u00a0tienen\u00a0la\u00a0ventaja\u00a0de\u00a0informar\u00a0del\u00a0efecto\u00a0neto\u00a0de\u00a0las\u00a0\ndistintas\u00a0concentraciones \u00a0sobre\u00a0la\u00a0sensibilidad \u00a0real\u00a0de\u00a0la\u00a0cepa\u00a0predominante \u00a0a\u00a0los\u00a0FAR,\u00a0\nhayan\u00a0sido\u00a0utilizados \u00a0o\u00a0no.\u00a0Existe\u00a0una\u00a0buena\u00a0correlaci\u00f3n \u00a0entre\u00a0las\u00a0dos\u00a0t\u00e9cnicas\u00a0existen\u2010\ntes\u00a0en\u00a0la\u00a0actualidad, \u00a0Virologic\u00a0Phenosense \u00a0y\u00a0Virco\u00a0Antivirogram78.\u00a0Sus\u00a0mayores\u00a0desven\u2010\ntajas\u00a0son\u00a0el\u00a0coste,\u00a0la\u00a0disponibilidad \u00a0limitada\u00a0y\u00a0demora\u00a0en\u00a0la\u00a0obtenci\u00f3n \u00a0de\u00a0resultados. \u00a0\nPara\u00a0superar\u00a0estas\u00a0desventajas \u00a0se\u00a0ha\u00a0desarrollado \u00a0el\u00a0fenotipo\u00a0virtual79,\u00a0obtenido\u00a0a\u00a0par\u2010\ntir\u00a0de\u00a0una\u00a0base\u00a0de\u00a0datos\u00a0que\u00a0tiene\u00a0miles\u00a0de\u00a0muestras \u00a0analizadas \u00a0por\u00a0ambas\u00a0t\u00e9cnicas.\u00a0\nAnte\u00a0un\u00a0determinado \u00a0genotipo\u00a0el\u00a0sistema\u00a0busca\u00a0todos\u00a0los\u00a0genotipos \u00a0coincidentes \u00a0en\u00a0la\u00a0\nbase\u00a0de\u00a0datos\u00a0\u00a0y\u00a0calcula\u00a0el\u00a0fenotipo\u00a0medio\u00a0de\u00a0estos\u00a0pacientes. \u00a0En\u00a0una\u00a0modificaci\u00f3n \u00a0\nreciente\u00a0(VircoType\u00ae) \u00a0se\u00a0a\u00f1ade\u00a0informaci\u00f3n \u00a0de\u00a0predicci\u00f3n \u00a0de\u00a0la\u00a0respuesta: \u00a0proporci\u00f3n \u00a0\nde\u00a0pacientes \u00a0con\u00a0respuesta \u00a0m\u00e1xima\u00a0o\u00a0reducida\u00a0y\u00a0ausencia\u00a0de\u00a0respuesta \u00a0(puntos\u00a0de\u00a0\ncorte\u00a0cl\u00ednicos).\u00a0Se\u00a0ha\u00a0demostrado \u00a0que\u00a0existe\u00a0una\u00a0buena\u00a0correlaci\u00f3n \u00a0entre\u00a0ambos\u00a0\nm\u00e9todos78,\u00a079\u00a0sobre\u00a0todo\u00a0con\u00a0los\u00a0NN\u00a0y\u00a0menos\u00a0con\u00a0los\u00a0AN.\u00a0La\u00a0correlaci\u00f3n \u00a0es\u00a0bastante\u00a0\nm\u00e1s\u00a0deficiente \u00a0en\u00a0pacientes \u00a0multitratados. \u00a0\u00a0\nNumerosos \u00a0trabajos\u00a0han\u00a0estudiado, \u00a0en\u00a0pa\u00edses\u00a0desarrollados, \u00a0la\u00a0prevalencia \u00a0de\u00a0resisten\u2010\ncias\u00a0primarias \u00a0en\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0aguda\u00a0o\u00a0cr\u00f3nica.\u00a0Se\u00a0sabe\u00a0que\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0\nlas\u00a0mutaciones \u00a0puede\u00a0detectarse \u00a0durante\u00a0a\u00f1os\u00a0y\u00a0que\u00a0su\u00a0prevalencia \u00a0ha\u00a0aumentado \u00a0\nllegando\u00a0a\u00a0superar\u00a0el\u00a010%\u00a080\u201082.\u00a0En\u00a0Espa\u00f1a\u00a0en\u00a0un\u00a0estudio\u00a0multic\u00e9ntrico \u00a0de\u00a0pacientes \u00a0con\u00a0\ninfecci\u00f3n\u00a0reciente\u00a0se\u00a0encontr\u00f3\u00a0que\u00a0el\u00a014%\u00a0de\u00a0las\u00a0cepas\u00a0ten\u00eda\u00a0mutaciones \u00a0primarias83,\u00a0\npero\u00a0datos\u00a0m\u00e1s\u00a0recientes\u00a0muestran \u00a0una\u00a0reducci\u00f3n \u00a0de\u00a0la\u00a0prevalencia \u00a0en\u00a0los\u00a0diagn\u00f3sticos \u00a0\nnuevos\u00a0a\u00a010%84,\u00a085.\u00a0Por\u00a0ello\u00a0se\u00a0debe\u00a0realizar\u00a0una\u00a0prueba\u00a0genot\u00edpica \u00a0en\u00a0el\u00a0momento \u00a0del\u00a0\ndiagn\u00f3stico. \u00a0Un\u00a0estudio\u00a0coste\u2010eficacia\u00a0relativo\u00a0a\u00a0la\u00a0ventaja\u00a0de\u00a0efectuar\u00a0la\u00a0prueba\u00a0ge\u2010\nnot\u00edpica\u00a0a\u00a0todos\u00a0los\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0cr\u00f3nica\u00a0antes\u00a0de\u00a0iniciar\u00a0el\u00a0TARV,\u00a0ha\u00a0demos\u2010\ntrado\u00a0que\u00a0la\u00a0misma\u00a0es\u00a0coste\u2010eficaz\u00a0a\u00a0la\u00a0hora\u00a0de\u00a0preservar \u00a0f\u00e1rmacos\u00a0y\u00a0que,\u00a0por\u00a0tanto,\u00a0\ndeber\u00eda\u00a0incluirse\u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0habitual86,\u00a087.\u00a0Se\u00a0deber\u00eda\u00a0considerar \u00a0repetir\u00a0el\u00a0genotipa\u2010\ndo\u00a0antes\u00a0de\u00a0iniciar\u00a0el\u00a0TARV\u00a0en\u00a0caso\u00a0de\u00a0diferir\u00a0\u00e9ste\u00a0por\u00a0la\u00a0posibilidad \u00a0de\u00a0haber\u00a0sufrido\u00a0\nuna\u00a0reinfecci\u00f3n. \u00a0\nEn\u00a0Espa\u00f1a\u00a0se\u00a0est\u00e1\u00a0llevando\u00a0a\u00a0cabo\u00a0una\u00a0recogida\u00a0de\u00a0informaci\u00f3n \u00a0sobre\u00a0mutaciones \u00a0de\u00a0\nresistencia \u00a0en\u00a0pacientes \u00a0en\u00a0fracaso\u00a0virol\u00f3gico \u00a0atendidos \u00a0en\u00a0diferentes \u00a0centros\u00a0hospita\u2010\nlarios\u00a0espa\u00f1oles \u00a0integrados \u00a0en\u00a0la\u00a0Plataforma \u00a0de\u00a0Resistencias \u00a0de\u00a0la\u00a0Red\u00a0Espa\u00f1ola\u00a0de\u00a0\nInvestigaci\u00f3n \u00a0en\u00a0Sida\u00a0(RIS).\u00a0Pr\u00f3ximamente \u00a0estar\u00e1\u00a0disponible \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0su\u00a0portal\u00a0\nelectr\u00f3nico*\u00a0y\u00a0permitir\u00e1 \u00a0el\u00a0acceso\u00a0a\u00a0un\u00a0sistema\u00a0de\u00a0interpretaci\u00f3n \u00a0en\u00a0tiempo\u00a0real\u00a0de\u00a0los\u00a0\ngenotipos \u00a0de\u00a0resistencia \u00a0seg\u00fan\u00a0los\u00a0criterios\u00a0de\u00a0la\u00a0RIS.\u00a0\nNo\u00a0se\u00a0conoce\u00a0la\u00a0utilidad\u00a0de\u00a0la\u00a0detecci\u00f3n \u00a0de\u00a0poblaciones \u00a0minoritarias \u00a0que\u00a0se\u00a0escapan\u00a0al\u00a0\nestudio\u00a0genot\u00edpico \u00a0convencional88\u201095.\u00a0\n\u00a0\n                                                           \n* http://www.retic-ris.net/default _principal.asp?idx=&cidioma=2) Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 16 \n Significado \u00a0cl\u00ednico\u00a0de\u00a0las\u00a0resistencias \u00a0del\u00a0VIH\u00a0a\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0\nCon\u00a0el\u00a0uso\u00a0de\u00a0la\u00a0CVP\u00a0en\u00a0el\u00a0seguimiento \u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0se\u00a0ha\u00a0\nevidenciado \u00a0la\u00a0relaci\u00f3n\u00a0entre\u00a0aparici\u00f3n \u00a0de\u00a0mutaciones \u00a0de\u00a0resistencias \u00a0y\u00a0fracaso\u00a0virol\u00f3\u2010\ngico.\u00a0Sin\u00a0embargo\u00a0este\u00a0fen\u00f3meno \u00a0no\u00a0es\u00a0homog\u00e9neo \u00a0para\u00a0todos\u00a0los\u00a0f\u00e1rmacos \u00a0ya\u00a0que\u00a0es\u00a0\nmuy\u00a0claro\u00a0en\u00a0los\u00a0AN\u00a0y\u00a0NN\u00a0pero\u00a0existen\u00a0datos\u00a0contradictorios \u00a0con\u00a0los\u00a0IP\u00a0con\u00a0los\u00a0que\u00a0se\u00a0\nha\u00a0constatado \u00a0fracaso\u00a0virol\u00f3gico \u00a0sin\u00a0evidencia \u00a0de\u00a0resistencias96.\u00a0En\u00a0este\u00a0sentido\u00a0se\u00a0ha\u00a0\ndefinido\u00a0el\u00a0fen\u00f3meno \u00a0de\u00a0resistencia \u00a0celular\u00a0ya\u00a0que\u00a0se\u00a0han\u00a0detectado \u00a0la\u00a0existencia \u00a0de\u00a0\nbombas\u00a0de\u00a0expulsi\u00f3n \u00a0de\u00a0los\u00a0FAR\u00a0en\u00a0la\u00a0membrana \u00a0de\u00a0los\u00a0linfocitos\u00a0y\u00a0otras\u00a0c\u00e9lulas.\u00a0Se\u00a0\nhan\u00a0descrito\u00a0el\u00a0MDRP\u20101\u00a0(glicoprote\u00edna \u2010P)\u00a0para\u00a0los\u00a0IP\u00a0y\u00a0la\u00a0MDRP\u20104\u00a0para\u00a0los\u00a0AN97.\u00a0Se\u00a0des\u2010\nconoce\u00a0la\u00a0relevancia \u00a0cl\u00ednica\u00a0de\u00a0estos\u00a0hallazgos. \u00a0\nLos\u00a0estudios\u00a0prospectivos \u00a0y\u00a0aleatorizados \u00a0que\u00a0han\u00a0utilizado\u00a0las\u00a0pruebas\u00a0de\u00a0resistencias \u00a0\npara\u00a0el\u00a0manejo\u00a0del\u00a0fracaso\u00a0virol\u00f3gico \u00a0comparan \u00a0la\u00a0eficacia\u00a0del\u00a0cambio\u00a0de\u00a0TARV\u00a0cuando\u00a0\nse\u00a0realiza\u00a0seg\u00fan\u00a0las\u00a0distintas\u00a0pruebas\u00a0de\u00a0resistencia \u00a0(genotipo, \u00a0fenotipo\u00a0o\u00a0fenotipo\u00a0vir\u2010\ntual)\u00a0con\u00a0o\u00a0sin\u00a0consejo\u00a0de\u00a0expertos\u00a0o\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0historia\u00a0terap\u00e9utica \u00a0previa\u00a0y/o\u00a0la\u00a0\nexperiencia \u00a0cl\u00ednica\u00a0de\u00a0los\u00a0m\u00e9dicos98\u2010106.\u00a0Un\u00a0metaan\u00e1lisis \u00a0de\u00a0los\u00a0primeros\u00a0estudios\u00a0co\u2010\nmunicados \u00a0puso\u00a0de\u00a0manifiesto \u00a0que\u00a0el\u00a0uso\u00a0del\u00a0genotipo\u00a0para\u00a0dise\u00f1ar\u00a0el\u00a0TARV\u00a0de\u00a0rescate\u00a0\nfrente\u00a0al\u00a0est\u00e1ndar\u00a0(historia\u00a0terap\u00e9utica \u00a0y\u00a0experiencia \u00a0del\u00a0m\u00e9dico)\u00a0se\u00a0asociaba\u00a0con\u00a0un\u00a0\ncontrol\u00a0virol\u00f3gico \u00a0significativamente \u00a0mayor\u00a0a\u00a0los\u00a03\u00a0y\u00a06\u00a0meses107.\u00a0Estas\u00a0diferencias \u00a0no\u00a0se\u00a0\nobservaron \u00a0en\u00a0los\u00a0estudios\u00a0que\u00a0compararon \u00a0los\u00a0m\u00e9todos\u00a0fenot\u00edpicos \u00a0frente\u00a0al\u00a0manejo\u00a0\nest\u00e1ndar107.\u00a0Por\u00a0otro\u00a0lado,\u00a0no\u00a0se\u00a0han\u00a0detectado \u00a0diferencias \u00a0cuando\u00a0se\u00a0han\u00a0comparado \u00a0\nel\u00a0fenotipo\u00a0virtual\u00a0y\u00a0el\u00a0fenotipo\u00a0real105,\u00a0106.\u00a0Se\u00a0requieren \u00a0pues\u00a0m\u00e1s\u00a0datos\u00a0para\u00a0aclarar\u00a0el\u00a0\npapel\u00a0de\u00a0las\u00a0pruebas\u00a0fenot\u00edpicas \u00a0para\u00a0guiar\u00a0el\u00a0TARV.\u00a0\nResistencias \u00a0a\u00a0los\u00a0FAR.\u00a0Recomendaciones \u00a0\n\u0083 Se\u00a0deben\u00a0estudiar\u00a0las\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0ya\u00a0que\u00a0su\u00a0conocimiento \u00a0permite\u00a0\nun\u00a0mejor\u00a0uso\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0(nivel\u00a0A)\u00a0\n\u0083 Se\u00a0considera \u00a0indicada\u00a0la\u00a0realizaci\u00f3n \u00a0de\u00a0las\u00a0t\u00e9cnicas\u00a0genot\u00edpicas \u00a0de\u00a0detecci\u00f3n \u00a0de\u00a0\nresistencias \u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0asistencial \u00a0en\u00a0las\u00a0situaciones \u00a0expuestas \u00a0en\u00a0la\u00a0Tabla\u00a02\u00a0(Ni\u2010\nvel\u00a0B).\u00a0\n\u00a0\n2.5.\u00a0Determinaci\u00f3n \u00a0del\u00a0HLA\u00a0B*5701\u00a0\nLa\u00a0reacci\u00f3n\u00a0de\u00a0hipersensibilidad \u00a0(RHS)\u00a0a\u00a0ABC\u00a0es\u00a0un\u00a0s\u00edndrome \u00a0multiorg\u00e1nico \u00a0que\u00a0se\u00a0ma\u2010\nnifiesta\u00a0con\u00a0una\u00a0combinaci\u00f3n \u00a0variable\u00a0de\u00a0fiebre,\u00a0mialgias,\u00a0s\u00edntomas\u00a0respiratorios \u00a0y\u00a0gas\u2010\ntrointestinales \u00a0y\u00a0un\u00a0exantema \u00a0de\u00a0intensidad \u00a0creciente, \u00a0pudiendo \u00a0ser\u00a0fatal\u00a0en\u00a0caso\u00a0de\u00a0\ncontinuar \u00a0con\u00a0el\u00a0f\u00e1rmaco\u00a0o\u00a0reintroducirlo. \u00a0\u00a0Suele\u00a0aparecer\u00a0durante\u00a0las\u00a0primeras\u00a06\u00a0se\u2010\nmanas\u00a0de\u00a0tratamiento, \u00a0se\u00a0presenta\u00a0en\u00a0el\u00a05\u20108%\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0toman\u00a0ABC\u00a0y\u00a0es\u00a0la\u00a0\ncausa\u00a0m\u00e1s\u00a0frecuente \u00a0de\u00a0sus\u00a0discontinuaci\u00f3n108.\u00a0Se\u00a0sabe\u00a0que\u00a0la\u00a0RHS\u00a0es\u00a0m\u00e1s\u00a0frecuente \u00a0en\u00a0\nla\u00a0poblaci\u00f3n \u00a0blanca\u00a0y\u00a0se\u00a0dispone\u00a0de\u00a0una\u00a0prueba\u00a0cut\u00e1nea\u00a0(parche)\u00a0para\u00a0su\u00a0confirmaci\u00f3n. \u00a0\nEstudios\u00a0farmacogen\u00e9ticos \u00a0han\u00a0identificado \u00a0que\u00a0la\u00a0RHS\u00a0ocurre\u00a0en\u00a0las\u00a0personas\u00a0porta\u2010\ndoras\u00a0del\u00a0alelo\u00a0HLA\u00a0B*5701.\u00a0En\u00a0un\u00a0ensayo\u00a0(PREDICT) \u00a0en\u00a0el\u00a0que\u00a0los\u00a0pacientes \u00a0se\u00a0aleato\u2010\nrizaron\u00a0a\u00a0comenzar \u00a0TARV\u00a0con\u00a0ABC\u00a0o\u00a0comenzarlo \u00a0s\u00f3lo\u00a0si\u00a0el\u00a0HLA*5701 \u00a0era\u00a0negativo, \u00a0se\u00a0\nvalor\u00f3\u00a0la\u00a0RHS\u00a0por\u00a0datos\u00a0cl\u00ednicos\u00a0que\u00a0se\u00a0confirmaron \u00a0con\u00a0una\u00a0prueba\u00a0cut\u00e1nea\u00a0(confir\u2010\nmaci\u00f3n\u00a0inmunol\u00f3gica). \u00a0La\u00a0prevalencia \u00a0del\u00a0HLA\u00a0B*5701\u00a0en\u00a0esta\u00a0cohorte\u00a0era\u00a0del\u00a05,6%.\u00a0La\u00a0\ngenotipificaci\u00f3n \u00a0del\u00a0HLA\u00a0B*5701\u00a0redujo\u00a0la\u00a0incidencia \u00a0de\u00a0sospecha \u00a0cl\u00ednica\u00a0de\u00a0RHS\u00a0(3,4%\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 17 \n frente\u00a07,8%)\u00a0y\u00a0la\u00a0inmunol\u00f3gica \u00a0(0%\u00a0frente\u00a0a\u00a02,7%)\u00a0siendo\u00a0el\u00a0valor\u00a0predictivo \u00a0negativo\u00a0\nde\u00a0esta\u00a0prueba\u00a0del\u00a0100%109.\u00a0Se\u00a0ha\u00a0validado\u00a0esta\u00a0prueba\u00a0en\u00a0poblaci\u00f3n \u00a0negra\u00a0confirman \u2010\ndo\u00a0los\u00a0resultados110.\u00a0\nEl\u00a0ABC\u00a0no\u00a0debe\u00a0utilizarse\u00a0en\u00a0personas\u00a0portadores \u00a0del\u00a0alelo\u00a0HLA\u00a0B*5701.\u00a0Si\u00a0el\u00a0HLA\u00a0\nB*5701\u00a0es\u00a0negativo\u00a0no\u00a0se\u00a0descarta\u00a0la\u00a0posibilidad \u00a0de\u00a0RHS\u00a0y\u00a0debe\u00a0informarse \u00a0y\u00a0controlar\u00a0\nestos\u00a0pacientes \u00a0respecto\u00a0a\u00a0la\u00a0RHS\u00a0cuando\u00a0se\u00a0inicia\u00a0tratamiento \u00a0con\u00a0ABC.\u00a0\n\u00a0\nHLA\u00a0B*5701.\u00a0Recomendaciones \u00a0\n\u0083 Se\u00a0deben\u00a0determinar \u00a0el\u00a0HLA\u00a0B*5701\u00a0a\u00a0todos\u00a0los\u00a0pacientes \u00a0en\u00a0el\u00a0momento \u00a0del\u00a0dia\u2010\ngn\u00f3stico\u00a0o\u00a0cuando\u00a0vayan\u00a0a\u00a0comenzar \u00a0TARV\u00a0con\u00a0ABC\u00a0(Nivel\u00a0A)\u00a0\n\u0083 Si\u00a0el\u00a0HLA\u00a0B*5701\u00a0es\u00a0positivo\u00a0no\u00a0se\u00a0debe\u00a0prescribir \u00a0ABC\u00a0(Nivel\u00a0A)\u00a0\n\u0083 Si\u00a0se\u00a0prescribe \u00a0ABC\u00a0sin\u00a0conocer\u00a0el\u00a0HLA\u00a0B*5701,\u00a0debe\u00a0informarse \u00a0al\u00a0paciente\u00a0y\u00a0estar\u00a0\nalerta\u00a0para\u00a0detectar\u00a0s\u00edntomas\u00a0de\u00a0la\u00a0RHS\u00a0(Nivel\u00a0C)\u00a0\n\u00a0\n2.6.\u00a0Determinaci\u00f3n \u00a0del\u00a0tropismo \u00a0del\u00a0VIH\u00a0\nEl\u00a0VIH\u00a0entra\u00a0en\u00a0la\u00a0c\u00e9lula\u00a0diana\u00a0por\u00a0un\u00a0mecanismo \u00a0que\u00a0incluye\u00a0el\u00a0reconocimiento \u00a0del\u00a0\nreceptor\u00a0CD4,\u00a0seguido\u00a0de\u00a0la\u00a0uni\u00f3n\u00a0a\u00a0uno\u00a0de\u00a0los\u00a0correceptores \u00a0CCR5\u00a0o\u00a0CXCR4\u00a0y\u00a0a\u00a0conti\u2010\nnuaci\u00f3n\u00a0se\u00a0produce\u00a0la\u00a0fusi\u00f3n\u00a0de\u00a0las\u00a0membranas \u00a0con\u00a0paso\u00a0del\u00a0ARN\u00a0del\u00a0VIH\u00a0a\u00a0la\u00a0c\u00e9lula\u00a0\ninvadida.\u00a0Los\u00a0antagonistas \u00a0del\u00a0CCR5\u00a0(MVC,\u00a0vicriviroc) \u00a0son\u00a0f\u00e1rmacos \u00a0que\u00a0bloquean \u00a0este\u00a0\nreceptor\u00a0impidiendo \u00a0la\u00a0entrada\u00a0del\u00a0VIH\u00a0en\u00a0la\u00a0c\u00e9lula111.\u00a0\nTras\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0pacientes \u00a0albergan\u00a0virus\u00a0que\u00a0usan\u00a0el\u00a0co\u2010\nrreceptor \u00a0CCR5\u00a0(R5).\u00a0En\u00a0caso\u00a0de\u00a0no\u00a0llevar\u00a0tratamiento \u00a0el\u00a0virus\u00a0evoluciona \u00a0a\u00a0cepas\u00a0que,\u00a0\nen\u00a0mayor\u00a0o\u00a0menor\u00a0proporci\u00f3n, \u00a0utilizan\u00a0el\u00a0correceptor \u00a0CXCR4\u00a0(X4),\u00a0pudiendo \u00a0encontrar \u00a0\nigualmente \u00a0cepas\u00a0duales\u00a0o\u00a0mixtas\u00a0(D/M)\u00a0que\u00a0pueden\u00a0usar\u00a0ambos\u00a0correceptores. \u00a0Este\u00a0\ncambio\u00a0se\u00a0relaciona\u00a0con\u00a0un\u00a0descenso \u00a0de\u00a0CD4\u00a0y\u00a0aumento\u00a0de\u00a0la\u00a0inmunodepresi\u00f3n \u00a0ya\u00a0que\u00a0\nse\u00a0consideran \u00a0m\u00e1s\u00a0patog\u00e9nicas112.\u00a0En\u00a0los\u00a0pacientes \u00a0multitratados \u00a0con\u00a0CVP\u00a0detectable \u00a0\nlas\u00a0cepas\u00a0X4\u00a0o\u00a0D/M\u00a0son\u00a0m\u00e1s\u00a0prevalentes, \u00a0pudiendo \u00a0llegar\u00a0a\u00a0superar\u00a0el\u00a050%\u00a0en\u00a0caso\u00a0de\u00a0\nCD4\u00a0<100\u00a0c\u00e9lulas/\u00b5L113,\u00a0114.\u00a0\nActualmente \u00a0existe\u00a0una\u00a0t\u00e9cnica\u00a0fenot\u00edpica \u00a0para\u00a0la\u00a0detecci\u00f3n \u00a0del\u00a0tropismo\u00a0(TrofileTM,\u00a0\nMonogram \u00a0Biosciences, \u00a0USA)\u00a0que\u00a0se\u00a0realiza\u00a0en\u00a0un\u00a0solo\u00a0centro\u00a0(California, \u00a0USA)\u00a0y\u00a0que\u00a0\nllega\u00a0a\u00a0detectar\u00a0la\u00a0poblaci\u00f3n \u00a0X4\u00a0o\u00a0D/M\u00a0cuya\u00a0proporci\u00f3n \u00a0supere\u00a0el\u00a00.3%\u00a0en\u00a0una\u00a0CVP\u00a0\n\u22651000\u00a0copias/mL \u00a0(prueba\u00a0ultrasensible)115,\u00a0116.\u00a0Existen\u00a0t\u00e9cnicas\u00a0genot\u00edpicas \u00a0de\u00a0detec\u2010\nci\u00f3n\u00a0de\u00a0tropismo\u00a0(actualmente \u00a0no\u00a0comercializadas) \u00a0en\u00a0las\u00a0que\u00a0se\u00a0efect\u00faa\u00a0\u00a0la\u00a0secuencia \u2010\nci\u00f3n\u00a0de\u00a0la\u00a0regi\u00f3n\u00a0V3\u00a0de\u00a0gp120\u00a0(semejante \u00a0a\u00a0la\u00a0realizaci\u00f3n \u00a0de\u00a0un\u00a0test\u00a0de\u00a0resistencias \u00a0\ngenot\u00edpico) \u00a0y\u00a0posteriormente \u00a0al\u00a0resultado \u00a0se\u00a0le\u00a0aplica\u00a0alguna\u00a0de\u00a0las\u00a0reglas\u00a0de\u00a0interpre\u2010\ntaci\u00f3n\u00a0disponibles \u00a0en\u00a0la\u00a0Web\u2020.\u00a0En\u00a0Espa\u00f1a,\u00a0en\u00a0la\u00a0misma\u00a0Web\u00a0de\u00a0resistencias \u00a0de\u00a0la\u00a0Red\u00a0\nde\u00a0Investigaci\u00f3n \u00a0en\u00a0Sida\u00a0se\u00a0podr\u00e1\u00a0interpretar \u00a0el\u00a0resultado \u00a0de\u00a0esta\u00a0secuenciaci\u00f3n. \u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\n                                                           \n\u2020 http://ubik.microbiol.washington.edu/computing/pssm/ . Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 18 \n Tropismo \u00a0viral.\u00a0Recomendaci\u00f3n \u00a0\n\u0083 Se\u00a0recomienda \u00a0siempre\u00a0la\u00a0realizaci\u00f3n \u00a0de\u00a0una\u00a0prueba\u00a0de\u00a0tropismo\u00a0(fenot\u00edpico \u00a0o\u00a0ge\u2010\nnot\u00edpico)\u00a0antes\u00a0de\u00a0iniciar\u00a0el\u00a0tratamiento \u00a0con\u00a0un\u00a0f\u00e1rmaco\u00a0antagonista \u00a0del\u00a0receptor\u00a0\nCCR5\u00a0(nivel\u00a0A)\u00a0\n\u00a0\u00a0\n\u00a0\n3.\u00a0INFECCI\u00d3N \u00a0AGUDA\u00a0POR\u00a0VIH\u00a0\nLa\u00a0primoinfecci\u00f3n \u00a0por\u00a0el\u00a0VIH\u00a0es\u00a0sintom\u00e1tica \u00a0en\u00a0m\u00e1s\u00a0de\u00a0la\u00a0mitad\u00a0de\u00a0los\u00a0casos,\u00a0pero\u00a0pue\u2010\nde\u00a0pasar\u00a0desapercibida \u00a0ya\u00a0que\u00a0sus\u00a0s\u00edntomas\u00a0son\u00a0los\u00a0de\u00a0una\u00a0virosis\u00a0com\u00fan117\u2010121.\u00a0El\u00a0cua\u2010\ndro\u00a0cl\u00ednico\u00a0es\u00a0similar\u00a0a\u00a0la\u00a0mononucleosis \u00a0o\u00a0a\u00a0una\u00a0meningoencefalitis \u00a0viral121.\u00a0Los\u00a0s\u00ednto\u2010\nmas\u00a0y\u00a0signos\u00a0m\u00e1s\u00a0comunes\u00a0son\u00a0fiebre,\u00a0adenopat\u00edas, \u00a0mialgias,\u00a0exantema, \u00a0sudoraci\u00f3n \u00a0\nnocturna\u00a0y\u00a0artralgias122.\u00a0Debe\u00a0\u00a0sospecharse \u00a0en\u00a0toda\u00a0persona\u00a0con\u00a0conducta \u00a0de\u00a0riesgo\u00a0y\u00a0\ns\u00edntomas\u00a0compatibles. \u00a0Las\u00a0determinaciones \u00a0necesarias \u00a0para\u00a0el\u00a0diagn\u00f3stico \u00a0difieren\u00a0de\u00a0\nla\u00a0infecci\u00f3n\u00a0cr\u00f3nica.\u00a0Como\u00a0en\u00a0esta\u00a0fase\u00a0todav\u00eda\u00a0no\u00a0hay\u00a0anticuerpos \u00a0(per\u00edodo\u00a0ventana)\u00a0\ndebe\u00a0determinarse \u00a0la\u00a0CVP123\u00a0que\u00a0se\u00a0detecta\u00a0a\u00a0partir\u00a0de\u00a0la\u00a0primera\u00a0semana,\u00a0precede\u00a0a\u00a0\nlos\u00a0s\u00edntomas\u00a0y\u00a0tiene\u00a0una\u00a0sensibilidad \u00a0y\u00a0una\u00a0especificidad \u00a0del\u00a0100%\u00a0y\u00a0del\u00a097%\u00a0respecti\u2010\nvamente. \u00a0La\u00a0CVP\u00a0suele\u00a0estar\u00a0muy\u00a0elevada\u00a0(>6\u00a0log 10)\u00a0en\u00a0la\u00a0infecci\u00f3n\u00a0aguda\u00a0y\u00a0se\u00a0relaciona\u00a0\ncon\u00a0la\u00a0intensidad \u00a0de\u00a0las\u00a0manifestaciones \u00a0cl\u00ednicas.\u00a0La\u00a0seroconversi\u00f3n \u00a0se\u00a0detecta\u00a01\u20102\u00a0se\u2010\nmanas\u00a0m\u00e1s\u00a0tarde122.\u00a0La\u00a0t\u00e9cnica\u00a0de\u00a0Western\u00a0blot\u00a0con\u00a0la\u00a0que\u00a0se\u00a0confirma\u00a0el\u00a0diagn\u00f3stico \u00a0\npuede\u00a0ser\u00a0negativa\u00a0o\u00a0indeterminada \u00a0y\u00a0deber\u00e1\u00a0repetirse\u00a0unas\u00a0semanas\u00a0despu\u00e9s\u00a0del\u00a0co\u2010\nmienzo\u00a0de\u00a0los\u00a0s\u00edntomas\u00a0para\u00a0confirmar \u00a0su\u00a0positivizaci\u00f3n. \u00a0El\u00a0t\u00e9rmino\u00a0infecci\u00f3n\u00a0aguda\u00a0\n(diagn\u00f3stico \u00a0antes\u00a0de\u00a0la\u00a0seroconversi\u00f3n) \u00a0no\u00a0debe\u00a0confundirse \u00a0con\u00a0infecci\u00f3n\u00a0reciente\u00a0\nque\u00a0es\u00a0la\u00a0que\u00a0tiene\u00a0menos\u00a0de\u00a0seis\u00a0meses\u00a0de\u00a0evoluci\u00f3n121.\u00a0\u00a0\nDesde\u00a0la\u00a0descripci\u00f3n \u00a0de\u00a0los\u00a0primeros\u00a0casos\u00a0de\u00a0infecci\u00f3n\u00a0aguda\u00a0se\u00a0sabe\u00a0que\u00a0la\u00a0progre\u2010\nsi\u00f3n\u00a0a\u00a0sida\u00a0es\u00a0m\u00e1s\u00a0r\u00e1pida\u00a0en\u00a0los\u00a0pacientes \u00a0sintom\u00e1ticos. \u00a0En\u00a0estudios\u00a0de\u00a0cohortes\u00a0que\u00a0\nhan\u00a0analizado \u00a0la\u00a0historia\u00a0natural\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0VIH\u00a0se\u00a0ha\u00a0evidenciado \u00a0que\u00a0la\u00a0progre\u2010\nsi\u00f3n\u00a0a\u00a0sida\u00a0o\u00a0muerte\u00a0se\u00a0asociaba\u00a0a\u00a0factores\u00a0iniciales\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0como\u00a0la\u00a0gravedad \u00a0\nde\u00a0la\u00a0sintomatolog\u00eda \u00a0en\u00a0la\u00a0infecci\u00f3n\u00a0aguda124\u00a0(mayor\u00a0riesgo\u00a0a\u00a0mayor\u00a0n\u00famero\u00a0de\u00a0s\u00ednto\u2010\nmas),\u00a0descenso \u00a0inicial\u00a0de\u00a0CD4\u00a0(mayor\u00a0riesgo\u00a0si\u00a0<500)125,\u00a0nivel\u00a0de\u00a0CVP\u00a0a\u00a0partir\u00a0del\u00a04\u00ba\u00a0mes\u00a0\n(mayor\u00a0progresi\u00f3n \u00a0si\u00a0setpoint\u00a0>100\u00a0000\u00a0copias/mL)124,\u00a0y\u00a0al\u00a0ADN\u00a0proviral\u00a0inicial\u00a0(mayor\u00a0\nprogresi\u00f3n \u00a0si\u00a0es\u00a0>3,4\u00a0log 10\u00a0copias/mill\u00f3n \u00a0de\u00a0c\u00e9lulas\u00a0mononucleares \u00a0en\u00a0sangre\u00a0perif\u00e9ri\u2010\nca)125.\u00a0\u00a0\nEl\u00a0TARV\u00a0en\u00a0la\u00a0infecci\u00f3n\u00a0aguda\u00a0puede\u00a0tener\u00a0ventajas\u00a0e\u00a0inconvenientes121,\u00a0126.\u00a0Ventajas\u00a0\nte\u00f3ricas\u00a0ser\u00edan\u00a0acortar\u00a0la\u00a0duraci\u00f3n\u00a0de\u00a0los\u00a0s\u00edntomas, \u00a0suprimir\u00a0la\u00a0replicaci\u00f3n \u00a0viral,\u00a0reducir\u00a0\nel\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0del\u00a0VIH\u00a0(muy\u00a0elevado\u00a0en\u00a0la\u00a0infecci\u00f3n\u00a0aguda)118,\u00a0reducir\u00a0la\u00a0di\u2010\nversidad\u00a0viral\u00a0y\u00a0el\u00a0n\u00famero\u00a0de\u00a0c\u00e9lulas\u00a0infectadas \u00a0(reservorio) \u00a0\u00a0y\u00a0preservar \u00a0o\u00a0restaurar \u00a0el\u00a0\nsistema\u00a0inmunitario \u00a0y\u00a0la\u00a0inmunidad \u00a0espec\u00edfica \u00a0frente\u00a0al\u00a0VIH,\u00a0tanto\u00a0proliferativa \u00a0(media\u2010\nda\u00a0por\u00a0los\u00a0linfocitos\u00a0CD4)\u00a0como\u00a0citot\u00f3xica \u00a0(mediada \u00a0por\u00a0los\u00a0linfocitos\u00a0CD8+)117,\u00a0127\u2010131,\u00a0lo\u00a0\nque\u00a0podr\u00eda\u00a0permitir\u00a0el\u00a0control\u00a0inmunol\u00f3gico \u00a0de\u00a0la\u00a0replicaci\u00f3n \u00a0viral,\u00a0modificar \u00a0la\u00a0historia\u00a0\nnatural,\u00a0disminuir \u00a0el\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0y\u00a0mejorar\u00a0el\u00a0pron\u00f3stico \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0\nVIH.\u00a0Por\u00a0el\u00a0contrario, \u00a0la\u00a0principal\u00a0desventaja \u00a0del\u00a0TARV\u00a0en\u00a0la\u00a0fase\u00a0aguda\u00a0es\u00a0su\u00a0duraci\u00f3n\u00a0\nindefinida \u00a0(ya\u00a0que\u00a0con\u00a0las\u00a0pautas\u00a0de\u00a0TARV\u00a0que\u00a0hasta\u00a0ahora\u00a0se\u00a0han\u00a0utilizado\u00a0no\u00a0se\u00a0erra\u2010\ndica\u00a0la\u00a0infecci\u00f3n117,\u00a0\u00a0ni\u00a0se\u00a0restaura\u00a0el\u00a0tejido\u00a0linf\u00e1tico\u00a0asociado\u00a0a\u00a0mucosas\u00a0(GALT)132)\u00a0y\u00a0el\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 19 \n riesgo\u00a0de\u00a0efectos\u00a0secundarios \u00a0o\u00a0desarrollo \u00a0de\u00a0resistencias, \u00a0as\u00ed\u00a0como\u00a0el\u00a0tratamiento \u00a0\ninnecesario \u00a0de\u00a0los\u00a0posibles\u00a0no\u00a0progresores. \u00a0\nEn\u00a0la\u00a0actualidad \u00a0el\u00a0inicio\u00a0del\u00a0TARV\u00a0durante\u00a0la\u00a0infecci\u00f3n\u00a0aguda\u00a0es\u00a0controvertido133,\u00a0134.\u00a0\nLa\u00a0informaci\u00f3n \u00a0disponible \u00a0se\u00a0ha\u00a0obtenido\u00a0de\u00a0series\u00a0peque\u00f1as, \u00a0generalmente \u00a0sin\u00a0grupo\u00a0\ncontrol,\u00a0en\u00a0pa\u00edses\u00a0desarrollados, \u00a0con\u00a0pacientes \u00a0infectados \u00a0por\u00a0el\u00a0subtipo\u00a0B\u00a0y\u00a0con\u00a0pautas\u00a0\nde\u00a0TARV\u00a0similares\u00a0a\u00a0las\u00a0utilizadas \u00a0en\u00a0la\u00a0infecci\u00f3n\u00a0cr\u00f3nica.\u00a0No\u00a0hay\u00a0estudios\u00a0publicados \u00a0\nque\u00a0hayan\u00a0evaluado\u00a0si\u00a0otras\u00a0pautas\u00a0(TARV\u00a0con\u00a0inhibidores \u00a0de\u00a0la\u00a0entrada\u00a0y/o\u00a0de\u00a0la\u00a0inte\u2010\ngrasa)\u00a0pueden\u00a0ser\u00a0m\u00e1s\u00a0efectivas\u00a0en\u00a0este\u00a0escenario. \u00a0Hasta\u00a0ahora\u00a0no\u00a0se\u00a0ha\u00a0demostrado \u00a0\nun\u00a0beneficio \u00a0cl\u00ednico\u00a0en\u00a0t\u00e9rminos\u00a0de\u00a0reducir\u00a0la\u00a0progresi\u00f3n \u00a0a\u00a0sida\u00a0o\u00a0muerte133,\u00a0aunque\u00a0en\u00a0\nalg\u00fan\u00a0estudio\u00a0se\u00a0ha\u00a0visto\u00a0una\u00a0mejor\u00a0evoluci\u00f3n \u00a0inmunol\u00f3gica \u00a0y\u00a0virol\u00f3gica \u00a0en\u00a0pacientes \u00a0\ntratados135\u2010137.\u00a0\u00a0\nEn\u00a0cualquier \u00a0caso,\u00a0si\u00a0se\u00a0decide\u00a0iniciar\u00a0TARV\u00a0las\u00a0pautas\u00a0recomendadas \u00a0son\u00a0las\u00a0mismas\u00a0\nque\u00a0en\u00a0la\u00a0infecci\u00f3n\u00a0cr\u00f3nica\u00a0y\u00a0la\u00a0respuesta \u00a0virol\u00f3gica \u00a0a\u00a0IP\u00a0o\u00a0NN\u00a0similar136,\u00a0138\u2010140.\u00a0\u00a0Como\u00a0\nen\u00a0la\u00a0infecci\u00f3n\u00a0cr\u00f3nica\u00a0siempre\u00a0debe\u00a0efectuarse \u00a0un\u00a0test\u00a0de\u00a0resistencias, \u00a0se\u00a0vaya\u00a0a\u00a0ini\u2010\nciar\u00a0TARV\u00a0o\u00a0no,\u00a0por\u00a0la\u00a0posibilidad \u00a0de\u00a0transmisi\u00f3n \u00a0de\u00a0cepas\u00a0resistentes. \u00a0En\u00a0pacientes \u00a0con\u00a0\nmultirresistencia \u00a0realizar\u00a0un\u00a0tropismo\u00a0viral\u00a0porque\u00a0se\u00a0han\u00a0descrito\u00a0cepas\u00a0con\u00a0fenotipo\u00a0\ndual\u00a0(R5\u00a0y\u00a0X4)\u00a0y\u00a0una\u00a0r\u00e1pida\u00a0progresi\u00f3n \u00a0a\u00a0sida141\u2010143.\u00a0Dado\u00a0que\u00a0la\u00a0prevalencia \u00a0de\u00a0cepas\u00a0\ncon\u00a0resistencia \u00a0a\u00a0NN\u00a0es\u00a0mayor\u00a0que\u00a0a\u00a0IP\u00a0en\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0aguda\u00a0o\u00a0reciente83,\u00a0\n144,\u00a0si\u00a0se\u00a0decide\u00a0iniciar\u00a0TARV\u00a0y\u00a0todav\u00eda\u00a0no\u00a0est\u00e1\u00a0disponible \u00a0el\u00a0resultado \u00a0del\u00a0estudio\u00a0de\u00a0\nresistencias \u00a0es\u00a0preferible \u00a0comenzar \u00a0con\u00a0una\u00a0pauta\u00a0basada\u00a0en\u00a0IP.\u00a0Se\u00a0ha\u00a0observado \u00a0que\u00a0\nla\u00a0prevalencia \u00a0de\u00a0lipodistrofia \u00a0y\u00a0dislipemia \u00a0asociadas \u00a0al\u00a0TARV\u00a0es\u00a0similar\u00a0a\u00a0la\u00a0de\u00a0los\u00a0pa\u2010\ncientes\u00a0con\u00a0infecci\u00f3n\u00a0cr\u00f3nica145\u2010147.\u00a0\nPara\u00a0evitar\u00a0el\u00a0TARV\u00a0indefinido \u00a0y\u00a0conseguir \u00a0los\u00a0objetivos\u00a0mencionados \u00a0previamente \u00a0se\u00a0\nhan\u00a0planteado \u00a0diversas\u00a0estrategias121,\u00a0126:\u00a01)\u00a0Administrar \u00a0el\u00a0TARV\u00a0durante\u00a0un\u00a0periodo\u00a0\nlimitado\u00a0de\u00a0tiempo;\u00a0\u00a02)\u00a0Administrarlo \u00a0de\u00a0forma\u00a0intermitente, \u00a0a\u00a0fin\u00a0de\u00a0potenciar \u00a0la\u00a0res\u2010\npuesta\u00a0VIH\u2010espec\u00edfica \u00a0y\u00a0controlar\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0sin\u00a0FAR;\u00a03)\u00a0Combinar \u00a0el\u00a0TARV\u00a0con\u00a0\ninmunosupresores \u00a0(hidroxiurea, \u00a0ciclosporina \u00a0A,\u00a0\u00e1cido\u00a0micofen\u00f3lico) \u00a0o\u00a0citoquinas \u00a0(IL\u20102);\u00a0\ny,\u00a04)\u00a0Asociar\u00a0TARV\u00a0y\u00a0vacunas\u00a0terap\u00e9uticas. \u00a0Sin\u00a0embargo, \u00a0ninguna\u00a0de\u00a0estas\u00a0estrategias \u00a0\nha\u00a0conseguido \u00a0que\u00a0el\u00a0sistema\u00a0inmune\u00a0controle\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0de\u00a0forma\u00a0sostenida \u00a0\nen\u00a0ausencia\u00a0de\u00a0TARV,\u00a0por\u00a0lo\u00a0que\u00a0en\u00a0la\u00a0actualidad \u00a0si\u00a0se\u00a0inicia\u00a0el\u00a0tratamiento \u00a0durante\u00a0la\u00a0\ninfecci\u00f3n\u00a0aguda\u00a0probablemente \u00a0se\u00a0deba\u00a0mantener \u00a0de\u00a0forma\u00a0indefinida. \u00a0\nLa\u00a0eficacia\u00a0del\u00a0TARV\u00a0durante\u00a0un\u00a0periodo\u00a0variable\u00a0se\u00a0ha\u00a0evaluado\u00a0en\u00a0estudios\u00a0de\u00a0cohor\u2010\ntes\u00a0en\u00a0los\u00a0que\u00a0se\u00a0han\u00a0comparado \u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0aguda\u00a0o\u00a0reciente\u00a0tratados\u00a0\nfrente\u00a0a\u00a0no\u00a0tratados.\u00a0Los\u00a0resultados \u00a0de\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0estos\u00a0estudios\u00a0no\u00a0han\u00a0conseguido \u00a0\ndemostrar \u00a0un\u00a0beneficio \u00a0cl\u00ednico,\u00a0virol\u00f3gico \u00a0ni\u00a0inmunol\u00f3gico \u00a0a\u00a0las\u00a048\u2010144\u00a0semanas\u00a0de\u00a0\ninterrumpir \u00a0el\u00a0tratamiento, \u00a0mientras\u00a0que\u00a0en\u00a0otros,\u00a0s\u00f3lo\u00a0una\u00a0peque\u00f1a\u00a0proporci\u00f3n \u00a0de\u00a0los\u00a0\npacientes \u00a0tratados\u00a0mostraban \u00a0un\u00a0setpoint\u00a0de\u00a0CVP\u00a0m\u00e1s\u00a0bajo,\u00a0mejores\u00a0cifras\u00a0de\u00a0CD4\u00a0o\u00a0\nmanten\u00edan \u00a0la\u00a0respuesta \u00a0inmunoespec\u00edfica \u00a0frente\u00a0al\u00a0VIH138,\u00a0148\u2010160.\u00a0Habr\u00e1\u00a0que\u00a0esperar\u00a0a\u00a0\nlos\u00a0resultados \u00a0de\u00a0ensayos\u00a0cl\u00ednicos\u00a0aleatorizados \u00a0que\u00a0est\u00e1n\u00a0en\u00a0marcha\u00a0(estudio\u00a0SPAR\u2010\nTAC)\u00a0para\u00a0poder\u00a0valorar\u00a0adecuadamente \u00a0los\u00a0potenciales \u00a0beneficios \u00a0de\u00a0esta\u00a0estrategia \u00a0\nterap\u00e9utica. \u00a0\u00a0\nLa\u00a0administraci\u00f3n \u00a0de\u00a0TARV\u00a0intermitente \u00a0con\u00a0el\u00a0fin\u00a0de\u00a0potenciar \u00a0la\u00a0respuesta \u00a0VIH\u00a0inmu\u2010\nnoespec\u00edfica \u00a0para\u00a0controlar\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0no\u00a0ha\u00a0conseguido \u00a0buenos\u00a0resultados, \u00a0\nsiendo\u00a0testimonial \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0que\u00a0manten\u00eda \u00a0la\u00a0respuesta \u00a0inmune\u00a0y\u00a0el\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 20 \n control\u00a0de\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0sin\u00a0TARV\u00a0a\u00a0las\u00a096\u00a0semanas131,\u00a0161,\u00a0162.\u00a0Adem\u00e1s\u00a0esta\u00a0estra\u2010\ntegia\u00a0de\u00a0interrupci\u00f3n \u00a0estructurada \u00a0no\u00a0est\u00e1\u00a0exenta\u00a0de\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0resistencias163,\u00a0164.\u00a0\u00a0\u00a0\nLa\u00a0estrategia \u00a0de\u00a0asociar\u00a0al\u00a0TARV\u00a0citoquinas \u00a0como\u00a0interfer\u00f3n \u2010pegilado\u00a0o\u00a0IL\u20102,\u00a0a\u00a0fin\u00a0de\u00a0\ndisminuir \u00a0el\u00a0reservorio \u00a0viral\u00a0y\u00a0mejorar\u00a0la\u00a0respuesta \u00a0inmunitaria165\u2010167\u00a0tampoco\u00a0ha\u00a0con\u2010\nseguido\u00a0sus\u00a0objetivos. \u00a0Se\u00a0han\u00a0efectuado \u00a0estudios\u00a0con\u00a0interfer\u00f3n \u00a0pegilado168\u00a0o\u00a0inmuno\u2010\nsupresores \u00a0(hidroxiurea, \u00a0ciclosporina, \u00a0\u00e1cido\u00a0micofen\u00f3lico) \u00a0para\u00a0reducir\u00a0la\u00a0activaci\u00f3n \u00a0del\u00a0\nsistema\u00a0inmune\u00a0y\u00a0controlar\u00a0la\u00a0replicaci\u00f3n \u00a0viral164,\u00a0169\u2010172.\u00a0Algunos\u00a0de\u00a0estos\u00a0estudios\u00a0so\u2010\nlamente\u00a0han\u00a0podido\u00a0demostrar \u00a0mayor\u00a0toxicidad164.\u00a0\u00a0\nFinalmente, \u00a0las\u00a0vacunas\u00a0terap\u00e9uticas \u00a0asociadas \u00a0o\u00a0no\u00a0a\u00a0TARV\u00a0con\u00a0el\u00a0fin\u00a0de\u00a0restaurar \u00a0o\u00a0\npotenciar \u00a0la\u00a0respuesta \u00a0inmunoespec\u00edfica \u00a0frente\u00a0al\u00a0VIH\u00a0tampoco\u00a0han\u00a0mostrado \u00a0mejores\u00a0\nresultados173.\u00a0Se\u00a0sab\u00eda\u00a0que\u00a0en\u00a0modelos\u00a0animales\u00a0algunas\u00a0vacunas\u00a0hab\u00edan\u00a0sido\u00a0satisfac\u2010\ntoria174,\u00a0175,\u00a0pero\u00a0los\u00a0resultados \u00a0de\u00a0dos\u00a0ensayos\u00a0cl\u00ednicos\u00a0doble\u00a0ciego\u00a0en\u00a0humanos \u00a0\u00a0han\u00a0\nsido\u00a0desalentadores176,\u00a0177.\u00a0Tanto\u00a0el\u00a0estudio\u00a0QUEST176\u00a0(TARV\u00a0frente\u00a0a\u00a0TARV\u00a0m\u00e1s\u00a0vacuna\u00a0\nALVAC\u2010HIV,\u00a0y\u00a0frente\u00a0a\u00a0TARV\u00a0m\u00e1s\u00a0vacuna\u00a0ALVAC\u2010HIV\u00a0m\u00e1s\u00a0Remune\u00a9)\u00a0como\u00a0en\u00a0el\u00a0ensayo\u00a0\ncl\u00ednico178\u00a0que\u00a0compar\u00f3\u00a0diferentes \u00a0dosis\u00a0de\u00a0una\u00a0vacuna\u00a0que\u00a0usaba\u00a0el\u00a0virus\u00a0de\u00a0la\u00a0viruela\u00a0\naviar\u00a0(Avipox )\u00a0con\u00a0los\u00a0genes\u00a0gag/pol\u00a0del\u00a0VIH\u00a0insertados, \u00a0la\u00a0respuesta \u00a0virol\u00f3gica \u00a0e\u00a0inmu\u2010\nnoespec\u00edfica \u00a0fue\u00a0similar\u00a0al\u00a0grupo\u00a0placebo.\u00a0\n\u00a0\nInfecci\u00f3n \u00a0aguda.\u00a0Recomendaciones \u00a0\u00a0\n\u0083 En\u00a0general,\u00a0no\u00a0se\u00a0recomienda \u00a0iniciar\u00a0TARV\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0aguda\u00a0\n(nivel\u00a0B)121,\u00a0126.\u00a0Solamente \u00a0se\u00a0recomienda \u00a0TARV\u00a0cuando\u00a0existan\u00a0manifestaciones \u00a0\ncl\u00ednicas\u00a0graves\u00a0o\u00a0una\u00a0duraci\u00f3n\u00a0prolongada \u00a0de\u00a0los\u00a0s\u00edntomas\u00a0y\u00a0tras\u00a0explicar\u00a0al\u00a0pacien\u2010\nte\u00a0sus\u00a0ventajas\u00a0e\u00a0inconvenientes \u00a0(nivel\u00a0C)\u00a0\n\u0083 Se\u00a0debe\u00a0efectuar\u00a0siempre\u00a0una\u00a0prueba\u00a0de\u00a0resistencias \u00a0al\u00a0diagn\u00f3stico \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0\naguda,\u00a0se\u00a0vaya\u00a0a\u00a0iniciar\u00a0TARV\u00a0o\u00a0no\u00a0(nivel\u00a0B)83,\u00a0141,\u00a0142\u00a0\n\u0083 Si\u00a0se\u00a0decide\u00a0iniciar\u00a0TARV\u00a0las\u00a0pautas\u00a0recomendadas \u00a0son\u00a0las\u00a0mismas\u00a0que\u00a0en\u00a0la\u00a0infec\u2010\nci\u00f3n\u00a0cr\u00f3nica\u00a0(nivel\u00a0C)136,\u00a0138\u2010140.\u00a0Si\u00a0no\u00a0se\u00a0dispone\u00a0del\u00a0resultado \u00a0del\u00a0estudio\u00a0de\u00a0resis\u2010\ntencias\u00a0es\u00a0preferible \u00a0comenzar \u00a0con\u00a0una\u00a0pauta\u00a0basada\u00a0en\u00a0un\u00a0IP/r\u00a0(nivel\u00a0C)\u00a0)83,\u00a0144\u00a0\n\u0083 En\u00a0los\u00a0pacientes \u00a0no\u00a0tratados\u00a0se\u00a0recomienda \u00a0evaluar\u00a0los\u00a0criterios\u00a0de\u00a0TARV\u00a0a\u00a0partir\u00a0de\u00a0\nlos\u00a06\u00a0meses,\u00a0cuando\u00a0ya\u00a0la\u00a0infecci\u00f3n\u00a0es\u00a0cr\u00f3nica\u00a0(nivel\u00a0A).\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n4.\u00a0TRATAMIENTO \u00a0ANTIRRETROVIRAL \u00a0INICIAL\u00a0\nEn\u00a0los\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo,\u00a0se\u00a0debe\u00a0valorar\u00a0individualmente \u00a0cu\u00e1ndo\u00a0iniciar\u00a0\nel\u00a0TARV\u00a0y\u00a0qu\u00e9\u00a0combinaci\u00f3n \u00a0de\u00a0f\u00e1rmacos \u00a0utilizar,\u00a0sopesando \u00a0siempre\u00a0las\u00a0ventajas\u00a0e\u00a0in\u2010\nconvenientes \u00a0de\u00a0cada\u00a0opci\u00f3n.\u00a0La\u00a0disposici\u00f3n \u00a0y\u00a0la\u00a0motivaci\u00f3n \u00a0del\u00a0paciente\u00a0para\u00a0iniciarlo\u00a0\nes\u00a0un\u00a0factor\u00a0cr\u00edtico\u00a0a\u00a0la\u00a0hora\u00a0de\u00a0tomar\u00a0la\u00a0decisi\u00f3n\u00a0de\u00a0empezar. \u00a0\n\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 21 \n 4.1.\u00a0Cu\u00e1ndo\u00a0iniciar\u00a0el\u00a0TARV\u00a0\nSe\u00a0dispone\u00a0de\u00a0combinaciones \u00a0de\u00a0FAR\u00a0que\u00a0bloquean \u00a0de\u00a0forma\u00a0duradera\u00a0la\u00a0replicaci\u00f3n \u00a0\nviral\u00a0en\u00a0plasma\u00a0y\u00a0tejido\u00a0linf\u00e1tico\u00a0permitiendo \u00a0la\u00a0restauraci\u00f3n, \u00a0al\u00a0menos\u00a0parcial,\u00a0del\u00a0sis\u2010\ntema\u00a0inmunol\u00f3gico6,\u00a011,\u00a0179.\u00a0En\u00a0ediciones \u00a0previas\u00a0de\u00a0estas\u00a0gu\u00edas\u00a0se\u00a0hac\u00eda\u00a0\u00e9nfasis\u00a0en\u00a0la\u00a0\ninfluencia \u00a0en\u00a0el\u00a0balance\u00a0riesgo/beneficio \u00a0del\u00a0TARV\u00a0de\u00a0la\u00a0toxicidad\u00a0a\u00a0medio\u2010largo\u00a0plazo\u00a0\nde\u00a0los\u00a0FAR,\u00a0los\u00a0problemas \u00a0de\u00a0adherencia, \u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0resistencias, \u00a0las\u00a0interacciones \u00a0\nmedicamentosas \u00a0y\u00a0el\u00a0impacto\u00a0en\u00a0la\u00a0calidad\u00a0de\u00a0vida8.\u00a0Aunque\u00a0todos\u00a0estos\u00a0factores\u00a0si\u2010\nguen\u00a0siendo\u00a0muy\u00a0importantes, \u00a0es\u00a0justo\u00a0reconocer \u00a0que\u00a0el\u00a0n\u00famero\u00a0de\u00a0opciones\u00a0terap\u00e9u\u2010\nticas,\u00a0la\u00a0eficacia,\u00a0la\u00a0seguridad \u00a0y\u00a0la\u00a0simplicidad \u00a0de\u00a0las\u00a0combinaciones \u00a0de\u00a0antirretrovirales \u00a0\nhan\u00a0aumentado \u00a0marcadamente \u00a0durante\u00a0los\u00a0\u00faltimos\u00a0cinco\u00a0a\u00f1os180.\u00a0Adem\u00e1s,\u00a0debido\u00a0\nfundamentalmente \u00a0al\u00a0uso\u00a0de\u00a0IP/r,\u00a0el\u00a0riesgo\u00a0de\u00a0desarrollo \u00a0de\u00a0multirresistencia \u00a0ha\u00a0dismi\u2010\nnuido\u00a0considerablemente. \u00a0\nGracias\u00a0al\u00a0TARV\u00a0se\u00a0ha\u00a0reducido\u00a0dr\u00e1sticamente \u00a0el\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0y\u00a0muerte\u00a0de\u00a0los\u00a0\npacientes \u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH.\u00a0A\u00a0pesar\u00a0de\u00a0todos\u00a0estos\u00a0avances\u00a0la\u00a0esperanza \u00a0de\u00a0vida\u00a0\ndel\u00a0paciente\u00a0infectado \u00a0por\u00a0el\u00a0VIH\u00a0que\u00a0recibe\u00a0TARV\u00a0\u00a0est\u00e1\u00a0acortada\u00a0con\u00a0respecto\u00a0a\u00a0la\u00a0de\u00a0\nla\u00a0poblaci\u00f3n \u00a0general181,\u00a0182.\u00a0Se\u00a0ha\u00a0comunicado \u00a0que\u00a0s\u00f3lo\u00a0los\u00a0pacientes \u00a0que\u00a0han\u00a0recibido\u00a0\nTARV\u00a0durante\u00a0al\u00a0menos\u00a06\u00a0a\u00f1os\u00a0y\u00a0han\u00a0alcanzado \u00a0una\u00a0cifra\u00a0de\u00a0CD4\u00a0>500\u00a0c\u00e9lulas/\u03bcL\u00a0tie\u2010\nnen\u00a0una\u00a0mortalidad \u00a0similar\u00a0a\u00a0la\u00a0poblaci\u00f3n \u00a0general183.\u00a0\u00a0\nEl\u00a0aumento\u00a0de\u00a0la\u00a0eficacia,\u00a0seguridad \u00a0y\u00a0simplicidad \u00a0del\u00a0TARV\u00a0junto\u00a0con\u00a0el\u00a0reconocimien \u2010\nto\u00a0de\u00a0que\u00a0a\u00fan\u00a0existe\u00a0margen\u00a0de\u00a0mejora\u00a0en\u00a0el\u00a0aumento\u00a0de\u00a0la\u00a0esperanza \u00a0de\u00a0vida\u00a0del\u00a0pa\u2010\nciente\u00a0infectado \u00a0por\u00a0VIH\u00a0ha\u00a0vuelto\u00a0a\u00a0plantear\u00a0el\u00a0debate\u00a0sobre\u00a0un\u00a0inicio\u00a0m\u00e1s\u00a0temprano \u00a0\ndel\u00a0TARV.\u00a0\n\u00a0\nEvaluaci\u00f3n \u00a0del\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0\nLa\u00a0CVP\u00a0y\u00a0la\u00a0cifra\u00a0de\u00a0linfocitos\u00a0CD4\u00a0son\u00a0marcadores \u00a0independientes \u00a0de\u00a0progresi\u00f3n \u00a0de\u00a0la\u00a0\ninfecci\u00f3n\u00a0por\u00a0el\u00a0VIH184,\u00a0185.\u00a0\u00a0\nExiste\u00a0evidencia, \u00a0basada\u00a0en\u00a0ensayos\u00a0cl\u00ednicos\u00a0y\u00a0estudios\u00a0observacionales, \u00a0que\u00a0apoya\u00a0el\u00a0\ninicio\u00a0del\u00a0TARV\u00a0en\u00a0pacientes \u00a0con\u00a0linfocitos\u00a0CD4\u00a0<200\u00a0c\u00e9lulas/\u00b5L, \u00a0pero\u00a0no\u00a0hay\u00a0ensayos\u00a0\nen\u00a0pacientes \u00a0con\u00a0>200\u00a0linfocitos\u00a0CD4/\u00b5L\u00a0que\u00a0indiquen\u00a0cual\u00a0es\u00a0el\u00a0momento \u00a0\u00f3ptimo\u00a0para\u00a0\niniciarlo.\u00a0Sin\u00a0embargo, \u00a0y\u00a0a\u00a0pesar\u00a0de\u00a0sus\u00a0limitaciones, \u00a0existen\u00a0estudios\u00a0de\u00a0cohortes\u00a0ob\u2010\nservacionales, \u00a0de\u00a0pacientes \u00a0tratados\u00a0o\u00a0no,\u00a0que\u00a0pueden\u00a0ayudar\u00a0a\u00a0la\u00a0hora\u00a0de\u00a0decidir\u00a0el\u00a0\ninicio\u00a0del\u00a0TARV\u00a0en\u00a0personas\u00a0con\u00a0infecci\u00f3n\u00a0VIH\u00a0asintom\u00e1ticas. \u00a0\nEl\u00a0debate\u00a0actual\u00a0se\u00a0centra\u00a0en\u00a0torno\u00a0a\u00a0si\u00a0es\u00a0necesario \u00a0iniciar\u00a0TARV\u00a0con\u00a0cifras\u00a0de\u00a0linfocitos\u00a0\nCD4\u00a0cercanas\u00a0o\u00a0incluso\u00a0superiores \u00a0a\u00a0350\u00a0c\u00e9lulas/\u00b5L. \u00a0Los\u00a0datos\u00a0que\u00a0sustentan \u00a0este\u00a0de\u2010\nbate\u00a0provienen \u00a0de\u00a0cohortes\u00a0de\u00a0pacientes \u00a0en\u00a0las\u00a0que\u00a0se\u00a0ha\u00a0evaluado\u00a0la\u00a0mortalidad, \u00a0la\u00a0\nprogresi\u00f3n \u00a0a\u00a0sida,\u00a0la\u00a0incidencia \u00a0de\u00a0enfermedades \u00a0no\u00a0definitorias \u00a0de\u00a0sida,\u00a0la\u00a0recupera\u2010\nci\u00f3n\u00a0inmunol\u00f3gica \u00a0y\u00a0la\u00a0toxicidad\u00a0del\u00a0tratamiento \u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0cifra\u00a0de\u00a0linfocitos\u00a0CD4\u00a0\nprevia\u00a0al\u00a0inicio\u00a0del\u00a0TARV.\u00a0Los\u00a0estudios\u00a0de\u00a0cohortes\u00a0tienen\u00a0importantes \u00a0problemas \u00a0me\u2010\ntodol\u00f3gicos \u00a0como\u00a0el\u00a0sesgo\u00a0de\u00a0prescripci\u00f3n \u00a0que\u00a0hacen\u00a0que\u00a0la\u00a0calidad\u00a0de\u00a0la\u00a0evidencia \u00a0sea\u00a0\nmenor\u00a0que\u00a0la\u00a0proveniente \u00a0de\u00a0ensayos\u00a0cl\u00ednicos\u00a0aleatorizados. \u00a0\n\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 22 \n Respuesta \u00a0cl\u00ednica\u00a0(progresi\u00f3n \u00a0a\u00a0sida\u00a0o\u00a0muerte)\u00a0\u00a0\nHay\u00a0datos\u00a0muy\u00a0limitados\u00a0sobre\u00a0la\u00a0comparaci\u00f3n \u00a0de\u00a0la\u00a0mortalidad \u00a0y/o\u00a0progresi\u00f3n \u00a0a\u00a0sida\u00a0\nen\u00a0pacientes \u00a0que\u00a0empiezan \u00a0TARV\u00a0por\u00a0encima\u00a0o\u00a0por\u00a0debajo\u00a0de\u00a0350\u00a0CD4/\u00b5L.\u00a0\u00a0\u00a0\nEn\u00a0un\u00a0an\u00e1lisis\u00a0de\u00a010.855\u00a0pacientes \u00a0de\u00a0varias\u00a0cohortes, \u00a0la\u00a0progresi\u00f3n \u00a0a\u00a0sida\u00a0o\u00a0muerte\u00a0fue\u00a0\nsignificativamente \u00a0mayor\u00a0en\u00a0los\u00a0que\u00a0iniciaban\u00a0el\u00a0TARV\u00a0con\u00a0<200\u00a0CD4/\u00b5L\u00a0(hazard\u00a0ratio ,\u00a0\n2,93)\u00a0que\u00a0en\u00a0los\u00a0que\u00a0lo\u00a0empezaron \u00a0entre\u00a0201\u00a0y\u00a0350,\u00a0pero\u00a0no\u00a0hubo\u00a0diferencia \u00a0(hazard\u00a0\nratio\u00a01,26)\u00a0cuando\u00a0se\u00a0compar\u00f3\u00a0inicio\u00a0entre\u00a0201\u00a0y\u00a0350\u00a0CD4\u00a0frente\u00a0a\u00a0los\u00a0que\u00a0empezaron \u00a0\ncon\u00a0>350\u00a0CD4/\u00b5L.\u00a0Sin\u00a0embargo\u00a0se\u00a0observ\u00f3\u00a0un\u00a0aumento\u00a0significativo \u00a0del\u00a0riesgo\u00a0de\u00a0sida\u00a0\n(no\u00a0de\u00a0sida\u00a0o\u00a0muerte )\u00a0en\u00a0los\u00a0que\u00a0empezaron \u00a0entre\u00a0201\u00a0y\u00a0350\u00a0frente\u00a0a\u00a0los\u00a0que\u00a0empeza\u2010\nron\u00a0con\u00a0>350\u00a0CD4/\u00b5L\u00a0(Hazard\u00a0ratio ,\u00a01,52.\u00a0IC95%:\u00a01,10\u20102,10)9.\u00a0\u00a0\nEn\u00a0la\u00a0cohorte\u00a0PISCIS\u00a0de\u00a0Catalu\u00f1a\u00a0y\u00a0Baleares\u00a0el\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0a\u00a0sida\u00a0o\u00a0muerte\u00a0tras\u00a0\ninicio\u00a0de\u00a0TARV\u00a0fue\u00a0significativamente \u00a0menor\u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0lo\u00a0iniciaron\u00a0con\u00a0cifras\u00a0\nde\u00a0CD4\u00a0\u2265350\u00a0c\u00e9lulas/\u00b5L \u00a0que\u00a0en\u00a0los\u00a0que\u00a0empezaron \u00a0entre\u00a0200\u2010350\u00a0CD4/\u00b5L\u00a0(HR\u00a0=\u00a01.85,\u00a0\n95%\u00a0CI:\u00a01.03\u00a0a\u00a03.33),\u00a0o\u00a0<200\u00a0CD4/\u00b5L\u00a0(HR\u00a0=\u00a02.97,\u00a095%\u00a0CI:\u00a01.91\u00a0a\u00a04.63)10.\u00a0\nEn\u00a0un\u00a0suban\u00e1lisis \u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0>350\u00a0CD4/\u00b5L\u00a0del\u00a0ensayo\u00a0SMART\u00a0\u00a0que\u00a0no\u00a0estaban\u00a0\nrecibiendo \u00a0TARV\u00a0al\u00a0inicio\u00a0del\u00a0estudio,\u00a0los\u00a0aleatorizados \u00a0a\u00a0demorar\u00a0el\u00a0TARV\u00a0hasta\u00a0alcan\u2010\nzar\u00a0la\u00a0cifra\u00a0de\u00a0250\u00a0CD4\u00a0/\u00b5L\u00a0tuvieron\u00a0mayor\u00a0riesgo\u00a0de\u00a0enfermedades \u00a0oportunistas \u00a0y/o\u00a0\nmuerte\u00a0por\u00a0causas\u00a0no\u00a0directamente \u00a0relacionadas \u00a0con\u00a0sida\u00a0que\u00a0quienes\u00a0iniciaron\u00a0TARV\u00a0\ninmediatamente \u00a0con\u00a0cifras\u00a0de\u00a0CD4\u00a0\u2265\u00a0350\u00a0c\u00e9lulas/\u00b5L186.\u00a0\u00a0\nPor\u00a0\u00faltimo,\u00a0en\u00a0un\u00a0an\u00e1lisis\u00a0paralelo\u00a0de\u00a017.517\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0asintom\u00e1 \u2010\ntica\u00a0en\u00a0EE.UU\u00a0y\u00a0Canad\u00e1\u00a0(estudio\u00a0NA\u2010ACCORD), \u00a0se\u00a0estratificaron \u00a0dichos\u00a0pacientes \u00a0en\u00a0\nfunci\u00f3n\u00a0del\u00a0recuento\u00a0de\u00a0linfocitos\u00a0CD4\u00a0(>351\u00a0a\u00a0500\u00a0c\u00e9lulas/\u00b5L \u00a0\u00f3\u00a0>\u00a0500\u00a0c\u00e9lulas/\u00b5L) \u00a0en\u00a0el\u00a0\nmomento \u00a0de\u00a0iniciar\u00a0el\u00a0tratamiento \u00a0antirretroviral. \u00a0En\u00a0cada\u00a0grupo\u00a0se\u00a0compar\u00f3\u00a0el\u00a0riesgo\u00a0\nrelativo\u00a0de\u00a0muerte\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0iniciaron\u00a0tratamiento \u00a0cuando\u00a0el\u00a0recuento\u00a0de\u00a0\nCD4\u00a0era\u00a0superior\u00a0a\u00a0cualquiera \u00a0de\u00a0los\u00a0dos\u00a0puntos\u00a0de\u00a0corte\u00a0(tratamiento \u00a0precoz)\u00a0con\u00a0el\u00a0\nde\u00a0los\u00a0pacientes \u00a0que\u00a0difirieron \u00a0el\u00a0tratamiento \u00a0hasta\u00a0que\u00a0el\u00a0recuento\u00a0de\u00a0CD4\u00a0cay\u00f3\u00a0por\u00a0\ndebajo\u00a0de\u00a0dichos\u00a0puntos\u00a0de\u00a0corte\u00a0(tratamiento \u00a0diferido).\u00a0El\u00a0primer\u00a0an\u00e1lisis\u00a0incluy\u00f3\u00a08362\u00a0\npacientes, \u00a02084\u00a0(25%)\u00a0que\u00a0inciaron\u00a0tratamiento \u00a0entre\u00a0351\u00a0y\u00a0500\u00a0c\u00e9lulas/mm3\u00a0y\u00a06278\u00a0\n(75%)\u00a0que\u00a0difirieron \u00a0el\u00a0tratamiento. \u00a0Tras\u00a0ajuste\u00a0por\u00a0a\u00f1o\u00a0de\u00a0tratamiento, \u00a0cohorte,\u00a0y\u00a0ca\u2010\nracter\u00edsticas \u00a0cl\u00ednicas\u00a0y\u00a0demogr\u00e1ficas \u00a0se\u00a0hall\u00f3\u00a0un\u00a0incremento \u00a0del\u00a0riesgo\u00a0de\u00a0muerte\u00a0del\u00a0\n69%\u00a0comparando \u00a0el\u00a0grupo\u00a0de\u00a0tratamiento \u00a0precoz\u00a0con\u00a0el\u00a0de\u00a0tratamiento \u00a0diferido\u00a0(RR\u00a0en\u00a0\nel\u00a0grupo\u00a0de\u00a0TARV\u00a0diferido:\u00a01,69;\u00a0IC95%\u00a01,26\u20102,26;\u00a0P\u00a0<\u00a00,001).\u00a0En\u00a0un\u00a0segundo\u00a0an\u00e1lisis\u00a0\ncon\u00a09155\u00a0pacientes, \u00a02220\u00a0(24%)\u00a0iniciaron\u00a0TARV\u00a0precozmente \u00a0(>\u00a0500\u00a0c\u00e9lulas/mm3)\u00a0y\u00a0\n6935\u00a0(76%)\u00a0difirieron \u00a0el\u00a0TARV.\u00a0Se\u00a0hall\u00f3\u00a0un\u00a0incremento \u00a0del\u00a0riesgo\u00a0relativo\u00a0de\u00a0muerte\u00a0en\u00a0\nel\u00a0grupo\u00a0de\u00a0TARV\u00a0diferido\u00a0del\u00a094%\u00a0(RR:\u00a01,94;\u00a0IC95%:\u00a01,37\u20102,79;\u00a0P\u00a0<\u00a00,001)187.\u00a0\nPor\u00a0\u00faltimo,\u00a0en\u00a0un\u00a0ensayo\u00a0cl\u00ednico,\u00a0controlado, \u00a0randomizado, \u00a0abierto,\u00a0llevado\u00a0a\u00a0cabo\u00a0en\u00a0\nHait\u00ed\u00a0(CIPRA\u00a0HT\u00a0001)\u00a0se\u00a0randomizaron \u00a0816\u00a0pacientes \u00a0mayores\u00a0de\u00a018\u00a0a\u00f1os\u00a0a\u00a0iniciar\u00a0TARV\u00a0\n(AZT+3TC+EFV) \u00a0entre\u00a0200\u00a0y\u00a0350\u00a0c\u00e9lulas\u00a0CD4/\u00b5L\u00a0o\u00a0diferirlo\u00a0hasta\u00a02\u00a0semanas\u00a0despu\u00e9s\u00a0del\u00a0\ndiagn\u00f3stico \u00a0cl\u00ednico\u00a0de\u00a0SIDA\u00a0o\u00a0que\u00a0su\u00a0recuento\u00a0de\u00a0CD4\u00a0descendiera \u00a0por\u00a0debajo\u00a0de\u00a0200\u00a0\nc\u00e9lulas/mL. \u00a0El\u00a0estudio\u00a0fue\u00a0interrumpido \u00a0prematuramente \u00a0tras\u00a0un\u00a0an\u00e1lisis\u00a0interino\u00a0pla\u2010\nneado\u00a0que\u00a0mostr\u00f3\u00a06\u00a0muertes\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0200\u00a0a\u00a0350\u00a0c\u00e9lulas/mm3\u00a0frente\u00a0a\u00a023\u00a0en\u00a0el\u00a0\ngrupo\u00a0de\u00a0pacientes \u00a0que\u00a0difirieron \u00a0TARV.\u00a0Adem\u00e1s,\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TARV\u00a0diferido\u00a0se\u00a0diag\u2010\nnosticaron \u00a0el\u00a0doble\u00a0de\u00a0casos\u00a0de\u00a0tuberculosis \u00a0que\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0inicio\u00a0inmediato188.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 23 \n En\u00a0resumen, \u00a0los\u00a0estudios\u00a0de\u00a0cohorte\u00a0sugieren\u00a0que\u00a0existe\u00a0una\u00a0relaci\u00f3n\u00a0progresiva \u00a0entre\u00a0\nla\u00a0inmunodeficiencia \u00a0y\u00a0el\u00a0riesgo\u00a0de\u00a0muerte\u00a0y/o\u00a0progresi\u00f3n \u00a0a\u00a0sida.\u00a0Comparado \u00a0con\u00a0los\u00a0\npacientes \u00a0que\u00a0empiezan \u00a0TARV\u00a0entre\u00a0200\u00a0y\u00a0350\u00a0CD4/\u03bcL,\u00a0el\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0est\u00e1\u00a0\nclaramente \u00a0aumentado \u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0empiezan \u00a0TARV\u00a0por\u00a0debajo\u00a0de\u00a0200\u00a0\nCD4/\u03bcL.\u00a0La\u00a0evidencia \u00a0m\u00e1s\u00a0reciente\u00a0sugiere\u00a0que\u00a0el\u00a0riesgo\u00a0de\u00a0muerte\u00a0y/o\u00a0progresi\u00f3n \u00a0a\u00a0\nsida\u00a0podr\u00eda\u00a0ser\u00a0a\u00fan\u00a0menor\u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0empiezan \u00a0TARV\u00a0por\u00a0encima\u00a0de\u00a0350\u00a0\nCD4/\u03bcL.\u00a0\u00a0\n\u00a0\nIncidencia \u00a0de\u00a0enfermedades \u00a0no\u00a0relacionadas \u00a0con\u00a0el\u00a0VIH\u00a0\nRecientemente \u00a0los\u00a0estudios\u00a0de\u00a0cohortes\u00a0han\u00a0puesto\u00a0\u00e9nfasis\u00a0en\u00a0el\u00a0riesgo\u00a0de\u00a0aparici\u00f3n \u00a0\nde\u00a0enfermedades \u00a0que\u00a0hasta\u00a0el\u00a0momento \u00a0no\u00a0se\u00a0hab\u00edan\u00a0considerado \u00a0relacionadas \u00a0con\u00a0la\u00a0\ninmunosupresi\u00f3n \u00a0y\u00a0por\u00a0lo\u00a0tanto\u00a0no\u00a0prevenibles \u00a0con\u00a0el\u00a0empleo\u00a0de\u00a0TARV.\u00a0Estas\u00a0enferme\u2010\ndades\u00a0son\u00a0de\u00a0tipo\u00a0cardiovascular \u00a0(infarto\u00a0de\u00a0miocardio, \u00a0ictus),\u00a0afectaci\u00f3n \u00a0de\u00a0\u00f3rganos\u00a0\n(insuficiencia \u00a0renal,\u00a0hepatopat\u00eda \u00a0descompensada) \u00a0y\u00a0aparici\u00f3n \u00a0de\u00a0c\u00e1nceres\u00a0no\u00a0definito\u2010\nrios\u00a0de\u00a0sida\u00a0(todo\u00a0tipo\u00a0excepto\u00a0sarcoma\u00a0de\u00a0Kaposi,\u00a0linfoma\u00a0no\u00a0hodgkiniano \u00a0y\u00a0carcinoma \u00a0\ncervical\u00a0invasor).\u00a0\nHay\u00a0que\u00a0resaltar\u00a0que\u00a0para\u00a0los\u00a0pacientes \u00a0que\u00a0empiezan \u00a0TARV\u00a0con\u00a0m\u00e1s\u00a0de\u00a0200\u00a0CD4/\u00b5L\u00a0la\u00a0\nincidencia \u00a0de\u00a0enfermedades \u00a0no\u00a0relacionadas \u00a0con\u00a0el\u00a0VIH\u00a0es\u00a0tan\u00a0frecuente \u00a0como\u00a0las\u00a0defi\u2010\nnitorias\u00a0de\u00a0sida189.\u00a0Por\u00a0lo\u00a0tanto,\u00a0es\u00a0muy\u00a0relevante \u00a0investigar \u00a0estrategias \u00a0encaminadas \u00a0a\u00a0\ndisminuir \u00a0la\u00a0incidencia \u00a0de\u00a0los\u00a0dos\u00a0tipos\u00a0de\u00a0complicaciones \u00a0y\u00a0no\u00a0s\u00f3lo\u00a0de\u00a0las\u00a0relacionadas \u00a0\ncl\u00e1sicamente \u00a0con\u00a0la\u00a0inmunosupresi\u00f3n. \u00a0El\u00a0TARV\u00a0podr\u00eda\u00a0ejercer\u00a0un\u00a0efecto\u00a0beneficioso \u00a0\nsobre\u00a0las\u00a0complicaciones \u00a0no\u2010sida\u00a0mediante \u00a0el\u00a0control\u00a0del\u00a0estado\u00a0pro\u00a0inflamatorio \u00a0y\u00a0la\u00a0\nactivaci\u00f3n \u00a0inmune\u00a0asociados \u00a0a\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0persistente. \u00a0\u00a0\nEn\u00a0la\u00a0cohorte\u00a0D.A.D.190\u00a0y\u00a0en\u00a0la\u00a0cohorte\u00a0CASCADE191\u00a0se\u00a0ha\u00a0comunicado \u00a0que\u00a0existe\u00a0una\u00a0\ndisminuci\u00f3n \u00a0progresiva \u00a0del\u00a0riesgo\u00a0de\u00a0enfermedades \u00a0no\u00a0relacionadas \u00a0con\u00a0el\u00a0VIH\u00a0a\u00a0medi\u2010\nda\u00a0que\u00a0aumenta\u00a0la\u00a0cifra\u00a0de\u00a0c\u00e9lulas\u00a0CD4.\u00a0Los\u00a0pacientes \u00a0que\u00a0presentan \u00a0el\u00a0menor\u00a0riesgo\u00a0\nde\u00a0desarrollar \u00a0enfermedades \u00a0no\u00a0definitorias \u00a0de\u00a0sida\u00a0son\u00a0los\u00a0que\u00a0mantienen \u00a0una\u00a0cifra\u00a0\nde\u00a0CD4\u00a0mayor\u00a0de\u00a0350\u00a0c\u00e9lulas/\u03bcL.\u00a0\u00a0\nEn\u00a0el\u00a0ensayo\u00a0cl\u00ednico\u00a0\u00a0SMART192\u00a0la\u00a0incidencia \u00a0de\u00a0enfermedades \u00a0no\u00a0relacionadas \u00a0con\u00a0el\u00a0\nVIH\u00a0aument\u00f3\u00a0significativamente \u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0pacientes \u00a0que\u00a0suspendieron \u00a0el\u00a0TARV\u00a0\ncuando\u00a0la\u00a0cifra\u00a0de\u00a0CD4\u00a0era\u00a0menor\u00a0de\u00a0350\u00a0c\u00e9lulas/\u03bcL.\u00a0En\u00a0el\u00a0ensayo\u00a0cl\u00ednico\u00a0FIRST189\u00a0tam\u2010\nbi\u00e9n\u00a0se\u00a0ha\u00a0puesto\u00a0de\u00a0manifiesto \u00a0una\u00a0relaci\u00f3n\u00a0entre\u00a0la\u00a0cifra\u00a0de\u00a0CD4\u00a0y\u00a0el\u00a0riesgo\u00a0de\u00a0des\u2010\narrollar\u00a0enfermedades \u00a0no\u00a0definitorias \u00a0de\u00a0sida,\u00a0siendo\u00a0menor\u00a0el\u00a0riesgo\u00a0en\u00a0aquellos\u00a0pa\u2010\ncientes\u00a0que\u00a0mantuvieron \u00a0la\u00a0cifra\u00a0de\u00a0CD4\u00a0por\u00a0encima\u00a0de\u00a0350\u00a0c\u00e9lulas/\u03bcL.\u00a0\n\u00a0\nSubgrupos \u00a0de\u00a0mayor\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0\nVarios\u00a0estudios10,\u00a0193,\u00a0194\u00a0han\u00a0demostrado \u00a0que\u00a0diversos\u00a0subgrupos \u00a0de\u00a0pacientes \u00a0tienen\u00a0\nun\u00a0mayor\u00a0riesgo\u00a0de\u00a0mortalidad \u00a0y/o\u00a0progresi\u00f3n \u00a0a\u00a0sida\u00a0independientemente \u00a0de\u00a0la\u00a0cifra\u00a0\nde\u00a0CD4\u00a0antes\u00a0de\u00a0iniciar\u00a0TARV.\u00a0El\u00a0uso\u00a0de\u00a0drogas\u00a0por\u00a0v\u00eda\u00a0parenteral, \u00a0la\u00a0coinfecci\u00f3n \u00a0por\u00a0\nvirus\u00a0de\u00a0la\u00a0hepatitis\u00a0C,\u00a0el\u00a0sexo\u00a0masculino \u00a0y\u00a0la\u00a0edad\u00a0avanzada \u00a0se\u00a0asocian\u00a0a\u00a0un\u00a0mayor\u00a0\nriesgo\u00a0de\u00a0progresi\u00f3n. \u00a0\u00a0Aunque\u00a0no\u00a0se\u00a0ha\u00a0establecido \u00a0claramente \u00a0un\u00a0corte\u00a0de\u00a0edad\u00a0a\u00a0par\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 24 \n tir\u00a0del\u00a0cual\u00a0sea\u00a0m\u00e1s\u00a0beneficioso \u00a0iniciar\u00a0TARV,\u00a0los\u00a0estudios\u00a0de\u00a0cohorte\u00a0sugieren\u00a0que\u00a0el\u00a0\nriesgo\u00a0de\u00a0progresi\u00f3n \u00a0est\u00e1\u00a0aumentado \u00a0por\u00a0encima\u00a0de\u00a0los\u00a055\u201060\u00a0a\u00f1os\u00a0de\u00a0edad195.\u00a0\u00a0\nSe\u00a0ha\u00a0estudiado \u00a0la\u00a0relaci\u00f3n\u00a0de\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0CD4\u00a0al\u00a0inicio\u00a0del\u00a0TARV\u00a0en\u00a0la\u00a0superviven \u2010\ncia\u00a0en\u00a0un\u00a0grupo\u00a0de\u00a0pacientes \u00a0cuyos\u00a0CD4\u00a0estaban\u00a0entre\u00a0200\u00a0y\u00a0350\u00a0c\u00e9lulas/\u00b5L. \u00a0La\u00a0super\u2010\nvivencia\u00a0era\u00a0m\u00e1s\u00a0corta\u00a0si\u00a0la\u00a0proporci\u00f3n \u00a0era\u00a0<5%\u00a0(hazard\u00a0ratio\u00a04,46)\u00a0o\u00a0entre\u00a05\u201014%\u00a0(HR\u00a0\n2,43)\u00a0que\u00a0si\u00a0era\u00a0\u00a0\u226515%\u00a0(p<0,01)196.\u00a0Sin\u00a0embargo, \u00a0en\u00a0la\u00a0cohorte\u00a0PISCIS\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0\nCD4\u00a0no\u00a0fue\u00a0un\u00a0factor\u00a0independiente \u00a0asociado\u00a0con\u00a0el\u00a0riesgo\u00a0de\u00a0progresi\u00f3n10.\u00a0\u00a0\n\u00a0\nRespuesta \u00a0inmunol\u00f3gica \u00a0\u00a0\nHay\u00a0datos\u00a0contradictorios \u00a0sobre\u00a0si\u00a0existe\u00a0un\u00a0l\u00edmite\u00a0en\u00a0la\u00a0reconstituci\u00f3n \u00a0inmunol\u00f3gica \u00a0\nde\u00a0los\u00a0pacientes \u00a0que\u00a0reciben\u00a0TARV.\u00a0La\u00a0cohorte\u00a0del\u00a0Hospital\u00a0Johns\u00a0Hopkins\u00a0y\u00a0la\u00a0cohorte\u00a0\nATHENA196,\u00a0197\u00a0con\u00a0un\u00a0seguimiento \u00a0de\u00a0hasta\u00a07\u00a0a\u00f1os\u00a0despu\u00e9s\u00a0del\u00a0inicio\u00a0de\u00a0TARV\u00a0sugieren\u00a0\nque\u00a0la\u00a0posibilidad \u00a0de\u00a0alcanzar\u00a0recuentos \u00a0de\u00a0CD4\u00a0normales \u00a0depende\u00a0del\u00a0n\u00famero\u00a0inicial.\u00a0\nEn\u00a0estas\u00a0dos\u00a0cohortes\u00a0s\u00f3lo\u00a0los\u00a0pacientes \u00a0que\u00a0iniciaron\u00a0TARV\u00a0con\u00a0>350\u00a0CD4\u00a0se\u00a0aproxi\u2010\nmaron\u00a0a\u00a0la\u00a0normalizaci\u00f3n \u00a0cuantitativa; \u00a0sin\u00a0embargo\u00a0los\u00a0datos\u00a0de\u00a0Eurosida198\u00a0sugieren\u00a0\nque\u00a0se\u00a0puede\u00a0normalizar \u00a0el\u00a0n\u00famero\u00a0de\u00a0CD4,\u00a0independientemente \u00a0del\u00a0nadir\u00a0alcanzado, \u00a0\nsi\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0persiste\u00a0suprimida \u00a0por\u00a0debajo\u00a0de\u00a050\u00a0copias/mL \u00a0de\u00a0forma\u00a0prolon\u2010\ngada.\u00a0\u00a0\u00a0\n\u00a0\nToxicidad \u00a0del\u00a0TARV\u00a0\nUn\u00a0argumento \u00a0para\u00a0diferir\u00a0el\u00a0TARV\u00a0es\u00a0evitar\u00a0la\u00a0toxicidad\u00a0asociada\u00a0al\u00a0empleo\u00a0de\u00a0antirre\u2010\ntrovirales. \u00a0Hay\u00a0pocos\u00a0estudios\u00a0actuales\u00a0que\u00a0hayan\u00a0evaluado\u00a0la\u00a0incidencia \u00a0de\u00a0efectos\u00a0\nadversos\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0cifra\u00a0de\u00a0CD4\u00a0antes\u00a0del\u00a0inicio\u00a0del\u00a0TARV.\u00a0Un\u00a0estudio\u00a0reciente\u00a0\nsugiere\u00a0que\u00a0la\u00a0incidencia \u00a0de\u00a0neuropat\u00eda \u00a0perif\u00e9rica, \u00a0anemia\u00a0e\u00a0insuficiencia \u00a0renal\u00a0no\u00a0est\u00e1\u00a0\naumentada \u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0inician\u00a0TARV\u00a0con\u00a0cifras\u00a0de\u00a0CD4\u00a0mayores\u00a0de\u00a0350\u00a0c\u00e9lu\u2010\nlas/\u03bcL199.\u00a0De\u00a0hecho\u00a0la\u00a0incidencia \u00a0de\u00a0neuropat\u00eda \u00a0perif\u00e9rica \u00a0y\u00a0de\u00a0anemia\u00a0fue\u00a0menor\u00a0en\u00a0los\u00a0\npacientes \u00a0que\u00a0iniciaron\u00a0TARV\u00a0por\u00a0encima\u00a0de\u00a0350\u00a0CD4/\u03bcL\u00a0que\u00a0en\u00a0quienes\u00a0empezaron \u00a0\nentre\u00a0200\u00a0y\u00a0350\u00a0CD4/\u03bcL.\u00a0\n\u00a0\nTARV\u00a0para\u00a0evitar\u00a0la\u00a0transmisi\u00f3n \u00a0del\u00a0VIH\u00a0(parejas\u00a0serodiscordantes) \u00a0\nAlgunos\u00a0expertos\u00a0han\u00a0sugerido\u00a0que\u00a0en\u00a0parejas\u00a0serodiscordantes \u00a0que\u00a0mantienen \u00a0rela\u2010\nciones\u00a0sexuales\u00a0no\u00a0protegidas, \u00a0el\u00a0tratamiento \u00a0del\u00a0miembro\u00a0infectado \u00a0a\u00a0fin\u00a0de\u00a0controlar\u00a0\nla\u00a0replicaci\u00f3n \u00a0viral\u00a0(carga\u00a0viral\u00a0indetectable) \u00a0puede\u00a0constituir \u00a0una\u00a0indicaci\u00f3n \u00a0de\u00a0TARV.\u00a0\nEn\u00a0un\u00a0metaan\u00e1lisis \u00a0reciente\u00a0que\u00a0incluy\u00f3\u00a05021\u00a0parejas\u00a0heterosexuales \u00a0y\u00a0461\u00a0eventos\u00a0de\u00a0\ntransmisi\u00f3n, \u00a0la\u00a0tasa\u00a0global\u00a0de\u00a0transmisi\u00f3n \u00a0para\u00a0pacientes \u00a0en\u00a0TARV\u00a0fue\u00a0de\u00a00,46\u00a0(IC95%:\u00a0\n0,19\u20101,09)\u00a0por\u00a0100\u00a0pacientes \u2010a\u00f1o.\u00a0La\u00a0tasa\u00a0de\u00a0transmisi\u00f3n \u00a0desde\u00a0un\u00a0sujeto\u00a0en\u00a0TARV\u00a0con\u00a0\nCVP\u00a0<400\u00a0copias/mL \u00a0fue\u00a0nula\u00a0(no\u00a0hubo\u00a0transmisiones) \u00a0con\u00a0un\u00a0l\u00edmite\u00a0superior\u00a0de\u00a0con\u2010\nfianza\u00a0al\u00a097,5%\u00a0de\u00a01,27\u00a0por\u00a0100\u00a0personas\u2010a\u00f1o.\u00a0Si\u00a0el\u00a0sujeto\u00a0no\u00a0tomaba\u00a0TARV\u00a0la\u00a0tasa\u00a0de\u00a0\ntransmisi\u00f3n \u00a0era\u00a0del\u00a00,16\u00a0(IC95%:\u00a00,02\u20101,13)\u00a0por\u00a0100\u00a0personas\u2010a\u00f1o.\u00a0No\u00a0hab\u00edan\u00a0suficien\u2010\ntes\u00a0datos\u00a0para\u00a0estratificar \u00a0el\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0presencia \u00a0de\u00a0ETS,\u00a0\nuso\u00a0de\u00a0cond\u00f3n\u00a0o\u00a0coito\u00a0vaginal\u00a0o\u00a0anal200.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 25 \n \u00a0\nCu\u00e1ndo\u00a0iniciar\u00a0el\u00a0TARV.\u00a0Recomendaciones \u00a0\n\u0083 El\u00a0inicio\u00a0del\u00a0TARV\u00a0debe\u00a0basarse\u00a0en\u00a0tres\u00a0elementos: \u00a0los\u00a0s\u00edntomas, \u00a0el\u00a0n\u00famero\u00a0de\u00a0CD4\u00a0\ny\u00a0la\u00a0CVP.\u00a0\n\u0083 En\u00a0caso\u00a0de\u00a0infecci\u00f3n \u00a0sintom\u00e1tica \u00a0(eventos\u00a0B\u00a0o\u00a0C)\u00a0se\u00a0recomienda \u00a0iniciar\u00a0el\u00a0TARV\u00a0en\u00a0\ntodos\u00a0los\u00a0casos\u00a0(nivel\u00a0A).\u00a0\u00a0\n\u0083 Si\u00a0la\u00a0infecci\u00f3n \u00a0es\u00a0asintom\u00e1tica \u00a0el\u00a0inicio\u00a0del\u00a0TARV\u00a0se\u00a0basa\u00a0en\u00a0el\u00a0n\u00famero\u00a0de\u00a0CD4,\u00a0la\u00a0\nCVP\u00a0o\u00a0en\u00a0determinadas \u00a0comorbilidades \u00a0o\u00a0caracter\u00edsticas \u00a0del\u00a0paciente\u00a0(Tabla\u00a03):\u00a0\n\u0083 Si\u00a0linfocitos\u00a0CD4\u00a0<350\u00a0c\u00e9lulas/\u00b5L \u00a0se\u00a0recomienda \u00a0el\u00a0TARV\u00a0(nivel\u00a0B)\u00a0\n\u0083 Si\u00a0los\u00a0linfocitos\u00a0CD4\u00a0est\u00e1n\u00a0entre\u00a0350\u00a0y\u00a0500\u00a0c\u00e9lulas/\u00b5L \u00a0se\u00a0recomienda \u00a0el\u00a0TARV\u00a0en\u00a0\nlos\u00a0pacientes \u00a0con\u00a0ciertas\u00a0comorbilidades \u00a0(cirrosis\u00a0hep\u00e1tica,\u00a0hepatitis\u00a0cr\u00f3nica\u00a0\npor\u00a0virus\u00a0C,\u00a0hepatitis\u00a0B\u00a0con\u00a0indicaci\u00f3n \u00a0de\u00a0tratamiento, \u00a0CVP\u00a0>105\u00a0copias/mL, \u00a0\nproporci\u00f3n \u00a0de\u00a0CD4\u00a0<14%,\u00a0edad\u00a0>55\u00a0a\u00f1os,\u00a0riesgo\u00a0cardiovascular \u00a0elevado\u00a0y\u00a0ne\u2010\nfropat\u00eda\u00a0VIH)\u00a0(nivel\u00a0B).\u00a0\n\u0083 Si\u00a0el\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0CD4\u00a0es\u00a0mayor\u00a0de\u00a0500\u00a0c\u00e9lulas/\u00b5L \u00a0se\u00a0recomienda \u00a0diferir\u00a0\nel\u00a0TARV\u00a0en\u00a0general.\u00a0Sin\u00a0embargo\u00a0debe\u00a0ser\u00a0considerado \u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0\ncomorbilidades \u00a0(cirrosis\u00a0hep\u00e1tica,\u00a0hepatitis\u00a0cr\u00f3nica\u00a0por\u00a0virus\u00a0C,\u00a0hepatitis\u00a0B\u00a0con\u00a0\nindicaci\u00f3n \u00a0de\u00a0tratamiento, \u00a0CVP\u00a0>105\u00a0copias/mL, \u00a0proporci\u00f3n \u00a0de\u00a0CD4\u00a0<14%,\u00a0\nedad\u00a0>55\u00a0a\u00f1os,\u00a0riesgo\u00a0cardiovascular \u00a0elevado\u00a0y\u00a0nefropat\u00eda \u00a0VIH)\u00a0(nivel\u00a0B).\u00a0\u00a0\n\u0083 En\u00a0parejas\u00a0serodiscordantes, \u00a0debe\u00a0valorarse\u00a0cuidadosamente \u00a0el\u00a0inicio\u00a0de\u00a0TARV\u00a0\npara\u00a0disminuir \u00a0la\u00a0transmisi\u00f3n \u00a0por\u00a0v\u00eda\u00a0sexual\u00a0(nivel\u00a0B).\u00a0En\u00a0ning\u00fan\u00a0caso\u00a0ello\u00a0debe\u00a0\nsuponer\u00a0la\u00a0abstenci\u00f3n \u00a0de\u00a0otras\u00a0medidas\u00a0para\u00a0impedir\u00a0la\u00a0transmisi\u00f3n \u00a0del\u00a0VIH.\u00a0\n\u0083 A\u00a0pesar\u00a0de\u00a0las\u00a0consideraciones \u00a0previas,\u00a0el\u00a0inicio\u00a0del\u00a0TARV\u00a0debe\u00a0valorarse\u00a0siempre\u00a0\nindividualmente. \u00a0Antes\u00a0de\u00a0tomar\u00a0la\u00a0decisi\u00f3n\u00a0de\u00a0iniciarlo\u00a0deben\u00a0confirmarse \u00a0la\u00a0cifra\u00a0\nde\u00a0CD4\u00a0y\u00a0de\u00a0CVP.\u00a0Adem\u00e1s,\u00a0debe\u00a0prepararse \u00a0al\u00a0paciente, \u00a0ofertando \u00a0las\u00a0distintas\u00a0op\u2010\nciones,\u00a0adaptando \u00a0el\u00a0esquema\u00a0terap\u00e9utico \u00a0al\u00a0estilo\u00a0de\u00a0vida,\u00a0comorbilidades, \u00a0posi\u2010\nbles\u00a0interacciones \u00a0y\u00a0valorando \u00a0el\u00a0riesgo\u00a0de\u00a0mala\u00a0adherencia. \u00a0\n\u00a0\n4.2.\u00a0\u00bfQu\u00e9\u00a0combinaci\u00f3n \u00a0de\u00a0antirretrovirales \u00a0debe\u00a0utilizarse? \u00a0\nEl\u00a0tratamiento \u00a0de\u00a0elecci\u00f3n\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0en\u00a0el\u00a0momento \u00a0actual\u00a0consiste\u00a0en\u00a0\nuna\u00a0combinaci\u00f3n \u00a0de\u00a0al\u00a0menos\u00a0tres\u00a0f\u00e1rmacos \u00a0que\u00a0incluyan\u00a0dos\u00a0AN\u00a0y\u00a0un\u00a0IP/r\u00a0o\u00a0un\u00a0NN\u00a0\n(tabla\u00a04).\u00a0Con\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0estas\u00a0combinaciones \u00a0se\u00a0puede\u00a0conseguir \u00a0CVP\u00a0<50\u00a0co\u2010\npias/mL\u00a0en\u00a0>70%\u00a0de\u00a0casos\u00a0a\u00a0las\u00a048\u00a0semanas201.\u00a0\nCriterios\u00a0para\u00a0la\u00a0elecci\u00f3n\u00a0de\u00a0las\u00a0pautas\u00a0antirretrovirales \u00a0\nSe\u00a0consideran \u00a0\u201cpautas\u00a0preferentes\u201d \u00a0las\u00a0combinaciones \u00a0avaladas\u00a0por\u00a0el\u00a0mayor\u00a0n\u00famero\u00a0\nde\u00a0ensayos\u00a0cl\u00ednicos\u00a0con\u00a0eficacia\u00a0y\u00a0durabilidad \u00a0\u00f3ptimas,\u00a0tolerancias \u00a0aceptables \u00a0y\u00a0f\u00e1ciles\u00a0\nde\u00a0usar.\u00a0Otras\u00a0pautas\u00a0que\u00a0han\u00a0demostrado \u00a0eficacia,\u00a0pero\u00a0con\u00a0menor\u00a0n\u00famero\u00a0de\u00a0pa\u2010\ncientes,\u00a0menor\u00a0duraci\u00f3n\u00a0de\u00a0los\u00a0estudios,\u00a0mayor\u00a0toxicidad\u00a0o\u00a0complejidad \u00a0en\u00a0su\u00a0posolog\u2010\n\u00eda\u00a0se\u00a0han\u00a0considerado \u00a0\u201cpautas\u00a0alternativas\u201d. \u00a0Se\u00a0dispone\u00a0de\u00a0m\u00faltiples \u00a0pautas\u00a0antirretro \u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 26 \n virales\u00a0de\u00a0eficacia\u00a0similar.\u00a0En\u00a0este\u00a0contexto\u00a0este\u00a0comit\u00e9\u00a0quiere\u00a0destacar\u00a0la\u00a0importancia \u00a0\ncreciente \u00a0del\u00a0costo\u00a0de\u00a0los\u00a0FAR\u00a0para\u00a0establecer \u00a0las\u00a0pautas\u00a0preferentes. \u00a0\u00a0\nConsideraciones \u00a0generales \u00a0sobre\u00a0las\u00a0combinaciones \u00a0de\u00a0FAR\u00a0\u00a0\nRespecto\u00a0a\u00a0las\u00a0distintas\u00a0combinaciones \u00a0de\u00a0TARV,\u00a0este\u00a0comit\u00e9\u00a0quiere\u00a0hacer\u00a0varias\u00a0pun\u2010\ntualizaciones. \u00a0Primera,\u00a0resaltar\u00a0que\u00a0las\u00a0combinaciones \u00a0de\u00a02\u00a0AN\u00a0con\u00a0LPV/r\u00a0o\u00a0EFV\u00a0son\u00a0las\u00a0\nm\u00e1s\u00a0experimentadas \u00a0en\u00a0caso\u00a0de\u00a0inmunodepresi\u00f3n \u00a0avanzada \u00a0(linfocitos \u00a0CD4\u00a0<100\u00a0c\u00e9lu\u2010\nlas/\u00b5L)202\u2010208.\u00a0Segunda,\u00a0las\u00a0pautas\u00a0de\u00a03\u00a0AN\u00a0son\u00a0menos\u00a0eficaces\u00a0que\u00a0las\u00a0pautas\u00a0de\u00a02\u00a0AN\u00a0+\u00a0\n1\u00a0NN209\u00a0\u00a0\u00f3\u00a02\u00a0AN\u00a0+\u00a01\u00a0IP210,\u00a0211.\u00a0Tercera,\u00a0el\u00a0tratamiento \u00a0con\u00a0f\u00e1rmacos\u00a0de\u00a0las\u00a0tres\u00a0familias\u00a0\n(AN,\u00a0NN\u00a0e\u00a0IP)\u00a0puede\u00a0ser\u00a0muy\u00a0potente,\u00a0pero\u00a0no\u00a0se\u00a0recomienda \u00a0de\u00a0inicio\u00a0por\u00a0su\u00a0comple\u2010\njidad,\u00a0toxicidad\u00a0y\u00a0limitaci\u00f3n \u00a0de\u00a0futuras\u00a0opciones\u00a0terap\u00e9uticas \u00a0en\u00a0caso\u00a0de\u00a0fracaso2,\u00a03,\u00a0212,\u00a0\n213.\u00a0Otro\u00a0tanto\u00a0ocurre\u00a0con\u00a0las\u00a0pautas\u00a0que\u00a0incluyen\u00a0solamente \u00a0dos\u00a0IPs.\u00a0Cuarta,\u00a0la\u00a0combi\u2010\nnaci\u00f3n\u00a0de\u00a0un\u00a0NN\u00a0y\u00a0un\u00a0IP\u00a0ha\u00a0demostrado \u00a0una\u00a0eficacia\u00a0similar\u00a0al\u00a0tratamiento \u00a0triple\u00a0con\u00a0\nIP202,\u00a0pero\u00a0produce\u00a0mayor\u00a0dislipemia214,\u00a0215.\u00a0Quinta:\u00a0los\u00a0inhibidores \u00a0de\u00a0la\u00a0fusi\u00f3n\u00a0no\u00a0se\u00a0\nutilizan\u00a0en\u00a0la\u00a0terapia\u00a0de\u00a0inicio\u00a0y\u00a0deben\u00a0reservarse \u00a0para\u00a0el\u00a0fracaso.\u00a0Sexta:\u00a0El\u00a0TARV\u00a0de\u00a0\ninicio\u00a0con\u00a0m\u00e1s\u00a0de\u00a0tres\u00a0f\u00e1rmacos \u00a0no\u00a0mejora\u00a0la\u00a0pauta\u00a0est\u00e1ndar\u00a0con\u00a0tres216\u2010219.\u00a0\nConsideraciones \u00a0sobre\u00a0la\u00a0elecci\u00f3n\u00a0de\u00a0un\u00a0NN\u00a0o\u00a0un\u00a0IP/r\u00a0\u00a0\nLas\u00a0pautas\u00a0basadas\u00a0en\u00a0NN\u00a0ofrecen\u00a0ciertas\u00a0ventajas\u00a0sobre\u00a0las\u00a0que\u00a0incluyen\u00a0un\u00a0IP/r:\u00a01)\u00a0\nMenos\u00a0interacciones \u00a0farmacocin\u00e9ticas; \u00a02)\u00a0Perfil\u00a0metab\u00f3lico \u00a0m\u00e1s\u00a0favorable; \u00a03)\u00a0Menor\u00a0\ncoste;\u00a0y\u00a04)\u00a0Menor\u00a0n\u00famero\u00a0de\u00a0comprimidos. \u00a0Adem\u00e1s,\u00a0dada\u00a0la\u00a0baja\u00a0barrera\u00a0gen\u00e9tica\u00a0de\u00a0\nlos\u00a0NN,\u00a0el\u00a0momento \u00a0id\u00f3neo\u00a0de\u00a0su\u00a0uso\u00a0es\u00a0el\u00a0primer\u00a0tratamiento. \u00a0En\u00a0pautas\u00a0de\u00a0rescate\u00a0\nlos\u00a0NN\u00a0de\u00a0primera\u00a0generaci\u00f3n \u00a0tienen\u00a0menos\u00a0actividad\u00a0que\u00a0otros\u00a0componentes \u00a0del\u00a0\nr\u00e9gimen.\u00a0\u00a0\nLa\u00a0ventaja\u00a0principal\u00a0de\u00a0los\u00a0IP/r\u00a0es\u00a0su\u00a0alta\u00a0barrera\u00a0gen\u00e9tica\u00a0para\u00a0el\u00a0desarrollo \u00a0de\u00a0resis\u2010\ntencias.\u00a0\u00a0\n\u00a0\nQu\u00e9\u00a0FAR\u00a0deben\u00a0usarse\u00a0en\u00a0el\u00a0TARV\u00a0inicial.\u00a0Recomendaci\u00f3n \u00a0\u00a0\n\u0083 Pueden\u00a0utilizarse\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a02\u00a0AN\u00a0+\u00a01\u00a0NN\u00a0\u00f3\u00a02\u00a0AN\u00a0+\u00a01\u00a0IP/r\u00a0como\u00a0tratamiento \u00a0\nde\u00a0inicio\u00a0(los\u00a0f\u00e1rmacos \u00a0preferentes \u00a0se\u00a0detallan\u00a0m\u00e1s\u00a0adelante). \u00a0Una\u00a0alternativa \u00a0v\u00e1li\u2010\nda\u00a0cuando\u00a0no\u00a0se\u00a0pueden\u00a0tomar\u00a0IP\u00a0\u00f3\u00a0NN\u00a0es\u00a0combinar \u00a03\u00a0AN\u00a0(ZDV+3TC+ABC) \u00a0o\u00a02\u00a0AN+\u00a0\nMVC\u00a0(nivel\u00a0A)\u00a0(Tabla\u00a04).\u00a0\u00a0\n\u00a0\n4.3.\u00a0Inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3sido \u00a0\nEn\u00a0Espa\u00f1a\u00a0est\u00e1n\u00a0comercializados \u00a06\u00a0AN:\u00a0zidovudina \u00a0(ZDV),\u00a0didanosina \u00a0(ddI),\u00a0estavudina \u00a0\n(d4T),\u00a0lamivudina \u00a0(3TC),\u00a0emtricitabina \u00a0(FTC)\u00a0y\u00a0abacavir\u00a0(ABC).\u00a0Tambi\u00e9n\u00a0se\u00a0dispone\u00a0de\u00a0\nun\u00a0an\u00e1logo\u00a0de\u00a0nucle\u00f3tido, \u00a0tenofovir\u00a0(TDF).\u00a0A\u00a0efectos\u00a0pr\u00e1cticos, \u00a0la\u00a0abreviatura \u00a0AN\u00a0inclu\u2010\nye\u00a0tambi\u00e9n\u00a0al\u00a0TDF\u00a0en\u00a0esta\u00a0gu\u00eda.\u00a0Las\u00a0principales \u00a0caracter\u00edsticas \u00a0de\u00a0los\u00a0AN\u00a0se\u00a0describen \u00a0\nen\u00a0la\u00a0Tabla\u00a05.\u00a0Las\u00a0combinaciones \u00a0TDF+FTC\u00a0(o\u00a03TC),\u00a0ABC+3TC\u00a0(o\u00a0FTC)\u00a0y\u00a0ddI+3TC\u00a0(o\u00a0FTC)\u00a0\npueden\u00a0administrarse \u00a0una\u00a0vez\u00a0al\u00a0d\u00eda;\u00a0de\u00a0ellas\u00a0TDF+FTC\u00a0y\u00a0ABC+3TC\u00a0se\u00a0presentan \u00a0en\u00a0un\u00a0\nsolo\u00a0comprimido. \u00a0\u00a0\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 27 \n \u00a0\nEnsayos\u00a0cl\u00ednicos\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0de\u00a0uso\u00a0de\u00a0AN\u00a0\u00a0\nGilead\u00a0903\u00a0\u00a0\nEl\u00a0estudio\u00a0Gilead\u00a0903\u00a0compar\u00f3\u00a0la\u00a0eficacia\u00a0y\u00a0seguridad \u00a0de\u00a0TDF\u00a0frente\u00a0a\u00a0d4T\u00a0administra \u2010\ndos\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0EFV\u00a0y\u00a03TC\u00a0en\u00a0pacientes \u00a0sin\u00a0TARV\u00a0previo.\u00a0Los\u00a0602\u00a0pacientes \u00a0\nincluidos\u00a0ten\u00edan\u00a0una\u00a0media\u00a0de\u00a0CD4\u00a0de\u00a0276\u2010283\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0de\u00a0CVP\u00a0de\u00a04,91\u00a0log 10\u00a0co\u2010\npias/mL.\u00a0En\u00a0un\u00a0an\u00e1lisis\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0tratar,\u00a0a\u00a0las\u00a0144\u00a0semanas, \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0\npacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0era\u00a0del\u00a067,9%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TDF\u00a0y\u00a062,5%\u00a0en\u00a0el\u00a0de\u00a0\nd4T.\u00a0Entre\u00a0los\u00a0tratados\u00a0con\u00a0TDF\u00a0fue\u00a0menos\u00a0frecuente \u00a0tanto\u00a0la\u00a0toxicidad\u00a0global\u00a0relacio\u2010\nnada\u00a0con\u00a0disfunci\u00f3n \u00a0mitocondrial \u00a0(6%\u00a0frente\u00a0a\u00a028%)\u00a0como\u00a0la\u00a0neuropat\u00eda \u00a0perif\u00e9rica \u00a0(3%\u00a0\nfrente\u00a0a\u00a010%)\u00a0o\u00a0lipodistrofia \u00a0(3%\u00a0frente\u00a0al\u00a019%).\u00a0Asimismo, \u00a0este\u00a0grupo\u00a0tuvo\u00a0un\u00a0mejor\u00a0\nperfil\u00a0lip\u00eddico.\u00a0Por\u00a0tanto,\u00a0este\u00a0estudio\u00a0apoy\u00f3\u00a0el\u00a0uso\u00a0de\u00a0TDF\u00a0+\u00a03TC\u00a0+\u00a0EFV\u00a0frente\u00a0al\u00a0d4T\u00a0+\u00a0\n3TC\u00a0+\u00a0EFV\u00a0como\u00a0terapia\u00a0de\u00a0inicio220.\u00a0\u00a0\n\u00a0\nGilead\u00a0934\u00a0\u00a0\nEl\u00a0estudio\u00a0aleatorizado \u00a0Gilead\u00a0934\u00a0compar\u00f3\u00a0TDF+FTC\u00a0QD\u00a0frente\u00a0a\u00a0ZDV+3TC\u00a0BID\u00a0combi\u2010\nnados\u00a0con\u00a0EFV.\u00a0Se\u00a0incluyeron \u00a0517\u00a0pacientes \u00a0sin\u00a0TARV\u00a0previo\u00a0con\u00a0CVP\u00a0basal\u00a0de\u00a05\u00a0log 10\u00a0y\u00a0\nmediana\u00a0de\u00a0CD4\u00a0de\u00a0233\u2010241\u00a0c\u00e9lulas/\u00b5L, \u00a0seg\u00fan\u00a0grupo\u00a0de\u00a0tratamiento. \u00a0En\u00a0el\u00a0an\u00e1lisis\u00a0por\u00a0\nintenci\u00f3n \u00a0de\u00a0tratar\u00a0a\u00a0las\u00a048\u00a0semanas, \u00a0se\u00a0observ\u00f3\u00a0que\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0\nCVP\u00a0<400\u00a0copias/mL \u00a0fue\u00a0del\u00a081%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TDF+FTC\u00a0y\u00a0del\u00a070%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0\nZDV+3TC\u00a0(p=0.005). \u00a0La\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0fue\u00a0de\u00a077%\u00a0\nfrente\u00a0a\u00a068%,\u00a0respectivamente \u00a0(p=0.034). \u00a0Los\u00a0linfocitos\u00a0CD4\u00a0aumentaron \u00a0190\u00a0c\u00e9lu\u2010\nlas/\u00b5L\u00a0en\u00a0el\u00a0grupo\u00a0TDF+FTC\u00a0frente\u00a0a\u00a0158\u00a0c\u00e9lulas/\u00b5L \u00a0en\u00a0el\u00a0de\u00a0ZDV+3TC\u00a0(p=\u00a00.002).\u00a0Hubo\u00a0\nmenos\u00a0efectos\u00a0adversos\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TDF+FTC\u00a0(4%\u00a0frente\u00a0al\u00a09%;\u00a0\u00a0p\u00a0=\u00a00.016)\u00a0y\u00a0menos\u00a0\nsuspensiones \u00a0de\u00a0tratamiento \u00a0por\u00a0reacciones \u00a0adversas\u00a0(4%\u00a0frente\u00a0a\u00a09%;\u00a0p=\u00a00.016).\u00a0El\u00a06%\u00a0\nde\u00a0los\u00a0pacientes \u00a0tratados\u00a0con\u00a0ZDV+3TC\u00a0tuvo\u00a0anemia\u00a0frente\u00a0al\u00a00%\u00a0en\u00a0los\u00a0tratados\u00a0con\u00a0\nTDF+FTC. \u00a0El\u00a0incremento \u00a0del\u00a0colesterol \u00a0fue\u00a0m\u00e1s\u00a0bajo\u00a0y\u00a0el\u00a0volumen\u00a0de\u00a0grasa\u00a0en\u00a0extremi\u2010\ndades\u00a0m\u00e1s\u00a0alto\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TDF+FTC\u00a0(diferencias \u00a0significativas)221.\u00a0A\u00a0las\u00a0144\u00a0sema\u2010\nnas\u00a0de\u00a0seguimiento \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0era\u00a0de\u00a075%\u00a0en\u00a0\nel\u00a0grupo\u00a0de\u00a0TDF+FTC\u00a0y\u00a058%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ZDV+3TC\u00a0(p=0.004), \u00a0pero\u00a0sin\u00a0diferencias \u00a0en\u00a0\nla\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(p=0,08).\u00a0En\u00a0caso\u00a0de\u00a0fracaso\u00a0virol\u00f3gico, \u00a0la\u00a0mutaci\u00f3n \u00a0M184V/I\u00a0fue\u00a0\nm\u00e1s\u00a0frecuente \u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ZDV+3TC222.\u00a0La\u00a0respuesta \u00a0inmunol\u00f3gica \u00a0fue\u00a0algo\u00a0mejor\u00a0\nen\u00a0los\u00a0tratados\u00a0con\u00a0TDF+FTC\u00a0(312\u00a0frente\u00a0a\u00a0271\u00a0c\u00e9lulas/\u00b5L; \u00a0p=\u00a00.09).\u00a0Por\u00a0otra\u00a0parte,\u00a0\u00a0la\u00a0\ncantidad\u00a0de\u00a0grasa\u00a0en\u00a0extremidades \u00a0fue\u00a0mayor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TDF+FTC\u00a0(7.9\u00a0vs.\u00a05.4\u00a0kg,\u00a0\np<0.001)223.\u00a0\n\u00a0\nCNA30024 \u00a0\u00a0\nEl\u00a0estudio\u00a0CNA30024 \u00a0es\u00a0un\u00a0ensayo\u00a0aleatorizado, \u00a0doble\u00a0ciego\u00a0que\u00a0compara\u00a0la\u00a0eficacia\u00a0y\u00a0\ntolerancia \u00a0de\u00a0ZDV\u00a0frente\u00a0a\u00a0ABC\u00a0(ambos\u00a0BID)\u00a0combinados \u00a0con\u00a03TC\u00a0y\u00a0EFV.\u00a0Se\u00a0incluyeron \u00a0\n649\u00a0pacientes \u00a0sin\u00a0TARV\u00a0previo\u00a0con\u00a0una\u00a0CVP\u00a0basal\u00a0media\u00a0de\u00a04.76\u20104.81\u00a0log 10\u00a0copias/mL \u00a0y\u00a0\nuna\u00a0media\u00a0de\u00a0linfocitos\u00a0CD4\u00a0de\u00a0256\u2010267\u00a0c\u00e9lulas/\u00b5L. \u00a0En\u00a0la\u00a0semana\u00a048,\u00a0la\u00a0eficacia\u00a0virol\u00f3\u2010\ngica\u00a0fue\u00a0similar\u00a0en\u00a0ambos\u00a0grupos.\u00a0Alrededor \u00a0del\u00a070%\u00a0alcanzaron \u00a0una\u00a0CVP\u00a0<50\u00a0co\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 28 \n pias/mL\u00a0(an\u00e1lisis\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0tratar).\u00a0Sin\u00a0embargo, \u00a0el\u00a0incremento \u00a0de\u00a0CD4\u00a0fue\u00a0signi\u2010\nficativamente \u00a0superior\u00a0en\u00a0el\u00a0grupo\u00a0tratado\u00a0con\u00a0ABC\u00a0(mediana, \u00a0205\u00a0frente\u00a0a\u00a0155\u00a0c\u00e9lu\u2010\nlas/\u00b5L).\u00a0Un\u00a08%\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0tomaron\u00a0ABC\u00a0desarroll\u00f3 \u00a0reacci\u00f3n\u00a0de\u00a0hipersensibili \u2010\ndad.\u00a0Bas\u00e1ndose \u00a0en\u00a0los\u00a0resultados \u00a0de\u00a0este\u00a0estudio\u00a0se\u00a0considera \u00a0que\u00a0ABC\u00a0es\u00a0equivalente \u00a0\na\u00a0ZDV\u00a0en\u00a0eficacia\u00a0antiviral,\u00a0aunque\u00a0debe\u00a0tenerse\u00a0en\u00a0cuenta\u00a0el\u00a0riesgo\u00a0de\u00a0aparici\u00f3n \u00a0de\u00a0la\u00a0\nreacci\u00f3n\u00a0de\u00a0hipersensibilidad224.\u00a0\n\u00a0\nCNA30021 \u00a0\u00a0\nEl\u00a0estudio\u00a0CNA30021 \u00a0es\u00a0un\u00a0ensayo\u00a0aleatorizado \u00a0que\u00a0compara\u00a0la\u00a0eficacia\u00a0del\u00a0ABC\u00a0QD\u00a0\nfrente\u00a0a\u00a0BID.\u00a0Incluy\u00f3\u00a0770\u00a0pacientes \u00a0sin\u00a0TARV\u00a0previo.\u00a0Los\u00a0pacientes \u00a0recibieron \u00a0ABC,\u00a0600\u00a0\nmg\u00a0QD,\u00a0o\u00a0ABC,\u00a0300\u00a0mg\u00a0BID,\u00a0adem\u00e1s\u00a0de\u00a03TC\u00a0(300\u00a0mg\u00a0QD)\u00a0+\u00a0EFV\u00a0(600\u00a0mg\u00a0QD).\u00a0A\u00a0las\u00a048\u00a0\nsemanas\u00a0el\u00a0porcentaje \u00a0de\u00a0pacientes \u00a0que\u00a0alcanzaron \u00a0<50\u00a0copias/mL \u00a0(an\u00e1lisis\u00a0por\u00a0inten\u2010\nci\u00f3n\u00a0de\u00a0tratar)\u00a0fue\u00a0de\u00a066%\u00a0en\u00a0la\u00a0rama\u00a0QD\u00a0y\u00a0de\u00a068%\u00a0en\u00a0la\u00a0rama\u00a0BID.\u00a0El\u00a0estudio\u00a0demostr\u00f3 \u00a0\nla\u00a0equivalencia \u00a0de\u00a0las\u00a0dos\u00a0pautas\u00a0de\u00a0administraci\u00f3n \u00a0de\u00a0ABC.\u00a0Las\u00a0reacciones \u00a0de\u00a0hiper\u2010\nsensibilidad \u00a0a\u00a0ABC\u00a0(grado\u00a03\u20104)\u00a0fueron\u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0la\u00a0rama\u00a0QD\u00a0que\u00a0en\u00a0la\u00a0BID\u00a0(5%\u00a0\nvs\u00a02%)225.\u00a0\u00a0\n\u00a0ABCDE\u00a0\nEl\u00a0ABCDE\u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0abierto\u00a0que\u00a0incluy\u00f3\u00a0237\u00a0pacientes \u00a0aleatorizados \u00a0a\u00a0recibir\u00a0\nABC\u00a0o\u00a0d4T\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a03TC\u00a0+\u00a0EFV.\u00a0En\u00a0la\u00a0semana\u00a096\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0\ncon\u00a0CVP<50\u00a0copias/mL \u00a0fue\u00a0mayor\u00a0en\u00a0los\u00a0tratados\u00a0con\u00a0ABC\u00a0(60.9%\u00a0frente\u00a0a\u00a047.5%,\u00a0p\u00a0=\u00a0\n0.05).\u00a0El\n\u00a0grupo\u00a0tratado\u00a0con\u00a0d4T\u00a0presentaba \u00a0lipoatrofia \u00a0cl\u00ednicamente \u00a0aparente\u00a0(para\u00a0\nm\u00e9dico\u00a0y\u00a0paciente) \u00a0en\u00a0el\u00a038,3%,\u00a0significativamente \u00a0superior\u00a0al\u00a04,8%\u00a0de\u00a0los\u00a0que\u00a0recibie\u2010\nron\u00a0ABC226.\u00a0\n\u00a0\nPREDICT\u00a0\nEl\u00a0ensayo\u00a0cl\u00ednico\u00a0PREDICT\u00a0ha\u00a0demostrado \u00a0que\u00a0la\u00a0incidencia \u00a0de\u00a0reacci\u00f3n\u00a0de\u00a0hipersensibi \u2010\nlidad\u00a0a\u00a0ABC\u00a0puede\u00a0disminuir \u00a0dr\u00e1sticamente \u00a0mediante \u00a0la\u00a0genotipificaci\u00f3n \u00a0del\u00a0HLA\u2010\u00a0\nB*5701109.\u00a0En\u00a0este\u00a0ensayo\u00a0cl\u00ednico\u00a0la\u00a0prueba\u00a0de\u00a0genotipificaci\u00f3n \u00a0del\u00a0HLA\u2010B*5701\u00a0tuvo\u00a0\nun\u00a0valor\u00a0predictivo \u00a0negativo\u00a0del\u00a0100%\u00a0para\u00a0descartar \u00a0la\u00a0reacci\u00f3n\u00a0de\u00a0hipersensibilidad \u00a0a\u00a0\nABC\u00a0confirmada \u00a0mediante \u00a0prueba\u00a0cut\u00e1nea.\u00a0\u00a0\n\u00a0FTC\u00a0301\u2010A\u00a0\nEl\u00a0FTC\u00a0301\u2010A\u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0aleatorizado \u00a0y\u00a0doble\u00a0ciego\u00a0que\u00a0compara\u00a0la\u00a0eficacia\u00a0y\n\u00a0\ntolerancia \u00a0de\u00a0FTC\u00a0frente\u00a0a\u00a0d4T,\u00a0ambos\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0ddI+EFV.\u00a0Se\u00a0incluyeron \u00a0571\u00a0\npacientes \u00a0sin\u00a0terapia\u00a0previa\u00a0con\u00a0una\u00a0media\u00a0de\u00a0linfocitos\u00a0CD4\u00a0de\u00a0312\u2010324\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0\nuna\u00a0media\u00a0de\u00a0CVP\u00a0de\u00a04.8\u00a0log 10.\u00a0A\u00a0la\u00a0semana\u00a048,\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0\n<50\u00a0copias/mL \u00a0para\u00a0los\u00a0grupos\u00a0de\u00a0FTC\u00a0y\u00a0d4T\u00a0fue\u00a0de\u00a074%\u00a0y\u00a058%\u00a0(p<0.0001). \u00a0El\u00a0incremen \u2010\nto\u00a0de\u00a0los\u00a0linfocitos\u00a0CD4\u00a0fue\u00a0mayor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0FTC\u00a0(168\u00a0frente\u00a0a\u00a0134\u00a0c\u00e9lulas/\u00b5L; \u00a0\np<0.05).\u00a0La\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0que\u00a0discontinuaron \u00a0por\u00a0efectos\u00a0adversos\u00a0fue\u00a0ma\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 29 \n yor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0d4T+ddI\u00a0(16.6\u00a0frente\u00a0a\u00a07.4%;\u00a0p=0.0028). \u00a0Los\u00a0pacientes \u00a0tratados\u00a0con\u00a0\nd4T+ddI\u00a0tuvieron\u00a0mayor\u00a0incidencia \u00a0de\u00a0neuropat\u00eda \u00a0perif\u00e9rica, \u00a0diarrea\u00a0y\u00a0n\u00e1useas227.\u00a0\u00a0\n\u00a0Gesida\u00a03903\u00a0\nEl\u00a0Gesida\u00a03903\u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0aleatorizado \u00a0y\u00a0abierto\u00a0que\u00a0estudia\u00a0la\u00a0eficacia\u00a0de\u00a0la\u00a0\ncombinaci\u00f3n \u00a0ddI+3TC\u00a0en\u00a0pauta\u00a0QD.\u00a0En\u00a0este\u00a0ensayo\u00a0se\u00a0compararon \u00a0ddI\u00a0(400\u00a0mg\u00a0QD\u00a0o\u00a0\n250\u00a0mg\u00a0si\u00a0peso\u00a0<60\u00a0Kg,\u00a0tomado\u00a0con\u00a0o\u00a0sin\u00a0comida)\u00a0+\u00a03TC\u00a0(300\u00a0mg\u00a0QD)\u00a0frente\n\u00a0a\u00a0ZDV+3TC\u00a0\n(coformulados, \u00a0300/150mg \u00a0BID)\u00a0en\u00a0369\u00a0pacientes \u00a0sin\u00a0TARV\u00a0previo.\u00a0Todos\u00a0los\u00a0pacientes \u00a0\nrecibieron \u00a0adem\u00e1s\u00a0EFV\u00a0600\u00a0mg\u00a0QD.\u00a0A\u00a0las\u00a048\u00a0semanas\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0\nCVP\u00a0<50\u00a0copias/mL \u00a0(an\u00e1lisis\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0tratar)\u00a0fue\u00a070%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ddI+3TC\u00a0y\u00a0\n63%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ZDV+3TC\u00a0(p=0,154, \u00a0diferencia \u00a07,1%;\u00a095%\u00a0CI\u00a02,39\u00a0a\u00a016,59%).\u00a0El\u00a0estu\u2010\ndio\u00a0demostr\u00f3 \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0ddI+3TC\u00a0frente\u00a0a\u00a0ZDV+3TC. \u00a0La\u00a0discontinuaci\u00f3n \u00a0del\u00a0\ntratamiento \u00a0por\u00a0efectos\u00a0adversos\u00a0fue\u00a0menor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ddI+3TC\u00a0(14,\u00a08%\u00a0frente\u00a0a\u00a0\n26%,\u00a0p=0.046), \u00a0as\u00ed\u00a0como\u00a0la\u00a0toxicidad\u00a0hematol\u00f3gica \u00a0y\u00a0la\u00a0anemia\u00a0(1%\u00a0y\u00a06%;\u00a0p=0.003). \u00a0No\u00a0\nhubo\u00a0diferencias \u00a0en\u00a0cuanto\u00a0a\u00a0la\u00a0recuperaci\u00f3n \u00a0inmunol\u00f3gica, \u00a0ni\u00a0en\u00a0la\u00a0prevalencia \u00a0de\u00a0\nlipoatrofia \u00a0y/o\u00a0lipoacumulaci\u00f3n, \u00a0valorada\u00a0por\u00a0criterio\u00a0del\u00a0investigador228.\u00a0\u00a0\n\u00a0ACTG\u2010384\u00a0\nEl\u00a0ACTG\u2010384\u00a0es\u00a0un\u00a0estudio\u00a0que\u00a0valora\u00a0la\u00a0eficacia\u00a0y\u00a0tolerancia \u00a0de\u00a0las\u00a0distintas\u00a0combina\u2010\nciones\u00a0de\u00a0AN\u00a0cuando\u00a0se\u00a0asocian\u00a0a\u00a0un\u00a0tercer\u00a0f\u00e1rmaco\u00a0(NN\u00a0o\u00a0IP).\u00a0Este\u00a0ensayo\u00a0cl\u00ednico\u00a0alea\u2010\ntorizado\u00a0se\u00a0plantea\u00a0responder \u00a0a\u00a0tres\u00a0preguntas: \u00a01\u00ba)\u00a0\u00bfes\u00a0mejor\u00a0empezar\u00a0con\u00a0ddI+d4T\u00a0o\u00a0\nZDV+3TC\n\u00a0como\u00a0combinaci\u00f3n \u00a0de\u00a0AN?;\u00a02\u00ba)\u00a0\u00bfEs\u00a0mejor\u00a0empezar\u00a0con\u00a0un\u00a0IP\u00a0(NFV)\u00a0o\u00a0un\u00a0NN\u00a0\n(EFV)?,\u00a03\u00ba)\u00a0\u00bfEs\u00a0mejor\u00a0utilizar\u00a0combinaciones \u00a0secuenciales \u00a0de\u00a0tres\u00a0FAR\u00a0o\u00a0una\u00a0combina\u2010\nci\u00f3n\u00a0de\u00a0cuatro?\u00a0Se\u00a0incluyeron \u00a0980\u00a0pacientes \u00a0sin\u00a0TARV\u00a0previo\u00a0con\u00a0una\u00a0mediana\u00a0de\u00a0linfo\u2010\ncitos\u00a0CD4\u00a0de\u00a0278\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0una\u00a0CVP\u00a0basal\u00a0de\u00a04.9\u00a0log 10\u00a0copias/mL. \u00a0Los\u00a0brazos\u00a0del\u00a0es\u2010\ntudio\u00a0fueron:\u00a01\u00ba)\u00a0d4T\u00a0+\u00a0ddI\u00a0+\u00a0EFV\u00a0\u2192\u00a0ZDV\u00a0+\u00a03TC\u00a0+\u00a0NFV;\u00a02\u00ba)\u00a0d4T\u00a0+\u00a0ddI\u00a0+\u00a0NFV\u00a0\u2192\u00a0ZDV\u00a0+\u00a03TC\u00a0\n+\u00a0EFV;\u00a0\u00a03\u00ba)\u00a0ZDV\u00a0+\u00a03TC\u00a0+\u00a0EFV\u00a0\u2192\u00a0d4T\u00a0+\u00a0ddI\u00a0+\u00a0NFV;\u00a04\u00ba)\u00a0ZDV\u00a0+\u00a03TC\u00a0+\u00a0NFV\u00a0\u2192\u00a0d4T\u00a0+\u00a0ddI\u00a0+\u00a0EFV;\u00a0\n5\u00ba)\u00a0d4T\u00a0+\u00a0ddI\u00a0+\u00a0EFV\u00a0+\u00a0NFV;\u00a06\u00ba)\u00a0ZDV\u00a0+3TC\u00a0+\u00a0EFV\u00a0+\u00a0NFV.\u00a0El\u00a0punto\u00a0de\u00a0valoraci\u00f3n \u00a0final\u00a0pri\u2010\nmario\u00a0fue\u00a0el\u00a0tiempo\u00a0hasta\u00a0el\u00a0fracaso\u00a0de\u00a0dos\u00a0reg\u00edmenes \u00a0secuenciales \u00a0de\u00a0tres\u00a0FAR\u00a0o\u00a0el\u00a0\nprimer\u00a0fracaso\u00a0de\u00a0reg\u00edmenes \u00a0de\u00a04.\u00a0La\u00a0mediana\u00a0de\u00a0seguimiento \u00a0fue\u00a0de\u00a02.3\u00a0a\u00f1os.\u00a0\u00a0Des\u2010\nafortunadamente \u00a0el\u00a0dise\u00f1o\u00a0factorial\u00a0fue\u00a0frustrado \u00a0por\u00a0el\u00a0hecho\u00a0\u00a0de\u00a0que\u00a0las\u00a0combina\u2010\nciones\u00a0de\u00a0AN\u00a0no\u00a0fueron\u00a0independientes \u00a0del\u00a0efecto\u00a0del\u00a0tercer\u00a0f\u00e1rmaco.\u00a0La\u00a0actividad\u00a0de\u00a0\nEFV\u00a0fue\u00a0diferente \u00a0cuando\u00a0se\u00a0combin\u00f3\u00a0con\u00a0ZDV\u00a0+\u00a03TC\u00a0que\u00a0con\u00a0ddI\u00a0+\u00a0d4T,\u00a0y\u00a0la\u00a0actividad\u00a0\nde\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0ZDV\u00a0+\u00a03TC\u00a0vari\u00f3\u00a0dependiendo \u00a0si\u00a0se\u00a0combinaba \u00a0inicialmente \u00a0con\u00a0\nEFV\u00a0o\u00a0NFV.\u00a0Por\u00a0estas\u00a0razones\u00a0el\u00a0an\u00e1lisis\u00a0factorial\u00a0no\u00a0se\u00a0pudo\u00a0realizar.\u00a0Sin\u00a0embargo, \u00a0de\u00a0\nlos\u00a0datos\u00a0de\u00a0este\u00a0estudio\u00a0se\u00a0pueden\u00a0hacer\u00a0varias\u00a0observaciones: \u00a01\u00ba)\u00a0En\u00a0relaci\u00f3n\u00a0con\u00a0el\u00a0\ntiempo\u00a0hasta\u00a0el\u00a0primer\u00a0fracaso\u00a0virol\u00f3gico, \u00a0es\u00a0significativamente \u00a0mejor\u00a0iniciar\u00a0la\u00a0terapia\u00a0\ncon\u00a0ZDV\u00a0+\u00a03TC\u00a0+\u00a0EFV\u00a0que\u00a0con\u00a0d4T\u00a0+\u00a0ddI\u00a0+\u00a0EFV\u00a0o\u00a0ZDV\u00a0+\u00a03TC\u00a0+\u00a0NFV.\u00a02\u00ba)\u00a0Si\u00a0la\u00a0terapia\u00a0se\u00a0\ninicia\u00a0con\u00a0ZDV\u00a0+\u00a03TC\u00a0+\u00a0EFV,\u00a0no\u00a0existe\u00a0beneficio \u00a0significativo \u00a0al\u00a0a\u00f1adir\u00a0NFV\u00a0como\u00a0cuarto\u00a0\nf\u00e1rmaco;\u00a03\u00ba)\u00a0d4T\u00a0+\u00a0ddI\u00a0producen \u00a0m\u00e1s\u00a0efectos\u00a0t\u00f3xicos\u00a0que\u00a0ZDV\u00a0+\u00a03TC.\u00a0Los\u00a0resultados \u00a0de\u00a0\neste\u00a0estudio\u00a0avalar\u00edan\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0ZDV\u00a0+\u00a03TC\u00a0+\u00a0EFV\u00a0como\u00a0terapia\u00a0de\u00a0inicio217,\u00a0229.\u00a0\n\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 30 \n ACTG\u00a05175\u00a0\nLa\u00a0combinaci\u00f3n \u00a0ZDV+\u00a03TC\u00a0+\u00a0EFV\u00a0se\u00a0ha\u00a0comparado \u00a0con\u00a0TDF\u00a0+\u00a0FTC\u00a0+\u00a0EFV\u00a0y\u00a0con\u00a0ddI\u00a0+\u00a0FTC\u00a0\n+\u00a0ATV\u00a0(sin\u00a0potenciar \u00a0con\u00a0ritonavir) \u00a0en\u00a01571\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0en\u00a0el\u00a0en\u2010\nsayo\u00a0cl\u00ednico\u00a0ACTG\u00a05175230.\u00a0Despu\u00e9s\u00a0de\u00a0una\u00a0mediana\u00a0de\u00a0seguimiento \u00a0de\u00a072\u00a0semanas, \u00a0el\u00a0\ncomit\u00e9\u00a0de\u00a0control\u00a0y\u00a0seguridad \u00a0del\u00a0estudio\u00a0decidi\u00f3\u00a0suspender \u00a0el\u00a0grupo\u00a0de\u00a0tratamiento \u00a0\ncon\u00a0ddI\u00a0+\u00a0FTC\u00a0+\u00a0ATV\u00a0debido\u00a0a\u00a0una\u00a0tasa\u00a0significativamente \u00a0mayor\u00a0de\u00a0fracaso\u00a0terap\u00e9uti \u2010\nco.\u00a0\u00a0\n\u00a0\nHEAT\u00a0\nLa\u00a0combinaci\u00f3n \u00a0ABC/3TC\u00a0se\u00a0ha\u00a0comparado \u00a0con\u00a0la\u00a0combinaci\u00f3n \u00a0TDF/FTC\u00a0en\u00a0688\u00a0pacien\u2010\ntes\u00a0sin\u00a0tratamiento \u00a0previo\u00a0en\u00a0el\u00a0estudio\u00a0HEAT.\u00a0Todos\u00a0los\u00a0pacientes \u00a0recibieron \u00a0adem\u00e1s\u00a0\nLPV/r\u00a0c\u00e1psulas\u00a0una\u00a0vez\u00a0al\u00a0d\u00eda.\u00a0Los\u00a0datos\u00a0disponibles \u00a0a\u00a048\u00a0y\u00a096\u00a0semanas231,\u00a0232\u00a0avalan\u00a0la\u00a0\nno\u00a0inferioridad \u00a0de\u00a0ABC/3TC\u00a0frente\u00a0a\u00a0TDF/FTC\u00a0cuando\u00a0se\u00a0administran \u00a0junto\u00a0a\u00a0LPV/r\u00a0una\u00a0\nvez\u00a0al\u00a0d\u00eda.\u00a0Tras\u00a096\u00a0semanas\u00a0de\u00a0seguimiento \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a0(intenci\u00f3n \u00a0de\u00a0tratar)\u00a0fue\u00a0del\u00a060%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ABC/3TC\u00a0y\u00a0del\u00a058%\u00a0en\u00a0el\u00a0\ngrupo\u00a0de\u00a0TDF/FTC.\u00a0La\u00a0tasa\u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0confirmado \u00a0fue\u00a0del\u00a012%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0\nABC\u00a0y\u00a011%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TDF.\u00a0Tampoco \u00a0hubo\u00a0diferencias \u00a0significativas \u00a0en\u00a0el\u00a0subgrupo \u00a0\nde\u00a0pacientes \u00a0que\u00a0iniciaron\u00a0tratamiento \u00a0con\u00a0m\u00e1s\u00a0de\u00a0100.000\u00a0copias/mL \u00a0aunque\u00a0el\u00a0estu\u2010\ndio\u00a0no\u00a0tiene\u00a0poder\u00a0para\u00a0demostrar \u00a0la\u00a0no\u2010inferioridad \u00a0de\u00a0ABC/3TC\u00a0en\u00a0pacientes \u00a0con\u00a0CVP\u00a0\nelevadas. \u00a0\n\u00a0ACTG\u00a05202\u00a0\nEl\u00a0estudio\u00a0ACTG\u00a05202\u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0factorial\u00a0que\u00a0compara\u00a0ABC/3TC\u00a0y\u00a0TDF/FTC\u00a0\nen\u00a01858\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo.\u00a0Los\u00a0pacientes \u00a0fueron\u00a0aleatorizados \u00a0adem\u00e1s\u00a0a\u00a0\nrecibir\u00a0ATV/r\u00a0o\u00a0EFV.\u00a0En\u00a0el\u00a0subgrupo \u00a0de\u00a0pacientes \u00a0que\u00a0iniciaron\u00a0el\u00a0TARV\u00a0con\u00a0una\u00a0\nCVP\u00a0\n>100000\u00a0copias/mL \u00a0el\u00a0tiempo\u00a0hasta\u00a0el\u00a0fracaso\u00a0virol\u00f3gico \u00a0fue\u00a0m\u00e1s\u00a0corto\u00a0en\u00a0los\u00a0que\u00a0reci\u2010\nbieron\u00a0ABC/3TC\u00a0y\u00a0el\u00a0n\u00famero\u00a0de\u00a0efectos\u00a0adversos\u00a0grado\u00a03\u20104\u00a0fue\u00a0mayor.\u00a0Despu\u00e9s\u00a0de\u00a0una\u00a0\nmediana\u00a0de\u00a0seguimiento \u00a0de\u00a060\u00a0semanas, \u00a0el\u00a0porcentaje \u00a0de\u00a0pacientes \u00a0con\u00a0fracaso\u00a0virol\u00f3\u2010\ngico\u00a0fue\u00a0del\u00a014%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ABC/3TC\u00a0y\u00a0del\u00a07%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0TDF/FTC\u00a0(P=0,0003). \u00a0\nSi\u00a0el\u00a0paciente\u00a0hab\u00eda\u00a0alcanzado \u00a0una\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0entonces\u00a0no\u00a0hubo\u00a0diferencias \u00a0en\u00a0\ncuanto\u00a0a\u00a0fracaso\u00a0posterior\u00a0independientemente \u00a0de\u00a0la\u00a0pareja\u00a0de\u00a0nucle\u00f3sidos \u00a0recibi\u2010\nda233.\u00a0\u00a0\n\u00a0\nEstudio\u00a0ASSERT\u00a0\nEl\u00a0estudio\u00a0ASSERT\u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0abierto\u00a0y\u00a0multic\u00e9ntrico \u00a0que\u00a0compara\u00a0ABC/3TC\u00a0y\u00a0\nTDF/3TC,\u00a0ambos\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0EFV,\u00a0en\u00a0385\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo.\u00a0El\u00a0\nobjetivo\u00a0primario\u00a0fue\u00a0demostrar \u00a0una\u00a0seguridad \u00a0renal\u00a0superior\u00a0para\u00a0ABC/3TC\u00a0frente\u00a0a\u00a0\nTDF/FTC.\u00a0Los\u00a0cambios\u00a0en\u00a0el\u00a0filtrado\u00a0glomerular \u00a0estimado \u00a0a\u00a0las\u00a048\u00a0semanas\u00a0fueron\u00a0simi\u2010\nlares\u00a0en\u00a0ambos\u00a0grupos.\u00a0No\u00a0obstante\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0que\u00a0consiguieron \u00a0CVP\u00a0\nindetectable \u00a0(<400\u00a0copias/mL) \u00a0a\u00a0las\u00a048\u00a0semanas\u00a0fue\u00a0inferior\u00a0en\u00a0el\u00a0grupo\u00a0con\u00a0ABC/3TC\u00a0\nrespecto\u00a0al\u00a0de\u00a0TDF/FTC\u00a0(67%\u00a0y\u00a077%\u00a0respectivamente, \u00a0P=0,049)\u00a0al\u00a0igual\u00a0que\u00a0para\u00a0CVP\u00a0\n<50\u00a0copias/mL \u00a0(59%\u00a0y\u00a071%\u00a0respectivamente, \u00a0P=0,022)234.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 31 \n \u00a0\nMetan\u00e1lisis \u00a0que\u00a0compara\u00a0la\u00a0base\u00a0de\u00a0nucle\u00f3sidos \u00a0ABC+3TC\u00a0con\u00a0TDF+FTC\u00a0\nEn\u00a0un\u00a0reciente\u00a0metan\u00e1lisis \u00a0se\u00a0analizaron \u00a0datos\u00a0de\u00a012\u00a0ensayos\u00a0cl\u00ednicos\u00a0en\u00a0los\u00a0que\u00a0se\u00a0uti\u2010\nlizaron\u00a0TDF/FTC\u00a0(3399)\u00a0o\u00a0ABC/3TC\u00a0(1769)\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0inhibidores \u00a0de\u00a0proteasa\u00a0\npotenciados \u00a0con\u00a0ritonavir.\u00a0En\u00a0los\u00a0ensayos\u00a0que\u00a0utilizaban \u00a0LPV/r,\u00a0ATV/r\u00a0y\u00a0FPV/r\u00a0como\u00a0\ntercer\u00a0f\u00e1rmaco,\u00a0la\u00a0tasa\u00a0de\u00a0respuesta \u00a0(por\u00a0ITT,\u00a0tiempo\u00a0hasta\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0\u00a0respuesta \u00a0\nvirol\u00f3gica, \u00a0ITT\u2010TLOVR),\u00a0fue\u00a0significativamente \u00a0inferior\u00a0para\u00a0ABC/3TC\u00a0que\u00a0para\u00a0TDF/FTC\u00a0\n(68,8%\u00a0vs.\u00a076,1%,\u00a0P\u00a0=\u00a00,0015).\u00a0En\u00a0pacientes \u00a0con\u00a0carga\u00a0viral\u00a0basal\u00a0inferior\u00a0a\u00a0100.000\u00a0co\u2010\npias/ml\u00a0la\u00a0diferencia \u00a0fue\u00a0de\u00a070,1%\u00a0para\u00a0ABC/3TC\u00a0vs.\u00a080.6%,\u00a0para\u00a0TDF/FTC\u00a0(p=0,0161), \u00a0\nmientras\u00a0que\u00a0en\u00a0los\u00a0que\u00a0ten\u00edan\u00a0una\u00a0carga\u00a0basal\u00a0superior\u00a0a\u00a0100.000\u00a0copias/ml, \u00a0la\u00a0dife\u2010\nrencia\u00a0roz\u00f3\u00a0la\u00a0significaci\u00f3n \u00a0estad\u00edstica \u00a0(67,5%\u00a0vs.\u00a071,5%,\u00a0p=0,0523)235.\u00a0\u00a0\n\u00a0\nCohortes\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0de\u00a0uso\u00a0de\u00a0AN\u00a0\u00a0\nD.A.D.\u00a0\nEn\u00a0la\u00a0cohorte\u00a0D.A.D.\u00a0se\u00a0ha\u00a0comunicado \u00a0que\u00a0el\u00a0uso\u00a0reciente\u00a0(pero\u00a0no\u00a0el\u00a0acumulado) \u00a0de\u00a0\nABC\u00a0(definido\u00a0como\u00a0estar\u00a0recibi\u00e9ndolo \u00a0en\u00a0el\u00a0momento \u00a0actual\u00a0o\u00a0haberlo\u00a0suspendido \u00a0\ndurante\u00a0los\u00a0\u00faltimos\u00a06\u00a0meses)\u00a0se\u00a0asoci\u00f3\u00a0con\u00a0un\u00a0incremento \u00a0de\u00a01,9\u00a0veces\u00a0en\u00a0el\u00a0riesgo\u00a0de\u00a0\npadecer\u00a0un\u00a0infarto\u00a0de\u00a0miocardio \u00a0(comparado \u00a0con\u00a0los\u00a0pacientes \u00a0que\u00a0no\u00a0han\u00a0utilizado\u00a0\nrecientemente \u00a0ABC).\u00a0Esta\u00a0asociaci\u00f3n \u00a0persist\u00eda\u00a0despu\u00e9s\u00a0del\u00a0ajuste\u00a0por\u00a0otros\u00a0factores\u00a0de\u00a0\nriesgo.\u00a0El\u00a0riesgo\u00a0de\u00a0infarto\u00a0de\u00a0miocardio \u00a0no\u00a0estaba\u00a0aumentado \u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0\nhac\u00eda\u00a0m\u00e1s\u00a0de\u00a06\u00a0meses\u00a0que\u00a0hab\u00edan\u00a0comenzado \u00a0el\u00a0tratamiento \u00a0con\u00a0ABC\u00a0o\u00a0en\u00a0los\u00a0que\u00a0se\u00a0\nhab\u00eda\u00a0suspendido \u00a0m\u00e1s\u00a0de\u00a06\u00a0meses\u00a0antes.\u00a0El\u00a0aumento\u00a0del\u00a0riesgo\u00a0de\u00a0infarto\u00a0de\u00a0miocardio \u00a0\nfue\u00a0m\u00e1s\u00a0relevante \u00a0desde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0cl\u00ednico\u00a0en\u00a0aquellos\u00a0pacientes \u00a0que\u00a0ya\u00a0ten\u00edan\u00a0\nun\u00a0riesgo\u00a0cardiovascular \u00a0alto\u00a0seg\u00fan\u00a0la\u00a0ecuaci\u00f3n\u00a0de\u00a0Framingham. \u00a0En\u00a0este\u00a0estudio\u00a0tam\u2010\nbi\u00e9n\u00a0se\u00a0encontr\u00f3\u00a0un\u00a0incremento \u00a0significativo \u00a0del\u00a0riesgo\u00a0de\u00a0infarto\u00a0de\u00a0miocardio \u00a0asocia\u2010\ndo\u00a0al\u00a0uso\u00a0reciente\u00a0de\u00a0ddI\u00a0si\u00a0bien\u00a0la\u00a0magnitud \u00a0de\u00a0la\u00a0asociaci\u00f3n \u00a0fue\u00a0menor236.\u00a0\u00a0\n\u00a0\nSMART\u00a0\nEl\u00a0estudio\u00a0SMART,\u00a0que\u00a0tambi\u00e9n\u00a0ha\u00a0evaluado\u00a0la\u00a0asociaci\u00f3n \u00a0entre\u00a0uso\u00a0de\u00a0ABC\u00a0y\u00a0riesgo\u00a0de\u00a0\nenfermedad \u00a0cardiovascular \u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0pacientes \u00a0aleatorizados \u00a0a\u00a0continuar \u00a0la\u00a0tera\u2010\npia\u00a0antirretroviral \u00a0se\u00a0ha\u00a0observado \u00a0una\u00a0asociaci\u00f3n \u00a0significativa \u00a0entre\u00a0estar\u00a0recibiendo \u00a0\nABC\u00a0y\u00a0un\u00a0incremento \u00a0del\u00a0riesgo\u00a0de\u00a0padecer\u00a0infarto\u00a0de\u00a0miocardio \u00a0(Hazard\u00a0ratio\u00a04,3),\u00a0\nsiendo\u00a0m\u00e1s\u00a0evidente\u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0ya\u00a0ten\u00edan\u00a0m\u00faltiples \u00a0factores\u00a0de\u00a0riesgo\u00a0o\u00a0con\u00a0\nalteraciones \u00a0electrocardiogr\u00e1ficas \u00a0en\u00a0el\u00a0momento \u00a0basal237.\u00a0\u00a0\n\u00a0\nOtras\u00a0Cohortes\u00a0\nEn\u00a0una\u00a0revisi\u00f3n\u00a0de\u00a0m\u00faltiples \u00a0ensayos\u00a0de\u00a0ABC\u00a0(9639\u00a0pacientes,7485 \u00a0personas\u2010a\u00f1o\u00a0de\u00a0\nseguimiento) \u00a0no\u00a0se\u00a0ha\u00a0encontrado \u00a0una\u00a0asociaci\u00f3n \u00a0entre\u00a0uso\u00a0de\u00a0este\u00a0AN\u00a0y\u00a0riesgo\u00a0de\u00a0\ninfarto\u00a0de\u00a0miocardio238.\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 32 \n Resumen \u00a0de\u00a0los\u00a0datos\u00a0de\u00a0ensayos\u00a0y\u00a0cohortes\u00a0\nLa\u00a0pauta\u00a0TDF+FTC\u00a0es\u00a0m\u00e1s\u00a0eficaz\u00a0y\u00a0tiene\u00a0menos\u00a0riesgo\u00a0de\u00a0lipoatrofia \u00a0que\u00a0la\u00a0combinaci\u00f3n \u00a0\nZDV+3TC. \u00a0La\u00a0combinaci\u00f3n \u00a0ABC+3TC\u00a0tiene\u00a0una\u00a0eficacia\u00a0similar\u00a0a\u00a0ZDV+3TC\u00a0con\u00a0menor\u00a0\nriesgo\u00a0de\u00a0lipoatrofia \u00a0y\u00a0ha\u00a0demostrado \u00a0la\u00a0no\u00a0inferioridad \u00a0frente\u00a0a\u00a0la\u00a0pauta\u00a0TDF+3TC\u00a0\ncuando\u00a0ambas\u00a0se\u00a0administran \u00a0con\u00a0LPV/r.\u00a0El\u00a0riesgo\u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0es\u00a0mayor\u00a0con\u00a0la\u00a0\npauta\u00a0ABC+3TC\u00a0que\u00a0con\u00a0la\u00a0pauta\u00a0TDF+3TC\u00a0en\u00a0pacientes \u00a0con\u00a0CVP\u00a0elevadas\u00a0cuando\u00a0\nABC+3TC\u00a0se\u00a0administra \u00a0con\u00a0efavirenz\u00a0o\u00a0ATV/r233.\u00a0No\u00a0se\u00a0han\u00a0realizado\u00a0grandes\u00a0estudios\u00a0\nde\u00a0la\u00a0combinaci\u00f3n \u00a0TDF+3TC\u00a0con\u00a0un\u00a0IP\u00a0como\u00a0tratamiento \u00a0inicial,\u00a0pero\u00a0s\u00ed\u00a0de\u00a0TDF+FTC\u00a0\n(con\u00a0ATV/r,\u00a0FPV/r,\u00a0LPV/r,\u00a0DRV/r\u00a0y\u00a0SQV/r).\u00a0No\u00a0existe\u00a0experiencia \u00a0de\u00a0ensayos\u00a0cl\u00ednicos\u00a0de\u00a0\nla\u00a0combinaci\u00f3n \u00a0ABC+3TC\u00a0con\u00a0NVP,\u00a0pero\u00a0s\u00ed\u00a0con\u00a0ATV/r,\u00a0LPV/r,\u00a0FPV/r239\u2010241.\u00a0\nLa\u00a0combinaci\u00f3n \u00a0ddI+3TC\u00a0asociada\u00a0a\u00a0EFV\u00a0no\u00a0es\u00a0inferior\u00a0a\u00a0ZDV+3TC+ \u00a0EFV228.\u00a0No\u00a0hay\u00a0datos\u00a0\nsobre\u00a0el\u00a0riesgo\u00a0de\u00a0lipoatrofia \u00a0de\u00a0la\u00a0combinaci\u00f3n \u00a0ddI+3TC\u00a0medida\u00a0por\u00a0DEXA.\u00a0No\u00a0existe\u00a0\nexperiencia \u00a0de\u00a0las\u00a0combinaciones \u00a0ddI+FTC\u00a0con\u00a0NVP\u00a0ni\u00a0con\u00a0IP.\u00a0La\u00a0combinaci\u00f3n \u00a0d4T+3TC\u00a0\nha\u00a0demostrado \u00a0su\u00a0eficacia\u00a0en\u00a0m\u00faltiples \u00a0estudios,\u00a0pero\u00a0produce\u00a0m\u00e1s\u00a0alteraciones \u00a0del\u00a0\nmetabolismo \u00a0de\u00a0los\u00a0l\u00edpidos,\u00a0lipodistrofia \u00a0y\u00a0neuropat\u00eda \u00a0perif\u00e9rica \u00a0que\u00a0la\u00a0combinaci\u00f3n \u00a0\nTDF+3TC. \u00a0\u00a0\u00a0\nEn\u00a0resumen, \u00a0la\u00a0elecci\u00f3n\u00a0final\u00a0de\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0AN\u00a0deber\u00e1\u00a0individualizarse \u00a0teniendo\u00a0\nen\u00a0cuenta\u00a0las\u00a0caracter\u00edsticas \u00a0del\u00a0f\u00e1rmaco,\u00a0la\u00a0situaci\u00f3n\u00a0cl\u00ednica\u00a0y\u00a0preferencias \u00a0del\u00a0pacien\u2010\nte.\u00a0Las\u00a0pautas\u00a0sencillas\u00a0pueden\u00a0facilitar\u00a0la\u00a0adherencia. \u00a0Estas\u00a0incluyen\u00a0FAR\u00a0que\u00a0se\u00a0admi\u2010\nnistran\u00a0una\u00a0vez\u00a0al\u00a0d\u00eda\u00a0(ABC,\u00a0ddI,\u00a0FTC,\u00a03TC\u00a0y\u00a0TDF)\u00a0o\u00a0coformulados \u00a0en\u00a0dosis\u00a0fijas\u00a0(TDF+FTC \u00a0\no\u00a0ABC+3TC). \u00a0\n\u00a0\nAN.\u00a0Recomendaciones \u00a0\nCombinaciones \u00a0preferentes \u00a0\n\u0083 Las\u00a0combinaciones \u00a0de\u00a0AN\u00a0de\u00a0elecci\u00f3n\u00a0para\u00a0reg\u00edmenes \u00a0de\u00a0inicio\u00a0son\u00a0TDF+FTC\u00a0(o\u00a03TC)\u00a0\no\u00a0ABC+3TC\u00a0(o\u00a0FTC).\u00a0Siempre\u00a0que\u00a0sea\u00a0posible\u00a0se\u00a0recomienda \u00a0el\u00a0uso\u00a0de\u00a0nucle\u00f3sidos \u00a0\ncoformulados \u00a0\u00a0(nivel\u00a0A).\u00a0\u00a0\u00a0\n\u0083 ABC+3TC\u00a0debe\u00a0ser\u00a0empleado \u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0con\u00a0CVP\u00a0elevadas\u00a0\n(>100.000 \u00a0copias/mL) \u00a0(nivel\u00a0A).\u00a0\u00a0\u00a0\n\u0083 Aunque\u00a0no\u00a0hay\u00a0datos\u00a0para\u00a0concluir\u00a0que\u00a0la\u00a0combinaci\u00f3n \u00a0ABC+3TC\u00a0incrementa \u00a0el\u00a0\nriesgo\u00a0de\u00a0paceder\u00a0infarto\u00a0de\u00a0miocardio, \u00a0se\u00a0debe\u00a0usar\u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0\ncon\u00a0riesgo\u00a0cardiovascular \u00a0elevado\u00a0(nivel\u00a0B).\u00a0\u00a0\nCombinaciones \u00a0alternativas \u00a0\n\u0083 Combinaciones \u00a0de\u00a0AN\u00a0alternativas \u00a0son\u00a0ddI+3TC\u00a0(nivel\u00a0A)\u00a0y\u00a0ddI+FTC,\u00a0aunque\u00a0de\u00a0esta\u00a0\ns\u00f3lo\u00a0existen\u00a0datos\u00a0de\u00a0la\u00a0combinaci\u00f3n \u00a0ddI+FTC\u00a0de\u00a0un\u00a0ensayo\u00a0cl\u00ednico,\u00a0por\u00a0lo\u00a0que\u00a0su\u00a0\nperfil\u00a0de\u00a0seguridad \u00a0no\u00a0est\u00e1\u00a0firmemente \u00a0establecido. \u00a0\u00a0\n\u0083 Otras\u00a0combinaciones \u00a0alternativas \u00a0son\u00a0\u00a0ZDV+3TC\u00a0(o\u00a0FTC)\u00a0y\u00a0ZDV+ddI\u00a0221,\u00a0223.\u00a0\u00a0\n\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 33 \n Combinaciones \u00a0no\u00a0recomendadas \u00a0\n\u0083 No\u00a0se\u00a0recomiendan \u00a0las\u00a0combinaciones \u00a0d4T+ddI\u00a0por\u00a0toxicidad, \u00a0TDF+ddI\u00a0por\u00a0toxici\u2010\ndad\u00a0y\u00a0menor\u00a0eficacia242\u2010246,\u00a0ZDV\u00a0+\u00a0d4T\u00a0por\u00a0antagonismo, \u00a0FTC\u00a0+\u00a03TC\u00a0por\u00a0similar\u00a0perfil\u00a0\nde\u00a0resistencias \u00a0y\u00a0pocos\u00a0beneficios \u00a0cl\u00ednicos\u00a0(Tabla\u00a04)2,\u00a03,\u00a0212,\u00a0247.\u00a0\u00a0\n\u00a0\nCombinaciones \u00a0de\u00a0TARV\u00a0con\u00a0tres\u00a0AN\u00a0\nLas\u00a0combinaciones \u00a0de\u00a03\u00a0AN\u00a0han\u00a0demostrado \u00a0eficacia\u00a0virol\u00f3gica \u00a0e\u00a0inmunol\u00f3gica \u00a0en\u00a0va\u2010\nrios\u00a0estudios,\u00a0pero\u00a0con\u00a0resultados \u00a0inferiores \u00a0cuando\u00a0se\u00a0han\u00a0comparado \u00a0a\u00a0combinacio \u2010\nnes\u00a0de\u00a02\u00a0AN\u00a0con\u00a0un\u00a0IP/r\u00a0\u00f3\u00a0NN.\u00a0\nExiste\u00a0una\u00a0coformulaci\u00f3n \u00a0con\u00a0la\u00a0asociaci\u00f3n \u00a0ZDV+3TC+ABC \u00a0que\u00a0permite\u00a0su\u00a0administra \u2010\nci\u00f3n\u00a0en\u00a0forma\u00a0de\u00a0un\u00a0comprimido \u00a0BID,\u00a0pauta\u00a0atractiva\u00a0desde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0de\u00a0la\u00a0ad\u2010\nherencia. \u00a0Otros\u00a0estudios\u00a0comparan \u00a0esta\u00a0combinaci\u00f3n \u00a0con\u00a0pautas\u00a0que\u00a0contienen \u00a0\u00a0IP\u00a0o\u00a0\nNN.\u00a0\n\u00a0\nEnsayos\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0de\u00a0uso\u00a0de\u00a0tres\u00a0AN\u00a0\nACTG\u00a0A5095\u00a0\nEl\u00a0ACTG\u00a0A5095\u00a0es\u00a0un\u00a0estudio\u00a0aleatorizado \u00a0y\u00a0controlado \u00a0con\u00a0placebo\u00a0que\u00a0eval\u00faa\u00a0la\u00a0efi\u2010\ncacia\u00a0y\u00a0tolerancia \u00a0de\u00a0tres\u00a0reg\u00edmenes: \u00a01\u00ba)\u00a0ZDV+3TC+ABC \u00a0(Trizivir\u00ae); \u00a02\u00ba)\u00a0ZDV+3TC+EFV; \u00a0y\u00a0\n3\u00ba)\u00a0ZDV+3TC+ABC+EFV \u00a0en\u00a0pacientes \u00a0sin\u00a0terapia\u00a0previa.\u00a0Se\u00a0incluyeron \u00a01.147\u00a0pacientes \u00a0\ncon\u00a0una\u00a0mediana\u00a0de\u00a0CD4\u00a0de\u00a0238\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0CVP\u00a0de\u00a071434\u00a0copias/mL. \u00a0Tras\u00a0una\u00a0me\u2010\ndiana\u00a0de\u00a0seguimiento \u00a0de\u00a032\u00a0semanas, \u00a0los\u00a0pacientes \u00a0tratados\u00a0con\u00a0ZDV+3TC+ABC \u00a0tuvie\u2010\nron\u00a0mayor\u00a0fracaso\u00a0virol\u00f3gico \u00a0(21%\u00a0frente\u00a0al\u00a011%\u00a0en\u00a0los\u00a0otros\u00a0grupos)\u00a0y\u00a0en\u00a0un\u00a0tiempo\u00a0\nm\u00e1s\u00a0corto\u00a0(p<0,001), \u00a0independientemente \u00a0del\u00a0nivel\u00a0de\u00a0CVP.\u00a0Dado\u00a0que\u00a0a\u00a0las\u00a048\u00a0sema\u2010\nnas\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<200\u00a0copias/mL \u00a0era\u00a0del\u00a074%\u00a0en\u00a0el\u00a0grupo\u00a0con\u00a03\u00a0\nAN\u00a0y\u00a089%\u00a0en\u00a0los\u00a0otros\u00a0dos\u00a0(an\u00e1lisis\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0tratar)\u00a0el\u00a0comit\u00e9\u00a0de\u00a0seguridad \u00a0re\u2010\ncomend\u00f3 \u00a0que\u00a0el\u00a0grupo\u00a0de\u00a0ZDV+3TC+ABC \u00a0se\u00a0interrumpiese, \u00a0continuando \u00a0el\u00a0estudio\u00a0de\u00a0\nforma\u00a0ciega\u00a0con\u00a0los\u00a0pacientes \u00a0en\u00a0los\u00a0brazos\u00a0que\u00a0conten\u00edan \u00a0EFV209.\u00a0Estos\u00a0resultados \u00a0han\u00a0\nhecho\u00a0que\u00a0se\u00a0replantee \u00a0el\u00a0papel\u00a0del\u00a0ZDV+3TC+ABC \u00a0en\u00a0el\u00a0tratamiento \u00a0de\u00a0inicio\u00a0y\u00a0se\u00a0con\u2010\nsidere\u00a0una\u00a0alternativa \u00a0a\u00a0otras\u00a0opciones\u00a0m\u00e1s\u00a0eficaces.\u00a0\u00a0\nA\u00a0los\u00a0tres\u00a0a\u00f1os\u00a0de\u00a0seguimiento, \u00a0la\u00a0pauta\u00a0ZDV+3TC+ABC+EFV \u00a0no\u00a0demostr\u00f3 \u00a0ser\u00a0superior\u00a0\na\u00a0la\u00a0pauta\u00a0ZDV+3TC+EFV. \u00a0La\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<200\u00a0y\u00a0<50\u00a0copias/mL \u00a0en\u00a0\nlas\u00a0dos\u00a0ramas\u00a0del\u00a0estudio\u00a0fue\u00a090%\u00a0y\u00a092%\u00a0(p=0,59)\u00a0y\u00a085%\u00a0y\u00a088%\u00a0(p=0,39)\u00a0respectiva \u2010\nmente.\u00a0El\u00a0ensayo\u00a0A5095\u00a0demostr\u00f3 \u00a0que\u00a0la\u00a0adici\u00f3n\u00a0de\u00a0un\u00a0tercer\u00a0AN\u00a0a\u00a0un\u00a0r\u00e9gimen\u00a0que\u00a0\nincluya\u00a02\u00a0AN\u00a0y\u00a0EFV\u00a0no\u00a0incrementa \u00a0la\u00a0respuesta \u00a0virol\u00f3gica248.\u00a0\u00a0\n\u00a0CNA3005 \u00a0\nEl\u00a0CNA3005 \u00a0es\u00a0un\u00a0estudio\u00a0controlado \u00a0con\u00a0placebo,\u00a0doble\u00a0ciego\u00a0y\u00a0de\u00a0equivalencia \u00a0que\u00a0\ncompar\u00f3\u00a0ZDV+3TC+ABC \u00a0\u00a0frente\u00a0a\u00a0ZDV+3TC+IDV. \u00a0La\u00a0principal\u00a0conclusi\u00f3n \u00a0fue\u00a0que\u00a0ambos\u00a0\nreg\u00edmenes \u00a0eran\u00a0equivalentes \u00a0para\u00a0alcanzar\u00a0CVP\u00a0<400\u00a0copias/mL, \u00a0pero\u00a0en\u00a0los\u00a0pacientes \u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 34 \n con\u00a0CVP\u00a0>100.000 \u00a0copias/mL, \u00a0el\u00a0r\u00e9gimen\u00a0con\u00a0ABC\u00a0era\u00a0inferior\u00a0al\u00a0de\u00a0IDV\u00a0para\u00a0conseguir \u00a0\nCVP\u00a0inferior\u00a0a\u00a050\u00a0copias/mL211.\u00a0\u00a0\nCLASS\u00a0\nEl\u00a0estudio\u00a0CLASS\u00a0compar\u00f3\u00a0la\u00a0eficacia\u00a0virol\u00f3gica \u00a0de\u00a0una\u00a0pauta\u00a0basada\u00a0en\u00a0NN\u00a0(EFV),\u00a0fren\u2010\nte\u00a0a\u00a0un\u00a0IP/r\u00a0(APV/r)\u00a0o\u00a0una\u00a0pauta\u00a0con\u00a0tres\u00a0AN\u00a0(d4T),\u00a0todos\u00a0ellos\u00a0combinados \u00a0con\u00a0ABC\u00a0y\u00a0\n3TC.\u00a0Los\u00a0datos\u00a0preliminares \u00a0de\u00a0la\u00a0semana\u00a048\u00a0(an\u00e1lisis\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0tratamiento) \u00a0\nmostraron \u00a0la\u00a0superioridad \u00a0de\u00a0la\u00a0pauta\u00a0de\u00a0EFV\u00a0frente\u00a0a\u00a0las\u00a0otras\u00a0(pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a076%,\u00a059%\u00a0y\u00a062%,\u00a0respectivamente)249.\u00a0\n\u00a0\nESS30009 \u00a0\nEl\u00a0estudio\u00a0ESS30009 \u00a0compar\u00f3\u00a0la\u00a0administraci\u00f3n \u00a0QD\u00a0de\u00a03\u00a0AN\u00a0(TDF+3TC+ABC) \u00a0frente\u00a0a\u00a0la\u00a0\ncombinaci\u00f3n \u00a0de\u00a0ABC+3TC+EFV. \u00a0Se\u00a0observ\u00f3\u00a0una\u00a0falta\u00a0de\u00a0respuesta \u00a0virol\u00f3gica \u00a0temprana \u00a0\n(descenso \u00a0de\u00a0CVP\u00a0\u22652\u00a0log 10\u00a0en\u00a0la\u00a0semana\u00a08\u00a0o\u00a0incremento \u00a0de\u00a01\u00a0log 10\u00a0sobre\u00a0el\u00a0nadir\u00a0alcan\u2010\nzado)\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0pacientes \u00a0con\u00a03\u00a0AN.\u00a0Entre\u00a0los\u00a0pacientes \u00a0que\u00a0llegaron\u00a0a\u00a0la\u00a0semana\u00a0\n12,\u00a0se\u00a0consider\u00f3 \u00a0no\u00a0respondedores \u00a0al\u00a049%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a03\u00a0AN\u00a0y\u00a05%\u00a0en\u00a0el\u00a0grupo\u00a0con\u00a0\nEFV\u00a0(p<0.001). \u00a0El\u00a0an\u00e1lisis\u00a0genot\u00edpico \u00a0de\u00a0los\u00a014\u00a0aislados\u00a0de\u00a0los\u00a0no\u2010respondedores \u00a0(brazo\u00a0\ncon\u00a03\u00a0AN)\u00a0mostraron \u00a0la\u00a0mutaci\u00f3n \u00a0M184V\u00a0y\u00a08\u00a0de\u00a0ellos\u00a0ten\u00edan\u00a0la\u00a0K65R,\u00a0que\u00a0puede\u00a0reducir\u00a0\nla\u00a0susceptibilidad \u00a0a\u00a0TDF\u00a0y\u00a0ABC250.\u00a0\n\u00a0Otros\u00a0\nEn\u00a0un\u00a0estudio\u00a0piloto\u00a0con\u00a0ddI+3TC+TDF, \u00a0el\u00a091%\u00a0de\u00a0los\u00a0pacientes \u00a0tuvieron\u00a0un\u00a0fracaso\u00a0\nvirol\u00f3gico \u00a0(descenso \u00a0de\u00a0la\u00a0CVP\u00a0\u22642\u00a0log\n10\u00a0en\u00a0la\u00a0semana\u00a012).\u00a0La\u00a0mutaci\u00f3n \u00a0M184I/V\u00a0se\u00a0de\u2010\ntect\u00f3\u00a0en\u00a0el\u00a095%\u00a0de\u00a0los\u00a0pacientes \u00a0y\u00a0el\u00a050%\u00a0ten\u00edan\u00a0tambi\u00e9n\u00a0la\u00a0K65R.\u00a0\u00a0\nEn\u00a0otro\u00a0estudio\u00a0reciente,\u00a0se\u00a0compar\u00f3\u00a0la\u00a0eficacia\u00a0y\u00a0tolerancia \u00a0de\u00a0d4T+ddI+ABC \u00a0frente\u00a0a\u00a0\nSQV+RTV \u00a0(400/400mg \u00a0BID)+ZDV+3TC \u00a0frente\u00a0a\u00a0NFV+NVP+ZDV+3TC. \u00a0Se\u00a0incluyeron \u00a0180\u00a0\npacientes, \u00a0con\u00a0una\u00a0mediana\u00a0de\u00a0CD4\u00a0de\u00a0161\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0CVP\u00a0de\u00a05\u00a0log 10.\u00a0A\u00a0las\u00a048\u00a0sema\u2010\nnas,\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<20\u00a0copias/mL \u00a0fue\u00a0inferior\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0tres\u00a0\nAN\u00a0(43%,\u00a062%\u00a0y\u00a069%,\u00a0respectivamente), \u00a0los\u00a0efectos\u00a0secundarios \u00a0fueron\u00a0m\u00e1s\u00a0frecuentes \u00a0\nen\u00a0este\u00a0grupo251.\u00a0\u00a0\nAdem\u00e1s,\u00a0en\u00a0un\u00a0estudio\u00a0multic\u00e9ntrico \u00a0espa\u00f1ol\u00a0no\u00a0comparativo \u00a0en\u00a0el\u00a0que\u00a0se\u00a0inici\u00f3\u00a0TARV\u00a0\na\u00a0pacientes \u00a0con\u00a04\u00a0AN\u00a0(Trizivir\u00ae+TDF)\u00a0y\u00a0seguido\u00a0hasta\u00a0la\u00a0semana\u00a096,\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0\npacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0era\u00a0del\u00a063%\u00a0(ITT)\u00a0y\u00a087%\u00a0(OT).\u00a0Los\u00a0resultados \u00a0fueron\u00a0\nmejores\u00a0si\u00a0la\u00a0CVP\u00a0era\u00a0<5\u00a0log 10\u00a0o\u00a0los\u00a0CD4\u00a0>250\u00a0c\u00e9lulas/\u00b5L.252\u00a0\nEl\u00a0estudio\u00a0TIMS\u00a0compar\u00f3\u00a0en\u00a0113\u00a0pacientes \u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a04\u00a0AN\u00a0(Trizivir\u00ae+TDF)\u00a0fren\u2010\nte\u00a0a\u00a0ZDV+3TC+EFV. \u00a0Tras\u00a048\u00a0semanas\u00a0de\u00a0seguimiento \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0\nCVP\u00a0<50\u00a0copias/mL \u00a0era\u00a0del\u00a067%\u00a0(ITT)\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a04\u00a0AN\u00a0y\u00a0del\u00a067%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0\nZDV+\u00a03TC\u00a0+\u00a0EFV253.\u00a0\n\u00a0\n\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 35 \n Combinaciones \u00a0de\u00a03\u00a0AN.\u00a0Recomendaciones \u00a0\n\u0083 Un\u00a0r\u00e9gimen\u00a0con\u00a0ZDV+3TC+ABC \u00a0con\u00a0o\u00a0sin\u00a0TDF\u00a0deber\u00eda\u00a0ser\u00a0usado\u00a0solamente \u00a0cuando\u00a0\nno\u00a0pueda\u00a0usarse\u00a0otra\u00a0pauta\u00a0m\u00e1s\u00a0potente\u00a0(nivel\u00a0A).\u00a0\u00a0\n\u0083 No\u00a0se\u00a0recomienda \u00a0utilizar\u00a0d4T+ddI+ABC \u00a0(nivel\u00a0A).\u00a0El\u00a0comit\u00e9\u00a0recomienda \u00a0no\u00a0utilizar\u00a0\nen\u00a0ning\u00fan\u00a0momento \u00a0pautas\u00a0con\u00a03\u00a0AN\u00a0con\u00a0ABC+3TC+TDF \u00a0o\u00a0ddI+3TC+TDF \u00a0(nivel\u00a0A).\u00a0\u00a0\n\u0083 No\u00a0deben\u00a0usarse\u00a0otras\u00a0combinaciones \u00a0de\u00a03\u00a0AN\u00a0en\u00a0una\u00a0pauta\u00a0de\u00a0TARV\u00a0porque\u00a0no\u00a0\nexiste\u00a0experiencia. \u00a0\n\u00a04.4.\u00a0Inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0nucle\u00f3sidos \u00a0(NN)\u00a0\u00a0\nEn\u00a0Espa\u00f1a\u00a0hay\u00a03\u00a0NN\u00a0comercializados: \u00a0nevirapina \u00a0(NVP),\u00a0efavirenz\u00a0(EFV)\u00a0y\u00a0etravirina \u00a0\n(ETR).\u00a0Sus\u00a0principales \u00a0caracter\u00edsticas \u00a0se\u00a0describen \u00a0en\u00a0la\u00a0Tabla\u00a063,\u00a0247.\u00a0EFV\u00a0y\u00a0NVP\u00a0son\u00a0in\u2010\nductores\u00a0del\u00a0citocromo \u00a0P450\u00a0pudiendo \u00a0interaccionar \u00a0con\u00a0otros\u00a0f\u00e1rmacos. \u00a0El\u00a0EFV\u00a0se\u00a0\nadministra \u00a0en\u00a0pauta\u00a0QD\u00a0(1\u00a0comprimido \u00a0de\u00a0600\u00a0mg/d\u00eda)\u00a0y\u00a0la\u00a0NVP\u00a0se\u00a0puede\u00a0administrar \u00a0\ntanto\u00a0en\u00a0pauta\u00a0BID\u00a0(200\u00a0mg/12\u00a0horas)\u00a0o\u00a0QD\u00a0(400\u00a0mg/d\u00eda)254\u2010256;\u00a0durante\u00a0los\u00a0primeros\u00a0\n14\u00a0d\u00edas\u00a0se\u00a0administra \u00a01\u00a0comprimido \u00a0al\u00a0d\u00eda.\u00a0La\u00a0ETR\u00a0se\u00a0administra \u00a0en\u00a0BID\u00a0(200\u00a0mg/12\u00a0\nhoras).\u00a0\u00a0\n\u00a0Ensayos\u00a0cl\u00ednicos\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0de\u00a0NVP\u00a0\nPautas\u00a0con\u00a0NVP\u00a0frente\u00a0a\u00a0pautas\u00a0con\u00a0IP\u00a0\nCombine\u00a0\nEn\u00a0el\u00a0ensayo\u00a0Combine\u00a0se\u00a0compar\u00f3\u00a0la\u00a0eficacia\u00a0de\u00a0NVP\u00a0frente\u00a0a\u00a0NFV\n257.\u00a0Es\u00a0de\u00a0destacar\u00a0\nque\u00a0el\u00a0ensayo\u00a0no\u00a0ten\u00eda\u00a0suficiente \u00a0poder\u00a0estad\u00edstico \u00a0para\u00a0evaluar\u00a0la\u00a0equivalencia \u00a0entre\u00a0\nambas\u00a0pautas.\u00a0El\u00a0n\u00famero\u00a0de\u00a0pacientes \u00a0incluidos\u00a0con\u00a0CVP\u00a0elevada\u00a0(>100000 \u00a0copias/mL) \u00a0\nfue\u00a0bajo\u00a0y\u00a0no\u00a0se\u00a0observaron \u00a0diferencias \u00a0entre\u00a0NVP\u00a0y\u00a0NFV.\u00a0En\u00a0una\u00a0recopilaci\u00f3n \u00a0de\u00a0diver\u2010\nsos\u00a0estudios\u00a0con\u00a0NVP\u00a0en\u00a0pacientes \u00a0sin\u00a0TARV\u00a0previo\u00a0el\u00a083%\u00a0de\u00a0los\u00a0que\u00a0ten\u00edan\u00a0CVP\u00a0\n>100000\u00a0copias/mL \u00a0ten\u00edan\u00a0CVP\u00a0indetectable \u00a0a\u00a0los\u00a06\u00a0meses258.\u00a0\nARTEN\u00a0\nEn\u00a0el\u00a0ensayo\u00a0ARTEN\u00a0se\u00a0compar\u00f3\u00a0la\u00a0eficacia\u00a0y\u00a0seguridad \u00a0de\u00a0NVP\u00a0administrada \u00a0una\u00a0o\u00a0dos\u00a0\nveces\u00a0al\u00a0d\u00eda\u00a0frente\u00a0a\u00a0ATV/r,\u00a0ambos\u00a0combinados \u00a0con\u00a0TDF/FTC.\u00a0Se\u00a0trata\u00a0de\u00a0un\u00a0ensayo\u00a0\naleatorizado, \u00a0abierto\u00a0y\u00a0multic\u00e9ntrico \u00a0que\u00a0incluy\u00f3\u00a0569\u00a0pacientes \u00a0(sin\u00a0tratamiento \u00a0pre\u2010\nvio;\u00a0con\u00a0<250\u00a0CD4/\u00b5L\u00a0en\u00a0mujeres\u00a0y\u00a0<400\u00a0CD4/\u00b5L\u00a0en\u00a0varones). \u00a0El\u00a0fracaso\u00a0virol\u00f3gico \u00a0se\u00a0\ndefini\u00f3\u00a0por\u00a0la\u00a0presencia \u00a0de\u00a0CVP\u00a0detectable \u00a0(>50\u00a0copias/mL) \u00a0a\u00a0las\u00a024\u00a0semanas\u00a0y\u00a0en\u00a0dos\u00a0\ndeterminaciones \u00a0posteriores \u00a0hasta\u00a048\u00a0semanas\u00a0en\u00a0las\u00a0dos\u00a0ramas\u00a0de\u00a0NVP,\u00a0analizadas \u00a0\nconjuntamente. \u00a0El\u00a0margen\u00a0de\u00a0no\u00a0inferioridad \u00a0se\u00a0estableci\u00f3 \u00a0en\u00a0\u201012%.\u00a0La\u00a0proporci\u00f3n \u00a0de\u00a0\npacientes \u00a0con\u00a0carga\u00a0viral\u00a0basal\u00a0>100.000 \u00a0copias/mL \u00a0fue\u00a0superior\u00a0al\u00a060%\u00a0en\u00a0los\u00a0tres\u00a0gru\u2010\npos\u00a0de\u00a0tratamiento. \u00a0A\u00a0la\u00a0semana\u00a048,\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0\nfue\u00a0del\u00a067%\u00a0y\u00a065%\u00a0para\u00a0NVP\u00a0y\u00a0ATV/r\u00a0respectivamente \u00a0(IC95%:\u00a0\u20105.9%\u00a0a\u00a09.8%;\u00a0p=0.63)\u00a0en\u00a0\nal\u00a0an\u00e1lisis\u00a0basado\u00a0en\u00a0el\u00a0objetivo\u00a0primario,\u00a0mientras\u00a0que\u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0por\u00a0TLVOR\u00a0fue\u00a0del\u00a0\n70%\u00a0y\u00a074%\u00a0respectivamente \u00a0(IC95%:\u00a0\u201010.4%\u00a0a\u00a04.5%;\u00a0p=0.44).\u00a0En\u00a0pacientes \u00a0con\u00a0\n>100.000 \u00a0copias/mL \u00a0de\u00a0CVP\u00a0basal,\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0indetectabilidad \u00a0para\u00a0NVP\u00a0y\u00a0ATV/r\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 36 \n fueron\u00a0del\u00a060%\u00a0y\u00a052%,\u00a0respectivamente256.\u00a0El\u00a0incremento \u00a0de\u00a0linfocitos\u00a0CD4\u00a0fue\u00a0similar\u00a0\nen\u00a0ambas\u00a0ramas,\u00a0as\u00ed\u00a0como\u00a0la\u00a0tasa\u00a0de\u00a0fracaso\u00a0virol\u00f3gico. \u00a0Las\u00a0discontinuaciones \u00a0del\u00a0tra\u2010\ntamiento\u00a0fueron\u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0las\u00a0ramas\u00a0de\u00a0NVP.\u00a0En\u00a0un\u00a0an\u00e1lisis\u00a0del\u00a0inicio\u00a0del\u00a0tra\u2010\ntamiento, \u00a0la\u00a0ca\u00edda\u00a0de\u00a0la\u00a0CVP\u00a0durante\u00a0las\u00a0primeras\u00a04\u00a0semanas\u00a0y\u00a0el\u00a0tiempo\u00a0hasta\u00a0la\u00a0res\u2010\npuesta\u00a0al\u00a0tratamiento \u00a0fueron\u00a0mejores\u00a0con\u00a0NVP\u00a0que\u00a0con\u00a0ATV/r259.\u00a0 \n\u00a0\nEnsayos\u00a0cl\u00ednicos\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0de\u00a0EFV\u00a0\nPautas\u00a0con\u00a0EFV\u00a0frente\u00a0a\u00a0pautas\u00a0con\u00a0IP\u00a0\nACTG\u00a05142\u00a0\nEl\u00a0estudio\u00a0ACTG\u00a05142\u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0aleatorizado \u00a0cuyo\u00a0objetivo\u00a0era\u00a0valorar\u00a0la\u00a0\neficacia\u00a0y\u00a0tolerancia \u00a0de\u00a0tres\u00a0reg\u00edmenes \u00a0de\u00a0tratamiento: \u00a0LPV/r+2\u00a0AN,\u00a0EFV+2\u00a0AN\u00a0y\u00a0LPV/r+\u00a0\nEFV.\u00a0Se\u00a0incluyeron \u00a0753\u00a0pacientes \u00a0con\u00a0una\u00a0mediana\u00a0de\u00a0CD4\u00a0de\u00a0182\u00a0c\u00e9lulas/\u00b5L\u00a0y\u00a0CVP\u00a0de\u00a0\n100.000\u00a0copias/mL. \u00a0Los\u00a0puntos\u00a0finales\u00a0de\u00a0valoraci\u00f3n \u00a0fueron:\u00a01\u00ba)\u00a0Fracaso\u00a0virol\u00f3gico: \u00a0a)\u00a0\nFracaso\u00a0temprano: \u00a0imposibilidad \u00a0de\u00a0reducir\u00a0la\u00a0CVP\u00a0>1\u00a0log 10\u00a0o\u00a0rebrote\u00a0antes\u00a0de\u00a0la\u00a0sema\u2010\nna\u00a032;\u00a0y\u00a0b)\u00a0fracaso\u00a0tard\u00edo:\u00a0imposibilidad \u00a0de\u00a0suprimir\u00a0la\u00a0CVP\u00a0por\u00a0debajo\u00a0de\u00a0200\u00a0co\u2010\npias/mL\u00a0o\u00a0rebrote\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0semana\u00a032.\u00a02\u00ba)\u00a0Finalizaci\u00f3n \u00a0del\u00a0r\u00e9gimen:\u00a0fracaso\u00a0vi\u2010\nrol\u00f3gico\u00a0o\u00a0suspensi\u00f3n \u00a0relacionada \u00a0con\u00a0la\u00a0toxicidad. \u00a0En\u00a0la\u00a0semana\u00a096\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0\npacientes \u00a0sin\u00a0fracaso\u00a0virol\u00f3gico \u00a0fue\u00a0de\u00a067,\u00a076\u00a0y\u00a073%\u00a0para\u00a0los\u00a0grupos\u00a0de\u00a0LPV/r+2\u00a0AN,\u00a0\nEFV+2\u00a0AN\u00a0y\u00a0LPV/r+EFV \u00a0respectivamente. \u00a0En\u00a0este\u00a0corte,\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0\nCVP\u00a0<200\u00a0copias/mL \u00a0(ITT)\u00a0fue\u00a0de\u00a086,\u00a093,\u00a092\u00a0%\u00a0para\u00a0cada\u00a0rama\u00a0de\u00a0tratamiento \u00a0(p=0,041, \u00a0\nLPV\u00a0frente\u00a0a\u00a0EFV),\u00a0y\u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0fue\u00a0de\u00a077,\u00a089\u00a0y\u00a083%,\u00a0respectivamente \u00a0\n(p=0.003; \u00a0LPV\u00a0frente\u00a0a\u00a0EFV).\u00a0El\u00a0incremento \u00a0de\u00a0linfocitos\u00a0CD4\u00a0\u00a0fue\u00a0mayor\u00a0en\u00a0los\u00a0brazos\u00a0\nque\u00a0conten\u00edan \u00a0LPV/r\u00a0frente\u00a0al\u00a0brazo\u00a0de\u00a0EFV\u00a0(p\u00a0=\u00a00,01\u00a0frente\u00a0EFV+2\u00a0AN.\u00a0Los\u00a0datos\u00a0de\u00a0\nresistencias \u00a0indican\u00a0que\u00a0en\u00a0caso\u00a0de\u00a0fracaso\u00a0virol\u00f3gico, \u00a0es\u00a0m\u00e1s\u00a0probable\u00a0que\u00a0aparezcan \u00a0\nresistencias \u00a0a\u00a0dos\u00a0clases\u00a0de\u00a0f\u00e1rmacos\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0EFV+2\u00a0AN\u00a0que\u00a0en\u00a0los\u00a0grupos\u00a0de\u00a0\nLPV/r,\u00a0mientras\u00a0que\u00a0hipertrigliceridemia \u00a0fue\u00a0m\u00e1s\u00a0frecuente \u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0\nLPV/r+EFV. \u00a0En\u00a0resumen, \u00a0el\u00a0estudio\u00a0ACTG\u00a05142,\u00a0demuestra \u00a0que\u00a0tanto\u00a0la\u00a0eficacia\u00a0virol\u00f3\u2010\ngica\u00a0como\u00a0el\u00a0tiempo\u00a0hasta\u00a0el\u00a0fracaso\u00a0virol\u00f3gico \u00a0son\u00a0mejores\u00a0con\u00a0la\u00a0pauta\u00a0de\u00a0EFV\u00a0+\u00a02\u00a0AN\u00a0\ny\u00a0el\u00a0incremento \u00a0de\u00a0los\u00a0linfocitos\u00a0CD4\u00a0es\u00a0mayor\u00a0en\u00a0los\u00a0brazos\u00a0con\u00a0LPV/r202.\u00a0\u00a0\n\u00a0\nEstudio\u00a0DMP\u2010006\u00a0\nEn\u00a0el\u00a0estudio\u00a0DMP\u2010006\u00a0se\u00a0ha\u00a0demostrado \u00a0que\u00a0EFV,\u00a0combinado \u00a0con\u00a0ZDV\u00a0y\u00a03TC\u00a0tiene\u00a0una\u00a0\nmayor\u00a0eficacia\u00a0virol\u00f3gica \u00a0(48\u00a0y\u00a0144\u00a0semanas) \u00a0que\u00a0IDV+ZDV+3TC260.\u00a0\u00a0\n\u00a0ACTG\u00a0384\u00a0\nEn\u00a0el\u00a0estudio\u00a0ACTG\u00a0384\u00a0se\u00a0demostr\u00f3 \u00a0que\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0EFV+ZDV+3TC \u00a0es\u00a0m\u00e1s\u00a0efi\u2010\ncaz\u00a0que\u00a0un\u00a0r\u00e9gimen\u00a0con\u00a0NFV+ZDV+3TC \u00a0o\u00a0\u00a0NFV+ddI+d4T\n229.\u00a0\n\u00a0\n\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 37 \n FOCUS\u00a0\nEn\u00a0el\u00a0ensayo\u00a0FOCUS\u00a0se\u00a0compar\u00f3\u00a0una\u00a0pauta\u00a0con\u00a0EFV\u00a0frente\u00a0a\u00a0SQV/r\u00a0(1600/100, \u00a0QD)\u00a0en\u00a0\n152\u00a0pacientes \u00a0sin\u00a0terapia\u00a0previa.\u00a0La\u00a0pauta\u00a0con\u00a0EFV\u00a0fue\u00a0m\u00e1s\u00a0eficaz\u00a0en\u00a0la\u00a0semana\u00a048\u00a0(CVP\u00a0\n<50\u00a0copias/mL, \u00a071\u00a0%\u00a0frente\u00a0a\u00a051%)\u00a0y\u00a0present\u00f3\u00a0menos\u00a0toxicidad261.\u00a0\n\u00a0\nCLASS\u00a0\nEn\u00a0el\u00a0ensayo\u00a0cl\u00ednico\u00a0CLASS\u00a0se\u00a0compar\u00f3\u00a0una\u00a0pauta\u00a0con\u00a0EFV\u00a0frente\u00a0a\u00a0otra\u00a0con\u00a0APV/r\u00a0con\u00a0\n1200/200 \u00a0mg\u00a0QD.\u00a0EFV\u00a0y\u00a0APV/r\u00a0mostraron \u00a0una\u00a0eficacia\u00a0similar\u00a0en\u00a0el\u00a0objetivo\u00a0primario\u00a0\n(CVP\u00a0<400\u00a0copias/mL \u00a0a\u00a096\u00a0semanas) \u00a0y\u00a0en\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0con\u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a0(ITT),\u00a0independientemente \u00a0de\u00a0la\u00a0CVP\u00a0alta.\u00a0EFV\u00a0consigui\u00f3 \u00a0tasas\u00a0de\u00a0respuesta \u00a0\nvirol\u00f3gica \u00a0superiores \u00a0en\u00a0las\u00a0semanas\u00a024\u00a0y\u00a048,\u00a0pero\u00a0no\u00a0en\u00a0la\u00a096,\u00a0objetivo\u00a0principal\u00a0del\u00a0\nestudio.\u00a0Sin\u00a0embargo\u00a0la\u00a0dosis\u00a0utilizada\u00a0no\u00a0se\u00a0considera \u00a0\u00f3ptima\u00a0y\u00a0no\u00a0est\u00e1\u00a0autorizada \u00a0\npara\u00a0tratamiento \u00a0inicial262.\u00a0\n\u00a0BMS\u2010034\u00a0\nEn\u00a0el\u00a0estudio\u00a0BMS\u00a0AI424\u2010034\u00a0se\u00a0demostr\u00f3 \u00a0que\u00a0ATV\u00a0(400\u00a0mg,\u00a0QD)\u00a0+\u00a0ZDV\u00a0+\u00a03TC\u00a0fue\u00a0tan\u00a0\neficaz\u00a0como\u00a0EFV\u00a0+\u00a0ZDV\u00a0+\u00a03TC\u00a0\u00a0en\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\n263.\u00a0Sin\u00a0embargo\u00a0los\u00a0\nresultados \u00a0de\u00a0este\u00a0estudio\u00a0son\u00a0dif\u00edciles\u00a0de\u00a0interpretar \u00a0por\u00a0un\u00a0error\u00a0en\u00a0la\u00a0determinaci\u00f3n \u00a0\nde\u00a0la\u00a0CVP\u00a0relacionado \u00a0con\u00a0el\u00a0procesamiento \u00a0y\u00a0tipo\u00a0de\u00a0tubos\u00a0empleados \u00a0para\u00a0el\u00a0trans\u2010\nporte\u00a0de\u00a0muestras. \u00a0\u00a0\n\u00a0Pautas\u00a0con\u00a0EFV\u00a0frente\u00a0a\u00a0pautas\u00a0con\u00a03\u00a0AN\u00a0\nACTG\u00a0A5095\u00a0\nComo\u00a0ya\u00a0se\u00a0ha\n\u00a0comentado \u00a0previamente, \u00a0el\u00a0estudio\u00a0ACTG\u2010A5095\u00a0demostr\u00f3 \u00a0que\u00a0las\u00a0\ncombinaciones \u00a0de\u00a0f\u00e1rmacos\u00a0de\u00a02\u00a0familias\u00a0(EFV\u00a0+\u00a0ZDV\u00a0+\u00a03TC\u00a0o\u00a0EFV\u00a0+\u00a0ZDV\u00a0+\u00a03TC\u00a0+\u00a0ABC)\u00a0\nson\u00a0m\u00e1s\u00a0eficaces\u00a0que\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a03\u00a0AN\u00a0(ZDV\u00a0+\u00a03TC\u00a0+\u00a0ABC)209.\u00a0\u00a0\n\u00a0Pautas\u00a0con\u00a0EFV\u00a0frente\u00a0a\u00a0pautas\u00a0con\u00a0NVP\u00a0\nEstudio\u00a02NN\u00a0\nEl\u00a0estudio\u00a02\u00a0NN\n254,\u00a0ensayo\u00a0cl\u00ednico\u00a0aleatorizado \u00a0y\u00a0abierto,\u00a0compar\u00f3\u00a0la\u00a0eficacia\u00a0y\u00a0toleran\u2010\ncia\u00a0de\u00a04\u00a0pautas\u00a0con\u00a0EFV,\u00a0NVP\u00a0(400\u00a0mg\u00a0QD),\u00a0NVP\u00a0(200\u00a0mg\u00a0BID)\u00a0y\u00a0EFV\u00a0+\u00a0NVP,\u00a0combinados \u00a0\ntodos\u00a0con\u00a0d4T+3TC. \u00a0Se\u00a0incluyeron \u00a01216\u00a0pacientes \u00a0con\u00a0una\u00a0mediana\u00a0de\u00a0CD4\u00a0de\u00a0190\u00a0\nc\u00e9lulas/\u00b5L \u00a0y\u00a0CVP\u00a0de\u00a04,7\u00a0log 10\u00a0copias/mL. \u00a0Se\u00a0consider\u00f3 \u00a0fracaso\u00a0de\u00a0tratamiento \u00a0el\u00a0fracaso\u00a0\nvirol\u00f3gico \u00a0(descenso \u00a0de\u00a0CVP\u00a0<1\u00a0log 10\u00a0en\u00a0la\u00a0semana\u00a012\u00a0o\u00a0dos\u00a0determinaciones \u00a0de\u00a0CVP\u00a0\n>50\u00a0copias/mL \u00a0a\u00a0partir\u00a0de\u00a0la\u00a0semana\u00a024\u00a0o\u00a0una\u00a0CVP\u00a0\u226550\u00a0copias/mL \u00a0en\u00a0la\u00a0semana\u00a048),\u00a0la\u00a0\nprogresi\u00f3n \u00a0cl\u00ednica\u00a0a\u00a0estadio\u00a0C\u00a0o\u00a0muerte\u00a0y\u00a0el\u00a0cambio\u00a0de\u00a0tratamiento. \u00a0En\u00a0la\u00a0semana\u00a048,\u00a0la\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0fracaso\u00a0de\u00a0tratamiento \u00a0fue\u00a043,6%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0NVP\u00a0QD;\u00a0\n43,7%\u00a0en\u00a0el\u00a0de\u00a0NVP\u00a0BID,\u00a037,8%\u00a0en\u00a0el\u00a0de\u00a0EFV,\u00a0y\u00a053,1%\u00a0en\u00a0el\u00a0de\u00a0NVP+EFV. \u00a0La\u00a0diferencia \u00a0\nde\u00a05,9%\u00a0(IC95%,\u00a0\u2010\u00a00,9\u00a0a\u00a012,8)\u00a0entre\u00a0las\u00a0ramas\u00a0con\u00a0NVP\u00a0BID\u00a0y\u00a0EFV\u00a0no\u00a0fue\u00a0significativa, \u00a0Documento \u00a0de\u00a0consenso \u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010) \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 38 \n por\u00a0lo\u00a0que\u00a0no\u00a0pudo\u00a0demostrarse \u00a0la\u00a0equivalencia \u00a0dentro\u00a0de\u00a0los\u00a0l\u00edmites\u00a0del\u00a010%.\u00a0No\u00a0hubo\u00a0\ndiferencias\u00a0 entre\u00a0 los\u00a0grupos\u00a0con\u00a0 NVP\u00a0(QD\u00a0o\u00a0BID).\u00a0El\u00a0fracaso\u00a0de\u00a0tratamiento \u00a0fue\u00a0m\u00e1s\u00a0\nfrecuente \u00a0en\u00a0la\u00a0rama\u00a0NVP+EFV\u00a0que\u00a0en\u00a0la\u00a0de\u00a0EFV\u00a0(15.3%,\u00a0 p=0,0003),\u00a0 pero\u00a0no\u00a0hubo\u00a0dife\u2010\nrencias\u00a0significativas \u00a0respecto\u00a0al\u00a0grupo\u00a0de\u00a0NVP\u00a0QD\u00a0(9,5%;\u00a0p=0,05).\u00a0Tam poco\u00a0hubo\u00a0 dife\u2010\nrencias\u00a0entre\u00a0las\u00a0distintas\u00a0ramas\u00a0con\u00a0 respecto\u00a0a\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0 CVP\u00a0\n<50\u00a0copias/mL: \u00a070%\u00a0con\u00a0 NVP\u00a0QD,\u00a065%\u00a0con\u00a0 NVP\u00a0BID,\u00a0 70%\u00a0con\u00a0 EFV\u00a0y\u00a0\u00a062,7%\u00a0con\u00a0\nEFV+NVP\u00a0(ITT).\u00a0En\u00a0el\u00a0subgrupo \u00a0con\u00a0 CVP\u00a0alta\u00a0(>100000 \u00a0copias/mL) \u00a0el\u00a0fracaso\u00a0de\u00a0trata\u2010\nmiento\u00a0fue\u00a0de\u00a019,9%\u00a0 en\u00a0la\u00a0rama\u00a0NVP\u00a0QD,\u00a015,8%\u00a0 en\u00a0la\u00a0de\u00a0NVP\u00a0BID,\u00a0 8,2%\u00a0en\u00a0la\u00a0de\u00a0\nNVP+EFV\u00a0y\u00a05,9%\u00a0en\u00a0la\u00a0de\u00a0EFV\u00a0(p=0,004). \u00a0El\u00a0incremento \u00a0de\u00a0linfocitos\u00a0CD4\u00a0fue\u00a0el\u00a0mismo\u00a0\nen\u00a0las\u00a04\u00a0ram\nas.\u00a0Los\u00a0efectos\u00a0adversos\u00a0fueron\u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0NVP+EFV\u00a0y\u00a0\nla\u00a0toxicidad\u00a0hepatobiliar \u00a0fue\u00a0m\u00e1s\u00a0 frecuente \u00a0en\u00a0el\u00a0de\u00a0NVP\u00a0QD\u00a0que\u00a0en\u00a0los\u00a0otros.\u00a0Se\u00a0regi\ns\u2010\ntraron\u00a025\u00a0muertes\u00a0de\u00a0las\u00a0que\u00a02\u00a0se\u00a0atribuyeron \u00a0a\u00a0NVP.\u00a0Como\u00a0conclusi\u00f3n \u00a0de\u00a0este\u00a0estudio\u00a0\nse\u00a0puede\u00a0decir\u00a0que\u00a0la\u00a0eficacia\u00a0 fue\u00a0similar\u00a0en\u00a0los\u00a0tres\u00a0brazos\u00a0que\u00a0conten\u00edan\u00a0 un\u00a0NN.\u00a0La\u00a0\neficacia\u00a0de\u00a0la\u00a0combinaci\n\u00f3n\u00a0NVP\u00a0+\u00a0EFV\u00a0es\u00a0inferior\u00a0a\u00a0la\u00a0que\u00a0contiene\u00a0solamente \u00a0EFV.\u00a0\u00a0\nA\u00a0la\u00a0hora\u00a0 de\u00a0valorar\u00a0los\u00a0resultados \u00a0de\u00a0este\u00a0estudio,\u00a0debe\u00a0tenerse\u00a0 en\u00a0cuenta\u00a0que\u00a0en\u00a0el\u00a0\u00a0\ndise\u00f1o\u00a0se\u00a0especific\u00f3 \u00a0que\u00a0ser\u00eda\u00a0 cl\u00ednicamente \u00a0significativa \u00a0una\u00a0diferencia \u00a0de\u00a0fracaso\u00a0te\u2010\nrap\u00e9utico \u00a0inferior\u00a0al\u00a010%\u00a0entre\u00a0 las\u00a0dos\u00a0pautas\u00a0(semana\u00a0 48).\u00a0Los\u00a0resultados \u00a0indicaron, \u00a0\nsin\u00a0embargo\n,\u00a0que\u00a0no\u00a0pod\u00eda\u00a0descartarse \u00a0una\u00a0diferencia \u00a0mayor\u00a0 ya\u00a0que\u00a0seg\u00fan\u00a0el\u00a0intervalo\u00a0\nde\u00a0confianza \u00a0del\u00a095%\u00a0la\u00a0eficacia\u00a0de\u00a0EFV\u00a0sobre\u00a0NVP\u00a0puede\u00a0superar\u00a0el\u00a010%.\u00a0En\u00a0un\u00a0an\u00e1lisis\u00a0\nde\u00a0sensibilidad \u00a0en\u00a0el\u00a0que\u00a0s\u00f3lo\u00a0se\u00a0incluyeron \u00a0los\u00a0pacientes \u00a0que\u00a0tomaron\u00a0 la\u00a0medi caci\u00f3n\u00a0la\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes\u00a0 con\u00a0 \u00e9xito\u00a0terap\u00e9utico \u00a0fue\u00a0significativamente \u00a0mayor\u00a0en\u00a0el\u00a0gru\u2010\npo\u00a0de\u00a0EFV\u00a0que\u00a0en\u00a0el\u00a0de\u00a0NVP\u00a0BID.\u00a0\u00a0\n\u00a0\nResumen \u00a0sobre\u00a0ensayos\u00a0de\u00a0NN\u00a0\nSe\u00a0ha\u00a0demostrado \u00a0que\u00a0pautas\u00a0con\u00a0 EFV\u00a0o\u00a0NVP\u00a0son\u00a0m\u00e1s\u00a0eficaces\u00a0que\u00a0pautas\u00a0con\u00a0 3\u00a0AN.\u00a0\nIgualmente \u00a0se\u00a0ha\u00a0demo strado \u00a0que\u00a0una\u00a0pauta\u00a0con\u00a0EFV\u00a0es\u00a0m\u00e1s\u00a0eficaz\u00a0que\u00a0con\u00a0algunos\u00a0 IP\u00a0\n(IDV,\u00a0NFV,\u00a0LPV/r202).\u00a0EFV\u00a0ha\u00a0demostrado \u00a0resultados \u00a0similares\u00a0a\u00a0APV/r\u00a0y\u00a0superiores \u00a0a\u00a0\nSQV/r\u00a0con\u00a0 dosis\u00a0de\u00a0IP\u00a0no\u00a0aprobadas \u00a0en\u00a0Europa;\u00a0EFV\u00a0no\u00a0se\u00a0ha\u00a0comparado \u00a0a\u00a0DRV/r\u00a0ni\u00a0a\u00a0\nATV/r.\u00a0Sin\u00a0embargo, \u00a0NVP\u00a0no\u00a0ha\u00a0demostrado \u00a0en\u00a0ning\u00fan\u00a0ensayo\u00a0cl\u00ednico\u00a0que\u00a0sea\u00a0m\u00e1s\u00a0efi\u2010\ncaz\u00a0que\u00a0un\u00a0IP,\u00a0pero\u00a0s\u00ed\u00a0no\u00a0inferioridad\u00a0 con\u00a0 ATV/r.\u00a0Por\u00a0\u00faltimo,\u00a0 la\u00a0comparaci\u00f3n \u00a0entre\u00a0 los\u00a0\ndos\u00a0NN\u00a0no\u00a0ha\u00a0permitido \u00a0obtener\u00a0conclusiones \u00a0definitivas. \u00a0\u00a0\n\u00a0Consideraciones \u00a0sobre\u00a0la\u00a0elecci\u00f3n\u00a0de\u00a0un\u00a0r\u00e9gimen\u00a0con\u00a0NVP\u00a0o\u00a0EFV\u00a0\n1)\u00a0EFV\u00a0ha\u00a0demostrado \u00a0su\u00a0eficacia\u00a0en\u00a0pacientes \u00a0con\u00a0 CVP\u00a0>100000\u00a0copias/mL \u00a0o\u00a0muy\u00a0in\u2010\nmunodeprimidos \u00a0(50\u2010100\u00a0linfocitos\u00a0CD4/\u00b5L)\n204\u00a0208y\u00a0es\u00a0capaz\u00a0de\u00a0suprimir\u00a0la\u00a0carga\u00a0viral\u00a0\nen\u00a0tejido\u00a0linf\u00e1tico\u00a0de\u00a0forma\u00a0similar\u00a0a\u00a0reg\u00edmenes \u00a0con\u00a0IP264.\u00a0\u00a0\n2)\u00a0EFV\u00a0est\u00e1\u00a0contraindicado \u00a0en\u00a0embarazadas \u00a0(riesgo\u00a0de\u00a0teratogenicidad) \u00a0y\u00a0deber\u00eda\u00a0 evi\u2010\ntarse\u00a0en\u00a0mujeres\u00a0que\u00a0quieran\u00a0quedarse \u00a0embarazadas \u00a0o\u00a0que\u00a0no\u00a0utilicen\u00a0m\u00e9todos\u00a0anti\u2010\nconceptivos\u00a0 seguros.\u00a0EFV\u00a0puede\u00a0producir\u00a0mareos,\u00a0 trastornos \u00a0de\u00a0la\u00a0concentraci\u00f3n\u00a0 y\u00a0\nsomnolencia, \u00a0por\u00a0lo\u00a0que\u00a0se\u00a0deber\u00e1\u00a0informar\u00a0a\u00a0los\u00a0pacientes \u00a0y\u00a0recomendarles \u00a0que,\u00a0 en\u00a0\npresenci\na\u00a0de\u00a0estos\u00a0s\u00edntomas, \u00a0eviten\u00a0tareas\u00a0peligrosas \u00a0como\u00a0conducir\u00a0o\u00a0usar\u00a0m\u00e1quinas \u00a0\npesadas.\u00a0 Asimismo \u00a0deber\u00eda\u00a0evitarse\u00a0en\u00a0pacientes\u00a0 con\u00a0 antecedentes \u00a0psiqui\u00e1tricos \u00a0gra\u2010\nves.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 39 \n 3)\u00a0EFV\u00a0est\u00e1\u00a0disponible \u00a0para\u00a0su\u00a0uso\u00a0en\u00a0coformulaci\u00f3n \u00a0junto\u00a0a\u00a0TDF+FTC\u00a0en\u00a0un\u00a0\u00fanico\u00a0\ncomprimido \u00a0de\u00a0administraci\u00f3n \u00a0una\u00a0vez\u00a0al\u00a0d\u00eda.\u00a0\n4)\u00a0En\u00a0pacientes \u00a0que\u00a0reciben\u00a0metadona \u00a0debe\u00a0tenerse\u00a0especial\u00a0cuidado\u00a0ya\u00a0que,\u00a0tanto\u00a0\nEFV\u00a0como\u00a0NVP,\u00a0suelen\u00a0inducir\u00a0su\u00a0metabolismo \u00a0y\u00a0producir\u00a0s\u00edndrome \u00a0de\u00a0abstinencia. \u00a0\n5)\u00a0La\u00a0NVP\u00a0puede\u00a0producir\u00a0exantema \u00a0cut\u00e1neo,\u00a0con\u00a0o\u00a0sin\u00a0fiebre\u00a0y\u00a0s\u00edntomas\u00a0pseudogripa \u2010\nles.\u00a0Se\u00a0han\u00a0descrito\u00a0eventos\u00a0hep\u00e1ticos \u00a0graves\u00a0e\u00a0incluso\u00a0fatales\u00a0durante\u00a0las\u00a0primeras\u00a0\nsemanas\u00a0de\u00a0tratamiento, \u00a0por\u00a0lo\u00a0que\u00a0NVP\u00a0debe\u00a0administrarse \u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pa\u2010\ncientes\u00a0con\u00a0hepatopat\u00eda \u00a0cr\u00f3nica\u00a0y\u00a0transaminasas \u00a0elevadas\u00a0(contraindicada \u00a0si\u00a0las\u00a0tran\u2010\nsaminasas \u00a0est\u00e1n\u00a0por\u00a0encima\u00a0de\u00a0cinco\u00a0veces\u00a0el\u00a0l\u00edmite\u00a0superior\u00a0de\u00a0la\u00a0normalidad). \u00a0Los\u00a0\neventos\u00a0hep\u00e1ticos \u00a0son\u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0el\u00a0primer\u00a0tratamiento \u00a0de\u00a0mujeres\u00a0con\u00a0CD4\u00a0\n>250\u00a0c\u00e9lulas/\u00b5L \u00a0(11%\u00a0frente\u00a0a\u00a00,9%)\u00a0o\u00a0de\u00a0hombres\u00a0con\u00a0CD4\u00a0>400\u00a0c\u00e9lulas/\u00b5L \u00a0(6,3%\u00a0fren\u2010\nte\u00a0a\u00a01,2%).\u00a0Sin\u00a0embargo\u00a0en\u00a0pacientes \u00a0von\u00a0CVP\u00a0indetectable \u00a0que\u00a0simplifican \u00a0el\u00a0trata\u2010\nmiento\u00a0a\u00a0NVP\u00a0no\u00a0se\u00a0observan\u00a0estas\u00a0alteraciones. \u00a0\u00a0\n6)\u00a0La\u00a0NVP\u00a0ha\u00a0demostrado \u00a0no\u00a0inferioridad \u00a0con\u00a0respecto\u00a0a\u00a0ATV/r,\u00a0incluso\u00a0en\u00a0pacientes \u00a0\ncon\u00a0CVP\u00a0>100.000 \u00a0copias/mL. \u00a0\n7)\u00a0Existe\u00a0muy\u00a0escasa\u00a0experiencia \u00a0en\u00a0cuanto\u00a0a\u00a0eficacia\u00a0y\u00a0tolerancia \u00a0de\u00a0la\u00a0combinaci\u00f3n \u00a0\nABC+3TC+NVP. \u00a0Tanto\u00a0ABC\u00a0como\u00a0NVP\u00a0pueden\u00a0presentar \u00a0reacci\u00f3n\u00a0de\u00a0hipersensibilidad. \u00a0\u00a0\n\u00a0\nNN.\u00a0Recomendaciones \u00a0\n\u0083 En\u00a0general\u00a0se\u00a0recomienda \u00a0EFV\u00a0frente\u00a0a\u00a0NVP,\u00a0por\u00a0el\u00a0mayor\u00a0n\u00famero\u00a0de\u00a0estudios\u00a0y\u00a0\nexperiencia \u00a0(nivel\u00a0C).\u00a0\u00a0\u00a0\n\u0083 EFV\u00a0est\u00e1\u00a0contraindicado \u00a0durante\u00a0el\u00a0primer\u00a0trimestre \u00a0de\u00a0la\u00a0gestaci\u00f3n. \u00a0Se\u00a0\u00a0recomien \u2010\nda\u00a0considerar \u00a0otras\u00a0opciones\u00a0en\u00a0mujeres\u00a0que\u00a0no\u00a0utilicen\u00a0m\u00e9todos\u00a0anticonceptivos \u00a0\neficaces.\u00a0Asimismo, \u00a0se\u00a0debe\u00a0evitar\u00a0en\u00a0pacientes \u00a0que\u00a0realicen\u00a0tareas\u00a0peligrosas \u00a0si\u00a0\npresentan \u00a0s\u00edntomas\u00a0de\u00a0somnolencia, \u00a0mareos\u00a0y/o\u00a0trastornos \u00a0de\u00a0la\u00a0concentraci\u00f3n. \u00a0\n\u0083 Se\u00a0desaconseja \u00a0la\u00a0NVP\u00a0en\u00a0el\u00a0inicio\u00a0del\u00a0TARV\u00a0en\u00a0mujeres\u00a0con\u00a0recuento\u00a0de\u00a0CD4\u00a0>250\u00a0\nc\u00e9lulas/\u03bcL\u00a0\u00a0y\u00a0en\u00a0varones\u00a0con\u00a0recuento\u00a0de\u00a0CD4\u00a0>400\u00a0c\u00e9lulas/\u03bcL\u00a0\n\u00a0\n4.5.\u00a0Inhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0\nEn\u00a0Espa\u00f1a\u00a0se\u00a0han\u00a0comercializado \u00a09\u00a0IP:\u00a0saquinavir \u00a0(SQV),\u00a0indinavir\u00a0(IDV),\u00a0ritonavir\u00a0(RTV),\u00a0\nnelfinavir \u00a0(NFV),\u00a0fosamprenavir \u00a0(FPV),\u00a0lopinavir\u00a0(LPV),\u00a0atazanavir \u00a0(ATV),\u00a0tipranavir \u00a0(TPV)\u00a0\ny\u00a0darunavir \u00a0(DRV).\u00a0TPV/r\u00a0est\u00e1\u00a0aprobado \u00a0por\u00a0la\u00a0EMEA\u00a0solamente \u00a0en\u00a0pacientes \u00a0pretrata\u2010\ndos.\u00a0Sus\u00a0principales \u00a0caracter\u00edsticas \u00a0se\u00a0muestran \u00a0en\u00a0la\u00a0Tabla\u00a07.\u00a0Los\u00a0IP\u00a0son\u00a0inductores \u00a0e\u00a0\ninhibidores \u00a0del\u00a0citocromo \u00a0P450\u00a0y\u00a0frecuentemente \u00a0pueden\u00a0originar\u00a0interacciones \u00a0far\u2010\nmacocin\u00e9ticas. \u00a0La\u00a0elecci\u00f3n\u00a0final\u00a0del\u00a0IP\u00a0se\u00a0basar\u00e1\u00a0en\u00a0datos\u00a0de\u00a0eficacia,\u00a0tolerancia, \u00a0inter\u2010\nacciones,\u00a0posolog\u00eda \u00a0y\u00a0farmacocin\u00e9tica. \u00a0LPV/r\u00a0se\u00a0administra \u00a0en\u00a0comprimidos \u00a0coformula \u2010\ndos\u00a0que\u00a0no\u00a0precisan\u00a0\u00a0refrigeraci\u00f3n. \u00a0Para\u00a0el\u00a0resto\u00a0de\u00a0IP/r\u00a0se\u00a0recomienda \u00a0mantener \u00a0las\u00a0\nc\u00e1psulas\u00a0de\u00a0ritonavir\u00a0refrigeradas \u00a0(la\u00a0ficha\u00a0t\u00e9cnica\u00a0informa\u00a0que\u00a0pueden\u00a0permanecer \u00a0\nhasta\u00a030\u00a0d\u00edas\u00a0a\u00a0temperatura \u00a0no\u00a0superior\u00a0a\u00a025\u00b0C).\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 40 \n Combinaciones \u00a0de\u00a0TARV\u00a0que\u00a0incluyan\u00a0IP\u00a0potenciados \u00a0\nSe\u00a0entiende\u00a0por\u00a0IP\u00a0potenciado \u00a0la\u00a0coadministraci\u00f3n \u00a0de\u00a0un\u00a0IP\u00a0con\u00a0dosis\u00a0reducidas \u00a0de\u00a0RTV.\u00a0\nEl\u00a0RTV\u00a0tiene\u00a0un\u00a0potente\u00a0efecto\u00a0inhibidor\u00a0del\u00a0citocromo \u00a0P450\u00a0que\u00a0inhibe\u00a0el\u00a0metabolis \u2010\nmo\u00a0del\u00a0segundo\u00a0IP\u00a0mejorando \u00a0su\u00a0perfil\u00a0farmacocin\u00e9tico \u00a0y\u00a0el\u00a0cociente\u00a0Cmin/CI50,\u00a0redu\u2010\nciendo\u00a0el\u00a0riesgo\u00a0de\u00a0aparici\u00f3n \u00a0de\u00a0resistencias. \u00a0Adem\u00e1s\u00a0al\u00a0potenciar \u00a0un\u00a0IP\u00a0se\u00a0reduce\u00a0el\u00a0\nn\u00famero\u00a0de\u00a0comprimidos, \u00a0la\u00a0frecuencia \u00a0de\u00a0dosis\u00a0y\u00a0las\u00a0restricciones \u00a0diet\u00e9ticas \u00a0lo\u00a0que\u00a0\nfavorece\u00a0la\u00a0adherencia. \u00a0Un\u00a0inconveniente \u00a0de\u00a0estas\u00a0combinaciones \u00a0es\u00a0su\u00a0potencial \u00a0toxi\u2010\ncidad.\u00a0\u00a0En\u00a0la\u00a0Tabla\u00a07\u00a0est\u00e1n\u00a0las\u00a0combinaciones \u00a0m\u00e1s\u00a0importantes \u00a0de\u00a0IP\u00a0y\u00a0sus\u00a0dosificacio \u2010\nnes\u00a0basadas\u00a0en\u00a0estudios\u00a0farmacocin\u00e9ticos. \u00a0\u00a0\n\u00a0\nEnsayos\u00a0que\u00a0avalan\u00a0las\u00a0recomendaciones \u00a0de\u00a0IP\u00a0\nComparaciones \u00a0entre\u00a0IP\u00a0\nM98\u2010863\u00a0\nEl\u00a0M98\u2010863\u00a0es\u00a0un\u00a0ensayo\u00a0aleatorizado, \u00a0doble\u00a0ciego,\u00a0multic\u00e9ntrico \u00a0que\u00a0compar\u00f3\u00a0LPV/r\u00a0\n(400/100\u00a0mg\u00a0BID;\u00a0n=326)\u00a0frente\u00a0a\u00a0NFV\u00a0(750\u00a0mg\u00a0TID;\u00a0n=327)\u00a0junto\u00a0a\u00a0d4T+3TC. \u00a0En\u00a0la\u00a0se\u2010\nmana\u00a060,\u00a0se\u00a0observ\u00f3\u00a0mejor\u00a0respuesta \u00a0virol\u00f3gica \u00a0(ITT)\u00a0en\u00a0los\u00a0pacientes \u00a0tratados\u00a0con\u00a0\nLPV/r\u00a0(CVP\u00a0<50\u00a0copias/mL, \u00a064%\u00a0y\u00a052%,\u00a0respectivamente, \u00a0p\u00a0=0,001)265.\u00a0\n\u00a0\nM02\u2010418\u00a0\u00a0\nEn\u00a0el\u00a0ensayo\u00a0cl\u00ednico\u00a0M02\u2010418\u00a0se\u00a0evalu\u00f3\u00a0la\u00a0eficacia\u00a0y\u00a0tolerancia \u00a0de\u00a0LPV/r\u00a0BID\u00a0frente\u00a0a\u00a0\nLPV/r\u00a0QD\u00a0combinados \u00a0con\u00a0TDF\u00a0y\u00a0FTC.\u00a0Se\u00a0incluyeron \u00a0190\u00a0pacientes \u00a0con\u00a0una\u00a0mediana\u00a0de\u00a0\nCD4\u00a0de\u00a0214\u2010232\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0de\u00a0CVP\u00a0de\u00a04,6\u20104,8\u00a0log 10\u00a0en\u00a0cada\u00a0grupo.\u00a0A\u00a0la\u00a0semana\u00a048\u00a0la\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0(ITT)\u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0fue\u00a0similar\u00a0(70%\u00a0y\u00a064%\u00a0seg\u00fan\u00a0\npauta,\u00a0LPV/r\u00a0QD\u00a0o\u00a0LPV/r\u00a0BID)266.\u00a0\n\u00a0\nKLEAN\u00a0\nEl\u00a0estudio\u00a0KLEAN\u00a0compar\u00f3\u00a0FPV/r\u00a0(700/100\u00a0mg\u00a0BID)\u00a0con\u00a0LPV/r\u00a0(300/100\u00a0mg\u00a0BID,\u00a0c\u00e1psu\u2010\nlas)\u00a0ambos\u00a0con\u00a0ABC+3TC\u00a0coformulados, \u00a0en\u00a0887\u00a0pacientes. \u00a0En\u00a0la\u00a0semana\u00a048\u00a0la\u00a0propor\u2010\nci\u00f3n\u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(ITT)\u00a0fue\u00a066%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0FPV/r\u00a0y\u00a065%\u00a0en\u00a0\nel\u00a0de\u00a0LPV/r,\u00a0demostrando \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0FPV/r\u00a0frente\u00a0a\u00a0las\u00a0c\u00e1psulas\u00a0de\u00a0LPV/r.\u00a0No\u00a0\nhubo\u00a0diferencia \u00a0significativa \u00a0en\u00a0cuanto\u00a0a\u00a0tolerancia \u00a0digestiva\u00a0(n\u00e1useas, \u00a0v\u00f3mitos,\u00a0di\u2010\narrea)\u00a0ni\u00a0alteraciones \u00a0lip\u00eddicas239.\u00a0\u00a0\n\u00a0\nAPV30001 \u00a0\u2010\u00a0NEAT\u00a0\nEn\u00a0el\u00a0estudio\u00a0NEAT\u00a0se\u00a0evalu\u00f3\u00a0la\u00a0eficacia\u00a0y\u00a0tolerancia \u00a0de\u00a0FPV\u00a0(1400\u00a0mg\u00a0BID)\u00a0frente\u00a0a\u00a0\nNFV,\u00a0ambos\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0ABC\u00a0y\u00a03TC.\u00a0Se\u00a0aleatorizaron \u00a0166\u00a0pacientes \u00a0a\u00a0FPV\u00a0y\u00a083\u00a0\na\u00a0NFV.\u00a0\u00a0A\u00a0las\u00a048\u00a0semanas, \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0fue\u00a0ma\u2010\nyor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0\u00a0FPV\u00a0que\u00a0en\u00a0el\u00a0de\u00a0NFV\u00a0(66%\u00a0y\u00a051%;\u00a0ITT).\u00a0En\u00a0el\u00a0grupo\u00a0de\u00a0CVP\u00a0elevada\u00a0\n(>100.000 \u00a0copias/mL) \u00a0la\u00a0proporci\u00f3n \u00a0fue\u00a0de\u00a067%\u00a0y\u00a035%\u00a0respectivamente \u00a0(p<0,05)267.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 41 \n APV30002 \u00a0\u2010\u00a0SOLO\u00a0\nEl\u00a0SOLO\u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0aleatorizado \u00a0en\u00a0el\u00a0que\u00a0compararon \u00a0322\u00a0pacientes \u00a0tratados\u00a0\ncon\u00a0FPV/r\u00a0QD\u00a0(1400/200 \u00a0mg)\u00a0con\u00a0327\u00a0pacientes \u00a0con\u00a0NFV,\u00a0ambos\u00a0asociados \u00a0a\u00a0ABC+3TC. \u00a0\nLa\u00a0mediana\u00a0de\u00a0CD4\u00a0fue\u00a0170\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0la\u00a0CVP\u00a04,8\u00a0log 10.\u00a0El\u00a020%\u00a0de\u00a0los\u00a0pacientes \u00a0ten\u00edan\u00a0\n<50\u00a0CD4/\u00b5L.\u00a0A\u00a0las\u00a048\u00a0semanas\u00a0no\u00a0hubo\u00a0diferencias \u00a0(ITT)\u00a0en\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0\ncon\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0(69%,\u00a0FPV/r\u00a0frente\u00a068%,\u00a0NFV)\u00a0ni\u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(55\u00a0vs\u00a0\n53%).\u00a0Sin\u00a0embargo, \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0que\u00a0presentaron \u00a0fallo\u00a0virol\u00f3gico \u00a0fue\u00a0\nsuperior\u00a0en\u00a0la\u00a0rama\u00a0de\u00a0NFV\u00a0(17%)\u00a0que\u00a0en\u00a0la\u00a0de\u00a0FPV/r\u00a0(7%)268.\u00a0\u00a0\n\u00a0\nCOL100758 \u00a0\nEl\u00a0estudio\u00a0COL100758 \u00a0compar\u00f3\u00a0FPV/r\u00a0(1400/100 \u00a0mg)\u00a0y\u00a0FPV/r\u00a0(1400/200 \u00a0mg)\u00a0\u00a0ambos\u00a0\nQD\u00a0junto\u00a0con\u00a0ABC+3TC\u00a0coformulados. \u00a0Se\u00a0incluyeron \u00a0115\u00a0pacientes. \u00a0A\u00a0las\u00a048\u00a0semanas\u00a0la\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(ITT)\u00a0fue\u00a079%\u00a0(FPV/r\u00a0100\u00a0mg)\u00a0y\u00a063%\u00a0\n(FPV/r\u00a0200\u00a0mg),\u00a0\u00a0p=0,061.\u00a0La\u00a0adherencia \u00a0fue\u00a0mejor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0100\u00a0mg\u00a0de\u00a0RTV269.\u00a0En\u00a0\nvoluntarios \u00a0sanos\u00a0se\u00a0ha\u00a0demostrado \u00a0que\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0FPV\u00a0(1400\u00a0mg\u00a0QD)\u00a0\nno\u00a0difieren\u00a0si\u00a0se\u00a0potencia\u00a0con\u00a0100\u00a0o\u00a0200\u00a0mg\u00a0de\u00a0RTV270.\u00a0\u00a0\n\u00a0\nARTEMIS \u00a0\nEl\u00a0estudio\u00a0ARTEMIS\u00a0compar\u00f3\u00a0DRV/r\u00a0(800/100\u00a0mg,\u00a0QD)\u00a0frente\u00a0a\u00a0LPV/r\u00a0(BID\u00a0y\u00a0QD)\u00a0en\u00a0689\u00a0\npacientes \u00a0que\u00a0recibieron \u00a0adem\u00e1s\u00a0TDF+FTC\u00a0coformulados. \u00a0La\u00a0dosificaci\u00f3n \u00a0de\u00a0LPV/r\u00a0fue\u00a0\nvariable:\u00a077%\u00a0recibieron \u00a0el\u00a0LPV/r\u00a0BID,\u00a015%\u00a0QD\u00a0y,\u00a0adem\u00e1s,\u00a0el\u00a07%\u00a0cambi\u00f3\u00a0de\u00a0BID\u00a0a\u00a0QD\u00a0\ndurante\u00a0el\u00a0estudio.\u00a0El\u00a015%\u00a0recibi\u00f3\u00a0LPV/r\u00a0en\u00a0c\u00e1psulas,\u00a0el\u00a02%\u00a0en\u00a0comprimidos \u00a0y\u00a0el\u00a083%\u00a0\ncambiaron \u00a0de\u00a0c\u00e1psulas\u00a0a\u00a0comprimidos \u00a0durante\u00a0el\u00a0estudio.\u00a0A\u00a0las\u00a048\u00a0semanas\u00a0la\u00a0propor\u2010\nci\u00f3n\u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(ITT)\u00a0fue\u00a084%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0DRV/r\u00a0y\u00a078%\u00a0en\u00a0el\u00a0de\u00a0LPV/r\u00a0\n(IC\u00a095%\u00a0CI\u00a0\u22120,3\u00a0a\u00a011.2;\u00a0p=0,062)\u00a0demostrando \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0DRV/r\u00a0frente\u00a0a\u00a0\nLPV/r.\u00a0Los\u00a0pacientes \u00a0tratados\u00a0con\u00a0DRV/r\u00a0presentaron \u00a0menos\u00a0diarrea\u00a0grado\u00a02\u20104\u00a0que\u00a0los\u00a0\ntratados\u00a0con\u00a0LPV/r\u00a0(4%\u00a0frente\u00a010%)\u00a0y\u00a0las\u00a0elevaciones \u00a0lip\u00eddicas\u00a0fueron\u00a0menores\u00a0(triglic\u00e9\u2010\nridos\u00a0y\u00a0colesterol \u00a0total)271.\u00a0En\u00a0una\u00a0actualizaci\u00f3n \u00a0a\u00a096\u00a0semanas272\u00a0alcanzaron \u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a0(ITT\u2010TLOVR)\u00a0el\u00a079%\u00a0de\u00a0los\u00a0pacientes \u00a0en\u00a0el\u00a0grupo\u00a0DRV/r\u00a0y\u00a0el\u00a071%\u00a0en\u00a0el\u00a0grupo\u00a0\nLPV/r\u00a0concluy\u00e9ndose \u00a0que\u00a0no\u00a0solo\u00a0se\u00a0consigue\u00a0la\u00a0no\u00a0inferioridad \u00a0(objetivo\u00a0primario\u00a0por\u00a0\nprotocolo, \u00a0p<0,001;\u00a0IC95%:\u00a01,9\u00a0a\u00a014,8)\u00a0sino\u00a0tambi\u00e9n\u00a0superioridad \u00a0de\u00a0DRV/r\u00a0(objetivo\u00a0\nsecundario, \u00a0p=0,012,\u00a0por\u00a0ITT).\u00a0Esta\u00a0diferencia \u00a0a\u00a0favor\u00a0del\u00a0DRV/r\u00a0se\u00a0demostr\u00f3 \u00a0tambi\u00e9n\u00a0\nen\u00a0pacientes \u00a0con\u00a0CVP\u00a0alta\u00a0y\u00a0en\u00a0los\u00a0muy\u00a0inmunodeprimidos. \u00a0En\u00a0el\u00a0grupo\u00a0de\u00a0DRV/r\u00a0hubo\u00a0\nmenos\u00a0fracasos\u00a0virol\u00f3gicos \u00a0y\u00a0menos\u00a0mutaciones \u00a0(ninguna\u00a0que\u00a0condicionara \u00a0resistencia \u00a0\na\u00a0IP),\u00a0as\u00ed\u00a0como\u00a0menos\u00a0efectos\u00a0adversos. \u00a0\n\u00a0GEMINI\u00a0\nEl\u00a0estudio\u00a0GEMINI\u00a0compar\u00f3\u00a0SQV/r\u00a0(1000/100 \u00a0mg,\u00a0BID)\u00a0frente\u00a0a\u00a0LPV/r\u00a0(300/100\u00a0mg\u00a0BID,\u00a0\nc\u00e1psulas)\u00a0en\u00a0337\u00a0pacientes. \u00a0Todos\u00a0recibieron \u00a0adem\u00e1s\u00a0TDF+FTC\u00a0coformulados. \u00a0A\u00a0las\u00a048\u00a0\nsemanas\u00a0la\u00a0proporci\u00f3n \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(ITT)\u00a0fue\u00a064,7%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0SQV/r\u00a0y\u00a0\nde\n\u00a063,5%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0LPV/r\u00a0(IC\u00a095%\u00a0CI\u00a0\u20139,6\u201311,9). \u00a0El\u00a0estudio\u00a0demostr\u00f3 \u00a0no\u00a0inferiori\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 42 \n dad\u00a0de\u00a0SQV/r\u00a0frente\u00a0a\u00a0LPV/r.\u00a0Las\u00a0elevaciones \u00a0lip\u00eddicas\u00a0fueron\u00a0similares\u00a0con\u00a0un\u00a0incre\u2010\nmento\u00a0mayor\u00a0de\u00a0triglic\u00e9ridos \u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0LPV/r\u00a0y\u00a0de\u00a0C\u2010LDL\u00a0en\u00a0el\u00a0de\u00a0SQV/r273.\u00a0\n\u00a0BMS\u2010089\u00a0\nEl\u00a0estudio\u00a0BMS\u00a0089\u00a0compar\u00f3\u00a0ATV\u00a0(400\u00a0mg\u00a0QD)\u00a0frente\u00a0a\u00a0ATV/r\u00a0(300/100\u00a0mg,\u00a0QD).\u00a0Se\u00a0\nincluyeron \u00a0200\u00a0pacientes \u00a0que\u00a0recibieron \u00a0adem\u00e1s\u00a0d4T\u00a0de\u00a0liberaci\u00f3n \u00a0retardada \u00a0(100\u00a0mg\u00a0\nQD)\u00a0y\u00a03TC\u00a0(300\u00a0mg\u00a0QD).\u00a0A\u00a0las\u00a048\u00a0semanas, \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0co\u2010\npias/mL\u00a0(ITT)\n\u00a0fue\u00a075%\u00a0(ATV/r)\u00a0y\u00a070%\u00a0(ATV).\u00a0En\u00a0este\u00a0estudio\u00a0se\u00a0demostr\u00f3 \u00a0la\u00a0no\u00a0inferiori\u2010\ndad\u00a0de\u00a0ATV/r\u00a0frente\u00a0a\u00a0ATV\u00a0sin\u00a0potenciar. \u00a0Las\u00a0causas\u00a0de\u00a0fracaso\u00a0terap\u00e9utico \u00a0fueron\u00a0dife\u2010\nrentes\u00a0en\u00a0los\u00a0dos\u00a0brazos.\u00a0Hubo\u00a0m\u00e1s\u00a0fracasos\u00a0virol\u00f3gicos \u00a0en\u00a0la\u00a0rama\u00a0de\u00a0ATV\u00a0no\u00a0poten\u2010\nciado\u00a0(10\u00a0frente\u00a0a\u00a03;\u00a0p:\u00a0ns).\u00a0Los\u00a0que\u00a0fracasaron \u00a0en\u00a0la\u00a0rama\u00a0de\u00a0ATV/r\u00a0no\u00a0tuvieron\u00a0muta\u2010\nciones\u00a0en\u00a0el\u00a0gen\u00a0de\u00a0la\u00a0proteasa\u00a0mientras\u00a0que\u00a0se\u00a0detectaron \u00a0en\u00a03\u00a0de\u00a0los\u00a010\u00a0que\u00a0fracasa\u2010\nron\u00a0con\u00a0ATV\u00a0sin\u00a0potenciar. \u00a0Tambi\u00e9n\u00a0hubo\u00a0m\u00e1s\u00a0mutaciones \u00a0a\u00a03TC\u00a0en\u00a0el\u00a0grupo\u00a0no\u00a0poten\u2010\nciado\u00a0(7\u00a0de\u00a010,\u00a0frente\u00a0a\u00a01\u00a0de\u00a03).\u00a0Las\u00a0suspensiones \u00a0de\u00a0tratamiento \u00a0por\u00a0hiperbilirrubine \u2010\nmia\u00a0fueron\u00a0m\u00e1s\u00a0frecuentes \u00a0con\u00a0ATV/r.\u00a0El\u00a0estudio\u00a0pone\u00a0de\u00a0manifiesto \u00a0la\u00a0mayor\u00a0eficacia\u00a0\nvirol\u00f3gica \u00a0y\u00a0barrera\u00a0gen\u00e9tica\u00a0de\u00a0ATV/r274.\u00a0\u00a0\n\u00a0Estudio\u00a01182.33\u00a0\u00a0\nEl\u00a0estudio\u00a01182.33\u00a0intent\u00f3\u00a0comparar \u00a0dos\u00a0dosis\u00a0de\u00a0TPV/r\u00a0(500/100\u00a0BID\u00a0y\u00a0500/200\u00a0BID)\u00a0\nfrente\u00a0a\u00a0LPV/r\u00a0(400/100\u00a0BID).\u00a0El\u00a0comit\u00e9\u00a0de\u00a0vigilancia\u00a0decidi\u00f3\u00a0parar\u00a0el\u00a0estudio\u00a0por\u00a0mayor\u00a0\ntasa\u00a0de\u00a0elevaci\u00f3n \u00a0asintom\u00e1tica \u00a0de\u00a0enzimas\u00a0hep\u00e1ticas \u00a0en\u00a0la\u00a0rama\u00a0de\u00a0TPV/r\u00a0\u00a0500/200\u00a0BID\u00a0\ny\u00a0por\u00a0no\u00a0alcanzar\u00a0el\n\u00a0criterio\u00a0de\u00a0no\u00a0inferioridad \u00a0a\u00a0la\u00a0semana\u00a060\u00a0en\u00a0la\u00a0rama\u00a0de\u00a0TPV/r\u00a0\u00a0\n500/100\u00a0BID.\u00a0Debido\u00a0a\u00a0estos\u00a0resultados \u00a0no\u00a0se\u00a0recomienda \u00a0el\u00a0uso\u00a0de\u00a0TPV/r\u00a0en\u00a0terapias\u00a0\nde\u00a0inicio.\u00a0\n\u00a0\nM05\u2010730\u00a0\nLa\u00a0combinaci\u00f3n \u00a0TDF+FTC+ \u00a0LPV/r\u00a0(comprimidos, \u00a0BID)\u00a0se\u00a0ha\u00a0comparado \u00a0con\u00a0la\u00a0combina\u2010\nci\u00f3n\u00a0TDF+FTC+LPV/r \u00a0(comprimidos, \u00a0QD)\u00a0en\u00a0664\u00a0pacientes \u00a0que\u00a0recib\u00edan\u00a0el\u00a0primer\u00a0tra\u2010\ntamiento. \u00a0Este\u00a0ensayo\u00a0cl\u00ednico\u00a0demuestra \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0LPV/r\u00a0comprimidos \u00a0ad\u2010\nministrado \u00a0una\u00a0vez\u00a0al\u00a0d\u00eda\u00a0frente\u00a0a\u00a0LPV/r\u00a0comprimidos \u00a0administrados \u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda.\u00a0\u00a0\nLa\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0cargas\u00a0virales\u00a0<50\u00a0copias/mL \u00a0(ITT)\u00a0fue\u00a0del\u00a077%\u00a0en\u00a0el\u00a0\ngrupo\u00a0QD\u00a0y\u00a0del\u00a076%\u00a0en\u00a0el\u00a0grupo\u00a0BID.\u00a0Durante\u00a0las\u00a0primeras\u00a08\u00a0semanas\u00a0del\u00a0estudio\u00a0los\u00a0\npacientes \u00a0en\u00a0cada\u00a0grupo\u00a0fueron\u00a0aleatorizados \u00a0adem\u00e1s\u00a0a\u00a0recibir\u00a0las\u00a0c\u00e1psulas\u00a0o\u00a0los\u00a0com\u2010\nprimidos\u00a0de\u00a0LPV/r\u00a0sin\u00a0encontrar \u00a0diferencias \u00a0entre\u00a0ambas\u00a0presentaciones \u00a0respecto\u00a0a\u00a0la\u00a0\nincidencia \u00a0de\u00a0efectos\u00a0adversos\u00a0o\u00a0a\u00a0discontinuaciones \u00a0por\u00a0toxicidad275.\u00a0\u00a0\n\u00a0\nEstudio\u00a0CASTLE\u00a0\u00a0\nEste\u00a0ensayo\u00a0compara\u00a0la\u00a0combinaci\u00f3n \u00a0TDF+FTC+ATV/r \u00a0QD\u00a0con\u00a0la\u00a0combinaci\u00f3n \u00a0\nTDF+FTC+LPV/r \u00a0(c\u00e1psulas) \u00a0BID\u00a0en\u00a0883\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo,\u00a0demostrando \u00a0\nla\u00a0no\u2010inferioridad \u00a0de\u00a0ATV/r\u00a0frente\u00a0a\u00a0LPV/r\u00a0en\u00a0su\u00a0forma\u00a0de\u00a0c\u00e1psulas.\u00a0La\u00a0proporci\u00f3n \u00a0de\u00a0\npacientes \u00a0con\u00a0cargas\u00a0virales\u00a0<50\u00a0copias/mL \u00a0(ITT)\u00a0fue\u00a0de\u00a078%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ATV/r\u00a0y\u00a0de\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 43 \n 76%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0LPV/r.\u00a0ATV/r\u00a0mostr\u00f3\u00a0mejor\u00a0perfil\u00a0lip\u00eddico\u00a0(colesterol \u00a0total,\u00a0triglic\u00e9ri\u2010\ndos\u00a0y\u00a0colesterol \u00a0no\u2010HDL).\u00a0La\u00a0ictericia\u00a0e\u00a0hiperbilirrubinemia \u00a0fueron\u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0el\u00a0\ngrupo\u00a0de\u00a0ATV/r\u00a0mientras\u00a0que\u00a0la\u00a0diarrea\u00a0y\u00a0las\u00a0n\u00e1useas\u00a0lo\u00a0fueron\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0LPV/r276.\u00a0\nEn\u00a0una\u00a0actualizaci\u00f3n \u00a0a\u00a096\u00a0semanas\u00a0se\u00a0mantuvo\u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0ATV/r\u00a0(CVP\u00a0<50\u00a0\ncopias/mL, \u00a074%\u00a0y\u00a068%\u00a0seg\u00fan\u00a0rama\u00a0con\u00a0ATV/r\u00a0o\u00a0LPV/r,\u00a0an\u00e1lisis\u00a0por\u00a0ITT.\u00a0\u00a0Discontinuaron \u00a0\nel\u00a0tratamiento \u00a0el\u00a016%\u00a0(ATV/r)\u00a0y\u00a021%\u00a0(LPV/r).\u00a0Tanto\u00a0los\u00a0efectos\u00a0adversos\u00a0como\u00a0las\u00a0alte\u2010\nraciones\u00a0lip\u00eddicas\u00a0fueron\u00a0menores\u00a0en\u00a0la\u00a0rama\u00a0del\u00a0ATV/r277.\u00a0\u00a0\n\u00a0Resumen \u00a0sobre\u00a0ensayos\u00a0de\u00a0IP\u00a0en\u00a0pacientes \u00a0sin\u00a0terapia\u00a0previa\u00a0\nLos\u00a0estudios\u00a0han\u00a0demostrado \u00a0que\u00a0la\u00a0administraci\u00f3n \u00a0de\u00a0un\u00a0IP/r\u00a0(LPV,\u00a0SQV,\u00a0FPV,\u00a0ATV,\u00a0\nDRV)\u00a0potenciado \u00a0tiene\u00a0ventajas\u00a0de\u00a0eficacia\u00a0y\u00a0barrera\u00a0gen\u00e9tica\u00a0respecto\u00a0a\u00a0los\u00a0IP\u00a0no\u00a0po\u2010\ntenciados. \u00a0El\u00a0principal\u00a0inconveniente \u00a0de\u00a0la\u00a0potenciaci\u00f3n \u00a0es\u00a0el\u00a0aumento\u00a0de\n\u00a0efectos\u00a0ad\u2010\nversos.\u00a0\n\u00a0\nIP.\u00a0Recomendaciones \u00a0\n\u0083 Se\u00a0recomienda \u00a0el\u00a0uso\u00a0habitual\u00a0de\u00a0IP/r\u00a0como\u00a0primer\u00a0TARV.\u00a0\n\u0083 Como\u00a0IP\u00a0de\u00a0primera\u00a0elecci\u00f3n\u00a0se\u00a0recomienda \u00a0ATV/r\u00a0QD,\u00a0DRV/r\u00a0QD,\u00a0FPV/r\u00a0BID,\u00a0LPV/r\u00a0\nBID\u00a0o\u00a0QD,\u00a0SQV/r\u00a0BID\u00a0y\u00a0o\u00a0(nivel\u00a0A).\u00a0Se\u00a0han\u00a0ordenado \u00a0alfab\u00e9ticamente, \u00a0pero\u00a0DRV/r\u00a0y\u00a0\nATV/r\u00a0han\u00a0demostrado \u00a0mayor\u00a0eficacia\u00a0y\u00a0menor\u00a0n\u00famero\u00a0de\u00a0efectos\u00a0adversos\u00a0(nivel\u00a0\nA).\u00a0\n\u0083 Se\u00a0deben\u00a0considerar \u00a0como\u00a0alternativas \u00a0otras\u00a0dosificaciones \u00a0de\u00a0IP/r\u00a0o\u00a0IP\u00a0no\u00a0poten\u2010\nciados:\u00a0ATV\u00a0(400\u00a0mg\u00a0QD),\u00a0FPV/r\u00a0(1400/200) \u00a0QD\u00a0o\u00a0FPV/r\u00a0(1400/100) \u00a0QD.\u00a0Estas\u00a0dosi\u2010\nficaciones \u00a0carecen\u00a0de\u00a0ensayos\u00a0cl\u00ednicos\u00a0con\u00a0tama\u00f1o\u00a0muestral\u00a0adecuado \u00a0que\u00a0valoren\u00a0\nsu\u00a0eficacia\u00a0frente\u00a0a\u00a0un\u00a0IP\u00a0de\u00a0primera\u00a0elecci\u00f3n\u00a0y\u00a0no\u00a0han\u00a0sido\u00a0aprobadas \u00a0por\u00a0la\u00a0EMEA.\u00a0\u00a0\n\u0083 La\u00a0combinaci\u00f3n \u00a0ddI+FTC+ATV \u00a0(no\u00a0potenciado) \u00a0no\u00a0debe\u00a0utilizarse\u00a0en\u00a0pacientes \u00a0sin\u00a0\nTARV\u00a0previo\u00a0por\u00a0alto\u00a0riesgo\u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0(nivel\u00a0A)\u00a0\n\u0083 NFV,\u00a0IDV\u00a0y\u00a0RTV\u00a0a\u00a0dosis\u00a0plenas\u00a0son\u00a0tres\u00a0IP\u00a0que\u00a0salvo\u00a0excepciones \u00a0no\u00a0deben\u00a0utilizarse\u00a0\ndebido\u00a0a\u00a0su\u00a0menor\u00a0eficacia,\u00a0mayor\u00a0toxicidad\u00a0y\u00a0complejidad \u00a0de\u00a0uso.\u00a0\u00a0\n\u0083 TPV/r\u00a0no\u00a0debe\u00a0utilizarse\u00a0en\u00a0pacientes \u00a0sin\u00a0TARV\u00a0previo\u00a0(nivel\u00a0A).\u00a0\u00a0\n\u00a0\n4.6.\u00a0Antagonistas \u00a0del\u00a0correceptor \u00a0CCR5\u00a0\nLos\u00a0antagonistas \u00a0del\u00a0correceptor \u00a0CCR5\u00a0act\u00faan\u00a0bloqueando \u00a0la\u00a0entrada\u00a0del\u00a0VIH\u00a0en\u00a0la\u00a0\nc\u00e9lula\u00a0diana.\u00a0Estos\u00a0f\u00e1rmacos \u00a0son\u00a0activos\u00a0solamente \u00a0si\u00a0el\u00a0virus\u00a0tiene\u00a0tropismo\u00a0R5.\u00a0\nMVC\u00a0es\u00a0el\u00a0antagonista \u00a0del\u00a0correceptor \u00a0CCR5\u00a0que\u00a0ha\u00a0sido\u00a0aprobado \u00a0por\u00a0la\u00a0EMEA\u00a0para\u00a0su\u00a0\nuso\u00a0en\u00a0tratamientos \u00a0en\u00a0pacientes \u00a0pretratados \u00a0con\u00a0VIH\u00a0con\u00a0tropismo\u00a0R5\u00a0y\u00a0resistente \u00a0a\u00a0\notras\u00a0familias\u00a0de\u00a0antirretrovirales. \u00a0Sin\u00a0embargo, \u00a0ya\u00a0se\u00a0conocen\u00a0los\u00a0datos\u00a0de\u00a0un\u00a0ensayo\u00a0\ncl\u00ednico\u00a0de\u00a0MVC\u00a0en\u00a0pacientes \u00a0sin\u00a0terapia\u00a0previa.\u00a0\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 44 \n \u00a0\nEnsayo\u00a0que\u00a0avala\u00a0la\u00a0recomendaci\u00f3n \u00a0de\u00a0antagonistas \u00a0del\u00a0CCR5\u00a0\nMERIT\u00a0\nEl\u00a0estudio\u00a0MERIT\u00a0es\u00a0un\u00a0ensayo\u00a0que\u00a0compar\u00f3\u00a0MVC\u00a0(300\u00a0mg,\u00a0BID),\u00a0con\u00a0MVC\u00a0(600\u00a0mg,\u00a0\nQD)\u00a0con\u00a0EFV\u00a0(600\u00a0mg,\u00a0QD)\u00a0en\u00a0pacientes \u00a0infectados \u00a0por\u00a0VIH\u00a0R5\u2010tr\u00f3pico\u00a0y\u00a0sin\u00a0terapia\u00a0\nprevia.\u00a0Los\u00a0pacientes \u00a0recibieron \u00a0adem\u00e1s\u00a0ZDV+3TC. \u00a0El\u00a0grupo\u00a0de\u00a0MVC\u00a0QD\u00a0fue\u00a0interrum\u2010\npido\u00a0a\u00a0la\u00a0semana\u00a016\u00a0por\u00a0no\u00a0alcanzar\u00a0el\u00a0criterio\u00a0virol\u00f3gico \u00a0definido\u00a0en\u00a0el\u00a0protocolo. \u00a0\nA\u00a0las\u00a048\u00a0semanas\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(ITT)\u00a0fue\u00a065,3%\u00a0y\u00a0\n69,3%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0MVC\u00a0y\u00a0de\u00a0EFV\u00a0(l\u00edmite\u00a0inferior\u00a0del\u00a0IC\u00a097,5%\u00a0=\u201310,9%). \u00a0\u00a0La\u00a0propor\u2010\nci\u00f3n\u00a0con\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0(an\u00e1lisis\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0tratar)\u00a0fue\u00a070,6\u00a0%\u00a0y\u00a073,1%\u00a0en\u00a0el\u00a0\ngrupo\u00a0de\u00a0MVC\u00a0y\u00a0de\u00a0EFV\u00a0(l\u00edmite\u00a0inferior\u00a0del\u00a0IC\u00a097,5%\u00a0\u22649,5%).\u00a0El\u00a0l\u00edmite\u00a0inferior\u00a0del\u00a0IC\u00a0al\u00a0\n97,5%,\u00a0de\u00a0no\u00a0inferioridad, \u00a0que\u00a0se\u00a0estableci\u00f3 \u00a0para\u00a0este\u00a0ensayo\u00a0cl\u00ednico\u00a0fue\u00a0de\u00a0\u201010%.\u00a0Por\u00a0\nlo\u00a0tanto\u00a0el\u00a0estudio\u00a0demostr\u00f3 \u00a0la\u00a0no\u2010inferioridad \u00a0de\u00a0MVC\u00a0para\u00a0el\u00a0criterio\u00a0de\u00a0400\u00a0co\u2010\npias/mL\u00a0pero\u00a0no\u00a0para\u00a0el\u00a0de\u00a050\u00a0copias/mL. \u00a0La\u00a0discontinuaci\u00f3n \u00a0del\u00a0TARV\u00a0por\u00a0falta\u00a0de\u00a0efi\u2010\ncacia\u00a0fue\u00a0m\u00e1s\u00a0frecuente \u00a0con\u00a0MVC\u00a0(11,9%)\u00a0que\u00a0con\u00a0EFV\u00a0(4,2%),\u00a0pero\u00a0por\u00a0efectos\u00a0adver\u2010\nsos\u00a0la\u00a0discontinuaci\u00f3n \u00a0fue\u00a0mayor\u00a0con\u00a0EFV\u00a0(13,6%)\u00a0que\u00a0con\u00a0MVC\u00a0(4,2%).\u00a0La\u00a0recupera\u2010\nci\u00f3n\u00a0inmunol\u00f3gica \u00a0fue\u00a0mayor\u00a0con\u00a0MVC\u00a0(170\u00a0frente\u00a0144\u00a0c\u00e9lulas/\u00b5L)278.\u00a0\n\u00a0\nAntagonistas \u00a0CCR5.\u00a0Recomendaciones \u00a0\n\u0083 Este\u00a0comit\u00e9\u00a0considera \u00a0que\u00a0MVC\u00a0s\u00f3lo\u00a0debe\u00a0emplearse \u00a0como\u00a0tratamiento \u00a0de\u00a0inicio\u00a0\nen\u00a0pacientes \u00a0con\u00a0virus\u00a0R5\u00a0tr\u00f3pico\u00a0y\u00a0cuando\u00a0no\u00a0sea\u00a0posible\u00a0un\u00a0tratamiento \u00a0con\u00a0NN\u00a0o\u00a0\ncon\u00a0un\u00a0IP.\u00a0MVC\u00a0no\u00a0est\u00e1\u00a0aprobado \u00a0por\u00a0la\u00a0EMEA\u00a0para\u00a0su\u00a0uso\u00a0en\u00a0pacientes \u00a0sin\u00a0trata\u2010\nmiento\u00a0previo;\u00a0la\u00a0recomendaci\u00f3n \u00a0se\u00a0basa\u00a0en\u00a0resultados \u00a0del\u00a0estudio\u00a0MERIT.\u00a0\n\u00a0\n\u00a0\n4.7.\u00a0Inhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0\nLos\u00a0inhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0act\u00faan\u00a0alterando \u00a0las\u00a0mol\u00e9culas \u00a0de\u00a0la\u00a0integrasa \u00a0viral\u00a0y\u00a0\n\u00e9stas\u00a0ya\u00a0no\u00a0pueden\u00a0unir\u00a0los\u00a0extremos \u00a0reactivos\u00a0del\u00a0ADN\u00a0viral\u00a0al\u00a0ADN\u00a0celular.\u00a0Raltegravir \u00a0\n(RAL)\u00a0ha\u00a0sido\u00a0aprobado \u00a0por\u00a0la\u00a0EMEA\u00a0para\u00a0su\u00a0uso\u00a0en\u00a0el\u00a0tratamiento \u00a0de\u00a0pacientes \u00a0con\u00a0\ninfecci\u00f3n\u00a0por\u00a0VIH,\u00a0con\u00a0o\u00a0sin\u00a0experiencia \u00a0previa\u00a0a\u00a0antirretrovirales \u00a0y\u00a0resistencia \u00a0a\u00a0otras\u00a0\nfamilias\u00a0de\u00a0antirretrovirales. \u00a0\u00a0\n\u00a0\nEnsayo\u00a0que\u00a0avala\u00a0la\u00a0recomendaci\u00f3n \u00a0de\u00a0inhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0\nSTARTMRK \u00a0\nEl\u00a0estudio\u00a0STARTMRK \u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico,\u00a0aleatorizado, \u00a0doble\u00a0ciego,\u00a0multic\u00e9ntrico \u00a0e\u00a0\ninternacional \u00a0que\u00a0compara\u00a0EFV\u00a0con\u00a0RAL,\u00a0ambos\u00a0combinados \u00a0con\u00a0TDF/FTC\u00a0en\u00a0566\u00a0pa\u2010\ncientes\u00a0sin\u00a0TARV\u00a0previo279.\u00a0El\u00a0objetivo\u00a0primario\u00a0de\u00a0eficacia\u00a0fue\u00a0la\u00a0consecuci\u00f3n \u00a0de\u00a0una\u00a0\nCVP\u00a0<50\u00a0copias/mL \u00a0a\u00a0la\u00a0semana\u00a048.\u00a0El\u00a0margen\u00a0de\u00a0no\u00a0inferioridad \u00a0fue\u00a0del\u00a012%.\u00a0El\u00a053%\u00a0\nde\u00a0los\u00a0pacientes \u00a0ten\u00edan\u00a0carga\u00a0viral\u00a0basal\u00a0>100.000 \u00a0copias/mL \u00a0y\u00a0un\u00a047%\u00a0un\u00a0recuento\u00a0de\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 45 \n CD4\u00a0<200\u00a0c\u00e9lulas/\u00b5L. \u00a0El\u00a0objetivo\u00a0primario\u00a0se\u00a0consigui\u00f3 \u00a0en\u00a0un\u00a086,1%\u00a0de\u00a0los\u00a0pacientes \u00a0del\u00a0\ngrupo\u00a0de\u00a0RAL\u00a0y\u00a0en\u00a0el\u00a081.9%\u00a0del\u00a0grupo\u00a0de\u00a0\u00a0EFV\u00a0(diferencia \u00a04,2%;\u00a0IC95%:\u00a0\u20101,9\u201010,3).\u00a0El\u00a0\ngrupo\u00a0de\u00a0RAL\u00a0tard\u00f3\u00a0menos\u00a0tiempo\u00a0en\u00a0alcanzar\u00a0la\u00a0indetectabilidad \u00a0que\u00a0el\u00a0grupo\u00a0de\u00a0EFV\u00a0\n(p<0,0001). \u00a0Los\u00a0efectos\u00a0adversos\u00a0relacionados \u00a0con\u00a0los\u00a0f\u00e1rmacos \u00a0fueron\u00a0m\u00e1s\u00a0frecuentes \u00a0\nen\u00a0el\u00a0grupo\u00a0de\u00a0EFV\u00a0que\u00a0en\u00a0el\u00a0de\u00a0RAL\u00a0(p<0,0001)279.\u00a0\u00a0\n\u00a0\nInhiidores \u00a0integrasa. \u00a0Recomendaciones \u00a0\nEste\u00a0comit\u00e9\u00a0considera \u00a0que\u00a0RAL\u00a0s\u00f3lo\u00a0debe\u00a0emplearse \u00a0como\u00a0tratamiento \u00a0de\u00a0inicio\u00a0cuan\u2010\ndo\u00a0no\u00a0sea\u00a0posible\u00a0un\u00a0tratamiento \u00a0con\u00a0NN\u00a0o\u00a0IP\u00a0(debido\u00a0a\u00a0su\u00a0precio\u00a0elevado)\u00a0\n\u00a0\n\u00a0\n5.\u00a0MODIFICACI\u00d3N \u00a0DEL\u00a0TRATAMIENTO \u00a0ANTIRRETROVIRAL \u00a0\n5.1.\u00a0Fracaso\u00a0del\u00a0tratamiento \u00a0antirretroviral \u00a0\nEl\u00a0fracaso\u00a0del\u00a0TARV\u00a0se\u00a0puede\u00a0entender \u00a0desde\u00a0tres\u00a0puntos\u00a0de\u00a0vista:\u00a0virol\u00f3gico, \u00a0inmu\u2010\nnol\u00f3gico\u00a0y\u00a0cl\u00ednico.\u00a0\nLa\u00a0incidencia \u00a0de\u00a0fracaso\u00a0virol\u00f3gico, \u00a0sus\u00a0causas\u00a0y\u00a0el\u00a0perfil\u00a0de\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0\nhan\u00a0cambiado \u00a0desde\u00a0el\u00a0inicio\u00a0de\u00a0TARV.\u00a0Tras\u00a0la\u00a0introducci\u00f3n \u00a0de\u00a0los\u00a0NN\u00a0y\u00a0los\u00a0IP/r\u00a0la\u00a0inci\u2010\ndencia\u00a0y\u00a0caracter\u00edsticas \u00a0del\u00a0fracaso\u00a0al\u00a0primer\u00a0TARV\u00a0se\u00a0han\u00a0reducido\u00a0sustancialmente180,\u00a0\n280,\u00a0281.\u00a0La\u00a0toxicidad\u00a0fue\u00a0la\u00a0causa\u00a0m\u00e1s\u00a0frecuente \u00a0de\u00a0retirada\u00a0del\u00a0tratamiento \u00a0y,\u00a0en\u00a0ese\u00a0\ncontexto, \u00a0se\u00a0document\u00f3 \u00a0una\u00a0mayor\u00a0duraci\u00f3n\u00a0de\u00a0la\u00a0eficacia\u00a0en\u00a0pacientes \u00a0tratados\u00a0con\u00a0\nNN\u00a0que\u00a0con\u00a0IP280.\u00a0\u00a0\nEn\u00a0la\u00a0\u00e9poca\u00a0moderna\u00a0existe\u00a0una\u00a0preferencia \u00a0a\u00a0utilizar\u00a0pautas\u00a0sencillas\u00a0y\u00a0con\u00a0escasa\u00a0\ntoxicidad\u00a0que\u00a0combinan \u00a0AN\u00a0no\u00a0timid\u00ednicos \u00a0y\u00a0NN\u00a0o\u00a0IP/r.\u00a0\u00a0\nSucesivos \u00a0fracasos\u00a0terap\u00e9uticos \u00a0con\u00a0acumulaci\u00f3n \u00a0de\u00a0mutaciones \u00a0de\u00a0resistencias \u00a0frente\u00a0\na\u00a0diferentes \u00a0familias\u00a0de\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0suponen\u00a0menores\u00a0posibilidades \u00a0de\u00a0\n\u00e9xito\u00a0del\u00a0tratamiento \u00a0antirretroviral \u00a0y\u00a0mayor\u00a0incidencia \u00a0de\u00a0sida\u00a0y\u00a0muerte282.\u00a0\n\u00a0\nFactores\u00a0que\u00a0influyen\u00a0en\u00a0el\u00a0fracaso\u00a0terap\u00e9utico \u00a0\nLos\u00a0factores\u00a0que\u00a0influyen\u00a0en\u00a0el\u00a0fracaso\u00a0del\u00a0TARV\u00a0pueden\u00a0clasificarse \u00a0en\u00a03\u00a0grupos\u00a0seg\u00fan\u00a0\ndependan \u00a0del\u00a0paciente, \u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0o\u00a0del\u00a0virus.\u00a0\u00a0\nEntre\u00a0los\u00a0primeros, \u00a0el\u00a0m\u00e1s\u00a0importante \u00a0es\u00a0la\u00a0adherencia \u00a0al\u00a0tratamiento \u00a0que\u00a0es\u00a0el\u00a0mejor\u00a0\npredictor \u00a0de\u00a0respuesta \u00a0terap\u00e9utica283\u2010285.\u00a0Si\u00a0se\u00a0detecta\u00a0un\u00a0fracaso\u00a0virol\u00f3gico \u00a0sin\u00a0muta\u2010\nciones\u00a0de\u00a0resistencia \u00a0debe\u00a0valorarse\u00a0la\u00a0falta\u00a0de\u00a0adherencia \u00a0como\u00a0causa\u00a0m\u00e1s\u00a0probable. \u00a0\nLa\u00a0ausencia\u00a0de\u00a0mutaciones \u00a0en\u00a0este\u00a0escenario, \u00a0no\u00a0excluye\u00a0que\u00a0puedan\u00a0existir\u00a0en\u00a0pobla\u2010\nciones\u00a0virales\u00a0minoritarias \u00a0no\u00a0detectables \u00a0por\u00a0las\u00a0pruebas\u00a0de\u00a0detecci\u00f3n \u00a0de\u00a0resistencia \u00a0\ngenot\u00edpicas \u00a0convencionales. \u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 46 \n Entre\u00a0los\u00a0factores\u00a0que\u00a0dependen \u00a0del\u00a0f\u00e1rmaco\u00a0se\u00a0considera \u00a0en\u00a0primer\u00a0lugar\u00a0la\u00a0potencia\u00a0\ndel\u00a0r\u00e9gimen\u00a0terap\u00e9utico, \u00a0la\u00a0falta\u00a0de\u00a0niveles\u00a0en\u00a0sangre\u00a0por\u00a0malabsorci\u00f3n \u00a0o\u00a0interacciones \u00a0\nmedicamentosas \u00a0y\u00a0los\u00a0errores\u00a0de\u00a0dosificaci\u00f3n. \u00a0\nEntre\u00a0los\u00a0factores\u00a0que\u00a0dependen \u00a0del\u00a0VIH,\u00a0el\u00a0m\u00e1s\u00a0importante \u00a0es\u00a0la\u00a0resistencia \u00a0a\u00a0los\u00a0FAR\u00a0\nque\u00a0resulta\u00a0de\u00a0la\u00a0interacci\u00f3n \u00a0de\u00a0la\u00a0capacidad \u00a0replicativa \u00a0y\u00a0diversidad \u00a0del\u00a0virus\u00a0y\u00a0la\u00a0pre\u2010\nsi\u00f3n\u00a0farmacol\u00f3gica. \u00a0La\u00a0resistencia \u00a0a\u00a0los\u00a0FAR\u00a0puede\u00a0ser\u00a0transmitida \u00a0a\u00a0otras\u00a0personas, \u00a0es\u00a0\nvariable\u00a0seg\u00fan\u00a0\u00e1rea\u00a0o\u00a0colectivo\u00a0de\u00a0pacientes \u00a0estudiados \u00a0y\u00a0m\u00e9todo\u00a0empleado. \u00a0Las\u00a0cifras\u00a0\nde\u00a0infecci\u00f3n\u00a0reciente\u00a0por\u00a0virus\u00a0resistentes \u00a0var\u00edan\u00a0entre\u00a0\u00a0en\u00a0un\u00a07,7\u00a0y\u00a019,2\u00a0%286,\u00a0287.\u00a0Se\u00a0\nestima\u00a0que\u00a0en\u00a0nuestro\u00a0medio\u00a0entre\u00a09\u201012\u00a0%\u00a0las\u00a0infecciones \u00a0recientes\u00a0por\u00a0VIH\u00a0tienen\u00a0\nmutaciones \u00a0de\u00a0resistencia83,\u00a0288\u2010290.\u00a0Las\u00a0mutaciones \u00a0\u00fanicas\u00a0con\u00a0resistencia \u00a0a\u00a0NN\u00a0o\u00a0AN\u00a0\ncomprometen \u00a0la\u00a0eficacia\u00a0de\u00a0los\u00a0tratamientos \u00a0de\u00a0primera\u00a0l\u00ednea290.\u00a0El\u00a0uso\u00a0de\u00a0t\u00e9cnicas\u00a0\nultrasensibles \u00a0que\u00a0permiten \u00a0detectar\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0en\u00a0variantes\u00a0virales\u00a0\nminoritarias \u00a0no\u00a0detectables \u00a0con\u00a0las\u00a0t\u00e9cnicas\u00a0convencionales \u00a0(v\u00e9ase\u00a0m\u00e1s\u00a0adelante) \u00a0\npodr\u00eda\u00a0explicar\u00a0algunos\u00a0de\u00a0los\u00a0fracasos\u00a0virol\u00f3gicos \u00a0en\u00a0pacientes \u00a0que\u00a0inician\u00a0un\u00a0TARV\u00a0\npotencialmente \u00a0eficaz88\u201095.\u00a0Dos\u00a0estudios\u00a0de\u00a0cohortes\u00a0han\u00a0coincidido \u00a0al\u00a0describir\u00a0que\u00a0si\u00a0\nse\u00a0logra\u00a0una\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0en\u00a0el\u00a0primer\u00a0TARV,\u00a0el\u00a0rebrote\u00a0de\u00a0la\u00a0CVP\u00a0suele\u00a0asociarse \u00a0\na\u00a0mal\u00a0cumplimiento \u00a0o\u00a0toxicidad\u00a0y\u00a0en\u00a0muy\u00a0escasas\u00a0ocasiones \u00a0puede\u00a0atribuirse \u00a0a\u00a0falta\u00a0de\u00a0\npotencia, \u00a0interacciones \u00a0medicamentosas \u00a0o\u00a0\u00a0problemas \u00a0de\u00a0absorci\u00f3n44,\u00a0291.\u00a0\nEl\u00a0fen\u00f3meno \u00a0de\u00a0la\u00a0inmigraci\u00f3n \u00a0obliga\u00a0a\u00a0valorar\u00a0el\u00a0origen\u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0\npor\u00a0VIH\u00a0en\u00a0situaci\u00f3n\u00a0de\u00a0fracaso\u00a0virol\u00f3gico. \u00a0El\u00a0uso\u00a0de\u00a0NVP\u00a0en\u00a0dosis\u00a0\u00fanica,\u00a0el\u00a0TARV\u00a0poco\u00a0\npotente,\u00a0la\u00a0escasa\u00a0monitorizaci\u00f3n \u00a0o\u00a0problemas \u00a0de\u00a0distribuci\u00f3n \u00a0y\u00a0almacenaje \u00a0de\u00a0los\u00a0\nf\u00e1rmacos \u00a0\u00a0explican\u00a0el\u00a0aumento\u00a0de\u00a0incidencia \u00a0de\u00a0\u00a0fracaso\u00a0virol\u00f3gico \u00a0en\u00a0la\u00a0poblaci\u00f3n \u00a0in\u2010\nfectada\u00a0en\u00a0los\u00a0pa\u00edses\u00a0desfavorecidos292\u2010294.\u00a0\u00a0Una\u00a0elevada\u00a0proporci\u00f3n \u00a0de\u00a0estos\u00a0pacientes \u00a0\nson\u00a0portadores \u00a0de\u00a0VIH\u00a0diferentes \u00a0al\u00a0subtipo\u00a0B\u00a0y\u00a0por\u00a0lo\u00a0tanto\u00a0con\u00a0distintos\u00a0patrones\u00a0de\u00a0\nmutaciones \u00a0de\u00a0resistencia. \u00a0Existe\u00a0una\u00a0mayor\u00a0predisposici\u00f3n \u00a0a\u00a0seleccionar \u00a0la\u00a0mutaci\u00f3n \u00a0\nK65R\u00a0en\u00a0el\u00a0subtipo\u00a0C295\u00a0y\u00a0se\u00a0ha\u00a0comunicado \u00a0que\u00a0los\u00a0pacientes \u00a0con\u00a0subtipos\u00a0no\u00a0B\u00a0(inde\u2010\npendientemente \u00a0de\u00a0exposici\u00f3n \u00a0a\u00a0FAR)\u00a0presentan \u00a0mayor\u00a0proporci\u00f3n \u00a0de\u00a0resistencia \u00a0a\u00a0\nTPV\u00a0que\u00a0los\u00a0infectados \u00a0por\u00a0subtipos\u00a0B296.\u00a0Por\u00a0otra\u00a0parte,\u00a0algunos\u00a0pacientes \u00a0de\u00a0origen\u00a0\nsubsahariano \u00a0padecen\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u20102\u00a0o\u00a0infecci\u00f3n\u00a0dual\u00a0por\u00a0VIH\u20101\u00a0y\u00a0VIH\u20102.\u00a0EL\u00a0VIH\u20102\u00a0\ndesarrolla \u00a0patrones\u00a0diferentes \u00a0de\u00a0mutaciones \u00a0tras\u00a0exposici\u00f3n \u00a0a\u00a0AN297.\u00a0\u00a0\u00a0\n\u00a0\nCriterios\u00a0de\u00a0cambio\u00a0de\u00a0TARV\u00a0por\u00a0fracaso\u00a0virol\u00f3gico \u00a0\nLas\u00a0definici\u00f3n \u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0se\u00a0ha\u00a0indicado\u00a0previamente \u00a0(v\u00e9ase\u00a0apartado\u00a02.2).\u00a0\nAnte\u00a0un\u00a0fracaso\u00a0virol\u00f3gico \u00a0es\u00a0recomendable \u00a0repetir\u00a0la\u00a0CVP\u00a0para\u00a0confirmarlo \u00a0y\u00a0cambiar\u00a0\nel\u00a0TARV\u00a0lo\u00a0antes\u00a0posible\u00a0para\u00a0evitar\u00a0el\u00a0ac\u00famulo\u00a0de\u00a0mutaciones \u00a0y\u00a0la\u00a0elevaci\u00f3n \u00a0de\u00a0la\u00a0CVP,\u00a0\nfacilitando \u00a0de\u00a0este\u00a0modo\u00a0la\u00a0respuesta \u00a0al\u00a0nuevo\u00a0tratamiento. \u00a0\u00a0\nLos\u00a0\u201cblips\u201d\u00a0son\u00a0rebrotes\u00a0o\u00a0elevaciones \u00a0transitorias \u00a0de\u00a0la\u00a0CVP\u00a0cerca\u00a0del\u00a0umbral\u00a0de\u00a0de\u2010\ntecci\u00f3n\u00a0en\u00a0pacientes \u00a0en\u00a0TARV\u00a0y\u00a0con\u00a0CVP\u00a0suprimida. \u00a0En\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0estudios\u00a0no\u00a0se\u00a0\nasocian\u00a0a\u00a0mayor\u00a0riesgo\u00a0de\u00a0fracaso43,\u00a045,\u00a046,\u00a0298,\u00a0299\u00a0aunque\u00a0otros\u00a0estudios\u00a0s\u00ed\u00a0que\u00a0han\u00a0rela\u2010\ncionado\u00a0los\u00a0\u201cblips\u201d\u00a0con\u00a0riesgo\u00a0de\u00a0fracaso\u00a0virol\u00f3gico41,\u00a048\u00a0e\u00a0incluso\u00a0se\u00a0ha\u00a0observado \u00a0evo\u2010\nluci\u00f3n\u00a0gen\u00e9tica\u00a0y\u00a0selecci\u00f3n\u00a0de\u00a0resistencias \u00a0en\u00a0los\u00a0\u201cblips\u201d45,\u00a0298.\u00a0En\u00a0un\u00a0paciente\u00a0con\u00a0\n\u201cblips\u201d\u00a0frecuentes \u00a0debe\u00a0evaluarse \u00a0la\u00a0potencia\u00a0del\u00a0TARV\u00a0y\u00a0la\u00a0adherencia \u00a0al\u00a0tratamiento. \u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 47 \n El\u00a0fracaso\u00a0inmunol\u00f3gico \u00a0suele\u00a0ir\u00a0precedido \u00a0de\u00a0un\u00a0fracaso\u00a0virol\u00f3gico. \u00a0Algunos\u00a0pacientes \u00a0\ncon\u00a0CVP\u00a0indetectable \u00a0presentan \u00a0permanentemente \u00a0un\u00a0n\u00famero\u00a0bajo\u00a0de\u00a0CD4\u00a0con\u00a0mayor\u00a0\nriesgo\u00a0de\u00a0morbimortalidad \u00a0secundaria \u00a0a\u00a0sida300\u00a0y\u00a0otros\u00a0procesos. \u00a0En\u00a0estos\u00a0casos\u00a0se\u00a0re\u2010\ncomienda \u00a0no\u00a0cambiar\u00a0el\u00a0TARV,\u00a0salvo\u00a0las\u00a0combinaciones \u00a0que\u00a0se\u00a0asocian\u00a0a\u00a0descenso \u00a0de\u00a0\nCD4\u00a0(p.e.\u00a0\u00a0ZDV\u00a0o\u00a0TDF\u00a0+\u00a0ddI).\u00a0\u00a0\nEl\u00a0fracaso\u00a0cl\u00ednico\u00a0en\u00a0un\u00a0paciente\u00a0en\u00a0TARV,\u00a0es\u00a0decir\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0eventos\u00a0cl\u00ednicos\u00a0B\u00a0\u00f3\u00a0\nC,\u00a0no\u00a0siempre\u00a0se\u00a0asocia\u00a0a\u00a0fracaso\u00a0virol\u00f3gico. \u00a0Puede\u00a0aparecer\u00a0en\u00a0los\u00a0primeros\u00a0meses\u00a0de\u00a0\ninstauraci\u00f3n \u00a0del\u00a0TARV\u00a0en\u00a0pacientes \u00a0muy\u00a0inmunodeprimidos, \u00a0o\u00a0relacionarse \u00a0con\u00a0fen\u00f3\u2010\nmenos\u00a0de\u00a0restauraci\u00f3n \u00a0inmunol\u00f3gica \u00a0pudiendo \u00a0obligar\u00a0a\u00a0modificar \u00a0el\u00a0TARV301.\u00a0\u00a0\n\u00a0\nObjetivo\u00a0del\u00a0tratamiento \u00a0tras\u00a0un\u00a0fracaso\u00a0virol\u00f3gico \u00a0\nEl\u00a0objetivo\u00a0terap\u00e9utico \u00a0es\u00a0conseguir \u00a0de\u00a0nuevo\u00a0la\u00a0m\u00e1xima\u00a0supresi\u00f3n \u00a0viral\u00a0(<50\u00a0co\u2010\npias/mL). \u00a0Para\u00a0ello,\u00a0se\u00a0debe\u00a0instaurar\u00a0un\u00a0nuevo\u00a0r\u00e9gimen\u00a0con\u00a0dos\u00a0o\u00a0tres\u00a0f\u00e1rmacos \u00a0ple\u2010\nnamente\u00a0activos\u00a0y\u00a0se\u00a0contar\u00e1\u00a0con\u00a0otros\u00a0que\u00a0conserven \u00a0actividad\u00a0(estudio\u00a0de\u00a0resisten\u2010\ncias)\u00a0y\u00a0sean\u00a0bien\u00a0tolerados. \u00a0\u00a0\nNo\u00a0se\u00a0debe\u00a0retrasar\u00a0el\u00a0cambio\u00a0de\u00a0tratamiento. \u00a0A\u00a0partir\u00a0de\u00a0datos\u00a0de\u00a0los\u00a0estudios\u00a0TORO\u00a0\nque\u00a0se\u00a0comentan \u00a0m\u00e1s\u00a0adelante, \u00a0se\u00a0han\u00a0establecido \u00a0cuatro\u00a0factores\u00a0asociados \u00a0a\u00a0eficacia\u00a0\nvirol\u00f3gica \u00a0del\u00a0TARV\u00a0de\u00a0rescate:\u00a0recuento\u00a0de\u00a0linfocitos\u00a0CD4\u00a0\u2265\u00a0100\u00a0c\u00e9lulas/\u00b5L \u00a0(OR:\u00a02,1\u00a0\u2013\nIC95%:\u00a01,5\u20103,1),\u00a0CVP\u00a0basal\u00a0<5\u00a0log 10\u00a0(OR:\u00a01,8\u00a0\u2013IC95%:\u00a01,2\u20102,6),\u00a0haber\u00a0recibido\u00a0\u226410\u00a0FAR\u00a0\n(OR:\u00a02,4\u00a0\u2013IC95%:\u00a01,6\u20103,4)\u00a0y\u00a0disponer\u00a0\u22652\u00a0f\u00e1rmacos\u00a0activos\u00a0en\u00a0el\u00a0nuevo\u00a0TARV\u00a0(OR:\u00a02,3:\u00a0\nIC95%:\u00a01,6\u20103,3)302.\u00a0\u00a0\nPara\u00a0conseguir \u00a0el\u00a0objetivo\u00a0de\u00a0CVP\u00a0indetectable \u00a0pueden\u00a0ser\u00a0\u00fatiles\u00a0algunas\u00a0estrategias \u00a0\ncomo:\u00a0\n\u2022 Facilitar\u00a0la\u00a0adherencia \u00a0al\u00a0TARV.\u00a0El\u00a0TARV\u00a0nuevo\u00a0debe\u00a0ser\u00a0c\u00f3modo\u00a0y\u00a0bien\u00a0tolerado;\u00a0\nlas\u00a0pautas\u00a0sencillas\u00a0(p.e\u00a0ZDV/3TC/ABC \u00a0+\u00a0TDF)\u00a0pueden\u00a0conseguir \u00a0resultados \u00a0inespe\u2010\nrados303.\u00a0En\u00a0algunos\u00a0colectivos \u00a0con\u00a0pobre\u00a0adherencia \u00a0al\u00a0tratamiento \u00a0puede\u00a0inten\u2010\ntarse\u00a0un\u00a0tratamiento \u00a0directamente \u00a0observado \u00a0dado\u00a0el\u00a0n\u00famero\u00a0considerable \u00a0de\u00a0\npautas\u00a0QD304,\u00a0305.\u00a0\u00a0\n\u2022 Pruebas\u00a0de\u00a0resistencia. \u00a0La\u00a0realizaci\u00f3n \u00a0de\u00a0una\u00a0prueba\u00a0de\u00a0resistencia \u00a0genot\u00edpica \u00a0o\u00a0\nfenot\u00edpica \u00a0en\u00a0cada\u00a0fracaso,\u00a0optimiza\u00a0el\u00a0nuevo\u00a0tratamiento, \u00a0aumenta\u00a0su\u00a0eficacia\u00a0y\u00a0\nmejora\u00a0el\u00a0pron\u00f3stico \u00a0de\u00a0los\u00a0pacientes306.\u00a0Los\u00a0resultados \u00a0m\u00e1s\u00a0\u00fatiles\u00a0se\u00a0obtienen\u00a0si\u00a0\nesta\u00a0prueba\u00a0se\u00a0realiza\u00a0mientras\u00a0el\u00a0paciente\u00a0se\u00a0encuentra \u00a0con\u00a0el\u00a0tratamiento \u00a0que\u00a0ha\u00a0\nfracasado. \u00a0En\u00a0pacientes \u00a0multitratados \u00a0puede\u00a0establecerse \u00a0el\u00a0\u00cdndice\u00a0de\u00a0Susceptibili \u2010\ndad\u00a0Fenot\u00edpica/Genot\u00edpica \u00a0\u2010ISF/G\u2010\u00a0(n\u00famero\u00a0de\u00a0f\u00e1rmacos\u00a0activos\u00a0seg\u00fan\u00a0la\u00a0prueba\u00a0de\u00a0\nresistencias \u00a0genot\u00edpica \u00a0o\u00a0fenot\u00edpica) \u00a0\u00a0como\u00a0predictor \u00a0de\u00a0respuesta \u00a0al\u00a0tratamien \u2010\nto307.\u00a0Existen\u00a0ciertas\u00a0discordancias \u00a0seg\u00fan\u00a0el\u00a0sistema\u00a0en\u00a0el\u00a0que\u00a0se\u00a0realiza\u00a0la\u00a0interpre\u2010\ntaci\u00f3n\u00a0de\u00a0resistencias \u00a0lo\u00a0que\u00a0puede\u00a0suponer\u00a0una\u00a0limitaci\u00f3n \u00a0en\u00a0el\u00a0uso\u00a0del\u00a0ISG\u00a0en\u00a0la\u00a0\npr\u00e1ctica\u00a0cl\u00ednica.\u00a0La\u00a0concordancia \u00a0mayor\u00a0se\u00a0observa\u00a0en\u00a0los\u00a0NN\u00a0(93%)\u00a0y\u00a0en\u00a0los\u00a0IP\u00a0\n(84%),\u00a0en\u00a0cambio\u00a0para\u00a0los\u00a0AN\u00a0s\u00f3lo\u00a0es\u00a0del\u00a076%308.\u00a0\u00a0\n\u2022 \u00cdndice\u00a0ponderado \u00a0(score )\u00a0de\u00a0resistencia \u00a0genot\u00edpica. \u00a0La\u00a0interpretaci\u00f3n \u00a0de\u00a0las\u00a0prue\u2010\nbas\u00a0genot\u00edpicas \u00a0a\u00a0IP\u00a0resulta\u00a0dif\u00edcil\u00a0en\u00a0pacientes \u00a0con\u00a0varios\u00a0fracasos\u00a0virol\u00f3gicos \u00a0acu\u2010\nmulados\u00a0y\u00a0depende\u00a0del\u00a0n\u00famero\u00a0de\u00a0mutaciones \u00a0seleccionadas, \u00a0de\u00a0su\u00a0patr\u00f3n\u00a0y\u00a0la\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 48 \n combinaci\u00f3n \u00a0de\u00a0ambos\u00a0aspectos. \u00a0En\u00a0la\u00a0actualidad \u00a0se\u00a0han\u00a0desarrollado \u00a0\u00edndices\u00a0pon\u2010\nderados\u00a0(scores)\u00a0que\u00a0definen\u00a0la\u00a0sensibilidad \u00a0a\u00a0determinados \u00a0IP\u00a0(ATV/r309,\u00a0SQV/r310,\u00a0\nLPV/r311,\u00a0DRV/r312\u00a0y\u00a0TPV/r313)\u00a0y\u00a0a\u00a0la\u00a0ETR\u00a0(v\u00e9ase\u00a0m\u00e1s\u00a0adelante) \u00a0basados\u00a0en\u00a0datos\u00a0ex\u2010\ntra\u00eddos\u00a0de\u00a0estudios\u00a0realizados \u00a0en\u00a0la\u00a0vida\u00a0real.\u00a0Estos\u00a0scores\u00a0\u00a0marcan\u00a0el\u00a0\u201cpeso\u201d\u00a0de\u00a0ca\u2010\nda\u00a0una\u00a0de\u00a0las\u00a0mutaciones \u00a0seg\u00fan\u00a0el\u00a0grado\u00a0de\u00a0resistencia \u00a0(valores\u00a0negativos) \u00a0o\u00a0de\u00a0\nsusceptibilidad \u00a0o\u00a0hipersusceptibilidad \u00a0(valores\u00a0positivos). \u00a0Los\u00a0scores\u00a0punt\u00faan\u00a0cada\u00a0\nuna\u00a0de\u00a0las\u00a0mutaciones \u00a0y\u00a0finalmente \u00a0se\u00a0obtiene\u00a0un\u00a0resultado \u00a0de\u00a0mayor\u00a0o\u00a0menor\u00a0\nsusceptibilidad \u00a0al\u00a0f\u00e1rmaco.\u00a0\n\u2022 Cociente\u00a0inhibitorio \u00a0genot\u00edpico. \u00a0El\u00a0cociente\u00a0inhibitorio \u00a0genot\u00edpico \u00a0(CIG)\u00a0es\u00a0la\u00a0raz\u00f3n\u00a0\nentre\u00a0las\u00a0concentraciones \u00a0plasm\u00e1ticas \u00a0del\u00a0f\u00e1rmaco\u00a0y\u00a0el\u00a0n\u00famero\u00a0de\u00a0mutaciones \u00a0re\u2010\nlevantes\u00a0en\u00a0el\u00a0gen\u00a0de\u00a0la\u00a0proteasa. \u00a0Se\u00a0considera \u00a0un\u00a0marcador \u00a0predictivo \u00a0de\u00a0respues\u2010\nta\u00a0a\u00a0un\u00a0IP314\u2010316.\u00a0Otra\u00a0aproximaci\u00f3n \u00a0es\u00a0el\u00a0coeficiente \u00a0inhibitorio \u00a0normalizado \u00a0que\u00a0\ncalcula\u00a0la\u00a0relaci\u00f3n\u00a0entre\u00a0las\u00a0concentraciones \u00a0m\u00ednimas\u00a0plasm\u00e1ticas \u00a0del\u00a0f\u00e1rmaco\u00a0y\u00a0el\u00a0\nn\u00famero\u00a0de\u00a0veces\u00a0por\u00a0encima\u00a0de\u00a0la\u00a0IC50\u00a0obtenido\u00a0en\u00a0el\u00a0fenotipo\u00a0viral317.\u00a0\n\u2022 Pruebas\u00a0de\u00a0resistencia \u00a0con\u00a0mayor\u00a0sensibilidad: \u00a0PCR\u00a0alelo\u2010espec\u00edfica, \u00a0ensayo\u00a0de\u00a0\nligaci\u00f3n\u00a0de\u00a0oligonucle\u00f3tidos, \u00a0Ultradeep \u2010sequencing \u00a0\u00a0(pirosecuenciaci\u00f3n \u00a0o\u00a0secuen\u2010\nciaci\u00f3n\u00a0masiva)\u00a0y\u00a0Single\u00a0genome\u00a0sequencing \u00a0(secuenciaci\u00f3n \u00a0clonal).\u00a0Son\u00a0\u00a0metodo\u2010\nlog\u00edas\u00a0actualmente \u00a0en\u00a0investigaci\u00f3n \u00a0que\u00a0permiten \u00a0conocer\u00a0el\u00a0papel\u00a0que\u00a0juegan\u00a0en\u00a0\nel\u00a0fracaso\u00a0virol\u00f3gico \u00a0las\u00a0variantes\u00a0virales\u00a0minoritarias \u00a0con\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0\n(especialmente \u00a0en\u00a0NN\u00a0por\u00a0su\u00a0baja\u00a0barrera\u00a0gen\u00e9tica) \u00a0y\u00a0que\u00a0est\u00e1n\u00a0presentes \u00a0antes\u00a0\ndel\u00a0inicio\u00a0del\u00a0tratamiento \u00a0pero\u00a0que\u00a0no\u00a0son\u00a0detectadas \u00a0por\u00a0las\u00a0pruebas\u00a0de\u00a0resisten\u2010\ncia\u00a0convencionales90,\u00a092.\u00a0Las\u00a0t\u00e9cnicas\u00a0basadas\u00a0en\u00a0la\u00a0PCR\u00a0en\u00a0tiempo\u00a0real\u00a0tienen\u00a0una\u00a0\ngran\u00a0sensibilidad \u00a0para\u00a0detectar\u00a0variantes\u00a0minoritarias \u00a0puntuales, \u00a0pero\u00a0presentan \u00a0\nbastantes \u00a0limitaciones. \u00a0Las\u00a0t\u00e9cnicas\u00a0ultrasensibles \u00a0basadas\u00a0en\u00a0la\u00a0secuenciaci\u00f3n \u00a0au\u2010\nmentan\u00a0la\u00a0sensibilidad \u00a0de\u00a0detecci\u00f3n \u00a0de\u00a0mutaciones \u00a0minoritarias \u00a0y,\u00a0al\u00a0disponer\u00a0de\u00a0\nsecuencias \u00a0completas \u00a0independientes, \u00a0permite\u00a0establecer \u00a0n\u00edtidamente \u00a0su\u00a0asocia\u2010\nci\u00f3n,\u00a0realizar\u00a0estudios\u00a0filogen\u00e9ticos \u00a0m\u00e1s\u00a0completos, \u00a0estudiar\u00a0la\u00a0evoluci\u00f3n \u00a0en\u00a0el\u00a0\ntiempo\u00a0de\u00a0las\u00a0diferentes \u00a0poblaciones. \u00a0Existen\u00a0pocos\u00a0estudios\u00a0bien\u00a0dise\u00f1ados \u00a0que\u00a0\neval\u00faen\u00a0el\u00a0impacto\u00a0cl\u00ednico\u00a0de\u00a0variantes\u00a0minoritarias \u00a0en\u00a0pacientes \u00a0que\u00a0inicien\u00a0TARV\u00a0\ncon\u00a0f\u00e1rmacos\u00a0de\u00a0barrera\u00a0gen\u00e9tica\u00a0baja88\u201095,\u00a0318\u00a0y\u00a0sus\u00a0resultados \u00a0son\u00a0inconsistentes \u00a0\ndebido\u00a0principalmente \u00a0a\u00a0las\u00a0diferencias \u00a0en\u00a0la\u00a0metodolog\u00eda \u00a0empleada \u00a0y\u00a0las\u00a0pobla\u2010\nciones\u00a0estudiadas, \u00a0por\u00a0lo\u00a0que\u00a0no\u00a0se\u00a0ha\u00a0establecido \u00a0la\u00a0utilidad\u00a0cl\u00ednica\u00a0de\u00a0su\u00a0detec\u2010\nci\u00f3n.\u00a0\u00a0\n\u2022 Monitorizaci\u00f3n \u00a0plasm\u00e1tica \u00a0de\u00a0f\u00e1rmacos. \u00a0Poco\u00a0\u00fatil\u00a0por\u00a0la\u00a0variabilidad \u00a0interindivi \u2010\ndual\u00a0pero\u00a0en\u00a0ocasiones \u00a0puede\u00a0ayudar\u00a0a\u00a0optimizar \u00a0el\u00a0tratamiento \u00a0mejorando \u00a0as\u00ed\u00a0su\u00a0\neficacia304,\u00a0319,\u00a0320.\u00a0\nEstas\u00a0estrategias \u00a0han\u00a0sido\u00a0escasamente \u00a0evaluadas \u00a0en\u00a0estudios\u00a0prospectivos \u00a0y\u00a0aleatori\u2010\nzados\u00a0para\u00a0poder\u00a0ser\u00a0recomendadas \u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0cl\u00ednica\u00a0diaria.\u00a0\n\u00a0\n5.1.1.\u00a0Cambio\u00a0de\u00a0TARV\u00a0tras\u00a0fracaso\u00a0precoz\u00a0\u00a0\nLos\u00a0ensayos\u00a0cl\u00ednicos\u00a0aleatorizados \u00a0que\u00a0han\u00a0evaluado\u00a0la\u00a0eficacia\u00a0de\u00a0diferentes \u00a0combina\u2010\nciones\u00a0de\u00a0FAR\u00a0en\u00a0tratamientos \u00a0de\u00a0segunda\u00a0l\u00ednea\u00a0son\u00a0escasos.\u00a0El\u00a0objetivo\u00a0terap\u00e9utico \u00a0es\u00a0\nla\u00a0resupresi\u00f3n \u00a0de\u00a0la\u00a0CVP\u00a0(CVP\u00a0<50\u00a0copias/mL). \u00a0Los\u00a0cambios\u00a0precoces\u00a0evitan\u00a0ac\u00famulo\u00a0de\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 49 \n mutaciones \u00a0y\u00a0permiten \u00a0secuenciar \u00a0FAR\u00a0incluso\u00a0dentro\u00a0de\u00a0cada\u00a0familia.\u00a0Con\u00a0los\u00a0FAR\u00a0ac\u2010\ntualmente \u00a0disponibles \u00a0resulta\u00a0sencillo\u00a0dise\u00f1ar\u00a0un\u00a0TARV\u00a0de\u00a0rescate\u00a0aunque\u00a0siempre\u00a0se\u00a0\ndebe\u00a0contar\u00a0con\u00a0una\u00a0prueba\u00a0de\u00a0resistencias. \u00a0\u00a0\nEn\u00a0el\u00a0caso\u00a0de\u00a0pacientes \u00a0que\u00a0iniciaran\u00a0el\u00a0tratamiento \u00a0con\u00a0tres\u00a0AN,\u00a0la\u00a0mutaci\u00f3n \u00a0m\u00e1s\u00a0fre\u2010\ncuente\u00a0es\u00a0la\u00a0M184V209\u00a0con\u00a0o\u00a0sin\u00a0la\u00a0K65R\u00a0si\u00a0el\u00a0TARV\u00a0inclu\u00eda\u00a0AN\u00a0no\u00a0timid\u00ednicos321\u2010323.\u00a0\u00a0\nSi\u00a0el\u00a0fracaso\u00a0es\u00a0en\u00a0un\u00a0paciente\u00a0que\u00a0lo\u00a0inici\u00f3\u00a0con\u00a02AN\u00a0y\u00a01NN\u00a0una\u00a0\u00fanica\u00a0mutaci\u00f3n \u00a0(p.e.\u00a0\n103N)\u00a0es\u00a0capaz\u00a0de\u00a0generar\u00a0resistencia \u00a0de\u00a0alto\u00a0nivel\u00a0a\u00a0EFV\u00a0y\u00a0NVP324.\u00a0El\u00a0fracaso\u00a0virol\u00f3gico \u00a0\nse\u00a0acompa\u00f1a \u00a0de\u00a0otras\u00a0mutaciones \u00a0a\u00a0AN\u00a0(M184V,\u00a0L74V\u00a0o\u00a0K65R)\u00a0con\u00a0una\u00a0incidencia \u00a0su\u2010\nperior\u00a0a\u00a0lo\u00a0que\u00a0ocurre\u00a0cuando\u00a0el\u00a0primer\u00a0r\u00e9gimen\u00a0est\u00e1\u00a0compuesto \u00a0por\u00a02\u00a0AN\u00a0y\u00a01\u00a0IP/r\u00a0325.\u00a0\u00a0\nUn\u00a0cambio\u00a0precoz\u00a0evitar\u00eda\u00a0la\u00a0acumulaci\u00f3n \u00a0de\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0que\u00a0compro\u2010\nmetiera\u00a0la\u00a0eficacia\u00a0de\u00a0los\u00a0NN\u00a0de\u00a0nueva\u00a0generaci\u00f3n. \u00a0En\u00a0este\u00a0escenario \u00a0no\u00a0se\u00a0recomienda \u00a0\nla\u00a0utilizaci\u00f3n \u00a0de\u00a0ETR\u00a0si\u00a0existen\u00a0\u22653\u00a0mutaciones \u00a0frente\u00a0a\u00a0NN\u00a0(v\u00e9ase\u00a0m\u00e1s\u00a0adelante)326.\u00a0\u00a0\u00a0\u00a0\u00a0\nEl\u00a0uso\u00a0de\u00a0IP/r\u00a0en\u00a0el\u00a0primer\u00a0TARV\u00a0ha\u00a0reducido\u00a0significativamente \u00a0el\u00a0n\u00famero\u00a0de\u00a0fracasos\u00a0\nvirol\u00f3gicos \u00a0y\u00a0la\u00a0selecci\u00f3n\u00a0de\u00a0mutaciones \u00a0frente\u00a0a\u00a0los\u00a0IP.\u00a0El\u00a0desarrollo \u00a0de\u00a0resistencias \u00a0en\u00a0\nlos\u00a0IP\u00a0es\u00a0un\u00a0proceso\u00a0gradual\u00a0que\u00a0requiere\u00a0normalmente \u00a0el\u00a0ac\u00famulo\u00a0de\u00a0varias\u00a0mutacio\u2010\nnes\u00a0en\u00a0el\u00a0gen\u00a0de\u00a0la\u00a0proteasa75.\u00a0Cada\u00a0mutaci\u00f3n \u00a0reduce\u00a0la\u00a0susceptibilidad \u00a0de\u00a0las\u00a0cepas\u00a0\nvirales\u00a0a\u00a0los\u00a0IP.\u00a0Existen\u00a0mutaciones \u00a0seleccionadas \u00a0espec\u00edficamente \u00a0por\u00a0un\u00a0IP\u00a0(no\u00a0poten\u2010\nciado)\u00a0y\u00a0no\u00a0presentan \u00a0resistencias \u00a0cruzadas: \u00a030N\u00a0(NFV)103,\u00a047A\u00a0y\u00a076V\u00a0(LPV)327,\u00a0328,\u00a048V\u00a0\n(SQV)329,\u00a050L\u00a0(ATV)330\u00a0o\u00a050V\u00a0(FPV\u00a0y\u00a0DRV331)\u00a0y\u00a0alguna\u00a0de\u00a0ellas\u00a0puede\u00a0producir\u00a0hipersus\u2010\nceptibilidad \u00a0a\u00a0otros\u00a0IP:\u00a0la\u00a047A\u00a0confiere\u00a0elevada\u00a0resistencia \u00a0fenot\u00edpica \u00a0a\u00a0LPV\u00a0(>100\u00a0ve\u2010\nces),\u00a0resistencia \u00a0cruzada\u00a0con\u00a0FPV\u00a0e\u00a0hipersusceptibilidad \u00a0a\u00a0SQV\u00a0327;\u00a0la\u00a050L\u00a0causa\u00a0hiper\u2010\nsusceptibilidad \u00a0a\u00a0todos\u00a0los\u00a0IP\u00a0excepto\u00a0ATV332,\u00a0o\u00a0la\u00a050V\u00a0causa\u00a0resistencia \u00a0a\u00a0LPV\u00a0e\u00a0hiper\u2010\nsusceptibilidad \u00a0a\u00a0TPV.\u00a0\u00a0La\u00a0continua\u00a0aparici\u00f3n \u00a0de\u00a0nuevas\u00a0mutaciones \u00a0obliga\u00a0a\u00a0consultar \u00a0\nlas\u00a0bases\u00a0de\u00a0datos\u00a0espec\u00edficas \u00a0con\u00a0informaci\u00f3n \u00a0actualizada \u00a0sobre\u00a0patrones\u00a0de\u00a0resisten\u2010\ncia\u00a0y\u00a0su\u00a0significado \u00a0cl\u00ednico\u00a0(Los\u00a0\u00c1lamos\u2021,\u00a0Universidad \u00a0de\u00a0Stanford\u00a7\u00a0o\u00a0la\u00a0Plataforma \u00a0de\u00a0\nResistencias \u00a0de\u00a0la\u00a0RIS**3).\u00a0El\u00a0rescate\u00a0de\u00a0un\u00a0tratamiento \u00a0a\u00a0dos\u00a0AN\u00a0m\u00e1s\u00a0un\u00a0IP/r\u00a0debe\u00a0reali\u2010\nzarse\u00a0con\u00a03\u00a0f\u00e1rmacos \u00a0activos\u00a0que\u00a0pueden\u00a0incluir\u00a0NN,\u00a0AN,\u00a0IP/r\u00a0y\u00a0otros\u00a0de\u00a0las\u00a0nuevas\u00a0fa\u2010\nmilias.\u00a0Si\u00a0se\u00a0pretende \u00a0utilizar\u00a0un\u00a0IP,\u00a0DRV/r\u00a0resulta\u00a0m\u00e1s\u00a0eficaz\u00a0que\u00a0LPV/r\u00a0cuando\u00a0existen\u00a0\nmutaciones \u00a0de\u00a0resistencia \u00a0frente\u00a0a\u00a0IP\u00a0o\u00a0no\u00a0existen\u00a0suficientes \u00a0f\u00e1rmacos\u00a0activos\u00a0(ensayo\u00a0\nTITAN,\u00a0v\u00e9ase\u00a0m\u00e1s\u00a0adelante). \u00a0\nCon\u00a0frecuencia, \u00a0el\u00a0fracaso\u00a0virol\u00f3gico \u00a0del\u00a0primer\u00a0tratamiento \u00a0antirretroviral \u00a0selecciona \u00a0\nmutaciones \u00a0de\u00a0resistencia \u00a0(M184V,\u00a0K65R,\u00a0L74V,\u00a0etc.)321\u00a0que\u00a0obliga\u00a0a\u00a0utilizar\u00a0otros\u00a0AN\u00a0\n(AZT\u00a0o\u00a0d4T)\u00a0en\u00a0los\u00a0tratamientos \u00a0de\u00a0segunda\u00a0l\u00ednea\u00a0que\u00a0inducen\u00a0toxicidad\u00a0cr\u00f3nica\u00a0y\u00a0a\u00a0\nmenudo\u00a0irreparable \u00a0(toxicidad \u00a0mitocondrial, \u00a0lipoatrofia, \u00a0resistencia \u00a0insul\u00ednica \u00a0y\u00a0otras\u00a0\nalteraciones \u00a0metab\u00f3licas). \u00a0Existe\u00a0una\u00a0tendencia \u00a0entre\u00a0los\u00a0cl\u00ednicos\u00a0a\u00a0evitar\u00a0estos\u00a0an\u00e1lo\u2010\ngos\u00a0y\u00a0utilizar\u00a0f\u00e1rmacos \u00a0de\u00a0las\u00a0nuevas\u00a0familias.\u00a0\n\u00a0\n5.1.2.\u00a0Cambio\u00a0de\u00a0TARV\u00a0en\u00a0el\u00a0fracaso\u00a0avanzado \u00a0(TARV\u00a0de\u00a0rescate)\u00a0\nEl\u00a0tratamiento \u00a0tras\u00a0el\u00a0fracaso\u00a0de\u00a0al\u00a0menos\u00a0dos\u00a0l\u00edneas\u00a0de\u00a0TARV\u00a0se\u00a0ha\u00a0denominado \u00a0tera\u2010\npia\u00a0de\u00a0rescate.\u00a0En\u00a0esta\u00a0situaci\u00f3n\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0enfermos \u00a0han\u00a0experimentado \u00a0fraca\u2010\n                                                           \n\u2021 http://resdb.lanl.gov/ Resist_DB/default.htm  \n\u00a7 http://hivdb6.stanford.edu/asi/deployed/hiv_cen tral.pl?program=hivdb&action=showMutationForm  \n** \u00a0http://www.retic-ris.ne t/default_principal.asp?idx=&cidioma=2 Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 50 \n so\u00a0con\u00a0las\u00a0tres\u00a0familias\u00a0de\u00a0FAR\u00a0m\u00e1s\u00a0utilizados: \u00a0AN,\u00a0NN\u00a0e\u00a0IP.\u00a0Sin\u00a0embargo, \u00a0en\u00a0los\u00a0estu\u2010\ndios\u00a0genot\u00edpicos, \u00a0todav\u00eda\u00a0existen\u00a0algunos\u00a0FAR\u00a0que\u00a0conservan \u00a0actividad\u00a0moderada \u00a0o\u00a0\nelevada\u00a0frente\u00a0al\u00a0VIH.\u00a0\u00a0\u00a0\nExisten\u00a0numerosos \u00a0ensayos\u00a0cl\u00ednicos\u00a0que\u00a0han\u00a0comparado \u00a0diferentes \u00a0tratamientos \u00a0de\u00a0\nrescate.\u00a0En\u00a0todos\u00a0ellos\u00a0se\u00a0han\u00a0utilizado\u00a0IP/r\u00a0o\u00a0f\u00e1rmacos \u00a0nuevos.\u00a0Son\u00a0estudios\u00a0dif\u00edcil\u2010\nmente\u00a0comparables \u00a0entre\u00a0s\u00ed\u00a0por\u00a0la\u00a0heterogeneidad \u00a0de\u00a0la\u00a0poblaci\u00f3n, \u00a0tratamientos \u00a0pre\u2010\nvios,\u00a0criterios\u00a0de\u00a0eficacia,\u00a0tiempo\u00a0de\u00a0seguimiento \u00a0y\u00a0tipo\u00a0de\u00a0terapia\u00a0optimizada \u00a0utilizada.\u00a0\u00a0\nInhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0potenciados \u00a0\nLopinavir/r \u00a0\nLa\u00a0experiencia \u00a0de\u00a0LPV/r\u00a0en\u00a0terapia\u00a0de\u00a0rescate\u00a0se\u00a0ha\u00a0obtenido\u00a0de\u00a0los\u00a0ensayos\u00a0cl\u00ednicos\u00a0\nrealizados \u00a0por\u00a0el\u00a0resto\u00a0de\u00a0IP/r,\u00a0que\u00a0utilizan\u00a0LPV/r\u00a0como\u00a0IP\u00a0comparador \u00a0(v\u00e9ase\u00a0m\u00e1s\u00a0ade\u2010\nlante).\u00a0\u00a0\u00a0\n\u00a0Fosamprenavir \u00a0\nCONTEXT \u00a0\nEl\u00a0CONTEXT \u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0aleatorizado \u00a0y\u00a0abierto\u00a0de\u00a0fase\u00a0III\u00a0que\u00a0compar\u00f3\u00a0la\u00a0efi\u2010\ncacia\u00a0de\u00a0FPV/r\u00a0frente\u00a0a\u00a0LPV/r\u00a0ambos\u00a0con\u00a02\u00a0AN\u00a0en\u00a0pacientes \u00a0tratados\u00a0previamente \u00a0con\n\u00a01\u00a0\n\u00f3\u00a02\u00a0IP.\u00a0Se\u00a0incluyeron \u00a0300\u00a0pacientes \u00a0que\u00a0se\u00a0asignaron \u00a0a\u00a0recibir\u00a0FPV/r\u00a01400/200 \u00a0mg,\u00a0QD,\u00a0\nFPV/r\u00a0700/100\u00a0mg,\u00a0BID\u00a0o\u00a0LPV/r\u00a0BID\u00a0(400/100\u00a0mg,\u00a0BID).\u00a0Los\u00a0resultados \u00a0mostraron \u00a0que\u00a0\nFPV/r\u00a0QD\u00a0era\u00a0inferior\u00a0a\u00a0LPV/r\u00a0y\u00a0no\u00a0se\u00a0pudo\u00a0demostrar \u00a0la\u00a0no\u2010inferioridad \u00a0de\u00a0FPV/r\u00a0BID\u00a0\nfrente\u00a0a\u00a0LPV/r.\u00a0La\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<400\u00a0y\u00a0<50\u00a0copias/mL \u00a0a\u00a0las\u00a048\u00a0se\u2010\nmanas\u00a0fue\u00a050%\u00a0y\u00a037%\u00a0para\u00a0FPV/r\u00a0QD,\u00a058%\u00a0y\u00a046%\u00a0para\u00a0FPV/r\u00a0BID\u00a0y\u00a061%\u00a0y\u00a050%\u00a0para\u00a0\nLPV/r333,\u00a0334.\u00a0\u00a0\n\u00a0\nSaquinavir \u00a0\nMaxCmin2 \u00a0\nEl\u00a0estudio\u00a0MaxCmin2 \u00a0evalu\u00f3\u00a0la\u00a0eficacia\u00a0de\u00a0SQV/r\u00a0(1000/100mg, \u00a0BID)\u00a0frente\u00a0a\u00a0LPV/r\u00a0\n(400/100\u00a0mg,\u00a0BID)\u00a0en\u00a0un\u00a0estudio\u00a0abierto\u00a0y\u00a0aleatorizado \u00a0que\u00a0incluy\u00f3\u00a0339\u00a0pacientes. \u00a0A\u00a0\nlas\u00a048\u00a0semanas\u00a0(ITT,\u00a0interrupci\u00f3n \u00a0=\u00a0fracaso)\u00a0el\u00a025%\u00a0de\u00a0los\u00a0tratados\u00a0con\u00a0LPV/r\u00a0y\u00a0el\u00a039%\u00a0\nde\u00a0los\u00a0tratados\u00a0con\u00a0SQV/r\u00a0presentaron \u00a0fracaso\u00a0terap\u00e9utico \u00a0definido\u00a0como\u00a0CVP\u00a0\u2265200\u00a0\ncopias/mL \u00a0en\u00a0cualquier \u00a0momento \u00a0del\u00a0estudio\u00a0\u00a0(p=0,005). \u00a0El\u00a0tiempo\u00a0hasta\u00a0el\u00a0fracaso\u00a0fue\u00a0\nsimilar\u00a0con\u00a0ambas\u00a0pautas\u00a0(p=0,27)\u00a0335.\u00a0\u00a0En\u00a0este\u00a0estudio\u00a0se\u00a0utilizaron \u00a0c\u00e1psulas\u00a0duras\u00a0con\u00a0\n200\u00a0mg\u00a0de\u00a0SQV\u00a0y\u00a0la\u00a0adherencia, \u00a0los\u00a0efectos\u00a0adversos\u00a0y\u00a0el\u00a0dise\u00f1o\u00a0abierto\u00a0probablemen \u2010\nte\u00a0resultaron \u00a0negativos \u00a0para\u00a0el\u00a0brazo\u00a0con\u00a0SQV/r.\u00a0Con\u00a0la\u00a0actual\u00a0presentaci\u00f3n \u00a0de\u00a0SQV\u00a0en\u00a0\nc\u00e1psulas\u00a0duras\u00a0de\u00a0500mg\u00a0es\u00a0posible\u00a0que\u00a0mejoraran \u00a0estos\u00a0resultados. \u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 51 \n Atazanavir \u00a0\nAI424\u00a0045\u00a0\nEl\u00a0estudio\u00a0AI424\u00a0045\u00a0compar\u00f3\u00a0ATV/r,\u00a0frente\u00a0a\u00a0ATV\u00a0m\u00e1s\u00a0SQV\u00a0y\u00a0frente\u00a0a\u00a0LPV/r\u00a0en\u00a0pacien\u2010\ntes\u00a0en\u00a0fracaso\u00a0virol\u00f3gico. \u00a0Se\u00a0requer\u00eda\u00a0CVP\u00a0>1000\u00a0copias/mL, \u00a0que\u00a0hubieran\u00a0llevado\u00a0al\u00a0\nmenos\u00a02\u00a0reg\u00edmenes \u00a0previos\u00a0y\u00a0experiencia \u00a0con\u00a0alg\u00fan\u00a0f\u00e1rmaco\u00a0de\u00a0las\u00a0tres\u00a0clases\u00a0(AN,\u00a0NN\u00a0\ne\u00a0IP).\u00a0Todos\u00a0los\u00a0pacientes \u00a0recibieron \u00a0adem\u00e1s\u00a0TDF\u00a0y\u00a0otro\u00a0AN.\u00a0\u00a0A\u00a0la\u00a0semana\u00a024\u00a0se\u00a0de\u2010\nmostr\u00f3\u00a0que\u00a0la\u00a0eficacia\u00a0del\u00a0brazo\u00a0que\u00a0combinaba \u00a0ATV\u00a0y\u00a0SQV\u00a0era\u00a0inferior\u00a0a\u00a0LPV/r,\u00a0por\u00a0lo\u00a0\nque\u00a0se\u00a0dio\u00a0opci\u00f3n\u00a0de\u00a0cambiar\u00a0el\u00a0tratamiento. \u00a0Tanto\u00a0a\u00a0las\u00a024\u00a0como\u00a048\u00a0semanas, \u00a0ATV/r\u00a0\nresult\u00f3\u00a0no\u00a0inferior\u00a0a\u00a0LPV/r\u00a0respecto\u00a0al\u00a0criterio\u00a0de\u00a0valoraci\u00f3n \u00a0primario\u00a0(reducci\u00f3n \u00a0de\u00a0\nCVP)\u00a0y\u00a0la\u00a0consecuci\u00f3n \u00a0de\u00a0CVP\u00a0<50\u00a0\u00f3\u00a0<400\u00a0copias/mL. \u00a0Sin\u00a0embargo, \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0\npacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias\u00a0fue\u00a038%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ATV/r\u00a0frente\u00a0a\u00a045%\u00a0en\u00a0el\u00a0de\u00a0\nLPV/r336.\u00a0A\u00a0las\u00a096\u00a0semanas\u00a0el\u00a0criterio\u00a0de\u00a0valoraci\u00f3n \u00a0primario\u00a0demostr\u00f3 \u00a0una\u00a0eficacia\u00a0si\u2010\nmilar\u00a0de\u00a0ATV/r\u00a0(\u20102,29\u00a0log 10)\u00a0frente\u00a0a\u00a0LPV/r\u00a0(\u20102,08\u00a0log 10).\u00a0En\u00a0los\u00a0pacientes \u00a0en\u00a0tratamien \u2010\nto,\u00a0la\u00a0proporci\u00f3n \u00a0con\u00a0CVP\u00a0indetectable \u00a0fue\u00a0similar\u00a0en\u00a0ambos\u00a0brazos,\u00a0pero\u00a0el\u00a0estudio\u00a0\ncarece\u00a0de\u00a0poder\u00a0estad\u00edstico \u00a0para\u00a0demostrar \u00a0diferencias \u00a0para\u00a0este\u00a0objetivo\u00a0secundario. \u00a0\nEn\u00a0un\u00a0subestudio337\u00a0que\u00a0analiz\u00f3\u00a0la\u00a0respuesta \u00a0virol\u00f3gica \u00a0a\u00a0las\u00a048\u00a0semanas\u00a0seg\u00fan\u00a0la\u00a0pre\u2010\nsencia\u00a0de\u00a0mutaciones \u00a0en\u00a0las\u00a0posiciones \u00a0D30,\u00a0V32,\u00a0M36,\u00a0M46,\u00a0I47,\u00a0G48,\u00a0I50,\u00a0F53,\u00a0I54,\u00a0\nA71,\u00a0G73,\u00a0V77,\u00a0V82,\u00a0I84,\u00a0N88\u00a0y\u00a0L90,\u00a0la\u00a0respuesta \u00a0fue\u00a0similar\u00a0si\u00a0hab\u00eda\u00a0\u22644\u00a0mutaciones. \u00a0Sin\u00a0\nembargo\u00a0cuando\u00a0el\u00a0n\u00famero\u00a0era\u00a0\u2265\u00a05,\u00a0ning\u00fan\u00a0paciente\u00a0(0/9)\u00a0del\u00a0grupo\u00a0de\u00a0ATV/r\u00a0y\u00a05/18\u00a0\n(28%)\u00a0de\u00a0los\u00a0de\u00a0LPV/r\u00a0lograron\u00a0indetectabilidad. \u00a0Por\u00a0otra\u00a0parte\u00a0se\u00a0identificaron \u00a0muta\u2010\nciones\u00a0asociadas \u00a0a\u00a0resistencia \u00a0a\u00a0ambos\u00a0f\u00e1rmacos. \u00a0Las\u00a0mutaciones \u00a0en\u00a0las\u00a0posiciones \u00a0\nM46,\u00a0G73,\u00a0I84,\u00a0o\u00a0L90\u00a0reducen\u00a0la\u00a0eficacia\u00a0de\u00a0ATV/r\u00a0a\u00a0menos\u00a0de\u00a0un\u00a030%,\u00a0al\u00a0igual\u00a0que\u00a0las\u00a0\nposiciones \u00a0M46,\u00a0I54\u00a0o\u00a0I84\u00a0en\u00a0LPV/r.\u00a0\u00a0\nATV/r\u00a0no\u00a0parece\u00a0ser\u00a0un\u00a0buen\u00a0f\u00e1rmaco\u00a0en\u00a0pacientes \u00a0con\u00a0experiencia \u00a0a\u00a0m\u00faltiples \u00a0f\u00e1rma\u2010\ncos\u00a0y\u00a0mutaciones \u00a0acumuladas \u00a0a\u00a0IP.\u00a0Sin\u00a0embargo\u00a0la\u00a0c\u00f3moda\u00a0posolog\u00eda, \u00a0su\u00a0bajo\u00a0perfil\u00a0de\u00a0\ntoxicidad\u00a0y\u00a0el\u00a0patr\u00f3n\u00a0de\u00a0mutaciones \u00a0favorable, \u00a0puede\u00a0convertirlo \u00a0en\u00a0el\u00a0IP\u00a0de\u00a0elecci\u00f3n\u00a0\nen\u00a0algunos\u00a0pacientes \u00a0multitratados. \u00a0\u00a0\n\u00a0\nTipranavir \u00a0\nRESIST\u00a01\u00a0y\u00a02\u00a0\nLos\u00a0estudios\u00a0RESIST\u00a0son\u00a0estudios\u00a0fase\u00a0III\u00a0en\u00a0los\u00a0que\u00a0se\u00a0compar\u00f3\u00a0TPV/r\u00a0con\u00a0otro\u00a0IP/r\u00a0ele\u2010\ngido\u00a0por\u00a0cada\u00a0investigador. \u00a0Los\u00a0criterios\u00a0de\u00a0inclusi\u00f3n\u00a0exig\u00edan\u00a0llevar\u00a0una\u00a0pauta\u00a0con\u00a0IP,\u00a0\nestar\u00a0en\u00a0fracaso\u00a0virol\u00f3gico \u00a0(CVP\u00a0>1000\u00a0copias/mL) \u00a0y\u00a0en\u00a0el\u00a0estudio\u00a0genot\u00edpico \u00a0deb\u00eda\u00a0\nhaber\u00a0\u22651\u00a0mutaciones \u00a0primarias \u00a0en\u00a0los\u00a0codones\u00a030,\u00a046,\u00a048,\u00a050,\u00a082,\u00a084\u00a0o\u00a090,\u00a0y\u00a0\u22642\u00a0en\u00a0los\u00a0\ncodones\u00a033,\u00a082,\u00a084\u00a0\u00f3\u00a090.\u00a0Los\u00a0pacientes \u00a0fueron\u00a0aleatorizados \u00a0a\u00a0TPV/r\u00a0o\u00a0un\u00a0IP/r\u00a0compa\u2010\nrador\u00a0(IP/rC).\u00a0\u00a0A\u00a0todos\u00a0los\u00a0pacientes \u00a0se\u00a0les\u00a0administr\u00f3 \u00a0un\u00a0tratamiento \u00a0optimizado \u00a0que\u00a0\npod\u00eda\u00a0incluir\u00a0ENF.\u00a0Los\u00a0pacientes \u00a0part\u00edan\u00a0de\u00a0CVP\u00a0elevadas\u00a0(mediana \u00a0de\u00a04,8\u00a0log 10\u00a0co\u2010\npias/mL)\u00a0y\u00a0CD4\u00a0bajos\u00a0(mediana \u00a0<200\u00a0c\u00e9lulas/\u00b5L). \u00a0En\u00a0el\u00a0RESIST\u20101\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0pa\u2010\ncientes\u00a0del\u00a0IP/rC\u00a0recibieron \u00a0LPV/r\u00a0(61%),\u00a0mientras\u00a0que\u00a0en\u00a0el\u00a0RESIST\u20102\u00a0los\u00a0m\u00e1s\u00a0usados\u00a0\nfueron\u00a0APV/r\u00a0(40%)\u00a0y\u00a0LPV/r\u00a0(38%).\u00a0La\u00a0ENF\u00a0se\u00a0indic\u00f3\u00a0en\u00a0el\u00a036%\u00a0del\u00a0RESIST\u20101\u00a0y\u00a0el\u00a012%\u00a0del\u00a0\nRESIST\u20102\u00a0(hab\u00eda\u00a0pacientes \u00a0tratados\u00a0previamente \u00a0con\u00a0este\u00a0f\u00e1rmaco)338.\u00a0\u00a0\nLos\u00a0resultados \u00a0conjuntos \u00a0de\u00a0ambos\u00a0estudios\u00a0a\u00a0las\u00a048\u00a0semanas\u00a0mostraron \u00a0una\u00a0propor\u2010\nci\u00f3n\u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0del\u00a030,4%\u00a0y\u00a013.8%\u00a0con\u00a0TPV/r\u00a0y\u00a0con\u00a0IP/rC\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 52 \n respectivamente, \u00a0y\u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0del\u00a022,8%\u00a0y\u00a010,2%\u00a0respectivamente. \u00a0El\u00a0uso\u00a0\nde\u00a0ENF\u00a0mejor\u00f3\u00a0los\u00a0resultados \u00a0en\u00a0ambos\u00a0brazos,\u00a0alcanzando \u00a0el\u00a052%\u00a0(<400\u00a0copias/mL) \u00a0y\u00a0\n35,8%\u00a0(50\u00a0copias/mL) \u00a0en\u00a0el\u00a0brazo\u00a0del\u00a0TPV/r\u00a0338.\u00a0\u00a0\nEl\u00a0TPV/r\u00a0tiene\u00a0un\u00a0perfil\u00a0de\u00a0interacciones \u00a0espec\u00edfico \u00a0que\u00a0debe\u00a0conocerse \u00a0antes\u00a0de\u00a0usarlo\u00a0\nen\u00a0tratamientos \u00a0de\u00a0rescate.\u00a0\n\u00a0Mutaciones \u00a0de\u00a0resistencia \u00a0a\u00a0TPV\u00a0\nSe\u00a0han\u00a0identificado \u00a019\u00a0mutaciones \u00a0en\u00a014\u00a0posiciones \u00a0de\u00a0amino\u00e1cidos \u00a0(10V,\u00a024I,\u00a036I,\u00a043T,\u00a0\n46L,\u00a047V,\u00a050L/V,\u00a054A/L/M/V, \u00a054L,\u00a058E,\u00a074P,\u00a076V,\u00a082L/T,\u00a083D,\u00a0y\u00a084V)\u00a0asociadas\n\u00a0a\u00a0resis\u2010\ntencia\u00a0a\u00a0TPV.\u00a0Seg\u00fan\u00a0el\u00a0peso\u00a0en\u00a0la\u00a0respuesta \u00a0al\u00a0tratamiento \u00a0con\u00a0TPV\u00a0(favorezcan \u00a0la\u00a0res\u2010\npuesta,\u00a0tengan\u00a0impacto\u00a0reducido\u00a0o\u00a0gran\u00a0impacto\u00a0en\u00a0la\u00a0resistencia) \u00a0se\u00a0les\u00a0ha\u00a0dado\u00a0un\u00a0\nvalor\u00a0en\u00a0el\u00a0score\u00a0(10V,\u00a01;\u00a024I,\u00a0\u20102;\u00a033F,\u00a01;\u00a036I,\u00a02;\u00a043T,\u00a02;\u00a046L,\u00a01;\u00a047V,\u00a04;\u00a050L/V,\u00a0\u20104;\u00a0\n54A/M/V, \u00a02;\u00a054L,\u00a0\u20106;\u00a058E,\u00a03;\u00a074P,\u00a04;\u00a076V,\u00a0\u20102;\u00a082L/T,\u00a04;\u00a083D,\u00a04;\u00a0y\u00a084V,\u00a03).\u00a0En\u00a0la\u00a0elabora\u2010\nci\u00f3n\u00a0de\u00a0este\u00a0score\u00a0se\u00a0ha\u00a0tenido\u00a0en\u00a0cuenta\u00a0la\u00a0eficacia\u00a0de\u00a0la\u00a0medicaci\u00f3n \u00a0que\u00a0acompa\u00f1aba \u00a0\nal\u00a0TPV.\u00a0Cuando\u00a0el\u00a0score\u00a0era\u00a0\u22643\u00a0la\u00a0respuesta \u00a0en\u00a0las\u00a0semanas\u00a08\u00a0y\u00a048\u00a0es\u00a0m\u00e1xima\u00a0y\u00a0m\u00ednima\u00a0\nsi\u00a0el\u00a0score\u00a0es\u00a0>10.\u00a0La\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0que\u00a0respond\u00edan \u00a0aumentaba \u00a0cuanto\u00a0ma\u2010\nyor\u00a0era\u00a0la\u00a0eficacia\u00a0de\u00a0la\u00a0medicaci\u00f3n \u00a0acompa\u00f1ante313.\u00a0\n\u00a0\nDarunavir \u00a0\nEste\u00a0IP\u00a0presenta\u00a0una\u00a0alta\u00a0afinidad\u00a0por\u00a0la\u00a0proteasa\u00a0y\u00a0es\u00a0muy\u00a0potente\u00a0in\u00a0vitro\u00a0e\u00a0in\u00a0vivo\u00a0\nfrente\u00a0a\u00a0la\u00a0cepa\u00a0salvaje\u00a0y\u00a0mutantes \u00a0con\u00a0resistencias \u00a0a\u00a0m\u00faltiples \u00a0FAR\u00a0incluyendo \u00a0IP339,\u00a0\n340.\u00a0\u00a0\nPOWER\u00a01\u00a0y\u00a02\u00a0\nLos\u00a0ensayos\u00a0POWER\u00a0compararon \u00a0la\u00a0eficacia\u00a0y\u00a0tolerancia \u00a0de\u00a0diferentes \u00a0dosis\u00a0de\u00a0DRV/r\u00a0\n(fase\u00a0II)\u00a0frente\u00a0a\u00a0un\u00a0IP/r\u00a0comparador \u00a0(IP/rC)\u00a0asociados \u00a0ambos\u00a0a\u00a0una\u00a0selecci\u00f3n\u00a0optimiza\u2010\nda\u00a0de\u00a0f\u00e1rmacos. \u00a0Los\u00a0pacientes \u00a0incluidos\u00a0ten\u00eda\u00a0CVP\u00a0>1000\u00a0copias/mL, \u00a0hab\u00edan\u00a0sido\u00a0trata\u2010\ndos\u00a0previamente \u00a0con\u00a0f\u00e1rmacos\u00a0de\u00a0las\u00a0tres\u00a0familias\u00a0y\u00a0ten\u00edan\u00a0\u22651\u00a0mutaciones \u00a0primarias \u00a0a\u00a0\nIP.\u00a0La\u00a0aleatorizaci\u00f3n \u00a0se\u00a0estratific\u00f3 \u00a0por\u00a0el\u00a0n\u00famero\u00a0de\u00a0mutaciones, \u00a0la\u00a0CVP\u00a0y\u00a0el\u00a0uso\u00a0de\u00a0ENF.\u00a0\nA\u00a0las\u00a024\u00a0semanas, \u00a0la\u00a0dosis\u00a0de\u00a0\u00a0DRV/r\u00a0se\u00a0unific\u00f3\u00a0a\u00a0600/100\u00a0mg\u00a0BID.\u00a0\u00a0En\u00a0el\u00a0an\u00e1lisis\u00a0combi\u2010\nnado\u00a0de\u00a0ambos\u00a0estudios,\u00a0a\u00a0las\u00a048\u00a0semanas, \u00a0se\u00a0incluyeron \u00a0solamente \u00a0los\u00a0pacientes \u00a0que\u00a0\nrecibieron \u00a0la\u00a0dosis\u00a0de\u00a0DRV/r\u00a0de\u00a0600/100\u00a0mg\u00a0BID\u00a0desde\u00a0el\u00a0principio\u00a0(n=131)\u00a0frente\u00a0al\u00a0\ngrupo\u00a0control\u00a0(n=120).\u00a0La\u00a0variable\u00a0principal\u00a0de\u00a0eficacia\u00a0fue\u00a0la\u00a0respuesta \u00a0virol\u00f3gica \u00a0con\u2010\nfirmada\u00a0(reducci\u00f3n \u00a0de\u00a0la\u00a0CVP\u00a0\u22651\u00a0log 10\u00a0copias/mL \u00a0y\u00a0tiempo\u00a0hasta\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0respues\u2010\nta\u00a0virol\u00f3gica, \u00a0TLOVR).\u00a0En\u00a0cuanto\u00a0a\u00a0eficacia,\u00a0la\u00a0reducci\u00f3n \u00a0de\u00a0la\u00a0CVP\u00a0se\u00a0alcanz\u00f3\u00a0en\u00a061%\u00a0de\u00a0\nlos\u00a0pacientes \u00a0del\u00a0grupo\u00a0de\u00a0DRV/r\u00a0y\u00a0en\u00a015%\u00a0del\u00a0grupo\u00a0comparador \u00a0(diferencia \u00a046%;\u00a0\nIC95%:\u00a035\u201057,\u00a0p<0,0001). \u00a0La\u00a0proporci\u00f3n \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(ITT\u2010TLOVR)\u00a0fue\u00a045%\u00a0\nen\u00a0los\u00a0tratados\u00a0con\u00a0DRV/r\u00a0y\u00a010%\u00a0en\u00a0el\u00a0grupo\u00a0control.\u00a0Esta\u00a0eficacia\u00a0de\u00a0DRV/r\u00a0se\u00a0mantuvo\u00a0\nindependientemente \u00a0del\u00a0uso\u00a0de\u00a0ENF,\u00a0de\u00a0la\u00a0CVP\u00a0basal,\u00a0mutaciones \u00a0primarias \u00a0frente\u00a0a\u00a0IP\u00a0\no\u00a0n\u00famero\u00a0de\u00a0FAR\u00a0activos\u00a0en\u00a0la\u00a0terapia\u00a0optimizada. \u00a0Tambi\u00e9n\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0disconti\u2010\nnuaciones \u00a0(fracaso\u00a0o\u00a0abandono \u00a0por\u00a0cualquier \u00a0motivo)\u00a0fue\u00a0menor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0DRV/r\u00a0\n(21%\u00a0vs\u00a081%)341.\u00a0En\u00a0la\u00a0semana\u00a096\u00a0el\u00a039%\u00a0de\u00a0los\u00a0tratados\u00a0con\u00a0DRV/r\u00a0y\u00a0el\u00a09%\u00a0del\u00a0grupo\u00a0\ncomparador \u00a0persist\u00edan \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(p<0,001, \u00a0ITT\u2010TLOVR)342.\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 53 \n El\u00a0estudio\u00a0POWER\u00a03\u00a0se\u00a0dise\u00f1\u00f3\u00a0para\u00a0incrementar \u00a0los\u00a0datos\u00a0de\u00a0eficacia,\u00a0seguridad \u00a0y\u00a0tole\u2010\nrancia\u00a0de\u00a0DRV/r\u00a0(dosis\u00a0de\u00a0600/100\u00a0mg,\u00a0BID)\u00a0ratificando \u00a0los\u00a0resultados \u00a0obtenidos \u00a0en\u00a0los\u00a0\nestudios\u00a0POWER\u00a01\u00a0y\u00a02343.\u00a0En\u00a0la\u00a0semana\u00a0144,\u00a0el\u00a037%\u00a0y\u00a0el\u00a09%\u00a0de\u00a0los\u00a0pacientes \u00a0respecti\u2010\nvamente\u00a0persist\u00edan \u00a0con\u00a0CVP\u00a0<\u00a050\u00a0copias/mL344.\u00a0\n\u00a0\nTITAN\u00a0\nEl\u00a0TITAN\u00a0es\u00a0un\u00a0ensayo\u00a0fase\u00a0III,\u00a0aleatorizado, \u00a0que\u00a0compar\u00f3\u00a0la\u00a0eficacia\u00a0de\u00a0DRV/r\u00a0frente\u00a0a\u00a0\nLPV/r,\u00a0ambos\u00a0con\u00a0un\u00a0tratamiento \u00a0optimizado, \u00a0en\u00a0pacientes \u00a0en\u00a0fracaso\u00a0virol\u00f3gico \u00a0pero\u00a0\ncon\u00a0menor\u00a0experiencia \u00a0en\u00a0tratamientos \u00a0que\u00a0en\u00a0los\u00a0estudios\u00a0POWER.\u00a0Los\u00a0criterios\u00a0de\u00a0\ninclusi\u00f3n\u00a0fueron\u00a0CVP\u00a0>1000\u00a0copias/mL, \u00a0duraci\u00f3n\u00a0de\u00a0TARV\u00a0\u226512\u00a0semanas\u00a0y\u00a0que\u00a0nunca\u00a0\nhubieran\u00a0recibido\u00a0LPV/r.\u00a0Los\u00a0datos\u00a0deber\u00edan\u00a0analizarse \u00a0con\u00a0criterios\u00a0de\u00a0no\u2010inferioridad. \u00a0\nNo\u00a0obstante, \u00a0con\u00a0la\u00a0finalidad\u00a0de\u00a0realizar\u00a0una\u00a0comparaci\u00f3n \u00a0entre\u00a0ambas\u00a0opciones\u00a0te\u2010\nrap\u00e9uticas, \u00a0el\u00a0dise\u00f1o\u00a0del\u00a0estudio\u00a0recog\u00eda,\u00a0a\u00a0priori,\u00a0que\u00a0se\u00a0realizar\u00eda\u00a0un\u00a0estudio\u00a0de\u00a0supe\u2010\nrioridad\u00a0por\u00a0ITT\u00a0en\u00a0caso\u00a0de\u00a0cumplirse \u00a0la\u00a0no\u2010inferioridad. \u00a0Se\u00a0incluyeron \u00a0595\u00a0pacientes. \u00a0A\u00a0\nlas\u00a048\u00a0semanas\u00a0se\u00a0observ\u00f3\u00a0(ITT)\u00a0que\u00a077%\u00a0de\u00a0los\u00a0tratados\u00a0con\u00a0DRV/r\u00a0y\u00a067%\u00a0del\u00a0grupo\u00a0\nLPV/r\u00a0alcanzaron \u00a0la\u00a0variable\u00a0principal\u00a0del\u00a0estudio:\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0(diferencia \u00a0me\u2010\ndia\u00a0estimada\u00a010%,\u00a0IC95%\u00a02\u201017,\u00a0p\u00a0<0,001);\u00a0DRV/r\u00a0cumpl\u00eda\u00a0por\u00a0tanto\u00a0criterios\u00a0de\u00a0superio\u2010\nridad\u00a0frente\u00a0a\u00a0LPV/r.\u00a0Tambi\u00e9n\u00a0se\u00a0observaron \u00a0diferencias \u00a0con\u00a0criterios\u00a0de\u00a0superioridad \u00a0\nde\u00a0DRV/r\u00a0cuando\u00a0se\u00a0analiz\u00f3\u00a0la\u00a0proporci\u00f3n \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(71%\u00a0frente\u00a0a\u00a060%,\u00a0\ndiferencia \u00a0media\u00a0estimada\u00a011%,\u00a0IC95%:\u00a03\u201019;\u00a0p=0,005). \u00a0En\u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0subgrupos \u00a0\nrespecto\u00a0a\u00a0CVP\u00a0<50\u00a0copias/mL, \u00a0DRV/r\u00a0result\u00f3\u00a0tambi\u00e9n\u00a0superior\u00a0a\u00a0LPV/r\u00a0si\u00a0los\u00a0CD4\u00a0basa\u2010\nles\u00a0eran\u00a0bajos,\u00a0CVP\u00a0>100000\u00a0copias/mL, \u00a0presencia \u00a0de\u00a0\u22651\u00a0mutaciones \u00a0primarias \u00a0a\u00a0IP,\u00a0\nfold\u2010change\u00a0de\u00a0LPV/r\u00a0>10\u00a0o\u00a0\u00a0fold\u2010change\u00a0a\u00a0DRV<10.\u00a0El\u00a0fracaso\u00a0virol\u00f3gico \u00a0fue\u00a0de\u00a010%\u00a0en\u00a0\nel\u00a0grupo\u00a0de\u00a0DRV/r\u00a0y\u00a0de\u00a022%\u00a0con\u00a0LPV/r.\u00a0En\u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0las\u00a0mutaciones \u00a0de\u00a0resistencia, \u00a0\ns\u00f3lo\u00a0el\u00a021%\u00a0(6/28)\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0fracasaron \u00a0con\u00a0DRV/r\u00a0desarrollaron \u00a0mutaciones \u00a0\nadicionales \u00a0en\u00a0el\u00a0gen\u00a0de\u00a0la\u00a0proteasa\u00a0mientras\u00a0que\u00a0s\u00ed\u00a0lo\u00a0hizo\u00a0el\u00a036%\u00a0(20/56)\u00a0del\u00a0grupo\u00a0\nLPV/r.\u00a0Las\u00a0mutaciones \u00a0frente\u00a0a\u00a0AN\u00a0fueron\u00a0menos\u00a0frecuentes \u00a0en\u00a0el\u00a0grupo\u00a0con\u00a0DRV/r\u00a0\n(14%\u00a0frente\u00a0a\u00a027%).\u00a0Los\u00a0autores\u00a0concluyen \u00a0que\u00a0en\u00a0pacientes \u00a0con\u00a0experiencia \u00a0limitada\u00a0a\u00a0\nTARV\u00a0y\u00a0en\u00a0fracaso\u00a0virol\u00f3gico, \u00a0DRV/r\u00a0no\u00a0es\u00a0inferior\u00a0a\u00a0LPV/r\u00a0respecto\u00a0a\u00a0la\u00a0variable\u00a0princi\u2010\npal\u00a0del\u00a0estudio\u00a0(CVP\u00a0<400\u00a0copias/mL) \u00a0y\u00a0es\u00a0superior\u00a0cuando\u00a0se\u00a0analiza\u00a0la\u00a0CVP\u00a0<50\u00a0co\u2010\npias/mL.\u00a0La\u00a0seguridad \u00a0y\u00a0tolerancia \u00a0de\u00a0DRV/r\u00a0fue\u00a0comparable \u00a0a\u00a0LPV/r,\u00a0con\u00a0menos\u00a0di\u2010\narrea\u00a0de\u00a0grado\u00a02\u20104\u00a0y\u00a0mejor\u00a0perfil\u00a0lip\u00eddico345.\u00a0\u00a0\u00a0\u00a0\n\u00a0\nGRACE\u00a0\nEl\u00a0estudio\u00a0GRACE\u00a0(Gender,\u00a0Race\u00a0and\u00a0Clinical\u00a0Experience) \u00a0es\u00a0un\u00a0estudio\u00a0en\u00a0fase\u00a0IIIb,\u00a0\nmultic\u00e9ntrico \u00a0y\u00a0abierto\u00a0que\u00a0incluy\u00f3\u00a0pacientes \u00a0con\u00a0experiencia \u00a0previa\u00a0a\u00a0f\u00e1rmacos \u00a0anti\u2010\nrretrovirales \u00a0y\u00a0con\u00a0CVP\u00a0\u22651000\u00a0copias/mL. \u00a0Todos\u00a0los\u00a0pacientes \u00a0recibieron \u00a0DRV/r\u00a0\n600/100mg \u00a0BID\u00a0con\u00a0un\u00a0tratamiento \u00a0optimizado \u00a0que\u00a0inclu\u00eda\u00a0AN\u00a0y\u00a0NN,\u00a0incluida\u00a0ETR.\u00a0El\u00a0\nobjetivo\u00a0principal\u00a0fue\u00a0evaluar\u00a0si\u00a0hab\u00eda\u00a0diferencias \u00a0seg\u00fan\u00a0el\u00a0g\u00e9nero\u00a0o\u00a0la\u00a0raza\u00a0de\u00a0los\u00a0pa\u2010\ncientes\u00a0respecto\u00a0a\u00a0la\u00a0eficacia\u00a0(CVP\u00a0<50\u00a0copias/mL) \u00a0del\u00a0tratamiento \u00a0a\u00a0las\u00a048\u00a0semanas. \u00a0Se\u00a0\nincluyeron \u00a0429\u00a0pacientes, \u00a0de\u00a0los\u00a0cuales\u00a0un\u00a067%\u00a0eran\u00a0mujeres\u00a0y\u00a0un\u00a084%\u00a0eran\u00a0de\u00a0raza\u00a0\nnegra.\u00a0Un\u00a032,8%\u00a0de\u00a0las\u00a0mujeres\u00a0suspendieron \u00a0el\u00a0TARV\u00a0frente\u00a0a\u00a0un\u00a023,2%\u00a0de\u00a0los\u00a0hom\u2010\nbres\u00a0(p\u00a0<0,05).\u00a0En\u00a0la\u00a0semana\u00a048,\u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0en\u00a0ITT\u2010TLOVR,\u00a0un\u00a050,9%\u00a0de\u00a0las\u00a0mujeres\u00a0y\u00a0\nun\u00a058,5%\u00a0de\u00a0los\u00a0hombres\u00a0alcanzaron \u00a0una\u00a0CVP\u00a0<50\u00a0copias/mL. \u00a0Las\u00a0diferencias \u00a0en\u00a0la\u00a0res\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 54 \n puesta\u00a0virol\u00f3gica \u00a0ajustada\u00a0por\u00a0la\u00a0CVP\u00a0y\u00a0recuento\u00a0de\u00a0linfocitos\u00a0CD4\u00a0basales\u00a0fue:\u00a0\u20109.6\u00a0\n(IC95%:\u00a0\u201019.85\u2010\u00a00.68).\u00a0En\u00a0el\u00a0an\u00e1lisis\u00a0en\u00a0ITT\u2010TLOVR\u00a0en\u00a0el\u00a0que\u00a0se\u00a0censuraron \u00a0los\u00a0pacientes \u00a0\nque\u00a0fracasaron \u00a0por\u00a0causas\u00a0diferentes \u00a0al\u00a0fracaso\u00a0virol\u00f3gico, \u00a0un\u00a073%\u00a0y\u00a0un\u00a073,5%\u00a0de\u00a0las\u00a0\nmujeres\u00a0y\u00a0hombres\u00a0alcanzaron \u00a0una\u00a0CVP\u00a0<50\u00a0copias/mL, \u00a0diferencia \u00a0\u20103.9\u00a0(IC95%:\u00a0\u201013.89\u2010\n6.02.\u00a0Los\u00a0autores\u00a0resaltan\u00a0la\u00a0eficacia\u00a0y\u00a0seguridad \u00a0de\u00a0DRV/r\u00a0en\u00a0los\u00a0tratamientos \u00a0de\u00a0res\u2010\ncate\u00a0tanto\u00a0en\u00a0hombres\u00a0como\u00a0en\u00a0mujeres,\u00a0aunque\u00a0una\u00a0elevada\u00a0proporci\u00f3n \u00a0de\u00a0mujeres\u00a0\nque\u00a0abandonan \u00a0el\u00a0TARV\u00a0por\u00a0razones\u00a0distintas\u00a0al\u00a0fracaso\u00a0virol\u00f3gico346.\u00a0\u00a0\u00a0\n\u00a0Mutaciones \u00a0de\u00a0resistencia \u00a0a\u00a0DRV\u00a0\nSe\u00a0han\u00a0identificado \u00a011\u00a0mutaciones \u00a0en\u00a0el\u00a0gen\u00a0de\u00a0la\u00a0proteasa\u00a0(V11I,\u00a0V32I,\u00a0L33F,\u00a0I47V,\u00a0\nI50V,\u00a0I54L\u00a0o\u00a0M,\u00a0T74P,\u00a0L76V,\u00a0I84V,\u00a0L89V)\u00a0relacionadas \u00a0con\u00a0p\u00e9rdida\u00a0de\u00a0sensibilidad \u00a0a\u00a0\nDRV.\u00a0La\u00a0presencia \u00a0de\u00a0\u22653\u00a0de\u00a0estas\u00a0mutaciones \u00a0al\u00a0inicio\u00a0del\u00a0tratamiento \u00a0supuso\u00a0una\u00a0me\u2010\nnor\n\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0indetectable \u00a0en\u00a0la\u00a0semana\u00a024\u00a0(aun\u00a0siendo\u00a0mayor\u00a0\nque\u00a0en\u00a0el\u00a0brazo\u00a0control).\u00a0Con\u00a0s\u00f3lo\u00a0una\u00a0o\u00a0dos\u00a0de\u00a0estas\u00a0mutaciones \u00a0esa\u00a0proporci\u00f3n \u00a0fue\u00a0\nde\u00a053%\u00a0y\u00a037%347.\u00a0\u00a0\nLas\u00a0interacciones \u00a0farmacol\u00f3gicas \u00a0de\u00a0DRV\u00a0son\u00a0m\u00ednimas,\u00a0sin\u00a0embargo\u00a0ciertas\u00a0combina\u2010\nciones\u00a0farmacol\u00f3gicas \u00a0est\u00e1n\u00a0contraindicadas \u00a0(v\u00e9ase\u00a0m\u00e1s\u00a0adelante) \u00a0\n\u00a0\nInhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0nucle\u00f3sidos \u00a0\nEtravirina \u00a0\u00a0\nEtravirina \u00a0(ETR)\u00a0es\u00a0un\u00a0NN\u00a0de\u00a0nueva\u00a0generaci\u00f3n \u00a0activo\u00a0en\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0VIH\u00a0\ncon\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0frente\u00a0a\u00a0EFV\u00a0y\u00a0NVP.\u00a0\u00a0\n\u00a0\nDUET\u00a01\u00a0y\u00a02\u00a0\u00a0\u00a0\nLos\u00a0ensayos\u00a0cl\u00ednicos\u00a0en\u00a0fase\u00a0III\u00a0DUET\u00a0se\u00a0dise\u00f1aron \u00a0para\u00a0analizar\u00a0la\u00a0eficacia\u00a0y\u00a0seguridad \u00a0\nde\u00a0ETR\u00a0en\u00a0pacientes \u00a0con\u00a0experiencia \u00a0previa\u00a0a\u00a0FAR.\u00a0Con\u00a0un\u00a0dise\u00f1o\u00a0similar,\u00a0DUET\u00a01\u00a0y\u00a02,\u00a0\nson\u00a0ensayos\u00a0multinacionales, \u00a0paralelos, \u00a0aleatorizados \u00a0y\u00a0doble\u00a0ciego\u00a0de\u00a0ETR\u00a0frente\u00a0a\u00a0\nplacebo.\u00a0Los\u00a0criterios\u00a0de\u00a0inclusi\u00f3n\u00a0eran:\u00a0CVP\u00a0>5000\u00a0copias/mL, \u00a0TARV\u00a0estable\u00a0durante\u00a0\n\u22658\u00a0semanas, \u00a0presencia \u00a0de\u00a0\u22651\u00a0mutaci\u00f3n \u00a0frente\u00a0a\u00a0NN\u00a0y\u00a0\u22653\u00a0mutaciones \u00a0frente\u00a0a\u00a0IP.\u00a0Todos\u00a0\nlos\u00a0pacientes \u00a0recibieron \u00a0DRV/r\u00a0y\u00a0AN\u00a0seg\u00fan\u00a0terapia\u00a0optimizada. \u00a0El\u00a0uso\u00a0de\u00a0ENF\u00a0fue\u00a0op\u2010\ncional.\u00a0La\u00a0variable\u00a0principal\u00a0del\u00a0estudio\u00a0era\u00a0conseguir \u00a0en\u00a0la\u00a0semana\u00a024\u00a0una\u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a0(an\u00e1lisis\u00a0por\u00a0ITT\u00a0y\u00a0TLOVR).\u00a0Se\u00a0incluyeron \u00a0612\u00a0pacientes \u00a0en\u00a0el\u00a0DUET\u20101\u00a0y\u00a0591\u00a0\nen\u00a0el\u00a0DUET\u20102.\u00a0Los\u00a0resultados \u00a0fueron:\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0en\u00a0tratados\u00a0con\u00a0ETR,\u00a056%\u00a0y\u00a0\n62%\u00a0(DUET\u20101\u00a0y\u00a0DUET\u20102)\u00a0\u00a0frente\u00a0a\u00a039%\u00a0y\u00a044%\u00a0(en\u00a0grupos\u00a0placebo)\u00a0respectivamente \u00a0\n(p<0,01\u00a0y\u00a0p\u00a0<0,001).\u00a0La\u00a0CVP\u00a0se\u00a0redujo\u00a0en\u00a02,4\u00a0y\u00a02,3\u00a0log 10\u00a0en\u00a0los\u00a0grupos\u00a0con\u00a0ETR\u00a0y\u00a02,3\u00a0y\u00a0\n1,7\u00a0log 10\u00a0en\u00a0los\u00a0de\u00a0placebo\u00a0(diferencia \u00a0no\u00a0significativa). \u00a0Entre\u00a0los\u00a0pacientes \u00a0que\u00a0recibie\u2010\nron\u00a0ETR\u00a0y\u00a0ENF\u00a0en\u00a0el\u00a0tratamiento \u00a0optimizado, \u00a060%\u00a0y\u00a073%\u00a0alcanzaron \u00a0CVP\u00a0<50\u00a0co\u2010\npias/mL,\u00a0frente\u00a0a\u00a056%\u00a0y\u00a068%\u00a0en\u00a0los\u00a0del\u00a0grupo\u00a0placebo348,\u00a0349.\u00a0Los\u00a0resultados \u00a0conjuntos \u00a0\nde\u00a0ambos\u00a0estudios\u00a0a\u00a0las\u00a048\u00a0semanas\u00a0confirman \u00a0los\u00a0datos\u00a0previos\u00a0con\u00a061%\u00a0de\u00a0los\u00a0pa\u2010\ncientes\u00a0con\u00a0ETR\u00a0alcanzaron \u00a0CVP\u00a0<50\u00a0copias/mL \u00a0frente\u00a0al\u00a040%\u00a0de\u00a0los\u00a0pacientes \u00a0asigna\u2010\ndos\u00a0al\u00a0grupo\u00a0placebo\u00a0(p<0,0001); \u00a0el\u00a0descenso \u00a0de\u00a0la\u00a0CVP\u00a0era\u00a0de\u00a0\u20102,25\u00a0log 10\u00a0y\u00a0\u20131,49\u00a0log 10\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 55 \n respectivamente350.\u00a0En\u00a0la\u00a0semana\u00a096,\u00a0el\u00a0an\u00e1lisis\u00a0combinado \u00a0de\u00a0ambos\u00a0estudios\u00a0se\u00f1ala\u00a0\nque\u00a0la\u00a0eficacia\u00a0de\u00a0ETR\u00a0m\u00e1s\u00a0terapia\u00a0optimizada \u00a0fue\u00a0superior\u00a0al\u00a0grupo\u00a0comparador: \u00a057%\u00a0\nfrente\u00a0al\u00a036%\u00a0respectivamente \u00a0(p<0,001). \u00a0El\u00a091%\u00a0de\u00a0los\u00a0pacientes \u00a0asignados \u00a0a\u00a0ETR\u00a0que\u00a0\nalcanzaron \u00a0una\u00a0CVP\u00a0<50\u00a0copias\u00a0en\u00a0la\u00a0semana\u00a048\u00a0persist\u00edan \u00a0con\u00a0la\u00a0misma\u00a0eficacia\u00a0virol\u00f3\u2010\ngica\u00a0en\u00a0la\u00a0semana\u00a096351.\u00a0Por\u00a0otra\u00a0parte\u00a0el\u00a0n\u00famero\u00a0de\u00a0eventos\u00a0cl\u00ednicos\u00a0asociados \u00a0a\u00a0sida\u00a0\no\u00a0muerte\u00a0fue\u00a0menor\u00a0en\u00a0el\u00a0grupo\u00a0que\u00a0recibi\u00f3\u00a0ETR\u00a0(p=0,06)\u00a0y\u00a0alcanz\u00f3\u00a0diferencias \u00a0estad\u00eds\u2010\nticamente \u00a0significativas \u00a0cuando\u00a0se\u00a0compararon \u00a0los\u00a0pacientes \u00a0de\u00a0ambos\u00a0grupos\u00a0que\u00a0\nadem\u00e1s\u00a0utilizaban \u00a0ENF\u00a0(5,9%\u00a0en\u00a0el\u00a0grupo\u00a0ETR\u00a0frente\u00a010,1%\u00a0en\u00a0el\u00a0grupo\u00a0placebo,\u00a0\np=0,02)352.\u00a0\u00a0\nLa\u00a0tolerancia \u00a0a\u00a0la\u00a0ETR\u00a0fue\u00a0buena,\u00a0su\u00a0efecto\u00a0secundario \u00a0m\u00e1s\u00a0frecuente \u00a0fue\u00a0un\u00a0exantema \u00a0\nleve\u00a0o\u00a0moderado \u00a0(el\u00a02%\u00a0suspendi\u00f3 \u00a0ETR).\u00a0\nLa\u00a0ETR\u00a0tiene\u00a0muy\u00a0pocas\u00a0interacciones \u00a0medicamentosas \u00a0(v\u00e9ase\u00a0m\u00e1s\u00a0adelante). \u00a0\n\u00a0Mutaciones \u00a0de\u00a0resistencia \u00a0a\u00a0ETR\u00a0\u00a0\nSe\u00a0han\u00a0identificado \u00a017\u00a0mutaciones \u00a0que\u00a0pueden\u00a0disminuir \u00a0la\u00a0respuesta \u00a0a\u00a0ETR:\u00a0V90I,\u00a0\nA98G,\u00a0L100I,\u00a0K101E/H/P, \u00a0V106I,\u00a0E138A,\u00a0\u00a0V179D/F/T, \u00a0Y181C/I/V, \u00a0G190A/S\u00a0y\u00a0M230L353.\u00a0\nEntre\u00a0estas\u00a0mutaciones, \u00a0la\u00a0presencia \u00a0de\u00a0la\u00a0Y181I\u00a0o\u00a0la\u00a0Y181V\u00a0seguidas\u00a0de\u00a0la\u00a0L100I,\u00a0\nK101P,\u00a0Y181C\u00a0y\u00a0M230L\u00a0son\u00a0las\u00a0que\u00a0generan\u00a0una\u00a0mayor\u00a0resistencia \u00a0a\u00a0ETR.\u00a0Estas\u00a0muta\u2010\nciones\u00a0tienen\u00a0una\u00a0baja\u00a0prevalencia \u00a0en\u00a0la\u00a0poblaci\u00f3n \u00a0VIH\u00a0con\u00a0fracaso\u00a0virol\u00f3gico312.\u00a0\u00a0\u00a0\nPor\u00a0otra\u00a0parte\u00a0Monogram \u00a0ha\u00a0desarrollado \u00a0un\u00a0score\u00a0que\u00a0asigna\u00a0a\u00a0cada\u00a0mutaci\u00f3n \u00a0un\u00a0\nvalor\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0su\u00a0peso\u00a0(Valor\u00a04:\u00a0L100I,\u00a0K101P,\u00a0Y181C/I/V; \u00a0valor\u00a03:\u00a0E138A/G, \u00a0\nV179E,\u00a0G190Q,\u00a0K238T,K101P, \u00a0V106A,\u00a0E138K,\u00a0179L,\u00a0Y188L;\u00a0y\u00a0valor\u00a01:\u00a0V90I,\u00a0K101H,\u00a0\nV106M,\u00a0E138Q,\u00a0V179D/F/M, \u00a0Y181F,\u00a0Y189I,\u00a0G190E/T, \u00a0H221Y,\u00a0P225H,\u00a0K238T).\u00a0Si\u00a0el\u00a0resul\u2010\ntado\u00a0es\u00a0inferior\u00a0a\u00a04,\u00a0la\u00a0ETR\u00a0tiene\u00a0un\u00a090%\u00a0de\u00a0probabilidades \u00a0de\u00a0ser\u00a0eficaz\u00a0(\u201cfold\u00a0change\u201d\u00a0\n<2,9)354.\u00a0La\u00a0Plataforma \u00a0de\u00a0resistencias \u00a0de\u00a0la\u00a0Red\u00a0de\u00a0Investigaci\u00f3n \u00a0en\u00a0sida\u00a0(RIS),\u00a0adjudica\u00a0\n2\u00a0puntos\u00a0a\u00a0las\u00a0mutaciones \u00a0Y181C/I/V, \u00a0L100I,\u00a0K101P,\u00a0M230L\u00a0y\u00a0\u00a0un\u00a0punto\u00a0al\u00a0resto,\u00a0consi\u2010\nderando\u00a0resistencia \u00a0un\u00a0score\u00a0\u22653312.\u00a0\n\u00a0\nInhibidores \u00a0de\u00a0la\u00a0uni\u00f3n\u00a0\nEnfuvirtida \u00a0\nLa\u00a0ENF\u00a0inhibe\u00a0la\u00a0fusi\u00f3n\u00a0del\u00a0VIH\u00a0evitando\u00a0su\u00a0penetraci\u00f3n \u00a0y\u00a0replicaci\u00f3n. \u00a0Se\u00a0administra \u00a0por\u00a0\nv\u00eda\u00a0subcut\u00e1nea \u00a0y\u00a0su\u00a0principal\u00a0efecto\u00a0adverso\u00a0es\u00a0la\u00a0reacci\u00f3n\u00a0en\u00a0el\u00a0punto\u00a0de\u00a0inyecci\u00f3n. \u00a0\u00a0\nTORO\u00a0I\u00a0y\u00a0II\u00a0\nLos\u00a0estudios\u00a0TORO\u00a0son\u00a0dos\u00a0ensayos\u00a0fase\u00a0III\u00a0en\u00a0los\u00a0que\u00a0se\u00a0compar\u00f3\u00a0la\u00a0actividad\u00a0antiviral\u00a0\nde\u00a0la\u00a0ENF\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0una\u00a0pauta\u00a0optimizada \u00a0frente\u00a0a\u00a0una\u00a0pauta\u00a0optimizada \u00a0en\u00a0\npacientes \u00a0en\u00a0fracaso\u00a0viral\u00a0con\u00a0m\u00faltiples \u00a0tratamientos \u00a0previos.\u00a0Se\u00a0incluyeron \u00a0alrededor \u00a0\nde\u00a01000\u00a0pacientes, \u00a0con\u00a0una\u00a0mediana\u00a0de\u00a0CVP\u00a0basal\u00a0>100000\u00a0copias/mL \u00a0y\u00a0de\u00a0CD4\u00a0<100\u00a0\nc\u00e9lulas/\u00b5L. \u00a0A\u00a0las\u00a024\u00a0semanas\u00a0el\u00a0descenso \u00a0de\u00a0la\u00a0CVP\u00a0fue\u00a0mayor\u00a0en\u00a0los\u00a0\u00a0tratados\u00a0con\u00a0ENF\u00a0\nque\u00a0en\u00a0los\u00a0tratados\u00a0con\u00a0la\u00a0pauta\u00a0optimizada. \u00a0ENF\u00a0produjo\u00a0un\u00a0descenso \u00a0de\u00a0CVP\u00a0de\u00a0\u20100,93\u00a0\nlog 10\u00a0(TORO\u00a0I)\u00a0y\u00a0\u20100,78\u00a0log 10\u00a0(TORO\u00a0II)\u00a0\u00a0(p<0,0001)355,\u00a0356.\u00a0A\u00a0la\u00a0semana\u00a048,\u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0\ncombinado \u00a0de\u00a0los\u00a0dos\u00a0estudios,\u00a0el\u00a0descenso \u00a0de\u00a0la\u00a0CVP\u00a0fue\u00a0de\u00a0\u20101.48\u00a0log 10\u00a0copias/mL \u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 56 \n (ENF)\u00a0y\u00a0\u20100,63\u00a0log 10\u00a0copias/mL \u00a0en\u00a0el\u00a0tratamiento \u00a0optimizado \u00a0(p<0,0001)357.\u00a0La\u00a0probabili\u2010\ndad\u00a0de\u00a0alcanzar\u00a0una\u00a0respuesta \u00a0virol\u00f3gica \u00a0fue\u00a0m\u00e1s\u00a0del\u00a0doble\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ENF\u00a0(des\u2010\ncenso\u00a0CVP\u00a0>1\u00a0log 10\u00a037%\u00a0frente\u00a017%;\u00a0CVP\u00a0<400\u00a0copias/mL, \u00a030%\u00a0frente\u00a012%\u00a0y\u00a0CVP\u00a0<50\u00a0\ncopias/mL, \u00a018%\u00a0frente\u00a0a\u00a08%\u00a0(p<0,0001)). \u00a0El\u00a0tiempo\u00a0hasta\u00a0el\u00a0fracaso\u00a0del\u00a0grupo\u00a0con\u00a0ENF\u00a0\ntriplic\u00f3\u00a0al\u00a0grupo\u00a0control\u00a0(32\u00a0y\u00a011\u00a0semanas, \u00a0p<0,0001)358.\u00a0Es\u00a0decir,\u00a0tanto\u00a0el\u00a0an\u00e1lisis\u00a0pri\u2010\nmario\u00a0de\u00a0eficacia\u00a0como\u00a0el\u00a0resto\u00a0de\u00a0an\u00e1lisis\u00a0secundarios \u00a0predefinidos, \u00a0demostraron \u00a0que\u00a0\nel\u00a0tratamiento \u00a0de\u00a0rescate\u00a0era\u00a0m\u00e1s\u00a0eficaz\u00a0cuando\u00a0se\u00a0utilizaba\u00a0ENF.\u00a0\nSe\u00a0han\u00a0identificado \u00a0mutaciones \u00a0en\u00a0la\u00a0regi\u00f3n\u00a0HR1\u00a0de\u00a0la\u00a0gp41\u00a0del\u00a0virus\u00a0que\u00a0reducen\u00a0la\u00a0\nsensibilidad \u00a0al\u00a0ENF\u00a0(G36D/S,\u00a0I37V,\u00a0V38A/M/E, \u00a0Q39R,\u00a0Q40H,\u00a0N42T,\u00a0N43D.\u00a0Otras\u00a0muta\u2010\nciones\u00a0o\u00a0polimorfismos \u00a0en\u00a0otras\u00a0regiones\u00a0de\u00a0la\u00a0envoltura, \u00a0como\u00a0por\u00a0ejemplo\u00a0la\u00a0regi\u00f3n\u00a0\nHR2)\u00a0podr\u00edan\u00a0disminuir \u00a0la\u00a0sensibilidad \u00a0a\u00a0ENF331.\u00a0Por\u00a0ello,\u00a0secuenciar \u00a0s\u00f3lo\u00a0las\u00a0mutacio\u2010\nnes\u00a0de\u00a0la\u00a0regi\u00f3n\u00a0HR1\u00a0podr\u00eda\u00a0ser\u00a0inadecuado \u00a0cuando\u00a0se\u00a0sospecha \u00a0resistencia \u00a0a\u00a0ENF.\u00a0\nUn\u00a0consenso \u00a0espa\u00f1ol\u00a0recomienda \u00a0su\u00a0uso\u00a0en\u00a0pacientes \u00a0en\u00a0los\u00a0que\u00a0no\u00a0se\u00a0pueda\u00a0confec\u2010\ncionar\u00a0un\u00a0tratamiento \u00a0\u00f3ptimo\u00a0con\u00a03\u00a0f\u00e1rmacos359.\u00a0\n\u00a0\nAntagonistas \u00a0del\u00a0correceptor \u00a0CCR5\u00a0\nMaraviroc \u00a0\nMVC\u00a0es\u00a0un\u00a0inhibidor\u00a0de\u00a0la\u00a0entrada\u00a0que\u00a0bloquea\u00a0uno\u00a0de\u00a0los\u00a0correceptores \u00a0de\u00a0quimio\u2010\nquinas\u00a0(CCR5)\u00a0utilizados \u00a0por\u00a0el\u00a0VIH\u00a0para\u00a0entrar\u00a0en\u00a0la\u00a0c\u00e9lula.\u00a0MVC\u00a0es\u00a0un\u00a0antagonista \u00a0del\u00a0\ncorreceptor \u00a0CCR5\u00a0e\u00a0impide\u00a0la\u00a0entrada\u00a0del\u00a0virus\u00a0con\u00a0tropismo\u00a0R5.\u00a0Presenta\u00a0una\u00a0activi\u2010\ndad\u00a0potente\u00a0frente\u00a0a\u00a0cepas\u00a0con\u00a0tropismo\u00a0R5\u00a0tanto\u00a0silvestres \u00a0como\u00a0con\u00a0mutaciones \u00a0\npara\u00a0AN,\u00a0NN\u00a0o\u00a0IP360.\u00a0\u00a0\n\u00a0MOTIVATE \u00a01\u00a0y\u00a02\u00a0\nLos\u00a0estudios\u00a0MOTIVATE \u00a0(1\u00a0y\u00a02)\u00a0son\u00a0dos\u00a0ensayos\u00a0cl\u00ednicos\u00a0en\u00a0fase\u00a0III,\u00a0paralelos\u00a0y\u00a0doble\u00a0\nciego,\u00a0donde\u00a0se\u00a0aleatoriz\u00f3 \u00a0a\u00a0los\u00a0pacientes \u00a0incluidos\u00a0a\u00a0recibir\u00a0MVC\u00a0(QD\u00a0o\u00a0BID)\u00a0frente\u00a0a\u00a0\nplacebo\u00a0y\u00a0a\u00f1adiendo \u00a0a\u00a0cada\u00a0uno\u00a0de\u00a0los\u00a0brazos\u00a0un\u00a0tratamiento \u00a0optimizado. \u00a0Los\u00a0criterios\n\u00a0\nde\u00a0inclusi\u00f3n\u00a0fueron\u00a0CVP\u00a0>5000\u00a0copias/mL, \u00a0tropismo\u00a0R5\u00a0y\u00a0resistencia \u00a0a\u00a0\u22651\u00a0FAR\u00a0o\u00a0\u2265\u00a02\u00a0IP.\u00a0\nLos\u00a0pacientes \u00a0se\u00a0estratificaron \u00a0seg\u00fan\u00a0uso\u00a0de\u00a0ENF\u00a0y\u00a0CVP.\u00a0Se\u00a0incluy\u00f3\u00a0a\u00a0m\u00e1s\u00a0de\u00a01000\u00a0pa\u2010\ncientes\u00a0de\u00a0los\u00a0que\u00a0209\u00a0recibieron \u00a0placebo,\u00a0414\u00a0MVC,\u00a0QD\u00a0(150\u00a0\u00f3\u00a0300\u00a0mg)\u00a0y\u00a0426\u00a0MVC\u00a0BID\u00a0\n(150\u00a0\u00f3\u00a0300\u00a0mg).\u00a0La\u00a0variable\u00a0principal\u00a0del\u00a0estudio\u00a0fue\u00a0la\u00a0reducci\u00f3n \u00a0de\u00a0la\u00a0CVP\u00a0en\u00a0la\u00a0sema\u2010\nna\u00a048\u00a0y\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<400\u00a0\u00f3\u00a050\u00a0copias/mL \u00a0fue\u00a0una\u00a0variable\u00a0se\u2010\ncundaria. \u00a0\nLos\u00a0resultados \u00a0combinados \u00a0de\u00a0ambos\u00a0estudios\u00a0a\u00a0las\u00a048\u00a0semanas\u00a0muestran \u00a0que\u00a0el\u00a0des\u2010\ncenso\u00a0de\u00a0CVP\u00a0fue:\u00a0MVC\u00a0QD:\u00a0\u20101,68\u00a0log,\u00a0MVC\u00a0BID:\u00a0\u20101,84\u00a0log\u00a0y\u00a0grupo\u00a0placebo:\u00a0\u20100,78\u00a0log;\u00a0la\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<400\u00a0copias/mL: \u00a051,7%,\u00a056,1%\u00a0y\u00a022,5%\u00a0respectiva \u2010\nmente\u00a0(valor\u00a0p\u00a0frente\u00a0a\u00a0placebo\u00a0\u00a0<0,0001); \u00a0y\u00a0CVP\u00a0<50\u00a0copias/mL: \u00a043,2%,\u00a045,5%\u00a0y\u00a016,7%\u00a0\n(valor\u00a0p\u00a0frente\u00a0a\u00a0placebo\u00a0<0,001).\u00a0El\u00a0incremento \u00a0de\u00a0linfocitos\u00a0CD4\u00a0fue\u00a0tambi\u00e9n\u00a0signifi\u2010\ncativamente \u00a0mayor\u00a0en\u00a0los\u00a0grupos\u00a0que\u00a0recibieron \u00a0MVC\u00a0independientemente \u00a0de\u00a0la\u00a0dosi\u2010\nficaci\u00f3n361.\u00a0Esta\u00a0ventaja\u00a0en\u00a0la\u00a0recuperaci\u00f3n \u00a0inmunol\u00f3gica \u00a0puede\u00a0tener\u00a0trascendencia \u00a0en\u00a0\nel\u00a0futuro,\u00a0ya\u00a0que\u00a0ha\u00a0sido\u00a0tambi\u00e9n\u00a0demostrada \u00a0con\u00a0\u00a0independencia \u00a0de\u00a0la\u00a0eficacia\u00a0virol\u00f3\u2010\ngica362.\u00a0La\u00a0eficacia\u00a0(CVP\u00a0<50\u00a0copias/mL) \u00a0fue\u00a0tambi\u00e9n\u00a0superior\u00a0cuando\u00a0los\u00a0pacientes \u00a0re\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 57 \n cibieron\u00a0ENF\u00a0por\u00a0primera\u00a0vez:\u00a064%\u00a0y\u00a061%\u00a0en\u00a0los\u00a0grupos\u00a0que\u00a0recibieron \u00a0MVC\u00a0y\u00a027%\u00a0en\u00a0\nlos\u00a0grupos\u00a0que\u00a0recibieron \u00a0placebo\u00a0+\u00a0ENF363.\u00a0En\u00a0la\u00a0semana\u00a096,\u00a0el\u00a041,3%\u00a0de\u00a0los\u00a0pacientes \u00a0\nque\u00a0recibieron \u00a0MVC\u00a0en\u00a0pauta\u00a0BID\u00a0persist\u00edan \u00a0con\u00a0una\u00a0CVP\u00a0<50\u00a0copias\u00a0frente\u00a0al\u00a07,2%\u00a0de\u00a0\nlos\u00a0pacientes \u00a0del\u00a0grupo\u00a0placebo364.\u00a0\nLos\u00a0efectos\u00a0adversos\u00a0producidos \u00a0por\u00a0MVC\u00a0no\u00a0fueron\u00a0superiores \u00a0a\u00a0los\u00a0del\u00a0grupo\u00a0place\u2010\nbo.\u00a0Los\u00a0temores\u00a0iniciales\u00a0de\u00a0mayor\u00a0riesgo\u00a0de\u00a0hepatotoxicidad \u00a0o\u00a0de\u00a0mayor\u00a0incidencia \u00a0de\u00a0\ntumores\u00a0no\u00a0se\u00a0han\u00a0confirmado363,\u00a0365,\u00a0366\u00a0.\u00a0\u00a0\nSe\u00a0analiz\u00f3\u00a0retrospectivamente \u00a0la\u00a0relaci\u00f3n\u00a0del\u00a0fracaso\u00a0virol\u00f3gico \u00a0en\u00a0los\u00a0pacientes \u00a0de\u00a0los\u00a0\nMOTIVATE \u00a0con\u00a0el\u00a0tropismo\u00a0viral.\u00a0Dos\u00a0tercios\u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0MVC\u00a0que\u00a0fracasaron \u00a0\nten\u00edan\u00a0un\u00a0tropismo\u00a0dual\u00a0(R5/X4)\u00a0o\u00a0bien\u00a0el\u00a0tropismo\u00a0vari\u00f3\u00a0entre\u00a0la\u00a0selecci\u00f3n\u00a0y\u00a0el\u00a0inicio\u00a0\ndel\u00a0tratamiento. \u00a0El\u00a0cambio\u00a0de\u00a0tropismo\u00a0del\u00a0R5\u00a0a\u00a0dual\u00a0o\u00a0X4\u00a0se\u00a0observ\u00f3\u00a0en\u00a0el\u00a07,5%\u00a0de\u00a0los\u00a0\npacientes \u00a0que\u00a0fracasaban \u00a0con\u00a0MVC\u00a0y\u00a0s\u00f3lo\u00a0el\u00a01,9%\u00a0del\u00a0grupo\u00a0placebo.\u00a0No\u00a0se\u00a0observ\u00f3\u00a0\ncambio\u00a0de\u00a0tropismo\u00a0en\u00a0el\u00a04%\u00a0de\u00a0los\u00a0fracasados \u00a0que\u00a0recib\u00edan\u00a0MVC.\u00a0Tras\u00a0la\u00a0retirada\u00a0del\u00a0\nMVC\u00a0las\u00a0cepas\u00a0revert\u00edan\u00a0r\u00e1pidamente \u00a0a\u00a0R5.\u00a0Todos\u00a0los\u00a0pacientes \u00a0que\u00a0recib\u00edan\u00a0MVC\u00a0pre\u2010\nsentaron\u00a0un\u00a0incremento \u00a0significativo \u00a0de\u00a0los\u00a0linfocitos\u00a0CD4367.\u00a0\n\u00a0\nResistencia \u00a0a\u00a0Maraviroc \u00a0\nLa\u00a0eficacia\u00a0de\u00a0MVC\u00a0exige\u00a0la\u00a0presencia \u00a0de\u00a0tropismo\u00a0viral\u00a0R5\u00a0y\u00a0no\u00a0es\u00a0activo\u00a0cuando\u00a0las\u00a0\npoblaciones \u00a0virales\u00a0presentan \u00a0tropismo\u00a0viral\u00a0X4\u00a0o\u00a0dual\u00a0(R5/X4).\u00a0Algunos\u00a0casos\u00a0de\u00a0FV\u00a0\ndurante\u00a0el\u00a0tratamiento \u00a0con\u00a0MVC\u00a0corresponden \u00a0a\u00a0un\u00a0sobrecrecimiento \u00a0de\u00a0poblaciones \u00a0\nvirales\u00a0con\u00a0tropismo\u00a0X4\u00a0preexistentes \u00a0y\u00a0no\u00a0detectadas \u00a0por\u00a0la\u00a0baja\u00a0sensibilidad \u00a0de\u00a0la\u00a0\nprueba\u00a0(TrophileTM,\u00a0detectaba \u00a0virus\u00a0X4\u00a0con\u00a0una\u00a0certeza\u00a0del\u00a0100%\u00a0s\u00f3lo\u00a0cuando\u00a0la\u00a0pro\u2010\nporci\u00f3n\u00a0era\u00a0\u226510\u00a0%\u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0viral\u00a0y\u00a0la\u00a0CVP\u00a0>1000\u00a0copias/mL). \u00a0La\u00a0t\u00e9cnica\u00a0de\u00a0Trop\u2010\nhile\u00a0ultrasensible \u00a0detecta\u00a0poblaciones \u00a0minoritarias \u00a0con\u00a0tropismo\u00a0X4\u00a0hasta\u00a0en\u00a0una\u00a0pro\u2010\nporci\u00f3n\u00a0<1%.\u00a0Adem\u00e1s,\u00a0se\u00a0han\u00a0identificado \u00a0mutaciones \u00a0en\u00a0la\u00a0mol\u00e9cula\u00a0gp120\u00a0que\u00a0per\u2010\nmite\u00a0al\u00a0virus\u00a0unirse\u00a0al\u00a0receptor\u00a0R5\u00a0en\u00a0presencia \u00a0de\u00a0MVC\u00a0sin\u00a0cambiar\u00a0de\u00a0tropismo\u00a0du\u2010\nrante\u00a0el\u00a0tratamiento331.\u00a0El\u00a0perfil\u00a0de\u00a0mutaciones \u00a0seleccionadas \u00a0por\u00a0MVC\u00a0es\u00a0complejo \u00a0y\u00a0\ntodav\u00eda\u00a0no\u00a0se\u00a0conoce\u00a0su\u00a0importancia \u00a0y\u00a0\u00a0frecuencia \u00a0de\u00a0aparici\u00f3n. \u00a0\u00a0\nMVC\u00a0es\u00a0un\u00a0substrato \u00a0de\u00a0la\u00a0glicoprote\u00edna \u2010P\u00a0y\u00a0su\u00a0metabolismo \u00a0se\u00a0realiza\u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\nCYP3A4;\u00a0por\u00a0lo\u00a0que\u00a0presenta\u00a0un\u00a0potencial \u00a0importante \u00a0de\u00a0interacciones \u00a0con\u00a0f\u00e1rmacos \u00a0\nque\u00a0utilizan\u00a0la\u00a0misma\u00a0v\u00eda\u00a0metab\u00f3lica \u00a0(v\u00e9ase\u00a0cap\u00edtulo\u00a0interacciones). \u00a0\n\u00a0Inhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0\nRaltegravir \u00a0\nLa\u00a0integrasa \u00a0es\u00a0una\u00a0de\u00a0las\u00a0tres\u00a0enzimas\u00a0fundamentales \u00a0del\u00a0ciclo\u00a0de\u00a0replicaci\u00f3n \u00a0del\u00a0VIH.\u00a0\nSu\u00a0funci\u00f3n\u00a0es\u00a0catalizar\u00a0la\u00a0inserci\u00f3n\u00a0del\u00a0ADN\u00a0proviral\u00a0en\u00a0el\u00a0genoma\u00a0de\u00a0la\u00a0c\u00e9lula\u00a0hu\u00e9sped.\u00a0\nEl\u00a0RAL\u00a0es\u00a0un\u00a0f\u00e1rmaco\u00a0capaz\u00a0de\u00a0\ninhibir\u00a0la\u00a0integrasa, \u00a0es\u00a0activo\u00a0frente\u00a0a\u00a0cepas\u00a0de\u00a0VIH\u00a0con\u00a0\nmutaciones \u00a0de\u00a0resistencia \u00a0a\u00a0las\u00a0tres\u00a0familias\u00a0cl\u00e1sicas\u00a0y\u00a0frente\u00a0a\u00a0cepa\u00a0silvestre368.\u00a0\u00a0\n\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 58 \n BENCHMRK \u00a01\u00a0y\u00a02\u00a0\nLos\u00a0ensayos\u00a0cl\u00ednicos\u00a0en\u00a0fase\u00a0III\u00a0BENCHMRK \u00a0(1\u00a0y\u00a02)\u00a0son\u00a0estudios\u00a0paralelos, \u00a0aleatorizados \u00a0\ny\u00a0doble\u00a0ciego\u00a0dise\u00f1ados \u00a0para\u00a0analizar\u00a0la\u00a0eficacia\u00a0de\u00a0RAL\u00a0en\u00a0rescate\u00a0de\u00a0pacientes \u00a0ex\u2010\npuestos\u00a0a\u00a0m\u00faltiples \u00a0FAR\u00a0y\u00a0en\u00a0fracaso\u00a0virol\u00f3gico. \u00a0Los\u00a0criterios\u00a0de\u00a0inclusi\u00f3n\u00a0fueron\u00a0CVP\u00a0\n>1000\u00a0copias/mL, \u00a0resistencia \u00a0genot\u00edpica \u00a0o\u00a0fenot\u00edpica \u00a0al\u00a0menos\u00a0a\u00a0un\u00a0f\u00e1rmaco\u00a0de\u00a0cada\u00a0\nuna\u00a0de\u00a0las\u00a0tres\u00a0clases\u00a0(AN,\u00a0NN\u00a0e\u00a0IP).\u00a0Se\u00a0incluyeron \u00a0350\u00a0pacientes \u00a0(BENCHMRK \u20101)\u00a0y\u00a0349\u00a0\n(BENCHMRK \u20102)\u00a0en\u00a0situaci\u00f3n\u00a0cl\u00ednica\u00a0muy\u00a0avanzada \u00a0(criterios\u00a0de\u00a0sida,\u00a082%)\u00a0y\u00a0que\u00a0hab\u00edan\u00a0\nrecibido\u00a0una\u00a0mediana\u00a0de\u00a012\u00a0FAR\u00a0durante\u00a09,9\u00a0a\u00f1os.\u00a0Los\u00a0pacientes \u00a0fueron\u00a0aleatorizados \u00a0\n(2:1)\u00a0a\u00a0recibir\u00a0RAL\u00a0o\u00a0placebo\u00a0ambos\u00a0con\u00a0terapia\u00a0optimizada. \u00a0En\u00a0los\u00a0resultados \u00a0combi\u2010\nnados\u00a0de\u00a0ambos\u00a0estudios\u00a0a\u00a0las\u00a016\u00a0semanas, \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0fue\u00a0\nde\u00a077,5\u00a0%\u00a0en\u00a0el\u00a0grupo\u00a0RAL\u00a0y\u00a041,9\u00a0%\u00a0en\u00a0los\u00a0del\u00a0placebo.\u00a0La\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0fue\u00a0del\u00a0\n61,8\u00a0%\u00a0en\u00a0el\u00a0grupo\u00a0RAL\u00a0y\u00a032,9\u00a0%\u00a0en\u00a0el\u00a0placebo\u00a0p\u00a0<0,001.\u00a0\u00a0En\u00a0la\u00a0semana\u00a048,\u00a0el\u00a0porcentaje \u00a0\nde\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0fue\u00a0del\u00a062,1%\u00a0para\u00a0el\u00a0grupo\u00a0de\u00a0pacientes \u00a0que\u00a0re\u2010\ncibi\u00f3\u00a0RAL\u00a0frente\u00a0al\u00a032,9%\u00a0del\u00a0grupo\u00a0placebo\u00a0(P<0,001)369.\u00a0La\u00a0eficacia\u00a0de\u00a0RAL\u00a0fue\u00a0inde\u2010\npendiente \u00a0de\u00a0la\u00a0CVP,\u00a0de\u00a0los\u00a0CD4+\u00a0o\u00a0del\u00a0\u00edndice\u00a0GSS/PSS\u00a0\u2265\u00a02.\u00a0\nCuando\u00a0en\u00a0la\u00a0terapia\u00a0optimizada \u00a0se\u00a0asoci\u00f3\u00a0DRV/r\u00a0y\u00a0ENF\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0CVP\u00a0<400\u00a0co\u2010\npias/mL\u00a0fue\u00a098%\u00a0(RAL)\u00a0y\u00a0de\u00a087%\u00a0(placebo); \u00a0si\u00a0solamente \u00a0recib\u00edan\u00a0ENF\u00a0el\u00a090%\u00a0(rama\u00a0\nRAL)\u00a0y\u00a063%\u00a0(rama\u00a0placebo)\u00a0ten\u00edan\u00a0<400\u00a0copias/mL, \u00a0mientras\u00a0que\u00a0si\u00a0s\u00f3lo\u00a0recib\u00edan\u00a0DRV/r\u00a0\nlas\u00a0proporciones \u00a0fueron\u00a0de\u00a090%\u00a0y\u00a055%370.\u00a0La\u00a0seguridad \u00a0y\u00a0tolerabilidad \u00a0de\u00a0RAL\u00a0result\u00f3\u00a0\ncomparable \u00a0al\u00a0placebo.\u00a0Se\u00a0observ\u00f3\u00a0una\u00a0mayor\u00a0incidencia \u00a0de\u00a0neoplasias \u00a0en\u00a0el\u00a0grupo\u00a0\nasignado\u00a0a\u00a0RAL\u00a0(3,5%\u00a0frente\u00a0a\u00a01,7%),\u00a0aunque\u00a0no\u00a0se\u00a0ha\u00a0comunicado \u00a0ninguna\u00a0relaci\u00f3n\u00a0\ndirecta\u00a0con\u00a0el\u00a0f\u00e1rmaco.\u00a0Estudios\u00a0posteriores \u00a0que\u00a0analizan\u00a0la\u00a0incidencia \u00a0de\u00a0neoplasias \u00a0en\u00a0\nensayos\u00a0cl\u00ednicos\u00a0y\u00a0programas \u00a0de\u00a0acceso\u00a0expandido \u00a0no\u00a0se\u00a0observa\u00a0una\u00a0mayor\u00a0incidencia \u00a0\nde\u00a0c\u00e1ncer\u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0reciben\u00a0RAL371.\u00a0\u00a0\nEl\u00a0an\u00e1lisis\u00a0combinado \u00a0en\u00a0la\u00a0semana\u00a096\u00a0de\u00a0los\u00a0estudios\u00a0BENCHMRK \u00a0demostr\u00f3 \u00a0la\u00a0eficacia\u00a0\nduradera\u00a0de\u00a0RAL.\u00a0El\u00a058%\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0recibieron \u00a0RAL\u00a0persist\u00edan \u00a0con\u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a0frente\u00a0al\u00a026%\u00a0de\u00a0los\u00a0pacientes \u00a0del\u00a0grupo\u00a0placebo.\u00a0Este\u00a0porcentaje \u00a0se\u00a0incre\u2010\nment\u00f3\u00a0al\u00a079%\u00a0cuando\u00a0los\u00a0pacientes \u00a0recib\u00edan\u00a0adem\u00e1s\u00a0otros\u00a0f\u00e1rmacos \u00a0activos372.\u00a0\u00a0\nRAL\u00a0se\u00a0metaboliza \u00a0por\u00a0glucuronizaci\u00f3n \u00a0hep\u00e1tica; \u00a0no\u00a0es\u00a0inductor\u00a0o\u00a0inhibidor\u00a0de\u00a0los\u00a0iso\u2010\nenzimas\u00a0del\u00a0citocromo \u00a0P450\u00a0por\u00a0lo\u00a0que\u00a0su\u00a0potencial \u00a0de\u00a0interacciones \u00a0farmacol\u00f3gicas \u00a0es\u00a0\nbajo\u00a0(v\u00e9ase\u00a0cap\u00edtulo\u00a0interacciones) \u00a0\n\u00a0\nEstudio\u00a0TRIO\u00a0\nEstudio\u00a0abierto\u00a0no\u00a0comparativo \u00a0que\u00a0tiene\u00a0como\u00a0objetivo\u00a0evaluar\u00a0la\u00a0eficacia\u00a0y\u00a0seguridad \u00a0\nde\u00a0un\u00a0tratamiento \u00a0antirretroviral \u00a0de\u00a0rescate\u00a0que\u00a0conten\u00eda\u00a0RAL\u00a0+\u00a0DRV/r\u00a0+\u00a0ETR.\u00a0Los\u00a0crite\u2010\nrios\u00a0de\u00a0inclusi\u00f3n\u00a0fueron\u00a0los\u00a0siguientes: \u00a0edad\u00a0\u226518\u00a0a\u00f1os,\u00a0CVP\u00a0>1000\u00a0copias/mL, \u00a0sin\u00a0tra\u2010\ntamiento\u00a0previo\u00a0con\u00a0f\u00e1rmacos \u00a0en\u00a0investigaci\u00f3n \u00a0y\u00a0con\u00a0historia\u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0a\u00a0\nNN.\u00a0Los\u00a0pacientes \u00a0deb\u00edan\u00a0ser\u00a0portadores \u00a0de\u00a0infecci\u00f3n\u00a0VIH\u00a0multirresistente \u00a0con\u00a0el\u00a0si\u2010\nguiente\u00a0patr\u00f3n\u00a0de\u00a0resistencias \u00a0genot\u00edpicas: \u00a0\u22653\u00a0mutaciones \u00a0primarias \u00a0de\u00a0resistencia \u00a0a\u00a0IP\u00a0\n(D30N,\u00a0V32I,\u00a0L33F,\u00a0M46I/L,\u00a0I47A/V,\u00a0G48V,\u00a0I50L/V,\u00a0I54M,\u00a0L76V,\u00a0V82A/F/L/T/S, \u00a0I84V,\u00a0\nN88S\u00a0y\u00a0\u00a0L90M);\u00a0\u22653\u00a0mutaciones \u00a0a\u00a0AN;\u00a0\u22643\u00a0mutaciones \u00a0a\u00a0DRV\u00a0(V11I,\u00a0V32I,\u00a0L33F,\u00a0I47V,\u00a0\nI50V,\u00a0I54L/M,\u00a0G73S,L76V, \u00a0I84V\u00a0y\u00a0L89V);\u00a0y\u00a0\u22643\u00a0mutaciones \u00a0a\u00a0NN\u00a0(A98G,\u00a0L100I,\u00a0\nK101Q/P/E, \u00a0K103H/N/S/T, \u00a0V106A/M, \u00a0V108I,\u00a0E138G/K/Q, \u00a0V179D/E/F/G/I, \u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 59 \n Y181C/I/V/C/H/L, \u00a0Y188C/H/L, \u00a0G190A/C/E/Q/S, \u00a0P225H,\u00a0F227C/L,\u00a0M230I/L,\u00a0P236L,\u00a0\nK238N/T\u00a0y\u00a0Y318F).\u00a0103\u00a0pacientes \u00a0cumplieron \u00a0los\u00a0criterios\u00a0de\u00a0inclusi\u00f3n\u00a0y\u00a0recibieron \u00a0el\u00a0\ntratamiento. \u00a0Los\u00a0resultados \u00a0del\u00a0estudio\u00a0son\u00a0los\u00a0siguientes: \u00a0en\u00a0la\u00a0semana\u00a024,\u00a093\u00a0pacien\u2010\ntes\u00a0(90%;\u00a0IC95%:\u00a085\u201096%)\u00a0y\u00a0en\u00a0la\u00a0semana\u00a048,\u00a089\u00a0pacientes \u00a0(86%,\u00a0IC95%:\u00a080\u201093%)\u00a0logra\u2010\nron\u00a0una\u00a0CVP\u00a0<50\u00a0copias/mL. \u00a0La\u00a0mediana\u00a0de\u00a0descenso \u00a0de\u00a0la\u00a0CVP\u00a0en\u00a0la\u00a0semana\u00a048\u00a0res\u2010\npecto\u00a0al\u00a0valor\u00a0basal\u00a0fue\u00a0de\u00a0\u22122.4\u00a0log\u00a0(IQR:\u20102.9\u00a0a\u00a0\u20101.9).\u00a0La\u00a0mediana\u00a0de\u00a0ascenso\u00a0de\u00a0los\u00a0lin\u2010\nfocitos\u00a0CD4\u00a0respecto\u00a0al\u00a0valor\u00a0basal\u00a0fue\u00a0de\u00a0108/\u00b5L\u00a0(IQR:\u00a058\u2010169).\u00a0Durante\u00a0el\u00a0periodo\u00a0del\u00a0\nestudio,\u00a0s\u00f3lo\u00a0un\u00a0paciente\u00a0tuvo\u00a0que\u00a0suspender \u00a0el\u00a0tratamiento \u00a0por\u00a0toxicidad373.\u00a0\n\u00a0Mutaciones \u00a0de\u00a0resistencia \u00a0a\u00a0RAL\u00a0\nEn\u00a0estudios\u00a0in\u00a0vitro\u00a0se\u00a0han\u00a0identificado \u00a0hasta\u00a041\u00a0mutaciones \u00a0del\u00a0gen\u00a0de\u00a0la\u00a0integrasa \u00a0\nasociadas \u00a0a\u00a0resistencia. \u00a0Un\u00a0total\u00a0de\u00a0105\u00a0pacientes \u00a0de\u00a0462\u00a0que\u00a0recibieron \u00a0RAL\u00a0en\u00a0los\u00a0\nestudios\u00a0BENCHMRK \u00a0desarrollaron \u00a0fracaso\u00a0virol\u00f3gico \u00a0en\u00a0la\u00a0semana\u00a048,\u00a0aunque\u00a0s\u00f3lo\u00a0en\u00a0\n94\u00a0se\u00a0pudo\n\u00a0realizar\u00a0estudio\u00a0de\u00a0resistencias. \u00a0En\u00a064/94\u00a0(68%)\u00a0se\u00a0detectaron \u00a0mutaciones \u00a0\nde\u00a0resistencia \u00a0a\u00a0RAL\u00a0con\u00a03\u00a0patrones\u00a0de\u00a0resistencia: \u00a0(1)\u00a0N155H\u00a0+\u00a0L74M,\u00a0E92Q,\u00a0T97A,\u00a0\nV151I,\u00a0G163R;\u00a0(2)\u00a0Q148K/R/H \u00a0+\u00a0G140S/A, \u00a0E138K\u00a0y\u00a0(3)\u00a0Y143R/C\u00a0+\u00a0L74A/I,\u00a0T97A,\u00a0I203M,\u00a0\nS230R.\u00a0RAL\u00a0es\u00a0un\u00a0f\u00e1rmaco\u00a0de\u00a0barrera\u00a0gen\u00e9tica\u00a0baja\u00a0o\u00a0intermedia, \u00a0siendo\u00a0necesarias \u00a02\u00a0\nmutaciones \u00a0para\u00a0la\u00a0resistencia \u00a0completa. \u00a0\n\u00a0\nOpciones \u00a0de\u00a0tratamiento \u00a0en\u00a0pacientes \u00a0con\u00a0m\u00faltiples \u00a0fracasos\u00a0virol\u00f3gicos \u00a0y\u00a0sin\u00a0opcio\u2010\nnes\u00a0terap\u00e9uticas \u00a0\nEn\u00a0general,\u00a0el\u00a0fracaso\u00a0virol\u00f3gico \u00a0en\u00a0el\u00a0paciente\u00a0multitratado \u00a0rara\u00a0vez\u00a0conduce\u00a0de\u00a0forma\u00a0\nr\u00e1pida\u00a0al\u00a0fracaso\u00a0inmunol\u00f3gico \u00a0y\u00a0progresi\u00f3n \u00a0cl\u00ednica24,\u00a0374,\u00a0375.\u00a0De\u00a0hecho,\u00a0muchos\u00a0pacien\u2010\ntes\u00a0contin\u00faan \u00a0con\u00a0recuentos \u00a0de\u00a0CD4\u00a0estables\u00a0y\u00a0aproximadamente \u00a0s\u00f3lo\u00a0un\u00a0tercio\u00a0expe\u2010\nrimenta\u00a0un\u00a0descenso376.\u00a0Este\u00a0\u00faltimo\u00a0hecho\u00a0se\u00a0observa\u00a0cuando\u00a0la\u00a0CVP\u00a0es\u00a0elevada,\u00a0habi\u2010\ntualmente \u00a0>10000\u201020000\u00a0copias/mL. \u00a0\u00a0\nEn\u00a0un\u00a0paciente\u00a0en\u00a0el\u00a0que\u00a0resulte\u00a0imposible \u00a0construir\u00a0un\u00a0TARV\u00a0potencialmente \u00a0eficaz\u00a0\ncon\u00a0al\u00a0menos\u00a0dos\u00a0f\u00e1rmacos \u00a0activos\u00a0por\u00a0problemas \u00a0de\u00a0resistencia, \u00a0toxicidad, \u00a0comorbili \u2010\ndad\u00a0grave,\u00a0no\u00a0adherencia \u00a0o\u00a0tolerancia, \u00a0pueden\u00a0plantearse \u00a0otras\u00a0opciones\u00a0diferentes \u00a0al\u00a0\ntratamiento \u00a0de\u00a0rescate\u00a0si\u00a0la\u00a0situaci\u00f3n\u00a0inmunitaria \u00a0del\u00a0paciente\u00a0lo\u00a0permite.\u00a0\u00a0\n\u00a0\nSuspensi\u00f3n \u00a0del\u00a0TARV\u00a0\u00a0\nLa\u00a0interrupci\u00f3n \u00a0del\u00a0tratamiento \u00a0en\u00a0pacientes \u00a0multirresistentes \u00a0se\u00a0plante\u00f3\u00a0ante\u00a0la\u00a0hip\u00f3\u2010\ntesis\u00a0de\u00a0que\u00a0la\u00a0reaparici\u00f3n \u00a0de\u00a0la\u00a0cepa\u00a0silvestre\u00a0permitir\u00eda \u00a0una\u00a0mejor\u00a0respuesta \u00a0tras\u00a0la\u00a0\nreintroducci\u00f3n \u00a0del\u00a0tratamiento. \u00a0Los\u00a0ensayos\u00a0cl\u00ednicos\u00a0realizados \u00a0para\u00a0evaluar\u00a0esta\u00a0estra\u2010\ntegia\u00a0han\u00a0evidenciado \u00a0un\u00a0descenso \u00a0importante \u00a0del\u00a0n\u00famero\u00a0de\u00a0CD4\u00a0durante\u00a0la\u00a0inte\u2010\nrrupci\u00f3n\u00a0frente\u00a0a\u00a0los\u00a0que\u00a0contin\u00faan \u00a0con\u00a0TARV377,\u00a0378.\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 60 \n Tratamientos \u00a0con\u00a0pautas\u00a0de\u00a0TARV\u00a0\u00a0no\u00a0supresoras \u00a0\nDiversos\u00a0estudios\u00a0han\u00a0demostrado \u00a0los\u00a0efectos\u00a0beneficiosos \u00a0de\u00a0mantener \u00a0un\u00a0tratamien \u2010\nto\u00a0no\u00a0supresor\u00a0en\u00a0caso\u00a0de\u00a0infecci\u00f3n\u00a0avanzada \u00a0multirresistente379.\u00a0En\u00a0una\u00a0publicaci\u00f3n \u00a0\nreciente\u00a0se\u00a0comunic\u00f3 \u00a0que\u00a0en\u00a0pacientes \u00a0con\u00a0un\u00a0recuento\u00a0de\u00a0linfocitos\u00a0CD4\u00a0<50/\u00b5L,\u00a0el\u00a0\nriesgo\u00a0de\u00a0desarrollar \u00a0una\u00a0enfermedad \u00a0oportunista \u00a0tipo\u00a0sida\u00a0era\u00a0un\u00a022%\u00a0inferior\u00a0si\u00a0el\u00a0\npaciente\u00a0continuaba \u00a0con\u00a0el\u00a0TARV\u00a0a\u00a0pesar\u00a0de\u00a0presentar \u00a0fracaso\u00a0virol\u00f3gico \u00a0respecto\u00a0a\u00a0los\u00a0\nque\u00a0lo\u00a0suspendieron380.\u00a0\u00a0\nEl\u00a0tratamiento \u00a0de\u00a0un\u00a0paciente\u00a0con\u00a0escasas\u00a0opciones\u00a0terap\u00e9uticas \u00a0puede\u00a0ser\u00a0un\u00a0trata\u2010\nmiento\u00a0no\u00a0supresor. \u00a0Deben\u00a0ser\u00a0tratamientos \u00a0c\u00f3modos, \u00a0poco\u00a0t\u00f3xicos\u00a0y\u00a0que\u00a0disminuyan \u00a0\nla\u00a0capacidad \u00a0replicativa \u00a0viral.\u00a0No\u00a0se\u00a0recomienda \u00a0continuar \u00a0con\u00a0pautas\u00a0no\u00a0supresoras \u00a0\nque\u00a0contengan \u00a0IP,\u00a0NN\u00a0\u00f3\u00a0IInt,\u00a0ya\u00a0que\u00a0la\u00a0acumulaci\u00f3n \u00a0de\u00a0resistencias \u00a0frente\u00a0a\u00a0estos\u00a0\nf\u00e1rmacos \u00a0dificultar\u00eda \u00a0la\u00a0eficacia\u00a0de\u00a0futuros\u00a0f\u00e1rmacos \u00a0de\u00a0estas\u00a0familias.\u00a0Pautas\u00a0con\u00a02\u00a0\u00f3\u00a03\u00a0\nAN,\u00a0que\u00a0incluyan\u00a03TC\u00a0o\u00a0FTC,\u00a0podr\u00edan\u00a0resultar\u00a0parcialmente \u00a0eficaces\u00a0en\u00a0algunos\u00a0pacien\u2010\ntes,\u00a0aunque\u00a0obligar\u00eda\u00a0a\u00a0una\u00a0monitorizaci\u00f3n \u00a0frecuente \u00a0del\u00a0recuento\u00a0de\u00a0linfocitos\u00a0CD4381.\u00a0\nLa\u00a0mutaci\u00f3n \u00a0M184V\u00a0compromete \u00a0la\u00a0capacidad \u00a0replicativa \u00a0del\u00a0VIH.\u00a0Un\u00a0ensayo\u00a0que\u00a0in\u2010\nclu\u00eda\u00a0pacientes \u00a0multirresistentes \u00a0con\u00a0esta\u00a0mutaci\u00f3n, \u00a0aleatorizados \u00a0a\u00a0continuar \u00a0s\u00f3lo\u00a0con\u00a0\n3TC\u00a0o\u00a0a\u00a0suspender \u00a0el\u00a0tratamiento, \u00a0mostr\u00f3\u00a0en\u00a0la\u00a0semana\u00a048,\u00a0que\u00a069%\u00a0(IC95%:\u00a051\u201083%)\u00a0\ndel\u00a0grupo\u00a0que\u00a0interrumpi\u00f3 \u00a0frente\u00a0a\u00a041%\u00a0(IC95%:\u00a026\u201059%)\u00a0de\u00a0los\u00a0que\u00a0continuaron \u00a0con\u00a0\n3TC,\u00a0presentaron \u00a0un\u00a0evento\u00a0cl\u00ednico\u00a0o\u00a0fracaso\u00a0inmunol\u00f3gico. \u00a0En\u00a0los\u00a0que\u00a0recib\u00edan\u00a03TC\u00a0el\u00a0\nfracaso\u00a0fue\u00a0m\u00e1s\u00a0tard\u00edo\u00a0(p=0,01)\u00a0y\u00a0el\u00a0descenso \u00a0de\u00a0CD4,\u00a0rebrote\u00a0de\u00a0CVP\u00a0y\u00a0aumento\u00a0de\u00a0\ncapacidad \u00a0replicativa \u00a0fueron\u00a0menores382.\u00a0En\u00a0funci\u00f3n\u00a0de\u00a0estos\u00a0estudios,\u00a0se\u00a0propone\u00a0que\u00a0\nel\u00a0tratamiento \u00a0de\u00a0pacientes \u00a0con\u00a0m\u00faltiples \u00a0fracasos\u00a0contenga \u00a03TC\u00a0\u00f3\u00a0FTC\u00a0para\u00a0mantener \u00a0\nen\u00a0la\u00a0poblaci\u00f3n \u00a0viral\u00a0la\u00a0mutaci\u00f3n \u00a0M184V\u00a0y\u00a0reducir\u00a0su\u00a0capacidad \u00a0replicativa383.\u00a0\n\u00a0\nReplicaci\u00f3n \u00a0viral\u00a0baja\u00a0en\u00a0pacientes \u00a0multitratados \u00a0\u00a0\nCon\u00a0las\u00a0recomendaciones \u00a0actuales\u00a0sobre\u00a0tratamiento \u00a0antirretroviral, \u00a0dos\u00a0determina \u2010\nciones\u00a0sucesivas \u00a0de\u00a0CVP\u00a0>50\u00a0copias/mL \u00a0tras\u00a06\u00a0meses\u00a0de\u00a0iniciado\u00a0el\u00a0TARV\u00a0o\u00a0tras\u00a0haber\u00a0\u00a0\nconseguido \u00a0previamente \u00a0una\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0se\u00a0considera \u00a0fracaso\u00a0virol\u00f3gico. \u00a0En\u00a0los\u00a0\nensayos\u00a0cl\u00ednicos\u00a0realizados \u00a0en\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0como\u00a0en\u00a0los\u00a0realizados \u00a0\nen\u00a0pacientes \u00a0con\u00a0fracasos\u00a0virol\u00f3gicos, \u00a0un\u00a0n\u00famero\u00a0no\u00a0desde\u00f1able \u00a0de\u00a0pacientes \u00a0consi\u2010\nguen\u00a0un\u00a0descenso \u00a0significativo \u00a0importante \u00a0de\u00a0la\u00a0CVP\u00a0(<400\u00a0copias/mL) \u00a0pero\u00a0no\u00a0alcan\u2010\nzan\u00a0la\u00a0m\u00e1xima\u00a0supresi\u00f3n \u00a0viral.\u00a0Esta\u00a0proporci\u00f3n \u00a0se\u00a0incrementa \u00a0en\u00a0pacientes \u00a0con\u00a0fraca\u2010\nsos\u00a0previos\u00a0y\u00a0acumulaci\u00f3n \u00a0de\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0frente\u00a0a\u00a0diferentes \u00a0FAR.\u00a0Con\u00a0\nfrecuencia, \u00a0los\u00a0pacientes \u00a0con\u00a0replicaci\u00f3n \u00a0viral\u00a0baja\u00a0(RVB)\u00a0y\u00a0persistente \u00a0del\u00a0VIH\u00a0y\u00a0que\u00a0\npodemos \u00a0definir\u00a0como\u00a0una\u00a0CVP\u00a0entre\u00a050\u2010500/1000 \u00a0copias/mL, \u00a0mantienen \u00a0o\u00a0incluso\u00a0\naumentan \u00a0el\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0CD4.\u00a0La\u00a0ausencia\u00a0de\u00a0alternativas \u00a0terap\u00e9uticas, \u00a0la\u00a0\nconservaci\u00f3n \u00a0de\u00a0la\u00a0inmunidad \u00a0y\u00a0la\u00a0dificultad \u00a0de\u00a0realizar\u00a0pruebas\u00a0de\u00a0resistencia \u00a0genot\u00ed\u2010\npicas\u00a0o\u00a0determinaci\u00f3n \u00a0del\u00a0tropismo\u00a0viral\u00a0por\u00a0la\u00a0baja\u00a0viremia\u00a0plasm\u00e1tica \u00a0aconsejan \u00a0man\u2010\ntener\u00a0al\u00a0paciente\u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0mientras\u00a0la\u00a0CVP\u00a0no\u00a0se\u00a0eleve\u00a0de\u00a0determina \u2010\ndo\u00a0valor.\u00a0En\u00a0este\u00a0escenario \u00a0se\u00a0han\u00a0propuesto \u00a0diferentes \u00a0estrategias \u00a0terap\u00e9uticas, \u00a0aun\u2010\nque\u00a0ninguna\u00a0de\u00a0ellas\u00a0ha\u00a0sido\u00a0evaluada\u00a0en\u00a0estudios\u00a0prospectivos \u00a0longitudinales \u00a0y\u00a0com\u2010\nparativos. \u00a0Algunos\u00a0autores\u00a0han\u00a0demostrado \u00a0que\u00a0la\u00a0intensificaci\u00f3n \u00a0de\u00a0la\u00a0terapia\u00a0podr\u00eda\u00a0\nconseguir \u00a0de\u00a0nuevo\u00a0valores\u00a0de\u00a0CVP\u00a0<50\u00a0copias/mL384\u00a0aunque\u00a0la\u00a0intensificaci\u00f3n \u00a0podr\u00eda\u00a0\nconstituir \u00a0un\u00a0tratamiento \u00a0sub\u00f3ptimo \u00a0especialmente \u00a0si\u00a0se\u00a0utilizan\u00a0f\u00e1rmacos\u00a0con\u00a0barrera\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 61 \n gen\u00e9tica\u00a0baja.\u00a0Otra\u00a0posibilidad \u00a0consistir\u00eda \u00a0en\u00a0realizar\u00a0una\u00a0pruebas\u00a0m\u00e1s\u00a0sensibles\u00a0de\u00a0\nresistencias \u00a0genot\u00edpicas \u00a0que\u00a0permiten \u00a0detectar\u00a0mutaciones \u00a0a\u00a0pesar\u00a0de\u00a0la\u00a0CVP\u00a0baja385,\u00a0\n386.\u00a0No\u00a0se\u00a0sabe\u00a0cu\u00e1l\u00a0es\u00a0la\u00a0mejor\u00a0actitud\u00a0en\u00a0pacientes \u00a0con\u00a0RVB,\u00a0aunque\u00a0se\u00a0conoce\u00a0que\u00a0\nlos\u00a0\u00a0pacientes \u00a0con\u00a0RVB\u00a0pueden\u00a0seleccionar \u00a0nuevas\u00a0mutaciones \u00a0de\u00a0resistencia, \u00a0fraca\u2010\nsos385,\u00a0386\u00a0y\u00a0contribuir \u00a0a\u00a0la\u00a0diseminaci\u00f3n \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0a\u00a0otras\u00a0personas387.\u00a0La\u00a0toleran\u2010\ncia\u00a0al\u00a0tratamiento, \u00a0la\u00a0opini\u00f3n\u00a0del\u00a0paciente, \u00a0la\u00a0posibilidad \u00a0de\u00a0realizar\u00a0pruebas\u00a0de\u00a0resis\u2010\ntencia\u00a0o\u00a0tropismo\u00a0viral\u00a0y\u00a0sobretodo \u00a0la\u00a0posibilidad \u00a0de\u00a0cambiar\u00a0el\u00a0TARV\u00a0incluyendo \u00a0al\u00a0\nmenos\u00a0dos\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0plenamente \u00a0activos\u00a0condicionan \u00a0la\u00a0actitud\u00a0del\u00a0\ncl\u00ednico\u00a0en\u00a0este\u00a0escenario \u00a0cl\u00ednico.\u00a0\u00a0\n\u00a0\nCambio\u00a0de\u00a0TARV\u00a0por\u00a0fracaso\u00a0virol\u00f3gico. \u00a0Recomendaciones \u00a0\n\u0083 Se\u00a0debe\u00a0conseguir \u00a0CVP\u00a0indetectable \u00a0(<50\u00a0copias/mL) \u00a0en\u00a0TARV\u00a0en\u00a0segunda\u00a0l\u00ednea\u00a0o\u00a0\nposterior\u00a0(nivel\u00a0A).\u00a0\n\u0083 El\u00a0TARV\u00a0nuevo\u00a0debe\u00a0contener\u00a03\u00a0f\u00e1rmacos\u00a0antirretrovirales \u00a0totalmente \u00a0activos\u00a0(ni\u2010\nvel\u00a0A).\u00a0\n\u0083 Se\u00a0debe\u00a0realizar\u00a0un\u00a0estudio\u00a0de\u00a0resistencias \u00a0y\u00a0una\u00a0prueba\u00a0de\u00a0tropismo\u00a0para\u00a0confec\u2010\ncionar\u00a0el\u00a0mejor\u00a0r\u00e9gimen\u00a0alternativo \u00a0(nivel\u00a0B).\u00a0La\u00a0prueba\u00a0de\u00a0resistencias \u00a0debe\u00a0reali\u2010\nzarse\u00a0mientras\u00a0el\u00a0paciente\u00a0est\u00e1\u00a0recibiendo \u00a0el\u00a0tratamiento \u00a0fallido\u00a0o\u00a0lo\u00a0m\u00e1s\u00a0precoz\u00a0\ntras\u00a0la\u00a0suspensi\u00f3n. \u00a0\u00a0\n\u0083 Si\u00a0es\u00a0imposible \u00a0dise\u00f1ar\u00a0un\u00a0TARV\u00a0de\u00a0rescate\u00a0con\u00a0tres\u00a0f\u00e1rmacos\u00a0activos,\u00a0la\u00a0combina\u2010\nci\u00f3n\u00a0de\u00a0dos\u00a0plenamente \u00a0activos\u00a0y\u00a0otros\u00a0que\u00a0conserven \u00a0cierta\u00a0actividad\u00a0puede\u00a0resul\u2010\ntar\u00a0eficaz\u00a0en\u00a0una\u00a0elevada\u00a0proporci\u00f3n \u00a0de\u00a0pacientes. \u00a0\n\u0083 El\u00a0cambio\u00a0del\u00a0TARV\u00a0por\u00a0fracaso\u00a0virol\u00f3gico \u00a0debe\u00a0efectuarse \u00a0de\u00a0modo\u00a0precoz\u00a0para\u00a0\nevitar\u00a0el\u00a0ac\u00famulo\u00a0de\u00a0mutaciones \u00a0y\u00a0facilitar\u00a0la\u00a0respuesta \u00a0al\u00a0nuevo\u00a0tratamiento \u00a0(nivel\u00a0\nC).\u00a0\u00a0\n\u0083 En\u00a0la\u00a0elecci\u00f3n\u00a0del\u00a0nuevo\u00a0TARV\u00a0se\u00a0deben\u00a0analizar\u00a0las\u00a0causas\u00a0que\u00a0motivaron \u00a0el\u00a0fraca\u2010\nso\u00a0(adherencia \u00a0o\u00a0interacciones \u00a0medicamentosas), \u00a0la\u00a0historia\u00a0farmacol\u00f3gica, \u00a0las\u00a0\ntoxicidades \u00a0que\u00a0haya\u00a0presentado \u00a0y\u00a0las\u00a0mutaciones \u00a0de\u00a0resistencia \u00a0previas\u00a0(nivel\u00a0C).\u00a0\n\u0083 El\u00a0nuevo\u00a0TARV\u00a0debe\u00a0ser\u00a0c\u00f3modo,\u00a0bien\u00a0tolerado\u00a0por\u00a0el\u00a0paciente\u00a0y\u00a0lo\u00a0menos\u00a0t\u00f3xico\u00a0\nposible.\u00a0Debe\u00a0insistirse\u00a0en\u00a0la\u00a0adherencia \u00a0antes\u00a0de\u00a0iniciar\u00a0un\u00a0rescate\u00a0(nivel\u00a0C).\u00a0\n\u0083 Debe\u00a0evitarse\u00a0los\u00a0an\u00e1logos\u00a0de\u00a0timidina,\u00a0especialmente \u00a0d4T,\u00a0si\u00a0existen\u00a0otras\u00a0alterna\u2010\ntivas\u00a0en\u00a0cualquiera \u00a0de\u00a0las\u00a0l\u00edneas\u00a0del\u00a0tratamiento \u00a0de\u00a0rescate\u00a0(nivel\u00a0C).\u00a0\n\u0083 No\u00a0se\u00a0deben\u00a0realizar\u00a0interrupciones \u00a0estructuradas \u00a0del\u00a0tratamiento \u00a0antirretroviral \u00a0\nen\u00a0situaciones \u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0con\u00a0el\u00a0objetivo\u00a0de\u00a0aumentar \u00a0la\u00a0eficacia\u00a0del\u00a0tra\u2010\ntamiento\u00a0de\u00a0rescate\u00a0\u00a0(nivel\u00a0A).\u00a0\n\u0083 No\u00a0se\u00a0recomienda \u00a0suspender \u00a0el\u00a0TARV\u00a0en\u00a0pacientes \u00a0en\u00a0situaci\u00f3n\u00a0de\u00a0fracaso\u00a0virol\u00f3gi\u2010\nco\u00a0y\u00a0sin\u00a0opciones\u00a0terap\u00e9uticas \u00a0de\u00a0rescate\u00a0(nivel\u00a0B).\u00a0En\u00a0esta\u00a0situaci\u00f3n\u00a0debe\u00a0buscarse\u00a0\nun\u00a0tratamiento \u00a0basado\u00a0en\u00a0f\u00e1rmacos\u00a0que\u00a0disminuyan \u00a0la\u00a0capacidad \u00a0replicativa \u00a0viral\u00a0\n(p.e.\u00a03TC\u00a0o\u00a0FTC\u00a0o\u00a0TDF)\u00a0y\u00a0debe\u00a0vigilarse\u00a0estrechamente \u00a0su\u00a0eficacia\u00a0mediante \u00a0deter\u2010\nminaciones \u00a0peri\u00f3dicas \u00a0del\u00a0recuento\u00a0de\u00a0linfocitos\u00a0CD4\u00a0y\u00a0CVP\u00a0(nivel\u00a0C).\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 62 \n \u0083 Es\u00a0recomendable, \u00a0en\u00a0determinas \u00a0circunstancias, \u00a0consultar \u00a0con\u00a0un\u00a0cl\u00ednico\u00a0con\u00a0expe\u2010\nriencia\u00a0en\u00a0TARV\u00a0de\u00a0rescate\u00a0o\u00a0remitir\u00a0al\u00a0paciente\u00a0a\u00a0otro\u00a0centro\u00a0hospitalario \u00a0que\u00a0dis\u2010\nponga\u00a0de\u00a0experiencia \u00a0y\u00a0f\u00e1rmacos\u00a0suficientes \u00a0para\u00a0conseguir \u00a0un\u00a0TARV\u00a0con\u00a0las\u00a0m\u00e1xi\u2010\nmas\u00a0posibilidades \u00a0de\u00a0\u00e9xito\u00a0(nivel\u00a0C).\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n5.2.\u00a0SIMPLIFICACION \u00a0DEL\u00a0TARV\u00a0\nSe\u00a0entiende\u00a0por\u00a0simplificaci\u00f3n \u00a0del\u00a0TARV\u00a0el\u00a0cambio\u00a0de\u00a0un\u00a0esquema\u00a0terap\u00e9utico \u00a0que\u00a0ha\u00a0\nconseguido \u00a0la\u00a0supresi\u00f3n \u00a0de\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0por\u00a0otro\u00a0m\u00e1s\u00a0sencillo\u00a0que\u00a0sigue\u00a0mante\u2010\nniendo\u00a0dicha\u00a0supresi\u00f3n. \u00a0Sus\u00a0objetivos\u00a0son\u00a0mejorar\u00a0la\u00a0calidad\u00a0de\u00a0vida,\u00a0facilitar\u00a0la\u00a0ad\u2010\nherencia\u00a0y\u00a0prevenir\u00a0o\u00a0revertir\u00a0algunos\u00a0efectos\u00a0adversos. \u00a0\u00a0\nCon\u00a0la\u00a0simplificaci\u00f3n \u00a0se\u00a0consigue\u00a0reducir\u00a0el\u00a0n\u00famero\u00a0de\u00a0comprimidos \u00a0o\u00a0la\u00a0frecuencia \u00a0de\u00a0\ntomas,\u00a0aprovechar \u00a0la\u00a0comodidad \u00a0de\u00a0las\u00a0coformulaciones, \u00a0eliminar\u00a0las\u00a0restricciones \u00a0ali\u2010\nmentarias, \u00a0mejorar\u00a0los\u00a0efectos\u00a0secundarios \u00a0y\u00a0reducir\u00a0o\u00a0eliminar\u00a0las\u00a0interacciones. \u00a0\u00a0\nEsta\u00a0estrategia \u00a0empez\u00f3\u00a0a\u00a0utilizarse\u00a0con\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0los\u00a0NN.\u00a0La\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0estu\u2010\ndios\u00a0de\u00a0simplificaci\u00f3n \u00a0iniciales\u00a0se\u00a0efectu\u00f3\u00a0a\u00a0partir\u00a0de\u00a0pautas\u00a0con\u00a0IP\u00a0no\u00a0potenciados. \u00a0La\u00a0\npotenciaci\u00f3n \u00a0con\u00a0RTV\u00a0de\u00a0los\u00a0IP\u00a0fue\u00a0el\u00a0primer\u00a0paso\u00a0para\u00a0elaborar\u00a0reg\u00edmenes \u00a0terap\u00e9uti \u2010\ncos\u00a0que\u00a0no\u00a0presentan \u00a0los\u00a0problemas \u00a0de\u00a0complejidad \u00a0y\u00a0tolerancia \u00a0de\u00a0los\u00a0IP\u00a0iniciales.\u00a0Los\u00a0\nIP\u00a0de\u00a0segunda\u00a0generaci\u00f3n \u00a0y\u00a0las\u00a0nuevas\u00a0formulaciones \u00a0de\u00a0los\u00a0antiguos,\u00a0as\u00ed\u00a0como\u00a0las\u00a0co\u2010\nformulaciones \u00a0y\u00a0los\u00a0f\u00e1rmacos \u00a0de\u00a0nuevas\u00a0clases\u00a0han\u00a0contribuido \u00a0tambi\u00e9n\u00a0a\u00a0construir\u00a0\ntratamientos \u00a0sencillos.\u00a0\u00a0\nEn\u00a0la\u00a0actualidad \u00a0la\u00a0mayor\u00eda\u00a0de\u00a0pacientes \u00a0inician\u00a0tratamiento \u00a0con\u00a0combinaciones \u00a0senci\u2010\nllas\u00a0y\u00a0con\u00a0posterioridad, \u00a0cuando\u00a0\u00e9stas\u00a0fracasan,\u00a0pasan\u00a0a\u00a0tratamientos \u00a0m\u00e1s\u00a0complejos. \u00a0\nLa\u00a0simplificaci\u00f3n \u00a0ha\u00a0sido\u00a0una\u00a0estrategia \u00a0muy\u00a0utilizada\u00a0durante\u00a0un\u00a0periodo\u00a0largo\u00a0de\u00a0\ntiempo,\u00a0pero\u00a0en\u00a0la\u00a0actualidad \u00a0las\u00a0pautas\u00a0con\u00a0tratamientos \u00a0sencillos\u00a0desde\u00a0el\u00a0principio, \u00a0\nson\u00a0la\u00a0pr\u00e1ctica\u00a0habitual,\u00a0quedando \u00a0pocos\u00a0para\u00a0simplificar. \u00a0\nSe\u00a0puede\u00a0simplificar \u00a0el\u00a0TARV\u00a0reduciendo \u00a0el\u00a0n\u00famero\u00a0de\u00a0f\u00e1rmacos, \u00a0el\u00a0n\u00famero\u00a0de\u00a0com\u2010\nprimidos\u00a0o\u00a0el\u00a0n\u00famero\u00a0de\u00a0tomas.\u00a0\u00a0\n\u00a0Reducci\u00f3n \u00a0del\u00a0n\u00famero\u00a0de\u00a0f\u00e1rmacos \u00a0\nLos\u00a0primeros\u00a0estudios\u00a0de\n\u00a0simplificaci\u00f3n \u00a0del\u00a0TARV\u00a0tuvieron\u00a0como\u00a0objetivo\u00a0la\u00a0reducci\u00f3n \u00a0\ndel\u00a0n\u00famero\u00a0de\u00a0f\u00e1rmacos \u00a0en\u00a0lo\u00a0que\u00a0se\u00a0denomin\u00f3 \u00a0estrategia \u00a0de\u00a0inducci\u00f3n \u2010\nmantenimiento \u00a0consistente \u00a0en\u00a0una\u00a0primera\u00a0fase\u00a0de\u00a0inducci\u00f3n \u00a0con\u00a0tres\u00a0o\u00a0cuatro\u00a0antirre\u2010\ntrovirales \u00a0seguida\u00a0del\u00a0mantenimiento \u00a0con\u00a0menos\u00a0de\u00a0tres\u00a0f\u00e1rmacos. \u00a0\u00a0\nEsta\u00a0estrategia \u00a0se\u00a0cuestion\u00f3 \u00a0por\u00a0el\u00a0fracaso\u00a0de\u00a0algunos\u00a0ensayos\u00a0iniciales.\u00a0Alg\u00fan\u00a0estudio\u00a0\nposterior\u00a0no\u00a0encontr\u00f3\u00a0diferencias \u00a0en\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0<50\u00a0copias/mL \u00a0\n(79%\u00a0frente\u00a077%)\u00a0a\u00a0las\u00a048\u00a0semanas\u00a0entre\u00a0la\u00a0rama\u00a0de\u00a0simplificaci\u00f3n \u00a0y\u00a0la\u00a0de\u00a0manteni\u2010\nmiento\u00a0del\u00a0TARV\u00a0inicial,\u00a0las\u00a0reacciones \u00a0adversas\u00a0fueron\u00a0menos\u00a0frecuentes \u00a0en\u00a0el\u00a0grupo\u00a0\nde\u00a0simplificaci\u00f3n \u00a0(15%,\u00a0frente\u00a0a\u00a06%)\u00a0y\u00a0mejor\u00f3\u00a0el\u00a0perfil\u00a0lip\u00eddico\u00a0y\u00a0la\u00a0adherencia216.\u00a0\nSe\u00a0ha\u00a0explorado \u00a0la\u00a0estrategia \u00a0de\u00a0simplificar \u00a0a\u00a0monoterapia \u00a0con\u00a0LPV/r,\u00a0tras\u00a0un\u00a0tiempo\u00a0\nde\u00a0inducci\u00f3n \u00a0con\u00a0triple\u00a0terapia\u00a0que\u00a0incluye\u00a0a\u00a0este\u00a0f\u00e1rmaco.\u00a0En\u00a0un\u00a0estudio\u00a0piloto\u00a0espa\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 63 \n \u00f1ol\u00a0comparativo, \u00a0aleatorizado \u00a0y\u00a0abierto\u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluyeron \u00a042\u00a0pacientes, \u00a021\u00a0se\u00a0\nsimplificaron \u00a0a\u00a0monoterapia \u00a0con\u00a0LPV/r388.\u00a0A\u00a0las\u00a072\u00a0semanas\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0CVP\u00a0inde\u2010\ntectable\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0monoterapia \u00a0era\u00a0la\u00a0misma\u00a0(81%)\u00a0y\u00a0hab\u00eda\u00a0descendido \u00a0a\u00a090,5%\u00a0\nen\u00a0el\u00a0grupo\u00a0de\u00a0terapia\u00a0triple\u00a0(p=0,38)389.\u00a0En\u00a0los\u00a0pacientes \u00a0que\u00a0fracasaron \u00a0no\u00a0se\u00a0objeti\u2010\nvaron\u00a0mutaciones \u00a0genot\u00edpicas \u00a0de\u00a0resistencia \u00a0y\u00a0se\u00a0re\u2010indujo\u00a0la\u00a0supresi\u00f3n \u00a0viral\u00a0reintrodu \u2010\nciendo\u00a0los\u00a0AN\u00a0previamente \u00a0retirados. \u00a0Los\u00a0datos\u00a0a\u00a0las\u00a096\u00a0semanas\u00a0confirman \u00a0la\u00a0durabili\u2010\ndad\u00a0y\u00a0la\u00a0seguridad \u00a0de\u00a0esta\u00a0estrategia390.\u00a0Tras\u00a0este\u00a0estudio\u00a0se\u00a0realiza\u00a0el\u00a0estudio\u00a0OK04\u00a0\nque\u00a0incluye\u00a0a\u00a0205\u00a0pacientes \u00a0con\u00a0CVP\u00a0indetectable \u00a0durante\u00a0al\u00a0menos\u00a06\u00a0meses\u00a0(mediana \u00a0\nde\u00a028),\u00a0que\u00a0estaban\u00a0tomando\u00a0un\u00a0TARV\u00a0que\u00a0inclu\u00eda\u00a0LPV/r\u00a0asociado\u00a0a\u00a0dos\u00a0AN.\u00a0Es\u00a0un\u00a0es\u2010\ntudio\u00a0aleatorizado, \u00a0abierto,\u00a0de\u00a0no\u00a0inferioridad \u00a0que\u00a0comparaba \u00a0la\u00a0estrategia \u00a0de\u00a0conti\u2010\nnuaci\u00f3n\u00a0del\u00a0tratamiento \u00a0triple\u00a0frente\u00a0a\u00a0la\u00a0monoterapia \u00a0con\u00a0LPV/r,\u00a0seguido\u00a0de\u00a0la\u00a0rein\u2010\nducci\u00f3n\u00a0con\u00a02\u00a0AN\u00a0si\u00a0aparec\u00eda\u00a0rebrote\u00a0viral.\u00a0A\u00a0las\u00a048\u00a0semanas\u00a0el\u00a0porcentaje \u00a0de\u00a0pacientes \u00a0\nsin\u00a0fracaso\u00a0virol\u00f3gico \u00a0fue\u00a0de\u00a090\u00a0y\u00a094%\u00a0respectivamente, \u00a0(diferencia, \u00a0\u20104%;\u00a0l\u00edmite\u00a0supe\u2010\nrior\u00a0del\u00a0IC\u00a095%\u00a0para\u00a0la\u00a0diferencia \u00a03,4%,\u00a0cumpliendo \u00a0el\u00a0criterio\u00a0de\u00a0no\u00a0inferioridad). \u00a0El\u00a0\nporcentaje \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0a\u00a0las\u00a048\u00a0semanas\u00a0(ITT),\u00a0considerando \u00a0\nlas\u00a0reinducciones \u00a0como\u00a0fallos,\u00a0fue\u00a0del\u00a085%\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0monoterapia \u00a0y\u00a090%\u00a0en\u00a0el\u00a0de\u00a0\ncontinuaci\u00f3n \u00a0(p=0,31).\u00a0Los\u00a0episodios \u00a0de\u00a0viremia\u00a0de\u00a0bajo\u00a0nivel,\u00a0entre\u00a050\u00a0y\u00a0500\u00a0co\u2010\npias/mL\u00a0fueron\u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0los\u00a0pacientes \u00a0tratados\u00a0con\u00a0monoterapia \u00a0(4\u00a0frente\u00a0a\u00a0\nninguno)391.\u00a0\u00a0\nCon\u00a0los\u00a0pacientes \u00a0de\u00a0estos\u00a0dos\u00a0estudios\u00a0se\u00a0efectu\u00f3\u00a0un\u00a0an\u00e1lisis\u00a0multivariante \u00a0de\u00a0los\u00a0fac\u2010\ntores\u00a0predictores \u00a0de\u00a0p\u00e9rdida\u00a0de\u00a0respuesta \u00a0virol\u00f3gica \u00a0del\u00a0grupo\u00a0tratado\u00a0con\u00a0LPV/r\u00a0en\u00a0\nmonoterapia. \u00a0El\u00a0fracaso\u00a0virol\u00f3gico \u00a0se\u00a0relacion\u00f3 \u00a0con\u00a0falta\u00a0de\u00a0adherencia, \u00a0niveles\u00a0bajos\u00a0\nde\u00a0hemoglobina \u00a0y\u00a0nadir\u00a0de\u00a0CD4\u00a0<100\u00a0c\u00e9lulas/\u00b5L392.\u00a0\u00a0\nEn\u00a0\u00a0otro\u00a0estudio\u00a0de\u00a0simplificaci\u00f3n \u00a0a\u00a0monoterapia \u00a0con\u00a0LPV/r\u00a0la\u00a0estrategia \u00a0fue\u00a0algo\u00a0distin\u2010\nta.\u00a0Se\u00a0incluyeron \u00a0155\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0a\u00a0los\u00a0que\u00a0se\u00a0aleatoriz\u00f3 \u00a02:1\u00a0a\u00a0ini\u2010\nciar\u00a0tratamiento \u00a0con\u00a0ZDV/3TC\u00a0junto\u00a0con\u00a0LPV/r\u00a0(n=104)\u00a0o\u00a0con\u00a0EFV\u00a0(n=51).\u00a0Entre\u00a0las\u00a024\u00a0y\u00a0\n48\u00a0semanas\u00a0de\u00a0tratamiento \u00a0y\u00a0tras\u00a0al\u00a0menos\u00a03\u00a0controles \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL, \u00a0los\u00a0\npacientes \u00a0que\u00a0tomaban\u00a0LPV/r\u00a0pasaron\u00a0a\u00a0mantenimiento \u00a0con\u00a0LPV/r\u00a0en\u00a0monoterapia. \u00a0\nConsiderando \u00a0fracaso\u00a0a\u00a0cualquier \u00a0viremia\u00a0positiva,\u00a0a\u00a0las\u00a096\u00a0semanas\u00a0de\u00a0seguimiento, \u00a0\nun\u00a048%\u00a0de\u00a0los\u00a0pacientes \u00a0en\u00a0tratamiento \u00a0con\u00a0LPV/r\u00a0y\u00a0un\u00a061%\u00a0con\u00a0EFV\u00a0presentaban \u00a0CVP\u00a0\n<50\u00a0copias/mL \u00a0(p=0,17;\u00a0IC\u00a095%\u00a0de\u00a0la\u00a0diferencia, \u00a0\u201029%\u00a0a\u00a04%).\u00a0En\u00a0un\u00a0nuevo\u00a0an\u00e1lisis\u00a0en\u00a0el\u00a0\nque\u00a0se\u00a0incluyeron \u00a0como\u00a0respondedores \u00a0a\u00a0los\u00a0pacientes \u00a0que\u00a0tras\u00a0reintroducir \u00a0los\u00a0mis\u2010\nmos\u00a0AN\u00a0consiguieron \u00a0de\u00a0nuevo\u00a0CVP\u00a0<50\u00a0copias/mL, \u00a0el\u00a060%\u00a0de\u00a0pacientes \u00a0en\u00a0tratamien \u2010\nto\u00a0con\u00a0LPV/r\u00a0y\u00a0el\u00a063%\u00a0con\u00a0EFV\u00a0respondieron \u00a0al\u00a0tratamiento \u00a0(p=0,73;\u00a0IC\u00a095%:\u00a0\u201019%\u00a013%).\u00a0\nSe\u00a0objetivaron \u00a0viremias\u00a0de\u00a0bajo\u00a0nivel\u00a0en\u00a0los\u00a0pacientes \u00a0en\u00a0monoterapia. \u00a0En\u00a0cuanto\u00a0a\u00a0la\u00a0\nseguridad, \u00a0se\u00a0observ\u00f3\u00a0lipoatrofia \u00a0en\u00a0el\u00a05%\u00a0del\u00a0brazo\u00a0de\u00a0monoterapia, \u00a0frente\u00a0a\u00a0un\u00a034%\u00a0\ndel\u00a0grupo\u00a0de\u00a0EFV.\u00a0No\u00a0se\u00a0observaron \u00a0diferencias \u00a0en\u00a0cuanto\u00a0a\u00a0la\u00a0lipohipertrofia. \u00a0Las\u00a0alte\u2010\nraciones\u00a0lip\u00eddicas\u00a0grado\u00a03\u20104\u00a0fueron\u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0el\u00a0grupo\u00a0del\u00a0LPV/r393.\u00a0\u00a0\nEn\u00a0estos\u00a0dos\u00a0estudios\u00a0se\u00a0pone\u00a0de\u00a0manifiesto \u00a0la\u00a0importancia \u00a0del\u00a0periodo\u00a0durante\u00a0el\u00a0cual\u00a0\nla\u00a0CVP\u00a0permanece \u00a0indetectable \u00a0previo\u00a0al\u00a0paso\u00a0a\u00a0monoterapia. \u00a0\u00a0\nEsta\u00a0misma\u00a0estrategia \u00a0se\u00a0est\u00e1\u00a0explorando \u00a0con\u00a0ATV/r394\u00a0y\u00a0DRV/r395,\u00a0396.\u00a0\u00a0\nSe\u00a0han\u00a0publicado \u00a0los\u00a0resultados \u00a0a\u00a048\u00a0semanas\u00a0de\u00a0un\u00a0estudio\u00a0piloto,\u00a0abierto\u00a0de\u00a0un\u00a0solo\u00a0\nbrazo\u00a0de\u00a0simplificaci\u00f3n \u00a0a\u00a0ATV/r,\u00a0el\u00a0ACTG\u00a05201394.\u00a0Se\u00a0incluyeron \u00a0en\u00a0el\u00a0mismo\u00a0a\u00a034\u00a0pa\u2010\ncientes\u00a0que\u00a0hab\u00edan\u00a0iniciado\u00a0tratamiento \u00a0con\u00a02\u00a0AN\u00a0e\u00a0IP,\u00a0que\u00a0estaban\u00a0con\u00a0carga\u00a0viral\u00a0in\u2010\ndetectable \u00a0(<50\u00a0copias/mL), \u00a0durante\u00a0al\u00a0menos\u00a048\u00a0semanas, \u00a0no\u00a0hab\u00edan\u00a0sido\u00a0tratados\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 64 \n con\u00a0NN\u00a0ni\u00a0fallo\u00a0virol\u00f3gico \u00a0previo\u00a0y\u00a0eran\u00a0HBsAg\u00a0negativos. \u00a0En\u00a0el\u00a0momento \u00a0de\u00a0entrar\u00a0en\u00a0\nel\u00a0estudio\u00a0se\u00a0sustitu\u00eda\u00a0el\u00a0IP\u00a0que\u00a0estaban\u00a0tomando\u00a0por\u00a0ATV/r\u00a0y\u00a06\u00a0semanas\u00a0despu\u00e9s\u00a0se\u00a0\nsuspend\u00edan \u00a0los\u00a0AN.\u00a0El\u00a0objetivo\u00a0primario\u00a0del\u00a0estudio\u00a0era\u00a0el\u00a0tiempo\u00a0hasta\u00a0el\u00a0fallo\u00a0virol\u00f3gi\u2010\nco.\u00a0A\u00a0las\u00a048\u00a0semanas, \u00a030\u00a0pacientes \u00a0(88%)\u00a0segu\u00edan\u00a0con\u00a0carga\u00a0viral\u00a0indetectable. \u00a0En\u00a0los\u00a0\nque\u00a0presentaron \u00a0fallo\u00a0virol\u00f3gico \u00a0no\u00a0se\u00a0detectaron \u00a0mutaciones \u00a0de\u00a0resistencia. \u00a0Adem\u00e1s,\u00a0\nen\u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0la\u00a0viremia\u00a0residual\u00a0se\u00a0observ\u00f3\u00a0que\u00a0no\u00a0se\u00a0modificaba \u00a0en\u00a0los\u00a0pacientes \u00a0\nen\u00a0los\u00a0que\u00a0no\u00a0hubo\u00a0fallo\u00a0virol\u00f3gico, \u00a0pero\u00a0aumentaba \u00a0progresivamente \u00a0en\u00a0los\u00a0que\u00a0lo\u00a0\ntuvieron\u00a0detect\u00e1ndose \u00a0desde\u00a04\u201012\u00a0semanas\u00a0antes\u00a0de\u00a0que\u00a0se\u00a0confirmara \u00a0el\u00a0fracaso.\u00a0M\u00e1s\u00a0\nrecientemente \u00a0se\u00a0han\u00a0comunicado \u00a0datos\u00a0del\u00a0estudio\u00a0OREY.\u00a0Se\u00a0trata\u00a0de\u00a0un\u00a0estudio\u00a0pilo\u2010\nto,\u00a0abierto,\u00a0multic\u00e9ntrico \u00a0de\u00a0brazo\u00a0\u00fanico\u00a0y\u00a096\u00a0semanas\u00a0de\u00a0seguimiento \u00a0que\u00a0evalua\u00a0la\u00a0\nmonoterapia \u00a0con\u00a0ATV/r.\u00a0Se\u00a0incluyeron \u00a061\u00a0pacientes \u00a0que\u00a0estaban\u00a0recibiendo \u00a0TARV,\u00a0que\u00a0\nno\u00a0hab\u00edan\u00a0tenido\u00a0ning\u00fan\u00a0fracaso\u00a0previo\u00a0(CVP\u00a0<50\u00a0copias/mL \u00a0al\u00a0menos\u00a024\u00a0semanas) \u00a0y\u00a0en\u00a0\ntratamiento \u00a0con\u00a0ATV/r\u00a0y\u00a02\u00a0AN\u00a0al\u00a0menos\u00a0las\u00a08\u00a0semanas\u00a0antes\u00a0de\u00a0su\u00a0inclusi\u00f3n. \u00a0En\u00a0el\u00a0an\u00e1\u2010\nlisis\u00a0a\u00a0las\u00a048\u00a0semanas, \u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0pacientes \u00a0mantuvieron \u00a0la\u00a0supresi\u00f3n \u00a0virol\u00f3gica \u00a0\n(79%\u00a0<400\u00a0copias/mL) \u00a0tras\u00a0cambiar\u00a0a\u00a0monoterapia, \u00a0la\u00a0reintroducci\u00f3n \u00a0de\u00a0la\u00a0triple\u00a0tera\u2010\npia\u00a0fue\u00a0generalmente \u00a0satisfactoria \u00a0(7\u00a0de\u00a09\u00a0pacientes). \u00a0El\u00a0desarrollo \u00a0de\u00a0mutaciones \u00a0pri\u2010\nmarias\u00a0a\u00a0IPs\u00a0fue\u00a0raro397.\u00a0\nEn\u00a0cuanto\u00a0al\u00a0DRV/r,\u00a0se\u00a0han\u00a0comunicado \u00a0dos\u00a0ensayos\u00a0cl\u00ednicos\u00a0que\u00a0exploran\u00a0dos\u00a0escena\u2010\nrios\u00a0distintos\u00a0en\u00a0los\u00a0que\u00a0se\u00a0explora\u00a0la\u00a0eficacia\u00a0y\u00a0la\u00a0seguridad \u00a0de\u00a0la\u00a0administraci\u00f3n \u00a0de\u00a0\nDRV/r\u00a0en\u00a0monoterapia. \u00a0El\u00a0estudio\u00a0MONET395\u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluyeron \u00a0256\u00a0pacientes \u00a0en\u00a0\ntratamiento \u00a0antirretroviral \u00a0con\u00a02\u00a0AN\u00a0y\u00a0un\u00a0NN\u00a0\u00f3\u00a0un\u00a0IP/r\u00a0sin\u00a0experiencia \u00a0previa\u00a0a\u00a0DRV/r\u00a0ni\u00a0\nhistoria\u00a0de\u00a0fallo\u00a0virol\u00f3gico, \u00a0con\u00a0carga\u00a0viral\u00a0indetectable \u00a0(<50\u00a0copias/mL) \u00a0durante\u00a0al\u00a0me\u2010\nnos\u00a06\u00a0meses.\u00a0Se\u00a0les\u00a0aleatoriz\u00f3 \u00a0a\u00a0tomar\u00a0DRV/r\u00a0(800/100\u00a0QD)\u00a0(n=\u00a0129)\u00a0en\u00a0monoterapia \u00a0o\u00a0\ncon\u00a02\u00a0AN\u00a0optimizados \u00a0(n=\u00a0127).\u00a0Se\u00a0trata\u00a0de\u00a0un\u00a0estudio\u00a0de\u00a0no\u00a0inferioridad \u00a0en\u00a0el\u00a0que\u00a0el\u00a0\nobjetivo\u00a0primario\u00a0es\u00a0el\u00a0tiempo\u00a0hasta\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0la\u00a0respuesta \u00a0virol\u00f3gica \u00a0(TLOVR).\u00a0\nAunque\u00a0el\u00a0seguimiento \u00a0programado \u00a0es\u00a0de\u00a096\u00a0semanas, \u00a0los\u00a0datos\u00a0comunicados \u00a0corres\u2010\nponden\u00a0a\u00a0la\u00a0semana\u00a048;\u00a0en\u00a0ellos\u00a0se\u00a0confirmaba \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0la\u00a0rama\u00a0de\u00a0DRV/r\u00a0\nen\u00a0monoterapia. \u00a0En\u00a0el\u00a0an\u00e1lisis\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0tratar,\u00a0considerando \u00a0cambio\u00a0de\u00a0trata\u2010\nmiento\u00a0como\u00a0un\u00a0fracaso,\u00a0el\u00a085,3%\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0tomaban\u00a0DRV/r\u00a0frente\u00a0al\u00a084,3%\u00a0\nde\u00a0los\u00a0que\u00a0tomaban\u00a0adem\u00e1s\u00a02\u00a0AN\u00a0presentaban \u00a0CVP\u00a0indetectable \u00a0(\u20101;\u00a0l\u00edmite\u00a0del\u00a0IC\u00a095%:\u00a0\n\u20109,9).\u00a0En\u00a0cuanto\u00a0a\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0resistencias, \u00a0se\u00a0ha\u00a0detectado \u00a0un\u00a0paciente\u00a0por\u00a0rama\u00a0\ncon\u00a0evidencia \u00a0de\u00a0resistencia \u00a0genot\u00edpica, \u00a0pero\u00a0no\u00a0fenot\u00edpica \u00a0a\u00a0DRV.\u00a0En\u00a0el\u00a0estudio\u00a0MO\u2010\nNOI396\u00a0el\u00a0dise\u00f1o\u00a0es\u00a0distinto.\u00a0Se\u00a0trata\u00a0de\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0aleatorizado \u00a0abierto\u00a0en\u00a0el\u00a0que\u00a0\nse\u00a0incluyeron \u00a0a\u00a0pacientes \u00a0que\u00a0hab\u00edan\u00a0recibido\u00a0tratamiento \u00a0antirretroviral \u00a0durante\u00a0al\u00a0\nmenos\u00a018\u00a0meses,\u00a0que\u00a0presentaban \u00a0CVP\u00a0<400\u00a0copias/mL \u00a0durante\u00a0los\u00a018\u00a0meses\u00a0previos\u00a0y\u00a0\nCVP\u00a0<50\u00a0copias/mL \u00a0en\u00a0el\u00a0momento \u00a0de\u00a0la\u00a0inclusi\u00f3n, \u00a0que\u00a0no\u00a0hab\u00edan\u00a0presentado \u00a0fallo\u00a0vi\u2010\nrol\u00f3gico\u00a0a\u00a0IP\u00a0y\u00a0no\u00a0hab\u00edan\u00a0recibido\u00a0nunca\u00a0DRV/r.\u00a0Consta\u00a0de\u00a0dos\u00a0fases,\u00a0en\u00a0la\u00a0primera\u00a0se\u00a0\nintroduce \u00a0en\u00a0el\u00a0tratamiento \u00a0DRV/r\u00a0y\u00a08\u00a0semanas\u00a0m\u00e1s\u00a0tarde\u00a0(segunda\u00a0fase)\u00a0se\u00a0aleatoriza \u00a0\n1:1\u00a0a\u00a0DRV/r\u00a0(600/100\u00a0mg\u00a0BID)\u00a0o\u00a0a\u00a0DRV/r\u00a0(600/100\u00a0BID)+\u00a02\u00a0AN.\u00a0Es\u00a0un\u00a0estudio\u00a0de\u00a0no\u00a0infe\u2010\nrioridad\u00a0de\u00a0la\u00a0pauta\u00a0de\u00a0monoterapia \u00a0frente\u00a0a\u00a0la\u00a0triterapia \u00a0y\u00a0el\u00a0objetivo\u00a0primario\u00a0es\u00a0el\u00a0\nporcentaje \u00a0de\u00a0pacientes \u00a0que\u00a0mantienen \u00a0respuesta \u00a0virol\u00f3gica \u00a0en\u00a0la\u00a0semana\u00a048,\u00a0aunque\u00a0\nel\u00a0seguimiento \u00a0programado \u00a0es\u00a0m\u00e1s\u00a0prolongado. \u00a0En\u00a0la\u00a0fase\u00a0inicial\u00a0se\u00a0incluyeron \u00a0242\u00a0pa\u2010\ncientes,\u00a0se\u00a0aleatorizaron \u00a0226.\u00a0Se\u00a0han\u00a0comunicado \u00a0los\u00a0datos\u00a0a\u00a0la\u00a0semana\u00a048\u00a0(110\u00a0pa\u2010\ncientes\u00a0en\u00a0triple\u00a0terapia\u00a0y\u00a0109\u00a0con\u00a0DRV/r).\u00a0En\u00a0los\u00a0resultados \u00a0por\u00a0protocolo \u00a0DRV/r\u00a0en\u00a0\nmonoterapia \u00a0muestra\u00a0no\u00a0inferioridad \u00a0frente\u00a0a\u00a0la\u00a0triple\u00a0terapia\u00a0(94.1%\u00a0vs\u00a099.0%\u00a0de\u00a0CVP\u00a0\n<50\u00a0copias/mL). \u00a0En\u00a0el\u00a0an\u00e1lisis\u00a0por\u00a0ITT\u00a0se\u00a0obtienen\u00a0resultados \u00a0similares\u00a0(87.5%\u00a0vs\u00a092%).\u00a0\nSe\u00a0objetivaron \u00a0tres\u00a0fracasos\u00a0virol\u00f3gicos \u00a0(>400\u00a0copias/mL) \u00a0en\u00a0pacientes \u00a0con\u00a0DRV/r\u00a0en\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 65 \n monoterapia, \u00a0sin\u00a0detectarse \u00a0mutaciones \u00a0de\u00a0resistencia \u00a0para\u00a0DRV,\u00a0y\u00a0con\u00a0posterior\u00a0resu\u2010\npresi\u00f3n\u00a0viral\u00a0tras\u00a0la\u00a0reintroducci\u00f3n \u00a0de\u00a0los\u00a0AN.\u00a0Se\u00a0rese\u00f1a\u00a0que\u00a0dos\u00a0pacientes \u00a0en\u00a0el\u00a0grupo\u00a0\nde\u00a0monoterapia \u00a0tuvieron\u00a0cl\u00ednica\u00a0relacionada \u00a0con\u00a0falta\u00a0de\u00a0supresi\u00f3n \u00a0del\u00a0VIH\u00a0en\u00a0el\u00a0siste\u2010\nma\u00a0nervioso\u00a0central.\u00a0\u00a0\u00a0\nIgualmente \u00a0se\u00a0han\u00a0presentado \u00a0datos\u00a0de\u00a0varios\u00a0estudios\u00a0en\u00a0los\u00a0que\u00a0se\u00a0explora\u00a0la\u00a0posibi\u2010\nlidad\u00a0de\u00a0realizar\u00a0otro\u00a0tipo\u00a0de\u00a0inducci\u00f3n \u2010mantenimiento \u00a0que\u00a0consiste\u00a0en\u00a0iniciar\u00a0un\u00a0tra\u2010\ntamiento\u00a0con\u00a0ATV/r\u00a0y\u00a0posteriormente \u00a0suspender \u00a0el\u00a0RTV.\u00a0Esta\u00a0estrategia \u00a0se\u00a0ha\u00a0plantea\u2010\ndo\u00a0dada\u00a0la\u00a0cantidad\u00a0de\u00a0problemas \u00a0que\u00a0produce\u00a0el\u00a0ritonavir\u00a0incluso\u00a0a\u00a0dosis\u00a0bajas.\u00a0Los\u00a0\nestudios\u00a0m\u00e1s\u00a0significativos \u00a0son\u00a0el\u00a0INDUMA\u00a0y\u00a0el\u00a0ARIES.\u00a0El\u00a0INDUMA398\u00a0es\u00a0un\u00a0estudio\u00a0alea\u2010\ntorizado,\u00a0abierto,\u00a0multic\u00e9ntrico \u00a0de\u00a0no\u00a0inferioridad, \u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluyeron \u00a0252\u00a0pacien\u2010\ntes\u00a0sin\u00a0tratamiento \u00a0previo\u00a0que\u00a0iniciaron\u00a0tratamiento \u00a0de\u00a0inducci\u00f3n \u00a0con\u00a02AN\u00a0+\u00a0ATV/r\u00a0y\u00a0\nque\u00a0en\u00a0la\u00a0semana\u00a026\u201030,\u00a0los\u00a0que\u00a0ten\u00edan\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0y\u00a0segu\u00edan\u00a0con\u00a0el\u00a0tratamien \u2010\nto\u00a0(172)\u00a0se\u00a0aleatorizan \u00a01:1\u00a0a\u00a0continuar \u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0o\u00a0a\u00a0tomar\u00a02\u00a0AN\u00a0+\u00a0ATV\u00a0\n400\u00a0mg\u00a0QD\u00a0con\u00a0un\u00a0seguimiento \u00a0de\u00a048\u00a0semanas. \u00a0El\u00a0objetivo\u00a0primario\u00a0es\u00a0la\u00a0proporci\u00f3n \u00a0\nde\u00a0pacientes \u00a0que\u00a0mantienen \u00a0CVP\u00a0<50\u00a0copias/mL \u00a0a\u00a0las\u00a048\u00a0semanas. \u00a0Objetivos \u00a0secunda\u2010\nrios\u00a0son\u00a0el\u00a0porcentaje \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<400\u00a0copias/mL, \u00a0la\u00a0cifra\u00a0de\u00a0CD4\u00a0y\u00a0los\u00a0datos\u00a0\nde\u00a0seguridad. \u00a0La\u00a0mitad\u00a0de\u00a0los\u00a0pacientes \u00a0llevaban\u00a0como\u00a0pareja\u00a0de\u00a0AN\u00a0ABC/3TC. \u00a0En\u00a0la\u00a0\nsemana\u00a048\u00a0la\u00a0rama\u00a0de\u00a0ATV\u00a0demuestra \u00a0no\u00a0inferioridad \u00a0con\u00a0respecto\u00a0a\u00a0la\u00a0de\u00a0ATV/r\u00a0(pro\u2010\nporci\u00f3n\u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0es\u00a0de\u00a075\u00a0%\u00a0en\u00a0la\u00a0rama\u00a0de\u00a0ATV/r\u00a0(n=\u00a085)\u00a0y\u00a0\nde\u00a078%\u00a0en\u00a0la\u00a0rama\u00a0de\u00a0ATV\u00a0(n=87);\u00a0con\u00a0una\u00a0diferencia \u00a0de\u00a02.9\u00a0y\u00a0un\u00a0IC\u00a095%:\u00a069.8\u201015.5).\u00a0En\u00a0\ncuanto\u00a0al\u00a0perfil\u00a0de\u00a0seguridad, \u00a0se\u00a0produjeron \u00a0menos\u00a0casos\u00a0de\u00a0hiperbilirrubinemia \u00a0y\u00a0de\u00a0\ndislipemia \u00a0en\u00a0la\u00a0rama\u00a0de\u00a0ATV.\u00a0Los\u00a0autores\u00a0concluyen \u00a0que\u00a0\u00e9sta\u00a0es\u00a0una\u00a0opci\u00f3n\u00a0adecuada \u00a0\ny\u00a0segura\u00a0en\u00a0pacientes \u00a0que\u00a0no\u00a0toman\u00a0tenofovir. \u00a0No\u00a0se\u00a0detectaron \u00a0resistencias \u00a0frente\u00a0a\u00a0\nIP\u00a0en\u00a0ninguno\u00a0de\u00a0los\u00a0brazos\u00a0entre\u00a0los\u00a0pacientes \u00a0que\u00a0presentaron \u00a0fracaso\u00a0virol\u00f3gico. \u00a0El\u00a0\nestudio\u00a0ARIES399\u00a0es\u00a0un\u00a0estudio\u00a0similar.\u00a0Se\u00a0trata\u00a0de\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0abierto,\u00a0multi\u2010\nc\u00e9ntrico,\u00a0de\u00a0no\u00a0inferioridad \u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluye\u00a0a\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0a\u00a0\nlos\u00a0que\u00a0se\u00a0pauta\u00a0ABC/3TC\u00a0+\u00a0ATV/r\u00a0y\u00a0posteriormente, \u00a0en\u00a0la\u00a0semana\u00a036,\u00a0se\u00a0aleatorizan \u00a0\n(1:1)\u00a0a\u00a0seguir\u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0o\u00a0a\u00a0suspender \u00a0el\u00a0ritonavir\u00a0durante\u00a048\u00a0semanas, \u00a0\nsi\u00a0su\u00a0CVP\u00a0es\u00a0<50\u00a0copias/mL \u00a0y\u00a0no\u00a0han\u00a0presentado \u00a0fallo\u00a0virol\u00f3gico \u00a0previo.\u00a0Se\u00a0aleatoriza \u2010\nron\u00a0419\u00a0pacientes, \u00a0incluy\u00e9ndose \u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0a\u00a0los\u00a0379\u00a0(90%)\u00a0que\u00a0completaron \u00a0las\u00a084\u00a0\nsemanas\u00a0de\u00a0seguimiento. \u00a0El\u00a0objetivo\u00a0primario\u00a0era\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0\nCVP<50\u00a0copias/mL \u00a0en\u00a0la\u00a0semana\u00a084\u00a0(TLOVR).\u00a0Los\u00a0autores\u00a0observan\u00a0que\u00a0la\u00a0eficacia\u00a0de\u00a0\nambos\u00a0tratamientos \u00a0es\u00a0similar\u00a0y\u00a0sostenida \u00a0independientemente \u00a0de\u00a0la\u00a0CVP\u00a0basal,\u00a0siendo\u00a0\ninfrecuente \u00a0el\u00a0fallo\u00a0virol\u00f3gico \u00a0(2%).\u00a0\n\u00a0Reducci\u00f3n \u00a0del\u00a0n\u00famero\u00a0de\u00a0comprimidos \u00a0y/o\u00a0de\u00a0dosis\u00a0\nLa\u00a0reducci\u00f3n \u00a0del\u00a0n\u00famero\u00a0de\u00a0comprimidos \u00a0y/o\u00a0de\u00a0dosis\u00a0se\u00a0consigue\u00a0sustituyendo \u00a0el\u00a0IP\u00a0\npor\u00a0un\u00a0f\u00e1rmaco\u00a0de\u00a0otro\u00a0grupo.\u00a0En\u00a0esta\u00a0estrategia, \u00a0ampliamente \u00a0estudiada, \u00a0se\u00a0ha\u00a0eva\u2010\nluado\u00a0la\u00a0sustituci\u00f3n \u00a0del\u00a0IP/r\u00a0por\u00a0EFV,\u00a0NVP\u00a0o\u00a0ABC\n\u00a0y\u00a0tambi\u00e9n\u00a0por\u00a0otro\u00a0IP/r\u00a0que\u00a0se\u00a0pueda\u00a0\nadministrar \u00a0en\u00a0QD.\u00a0\nSimplificaci\u00f3n \u00a0con\u00a0EFV\u00a0\nSe\u00a0han\u00a0realizado\u00a0m\u00faltiples \u00a0estudios\u00a0al\u00a0respecto, \u00a0pero\u00a0pocos\u00a0de\u00a0ellos\u00a0son\u00a0comparativos. \u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 66 \n En\u00a0los\u00a0estudios\u00a0DMP\u2010049\u00a0y\u00a0\u2010027\u00a0se\u00a0aleatorizaron \u00a0a\u00a0pacientes \u00a0que\u00a0estaban\u00a0tomando\u00a0un\u00a0\nTARV\u00a0con\u00a0IP\u00a0a\u00a0seguir\u00a0con\u00a0el\u00a0mismo\u00a0o\u00a0sustituirlo \u00a0por\u00a0EFV.\u00a0En\u00a0los\u00a0dos\u00a0el\u00a0fracaso\u00a0virol\u00f3gico \u00a0\nfue\u00a0menor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0EFV400,\u00a0401\u00a0.\u00a0\nEn\u00a0otro\u00a0estudio\u00a0se\u00a0compar\u00f3\u00a0el\u00a0cambio\u00a0de\u00a0IP\u00a0por\u00a0EFV\u00a0(n=25),\u00a0NVP\u00a0(n=26)\u00a0o\u00a0continuar \u00a0\ncon\u00a0el\u00a0IP\u00a0(n=26),\u00a0en\u00a0pacientes \u00a0en\u00a0TARV\u00a0con\u00a0IP\u00a0con\u00a0CD4\u00a0>300\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0CVP\u00a0<80\u00a0co\u2010\npias/mL\u00a0mantenida \u00a0m\u00e1s\u00a0de\u00a09\u00a0meses.\u00a0A\u00a0las\u00a048\u00a0semanas\u00a0(ITT)\u00a0no\u00a0hubo\u00a0diferencia \u00a0en\u00a0la\u00a0\nproporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0indetectable \u00a0con\u00a0EFV\u00a0(80%)\u00a0o\u00a0IP\u00a0(77%)402.\u00a0\u00a0\nEn\u00a0un\u00a0estudio\u00a0con\u00a0dise\u00f1o\u00a0combinado \u00a0(caso\u2010control\u00a0y\u00a0aleatorizado) \u00a0se\u00a0compar\u00f3\u00a0la\u00a0evo\u2010\nluci\u00f3n\u00a0de\u00a0167\u00a0pacientes \u00a0(a\u00a0los\u00a0que\u00a0tras\u00a0suspender \u00a0el\u00a0IP\u00a0se\u00a0aleatorizaron \u00a0a\u00a0EFV\u00a0o\u00a0ABC),\u00a0\ncon\u00a0otros\u00a0167\u00a0pacientes \u00a0que\u00a0continuaron \u00a0con\u00a0IP\u00a0(control). \u00a0A\u00a0las\u00a048\u00a0semanas\u00a0(ITT)\u00a0el\u00a0\n70%\u00a0de\u00a0los\u00a0tratados\u00a0con\u00a0EFV\u00a0y\u00a0el\u00a054%\u00a0con\u00a0IP\u00a0presentaban \u00a0CVP\u00a0<500\u00a0copias/mL \u00a0\n(p<0,05)403.\u00a0\u00a0\u00a0\n\u00a0\u00a0Simplificaci\u00f3n \u00a0con\u00a0NVP\u00a0\nExisten\u00a0varios\u00a0estudios\u00a0aleatorizados \u00a0y\u00a0un\u00a0estudio\u00a0con\u00a0dise\u00f1o\u00a0caso\u2010control\u00a0en\u00a0los\u00a0que\u00a0\nse\u00a0compara\u00a0seguir\u00a0con\u00a0un\u00a0IP\u00a0con\u00a0cambiar\u00a0a\u00a0NVP.\u00a0\u00a0\nEn\u00a0varios\u00a0estudios\u00a0aleatorizados \u00a0a\u00a0seguir\u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0o\u00a0simplificar \u00a0el\u00a0IP,\u00a0la\u00a0\neficacia\u00a0terap\u00e9utica \u00a0a\u00a0las\u00a024\u201048\u00a0semanas, \u00a0\nfue\u00a0similar\u00a0en\u00a0las\u00a0dos\u00a0ramas\u00a0y\u00a0se\u00a0observ\u00f3\u00a0una\u00a0\nmejor\u00eda\u00a0del\u00a0perfil\u00a0lip\u00eddico404\u2010406.\u00a0En\u00a0uno\u00a0de\u00a0los\u00a0estudios\u00a0se\u00a0observ\u00f3\u00a0una\u00a0mayor\u00a0eficacia\u00a0\nvirol\u00f3gica \u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0simplificaci\u00f3n407.\u00a0\nEn\u00a0un\u00a0estudio\u00a0caso\u2010control\u00a0de\u00a0una\u00a0cohorte\u00a0de\u00a0pacientes \u00a0que\u00a0recibieron \u00a0un\u00a0IP\u00a0en\u00a0su\u00a0\nprimer\u00a0TARV\u00a0y\u00a0que\u00a0sustituyeron \u00a0por\u00a0NVP\u00a0(n=125)\u00a0o\u00a0por\u00a0otro\u00a0IP\u00a0(nueva\u00a0formulaci\u00f3n \u00a0de\u00a0\nSQV\u00a0o\u00a0a\u00a0IP/r,\u00a0n=321),\u00a0se\u00a0encontr\u00f3\u00a0a\u00a0las\u00a048\u00a0semanas\u00a0que\u00a0el\u00a0riesgo\u00a0relativo\u00a0de\u00a0fracasar\u00a0\npor\u00a0cambio\u00a0de\u00a0tratamiento \u00a0fue\u00a05\u00a0veces\u00a0superior\u00a0con\u00a0el\u00a0IP\u00a0que\u00a0con\u00a0NVP\u00a0sin\u00a0que\u00a0existie\u2010\nran\u00a0diferencias \u00a0en\u00a0el\u00a0riesgo\u00a0de\u00a0fracaso\u00a0virol\u00f3gico408.\u00a0\u00a0\nCon\u00a0un\u00a0dise\u00f1o\u00a0distinto,\u00a0en\u00a0otro\u00a0estudio\u00a0espa\u00f1ol\u00a0(MULTINEKA) \u00a0se\u00a0aleatoriz\u00f3 \u00a0a\u00a067\u00a0pa\u2010\ncientes\u00a0en\u00a0tratamiento \u00a0estable\u00a0y\u00a0con\u00a0CVP<50\u00a0copias/mL \u00a0durante\u00a0al\u00a0menos\u00a06\u00a0meses\u00a0a\u00a0\nrecibir\u00a0LPV/r\u00a0con\u00a0NVP\u00a0o\u00a0con\u00a0dos\u00a0AN.\u00a0A\u00a0las\u00a048\u00a0semanas\u00a0de\u00a0tratamiento, \u00a0no\u00a0se\u00a0detect\u00f3\u00a0\nfracaso\u00a0virol\u00f3gico \u00a0en\u00a0ninguno\u00a0de\u00a0los\u00a0pacientes. \u00a0Se\u00a0describi\u00f3\u00a0un\u00a0posible\u00a0beneficio \u00a0en\u00a0la\u00a0\ntoxicidad\u00a0mitocondrial, \u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0NVP409.\u00a0\nLa\u00a0NVP\u00a0est\u00e1\u00a0contraindicada \u00a0como\u00a0tratamiento \u00a0de\u00a0inicio\u00a0en\u00a0mujeres\u00a0con\u00a0CD4\u00a0>250\u00a0c\u00e9lu\u2010\nlas/\u00b5L\u00a0y\u00a0en\u00a0varones\u00a0con\u00a0>400\u00a0por\u00a0riesgo\u00a0de\u00a0hepatotoxicidad \u00a0grave.\u00a0Sin\u00a0embargo, \u00a0varios\u00a0\nestudios\u00a0independientes410\u2010415\u00a0coinciden \u00a0en\u00a0se\u00f1alar\u00a0que\u00a0no\u00a0se\u00a0ha\u00a0objetivado \u00a0un\u00a0incre\u2010\nmento\u00a0de\u00a0la\u00a0hepatotoxicidad \u00a0o\u00a0del\u00a0exantema \u00a0en\u00a0pacientes \u00a0en\u00a0los\u00a0que\u00a0se\u00a0introduce \u00a0NVP\u00a0\ncomo\u00a0estrategia \u00a0de\u00a0simplificaci\u00f3n \u00a0o\u00a0sustituci\u00f3n \u00a0por\u00a0toxicidad\u00a0independientemente \u00a0del\u00a0\nn\u00famero\u00a0de\u00a0CD4.\u00a0Estos\u00a0resultados \u00a0son\u00a0muy\u00a0consistentes \u00a0por\u00a0el\u00a0n\u00famero\u00a0de\u00a0pacientes. \u00a0\u00a0\n\u00a0Simplificaci\u00f3n \u00a0con\u00a0\nABC\u00a0\n\u00a0Se\u00a0han\u00a0realizado\u00a0m\u00faltiples \u00a0estudios\u00a0aleatorizados \u00a0y\u00a0un\u00a0estudio\u00a0caso\u2010control\u00a0prospecti \u2010\nvo\u00a0que\u00a0analizan\u00a0esta\u00a0estrategia. \u00a0Los\u00a0resultados \u00a0son\u00a0dispares.\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 67 \n En\u00a0uno\u00a0de\u00a0ellos\u00a0la\u00a0eficacia\u00a0terap\u00e9utica \u00a0fue\u00a0superior\u00a0en\u00a0la\u00a0rama\u00a0del\u00a0ABC416\u2010418.\u00a0En\u00a0los\u00a0\notros,\u00a0incluido\u00a0el\u00a0estudio\u00a0TRIZAL\u00a0y\u00a0el\u00a0COLA30305, \u00a0la\u00a0eficacia\u00a0fue\u00a0similar,\u00a0pero\u00a0se\u00a0ob\u2010\nserv\u00f3\u00a0una\u00a0mayor\u00a0incidencia \u00a0de\u00a0fracasos\u00a0en\u00a0aquellos\u00a0pacientes \u00a0que\u00a0hab\u00edan\u00a0pasado\u00a0a\u00a0\ntomar\u00a0ABC\u00a0y\u00a0previamente \u00a0hab\u00edan\u00a0tomado\u00a0tratamientos \u00a0sub\u00f3ptimos403.\u00a0\nEn\u00a0el\u00a0estudio\u00a0ya\u00a0comentado \u00a0de\u00a0dise\u00f1o\u00a0combinado \u00a0(caso\u2010control\u00a0y\u00a0aleatorizado) \u00a0que\u00a0\ncomparaba \u00a0IP\u00a0con\u00a0EFV\u00a0o\u00a0ABC,\u00a0el\u00a065%\u00a0de\u00a0los\u00a0pacientes \u00a0tratados\u00a0con\u00a0ABC\u00a0y\u00a0el\u00a054%\u00a0de\u00a0los\u00a0\nque\u00a0continuaron \u00a0con\u00a0IP\u00a0presentaron \u00a0CVP\u00a0<500\u00a0copias/mL \u00a0(p<0,05)\u00a0a\u00a0las\u00a048\u00a0semanas419.\u00a0\nEn\u00a0otro\u00a0estudio,\u00a0209\u00a0pacientes \u00a0fueron\u00a0aleatorizados \u00a0a\u00a0recibir\u00a0ZDV/3TC/ABC \u00a0en\u00a0combi\u2010\nnaci\u00f3n\u00a0fija\u00a0con\u00a0EFV\u00a0o\u00a0LPV/r,\u00a0durante\u00a024\u201036\u00a0semanas. \u00a0Los\u00a0pacientes \u00a0que\u00a0tuvieron\u00a0CVP\u00a0\n<50\u00a0copias/mL \u00a0en\u00a0ambos\u00a0brazos\u00a0continuaron \u00a0s\u00f3lo\u00a0con\u00a0ZDV/3TC/ABC. \u00a0A\u00a0las\u00a072\u00a0semanas\u00a0\nun\u00a031\u00a0y\u00a0un\u00a043%\u00a0mantuvieron \u00a0la\u00a0CVP\u00a0indetectable \u00a0(ITT),\u00a0pero\u00a0el\u00a034%\u00a0y\u00a0el\u00a025%\u00a0cambiaron \u00a0\nla\u00a0pauta\u00a0por\u00a0toxicidad420.\u00a0\nOtro\u00a0estudio\u00a0piloto\u00a0incluye\u00a0a\u00a017\u00a0pacientes \u00a0que\u00a0tras\u00a012\u00a0meses\u00a0recibiendo \u00a0un\u00a0TARV\u00a0esta\u2010\nble\u00a0que\u00a0conten\u00eda\u00a0un\u00a0IP,\u00a0pasaban\u00a0a\u00a0tomar\u00a0ZDV+3TC+ABC \u00a0coformulados \u00a0y\u00a0TDF.\u00a0A\u00a0los\u00a024\u00a0\nmeses,\u00a0todos\u00a0continuaban \u00a0con\u00a0CVP\u00a0indetectable, \u00a0ten\u00edan\u00a0una\u00a0mejor\u00eda\u00a0del\u00a0perfil\u00a0lip\u00eddico\u00a0y\u00a0\nreducci\u00f3n \u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0precisaban \u00a0hipolipemiantes. \u00a0Adem\u00e1s\u00a0se\u00a0objetiv\u00f3\u00a0un\u00a0\ndescenso \u00a0significativo \u00a0de\u00a0los\u00a0niveles\u00a0de\u00a0ADN\u00a0proviral420.\u00a0\u00a0\u00a0\nEn\u00a0distintos\u00a0estudios\u00a0se\u00a0ha\u00a0puesto\u00a0de\u00a0manifiesto \u00a0la\u00a0existencia \u00a0de\u00a0un\u00a0riesgo\u00a0elevado\u00a0de\u00a0\nfracaso\u00a0terap\u00e9utico \u00a0y\u00a0desarrollo \u00a0de\u00a0mutaciones \u00a0a\u00a0AN\u00a0cuando\u00a0se\u00a0utilizan\u00a0pautas\u00a0de\u00a0sim\u2010\nplificaci\u00f3n \u00a0con\u00a03TC+ABC+TDF421\u00a0y\u00a03TC+ddI+TDF \u00a0por\u00a0lo\u00a0que\u00a0se\u00a0desaconsejan \u00a0como\u00a0es\u2010\ntrategia\u00a0de\u00a0simplificaci\u00f3n \u00a0pese\u00a0a\u00a0su\u00a0sencillez.\u00a0\n\u00a0Comparaci\u00f3n \u00a0directa\u00a0de\u00a0EFV,\u00a0NVP\u00a0y\u00a0ABC\u00a0en\u00a0simplificaci\u00f3n \u00a0de\u00a0TARV\u00a0\nEl\u00a0NEFA\u00a0es\u00a0un\u00a0estudio\u00a0prospectivo \u00a0en\u00a0el\u00a0que\u00a0se\u00a0aleatorizaron \u00a0460\u00a0pacientes \u00a0en\u00a0trata\u2010\nmiento\u00a0con\u00a0dos\u00a0AN\u00a0m\u00e1s\u00a0un\u00a0IP,\u00a0con\u00a0\nCVP<200\u00a0copias/mL \u00a0durante\u00a0\u22656\u00a0meses422,\u00a0423.\u00a0Se\u00a0sus\u2010\ntitu\u00eda\u00a0el\u00a0IP\u00a0por\u00a0NVP\u00a0(n=155),\u00a0EFV\u00a0(n=156)\u00a0o\u00a0ABC\u00a0(n=149).\u00a0El\u00a050%,\u00a058%\u00a0y\u00a046%\u00a0de\u00a0pacien\u2010\ntes\u00a0respectivamente \u00a0hab\u00edan\u00a0recibido\u00a0tratamientos \u00a0previos\u00a0sub\u00f3ptimos \u00a0con\u00a0uno\u00a0o\u00a0dos\u00a0\nAN.\u00a0La\u00a0eficacia\u00a0terap\u00e9utica \u00a0(ITT)\u00a0a\u00a0las\u00a048\u00a0semanas\u00a0(CVP\u00a0<200\u00a0copias/mL) \u00a0fue\u00a0similar\u00a0en\u00a0\nlos\u00a0tres\u00a0grupos\u00a0(77%,\u00a072%\u00a0y\u00a077%;\u00a0p=NS).\u00a0El\u00a0fracaso\u00a0virol\u00f3gico \u00a0fue\u00a0superior\u00a0en\u00a0el\u00a0grupo\u00a0\nde\u00a0ABC\u00a0(6%,\u00a04%\u00a0y\u00a012%;\u00a0p<0,05)\u00a0y\u00a0ocurr\u00eda\u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0hab\u00edan\u00a0recibido\u00a0trata\u2010\nmiento\u00a0sub\u00f3ptimo. \u00a0Estos\u00a0resultados \u00a0se\u00a0han\u00a0confirmado \u00a0a\u00a0los\u00a03\u00a0a\u00f1os424.\u00a0El\u00a0an\u00e1lisis\u00a0ge\u2010\nnot\u00edpico\u00a0de\u00a0las\u00a0cepas\u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0fracaso\u00a0virol\u00f3gico \u00a0evidenci\u00f3 \u00a0un\u00a0n\u00famero\u00a0ma\u2010\nyor\u00a0de\u00a0mutaciones \u00a0de\u00a0resistencias \u00a0a\u00a0AN\u00a0en\u00a0los\u00a0que\u00a0recibieron \u00a0ABC425.\u00a0El\u00a0n\u00famero\u00a0de\u00a0\npacientes \u00a0que\u00a0suspendi\u00f3 \u00a0el\u00a0tratamiento \u00a0por\u00a0efectos\u00a0adversos\u00a0fue\u00a0menor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0\nABC\u00a0(17%,\u00a017%\u00a0y\u00a06%;\u00a0p<0,01).\u00a0La\u00a0simplificaci\u00f3n \u00a0a\u00a0cualquiera \u00a0de\u00a0los\u00a0NN,\u00a0sobre\u00a0todo\u00a0a\u00a0\nNVP,\u00a0produjo\u00a0beneficios \u00a0en\u00a0el\u00a0perfil\u00a0lip\u00eddico,\u00a0con\u00a0reducci\u00f3n \u00a0de\u00a0colesterol \u2010no\u2010HDL\u00a0con\u00a0\nABC.\u00a0Los\u00a0niveles\u00a0de\u00a0triglic\u00e9ridos \u00a0se\u00a0redujeron \u00a0en\u00a0los\u00a0tres\u00a0brazos.\u00a0Los\u00a0marcadores \u00a0de\u00a0\nresistencia \u00a0a\u00a0la\u00a0insulina\u00a0mostraron \u00a0una\u00a0tendencia \u00a0a\u00a0la\u00a0mejor\u00eda.\u00a0Sin\u00a0embargo, \u00a0no\u00a0mejora\u2010\nron\u00a0las\u00a0alteraciones \u00a0en\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0grasa426.\u00a0\u00a0\nUn\u00a0estudio\u00a0de\u00a0cohortes\u00a0con\u00a0los\u00a0datos\u00a0de\u00a0la\u00a0French\u00a0Hospital\u00a0Database \u00a0on\u00a0HIV\u00a0trata\u00a0de\u00a0\nreproducir \u00a0los\u00a0datos\u00a0del\u00a0estudio\u00a0NEFA\u00a0pero\u00a0en\u00a0la\u00a0vida\u00a0real.\u00a0Se\u00a0incluyeron \u00a02462\u00a0pacien\u2010\ntes\u00a0seguidos\u00a0durante\u00a012\u00a0meses\u00a0y\u00a0en\u00a0los\u00a0que\u00a0el\u00a0primer\u00a0tratamiento \u00a0incluyera\u00a0un\u00a0IP;\u00a0se\u00a0\ncambi\u00f3\u00a0el\u00a0IP\u00a0por\u00a0EFV,\u00a0NVP\u00a0\u00f3\u00a0ABC.\u00a0Los\u00a0factores\u00a0predictivos \u00a0de\u00a0rebrote\u00a0de\u00a0la\u00a0CVP\u00a0fueron:\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 68 \n sexo\u00a0femenino, \u00a0menor\u00a0edad,\u00a0exposici\u00f3n \u00a0sub\u00f3ptima \u00a0previa\u00a0a\u00a0antirretrovirales, \u00a0CPV\u00a0ele\u2010\nvada,\u00a0uso\u00a0de\u00a0ddI/d4T\u00a0tras\u00a0el\u00a0cambio\u00a0y\u00a0cambio\u00a0a\u00a0NVP\u00a0o\u00a0ABC\u00a0(si\u00a0se\u00a0hab\u00eda\u00a0recibido\u00a0trata\u2010\nmientos\u00a0sub\u00f3ptimos). \u00a0Las\u00a0diferencias \u00a0respecto\u00a0al\u00a0NEFA\u00a0probablemente \u00a0se\u00a0deban\u00a0a\u00a0dife\u2010\nrencias\u00a0metodol\u00f3gicas427.\u00a0\u00a0\u00a0\u00a0\nComparando \u00a0la\u00a0simplificaci\u00f3n \u00a0a\u00a0tres\u00a0AN\u00a0(ZDV+3TC+ABC \u00a0coformulados) \u00a0frente\u00a0a\u00a0la\u00a0com\u2010\nbinaci\u00f3n\u00a0de\u00a0dos\u00a0AN\u00a0(ZDV+3TC \u00a0coformulados) \u00a0m\u00e1s\u00a0NVP,\u00a0en\u00a0el\u00a0an\u00e1lisis\u00a0(ITT)\u00a0a\u00a0las\u00a048\u00a0se\u2010\nmanas\u00a0no\u00a0hubo\u00a0diferencias \u00a0significativas \u00a0en\u00a0cuanto\u00a0CVP\u00a0indetectable428.\u00a0\u00a0\n\u00a0Simplificaci\u00f3n \u00a0con\u00a0atazanavir \u00a0\nEl\u00a0ATV\u00a0es\u00a0un\u00a0IP\u00a0de\u00a0dosificaci\u00f3n \u00a0QD,\u00a0bien\u00a0tolerado,\u00a0con\u00a0buen\u00a0perfil\u00a0metab\u00f3lico \u00a0y\u00a0pocos\u00a0\ncomprimidos \u00a0que\u00a0ha\u00a0permitido \u00a0una\u00a0nueva\u00a0estrategia \u00a0de\u00a0simplificaci\u00f3n \u00a0en\u00a0la\u00a0que\u00a0un\u00a0IP\u00a0\nsustituye\u00a0a\u00a0otro.\u00a0\nEl\u00a0SWAN\u00a0es\u00a0un\u00a0estudio\u00a0abierto\u00a0en\u00a0fase\u00a0IIIb,\u00a0en\u00a0el\u00a0que\u00a0419\u00a0pacientes\n\u00a0en\u00a0tratamiento \u00a0\nestable\u00a0con\u00a0IP\u00a0(potenciado \u00a0o\u00a0no)\u00a0y\u00a0con\u00a0CVP\u00a0indetectable \u00a0se\u00a0aleatorizaron \u00a0(2:1)\u00a0a\u00a0ATV\u00a0\n400\u00a0mg\u00a0QD\u00a0(en\u00a0caso\u00a0de\u00a0tomar\u00a0TDF\u00a0se\u00a0paut\u00f3\u00a0ATV/r\u00a0300/100\u00a0mg)\u00a0(n=278)\u00a0o\u00a0continuar \u00a0\ncon\u00a0el\u00a0IP\u00a0(n=141).\u00a0A\u00a0la\u00a0semana\u00a048\u00a0el\u00a0fracaso\u00a0virol\u00f3gico \u00a0fue\u00a0menor\u00a0en\u00a0los\u00a0que\u00a0simplifica \u2010\nron\u00a0(7%\u00a0frente\u00a0a\u00a016%;\u00a0p<0,01).\u00a0La\u00a0eficacia\u00a0virol\u00f3gica \u00a0fue\u00a0superior\u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0\npasaron\u00a0de\u00a0tomar\u00a0un\u00a0IP\u00a0no\u00a0potenciado \u00a0a\u00a0ATV\u00a0(22%\u00a0frente\u00a0a\u00a05%;\u00a0p<0,001); \u00a0no\u00a0hubo\u00a0dife\u2010\nrencias\u00a0entre\u00a0los\u00a0que\u00a0siguieron\u00a0con\u00a0IP/r\u00a0y\u00a0los\u00a0que\u00a0pasaron\u00a0de\u00a0IP/r\u00a0a\u00a0ATV\u00a0(11%\u00a0frente\u00a0a\u00a0\n8%;\u00a0p=NS)429.\u00a0En\u00a0cuanto\u00a0a\u00a0la\u00a0seguridad, \u00a0la\u00a0suspensi\u00f3n \u00a0de\u00a0tratamiento \u00a0fue\u00a0mayor\u00a0en\u00a0los\u00a0\npacientes \u00a0del\u00a0grupo\u00a0control\u00a0(21%\u00a0frente\u00a0a\u00a034%;\u00a0p<0,01)\u00a0y\u00a0el\u00a0perfil\u00a0lip\u00eddico\u00a0fue\u00a0mejor\u00a0en\u00a0\nel\u00a0grupo\u00a0que\u00a0simplific\u00f3 \u00a0a\u00a0ATV.\u00a0Los\u00a0datos\u00a0de\u00a0los\u00a0estudios\u00a0ATAZIP\u00a0y\u00a0SIMPATAZ \u00a0confirman \u00a0\nla\u00a0seguridad \u00a0y\u00a0eficacia\u00a0de\u00a0esta\u00a0estrategia \u00a0de\u00a0simplificaci\u00f3n, \u00a0en\u00a0este\u00a0caso\u00a0cambiando \u00a0\nLPV/r\u00a0por\u00a0ATV/r430,\u00a0431.\u00a0\nEl\u00a0estudio\u00a0REAL,\u00a0del\u00a0que\u00a0se\u00a0han\u00a0presentado \u00a0datos\u00a0a\u00a0las\u00a048\u00a0semanas, \u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00edni\u2010\nco\u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluye\u00a0a\u00a0pacientes \u00a0en\u00a0TARV\u00a0estable\u00a0al\u00a0menos\u00a0durante\u00a012\u00a0semanas\u00a0que\u00a0\ncontiene\u00a0un\u00a0IP\u00a0administrado \u00a0BID,\u00a0con\u00a0CVP\u00a0indetectable \u00a0y\u00a0lipohipertrofia, \u00a0a\u00a0los\u00a0que\u00a0se\u00a0\naleatoriza \u00a0a\u00a0continuar \u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0o\u00a0cambiar\u00a0el\u00a0IP\u00a0a\u00a0ATV/r\u00a0\u00a0300/100\u00a0mg.\u00a0\nEl\u00a0control\u00a0inmunovirol\u00f3gico \u00a0se\u00a0mantuvo, \u00a0se\u00a0observ\u00f3\u00a0una\u00a0mejor\u00eda\u00a0del\u00a0perfil\u00a0lip\u00eddico\u00a0en\u00a0la\u00a0\nrama\u00a0de\u00a0ATV\u00a0pero\u00a0no\u00a0se\u00a0objetivaron \u00a0diferencias \u00a0en\u00a0cuanto\u00a0a\u00a0la\u00a0composici\u00f3n \u00a0corpo\u2010\nral432.\u00a0\u00a0\u00a0\nOtra\u00a0estrategia \u00a0es\u00a0la\u00a0desarrollada \u00a0en\u00a0el\u00a0ensayo\u00a0cl\u00ednico\u00a0AI424\u2010067\u00a0a\u00a048\u00a0semanas433.\u00a0Se\u00a0\ntrata\u00a0de\u00a0un\u00a0estudio\u00a0aleatorizado, \u00a0abierto,\u00a0prospectivo, \u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluyeron \u00a0246\u00a0pa\u2010\ncientes\u00a0en\u00a0tratamiento \u00a0con\u00a0IP/r\u00a0y\u00a0con\u00a0hiperlipidemia \u00a0y\u00a0CVP\u00a0<50\u00a0copias/mL. \u00a0Se\u00a0aleatori\u2010\nzaron\u00a0los\u00a0pacientes \u00a0a\u00a0cambiar\u00a0a\u00a0ATV\u00a0(400\u00a0mg)\u00a0en\u00a0el\u00a0d\u00eda\u00a01\u00a0(cambio\u00a0inmediato) \u00a0\u00f3\u00a0mante\u2010\nner\u00a0su\u00a0tratamiento \u00a0y\u00a0cambiar\u00a0a\u00a0ATV\u00a0(400\u00a0mg)\u00a0a\u00a0las\u00a024\u00a0semanas\u00a0(cambio\u00a0retrasado). \u00a0A\u00a0\nlas\u00a012\u00a0semanas\u00a0ambos\u00a0grupos\u00a0manten\u00edan \u00a0un\u00a0control\u00a0virol\u00f3gico \u00a0similar\u00a0y\u00a0aquellos\u00a0pa\u2010\ncientes\u00a0que\u00a0tomaban\u00a0ATV\u00a0una\u00a0mejor\u00eda\u00a0significativa \u00a0de\u00a0las\u00a0cifras\u00a0de\u00a0LDL\u2010colesterol \u00a0(\u201015\u00a0\u00a0\ny\u00a0+1%;\u00a0p<0.0001). \u00a0Los\u00a0autores\u00a0concluyen \u00a0que\u00a0el\u00a0cambio\u00a0inmediato \u00a0o\u00a0diferido\u00a0de\u00a0un\u00a0IP\u00a0\npotenciado \u00a0o\u00a0no\u00a0a\u00a0ATV\u00a0no\u00a0potenciado \u00a0en\u00a0pacientes \u00a0con\u00a0hiperlipemia \u00a0se\u00a0asocia\u00a0con\u00a0me\u2010\njor\u00eda\u00a0en\u00a0los\u00a0par\u00e1metros \u00a0lip\u00eddicos\u00a0sin\u00a0p\u00e9rdida\u00a0de\u00a0supresi\u00f3n \u00a0virol\u00f3gica. \u00a0\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 69 \n Simplificaci\u00f3n \u00a0a\u00a0reg\u00edmenes \u00a0de\u00a0administraci\u00f3n \u00a0en\u00a0una\u00a0vez\u00a0al\u00a0d\u00eda\u00a0\nEl\u00a0cambio\u00a0a\u00a0un\u00a0r\u00e9gimen\u00a0QD\u00a0es\u00a0otra\u00a0forma\u00a0de\u00a0simplificaci\u00f3n \u00a0en\u00a0pacientes \u00a0que\u00a0est\u00e9n\u00a0bien\u00a0\ncontrolados. \u00a0Varios\u00a0ensayos\u00a0han\u00a0comprobado \u00a0la\u00a0validez\u00a0de\u00a0esta\u00a0estrategia. \u00a0\nEn\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0se\u00a0aleatorizaron \u00a0355\u00a0pacientes \u00a0a\u00a0seguir\u00a0con\u00a0su\u00a0TARV\u00a0o\u00a0cambiar\u00a0a\u00a0\nuna\u00a0terapia\u00a0QD\u00a0(ddI+FTC+EFV). \u00a0A\u00a0la\u00a0semana\u00a048\u00a0segu\u00edan\u00a0con\u00a0CVP\u00a0indetectable \u00a0el\u00a087%\u00a0de\u00a0\nla\u00a0rama\u00a0QD\u00a0y\u00a0el\u00a079%\u00a0de\u00a0los\u00a0que\u00a0no\u00a0hab\u00edan\u00a0cambiado \u00a0(p<0,05\u00a0)434.\u00a0En\u00a0otro\u00a0estudio\u00a0no\u00a0\naleatorizado \u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluyeron \u00a0169\u00a0pacientes, \u00a084\u00a0siguieron\u00a0su\u00a0TARV\u00a0y\u00a085\u00a0se\u00a0cam\u2010\nbiaron\u00a0a\u00a0ddI\u00a0+TDF+\u00a0NVP\u00a0QD;\u00a0la\u00a0eficacia\u00a0virol\u00f3gica \u00a0fue\u00a0buena\u00a0(76\u00a0frente\u00a0a\u00a086%,\u00a0ITT)\u00a0pero\u00a0\nlos\u00a0linfocitos\u00a0CD4\u00a0disminuyeron \u00a0en\u00a0la\u00a0rama\u00a0QD\u00a0con\u00a0un\u00a0decremento \u00a0medio\u00a0de\u00a095\u00a0c\u00e9lu\u2010\nlas/\u00b5L435.\u00a0\nLa\u00a0combinaci\u00f3n \u00a0ddI+TDF\u00a0ha\u00a0demostrado \u00a0eficacia\u00a0virol\u00f3gica \u00a0pero\u00a0pobre\u00a0recuperaci\u00f3n \u00a0de\u00a0\nlinfocitos\u00a0CD4\u00a0o\u00a0incluso\u00a0descenso \u00a0de\u00a0su\u00a0n\u00famero\u00a0aunque\u00a0la\u00a0CVP\u00a0est\u00e9\u00a0suprimida. \u00a0Este\u00a0\ndescenso \u00a0era\u00a0m\u00e1s\u00a0patente\u00a0cuando\u00a0se\u00a0administraban \u00a0las\u00a0dosis\u00a0est\u00e1ndar\u00a0(plenas)\u00a0de\u00a0\nddI436.\u00a0Los\u00a0reg\u00edmenes \u00a0de\u00a0administraci\u00f3n \u00a0QD\u00a0que\u00a0contengan \u00a0la\u00a0combinaci\u00f3n \u00a0ddI+TDF\u00a0\ndeben\u00a0evitarse.\u00a0De\u00a0hacerlo\u00a0se\u00a0debe\u00a0reducir\u00a0la\u00a0dosis\u00a0de\u00a0ddI\u00a0a\u00a0250\u00a0mg/d\u00eda\u00a0en\u00a0pacientes \u00a0\ncon\u00a0m\u00e1s\u00a0de\u00a060\u00a0Kg\u00a0de\u00a0peso\u00a0y\u00a0a\u00a0200\u00a0mg/d\u00eda\u00a0en\u00a0pacientes \u00a0por\u00a0debajo\u00a0de\u00a0dicho\u00a0peso.\u00a0\nCon\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0las\u00a0combinaciones \u00a0a\u00a0dosis\u00a0fijas\u00a0de\u00a0AN\u00a0administrados \u00a0QD\u00a0se\u00a0ha\u00a0sim\u2010\nplificado\u00a0a\u00fan\u00a0m\u00e1s\u00a0la\u00a0situaci\u00f3n. \u00a0Est\u00e1\u00a0cada\u00a0vez\u00a0m\u00e1s\u00a0claro\u00a0su\u00a0papel\u00a0en\u00a0terapia\u00a0de\u00a0inicio\u00a0y\u00a0ya\u00a0\nse\u00a0han\u00a0puesto\u00a0en\u00a0marcha\u00a0ensayos\u00a0para\u00a0valorar\u00a0su\u00a0uso\u00a0en\u00a0reg\u00edmenes \u00a0m\u00e1s\u00a0sencillos.\u00a0El\u00a0\nSWEET\u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0en\u00a0el\u00a0que\u00a0234\u00a0pacientes \u00a0en\u00a0tratamiento \u00a0durante\u00a0al\u00a0menos\u00a06\u00a0\nmeses\u00a0con\u00a0ZDV+3TC\u00a0(coformulados) \u00a0+\u00a0EFV\u00a0y\u00a0con\u00a0CVP\u00a0<50\u00a0copias/mL, \u00a0se\u00a0aleatorizaron \u00a0a\u00a0\nTDF+FTC\u00a0(coformulados) \u00a0+\u00a0EFV\u00a0\u00f3\u00a0a\u00a0seguir\u00a0con\u00a0el\u00a0mismo\u00a0tratamiento. \u00a0A\u00a0las\u00a024\u00a0semanas\u00a0\nse\u00a0observ\u00f3\u00a0una\u00a0mejor\u00eda\u00a0en\u00a0las\u00a0cifras\u00a0de\u00a0hemoglobina \u00a0y\u00a0en\u00a0el\u00a0perfil\u00a0lip\u00eddico\u00a0en\u00a0la\u00a0rama\u00a0\nTDF+FTC, \u00a0manteni\u00e9ndose \u00a0la\u00a0respuesta \u00a0al\u00a0tratamiento \u00a0(CVP<50\u00a0copias/mL, \u00a093%\u00a0frente\u00a0a\u00a0\n88%;\u00a0p=0,26).\u00a0Recientemente \u00a0se\u00a0han\u00a0publicado \u00a0los\u00a0resultados \u00a0a\u00a048\u00a0semanas437\u00a0a\u00a0las\u00a0\nque\u00a0han\u00a0llegado\u00a0206\u00a0pacientes. \u00a0Un\u00a05%\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0continuaron \u00a0con\u00a0el\u00a0mismo\u00a0\ntratamiento \u00a0y\u00a0un\u00a03%\u00a0de\u00a0los\u00a0que\u00a0lo\u00a0cambiaron, \u00a0discontinuaron \u00a0el\u00a0estudio\u00a0por\u00a0efectos\u00a0\nadversos. \u00a0No\u00a0se\u00a0objetivaron \u00a0diferencias \u00a0estad\u00edsticamente \u00a0significativas \u00a0entre\u00a0las\u00a0dos\u00a0\nramas\u00a0por\u00a0intenci\u00f3n \u00a0de\u00a0tratar\u00a0(85%\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0continuaron \u00a0el\u00a0tratamiento \u00a0\nfrente\u00a0al\u00a088%\u00a0de\u00a0los\u00a0que\u00a0cambiaron \u00a0ten\u00edan\u00a0CVP\u00a0<50\u00a0copias/mL). \u00a0En\u00a0el\u00a0subestudio \u00a0de\u00a0\n100\u00a0pacientes \u00a0a\u00a0los\u00a0que\u00a0se\u00a0ha\u00a0realizado\u00a0DEXA\u00a0del\u00a0tejido\u00a0graso,\u00a0se\u00a0observa\u00a0que\u00a0la\u00a0grasa\u00a0\nse\u00a0mantiene \u00a0o\u00a0aumenta\u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0cambian\u00a0el\u00a0tratamiento, \u00a0pero\u00a0disminuye \u00a0\nen\u00a0el\u00a0grupo\u00a0que\u00a0contin\u00faa\u00a0(diferencia \u00a0media\u00a0de\u00a0448\u00a0g,\u00a0IC\u00a095%:\u00a057\u2010839\u00a0g;\u00a0p=0.025). \u00a0Al\u00a0\nigual\u00a0que\u00a0en\u00a0otros\u00a0estudios,\u00a0el\u00a0incremento \u00a0de\u00a0grasa\u00a0es\u00a0menor\u00a0en\u00a0aquellos\u00a0pacientes \u00a0\nque\u00a0tomaban\u00a0ZDV\u00a0y\u00a0en\u00a0los\u00a0que\u00a0presentaban \u00a0menor\u00a0cantidad\u00a0de\u00a0grasa\u00a0perif\u00e9rica. \u00a0No\u00a0se\u00a0\nobservaron \u00a0diferencias \u00a0entre\u00a0grupos\u00a0en\u00a0cuanto\u00a0a\u00a0toxicidad\u00a0renal.\u00a0Los\u00a0investigadores \u00a0\nconcluyen \u00a0que\u00a0el\u00a0cambio\u00a0de\u00a0ZDV/3TC\u00a0por\u00a0TDF/FTC\u00a0en\u00a0pacientes \u00a0en\u00a0tratamiento \u00a0con\u00a0\nEFV\u00a0y\u00a0respuesta \u00a0virol\u00f3gica \u00a0mantenida \u00a0es\u00a0seguro\u00a0desde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0virol\u00f3gico \u00a0y\u00a0se\u00a0\nasocia\u00a0con\u00a0un\u00a0incremento \u00a0de\u00a0la\u00a0cifra\u00a0de\u00a0hemoglobina \u00a0y\u00a0una\u00a0mejor\u00eda\u00a0de\u00a0los\u00a0par\u00e1metros \u00a0\nlip\u00eddicos\u00a0y\u00a0de\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0grasa\u00a0corporal.\u00a0\u00a0\u00a0\nEn\u00a0otro\u00a0ensayo\u00a0cl\u00ednico\u00a0aleatorizado, \u00a0abierto\u00a0que\u00a0incluye\u00a0a\u00a080\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0\ncopias/mL \u00a0y\u00a0que\u00a0est\u00e1n\u00a0en\u00a0tratamiento \u00a0con\u00a0ZDV/3TC\u00a0(+\u00a0IP\u00a0\u00f3\u00a0NN),\u00a0\u00a0a\u00a0los\u00a0que\u00a0se\u00a0aleatoriza \u00a0\na\u00a0seguir\u00a0con\u00a0ZDV/3TC\u00a0\u00f3\u00a0cambiar\u00a0a\u00a0TDF/FTC\u00a0(RECOMB), \u00a0en\u00a0la\u00a0semana\u00a024\u00a0el\u00a085%\u00a0de\u00a0los\u00a0\npacientes \u00a0en\u00a0tratamiento \u00a0con\u00a0TDF\u2010FTC,\u00a0presentaban \u00a0CVP\u00a0<50\u00a0copias/mL \u00a0frente\u00a0a\u00a0un\u00a0\n80%\u00a0con\u00a0ZDV/3TC\u00a0(p=0,77)438.\u00a0Se\u00a0observ\u00f3\u00a0adem\u00e1s\u00a0un\u00a0incremento \u00a0significativo \u00a0de\u00a0grasa\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 70 \n en\u00a0las\u00a0extremidades \u00a0en\u00a0los\u00a0pacientes \u00a0cuya\u00a0masa\u00a0grasa\u00a0era\u00a0<7,2\u00a0kg\u00a0basalmente. \u00a0Por\u00a0\n\u00faltimo\u00a0mejoraron \u00a0las\u00a0cifras\u00a0de\u00a0colesterol \u2010LDL\u00a0en\u00a0la\u00a0rama\u00a0de\u00a0TDF/FTC.\u00a0En\u00a0los\u00a0datos\u00a0a\u00a072\u00a0\nsemanas439,\u00a0no\u00a0se\u00a0ha\u00a0observado \u00a0ning\u00fan\u00a0fallo\u00a0virol\u00f3gico; \u00a0el\u00a090%\u00a0de\u00a0la\u00a0rama\u00a0de\u00a0TDF/FTC\u00a0\nfrente\u00a0a\u00a0un\u00a083%\u00a0de\u00a0la\u00a0rama\u00a0de\u00a0AZT/3TC\u00a0presentan \u00a0CVP\u00a0<50\u00a0copias/mL \u00a0(p=\u00a00.52);\u00a0la\u00a0me\u2010\ndiana\u00a0de\u00a0incremento \u00a0de\u00a0la\u00a0cifra\u00a0de\u00a0CD4\u00a0fue\u00a0similar.\u00a0Adem\u00e1s,\u00a0en\u00a0estos\u00a0pacientes \u00a0se\u00a0ob\u2010\njetiva\u00a0una\u00a0mejor\u00eda\u00a0significativa, \u00a0incremento \u00a0progresivo \u00a0de\u00a0grasa\u00a0en\u00a0las\u00a0extremidades, \u00a0\nsobre\u00a0todo\u00a0si\u00a0el\u00a0IMC\u00a0basal\u00a0es\u00a0>25\u00a0Kg/m2\u00a0y\u00a0llevan\u00a0m\u00e1s\u00a0de\u00a05\u00a0a\u00f1os\u00a0con\u00a0AZT/3TC.\u00a0El\u00a0an\u00e1lisis\u00a0\nse\u00a0realiza\u00a0seg\u00fan\u00a0el\u00a0IMC\u00a0basal\u00a0sea\u00a0superior\u00a0o\u00a0no\u00a0a\u00a025\u00a0Kg/m2\u00a0y\u00a0el\u00a0n\u00famero\u00a0de\u00a0a\u00f1os\u00a0en\u00a0tra\u2010\ntamiento\u00a0con\u00a0AZT/3TC\u00a0y\u00a0en\u00a0todos\u00a0los\u00a0escenarios \u00a0la\u00a0mejor\u00eda\u00a0de\u00a0grasa\u00a0perif\u00e9rica \u00a0es\u00a0es\u2010\ntad\u00edsticamente \u00a0significativa \u00a0en\u00a0la\u00a0rama\u00a0de\u00a0TDF/FTC.\u00a0Los\u00a0autores\u00a0concluyen \u00a0que\u00a0\u00e9sta\u00a0es\u00a0\nuna\u00a0estrategia \u00a0segura\u00a0desde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0inmunovirol\u00f3gico \u00a0y\u00a0de\u00a0efectos\u00a0adversos, \u00a0\nque\u00a0mejora\u00a0la\u00a0lipoatrofia \u00a0y\u00a0distintos\u00a0par\u00e1metros \u00a0bioqu\u00edmicos \u00a0(hemoglobina, \u00a0hematocri \u2010\nto\u00a0y\u00a0colesterol \u2010LDL).\u00a0Otro\u00a0ensayo\u00a0similar\u00a0es\u00a0el\u00a0TOTEM,\u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluye\u00a0a\u00a091\u00a0pacien\u2010\ntes\u00a0con\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0y\u00a0dislipemia, \u00a0a\u00a0los\u00a0que\u00a0se\u00a0aleatoriza \u00a0a\u00a0seguir\u00a0con\u00a0el\u00a0mismo\u00a0\ntratamiento \u00a0o\u00a0cambiar\u00a0a\u00a0TDF/FTC.\u00a0En\u00a0los\u00a0pacientes \u00a0que\u00a0cambiaron \u00a0se\u00a0observ\u00f3\u00a0una\u00a0me\u2010\njor\u00eda\u00a0significativa \u00a0en\u00a0el\u00a0perfil\u00a0lip\u00eddico\u00a0a\u00a0las\u00a012\u00a0semanas440.\u00a0Se\u00a0conoce\u00a0igualmente \u00a0los\u00a0re\u2010\nsultados\u00a0del\u00a0BICOMBO, \u00a0estudio\u00a0aleatorizado \u00a0y\u00a0abierto\u00a0que\u00a0incluy\u00f3\u00a0a\u00a0335\u00a0pacientes \u00a0que\u00a0\nrecib\u00edan\u00a0tratamiento \u00a0con\u00a0un\u00a0r\u00e9gimen\u00a0que\u00a0inclu\u00eda\u00a03TC,\u00a0con\u00a0supresi\u00f3n \u00a0virol\u00f3gica \u00a0durante\u00a0\n\u22656\u00a0meses\u00a0y\u00a0que\u00a0fueron\u00a0aleatorizados \u00a0a\u00a0sustituir\u00a0los\u00a0AN\u00a0por\u00a0las\u00a0combinaciones \u00a0coformu\u2010\nladas\u00a0ABC+3TC\u00a0(n=\u00a0167)\u00a0o\u00a0TDF+FTC\u00a0(n=\u00a0168)441.\u00a0El\u00a0estudio\u00a0se\u00a0dise\u00f1\u00f3\u00a0para\u00a0evaluar\u00a0la\u00a0no\u00a0\ninferioridad \u00a0de\u00a0ambas\u00a0combinaciones \u00a0respecto\u00a0a\u00a0fracaso\u00a0terap\u00e9utico \u00a0o\u00a0virol\u00f3gico. \u00a0En\u00a0el\u00a0\ngrupo\u00a0de\u00a0TDF+FTC, \u00a0el\u00a0fracaso\u00a0terap\u00e9utico \u00a0fue\u00a0de\u00a013,3%\u00a0frente\u00a0a\u00a019,2%\u00a0en\u00a0el\u00a0de\u00a0\nABC+3TC, \u00a0no\u00a0demostr\u00e1ndose \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0ABC+3TC\u00a0frente\u00a0a\u00a0TDF+FTC\u00a0(IC95%:\u2010\n2%\u00a0a\u00a014%).\u00a0Sin\u00a0embargo\u00a0ABC+3TC\u00a0demostr\u00f3 \u00a0la\u00a0no\u00a0inferioridad \u00a0frente\u00a0a\u00a0TDF+FTC\u00a0en\u00a0el\u00a0\nobjetivo\u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0(2,4%\u00a0frente\u00a0a\u00a00%;\u00a0IC\u00a095%:\u00a00,05%\u00a0a\u00a06%).\u00a0Las\u00a0suspensiones \u00a0\npor\u00a0eventos\u00a0adversos\u00a0fueron\u00a0de\u00a010%\u00a0del\u00a0grupo\u00a0de\u00a0ABC+3TC\u00a0frente\u00a0al\u00a05%\u00a0del\u00a0grupo\u00a0\nTDF+FTC\u00a0(p=0,004). \u00a0En\u00a0cuanto\u00a0al\u00a0perfil\u00a0lip\u00eddico,\u00a0las\u00a0reducciones \u00a0del\u00a0colesterol \u00a0total,\u00a0\nHDL,\u00a0LDL\u00a0y\u00a0triglic\u00e9ridos \u00a0fueron\u00a0mayores\u00a0en\u00a0la\u00a0rama\u00a0del\u00a0TDF+FTC. \u00a0El\u00a0incremento \u00a0en\u00a0la\u00a0\ngrasa\u00a0perif\u00e9rica \u00a0y\u00a0las\u00a0alteraciones \u00a0en\u00a0la\u00a0funci\u00f3n\u00a0renal\u00a0\u00a0o\u00a0la\u00a0densidad\u00a0mineral\u00a0\u00f3sea\u00a0fue\u2010\nron\u00a0similares. \u00a0La\u00a0toxicidad\u00a0hep\u00e1tica\u00a0fue\u00a0muy\u00a0baja\u00a0en\u00a0ambos\u00a0grupos.\u00a0Por\u00a0el\u00a0contrario, \u00a0la\u00a0\nrespuesta \u00a0inmunol\u00f3gica \u00a0fue\u00a0mejor\u00a0en\u00a0el\u00a0grupo\u00a0de\u00a0ABC+3TC. \u00a0La\u00a0determinaci\u00f3n \u00a0previa\u00a0\ndel\u00a0HLA\u00a0B*5701\u00a0podr\u00eda\u00a0haber\u00a0modificado \u00a0estos\u00a0resultados. \u00a0\u00a0\u00a0\nSe\u00a0ha\u00a0publicado \u00a0recientemente \u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0prospectivo, \u00a0aleatorizado, \u00a0controla\u2010\ndo,\u00a0abierto,\u00a0multic\u00e9ntrico, \u00a0que\u00a0incluye\u00a0a\u00a0pacientes \u00a0en\u00a0tratamiento \u00a0con\u00a0CVP\u00a0indetecta \u2010\nble\u00a0a\u00a0los\u00a0que\u00a0se\u00a0aleatoriza \u00a0a\u00a0seguir\u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0o\u00a0tomar\u00a0TDF+FTC+EFV \u00a0\ncoformulados \u00a0con\u00a0un\u00a0seguimiento \u00a0a\u00a048\u00a0semanas442,\u00a0demostrando \u00a0la\u00a0misma\u00a0eficacia\u00a0en\u00a0\nlas\u00a0dos\u00a0ramas.\u00a0Se\u00a0incluy\u00f3\u00a0a\u00a0300\u00a0pacientes \u00a0que\u00a0presentaban \u00a0CVP\u00a0<200\u00a0copias/mL \u00a0duran\u2010\nte\u00a0>3\u00a0meses\u00a0y\u00a0sin\u00a0ning\u00fan\u00a0cambio\u00a0de\u00a0tratamiento. \u00a0Se\u00a0estatificaron \u00a0seg\u00fan\u00a0estuvieran \u00a0to\u2010\nmando\u00a0NN\u00a0o\u00a0IP\u00a0y\u00a0aleatorizaron \u00a02:1\u00a0a\u00a0simplificar \u00a0el\u00a0tratamiento \u00a0(tomar\u00a0la\u00a0tableta\u00a0\u00fanica)\u00a0\no\u00a0seguir\u00a0con\u00a0su\u00a0mismo\u00a0tratamiento. \u00a0Se\u00a0evalu\u00f3\u00a0la\u00a0eficacia\u00a0y\u00a0la\u00a0seguridad \u00a0en\u00a0el\u00a0momento \u00a0\nbasal\u00a0y\u00a0a\u00a0las\u00a0semanas\u00a04,\u00a012,\u00a024,\u00a036\u00a0y\u00a048.\u00a0Adem\u00e1s\u00a0a\u00a0los\u00a0pacientes \u00a0se\u00a0les\u00a0realiz\u00f3\u00a0una\u00a0valo\u2010\nraci\u00f3n\u00a0de\u00a0la\u00a0calidad\u00a0de\u00a0vida\u00a0as\u00ed\u00a0como\u00a0de\u00a0sus\u00a0preferencias \u00a0en\u00a0cuanto\u00a0a\u00a0los\u00a0f\u00e1rmacos. \u00a0De\u00a0\nlos\u00a0300\u00a0pacientes \u00a0incluidos, \u00a097\u00a0continuaron \u00a0con\u00a0el\u00a0mismo\u00a0tratamiento. \u00a0A\u00a0las\u00a048\u00a0sema\u2010\nnas,\u00a0el\u00a089%\u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0TDF/FTC/EFV \u00a0vs\u00a088%\u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0pre\u2010\nsentaban \u00a0CVP\u00a0<200\u00a0copias/mL \u00a0(TLOVR;\u00a0IC\u00a095%)\u00a0con\u00a0una\u00a0diferencia \u00a0entre\u00a0ramas\u00a0de\u00a01,1%\u00a0\n(\u20106.7%\u00a0a\u00a08.8%),\u00a0indicando \u00a0no\u00a0inferioridad \u00a0de\u00a0la\u00a0rama\u00a0de\u00a0TDF/FTC/EFV. \u00a0El\u00a087%\u00a0de\u00a0los\u00a0\npacientes \u00a0que\u00a0cambiaron \u00a0a\u00a0TDF/FTC/EFV \u00a0vs\u00a085%\u00a0de\u00a0los\u00a0que\u00a0no\u00a0cambiaron \u00a0el\u00a0tratamien \u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 71 \n to\u00a0presentaban \u00a0CVP\u00a0<50\u00a0copias/mL \u00a0analizados \u00a0de\u00a0la\u00a0misma\u00a0manera:\u00a0diferencia \u00a0entre\u00a0\nlas\u00a0dos\u00a0ramas\u00a0de\u00a02.6%\u00a0(IC\u00a095%\u00a0\u20105,9%\u00a0a\u00a011.1%).\u00a0Las\u00a0tasas\u00a0de\u00a0discontinuaci\u00f3n \u00a0fueron\u00a0si\u2010\nmilares,\u00a0aunque\u00a0la\u00a0suspensi\u00f3n \u00a0por\u00a0efectos\u00a0adversos\u00a0fue\u00a0superior\u00a0en\u00a0la\u00a0rama\u00a0de\u00a0\nTDF/FTC/EFV \u00a0(5%\u00a0vs\u00a01%),\u00a0sobre\u00a0todo\u00a0por\u00a0sintomatolog\u00eda \u00a0relacionada \u00a0con\u00a0el\u00a0SNC.\u00a0No\u00a0se\u00a0\nobjetivaron \u00a0diferencias \u00a0en\u00a0cuanto\u00a0a\u00a0tasa\u00a0de\u00a0filtrado\u00a0glomerular, \u00a0ni\u00a0en\u00a0la\u00a0adherencia. \u00a0S\u00ed\u00a0\nse\u00a0observ\u00f3\u00a0una\u00a0mejor\u00eda\u00a0en\u00a0la\u00a0cifra\u00a0de\u00a0triglic\u00e9ridos \u00a0en\u00a0la\u00a0rama\u00a0de\u00a0TDF/FTC/EFV \u00a0(\u201020\u00a0vs\u00a0\u20103\u00a0\nmg/dl;\u00a0p=\u00a00.035).\u00a0En\u00a0cuanto\u00a0a\u00a0los\u00a0datos\u00a0de\u00a0calidad\u00a0de\u00a0vida443,\u00a0los\u00a0pacientes \u00a0que\u00a0simpli\u2010\nficaron\u00a0refer\u00edan\u00a0mejor\u00eda\u00a0en\u00a0muchos\u00a0de\u00a0los\u00a0s\u00edntomas\u00a0relacionados \u00a0con\u00a0el\u00a0VIH,\u00a0encontra\u2010\nban\u00a0el\u00a0nuevo\u00a0tratamiento \u00a0m\u00e1s\u00a0f\u00e1cil\u00a0de\u00a0tomar\u00a0y\u00a0seguir\u00a0\u00a0y\u00a0lo\u00a0prefer\u00edan \u00a0frente\u00a0a\u00a0los\u00a0trata\u2010\nmientos\u00a0previos.\u00a0\nDesde\u00a0la\u00a0publicaci\u00f3n \u00a0del\u00a0estudio\u00a0NODY255\u00a0disponemos \u00a0de\u00a0una\u00a0nueva\u00a0opci\u00f3n\u00a0para\u00a0sim\u2010\nplificar\u00a0a\u00a0una\u00a0terapia\u00a0QD,\u00a0ya\u00a0que\u00a0ha\u00a0demostrado \u00a0la\u00a0eficacia\u00a0y\u00a0la\u00a0seguridad \u00a0de\u00a0la\u00a0simplifi\u2010\ncaci\u00f3n\u00a0de\u00a0Nevirapina \u00a0administrada \u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda\u00a0a\u00a0una\u00a0vez\u00a0al\u00a0d\u00eda.\u00a0Se\u00a0trata\u00a0de\u00a0un\u00a0es\u2010\ntudio\u00a0con\u00a0una\u00a0duraci\u00f3n\u00a0de\u00a048\u00a0semanas, \u00a0abierto,\u00a0aleatorizado, \u00a0multic\u00e9ntrico \u00a0en\u00a0el\u00a0que\u00a0\nse\u00a0incluyeron \u00a0298\u00a0pacientes \u00a0estables\u00a0que\u00a0estaban\u00a0tomando\u00a0nevirapina \u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda\u00a0\ndurante\u00a0al\u00a0menos\u00a012\u201018\u00a0semanas\u00a0y\u00a0presentaban \u00a0CVP\u00a0<50\u00a0copias/mL. \u00a0Estos\u00a0pacientes \u00a0se\u00a0\naleatorizaron \u00a0a\u00a0continuar \u00a0con\u00a0el\u00a0mismo\u00a0tratamiento \u00a0o\u00a0a\u00a0tomar\u00a0nevirapina \u00a0QD.\u00a0El\u00a0objeti\u2010\nvo\u00a0primario\u00a0del\u00a0estudio\u00a0era\u00a0valorar\u00a0la\u00a0seguridad \u00a0hep\u00e1tica\u00a0del\u00a0tratamiento \u00a0QD,\u00a0analizan\u2010\ndo\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0ALT/AST\u00a0grado\u00a03\u20104;\u00a0y\u00a0los\u00a0objetivos\u00a0secundarios \u00a0eran\u00a0\nel\u00a0desarrollo \u00a0de\u00a0hepatitis\u00a0cl\u00ednica\u00a0y\u00a0la\u00a0eficacia\u00a0inmuno\u2010virol\u00f3gica \u00a0y\u00a0cl\u00ednica.\u00a0El\u00a0estudio\u00a0de\u2010\nmostr\u00f3\u00a0no\u00a0inferioridad \u00a0\u00a0por\u00a0protocolo \u00a0frente\u00a0a\u00a0mantener \u00a0la\u00a0pauta\u00a0inicial,\u00a0habi\u00e9ndose \u00a0\npredefinido \u00a0la\u00a0no\u00a0inferioridad \u00a0como\u00a0un\u00a0margen\u00a0del\u00a010%\u00a0para\u00a0hepatotoxicidad \u00a0que\u00a0era\u00a0\nel\u00a0objetivo\u00a0primario.\u00a0\nUna\u00a0de\u00a0las\u00a0grandes\u00a0cuestiones \u00a0por\u00a0resolver\u00a0es\u00a0si\u00a0el\u00a0impacto\u00a0de\u00a0no\u00a0tomar\u00a0una\u00a0dosis\u00a0de\u00a0\nmedicaci\u00f3n \u00a0por\u00a0olvido\u00a0o\u00a0incumplimiento \u00a0puede\u00a0ser\u00a0mayor\u00a0en\u00a0un\u00a0r\u00e9gimen\u00a0QD\u00a0que\u00a0en\u00a0un\u00a0\nr\u00e9gimen\u00a0de\u00a0varias\u00a0dosis\u00a0diarias\u00a0en\u00a0cuanto\u00a0a\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0mutaciones \u00a0de\u00a0resisten\u2010\ncia444.\u00a0En\u00a0la\u00a0actualidad \u00a0disponemos \u00a0de\u00a0m\u00faltiples \u00a0f\u00e1rmacos\u00a0que\u00a0se\u00a0pueden\u00a0administrar \u00a0\nuna\u00a0vez\u00a0al\u00a0d\u00eda,\u00a0con\u00a0una\u00a0vida\u00a0media\u00a0suficientemente \u00a0larga\u00a0como\u00a0para\u00a0evitar\u00a0este\u00a0pro\u2010\nblema.\u00a0\n\u00a0\nOtros\u00a0tipos\u00a0de\u00a0simplificaci\u00f3n \u00a0\nCon\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0nuevos\u00a0f\u00e1rmacos \u00a0de\u00a0nuevas\u00a0familias,\u00a0se\u00a0ha\u00a0podido\u00a0simplificar \u00a0el\u00a0\ntratamiento \u00a0administrado \u00a0a\u00a0pacientes \u00a0multitratados. \u00a0Esta\u00a0simplificaci\u00f3n \u00a0no\u00a0radica\u00a0en\u00a0el\u00a0\nn\u00famero\u00a0de\u00a0comprimidos \u00a0sino\u00a0en\u00a0la\u00a0forma\u00a0de\u00a0administraci\u00f3n \u00a0de\u00a0los\u00a0f\u00e1rmacos. \u00a0As\u00ed\u00a0se\u00a0\nhan\u00a0presentado \u00a0ya\u00a0estudios\u00a0en\u00a0los\u00a0que\u00a0se\u00a0sustituye\u00a0el\u00a0ENF\u00a0por\u00a0RAL,\u00a0manteni\u00e9ndose \u00a0la\u00a0\neficacia\u00a0del\u00a0tratamiento445\u2010450.\u00a0Aunque\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0trabajos\u00a0son\u00a0observacionales, \u00a0ya\u00a0\nse\u00a0ha\u00a0realizado\u00a0un\u00a0ensayo\u00a0cl\u00ednico447\u00a0en\u00a0el\u00a0que\u00a0se\u00a0incluy\u00f3\u00a0a\u00a0170\u00a0pacientes \u00a0con\u00a0VIH\u00a0resis\u2010\ntente\u00a0a\u00a0los\u00a0tres\u00a0grupos\u00a0de\u00a0f\u00e1rmacos\u00a0y\u00a0CVP\u00a0<400\u00a0copias/mL \u00a0durante\u00a0al\u00a0menos\u00a03\u00a0meses\u00a0\nen\u00a0tratamiento \u00a0con\u00a0ENF.\u00a0Se\u00a0les\u00a0aleatoriz\u00f3 \u00a01:1\u00a0a\u00a0seguir\u00a0con\u00a0ENF\u00a0o\u00a0cambiar\u00a0a\u00a0RAL.\u00a0El\u00a0obje\u2010\ntivo\u00a0primario\u00a0era\u00a0la\u00a0proporci\u00f3n \u00a0acumulada \u00a0de\u00a0pacientes \u00a0con\u00a0fallo\u00a0virol\u00f3gico \u00a0definido\u00a0\ncomo\u00a0CVP\u00a0\u2265400\u00a0copias/mL \u00a0hasta\u00a0la\u00a0semana\u00a024.\u00a0Se\u00a0observ\u00f3\u00a0fallo\u00a0virol\u00f3gico \u00a0en\u00a0un\u00a0pa\u2010\nciente\u00a0por\u00a0rama.\u00a0La\u00a0conclusi\u00f3n \u00a0de\u00a0los\u00a0autores\u00a0es\u00a0que\u00a0el\u00a0cambio\u00a0a\u00a0RAL\u00a0es\u00a0eficaz\u00a0y\u00a0bien\u00a0\ntolerado\u00a0a\u00a0las\u00a024\u00a0semanas\u00a0del\u00a0mismo,\u00a0que\u00a0ofrece\u00a0la\u00a0ventaja\u00a0de\u00a0la\u00a0simplicidad, \u00a0un\u00a0mis\u2010\nmo\u00a0perfil\u00a0de\u00a0seguridad \u00a0y\u00a0que\u00a0se\u00a0necesita\u00a0un\u00a0seguimiento \u00a0m\u00e1s\u00a0a\u00a0largo\u00a0plazo.\u00a0No\u00a0se\u00a0podr\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 72 \n \u00eda\u00a0utilizar\u00a0MVC\u00a0en\u00a0el\u00a0contexto\u00a0de\u00a0la\u00a0simplificaci\u00f3n, \u00a0en\u00a0estudios\u00a0similares\u00a0a\u00a0los\u00a0ya\u00a0reali\u2010\nzados\u00a0ya\u00a0que\u00a0en\u00a0estas\u00a0circunstancias \u00a0no\u00a0se\u00a0puede\u00a0realizar\u00a0el\u00a0test\u00a0de\u00a0tropismo. \u00a0\nPero\u00a0la\u00a0simplificaci\u00f3n \u00a0a\u00a0veces\u00a0no\u00a0es\u00a0tan\u00a0sencilla\u00a0y\u00a0no\u00a0debe\u00a0realizarse \u00a0si\u00a0puede\u00a0compro\u2010\nmeter\u00a0la\u00a0eficacia\u00a0del\u00a0tratamiento. \u00a0Como\u00a0ejemplo,\u00a0destacan\u00a0dos\u00a0ensayos\u00a0cl\u00ednicos\u00a0pre\u2010\nsentados\u00a0recientemente, \u00a0SWITCHMRK \u00a01\u00a0y\u00a02451.\u00a0Se\u00a0trata\u00a0de\u00a0dos\u00a0ensayos\u00a0cl\u00ednicos\u00a0parale\u2010\nlos,\u00a0multic\u00e9ntricos, \u00a0doble\u00a0ciego,\u00a0aleatorizados \u00a0en\u00a0los\u00a0que\u00a0se\u00a0incluy\u00f3\u00a0a\u00a0pacientes \u00a0virol\u00f3\u2010\ngicamente \u00a0controlados, \u00a0en\u00a0tratamiento \u00a0del\u00a0que\u00a0formaba\u00a0parte\u00a0lopinavir/r \u00a0de\u00a0forma\u00a0\nestable,\u00a0no\u00a0se\u00a0excluy\u00f3\u00a0a\u00a0pacientes \u00a0que\u00a0hab\u00edan\u00a0fracasado \u00a0a\u00a0otros\u00a0reg\u00edmenes \u00a0terap\u00e9uti \u2010\ncos,\u00a0siempre\u00a0que\u00a0en\u00a0el\u00a0momento \u00a0de\u00a0inclusi\u00f3n\u00a0presentaran \u00a0CVP\u00a0<50\u00a0copias/mL \u00a0durante\u00a0\nal\u00a0menos\u00a03\u00a0meses.\u00a0Los\u00a0pacientes \u00a0se\u00a0aleatorizaron \u00a01:1\u00a0a\u00a0mantener \u00a0LPV/r\u00a0o\u00a0cambiar\u00a0a\u00a0\nRAL,\u00a0con\u00a0la\u00a0misma\u00a0base\u00a0de\u00a0an\u00e1logos. \u00a0Los\u00a0objetivos\u00a0primarios \u00a0eran:\u00a0porcentaje \u00a0de\u00a0cam\u2010\nbio\u00a0en\u00a0las\u00a0cifras\u00a0de\u00a0l\u00edpidos\u00a0en\u00a0la\u00a0semana\u00a012,\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<50\u00a0co\u2010\npias/mL\u00a0en\u00a0la\u00a0semana\u00a024\u00a0as\u00ed\u00a0como\u00a0eficacia\u00a0y\u00a0seguridad \u00a0a\u00a0las\u00a024\u00a0semanas. \u00a0En\u00a0el\u00a0\nSWITCHMRK \u00a02,\u00a0se\u00a0aleatorizaron \u00a0355\u00a0pacientes \u00a0y\u00a0se\u00a0trat\u00f3\u00a0a\u00a0354\u00a0(176\u00a0con\u00a0RAL\u00a0y\u00a0178\u00a0con\u00a0\nLPV/r).\u00a0Tras\u00a0el\u00a0cambio,\u00a0el\u00a0RAL\u00a0se\u00a0confirm\u00f3\u00a0como\u00a0bien\u00a0tolerado\u00a0y\u00a0se\u00a0produjo\u00a0una\u00a0mejor\u00eda\u00a0\nsignificativa \u00a0de\u00a0los\u00a0par\u00e1metros \u00a0lip\u00eddicos,\u00a0pero\u00a0no\u00a0demostr\u00f3 \u00a0no\u00a0inferioridad \u00a0desde\u00a0el\u00a0\npunto\u00a0de\u00a0vista\u00a0virol\u00f3gico \u00a0en\u00a0la\u00a0semana\u00a024:\u00a0154\u00a0de\u00a0175\u00a0pacientes \u00a0(88%)\u00a0vs\u00a0167\u00a0de\u00a0178\u00a0\n(93.8%)\u00a0ten\u00edan\u00a0CVP\u00a0<50\u00a0copias/mL \u00a0en\u00a0los\u00a0grupos\u00a0de\u00a0RAL\u00a0y\u00a0LPV/r\u00a0respectivamente; \u00a0la\u00a0\ndiferencia \u00a0observada \u00a0entre\u00a0los\u00a0dos\u00a0tratamientos \u00a0es\u00a0de\u00a0\u20105.8\u00a0%\u00a0(IC\u00a095%:\u00a0\u201012.2\u00a0a\u00a00.22;\u00a0ITT).\u00a0\nProbablemente \u00a0estos\u00a0resultados \u00a0son\u00a0debidos\u00a0a\u00a0los\u00a0criterios\u00a0de\u00a0inclusi\u00f3n\u00a0de\u00a0los\u00a0pacien\u2010\ntes\u00a0y\u00a0m\u00e1s\u00a0en\u00a0concreto\u00a0a\u00a0permitir\u00a0la\u00a0entrada\u00a0en\u00a0el\u00a0estudio\u00a0de\u00a0pacientes \u00a0con\u00a0fracaso\u00a0vi\u2010\nrol\u00f3gico\u00a0previo\u00a0cuando\u00a0se\u00a0plantea\u00a0sustituir\u00a0el\u00a0LPV/r\u00a0por\u00a0RAL\u00a0que\u00a0tienen\u00a0distinta\u00a0barrera\u00a0\ngen\u00e9tica.\u00a0La\u00a0ense\u00f1anza \u00a0de\u00a0este\u00a0estudio\u00a0es\u00a0que\u00a0se\u00a0debe\u00a0elegir\u00a0muy\u00a0bien\u00a0a\u00a0los\u00a0pacientes \u00a0\ncuyo\u00a0tratamiento \u00a0se\u00a0simplifica \u00a0y\u00a0la\u00a0estrategia \u00a0de\u00a0simplificaci\u00f3n \u00a0a\u00a0seguir.\u00a0\u00a0\u00a0\u00a0\n\u00a0\nSimplificaci\u00f3n \u00a0del\u00a0TARV.\u00a0Recomendaciones \u00a0\n\u0083 En\u00a0pacientes, \u00a0sin\u00a0historia\u00a0de\u00a0fracaso\u00a0previo\u00a0a\u00a0IP,\u00a0con\u00a0CVP\u00a0indetectable \u00a0al\u00a0menos\u00a06\u00a0\nmeses\u00a0y\u00a0signos\u00a0o\u00a0s\u00edntomas\u00a0de\u00a0toxicidad\u00a0por\u00a0los\u00a0AN\u00a0es\u00a0posible\u00a0la\u00a0simplificaci\u00f3n \u00a0a\u00a0\nDRV/r\u00a0o\u00a0LPV/r\u00a0en\u00a0monoterapia393,\u00a0395,\u00a0452\u00a0(nivel\u00a0A).\u00a0\n\u0083 Si\u00a0no\u00a0ha\u00a0existido\u00a0fracaso\u00a0previo\u00a0a\u00a0AN\u00a0se\u00a0puede\u00a0sustituir\u00a0el\u00a0IP\u00a0por\u00a0EFV,\u00a0NVP.\u00a0No\u00a0se\u00a0\nrecomienda \u00a0simplificar \u00a0de\u00a0un\u00a0IP\u00a0a\u00a0ABC\u00a0si\u00a0el\u00a0paciente\u00a0ha\u00a0recibido\u00a0tratamientos \u00a0sub\u2010\n\u00f3ptimos\u00a0previos\u00a0con\u00a0AN\u00a0(nivel\u00a0A)423.\u00a0\n\u0083 Est\u00e1\u00a0contraindicada \u00a0la\u00a0simplificaci\u00f3n \u00a0a\u00a0ABC\u00a0asociado\u00a0a\u00a0TDF\u00a0y\u00a03TC\u00a0o\u00a0a\u00a0TDF\u00a0y\u00a0ddI421,\u00a0\n435,\u00a0436,\u00a0453\u00a0(nivel\u00a0B).\u00a0\n\u0083 En\u00a0pacientes \u00a0con\u00a0riesgo\u00a0cardiovascular \u00a0elevado\u00a0la\u00a0simplificaci\u00f3n \u00a0a\u00a0ATV\u00a0o\u00a0ATV/r,\u00a0NVP\u00a0\no\u00a0RAL\u00a0puede\u00a0a\u00f1adir\u00a0ventajas\u00a0metab\u00f3licas431,\u00a0433,\u00a0435,\u00a0445\u00a0(nivel\u00a0A).\u00a0\n\u0083 En\u00a0pacientes \u00a0en\u00a0su\u00a0primera\u00a0pauta\u00a0terap\u00e9utica \u00a0con\u00a0IP\u00a0y\u00a0con\u00a0CVP\u00a0indetectable \u00a0se\u00a0\npuede\u00a0simplificar \u00a0a\u00a0una\u00a0pauta\u00a0QD\u00a0como\u00a0EFV+TDF+FTC \u00a0(o\u00a03TC),\u00a0EFV+ddI+3TC \u00a0(o\u00a0\nFTC),\u00a0o\u00a0ATV/r\u00a0(o\u00a0ATV)+TDF+FTC442,\u00a0454\u00a0(nivel\u00a0A).\u00a0\n\u0083 La\u00a0sustituci\u00f3n \u00a0de\u00a0ENF\u00a0por\u00a0RAL\u00a0en\u00a0pacientes \u00a0suprimidos \u00a0virol\u00f3gicamente \u00a0se\u00a0ha\u00a0de\u2010\nmostrado \u00a0como\u00a0eficaz\u00a0y\u00a0segura450\u00a0(nivel\u00a0A).\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 73 \n \u0083 Es\u00a0importante \u00a0seleccionar \u00a0muy\u00a0bien\u00a0los\u00a0pacientes \u00a0a\u00a0los\u00a0que\u00a0se\u00a0debe\u00a0simplificar \u00a0y\u00a0la\u00a0\nestrategia \u00a0a\u00a0seguir.\u00a0La\u00a0simplificaci\u00f3n \u00a0no\u00a0se\u00a0puede\u00a0realizar\u00a0a\u00a0costa\u00a0de\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0\neficacia\u00a0virol\u00f3gica. \u00a0S\u00f3lo\u00a0se\u00a0puede\u00a0plantear\u00a0una\u00a0simplificaci\u00f3n \u00a0si\u00a0no\u00a0ha\u00a0existido\u00a0fraca\u2010\nso\u00a0previo\u00a0o\u00a0si\u00a0se\u00a0utilizan\u00a0f\u00e1rmacos \u00a0plenamente \u00a0activos\u00a0para\u00a0mantener \u00a0el\u00a0\u00e9xito\u00a0vi\u2010\nrol\u00f3gico451\u00a0(nivel\u00a0A).\u00a0\n\u0083 Otras\u00a0posibles\u00a0simplificaciones \u00a0deben\u00a0ser\u00a0realizadas \u00a0en\u00a0el\u00a0seno\u00a0de\u00a0ensayos\u00a0cl\u00ednicos,\u00a0\nno\u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0cl\u00ednica\u00a0(nivel\u00a0C).\u00a0\u00a0\n\u00a0\n\u00a0\n6.\u00a0ADHERENCIA \u00a0\nSe\u00a0entiende\u00a0por\u00a0adherencia \u00a0al\u00a0TARV\u00a0la\u00a0capacidad \u00a0del\u00a0paciente\u00a0para\u00a0implicarse \u00a0correc\u2010\ntamente\u00a0en\u00a0la\u00a0elecci\u00f3n,\u00a0inicio\u00a0y\u00a0cumplimiento \u00a0del\u00a0mismo\u00a0a\u00a0fin\u00a0de\u00a0conseguir \u00a0una\u00a0ade\u2010\ncuada\u00a0supresi\u00f3n \u00a0de\u00a0la\u00a0replicaci\u00f3n \u00a0viral.\u00a0\u00a0\nEl\u00a0control\u00a0virol\u00f3gico \u00a0depende\u00a0de\u00a0m\u00faltiples \u00a0factores\u00a0pero\u00a0la\u00a0adherencia \u00a0incorrecta \u00a0es\u00a0la\u00a0\nprimera\u00a0causa\u00a0de\u00a0fracaso\u00a0terap\u00e9utico, \u00a0relacion\u00e1ndose \u00a0con\u00a0mala\u00a0respuesta \u00a0virol\u00f3gica455\u00a0\npeor\u00a0reconstituci\u00f3n \u00a0inmune456,\u00a0y\u00a0mayor\u00a0riesgo\u00a0de\u00a0mortalidad457,\u00a0458.\u00a0Por\u00a0tanto,\u00a0es\u00a0muy\u00a0\nimportante \u00a0que\u00a0los\u00a0pacientes \u00a0sean\u00a0conscientes \u00a0de\u00a0su\u00a0enfermedad, \u00a0entiendan \u00a0clara\u2010\nmente\u00a0el\u00a0objetivo\u00a0del\u00a0TARV,\u00a0participen \u00a0en\u00a0la\u00a0decisi\u00f3n\u00a0de\u00a0iniciarlo,\u00a0se\u00a0sientan\u00a0capaces\u00a0de\u00a0\ncumplir\u00a0dicho\u00a0tratamiento \u00a0y\u00a0comprendan \u00a0la\u00a0enorme\u00a0importancia \u00a0que\u00a0tiene\u00a0una\u00a0toma\u00a0\ncontinuada \u00a0y\u00a0correcta\u00a0de\u00a0la\u00a0medicaci\u00f3n. \u00a0\u00a0\nDurante\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os\u00a0se\u00a0ha\u00a0intentado \u00a0conocer\u00a0los\u00a0factores\u00a0asociados \u00a0a\u00a0mala\u00a0ad\u2010\nherencia. \u00a0Las\u00a0diferencias \u00a0entre\u00a0los\u00a0estudios,\u00a0muchos\u00a0de\u00a0ellos\u00a0carentes\u00a0del\u00a0adecuado \u00a0\nrigor\u00a0metodol\u00f3gico, \u00a0hacen\u00a0dif\u00edcil\u00a0realizar\u00a0generalizaciones \u00a0con\u00a0alto\u00a0grado\u00a0de\u00a0eviden\u2010\ncia459.\u00a0Se\u00a0han\u00a0identificado \u00a0varios\u00a0factores\u00a0asociados \u00a0con\u00a0mala\u00a0adherencia, \u00a0entre\u00a0los\u00a0que\u00a0\ndestacan\u00a0la\u00a0mala\u00a0relaci\u00f3n\u00a0m\u00e9dico\u2010paciente, \u00a0consumo\u00a0activo\u00a0de\u00a0drogas,\u00a0enfermedad \u00a0\nmental,\u00a0edad\u00a0m\u00e1s\u00a0joven,\u00a0nivel\u00a0educativo \u00a0del\u00a0paciente, \u00a0idioma,\u00a0falta\u00a0de\u00a0apoyo\u00a0social,\u00a0\ncomplejidad \u00a0del\u00a0tratamiento, \u00a0efectos\u00a0secundarios \u00a0y,\u00a0m\u00e1s\u00a0recientemente, \u00a0temor\u00a0acerca\u00a0\nde\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0alteraciones \u00a0metab\u00f3licas \u00a0y\u00a0morfol\u00f3gicas8,\u00a0460,\u00a0461.\u00a0Un\u00a0tema\u00a0controver \u2010\ntido\u00a0es\u00a0la\u00a0relaci\u00f3n\u00a0de\u00a0la\u00a0adherencia \u00a0con\u00a0la\u00a0edad;\u00a0su\u00a0importancia \u00a0va\u00a0ser\u00a0creciente \u00a0dado\u00a0el\u00a0\nenvejecimiento \u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0infectada \u00a0por\u00a0el\u00a0VIH.\u00a0Ciertos\u00a0autores\u00a0encuentran \u00a0mayor\u00a0\nadherencia \u00a0en\u00a0los\u00a0mayores\u00a0de\u00a050\u00a0a\u00f1os\u00a0mientras\u00a0que\u00a0otros\u00a0no.\u00a0Trabajos\u00a0recientes \u00a0se\u00f1a\u2010\nlan\u00a0que\u00a0el\u00a0uso\u00a0concomitante \u00a0de\u00a0otras\u00a0medicaciones, \u00a0la\u00a0mayor\u00a0prevalencia \u00a0de\u00a0efectos\u00a0\nadversos\u00a0y\u00a0de\u00a0interacciones, \u00a0la\u00a0depresi\u00f3n \u00a0y\u00a0las\u00a0alteraciones \u00a0de\u00a0memoria\u00a0generan\u00a0una\u00a0\nmenor\u00a0adherencia \u00a0en\u00a0los\u00a0mayores462.\u00a0Lo\u00a0que\u00a0parece\u00a0claro\u00a0es\u00a0que\u00a0los\u00a0trastornos \u00a0neuro\u2010\ncognitivos, \u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0la\u00a0poblaci\u00f3n \u00a0de\u00a0m\u00e1s\u00a0edad,\u00a0suponen\u00a0un\u00a0factor\u00a0negativo\u00a0\npara\u00a0la\u00a0adherencia463y\u00a0que\u00a0este\u00a0aspecto\u00a0deber\u00e1\u00a0ser\u00a0estudiado \u00a0y\u00a0atendido\u00a0en\u00a0los\u00a0pr\u00f3xi\u2010\nmos\u00a0a\u00f1os . Por\u00a0el\u00a0contrario, \u00a0el\u00a0apoyo\u00a0emocional \u00a0y\u00a0vital,\u00a0la\u00a0capacidad \u00a0para\u00a0incluir\u00a0la\u00a0me\u2010\ndicaci\u00f3n\u00a0en\u00a0las\u00a0actividades \u00a0de\u00a0la\u00a0vida\u00a0diaria\u00a0sin\u00a0ocultarla\u00a0y\u00a0la\u00a0comprensi\u00f3n \u00a0de\u00a0la\u00a0relaci\u00f3n\u00a0\nentre\u00a0adherencia \u00a0y\u00a0desarrollo \u00a0de\u00a0resistencias \u00a0son\u00a0factores\u00a0que\u00a0predicen\u00a0una\u00a0adheren\u2010\ncia\u00a0correcta.\u00a0Corregir\u00a0los\u00a0primeros\u00a0e\u00a0incrementar \u00a0los\u00a0segundos \u00a0forma\u00a0parte\u00a0de\u00a0la\u00a0opti\u2010\nmizaci\u00f3n\u00a0del\u00a0TARV\u00a0(Tabla\u00a010).\u00a0\nEl\u00a0inicio\u00a0del\u00a0TARV\u00a0no\u00a0es\u00a0urgente\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0cr\u00f3nica.\u00a0Antes\u00a0de\u00a0iniciar\u00a0\nla\u00a0terapia\u00a0conviene\u00a0preparar\u00a0al\u00a0paciente, \u00a0identificar \u00a0las\u00a0situaciones \u00a0que\u00a0puedan\u00a0dificul\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 74 \n tar\u00a0la\u00a0adherencia \u00a0correcta\u00a0y\u00a0corregirlas464.\u00a0Es\u00a0importante \u00a0conocer\u00a0los\u00a0factores\u00a0depen\u2010\ndientes\u00a0del\u00a0paciente\u00a0(laborales, \u00a0restricciones \u00a0diet\u00e9ticas, \u00a0etc.)\u00a0para\u00a0dise\u00f1ar\u00a0un\u00a0TARV\u00a0a\u00a0la\u00a0\nmedida.\u00a0Cuando\u00a0se\u00a0inicie\u00a0el\u00a0TARV\u00a0es\u00a0imprescindible \u00a0que\u00a0se\u00a0ofrezca\u00a0una\u00a0informaci\u00f3n \u00a0\ndetallada, \u00a0soporte\u00a0y\u00a0accesibilidad \u00a0en\u00a0los\u00a0aspectos\u00a0relacionados \u00a0con\u00a0el\u00a0tratamiento. \u00a0En\u00a0\neste\u00a0sentido\u00a0el\u00a0uso\u00a0de\u00a0un\u00a0tel\u00e9fono\u00a0directo\u00a0puede\u00a0facilitar\u00a0el\u00a0contacto\u00a0entre\u00a0el\u00a0paciente\u00a0\ny\u00a0los\u00a0profesionales. \u00a0\u00a0\nDurante\u00a0el\u00a0TARV\u00a0es\u00a0fundamental \u00a0evaluar\u00a0peri\u00f3dicamente \u00a0la\u00a0adherencia, \u00a0que\u00a0debe\u00a0te\u2010\nnerse\u00a0en\u00a0cuenta\u00a0en\u00a0las\u00a0decisiones \u00a0terap\u00e9uticas. \u00a0Dado\u00a0que\u00a0no\u00a0existe\u00a0un\u00a0m\u00e9todo\u00a0fiable\u00a0\nde\u00a0evaluaci\u00f3n, \u00a0se\u00a0recomienda \u00a0utilizar\u00a0varias\u00a0t\u00e9cnicas\u00a0como\u00a0la\u00a0entrevista, \u00a0pasar\u00a0un\u00a0cues\u2010\ntionario\u00a0estructurado \u00a0(existen\u00a0cuestionarios \u00a0disponibles \u00a0validados \u00a0en\u00a0Espa\u00f1a465,\u00a0466)\u00a0\nrecuento\u00a0de\u00a0medicaci\u00f3n \u00a0sobrante\u00a0y\u00a0recogida\u00a0de\u00a0la\u00a0misma\u00a0as\u00ed\u00a0como\u00a0la\u00a0evoluci\u00f3n \u00a0cl\u00ednica\u00a0\ny\u00a0virol\u00f3gica. \u00a0Para\u00a0ello\u00a0es\u00a0indispensable \u00a0que\u00a0exista\u00a0una\u00a0buena\u00a0coordinaci\u00f3n \u00a0entre\u00a0todos\u00a0\nlos\u00a0estamentos \u00a0implicados \u00a0y\u00a0en\u00a0particular \u00a0entre\u00a0cl\u00ednicos\u00a0y\u00a0farmac\u00e9uticos. \u00a0\u00a0\nLa\u00a0entrevista \u00a0y\u00a0los\u00a0cuestionarios \u00a0estructurados, \u00a0son\u00a0de\u00a0f\u00e1cil\u00a0acceso\u00a0en\u00a0cualquier \u00a0\u00e1mbito\u00a0\nasistencial, \u00a0sin\u00a0embargo, \u00a0no\u00a0son\u00a0muy\u00a0precisos,\u00a0y\u00a0en\u00a0determinadas \u00a0circunstancias \u00a0(por\u00a0\nejemplo\u00a0en\u00a0UDVP)\u00a0pueden\u00a0arrojar\u00a0resultados \u00a0no\u00a0v\u00e1lidos.\u00a0Los\u00a0m\u00e9todos\u00a0m\u00e1s\u00a0sofisticados \u00a0\ny\u00a0caros\u00a0para\u00a0evaluar\u00a0la\u00a0adherencia \u00a0como\u00a0determinaci\u00f3n \u00a0de\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0\nf\u00e1rmacos467\u00a0o\u00a0dispositivos \u00a0electr\u00f3nicos \u00a0que\u00a0registran\u00a0la\u00a0toma\u00a0de\u00a0medicaci\u00f3n \u00a0(MEMS\u00a0o\u00a0\nMedication \u00a0Event\u00a0Monitoring \u00a0System ),\u00a0se\u00a0circunscriben \u00a0al\u00a0campo\u00a0de\u00a0la\u00a0investigaci\u00f3n468.\u00a0\u00a0\nLas\u00a0caracter\u00edsticas \u00a0virol\u00f3gicas \u00a0del\u00a0VIH\u00a0determinan \u00a0que\u00a0cuando\u00a0existen\u00a0niveles\u00a0subte\u2010\nrap\u00e9uticos \u00a0de\u00a0los\u00a0FAR\u00a0el\u00a0virus\u00a0pueda\u00a0replicarse \u00a0y\u00a0desarrollar \u00a0resistencias. \u00a0Los\u00a0datos\u00a0ob\u2010\ntenidos\u00a0durante\u00a0los\u00a0primeros\u00a0tratamientos \u00a0combinados, \u00a0basados\u00a0en\u00a0IP\u00a0sin\u00a0potenciar \u00a0\nconstataron \u00a0que\u00a0la\u00a0m\u00e1xima\u00a0eficacia\u00a0requer\u00eda\u00a0una\u00a0adherencia \u00a0pr\u00e1cticamente \u00a0perfecta,\u00a0\ncl\u00e1sicamente \u00a0>95%283.\u00a0Estudios\u00a0recientes \u00a0sugieren\u00a0que\u00a0con\u00a0niveles\u00a0menores\u00a0se\u00a0pueden\u00a0\nalcanzar\u00a0los\u00a0objetivos\u00a0terap\u00e9uticos \u00a0en\u00a0reg\u00edmenes \u00a0basados\u00a0en\u00a0NN\u00a0o\u00a0IP/r,\u00a0especialmente \u00a0\nen\u00a0pacientes \u00a0que\u00a0consiguen \u00a0viremias\u00a0indetectables272,\u00a0469,\u00a0470.\u00a0Debe\u00a0destacarse \u00a0que\u00a0no\u00a0\ns\u00f3lo\u00a0es\u00a0importante \u00a0el\u00a0porcentaje \u00a0de\u00a0dosis\u00a0omitidas\u00a0sino\u00a0tambi\u00e9n\u00a0los\u00a0patrones\u00a0de\u00a0ad\u2010\nhesi\u00f3n\u00a0sub\u00f3ptima. \u00a0Las\u00a0interrupciones \u00a0de\u00a0tratamiento \u00a0(m\u00e1s\u00a0de\u00a0dos\u00a0d\u00edas\u00a0sin\u00a0tomar\u00a0\nning\u00fan\u00a0f\u00e1rmaco)\u00a0presentan \u00a0mayor\u00a0repercusi\u00f3n \u00a0en\u00a0la\u00a0respuesta \u00a0virol\u00f3gica \u00a0que\u00a0la\u00a0omi\u2010\nsi\u00f3n\u00a0ocasional \u00a0de\u00a0dosis471.\u00a0En\u00a0terapia\u00a0de\u00a0inicio,\u00a0tambi\u00e9n\u00a0se\u00a0ha\u00a0demostrado \u00a0una\u00a0relaci\u00f3n\u00a0\nlineal\u00a0entre\u00a0nivel\u00a0de\u00a0adherencia \u00a0y\u00a0efectividad: \u00a0en\u00a0tratamientos \u00a0basados\u00a0en\u00a0NN,\u00a0por\u00a0ca\u2010\nda\u00a010\u00a0%\u00a0de\u00a0incremento \u00a0en\u00a0el\u00a0cumplimiento, \u00a0se\u00a0observ\u00f3\u00a0un\u00a010\u00a0%\u00a0\u00a0m\u00e1s\u00a0de\u00a0pacientes \u00a0que\u00a0\nconsiguen \u00a0viremias\u00a0indetectables \u00a0sostenidas472.\u00a0\u00a0\nLa\u00a0relaci\u00f3n\u00a0entre\u00a0adherencia \u00a0y\u00a0desarrollo \u00a0de\u00a0resistencias \u00a0es\u00a0m\u00e1s\u00a0compleja\u00a0que\u00a0la\u00a0idea\u00a0\nestablecida \u00a0de\u00a0que\u00a0\u201cla\u00a0no\u00a0adherencia \u00a0aumenta\u00a0el\u00a0riesgo\u00a0de\u00a0resistencias\u201d. \u00a0Se\u00a0han\u00a0encon\u2010\ntrado\u00a0diferencias \u00a0en\u00a0funci\u00f3n\u00a0de\u00a0las\u00a0familias\u00a0de\u00a0f\u00e1rmacos; \u00a0as\u00ed\u00a0en\u00a0pautas\u00a0basadas\u00a0en\u00a0IP\u00a0no\u00a0\npotenciados \u00a0se\u00a0comprob\u00f3 \u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0resistencias \u00a0con\u00a0niveles\u00a0altos\u00a0de\u00a0cumplimien \u2010\nto,\u00a0mientras\u00a0que\u00a0en\u00a0pautas\u00a0con\u00a0NN\u00a0las\u00a0resistencias \u00a0son\u00a0inusuales \u00a0en\u00a0los\u00a0pacientes \u00a0muy\u00a0\ncumplidores, \u00a0d\u00e1ndose\u00a0en\u00a0los\u00a0poco\u00a0adherentes \u00a0o\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0interrupciones \u00a0\nprolongadas \u00a0del\u00a0tratamiento473;\u00a0por\u00a0el\u00a0contrario, \u00a0en\u00a0el\u00a0caso\u00a0de\u00a0los\u00a0IP\u00a0potenciados, \u00a0la\u00a0\naparici\u00f3n \u00a0de\u00a0resistencias \u00a0es\u00a0m\u00e1s\u00a0dif\u00edcil\u00a0en\u00a0cualquier \u00a0nivel\u00a0de\u00a0adherencia474,\u00a0475.\u00a0\u00a0\nSi\u00a0se\u00a0detecta\u00a0una\u00a0falta\u00a0de\u00a0adherencia \u00a0debe\u00a0intervenirse \u00a0de\u00a0forma\u00a0activa\u00a0para\u00a0corregirla. \u00a0\nLa\u00a0monitorizaci\u00f3n \u00a0de\u00a0la\u00a0adherencia \u00a0no\u00a0debe\u00a0utilizarse\u00a0para\u00a0explicar\u00a0un\u00a0fracaso\u00a0o\u00a0el\u00a0de\u2010\nsarrollo\u00a0de\u00a0resistencias, \u00a0sino\u00a0para\u00a0prevenir\u00a0que\u00a0\u00e9stos\u00a0se\u00a0produzcan \u00a0mediante \u00a0la\u00a0detec\u2010\nci\u00f3n\u00a0precoz\u00a0de\u00a0los\u00a0problemas \u00a0e\u00a0implementar \u00a0r\u00e1pidamente \u00a0medidas\u00a0correctoras476.\u00a0A\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 75 \n modo\u00a0de\u00a0ejemplo,\u00a0cuando\u00a0se\u00a0analiz\u00f3\u00a0la\u00a0adherencia \u00a0no\u00a0de\u00a0forma\u00a0global,\u00a0sino\u00a0f\u00e1rmaco\u00a0\npor\u00a0f\u00e1rmaco,\u00a0se\u00a0detect\u00f3\u00a0que\u00a0en\u00a0un\u00a030\u00a0%\u00a0de\u00a0los\u00a0pacientes \u00a0ten\u00eda\u00a0falta\u00a0de\u00a0adherencia \u00a0dife\u2010\nrencial,\u00a0es\u00a0decir\u00a0a\u00a0alguno\u00a0de\u00a0los\u00a0componentes \u00a0del\u00a0tratamiento \u00a0y\u00a0esta\u00a0falta\u00a0de\u00a0adheren\u2010\ncia\u00a0se\u00a0relacion\u00f3 \u00a0con\u00a0fracaso\u00a0virol\u00f3gico477.\u00a0En\u00a0estos\u00a0pacientes \u00a0la\u00a0coformulaci\u00f3n \u00a0de\u00a0\nf\u00e1rmacos \u00a0podr\u00eda\u00a0ser\u00a0una\u00a0alternativa. \u00a0\nLas\u00a0estrategias \u00a0son\u00a0m\u00faltiples, \u00a0algunas\u00a0basadas\u00a0en\u00a0teor\u00edas\u00a0psicol\u00f3gicas \u00a0y\u00a0la\u00a0mayor\u00eda\u00a0diri\u2010\ngidas\u00a0a\u00a0paliar\u00a0los\u00a0condicionantes \u00a0sociales\u00a0o\u00a0individuales \u00a0de\u00a0los\u00a0pacientes. \u00a0Desde\u00a0esta\u00a0\nperspectiva \u00a0cabe\u00a0analizar\u00a0las\u00a0intervenciones \u00a0sobre\u00a0adherencia \u00a0mediante \u00a0las\u00a0denomina \u2010\ndas\u00a0\u201centrevistas \u00a0motivacionales\u201d \u00a0478,\u00a0las\u00a0visitas\u00a0domiciliarias \u00a0y\u00a0la\u00a0intervenci\u00f3n \u00a0espec\u00edfica \u00a0\nsobre\u00a0la\u00a0pareja\u00a0del\u00a0paciente, \u00a0todas\u00a0ellas\u00a0relativamente \u00a0complejas, \u00a0sin\u00a0resultados \u00a0defini\u2010\ntivos\u00a0y\u00a0sin\u00a0grandes\u00a0diferencias \u00a0frente\u00a0al\u00a0grupo\u00a0control\u00a0asesorado \u00a0acorde\u00a0a\u00a0una\u00a0buena\u00a0\npr\u00e1ctica\u00a0cl\u00ednica.\u00a0Las\u00a0intervenciones \u00a0dirigidas\u00a0a\u00a0ciertas\u00a0poblaciones \u00a0especiales \u00a0\u2013\u00a0mujeres,\u00a0\nlatinos\u00a0en\u00a0EEUU,\u00a0y\u00a0pacientes \u00a0con\u00a0historia\u00a0previa\u00a0de\u00a0alcoholismo \u00a0\u2013\u00a0no\u00a0han\u00a0logrado\u00a0mejo\u2010\nrar\u00a0la\u00a0adherencia \u00a0al\u00a0tratamiento459.\u00a0\u00a0\nHan\u00a0demostrado \u00a0ser\u00a0beneficiosas \u00a0las\u00a0intervenciones \u00a0sencillas\u00a0de\u00a0educaci\u00f3n \u00a0y\u00a0soporte\u00a0\nen\u00a0aspectos\u00a0pr\u00e1cticos\u00a0del\u00a0tratamiento479.Probablemente \u00a0la\u00a0intervenci\u00f3n \u00a0que\u00a0ha\u00a0de\u2010\nmostrado \u00a0mayor\u00a0eficacia\u00a0ha\u00a0sido\u00a0el\u00a0soporte\u00a0interpersonal \u00a0estructurado, \u00a0en\u00a0el\u00a0que\u00a0per\u2010\nsonal\u00a0sanitario\u00a0entrenado \u00a0emplea\u00a0estrategias \u00a0individualizadas. \u00a0Respecto\u00a0al\u00a0tratamiento \u00a0\ndirectamente \u00a0observado, \u00a0los\u00a0estudios\u00a0controlados \u00a0arrojan\u00a0resultados \u00a0contradictorios, \u00a0\nen\u00a0general\u00a0han\u00a0demostrado \u00a0beneficio \u00a0respecto\u00a0al\u00a0tratamiento \u00a0auto\u00a0administrado \u00a0en\u00a0\npoblaciones \u00a0especiales \u00a0(usuarios\u00a0de\u00a0drogas\u00a0o\u00a0en\u00a0prisiones) \u00a0pero\u00a0no\u00a0han\u00a0demostrado \u00a0\ndiferencias \u00a0a\u00a0largo\u00a0plazo\u00a0en\u00a0la\u00a0cl\u00ednica\u00a0convencional480,\u00a0481.\u00a0\u00a0\nEs\u00a0importante \u00a0recordar\u00a0que\u00a0la\u00a0adherencia \u00a0decae\u00a0con\u00a0el\u00a0tiempo\u00a0y\u00a0por\u00a0tanto\u00a0las\u00a0estrate\u2010\ngias\u00a0dise\u00f1adas \u00a0para\u00a0optimizarla \u00a0deben\u00a0dirigirse\u00a0no\u00a0s\u00f3lo\u00a0a\u00a0incrementarla \u00a0sino\u00a0a\u00a0mante\u2010\nnerla\u00a0constante482.\u00a0\u00a0\nGESIDA\u00a0y\u00a0el\u00a0PNS,\u00a0conjuntamente \u00a0con\u00a0la\u00a0Sociedad\u00a0Espa\u00f1ola\u00a0de\u00a0Farmacia\u00a0Hospitalaria8\u00a0\nhan\u00a0revisado\u00a0los\u00a0factores\u00a0que\u00a0influyen\u00a0en\u00a0la\u00a0adherencia, \u00a0los\u00a0m\u00e9todos\u00a0de\u00a0evaluaci\u00f3n \u00a0y\u00a0\nlas\u00a0posibles\u00a0estrategias \u00a0de\u00a0intervenci\u00f3n \u00a0y\u00a0actuaci\u00f3n \u00a0de\u00a0un\u00a0equipo\u00a0multidisciplinar \u00a0que\u00a0\ndebe\u00a0ser\u00a0integrado \u00a0por\u00a0m\u00e9dicos,\u00a0farmac\u00e9uticos, \u00a0enfermeras, \u00a0psic\u00f3logos \u00a0y\u00a0personal\u00a0de\u00a0\nsoporte.\u00a0Remitimos \u00a0a\u00a0ese\u00a0documento \u00a0para\u00a0profundizar \u00a0en\u00a0el\u00a0tema\u00a0de\u00a0la\u00a0adherencia \u00a0al\u00a0\nTARV.\u00a0\u00a0\u00a0\n\u00a0\nAdherencia. \u00a0Recomendaciones \u00a0\n\u0083 Antes\u00a0de\u00a0iniciar\u00a0el\u00a0TARV\u00a0se\u00a0debe\u00a0preparar\u00a0al\u00a0paciente, \u00a0identificar \u00a0y\u00a0corregir\u00a0las\u00a0cau\u2010\nsas\u00a0que\u00a0pueden\u00a0limitar\u00a0su\u00a0adherencia. \u00a0Si\u00a0el\u00a0paciente\u00a0no\u00a0est\u00e1\u00a0preparado, \u00a0en\u00a0general\u00a0\nes\u00a0mejor\u00a0retrasar\u00a0el\u00a0inicio\u00a0del\u00a0TARV.\u00a0\u00a0\n\u0083 Una\u00a0vez\u00a0iniciado\u00a0el\u00a0TARV\u00a0se\u00a0recomienda \u00a0efectuar\u00a0un\u00a0primer\u00a0control\u00a0a\u00a0las\u00a02\u20104\u00a0sema\u2010\nnas\u00a0para\u00a0corregir\u00a0los\u00a0factores\u00a0inherentes \u00a0al\u00a0tratamiento \u00a0o\u00a0del\u00a0propio\u00a0paciente\u00a0que\u00a0\npuedan\u00a0limitar\u00a0la\u00a0adherencia. \u00a0\u00a0\n\u0083 Debe\u00a0facilitarse \u00a0el\u00a0contacto\u00a0entre\u00a0el\u00a0paciente\u00a0y\u00a0los\u00a0profesionales. \u00a0\u00a0\n\u0083 Si\u00a0la\u00a0adherencia \u00a0es\u00a0correcta,\u00a0debe\u00a0monitorizarse \u00a0y\u00a0reforzarse, \u00a0coincidiendo \u00a0con\u00a0las\u00a0\nvisitas\u00a0cl\u00ednicas\u00a0(nivel\u00a0C).\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 76 \n \u0083 El\u00a0control\u00a0de\u00a0la\u00a0adherencia \u00a0debe\u00a0realizarse \u00a0por\u00a0un\u00a0equipo\u00a0multidisciplinar, \u00a0y\u00a0en\u00a0\u00e9l\u00a0\ndeben\u00a0estar\u00a0implicados \u00a0no\u00a0s\u00f3lo\u00a0el\u00a0m\u00e9dico\u00a0sino\u00a0tambi\u00e9n\u00a0la\u00a0enfermer\u00eda, \u00a0los\u00a0profesio\u2010\nnales\u00a0de\u00a0apoyo\u00a0psicol\u00f3gico \u00a0y\u00a0la\u00a0farmacia\u00a0hospitalaria \u00a0(nivel\u00a0C).\u00a0\n\u0083 Cada\u00a0unidad\u00a0asistencial \u00a0debiera\u00a0realizar\u00a0un\u00a0seguimiento \u00a0peri\u00f3dico \u00a0de\u00a0la\u00a0adherencia, \u00a0\nno\u00a0s\u00f3lo\u00a0con\u00a0vistas\u00a0a\u00a0detectar\u00a0las\u00a0faltas\u00a0individuales \u00a0de\u00a0cumplimiento \u00a0sino\u00a0para\u00a0co\u2010\nnocer\u00a0la\u00a0magnitud \u00a0del\u00a0problema \u00a0en\u00a0su\u00a0\u00e1mbito\u00a0de\u00a0trabajo;\u00a0el\u00a0an\u00e1lisis\u00a0de\u00a0los\u00a0datos\u00a0\npermitir\u00e1 \u00a0determinar \u00a0las\u00a0causas\u00a0de\u00a0los\u00a0problemas \u00a0detectados \u00a0(abandonos, \u00a0vacacio\u2010\nnes\u00a0terap\u00e9uticas, \u00a0incumplimientos\u2026) \u00a0y\u00a0elaborar\u00a0estrategias \u00a0concretas \u00a0de\u00a0actuaci\u00f3n, \u00a0\ntanto\u00a0con\u00a0los\u00a0enfermos \u00a0como\u00a0en\u00a0la\u00a0estructura \u00a0y\u00a0funcionamiento \u00a0del\u00a0equipo\u00a0asisten\u2010\ncial\u00a0(nivel\u00a0C).\u00a0\n\u00a0\n\u00a0\n7.\u00a0EFECTOS\u00a0ADVERSOS \u00a0DEL\u00a0TRATAMIENTO \u00a0ANTIRRETROVIRAL \u00a0\nLos\u00a0FAR\u00a0pueden\u00a0producir\u00a0numerosos \u00a0efectos\u00a0secundarios \u00a0que\u00a0se\u00a0presentan \u00a0al\u00a0inicio\u00a0del\u00a0\ntratamiento \u00a0o\u00a0a\u00a0medio\u2010largo\u00a0plazo.\u00a0En\u00a0este\u00a0\u00faltimo\u00a0caso\u00a0suelen\u00a0asociarse \u00a0a\u00a0procesos\u00a0\nfisiol\u00f3gicos \u00a0o\u00a0comorbilidades \u00a0relacionados \u00a0con\u00a0el\u00a0envejecimiento. \u00a0Algunos\u00a0de\u00a0ellos\u00a0son\u00a0\nespec\u00edficos \u00a0de\u00a0f\u00e1rmacos\u00a0y\u00a0otros\u00a0de\u00a0grupo.\u00a0En\u00a0las\u00a0tablas\u00a011\u201016\u00a0se\u00a0muestra\u00a0la\u00a0toxicidad\u00a0\ncaracter\u00edstica \u00a0de\u00a0cada\u00a0familia\u00a0y\u00a0se\u00a0resume\u00a0la\u00a0toxicidad\u00a0por\u00a0\u00f3rganos\u00a0y\u00a0aparatos, \u00a0la\u00a0pato\u2010\ngenia,\u00a0la\u00a0relaci\u00f3n\u00a0individual \u00a0con\u00a0cada\u00a0f\u00e1rmaco,\u00a0el\u00a0diagn\u00f3stico \u00a0y\u00a0el\u00a0tratamiento \u00a0de\u00a0los\u00a0\nmismos483.\u00a0A\u00a0continuaci\u00f3n \u00a0se\u00a0comentan \u00a0los\u00a0que,\u00a0por\u00a0su\u00a0frecuencia \u00a0y/o\u00a0potencial \u00a0grave\u2010\ndad,\u00a0tienen\u00a0mayor\u00a0relevancia \u00a0cl\u00ednica.\u00a0\n\u00a0Toxicidad \u00a0mitocondrial \u00a0\u00a0\nEn\u00a0la\u00a0Tabla\u00a011\u00a0se\u00a0exponen\u00a0los\u00a0posibles\u00a0efectos\u00a0adversos\u00a0debidos\u00a0al\u00a0da\u00f1o\u00a0mitocondrial \u00a0\nproducido \u00a0por\u00a0la\u00a0inhibici\u00f3n \u00a0de\u00a0la\u00a0enzima\u00a0ADN\u2010polimerasa \u00a0mitocondrial. \u00a0El\u00a0m\u00e1s\u00a0grave\u00a0de\u00a0\nellos,\u00a0una\u00a0combinaci\u00f3n\n\u00a0de\u00a0acidosis\u00a0l\u00e1ctica\u00a0y\u00a0esteatosis \u00a0hep\u00e1tica\u00a0(ALEH),\u00a0es\u00a0inducido\u00a0por\u00a0\nd4T\u00a0y,\u00a0en\u00a0menor\u00a0medida,\u00a0por\u00a0ZDV\u00a0y\u00a0ddI.\u00a0Su\u00a0incidencia \u00a0es\u00a0baja,\u00a0pero\u00a0si\u00a0no\u00a0se\u00a0diagnostica \u00a0\na\u00a0tiempo\u00a0puede\u00a0ser\u00a0mortal483.\u00a0Las\u00a0manifestaciones \u00a0cl\u00ednicas,\u00a0subagudas \u00a0e\u00a0inespec\u00edficas \u00a0\n(astenia,\u00a0disnea\u00a0e\u00a0insuficiencia \u00a0hep\u00e1tica), \u00a0o\u00a0la\u00a0acidosis\u00a0aparecen \u00a0cuando\u00a0el\u00a0lactato\u00a0es\u00a0\n>5\u201310\u00a0mmol/L.\u00a0Debe\u00a0tenerse\u00a0un\u00a0alto\u00a0grado\u00a0de\u00a0sospecha \u00a0y\u00a0realizar\u00a0el\u00a0diagn\u00f3stico \u00a0antes\u00a0\nde\u00a0que\u00a0aparezca\u00a0acidosis,\u00a0pues\u00a0en\u00a0esta\u00a0fase\u00a0(hiperlactatemia \u00a0asintom\u00e1tica) \u00a0la\u00a0mortali\u2010\ndad\u00a0es\u00a0muy\u00a0inferior\u00a0a\u00a0la\u00a0de\u00a0la\u00a0ALEH.\u00a0Su\u00a0tratamiento \u00a0consiste\u00a0en\u00a0retirar\u00a0los\u00a0AN\u00a0respon\u2010\nsables\u00a0y\u00a0monitorizar \u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0lactato484.\u00a0\u00a0\nLa\u00a0lipoatrofia108,\u00a0485,\u00a0aunque\u00a0tambi\u00e9n\u00a0es\u00a0secundaria \u00a0a\u00a0toxicidad\u00a0mitocondrial, \u00a0se\u00a0comen\u2010\nta\u00a0en\u00a0el\u00a0apartado\u00a0de\u00a0anomal\u00edas \u00a0de\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0grasa\u00a0corporal.\u00a0\u00a0\n\u00a0\nReacciones \u00a0de\u00a0hipersensibilidad \u00a0\u00a0\nAunque\u00a0todos\u00a0los\u00a0FAR\u00a0pueden\u00a0provocar\u00a0RHS,\u00a0son\u00a0mucho\u00a0m\u00e1s\u00a0frecuentes \u00a0con\u00a0ABC\u00a0y\u00a0los\u00a0\nNN\u00a0(la\u00a0RHS\u00a0a\u00a0ABC\u00a0se\u00a0ha\u00a0descrito\u00a0m\u00e1s\u00a0arriba).\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 77 \n Las\u00a0RHS\u00a0frente\u00a0a\u00a0los\u00a0NN\u00a0suelen\u00a0presentarse \u00a0con\u00a0un\u00a0exantema \u00a0cut\u00e1neo\u00a0y\u00a0rara\u00a0vez\u00a0con\u00a0un\u00a0\ncuadro\u00a0sist\u00e9mico \u00a0grave\u00a0o\u00a0con\u00a0s\u00edndrome \u00a0de\u00a0Stevens\u2010Johnson\u00a0o\u00a0necr\u00f3lisis \u00a0epid\u00e9rmica \u00a0\nt\u00f3xica\u00a0(Tabla\u00a012).\u00a0\u00a0\n\u00a0\nHepatotoxicidad \u00a0\nEs,\u00a0junto\u00a0al\u00a0exantema, \u00a0el\u00a0efecto\u00a0adverso\u00a0espec\u00edfico \u00a0de\u00a0grupo\u00a0m\u00e1s\u00a0importante \u00a0de\u00a0los\u00a0NN,\u00a0\nsi\u00a0bien\u00a0su\u00a0intensidad \u00a0suele\u00a0ser\u00a0leve\u00a0o\u00a0moderada \u00a0y\u00a0son\u00a0raros\u00a0los\u00a0casos\u00a0de\u00a0hepatitis\u00a0sin\u2010\ntom\u00e1tica486.\u00a0NVP\u00a0provoca\u00a0elevaci\u00f3n \u00a0de\u00a0transaminasas \u00a0con\u00a0mayor\u00a0frecuencia \u00a0y\u00a0se\u00a0des\u2010\naconseja\u00a0como\u00a0TARV\u00a0de\u00a0inicio\u00a0en\u00a0mujeres\u00a0con\u00a0>250\u00a0CD4/\u00b5L\u00a0y\u00a0varones\u00a0con\u00a0>400\u00a0CD4/\u00b5L\u00a0\ndebido\u00a0a\u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0hepatotoxicidad \u00a0grave410,\u00a0487.\u00a0No\u00a0obstante, \u00a0parece\u00a0ser\u00a0que\u00a0\nlos\u00a0pacientes \u00a0pre\u2010tratados,\u00a0especialmente \u00a0en\u00a0el\u00a0contexto\u00a0de\u00a0una\u00a0simplificaci\u00f3n \u00a0del\u00a0\nTARV,\u00a0tienen\u00a0un\u00a0riesgo\u00a0similar\u00a0al\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0nunca\u00a0llevaron\u00a0TARV\u00a0con\u00a0inmu\u2010\nnodepresi\u00f3n \u00a0m\u00e1s\u00a0profunda413,\u00a0414.\u00a0Los\u00a0IP\u00a0potenciados \u00a0que\u00a0se\u00a0usan\u00a0actualmente \u00a0y\u00a0los\u00a0\nFAR\u00a0de\u00a0otras\u00a0familias\u00a0(incluido\u00a0los\u00a0NN\u00a0de\u00a0segunda\u00a0generaci\u00f3n) \u00a0tienen\u00a0unas\u00a0tasas\u00a0de\u00a0\nhepatotoxicidad \u00a0m\u00e1s\u00a0reducidas \u00a0que\u00a0los\u00a0NN\u00a0cl\u00e1sicos488\u2010490\u00a0(Tabla\u00a012).\u00a0\n\u00a0Trastornos \u00a0neuropsiqui\u00e1tricos \u00a0\nEFV\u00a0produce\u00a0diversos\u00a0s\u00edntomas\u00a0neuropsiqui\u00e1tricos \u00a0(mareo,\u00a0somnolencia, \u00a0insomnio, \u00a0\nsue\u00f1os\u00a0v\u00edvidos,\u00a0confusi\u00f3n, \u00a0ansiedad, \u00a0despersonalizaci\u00f3n, \u00a0etc.)\u00a0en\u00a0m\u00e1s\u00a0del\u00a050%\u00a0de\u00a0los\u00a0\ncasos,\u00a0los\u00a0cuales,\u00a0aunque\u00a0suelen\u00a0remitir\u00a0en\u00a0las\u00a0primeras\u00a02\u20104\u00a0semanas, \u00a0obligan\u00a0a\u00a0inte\u2010\nrrumpir\u00a0el\u00a0tratamiento \u00a0en\u00a0un\u00a0peque\u00f1o\u00a0porcentaje \u00a0de\u00a0los\u00a0casos\n491,\u00a0492\u00a0(Tabla\u00a012).\u00a0Se\u00a0\naconseja\u00a0evitar\u00a0este\u00a0f\u00e1rmaco\u00a0en\u00a0pacientes \u00a0con\u00a0trastornos \u00a0psiqui\u00e1tricos \u00a0mayores,\u00a0aun\u2010\nque\u00a0en\u00a0un\u00a0estudio\u00a0aleatorizado \u00a0el\u00a0riesgo\u00a0de\u00a0depresi\u00f3n \u00a0fue\u00a0similar\u00a0con\u00a0EFV\u00a0que\u00a0con\u00a0los\u00a0\nIP493.\u00a0Aunque\u00a0otros\u00a0FAR,\u00a0como\u00a0ZDV,\u00a0pueden\u00a0provocar\u00a0s\u00edntomas\u00a0neurol\u00f3gicos, \u00a0\u00e9stos\u00a0son\u00a0\nmucho\u00a0menos\u00a0frecuentes \u00a0que\u00a0los\u00a0de\u00a0EFV.\u00a0\n\u00a0\nNefrotoxicidad \u00a0\nTDF\u00a0puede\u00a0inducir\u00a0toxicidad\u00a0renal\u00a0en\u00a0una\u00a0peque\u00f1a\u00a0proporci\u00f3n \u00a0de\u00a0pacientes. \u00a0Su\u00a0inci\u2010\ndencia\u00a0en\u00a0estudios\u00a0de\u00a0cohorte494,\u00a0495\u00a0es\u00a0mayor\u00a0que\u00a0la\u00a0observada \u00a0en\u00a0ensayos\u00a0cl\u00ednicos,\u00a0en\u00a0\nlos\u00a0que\u00a0solamente \u00a0se\u00a0ha\u00a0encontrado \u00a0una\u00a0reducci\u00f3n \u00a0discreta\u00a0(\u224810%)\u00a0y\u00a0no\u00a0progresiva \u00a0del\u00a0\nfiltrado\u00a0glomerular496,\u00a0497.\u00a0Esta\u00a0complicaci\u00f3n \u00a0consiste\u00a0en\u00a0una\u00a0disfunci\u00f3n \u00a0tubular\u00a0y\u00a0se\u00a0\nmanifiesta \u00a0como\u00a0un\u00a0s\u00edndrome \u00a0de\u00a0Fanconi\u00a0acompa\u00f1ado \u00a0de\u00a0una\u00a0disminuci\u00f3n \u00a0del\u00a0filtrado\u00a0\nglomerular498.\u00a0Es\u00a0m\u00e1s\u00a0frecuente \u00a0cuando\u00a0coincide\u00a0con\u00a0otros\u00a0factores\u00a0de\u00a0riesgo\u00a0(insufi\u2010\nciencia\u00a0renal\u00a0previa\u00a0o\u00a0concomitante, \u00a0diabetes,\u00a0hipertensi\u00f3n \u00a0arterial,\u00a0f\u00e1rmacos\u00a0ne\u2010\nfrot\u00f3xicos, \u00a0edad\u00a0avanzada, \u00a0bajo\u00a0peso\u00a0corporal\u00a0y\u00a0cifras\u00a0bajas\u00a0de\u00a0CD4)\u00a0221,\u00a0226,\u00a0496,\u00a0498,\u00a0499.\u00a0La\u00a0\nnefrotoxicidad \u00a0por\u00a0TDF\u00a0suele\u00a0revertir\u00a0al\u00a0retirar\u00a0el\u00a0f\u00e1rmaco.\u00a0Con\u00a0ABC\u00a0se\u00a0ha\u00a0encontrado \u00a0\nuna\u00a0discreta\u00a0reducci\u00f3n \u00a0del\u00a0filtrado\u00a0glomerular234.\u00a0IDV\u00a0y,\u00a0con\u00a0mucha\u00a0menor\u00a0frecuencia \u00a0\nATV,\u00a0producen \u00a0nefrolitiasis \u00a0por\u00a0dep\u00f3sito\u00a0tubular\u00a0de\u00a0cristales\u00a0(Tabla\u00a012).\u00a0\n\u00a0\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 78 \n Trastornos \u00a0metab\u00f3licos \u00a0y\u00a0riesgo\u00a0cardiovascular \u00a0\nEste\u00a0grupo\u00a0de\u00a0trastornos \u00a0incluye\u00a0dislipemia, \u00a0resistencia \u00a0a\u00a0la\u00a0insulina\u00a0y\u00a0diabetes\u00a0mellitus,\u00a0\ntodos\u00a0los\u00a0cuales\u00a0son\u00a0m\u00e1s\u00a0frecuentes \u00a0con\u00a0los\u00a0IP\u00a0cl\u00e1sicos\u00a0\u00a0que\u00a0con\u00a0los\u00a0IP\u00a0potenciados \u00a0ac\u2010\ntualmente \u00a0utilizados \u00a0y\u00a0con\u00a0los\u00a0an\u00e1logos\u00a0de\u00a0timidina\u00a0que\u00a0con\u00a0los\u00a0dem\u00e1s\u00a0AN.\u00a0Asimismo, \u00a0\ntodas\u00a0estas\u00a0anomal\u00edas \u00a0son\u00a0m\u00e1s\u00a0comunes\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0redistribuci\u00f3n \u00a0de\u00a0la\u00a0grasa\u00a0\ncorporal.\u00a0\u00a0\nUna\u00a0dislipemia \u00a0caracterizada \u00a0por\u00a0aumento\u00a0de\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0colesterol \u00a0to\u2010\ntal,\u00a0colesterol \u2010LDL\u00a0y,\u00a0sobre\u00a0todo,\u00a0triglic\u00e9ridos, \u00a0es\u00a0la\u00a0anomal\u00eda\u00a0metab\u00f3lica \u00a0que\u00a0con\u00a0ma\u2010\nyor\u00a0frecuencia \u00a0se\u00a0asocia\u00a0al\u00a0TARV.\u00a0Aunque\u00a0tradicionalmente \u00a0se\u00a0ha\u00a0relacionado \u00a0esta\u00a0dis\u2010\nlipemia\u00a0con\u00a0los\u00a0IP,\u00a0no\u00a0todos\u00a0ellos\u00a0tienen\u00a0el\u00a0mismo\u00a0impacto\u00a0sobre\u00a0los\u00a0l\u00edpidos\u00a0y\u00a0otros\u00a0FAR,\u00a0\nespecialmente \u00a0los\u00a0an\u00e1logos\u00a0de\u00a0timidina,\u00a0tambi\u00e9n\u00a0inducen\u00a0dislipemia263,\u00a0274,\u00a0500\u2010502.\u00a0Res\u2010\npecto\u00a0a\u00a0los\u00a0IP,\u00a0diversos\u00a0ensayos\u00a0cl\u00ednicos\u00a0han\u00a0revelado\u00a0que\u00a0ATV,\u00a0y\u00a0FPV,\u00a0sobre\u00a0todo\u00a0sin\u00a0\npotenciar, \u00a0tienen\u00a0un\u00a0mejor\u00a0perfil\u00a0lip\u00eddico;\u00a0ATV/r,\u00a0SQV/r\u00a0(1500/100 \u00a0BID\u00a0\u00f3\u00a01500/100 \u00a0QD)\u00a0\ny\u00a0DRV/r\u00a0(600/100\u00a0BID\u00a0u\u00a0800/100\u00a0QD)\u00a0presentan \u00a0perfiles\u00a0intermedios; \u00a0mientras\u00a0que\u00a0\nFPV/r\u00a0(1400/100 \u00a0QD\u00a0o\u00a0700/100\u00a0BID),\u00a0LPV/r\u00a0(400/100\u00a0BID)\u00a0y\u00a0TPV/r\u00a0(500/200\u00a0BID)\u00a0tienen\u00a0\nperfiles\u00a0m\u00e1s\u00a0desfavorables, \u00a0sobre\u00a0todo\u00a0en\u00a0lo\u00a0que\u00a0respecta\u00a0a\u00a0los\u00a0triglic\u00e9ridos239,\u00a0272,\u00a0273,\u00a0\n276,\u00a0336,\u00a0341,\u00a0348,\u00a0349,\u00a0429,\u00a0503\u2010505.\u00a0El\u00a0manejo\u00a0de\u00a0la\u00a0dislipemia \u00a0se\u00a0comenta\u00a0en\u00a0las\u00a0tablas\u00a013\u201015506\u2010\n510.\u00a0\u00a0\nLos\u00a0IP\u00a0pueden\u00a0disminuir \u00a0la\u00a0disponibilidad \u00a0de\u00a0la\u00a0glucosa\u00a0perif\u00e9rica \u00a0y\u00a0la\u00a0secreci\u00f3n \u00a0pan\u2010\ncre\u00e1tica\u00a0de\u00a0insulina\u00a0de\u00a0forma\u00a0aguda\u00a0y\u00a0pueden\u00a0descompensar \u00a0o\u00a0desencadenar \u00a0una\u00a0di\u2010\nabetes\u00a0en\u00a0pacientes \u00a0ya\u00a0diab\u00e9ticos \u00a0o\u00a0en\u00a0personas\u00a0predispuestas \u00a0a\u00a0serlo.\u00a0En\u00a0general,\u00a0es\u2010\ntas\u00a0alteraciones \u00a0no\u00a0se\u00a0mantienen \u00a0a\u00a0medio\u2010largo\u00a0plazo,\u00a0por\u00a0lo\u00a0que\u00a0deben\u00a0existir\u00a0meca\u2010\nnismos\u00a0compensadores \u00a0de\u00a0las\u00a0mismas511,\u00a0512.\u00a0Entre\u00a0ellos,\u00a0IDV,\u00a0RTV\u00a0a\u00a0dosis\u00a0plenas,\u00a0y\u00a0en\u00a0\nmenor\u00a0medida\u00a0LPV/r,\u00a0son\u00a0los\u00a0que\u00a0se\u00a0han\u00a0relacionado \u00a0con\u00a0el\u00a0desarrollo \u00a0de\u00a0resistencia \u00a0a\u00a0\nla\u00a0insulina513\u2010515,\u00a0mientras\u00a0que\u00a0los\u00a0dem\u00e1s\u00a0IP\u00a0parecen\u00a0tener\u00a0poco\u00a0o\u00a0ning\u00fan\u00a0efecto\u00a0sobre\u00a0\nla\u00a0homeostasis \u00a0de\u00a0la\u00a0glucosa.\u00a0La\u00a0diabetes\u00a0mellitus\u00a0es\u00a0menos\u00a0com\u00fan\u00a0(Tabla\u00a014)\u00a0y\u00a0su\u00a0aso\u2010\nciaci\u00f3n\u00a0con\u00a0los\u00a0IP\u00a0no\u00a0es\u00a0constante \u00a0en\u00a0todos\u00a0los\u00a0estudios511,\u00a0513,\u00a0515.\u00a0El\u00a0tratamiento \u00a0con\u00a0\nan\u00e1logos\u00a0de\u00a0la\u00a0timidina\u00a0(en\u00a0particular \u00a0d4T)\u00a0y\u00a0ddI,\u00a0constituye \u00a0un\u00a0factor\u00a0de\u00a0riesgo\u00a0para\u00a0el\u00a0\ndesarrollo \u00a0de\u00a0resistencia \u00a0a\u00a0la\u00a0insulina\u00a0y\u00a0diabetes\u00a0mellitus516.\u00a0\u00a0Los\u00a0inhibidores \u00a0de\u00a0la\u00a0inte\u2010\ngrasa\u00a0y\u00a0los\u00a0antagonistas \u00a0del\u00a0CCR5\u00a0parecen\u00a0tener\u00a0un\u00a0perfil\u00a0metab\u00f3lico \u00a0favorable517\u2010520.\u00a0\nAl\u00a0igual\u00a0que\u00a0en\u00a0la\u00a0poblaci\u00f3n \u00a0general,\u00a0los\u00a0factores\u00a0de\u00a0riesgo\u00a0tradicionales \u00a0son\u00a0los\u00a0que\u00a0\ndeterminan \u00a0principalmente \u00a0el\u00a0riesgo\u00a0de\u00a0desarrollar \u00a0enfermedad \u00a0cardiovascular \u00a0en\u00a0los\u00a0\npacientes \u00a0infectados \u00a0por\u00a0el\u00a0VIH.\u00a0En\u00a0\u00e9stos,\u00a0no\u00a0obstante, \u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0no\u00a0contro\u2010\nlada\u00a0y\u00a0ciertos\u00a0reg\u00edmenes \u00a0de\u00a0TARV\u00a0incrementan \u00a0tambi\u00e9n\u00a0dicho\u00a0riesgo,\u00a0aunque\u00a0es\u00a0muy\u00a0\nprobable\u00a0que\u00a0la\u00a0contribuci\u00f3n \u00a0de\u00a0estos\u00a0\u00faltimos\u00a0sea\u00a0menor\u00a0que\u00a0la\u00a0de\u00a0los\u00a0otros\u00a0factores\u00a0\nanteriormente \u00a0mencionados. \u00a0Aunque\u00a0algunos\u00a0estudios\u00a0de\u00a0cohortes\u00a0han\u00a0puesto\u00a0de\u00a0ma\u2010\nnifiesto\u00a0que\u00a0la\u00a0duraci\u00f3n\u00a0del\u00a0tratamiento \u00a0con\u00a0IP\u00a0es\u00a0un\u00a0factor\u00a0de\u00a0riesgo\u00a0independiente \u00a0\npara\u00a0el\u00a0desarrollo \u00a0de\u00a0cardiopat\u00eda \u00a0isqu\u00e9mica521\u2010523,\u00a0otros,\u00a0en\u00a0su\u00a0mayor\u00eda\u00a0retrospectivos \u00a0y\u00a0\ncon\u00a0poco\u00a0tiempo\u00a0de\u00a0seguimiento, \u00a0han\u00a0obtenido\u00a0resultados \u00a0contrapuestos \u00a0523\u2010526.\u00a0El\u00a0\nefecto\u00a0sobre\u00a0el\u00a0riesgo\u00a0cardiovascular \u00a0de\u00a0los\u00a0IP\u00a0como\u00a0familia\u00a0est\u00e1\u00a0mediado, \u00a0al\u00a0menos\u00a0en\u00a0\nparte,\u00a0por\u00a0la\u00a0dislipemia \u00a0asociada\u00a0con\u00a0el\u00a0uso\u00a0de\u00a0estos\u00a0f\u00e1rmacos. \u00a0Adem\u00e1s,\u00a0un\u00a0an\u00e1lisis\u00a0de\u00a0\nla\u00a0cohorte\u00a0D:A:D\u00a0ha\u00a0revelado\u00a0que\u00a0determinados \u00a0IP\u00a0(IDV,\u00a0LPV/r)\u00a0est\u00e1n\u00a0relacionados \u00a0con\u00a0\nun\u00a0mayor\u00a0riesgo\u00a0de\u00a0infarto\u00a0de\u00a0miocardio, \u00a0que\u00a0no\u00a0puede\u00a0ser\u00a0exclusivamente \u00a0justificado \u00a0\npor\u00a0dicha\u00a0anomal\u00eda\u00a0metab\u00f3lica527.\u00a0Este\u00a0mismo\u00a0estudio\u00a0ha\u00a0mostrado \u00a0tambi\u00e9n\u00a0que\u00a0el\u00a0uso\u00a0\nreciente\u00a0(\u00faltimos\u00a0seis\u00a0meses)\u00a0de\u00a0ABC\u00a0o\u00a0ddI\u00a0se\u00a0asocia\u00a0con\u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0infarto\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 79 \n agudo\u00a0de\u00a0miocardio, \u00a0especialmente \u00a0en\u00a0los\u00a0pacientes \u00a0que\u00a0tienen\u00a0un\u00a0riesgo\u00a0cardiovascu \u2010\nlar\u00a0m\u00e1s\u00a0elevado527.\u00a0No\u00a0obstante, \u00a0la\u00a0relaci\u00f3n\u00a0entre\u00a0ABC\u00a0e\u00a0infarto\u00a0de\u00a0miocardio \u00a0es\u00a0un\u00a0\nmotivo\u00a0de\u00a0controversia, \u00a0pues,\u00a0aunque\u00a0\u00a0ha\u00a0sido\u00a0constatada \u00a0tambi\u00e9n\u00a0en\u00a0el\u00a0estudio\u00a0\nSMART237\u00a0y\u00a0en\u00a0sendos\u00a0estudios\u00a0de\u00a0casos\u00a0y\u00a0controles528,\u00a0529,\u00a0ni\u00a0un\u00a0an\u00e1lisis\u00a0conjunto\u00a0de\u00a052\u00a0\nensayos\u00a0cl\u00ednicos\u00a0aleatorizados \u00a0que\u00a0inclu\u00edan\u00a0un\u00a0brazo\u00a0de\u00a0tratamiento \u00a0con\u00a0ABC530\u00a0ni\u00a0otros\u00a0\nensayos\u00a0cl\u00ednicos\u00a0y\u00a0estudios\u00a0de\u00a0cohorte\u00a0han\u00a0observado \u00a0tal\u00a0asociaci\u00f3n531\u2010533\u00a0as\u00ed\u00a0como\u00a0\ntampoco\u00a0ninguna\u00a0relaci\u00f3n\u00a0de\u00a0ABC\u00a0con\u00a0potenciales \u00a0mecanismos \u00a0patog\u00e9nicos \u00a0que\u00a0pudie\u2010\nran\u00a0explicarla534,\u00a0535.\u00a0Todos\u00a0estos\u00a0estudios\u00a0tienen\u00a0numerosos \u00a0sesgos\u00a0que\u00a0no\u00a0es\u00a0posible\u00a0\ncontrolar\u00a0de\u00a0forma\u00a0adecuada \u00a0y\u00a0que\u00a0ponen\u00a0en\u00a0duda\u00a0la\u00a0contribuci\u00f3n \u00a0causal\u00a0de\u00a0los\u00a0men\u2010\ncionados\u00a0AN\u00a0en\u00a0el\u00a0desarrollo \u00a0de\u00a0la\u00a0enfermedad \u00a0cardiovascular. \u00a0\u00a0\n\u00a0\nAnomal\u00edas \u00a0de\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0grasa\u00a0corporal\u00a0\nEl\u00a0s\u00edndrome \u00a0de\u00a0lipodistrofia \u00a0se\u00a0caracteriza \u00a0por\u00a0la\u00a0presencia, \u00a0combinada \u00a0o\u00a0no,\u00a0de\u00a0p\u00e9rdi\u2010\nda\u00a0de\u00a0grasa\u00a0perif\u00e9rica \u00a0(lipoatrofia) \u00a0y\u00a0de\u00a0ac\u00famulo\u00a0de\u00a0grasa\u00a0perivisceral \u00a0y/o\u00a0en\u00a0abdomen, \u00a0\nmamas\u00a0y\u00a0cuello\u00a0(lipoacumulaci\u00f3n). \u00a0La\u00a0lipoatrofia, \u00a0el\u00a0efecto\u00a0adverso\u00a0m\u00e1s\u00a0temido\u00a0por\u00a0los\u00a0\npacientes, \u00a0se\u00a0relaciona\u00a0particularmente \u00a0con\u00a0los\u00a0an\u00e1logos\u00a0de\u00a0la\u00a0timidina220,\u00a0221,\u00a0226,\u00a0484,\u00a0496,\u00a0\n500,\u00a0509,\u00a0510.\u00a0Aunque\u00a0en\u00a0su\u00a0aparici\u00f3n \u00a0pueden\u00a0influir\u00a0m\u00faltiples \u00a0factores,\u00a0las\u00a0pautas\u00a0con\u00a0d4T\u00a0\ny\u00a0ZDV\u00a0(particularmente \u00a0junto\u00a0con\u00a0IP\u00a0cl\u00e1sicos\u00a0y\u00a0EFV)\u00a0han\u00a0evidenciado \u00a0un\u00a0mayor\u00a0riesgo\u00a0\nde\u00a0lipoatrofia \u00a0y\u00a0su\u00a0sustituci\u00f3n \u00a0por\u00a0ABC\u00a0o\u00a0TDF\u00a0o\u00a0por\u00a0pautas\u00a0sin\u00a0AN\u00a0se\u00a0asocia\u00a0a\u00a0una\u00a0me\u2010\njor\u00eda\u00a0de\u00a0la\u00a0misma226,\u00a0496,\u00a0497,\u00a0499,\u00a0500,\u00a0504,\u00a0507\u2010510\u00a0(Tabla\u00a012).\u00a0Los\u00a0resultados \u00a0de\u00a0dos\u00a0estudios\u00a0\ncomparativos \u00a0entre\u00a0EFV\u00a0y\u00a0LPV/r\u00a0sugieren\u00a0que\u00a0el\u00a0uso\u00a0de\u00a0EFV\u00a0puede\u00a0asociarse \u00a0a\u00a0una\u00a0ma\u2010\nyor\u00a0p\u00e9rdida\u00a0de\u00a0grasa\u00a0subcut\u00e1nea \u00a0en\u00a0comparaci\u00f3n \u00a0con\u00a0LPV/r,\u00a0lo\u00a0cual\u00a0es\u00a0particularmente \u00a0\nevidente\u00a0cuando\u00a0el\u00a0r\u00e9gimen\u00a0incluye\u00a0an\u00e1logos\u00a0de\u00a0la\u00a0timidina393,\u00a0536.\u00a0No\u00a0obstante, \u00a0el\u00a0que\u00a0\nno\u00a0se\u00a0haya\u00a0observado \u00a0lipoatrofia \u00a0en\u00a0numerosos \u00a0ensayos\u00a0en\u00a0los\u00a0que\u00a0EFV\u00a0no\u00a0estaba\u00a0aso\u2010\nciado\u00a0a\u00a0an\u00e1logos\u00a0de\u00a0la\u00a0timidina226,\u00a0496,\u00a0497,\u00a0504,\u00a0510,\u00a0plantea\u00a0la\u00a0necesidad \u00a0de\u00a0nuevos\u00a0estu\u2010\ndios\u00a0que\u00a0esclarezcan \u00a0este\u00a0aspecto.\u00a0En\u00a0la\u00a0Tabla\u00a016\u00a0se\u00a0comentan \u00a0la\u00a0evaluaci\u00f3n \u00a0y\u00a0opciones\u00a0\nterap\u00e9uticas \u00a0para\u00a0las\u00a0anomal\u00edas \u00a0de\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0grasa\u00a0corporal537\u2010540.\u00a0\n\u00a0\nOtros\u00a0efectos\u00a0adversos\u00a0\u00a0\nLa\u00a0osteopenia \u00a0y\u00a0la\u00a0osteoporosis \u00a0son\u00a0m\u00e1s\u00a0frecuentes \u00a0en\u00a0los\u00a0pacientes \u00a0infectados \u00a0por\u00a0el\u00a0\nVIH,\u00a0pero\u00a0se\u00a0desconoce \u00a0la\u00a0importancia \u00a0relativa\u00a0de\u00a0los\u00a0distintos\u00a0factores\u00a0invocados \u00a0co\u2010\nmo\u00a0favorecedores \u00a0de\u00a0la\u00a0misma,\u00a0entre\u00a0los\u00a0que\u00a0se\u00a0incluyen\u00a0el\u00a0propio\u00a0VIH\u00a0y\u00a0el\u00a0TARV.\u00a0Aun\u2010\nque\u00a0los\u00a0IP\u00a0podr\u00edan\u00a0jugar\u00a0un\u00a0papel\u00a0patog\u00e9nico \u00a0en\u00a0el\u00a0desarrollo \u00a0de\u00a0estos\u00a0trastornos \u00a0en\u00a0los\u00a0\npacientes \u00a0infectados \u00a0por\u00a0el\u00a0VIH,\u00a0los\u00a0datos\u00a0disponibles \u00a0hasta\u00a0ahora\u00a0no\u00a0son\u00a0concluyen \u2010\ntes541.\u00a0M\u00e1s\u00a0ambigua\u00a0es\u00a0a\u00fan\u00a0la\u00a0presunta\u00a0relaci\u00f3n\u00a0entre\u00a0el\u00a0TARV\u00a0y\u00a0la\u00a0osteonecrosis542.\u00a0\u00a0\nPor\u00a0\u00faltimo,\u00a0EFV\u00a0es\u00a0teratog\u00e9nico, \u00a0por\u00a0lo\u00a0que\u00a0est\u00e1\u00a0contraindicado \u00a0su\u00a0uso\u00a0durante\u00a0el\u00a0pri\u2010\nmer\u00a0trimestre \u00a0de\u00a0la\u00a0gestaci\u00f3n.506,\u00a0507,\u00a0543,\u00a0544\u00a0\n\u00a0\nEfectos\u00a0adversos\u00a0del\u00a0TARV.\u00a0Recomendaciones \u00a0\n\u2022 Se\u00a0debe\u00a0monitorizar \u00a0la\u00a0tolerancia \u00a0y\u00a0las\u00a0reacciones \u00a0adversas\u00a0agudas\u00a0del\u00a0TARV\u00a0duran\u2010\nte\u00a0las\u00a0primeras\u00a02\u20104\u00a0semanas, \u00a0particularmente \u00a0en\u00a0aquellos\u00a0pacientes \u00a0que\u00a0tengan\u00a0\ncomorbilidades \u00a0predisponentes \u00a0o\u00a0tomen\u00a0concomitantemente \u00a0otros\u00a0f\u00e1rmacos \u00a0cuyas\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 80 \n interacciones \u00a0puedan\u00a0tener\u00a0consecuencias \u00a0cl\u00ednicas,\u00a0y\u00a0llevar\u00a0a\u00a0cabo\u00a0una\u00a0eventual\u00a0\nmodificaci\u00f3n \u00a0del\u00a0tratamiento \u00a0seg\u00fan\u00a0la\u00a0gravedad \u00a0de\u00a0la\u00a0reacci\u00f3n\u00a0adversa\u00a0y\u00a0el\u00a0f\u00e1rmaco\u00a0\nimplicado. \u00a0Para\u00a0ello\u00a0debe\u00a0facilitarse \u00a0el\u00a0contacto\u00a0entre\u00a0el\u00a0paciente\u00a0y\u00a0los\u00a0profesiona \u2010\nles\u00a0(nivel\u00a0C).\u00a0\u00a0\n\u2022 Se\u00a0deben\u00a0evitar\u00a0f\u00e1rmacos\u00a0que\u00a0puedan\u00a0reagudizar \u00a0o\u00a0empeorar \u00a0enfermedades \u00a0pre\u2010\nexistentes \u00a0(nivel\u00a0C).\u00a0\u00a0\n\u2022 Se\u00a0recomienda \u00a0monitorizar \u00a0la\u00a0glucemia\u00a0y\u00a0los\u00a0l\u00edpidos\u00a0plasm\u00e1ticos \u00a0(colesterol \u00a0total,\u00a0\ncolesterol \u2010HDL,\u00a0colesterol \u2010LDL\u00a0y\u00a0triglic\u00e9ridos) \u00a0en\u00a0cada\u00a0visita\u00a0de\u00a0control\u00a0(nivel\u00a0C)508,\u00a0\n511,\u00a0544.\u00a0\n\u2022 Se\u00a0recomienda \u00a0calcular\u00a0el\u00a0riesgo\u00a0cardiovascular \u00a0en\u00a0la\u00a0primera\u00a0visita,\u00a0al\u00a0inicio\u00a0del\u00a0\nTARV\u00a0y\u00a0con\u00a0posterioridad \u00a0una\u00a0vez\u00a0al\u00a0a\u00f1o\u00a0(nivel\u00a0C).\u00a0\u00a0\n\u2022 Se\u00a0recomienda \u00a0evitar\u00a0el\u00a0tratamiento \u00a0con\u00a0an\u00e1logos\u00a0de\u00a0la\u00a0timidina\u00a0siempre\u00a0que\u00a0sea\u00a0\nposible,\u00a0pero\u00a0muy\u00a0particularmente \u00a0ante\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0lipoatrofia \u00a0(nivel\u00a0A).\u00a0\n\u2022 Se\u00a0recomienda \u00a0efectuar\u00a0un\u00a0estudio\u00a0elemental \u00a0de\u00a0orina\u00a0con\u00a0proteinuria \u00a0y\u00a0calcular\u00a0la\u00a0\ntasa\u00a0de\u00a0filtrado\u00a0glomerular \u00a0renal\u00a0(f\u00f3rmula\u00a0MDRD\u00a0o\u00a0Cockroft\u2010Gault)\u00a0en\u00a0la\u00a0primera\u00a0vi\u2010\nsita\u00a0y\u00a0luego\u00a0una\u00a0vez\u00a0al\u00a0a\u00f1o\u00a0si\u00a0no\u00a0hay\u00a0factores\u00a0de\u00a0riesgo\u00a0para\u00a0el\u00a0desarrollo \u00a0de\u00a0nefro\u2010\ntoxicidad\u00a0o\u00a0cada\u00a0seis\u00a0meses\u00a0si\u00a0\u00e9stos\u00a0est\u00e1n\u00a0presentes \u00a0as\u00ed\u00a0como\u00a0tambi\u00e9n\u00a0antes\u00a0de\u00a0ini\u2010\nciar\u00a0el\u00a0TARV\u00a0(nivel\u00a0A)545,\u00a0546.\u00a0En\u00a0los\u00a0pacientes \u00a0que\u00a0ya\u00a0reciben\u00a0TARV\u00a0se\u00a0recomienda \u00a0\nefectuar\u00a0este\u00a0estudio\u00a0en\u00a0todas\u00a0las\u00a0revisiones \u00a0(nivel\u00a0B),\u00a0en\u00a0especial\u00a0si\u00a0toman\u00a0TDF\u00a0(ni\u2010\nvel\u00a0C)546.\u00a0Si\u00a0el\u00a0filtrado\u00a0glomerular \u00a0es\u00a0<50\u00a0mL/min\u00a0o\u00a0hay\u00a0proteinuria \u00a0manifiesta \u00a0no\u00a0se\u00a0\ndeben\u00a0usar\u00a0TDF\u00a0(salvo\u00a0que\u00a0no\u00a0haya\u00a0otra\u00a0opci\u00f3n\u00a0disponible, \u00a0adecuando \u00a0la\u00a0dosis\u00a0a\u00a0la\u00a0\nfunci\u00f3n\u00a0renal)\u00a0ni\u00a0IDV\u00a0y\u00a0se\u00a0deben\u00a0ajustar\u00a0las\u00a0dosis\u00a0de\u00a0los\u00a0AN\u00a0excepto\u00a0ABC\u00a0(nivel\u00a0C)545,\u00a0\n546.\u00a0No\u00a0se\u00a0recomienda \u00a0usar\u00a0TDF\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0deterioro \u00a0agudo\u00a0de\u00a0la\u00a0funci\u00f3n\u00a0\nrenal\u00a0o\u00a0que\u00a0el\u00a0deterioro \u00a0est\u00e9\u00a0directamente \u00a0relacionado \u00a0con\u00a0este\u00a0f\u00e1rmaco\u00a0(nivel\u00a0\nC)546.\u00a0\n\u00a0\n\u00a0\n8.\u00a0INTERACCIONES \u00a0FARMACOCIN\u00c9TICAS \u00a0Y\u00a0FARMACODIN\u00c1MICAS \u00a0\nLas\u00a0interacciones \u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0(FAR)\u00a0entre\u00a0s\u00ed\u00a0o\u00a0con\u00a0otros\u00a0medica\u2010\nmentos\u00a0constituyen \u00a0un\u00a0problema \u00a0de\u00a0primera\u00a0magnitud \u00a0en\u00a0el\u00a0tratamiento \u00a0de\u00a0los\u00a0pa\u2010\ncientes\u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0ya\u00a0que\u00a0sus\u00a0consecuencias \u00a0pueden\u00a0tener\u00a0una\u00a0importan \u2010\nte\u00a0repercusi\u00f3n \u00a0cl\u00ednica547\u2010550.\u00a0Las\u00a0m\u00e1s\u00a0relevantes \u00a0suelen\u00a0ser\u00a0las\u00a0interacciones \u00a0farmaco\u2010\ncin\u00e9ticas, \u00a0especialmente \u00a0a\u00a0nivel\u00a0del\u00a0metabolismo \u00a0de\u00a0los\u00a0f\u00e1rmacos. \u00a0Diferentes \u00a0sistemas\u00a0\nenzim\u00e1ticos \u00a0est\u00e1n\u00a0implicados \u00a0en\u00a0dicho\u00a0metabolismo \u00a0y\u00a0en\u00a0todos\u00a0ellos\u00a0pueden\u00a0producir\u2010\nse\u00a0interacciones. \u00a0Los\u00a0FAR\u00a0son\u00a0sustratos\u00a0de\u00a0uno\u00a0o\u00a0varios\u00a0de\u00a0estos\u00a0sistemas\u00a0enzim\u00e1ticos \u00a0y\u00a0\na\u00a0la\u00a0vez\u00a0pueden\u00a0comportarse \u00a0como\u00a0inductores \u00a0y/o\u00a0inhibidores \u00a0de\u00a0cualquiera \u00a0de\u00a0ellos.\u00a0\nLa\u00a0inducci\u00f3n \u00a0del\u00a0metabolismo \u00a0producir\u00e1 \u00a0una\u00a0disminuci\u00f3n \u00a0de\u00a0las\u00a0concentraciones \u00a0del\u00a0\nf\u00e1rmaco\u00a0en\u00a0el\u00a0lugar\u00a0de\u00a0acci\u00f3n,\u00a0pudiendo \u00a0disminuir \u00a0la\u00a0eficacia\u00a0del\u00a0tratamiento, \u00a0mientras\u00a0\nque\u00a0la\u00a0inhibici\u00f3n \u00a0ocasionar\u00e1 \u00a0un\u00a0aumento\u00a0de\u00a0las\u00a0concentraciones \u00a0con\u00a0un\u00a0mayor\u00a0riesgo\u00a0\nde\u00a0toxicidad. \u00a0En\u00a0general,\u00a0la\u00a0inducci\u00f3n \u00a0se\u00a0produce\u00a0por\u00a0un\u00a0aumento\u00a0de\u00a0la\u00a0s\u00edntesis\u00a0protei\u2010\nca\u00a0(enzimas), \u00a0siendo\u00a0un\u00a0proceso\u00a0lento\u00a0que\u00a0requiere\u00a0d\u00edas\u00a0o\u00a0semanas, \u00a0mientras\u00a0que\u00a0la\u00a0\ninhibici\u00f3n \u00a0suele\u00a0ser\u00a0competitiva \u00a0y\u00a0se\u00a0produce\u00a0de\u00a0manera\u00a0r\u00e1pida,\u00a0dependiendo \u00a0de\u00a0la\u00a0\nconcentraci\u00f3n \u00a0del\u00a0inhibidor, \u00a0pudiendo \u00a0aparecer\u00a0los\u00a0efectos\u00a0t\u00f3xicos\u00a0de\u00a0los\u00a0sustratos\u00a0en\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 81 \n pocas\u00a0horas.\u00a0Dado\u00a0que\u00a0ambos\u00a0mecanismos \u00a0son\u00a0diferentes \u00a0e\u00a0independientes, \u00a0algunos\u00a0\nf\u00e1rmacos \u00a0pueden\u00a0ser\u00a0inhibidores \u00a0e\u00a0inductores \u00a0al\u00a0mismo\u00a0tiempo,\u00a0predominando \u00a0uno\u00a0u\u00a0\notro\u00a0efecto.\u00a0\nEl\u00a0sistema\u00a0metab\u00f3lico \u00a0m\u00e1s\u00a0importante \u00a0es\u00a0el\u00a0citocromo \u00a0P450\u00a0(CYP)\u00a0y\u00a0su\u00a0principal\u00a0isoen\u2010\nzima\u00a0el\u00a0CYP3A4.\u00a0Muchos\u00a0FAR,\u00a0especialmente \u00a0los\u00a0IP\u00a0y\u00a0NN,\u00a0y\u00a0muchos\u00a0otros\u00a0f\u00e1rmacos \u00a0que\u00a0\na\u00a0menudo\u00a0reciben\u00a0los\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0son\u00a0inhibidores \u00a0o\u00a0inductores \u00a0\nde\u00a0diferentes \u00a0isoenzimas \u00a0de\u00a0CYP.\u00a0La\u00a0potente\u00a0inhibici\u00f3n \u00a0enzim\u00e1tica \u00a0que\u00a0produce\u00a0RTV\u00a0se\u00a0\nutiliza\u00a0para\u00a0potenciar \u00a0la\u00a0farmacocin\u00e9tica \u00a0de\u00a0otros\u00a0IP\u00a0(substratos \u00a0de\u00a0CYP3A4),\u00a0logrando\u00a0\nconcentraciones \u00a0plasm\u00e1ticas \u00a0m\u00e1s\u00a0eficaces\u00a0y\u00a0menos\u00a0susceptibles \u00a0al\u00a0efecto\u00a0inductor\u00a0de\u00a0\notros\u00a0f\u00e1rmacos \u00a0(ej.\u00a0NN)\u00a0y\u00a0al\u00a0mismo\u00a0tiempo\u00a0pautas\u00a0m\u00e1s\u00a0simples,\u00a0con\u00a0menos\u00a0restriccio \u2010\nnes\u00a0diet\u00e9ticas. \u00a0\nOtra\u00a0v\u00eda\u00a0metab\u00f3lica \u00a0es\u00a0la\u00a0conjugaci\u00f3n \u00a0de\u00a0los\u00a0FAR\u00a0o\u00a0de\u00a0sus\u00a0metabolitos \u00a0procedentes \u00a0de\u00a0\nla\u00a0oxidaci\u00f3n \u00a0del\u00a0f\u00e1rmaco\u00a0por\u00a0el\u00a0CYP.\u00a0Diversos\u00a0FAR\u00a0son\u00a0inductores \u00a0o\u00a0inhibidores \u00a0del\u00a0\ncomplejo \u00a0enzim\u00e1tico \u00a0de\u00a0las\u00a0uridindifosfato \u2010glucuroniltransferasas \u00a0(UDPGT)\u00a0(glucuroni \u2010\nzaci\u00f3n).\u00a0A\u00a0menudo\u00a0los\u00a0inductores \u00a0del\u00a0CYP\u00a0son\u00a0tambi\u00e9n\u00a0inductores \u00a0de\u00a0la\u00a0UDPGT\u00a0y\u00a0los\u00a0\ninhibidores \u00a0del\u00a0CYP\u00a0son\u00a0inhibidores \u00a0de\u00a0la\u00a0UDPGT,\u00a0pero\u00a0algunos\u00a0inhibidores \u00a0del\u00a0CYP\u00a0son\u00a0\ninductores \u00a0de\u00a0la\u00a0glucuronizaci\u00f3n \u00a0y\u00a0viceversa. \u00a0As\u00ed,\u00a0por\u00a0ejemplo,\u00a0RTV\u00a0y,\u00a0en\u00a0menor\u00a0medi\u2010\nda,\u00a0NFV\u00a0inhiben\u00a0varias\u00a0subfamilias \u00a0del\u00a0citocromo \u00a0P450\u00a0y\u00a0son\u00a0inductores \u00a0de\u00a0las\u00a0UDPGT.\u00a0\nLa\u00a0combinaci\u00f3n \u00a0TPV/r\u00a0muestra\u00a0un\u00a0efecto\u00a0inductor\u00a0de\u00a0la\u00a0glucuronizaci\u00f3n. \u00a0ATV\u00a0inhibe\u00a0\nambos\u00a0sistemas\u00a0enzim\u00e1ticos. \u00a0\nCada\u00a0vez\u00a0est\u00e1n\u00a0adquiriendo \u00a0mayor\u00a0protagonismo \u00a0una\u00a0serie\u00a0de\u00a0prote\u00ednas \u00a0transportado \u2010\nras\u00a0transmembrana, \u00a0tales\u00a0como\u00a0la\u00a0glicoprote\u00edna \u2010P\u00a0(P\u2010gp),\u00a0capaces\u00a0de\u00a0alterar\u00a0la\u00a0biodis\u2010\nponibilidad \u00a0de\u00a0diversos\u00a0FAR\u00a0y\u00a0su\u00a0distribuci\u00f3n \u00a0por\u00a0el\u00a0organismo. \u00a0Estas\u00a0prote\u00ednas \u00a0pueden\u00a0\nser\u00a0inducidas \u00a0o\u00a0inhibidas\u00a0por\u00a0diversos\u00a0f\u00e1rmacos. \u00a0Habitualmente \u00a0la\u00a0inducci\u00f3n \u00a0o\u00a0la\u00a0inhibi\u2010\nci\u00f3n\u00a0del\u00a0CYP\u00a0y\u00a0de\u00a0la\u00a0P\u2010gp\u00a0van\u00a0en\u00a0el\u00a0mismo\u00a0sentido,\u00a0pero\u00a0al\u00a0igual\u00a0que\u00a0sucede\u00a0con\u00a0la\u00a0glu\u2010\ncuronizaci\u00f3n \u00a0ambos\u00a0efectos\u00a0pueden\u00a0ser\u00a0discordantes. \u00a0\nEn\u00a0las\u00a0Tablas\u00a05\u00a0a\u00a09\u00a0se\u00a0detallan\u00a0las\u00a0interacciones \u00a0de\u00a0los\u00a0diferentes \u00a0FAR:\u00a0\n\u0083 Los\u00a0AN\u00a0tienen\u00a0pocas\u00a0interacciones \u00a0metab\u00f3licas. \u00a0ZDV\u00a0y\u00a0ABC\u00a0se\u00a0glucuronizan. \u00a03TC,\u00a0\nFTC,\u00a0d4T\u00a0y\u00a0TDF\u00a0se\u00a0eliminan\u00a0principalmente \u00a0por\u00a0v\u00eda\u00a0renal\u00a0y\u00a0son\u00a0poco\u00a0susceptibles \u00a0de\u00a0\npadecer\u00a0interacciones \u00a0metab\u00f3licas \u00a0relevantes. \u00a0\u00a0\n\u0083 En\u00a0cuanto\u00a0a\u00a0los\u00a0NN,\u00a0NVP\u00a0se\u00a0comporta \u00a0como\u00a0inductor\u00a0del\u00a0CYP3A\u00a0y\u00a0del\u00a0CYP2B6;\u00a0EFV\u00a0\nes\u00a0fundamentalmente \u00a0un\u00a0inductor\u00a0del\u00a0CYP3A4,\u00a0aunque\u00a0in\u00a0vitro\u00a0se\u00a0comporta \u00a0tam\u2010\nbi\u00e9n\u00a0como\u00a0inhibidor\u00a0de\u00a0\u00e9ste\u00a0y\u00a0de\u00a0otros\u00a0isoenzimas \u00a0del\u00a0CYP\u00a0(CYP2C9,\u00a02C19).\u00a0ETR\u00a0\nact\u00faa\u00a0como\u00a0sustrato\u00a0e\u00a0inductor\u00a0del\u00a0CYP3A4\u00a0y\u00a0como\u00a0inhibidor\u00a0del\u00a0CYP2C9\u00a0y\u00a02C19551.\u00a0\n\u0083 Por\u00a0lo\u00a0que\u00a0respecta\u00a0a\u00a0los\u00a0IP,\u00a0RTV\u00a0es\u00a0un\u00a0potente\u00a0inhibidor\u00a0de\u00a0los\u00a0isoenzimas \u00a0CYP3A4,\u00a0\n2D6\u00a0y\u00a0tambi\u00e9n\u00a0tiene\u00a0un\u00a0efecto\u00a0inductor\u00a0de\u00a0varios\u00a0isoenzimas \u00a0del\u00a0CYP\u00a0(1A2,\u00a03A4,\u00a0\n2B6,\u00a02C9,\u00a02C19)552,\u00a0as\u00ed\u00a0como\u00a0de\u00a0la\u00a0glucuronizaci\u00f3n; \u00a0adem\u00e1s\u00a0es\u00a0capaz\u00a0de\u00a0autoinducir \u00a0\nsu\u00a0propio\u00a0metabolismo. \u00a0NFV\u00a0es\u00a0inhibidor\u00a0del\u00a0CYP3A4\u00a0y\u00a0de\u00a0forma\u00a0m\u00e1s\u00a0d\u00e9bil\u00a0de\u00a0\nCYP2C19, \u00a02D6,\u00a01A2\u00a0y\u00a02B6;\u00a0en\u00a0cambio,\u00a0es\u00a0inductor\u00a0de\u00a0la\u00a0glucuronizaci\u00f3n. \u00a0IDV\u00a0es\u00a0un\u00a0\ninhibidor\u00a0del\u00a0CYP3A4.\u00a0SQV\u00a0es\u00a0un\u00a0inhibidor\u00a0d\u00e9bil\u00a0del\u00a0CYP3A4.\u00a0APV\u00a0puede\u00a0ser\u00a0inhibi\u2010\ndor\u00a0o\u00a0inductor\u00a0del\u00a0CYP3A4.\u00a0\u00a0LPV/r\u00a0inhibe\u00a0el\u00a0CYP3A4\u00a0in\u00a0vitro\u00a0y,\u00a0en\u00a0menor\u00a0proporci\u00f3n, \u00a0\nel\u00a0CYP\u00a02D6;\u00a0in\u00a0vivo\u00a0induce\u00a0su\u00a0propio\u00a0metabolismo, \u00a0los\u00a0CYP2C9\u00a0y\u00a02C19553\u00a0y\u00a0la\u00a0glucu\u2010\nronizaci\u00f3n. \u00a0ATV\u00a0es\u00a0inhibidor\u00a0del\u00a0CYP3A4\u00a0y\u00a0de\u00a0la\u00a0UDPGT1A1 \u00a0(enzima\u00a0encargado \u00a0de\u00a0la\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 82 \n glucuronizaci\u00f3n \u00a0de\u00a0la\u00a0bilirrubina). \u00a0\u00a0TPV/r\u00a0in\u00a0vivo\u00a0y\u00a0en\u00a0estado\u00a0de\u00a0equilibrio \u00a0es\u00a0un\u00a0in\u2010\nductor\u00a0de\u00a0CYP2C9,\u00a0CYP1A2\u00a0y\u00a0de\u00a0la\u00a0glucuronizaci\u00f3n \u00a0e\u00a0inhibidor\u00a0del\u00a0CYP3A4\u00a0y\u00a02D6554.\u00a0\nRespecto\u00a0a\u00a0su\u00a0efecto\u00a0sobre\u00a0la\u00a0P\u2010pg,\u00a0los\u00a0datos\u00a0sugieren\u00a0que\u00a0el\u00a0efecto\u00a0neto\u00a0de\u00a0la\u00a0\ncombinaci\u00f3n \u00a0TPV/r\u00a0en\u00a0estado\u00a0de\u00a0equilibrio \u00a0es\u00a0de\u00a0inducci\u00f3n \u00a0de\u00a0la\u00a0P\u2010gp.\u00a0Debido\u00a0al\u00a0\nefecto\u00a0antag\u00f3nico \u00a0de\u00a0inhibici\u00f3n \u00a0del\u00a0CYP3A4\u00a0e\u00a0inducci\u00f3n \u00a0de\u00a0la\u00a0P\u2010gp,\u00a0es\u00a0dif\u00edcil\u00a0prede\u2010\ncir\u00a0el\u00a0efecto\u00a0neto\u00a0de\u00a0TPV/r\u00a0sobre\u00a0f\u00e1rmacos \u00a0que\u00a0sean\u00a0substratos \u00a0de\u00a0ambos.\u00a0\n\u0083 Antagonistas \u00a0del\u00a0correceptor \u00a0CCR5:\u00a0MVC\u00a0es\u00a0sustrato\u00a0de\u00a0CYP3A4,\u00a0pero\u00a0no\u00a0es\u00a0inhibi\u2010\ndor\u00a0ni\u00a0inductor.\u00a0Los\u00a0inhibidores \u00a0e\u00a0inductores \u00a0de\u00a0CYP3A4\u00a0alteran\u00a0los\u00a0par\u00e1metros \u00a0\nfarmacocin\u00e9ticos \u00a0de\u00a0MVC,\u00a0recomend\u00e1ndose \u00a0cambios\u00a0en\u00a0su\u00a0dosis\u00a0(Tabla\u00a08)555\u2010558.\u00a0\u00a0En\u00a0\ngeneral\u00a0se\u00a0ajustar\u00e1n \u00a0las\u00a0dosis\u00a0como\u00a0sigue:\u00a0150\u00a0mg\u00a0BID\u00a0cuando\u00a0se\u00a0administra \u00a0con\u00a0in\u2010\nhibidores \u00a0del\u00a0CYP3A4\u00a0como\u00a0por\u00a0ejemplo\u00a0IP/r\u00a0(con\u00a0excepci\u00f3n \u00a0de\u00a0TPV/r\u00a0y\u00a0FPV/r);\u00a0600\u00a0\nmg\u00a0BID\u00a0cuando\u00a0se\u00a0administra \u00a0con\u00a0f\u00e1rmacos\u00a0inductores \u00a0como\u00a0EFV\u00a0o\u00a0rifampicina \u00a0(con\u00a0\nexcepci\u00f3n \u00a0de\u00a0NVP),\u00a0en\u00a0ausencia\u00a0de\u00a0inhibidores \u00a0potentes, \u00a0en\u00a0cuya\u00a0presencia \u00a0pre\u2010\ndomina\u00a0el\u00a0efecto\u00a0inhibidor\u00a0y\u00a0se\u00a0administrar\u00e1n \u00a0150\u00a0mg\u00a0BID;\u00a0300\u00a0mg\u00a0BID\u00a0con\u00a0otros\u00a0\nf\u00e1rmacos \u00a0(incluyendo \u00a0TPV/r\u00a0y\u00a0FPV/r)559\u2010581.\u00a0\u00a0\n\u0083 Inhibidores \u00a0de\u00a0la\u00a0integrasa. \u00a0RAL\u00a0no\u00a0es\u00a0sustrato\u00a0ni\u00a0influye\u00a0en\u00a0la\u00a0actividad\u00a0del\u00a0CYP.\u00a0Se\u00a0\nmetaboliza \u00a0por\u00a0glucuronizaci\u00f3n, \u00a0sin\u00a0inhibir\u00a0ni\u00a0inducir\u00a0esta\u00a0enzima.\u00a0Los\u00a0inhibidores \u00a0e\u00a0\ninductores \u00a0de\u00a0UGT1A1\u00a0modifican \u00a0los\u00a0par\u00e1metros \u00a0farmacocin\u00e9ticos \u00a0de\u00a0RAL,\u00a0pero\u00a0en\u00a0\nla\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0casos\u00a0no\u00a0se\u00a0recomiendan \u00a0cambios\u00a0en\u00a0su\u00a0dosificaci\u00f3n \u00a0por\u00a0el\u00a0amplio\u00a0\nmargen\u00a0terap\u00e9utico \u00a0de\u00a0este\u00a0f\u00e1rmaco\u00a0(Tabla\u00a08)582\u2010596.\u00a0\n\u0083 Inhibidores \u00a0de\u00a0la\u00a0fusi\u00f3n.\u00a0ENF\u00a0se\u00a0metaboliza \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0las\u00a0v\u00edas\u00a0catab\u00f3licas \u00a0de\u00a0las\u00a0\nprote\u00ednas \u00a0y\u00a0amino\u00e1cidos. \u00a0No\u00a0es\u00a0sustrato\u00a0ni\u00a0influye\u00a0en\u00a0la\u00a0actividad\u00a0de\u00a0ninguno\u00a0de\u00a0los\u00a0\nsistemas\u00a0metab\u00f3licos \u00a0de\u00a0los\u00a0otros\u00a0FAR.\u00a0No\u00a0es\u00a0susceptible \u00a0de\u00a0presentar \u00a0interaccio \u2010\nnes\u00a0metab\u00f3licas \u00a0relevantes. \u00a0\nEn\u00a0las\u00a0tablas\u00a06\u00a0a\u00a08\u00a0se\u00a0especifican \u00a0las\u00a0dosis\u00a0de\u00a0los\u00a0FAR\u00a0cuando\u00a0se\u00a0administran \u00a0en\u00a0combi\u2010\nnaci\u00f3n\u00a0con\u00a0otros\u00a0FAR597\u2010604o\u00a0con\u00a0otros\u00a0f\u00e1rmacos \u00a0(antituberculosos605,\u00a0606,\u00a0metadona607\u2010\n654,\u00a0estatinas655\u2010697,\u00a0interfer\u00f3n/ribavirina \u00a0u\u00a0otros547,\u00a0698\u2010723\u00a0y\u00a0las\u00a0asociaciones \u00a0contraindi \u2010\ncadas\u00a0o\u00a0no\u00a0recomendadas)\u2217.\u00a0Debido\u00a0a\u00a0que\u00a0la\u00a0informaci\u00f3n \u00a0cient\u00edfica\u00a0relacionada \u00a0con\u00a0los\u00a0\nFAR\u00a0se\u00a0renueva\u00a0constantemente, \u00a0se\u00a0recomienda \u00a0consultar \u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0y\u00a0la\u00a0informa\u2010\nci\u00f3n\u00a0actualizada \u00a0de\u00a0las\u00a0compa\u00f1\u00edas \u00a0farmac\u00e9uticas \u00a0y\u00a0las\u00a0autoridades \u00a0sanitarias. \u00a0\u00a0\nEn\u00a0la\u00a0tabla\u00a017\u00a0se\u00a0especifican \u00a0los\u00a0ajustes\u00a0de\u00a0dosis\u00a0de\u00a0los\u00a0FAR\u00a0en\u00a0caso\u00a0de\u00a0insuficiencia \u00a0\nrenal\u00a0o\u00a0hep\u00e1tica.\u00a0\nAlgunas\u00a0interacciones \u00a0farmacodin\u00e1micas \u00a0son\u00a0de\u00a0inter\u00e9s,\u00a0como\u00a0el\u00a0antagonismo \u00a0en\u00a0la\u00a0\nfosforilaci\u00f3n \u00a0intracelular \u00a0que\u00a0se\u00a0produce\u00a0entre\u00a0ZDV\u00a0y\u00a0d4T.\u00a0Desde\u00a0el\u00a0punto\u00a0de\u00a0vista\u00a0de\u00a0la\u00a0\ncoinfecci\u00f3n \u00a0con\u00a0el\u00a0VHC\u00a0tiene\u00a0inter\u00e9s\u00a0conocer\u00a0que\u00a0ribavirina \u00a0ha\u00a0mostrado \u00a0antagonismo \u00a0\nin\u00a0vitro\u00a0con\u00a0ZDV\u00a0y\u00a0d4T724.\u00a0Sin\u00a0embargo\u00a0en\u00a0el\u00a0subestudio \u00a0farmacocin\u00e9tico \u00a0del\u00a0APRICOT\u00a0\nesta\u00a0interacci\u00f3n \u00a0no\u00a0se\u00a0produjo\u00a0in\u00a0vivo.\u00a0\u00a0\nLa\u00a0ribavirina \u00a0y\u00a0ddI\u00a0producen \u00a0toxicidad\u00a0mitocondrial. \u00a0Su\u00a0incidencia \u00a0se\u00a0multiplic\u00f3 \u00a0por\u00a05\u00a0en\u00a0\ncomparaci\u00f3n \u00a0con\u00a0uso\u00a0de\u00a0ribavirina \u00a0y\u00a0otros\u00a0AN.\u00a0Tres\u00a0de\u00a0los\u00a023\u00a0casos\u00a0comunicados \u00a0a\u00a0la\u00a0\nFDA\u00a0fueron\u00a0mortales, \u00a0por\u00a0lo\u00a0que\u00a0se\u00a0recomienda \u00a0evitar\u00a0esta\u00a0asociaci\u00f3n. \u00a0En\u00a0lo\u00a0posible\u00a0se\u00a0\n                                                           \n\u2217 Se\u00a0han\u00a0incluido\u00a0solamente \u00a0las\u00a0referencias \u00a0sobre\u00a0interacciones \u00a0de\u00a0los\u00a0\u00faltimos\u00a03\u00a0a\u00f1os,\u00a0el\u00a0resto\u00a0pueden\u00a0consultarse \u00a0en\u00a0la\u00a0p\u00e1gina\u00a0web\u00a0\nhttp://www.interaccioneshiv.com  Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 83 \n evitar\u00e1\u00a0tambi\u00e9n\u00a0el\u00a0uso\u00a0simult\u00e1neo \u00a0de\u00a0ribavirina \u00a0con\u00a0ZDV\u00a0o\u00a0d4T\u00a0por\u00a0toxicidad\u00a0hematol\u00f3 \u2010\ngica\u00a0o\u00a0mitocondrial. \u00a0\n\u00a0\nInteracciones \u00a0del\u00a0TARV.\u00a0Recomendaciones \u00a0\n\u0083 Se\u00a0debe\u00a0rese\u00f1ar\u00a0en\u00a0la\u00a0historia\u00a0cl\u00ednica\u00a0todos\u00a0los\u00a0medicamentos, \u00a0productos \u00a0naturales \u00a0\ny\u00a0medicinas \u00a0alternativas, \u00a0para\u00a0evaluar\u00a0posibles\u00a0interacciones. \u00a0\u00a0\n\u0083 Se\u00a0deben\u00a0tener\u00a0en\u00a0cuenta\u00a0las\u00a0contraindicaciones \u00a0y\u00a0realizar\u00a0los\u00a0ajustes\u00a0de\u00a0dosis\u00a0co\u2010\nrrespondientes \u00a0cuando\u00a0sea\u00a0necesario. \u00a0\u00a0\n\u0083 Se\u00a0debe\u00a0considerar \u00a0la\u00a0monitorizaci\u00f3n \u00a0de\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0cuando\u00a0se\u00a0adminis\u2010\ntren\u00a0dos\u00a0o\u00a0m\u00e1s\u00a0f\u00e1rmacos\u00a0con\u00a0posibles\u00a0interacciones \u00a0farmacocin\u00e9ticas \u00a0relevantes \u00a0\npara\u00a0evitar\u00a0toxicidad\u00a0o\u00a0ineficacia \u00a0terap\u00e9utica \u00a0(nivel\u00a0C).\u00a0\n\u00a0\n\u00a0\n9.\u00a0HEPATOPATIA \u00a0CRONICA \u00a0Y\u00a0TRATAMIENTO \u00a0ANTIRRETROVIRAL \u00a0\nLa\u00a0hepatopat\u00eda \u00a0cr\u00f3nica\u00a0por\u00a0virus\u00a0de\u00a0la\u00a0hepatitis\u00a0es\u00a0la\u00a0comorbilidad \u00a0m\u00e1s\u00a0relevante \u00a0que\u00a0\npresentan \u00a0los\u00a0sujetos\u00a0infectados \u00a0por\u00a0el\u00a0VIH\u00a0en\u00a0Espa\u00f1a\u00a0por\u00a0su\u00a0frecuencia, \u00a0por\u00a0la\u00a0progre\u2010\nsi\u00f3n\u00a0a\u00a0enfermedad \u00a0hep\u00e1tica\u00a0terminal\u00a0y\u00a0por\u00a0aumentar \u00a0la\u00a0hepatotoxicidad \u00a0del\u00a0TARV.\u00a0\u00a0\n\u00a0\n9.\u00a01.\u00a0Infecci\u00f3n \u00a0VIH,\u00a0TARV\u00a0e\u00a0historia\u00a0natural\u00a0de\u00a0la\u00a0hepatitis\u00a0cr\u00f3nica\u00a0por\u00a0VHC\u00a0y\u00a0VHB\u00a0\nEn\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0VIH\u00a0y\u00a0virus\u00a0hepatotropos \u00a0la\u00a0buena\u00a0situaci\u00f3n\u00a0inmunol\u00f3gi \u2010\nca,\u00a0el\u00a0control\u00a0de\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0del\u00a0VIH\u00a0y\u00a0el\u00a0recibir\u00a0TARV\u00a0se\u00a0asocian\u00a0con\u00a0un\u00a0mejor\u00a0\npron\u00f3stico \u00a0global,\u00a0menor\u00a0velocidad \u00a0de\u00a0progresi\u00f3n \u00a0de\u00a0la\u00a0enfermedad \u00a0hep\u00e1tica\u00a0y\u00a0menor\u00a0\nriesgo\u00a0de\u00a0complicaciones \u00a0y\u00a0muerte\u00a0por\u00a0causa\u00a0hep\u00e1tica725\u2010731.\u00a0Se\u00a0ha\u00a0descrito\u00a0la\u00a0capaci\u2010\ndad\u00a0del\u00a0VIH\u00a0para\u00a0infectar\u00a0c\u00e9lulas\u00a0estrelladas \u00a0hep\u00e1ticas \u00a0y\u00a0promover \u00a0su\u00a0activaci\u00f3n \u00a0con\u00a0\nincremento \u00a0de\u00a0la\u00a0s\u00edntesis\u00a0de\u00a0col\u00e1geno, \u00a0lo\u00a0que\u00a0sugiere\u00a0que\u00a0la\u00a0replicaci\u00f3n \u00a0del\u00a0VIH\u00a0puede\u00a0\ncontribuir \u00a0directamente \u00a0al\u00a0mayor\u00a0desarrollo \u00a0de\u00a0la\u00a0fibrosis\u00a0hep\u00e1tica\u00a0en\u00a0pacientes \u00a0coin\u2010\nfectados724.\u00a0Por\u00a0ello,\u00a0aun\u00a0en\u00a0ausencia\u00a0de\u00a0ensayos\u00a0cl\u00ednicos\u00a0o\u00a0estudios\u00a0de\u00a0observaci\u00f3n \u00a0\nprospectiva \u00a0que\u00a0valoren\u00a0el\u00a0impacto\u00a0del\u00a0TARV\u00a0en\u00a0la\u00a0evoluci\u00f3n \u00a0de\u00a0la\u00a0fibrosis\u00a0hep\u00e1tica\u00a0en\u00a0\ncohortes\u00a0de\u00a0pacientes \u00a0coinfectados, \u00a0las\u00a0evidencias \u00a0anteriormente \u00a0descritas\u00a0respaldan \u00a0\nel\u00a0control\u00a0precoz\u00a0de\u00a0la\u00a0replicaci\u00f3n \u00a0del\u00a0VIH\u00a0y\u00a0el\u00a0mantenimiento \u00a0de\u00a0una\u00a0buena\u00a0situaci\u00f3n\u00a0\ninmunol\u00f3gica \u00a0en\u00a0estos\u00a0pacientes. \u00a0\u00a0\n\u00a0\nTARV\u00a0e\u00a0historia\u00a0natural\u00a0de\u00a0la\u00a0hepatitis. \u00a0Recomendaciones \u00a0\n\u2022 En\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0el\u00a0VHC\u00a0se\u00a0debe\u00a0adelantar \u00a0el\u00a0inicio\u00a0del\u00a0TARV\u00a0por\u00a0en\u2010\ncima\u00a0de\u00a0350\u00a0CD4/\u00b5L,\u00a0individualizando \u00a0la\u00a0decisi\u00f3n\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0variables\u00a0virol\u00f3gi\u2010\ncas,\u00a0histol\u00f3gicas \u00a0y\u00a0de\u00a0motivaci\u00f3n \u00a0del\u00a0paciente\u00a0(nivel\u00a0C)729\u2010732.\u00a0\n\u2022 En\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0el\u00a0VHB\u00a0el\u00a0TARV\u00a0se\u00a0debe\u00a0iniciar\u00a0cuando\u00a0est\u00e9\u00a0indicado\u00a0\nel\u00a0tratamiento \u00a0del\u00a0VHB\u00a0(nivel\u00a0C)732.\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 84 \n 9.\u00a02.\u00a0Toxicidad \u00a0hep\u00e1tica\u00a0de\u00a0los\u00a0FAR\u00a0en\u00a0pacientes \u00a0con\u00a0hepatopat\u00eda \u00a0\nLa\u00a0toxicidad\u00a0hep\u00e1tica\u00a0se\u00a0ha\u00a0descrito\u00a0con\u00a0todas\u00a0las\u00a0familias\u00a0de\u00a0FAR\u00a0aunque\u00a0con\u00a0inciden\u2010\ncia\u00a0y\u00a0mecanismos \u00a0patog\u00e9nicos \u00a0diferentes13,\u00a0733\u2010735.\u00a0La\u00a0incidencia \u00a0real\u00a0es\u00a0dif\u00edcil\u00a0de\u00a0estimar\u00a0\npor\u00a0problemas \u00a0metodol\u00f3gicos736.\u00a0En\u00a0primer\u00a0lugar\u00a0el\u00a0diagn\u00f3stico \u00a0de\u00a0toxicidad\u00a0hep\u00e1tica\u00a0\npor\u00a0un\u00a0f\u00e1rmaco\u00a0implica\u00a0una\u00a0relaci\u00f3n\u00a0temporal\u00a0y\u00a0la\u00a0exclusi\u00f3n \u00a0de\u00a0otras\u00a0causas\u00a0de\u00a0eleva\u2010\nci\u00f3n\u00a0de\u00a0enzimas\u00a0hep\u00e1ticas \u00a0(EEH)\u00a0y\u00a0estos\u00a0criterios\u00a0no\u00a0se\u00a0cumplen\u00a0en\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0pa\u2010\ncientes\u00a0coinfectados \u00a0por\u00a0VIH\u00a0y\u00a0VHC/VHB \u00a0con\u00a0EEH.\u00a0En\u00a0segundo\u00a0lugar,\u00a0la\u00a0definici\u00f3n \u00a0de\u00a0los\u00a0\ndistintos\u00a0grados\u00a0de\u00a0hepatotoxicidad \u00a0no\u00a0es\u00a0uniforme. \u00a0En\u00a0los\u00a0ensayos\u00a0cl\u00ednicos\u00a0se\u00a0suele\u00a0\ndefinir\u00a0como\u00a0hepatotoxicidad \u00a0grave\u00a0a\u00a0una\u00a0elevaci\u00f3n \u00a0mayor\u00a0de\u00a05\u00a0veces\u00a0el\u00a0l\u00edmite\u00a0superior\u00a0\nde\u00a0la\u00a0normalidad \u00a0de\u00a0ALT\u00a0y/o\u00a0AST737.\u00a0Sin\u00a0embargo\u00a0esta\u00a0definici\u00f3n \u00a0est\u00e1\u00a0limitada\u00a0al\u00a0no\u00a0\nconsiderar \u00a0el\u00a0fallo\u00a0hep\u00e1tico, \u00a0no\u00a0tener\u00a0en\u00a0cuenta\u00a0la\u00a0hepatotoxicidad \u00a0colest\u00e1sica \u00a0o\u00a0mixta\u00a0\ny\u00a0ser\u00a0m\u00e1s\u00a0sensible\u00a0para\u00a0detectar\u00a0hepatotoxicidad \u00a0en\u00a0pacientes \u00a0con\u00a0valores\u00a0basales\u00a0de\u00a0\ntransaminasas \u00a0elevados. \u00a0Para\u00a0resolver\u00a0este\u00a0\u00faltimo\u00a0problema \u00a0se\u00a0acepta\u00a0considerar \u00a0EEH\u00a0\ngrave\u00a0asintom\u00e1tica \u00a0a\u00a0los\u00a0incrementos \u00a0de\u00a0ALT\u00a0y/o\u00a0AST\u00a0superiores \u00a0a\u00a03,5\u00a0veces\u00a0la\u00a0cifra\u00a0\nbasal\u00a0para\u00a0los\u00a0pacientes \u00a0con\u00a0de\u00a0niveles\u00a0elevados\u00a0transaminasa \u00a0basales738.\u00a0\nEn\u00a0pacientes \u00a0infectados \u00a0por\u00a0el\u00a0VIH\u00a0la\u00a0coinfecci\u00f3n \u00a0por\u00a0VHC/VHB \u00a0aumenta\u00a0de\u00a02\u00a0a\u00a010\u00a0ve\u2010\nces\u00a0las\u00a0posibilidades \u00a0de\u00a0desarrollar \u00a0EEH\u00a0durante\u00a0el\u00a0TARV,\u00a0aunque\u00a0el\u00a0desarrollo \u00a0de\u00a0fallo\u00a0\nhep\u00e1tico\u00a0debido\u00a0a\u00a0la\u00a0hepatotoxicidad \u00a0por\u00a0TARV\u00a0es\u00a0raro,\u00a0y\u00a0generalmente \u00a0sucede\u00a0en\u00a0pa\u2010\ncientes\u00a0con\u00a0hepatopat\u00eda \u00a0avanzada \u00a0subyacente. \u00a0La\u00a0incidencia \u00a0de\u00a0hepatotoxicidad \u00a0au\u2010\nmenta\u00a0en\u00a0pacientes \u00a0con\u00a0hepatopat\u00eda \u00a0previa738\u2010740.\u00a0De\u00a0este\u00a0modo\u00a0en\u00a0pacientes \u00a0coinfec\u2010\ntados\u00a0por\u00a0VIH/VHC\u00a0tratados\u00a0con\u00a0TARV,\u00a0la\u00a0frecuencia \u00a0de\u00a0EEH\u00a0grave\u00a0asintom\u00e1tica \u00a0es\u00a0su\u2010\nperior\u00a0en\u00a0los\u00a0que\u00a0presentan \u00a0una\u00a0fibrosis\u00a0avanzada \u00a0(estadios\u00a0F\u22653)741.\u00a0\nEn\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0VIH\u00a0y\u00a0VHC\u00a0el\u00a0tratamiento \u00a0de\u00a0la\u00a0hepatitis\u00a0C\u00a0reduce\u00a0de\u00a0\nmodo\u00a0notable\u00a0el\u00a0riesgo\u00a0de\u00a0toxicidad\u00a0hep\u00e1tica742,\u00a0743.\u00a0\u00a0\n\u00a0\nToxicidad \u00a0hep\u00e1tica\u00a0de\u00a0los\u00a0FAR\u00a0en\u00a0hepatopat\u00eda. \u00a0Recomendaciones \u00a0\n\u0083 No\u00a0se\u00a0puede\u00a0contraindicar \u00a0ning\u00fan\u00a0FAR\u00a0en\u00a0caso\u00a0de\u00a0coinfecci\u00f3n \u00a0con\u00a0VHC\u00a0o\u00a0VHB\u00a0si\u00a0la\u00a0\nfunci\u00f3n\u00a0hep\u00e1tica\u00a0est\u00e1\u00a0preservada \u00a0(nivel\u00a0B),\u00a0pero\u00a0se\u00a0debe\u00a0priorizar\u00a0el\u00a0uso\u00a0de\u00a0FAR\u00a0con\u00a0\nel\u00a0menor\u00a0potencial \u00a0de\u00a0hepatotoxicidad \u00a0(nivel\u00a0C)\u00a013,\u00a0733\u2010735\u00a0\n\u0083 Se\u00a0debe\u00a0retirar\u00a0el\u00a0TARV\u00a0en\u00a0caso\u00a0de\u00a0hepatitis\u00a0sintom\u00e1tica, \u00a0y\u00a0en\u00a0la\u00a0asintom\u00e1tica \u00a0si\u00a0se\u00a0\nsospecha \u00a0que\u00a0se\u00a0debe\u00a0a\u00a0toxicidad\u00a0mitocondrial, \u00a0reacci\u00f3n\u00a0de\u00a0hipersensibilidad \u00a0o\u00a0\nhipertransaminemia \u00a0grado\u00a04\u00a0(nivel\u00a0C)\u00a0734,\u00a0735\u00a0\n\u0083 En\u00a0caso\u00a0de\u00a0hepatitis\u00a0asintom\u00e1tica \u00a0con\u00a0hipertransaminemia \u00a0grado\u00a03,\u00a0se\u00a0debe\u00a0consi\u2010\nderar\u00a0la\u00a0suspensi\u00f3n \u00a0del\u00a0TARV\u00a0en\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0situaci\u00f3n\u00a0cl\u00ednica,\u00a0inmunol\u00f3gica \u00a0y\u00a0vi\u2010\nrol\u00f3gica,\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0utilizados \u00a0y\u00a0de\u00a0la\u00a0historia\u00a0previa\u00a0de\u00a0exposici\u00f3n \u00a0a\u00a0FAR\u00a0(nivel\u00a0\nC)\u00a0734,\u00a0735\u00a0\n\u00a0\n9.\u00a03.\u00a0Uso\u00a0de\u00a0antirretrovirales \u00a0en\u00a0pacientes \u00a0con\u00a0hepatopat\u00eda \u00a0\nLa\u00a0hepatopat\u00eda \u00a0cr\u00f3nica\u00a0puede\u00a0alterar\u00a0el\u00a0metabolismo \u00a0y\u00a0la\u00a0biodisponibilidad \u00a0de\u00a0los\u00a0FAR\u00a0\ncon\u00a0incremento \u00a0de\u00a0toxicidad\u00a0o\u00a0alteraci\u00f3n \u00a0de\u00a0la\u00a0actividad\u00a0antiviral657,\u00a0681,\u00a0690,\u00a0744\u2010748.\u00a0Se\u00a0\nsabe\u00a0que\u00a0la\u00a0hepatitis\u00a0cr\u00f3nica\u00a0sin\u00a0insuficiencia \u00a0hepatocelular \u00a0es\u00a0una\u00a0situaci\u00f3n\u00a0muy\u00a0fre\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 85 \n cuente\u00a0y\u00a0la\u00a0experiencia \u00a0acumulada \u00a0sugiere\u00a0que\u00a0se\u00a0pueden\u00a0usar\u00a0los\u00a0FAR\u00a0a\u00a0las\u00a0dosis\u00a0habi\u2010\ntuales\u00a0y\u00a0que\u00a0su\u00a0eficacia\u00a0no\u00a0est\u00e1\u00a0comprometida. \u00a0Sin\u00a0embargo\u00a0en\u00a0la\u00a0insuficiencia \u00a0hepato\u2010\ncelular\u00a0se\u00a0reduce\u00a0el\u00a0metabolismo \u00a0de\u00a0f\u00e1rmacos \u00a0v\u00eda\u00a0P450\u00a0y\u00a0la\u00a0glucuronoconjugaci\u00f3n. \u00a0No\u00a0\nhay\u00a0datos\u00a0sobre\u00a0el\u00a0TARV\u00a0en\u00a0casos\u00a0de\u00a0hepatitis\u00a0aguda.\u00a0\n\u00a0\n\u00a0\nUso\u00a0de\u00a0FAR\u00a0en\u00a0hapatopat\u00eda. \u00a0Recomendaciones \u00a0\n\u0083 Se\u00a0debe\u00a0evaluar\u00a0el\u00a0grado\u00a0de\u00a0fibrosis\u00a0hep\u00e1tica\u00a0y\u00a0el\u00a0grado\u00a0de\u00a0funci\u00f3n\u00a0hep\u00e1tica\u00a0en\u00a0los\u00a0\npacientes \u00a0coinfectados \u00a0por\u00a0virus\u00a0hepatotropos \u00a0ya\u00a0que\u00a0pueden\u00a0condicionar \u00a0la\u00a0elec\u2010\nci\u00f3n\u00a0del\u00a0TARV,\u00a0las\u00a0dosis\u00a0prescritas \u00a0de\u00a0los\u00a0FAR\u00a0y\u00a0la\u00a0estrategia \u00a0de\u00a0monitorizaci\u00f3n \u00a0de\u00a0\nsu\u00a0eficacia\u00a0y\u00a0toxicidad\u00a0(nivel\u00a0C)738\u2010741.\u00a0\u00a0\n\u0083 Los\u00a0FAR\u00a0se\u00a0pueden\u00a0usar\u00a0a\u00a0las\u00a0dosis\u00a0habituales \u00a0en\u00a0caso\u00a0de\u00a0hepatitis\u00a0cr\u00f3nica\u00a0sin\u00a0insu\u2010\nficiencia\u00a0hepatocelular \u00a0o\u00a0con\u00a0insuficiencia \u00a0hepatocelular \u00a0leve\u00a0(Child\u00a0\u00a0A)\u00a0extremando \u00a0\nla\u00a0vigilancia \u00a0por\u00a0el\u00a0mayor\u00a0riesgo\u00a0de\u00a0toxicidad\u00a0(nivel\u00a0B)\u00a0657,\u00a0681,\u00a0690,\u00a0744\u2010748.\u00a0\n\u0083 En\u00a0caso\u00a0de\u00a0hepatopat\u00eda \u00a0cr\u00f3nica\u00a0con\u00a0signos\u00a0de\u00a0insuficiencia \u00a0hepatocelular \u00a0se\u00a0deber\u00e1\u00a0\najustar\u00a0la\u00a0dosis\u00a0de\u00a0los\u00a0f\u00e1rmacos, \u00a0idealmente \u00a0mediante \u00a0la\u00a0determinaci\u00f3n \u00a0de\u00a0niveles\u00a0\u00a0\nplasm\u00e1ticos, \u00a0o\u00a0en\u00a0su\u00a0ausencia, \u00a0mediante \u00a0las\u00a0recomendaciones \u00a0de\u00a0la\u00a0Tabla\u00a017\u00a0(nivel\u00a0\nC)\u00a0657,\u00a0681,\u00a0690,\u00a0744\u2010748.\u00a0\n\u0083 En\u00a0caso\u00a0de\u00a0hepatitis\u00a0aguda\u00a0grave\u00a0debe\u00a0interrumpirse \u00a0el\u00a0TARV\u00a0y\u00a0reintroducirlo \u00a0una\u00a0\nvez\u00a0superado \u00a0el\u00a0problema \u00a0(nivel\u00a0C)\u00a0657,\u00a0681,\u00a0690,\u00a0744\u2010748.\u00a0\u00a0\n\u00a0\n9.\u00a04.\u00a0TARV\u00a0en\u00a0pacientes \u00a0en\u00a0tratamiento \u00a0\u00a0de\u00a0la\u00a0hepatitis\u00a0por\u00a0virus\u00a0C\u00a0\u00a0\nEl\u00a0tratamiento \u00a0recomendado \u00a0de\u00a0la\u00a0hepatitis\u00a0cr\u00f3nica\u00a0por\u00a0VHC\u00a0en\u00a0pacientes \u00a0coinfectados \u00a0\npor\u00a0el\u00a0VIH\u00a0es\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0interfer\u00f3n \u00a0pegilado\u00a0y\u00a0ribavirina749\u2010757.\u00a0Por\u00a0otro\u00a0lado,\u00a0se\u00a0\nhan\u00a0descrito\u00a0brotes\u00a0de\u00a0hepatitis\u00a0aguda\u00a0C\u00a0en\u00a0homosexuales \u00a0infectados \u00a0por\u00a0VIH758\u2010761,\u00a0\npara\u00a0cuyo\u00a0tratamiento \u00a0se\u00a0recomienda \u00a0interfer\u00f3n \u00a0pegilado,\u00a0en\u00a0caso\u00a0de\u00a0que\u00a0la\u00a0viremia\u00a0C\u00a0\npersista\u00a0detectable \u00a0a\u00a0las\u00a012\u00a0semanas762\u2010765.\u00a0La\u00a0duraci\u00f3n\u00a0\u00f3ptima\u00a0del\u00a0tratamiento \u00a0en\u00a0am\u2010\nbos\u00a0casos\u00a0est\u00e1\u00a0por\u00a0definir765.\u00a0El\u00a0uso\u00a0simult\u00e1neo \u00a0de\u00a0interfer\u00f3n \u00a0pegilado\u00a0y\u00a0ribavirina \u00a0con\u00a0\nlos\u00a0FAR\u00a0puede\u00a0afectar\u00a0tanto\u00a0a\u00a0la\u00a0eficacia\u00a0como\u00a0a\u00a0la\u00a0seguridad \u00a0de\u00a0ambos765\u2010767.\u00a0Se\u00a0han\u00a0\ncomunicado \u00a0datos\u00a0de\u00a0estudios\u00a0retrospectivos \u00a0que\u00a0sugieren\u00a0una\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0res\u2010\npuesta\u00a0al\u00a0tratamiento \u00a0con\u00a0interfer\u00f3n \u00a0pegilado\u00a0y\u00a0ribavirina \u00a0si\u00a0el\u00a0TARV\u00a0inclu\u00eda\u00a0ABC702,\u00a0768,\u00a0\n769.\u00a0Por\u00a0el\u00a0contrario, \u00a0en\u00a0estudios\u00a0donde\u00a0la\u00a0ribavirina \u00a0se\u00a0ajustaba\u00a0al\u00a0peso\u00a0no\u00a0se\u00a0ha\u00a0obser\u2010\nvado\u00a0esta\u00a0asociaci\u00f3n770,\u00a0771.\u00a0Hasta\u00a0que\u00a0se\u00a0confirmen \u00a0estos\u00a0datos\u00a0no\u00a0se\u00a0pueden\u00a0estable\u2010\ncer\u00a0recomendaciones \u00a0firmes.\u00a0Sin\u00a0embargo, \u00a0parece\u00a0razonable \u00a0evitar,\u00a0si\u00a0es\u00a0posible,\u00a0el\u00a0\nABC\u00a0durante\u00a0el\u00a0tratamiento \u00a0de\u00a0la\u00a0hepatitis\u00a0C\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0menor\u00a0probabilidad \u00a0\nde\u00a0respuesta. \u00a0En\u00a0caso\u00a0de\u00a0que\u00a0el\u00a0TARV\u00a0incluya\u00a0ABC,\u00a0deber\u00e1\u00a0asegurarse \u00a0que\u00a0la\u00a0dosis\u00a0de\u00a0\nribavirina \u00a0sea\u00a0superior\u00a0a\u00a013,6\u00a0mg/Kg.\u00a0\u00a0\nLos\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0EFV\u00a0aumentan \u00a0en\u00a0pacientes \u00a0cirr\u00f3ticos \u00a0por\u00a0encima\u00a0del\u00a0dintel\u00a0\nde\u00a0toxicidad\u00a0del\u00a0sistema\u00a0nervioso\u00a0central\u00a0en\u00a0un\u00a0alto\u00a0porcentaje \u00a0de\u00a0pacientes657,\u00a0772\u00a0por\u00a0\nlo\u00a0que,\u00a0si\u00a0se\u00a0usa\u00a0EFV\u00a0en\u00a0este\u00a0escenario, \u00a0deber\u00eda\u00a0hacerse\u00a0con\u00a0monitorizaci\u00f3n \u00a0de\u00a0niveles\u00a0\nde\u00a0f\u00e1rmaco,\u00a0para\u00a0evitar\u00a0la\u00a0sobreexposici\u00f3n \u00a0al\u00a0mismo.\u00a0Por\u00a0\u00faltimo\u00a0se\u00a0ha\u00a0comunicado \u00a0que\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 86 \n una\u00a0sustancial \u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0en\u00a0tratamiento \u00a0estable\u00a0con\u00a0ATV\u00a0experimentan \u00a0\nhiperbilirrubinemia \u00a0e\u00a0ictericia\u00a0tras\u00a0el\u00a0inicio\u00a0de\u00a0tratamiento \u00a0para\u00a0la\u00a0hepatitis\u00a0C\u00a0con\u00a0inter\u2010\nfer\u00f3n\u00a0mas\u00a0ribavirina. \u00a0Este\u00a0hecho\u00a0podr\u00eda\u00a0ser\u00a0debido\u00a0al\u00a0incremento \u00a0de\u00a0bilirrubina \u00a0asocia\u2010\ndo\u00a0a\u00a0la\u00a0hemolisis \u00a0por\u00a0ribavirina \u00a0y\u00a0al\u00a0compromiso \u00a0del\u00a0normal\u00a0aclaramiento \u00a0de\u00a0bilirrubina \u00a0\ndebido\u00a0a\u00a0la\u00a0inhibici\u00f3n \u00a0competitiva \u00a0de\u00a0ATV773.\u00a0\n\u00a0\n\u00a0\nTratamiento \u00a0de\u00a0la\u00a0hepatitis\u00a0C\u00a0en\u00a0coinfectados. \u00a0Recomendaciones \u00a0\n\u0083 El\u00a0TARV\u00a0no\u00a0debe\u00a0iniciarse\u00a0simult\u00e1neamente \u00a0con\u00a0el\u00a0tratamiento \u00a0del\u00a0VHC\u00a0(nivel\u00a0C)764.\u00a0\n\u0083 Cuando\u00a0se\u00a0traten\u00a0simult\u00e1neamente \u00a0el\u00a0VIH\u00a0y\u00a0el\u00a0VHC,\u00a0debe\u00a0realizarse \u00a0un\u00a0seguimiento \u00a0\nestrecho\u00a0del\u00a0paciente\u00a0para\u00a0detectar\u00a0reacciones \u00a0adversas\u00a0(nivel\u00a0B)\u00a0765\u2010767.\u00a0\n\u0083 No\u00a0se\u00a0debe\u00a0asociar\u00a0la\u00a0ribavirina \u00a0con\u00a0ddI\u00a0(nivel\u00a0B)764.\u00a0\n\u0083 Se\u00a0evitar\u00e1\u00a0el\u00a0uso\u00a0simult\u00e1neo \u00a0de\u00a0ribavirina \u00a0con\u00a0ZDV\u00a0(nivel\u00a0B)764.\u00a0\n\u0083 En\u00a0todo\u00a0paciente\u00a0coinfectado \u00a0por\u00a0el\u00a0VIH\u00a0y\u00a0virus\u00a0hepatotropos \u00a0se\u00a0debe\u00a0procurar\u00a0que\u00a0\nel\u00a0tratamiento \u00a0con\u00a0ribavirina \u00a0se\u00a0ajuste\u00a0al\u00a0peso.\u00a0Esta\u00a0recomendaci\u00f3n \u00a0debe\u00a0extremar\u2010\nse\u00a0en\u00a0caso\u00a0de\u00a0tratamiento \u00a0concomitante \u00a0con\u00a0ABC\u00a0(nivel\u00a0C).\u00a0\n\u0083 \u00a0No\u00a0se\u00a0considera \u00a0necesario \u00a0modificar \u00a0la\u00a0estrategia \u00a0de\u00a0monitorizaci\u00f3n \u00a0del\u00a0VIH\u00a0duran\u2010\nte\u00a0el\u00a0tratamiento \u00a0simult\u00e1neo \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VHC\u00a0(nivel\u00a0C)764.\u00a0\n\u00a0\n9.\u00a05.\u00a0Tratamiento \u00a0de\u00a0la\u00a0hepatitis\u00a0cr\u00f3nica\u00a0B\u00a0en\u00a0pacientes \u00a0coinfectados \u00a0\u00a0\nLos\u00a0FAR\u00a0activos\u00a0frente\u00a0al\u00a0VIH\u00a0y\u00a0al\u00a0VHB\u00a0son\u00a03TC,\u00a0FTC\u00a0y\u00a0TDF732,\u00a0774\u2010782.\u00a0Si\u00a0alguno\u00a0de\u00a0ellos\u00a0se\u00a0\nretirara\u00a0de\u00a0un\u00a0TARV\u00a0que\u00a0fracase\u00a0puede\u00a0originar\u00a0en\u00a0coinfectados \u00a0por\u00a0VHB\u00a0un\u00a0rebrote\u00a0del\u00a0\nvirus\u00a0con\u00a0da\u00f1o\u00a0hepatocelular783.\u00a0El\u00a0tratamiento \u00a0de\u00a0la\u00a0hepatitis\u00a0por\u00a0VHB\u00a0con\u00a03TC\u00a0o\u00a0FTC\u00a0\nen\u00a0monoterapia \u00a0facilita\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0resistencias \u00a0al\u00a0VIH777\u2010782.\u00a0Entecavir, \u00a0f\u00e1rmaco\u00a0\nactivo\u00a0frente\u00a0al\u00a0VHB,\u00a0ha\u00a0demostrado \u00a0actividad\u00a0frente\u00a0a\u00a0VIH\u00a0y\u00a0capacidad \u00a0para\u00a0inducir\u00a0\nigualmente \u00a0\u00a0mutaciones, \u00a0como\u00a0la\u00a0M184V777,\u00a0779.\u00a0\n\u00a0\nTratamiento \u00a0de\u00a0la\u00a0hepatitis\u00a0B\u00a0en\u00a0coinfectados. \u00a0Recomendaciones \u00a0\n\u2022 Se\u00a0recomienda \u00a0iniciar\u00a0el\u00a0TARV\u00a0usando\u00a0la\u00a0asociaci\u00f3n \u00a0de\u00a0TDF\u00a0+\u00a0FTC\u00a0(o\u00a03TC)\u00a0como\u00a0AN\u00a0\nen\u00a0pacientes \u00a0coinfectados \u00a0que\u00a0requieran \u00a0tratamiento \u00a0de\u00a0VIH\u00a0o\u00a0VHB\u00a0(nivel\u00a0C)732,\u00a0779\u00a0\n\u2022 Si\u00a0se\u00a0requiere\u00a0tratamiento \u00a0del\u00a0VHB\u00a0y\u00a0se\u00a0decide\u00a0no\u00a0tratar\u00a0el\u00a0VIH\u00a0se\u00a0recomienda \u00a0\u00a0usar\u00a0\nf\u00e1rmacos \u00a0que\u00a0no\u00a0induzcan\u00a0resistencias \u00a0al\u00a0VIH\u00a0(nivel\u00a0C)732,\u00a0779\u00a0\n\u2022 No\u00a0debe\u00a0usarse\u00a0entecavir \u00a0en\u00a0pacientes \u00a0infectados \u00a0por\u00a0el\u00a0VIH\u00a0salvo\u00a0que\u00a0su\u00a0replica\u2010\nci\u00f3n\u00a0est\u00e9\u00a0controlada \u00a0con\u00a0otros\u00a0f\u00e1rmacos \u00a0(Nivel\u00a0B)\u00a0732,\u00a0779\u00a0\u00a0\n\u2022 En\u00a0pacientes \u00a0coinfectados \u00a0en\u00a0los\u00a0que\u00a0por\u00a0cualquier \u00a0motivo\u00a0se\u00a0suspenda \u00a03TC,\u00a0FTC\u00a0\u00f3\u00a0\nTDF,\u00a0se\u00a0debe\u00a0incluir\u00a0en\u00a0el\u00a0TARV\u00a0otro\u00a0f\u00e1rmaco\u00a0con\u00a0actividad\u00a0anti\u2010VHB\u00a0(nivel\u00a0C)\u00a0732,\u00a0779\u00a0\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 87 \n \u00a0\n10.\u00a0TARV\u00a0EN\u00a0EL\u00a0EMBARAZO \u00a0Y\u00a0PREVENCI\u00d3N \u00a0DE\u00a0LA\u00a0TRANSMISI\u00d3N \u00a0MA\u2010\nTERNO\u2010FETAL\u00a0\u00a0\nLa\u00a0transmisi\u00f3n \u00a0materno\u2010fetal\u00a0es\u00a0la\u00a0causa\u00a0de\u00a0pr\u00e1cticamente \u00a0la\u00a0totalidad\u00a0de\u00a0los\u00a0casos\u00a0de\u00a0\ninfecci\u00f3n\u00a0por\u00a0VIH\u00a0en\u00a0ni\u00f1os.\u00a0\u00a0\nLa\u00a0tasa\u00a0de\u00a0transmisi\u00f3n \u00a0vertical\u00a0ha\u00a0variado\u00a0entre\u00a02\u201048%,\u00a0dependiendo \u00a0del\u00a0tratamiento \u00a0\nde\u00a0la\u00a0madre,\u00a0la\u00a0profilaxis\u00a0del\u00a0ni\u00f1o\u00a0expuesto\u00a0y\u00a0del\u00a0tipo\u00a0de\u00a0lactancia784,\u00a0785.\u00a0En\u00a0el\u00a0mundo\u00a0\ndesarrollado, \u00a0el\u00a0\u00e9xito\u00a0del\u00a0TARV\u00a0y\u00a0las\u00a0noticias\u00a0difundidas \u00a0por\u00a0los\u00a0medios\u00a0de\u00a0comunica \u2010\nci\u00f3n\u00a0sobre\u00a0la\u00a0disminuci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0vertical\u00a0han\u00a0reavivado \u00a0el\u00a0inter\u00e9s\u00a0por\u00a0la\u00a0pro\u2010\ncreaci\u00f3n\u00a0en\u00a0parejas\u00a0en\u00a0las\u00a0que\u00a0uno\u00a0o\u00a0ambos\u00a0miembros \u00a0est\u00e1n\u00a0infectados. \u00a0A\u00a0continua\u2010\nci\u00f3n\u00a0se\u00a0resumen\u00a0las\u00a0evidencias \u00a0sobre\u00a0las\u00a0que\u00a0se\u00a0basan\u00a0las\u00a0recomendaciones \u00a0del\u00a0TARV\u00a0\nen\u00a0el\u00a0embarazo \u00a0y\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0vertical.\u00a0Si\u00a0se\u00a0quiere\u00a0m\u00e1s\u00a0informaci\u00f3n \u00a0se\u00a0\naconseja\u00a0la\u00a0lectura\u00a0de\u00a0los\u00a0documentos \u00a0m\u00e1s\u00a0amplios\u00a0incluidos\u00a0en\u00a0la\u00a0bibliograf\u00eda784.\u00a0\u00a0\nEl\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0vertical\u00a0depende\u00a0de\u00a0varios\u00a0factores\u00a0(maternos, \u00a0virales,\u00a0placen\u2010\ntarios,\u00a0obst\u00e9tricos, \u00a0lactancia, \u00a0fetales,\u00a0neonatales, \u00a0etc.)\u00a0pero\u00a0la\u00a0CVP\u00a0de\u00a0la\u00a0madre\u00a0durante\u00a0\nel\u00a0embarazo \u00a0y\u00a0en\u00a0el\u00a0parto\u00a0es\u00a0el\u00a0factor\u00a0determinante786.\u00a0Aunque\u00a0existe\u00a0una\u00a0relaci\u00f3n\u00a0cla\u2010\nra\u00a0entre\u00a0CVP\u00a0materna\u00a0y\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n, \u00a0no\u00a0se\u00a0conoce\u00a0un\u00a0nivel\u00a0por\u00a0encima\u00a0del\u00a0\ncual\u00a0la\u00a0transmisi\u00f3n \u00a0sea\u00a0del\u00a0100%,\u00a0ni\u00a0tampoco\u00a0un\u00a0dintel\u00a0por\u00a0debajo\u00a0del\u00a0cual\u00a0se\u00a0garantice \u00a0\nla\u00a0no\u00a0transmisi\u00f3n. \u00a0Se\u00a0ha\u00a0descrito\u00a0que\u00a0la\u00a0tasa\u00a0de\u00a0transmisi\u00f3n \u00a0en\u00a0mujeres\u00a0en\u00a0TARV\u00a0y\u00a0con\u00a0\nCVP\u00a0<1000\u00a0copias/mL \u00a0es\u00a0de\u00a00,96%,\u00a0y\u00a0diez\u00a0veces\u00a0superior\u00a0(9,8%)\u00a0en\u00a0mujeres\u00a0no\u00a0tratadas\u00a0\ncon\u00a0CVP\u00a0inferior\u00a0a\u00a01000\u00a0copias/mL, \u00a0lo\u00a0que\u00a0enfatiza\u00a0la\u00a0importancia \u00a0del\u00a0TARV\u00a0incluso\u00a0en\u00a0\ncaso\u00a0de\u00a0CVP\u00a0baja787,\u00a0788.\u00a0\nPara\u00a0una\u00a0correcta\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0vertical\u00a0es\u00a0imprescindible \u00a0que\u00a0la\u00a0mujer\u00a0\nsepa\u00a0su\u00a0situaci\u00f3n\u00a0de\u00a0infectada. \u00a0Por\u00a0ello\u00a0es\u00a0obligado\u00a0efectuar\u00a0la\u00a0serolog\u00eda\u00a0frente\u00a0al\u00a0VIH\u00a0a\u00a0\ntodas\u00a0las\u00a0embarazadas \u00a0independientemente \u00a0de\u00a0sus\u00a0antecedentes \u00a0epidemiol\u00f3gicos. \u00a0\nUna\u00a0vez\u00a0conocida\u00a0la\u00a0seropositividad \u00a0las\u00a0estrategias \u00a0que\u00a0se\u00a0han\u00a0perfilado\u00a0como\u00a0m\u00e1s\u00a0im\u2010\nportantes \u00a0han\u00a0sido\u00a0el\u00a0TARV,\u00a0la\u00a0ces\u00e1rea\u00a0programada \u00a0y\u00a0evitar\u00a0la\u00a0lactancia789.\u00a0\nLos\u00a0ensayos\u00a0cl\u00ednicos\u00a0aleatorizados \u00a0efectuados \u00a0en\u00a0el\u00a0campo\u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0materno\u2010\nfetal\u00a0han\u00a0permitido \u00a0extraer\u00a0una\u00a0serie\u00a0de\u00a0conclusiones \u00a0aplicables \u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0diaria:\u00a0el\u00a0\ntratamiento \u00a0con\u00a0ZDV\u00a0(500\u00a0mg/d\u00eda\u00a0v\u00eda\u00a0oral,\u00a0desde\u00a0las\u00a0semanas\u00a014\u00a0y\u00a034,\u00a0ZDV\u00a0intravenosa \u00a0\nen\u00a0el\u00a0parto\u00a0y\u00a0ZDV\u00a0oral\u00a0al\u00a0neonato\u00a0durante\u00a06\u00a0semanas) \u00a0disminuye \u00a0el\u00a0riesgo\u00a0de\u00a0transmi\u2010\nsi\u00f3n\u00a0de\u00a025,5%\u00a0a\u00a08,3790.\u00a0S\u00f3lo\u00a0una\u00a0parte\u00a0de\u00a0esta\u00a0eficacia\u00a0se\u00a0correlaciona \u00a0con\u00a0un\u00a0descenso \u00a0\nde\u00a0la\u00a0CVP\u00a0materna;\u00a0la\u00a0hip\u00f3tesis\u00a0m\u00e1s\u00a0aceptada\u00a0es\u00a0que\u00a0se\u00a0deba\u00a0a\u00a0efecto\u00a0profilaxis\u00a0post\u2010\nexposici\u00f3n791.\u00a0\nUna\u00a0dosis\u00a0\u00fanica\u00a0de\u00a0NVP\u00a0en\u00a0el\u00a0momento \u00a0del\u00a0parto\u00a0reduce\u00a0el\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0en\u00a0un\u00a0\n50%,\u00a0y\u00a0mantiene \u00a0su\u00a0efectividad \u00a0a\u00a0los\u00a018\u00a0meses\u00a0en\u00a0ni\u00f1os\u00a0que\u00a0se\u00a0alimentan \u00a0con\u00a0lactancia\u00a0\nmaterna792,\u00a0793.\u00a0Sin\u00a0embargo, \u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0la\u00a0mutaci\u00f3n \u00a0K103N\u00a0en\u00a0>65%\u00a0de\u00a0los\u00a0ca\u2010\nsos293\u00a0desaconseja \u00a0el\u00a0uso\u00a0de\u00a0esta\u00a0estrategia \u00a0en\u00a0nuestro\u00a0medio\u00a0y\u00a0la\u00a0cuestiona \u00a0en\u00a0pa\u00edses\u00a0\npobres\u00a0en\u00a0recursos794.\u00a0\u00a0\nSe\u00a0ha\u00a0demostrado \u00a0en\u00a0estudios\u00a0de\u00a0cohortes\u00a0que\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0ZDV\u00a0y\u00a03TC\u00a0reduce\u00a0la\u00a0\ntransmisi\u00f3n \u00a0vertical\u00a0a\u00a0un\u00a01,6%795\u2010798,\u00a0y\u00a0en\u00a0algunos\u00a0estudios\u00a0observacionales \u00a0que\u00a0inclu\u2010\nyen\u00a0mujeres\u00a0con\u00a0TARV\u00a0con\u00a0un\u00a0IP,\u00a0no\u00a0ha\u00a0habido\u00a0transmisi\u00f3n \u00a0vertical\u00a0(0%;\u00a0IC\u00a095%:\u00a00\u20102%).\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 88 \n Cifras\u00a0inferiores \u00a0al\u00a03%\u00a0se\u00a0est\u00e1n\u00a0observando \u00a0tanto\u00a0en\u00a0nuestro\u00a0pa\u00eds\u00a0como\u00a0en\u00a0Europa\u00a0y\u00a0\nEEUU799,\u00a0800.\u00a0\u00a0\nLos\u00a0datos\u00a0de\u00a0seguridad \u00a0de\u00a0los\u00a0FAR\u00a0para\u00a0el\u00a0feto\u00a0son\u00a0limitados\u00a0(Tabla\u00a018).\u00a0De\u00a0los\u00a0datos\u00a0\ndisponibles, \u00a0se\u00a0puede\u00a0destacar:\u00a01)\u00a0ZDV\u00a0es\u00a0segura\u00a0al\u00a0menos\u00a0a\u00a0corto\u00a0y\u00a0medio\u00a0plazo,\u00a0aun\u2010\nque\u00a0un\u00a0estudio\u00a0sugiri\u00f3\u00a0riesgo\u00a0de\u00a0toxicidad\u00a0mitocondrial \u00a0en\u00a0ni\u00f1os;\u00a02)\u00a0EFV\u00a0es\u00a0un\u00a0f\u00e1rmaco\u00a0\npotencialmente \u00a0terat\u00f3geno, \u00a0por\u00a0lo\u00a0que\u00a0est\u00e1\u00a0contraindicado \u00a0al\u00a0menos\u00a0durante\u00a0el\u00a0primer\u00a0\ntrimestre; \u00a03)\u00a0Es\u00a0posible\u00a0que\u00a0los\u00a0IP\u00a0se\u00a0asocien\u00a0con\u00a0bajo\u00a0peso\u00a0al\u00a0nacer801\u00a0o\u00a0prematuri \u2010\ndad802;\u00a04)\u00a0La\u00a0seguridad \u00a0de\u00a0otros\u00a0f\u00e1rmacos \u00a0es\u00a0a\u00fan\u00a0peor\u00a0conocida, \u00a0y\u00a0aunque\u00a0se\u00a0catalogan \u00a0\ncomo\u00a0categor\u00eda \u00a0\u201cB\u201d\u00a0o\u00a0\u201cC\u201d\u00a0de\u00a0la\u00a0FDA\u00a0(Tabla\u00a018),\u00a0los\u00a0datos\u00a0disponibles \u00a0de\u00a0seguridad, \u00a0es\u2010\npecialmente \u00a0a\u00a0largo\u00a0plazo,\u00a0son\u00a0limitados. \u00a0Se\u00a0tiene\u00a0escasa\u00a0informaci\u00f3n \u00a0de\u00a0TDF,\u00a0ATV,\u00a0FPV\u00a0\ne\u00a0IDV\u00a0y\u00a0muy\u00a0escasa\u00a0de\u00a0TPV,\u00a0DRV,\u00a0RAL,\u00a0ETR\u00a0y\u00a0MVC.\u00a0Por\u00a0ello\u00a0se\u00a0deben\u00a0evitar\u00a0estos\u00a0f\u00e1rma\u2010\ncos,\u00a0salvo\u00a0en\u00a0pacientes \u00a0embarazadas \u00a0en\u00a0fracaso,\u00a0en\u00a0cuyo\u00a0caso\u00a0deberemos \u00a0orientarnos \u00a0\nen\u00a0funci\u00f3n\u00a0de\u00a0la\u00a0poca\u00a0informaci\u00f3n \u00a0disponible; \u00a0\u00a04)\u00a0En\u00a0un\u00a0registro\u00a0establecido \u00a0en\u00a01989\u00a0\n(Antiretroviral \u00a0Pregnancy \u00a0Registry)\u00a0se\u00a0recogen\u00a0de\u00a0forma\u00a0prospectiva \u00a0los\u00a0datos\u00a0de\u00a0expo\u2010\nsici\u00f3n\u00a0a\u00a0FAR\u00a0y\u00a0la\u00a0evoluci\u00f3n \u00a0de\u00a010.405\u00a0ni\u00f1os\u00a0expuestos \u00a0a\u00a0antirretrovirales \u00a0durante\u00a0el\u00a0\nembarazo. \u00a0La\u00a0prevalencia \u00a0de\u00a0malformaciones \u00a0entre\u00a0los\u00a0expuestos \u00a0en\u00a0el\u00a0primer\u00a0trimes\u2010\ntre\u00a0es\u00a0del\u00a02,9%\u00a0de\u00a0los\u00a0nacidos\u00a0vivos,\u00a0cifra\u00a0que\u00a0no\u00a0difiere\u00a0de\u00a0la\u00a0poblaci\u00f3n \u00a0no\u00a0expuesta\u00a0\n(2,7%)803.\u00a0\u00a0\nEn\u00a0cuanto\u00a0a\u00a0la\u00a0madre,\u00a0cabe\u00a0rese\u00f1ar\u00a0que\u00a0se\u00a0han\u00a0descrito\u00a0casos\u00a0de\u00a0toxicidad\u00a0mitocon\u2010\ndrial\u00a0y\u00a0acidosis\u00a0l\u00e1ctica\u00a0en\u00a0gestantes, \u00a0las\u00a0cuales\u00a0pueden\u00a0estar\u00a0m\u00e1s\u00a0predispuestas \u00a0a\u00a0esta\u00a0\ncomplicaci\u00f3n. \u00a0Estos\u00a0efectos\u00a0secundarios \u00a0se\u00a0asociaron \u00a0inicialmente \u00a0a\u00a0ZDV\u00a0pero\u00a0poste\u2010\nriormente \u00a0se\u00a0han\u00a0descrito\u00a0casos\u00a0relacionados \u00a0con\u00a0d4T.\u00a0La\u00a0FDA\u00a0ha\u00a0comunicado \u00a0tres\u00a0\nmuertes\u00a0maternas \u00a0por\u00a0acidosis\u00a0l\u00e1ctica\u00a0y\u00a0tres\u00a0muertes\u00a0fetales\u00a0en\u00a0mujeres\u00a0tratadas\u00a0con\u00a0\nd4T\u00a0y\u00a0ddI\u00a0como\u00a0AN,\u00a0por\u00a0lo\u00a0que\u00a0desaconseja \u00a0esta\u00a0combinaci\u00f3n. \u00a0La\u00a0acidosis\u00a0l\u00e1ctica\u00a0grave,\u00a0\nno\u00a0letal,\u00a0se\u00a0ha\u00a0comunicado \u00a0con\u00a0otros\u00a0AN803.\u00a0\u00a0Adem\u00e1s\u00a0se\u00a0ha\u00a0descrito\u00a0que\u00a0la\u00a0hepatotoxi \u2010\ncidad\u00a0por\u00a0NVP\u00a0ser\u00eda\u00a012\u00a0veces\u00a0m\u00e1s\u00a0frecuente \u00a0en\u00a0gestantes \u00a0con\u00a0CD4\u00a0>250\u00a0c\u00e9lulas/\u00b5L. \u00a0\nLa\u00a0ces\u00e1rea\u00a0programada \u00a0(antes\u00a0del\u00a0inicio\u00a0del\u00a0parto)\u00a0como\u00a0instrumento \u00a0potencial \u00a0para\u00a0\nreducir\u00a0la\u00a0transmisi\u00f3n \u00a0vertical\u00a0se\u00a0ha\u00a0mostrado \u00a0\u00fatil\u00a0en\u00a0algunas\u00a0situaciones804.\u00a0En\u00a0un\u00a0me\u2010\ntaan\u00e1lisis \u00a0de\u00a0estudios\u00a0de\u00a0cohorte\u00a0la\u00a0ces\u00e1rea\u00a0programada \u00a0redujo\u00a0el\u00a0riesgo\u00a0de\u00a0transmi\u2010\nsi\u00f3n\u00a0cerca\u00a0del\u00a050%\u00a0(OR\u00a00,43;\u00a0IC\u00a095:\u00a00,33\u20100,56).\u00a0La\u00a0transmisi\u00f3n \u00a0disminuy\u00f3 \u00a0en\u00a0un\u00a087%\u00a0\ncuando\u00a0coincid\u00edan \u00a0ces\u00e1rea\u00a0programada \u00a0y\u00a0tratamiento \u00a0con\u00a0ZDV\u00a0(anteparto, \u00a0intraparto \u00a0y\u00a0\nposparto)796.\u00a0En\u00a0parejas\u00a0madre\u2010hijo\u00a0que\u00a0recibieron \u00a0ZDV\u00a0(anteparto, \u00a0intraparto \u00a0y\u00a0post\u2010\nparto)\u00a0la\u00a0transmisi\u00f3n \u00a0vertical\u00a0fue\u00a0del\u00a02%\u00a0entre\u00a0las\u00a0196\u00a0madres\u00a0sometidas \u00a0a\u00a0ces\u00e1rea\u00a0\nelectiva\u00a0y\u00a0del\u00a07,3%\u00a0en\u00a0las\u00a01255\u00a0madres\u00a0con\u00a0otras\u00a0formas\u00a0de\u00a0parto.\u00a0\u00a0\nLos\u00a0datos\u00a0disponibles \u00a0sugieren\u00a0que\u00a0si\u00a0en\u00a0el\u00a0momento \u00a0del\u00a0parto\u00a0la\u00a0CVP\u00a0es\u00a0<1000\u00a0co\u2010\npias/mL\u00a0la\u00a0ces\u00e1rea\u00a0electiva\u00a0no\u00a0disminuye \u00a0el\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0del\u00a0parto\u00a0vaginal\u00a0\n(0,8%\u00a0frente\u00a0a\u00a00,7%)805.\u00a0La\u00a0morbilidad \u00a0relacionada \u00a0con\u00a0la\u00a0ces\u00e1rea\u00a0en\u00a0los\u00a0pa\u00edses\u00a0desarro\u2010\nllados\u00a0no\u00a0parece\u00a0ser\u00a0importante806.\u00a0La\u00a0lactancia\u00a0est\u00e1\u00a0contraindicada. \u00a0En\u00a0pa\u00edses\u00a0en\u00a0v\u00edas\u00a0\nde\u00a0desarrollo \u00a0existen\u00a0datos\u00a0sobre\u00a0la\u00a0utilidad\u00a0del\u00a0TARV\u00a0para\u00a0reducir\u00a0la\u00a0transmisi\u00f3n, \u00a0limi\u2010\ntando\u00a0la\u00a0lactancia\u00a0a\u00a0los\u00a0seis\u00a0primeros\u00a0meses\u00a0de\u00a0vida.\u00a0\n\u00a0\n\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 89 \n Embarazo \u00a0y\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0vertical.\u00a0Recomendaciones \u00a0\n\u0083 El\u00a0test\u00a0de\u00a0VIH\u00a0debe\u00a0efectuarse \u00a0a\u00a0toda\u00a0mujer\u00a0embarazada \u00a0(nivel\u00a0B).\u00a0Si\u00a0hay\u00a0pr\u00e1cticas\u00a0\nde\u00a0riesgo\u00a0debe\u00a0repetirse\u00a0en\u00a0el\u00a0tercer\u00a0trimestre807.\u00a0\n\u0083 En\u00a0las\u00a0mujeres\u00a0que\u00a0llegan\u00a0al\u00a0parto\u00a0sin\u00a0conocer\u00a0su\u00a0estado\u00a0respecto\u00a0al\u00a0VIH,\u00a0se\u00a0debe\u00a0\nhacer\u00a0un\u00a0test\u00a0r\u00e1pido,\u00a0ya\u00a0que\u00a0la\u00a0ces\u00e1rea\u00a0electiva\u00a0reduce\u00a0la\u00a0transmisi\u00f3n \u00a0un\u00a050%\u00a0(nivel\u00a0\nB).\u00a0\n\u0083 El\u00a0objetivo\u00a0del\u00a0TARV\u00a0\u00a0en\u00a0la\u00a0gestaci\u00f3n \u00a0es\u00a0conseguir \u00a0CVP\u00a0indetectable \u00a0(nivel\u00a0B).\u00a0La\u00a0\nZDV\u00a0debe\u00a0incluirse\u00a0en\u00a0el\u00a0TARV,\u00a0siempre\u00a0que\u00a0no\u00a0haya\u00a0resistencia \u00a0o\u00a0toxicidad\u00a0grave\u00a0\ndocumentadas \u00a0previamente, \u00a0o\u00a0dudas\u00a0respecto\u00a0a\u00a0la\u00a0adherencia, \u00a0que\u00a0se\u00a0administrar\u00e1 \u00a0\ndurante\u00a0el\u00a0embarazo, \u00a0en\u00a0el\u00a0parto\u00a0y\u00a0al\u00a0reci\u00e9n\u00a0nacido.\u00a0Si\u00a0se\u00a0sabe\u00a0que\u00a0hay\u00a0resistencias \u00a0\na\u00a0la\u00a0ZDV,\u00a0debe\u00a0indicarse\u00a0por\u00a0v\u00eda\u00a0intravenosa \u00a0durante\u00a0el\u00a0parto\u00a0y\u00a0al\u00a0reci\u00e9n\u00a0nacido\u00a0(ni\u2010\nvel\u00a0A).\u00a0\n\u0083 Se\u00a0debe\u00a0informar\u00a0a\u00a0la\u00a0madre\u00a0de\u00a0las\u00a0ventajas\u00a0del\u00a0TARV\u00a0para\u00a0ella\u00a0y\u00a0su\u00a0utilidad\u00a0para\u00a0\nreducir\u00a0la\u00a0transmisi\u00f3n \u00a0vertical.\u00a0Se\u00a0debe\u00a0informar\u00a0igualmente \u00a0de\u00a0los\u00a0efectos\u00a0secun\u2010\ndarios\u00a0conocidos \u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0y\u00a0de\u00a0las\u00a0incertidumbres \u00a0respecto\u00a0a\u00a0la\u00a0seguridad \u00a0\ntanto\u00a0para\u00a0ella\u00a0como\u00a0para\u00a0el\u00a0feto\u00a0a\u00a0medio\u00a0y\u00a0largo\u00a0plazo.\u00a0Se\u00a0deben\u00a0realizar\u00a0controles \u00a0\nperi\u00f3dicos. \u00a0Es\u00a0fundamental \u00a0planificar \u00a0el\u00a0control\u00a0de\u00a0la\u00a0CVP\u00a0antes\u00a0del\u00a0parto,\u00a0hacia\u00a0la\u00a0\nsemana\u00a032\u201036\u00a0para\u00a0decidir\u00a0si\u00a0se\u00a0va\u00a0a\u00a0realizar\u00a0ces\u00e1rea\u00a0electiva\u00a0o\u00a0no\u00a0(niveles\u00a0B\u00a0y\u00a0C).\u00a0\n\u0083 No\u00a0deben\u00a0utilizarse\u00a0f\u00e1rmacos\u00a0con\u00a0riesgo\u00a0teratog\u00e9nico \u00a0(como\u00a0EFV)\u00a0(nivel\u00a0A),\u00a0o\u00a0con\u00a0\nriego\u00a0de\u00a0toxicidad\u00a0sobre\u00a0el\u00a0feto\u00a0(IDV) .\u00a0Asimismo, \u00a0deben\u00a0evitarse,\u00a0en\u00a0la\u00a0medida\u00a0de\u00a0lo\u00a0\nposible,\u00a0f\u00e1rmacos\u00a0cuyo\u00a0riesgo\u00a0no\u00a0es\u00a0bien\u00a0conocido\u00a0(FPV,\u00a0TDF,\u00a0ATV,\u00a0DRV,\u00a0TPV,\u00a0ENF,\u00a0\nMVC,\u00a0ETR\u00a0y\u00a0RAL)\u00a0(nivel\u00a0C).\u00a0\n\u0083 Se\u00a0desaconseja \u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0d4T+ddI\u00a0por\u00a0el\u00a0riesgo\u00a0de\u00a0acidosis\u00a0l\u00e1ctica\u00a0(nivel\u00a0\nB).\u00a0Si\u00a0no\u00a0hay\u00a0otras\u00a0alternativas, \u00a0el\u00a0uso\u00a0de\u00a0esta\u00a0combinaci\u00f3n \u00a0obliga\u00a0a\u00a0un\u00a0seguimiento \u00a0\nmuy\u00a0estrecho\u00a0de\u00a0la\u00a0paciente\u00a0(nivel\u00a0C).\u00a0\n\u0083 Se\u00a0desaconseja \u00a0la\u00a0utilizaci\u00f3n \u00a0de\u00a0NVP\u00a0en\u00a0monoterapia \u00a0(nivel\u00a0A).\u00a0Tampoco \u00a0se\u00a0reco\u2010\nmienda\u00a0el\u00a0inicio\u00a0de\u00a0TARV\u00a0con\u00a0NVP\u00a0en\u00a0mujeres\u00a0con\u00a0CD4\u00a0>250/mL\u00a0si\u00a0existen\u00a0otras\u00a0al\u2010\nternativas \u00a0(nivel\u00a0B).\u00a0\n\u0083 Si\u00a0no\u00a0se\u00a0consigue\u00a0una\u00a0CVP\u00a0suficientemente \u00a0baja\u00a0(<1000\u00a0copias/mL) \u00a0o\u00a0en\u00a0el\u00a0caso\u00a0en\u00a0\nque\u00a0la\u00a0mujer\u00a0decida\u00a0no\u00a0llevar\u00a0TARV\u00a0o\u00a0hacerlo\u00a0s\u00f3lo\u00a0con\u00a0ZDV\u00a0se\u00a0debe\u00a0indicar\u00a0una\u00a0\nces\u00e1rea\u00a0programada \u00a0en\u00a0la\u00a0semana\u00a037\u201038\u00a0(nivel\u00a0A).\u00a0\n\u0083 Las\u00a0pacientes \u00a0que\u00a0quedan\u00a0embarazadas \u00a0en\u00a0fracaso\u00a0virol\u00f3gico \u00a0tienen\u00a0el\u00a0mayor\u00a0ries\u2010\ngo\u00a0de\u00a0transmisi\u00f3n. \u00a0En\u00a0esta\u00a0situaci\u00f3n, \u00a0se\u00a0debe\u00a0efectuar\u00a0un\u00a0estudio\u00a0de\u00a0resistencias \u00a0\npara\u00a0guiar\u00a0el\u00a0TARV\u00a0(nivel\u00a0C);\u00a0debe\u00a0utilizarse\u00a0tambi\u00e9n\u00a0ZDV\u00a0(en\u00a0el\u00a0parto)\u00a0e\u00a0indicar\u00a0\nces\u00e1rea\u00a0programada \u00a0en\u00a0la\u00a0semana\u00a037\u201038\u00a0(nivel\u00a0C).\u00a0\n\u0083 Las\u00a0pacientes \u00a0que\u00a0conozcan \u00a0su\u00a0condici\u00f3n \u00a0de\u00a0infectadas \u00a0muy\u00a0cerca\u00a0del\u00a0parto\u00a0deben\u00a0\nrecibir\u00a0TARV.\u00a0Adem\u00e1s\u00a0debe\u00a0recomendarse \u00a0la\u00a0ces\u00e1rea\u00a0programada \u00a0si\u00a0no\u00a0consiguen \u00a0\nCVP\u00a0<1000\u00a0copias/mL \u00a0(nivel\u00a0A).\u00a0\n\u0083 La\u00a0dosis\u00a0de\u00a0ZDV\u00a0intravenosa \u00a0durante\u00a0el\u00a0parto\u00a0es\u00a02\u00a0mg/kg\u00a0la\u00a0primera\u00a0hora\u00a0y\u00a0poste\u2010\nriormente \u00a01\u00a0mg/kg/h\u00a0hasta\u00a0la\u00a0ligadura\u00a0del\u00a0cord\u00f3n.\u00a0Al\u00a0reci\u00e9n\u00a0nacido\u00a0se\u00a0le\u00a0adminis\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 90 \n tran\u00a02\u00a0mg/kg/cada \u00a06\u00a0horas\u00a0durante\u00a06\u00a0semanas\u00a0empezando \u00a0tras\u00a0el\u00a0alumbramiento \u00a0\n(nivel\u00a0A).\u00a0\n\u00a011.\u00a0PROFILAXIS \u00a0POST\u2010EXPOSICI\u00d3N \u00a0(PPE)\u00a0\n11.\u00a01.\u00a0Profilaxis \u00a0post\u2010exposici\u00f3n \u00a0ocupacional \u00a0\nEl\u00a0uso\u00a0de\u00a0TARV\u00a0tras\u00a0una\u00a0exposici\u00f3n \u00a0profesional \u00a0al\u00a0VIH\u00a0reduce\u00a0el\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0\ndel\u00a0mismo,\u00a0aunque\u00a0se\u00a0han\u00a0documentado \u00a0transmisiones \u00a0a\u00a0pesar\u00a0de\u00a0una\u00a0PPE\u00a0correcta\u00a0\ncon\u00a0tres\u00a0f\u00e1rmacos. \u00a0El\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0del\u00a0VIH\n\u00a0tras\u00a0exposici\u00f3n \u00a0percut\u00e1nea \u00a0a\u00a0sangre\u00a0\ninfectada \u00a0oscila\u00a0entre\u00a00,24\u00a0a\u00a00,65\u00a0%\u00a0y\u00a0es\u00a0del\u00a00,09%\u00a0tras\u00a0un\u00a0contacto\u00a0con\u00a0mucosas\u00a0o\u00a0piel\u00a0\nno\u00a0intacta808.\u00a0Los\u00a0factores\u00a0asociados \u00a0a\u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0del\u00a0VIH\u00a0son:\u00a0\npinchazo\u00a0profundo \u00a0(OR\u00a015,\u00a0IC95%:\u00a06.0\u201041),\u00a0con\u00a0sangre\u00a0visible\u00a0en\u00a0el\u00a0dispositivo \u00a0(OR\u00a06.2,\u00a0\nIC95%:\u00a02.2\u201021),\u00a0reci\u00e9n\u00a0extra\u00eddo\u00a0de\u00a0vena\u00a0o\u00a0arteria\u00a0(OR\u00a04.3,\u00a0IC95%:\u00a01.7\u201012)\u00a0en\u00a0paciente\u00a0\nfuente\u00a0con\u00a0enfermedad \u00a0avanzada \u00a0(OR\u00a05.6,\u00a0IC95%:\u00a02\u201016).\u00a0La\u00a0PPE\u00a0con\u00a0monoterapia \u00a0(ZDV)\u00a0\nreduce\u00a0la\u00a0transmisi\u00f3n \u00a0un\u00a081%\u00a0(OR\u00a00,19,\u00a0IC95%:\u00a00,06\u20100,52)809.\u00a0No\u00a0existen\u00a0estudios\u00a0com\u2010\nparados\u00a0que\u00a0permitan\u00a0establecer \u00a0recomendaciones \u00a0firmes\u00a0sobre\u00a0el\u00a0momento \u00a0de\u00a0inicio,\u00a0\nla\u00a0duraci\u00f3n\u00a0o\u00a0los\u00a0f\u00e1rmacos\u00a0o\u00a0combinaciones \u00a0a\u00a0emplear\u00a0tras\u00a0una\u00a0exposici\u00f3n \u00a0accidental. \u00a0\u00a0\nPor\u00a0modelos\u00a0animales, \u00a0y\u00a0estudios\u00a0de\u00a0caso\u2010control\u00a0sabemos\u00a0que\u00a0la\u00a0PPE\u00a0es\u00a0tanto\u00a0m\u00e1s\u00a0\neficaz\u00a0cuanto\u00a0antes\u00a0se\u00a0inicie499.\u00a0Su\u00a0duraci\u00f3n\u00a0no\u00a0est\u00e1\u00a0establecida \u00a0pero\u00a0en\u00a0modelos\u00a0ani\u2010\nmales\u00a0los\u00a0periodos\u00a0de\u00a03\u00a0\u00f3\u00a010\u00a0d\u00edas\u00a0son\u00a0menos\u00a0eficaces\u00a0que\u00a028\u00a0d\u00edas,\u00a0por\u00a0ello\u00a0se\u00a0ha\u00a0con\u2010\nsensuado \u00a0el\u00a0recomendar \u00a04\u00a0semanas. \u00a0No\u00a0existen\u00a0estudios\u00a0que\u00a0demuestren \u00a0que\u00a0la\u00a0PPE\u00a0\ncon\u00a03\u00a0f\u00e1rmacos\u00a0sea\u00a0mejor\u00a0que\u00a0con\u00a02,\u00a0aunque\u00a0prevalece \u00a0la\u00a0opci\u00f3n\u00a0de\u00a0indicar\u00a0triple\u00a0tera\u2010\npia\u00a0de\u00a0modo\u00a0similar\u00a0al\u00a0TARV\u00a0de\u00a0inicio.\u00a0La\u00a0elecci\u00f3n\u00a0de\u00a0los\u00a0FAR\u00a0depender\u00e1 \u00a0de\u00a0los\u00a0efectos\u00a0\nadversos\u00a0potenciales \u00a0y\u00a0de\u00a0las\u00a0preferencias \u00a0de\u00a0los\u00a0sanitarios \u00a0teniendo\u00a0en\u00a0cuenta\u00a0que\u00a0la\u00a0\nintolerancia \u00a0a\u00a0los\u00a0FAR\u00a0entre\u00a0el\u00a0personal\u00a0sanitario\u00a0es\u00a0muy\u00a0elevada\u00a0(50%).\u00a0\u00a0\nPara\u00a0establecer \u00a0la\u00a0necesidad \u00a0de\u00a0profilaxis\u00a0debemos \u00a0conocer\u00a0el\u00a0tipo\u00a0de\u00a0exposici\u00f3n \u00a0y\u00a0\nsolicitar,\u00a0tras\u00a0consentimiento \u00a0informado, \u00a0serolog\u00eda\u00a0r\u00e1pida\u00a0frente\u00a0al\u00a0VIH,\u00a0VHB\u00a0y\u00a0VHC\u00a0del\u00a0\npaciente\u2010fuente\u00a0y\u00a0del\u00a0trabajador. \u00a0\nEn\u00a0las\u00a0exposiciones \u00a0que\u00a0precisen\u00a0profilaxis\u00a0se\u00a0recomienda \u00a0un\u00a0TARV\u00a0que\u00a0incluya\u00a0dos\u00a0AN,\u00a0\ncon\u00a0un\u00a0IP\u00a0potenciado. \u00a0En\u00a0los\u00a0casos\u00a0que\u00a0no\u00a0pueda\u00a0administrase \u00a0un\u00a0TARV\u00a0basado\u00a0en\u00a0IP,\u00a0o\u00a0\nque\u00a0sea\u00a0intolerante, \u00a0la\u00a0sustituci\u00f3n \u00a0de\u00a0\u00e9ste\u00a0por\u00a0EFV,\u00a0recordando \u00a0que\u00a0no\u00a0puede\u00a0adminis\u2010\ntrarse\u00a0embarazadas, \u00a0o\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0ZDV+3TC+TDF \u00a0podr\u00edan\u00a0ser\u00a0buenas\u00a0opcio\u2010\nnes810\u2010812.\u00a0La\u00a0NVP\u00a0no\u00a0es\u00a0aconsejable \u00a0por\u00a0las\u00a0posibles\u00a0toxicidades \u00a0cut\u00e1neas\u00a0y\u00a0hep\u00e1ti\u2010\ncas810.\u00a0\u00a0\u00a0\nEn\u00a0caso\u00a0de\u00a0conocer\u00a0o\u00a0sospechar \u00a0que\u00a0el\u00a0paciente\u00a0fuente\u00a0tiene\u00a0un\u00a0virus\u00a0resistente, \u00a0se\u00a0\ndeben\u00a0seleccionar \u00a0FAR\u00a0sin\u00a0resistencia \u00a0cruzada.\u00a0Se\u00a0ha\u00a0demostrado \u00a0una\u00a0elevada\u00a0propor\u2010\nci\u00f3n\u00a0de\u00a0virus\u00a0de\u00a0los\u00a0casos\u00a0fuente\u00a0presentan \u00a0mutaciones \u00a0de\u00a0resistencia, \u00a0especialmente \u00a0a\u00a0\nAN\u00a0y\u00a0NN813.\u00a0MVC,\u00a0RAL\u00a0o\u00a0T20\u00a0no\u00a0se\u00a0recomiendan \u00a0para\u00a0PPE,\u00a0salvo\u00a0en\u00a0casos\u00a0excepcionales \u00a0\nde\u00a0multirresistencia. \u00a0El\u00a0PNS/Gesida814\u00a0la\u00a0EACS548,\u00a0815\u00a0\u00a0y\u00a0otros\u00a0organismos \u00a0han\u00a0actuali\u2010\nzando\u00a0las\u00a0recomendaciones \u00a0de\u00a0tratamiento \u00a0antirretroviral \u00a0postexposici\u00f3n \u00a0ocupacional \u00a0\ny\u00a0no\u00a0ocupacional \u00a0cuyo\u00a0texto\u00a0est\u00e1\u00a0disponible \u00a0en\u00a0sus\u00a0respectivas \u00a0p\u00e1ginas\u00a0web.\u00a0\u00a0\nA\u00a0toda\u00a0persona\u00a0que\u00a0se\u00a0haya\u00a0evaluado\u00a0por\u00a0PPE\u00a0debe\u00a0ofrec\u00e9rsele \u00a0un\u00a0plan\u00a0de\u00a0seguimiento \u00a0\nque\u00a0incluir\u00e1\u00a0informaci\u00f3n, \u00a0apoyo\u00a0psicol\u00f3gico \u00a0y\u00a0control\u00a0de\u00a0los\u00a0posibles\u00a0s\u00edntomas\u00a0de\u00a0pri\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 91 \n moinfecci\u00f3n. \u00a0Si\u00a0se\u00a0prescribi\u00f3 \u00a0PPE\u00a0se\u00a0deben\u00a0controlar\u00a0dentro\u00a0de\u00a0las\u00a0primeras\u00a072\u00a0hs\u00a0para\u00a0\nrevalorar\u00a0necesidad \u00a0de\u00a0profilaxis\u00a0y\u00a0conocer\u00a0si\u00a0el\u00a0trabajador \u00a0ha\u00a0presentado \u00a0reacciones \u00a0\nadversas, \u00a0interacciones \u00a0y\u00a0problemas \u00a0de\u00a0adherencia. \u00a0Se\u00a0programar\u00e1n \u00a0controles \u00a0anal\u00edti\u2010\ncos\u00a0y\u00a0serol\u00f3gicos \u00a0a\u00a0las\u00a04\u00a0semanas\u00a0y\u00a0a\u00a0los\u00a03\u00a0y\u00a06\u00a0meses.\u00a0\u00a0\n\u00a0\nPPE\u00a0ocupacional. \u00a0Recomendaciones \u00a0(niveles\u00a0B\u00a0y\u00a0C)\u00a0\n\u2022 Los\u00a0servicios\u00a0sanitarios \u00a0deben\u00a0disponer\u00a0de\u00a0un\u00a0manual\u00a0escrito\u00a0sobre\u00a0las\u00a0actuaciones \u00a0\ny\u00a0derivaciones \u00a0a\u00a0seguir\u00a0en\u00a0el\u00a0caso\u00a0de\u00a0exposici\u00f3n \u00a0al\u00a0VIH,\u00a0profesional \u00a0o\u00a0no,\u00a0con\u00a0dispo\u2010\nnibilidad\u00a0de\u00a0diagn\u00f3stico \u00a0serol\u00f3gico \u00a0r\u00e1pido\u00a0y\u00a0con\u00a0accesibilidad \u00a0de\u00a024\u00a0horas\u00a0a\u00a0los\u00a0\nf\u00e1rmacos \u00a0utilizados \u00a0en\u00a0la\u00a0PPE.\u00a0\u00a0\n\u2022 Se\u00a0debe\u00a0valorar\u00a0el\u00a0caso\u00a0fuente\u00a0(VIH\u00a0confirmado \u00a0o\u00a0sospechoso), \u00a0el\u00a0estado\u00a0serol\u00f3gico \u00a0\nde\u00a0la\u00a0persona\u00a0expuesta\u00a0y\u00a0las\u00a0caracter\u00edsticas \u00a0de\u00a0la\u00a0exposici\u00f3n \u00a0para\u00a0indicar\u00a0la\u00a0PPE.\u00a0\u00a0\u00a0\n\u2022 La\u00a0administraci\u00f3n \u00a0de\u00a0PPE\u00a0debe\u00a0iniciarse\u00a0lo\u00a0antes\u00a0posible,\u00a0mejor\u00a0en\u00a0las\u00a0primeras\u00a0cua\u2010\ntro\u00a0horas,\u00a0y\u00a0hasta\u00a0las\u00a072\u00a0horas.\u00a0No\u00a0est\u00e1\u00a0indicada\u00a0despu\u00e9s\u00a0de\u00a072\u00a0horas\u00a0y\u00a0su\u00a0duraci\u00f3n\u00a0\nser\u00e1\u00a0de\u00a04\u00a0semanas. \u00a0\n\u2022 Cuando\u00a0est\u00e9\u00a0indicada\u00a0la\u00a0PPE\u00a0se\u00a0recomienda \u00a0una\u00a0pauta\u00a0convencional \u00a0con\u00a0tres\u00a0FAR.\u00a0\nSe\u00a0recomiendan \u00a0combinaciones \u00a0fijas\u00a0(TDF+FTC \u00a0\u00a0\u00f3\u00a0ZDV+3TC), \u00a0asociadas \u00a0a\u00a0un\u00a0IP\u00a0po\u2010\ntenciado\u00a0(similar\u00a0a\u00a0la\u00a0terapia\u00a0de\u00a0inicio).\u00a0Si\u00a0no\u00a0se\u00a0puede\u00a0administrar \u00a0TARV\u00a0basado\u00a0en\u00a0\nIP,\u00a0podr\u00eda\u00a0sustituirse \u00a0el\u00a0IP\u00a0potenciado \u00a0por\u00a0EFV\u00a0o\u00a0bien\u00a0una\u00a0terapia\u00a0con\u00a03\u00a0AN:\u00a0\u00a0\nZDV/3TC+TDF \u00a0o\u00a0TDF/FTC+ZDV. \u00a0\u00a0\n\u2022 Si\u00a0se\u00a0sospecha \u00a0que\u00a0el\u00a0virus\u00a0del\u00a0caso\u00a0\u00edndice\u00a0puede\u00a0tener\u00a0resistencia \u00a0a\u00a0uno\u00a0o\u00a0varios\u00a0\nf\u00e1rmacos, \u00a0la\u00a0profilaxis\u00a0no\u00a0debe\u00a0retrasarse \u00a0y\u00a0debe\u00a0incluir\u00a0medicamentos \u00a0sin\u00a0resisten\u2010\ncia\u00a0cruzada.\u00a0\n\u2022 En\u00a0caso\u00a0de\u00a0duda\u00a0sobre\u00a0la\u00a0indicaci\u00f3n \u00a0de\u00a0la\u00a0PPE,\u00a0se\u00a0recomienda \u00a0administrar \u00a0la\u00a0\nprimera\u00a0dosis\u00a0de\u00a0forma\u00a0inmediata \u00a0y\u00a0valorar\u00a0su\u00a0continuidad \u00a0en\u00a0las\u00a024\u00a0h\u00a0posteriores \u00a0\npor\u00a0un\u00a0experto\u00a0en\u00a0infecci\u00f3n\u00a0VIH.\u00a0\n\u2022 El\u00a0seguimiento \u00a0debe\u00a0incluir\u00a0la\u00a0revaloraci\u00f3n \u00a0de\u00a0la\u00a0indicaci\u00f3n \u00a0a\u00a0las\u00a024\u201072\u00a0h\u00a0del\u00a0inicio\u00a0\ndel\u00a0TARV\u00a0y\u00a0control\u00a0del\u00a0cumplimiento \u00a0y\u00a0tolerabilidad \u00a0del\u00a0TARV\u00a0as\u00ed\u00a0como\u00a0serolog\u00eda\u00a0al\u00a0\nVIH,\u00a0VHB\u00a0y\u00a0VHC\u00a0(estos\u00a0en\u00a0caso\u00a0de\u00a0fuente\u00a0infectada \u00a0o\u00a0con\u00a0sospecha) \u00a0en\u00a0los\u00a0meses\u00a01,\u00a0\n3\u00a0y\u00a06\u00a0tras\u00a0la\u00a0exposici\u00f3n \u00a0\n\u00a0\n11.\u00a02.\u00a0Profilaxis \u00a0post\u2010exposici\u00f3n \u00a0no\u00a0ocupacional \u00a0\nLa\u00a0indicaci\u00f3n \u00a0de\u00a0la\u00a0PPE\u00a0no\u2010ocupacional \u00a0se\u00a0basa\u00a0en\u00a0la\u00a0patogenia \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0VIH,\u00a0en\u00a0\nestudios\u00a0observacionales \u00a0realizados \u00a0principalmente \u00a0en\u00a0mujeres\u00a0v\u00edctimas\u00a0de\u00a0violaciones \u00a0\ny\u00a0en\u00a0hombres\u00a0con\u00a0pr\u00e1cticas\u00a0sexuales\u00a0con\u00a0otros\u00a0hombres\u00a0de\u00a0alto\u00a0riesgo\u00a0y\u00a0la\u00a0informaci\u00f3n \u00a0\nprocedente \u00a0de\u00a0otras\u00a0profilaxis\u00a0frente\u00a0al\u00a0VIH\u00a0(exposici\u00f3n \u00a0ocupacional, \u00a0transmisi\u00f3n \u00a0verti\u2010\ncal)\u00a0y\u00a0de\u00a0datos\u00a0de\u00a0experimentaci\u00f3n \u00a0animal.\u00a0Todos\u00a0ellos\u00a0apoyan\u00a0en\u00a0mayor\u00a0o\u00a0menor\u00a0gra\u2010\ndo\u00a0la\u00a0PPE\u00a0no\u2010ocupacional \u00a0con\u00a0FAR.\u00a0\u00a0\nEl\u00a0mayor\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0es\u00a0la\u00a0relaci\u00f3n\u00a0anal\u00a0receptiva \u00a0no\u00a0protegida \u00a0(0,5\u20103%)\u00a0con\u00a0\nvar\u00f3n\u00a0VIH+,\u00a0seguido\u00a0del\u00a0intercambio \u00a0de\u00a0jeringuillas \u00a0(0,67%),\u00a0de\u00a0la\u00a0punci\u00f3n\u00a0percut\u00e1nea \u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 92 \n con\u00a0VIH+\u00a0(0,3%),\u00a0la\u00a0relaci\u00f3n\u00a0vaginal\u00a0receptiva \u00a0(0,05\u20100,8),\u00a0o\u00a0la\u00a0vaginal\u00a0o\u00a0anal\u00a0insertiva\u00a0\n(0,05\u20100,065).\u00a0La\u00a0relaci\u00f3n\u00a0orogenital \u00a0receptiva \u00a0e\u00a0insertiva\u00a0tiene\u00a0un\u00a0riesgo\u00a0menor\u00a0(0,005\u2010\n0,01)\u00a0815\u2010817.\u00a0\u00a0Aumentan \u00a0tambi\u00e9n\u00a0el\u00a0riesgo\u00a0la\u00a0presencia \u00a0de\u00a0ITS\u00a0y\u00a0las\u00a0relaciones \u00a0secunda\u2010\nrias\u00a0a\u00a0agresiones \u00a0sexuales.\u00a0\nInicialmente \u00a0existi\u00f3\u00a0cierta\u00a0preocupaci\u00f3n \u00a0de\u00a0que\u00a0la\u00a0extensi\u00f3n \u00a0de\u00a0la\u00a0PPE\u00a0no\u00a0ocupacional \u00a0\npudiera\u00a0reducir\u00a0las\u00a0medidas\u00a0de\u00a0prevenci\u00f3n \u00a0primaria,\u00a0al\u00a0existir\u00a0una\u00a0supuesta\u00a0\u201cprofilaxis \u00a0\npara\u00a0el\u00a0d\u00eda\u00a0despu\u00e9s\u201d, \u00a0y\u00a0\u00a0relajar\u00a0la\u00a0seguridad \u00a0en\u00a0las\u00a0pr\u00e1cticas\u00a0sexuales\u00a0o\u00a0de\u00a0las\u00a0inyecci\u00f3n \u00a0\nde\u00a0drogas.\u00a0Sin\u00a0embargo, \u00a0se\u00a0ha\u00a0demostrado \u00a0que\u00a0si\u00a0la\u00a0PPE\u00a0no\u00a0ocupacional \u00a0\u00a0se\u00a0acompa\u00f1a \u00a0\nde\u00a0la\u00a0oportuna \u00a0intervenci\u00f3n \u00a0educativa \u00a0se\u00a0pueden\u00a0reducir\u00a0las\u00a0pr\u00e1cticas\u00a0de\u00a0riesgo818.\u00a0Es\u00a0\nimportante \u00a0en\u00a0este\u00a0sentido\u00a0realizar\u00a0historia\u00a0sexual\u00a0en\u00a0la\u00a0primera\u00a0visita\u00a0y\u00a0de\u00a0forma\u00a0pe\u2010\nri\u00f3dica,\u00a0junto\u00a0con\u00a0despistaje \u00a0de\u00a0ITS\u00a0y\u00a0discutir\u00a0con\u00a0el\u00a0paciente\u00a0los\u00a0m\u00e9todos\u00a0para\u00a0la\u00a0pre\u2010\nvenci\u00f3n\u00a0de\u00a0la\u00a0transmisi\u00f3n \u00a0del\u00a0VIH\u00a0en\u00a0las\u00a0relaciones \u00a0sexuales.\u00a0Problemas \u00a0de\u00a0la\u00a0PPE\u00a0no\u2010\nocupacional \u00a0son\u00a0que\u00a0a\u00a0menudo\u00a0no\u00a0se\u00a0conoce\u00a0la\u00a0situaci\u00f3n\u00a0serol\u00f3gica \u00a0de\u00a0la\u00a0fuente,\u00a0el\u00a0\ninicio\u00a0de\u00a0la\u00a0profilaxis\u00a0suele\u00a0ser\u00a0m\u00e1s\u00a0tard\u00edo\u00a0y\u00a0el\u00a0nivel\u00a0de\u00a0abandonos \u00a0suele\u00a0ser\u00a0m\u00e1s\u00a0alto,\u00a0ya\u00a0\nsea\u00a0por\u00a0efectos\u00a0adversos\u00a0de\u00a0los\u00a0FAR,\u00a0o\u00a0por\u00a0simples\u00a0p\u00e9rdidas\u00a0del\u00a0seguimiento818..\u00a0Estu\u2010\ndios\u00a0de\u00a0coste\u2010eficacia\u00a0demuestran \u00a0que\u00a0\u00fanicamente \u00a0las\u00a0relaciones \u00a0de\u00a0alto\u00a0riesgo\u00a0con\u00a0\nfuentes\u00a0documentadas \u00a0HIV\u00a0positivas\u00a0son\u00a0coste\u2010efectivas819.\u00a0\u00a0\nEn\u00a0las\u00a0recomendaciones \u00a0de\u00a0los\u00a0CDC815\u00a0y\u00a0del\u00a0PNS/Gesida814\u00a0\u00a0se\u00a0insiste\u00a0en\u00a0dos\u00a0aspectos\u00a0\nclaves\u00a0de\u00a0la\u00a0PPE\u00a0no\u00a0ocupacional \u00a0:\u00a01)\u00a0la\u00a0actuaci\u00f3n \u00a0m\u00e9dica\u00a0no\u00a0debe\u00a0ce\u00f1irse\u00a0exclusivamen \u2010\nte\u00a0a\u00a0valorar\u00a0la\u00a0indicaci\u00f3n \u00a0de\u00a0PPE\u00a0con\u00a0FAR,\u00a0sino\u00a0que\u00a0debe\u00a0contemplar \u00a0la\u00a0oferta\u00a0de\u00a0la\u00a0\nprueba\u00a0para\u00a0el\u00a0VIH,\u00a0educaci\u00f3n \u00a0sanitaria\u00a0para\u00a0la\u00a0reducci\u00f3n \u00a0del\u00a0riesgo\u00a0de\u00a0adquisici\u00f3n \u00a0del\u00a0\nVIH,\u00a0valoraci\u00f3n \u00a0del\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0de\u00a0otras\u00a0infecciones \u00a0y\u00a0seguimiento \u00a0cl\u00ednico;\u00a0y,\u00a0\n2)\u00a0la\u00a0decisi\u00f3n\u00a0de\u00a0llevar\u00a0a\u00a0cabo\u00a0PPE\u00a0con\u00a0FAR\u00a0ha\u00a0de\u00a0ser\u00a0tomada\u00a0por\u00a0el\u00a0m\u00e9dico\u00a0y\u00a0el\u00a0pacien\u2010\nte\u00a0de\u00a0forma\u00a0individualizada, \u00a0valorando \u00a0sus\u00a0beneficios \u00a0y\u00a0riesgos\u00a0y\u00a0desaconsej\u00e1ndola \u00a0en\u00a0\npersonas\u00a0con\u00a0exposiciones \u00a0repetidas. \u00a0La\u00a0PPE\u00a0debe\u00a0considerase \u00a0teniendo\u00a0en\u00a0cuenta\u00a0el\u00a0\nnivel\u00a0de\u00a0riesgo,\u00a0la\u00a0v\u00eda\u00a0de\u00a0exposici\u00f3n, \u00a0el\u00a0estado\u00a0serol\u00f3gico \u00a0y/o\u00a0pr\u00e1cticas\u00a0de\u00a0riesgo\u00a0de\u00a0la\u00a0\npersona\u00a0fuente,\u00a0as\u00ed\u00a0como\u00a0el\u00a0TARV\u00a0recibido\u00a0por\u00a0el\u00a0paciente\u00a0fuente\u00a0caso\u00a0de\u00a0estar\u00a0infec\u2010\ntado\u00a0por\u00a0el\u00a0VIH\u00a0y\u00a0la\u00a0existencia \u00a0de\u00a0factores\u00a0de\u00a0riesgo\u00a0a\u00f1adidos820\u2010823\u00a0(Tabla\u00a019).\u00a0\u00a0\nLa\u00a0elecci\u00f3n\u00a0de\u00a0los\u00a0FAR\u00a0,\u00a0inicio\u00a0y\u00a0duraci\u00f3n\u00a0es\u00a0similar\u00a0a\u00a0la\u00a0PPE\u00a0ocupacional, \u00a0con\u00a0la\u00a0salve\u2010\ndad\u00a0de\u00a0que\u00a0EFV\u00a0no\u00a0es\u00a0aconsejable \u00a0por\u00a0su\u00a0baja\u00a0concentraci\u00f3n \u00a0en\u00a0las\u00a0secreciones \u00a0genita\u2010\nles\u00a0(inferior\u00a0al\u00a010%\u00a0de\u00a0las\u00a0plasm\u00e1ticas) \u00a0y\u00a0su\u00a0posible\u00a0efecto\u00a0terat\u00f3geno812.\u00a0\u00a0\n\u00a0\nPPE\u00a0no\u00a0ocupacional. \u00a0Recomendaciones \u00a0(nivel\u00a0C)\u00a0\n\u0083 La\u00a0PPE\u00a0no\u00a0ocupacional \u00a0debe\u00a0individualizarse \u00a0y\u00a0llevarse\u00a0a\u00a0cabo\u00a0en\u00a0el\u00a0marco\u00a0de\u00a0una\u00a0\nintervenci\u00f3n \u00a0m\u00e9dica\u00a0integral.\u00a0\n\u0083 La\u00a0PPE\u00a0no\u00a0ocupacional \u00a0debe\u00a0recomendarse \u00a0en\u00a0las\u00a0situaciones \u00a0denominadas \u00a0de\u00a0\n\u201criesgo\u00a0apreciable\u201d \u00a0si\u00a0se\u00a0dan\u00a0las\u00a0siguientes \u00a0condiciones: \u00a0a)\u00a0instauraci\u00f3n \u00a0precoz\u00a0(si\u2010\nmilar\u00a0a\u00a0la\u00a0PPE\u00a0ocupacional), \u00a0b)\u00a0ausencia\u00a0de\u00a0contraindicaciones \u00a0para\u00a0tomar\u00a0FAR,\u00a0c)\u00a0\nexposici\u00f3n \u00a0excepcional \u00a0y\u00a0d)\u00a0garant\u00eda\u00a0de\u00a0seguimiento \u00a0cl\u00ednico\u00a0y\u00a0anal\u00edtico\u00a0del\u00a0paciente. \u00a0\n\u0083 Los\u00a0f\u00e1rmacos \u00a0a\u00a0emplear,\u00a0su\u00a0duraci\u00f3n\u00a0y\u00a0el\u00a0seguimiento \u00a0de\u00a0los\u00a0pacientes \u00a0ser\u00e1\u00a0igual\u00a0\nque\u00a0\u00a0en\u00a0la\u00a0PPE\u00a0ocupacional. \u00a0\n\u0083 En\u00a0caso\u00a0de\u00a0exposici\u00f3n \u00a0sexual\u00a0debe\u00a0valorarse\u00a0el\u00a0riesgo\u00a0de\u00a0ITS\u00a0y\u00a0embarazo. \u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 93 \n \u00a0\n\u00a0\n12.\u00a0NUEVAS\u00a0ESTRATEGIAS \u00a0\nInterrupciones \u00a0supervisadas \u00a0del\u00a0tratamiento \u00a0\nLas\u00a0interrupciones \u00a0supervisadas \u00a0del\u00a0TARV\u00a0(IST)\u00a0se\u00a0plantearon \u00a0inicialmente \u00a0con\u00a0algunos\u00a0\nde\u00a0los\u00a0siguientes \u00a0objetivos: \u00a01)\u00a0estimulaci\u00f3n \u00a0de\u00a0la\u00a0respuesta \u00a0inmune\u00a0celular\u00a0en\u00a0pacien\u2010\ntes\u00a0con\u00a0CVP\u00a0indetectable \u00a0(auto\u2010inmunizaci\u00f3n); \u00a02)\u00a0reversi\u00f3n \u00a0de\u00a0mutaciones \u00a0del\u00a0VIH,\u00a0en\u00a0\npacientes \u00a0en\u00a0multifracaso \u00a0antes\u00a0del\u00a0TARV\u00a0de\u00a0rescate;\u00a0y,\u00a03)\u00a0reducci\u00f3n \u00a0de\u00a0la\u00a0exposici\u00f3n \u00a0al\u00a0\nTARV,\u00a0principalmente \u00a0en\u00a0pacientes \u00a0con\u00a0CVP\u00a0indetectable, \u00a0para\u00a0prevenir\u00a0o\u00a0revertir\u00a0efec\u2010\ntos\u00a0adversos, \u00a0mejorar\u00a0la\u00a0calidad\u00a0de\u00a0vida\u00a0y\u00a0en\u00a0menor\u00a0grado,\u00a0disminuir \u00a0el\u00a0gasto\u00a0sanitario\u00a0\n(vacaciones \u00a0terap\u00e9uticas). \u00a0\nPr\u00e1cticamente \u00a0se\u00a0han\u00a0abandonado \u00a0los\u00a0dos\u00a0primeros\u00a0planteamientos \u00a0al\u00a0no\u00a0obtener\u00a0re\u2010\nsultados\u00a0positivos820\u2010823.\u00a0El\u00a0planteamiento \u00a0te\u00f3rico\u00a0de\u00a0la\u00a0IST\u00a0para\u00a0la\u00a0auto\u2010inmunizaci\u00f3n \u00a0\nera\u00a0conseguir \u00a0mediante \u00a0brotes\u00a0de\u00a0replicaci\u00f3n \u00a0viral\u00a0intermitente, \u00a0la\u00a0estimulaci\u00f3n \u00a0de\u00a0la\u00a0\nrespuesta \u00a0inmune\u00a0espec\u00edfica \u00a0frente\u00a0al\u00a0VIH\u00a0con\u00a0el\u00a0fin\u00a0de\u00a0conseguir \u00a0una\u00a0baja\u00a0replicaci\u00f3n \u00a0\nviral\u00a0que\u00a0permitiera \u00a0mantener \u00a0a\u00a0los\u00a0pacientes \u00a0libres\u00a0de\u00a0TARV\u00a0durante\u00a0per\u00edodos\u00a0prolon\u2010\ngados.\u00a0Algunos\u00a0estudios\u00a0demostraron \u00a0que\u00a0aunque\u00a0era\u00a0posible\u00a0inducir\u00a0una\u00a0respuesta \u00a0\ninmunoespec\u00edfica \u00a0frente\u00a0al\u00a0VIH,\u00a0el\u00a0porcentaje \u00a0de\u00a0pacientes \u00a0que\u00a0controlaron \u00a0la\u00a0replica\u2010\nci\u00f3n\u00a0viral\u00a0en\u00a0ausencia\u00a0de\u00a0TARV\u00a0fue\u00a0muy\u00a0bajo821\u2010823.\u00a0\u00a0\nLas\u00a0IST\u00a0previas\u00a0a\u00a0un\u00a0TARV\u00a0de\u00a0rescate\u00a0con\u00a0el\u00a0objetivo\u00a0de\u00a0revertir\u00a0las\u00a0resistencias \u00a0a\u00a0los\u00a0\nFAR824,\u00a0825\u00a0y\u00a0mejorar\u00a0la\u00a0respuesta \u00a0al\u00a0mismo\u00a0no\u00a0han\u00a0demostrado \u00a0beneficio \u00a0virol\u00f3gico \u00a0o\u00a0\ninmunol\u00f3gico377,\u00a0378,\u00a0826,\u00a0827\u00a0\u00a0y\u00a0durante\u00a0la\u00a0IST\u00a0existe\u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0progresi\u00f3n \u00a0cl\u00edni\u2010\nca.\u00a0\u00a0\nEn\u00a0un\u00a0contexto\u00a0similar,\u00a0en\u00a0pacientes \u00a0con\u00a0CVP\u00a0detectable \u00a0y\u00a0en\u00a0multifracaso, \u00a0se\u00a0han\u00a0ex\u2010\nperimentado \u00a0las\u00a0llamadas\u00a0interrupciones \u00a0parciales\u00a0de\u00a0tratamiento \u00a0(IPT).\u00a0Estas\u00a0consis\u2010\nten\u00a0en\u00a0interrumpir \u00a0los\u00a0IP\u00a0manteniendo \u00a0los\u00a0AN\u00a0a\u00a0los\u00a0que\u00a0el\u00a0virus\u00a0es\u00a0resistente. \u00a0Con\u00a0esta\u00a0\nestrategia \u00a0se\u00a0perpetu\u00e1n \u00a0las\u00a0mutaciones \u00a0virales\u00a0que\u00a0condicionan \u00a0baja\u00a0capacidad \u00a0replica\u2010\ntiva\u00a0conteniendo \u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0y\u00a0preservando \u00a0los\u00a0CD4192,\u00a0827.\u00a0Por\u00a0lo\u00a0tanto,\u00a0esta\u00a0\nestrategia \u00a0de\u00a0IPT\u00a0podr\u00eda\u00a0plantearse \u00a0en\u00a0pacientes \u00a0seleccionados \u00a0hasta\u00a0disponer\u00a0de\u00a0nue\u2010\nvos\u00a0f\u00e1rmacos \u00a0de\u00a0rescate.\u00a0\nLas\u00a0IST\u00a0para\u00a0reducir\u00a0la\u00a0exposici\u00f3n \u00a0al\u00a0TARV\u00a0(vacaciones \u00a0terap\u00e9uticas) \u00a0tienen\u00a0como\u00a0obje\u2010\ntivo\u00a0evitar\u00a0o\u00a0revertir\u00a0toxicidades, \u00a0mejorar\u00a0la\u00a0calidad\u00a0de\u00a0vida\u00a0y\u00a0reducir\u00a0costes\u00a0mante\u2010\nniendo\u00a0la\u00a0eficacia\u00a0cl\u00ednica\u00a0e\u00a0inmunol\u00f3gica828\u2010838.\u00a0Los\u00a0riesgos\u00a0ser\u00edan\u00a0la\u00a0presentaci\u00f3n \u00a0de\u00a0un\u00a0\ns\u00edndrome \u00a0retroviral \u00a0agudo\u00a0con\u00a0rebrote\u00a0viral,\u00a0el\u00a0deterioro \u00a0inmunol\u00f3gico \u00a0y\u00a0progresi\u00f3n \u00a0\ncl\u00ednica,\u00a0aparici\u00f3n \u00a0de\u00a0nuevas\u00a0mutaciones \u00a0(resistencia), \u00a0m\u00e1s\u00a0posibilidades \u00a0de\u00a0transmisi\u00f3n \u00a0\ndel\u00a0VIH\u00a0y\u00a0aumento\u00a0de\u00a0enfermedades \u00a0cardiovasculares \u00a0y\u00a0hep\u00e1ticas, \u00a0no\u00a0diagn\u00f3sticas \u00a0de\u00a0\nsida830,\u00a0833.\u00a0\u00a0\u00a0\nNo\u00a0es\u00a0f\u00e1cil\u00a0comparar \u00a0los\u00a0resultados \u00a0de\u00a0los\u00a0estudios\u00a0publicados \u00a0o\u00a0comunicados \u00a0por\u00a0dife\u2010\nrencias\u00a0en\u00a0el\u00a0dise\u00f1o,\u00a0tipo\u00a0de\u00a0pacientes \u00a0incluidos, \u00a0criterios\u00a0para\u00a0suspender \u00a0o\u00a0reiniciar\u00a0el\u00a0\ntratamiento, \u00a0etc.\u00a0Algunos\u00a0estudios\u00a0han\u00a0mantenido \u00a0interrupciones \u00a0fijas830,\u00a0833,\u00a0839\u00a0\u00a0mien\u2010\ntras\u00a0que\u00a0en\u00a0otros\u00a0las\u00a0IST\u00a0se\u00a0han\u00a0basado\u00a0en\u00a0las\u00a0cifras\u00a0de\u00a0CD4831,\u00a0834,\u00a0839,\u00a0e\u00a0incluso\u00a0de\u00a0la\u00a0\nCVP192.\u00a0En\u00a0el\u00a0mayor\u00a0estudio\u00a0aleatorizado \u00a0realizado\u00a0hasta\u00a0la\u00a0fecha,\u00a0el\u00a0SMART,\u00a0los\u00a0pacien\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 94 \n tes\u00a0con\u00a0IST\u00a0progresaron \u00a0m\u00e1s\u00a0a\u00a0sida\u00a0o\u00a0muerte,\u00a0y\u00a0adem\u00e1s\u00a0presentaron \u00a0en\u00a0mayor\u00a0propor\u2010\nci\u00f3n\u00a0eventos\u00a0cardiol\u00f3gicos \u00a0o\u00a0hep\u00e1ticos192.\u00a0Es\u00a0probable\u00a0que\u00a0la\u00a0cifra\u00a0de\u00a0250\u00a0CD4\u00a0como\u00a0\ncriterio\u00a0de\u00a0reinicio\u00a0fuera\u00a0demasiado \u00a0baja\u00a0y\u00a0favoreciera \u00a0un\u00a0curso\u00a0desfavorable. \u00a0As\u00ed\u00a0en\u00a0\notros\u00a0estudios\u00a0en\u00a0los\u00a0que\u00a0el\u00a0TARV\u00a0se\u00a0reiniciaba \u00a0a\u00a0las\u00a0350\u00a0CD4/\u00b5L834,\u00a0836\u2010839,\u00a0la\u00a0evoluci\u00f3n \u00a0\nfue\u00a0favorable, \u00a0especialmente \u00a0en\u00a0pacientes \u00a0cuyo\u00a0nadir\u00a0de\u00a0CD4\u00a0era\u00a0>200\u00a0c\u00e9lulas/\u00b5L836,\u00a0\n838.\u00a0Esta\u00a0estrategia \u00a0podr\u00eda\u00a0ser\u00a0de\u00a0utilidad\u00a0en\u00a0los\u00a0que\u00a0iniciaron\u00a0TARV\u00a0con\u00a0cifras\u00a0de\u00a0CD4\u00a0\n>350\u2010500\u00a0c\u00e9lulas/\u00b5L, \u00a0y\u00a0que\u00a0permanecen \u00a0con\u00a0CVP\u00a0indetectable, \u00a0si\u00a0no\u00a0han\u00a0presentado \u00a0\ntrombocitopenia. \u00a0\u00a0\nEl\u00a0riesgo\u00a0de\u00a0desarrollo \u00a0de\u00a0resistencias \u00a0en\u00a0las\u00a0pautas\u00a0que\u00a0incluyen\u00a0un\u00a0NN829,\u00a0se\u00a0puede\u00a0\nreducir\u00a0interrumpiendo \u00a0la\u00a0NVP\u00a0o\u00a0EFV\u00a0una\u00a0semana\u00a0antes,\u00a0evitando\u00a0as\u00ed\u00a0la\u00a0\u201cmonoterapia\u201d \u00a0\ncon\u00a0f\u00e1rmacos\u00a0de\u00a0vida\u00a0media\u00a0prolongada834.\u00a0\nEn\u00a0cualquier \u00a0caso,\u00a0la\u00a0principal\u00a0raz\u00f3n\u00a0para\u00a0no\u00a0recomendar \u00a0en\u00a0la\u00a0actualidad \u00a0las\u00a0estrate\u2010\ngias\u00a0de\u00a0\u201cvacaciones \u00a0terap\u00e9uticas\u201d, \u00a0es\u00a0el\u00a0hallazgo\u00a0en\u00a0el\u00a0estudio\u00a0SMART\u00a0de\u00a0un\u00a0aumento\u00a0\nen\u00a0la\u00a0incidencia \u00a0de\u00a0enfermedades \u00a0cardiovasculares \u00a0y\u00a0hep\u00e1ticos192,\u00a0840.\u00a0En\u00a0subestudios \u00a0\ndel\u00a0SMART840\u00a0y\u00a0otros\u00a0estudios\u00a0como\u00a0el\u00a0STACCATO841\u00a0y\u00a0el\u00a0estudio\u00a0espa\u00f1ol\u00a0STOPPAR842\u00a0\nse\u00a0ha\u00a0demostrado \u00a0que\u00a0la\u00a0p\u00e9rdida\u00a0de\u00a0control\u00a0de\u00a0la\u00a0replicaci\u00f3n \u00a0viral\u00a0dar\u00eda\u00a0lugar\u00a0al\u00a0au\u2010\nmento\u00a0de\u00a0citoquinas \u00a0pro\u00a0inflamatorias \u00a0como\u00a0MCP\u20101,\u00a0sVCAM\u20101,\u00a0o\u00a0IL\u20106,\u00a0entre\u00a0otras,\u00a0lo\u00a0\nque\u00a0contribuir\u00eda \u00a0al\u00a0aumento\u00a0del\u00a0riesgo\u00a0cardiovascular \u00a0tras\u00a0la\u00a0interrupci\u00f3n \u00a0del\u00a0TARV.\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\nInterrupciones \u00a0del\u00a0TARV.\u00a0Recomendaciones \u00a0\n\u0083 No\u00a0se\u00a0recomienda \u00a0la\u00a0IST\u00a0como\u00a0forma\u00a0de\u00a0autoinmunizaci\u00f3n \u00a0(nivel\u00a0B),\u00a0ni\u00a0como\u00a0parte\u00a0\nde\u00a0una\u00a0estrategia \u00a0de\u00a0rescate\u00a0(nivel\u00a0A)\u00a0821\u2010823,\u00a0825,\u00a0825,\u00a0826\u00a0\n\u0083 Se\u00a0desaconseja \u00a0la\u00a0IST\u00a0guiada\u00a0por\u00a0CD4.\u00a0Si\u00a0se\u00a0plantea\u00a0en\u00a0una\u00a0situaci\u00f3n\u00a0muy\u00a0seleccio\u2010\nnada,\u00a0se\u00a0deber\u00edan\u00a0cumplir\u00a0las\u00a0siguientes \u00a0condiciones: \u00a01)\u00a0el\u00a0paciente\u00a0no\u00a0est\u00e1\u00a0dis\u2010\npuesto\u00a0a\u00a0continuar \u00a0el\u00a0TARV\u00a0de\u00a0forma\u00a0indefinida; \u00a02)\u00a0tiene\u00a0CD4\u00a0>500\u00a0c\u00e9lulas/\u00b5L, \u00a0\u00a03)\u00a0\nnadir\u00a0de\u00a0CD4\u00a0>200\u00a0c\u00e9lulas/\u00b5L; \u00a04)\u00a0se\u00a0reiniciar\u00e1 \u00a0el\u00a0TARV\u00a0si\u00a0CD4\u00a0<350\u00a0c\u00e9lulas/\u00b5L; \u00a05)\u00a0el\u00a0\npaciente\u00a0debe\u00a0conocer\u00a0que\u00a0existe\u00a0un\u00a0incremento \u00a0del\u00a0riesgo\u00a0de\u00a0enfermedades \u00a0car\u2010\ndiovasculares \u00a0y\u00a0hep\u00e1ticas \u00a0si\u00a0se\u00a0interrumpe \u00a0el\u00a0TARV\u00a0y\u00a0se\u00a0reinicia\u00a0cuando\u00a0los\u00a0CD4\u00a0\ndescienden \u00a0a\u00a0<250\u00a0c\u00e9lulas/\u00b5L; \u00a06)\u00a0el\u00a0paciente\u00a0es\u00a0consciente \u00a0de\u00a0que\u00a0la\u00a0replicaci\u00f3n \u00a0vi\u2010\nral\u00a0y\u00a0el\u00a0aumento\u00a0de\u00a0la\u00a0CVP\u00a0suponen\u00a0m\u00e1s\u00a0posibilidades \u00a0de\u00a0transmitir \u00a0el\u00a0VIH\u00a0y\u00a0tomar\u00e1\u00a0\nlas\u00a0medidas\u00a0adecuadas \u00a0(nivel\u00a0C)192,\u00a0828\u00a0\n\u00a0Tratamientos \u00a0inmunomediados \u00a0\nEl\u00a0TARV\u00a0suprime\u00a0de\u00a0forma\u00a0eficaz\u00a0la\u00a0replicaci\u00f3n \u00a0viral,\u00a0lo\u00a0que\u00a0se\u00a0sigue\u00a0de\u00a0una\u00a0reconstitu \u2010\nci\u00f3n\u00a0importante \u00a0del\u00a0sistema\u00a0inmune.\u00a0Sin\u00a0embargo, \u00a0la\u00a0respuesta \u00a0inmunoespec\u00edfica \u00a0fren\u2010\nte\u00a0al\u00a0VIH\u00a0no\u00a0suele\u00a0recuperarse \u00a0y\u00a0adem\u00e1s\u00a0en\u00a0algunos\u00a0casos\u00a0la\u00a0reconstituci\u00f3n \u00a0inmunol\u00f3 \u2010\ngica\u00a0es\u00a0parcial.\u00a0Para\u00a0el\u00a0primer\u00a0caso\u00a0\nse\u00a0han\u00a0ensayado \u00a0las\u00a0vacunas\u00a0terap\u00e9uticas \u00a0y\u00a0en\u00a0el\u00a0\nsegundo\u00a0caso\u00a0el\u00a0tratamiento \u00a0con\u00a0inmunomoduladores \u00a0como\u00a0la\u00a0interleuquina \u20102\u00a0(IL\u20102).\u00a0\u00a0\n\u00a0Citoquinas: \u00a0IL\u20102.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 95 \n En\u00a0alg\u00fan\u00a0ensayo\u00a0cl\u00ednico\u00a0y\u00a0series\u00a0prospectivas \u00a0843\u2010845\u00a0se\u00a0ha\u00a0demostrado \u00a0que\u00a0la\u00a0IL\u20102,\u00a0admi\u2010\nnistrada\u00a0de\u00a0forma\u00a0intermitente \u00a0por\u00a0v\u00eda\u00a0subcut\u00e1nea \u00a0(4,5\u00a0a\u00a07,5\u00a0MU\u00a0cada\u00a012\u00a0horas\u00a0duran\u2010\nte\u00a05\u00a0d\u00edas\u00a0cada\u00a08\u00a0semanas) \u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0TARV\u00a0aumentaba \u00a0de\u00a0forma\u00a0importante \u00a0\nel\u00a0n\u00famero\u00a0de\u00a0linfocitos\u00a0CD4\u00a0y\u00a0se\u00a0asociaba\u00a0con\u00a0una\u00a0mejor\u00a0respuesta \u00a0virol\u00f3gica \u00a0en\u00a0com\u2010\nparaci\u00f3n\u00a0con\u00a0el\u00a0TARV.\u00a0Para\u00a0saber\u00a0si\u00a0estos\u00a0cambios\u00a0inmunol\u00f3gicos \u00a0se\u00a0traduc\u00edan \u00a0en\u00a0me\u2010\njor\u00edas\u00a0cl\u00ednicas\u00a0se\u00a0llevaron\u00a0a\u00a0cabo\u00a0dos\u00a0grandes\u00a0ensayos\u00a0cl\u00ednicos\u00a0\u00a0denominados \u00a0SILCAAT\u00a0\n(1695\u00a0sujetos\u00a0con\u00a0cifra\u00a0de\u00a0linfocitos\u00a0CD4\u00a0entre\u00a050\u00a0y\u00a0299\u00a0c\u00e9lulas/\u00b5L \u00a0y\u00a0ESPRIT\u00a0(4111\u00a0pa\u2010\ncientes\u00a0con\u00a0cifra\u00a0de\u00a0linfocitos\u00a0CD4\u00a0superiores \u00a0a\u00a0300\u00a0c\u00e9lulas/\u00b5L) \u00a0cuyos\u00a0resultados \u00a0se\u00a0han\u00a0\npublicado846.\u00a0El\u00a0punto\u00a0final\u00a0de\u00a0evaluaci\u00f3n \u00a0era\u00a0el\u00a0mismo\u00a0en\u00a0ambos\u00a0estudios:\u00a0presencia \u00a0\nde\u00a0eventos\u00a0oportunistas \u00a0o\u00a0muerte.\u00a0A\u00a0pesar\u00a0de\u00a0que\u00a0en\u00a0ambos\u00a0se\u00a0evidenci\u00f3 \u00a0un\u00a0aumento\u00a0\nsignificativo \u00a0de\u00a0CD4\u00a0(una\u00a0diferencia \u00a0de\u00a059\u00a0c\u00e9lulas\u00a0a\u00a0favor\u00a0del\u00a0grupo\u00a0de\u00a0IL\u20102\u00a0en\u00a0el\u00a0SILCA\u2010\nAT\u00a0y\u00a0de\u00a0160\u00a0en\u00a0el\u00a0ESPRIT),\u00a0lamentablemente \u00a0ambos\u00a0estudios\u00a0demostraron \u00a0que\u00a0el\u00a0au\u2010\nmento\u00a0de\u00a0CD4\u00a0como\u00a0consecuencia \u00a0del\u00a0uso\u00a0de\u00a0IL\u20102\u00a0no\u00a0se\u00a0asociaba\u00a0a\u00a0una\u00a0reducci\u00f3n \u00a0de\u00a0\neventos\u00a0oportunistas \u00a0o\u00a0un\u00a0aumento\u00a0en\u00a0la\u00a0supervivencia \u00a0de\u00a0estos\u00a0pacientes. \u00a0El\u00a0riesgo\u00a0\nrelativo\u00a0de\u00a0EO/muerte \u00a0fue\u00a0de\u00a00,91\u00a0(0,70\u20101,18)\u00a0p=0,47\u00a0y\u00a00,93\u00a0(0,75\u20101,16),\u00a0p=0,52,\u00a0res\u2010\npectivamente. \u00a0En\u00a0cambio,\u00a0los\u00a0pacientes \u00a0de\u00a0las\u00a0ramas\u00a0de\u00a0IL\u20102\u00a0presentaron \u00a0mayor\u00a0toxici\u2010\ndad,\u00a0sobre\u00a0todo\u00a0grado\u00a04,\u00a0gastrointestinal \u00a0y\u00a0psiqui\u00e1trica. \u00a0Los\u00a0autores\u00a0concluyeron \u00a0que\u00a0\nlos\u00a0linfocitos\u00a0CD4\u00a0aumentados \u00a0tras\u00a0el\u00a0uso\u00a0de\u00a0IL\u20102\u00a0no\u00a0ser\u00edan\u00a0funcionalmente \u00a0equivalen \u2010\ntes\u00a0a\u00a0los\u00a0CD4\u00a0resultantes \u00a0de\u00a0la\u00a0supresi\u00f3n \u00a0virol\u00f3gica \u00a0tras\u00a0el\u00a0uso\u00a0de\u00a0TARV.\u00a0\u00a0\u00a0\n\u00a0\nTratamientos \u00a0inmunomediados. \u00a0Recomendaci\u00f3n \u00a0\n\u0083 Los\u00a0resultados \u00a0de\u00a0dos\u00a0grandes\u00a0ensayos\u00a0cl\u00ednicos\u00a0desaconsejan \u00a0el\u00a0uso\u00a0de\u00a0IL\u20102\u00a0en\u00a0pa\u2010\ncientes\u00a0infectados \u00a0por\u00a0el\u00a0VIH\u00a0con\u00a0el\u00a0objetivo\u00a0de\u00a0aumentar \u00a0su\u00a0inmunidad, \u00a0porque\u00a0no\u00a0\nse\u00a0asocia\u00a0a\u00a0una\u00a0reducci\u00f3n \u00a0de\u00a0eventos\u00a0oportunistas \u00a0ni\u00a0de\u00a0mortalidad \u00a0y\u00a0s\u00ed\u00a0a\u00a0un\u00a0au\u2010\nmento\u00a0de\u00a0toxicidad\u00a0(nivel\u00a0A)846\u00a0\n\u00a0\nInmunizaciones \u00a0terap\u00e9uticas. \u00a0\nEl\u00a0objetivo\u00a0de\u00a0las\u00a0inmunizaciones \u00a0terap\u00e9uticas \u00a0es\u00a0potenciar \u00a0la\u00a0respuesta \u00a0inmunoespec\u00ed \u2010\nfica\u00a0frente\u00a0al\u00a0VIH.\u00a0Se\u00a0han\u00a0realizado\u00a0varios\u00a0estudios\u00a0con\u00a0diferentes \u00a0vacunas\u00a0terap\u00e9uticas \u00a0\nen\u00a0los\u00a0que\u00a0se\u00a0ha\u00a0observado \u00a0una\u00a0respuesta \u00a0inmunoespec\u00edfica \u00a0variable\u00a0frente\u00a0al\u00a0VIH,\u00a0pe\u2010\nro\u00a0no\u00a0se\u00a0ha\u00a0observado \u00a0un\u00a0claro\u00a0beneficio \u00a0inmunol\u00f3gico, \u00a0virol\u00f3gico \u00a0o\u00a0cl\u00ednico847.\u00a0\u00a0En\u00a0la\u00a0\nactualidad \u00a0las\u00a0vacunaciones \u00a0terap\u00e9uticas \u00a0est\u00e1n\u00a0en\u00a0el\u00a0\u00e1mbito\u00a0exclusivamente \u00a0experi\u2010\nmental848,\u00a0849.\u00a0\n\u00a0\nNuevos\u00a0antirretrovirales \u00a0\nA\u00a0pesar\u00a0de\u00a0la\u00a0larga\u00a0lista\u00a0de\u00a0FAR\u00a0disponibles \u00a0la\u00a0imposibilidad \u00a0de\u00a0erradicar\u00a0el\u00a0VIH,\u00a0los\u00a0re\u2010\nquerimientos \u00a0de\u00a0adherencia, \u00a0las\u00a0toxicidades \u00a0a\u00a0largo\u00a0plazo\u00a0y\u00a0el\u00a0desarrollo \u00a0de\u00a0resistencias \u00a0\ncruzadas\u00a0entre\u00a0clases\u00a0o\u00a0familias\u00a0de\u00a0FAR\u00a0obligan\u00a0a\u00a0buscar\u00a0nuevos\u00a0f\u00e1rmacos \u00a0para\u00a0el\u00a0con\u2010\ntrol\u00a0duradero \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH.\u00a0\u00a0\nExisten\u00a0f\u00e1rmacos\u00a0no\u00a0comercializados \u00a0pero\u00a0en\u00a0fases\u00a0avanzadas \u00a0de\u00a0investigaci\u00f3n \u00a0y\u00a0acce\u2010\nsibles\u00a0dentro\u00a0de\u00a0programas \u00a0de\u00a0acceso\u00a0expandido \u00a0o\u00a0en\u00a0Fase\u00a0III\u00a0de\u00a0investigaci\u00f3n: \u00a0el\u00a0NN\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 96 \n rilpivirina \u00a0(TMC278), \u00a0el\u00a0inhibidor\u00a0de\u00a0la\u00a0integrasa \u00a0elvitegravir \u00a0y\u00a0el\u00a0antagonista \u00a0CCR5\u00a0vi\u2010\ncriviroc.\u00a0\u00a0\nRilpivirina \u00a0(TMC278) \u00a0es\u00a0otro\u00a0NN\u00a0en\u00a0fase\u00a0III,\u00a0con\u00a0buenos\u00a0datos\u00a0preliminares \u00a0que\u00a0muestra\u00a0\nuna\u00a0eficacia\u00a0similar\u00a0a\u00a0EFV\u00a0en\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0y\u00a0con\u00a0menor\u00a0toxicidad\u00a0\nsobre\u00a0sistema\u00a0nervioso\u00a0central850.\u00a0Tiene\u00a0una\u00a0vida\u00a0media\u00a0larga\u00a0y\u00a0se\u00a0puede\u00a0dar\u00a0una\u00a0vez\u00a0al\u00a0\nd\u00eda\u00a0\nElvitegravir \u00a0(EVG)\u00a0es\u00a0un\u00a0nuevo\u00a0\u00a0inhibidor\u00a0de\u00a0la\u00a0integrasa \u00a0que\u00a0se\u00a0administra \u00a0en\u00a0dosis\u00a0de\u00a0\n125\u00a0mg/d\u00eda\u00a0potenciado \u00a0con\u00a0100\u00a0mg\u00a0de\u00a0RTV851.\u00a0Tiene\u00a0el\u00a0inconveniente \u00a0de\u00a0presentar \u00a0\nresistencia \u00a0cruzada\u00a0con\u00a0RAL.\u00a0En\u00a0un\u00a0estudio\u00a0de\u00a0b\u00fasqueda \u00a0de\u00a0dosis,\u00a0parcialmente \u00a0ciego\u00a0y\u00a0\ncon\u00a0resultados \u00a0a\u00a048\u00a0semanas\u00a0se\u00a0est\u00e1\u00a0evaluando \u00a0la\u00a0no\u00a0inferioridad \u00a0de\u00a0EVG\u00a0frente\u00a0a\u00a0un\u00a0\nIP/r\u00a0en\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0VIH\u00a0con\u00a0experiencia \u00a0previa\u00a0a\u00a0otros\u00a0FAR852.\u00a0A\u00a0las\u00a024\u00a0\nsemanas\u00a0el\u00a0descenso \u00a0de\u00a0la\u00a0CVP\u00a0fue\u00a0de\u00a0\u20101,4,\u00a0\u20101,7,\u00a0\u20101,2\u00a0log 10\u00a0copias/mL \u00a0en\u00a0las\u00a0ramas\u00a0de\u00a0\u00a0\nEVG\u00a050\u00a0mg,\u00a0EVG\u00a0125mg\u00a0y\u00a0el\u00a0IP/r\u00a0comparador \u00a0respectivamente \u00a0(valor\u00a0de\u00a0p\u00a0significativa \u00a0\n0,02\u00a0dosis\u00a0de\u00a0125\u00a0mg\u00a0frente\u00a0al\u00a0IP/r\u00a0comparador). \u00a0EVG/r\u00a0fue\u00a0bien\u00a0tolerado\u00a0y\u00a0no\u00a0se\u00a0iden\u2010\ntificaron\u00a0toxicidades \u00a0relacionadas \u00a0con\u00a0la\u00a0dosis\u00a0del\u00a0f\u00e1rmaco.\u00a0\nEl\u00a0S/GSK\u00a01349572\u00a0es\u00a0un\u00a0inhibidor\u00a0de\u00a0la\u00a0integrasa \u00a0de\u00a0nueva\u00a0generaci\u00f3n \u00a0con\u00a0un\u00a0perfil\u00a0de\u00a0\nresistencias \u00a0diferente \u00a0a\u00a0RAL\u00a0y\u00a0que\u00a0presenta\u00a0actividad\u00a0in\u00a0vitro\u00a0\u00a0frente\u00a0a\u00a0cepas\u00a0de\u00a0VIH\u00a0\nresistentes \u00a0a\u00a0RAL.\u00a0En\u00a0la\u00a0actualidad \u00a0su\u00a0desarrollo \u00a0cl\u00ednico\u00a0est\u00e1\u00a0inici\u00e1ndose853.\u00a0\u00a0\nVicriviroc \u00a0(VCV)\u00a0es\u00a0nuevo\u00a0antagonista \u00a0de\u00a0los\u00a0correceptores \u00a0CCR5\u00a0que\u00a0se\u00a0administra \u00a0una\u00a0\nvez\u00a0al\u00a0d\u00eda\u00a0potenciado \u00a0con\u00a0RTV\u00a0y\u00a0cuya\u00a0eficacia\u00a0y\u00a0tolerancia \u00a0se\u00a0est\u00e1\u00a0estudiando \u00a0en\u00a0pa\u2010\ncientes\u00a0que\u00a0reciben\u00a0el\u00a0primer\u00a0tratamiento \u00a0y\u00a0en\u00a0pretratados854\u2010856.\u00a0Un\u00a0ensayo\u00a0cl\u00ednico\u00a0en\u00a0\npacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0comparando \u00a0VCV\u00a0con\u00a0EFV\u00a0se\u00a0suspendi\u00f3 \u00a0por\u00a0menor\u00a0\neficacia\u00a0virol\u00f3gica \u00a0de\u00a0VCV855.\u00a0En\u00a0pretratados, \u00a0VICTOR\u00a0E\u20101856\u00a0es\u00a0un\u00a0ensayo\u00a0cl\u00ednico\u00a0doble\u00a0\nciego\u00a0que\u00a0compara\u00a0VCV\u00a030\u00a0y\u00a020\u00a0mg\u00a0QD\u00a0frente\u00a0a\u00a0placebo,\u00a0ambos\u00a0combinados \u00a0con\u00a0un\u00a0\nnuevo\u00a0IP/r\u00a0adem\u00e1s\u00a0de\u00a0la\u00a0terapia\u00a0optimizada, \u00a0en\u00a0pacientes \u00a0con\u00a0tropismo\u00a0R5,\u00a0con\u00a0expe\u2010\nriencia\u00a0a\u00a0\u22653\u00a0clases\u00a0de\u00a0FAR\u00a0y\u00a0con\u00a0CVP\u00a0\u22651000\u00a0copias/mL \u00a0a\u00a0pesar\u00a0de\u00a0recibir\u00a0TARV\u00a0durante\u00a0\n\u22656\u00a0semanas. \u00a0El\u00a0objetivo\u00a0primario\u00a0fue\u00a0el\u00a0cambio\u00a0en\u00a0la\u00a0CVP\u00a0en\u00a0la\u00a0semana\u00a048\u00a0y\u00a0fueron\u00a0\nobjetivos\u00a0secundarios \u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0CVP\u00a0<400\u00a0y\u00a0<50\u00a0copias/mL. \u00a0Se\u00a0\nincluyeron \u00a0116\u00a0pacientes \u00a0de\u00a0los\u00a0que\u00a0lo\u00a0completaron \u00a033\u00a0(85%),\u00a035(88%)\u00a0y\u00a018(49%)\u00a0pa\u2010\ncientes\u00a0en\u00a0cada\u00a0brazo\u00a0(VCV\u00a030\u00a0mg,\u00a0VCV\u00a020\u00a0mg\u00a0y\u00a0placebo). \u00a0A\u00a0las\u00a048\u00a0semanas\u00a0el\u00a0descenso \u00a0\nmedio\u00a0de\u00a0CVP\u00a0fue\u00a0de\u00a0\u20101.77,\u00a0\u20131.75\u00a0y\u00a0\u20130,79\u00a0log 10,\u00a0respectivamente; \u00a0el\u00a0incremento \u00a0medio\u00a0\nde\u00a0linfocitos\u00a0CD4:\u00a0102,\u00a0136\u00a0y\u00a063\u00a0c\u00e9lulas/\u00b5L; \u00a0y\u00a0la\u00a0proporci\u00f3n \u00a0de\u00a0pacientes \u00a0que\u00a0alcanza\u2010\nron\u00a0CVP\u00a0<50\u00a0copias/mL: \u00a056,\u00a052\u00a0y\u00a014%\u00a0respectivamente. \u00a0La\u00a0dosis\u00a0de\u00a0VCV\u00a0de\u00a030\u00a0mg\u00a0\nmostr\u00f3\u00a0una\u00a0mayor\u00a0eficacia\u00a0virol\u00f3gica \u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0CVP\u00a0basal\u00a0>100\u00a0000\u00a0co\u2010\npias/mL.\u00a0El\u00a0porcentaje \u00a0de\u00a0efectos\u00a0adversos\u00a0grado\u00a03\u20104\u00a0fue\u00a0similar\u00a0en\u00a0los\u00a0tres\u00a0grupos\u00a0y\u00a0no\u00a0\nse\u00a0relacionaron \u00a0con\u00a0la\u00a0dosis\u00a0de\u00a0VCV.\u00a0\nTambi\u00e9n\u00a0est\u00e1n\u00a0en\u00a0fase\u00a0relativamente \u00a0avanzada \u00a0de\u00a0investigaci\u00f3n \u00a0los\u00a0inhibidores \u00a0de\u00a0la\u00a0\nmaduraci\u00f3n857,\u00a0y\u00a0hay\u00a0potenciales \u00a0avances\u00a0dentro\u00a0de\u00a0las\u00a0familias\u00a0existentes \u00a0como\u00a0in\u2010\nhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0con\u00a0un\u00a0nuevo\u00a0mecanismo \u00a0de\u00a0acci\u00f3n\u00a0o\u00a0inhibidores \u00a0\nde\u00a0la\u00a0fusi\u00f3n\u00a0de\u00a0vida\u00a0media\u00a0prolongada. \u00a0Aunque\u00a0la\u00a0descripci\u00f3n \u00a0de\u00a0estos\u00a0f\u00e1rmacos \u00a0esca\u2010\npa\u00a0a\u00a0los\u00a0objetivos\u00a0de\u00a0estas\u00a0gu\u00edas,\u00a0vale\u00a0la\u00a0pena\u00a0comentar \u00a0que\u00a0es\u00a0probable\u00a0que\u00a0en\u00a0pocos\u00a0\na\u00f1os\u00a0aumente\u00a0de\u00a0forma\u00a0considerable \u00a0el\u00a0arsenal\u00a0terap\u00e9utico \u00a0frente\u00a0a\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0\nVIH.\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 97 \n \u00a0\n \n13.\u00a0COSTE\u00a0COMPARATIVO \u00a0DE\u00a0LAS\u00a0DIFERENTES \u00a0COMBINACIONES \u00a0DE\u00a0FAR\u00a0\nEn\u00a0los\u00a0\u00faltimos\u00a0a\u00f1os,\u00a0gracias\u00a0al\u00a0TARV,\u00a0se\u00a0ha\u00a0reducido\u00a0la\u00a0mortalidad \u00a0relacionada \u00a0con\u00a0el\u00a0\nsida\u00a0y\u00a0mejorado \u00a0la\u00a0calidad\u00a0de\u00a0vida\u00a0de\u00a0los\u00a0pacientes. \u00a0Sin\u00a0embargo, \u00a0la\u00a0terapia\u00a0antirretro \u2010\nviral\u00a0tiene\u00a0un\u00a0elevado\u00a0coste\u00a0y,\u00a0en\u00a0un\u00a0entorno\u00a0donde\u00a0los\u00a0recursos\u00a0son\u00a0limitados, \u00a0es\u00a0ne\u2010\ncesario\u00a0gestionar \u00a0correctamente \u00a0el\u00a0gasto.\u00a0Por\u00a0ello,\u00a0se\u00a0considera \u00a0conveniente \u00a0introducir \u00a0\nen\u00a0estas\u00a0gu\u00edas\u00a0unas\u00a0tablas\u00a0comparativas \u00a0de\u00a0los\u00a0costes\u00a0de\u00a0las\u00a0diferentes \u00a0combinaciones \u00a0\nde\u00a0TARV\u00a0utilizadas \u00a0como\u00a0terapia\u00a0de\u00a0inicio\u00a0(Tabla\u00a0/\u00a0Figura\u00a020a),\u00a0ya\u00a0que\u00a0existen\u00a0diferen\u2010\ncias\u00a0sustanciales \u00a0entre\u00a0ellas:\u00a0el\u00a0gasto\u00a0mensual\u00a0con\u00a0pautas\u00a0de\u00a0eficacia\u00a0similar\u00a0puede\u00a0di\u2010\nferir\u00a0en\u00a0cantidades \u00a0superiores \u00a0a\u00a0los\u00a0600\u00a0euros.\u00a0\u00a0\nEn\u00a0la\u00a0tabla\u00a020b\u00a0se\u00a0indica\u00a0el\u00a0precio\u00a0de\u00a0venta\u00a0laboratorio \u00a0(PVL)\u00a0con\u00a0IVA\u00a0(4%)\u00a0de\u00a0los\u00a0anti\u2010\nrretrovirales \u00a0disponibles \u00a0en\u00a0Espa\u00f1a\u00a0en\u00a0el\u00a02010.\u00a0\u00a0\nA\u00a0la\u00a0hora\u00a0de\u00a0utilizar\u00a0la\u00a0informaci\u00f3n \u00a0del\u00a0coste\u00a0hay\u00a0que\u00a0tener\u00a0en\u00a0cuenta\u00a0que\u00a0adem\u00e1s\u00a0de\u00a0\nlos\u00a0costes\u00a0directos,\u00a0cada\u00a0alternativa \u00a0posible\u00a0presenta\u00a0aspectos\u00a0espec\u00edficos, \u00a0como\u00a0dife\u2010\nrente\u00a0perfil\u00a0de\u00a0reacciones \u00a0adversas\u00a0y\u00a0otros\u00a0aspectos\u00a0relacionados \u00a0con\u00a0el\u00a0seguimiento \u00a0\ncl\u00ednico,\u00a0que\u00a0podr\u00edan\u00a0requerir\u00a0distinto\u00a0consumo\u00a0de\u00a0recursos.\u00a0Por\u00a0ello,\u00a0y\u00a0a\u00a0pesar\u00a0de\u00a0sus\u00a0\nlimitaciones, \u00a0es\u00a0deseable\u00a0que\u00a0se\u00a0incorpore \u00a0la\u00a0evaluaci\u00f3n \u00a0farmacoecon\u00f3mica \u00a0con\u00a0objeto\u00a0\nde\u00a0determinar \u00a0la\u00a0eficiencia \u00a0de\u00a0las\u00a0nuevas\u00a0estrategias \u00a0o\u00a0de\u00a0los\u00a0nuevos\u00a0medicamentos. \u00a0\nEste\u00a0aspecto\u00a0es\u00a0especialmente \u00a0relevante \u00a0en\u00a0el\u00a0momento \u00a0actual,\u00a0ya\u00a0que\u00a0disponemos \u00a0de\u00a0\nm\u00faltiples \u00a0alternativas \u00a0de\u00a0elevada\u00a0eficacia\u00a0para\u00a0el\u00a0control\u00a0cr\u00f3nico\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0\nVIH.\u00a0Aunque\u00a0las\u00a0decisiones \u00a0de\u00a0tratamiento \u00a0en\u00a0el\u00a0caso\u00a0de\u00a0la\u00a0terapia\u00a0de\u00a0rescate\u00a0est\u00e1n\u00a0\nmuy\u00a0condicionadas \u00a0por\u00a0factores\u00a0tales\u00a0como\u00a0resistencias, \u00a0adherencia \u00a0o\u00a0toxicidad, \u00a0es\u00a0\nprobable\u00a0que,\u00a0en\u00a0el\u00a0caso\u00a0del\u00a0paciente\u00a0sin\u00a0fracaso\u00a0previo\u00a0o\u00a0en\u00a0situaci\u00f3n\u00a0de\u00a0primer\u00a0fraca\u2010\nso,\u00a0pudiera\u00a0incluirse\u00a0el\u00a0concepto \u00a0de\u00a0eficiencia \u00a0(relaci\u00f3n\u00a0entre\u00a0coste\u00a0y\u00a0resultados) \u00a0en\u00a0la\u00a0\ntoma\u00a0de\u00a0decisiones \u00a0para\u00a0seleccionar \u00a0la\u00a0alternativa. \u00a0Esta\u00a0idea\u00a0se\u00a0ha\u00a0aplicado\u00a0por\u00a0algunos\u00a0\nautores\u00a0en\u00a0an\u00e1lisis\u00a0farmacoecon\u00f3mico \u00a0aplicado\u00a0al\u00a0TARV.\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 98 \n \u00a0\n\u00a0\n\u00a0\nREFERENCIAS \u00a0BIBLIOGRAFICAS \u00a0\n\u00a0\n\u00a0 1.\u00a0\u00a0Consejo\u00a0Asesor\u00a0Cl\u00ednico\u00a0del\u00a0Plan\u00a0Nacional\u00a0sobre\u00a0el\u00a0SIDA.\u00a0Tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0\n(4\u00aa\u00a0edici\u00f3n).\u00a0Madrid.\u00a0Ministerio \u00a0de\u00a0Sanidad\u00a0y\u00a0Consumo, \u00a01997:\u00a0(10)\u00a01\u201016.\u00a0\u00a0\n\u00a0 2.\u00a0\u00a0Hammer\u00a0SM,\u00a0Eron\u00a0JJ,\u00a0Jr.,\u00a0Reiss\u00a0P,\u00a0Schooley\u00a0RT,\u00a0Thompson \u00a0MA,\u00a0Walmsley \u00a0S\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0\ntreatment \u00a0of\u00a0adult\u00a0HIV\u00a0infection: \u00a02008\u00a0recommendations \u00a0of\u00a0the\u00a0International \u00a0AIDS\u00a0Society\u2010\nUSA\u00a0panel.\u00a0Jama\u00a02008;\u00a0300(5):555 \u2010570.\u00a0\n\u00a0 3.\u00a0\u00a0Panel\u00a0on\u00a0Antiretroviral \u00a0Guidelines \u00a0for\u00a0Adults\u00a0and\u00a0Adolescents. \u00a0Guidelines \u00a0for\u00a0the\u00a0use\u00a0of\u00a0anti\u2010\nretroviral \u00a0agents\u00a0in\u00a0HIV\u2010infected\u00a0adults\u00a0and\u00a0adolescents. \u00a0Department \u00a0of\u00a0Health\u00a0and\u00a0Human\u00a0\nServices.December \u00a01,\u00a02009;\u00a01\u2010161.Disponible \u00a0en:\u00a0\nwww.AIDSinfo.nih.gov/ContentF iles/AdultandAdolescentGL.pdf \u00a0(Acceso\u00a09.12.09)\u00a0\u00a0\n\u00a0 4.\u00a0\u00a0Guyatt\u00a0G,\u00a0Rennie\u00a0D.\u00a0Users'\u00a0Guides\u00a0to\u00a0the\u00a0Medical\u00a0Literature: \u00a0A\u00a0Manual\u00a0for\u00a0Evidence\u2010Based\u00a0\nClinical\u00a0Practice.\u00a0Chicago:\u00a0AMA\u00a0Press;\u00a02002.\u00a0\n\u00a0 5.\u00a0\u00a0Kish\u00a0MA.\u00a0Guide\u00a0to\u00a0development \u00a0of\u00a0practice\u00a0guidelines. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02001;\u00a032(6):851 \u2010854.\u00a0\n\u00a0 6.\u00a0\u00a0Mocroft\u00a0A,\u00a0Vella\u00a0S,\u00a0Benfield\u00a0TL,\u00a0Chiesi\u00a0A,\u00a0Miller\u00a0V,\u00a0Gargalianos \u00a0P\u00a0et\u00a0al.\u00a0Changing\u00a0patterns\u00a0of\u00a0\nmortality\u00a0across\u00a0Europe\u00a0in\u00a0patients\u00a0infected\u00a0with\u00a0HIV\u20101.\u00a0EuroSIDA \u00a0Study\u00a0Group.\u00a0Lancet\u00a01998;\u00a0\n352(9142):1725 \u201030.\u00a0\n\u00a0 7.\u00a0\u00a0Palella\u00a0FJ,\u00a0Jr.,\u00a0Delaney\u00a0KM,\u00a0Moorman \u00a0AC,\u00a0Loveless\u00a0MO,\u00a0Fuhrer\u00a0J,\u00a0Satten\u00a0GA\u00a0et\u00a0al.\u00a0Declining\u00a0\nmorbidity \u00a0and\u00a0mortality\u00a0among\u00a0patients\u00a0with\u00a0advanced \u00a0human\u00a0immunodeficiency \u00a0virus\u00a0infec\u2010\ntion.\u00a0HIV\u00a0Outpatient \u00a0Study\u00a0Investigators. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a01998;\u00a0338(13):853 \u201060.\u00a0\n\u00a0 8.\u00a0\u00a0Knobel\u00a0H,\u00a0Polo\u00a0R,\u00a0Escobar\u00a0I,\u00a0(Coordinadores). \u00a0Recomendaciones \u00a0Gesida\u00a0/\u00a0SEFH\u00a0/\u00a0PNS\u00a0para\u00a0\nmejorar\u00a0la\u00a0adherencia \u00a0al\u00a0tratamiento \u00a0antirretroviral \u00a0(Actualizaci\u00f3n \u00a0junio\u00a0de\u00a02008).\u00a0\nhttp://www.gesida.seimc.org/pcientifica/fuen tes/DcyRc/Gesida_dcyr c2008_adherenciaTAR.\npdf\u00a0(Acceso\u00a08.12.09)\u00a0\u00a0\n\u00a0 9.\u00a0\u00a0Sterne\u00a0J,\u00a0May\u00a0M,\u00a0Costagliola \u00a0D,\u00a0Egger\u00a0M,\u00a0Hogg\u00a0R,\u00a0d'Arminio \u00a0Monforte \u00a0A\u00a0et\u00a0al.\u00a0Estimating \u00a0the\u00a0\noptimum\u00a0CD4\u00a0threshold \u00a0for\u00a0starting\u00a0HAART\u00a0in\u00a0ART\u2010na\u00efve\u00a0HIV\u2010infected\u00a0individuals. \u00a013\u00a0th\u00a0Con\u2010\nference\u00a0on\u00a0Retrovirus \u00a0and\u00a0Opportunistic \u00a0Infection, \u00a0Denver,\u00a0February\u00a05\u20108,\u00a02006\u00a0(Abstract\u00a0525)\u00a0\n\u00a0 10.\u00a0\u00a0Jaen\u00a0A,\u00a0Esteve\u00a0A,\u00a0Miro\u00a0JM,\u00a0Tural\u00a0C,\u00a0Montoliu\u00a0A,\u00a0Ferrer\u00a0E\u00a0et\u00a0al.\u00a0Determinants \u00a0of\u00a0HIV\u00a0progres\u2010\nsion\u00a0and\u00a0assessment \u00a0of\u00a0the\u00a0optimal\u00a0time\u00a0to\u00a0initiate\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy:\u00a0PISCIS\u00a0\nCohort\u00a0(Spain).\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02008;\u00a047(2):212 \u2010220.\u00a0\n\u00a0 11.\u00a0\u00a0Autran\u00a0B,\u00a0Carcelain\u00a0G,\u00a0Li\u00a0TS,\u00a0Blanc\u00a0C,\u00a0Mathez\u00a0D,\u00a0Tubiana\u00a0R\u00a0et\u00a0al.\u00a0Positive\u00a0effects\u00a0of\u00a0combined \u00a0\nantiretroviral \u00a0therapy\u00a0on\u00a0CD4+\u00a0T\u00a0cell\u00a0homeostasis \u00a0and\u00a0function\u00a0in\u00a0advanced \u00a0HIV\u00a0disease.\u00a0\nScience\u00a01997;\u00a0277(5322):112 \u20106.\u00a0\n\u00a0 12.\u00a0\u00a0Kelleher\u00a0AD,\u00a0Carr\u00a0A,\u00a0Zaunders\u00a0J,\u00a0Cooper\u00a0DA.\u00a0Alterations \u00a0in\u00a0the\u00a0immune\u00a0response\u00a0of\u00a0human\u00a0\nimmunodeficiency \u00a0virus\u00a0(HIV)\u2010infected\u00a0subjects\u00a0treated\u00a0with\u00a0an\u00a0HIV\u2010specific\u00a0protease\u00a0inhibi\u2010\ntor,\u00a0ritonavir.\u00a0J\u00a0Infect\u00a0Dis\u00a01996;\u00a0173(2):321 \u20109.\u00a0\n\u00a0 13.\u00a0\u00a0Carr\u00a0A,\u00a0Cooper\u00a0DA.\u00a0Adverse\u00a0effects\u00a0of\u00a0antiretroviral \u00a0therapy.\u00a0Lancet\u00a02000;\u00a0356(9239):1423 \u2010\n30.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 99 \n \u00a0 14.\u00a0\u00a0Carr\u00a0A,\u00a0Samaras\u00a0K,\u00a0Thorisdottir \u00a0A,\u00a0Kaufmann \u00a0GR,\u00a0Chisholm\u00a0DJ,\u00a0Cooper\u00a0DA.\u00a0Diagnosis, \u00a0predic\u2010\ntion,\u00a0and\u00a0natural\u00a0course\u00a0of\u00a0HIV\u20101\u00a0protease\u2010inhibitor\u2010associated \u00a0lipodystrophy, \u00a0hyperlipidae \u2010\nmia,\u00a0and\u00a0diabetes\u00a0mellitus:\u00a0a\u00a0cohort\u00a0study.\u00a0Lancet\u00a01999;\u00a0353(9170):2093 \u20109.\u00a0\n\u00a0 15.\u00a0\u00a0Hirsch\u00a0MS,\u00a0Brun\u2010Vezinet\u00a0F,\u00a0Clotet\u00a0B,\u00a0Conway\u00a0B,\u00a0Kuritzkes\u00a0DR,\u00a0D'Aquila\u00a0RT\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0\ndrug\u00a0resistance \u00a0testing\u00a0in\u00a0adults\u00a0infected\u00a0with\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01:\u00a02003\u00a0\nrecommendations \u00a0of\u00a0an\u00a0International \u00a0AIDS\u00a0Society\u2010USA\u00a0Panel.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02003;\u00a037(1):113 \u2010\n128.\u00a0\n\u00a0 16.\u00a0\u00a0Finzi\u00a0D,\u00a0Blankson\u00a0J,\u00a0Siliciano\u00a0JD,\u00a0Margolick \u00a0JB,\u00a0Chadwick \u00a0K,\u00a0Pierson\u00a0T\u00a0et\u00a0al.\u00a0Latent\u00a0infection\u00a0of\u00a0\nCD4+\u00a0T\u00a0cells\u00a0provides\u00a0a\u00a0mechanism \u00a0for\u00a0lifelong\u00a0persistence \u00a0of\u00a0HIV\u20101,\u00a0even\u00a0in\u00a0patients\u00a0on\u00a0ef\u2010\nfective\u00a0combination \u00a0therapy.\u00a0Nat\u00a0Med\u00a01999;\u00a05(5):512\u20107.\u00a0\n\u00a0 17.\u00a0\u00a0Plana\u00a0M,\u00a0Garcia\u00a0F,\u00a0Gallart\u00a0T,\u00a0Miro\u00a0JM,\u00a0Gatell\u00a0JM.\u00a0Lack\u00a0of\u00a0T\u2010cell\u00a0proliferative \u00a0response\u00a0to\u00a0HIV\u20101\u00a0\nantigens\u00a0after\u00a01\u00a0year\u00a0of\u00a0highly\u00a0active\u00a0antiretroviral \u00a0treatment \u00a0in\u00a0early\u00a0HIV\u20101\u00a0disease.\u00a0Immuno\u2010\nlogy\u00a0Study\u00a0Group\u00a0of\u00a0Spanish\u00a0EARTH\u20101\u00a0Study.\u00a0Lancet\u00a01998;\u00a0352(9135):1194 \u20105.\u00a0\n\u00a0 18.\u00a0\u00a0Landon\u00a0BE,\u00a0Wilson\u00a0IB,\u00a0McInnes\u00a0K,\u00a0Landrum\u00a0MB,\u00a0Hirschhorn \u00a0LR,\u00a0Marsden\u00a0PV\u00a0et\u00a0al.\u00a0Physician \u00a0\nspecialization \u00a0and\u00a0the\u00a0quality\u00a0of\u00a0care\u00a0for\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0infection. \u00a0Arch\u00a0In\u2010\ntern\u00a0Med\u00a02005;\u00a0165(10):1133 \u20101139.\u00a0\n\u00a0 19.\u00a0\u00a0Pe\u00f1a\u00a0JM,\u00a0Miro\u00a0JM.\u00a0Restauraci\u00f3n \u00a0inmunol\u00f3gica \u00a0en\u00a0pacientes \u00a0con\u00a0Sida.\u00a0\u00bfRequiem \u00a0por\u00a0las\u00a0profi\u2010\nlaxis?\u00a0Med\u00a0Clin\u00a0(Barc)\u00a01999;\u00a0113(10):375 \u20108.\u00a0\n\u00a0 20.\u00a0\u00a0Li\u00a0TS,\u00a0Tubiana\u00a0R,\u00a0Katlama\u00a0C,\u00a0Calvez\u00a0V,\u00a0Ait\u00a0Mohand\u00a0H,\u00a0Autran\u00a0B.\u00a0Long\u2010lasting\u00a0recovery\u00a0in\u00a0CD4\u00a0T\u2010\ncell\u00a0function\u00a0and\u00a0viral\u2010load\u00a0reduction \u00a0after\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0advanced \u00a0\nHIV\u20101\u00a0disease.\u00a0Lancet\u00a01998;\u00a0351(9117):1682 \u20106.\u00a0\n\u00a0 21.\u00a0\u00a0Kostense\u00a0S,\u00a0Raaphorst \u00a0FM,\u00a0Notermans \u00a0DW,\u00a0Joling\u00a0J,\u00a0Hooibrink \u00a0B,\u00a0Pakker\u00a0NG\u00a0et\u00a0al.\u00a0Diversity\u00a0of\u00a0\nthe\u00a0T\u2010cell\u00a0receptor\u00a0BV\u00a0repertoire \u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0reflects\u00a0the\u00a0biphasic\u00a0CD4+\u00a0T\u2010cell\u00a0\nrepopulation \u00a0kinetics\u00a0during\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0AIDS\u00a01998;\u00a012(18):235 \u201040.\u00a0\n\u00a0 22.\u00a0\u00a0Lopez\u00a0Bernaldo\u00a0de\u00a0Quiros\u00a0JC,\u00a0Miro\u00a0JM,\u00a0Pena\u00a0JM,\u00a0Podzamczer \u00a0D,\u00a0Alberdi\u00a0JC,\u00a0Martinez\u00a0E\u00a0et\u00a0al.\u00a0A\u00a0\nrandomized \u00a0trial\u00a0of\u00a0the\u00a0discontinuation \u00a0of\u00a0primary\u00a0and\u00a0secondary \u00a0prophylaxis \u00a0against\u00a0Pneu\u2010\nmocystis\u00a0carinii\u00a0pneumonia \u00a0after\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0patients\u00a0with\u00a0HIV\u00a0in\u2010\nfection.\u00a0Grupo\u00a0de\u00a0Estudio\u00a0del\u00a0SIDA\u00a004/98.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02001;\u00a0344(3):159 \u2010167.\u00a0\n\u00a0 23.\u00a0\u00a0Deeks\u00a0SG,\u00a0Hecht\u00a0FM,\u00a0Swanson\u00a0M,\u00a0Elbeik\u00a0T,\u00a0Loftus\u00a0R,\u00a0Cohen\u00a0PT\u00a0et\u00a0al.\u00a0HIV\u00a0RNA\u00a0and\u00a0CD4\u00a0cell\u00a0\ncount\u00a0response\u00a0to\u00a0protease\u00a0inhibitor\u00a0therapy\u00a0in\u00a0an\u00a0urban\u00a0AIDS\u00a0clinic:\u00a0response\u00a0to\u00a0both\u00a0initial\u00a0\nand\u00a0salvage\u00a0therapy.\u00a0AIDS\u00a01999;\u00a013(6):35\u201043.\u00a0\n\u00a0 24.\u00a0\u00a0Deeks\u00a0SG,\u00a0Barbour\u00a0JD,\u00a0Martin\u00a0JN,\u00a0Swanson\u00a0MS,\u00a0Grant\u00a0RM.\u00a0Sustained \u00a0CD4+\u00a0T\u00a0cell\u00a0response\u00a0\nafter\u00a0virologic\u00a0failure\u00a0of\u00a0protease\u00a0inhibitor\u2010based\u00a0regimens\u00a0in\u00a0patients\u00a0with\u00a0human\u00a0immuno\u2010\ndeficiency \u00a0virus\u00a0infection. \u00a0J\u00a0Infect\u00a0Dis\u00a02000;\u00a0181(3):946 \u201053.\u00a0\n\u00a0 25.\u00a0\u00a0Kaufmann \u00a0D,\u00a0Pantaleo\u00a0G,\u00a0Sudre\u00a0P,\u00a0Telenti\u00a0A.\u00a0CD4\u2010cell\u00a0count\u00a0in\u00a0HIV\u20101\u2010infected\u00a0individuals \u00a0re\u2010\nmaining\u00a0viraemic\u00a0with\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0(HAART).\u00a0Swiss\u00a0HIV\u00a0Cohort\u00a0Study.\u00a0\nLancet\u00a01998;\u00a0351(9104):723 \u20104.\u00a0\n\u00a0 26.\u00a0\u00a0Garcia\u00a0F,\u00a0Vidal\u00a0C,\u00a0Plana\u00a0M,\u00a0Cruceta\u00a0A,\u00a0Gallart\u00a0MT,\u00a0Pumarola \u00a0T\u00a0et\u00a0al.\u00a0Residual\u00a0low\u2010level\u00a0viral\u00a0\nreplication \u00a0could\u00a0explain\u00a0discrepancies \u00a0between\u00a0viral\u00a0load\u00a0and\u00a0CD4+\u00a0cell\u00a0response\u00a0in\u00a0human\u00a0\nimmunodeficiency \u00a0virus\u2010infected\u00a0patients\u00a0receiving\u00a0antiretroviral \u00a0therapy.\u00a0Clin\u00a0Infect\u00a0Dis\u00a0\n2000;\u00a030(2):392 \u20104.\u00a0\n\u00a0 27.\u00a0\u00a0Dronda\u00a0F,\u00a0Moreno\u00a0S,\u00a0Moreno\u00a0A,\u00a0Casado\u00a0JL,\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Antela\u00a0A.\u00a0Long\u2010term\u00a0outcomes \u00a0\namong\u00a0antiretroviral \u2010naive\u00a0human\u00a0immunodeficiency \u00a0virus\u2010infected\u00a0patients\u00a0with\u00a0small\u00a0in\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 100 \n creases\u00a0in\u00a0CD4+\u00a0cell\u00a0counts\u00a0after\u00a0successful \u00a0virologic\u00a0suppression. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02002;\u00a0\n35(8):1005 \u20101009.\u00a0\n\u00a0 28.\u00a0\u00a0Gandhi\u00a0RT.\u00a0Cirrhosis\u00a0is\u00a0associated \u00a0with\u00a0low\u00a0CD4+\u00a0T\u00a0cell\u00a0counts:\u00a0implications \u00a0for\u00a0HIV\u2010infected\u00a0\npatients\u00a0with\u00a0liver\u00a0disease.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02007;\u00a044(3):438 \u2010440.\u00a0\n\u00a0 29.\u00a0\u00a0McGovern \u00a0BH,\u00a0Golan\u00a0Y,\u00a0Lopez\u00a0M,\u00a0Pratt\u00a0D,\u00a0Lawton\u00a0A,\u00a0Moore\u00a0G\u00a0et\u00a0al.\u00a0The\u00a0impact\u00a0of\u00a0cirrhosis\u00a0on\u00a0\nCD4+\u00a0T\u00a0cell\u00a0counts\u00a0in\u00a0HIV\u2010seronegative \u00a0patients.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02007;\u00a044(3):431 \u2010437.\u00a0\n\u00a0 30.\u00a0\u00a0Bongiovanni \u00a0M,\u00a0Gori\u00a0A,\u00a0Lepri\u00a0AC,\u00a0Antinori\u00a0A,\u00a0De\u00a0LA,\u00a0Pagano\u00a0G\u00a0et\u00a0al.\u00a0Is\u00a0the\u00a0CD4\u00a0cell\u00a0percentage \u00a0\na\u00a0better\u00a0marker\u00a0of\u00a0immunosuppression \u00a0than\u00a0the\u00a0absolute\u00a0CD4\u00a0cell\u00a0count\u00a0in\u00a0HIV\u2010infected\u00a0pa\u2010\ntients\u00a0with\u00a0cirrhosis? \u00a0Clin\u00a0Infect\u00a0Dis\u00a02007;\u00a045(5):650 \u2010653.\u00a0\n\u00a0 31.\u00a0\u00a0D'Egidio\u00a0GE,\u00a0Kravcik\u00a0S,\u00a0Cooper\u00a0CL,\u00a0Cameron\u00a0DW,\u00a0Fergusson \u00a0DA,\u00a0Angel\u00a0JB.\u00a0Pneumocystis \u00a0jiro\u2010\nveci\u00a0pneumonia \u00a0prophylaxis \u00a0is\u00a0not\u00a0required\u00a0with\u00a0a\u00a0CD4+\u00a0T\u2010cell\u00a0count\u00a0<\u00a0200\u00a0cells/microl \u00a0when\u00a0\nviral\u00a0replication \u00a0is\u00a0suppressed. \u00a0AIDS\u00a02007;\u00a021(13):1711 \u20101715.\u00a0\n\u00a0 32.\u00a0\u00a0Brambilla \u00a0D,\u00a0Reichelderfer \u00a0PS,\u00a0Bremer\u00a0JW,\u00a0Shapiro\u00a0DE,\u00a0Hershow\u00a0RC,\u00a0Katzenstein \u00a0DA\u00a0et\u00a0al.\u00a0The\u00a0\ncontribution \u00a0of\u00a0assay\u00a0variation\u00a0and\u00a0biological \u00a0variation\u00a0to\u00a0the\u00a0total\u00a0variability \u00a0of\u00a0plasma\u00a0HIV\u20101\u00a0\nRNA\u00a0measurements. \u00a0The\u00a0Women\u00a0Infant\u00a0Transmission \u00a0Study\u00a0Clinics.\u00a0Virology\u00a0Quality\u00a0Assuran\u2010\nce\u00a0Program.\u00a0AIDS\u00a01999;\u00a013(16):2269 \u201079.\u00a0\n\u00a0 33.\u00a0\u00a0Lopez\u00a0A,\u00a0Caragol\u00a0I,\u00a0Candeias\u00a0J,\u00a0Villamor\u00a0N,\u00a0Echaniz\u00a0P,\u00a0Ortuno\u00a0F\u00a0et\u00a0al.\u00a0Enumeration \u00a0of\u00a0CD4(+)\u00a0T\u2010\ncells\u00a0in\u00a0the\u00a0peripheral \u00a0blood\u00a0of\u00a0HIV\u2010infected\u00a0patients:\u00a0an\u00a0interlaboratory \u00a0study\u00a0of\u00a0the\u00a0FACS\u2010\nCount\u00a0system.\u00a0Cytometry \u00a01999;\u00a038(5):231 \u2010237.\u00a0\n\u00a0 34.\u00a0\u00a0Kempf\u00a0DJ,\u00a0Rode\u00a0RA,\u00a0Xu\u00a0Y,\u00a0Sun\u00a0E,\u00a0Heath\u2010Chiozzi\u00a0ME,\u00a0Valdes\u00a0J\u00a0et\u00a0al.\u00a0The\u00a0duration\u00a0of\u00a0viral\u00a0sup\u2010\npression\u00a0during\u00a0protease\u00a0inhibitor\u00a0therapy\u00a0for\u00a0HIV\u20101\u00a0infection\u00a0is\u00a0predicted \u00a0by\u00a0plasma\u00a0HIV\u20101\u00a0\nRNA\u00a0at\u00a0the\u00a0nadir.\u00a0AIDS\u00a01998;\u00a012(5):9\u201014.\u00a0\n\u00a0 35.\u00a0\u00a0Raboud\u00a0JM,\u00a0Montaner \u00a0JS,\u00a0Conway\u00a0B,\u00a0Rae\u00a0S,\u00a0Reiss\u00a0P,\u00a0Vella\u00a0S\u00a0et\u00a0al.\u00a0Suppression \u00a0of\u00a0plasma\u00a0viral\u00a0\nload\u00a0below\u00a020\u00a0copies/ml \u00a0is\u00a0required\u00a0to\u00a0achieve\u00a0a\u00a0long\u2010term\u00a0response\u00a0to\u00a0therapy.\u00a0AIDS\u00a01998;\u00a0\n12(13):1619 \u201024.\u00a0\n\u00a0 36.\u00a0\u00a0Demeter\u00a0LM,\u00a0Hughes\u00a0MD,\u00a0Coombs\u00a0RW,\u00a0Jackson\u00a0JB,\u00a0Grimes\u00a0JM,\u00a0Bosch\u00a0RJ\u00a0et\u00a0al.\u00a0Predictors \u00a0of\u00a0\nvirologic\u00a0and\u00a0clinical\u00a0outcomes \u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0receiving\u00a0concurrent \u00a0treatment \u00a0\nwith\u00a0indinavir, \u00a0zidovudine, \u00a0and\u00a0lamivudine. \u00a0AIDS\u00a0Clinical\u00a0Trials\u00a0Group\u00a0Protocol\u00a0320.\u00a0Ann\u00a0In\u2010\ntern\u00a0Med\u00a02001;\u00a0135(11):954 \u201064.\u00a0\n\u00a0 37.\u00a0\u00a0Huang\u00a0W,\u00a0De\u00a0G,\u00a0V,\u00a0Fischl\u00a0M,\u00a0Hammer\u00a0S,\u00a0Richman\u00a0D,\u00a0Havlir\u00a0D\u00a0et\u00a0al.\u00a0Patterns\u00a0of\u00a0plasma\u00a0human\u00a0\nimmunodeficiency \u00a0virus\u00a0type\u00a01\u00a0RNA\u00a0response\u00a0to\u00a0antiretroviral \u00a0therapy.\u00a0J\u00a0Infect\u00a0Dis\u00a02001;\u00a0\n183(10):1455 \u20101465.\u00a0\n\u00a0 38.\u00a0\u00a0Hicks\u00a0C,\u00a0King\u00a0MS,\u00a0Gulick\u00a0RM,\u00a0White\u00a0Jr\u00a0AC,\u00a0Eron\u00a0Jr\u00a0JJ,\u00a0Kessler\u00a0HA\u00a0et\u00a0al.\u00a0Long\u2010term\u00a0safety\u00a0and\u00a0\ndurable\u00a0antiretroviral \u00a0activity\u00a0of\u00a0lopinavir/ritonavir \u00a0in\u00a0treatment \u2010naive\u00a0patients:\u00a04\u00a0year\u00a0fo\u2010\nllow\u2010up\u00a0study.\u00a0AIDS\u00a02004;\u00a018(5):775 \u2010779.\u00a0\n\u00a0 39.\u00a0\u00a0Siliciano\u00a0RF.\u00a0Scientific\u00a0rationale\u00a0for\u00a0antiretroviral \u00a0therapy\u00a0in\u00a02005:\u00a0viral\u00a0reservoirs \u00a0and\u00a0resis\u2010\ntance\u00a0evolution. \u00a0Top\u00a0HIV\u00a0Med\u00a02005;\u00a013(3):96\u2010100.\u00a0\n\u00a0 40.\u00a0\u00a0Nettles\u00a0RE,\u00a0Kieffer\u00a0TL,\u00a0Simmons\u00a0RP,\u00a0Cofrancesco \u00a0J,\u00a0Jr.,\u00a0Moore\u00a0RD,\u00a0Gallant\u00a0JE\u00a0et\u00a0al.\u00a0Genotypic \u00a0\nresistance \u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0with\u00a0persistently \u00a0detectable \u00a0low\u2010level\u00a0viremia\u00a0while\u00a0re\u2010\nceiving\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02004;\u00a039(7):1030 \u20101037.\u00a0\n\u00a0 41.\u00a0\u00a0Greub\u00a0G,\u00a0Cozzi\u2010Lepri\u00a0A,\u00a0Ledergerber \u00a0B,\u00a0Staszewski \u00a0S,\u00a0Perrin\u00a0L,\u00a0Miller\u00a0V\u00a0et\u00a0al.\u00a0Intermittent \u00a0and\u00a0\nsustained \u00a0low\u2010level\u00a0HIV\u00a0viral\u00a0rebound\u00a0in\u00a0patients\u00a0receiving\u00a0potent\u00a0antiretroviral \u00a0therapy.\u00a0AIDS\u00a0\n2002;\u00a016(14):1967 \u20109.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 101 \n \u00a0 42.\u00a0\u00a0Jones\u00a0LE,\u00a0Perelson\u00a0AS.\u00a0Transient \u00a0viremia,\u00a0plasma\u00a0viral\u00a0load,\u00a0and\u00a0reservoir\u00a0replenishment \u00a0in\u00a0\nHIV\u2010infected\u00a0patients\u00a0on\u00a0antiretroviral \u00a0therapy.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a045(5):483 \u2010\n493.\u00a0\n\u00a0 43.\u00a0\u00a0Havlir\u00a0DV,\u00a0Bassett\u00a0R,\u00a0Levitan\u00a0D,\u00a0Gilbert\u00a0P,\u00a0Tebas\u00a0P,\u00a0Collier\u00a0AC\u00a0et\u00a0al.\u00a0Prevalence \u00a0and\u00a0predictive \u00a0\nvalue\u00a0of\u00a0intermittent \u00a0viremia\u00a0with\u00a0combination \u00a0HIV\u00a0therapy.\u00a0Jama\u00a02001;\u00a0286(2):171 \u20109.\u00a0\n\u00a0 44.\u00a0\u00a0Lampe\u00a0FC,\u00a0Johnson\u00a0MA,\u00a0Lipman\u00a0M,\u00a0Loveday\u00a0C,\u00a0Youle\u00a0M,\u00a0Ransom\u00a0D\u00a0et\u00a0al.\u00a0Viral\u00a0breakthrough \u00a0\nafter\u00a0suppression \u00a0with\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy:\u00a0experience \u00a0from\u00a0233\u00a0individuals \u00a0\nwith\u00a0viral\u00a0loads\u00a0of\u00a0less\u00a0than\u00a050\u00a0copies/ml \u00a0followed\u00a0for\u00a0up\u00a0to\u00a04\u00a0years.\u00a0AIDS\u00a02003;\u00a017(5):768 \u201070.\u00a0\n\u00a0 45.\u00a0\u00a0Mira\u00a0JA,\u00a0Macias\u00a0J,\u00a0Nogales\u00a0C,\u00a0Fernandez \u2010Rivera\u00a0J,\u00a0Garcia\u2010Garcia\u00a0JA,\u00a0Ramos\u00a0A\u00a0et\u00a0al.\u00a0Transient \u00a0\nrebounds \u00a0of\u00a0low\u2010level\u00a0viraemia\u00a0among\u00a0HIV\u2010infected\u00a0patients\u00a0under\u00a0HAART\u00a0are\u00a0not\u00a0associated \u00a0\nwith\u00a0virological \u00a0or\u00a0immunological \u00a0failure.\u00a0Antivir\u00a0Ther\u00a02002;\u00a07(4):251\u2010256.\u00a0\n\u00a0 46.\u00a0\u00a0Lee\u00a0PK,\u00a0Kieffer\u00a0TL,\u00a0Siliciano\u00a0RF,\u00a0Nettles\u00a0RE.\u00a0HIV\u20101\u00a0viral\u00a0load\u00a0blips\u00a0are\u00a0of\u00a0limited\u00a0clinical\u00a0signifi\u2010\ncance.\u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02006;\u00a057(5):803 \u2010805.\u00a0\n\u00a0 47.\u00a0\u00a0Macias\u00a0J,\u00a0Palomares \u00a0JC,\u00a0Mira\u00a0JA,\u00a0Torres\u00a0MJ,\u00a0Garcia\u2010Garcia\u00a0JA,\u00a0Rodriquez \u00a0JM\u00a0et\u00a0al.\u00a0Transient \u00a0\nrebounds \u00a0of\u00a0HIV\u00a0plasma\u00a0viremia\u00a0are\u00a0associated \u00a0with\u00a0the\u00a0emergence \u00a0of\u00a0drug\u00a0resistance \u00a0muta\u2010\ntions\u00a0in\u00a0patients\u00a0on\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0J\u00a0Infect\u00a02005;\u00a051(3):195 \u2010200.\u00a0\n\u00a0 48.\u00a0\u00a0Garcia\u2010Gasco\u00a0P,\u00a0Maida\u00a0I,\u00a0Blanco\u00a0F,\u00a0Barreiro\u00a0P,\u00a0Martin\u2010Carbonero \u00a0L,\u00a0Vispo\u00a0E\u00a0et\u00a0al.\u00a0Episodes\u00a0of\u00a0\nlow\u2010level\u00a0viral\u00a0rebound\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0on\u00a0antiretroviral \u00a0therapy:\u00a0frequency, \u00a0predic\u2010\ntors\u00a0and\u00a0outcome. \u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02008;\u00a061(3):699 \u2010704.\u00a0\n\u00a0 49.\u00a0\u00a0Saag\u00a0MS,\u00a0Holodniy\u00a0M,\u00a0Kuritzkes\u00a0DR,\u00a0O'Brien\u00a0WA,\u00a0Coombs\u00a0R,\u00a0Poscher\u00a0ME\u00a0et\u00a0al.\u00a0HIV\u00a0viral\u00a0load\u00a0\nmarkers\u00a0in\u00a0clinical\u00a0practice.\u00a0Nat\u00a0Med\u00a01996;\u00a02(6):625\u20109.\u00a0\n\u00a0 50.\u00a0\u00a0Khoo\u00a0SH,\u00a0Gibbons\u00a0SE,\u00a0Back\u00a0DJ.\u00a0Therapeutic \u00a0drug\u00a0monitoring \u00a0as\u00a0a\u00a0tool\u00a0in\u00a0treating\u00a0HIV\u00a0infection. \u00a0\nAIDS\u00a02001;\u00a015\u00a0Suppl\u00a05:171\u201081.\u00a0\n\u00a0 51.\u00a0\u00a0Nettles\u00a0RE,\u00a0Kieffer\u00a0TL,\u00a0Parsons\u00a0T,\u00a0Johnson\u00a0J,\u00a0Cofrancesco \u00a0J,\u00a0Jr.,\u00a0Gallant\u00a0JE\u00a0et\u00a0al.\u00a0Marked\u00a0in\u2010\ntraindividual \u00a0variability \u00a0in\u00a0antiretroviral \u00a0concentrations \u00a0may\u00a0limit\u00a0the\u00a0utility\u00a0of\u00a0therapeutic \u00a0\ndrug\u00a0monitoring. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02006;\u00a042(8):1189 \u20101196.\u00a0\n\u00a0 52.\u00a0\u00a0Schapiro\u00a0JM,\u00a0Winters\u00a0MA,\u00a0Stewart\u00a0F,\u00a0Efron\u00a0B,\u00a0Norris\u00a0J,\u00a0Kozal\u00a0MJ\u00a0et\u00a0al.\u00a0The\u00a0effect\u00a0of\u00a0high\u2010dose\u00a0\nsaquinavir \u00a0on\u00a0viral\u00a0load\u00a0and\u00a0CD4+\u00a0T\u2010cell\u00a0counts\u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0Ann\u00a0Intern\u00a0Med\u00a0\n1996;\u00a0124(12):1039 \u201050.\u00a0\n\u00a0 53.\u00a0\u00a0Hoetelmans \u00a0RM,\u00a0Reijers\u00a0MH,\u00a0Weverling \u00a0GJ,\u00a0Ten\u00a0Kate\u00a0RW,\u00a0Wit\u00a0FW,\u00a0Mulder\u00a0JW\u00a0et\u00a0al.\u00a0The\u00a0effect\u00a0\nof\u00a0plasma\u00a0drug\u00a0concentrations \u00a0on\u00a0HIV\u20101\u00a0clearance \u00a0rate\u00a0during\u00a0quadruple \u00a0drug\u00a0therapy.\u00a0AIDS\u00a0\n1998;\u00a012(11):111 \u20105.\u00a0\n\u00a0 54.\u00a0\u00a0Casado\u00a0JL,\u00a0Moreno\u00a0S,\u00a0Hertogs\u00a0K,\u00a0Dronda\u00a0F,\u00a0Antela\u00a0A,\u00a0Dehertogh \u00a0P\u00a0et\u00a0al.\u00a0Plasma\u00a0drug\u00a0levels,\u00a0\ngenotypic \u00a0resistance, \u00a0and\u00a0virological \u00a0response\u00a0to\u00a0a\u00a0nelfinavir \u00a0plus\u00a0saquinavir \u2010containing \u00a0regi\u2010\nmen.\u00a0AIDS\u00a02002;\u00a016(1):47\u201052.\u00a0\n\u00a0 55.\u00a0\u00a0Harris\u00a0M,\u00a0Durakovic \u00a0C,\u00a0Rae\u00a0S,\u00a0Raboud\u00a0J,\u00a0Fransen\u00a0S,\u00a0Shillington \u00a0A\u00a0et\u00a0al.\u00a0A\u00a0pilot\u00a0study\u00a0of\u00a0nevira\u2010\npine,\u00a0indinavir, \u00a0and\u00a0lamivudine \u00a0among\u00a0patients\u00a0with\u00a0advanced \u00a0human\u00a0immunodeficiency \u00a0vi\u2010\nrus\u00a0disease\u00a0who\u00a0have\u00a0had\u00a0failure\u00a0of\u00a0combination \u00a0nucleoside \u00a0therapy.\u00a0J\u00a0Infect\u00a0Dis\u00a01998;\u00a0\n177(6):1514 \u201020.\u00a0\n\u00a0 56.\u00a0\u00a0Fatkenheuer \u00a0G,\u00a0Hoetelmans \u00a0RM,\u00a0Hunn\u00a0N,\u00a0Schwenk\u00a0A,\u00a0Franzen\u00a0C,\u00a0Reiser\u00a0M\u00a0et\u00a0al.\u00a0Salvage\u00a0the\u2010\nrapy\u00a0with\u00a0regimens\u00a0containing \u00a0ritonavir\u00a0and\u00a0saquinavir \u00a0in\u00a0extensively \u00a0pretreated \u00a0HIV\u2010infected\u00a0\npatients.\u00a0AIDS\u00a01999;\u00a013(12):1485 \u20109.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 102 \n \u00a0 57.\u00a0\u00a0Veldkamp \u00a0AI,\u00a0Weverling \u00a0GJ,\u00a0Lange\u00a0JM,\u00a0Montaner \u00a0JS,\u00a0Reiss\u00a0P,\u00a0Cooper\u00a0DA\u00a0et\u00a0al.\u00a0High\u00a0exposure\u00a0\nto\u00a0nevirapine \u00a0in\u00a0plasma\u00a0is\u00a0associated \u00a0with\u00a0an\u00a0improved \u00a0virological \u00a0response\u00a0in\u00a0HIV\u20101\u2010infected\u00a0\nindividuals. \u00a0AIDS\u00a02001;\u00a015(9):1089 \u201095.\u00a0\n\u00a0 58.\u00a0\u00a0DiCenzo\u00a0R,\u00a0Forrest\u00a0A,\u00a0Fischl\u00a0MA,\u00a0Collier\u00a0A,\u00a0Feinberg\u00a0J,\u00a0Ribaudo\u00a0H\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0of\u00a0\nindinavir\u00a0and\u00a0nelfinavir \u00a0in\u00a0treatment \u2010naive,\u00a0human\u00a0immunodeficiency \u00a0virus\u2010infected\u00a0subjects.\u00a0\nAntimicrob \u00a0Agents\u00a0Chemother \u00a02004;\u00a048(3):918 \u2010923.\u00a0\n\u00a0 59.\u00a0\u00a0Csajka\u00a0C,\u00a0Marzolini \u00a0C,\u00a0Fattinger\u00a0K,\u00a0Decosterd \u00a0LA,\u00a0Fellay\u00a0J,\u00a0Telenti\u00a0A\u00a0et\u00a0al.\u00a0Population \u00a0pharma\u2010\ncokinetics \u00a0and\u00a0effects\u00a0of\u00a0efavirenz\u00a0in\u00a0patients\u00a0with\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0infection. \u00a0\nClin\u00a0Pharmacol \u00a0Ther\u00a02003;\u00a073(1):20\u201030.\u00a0\n\u00a0 60.\u00a0\u00a0Dieleman \u00a0JP,\u00a0Gyssens\u00a0IC,\u00a0Van\u00a0Der\u00a0Ende\u00a0ME,\u00a0de\u00a0Marie\u00a0S,\u00a0Burger\u00a0DM.\u00a0Urological \u00a0complaints \u00a0in\u00a0\nrelation\u00a0to\u00a0indinavir\u00a0plasma\u00a0concentrations \u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0AIDS\u00a01999;\u00a013(4):473 \u20108.\u00a0\n\u00a0 61.\u00a0\u00a0Gonzalez\u00a0de\u00a0Requena\u00a0D,\u00a0Nunez\u00a0M,\u00a0Jimenez\u2010Nacher\u00a0I,\u00a0Soriano\u00a0V.\u00a0Liver\u00a0toxicity\u00a0caused\u00a0by\u00a0nevi\u2010\nrapine.\u00a0AIDS\u00a02002;\u00a016(2):290 \u20101.\u00a0\n\u00a0 62.\u00a0\u00a0Gonzalez\u2010Requena\u00a0D,\u00a0Nunez\u00a0M,\u00a0Jimenez\u2010Nacher\u00a0I,\u00a0Gonzalez\u2010Lahoz\u00a0J,\u00a0Soriano\u00a0V.\u00a0Short\u00a0com\u2010\nmunication: \u00a0liver\u00a0toxicity\u00a0of\u00a0lopinavir\u2010containing \u00a0regimens\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0or\u00a0\nwithout\u00a0hepatitis\u00a0C\u00a0coinfection. \u00a0AIDS\u00a0Res\u00a0Hum\u00a0Retroviruses \u00a02004;\u00a020(7):698 \u2010700.\u00a0\n\u00a0 63.\u00a0\u00a0Gutierrez \u00a0F,\u00a0Padilla\u00a0S,\u00a0Navarro\u00a0A,\u00a0Masia\u00a0M,\u00a0Hernandez \u00a0I,\u00a0Ramos\u00a0J\u00a0et\u00a0al.\u00a0Lopinavir\u00a0plasma\u00a0con\u2010\ncentrations \u00a0and\u00a0changes\u00a0in\u00a0lipid\u00a0levels\u00a0during\u00a0salvage\u00a0therapy\u00a0with\u00a0lopinavir/ritonavir \u2010\ncontaining \u00a0regimens. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02003;\u00a033(5):594 \u2010600.\u00a0\n\u00a0 64.\u00a0\u00a0Gonzalez\u00a0de\u00a0Requena\u00a0D,\u00a0Blanco\u00a0F,\u00a0Garcia\u2010Benayas\u00a0T,\u00a0Jimenez\u2010Nacher\u00a0I,\u00a0Gonzalez\u2010Lahoz\u00a0J,\u00a0\nSoriano\u00a0V.\u00a0Correlation \u00a0between\u00a0lopinavir\u00a0plasma\u00a0levels\u00a0and\u00a0lipid\u00a0abnormalities \u00a0in\u00a0patients\u00a0ta\u2010\nking\u00a0lopinavir/ritonavir. \u00a0AIDS\u00a0Patient\u00a0Care\u00a0STDS\u00a02003;\u00a017(9):443 \u2010445.\u00a0\n\u00a0 65.\u00a0\u00a0Gallego\u00a0L,\u00a0Barreiro\u00a0P,\u00a0del\u00a0Rio\u00a0R,\u00a0Gonzalez\u00a0de\u00a0Requena\u00a0D,\u00a0Rodriguez \u2010Albarino\u00a0A,\u00a0Gonzalez\u2010\nLahoz\u00a0J\u00a0et\u00a0al.\u00a0Analyzing \u00a0sleep\u00a0abnormalities \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0treated\u00a0with\u00a0Efavirenz. \u00a0\nClin\u00a0Infect\u00a0Dis\u00a02004;\u00a038(3):430 \u2010432.\u00a0\n\u00a0 66.\u00a0\u00a0Gutierrez \u00a0F,\u00a0Navarro\u00a0A,\u00a0Padilla\u00a0S,\u00a0Anton\u00a0R,\u00a0Masia\u00a0M,\u00a0Borras\u00a0J\u00a0et\u00a0al.\u00a0Prediction \u00a0of\u00a0neuropsychia \u2010\ntric\u00a0adverse\u00a0events\u00a0associated \u00a0with\u00a0long\u2010term\u00a0efavirenz\u00a0therapy,\u00a0using\u00a0plasma\u00a0drug\u00a0level\u00a0mo\u2010\nnitoring.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02005;\u00a041(11):1648 \u20101653.\u00a0\n\u00a0 67.\u00a0\u00a0Drake\u00a0JW.\u00a0Rates\u00a0of\u00a0spontaneous \u00a0mutation\u00a0among\u00a0RNA\u00a0viruses.\u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a01993;\u00a0\n90(9):4171 \u20105.\u00a0\n\u00a0 68.\u00a0\u00a0Drake\u00a0JW,\u00a0Charlesworth \u00a0B,\u00a0Charlesworth \u00a0D,\u00a0Crow\u00a0JF.\u00a0Rates\u00a0of\u00a0spontaneous \u00a0mutation. \u00a0Gene\u2010\ntics\u00a01998;\u00a0148(4):1667 \u201086.\u00a0\n\u00a0 69.\u00a0\u00a0Mansky\u00a0LM,\u00a0Temin\u00a0HM.\u00a0Lower\u00a0in\u00a0vivo\u00a0mutation\u00a0rate\u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0\nthan\u00a0that\u00a0predicted \u00a0from\u00a0the\u00a0fidelity\u00a0of\u00a0purified\u00a0reverse\u00a0transcriptase. \u00a0J\u00a0Virol\u00a01995;\u00a0\n69(8):5087 \u201094.\u00a0\n\u00a0 70.\u00a0\u00a0Ho\u00a0DD,\u00a0Neumann \u00a0AU,\u00a0Perelson\u00a0AS,\u00a0Chen\u00a0W,\u00a0Leonard\u00a0JM,\u00a0Markowitz \u00a0M.\u00a0Rapid\u00a0turnover\u00a0of\u00a0\nplasma\u00a0virions\u00a0and\u00a0CD4\u00a0lymphocytes \u00a0in\u00a0HIV\u20101\u00a0infection. \u00a0Nature\u00a01995;\u00a0373(6510):123 \u20106.\u00a0\n\u00a0 71.\u00a0\u00a0Wei\u00a0X,\u00a0Ghosh\u00a0SK,\u00a0Taylor\u00a0ME,\u00a0Johnson\u00a0VA,\u00a0Emini\u00a0EA,\u00a0Deutsch\u00a0P\u00a0et\u00a0al.\u00a0Viral\u00a0dynamics \u00a0in\u00a0human\u00a0\nimmunodeficiency \u00a0virus\u00a0type\u00a01\u00a0infection. \u00a0Nature\u00a01995;\u00a0373(6510):117 \u201022.\u00a0\n\u00a0 72.\u00a0\u00a0Coffin\u00a0JM.\u00a0HIV\u00a0population \u00a0dynamics \u00a0in\u00a0vivo:\u00a0implications \u00a0for\u00a0genetic\u00a0variation, \u00a0pathogenesis, \u00a0\nand\u00a0therapy.\u00a0Science\u00a01995;\u00a0267(5197):483 \u20109.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 103 \n \u00a0 73.\u00a0\u00a0Perelson\u00a0AS,\u00a0Neumann \u00a0AU,\u00a0Markowitz \u00a0M,\u00a0Leonard\u00a0JM,\u00a0Ho\u00a0DD.\u00a0HIV\u20101\u00a0dynamics \u00a0in\u00a0vivo:\u00a0virion\u00a0\nclearance \u00a0rate,\u00a0infected\u00a0cell\u00a0life\u2010span,\u00a0and\u00a0viral\u00a0generation \u00a0time.\u00a0Science\u00a01996;\u00a0\n271(5255):1582 \u20106.\u00a0\n\u00a0 74.\u00a0\u00a0Schuurman \u00a0R,\u00a0Nijhuis\u00a0M,\u00a0van\u00a0Leeuwen\u00a0R,\u00a0Schipper\u00a0P,\u00a0de\u00a0Jong\u00a0D,\u00a0Collis\u00a0P\u00a0et\u00a0al.\u00a0Rapid\u00a0changes\u00a0\nin\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0RNA\u00a0load\u00a0and\u00a0appearance \u00a0of\u00a0drug\u2010resistant\u00a0virus\u00a0\npopulations \u00a0in\u00a0persons\u00a0treated\u00a0with\u00a0lamivudine \u00a0(3TC).\u00a0J\u00a0Infect\u00a0Dis\u00a01995;\u00a0171(6):1411 \u20109.\u00a0\n\u00a0 75.\u00a0\u00a0Molla\u00a0A,\u00a0Korneyeva \u00a0M,\u00a0Gao\u00a0Q,\u00a0Vasavanonda \u00a0S,\u00a0Schipper\u00a0PJ,\u00a0Mo\u00a0HM\u00a0et\u00a0al.\u00a0Ordered\u00a0accumula \u2010\ntion\u00a0of\u00a0mutations \u00a0in\u00a0HIV\u00a0protease\u00a0confers\u00a0resistance \u00a0to\u00a0ritonavir.\u00a0Nat\u00a0Med\u00a01996;\u00a02(7):760\u20106.\u00a0\n\u00a0 76.\u00a0\u00a0Johnson\u00a0VA,\u00a0Brun\u2010Vezinet\u00a0F,\u00a0Clotet\u00a0B,\u00a0Kuritzkes\u00a0DR,\u00a0Pillay\u00a0D,\u00a0Schapiro\u00a0JM\u00a0et\u00a0al.\u00a0Update\u00a0of\u00a0drug\u00a0\nresistance \u00a0mutations \u00a0in\u00a0HIV\u20101:\u00a0Fall\u00a02006.\u00a0Top\u00a0HIV\u00a0Med\u00a02006;\u00a014(3):125 \u2010130.\u00a0\n\u00a0 77.\u00a0\u00a0Devereux \u00a0HL,\u00a0Youle\u00a0M,\u00a0Johnson\u00a0MA,\u00a0Loveday\u00a0C.\u00a0Rapid\u00a0decline\u00a0in\u00a0detectability \u00a0of\u00a0HIV\u20101\u00a0drug\u00a0\nresistance \u00a0mutations \u00a0after\u00a0stopping\u00a0therapy.\u00a0AIDS\u00a01999;\u00a013(18):123 \u20107.\u00a0\n\u00a0 78.\u00a0\u00a0Qari\u00a0SH,\u00a0Respess\u00a0R,\u00a0Weinstock \u00a0H,\u00a0Beltrami\u00a0EM,\u00a0Hertogs\u00a0K,\u00a0Larder\u00a0BA\u00a0et\u00a0al.\u00a0Comparative \u00a0analy\u2010\nsis\u00a0of\u00a0two\u00a0commercial \u00a0phenotypic \u00a0assays\u00a0for\u00a0drug\u00a0susceptibility \u00a0testing\u00a0of\u00a0human\u00a0immunode \u2010\nficiency\u00a0virus\u00a0type\u00a01.\u00a0J\u00a0Clin\u00a0Microbiol \u00a02002;\u00a040(1):31\u201035.\u00a0\n\u00a0 79.\u00a0\u00a0Larder\u00a0BA,\u00a0Kemp\u00a0SD,\u00a0Hertogs\u00a0K.\u00a0Quantitative \u00a0prediction \u00a0of\u00a0HIV\u20101\u00a0phenotypic \u00a0drug\u00a0resistance \u00a0\nfrom\u00a0genotypes: \u00a0the\u00a0virtual\u00a0phenotype \u00a0(VirtualPhenopyte). \u00a0Antivir\u00a0Ther\u00a02000;\u00a05(Suppl\u00a03):49.\u00a0\n\u00a0 80.\u00a0\u00a0Novak\u00a0RM,\u00a0Chen\u00a0L,\u00a0MacArthur \u00a0RD,\u00a0Baxter\u00a0JD,\u00a0Huppler\u00a0HK,\u00a0Peng\u00a0G\u00a0et\u00a0al.\u00a0Prevalence \u00a0of\u00a0antire\u2010\ntroviral\u00a0drug\u00a0resistance \u00a0mutations \u00a0in\u00a0chronically \u00a0HIV\u2010infected,\u00a0treatment \u2010naive\u00a0patients:\u00a0im\u2010\nplications \u00a0for\u00a0routine\u00a0resistance \u00a0screening \u00a0before\u00a0initiation\u00a0of\u00a0antiretroviral \u00a0therapy.\u00a0Clin\u00a0In\u2010\nfect\u00a0Dis\u00a02005;\u00a040(3):468 \u2010474.\u00a0\n\u00a0 81.\u00a0\u00a0Wensing\u00a0AM,\u00a0van\u00a0d,\u00a0V,\u00a0Angarano \u00a0G,\u00a0Asjo\u00a0B,\u00a0Balotta\u00a0C,\u00a0Boeri\u00a0E\u00a0et\u00a0al.\u00a0Prevalence \u00a0of\u00a0drug\u2010\nresistant\u00a0HIV\u20101\u00a0variants\u00a0in\u00a0untreated \u00a0individuals \u00a0in\u00a0Europe:\u00a0implications \u00a0for\u00a0clinical\u00a0manage\u2010\nment.\u00a0J\u00a0Infect\u00a0Dis\u00a02005;\u00a0192(6):958 \u2010966.\u00a0\n\u00a0 82.\u00a0\u00a0Cane\u00a0P,\u00a0Chrystie\u00a0I,\u00a0Dunn\u00a0D,\u00a0Evans\u00a0B,\u00a0Geretti\u00a0AM,\u00a0Green\u00a0H\u00a0et\u00a0al.\u00a0Time\u00a0trends\u00a0in\u00a0primary\u00a0resis\u2010\ntance\u00a0to\u00a0HIV\u00a0drugs\u00a0in\u00a0the\u00a0United\u00a0Kingdom: \u00a0multicentre \u00a0observational \u00a0study.\u00a0BMJ\u00a02005;\u00a0\n331(7529):1368. \u00a0\n\u00a0 83.\u00a0\u00a0de\u00a0Mendoza \u00a0C.,\u00a0Rodriguez \u00a0C,\u00a0Colomina \u00a0J,\u00a0Tuset\u00a0C,\u00a0Garcia\u00a0F,\u00a0Eiros\u00a0JM\u00a0et\u00a0al.\u00a0Resistance \u00a0to\u00a0non\u2010\nnucleoside \u00a0reverse\u2010transcriptase \u00a0inhibitors \u00a0and\u00a0prevalence \u00a0of\u00a0HIV\u00a0type\u00a01\u00a0non\u2010B\u00a0subtypes\u00a0are\u00a0\nincreasing \u00a0among\u00a0persons\u00a0with\u00a0recent\u00a0infection\u00a0in\u00a0Spain.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02005;\u00a041(9):1350 \u2010\n1354.\u00a0\n\u00a0 84.\u00a0\u00a0Palacios\u00a0R,\u00a0Viciana\u00a0I,\u00a0P\u00e9rez\u00a0de\u00a0Pedro\u00a0I,\u00a0De\u00a0la\u00a0TJ,\u00a0Ropero\u00a0F,\u00a0Fern\u00e1ndez \u00a0S\u00a0et\u00a0al.\u00a0Prevalencia \u00a0de\u00a0\nmutaciones \u00a0de\u00a0resistencia \u00a0primaria\u00a0en\u00a0los\u00a0nuevos\u00a0diagn\u00f3sticos \u00a0de\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0en\u00a0la\u00a0\nprovincia\u00a0de\u00a0M\u00e1laga.\u00a0Enferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a02008;\u00a026:141\u2010145.\u00a0\n\u00a0 85.\u00a0\u00a0Sanchez\u2010Onoro\u00a0M.,\u00a0Lopez\u00a0MJ,\u00a0Santana\u00a0MA,\u00a0Andes\u00a0JM,\u00a0Campelo\u00a0FA.\u00a0Resistencias \u00a0primarias \u00a0a\u00a0\nlos\u00a0f\u00e1rmacos\u00a0antirretrovirales \u00a0en\u00a0los\u00a0pacientes \u00a0diagnosticados \u00a0de\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0en\u00a0Gran\u00a0\nCanaria\u00a0entre\u00a02002\u00a0y\u00a02005.\u00a0Enferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a02007;\u00a025(7):437 \u2010440.\u00a0\n\u00a0 86.\u00a0\u00a0Sax\u00a0PE,\u00a0Islam\u00a0R,\u00a0Walensky \u00a0RP,\u00a0Losina\u00a0E,\u00a0Weinstein \u00a0MC,\u00a0Goldie\u00a0SJ\u00a0et\u00a0al.\u00a0Should\u00a0resistance \u00a0tes\u2010\nting\u00a0be\u00a0performed \u00a0for\u00a0treatment \u2010naive\u00a0HIV\u2010infected\u00a0patients? \u00a0A\u00a0cost\u2010effectiveness \u00a0analysis.\u00a0\nClin\u00a0Infect\u00a0Dis\u00a02005;\u00a041(9):1316 \u20101323.\u00a0\n\u00a0 87.\u00a0\u00a0Hecht\u00a0FM,\u00a0Grant\u00a0RM.\u00a0Resistance \u00a0testing\u00a0in\u00a0drug\u2010naive\u00a0HIV\u2010infected\u00a0patients:\u00a0is\u00a0it\u00a0time?\u00a0Clin\u00a0\nInfect\u00a0Dis\u00a02005;\u00a041(9):1324 \u20101325.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 104 \n \u00a0 88.\u00a0\u00a0Geretti\u00a0AM,\u00a0Fox\u00a0ZV,\u00a0Booth\u00a0CL,\u00a0Smith\u00a0CJ,\u00a0Phillips\u00a0AN,\u00a0Johnson\u00a0M\u00a0et\u00a0al.\u00a0Low\u2010frequency \u00a0K103N\u00a0\nstrengthens \u00a0the\u00a0impact\u00a0of\u00a0transmitted \u00a0drug\u00a0resistance \u00a0on\u00a0virologic\u00a0responses \u00a0to\u00a0first\u2010line\u00a0efa\u2010\nvirenz\u00a0or\u00a0nevirapine \u2010based\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a0\n2009;\u00a052(5):569 \u2010573.\u00a0\n\u00a0 89.\u00a0\u00a0Balduin\u00a0M,\u00a0Oette\u00a0M,\u00a0Daumer\u00a0MP,\u00a0Hoffmann \u00a0D,\u00a0Pfister\u00a0HJ,\u00a0Kaiser\u00a0R.\u00a0Prevalence \u00a0of\u00a0minor\u00a0va\u2010\nriants\u00a0of\u00a0HIV\u00a0strains\u00a0at\u00a0reverse\u00a0transcriptase \u00a0position\u00a0103\u00a0in\u00a0therapy\u2010naive\u00a0patients\u00a0and\u00a0their\u00a0\nimpact\u00a0on\u00a0the\u00a0virological \u00a0failure.\u00a0J\u00a0Clin\u00a0Virol\u00a02009;\u00a045(1):34\u201038.\u00a0\n\u00a0 90.\u00a0\u00a0Coovadia\u00a0A,\u00a0Hunt\u00a0G,\u00a0Abrams\u00a0EJ,\u00a0Sherman\u00a0G,\u00a0Meyers\u00a0T,\u00a0Barry\u00a0G\u00a0et\u00a0al.\u00a0Persistent \u00a0minority\u00a0\nK103N\u00a0mutations \u00a0among\u00a0women\u00a0exposed\u00a0to\u00a0single\u2010dose\u00a0nevirapine \u00a0and\u00a0virologic\u00a0response\u00a0to\u00a0\nnonnucleoside \u00a0reverse\u2010transcriptase \u00a0inhibitor\u2010based\u00a0therapy.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02009;\u00a048(4):462 \u2010\n472.\u00a0\n\u00a0 91.\u00a0\u00a0Mitsuya\u00a0Y,\u00a0Varghese \u00a0V,\u00a0Wang\u00a0C,\u00a0Liu\u00a0TF,\u00a0Holmes\u00a0SP,\u00a0Jayakumar \u00a0P\u00a0et\u00a0al.\u00a0Minority\u00a0human\u00a0immu\u2010\nnodeficiency \u00a0virus\u00a0type\u00a01\u00a0variants\u00a0in\u00a0antiretroviral \u2010naive\u00a0persons\u00a0with\u00a0reverse\u00a0transcriptase \u00a0\ncodon\u00a0215\u00a0revertant \u00a0mutations. \u00a0J\u00a0Virol\u00a02008;\u00a082(21):10747 \u201010755.\u00a0\n\u00a0 92.\u00a0\u00a0Johnson\u00a0JA,\u00a0Li\u00a0JF,\u00a0Wei\u00a0X,\u00a0Lipscomb \u00a0J,\u00a0Irlbeck\u00a0D,\u00a0Craig\u00a0C\u00a0et\u00a0al.\u00a0Minority\u00a0HIV\u20101\u00a0drug\u00a0resistance \u00a0\nmutations \u00a0are\u00a0present\u00a0in\u00a0antiretroviral \u00a0treatment \u2010naive\u00a0populations \u00a0and\u00a0associate\u00a0with\u00a0redu\u2010\nced\u00a0treatment \u00a0efficacy.\u00a0PLoS\u00a0Med\u00a02008;\u00a05(7):e158. \u00a0\n\u00a0 93.\u00a0\u00a0Peuchant \u00a0O,\u00a0Thiebaut\u00a0R,\u00a0Capdepont \u00a0S,\u00a0Lavignolle \u2010Aurillac\u00a0V,\u00a0Neau\u00a0D,\u00a0Morlat\u00a0P\u00a0et\u00a0al.\u00a0Transmis\u2010\nsion\u00a0of\u00a0HIV\u20101\u00a0minority\u2010resistant\u00a0variants\u00a0and\u00a0response\u00a0to\u00a0first\u2010line\u00a0antiretroviral \u00a0therapy.\u00a0AIDS\u00a0\n2008;\u00a022(12):1417 \u20101423.\u00a0\n\u00a0 94.\u00a0\u00a0Simen\u00a0BB,\u00a0Simons\u00a0JF,\u00a0Hullsiek\u00a0KH,\u00a0Novak\u00a0RM,\u00a0MacArthur \u00a0RD,\u00a0Baxter\u00a0JD\u00a0et\u00a0al.\u00a0Low\u2010abundance \u00a0\ndrug\u2010resistant\u00a0viral\u00a0variants\u00a0in\u00a0chronically \u00a0HIV\u2010infected,\u00a0antiretroviral \u00a0treatment \u2010naive\u00a0pa\u2010\ntients\u00a0significantly \u00a0impact\u00a0treatment \u00a0outcomes. \u00a0J\u00a0Infect\u00a0Dis\u00a02009;\u00a0199(5):693 \u2010701.\u00a0\n\u00a0 95.\u00a0\u00a0Metzner\u00a0KJ,\u00a0Giulieri\u00a0SG,\u00a0Knoepfel\u00a0SA,\u00a0Rauch\u00a0P,\u00a0Burgisser\u00a0P,\u00a0Yerly\u00a0S\u00a0et\u00a0al.\u00a0Minority\u00a0quasispecies \u00a0\nof\u00a0drug\u2010resistant\u00a0HIV\u20101\u00a0that\u00a0lead\u00a0to\u00a0early\u00a0therapy\u00a0failure\u00a0in\u00a0treatment \u2010naive\u00a0and\u00a0\u2010adherent\u00a0\npatients.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02009;\u00a048(2):239 \u2010247.\u00a0\n\u00a0 96.\u00a0\u00a0Havlir\u00a0DV,\u00a0Marschner \u00a0IC,\u00a0Hirsch\u00a0MS,\u00a0Collier\u00a0AC,\u00a0Tebas\u00a0P,\u00a0Bassett\u00a0RL\u00a0et\u00a0al.\u00a0Maintenance \u00a0antire\u2010\ntroviral\u00a0therapies \u00a0in\u00a0HIV\u00a0infected\u00a0patients\u00a0with\u00a0undetectable \u00a0plasma\u00a0HIV\u00a0RNA\u00a0after\u00a0triple\u2010drug\u00a0\ntherapy.\u00a0AIDS\u00a0Clinical\u00a0Trials\u00a0Group\u00a0Study\u00a0343\u00a0Team.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a01998;\u00a0339(18):1261 \u20101268.\u00a0\n\u00a0 97.\u00a0\u00a0Huisman\u00a0MT,\u00a0Smit\u00a0JW,\u00a0Schinkel\u00a0AH.\u00a0Significance \u00a0of\u00a0P\u2010glycoprotein \u00a0for\u00a0the\u00a0pharmacology \u00a0and\u00a0\nclinical\u00a0use\u00a0of\u00a0HIV\u00a0protease\u00a0inhibitors. \u00a0AIDS\u00a02000;\u00a014(3):237 \u201042.\u00a0\n\u00a0 98.\u00a0\u00a0Baxter\u00a0JD,\u00a0Mayers\u00a0DL,\u00a0Wentworth \u00a0DN,\u00a0Neaton\u00a0JD,\u00a0Hoover\u00a0ML,\u00a0Winters\u00a0MA\u00a0et\u00a0al.\u00a0A\u00a0randomi\u2010\nzed\u00a0study\u00a0of\u00a0antiretroviral \u00a0management \u00a0based\u00a0on\u00a0plasma\u00a0genotypic \u00a0antiretroviral \u00a0resistance \u00a0\ntesting\u00a0in\u00a0patients\u00a0failing\u00a0therapy.\u00a0CPCRA\u00a0046\u00a0Study\u00a0Team\u00a0for\u00a0the\u00a0Terry\u00a0Beirn\u00a0Community \u00a0\nPrograms \u00a0for\u00a0Clinical\u00a0Research\u00a0on\u00a0AIDS.\u00a0AIDS\u00a02000;\u00a014(9):83\u201093.\u00a0\n\u00a0 99.\u00a0\u00a0Clevenbergh \u00a0P,\u00a0Durant\u00a0J,\u00a0Halfon\u00a0P,\u00a0del\u00a0Giudice\u00a0P,\u00a0Mondain\u00a0V,\u00a0Montagne \u00a0N\u00a0et\u00a0al.\u00a0Persisting \u00a0\nlong\u2010term\u00a0benefit\u00a0of\u00a0genotype \u2010guided\u00a0treatment \u00a0for\u00a0HIV\u2010infected\u00a0patients\u00a0failing\u00a0HAART.\u00a0The\u00a0\nViradapt\u00a0Study:\u00a0week\u00a048\u00a0follow\u2010up.\u00a0Antivir\u00a0Ther\u00a02000;\u00a05(1):65\u201070.\u00a0\n\u00a0 100.\u00a0\u00a0Tural\u00a0C,\u00a0Ruiz\u00a0L,\u00a0Holtzer\u00a0C,\u00a0Schapiro\u00a0J,\u00a0Viciana\u00a0P,\u00a0Gonzalez\u00a0J\u00a0et\u00a0al.\u00a0Clinical\u00a0utility\u00a0of\u00a0HIV\u20101\u00a0geno\u2010\ntyping\u00a0and\u00a0expert\u00a0advice:\u00a0the\u00a0Havana\u00a0trial.\u00a0AIDS\u00a02002;\u00a016(2):209 \u2010218.\u00a0\n\u00a0 101.\u00a0\u00a0Cohen\u00a0CJ,\u00a0Hunt\u00a0S,\u00a0Sension\u00a0M,\u00a0Farthing\u00a0C,\u00a0Conant\u00a0M,\u00a0Jacobson\u00a0S\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0trial\u00a0as\u2010\nsessing\u00a0the\u00a0impact\u00a0of\u00a0phenotypic \u00a0resistance \u00a0testing\u00a0on\u00a0antiretroviral \u00a0therapy.\u00a0AIDS\u00a02002;\u00a0\n16(4):579 \u201088.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 105 \n \u00a0 102.\u00a0\u00a0Cingolani\u00a0A,\u00a0Antinori\u00a0A,\u00a0Rizzo\u00a0MG,\u00a0Murri\u00a0R,\u00a0Ammassari \u00a0A,\u00a0Baldini\u00a0F\u00a0et\u00a0al.\u00a0Usefulness \u00a0of\u00a0moni\u2010\ntoring\u00a0HIV\u00a0drug\u00a0resistance \u00a0and\u00a0adherence \u00a0in\u00a0individuals \u00a0failing\u00a0highly\u00a0active\u00a0antiretroviral \u00a0the\u2010\nrapy:\u00a0a\u00a0randomized \u00a0study\u00a0(ARGENTA). \u00a0AIDS\u00a02002;\u00a016(3):369 \u201079.\u00a0\n\u00a0 103.\u00a0\u00a0Kemper\u00a0CA,\u00a0Witt\u00a0MD,\u00a0Keiser\u00a0PH,\u00a0Dube\u00a0MP,\u00a0Forthal\u00a0DN,\u00a0Leibowitz \u00a0M\u00a0et\u00a0al.\u00a0Sequencing \u00a0of\u00a0pro\u2010\ntease\u00a0inhibitor\u00a0therapy:\u00a0insights\u00a0from\u00a0an\u00a0analysis\u00a0of\u00a0HIV\u00a0phenotypic \u00a0resistance \u00a0in\u00a0patients\u00a0fai\u2010\nling\u00a0protease\u00a0inhibitors. \u00a0AIDS\u00a02001;\u00a015(5):609 \u201015.\u00a0\n\u00a0 104.\u00a0\u00a0Meynard\u00a0JL,\u00a0Vray\u00a0M,\u00a0Morand\u2010Joubert\u00a0L,\u00a0Race\u00a0E,\u00a0Descamps \u00a0D,\u00a0Peytavin\u00a0G\u00a0et\u00a0al.\u00a0Phenotypic \u00a0or\u00a0\ngenotypic \u00a0resistance \u00a0testing\u00a0for\u00a0choosing\u00a0antiretroviral \u00a0therapy\u00a0after\u00a0treatment \u00a0failure:\u00a0a\u00a0\nrandomized \u00a0trial.\u00a0AIDS\u00a02002;\u00a016(5):727 \u201036.\u00a0\n\u00a0 105.\u00a0\u00a0Mazzotta \u00a0F,\u00a0Lo\u00a0CS,\u00a0Torti\u00a0C,\u00a0Tinelli\u00a0C,\u00a0Pierotti\u00a0P,\u00a0Castelli\u00a0F\u00a0et\u00a0al.\u00a0Real\u00a0versus\u00a0virtual\u00a0phenotype \u00a0to\u00a0\nguide\u00a0treatment \u00a0in\u00a0heavily\u00a0pretreated \u00a0patients:\u00a048\u2010week\u00a0follow\u2010up\u00a0of\u00a0the\u00a0Genotipo \u2010Fenotipo\u00a0\ndi\u00a0Resistenza \u00a0(GenPheRex) \u00a0trial.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02003;\u00a032(3):268 \u2010280.\u00a0\n\u00a0 106.\u00a0\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Garcia\u2010Arota\u00a0I,\u00a0Munoz\u00a0V,\u00a0Santos\u00a0I,\u00a0Sanz\u00a0J,\u00a0Abraira\u00a0V\u00a0et\u00a0al.\u00a0Phenotype \u00a0or\u00a0virtual\u00a0\nphenotype \u00a0for\u00a0choosing\u00a0antiretroviral \u00a0therapy\u00a0after\u00a0failure:\u00a0a\u00a0prospective, \u00a0randomized \u00a0study.\u00a0\nAntivir\u00a0Ther\u00a02003;\u00a08(6):577\u2010584.\u00a0\n\u00a0 107.\u00a0\u00a0Torre\u00a0D,\u00a0Tambini\u00a0R.\u00a0Antiretroviral \u00a0drug\u00a0resistance \u00a0testing\u00a0in\u00a0patients\u00a0with\u00a0HIV\u20101\u00a0infection: \u00a0A\u00a0\nmeta\u2010analysis\u00a0study.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02002;\u00a03(1):1\u20108.\u00a0\n\u00a0 108.\u00a0\u00a0Hughes\u00a0CA,\u00a0Foisy\u00a0MM,\u00a0Dewhurst \u00a0N,\u00a0Higgins\u00a0N,\u00a0Robinson \u00a0L,\u00a0Kelly\u00a0DV\u00a0et\u00a0al.\u00a0Abacavir\u00a0hypersen \u2010\nsitivity\u00a0reaction:\u00a0an\u00a0update.\u00a0Ann\u00a0Pharmacother \u00a02008;\u00a042(3):387 \u2010396.\u00a0\n\u00a0 109.\u00a0\u00a0Mallal\u00a0S,\u00a0Phillips\u00a0E,\u00a0Carosi\u00a0G,\u00a0Molina\u00a0JM,\u00a0Workman \u00a0C,\u00a0Tomazic\u00a0J\u00a0et\u00a0al.\u00a0HLA\u2010B*5701\u00a0screening \u00a0\nfor\u00a0hypersensitivity \u00a0to\u00a0abacavir.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02008;\u00a0358(6):568 \u2010579.\u00a0\n\u00a0 110.\u00a0\u00a0Saag\u00a0M,\u00a0Balu\u00a0R,\u00a0Phillips\u00a0E,\u00a0Brachman \u00a0P,\u00a0Martorell \u00a0C,\u00a0Burman\u00a0W\u00a0et\u00a0al.\u00a0High\u00a0sensitivity \u00a0of\u00a0\nhuman\u00a0leukocyte \u00a0antigen\u2010b*5701\u00a0as\u00a0a\u00a0marker\u00a0for\u00a0immunologically \u00a0confirmed \u00a0abacavir\u00a0hyper\u2010\nsensitivity \u00a0in\u00a0white\u00a0and\u00a0black\u00a0patients.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02008;\u00a046(7):1111 \u20101118.\u00a0\n\u00a0 111.\u00a0\u00a0Moore\u00a0JP,\u00a0Kitchen\u00a0SG,\u00a0Pugach\u00a0P,\u00a0Zack\u00a0JA.\u00a0The\u00a0CCR5\u00a0and\u00a0CXCR4\u00a0coreceptors \u2010\u2010central\u00a0to\u00a0un\u2010\nderstanding \u00a0the\u00a0transmission \u00a0and\u00a0pathogenesis \u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0in\u2010\nfection.\u00a0AIDS\u00a0Res\u00a0Hum\u00a0Retroviruses \u00a02004;\u00a020(1):111 \u2010126.\u00a0\n\u00a0 112.\u00a0\u00a0Connor\u00a0RI,\u00a0Sheridan\u00a0KE,\u00a0Ceradini\u00a0D,\u00a0Choe\u00a0S,\u00a0Landau\u00a0NR.\u00a0Change\u00a0in\u00a0coreceptor \u00a0use\u00a0coreceptor \u00a0\nuse\u00a0correlates \u00a0with\u00a0disease\u00a0progression \u00a0in\u00a0HIV\u20101\u2010\u2010infected\u00a0individuals. \u00a0J\u00a0Exp\u00a0Med\u00a01997;\u00a0\n185(4):621 \u2010628.\u00a0\n\u00a0 113.\u00a0\u00a0Hunt\u00a0PW,\u00a0Harrigan\u00a0PR,\u00a0Huang\u00a0W,\u00a0Bates\u00a0M,\u00a0Williamson \u00a0DW,\u00a0McCune\u00a0JM\u00a0et\u00a0al.\u00a0Prevalence \u00a0of\u00a0\nCXCR4\u00a0tropism\u00a0among\u00a0antiretroviral \u2010treated\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0with\u00a0detectable \u00a0viremia.\u00a0\nJ\u00a0Infect\u00a0Dis\u00a02006;\u00a0194(7):926 \u2010930.\u00a0\n\u00a0 114.\u00a0\u00a0Wilkin\u00a0TJ,\u00a0Su\u00a0Z,\u00a0Kuritzkes\u00a0DR,\u00a0Hughes\u00a0M,\u00a0Flexner\u00a0C,\u00a0Gross\u00a0R\u00a0et\u00a0al.\u00a0HIV\u00a0type\u00a01\u00a0chemokine \u00a0core\u2010\nceptor\u00a0use\u00a0among\u00a0antiretroviral \u2010experienced \u00a0patients\u00a0screened\u00a0for\u00a0a\u00a0clinical\u00a0trial\u00a0of\u00a0a\u00a0CCR5\u00a0\ninhibitor:\u00a0AIDS\u00a0Clinical\u00a0Trial\u00a0Group\u00a0A5211.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02007;\u00a044(4):591 \u2010595.\u00a0\n\u00a0 115.\u00a0\u00a0Whitcomb \u00a0JM,\u00a0Huang\u00a0W,\u00a0Fransen\u00a0S,\u00a0Limoli\u00a0K,\u00a0Toma\u00a0J,\u00a0Wrin\u00a0T\u00a0et\u00a0al.\u00a0Development \u00a0and\u00a0charac\u2010\nterization \u00a0of\u00a0a\u00a0novel\u00a0single\u2010cycle\u00a0recombinant \u2010virus\u00a0assay\u00a0to\u00a0determine \u00a0human\u00a0immunodefi \u2010\nciency\u00a0virus\u00a0type\u00a01\u00a0coreceptor \u00a0tropism.\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02007;\u00a051(2):566 \u2010575.\u00a0\n\u00a0 116.\u00a0\u00a0Reeves\u00a0J,\u00a0Han\u00a0D,\u00a0Wilkin\u00a0T,\u00a0Wrin\u00a0T,\u00a0Kuritzkes\u00a0DR,\u00a0Petropoulos \u00a0C\u00a0et\u00a0al.\u00a0Enhanced \u00a0Version\u00a0of\u00a0the\u00a0\nTrofile\u00a0HIV\u00a0Co\u2010receptor\u00a0Tropism\u00a0Assay\u00a0Predicts\u00a0Emergence \u00a0of\u00a0CXCR4\u00a0Use\u00a0in\u00a0ACTG5211 \u00a0Vicrivi\u2010\nroc\u00a0Trial\u00a0Samples.\u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a0\n2008;\u00a0Boston,\u00a0Massachusetts \u00a0Abstract\u00a0869\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 106 \n \u00a0 117.\u00a0\u00a0Stekler\u00a0J,\u00a0Collier\u00a0A.\u00a0Treatment \u00a0of\u00a0primary\u00a0HIV.\u00a0Curr\u00a0Infect\u00a0Dis\u00a0Rep\u00a02002;\u00a04(1):81\u201087.\u00a0\n\u00a0 118.\u00a0\u00a0Pilcher\u00a0CD,\u00a0Eron\u00a0JJ,\u00a0Jr.,\u00a0Galvin\u00a0S,\u00a0Gay\u00a0C,\u00a0Cohen\u00a0MS.\u00a0Acute\u00a0HIV\u00a0revisited: \u00a0new\u00a0opportunities \u00a0for\u00a0\ntreatment \u00a0and\u00a0prevention. \u00a0J\u00a0Clin\u00a0Invest\u00a02004;\u00a0113(7):937 \u2010945.\u00a0\n\u00a0 119.\u00a0\u00a0Kassutto\u00a0S,\u00a0Rosenberg \u00a0E.\u00a0Primary\u00a0HIV\u00a0Type\u00a01\u00a0Infection. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02004;\u00a038:1452\u20101458.\u00a0\n\u00a0 120.\u00a0\u00a0Weintrob \u00a0AC,\u00a0Giner\u00a0J,\u00a0Menezes\u00a0P,\u00a0Patrick\u00a0E,\u00a0Benjamin \u00a0DK,\u00a0Jr.,\u00a0Lennox\u00a0J\u00a0et\u00a0al.\u00a0Infrequent \u00a0dia\u2010\ngnosis\u00a0of\u00a0primary\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0infection: \u00a0missed\u00a0opportunities \u00a0in\u00a0acute\u00a0ca\u2010\nre\u00a0settings.\u00a0Arch\u00a0Intern\u00a0Med\u00a02003;\u00a0163(17):2097 \u20102100.\u00a0\n\u00a0 121.\u00a0\u00a0Miro\u00a0JM,\u00a0Sued\u00a0O,\u00a0Plana\u00a0M,\u00a0Pumarola \u00a0T,\u00a0Gallart\u00a0T.\u00a0Avances\u00a0en\u00a0el\u00a0diagn\u00f3stico \u00a0y\u00a0tratamiento \u00a0de\u00a0\nla\u00a0infecci\u00f3n\u00a0aguda\u00a0por\u00a0el\u00a0VIH\u20101.\u00a0Enferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a02004;\u00a022(10):643 \u2010659.\u00a0\n\u00a0 122.\u00a0\u00a0Lindback\u00a0S,\u00a0Thorstensson \u00a0R,\u00a0Karlsson\u00a0AC,\u00a0von\u00a0Sydow\u00a0M,\u00a0Flamholc\u00a0L,\u00a0Blaxhult\u00a0A\u00a0et\u00a0al.\u00a0Diagnosis \u00a0\nof\u00a0primary\u00a0HIV\u20101\u00a0infection\u00a0and\u00a0duration\u00a0of\u00a0follow\u2010up\u00a0after\u00a0HIV\u00a0exposure. \u00a0Karolinska \u00a0Institute\u00a0\nPrimary\u00a0HIV\u00a0Infection\u00a0Study\u00a0Group.\u00a0AIDS\u00a02000;\u00a014(15):2333 \u20109.\u00a0\n\u00a0 123.\u00a0\u00a0Daar\u00a0ES,\u00a0Little\u00a0S,\u00a0Pitt\u00a0J,\u00a0Santangelo \u00a0J,\u00a0Ho\u00a0P,\u00a0Harawa\u00a0N\u00a0et\u00a0al.\u00a0Diagnosis \u00a0of\u00a0primary\u00a0HIV\u20101\u00a0infec\u2010\ntion.\u00a0Los\u00a0Angeles\u00a0County\u00a0Primary\u00a0HIV\u00a0Infection\u00a0Recruitment \u00a0Network. \u00a0Ann\u00a0Intern\u00a0Med\u00a02001;\u00a0\n134(1):25 \u20109.\u00a0\n\u00a0 124.\u00a0\u00a0Lavreys\u00a0L,\u00a0Baeten\u00a0JM,\u00a0Chohan\u00a0V,\u00a0McClelland \u00a0RS,\u00a0Hassan\u00a0WM,\u00a0Richardson \u00a0BA\u00a0et\u00a0al.\u00a0Higher\u00a0set\u00a0\npoint\u00a0plasma\u00a0viral\u00a0load\u00a0and\u00a0more\u2010severe\u00a0acute\u00a0HIV\u00a0type\u00a01\u00a0(HIV\u20101)\u00a0illness\u00a0predict\u00a0mortality\u00a0\namong\u00a0high\u2010risk\u00a0HIV\u20101\u2010infected\u00a0African\u00a0women.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02006;\u00a042(9):1333 \u20101339.\u00a0\n\u00a0 125.\u00a0\u00a0Goujard\u00a0C,\u00a0Bonarek\u00a0M,\u00a0Meyer\u00a0L,\u00a0Bonnet\u00a0F,\u00a0Chaix\u00a0ML,\u00a0Deveau\u00a0C\u00a0et\u00a0al.\u00a0CD4\u00a0cell\u00a0count\u00a0and\u00a0HIV\u00a0\nDNA\u00a0level\u00a0are\u00a0independent \u00a0predictors \u00a0of\u00a0disease\u00a0progression \u00a0after\u00a0primary\u00a0HIV\u00a0type\u00a01\u00a0infec\u2010\ntion\u00a0in\u00a0untreated \u00a0patients.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02006;\u00a042(5):709 \u2010715.\u00a0\n\u00a0 126.\u00a0\u00a0Fidler\u00a0S,\u00a0Fox\u00a0J,\u00a0Porter\u00a0K,\u00a0Weber\u00a0J.\u00a0Primary\u00a0HIV\u00a0infection: \u00a0to\u00a0treat\u00a0or\u00a0not\u00a0to\u00a0treat?\u00a0Curr\u00a0Opin\u00a0\nInfect\u00a0Dis\u00a02008;\u00a021(1):4\u201010.\u00a0\n\u00a0 127.\u00a0\u00a0Altfeld\u00a0M,\u00a0Rosenberg \u00a0ES,\u00a0Shankarappa \u00a0R,\u00a0Mukherjee \u00a0JS,\u00a0Hecht\u00a0FM,\u00a0Eldridge\u00a0RL\u00a0et\u00a0al.\u00a0Cellular\u00a0\nimmune\u00a0responses \u00a0and\u00a0viral\u00a0diversity\u00a0in\u00a0individuals \u00a0treated\u00a0during\u00a0acute\u00a0and\u00a0early\u00a0HIV\u20101\u00a0in\u2010\nfection.\u00a0J\u00a0Exp\u00a0Med\u00a02001;\u00a0193(2):169 \u201080.\u00a0\n\u00a0 128.\u00a0\u00a0Cohen\u00a0DE,\u00a0Walker\u00a0BD.\u00a0Human\u00a0immunodeficiency \u00a0virus\u00a0pathogenesis \u00a0and\u00a0prospects \u00a0for\u00a0im\u2010\nmune\u00a0control\u00a0in\u00a0patients\u00a0with\u00a0established \u00a0infection. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02001;\u00a032(12):1756 \u201068.\u00a0\n\u00a0 129.\u00a0\u00a0Oxenius\u00a0A,\u00a0Yerly\u00a0S,\u00a0Ramirez\u00a0E,\u00a0Phillips\u00a0RE,\u00a0Price\u00a0DA,\u00a0Perrin\u00a0L.\u00a0Distribution \u00a0of\u00a0functional \u00a0HIV\u2010\nspecific\u00a0CD8\u00a0T\u00a0lymphocytes \u00a0between\u00a0blood\u00a0and\u00a0secondary \u00a0lymphoid \u00a0organs\u00a0after\u00a08\u201018\u00a0\nmonths\u00a0of\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0acutely\u00a0infected\u00a0patients.\u00a0AIDS\u00a02001;\u00a015(13):1653 \u20106.\u00a0\n\u00a0 130.\u00a0\u00a0Oxenius\u00a0A,\u00a0Fidler\u00a0S,\u00a0Brady\u00a0M,\u00a0Dawson\u00a0SJ,\u00a0Ruth\u00a0K,\u00a0Easterbrook \u00a0PJ\u00a0et\u00a0al.\u00a0Variable\u00a0fate\u00a0of\u00a0virus\u2010\nspecific\u00a0CD4(+)\u00a0T\u00a0cells\u00a0during\u00a0primary\u00a0HIV\u20101\u00a0infection. \u00a0Eur\u00a0J\u00a0Immunol\u00a02001;\u00a031(12):3782 \u20108.\u00a0\n\u00a0 131.\u00a0\u00a0Rosenberg \u00a0ES,\u00a0Altfeld\u00a0M,\u00a0Poon\u00a0SH,\u00a0Phillips\u00a0MN,\u00a0Wilkes\u00a0BM,\u00a0Eldridge\u00a0RL\u00a0et\u00a0al.\u00a0Immune\u00a0control\u00a0\nof\u00a0HIV\u20101\u00a0after\u00a0early\u00a0treatment \u00a0of\u00a0acute\u00a0infection. \u00a0Nature\u00a02000;\u00a0407(6803):523 \u20106.\u00a0\n\u00a0 132.\u00a0\u00a0Mehandru \u00a0S,\u00a0Poles\u00a0MA,\u00a0Tenner\u2010Racz\u00a0K,\u00a0Jean\u2010Pierre\u00a0P,\u00a0Manuelli\u00a0V,\u00a0Lopez\u00a0P\u00a0et\u00a0al.\u00a0Lack\u00a0of\u00a0muco\u2010\nsal\u00a0immune\u00a0reconstitution \u00a0during\u00a0prolonged \u00a0treatment \u00a0of\u00a0acute\u00a0and\u00a0early\u00a0HIV\u20101\u00a0infection. \u00a0\nPLoS\u00a0Med\u00a02006;\u00a03(12):e484. \u00a0\n\u00a0 133.\u00a0\u00a0Smith\u00a0DE,\u00a0Walker\u00a0BD,\u00a0Cooper\u00a0DA,\u00a0Rosenberg \u00a0ES,\u00a0Kaldor\u00a0JM.\u00a0Is\u00a0antiretroviral \u00a0treatment \u00a0of\u00a0\nprimary\u00a0HIV\u00a0infection\u00a0clinically\u00a0justified\u00a0on\u00a0the\u00a0basis\u00a0of\u00a0current\u00a0evidence? \u00a0AIDS\u00a02004;\u00a0\n18(5):709 \u2010718.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 107 \n \u00a0 134.\u00a0\u00a0Kinloch\u2010de\u00a0LS.\u00a0Treatment \u00a0of\u00a0acute\u00a0HIV\u20101\u00a0infection: \u00a0is\u00a0it\u00a0coming\u00a0of\u00a0age?\u00a0J\u00a0Infect\u00a0Dis\u00a02006;\u00a0\n194(6):721 \u2010724.\u00a0\n\u00a0 135.\u00a0\u00a0Voirin\u00a0N,\u00a0Smith\u00a0D,\u00a0Routy\u00a0JP,\u00a0Legault\u00a0M,\u00a0Baratin\u00a0D,\u00a0Trepo\u00a0C\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0treatment \u00a0during\u00a0\nversus\u00a0after\u00a0acute\u00a0retroviral \u00a0syndrome \u00a0on\u00a0HIV\u00a0viral\u00a0load\u00a0and\u00a0CD4\u00a0cell\u00a0counts\u00a0within\u00a03\u00a0years\u00a0of\u00a0\ninfection. \u00a011th\u00a0Conference \u00a0on\u00a0Retrovirus \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0Februa\u2010\nry\u00a08\u2010\u201011,\u00a02004\u00a0[Abstract\u00a023]\u00a0\n\u00a0 136.\u00a0\u00a0Kassutto\u00a0S,\u00a0Maghsoudi \u00a0K,\u00a0Johnston\u00a0MN,\u00a0Robbins\u00a0GK,\u00a0Burgett\u00a0NC,\u00a0Sax\u00a0PE\u00a0et\u00a0al.\u00a0Longitudinal \u00a0\nanalysis\u00a0of\u00a0clinical\u00a0markers\u00a0following\u00a0antiretroviral \u00a0therapy\u00a0initiated\u00a0during\u00a0acute\u00a0or\u00a0early\u00a0HIV\u00a0\ntype\u00a01\u00a0infection. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02006;\u00a042(7):1024 \u20101031.\u00a0\n\u00a0 137.\u00a0\u00a0Sued\u00a0O,\u00a0Miro\u00a0JM,\u00a0Alquezar\u00a0A,\u00a0Claramonte \u00a0X,\u00a0Garcia\u00a0F,\u00a0Plana\u00a0M\u00a0et\u00a0al.\u00a0Primary\u00a0human\u00a0immuno\u2010\ndeficiency \u00a0virus\u00a0type\u00a01\u00a0infection: \u00a0clinical,\u00a0virological \u00a0and\u00a0immunological \u00a0characteristics \u00a0of\u00a075\u00a0\npatients\u00a0(1997\u20102003).\u00a0Enferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a02006;\u00a024(4):238 \u2010244.\u00a0\n\u00a0 138.\u00a0\u00a0Fidler\u00a0S,\u00a0Oxenius\u00a0A,\u00a0Brady\u00a0M,\u00a0Clarke\u00a0J,\u00a0Cropley\u00a0I,\u00a0Babiker\u00a0A\u00a0et\u00a0al.\u00a0Virological \u00a0and\u00a0immunologi \u2010\ncal\u00a0effects\u00a0of\u00a0short\u00a0course\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0primary\u00a0HIV\u00a0infection. \u00a0AIDS\u00a02002;\u00a0\n16:2049\u20102054.\u00a0\n\u00a0 139.\u00a0\u00a0Fidler\u00a0S,\u00a0Fraser\u00a0C,\u00a0Fox\u00a0J,\u00a0Tamm\u00a0N,\u00a0Griffin\u00a0JT,\u00a0Weber\u00a0J.\u00a0Comparative \u00a0potency\u00a0of\u00a0three\u00a0antiretro\u2010\nviral\u00a0therapy\u00a0regimes\u00a0in\u00a0primary\u00a0HIV\u00a0infection. \u00a0AIDS\u00a02006;\u00a020(2):247 \u2010252.\u00a0\n\u00a0 140.\u00a0\u00a0Apuzzo\u00a0LG,\u00a0Vaida\u00a0F,\u00a0Gallant\u00a0JE,\u00a0Ernstrom \u00a0KB,\u00a0Little\u00a0SJ,\u00a0Routy\u00a0JP\u00a0et\u00a0al.\u00a0Tolerability \u00a0and\u00a0efficacy\u00a0\nof\u00a0PI\u00a0versus\u00a0NNRTI\u2010based\u00a0regimens\u00a0in\u00a0subjects\u00a0receiving\u00a0HAART\u00a0during\u00a0acute\u00a0or\u00a0early\u00a0HIV\u00a0in\u2010\nfection.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a050(3):267 \u2010275.\u00a0\n\u00a0 141.\u00a0\u00a0Markowitz \u00a0M,\u00a0Mohri\u00a0H,\u00a0Mehandru \u00a0S,\u00a0Shet\u00a0A,\u00a0Berry\u00a0L,\u00a0Kalyanaraman \u00a0R\u00a0et\u00a0al.\u00a0Infection\u00a0with\u00a0\nmultidrug \u00a0resistant, \u00a0dual\u2010tropic\u00a0HIV\u20101\u00a0and\u00a0rapid\u00a0progression \u00a0to\u00a0AIDS:\u00a0a\u00a0case\u00a0report.\u00a0Lancet\u00a0\n2005;\u00a0365(9464):1031 \u20101038.\u00a0\n\u00a0 142.\u00a0\u00a0Gottlieb\u00a0GS,\u00a0Nickle\u00a0DC,\u00a0Jensen\u00a0MA,\u00a0Wong\u00a0KG,\u00a0Grobler\u00a0J,\u00a0Li\u00a0F\u00a0et\u00a0al.\u00a0Dual\u00a0HIV\u20101\u00a0infection\u00a0asso\u2010\nciated\u00a0with\u00a0rapid\u00a0disease\u00a0progression. \u00a0Lancet\u00a02004;\u00a0363(9409):619 \u2010622.\u00a0\n\u00a0 143.\u00a0\u00a0Dalmau\u00a0J,\u00a0Puertas\u00a0MC,\u00a0Azuara\u00a0M,\u00a0Marino\u00a0A,\u00a0Frahm\u00a0N,\u00a0Mothe\u00a0B\u00a0et\u00a0al.\u00a0Contribution \u00a0of\u00a0immu\u2010\nnological\u00a0and\u00a0virological \u00a0factors\u00a0to\u00a0extremely \u00a0severe\u00a0primary\u00a0HIV\u00a0type\u00a01\u00a0infection. \u00a0Clin\u00a0Infect\u00a0\nDis\u00a02009;\u00a048(2):229 \u2010238.\u00a0\n\u00a0 144.\u00a0\u00a0Chaix\u00a0ML,\u00a0Descamps \u00a0D,\u00a0Wirden\u00a0M,\u00a0Bocket\u00a0L,\u00a0Delaugerre \u00a0C,\u00a0Tamalet\u00a0C\u00a0et\u00a0al.\u00a0Stable\u00a0frequency \u00a0\nof\u00a0HIV\u20101\u00a0transmitted \u00a0drug\u00a0resistance \u00a0in\u00a0patients\u00a0at\u00a0the\u00a0time\u00a0of\u00a0primary\u00a0infection\u00a0over\u00a01996\u2010\n2006\u00a0in\u00a0France.\u00a0AIDS\u00a02009;\u00a023(6):717 \u2010724.\u00a0\n\u00a0 145.\u00a0\u00a0Goujard\u00a0C,\u00a0Boufassa\u00a0F,\u00a0Deveau\u00a0C,\u00a0Laskri\u00a0D,\u00a0Meyer\u00a0L.\u00a0Incidence \u00a0of\u00a0clinical\u00a0lipodystrophy \u00a0in\u00a0HIV\u2010\ninfected\u00a0patients\u00a0treated\u00a0during\u00a0primary\u00a0infection. \u00a0AIDS\u00a02001;\u00a015(2):282 \u20104.\u00a0\n\u00a0 146.\u00a0\u00a0Miller\u00a0J,\u00a0Carr\u00a0A,\u00a0Smith\u00a0D,\u00a0Emery\u00a0S,\u00a0Law\u00a0MG,\u00a0Grey\u00a0P\u00a0et\u00a0al.\u00a0Lipodystrophy \u00a0following\u00a0antiretrovi \u2010\nral\u00a0therapy\u00a0of\u00a0primary\u00a0HIV\u00a0infection. \u00a0AIDS\u00a02000;\u00a014(15):2406 \u20107.\u00a0\n\u00a0 147.\u00a0\u00a0Narciso\u00a0P,\u00a0Tozzi\u00a0V,\u00a0D'Offizi\u00a0G,\u00a0De\u00a0Carli\u00a0G,\u00a0Orchi\u00a0N,\u00a0Galati\u00a0V\u00a0et\u00a0al.\u00a0Metabolic \u00a0and\u00a0morphologic \u00a0\ndisorders \u00a0in\u00a0patients\u00a0treated\u00a0with\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0since\u00a0primary\u00a0HIV\u00a0infec\u2010\ntion.\u00a0Ann\u00a0N\u00a0Y\u00a0Acad\u00a0Sci\u00a02001;\u00a0946:214\u201022.\u00a0\n\u00a0 148.\u00a0\u00a0Streeck\u00a0H,\u00a0Jessen\u00a0H,\u00a0Alter\u00a0G,\u00a0Teigen\u00a0N,\u00a0Waring\u00a0MT,\u00a0Jessen\u00a0A\u00a0et\u00a0al.\u00a0Immunological \u00a0and\u00a0virologi\u2010\ncal\u00a0impact\u00a0of\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0initiated\u00a0during\u00a0acute\u00a0HIV\u20101\u00a0infection. \u00a0J\u00a0In\u2010\nfect\u00a0Dis\u00a02006;\u00a0194(6):734 \u2010739.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 108 \n \u00a0 149.\u00a0\u00a0Markowitz \u00a0M,\u00a0Jin\u00a0X,\u00a0Hurley\u00a0A,\u00a0Simon\u00a0V,\u00a0Ramratnam \u00a0B,\u00a0Louie\u00a0M\u00a0et\u00a0al.\u00a0Discontinuation \u00a0of\u00a0anti\u2010\nretroviral \u00a0therapy\u00a0commenced \u00a0early\u00a0during\u00a0the\u00a0course\u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0ty\u2010\npe\u00a01\u00a0infection, \u00a0with\u00a0or\u00a0without\u00a0adjunctive \u00a0vaccination. \u00a0J\u00a0Infect\u00a0Dis\u00a02002;\u00a0186(5):634 \u2010643.\u00a0\n\u00a0 150.\u00a0\u00a0Desquilbet \u00a0L,\u00a0Goujard\u00a0C,\u00a0Rouzioux\u00a0C,\u00a0Sinet\u00a0M,\u00a0Deveau\u00a0C,\u00a0Chaix\u00a0ML\u00a0et\u00a0al.\u00a0Does\u00a0transient\u00a0HAART\u00a0\nduring\u00a0primary\u00a0HIV\u20101\u00a0infection\u00a0lower\u00a0the\u00a0virological \u00a0set\u2010point?\u00a0AIDS\u00a02004;\u00a018(18):2361 \u20102369.\u00a0\n\u00a0 151.\u00a0\u00a0Hecht\u00a0FM,\u00a0Wang\u00a0L,\u00a0Collier\u00a0A,\u00a0Little\u00a0S,\u00a0Markowitz \u00a0M,\u00a0Margolick \u00a0J\u00a0et\u00a0al.\u00a0A\u00a0multicenter \u00a0observa\u2010\ntional\u00a0study\u00a0of\u00a0the\u00a0potential\u00a0benefits\u00a0of\u00a0initiating\u00a0combination \u00a0antiretroviral \u00a0therapy\u00a0during\u00a0\nacute\u00a0HIV\u00a0infection. \u00a0J\u00a0Infect\u00a0Dis\u00a02006;\u00a0194(6):725 \u2010733.\u00a0\n\u00a0 152.\u00a0\u00a0Steingrover \u00a0R,\u00a0Bezemer\u00a0D,\u00a0Fernandez \u00a0Garcia\u00a0E,\u00a0Kroon\u00a0F,\u00a0de\u00a0Wolf\u00a0F,\u00a0Prins\u00a0M\u00a0et\u00a0al.\u00a0Early\u00a0treat\u2010\nment\u00a0of\u00a0primary\u00a0HIV\u20101\u00a0infection\u00a0lowers\u00a0the\u00a0viral\u00a0set\u00a0point.\u00a014th\u00a0Conference \u00a0on\u00a0retrovirus \u00a0and\u00a0\nopportunistic \u00a0infections.Los \u00a0Angeles,\u00a02007\u00a0Abstract\u00a0124LB\u00a0\n\u00a0 153.\u00a0\u00a0Koegl\u00a0C,\u00a0Wolf\u00a0E,\u00a0Jessen\u00a0H,\u00a0Schewe\u00a0K,\u00a0Rausch\u00a0M,\u00a0Goelz\u00a0J\u00a0et\u00a0al.\u00a0No\u00a0Benefit\u00a0from\u00a0Early\u00a0Treatment \u00a0\nin\u00a0Primary\u00a0HIV\u2010Infection? \u00a014th\u00a0Conference \u00a0on\u00a0retrovirus \u00a0and\u00a0opportunistic \u00a0infections.Los \u00a0An\u2010\ngeles,\u00a02007\u00a0(Abstract\u00a0125LB)\u00a0\n\u00a0 154.\u00a0\u00a0Seng\u00a0R,\u00a0Goujard\u00a0C,\u00a0Desquilbet \u00a0L,\u00a0Sinet\u00a0M,\u00a0Deveau\u00a0C,\u00a0Boufassa\u00a0F\u00a0et\u00a0al.\u00a0CD4\u00a0T\u2010cell\u00a0Count\u00a0Increa\u2010\nse\u00a0during\u00a0HAART\u00a0Initiated\u00a0in\u00a0Primary\u00a0Infection\u00a0In\u00a0Transient \u00a0after\u2010Long\u00a0term\u00a0HAART\u00a0Interrup\u2010\ntion.\u00a014th\u00a0Conference \u00a0on\u00a0retrovirus \u00a0and\u00a0opportunistic \u00a0infections.Los \u00a0Angeles,\u00a02007\u00a0(Abstract\u00a0\n347)\u00a0\n\u00a0 155.\u00a0\u00a0Lampe\u00a0FC,\u00a0Porter\u00a0K,\u00a0Kaldor\u00a0J,\u00a0Law\u00a0M,\u00a0Kinloch\u2010de\u00a0LS,\u00a0Phillips\u00a0AN.\u00a0Effect\u00a0of\u00a0transient\u00a0antiretrovi \u2010\nral\u00a0treatment \u00a0during\u00a0acute\u00a0HIV\u00a0infection: \u00a0comparison \u00a0of\u00a0the\u00a0Quest\u00a0trial\u00a0results\u00a0with\u00a0CASCADE \u00a0\nnatural\u00a0history\u00a0study.\u00a0Antivir\u00a0Ther\u00a02007;\u00a012(2):189 \u2010193.\u00a0\n\u00a0 156.\u00a0\u00a0Stekler\u00a0J,\u00a0Holte\u00a0S,\u00a0Maenza\u00a0J,\u00a0Stevens\u00a0C,\u00a0Collier\u00a0A.\u00a0Clinical\u00a0outcomes \u00a0of\u00a0ART\u00a0initiated\u00a0during\u00a0\nprimary\u00a0HIV\u00a0infection. \u00a014th\u00a0Conference \u00a0on\u00a0retrovirus \u00a0and\u00a0opportunistic \u00a0infections.Los \u00a0Ange\u2010\nles,\u00a02007\u00a0(Abstract\u00a0346)\u00a0\n\u00a0 157.\u00a0\u00a0Prazuck\u00a0T,\u00a0Lafeuillade \u00a0A,\u00a0Hocqueloux \u00a0L,\u00a0Viard\u00a0JP,\u00a0Avettand\u00a0V,\u00a0Rouzoux\u00a0C.\u00a0Can\u00a0HAART\u00a0Initiation\u00a0\nat\u00a0Early\u00a0Acute\u00a0HIV\u00a0Infection\u00a0Benefit\u00a0the\u00a0Immune\u2010virology\u00a0Outcome \u00a0Despite\u00a0Subsequent \u00a0Tre\u2010\natment\u00a0Cessation? \u00a0The\u00a0ANRS\u00a0Reservoirs \u00a0Study\u00a0Group.\u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections; \u00a0February\u00a02008;\u00a0Boston,\u00a0Massachusetts \u00a0(Abstract\u00a0695)\u00a0\n\u00a0 158.\u00a0\u00a0Desquilbet \u00a0L,\u00a0Hoen\u00a0B,\u00a0Goujard\u00a0C,\u00a0Deveau\u00a0C,\u00a0Warszawski \u00a0J,\u00a0Meyer\u00a0L\u00a0et\u00a0al.\u00a0Early\u00a0Short\u2010course\u00a0\nHAART\u00a0Initiated\u00a0at\u00a0the\u00a0Time\u00a0of\u00a0Primary\u00a0HIV\u00a0Infection\u00a0Provides\u00a0No\u00a0Sustained \u00a0Benefit\u00a0in\u00a0Terms\u00a0\nof\u00a0Time\u00a0to\u00a0CD4\u00a0Decline\u00a0below\u00a0350/mm3:\u00a0Results\u00a0of\u00a0a\u00a0Propensity \u00a0Analysis\u00a0within\u00a0the\u00a0ANRS\u00a0\nPRIMO\u00a0Cohort.\u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a0\n2008;\u00a0Boston,\u00a0Massachusetts \u00a0(Abstract\u00a0694)\u00a0\n\u00a0 159.\u00a0\u00a0Fox\u00a0J,\u00a0Scriba\u00a0TJ,\u00a0Robinson \u00a0N,\u00a0Weber\u00a0JN,\u00a0Phillips\u00a0RE,\u00a0Fidler\u00a0S.\u00a0Human\u00a0immunodeficiency \u00a0virus\u00a0\n(HIV)\u2010specific\u00a0T\u00a0helper\u00a0responses \u00a0fail\u00a0to\u00a0predict\u00a0CD4+\u00a0T\u00a0cell\u00a0decline\u00a0following \u00a0short\u2010course\u00a0\ntreatment \u00a0at\u00a0primary\u00a0HIV\u20101\u00a0infection. \u00a0Clin\u00a0Exp\u00a0Immunol\u00a02008;\u00a0152(3):532 \u2010537.\u00a0\n\u00a0 160.\u00a0\u00a0Pantazis\u00a0N,\u00a0Touloumi \u00a0G,\u00a0Vanhems \u00a0P,\u00a0Gill\u00a0J,\u00a0Bucher\u00a0HC,\u00a0Porter\u00a0K.\u00a0The\u00a0effect\u00a0of\u00a0antiretroviral \u00a0\ntreatment \u00a0of\u00a0different\u00a0durations \u00a0in\u00a0primary\u00a0HIV\u00a0infection. \u00a0AIDS\u00a02008;\u00a022(18):2441 \u20102450.\u00a0\n\u00a0 161.\u00a0\u00a0Kaufmann \u00a0DE,\u00a0Lichterfeld \u00a0M,\u00a0Altfeld\u00a0M,\u00a0Addo\u00a0MM,\u00a0Johnston\u00a0MN,\u00a0Lee\u00a0PK\u00a0et\u00a0al.\u00a0Limited\u00a0durabi\u2010\nlity\u00a0of\u00a0viral\u00a0control\u00a0following \u00a0treated\u00a0acute\u00a0HIV\u00a0infection. \u00a0PLoS\u00a0Med\u00a02004;\u00a01(2):e36.\u00a0\n\u00a0 162.\u00a0\u00a0Miro\u00a0JM,\u00a0Plana\u00a0M,\u00a0Garcia\u00a0F,\u00a0Ortiz\u00a0GM,\u00a0Maleno\u00a0MJ,\u00a0Arnedo\u00a0M\u00a0et\u00a0al.\u00a0Structured \u00a0Treatment \u00a0\nInterruptions \u00a0in\u00a0Patients\u00a0Receiving \u00a0HAART\u00a0within\u00a090\u00a0days\u00a0after\u00a0onset\u00a0of\u00a0Primary\u00a0HIV\u20101\u00a0Infec\u2010\ntion\u00a0Symptoms: \u00a0Spontaneous \u00a0Control\u00a0of\u00a0Viremia\u00a0in\u00a0only\u00a0one\u00a0Third\u00a0of\u00a0Cases\u00a0after\u00a0Four\u00a0Cycles\u00a0\nOff\u00a0Therapy.\u00a0XIV\u00a0International \u00a0AIDS\u00a0Conference, \u00a0Barcelona, \u00a02002\u00a0[Abstract\u00a0ThOrB1437] \u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 109 \n \u00a0 163.\u00a0\u00a0Tremblay \u00a0CL,\u00a0Hicks\u00a0JL,\u00a0Sutton\u00a0L,\u00a0Giguel\u00a0F,\u00a0Flynn\u00a0T,\u00a0Johnston\u00a0M\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0resistance \u00a0\nassociated \u00a0with\u00a0supervised \u00a0treatment \u00a0interruptions \u00a0in\u00a0treated\u00a0acute\u00a0HIV\u00a0infection. \u00a0AIDS\u00a02003;\u00a0\n17:1086\u20101089.\u00a0\n\u00a0 164.\u00a0\u00a0Hoen\u00a0B,\u00a0Fournier\u00a0I,\u00a0Lacabaratz \u00a0C,\u00a0Burgard\u00a0M,\u00a0Charreau\u00a0I,\u00a0Chaix\u00a0ML\u00a0et\u00a0al.\u00a0Structured \u00a0treatment \u00a0\ninterruptions \u00a0in\u00a0primary\u00a0HIV\u20101\u00a0infection: \u00a0the\u00a0ANRS\u00a0100\u00a0PRIMSTOP \u00a0trial.\u00a0J\u00a0Acquir\u00a0Immune\u00a0De\u2010\nfic\u00a0Syndr\u00a02005;\u00a040(3):307 \u2010316.\u00a0\n\u00a0 165.\u00a0\u00a0Emilie\u00a0D,\u00a0Burgard\u00a0M,\u00a0Lascoux\u00a0Combre\u00a0C,\u00a0Lauglin\u00a0M,\u00a0Krzyiek\u00a0R,\u00a0Pignosn\u00a0C\u00a0et\u00a0al.\u00a0Early\u00a0control\u00a0of\u00a0\nHIV\u00a0replication \u00a0in\u00a0primary\u00a0HIV\u2010Infection\u00a0treated\u00a0with\u00a0antiretroviral \u00a0drugs\u00a0and\u00a0pegylated \u00a0IFN\u00a0\nalpha:\u00a0results\u00a0from\u00a0the\u00a0Primoferon \u00a0A\u00a0(ANRS\u00a0086)\u00a0Study.\u00a0AIDS\u00a02001;\u00a015(1435):1437. \u00a0\n\u00a0 166.\u00a0\u00a0Dybul\u00a0M,\u00a0Hidalgo\u00a0B,\u00a0Chun\u00a0TW,\u00a0Belson\u00a0M,\u00a0Migueles\u00a0SA,\u00a0Justement \u00a0JS\u00a0et\u00a0al.\u00a0Pilot\u00a0study\u00a0of\u00a0the\u00a0\neffects\u00a0of\u00a0intermittent \u00a0interleukin \u20102\u00a0on\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0specific\u00a0responses \u00a0in\u00a0\npatients\u00a0treated\u00a0during\u00a0recently\u00a0acquired\u00a0HIV\u00a0infection. \u00a0J\u00a0Infect\u00a0Dis\u00a02002;\u00a0185:61\u201068.\u00a0\n\u00a0 167.\u00a0\u00a0Miro\u00a0JM,\u00a0Plana\u00a0M,\u00a0Garcia\u00a0F,\u00a0Ortiz\u00a0GM,\u00a0Maleno\u00a0MJ,\u00a0Sued\u00a0O\u00a0et\u00a0al.\u00a0Low\u2010dose\u00a0daily\u00a0IL\u20102\u00a0combined \u00a0\nwith\u00a0structured \u00a0treatment \u00a0interruptions \u00a0did\u00a0not\u00a0increase\u00a0the\u00a0HIV\u20101\u2010specific\u00a0T\u2010cell\u00a0responses \u00a0\nin\u00a0patients\u00a0receiving\u00a0HAART\u00a0with\u00a090\u00a0days\u00a0after\u00a0onset\u00a0primary\u00a0HIV\u20101\u00a0infection\u00a0symptoms. \u00a0XV\u00a0\nInternational \u00a0AIDS\u00a0Conference.Bangkok \u00a0(Thailand).July \u00a011\u201016,\u00a02004.\u00a0Abstract\u00a0WePeB5690 \u00a0\n\u00a0 168.\u00a0\u00a0Adalid\u2010Peralta\u00a0L,\u00a0Godot\u00a0V,\u00a0Colin\u00a0C,\u00a0Krzysiek\u00a0R,\u00a0Tran\u00a0T,\u00a0Poignard\u00a0P\u00a0et\u00a0al.\u00a0Stimulation \u00a0of\u00a0the\u00a0\nprimary\u00a0anti\u2010HIV\u00a0antibody\u00a0response\u00a0by\u00a0IFN\u2010alpha\u00a0in\u00a0patients\u00a0with\u00a0acute\u00a0HIV\u20101\u00a0infection. \u00a0J\u00a0\nLeukoc\u00a0Biol\u00a02008;\u00a083(4):1060 \u20101067.\u00a0\n\u00a0 169.\u00a0\u00a0Ravot\u00a0E,\u00a0Tambussi \u00a0G,\u00a0Jessen\u00a0H,\u00a0Tinelli\u00a0C,\u00a0Lazzarin\u00a0A,\u00a0Lisziexicz\u00a0J\u00a0et\u00a0al.\u00a0Effects\u00a0of\u00a0hidroxiurea \u00a0on\u00a0\nT\u00a0cell\u00a0count\u00a0changes\u00a0during\u00a0primary\u00a0HIV\u00a0infection. \u00a0AIDS\u00a02000;\u00a014:619\u2010622.\u00a0\n\u00a0 170.\u00a0\u00a0Rizzardi\u00a0GP,\u00a0Harari\u00a0A,\u00a0Capiluppi \u00a0B,\u00a0Tambussi \u00a0G,\u00a0Ellfsen\u00a0K,\u00a0Ciuffreda\u00a0D\u00a0et\u00a0al.\u00a0Treatment \u00a0of\u00a0pri\u2010\nmary\u00a0HIV\u20101\u00a0infection\u00a0with\u00a0ciclosporin \u00a0A\u00a0coupled\u00a0with\u00a0HAART.\u00a0J\u00a0Clin\u00a0Invest\u00a02002;\u00a0109:681\u2010688.\u00a0\n\u00a0 171.\u00a0\u00a0Markowitz \u00a0M,\u00a0Vaida\u00a0F,\u00a0Little\u00a0S,\u00a0Hare\u00a0C,\u00a0Balfour\u00a0H,\u00a0Ferguson\u00a0E\u00a0et\u00a0al.\u00a0An\u00a0Open\u2010label\u00a0Randomized \u00a0\nTrial\u00a0to\u00a0Determine \u00a0the\u00a0Virologic\u00a0and\u00a0Immunologic \u00a0Effects\u00a0of\u00a04\u2010Weeks\u00a0of\u00a0Cyclosporine \u00a0A\u00a0Given\u00a0\nin\u00a0Combination \u00a0with\u00a0ART\u00a0during\u00a0Acute\u00a0and\u00a0Early\u00a0Infection. \u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0\nand\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a02008;\u00a0Boston,\u00a0Massachusetts \u00a0(Abstract\u00a0698c)\u00a0\n\u00a0 172.\u00a0\u00a0Miro\u00a0JM,\u00a0Lopez\u2010Dieguez\u00a0M,\u00a0Plana\u00a0M,\u00a0Pumarola \u00a0T,\u00a0Brunet\u00a0M,\u00a0Tuset\u00a0M\u00a0et\u00a0al.\u00a0Randomized \u00a0Clini\u2010\ncal\u00a0Trial\u00a0with\u00a0Immune\u2010based\u00a0Therapy\u00a0in\u00a0Patients\u00a0with\u00a0Primary\u00a0HIV\u20101\u00a0Infection. \u00a016th\u00a0Confe\u2010\nrence\u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a02009;\u00a0Montreal \u00a02009;\u00a0Abstract\u00a0\nP531.\u00a0\n\u00a0 173.\u00a0\u00a0Goh\u00a0LE,\u00a0Perrin\u00a0L,\u00a0Hoen\u00a0B,\u00a0Cooper\u00a0D,\u00a0Phillips\u00a0A,\u00a0Janossy\u00a0G\u00a0et\u00a0al.\u00a0Study\u00a0protocol\u00a0for\u00a0the\u00a0evalua\u2010\ntion\u00a0of\u00a0the\u00a0potential\u00a0for\u00a0durable\u00a0viral\u00a0suppression \u00a0after\u00a0quadruple \u00a0HAART\u00a0with\u00a0or\u00a0without\u00a0HIV\u00a0\nvaccination: \u00a0the\u00a0QUEST\u00a0study.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02001;\u00a02(5):438\u201044.\u00a0\n\u00a0 174.\u00a0\u00a0Shiver\u00a0JW,\u00a0Fu\u00a0TM,\u00a0Chen\u00a0L,\u00a0Casimiro\u00a0DR,\u00a0Davies\u00a0ME,\u00a0Evans\u00a0RK\u00a0et\u00a0al.\u00a0Replication \u2010incompetent \u00a0\nadenoviral \u00a0vaccine\u00a0vector\u00a0elicits\u00a0effective\u00a0anti\u2010immunodeficiency \u2010virus\u00a0immunity. \u00a0Nature\u00a0\n2002;\u00a0415(6869):331 \u2010335.\u00a0\n\u00a0 175.\u00a0\u00a0Lu\u00a0W,\u00a0Wu\u00a0X,\u00a0Lu\u00a0Y,\u00a0Guo\u00a0W,\u00a0Andrieu\u00a0JM.\u00a0Therapeutic \u00a0dendritic\u2010cell\u00a0vaccine\u00a0for\u00a0simian\u00a0AIDS.\u00a0Nat\u00a0\nMed\u00a02003;\u00a09(1):27\u201032.\u00a0\n\u00a0 176.\u00a0\u00a0Kinloch\u2010de\u00a0LS,\u00a0Hoen\u00a0B,\u00a0Smith\u00a0DE,\u00a0Autran\u00a0B,\u00a0Lampe\u00a0FC,\u00a0Phillips\u00a0AN\u00a0et\u00a0al.\u00a0Impact\u00a0of\u00a0therapeutic \u00a0\nimmunization \u00a0on\u00a0HIV\u20101\u00a0viremia\u00a0after\u00a0discontinuation \u00a0of\u00a0antiretroviral \u00a0therapy\u00a0initiated\u00a0during\u00a0\nacute\u00a0infection. \u00a0J\u00a0Infect\u00a0Dis\u00a02005;\u00a0192(4):607 \u2010617.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 110 \n \u00a0 177.\u00a0\u00a0Emery\u00a0S,\u00a0Kelleher\u00a0AD,\u00a0Workman \u00a0C,\u00a0Puls\u00a0RL,\u00a0Bloch\u00a0M,\u00a0Baker\u00a0D\u00a0et\u00a0al.\u00a0Influence \u00a0of\u00a0IFNgamma \u00a0co\u2010\nexpression \u00a0on\u00a0the\u00a0safety\u00a0and\u00a0antiviral\u00a0efficacy\u00a0of\u00a0recombinant \u00a0fowlpox\u00a0virus\u00a0HIV\u00a0therapeutic \u00a0\nvaccines\u00a0following\u00a0interruption \u00a0of\u00a0antiretroviral \u00a0therapy.\u00a0Hum\u00a0Vaccin\u00a02007;\u00a03(6):260\u2010267.\u00a0\n\u00a0 178.\u00a0\u00a0Cooper\u00a0D,\u00a0Workman \u00a0C,\u00a0Puls\u00a0R,\u00a0Bloch\u00a0M,\u00a0Baker\u00a0D,\u00a0Bodsworth \u00a0N\u00a0et\u00a0al.\u00a0Randomized, \u00a0Placebo\u2010\ncontrolled, \u00a0Phase1/2a \u00a0Evaluation \u00a0of\u00a0the\u00a0Safety,\u00a0Biological \u00a0Activity\u00a0and\u00a0Antiretroviral \u00a0Proper\u2010\nties\u00a0of\u00a0an\u00a0Avipox\u00a0Virus\u00a0Vaccine\u00a0Expressing \u00a0HIV\u00a0gag\u2010pol\u00a0and\u00a0Interferon \u2010gamma\u00a0in\u00a0HIV\u20101\u00a0Infec\u2010\nted\u00a0Subjects.\u00a011th\u00a0Conference \u00a0on\u00a0Retrovirus \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0Fe\u2010\nbruary\u00a08\u2010\u201011,\u00a02004\u00a0[Abstract\u00a0169]\u00a0\n\u00a0 179.\u00a0\u00a0Paul\u00a0S,\u00a0Gilbert\u00a0HM,\u00a0Ziecheck\u00a0W,\u00a0Jacobs\u00a0J,\u00a0Sepkowitz \u00a0KA.\u00a0The\u00a0impact\u00a0of\u00a0potent\u00a0antiretroviral \u00a0\ntherapy\u00a0on\u00a0the\u00a0characteristics \u00a0of\u00a0hospitalized \u00a0patients\u00a0with\u00a0HIV\u00a0infection. \u00a0AIDS\u00a01999;\u00a0\n13(3):415 \u20108.\u00a0\n\u00a0 180.\u00a0\u00a0Lampe\u00a0FC,\u00a0Gatell\u00a0JM,\u00a0Staszewski \u00a0S,\u00a0Johnson\u00a0MA,\u00a0Pradier\u00a0C,\u00a0Gill\u00a0MJ\u00a0et\u00a0al.\u00a0Changes\u00a0over\u00a0time\u00a0in\u00a0\nrisk\u00a0of\u00a0initial\u00a0virological \u00a0failure\u00a0of\u00a0combination \u00a0antiretroviral \u00a0therapy:\u00a0a\u00a0multicohort \u00a0analysis,\u00a0\n1996\u00a0to\u00a02002.\u00a0Arch\u00a0Intern\u00a0Med\u00a02006;\u00a0166(5):521 \u2010528.\u00a0\n\u00a0 181.\u00a0\u00a0Lohse\u00a0N,\u00a0Hansen\u00a0AB,\u00a0Pedersen \u00a0G,\u00a0Kronborg \u00a0G,\u00a0Gerstoft\u00a0J,\u00a0Sorensen \u00a0HT\u00a0et\u00a0al.\u00a0Survival\u00a0of\u00a0per\u2010\nsons\u00a0with\u00a0and\u00a0without\u00a0HIV\u00a0infection\u00a0in\u00a0Denmark, \u00a01995\u20102005.\u00a0Ann\u00a0Intern\u00a0Med\u00a02007;\u00a0\n146(2):87 \u201095.\u00a0\n\u00a0 182.\u00a0\u00a0Life\u00a0expectancy \u00a0of\u00a0individuals \u00a0on\u00a0combination \u00a0antiretroviral \u00a0therapy\u00a0in\u00a0high\u2010income\u00a0coun\u2010\ntries:\u00a0a\u00a0collaborative \u00a0analysis\u00a0of\u00a014\u00a0cohort\u00a0studies.\u00a0Lancet\u00a02008;\u00a0372(9635):293 \u2010299.\u00a0\n\u00a0 183.\u00a0\u00a0Lewden\u00a0C,\u00a0Chene\u00a0G,\u00a0Morlat\u00a0P,\u00a0Raffi\u00a0F,\u00a0Dupon\u00a0M,\u00a0Dellamonica \u00a0P\u00a0et\u00a0al.\u00a0HIV\u2010infected\u00a0adults\u00a0with\u00a0\na\u00a0CD4\u00a0cell\u00a0count\u00a0greater\u00a0than\u00a0500\u00a0cells/mm3 \u00a0on\u00a0long\u2010term\u00a0combination \u00a0antiretroviral \u00a0therapy\u00a0\nreach\u00a0same\u00a0mortality\u00a0rates\u00a0as\u00a0the\u00a0general\u00a0population. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a0\n46(1):72\u201077.\u00a0\n\u00a0 184.\u00a0\u00a0Marschner \u00a0IC,\u00a0Collier\u00a0AC,\u00a0Coombs\u00a0RW,\u00a0D'Aquila\u00a0RT,\u00a0DeGruttola \u00a0V,\u00a0Fischl\u00a0MA\u00a0et\u00a0al.\u00a0Use\u00a0of\u00a0\nchanges\u00a0in\u00a0plasma\u00a0levels\u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0RNA\u00a0to\u00a0assess\u00a0the\u00a0clinical\u00a0\nbenefit\u00a0of\u00a0antiretroviral \u00a0therapy.\u00a0J\u00a0Infect\u00a0Dis\u00a01998;\u00a0177(1):40 \u20107.\u00a0\n\u00a0 185.\u00a0\u00a0Mellors\u00a0JW,\u00a0Munoz\u00a0A,\u00a0Giorgi\u00a0JV,\u00a0Margolick \u00a0JB,\u00a0Tassoni\u00a0CJ,\u00a0Gupta\u00a0P\u00a0et\u00a0al.\u00a0Plasma\u00a0viral\u00a0load\u00a0and\u00a0\nCD4+\u00a0lymphocytes \u00a0as\u00a0prognostic \u00a0markers\u00a0of\u00a0HIV\u20101\u00a0infection. \u00a0Ann\u00a0Intern\u00a0Med\u00a01997;\u00a0\n126(12):946 \u201054.\u00a0\n\u00a0 186.\u00a0\u00a0The\u00a0SMART\u00a0Study\u00a0Group.\u00a0Major\u00a0Clinical\u00a0Outcomes \u00a0in\u00a0Antiretroviral \u00a0Therapy\u00a0(ART)\u2010Naive\u00a0Par\u2010\nticipants\u00a0and\u00a0in\u00a0Those\u00a0Not\u00a0Receiving \u00a0ART\u00a0at\u00a0Baseline\u00a0in\u00a0the\u00a0SMART\u00a0Study.\u00a0The\u00a0Journal\u00a0of\u00a0In\u2010\nfectious\u00a0Diseases\u00a02008;\u00a0197(8):1133 \u20101144.\u00a0\n\u00a0 187.\u00a0\u00a0Kitahata\u00a0MM,\u00a0Gange\u00a0SJ,\u00a0Abraham\u00a0AG,\u00a0Merriman \u00a0B,\u00a0Saag\u00a0MS,\u00a0Justice\u00a0AC\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0early\u00a0\nversus\u00a0deferred\u00a0antiretroviral \u00a0therapy\u00a0for\u00a0HIV\u00a0on\u00a0survival.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02009;\u00a0360(18):1815 \u2010\n1826.\u00a0\n\u00a0 188.\u00a0\u00a0The\u00a0CIPRA\u00a0HT\u00a0001\u00a0Clinical\u00a0Trial.\u00a0http://www \u00a0nih\u00a0gov/news/health/jun2009/niaid \u201008a\u00a0htm\u00a0\n(Consulta \u00a08\u00a012\u00a009)\u00a02009.\u00a0\n\u00a0 189.\u00a0\u00a0Baker\u00a0JV,\u00a0Peng\u00a0G,\u00a0Rapkin\u00a0J,\u00a0Abrams\u00a0DI,\u00a0Silverberg \u00a0MJ,\u00a0MacArthur \u00a0RD\u00a0et\u00a0al.\u00a0CD4+\u00a0count\u00a0and\u00a0\nrisk\u00a0of\u00a0non\u2010AIDS\u00a0diseases\u00a0following\u00a0initial\u00a0treatment \u00a0for\u00a0HIV\u00a0infection. \u00a0AIDS\u00a02008;\u00a022(7):841 \u2010\n848.\u00a0\n\u00a0 190.\u00a0\u00a0d'Arminio \u00a0Monforte \u00a0A,\u00a0Abrams\u00a0D,\u00a0Pradier\u00a0C,\u00a0Weber\u00a0R,\u00a0Bonnet\u00a0F,\u00a0DeWit\u00a0S\u00a0et\u00a0al.\u00a0HIV\u2010induced\u00a0\nimmunodeficiency \u00a0and\u00a0risk\u00a0of\u00a0fatal\u00a0AIDS\u2010defining\u00a0and\u00a0non\u2010AIDS\u00a0defining\u00a0malignancies:results \u00a0\nfrom\u00a0the\u00a0D:A:D\u00a0study.\u00a014th\u00a0Conference \u00a0on\u00a0retrovirus \u00a0and\u00a0opportunistic \u00a0infections.Los \u00a0Ange\u2010\nles,\u00a02007\u00a0\u00a0[abstract\u00a084]\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 111 \n \u00a0 191.\u00a0\u00a0Marin\u00a0B,\u00a0Thi\u00e9baut\u00a0R,\u00a0Rondeau\u00a0V,\u00a0Costagliola \u00a0D,\u00a0Dorrucci\u00a0M,\u00a0Bucher\u00a0H\u00a0et\u00a0al.\u00a0Association \u00a0bet\u2010\nween\u00a0CD4\u00a0and\u00a0HIV\u00a0RNA\u00a0with\u00a0non\u00a0AIDS\u2010related\u00a0causes\u00a0of\u00a0death\u00a0in\u00a0the\u00a0era\u00a0of\u00a0combination \u00a0anti\u2010\nretroviral \u00a0therapy.\u00a04th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Syd\u2010\nney,\u00a02007\u00a0(Abstract\u00a0WEPEB019) \u00a0\n\u00a0 192.\u00a0\u00a0El\u2010Sadr\u00a0WM,\u00a0Lundgren \u00a0JD,\u00a0Neaton\u00a0JD,\u00a0Gordin\u00a0F,\u00a0Abrams\u00a0D,\u00a0Arduino\u00a0RC\u00a0et\u00a0al.\u00a0CD4+\u00a0count\u2010\nguided\u00a0interruption \u00a0of\u00a0antiretroviral \u00a0treatment. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02006;\u00a0355(22):2283 \u20102296.\u00a0\n\u00a0 193.\u00a0\u00a0Bhaskaran \u00a0K,\u00a0Hamouda \u00a0O,\u00a0Sannes\u00a0M,\u00a0Boufassa\u00a0F,\u00a0Johnson\u00a0AM,\u00a0Lambert\u00a0PC\u00a0et\u00a0al.\u00a0Changes\u00a0in\u00a0\nthe\u00a0risk\u00a0of\u00a0death\u00a0after\u00a0HIV\u00a0seroconversion \u00a0compared \u00a0with\u00a0mortality\u00a0in\u00a0the\u00a0general\u00a0popula\u2010\ntion.\u00a0Jama\u00a02008;\u00a0300(1):51 \u201059.\u00a0\n\u00a0 194.\u00a0\u00a0May\u00a0M,\u00a0Sterne\u00a0JA,\u00a0Sabin\u00a0C,\u00a0Costagliola \u00a0D,\u00a0Justice\u00a0AC,\u00a0Thiebaut\u00a0R\u00a0et\u00a0al.\u00a0Prognosis \u00a0of\u00a0HIV\u20101\u2010\ninfected\u00a0patients\u00a0up\u00a0to\u00a05\u00a0years\u00a0after\u00a0initiation\u00a0of\u00a0HAART:\u00a0collaborative \u00a0analysis\u00a0of\u00a0prospective \u00a0\nstudies.\u00a0AIDS\u00a02007;\u00a021(9):1185 \u20101197.\u00a0\n\u00a0 195.\u00a0\u00a0Branas\u00a0F,\u00a0Berenguer \u00a0J,\u00a0Sanchez\u2010Conde\u00a0M,\u00a0Lopez\u2010Bernaldo\u00a0de\u00a0Quiros\u00a0JC,\u00a0Miralles\u00a0P,\u00a0Cosin\u00a0J\u00a0et\u00a0\nal.\u00a0The\u00a0eldest\u00a0of\u00a0older\u00a0adults\u00a0living\u00a0with\u00a0HIV:\u00a0response\u00a0and\u00a0adherence \u00a0to\u00a0highly\u00a0active\u00a0antire\u2010\ntroviral\u00a0therapy.\u00a0Am\u00a0J\u00a0Med\u00a02008;\u00a0121(9):820 \u2010824.\u00a0\n\u00a0 196.\u00a0\u00a0Moore\u00a0DM,\u00a0Hogg\u00a0RS,\u00a0Yip\u00a0B,\u00a0Craib\u00a0K,\u00a0Wood\u00a0E,\u00a0Montaner \u00a0JS.\u00a0CD4\u00a0percentage \u00a0is\u00a0an\u00a0independent \u00a0\npredictor \u00a0of\u00a0survival\u00a0in\u00a0patients\u00a0starting\u00a0antiretroviral \u00a0therapy\u00a0with\u00a0absolute\u00a0CD4\u00a0cell\u00a0counts\u00a0\nbetween\u00a0200\u00a0and\u00a0350\u00a0cells/microL. \u00a0HIV\u00a0Med\u00a02006;\u00a07(6):383\u2010388.\u00a0\n\u00a0 197.\u00a0\u00a0Gras\u00a0L,\u00a0Kesselring \u00a0AM,\u00a0Griffin\u00a0JT,\u00a0van\u00a0Sighem\u00a0AI,\u00a0Fraser\u00a0C,\u00a0Ghani\u00a0AC\u00a0et\u00a0al.\u00a0CD4\u00a0cell\u00a0counts\u00a0of\u00a0\n800\u00a0cells/mm3 \u00a0or\u00a0greater\u00a0after\u00a07\u00a0years\u00a0of\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0are\u00a0feasible\u00a0in\u00a0\nmost\u00a0patients\u00a0starting\u00a0with\u00a0350\u00a0cells/mm3 \u00a0or\u00a0greater.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a0\n45(2):183 \u2010192.\u00a0\n\u00a0 198.\u00a0\u00a0Mocroft\u00a0A,\u00a0Phillips\u00a0AN,\u00a0Gatell\u00a0J,\u00a0Ledergerber \u00a0B,\u00a0Fisher\u00a0M,\u00a0Clumeck\u00a0N\u00a0et\u00a0al.\u00a0Normalisation \u00a0of\u00a0\nCD4\u00a0counts\u00a0in\u00a0patients\u00a0with\u00a0HIV\u20101\u00a0infection\u00a0and\u00a0maximum \u00a0virological \u00a0suppression \u00a0who\u00a0are\u00a0\ntaking\u00a0combination \u00a0antiretroviral \u00a0therapy:\u00a0an\u00a0observational \u00a0cohort\u00a0study.\u00a0Lancet\u00a02007;\u00a0\n370(9585):407 \u2010413.\u00a0\n\u00a0 199.\u00a0\u00a0Lichtenstein \u00a0KA,\u00a0Armon\u00a0C,\u00a0Buchacz\u00a0K,\u00a0Chmiel\u00a0JS,\u00a0Moorman \u00a0AC,\u00a0Wood\u00a0KC\u00a0et\u00a0al.\u00a0Initiation\u00a0of\u00a0\nantiretroviral \u00a0therapy\u00a0at\u00a0CD4\u00a0cell\u00a0counts\u00a0>/=350\u00a0cells/mm3 \u00a0does\u00a0not\u00a0increase\u00a0incidence \u00a0or\u00a0\nrisk\u00a0of\u00a0peripheral \u00a0neuropathy, \u00a0anemia,\u00a0or\u00a0renal\u00a0insufficiency. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a0\n2008;\u00a047(1):27\u201035.\u00a0\n\u00a0 200.\u00a0\u00a0Attia\u00a0S,\u00a0Egger\u00a0M,\u00a0Muller\u00a0M,\u00a0Zwahlen\u00a0M,\u00a0Low\u00a0N.\u00a0Sexual\u00a0transmission \u00a0of\u00a0HIV\u00a0according \u00a0to\u00a0viral\u00a0\nload\u00a0and\u00a0antiretroviral \u00a0therapy:\u00a0systematic \u00a0review\u00a0and\u00a0meta\u2010analysis.\u00a0AIDS\u00a02009;\u00a0\n23(11):1397 \u20101404.\u00a0\n\u00a0 201.\u00a0\u00a0Bartlett\u00a0JA,\u00a0Fath\u00a0MJ,\u00a0DeMasi\u00a0R,\u00a0Hermes\u00a0A,\u00a0Quinn\u00a0J,\u00a0Mondou\u00a0E\u00a0et\u00a0al.\u00a0An\u00a0updated\u00a0systematic \u00a0\noverview\u00a0of\u00a0triple\u00a0combination \u00a0therapy\u00a0in\u00a0antiretroviral \u2010naive\u00a0HIV\u2010infected\u00a0adults.\u00a0AIDS\u00a02006;\u00a0\n20(16):2051 \u20102064.\u00a0\n\u00a0 202.\u00a0\u00a0Riddler\u00a0SA,\u00a0Haubrich\u00a0R,\u00a0DiRienzo\u00a0G,\u00a0Peeples\u00a0L,\u00a0Powderly \u00a0WG,\u00a0Klingman \u00a0KL\u00a0et\u00a0al.\u00a0A\u00a0prospective, \u00a0\nrandomized, \u00a0Phase\u00a0III\u00a0trial\u00a0of\u00a0NRTI\u2010,\u00a0PI\u2010,\u00a0and\u00a0NNRTI\u2010sparing\u00a0regimens \u00a0for\u00a0initial\u00a0treatment \u00a0of\u00a0\nHIV\u20101\u00a0infection\u00a0\u2010\u00a0ACTG\u00a05142.\u00a0XVI\u00a0International \u00a0AIDS\u00a0Conference, \u00a0Toronto,\u00a0Canada,\u00a02006\u00a0Abs\u2010\ntract\u00a0THLB\u00a00204\u00a0\n\u00a0 203.\u00a0\u00a0King\u00a0MS,\u00a0Bernstein \u00a0BM,\u00a0Walmsley \u00a0SL,\u00a0Sherer\u00a0R,\u00a0Feinberg\u00a0J,\u00a0Sanne\u00a0I\u00a0et\u00a0al.\u00a0Baseline\u00a0HIV\u20101\u00a0RNA\u00a0\nlevel\u00a0and\u00a0CD4\u00a0cell\u00a0count\u00a0predict\u00a0time\u00a0to\u00a0loss\u00a0of\u00a0virologic\u00a0response\u00a0to\u00a0nelfinavir, \u00a0but\u00a0not\u00a0lopi\u2010\nnavir/ritonavir, \u00a0in\u00a0antiretroviral \u00a0therapy\u2010naive\u00a0patients.\u00a0J\u00a0Infect\u00a0Dis\u00a02004;\u00a0190(2):280 \u2010284.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 112 \n \u00a0 204.\u00a0\u00a0Pulido\u00a0F,\u00a0Arribas\u00a0JR,\u00a0Miro\u00a0JM,\u00a0Costa\u00a0MA,\u00a0Gonz\u00e1lez\u00a0J,\u00a0Rubio\u00a0R\u00a0et\u00a0al.\u00a0Clinical,\u00a0virologic,\u00a0and\u00a0im\u2010\nmunologic \u00a0response\u00a0to\u00a0efavirenz\u00a0or\u00a0protease\u00a0inhibitor\u00a0based\u00a0highly\u00a0active\u00a0antiretroviral \u00a0the\u2010\nrapy\u00a0in\u00a0a\u00a0cohort\u00a0of\u00a0antiretroviral \u2010naive\u00a0patients\u00a0with\u00a0advanced \u00a0HIV\u00a0infection\u00a0(EfaVIP\u00a02\u00a0Study).\u00a0\nJ\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02004;\u00a035(4):343 \u2010350.\u00a0\n\u00a0 205.\u00a0\u00a0Miro\u00a0JM,\u00a0Pich\u00a0J,\u00a0Plana\u00a0M,\u00a0Domingo\u00a0P,\u00a0Podzamczer \u00a0D,\u00a0Arribas\u00a0JR\u00a0et\u00a0al.\u00a0Immunological \u00a0reconsti\u2010\ntution\u00a0in\u00a0severely\u00a0immunosuppressed \u00a0antiretroviral \u2010naive\u00a0patients\u00a0(<100\u00a0CD4+\u00a0cells/mm3) \u00a0\nusing\u00a0a\u00a0non\u2010nucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitor\u2010\u00a0or\u00a0a\u00a0boosted\u00a0protease\u00a0inhibitor\u2010based\u00a0\nantiretroviral \u00a0therapy\u00a0regimen:\u00a096\u2010week\u00a0results\u00a0(the\u00a0Advanz\u00a0trial).\u00a010th\u00a0European \u00a0AIDS\u00a0Con\u2010\nference.November \u00a017\u201020,\u00a02005.Dublin. \u00a0Abstract\u00a0PS1/4\u00a0\n\u00a0 206.\u00a0\u00a0Ribaudo\u00a0H,\u00a0Kuritzkes\u00a0DR,\u00a0Lalama\u00a0C,\u00a0et\u00a0al.\u00a0Efavirenz\u2010based\u00a0regimens\u00a0are\u00a0potent\u00a0in\u00a0treatment \u2010\nnaive\u00a0subjects\u00a0across\u00a0a\u00a0wide\u00a0range\u00a0of\u00a0pre\u2010treatment \u00a0HIV\u20101\u00a0RNA\u00a0and\u00a0CD4\u00a0cell\u00a0counts:\u00a03\u2010year\u00a0\nresults\u00a0from\u00a0ACTG\u00a05095.\u00a0XVI\u00a0International \u00a0AIDS\u00a0Conference; \u00a0August\u00a013\u201018,\u00a02006;\u00a0Toronto,\u00a0\nOntario,\u00a0Canada\u00a0Abstract\u00a0THLB0211 \u00a0\n\u00a0 207.\u00a0\u00a0Pulido\u00a0F,\u00a0Arribas\u00a0J,\u00a0Moreno\u00a0S,\u00a0Gatell\u00a0J,\u00a0Vendrell\u00a0B,\u00a0Serrano\u00a0O\u00a0et\u00a0al.\u00a0Similar\u00a0virologic\u00a0and\u00a0immu\u2010\nnologic\u00a0response\u00a0to\u00a0efavirenz\u00a0or\u00a0lopinavir/ritonavir \u2010based\u00a0HAART\u00a0in\u00a0a\u00a0large\u00a0cohort\u00a0of\u00a0antire\u2010\ntroviral\u2010naive\u00a0patients\u00a0with\u00a0advanced \u00a0HIV\u00a0infection. \u00a08th\u00a0International \u00a0Congress\u00a0on\u00a0Drug\u00a0The\u2010\nrapy\u00a0in\u00a0HIV\u00a0Infection, \u00a0Glasgow,\u00a02006.\u00a0(Abstract\u00a0P9)\u00a0\n\u00a0 208.\u00a0\u00a0Sierra\u00a0Madero\u00a0J,\u00a0Villasis\u00a0A,\u00a0Mendez\u00a0P,\u00a0Mosqueda \u00a0JL,\u00a0Torres\u00a0I,\u00a0Gutierrez \u00a0F\u00a0et\u00a0al.\u00a0A\u00a0prospective, \u00a0\nrandomized, \u00a0open\u00a0label\u00a0trial\u00a0of\u00a0efavirenz\u00a0versus\u00a0lopinavir/ritonavir \u00a0based\u00a0HAART\u00a0among\u00a0anti\u2010\nretroviral \u00a0therapy\u00a0na\u00efve,\u00a0HIV\u2010infected\u00a0individuals \u00a0presenting \u00a0for\u00a0care\u00a0with\u00a0CD4\u00a0cell\u00a0counts\u00a0\n<200/mm3 \u00a0in\u00a0Mexico.\u00a017th\u00a0International \u00a0AIDS\u00a0Conference; \u00a03\u20108\u00a0August,\u00a02008;\u00a0Mexico\u00a0DF.\u00a0\n(Abstract\u00a0TUAB0104) \u00a0\n\u00a0 209.\u00a0\u00a0Gulick\u00a0RM,\u00a0Ribaudo\u00a0HJ,\u00a0Shikuma\u00a0CM,\u00a0Lustgarten \u00a0S,\u00a0Squires\u00a0KE,\u00a0Meyer\u00a0III\u00a0WA\u00a0et\u00a0al.\u00a0Triple\u2010\nNucleoside \u00a0Regimens \u00a0versus\u00a0Efavirenz\u2010Containing \u00a0Regimens \u00a0for\u00a0the\u00a0Initial\u00a0Treatment \u00a0of\u00a0HIV\u20101\u00a0\nInfection. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02004;\u00a0350:1850 \u20101861.\u00a0\n\u00a0 210.\u00a0\u00a0van\u00a0Leeuwen\u00a0R,\u00a0Katlama\u00a0C,\u00a0Murphy\u00a0RL,\u00a0Squires\u00a0K,\u00a0Gatell\u00a0J,\u00a0Horban\u00a0A\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0trial\u00a0\nto\u00a0study\u00a0first\u2010line\u00a0combination \u00a0therapy\u00a0with\u00a0or\u00a0without\u00a0a\u00a0protease\u00a0inhibitor\u00a0in\u00a0HIV\u20101\u2010infected\u00a0\npatients.\u00a0AIDS\u00a02003;\u00a017(7):987 \u2010999.\u00a0\n\u00a0 211.\u00a0\u00a0Staszewski \u00a0S,\u00a0Keiser\u00a0P,\u00a0Montaner \u00a0J,\u00a0Raffi\u00a0F,\u00a0Gathe\u00a0J,\u00a0Brotas\u00a0V\u00a0et\u00a0al.\u00a0Abacavir\u2010lamivudine \u2010\nzidovudine \u00a0vs\u00a0indinavir\u2010lamivudine \u2010zidovudine \u00a0in\u00a0antiretroviral \u2010naive\u00a0HIV\u2010infected\u00a0adults:\u00a0A\u00a0\nrandomized \u00a0equivalence \u00a0trial.\u00a0Jama\u00a02001;\u00a0285(9):1155 \u201063.\u00a0\n\u00a0 212.\u00a0\u00a0Panel\u00a0de\u00a0de\u00a0Expertos\u00a0de\u00a0Gesida\u00a0y\u00a0Plan\u00a0Nacional\u00a0sobre\u00a0el\u00a0Sida.\u00a0Recomendaciones \u00a0de\u00a0Gesi\u2010\nda/Plan\u00a0Nacional\u00a0sobre\u00a0el\u00a0Sida\u00a0respecto\u00a0al\u00a0tratamiento \u00a0antirretroviral \u00a0en\u00a0adultos\u00a0infectados \u00a0\npor\u00a0el\u00a0virus\u00a0de\u00a0la\u00a0inmunodeficiencia \u00a0humana\u00a0(Febrero\u00a02009).\u00a0Enferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a0\n2009;\u00a027(4):222 \u2010235.\u00a0\n\u00a0 213.\u00a0\u00a0Gazzard\u00a0BG.\u00a0British\u00a0HIV\u00a0Association \u00a0Guidelines \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0HIV\u20101\u2010infected\u00a0adults\u00a0\nwith\u00a0antiretroviral \u00a0therapy\u00a02008.\u00a0HIV\u00a0Med\u00a02008;\u00a09(8):563\u2010608.\u00a0\n\u00a0 214.\u00a0\u00a0Duvivier\u00a0C,\u00a0Ghosn\u00a0J,\u00a0Assoumou \u00a0L,\u00a0Soulie\u00a0C,\u00a0Peytavin\u00a0G,\u00a0Calvez\u00a0V\u00a0et\u00a0al.\u00a0Lower\u00a0rate\u00a0of\u00a0virological \u00a0\nsuppression \u00a0in\u00a0naive\u00a0patients\u00a0initiating\u00a0HAART\u00a0with\u00a0NRTI\u2010sparing\u00a0regimen\u00a0compared \u00a0to\u00a0stan\u2010\ndard\u00a0NRTI\u2010containing \u00a0regimen:\u00a0results\u00a0from\u00a0Hippocampe \u00a0\u2013\u00a0ANRS\u00a0121\u00a0Trial.\u00a010th\u00a0European \u00a0\nAIDS\u00a0Conference; \u00a0November \u00a017\u201020,\u00a02005;\u00a0Dublin,\u00a0Ireland.\u00a0Abstract\u00a0PS1/3\u00a0\n\u00a0 215.\u00a0\u00a0Fischl\u00a0MA,\u00a0Bassett\u00a0R,\u00a0Collier\u00a0A,\u00a0Mukherjee \u00a0L,\u00a0Demeter\u00a0L,\u00a0Tebas\u00a0P\u00a0et\u00a0al.\u00a0Randomized, \u00a0contro\u2010\nlled\u00a0trial\u00a0of\u00a0lopinavir/ritonavir \u00a0+\u00a0efavirenz\u00a0vs\u00a0efavirenz\u00a0+\u00a02\u00a0nucleoside \u00a0reverse\u00a0transcriptase \u00a0\ninhibitors \u00a0following\u00a0a\u00a0first\u00a0suppressive \u00a03\u2010\u00a0or\u00a04\u2010drug\u00a0regimen\u00a0in\u00a0advanced \u00a0HIV\u00a0disease.\u00a012th\u00a0\nConference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Boston,\u00a02005\u00a0Abstract\u00a0162\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 113 \n \u00a0 216.\u00a0\u00a0Markowitz \u00a0M,\u00a0Hill\u2010Zabala\u00a0C,\u00a0Lang\u00a0J,\u00a0DeJesus\u00a0E,\u00a0Liao\u00a0Q,\u00a0Lanier\u00a0ER\u00a0et\u00a0al.\u00a0Induction \u00a0with\u00a0abaca\u2010\nvir/lamivudine/zidovudine \u00a0plus\u00a0efavirenz\u00a0for\u00a048\u00a0weeks\u00a0followed\u00a0by\u00a048\u2010week\u00a0maintenance \u00a0\nwith\u00a0abacavir/lamivudine/zidovudine \u00a0alone\u00a0in\u00a0antiretroviral \u2010naive\u00a0HIV\u20101\u2010infected\u00a0patients.\u00a0J\u00a0\nAcquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02005;\u00a039(3):257 \u2010264.\u00a0\n\u00a0 217.\u00a0\u00a0Shafer\u00a0RW,\u00a0Smeaton\u00a0MS,\u00a0Robbins\u00a0GK,\u00a0De\u00a0Gruttola\u00a0V,\u00a0Snyder\u00a0SW,\u00a0D'\u00a0Aquila\u00a0RT\u00a0et\u00a0al.\u00a0Compari\u2010\nson\u00a0of\u00a0four\u2010drug\u00a0regimens\u00a0and\u00a0pairs\u00a0of\u00a0sequential \u00a0three\u2010drugs\u00a0regimens\u00a0as\u00a0inicial\u00a0therapy\u00a0for\u00a0\nHIV\u20101\u00a0infection. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02003;\u00a0349:2304 \u20102315.\u00a0\n\u00a0 218.\u00a0\u00a0Gulick\u00a0RM,\u00a0Ribaudo\u00a0HJ,\u00a0Shikuma\u00a0CM,\u00a0Lalama\u00a0C,\u00a0Schackman \u00a0BR,\u00a0Meyer\u00a0WA,\u00a0III\u00a0et\u00a0al.\u00a0Three\u2010\u00a0vs\u00a0\nfour\u2010drug\u00a0antiretroviral \u00a0regimens \u00a0for\u00a0the\u00a0initial\u00a0treatment \u00a0of\u00a0HIV\u20101\u00a0infection: \u00a0a\u00a0randomized \u00a0\ncontrolled \u00a0trial.\u00a0Jama\u00a02006;\u00a0296(7):769 \u2010781.\u00a0\n\u00a0 219.\u00a0\u00a0Ribaudo\u00a0HJ,\u00a0Kuritzkes\u00a0DR,\u00a0Gulick\u00a0RM.\u00a0A\u00a0comparison \u00a0of\u00a0three\u00a0initial\u00a0antiretroviral \u00a0AIDS\u00a0regi\u2010\nmens.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02007;\u00a0357(10):1056 \u20101057.\u00a0\n\u00a0 220.\u00a0\u00a0Gallant\u00a0JE,\u00a0Staszewski \u00a0S,\u00a0Pozniak\u00a0AL,\u00a0DeJesus\u00a0E,\u00a0Suleiman\u00a0JM,\u00a0Miller\u00a0MD\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0\nsafety\u00a0of\u00a0tenofovir\u00a0DF\u00a0vs\u00a0stavudine \u00a0in\u00a0combination \u00a0therapy\u00a0in\u00a0antiretroviral \u2010naive\u00a0patients:\u00a0a\u00a0\n3\u2010year\u00a0randomized \u00a0trial.\u00a0Jama\u00a02004;\u00a0292(2):191 \u2010201.\u00a0\n\u00a0 221.\u00a0\u00a0Gallant\u00a0JE,\u00a0DeJesus\u00a0E,\u00a0Arribas\u00a0JR,\u00a0Pozniak\u00a0AL,\u00a0Gazzard\u00a0B,\u00a0Campo\u00a0RE\u00a0et\u00a0al.\u00a0Tenofovir \u00a0DF,\u00a0emtri\u2010\ncitabine,\u00a0and\u00a0efavirenz\u00a0vs.\u00a0zidovudine, \u00a0lamivudine, \u00a0and\u00a0efavirenz\u00a0for\u00a0HIV.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02006;\u00a0\n354(3):251 \u2010260.\u00a0\n\u00a0 222.\u00a0\u00a0McColl\u00a0D,\u00a0Margot\u00a0N,\u00a0Chuang\u00a0SM,\u00a0Chen\u00a0SS,\u00a0Miller\u00a0M.\u00a0Final\u00a0week\u00a0144\u00a0resistance \u00a0analysis\u00a0of\u00a0\nstudy\u00a0934:\u00a0No\u00a0K65R\u00a0detected\u00a0and\u00a0lower\u00a0frequency \u00a0of\u00a0M184V\u00a0on\u00a0tenofovir\u00a0Df\u00a0+\u00a0emtricitabine \u00a0\n+\u00a0efavirenz\u00a0compared \u00a0to\u00a0combivir\u00a0+\u00a0efavirenz. \u00a011th\u00a0European \u00a0Aids\u00a0Conference, \u00a0Madrid,\u00a02007\u00a0\nP3.1/08\u00a0\n\u00a0 223.\u00a0\u00a0Arribas\u00a0JR,\u00a0Pozniak\u00a0AL,\u00a0Gallant\u00a0JE,\u00a0DeJesus\u00a0E,\u00a0Gazzard\u00a0B,\u00a0Campo\u00a0RE\u00a0et\u00a0al.\u00a0Tenofovir \u00a0disoproxil \u00a0\nfumarate, \u00a0emtricitabine, \u00a0and\u00a0efavirenz\u00a0compared \u00a0with\u00a0zidovudine/lamivudine \u00a0and\u00a0efavirenz\u00a0\nin\u00a0treatment \u2010naive\u00a0patients:\u00a0144\u2010week\u00a0analysis.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02008;\u00a047(1):74\u2010\n78.\u00a0\n\u00a0 224.\u00a0\u00a0DeJesus\u00a0E,\u00a0Herrera\u00a0G,\u00a0Teofilo\u00a0E,\u00a0Gerstoft\u00a0J,\u00a0Buendia\u00a0CB,\u00a0Brand\u00a0JD\u00a0et\u00a0al.\u00a0Abacavir\u00a0versus\u00a0zido\u2010\nvudine\u00a0combined \u00a0with\u00a0lamivudine \u00a0and\u00a0efavirenz, \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0antiretroviral \u2010naive\u00a0\nHIV\u2010infected\u00a0adults.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02004;\u00a039(7):1038 \u20101046.\u00a0\n\u00a0 225.\u00a0\u00a0Moyle\u00a0GJ,\u00a0DeJesus\u00a0E,\u00a0Cahn\u00a0P,\u00a0Castillo\u00a0SA,\u00a0Zhao\u00a0H,\u00a0Gordon\u00a0DN\u00a0et\u00a0al.\u00a0Abacavir\u00a0once\u00a0or\u00a0twice\u00a0\ndaily\u00a0combined \u00a0with\u00a0once\u2010daily\u00a0lamivudine \u00a0and\u00a0efavirenz\u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0antiretroviral \u2010\nnaive\u00a0HIV\u2010infected\u00a0adults:\u00a0results\u00a0of\u00a0the\u00a0Ziagen\u00a0Once\u00a0Daily\u00a0in\u00a0Antiretroviral \u00a0Combination \u00a0Stu\u2010\ndy.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02005;\u00a038(4):417 \u2010425.\u00a0\n\u00a0 226.\u00a0\u00a0Podzamczer \u00a0D,\u00a0Ferrer\u00a0E,\u00a0Sanchez\u00a0P,\u00a0Gatell\u00a0JM,\u00a0Crespo\u00a0M,\u00a0Fisac\u00a0C\u00a0et\u00a0al.\u00a0Less\u00a0lipoatrophy \u00a0and\u00a0\nbetter\u00a0lipid\u00a0profile\u00a0with\u00a0abacavir\u00a0as\u00a0compared \u00a0to\u00a0stavudine: \u00a096\u2010week\u00a0results\u00a0of\u00a0a\u00a0randomized \u00a0\nstudy.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a044(2):139 \u2010147.\u00a0\n\u00a0 227.\u00a0\u00a0Saag\u00a0MS,\u00a0Cahn\u00a0P,\u00a0Raffi\u00a0F,\u00a0Wolff\u00a0M,\u00a0Pearce\u00a0D,\u00a0Molina\u00a0JM\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0emtricita\u2010\nbine\u00a0vs\u00a0stavudine \u00a0in\u00a0combination \u00a0therapy\u00a0in\u00a0antiretroviral \u2010naive\u00a0patients:\u00a0a\u00a0randomized \u00a0trial.\u00a0\nJama\u00a02004;\u00a0292(2):180 \u2010189.\u00a0\n\u00a0 228.\u00a0\u00a0Berenguer \u00a0J,\u00a0Gonzalez\u00a0J,\u00a0Ribera\u00a0E,\u00a0Domingo\u00a0P,\u00a0Santos\u00a0J,\u00a0Miralles\u00a0P\u00a0et\u00a0al.\u00a0Didanosine, \u00a0lamivudi\u2010\nne,\u00a0and\u00a0efavirenz\u00a0versus\u00a0zidovudine, \u00a0lamivudine, \u00a0and\u00a0efavirenz\u00a0for\u00a0the\u00a0initial\u00a0treatment \u00a0of\u00a0HIV\u00a0\ntype\u00a01\u00a0infection: \u00a0final\u00a0analysis\u00a0(48\u00a0weeks)\u00a0of\u00a0a\u00a0prospective, \u00a0randomized, \u00a0noninferiority \u00a0clinical\u00a0\ntrial,\u00a0GESIDA\u00a03903.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02008;\u00a047(8):1083 \u20101092.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 114 \n \u00a0 229.\u00a0\u00a0Robbins\u00a0GK,\u00a0De\u00a0Gruttola\u00a0V,\u00a0Shafer\u00a0RW,\u00a0Smeaton\u00a0LM,\u00a0Snyder\u00a0SW,\u00a0Pettinelli\u00a0C\u00a0et\u00a0al.\u00a0Compari\u2010\nson\u00a0of\u00a0secuential \u00a0three\u2010drug\u00a0regimens\u00a0as\u00a0inicial\u00a0therapy\u00a0for\u00a0HIV\u20101\u00a0infecti\u00f3n. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a0\n2003;\u00a0349:2293 \u20102303.\u00a0\n\u00a0 230.\u00a0\u00a0Campbell \u00a0T,\u00a0Smeaton\u00a0L,\u00a0De\u00a0Gruttola\u00a0V,\u00a0(for\u00a0ACTG\u00a0A5175\u00a0study\u00a0group).\u00a0PEARLS\u00a0(ACTG\u00a0A5175):\u00a0\na\u00a0multinational \u00a0study\u00a0of\u00a0didanosine \u2010EC,\u00a0emtricitabine \u00a0and\u00a0atazanavir \u00a0vs.\u00a0co\u2010formulated \u00a0zido\u2010\nvudine/lamivudine \u00a0and\u00a0efavirenz\u00a0for\u00a0initial\u00a0treatment \u00a0of\u00a0HIV\u20101\u00a0infection. \u00a017th\u00a0International \u00a0\nAIDS\u00a0Conference; \u00a03\u20108\u00a0August,\u00a02008;\u00a0Mexico\u00a0DF.\u00a0(Abstract\u00a0\u2010\u2010\u2010\u2010)\u00a0\n\u00a0 231.\u00a0\u00a0Smith\u00a0K,\u00a0Fine\u00a0D,\u00a0Patel\u00a0P,\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0abacavir/lamivudine \u00a0compared \u00a0to\u00a0enofo\u2010\nvir/emtricitabine \u00a0in\u00a0combination \u00a0with\u00a0once\u2010daily\u00a0lopinavir/ritonavir \u00a0through\u00a048\u00a0weeks\u00a0in\u00a0the\u00a0\nHEAT\u00a0Study.\u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a02008;\u00a0\nBoston,\u00a0Massachusetts \u00a0(Abstrac\u00a0774)\u00a0\n\u00a0 232.\u00a0\u00a0Smith\u00a0K,\u00a0Fine\u00a0D,\u00a0Patel\u00a0P,\u00a0et\u00a0al.\u00a0Similarity \u00a0in\u00a0efficacy\u00a0and\u00a0safety\u00a0of\u00a0abacavir/lamivudine \u00a0compa\u2010\nred\u00a0to\u00a0tenofovir/emtricitabine \u00a0in\u00a0combination \u00a0with\u00a0QD\u00a0lopinavir/ritonavir \u00a0(LPV/r)\u00a0over\u00a096\u00a0\nweeks\u00a0in\u00a0the\u00a0HEAT\u00a0study.\u00a017th\u00a0International \u00a0AIDS\u00a0Conference; \u00a03\u20108\u00a0August,\u00a02008;\u00a0Mexico\u00a0DF.\u00a0\n(Abstract\u00a0LBPE1138) \u00a0\n\u00a0 233.\u00a0\u00a0Sax\u00a0PE,\u00a0Tierney\u00a0C,\u00a0Collier\u00a0AC,\u00a0Fischl\u00a0MA,\u00a0Mollan\u00a0K,\u00a0Peeples\u00a0L\u00a0et\u00a0al.\u00a0Abacavir\u2010Lamivudine \u00a0versus\u00a0\nTenofovir \u2010Emtricitabine \u00a0for\u00a0Initial\u00a0HIV\u20101\u00a0Therapy.\u00a0The\u00a0New\u00a0England\u00a0Journal\u00a0of\u00a0Medicine \u00a02009;\u00a0\n361(23):2230 \u20102240.\u00a0\n\u00a0 234.\u00a0\u00a0Stellbrink \u00a0H\u2010J,\u00a0Moyle\u00a0G,\u00a0Orkin\u00a0C,\u00a0Arribas\u00a0JR,\u00a0Pearce\u00a0H,\u00a0Zucchi\u00a0P\u00a0et\u00a0al.\u00a0Comparison \u00a0of\u00a0renal\u00a0and\u00a0\nbone\u00a0toxicities, \u00a0and\u00a0CV\u00a0serum\u00a0risk\u00a0markers,\u00a0in\u00a0the\u00a0ASSERT\u00a0study:\u00a048\u2010week\u00a0results\u00a0from\u00a0a\u00a0\nprospective \u00a0randomised \u00a0trial.\u00a012th\u00a0European \u00a0AIDS\u00a0Conference \u00a0/EACS.Cologne, \u00a0Germany, \u00a0No\u2010\nvember\u00a011\u201014,\u00a02009\u00a0Abstract\u00a0PS\u00a010/1\u00a0\n\u00a0 235.\u00a0\u00a0Hill\u00a0A,\u00a0Sawyer\u00a0W.\u00a0Effects\u00a0of\u00a0nucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitor\u00a0backbone \u00a0on\u00a0the\u00a0effica\u2010\ncy\u00a0of\u00a0first\u2010line\u00a0boosted\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0based\u00a0on\u00a0protease\u00a0inhibitors: \u00a0me\u2010\nta\u2010regression \u00a0analysis\u00a0of\u00a012\u00a0clinical\u00a0trials\u00a0in\u00a05168\u00a0patients.\u00a0HIV\u00a0Med\u00a02009;\u00a010(9):527 \u2010535.\u00a0\n\u00a0 236.\u00a0\u00a0Sabin\u00a0CA,\u00a0Worm\u00a0SW,\u00a0Weber\u00a0R,\u00a0Reiss\u00a0P,\u00a0El\u2010Sadr\u00a0W,\u00a0Dabis\u00a0F\u00a0et\u00a0al.\u00a0Use\u00a0of\u00a0nucleoside \u00a0reverse\u00a0\ntranscriptase \u00a0inhibitors \u00a0and\u00a0risk\u00a0of\u00a0myocardial \u00a0infarction \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0enrolled\u00a0in\u00a0\nthe\u00a0D:A:D\u00a0study:\u00a0a\u00a0multi\u2010cohort\u00a0collaboration. \u00a0Lancet\u00a02008;\u00a0371(9622):1417 \u20101426.\u00a0\n\u00a0 237.\u00a0\u00a0The\u00a0SMART\u2010INSIGHT\u00a0and\u00a0the\u00a0D:A:D\u00a0Study\u00a0Groups.\u00a0Use\u00a0of\u00a0nucleoside \u00a0reverse\u00a0transcriptase \u00a0\ninhibitors \u00a0and\u00a0risk\u00a0of\u00a0myocardial \u00a0infarction \u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0AIDS\u00a02008;\u00a022(14):F17 \u2010\nF24.\u00a0\n\u00a0 238.\u00a0\u00a0Cutrell\u00a0A,\u00a0Hernandez \u00a0J,\u00a0Yeo\u00a0J,\u00a0et\u00a0al.\u00a0Is\u00a0abacavir\u2010containing \u00a0combination \u00a0antiretroviral \u00a0therapy\u00a0\nassociated \u00a0with\u00a0myocardial \u00a0infarction? \u00a0No\u00a0association \u00a0identified \u00a0in\u00a0pooled\u00a0summary \u00a0of\u00a054\u00a0cli\u2010\nnical\u00a0trials.\u00a017th\u00a0International \u00a0AIDS\u00a0Conference; \u00a03\u20108\u00a0August,\u00a02008;\u00a0Mexico\u00a0DF.\u00a0(Abstract\u00a0Abs\u2010\ntract\u00a0WEAB0106) \u00a0\n\u00a0 239.\u00a0\u00a0Eron\u00a0J,\u00a0Jr.,\u00a0Yeni\u00a0P,\u00a0Gathe\u00a0J,\u00a0Jr.,\u00a0Estrada\u00a0V,\u00a0DeJesus\u00a0E,\u00a0Staszewski \u00a0S\u00a0et\u00a0al.\u00a0The\u00a0KLEAN\u00a0study\u00a0of\u00a0\nfosamprenavir \u2010ritonavir\u00a0versus\u00a0lopinavir\u2010ritonavir,\u00a0each\u00a0in\u00a0combination \u00a0with\u00a0abacavir\u2010\nlamivudine, \u00a0for\u00a0initial\u00a0treatment \u00a0of\u00a0HIV\u00a0infection\u00a0over\u00a048\u00a0weeks:\u00a0a\u00a0randomised \u00a0non\u2010inferiority \u00a0\ntrial.\u00a0Lancet\u00a02006;\u00a0368(9534):476 \u2010482.\u00a0\n\u00a0 240.\u00a0\u00a0Hicks\u00a0C,\u00a0DeJesus\u00a0E,\u00a0Wohl\u00a0D,\u00a0Liao\u00a0Q,\u00a0Pappa\u00a0K,\u00a0Lancaster \u00a0T\u00a0et\u00a0al.\u00a0Once\u2010daily\u00a0fosamprenavir \u00a0bo\u2010\nosted\u00a0with\u00a0either\u00a0100mg\u00a0or\u00a0200mg\u00a0of\u00a0ritonavir\u00a0and\u00a0combined \u00a0with\u00a0abacavir\u00a0/lamivudine: \u00a048\u2010\nweek\u00a0safety\u00a0and\u00a0efficacy\u00a0results\u00a0from\u00a0COL100758. \u00a011th\u00a0European \u00a0AIDS\u00a0Conference \u00a0\n/EACS.Madrid, \u00a0Spain,\u00a0October\u00a024\u201027,\u00a02007\u00a0Abstract\u00a0P5.7/01\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 115 \n \u00a0 241.\u00a0\u00a0Elion\u00a0R,\u00a0DeJesus\u00a0E,\u00a0Sension\u00a0M,\u00a0Berger\u00a0D,\u00a0Towner\u00a0W,\u00a0Richmond \u00a0G\u00a0et\u00a0al.\u00a0Once\u2010daily\u00a0abaca\u2010\nvir/lamivudine \u00a0and\u00a0ritonavir\u2010boosted\u00a0atazanavir \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0HIV\u20101\u00a0infection\u00a0in\u00a0anti\u2010\nretroviral \u2010naive\u00a0patients:\u00a0a\u00a048\u2010week\u00a0pilot\u00a0study.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02008;\u00a09(3):152\u2010163.\u00a0\n\u00a0 242.\u00a0\u00a0Leon\u00a0A,\u00a0Martinez\u00a0E,\u00a0Mallolas\u00a0J,\u00a0Laguno\u00a0M,\u00a0Blanco\u00a0JL,\u00a0Pumarola \u00a0T\u00a0et\u00a0al.\u00a0Early\u00a0virological \u00a0failure\u00a0\nin\u00a0treatment \u2010naive\u00a0HIV\u2010infected\u00a0adults\u00a0receiving\u00a0didanosine \u00a0and\u00a0tenofovir\u00a0plus\u00a0efavirenz\u00a0or\u00a0\nnevirapine. \u00a0AIDS\u00a02005;\u00a019(2):213 \u2010215.\u00a0\n\u00a0 243.\u00a0\u00a0Negredo\u00a0E,\u00a0Bonjoch\u00a0A,\u00a0Paredes\u00a0R,\u00a0Puig\u00a0J,\u00a0Clotet\u00a0B.\u00a0Compromised \u00a0immunologic \u00a0recovery\u00a0in\u00a0\ntreatment \u2010experienced \u00a0patients\u00a0with\u00a0HIV\u00a0infection\u00a0receiving\u00a0both\u00a0tenofovir\u00a0disoproxil \u00a0fuma\u2010\nrate\u00a0and\u00a0didanosine \u00a0in\u00a0the\u00a0TORO\u00a0studies.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02005;\u00a041(6):901 \u2010905.\u00a0\n\u00a0 244.\u00a0\u00a0Martinez\u00a0E,\u00a0Milinkovic \u00a0A,\u00a0de\u00a0Lazzari\u00a0E,\u00a0Ravasi\u00a0G,\u00a0Blanco\u00a0JL,\u00a0Larrousse \u00a0M\u00a0et\u00a0al.\u00a0Pancreatic \u00a0toxic\u00a0\neffects\u00a0associated \u00a0with\u00a0the\u00a0co\u2010administration \u00a0of\u00a0didanosine \u00a0and\u00a0tenofovir\u00a0in\u00a0HIV\u2010infected\u00a0\nadults.\u00a0Lancet\u00a02004;\u00a0364:65\u201067.\u00a0\n\u00a0 245.\u00a0\u00a0Podzamczer \u00a0D,\u00a0Ferrer\u00a0E,\u00a0Gatell\u00a0JM,\u00a0Niubo\u00a0J,\u00a0Dalmau\u00a0D,\u00a0Leon\u00a0A\u00a0et\u00a0al.\u00a0Early\u00a0virological \u00a0failure\u00a0\nwith\u00a0a\u00a0combination \u00a0of\u00a0tenofovir, \u00a0didanosine \u00a0and\u00a0efavirenz. \u00a0Antivir\u00a0Ther\u00a02005;\u00a010(1):171 \u2010177.\u00a0\n\u00a0 246.\u00a0\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Moreno\u00a0S,\u00a0Gutierrez \u00a0C,\u00a0Lopez\u00a0D,\u00a0Abraira\u00a0V,\u00a0Moreno\u00a0A\u00a0et\u00a0al.\u00a0High\u00a0virological \u00a0\nfailure\u00a0rate\u00a0in\u00a0HIV\u00a0patients\u00a0after\u00a0switching \u00a0to\u00a0a\u00a0regimen\u00a0with\u00a0two\u00a0nucleoside \u00a0reverse\u00a0trans\u2010\ncriptase\u00a0inhibitors \u00a0plus\u00a0tenofovir. \u00a0AIDS\u00a02005;\u00a019(7):695 \u2010698.\u00a0\n\u00a0 247.\u00a0\u00a0Gatell\u00a0JM,\u00a0Clotet\u00a0B,\u00a0Mallolas\u00a0J,\u00a0Podzamczer \u00a0D,\u00a0Mir\u00f3\u00a0JM.\u00a0Gu\u00eda\u00a0Practica\u00a0del\u00a0SIDA.\u00a0Cl\u00ednica,\u00a0diag\u2010\nnostico\u00a0y\u00a0tratamiento. \u00a08\u00aa\u00a0Edici\u00f3n.\u00a08\u00aa\u00a0ed.\u00a0Barcelona: \u00a0Masson\u2010Salvat;\u00a02004.\u00a0\n\u00a0 248.\u00a0\u00a0Gulick\u00a0R,\u00a0et\u00a0al.\u00a0ACTG\u00a05095:\u00a0zidovudine/lamivudine/abacavir \u00a0Vs.\u00a0zidovudine/lamivudine \u00a0+\u00a0\nefavirenz\u00a0vs.\u00a0zidovudine/lamivudine/abacavir \u00a0+\u00a0efavirenz\u00a0for\u00a0initial\u00a0HIV\u00a0therapy.\u00a045th\u00a0Inters\u2010\ncience\u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy.December \u00a016\u201019,\u00a0\n2005.Washington, \u00a0DC.\u00a0Abstract\u00a0H\u2010416a\u00a0(slide\u00a0session)\u00a0\n\u00a0 249.\u00a0\u00a0Bartlett\u00a0JA,\u00a0Johnson\u00a0\u00a0J,\u00a0Herrera\u00a0G,\u00a0Sosa\u00a0N,\u00a0Rodriguez \u00a0AE,\u00a0Shaefer\u00a0MS.\u00a0Abacavir/Lamivudine \u00a0\n(ABC/3TC) \u00a0in\u00a0combination \u00a0with\u00a0Efavirenz\u00a0(NNRTI),\u00a0Amprenavir/Ritonavir \u00a0(PI)\u00a0or\u00a0Stavudine \u00a0\n(NRTI):\u00a0ESS40001(CLASS) \u00a0preliminary \u00a048\u00a0week\u00a0results.\u00a0XIV\u00a0International \u00a0AIDS\u00a0Conference, \u00a0\nBarcelona, \u00a02002\u00a0[Abstract\u00a0TuOrB1189] \u00a0\n\u00a0 250.\u00a0\u00a0Gallant\u00a0JE,\u00a0Rodriguez \u00a0AE,\u00a0Weinberg \u00a0W,\u00a0Young\u00a0B,\u00a0Berger\u00a0D,\u00a0Lim\u00a0ML\u00a0et\u00a0al.\u00a0Early\u00a0Non\u2010Response \u00a0\nto\u00a0Tenofovir \u00a0DF\u00a0(TDF)\u00a0+\u00a0Abacavir\u00a0(ABC)\u00a0and\u00a0Lamivudine \u00a0(3TC)\u00a0in\u00a0a\u00a0Randomized \u00a0Trial\u00a0Compa\u2010\nred\u00a0to\u00a0Efavirenz\u00a0(EFV)\u00a0+\u00a0ABC\u00a0and\u00a03TC:\u00a0ESS30009 \u00a0Unplanned \u00a0Interim\u00a0Analysis.\u00a043rd\u00a0Interscien \u2010\nce\u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy, \u00a0Chicago,\u00a02003\u00a0[Abstract: \u00a0H\u2010\n1722a]\u00a0\n\u00a0 251.\u00a0\u00a0Gerstoft\u00a0J,\u00a0Kirk\u00a0O,\u00a0Obel\u00a0N,\u00a0Pedersen \u00a0C,\u00a0Mathiesen \u00a0L,\u00a0Nielsen\u00a0H.\u00a0Low\u00a0efficacy\u00a0and\u00a0high\u00a0frequen\u2010\ncy\u00a0of\u00a0adverse\u00a0events\u00a0in\u00a0a\u00a0randomized \u00a0trial\u00a0of\u00a0the\u00a0triple\u00a0NRTI\u00a0regimen\u00a0abacavir,\u00a0stavudine \u00a0and\u00a0\ndidanosine. \u00a0AIDS\u00a02003;\u00a017:2045\u20102052.\u00a0\n\u00a0 252.\u00a0\u00a0Ferrer\u00a0E,\u00a0Gatell\u00a0JM,\u00a0Sanchez\u00a0P,\u00a0Domingo\u00a0P,\u00a0Puig\u00a0T,\u00a0Niubo\u00a0J\u00a0et\u00a0al.\u00a0Zidovudi\u2010\nne/lamivudine/abacavir \u00a0plus\u00a0tenofovir\u00a0in\u00a0HIV\u2010infected\u00a0naive\u00a0patients:\u00a0a\u00a096\u2010week\u00a0prospective \u00a0\none\u2010arm\u00a0pilot\u00a0study.\u00a0AIDS\u00a0Res\u00a0Hum\u00a0Retroviruses \u00a02008;\u00a024(7):931 \u2010934.\u00a0\n\u00a0 253.\u00a0\u00a0Moyle\u00a0G,\u00a0Nelson\u00a0M,\u00a0Higgs\u00a0C,\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0open\u00a0label\u00a0comparative \u00a0study\u00a0of\u00a0combi\u2010\nvir+efavirenz \u00a0(2\u00a0class\u00a0triple\u00a0therapy)\u00a0versus\u00a0trizivir\u00a0+tenofovir \u00a0(single\u00a0class\u00a0quadruple \u00a0therapy)\u00a0\nin\u00a0initial\u00a0therapy\u00a0for\u00a0HIV\u20101\u00a0infection. \u00a044th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0\nand\u00a0Chemotherapy.Washington, \u00a0DC.,\u00a02004.\u00a0Abstract\u00a0H\u20101131\u00a0\n\u00a0 254.\u00a0\u00a0Van\u00a0Leth\u00a0F,\u00a0Phanuphak \u00a0P,\u00a0Ruxrungtham \u00a0K,\u00a0Baraldi\u00a0E,\u00a0Miller\u00a0S,\u00a0Gazzard\u00a0B\u00a0et\u00a0al.\u00a0Comparison \u00a0of\u00a0\nfirst\u2010line\u00a0antiretroviral \u00a0therapy\u00a0with\u00a0regimens\u00a0including\u00a0nevirapine, \u00a0efavirenz, \u00a0or\u00a0both\u00a0drugs,\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 116 \n plus\u00a0stavudine \u00a0and\u00a0lamivudine: \u00a0a\u00a0randomised \u00a0open\u2010label\u00a0trial,\u00a0the\u00a02NN\u00a0Study.\u00a0Lancet\u00a02004;\u00a0\n363(9417):1253 \u20101263.\u00a0\n\u00a0 255.\u00a0\u00a0Podzamczer \u00a0D,\u00a0Olmo\u00a0M,\u00a0Sanz\u00a0J,\u00a0Boix\u00a0V,\u00a0Negredo\u00a0E,\u00a0Knobel\u00a0H\u00a0et\u00a0al.\u00a0Safety\u00a0of\u00a0switching \u00a0nevira\u2010\npine\u00a0twice\u00a0daily\u00a0to\u00a0nevirapine \u00a0once\u00a0daily\u00a0in\u00a0virologically \u00a0suppressed \u00a0patients.\u00a0J\u00a0Acquir\u00a0Immune\u00a0\nDefic\u00a0Syndr\u00a02009;\u00a050(4):390 \u2010396.\u00a0\n\u00a0 256.\u00a0\u00a0Soriano\u00a0V,\u00a0K\u00f6ppe\u00a0S,\u00a0Mingrone \u00a0H,\u00a0Lutz\u00a0T,\u00a0Opravil\u00a0M,\u00a0Andrade\u2010Villanueva \u00a0J\u00a0et\u00a0al.\u00a0Prospective \u00a0\ncomparison \u00a0of\u00a0nevirapine \u00a0and\u00a0atazanavir/ritonavir \u00a0both\u00a0combined \u00a0with\u00a0tenofovir\u00a0\nDF/emtricitabine \u00a0in\u00a0treatment \u2010na\u00efve\u00a0HIV\u20101\u00a0infected\u00a0patients:\u00a0ARTEN\u00a0study\u00a0week\u00a048\u00a0results.\u00a0\n5th\u00a0International \u00a0AIDS\u00a0Society\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention \u00a0\nCape\u00a0Town,\u00a0South\u00a0Africa\u00a0July\u00a019\u201022,\u00a02009\u00a02009;\u00a0Abstract\u00a0LBPEB07. \u00a0\n\u00a0 257.\u00a0\u00a0Podzamczer \u00a0D,\u00a0Ferrer\u00a0E,\u00a0Consiglio\u00a0E,\u00a0Gatell\u00a0JM,\u00a0Perez\u00a0P,\u00a0Perez\u00a0JL\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0clinical\u00a0\ntrial\u00a0comparing \u00a0nelfinavir \u00a0or\u00a0nevirapine \u00a0associated \u00a0to\u00a0zidovudine/lamivudine \u00a0in\u00a0HIV\u2010infected\u00a0\nnaive\u00a0patients\u00a0(the\u00a0Combine\u00a0Study).\u00a0Antivir\u00a0Ther\u00a02002;\u00a07(2):81\u201090.\u00a0\n\u00a0 258.\u00a0\u00a0Raffi\u00a0F,\u00a0Reliquet\u00a0V,\u00a0Podzamczer \u00a0D,\u00a0Pollard\u00a0RB.\u00a0Efficacy\u00a0of\u00a0nevirapine \u2010based\u00a0HAART\u00a0in\u00a0HIV\u20101\u2010\ninfected,\u00a0treatment \u2010naive\u00a0persons\u00a0with\u00a0high\u00a0and\u00a0low\u00a0baseline\u00a0viral\u00a0loads.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02001;\u00a0\n2(4):317\u201022.\u00a0\n\u00a0 259.\u00a0\u00a0Johnson\u00a0M,\u00a0Soriano\u00a0V,\u00a0Brockmeyer \u00a0N,\u00a0Winston\u00a0A,\u00a0Gellermann \u00a0HJ,\u00a0Cairns\u00a0V\u00a0et\u00a0al.\u00a0Virological \u00a0\nand\u00a0immunological \u00a0responses \u00a0are\u00a0comparable \u00a0between\u00a0nevirapine \u00a0and\u00a0RTV\u2010boosted\u00a0ataza\u2010\nnavir:\u00a0An\u00a0ARTEN\u00a0subanalysis. \u00a049th\u00a0ICAAC\u00a0San\u00a0Francisco, \u00a0CA\u00a0,\u00a0September \u00a012\u201015,\u00a02009\u00a02009;\u00a0\n(Abstract\u00a0H\u2010942c).\u00a0\n\u00a0 260.\u00a0\u00a0Staszewski \u00a0S,\u00a0Morales\u2010Ramirez\u00a0J,\u00a0Tashima\u00a0KT,\u00a0Rachlis\u00a0A,\u00a0Skiest\u00a0D,\u00a0Stanford\u00a0J\u00a0et\u00a0al.\u00a0Efavirenz\u00a0\nplus\u00a0zidovudine \u00a0and\u00a0lamivudine, \u00a0efavirenz\u00a0plus\u00a0indinavir, \u00a0and\u00a0indinavir\u00a0plus\u00a0zidovudine \u00a0and\u00a0\nlamivudine \u00a0in\u00a0the\u00a0treatment \u00a0of\u00a0HIV\u20101\u00a0infection\u00a0in\u00a0adults.\u00a0Study\u00a0006\u00a0Team.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a01999;\u00a0\n341(25):1865 \u201073.\u00a0\n\u00a0 261.\u00a0\u00a0Montaner \u00a0JS,\u00a0Schutz\u00a0M,\u00a0Schwartz\u00a0R,\u00a0Jayaweera \u00a0DT,\u00a0Burnside\u00a0AF,\u00a0Walmsley \u00a0S\u00a0et\u00a0al.\u00a0Efficacy,\u00a0\nsafety\u00a0and\u00a0pharmacokinetics \u00a0of\u00a0once\u2010daily\u00a0saquinavir \u00a0soft\u2010gelatin\u00a0capsule/ritonavir \u00a0in\u00a0antire\u2010\ntroviral\u2010naive,\u00a0HIV\u2010infected\u00a0patients.\u00a0MedGenMed \u00a02006;\u00a08(2):36.\u00a0\n\u00a0 262.\u00a0\u00a0Bartlett\u00a0JA,\u00a0Johnson\u00a0J,\u00a0Herrera\u00a0G,\u00a0Sosa\u00a0N,\u00a0Rodriguez \u00a0A,\u00a0Liao\u00a0Q\u00a0et\u00a0al.\u00a0Long\u2010term\u00a0results\u00a0of\u00a0initial\u00a0\ntherapy\u00a0with\u00a0abacavir\u00a0and\u00a0Lamivudine \u00a0combined \u00a0with\u00a0Efavirenz, \u00a0Amprenavir/Ritonavir, \u00a0or\u00a0\nStavudine. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02006;\u00a043(3):284 \u2010292.\u00a0\n\u00a0 263.\u00a0\u00a0Squires\u00a0K,\u00a0Lazzarin\u00a0A,\u00a0Gatell\u00a0JM,\u00a0Powderly \u00a0WG,\u00a0Pokrovskiy \u00a0V,\u00a0Delfraissy \u00a0JF\u00a0et\u00a0al.\u00a0Comparison \u00a0\nof\u00a0once\u2010daily\u00a0atazanavir \u00a0with\u00a0efavirenz, \u00a0each\u00a0in\u00a0combination \u00a0with\u00a0fixed\u2010dose\u00a0zidovudine \u00a0and\u00a0\nlamivudine, \u00a0as\u00a0initial\u00a0therapy\u00a0for\u00a0patients\u00a0infected\u00a0with\u00a0HIV.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a0\n2004;\u00a036(5):1011 \u20101019.\u00a0\n\u00a0 264.\u00a0\u00a0Dybul\u00a0M,\u00a0Chun\u00a0TW,\u00a0Ward\u00a0DJ,\u00a0Hertogs\u00a0K,\u00a0Larder\u00a0B,\u00a0Fox\u00a0CH\u00a0et\u00a0al.\u00a0Evaluation \u00a0of\u00a0lymph\u00a0node\u00a0\nvirus\u00a0burden\u00a0in\u00a0human\u00a0immunodeficiency \u00a0virus\u2010infected\u00a0patients\u00a0receiving\u00a0efavirenz\u2010based\u00a0\nprotease\u00a0inhibitor\u2010\u2010sparing\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0J\u00a0Infect\u00a0Dis\u00a02000;\u00a0181(4):1273 \u2010\n9.\u00a0\n\u00a0 265.\u00a0\u00a0Walmsley \u00a0S,\u00a0Bernstein \u00a0B,\u00a0King\u00a0M,\u00a0Arribas\u00a0J,\u00a0Beall\u00a0G,\u00a0Ruane\u00a0P\u00a0et\u00a0al.\u00a0Lopinavir\u2010ritonavir\u00a0versus\u00a0\nnelfinavir \u00a0for\u00a0the\u00a0initial\u00a0treatment \u00a0of\u00a0HIV\u00a0infection. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02002;\u00a0346(26):2039 \u20102046.\u00a0\n\u00a0 266.\u00a0\u00a0Gathe\u00a0J,\u00a0da\u00a0Silva\u00a0BA,\u00a0Cohen\u00a0DE,\u00a0Loutfy\u00a0MR,\u00a0Podzamczer \u00a0D,\u00a0Rubio\u00a0R\u00a0et\u00a0al.\u00a0A\u00a0once\u2010daily\u00a0lopina\u2010\nvir/ritonavir \u2010based\u00a0regimen\u00a0is\u00a0noninferior \u00a0to\u00a0twice\u2010daily\u00a0dosing\u00a0and\u00a0results\u00a0in\u00a0similar\u00a0safety\u00a0\nand\u00a0tolerability \u00a0in\u00a0antiretroviral \u2010naive\u00a0subjects\u00a0through\u00a048\u00a0weeks.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0\nSyndr\u00a02009;\u00a050(5):474 \u2010481.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 117 \n \u00a0 267.\u00a0\u00a0Rodriguez \u2010French\u00a0A,\u00a0Boghossian \u00a0J,\u00a0Gray\u00a0GE,\u00a0Nadler\u00a0JP,\u00a0Quinones \u00a0AR,\u00a0Sepulveda \u00a0GE\u00a0et\u00a0al.\u00a0The\u00a0\nNEAT\u00a0Study:\u00a0A\u00a048\u2010week\u00a0open\u2010label\u00a0study\u00a0to\u00a0compare\u00a0the\u00a0antiviral\u00a0efficacy\u00a0and\u00a0safety\u00a0of\u00a0\nGW433908 \u00a0versus\u00a0nelfinavir \u00a0in\u00a0antiretroviral \u00a0therapy\u00a0na\u00efve\u00a0HIV\u20101\u2010infected\u00a0patients.\u00a0J\u00a0Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr\u00a02004;\u00a035(1):22\u201032.\u00a0\n\u00a0 268.\u00a0\u00a0Gathe\u00a0JC,\u00a0Jr.,\u00a0Ive\u00a0P,\u00a0Wood\u00a0R,\u00a0Schurmann \u00a0D,\u00a0Bellos\u00a0NC,\u00a0DeJesus\u00a0E\u00a0et\u00a0al.\u00a0SOLO:\u00a048\u2010week\u00a0efficacy\u00a0\nand\u00a0safety\u00a0comparison \u00a0of\u00a0once\u2010daily\u00a0fosamprenavir \u00a0/ritonavir \u00a0versus\u00a0twice\u2010daily\u00a0nelfinavir \u00a0in\u00a0\nnaive\u00a0HIV\u20101\u2010infected\u00a0patients.\u00a0AIDS\u00a02004;\u00a018(11):1529 \u20101537.\u00a0\n\u00a0 269.\u00a0\u00a0Wohl\u00a0D,\u00a0Lancaster \u00a0T,\u00a0DeJesus\u00a0E,\u00a0Sloan\u00a0L,\u00a0Sension\u00a0M,\u00a0Liao\u00a0Q\u00a0et\u00a0al.\u00a0Determination \u00a0of\u00a0body\u00a0com\u2010\nposition\u00a0changes\u00a0by\u00a0total\u00a0body\u00a0DEXA\u00a0after\u00a048\u00a0weeks\u00a0of\u00a0treatment \u00a0with\u00a0once\u2010daily\u00a0fosampre \u2010\nnavir\u00a0(FPV)\u00a0boosted\u00a0with\u00a0two\u00a0different\u00a0doses\u00a0of\u00a0ritonavir(r) \u00a0plus\u00a0abacavir\u00a0\n(ABC)/lamivudine(3TC): \u00a0COL100758. \u00a04th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0\nPrevention, \u00a0Sydney,\u00a02007\u00a0(Abstract\u00a0TUPEB080) \u00a0\n\u00a0 270.\u00a0\u00a0Ruane\u00a0PJ,\u00a0Luber\u00a0AD,\u00a0Wire\u00a0MB,\u00a0Lou\u00a0Y,\u00a0Shelton\u00a0MJ,\u00a0Lancaster \u00a0CT\u00a0et\u00a0al.\u00a0Plasma\u00a0amprenavir \u00a0\npharmacokinetics \u00a0and\u00a0tolerability \u00a0following\u00a0administration \u00a0of\u00a01,400\u00a0milligrams \u00a0of\u00a0fosampre \u2010\nnavir\u00a0once\u00a0daily\u00a0in\u00a0combination \u00a0with\u00a0either\u00a0100\u00a0or\u00a0200\u00a0milligrams \u00a0of\u00a0ritonavir\u00a0in\u00a0healthy\u00a0vo\u2010\nlunteers.\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02007;\u00a051(2):560 \u2010565.\u00a0\n\u00a0 271.\u00a0\u00a0Ortiz\u00a0R,\u00a0DeJesus\u00a0E,\u00a0Khanlou\u00a0H,\u00a0Voronin\u00a0E,\u00a0van\u00a0LJ,\u00a0ndrade\u2010Villanueva \u00a0J\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0\nof\u00a0once\u2010daily\u00a0darunavir/ritonavir \u00a0versus\u00a0lopinavir/ritonavir \u00a0in\u00a0treatment \u2010naive\u00a0HIV\u20101\u2010infected\u00a0\npatients\u00a0at\u00a0week\u00a048.\u00a0AIDS\u00a02008;\u00a022(12):1389 \u20101397.\u00a0\n\u00a0 272.\u00a0\u00a0Mills\u00a0AM,\u00a0Nelson\u00a0M,\u00a0Jayaweera \u00a0D,\u00a0Ruxrungtham \u00a0K,\u00a0Cassetti\u00a0I,\u00a0Girard\u00a0PM\u00a0et\u00a0al.\u00a0Once\u2010daily\u00a0\ndarunavir/ritonavir \u00a0vs.\u00a0lopinavir/ritonavir \u00a0in\u00a0treatment \u2010naive,\u00a0HIV\u20101\u2010infected\u00a0patients:\u00a096\u2010\nweek\u00a0analysis.\u00a0AIDS\u00a02009;\u00a023(13):1679 \u20101688.\u00a0\n\u00a0 273.\u00a0\u00a0Walmsley \u00a0S,\u00a0Ruxrungtham \u00a0K,\u00a0Slim\u00a0J,\u00a0et\u00a0al.\u00a0Saquinavir/r \u00a0BiD\u00a0versus\u00a0lopinavir/r \u00a0BiD,\u00a0plus\u00a0emtrici\u2010\ntabine/tenofovir \u00a0QD\u00a0as\u00a0initial\u00a0therapy\u00a0in\u00a0HIV\u20101\u00a0infected\u00a0patients:\u00a0the\u00a0GEMINI\u00a0study.\u00a011th\u00a0Eu\u2010\nropean\u00a0Aids\u00a0Conference, \u00a0Madrid,\u00a02007\u00a0(Abstract\u00a0PS1/4)\u00a0\n\u00a0 274.\u00a0\u00a0Malan\u00a0DR,\u00a0Krantz\u00a0E,\u00a0David\u00a0N,\u00a0Wirtz\u00a0V,\u00a0Hammond \u00a0J,\u00a0McGrath\u00a0D.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0atazana\u2010\nvir,\u00a0with\u00a0or\u00a0without\u00a0ritonavir,\u00a0as\u00a0part\u00a0of\u00a0once\u2010daily\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0regi\u2010\nmens\u00a0in\u00a0antiretroviral \u2010naive\u00a0patients.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02008;\u00a047(2):161 \u2010167.\u00a0\n\u00a0 275.\u00a0\u00a0Gathe\u00a0J,\u00a0da\u00a0Silva\u00a0B,\u00a0Loutfy\u00a0M,\u00a0et\u00a0al.\u00a0Study\u00a0M05\u2010730\u00a0primary\u00a0efficacy\u00a0results\u00a0at\u00a0week\u00a048:\u00a0phase\u00a0\n3,\u00a0randomized, \u00a0open\u2010label\u00a0study\u00a0of\u00a0lopinavir/ritonavir \u00a0tablets\u00a0once\u00a0daily\u00a0vs\u00a0twice\u00a0daily,\u00a0co\u2010\nadministered \u00a0with\u00a0tenofovir\u00a0DF\u00a0+\u00a0emtricitabine \u00a0in\u00a0ARV\u2010naive\u00a0HIV\u20101\u2010infected\u00a0subjects.\u00a015th\u00a0\nConference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a02008;\u00a0Boston,\u00a0Massachu \u2010\nsetts\u00a0(Abstract\u00a0775)\u00a0\n\u00a0 276.\u00a0\u00a0Molina\u00a0JM,\u00a0Andrade\u2010Villanueva \u00a0J,\u00a0Echevarria \u00a0J,\u00a0Chetchotisakd \u00a0P,\u00a0Corral\u00a0J,\u00a0David\u00a0N\u00a0et\u00a0al.\u00a0Once\u2010\ndaily\u00a0atazanavir/ritonavir \u00a0versus\u00a0twice\u2010daily\u00a0lopinavir/ritonavir, \u00a0each\u00a0in\u00a0combination \u00a0with\u00a0te\u2010\nnofovir\u00a0and\u00a0emtricitabine, \u00a0for\u00a0management \u00a0of\u00a0antiretroviral \u2010naive\u00a0HIV\u20101\u2010infected\u00a0patients:\u00a048\u00a0\nweek\u00a0efficacy\u00a0and\u00a0safety\u00a0results\u00a0of\u00a0the\u00a0CASTLE\u00a0study.\u00a0Lancet\u00a02008;\u00a0372(9639):646 \u2010655.\u00a0\n\u00a0 277.\u00a0\u00a0Molina\u00a0J,\u00a0Andrade\u2010Villanueva \u00a0J,\u00a0Echevarria \u00a0J,\u00a0et\u00a0al.\u00a0CASTLE:\u00a0Atazanavir \u2010ritonavir\u00a0versus\u00a0lopina\u2010\nvir\u2010ritonavir\u00a0in\u00a0antiretroviral \u2010naive\u00a0HIV\u20101\u2010infected\u00a0patients:\u00a096\u00a0week\u00a0efficacy\u00a0and\u00a0safety.\u00a048th\u00a0\nAnnual\u00a0ICCAC/IDSA \u00a046th\u00a0Annual\u00a0Meeting;\u00a0October\u00a025\u201028,\u00a02008;\u00a0Washington, \u00a0DC\u00a02009;\u00a0Abs\u2010\ntract\u00a0H\u20101250d.\u00a0\n\u00a0 278.\u00a0\u00a0Saag\u00a0M,\u00a0Ive\u00a0P,\u00a0Heera\u00a0J,\u00a0Tawadrous \u00a0M,\u00a0DeJesus\u00a0E,\u00a0Clumeck\u00a0N\u00a0et\u00a0al.\u00a0A\u00a0multicenter, \u00a0randomized, \u00a0\ndouble\u2010blind,\u00a0comparative \u00a0trial\u00a0of\u00a0a\u00a0novel\u00a0CCR5\u00a0antagonist, \u00a0maraviroc \u00a0versus\u00a0efavirenz, \u00a0both\u00a0\nin\u00a0combination \u00a0with\u00a0Combivir\u00a0(zidovudine \u00a0/\u00a0lamivudine), \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0antiretroviral \u00a0\nna\u00efve\u00a0patients\u00a0infected\u00a0with\u00a0R5\u00a0HIV\u20101:\u00a0week\u00a048\u00a0results\u00a0of\u00a0the\u00a0MERIT\u00a0study.\u00a04th\u00a0IAS\u00a0Conferen\u2010\nce\u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Sydney,\u00a02007\u00a0(abstract\u00a0WESS104) \u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 118 \n \u00a0 279.\u00a0\u00a0Lennox\u00a0JL,\u00a0DeJesus\u00a0E,\u00a0Lazzarin\u00a0A,\u00a0Pollard\u00a0RB,\u00a0Madruga\u00a0JV,\u00a0Berger\u00a0DS\u00a0et\u00a0al.\u00a0Safety\u00a0and\u00a0efficacy\u00a0\nof\u00a0raltegravir \u2010based\u00a0versus\u00a0efavirenz\u2010based\u00a0combination \u00a0therapy\u00a0in\u00a0treatment \u2010naive\u00a0patients\u00a0\nwith\u00a0HIV\u20101\u00a0infection: \u00a0a\u00a0multicentre, \u00a0double\u2010blind\u00a0randomised \u00a0controlled \u00a0trial.\u00a0Lancet\u00a02009;\u00a0\n374(9692):796 \u2010806.\u00a0\n\u00a0 280.\u00a0\u00a0Gratacos\u00a0L,\u00a0Tuset\u00a0M,\u00a0Codina\u00a0C,\u00a0Miro\u00a0JM,\u00a0Mallolas\u00a0J,\u00a0Miserachs \u00a0N\u00a0et\u00a0al.\u00a0Tratamiento \u00a0antirre\u2010\ntroviral\u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0virus\u00a0de\u00a0la\u00a0inmunodeficiencia \u00a0humana:\u00a0duraci\u00f3n\u00a0y\u00a0motivos\u00a0de\u00a0\ncambio\u00a0del\u00a0primer\u00a0esquema\u00a0terap\u00e9utico \u00a0en\u00a0518\u00a0pacientes. \u00a0Med\u00a0Clin\u00a0(Barc)\u00a02006;\u00a0126(7):241 \u2010\n245.\u00a0\n\u00a0 281.\u00a0\u00a0Klein\u00a0MB,\u00a0Willemot\u00a0P,\u00a0Murphy\u00a0T,\u00a0Lalonde\u00a0RG.\u00a0The\u00a0impact\u00a0of\u00a0initial\u00a0highly\u00a0active\u00a0antiretroviral \u00a0\ntherapy\u00a0on\u00a0future\u00a0treatment \u00a0sequences \u00a0in\u00a0HIV\u00a0infection. \u00a0AIDS\u00a02004;\u00a018(14):1895 \u20101904.\u00a0\n\u00a0 282.\u00a0\u00a0Cozzi\u2010Lepri\u00a0A,\u00a0Phillips\u00a0AN,\u00a0Clotet\u00a0B,\u00a0Mocroft\u00a0A,\u00a0Ruiz\u00a0L,\u00a0Kirk\u00a0O\u00a0et\u00a0al.\u00a0Detection \u00a0of\u00a0HIV\u00a0drug\u00a0resis\u2010\ntance\u00a0during\u00a0antiretroviral \u00a0treatment \u00a0and\u00a0clinical\u00a0progression \u00a0in\u00a0a\u00a0large\u00a0European \u00a0cohort\u00a0stu\u2010\ndy.\u00a0AIDS\u00a02008;\u00a022(16):2187 \u20102198.\u00a0\n\u00a0 283.\u00a0\u00a0Paterson\u00a0DL,\u00a0Swindells \u00a0S,\u00a0Mohr\u00a0J,\u00a0Brester\u00a0M,\u00a0Vergis\u00a0EN,\u00a0Squier\u00a0C\u00a0et\u00a0al.\u00a0Adherence \u00a0to\u00a0protease\u00a0\ninhibitor\u00a0therapy\u00a0and\u00a0outcomes \u00a0in\u00a0patients\u00a0with\u00a0HIV\u00a0infection. \u00a0Ann\u00a0Intern\u00a0Med\u00a02000;\u00a0\n133(1):21 \u201030.\u00a0\n\u00a0 284.\u00a0\u00a0Chesney\u00a0MA,\u00a0Ickovics\u00a0J,\u00a0Hecht\u00a0FM,\u00a0Sikipa\u00a0G,\u00a0Rabkin\u00a0J.\u00a0Adherence: \u00a0a\u00a0necessity\u00a0for\u00a0successful \u00a0\nHIV\u00a0combination \u00a0therapy.\u00a0AIDS\u00a01999;\u00a013(Suppl\u00a0A):271\u20108.\u00a0\n\u00a0 285.\u00a0\u00a0Haubrich\u00a0RH,\u00a0Little\u00a0SJ,\u00a0Currier\u00a0JS,\u00a0Forthal\u00a0DN,\u00a0Kemper\u00a0CA,\u00a0Beall\u00a0GN\u00a0et\u00a0al.\u00a0The\u00a0value\u00a0of\u00a0patient\u2010\nreported\u00a0adherence \u00a0to\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0predicting \u00a0virologic\u00a0and\u00a0immunologic \u00a0respon\u2010\nse.\u00a0California \u00a0Collaborative \u00a0Treatment \u00a0Group.\u00a0AIDS\u00a01999;\u00a013(9):1099 \u2010107.\u00a0\n\u00a0 286.\u00a0\u00a0Shet\u00a0A,\u00a0Berry\u00a0L,\u00a0Mohri\u00a0H,\u00a0Mehandru \u00a0S,\u00a0Chung\u00a0C,\u00a0Kim\u00a0A\u00a0et\u00a0al.\u00a0Tracking\u00a0the\u00a0prevalence \u00a0of\u00a0\ntransmitted \u00a0antiretroviral \u00a0drug\u2010resistant\u00a0HIV\u20101:\u00a0a\u00a0decade\u00a0of\u00a0experience. \u00a0J\u00a0Acquir\u00a0Immune\u00a0De\u2010\nfic\u00a0Syndr\u00a02006;\u00a041(4):439 \u2010446.\u00a0\n\u00a0 287.\u00a0\u00a0Yerly\u00a0S,\u00a0von\u00a0W,\u00a0V,\u00a0Ledergerber \u00a0B,\u00a0Boni\u00a0J,\u00a0Schupbach \u00a0J,\u00a0Burgisser\u00a0P\u00a0et\u00a0al.\u00a0Transmission \u00a0of\u00a0HIV\u20101\u00a0\ndrug\u00a0resistance \u00a0in\u00a0Switzerland: \u00a0a\u00a010\u2010year\u00a0molecular \u00a0epidemiology \u00a0survey.\u00a0AIDS\u00a02007;\u00a0\n21(16):2223 \u20102229.\u00a0\n\u00a0 288.\u00a0\u00a0Little\u00a0SJ,\u00a0Holte\u00a0S,\u00a0Routy\u00a0JP,\u00a0Daar\u00a0ES,\u00a0Markowitz \u00a0M,\u00a0Collier\u00a0AC\u00a0et\u00a0al.\u00a0Antiretroviral \u2010drug\u00a0resis\u2010\ntance\u00a0among\u00a0patients\u00a0recently\u00a0infected\u00a0with\u00a0HIV.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02002;\u00a0347(6):385 \u201094.\u00a0\n\u00a0 289.\u00a0\u00a0de\u00a0Mendoza \u00a0C.,\u00a0Rodriguez \u00a0C,\u00a0Garcia\u00a0F,\u00a0Eiros\u00a0JM,\u00a0Ruiz\u00a0L,\u00a0Caballero \u00a0E\u00a0et\u00a0al.\u00a0Prevalence \u00a0of\u00a0X4\u00a0\ntropic\u00a0viruses\u00a0in\u00a0patients\u00a0recently\u00a0infected\u00a0with\u00a0HIV\u20101\u00a0and\u00a0lack\u00a0of\u00a0association \u00a0with\u00a0transmis\u2010\nsion\u00a0of\u00a0drug\u00a0resistance. \u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02007;\u00a059(4):698 \u2010704.\u00a0\n\u00a0 290.\u00a0\u00a0SPREAD\u00a0Programme. \u00a0Transmission \u00a0of\u00a0drug\u2010resistant\u00a0HIV\u20101\u00a0in\u00a0Europe\u00a0remains\u00a0limited\u00a0to\u00a0single\u00a0\nclasses.\u00a0AIDS\u00a02008;\u00a022(5):625 \u2010635.\u00a0\n\u00a0 291.\u00a0\u00a0Phillips\u00a0AN,\u00a0Miller\u00a0V,\u00a0Sabin\u00a0C,\u00a0Cozzi\u00a0Lepri\u00a0A,\u00a0Klauke\u00a0S,\u00a0Bickel\u00a0M\u00a0et\u00a0al.\u00a0Durability \u00a0of\u00a0HIV\u20101\u00a0viral\u00a0\nsuppression \u00a0over\u00a03.3\u00a0years\u00a0with\u00a0multi\u2010drug\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0previously \u00a0drug\u2010naive\u00a0in\u2010\ndividuals. \u00a0AIDS\u00a02001;\u00a015(18):2379 \u201084.\u00a0\n\u00a0 292.\u00a0\u00a0Sungkanuparph \u00a0S,\u00a0Manosuthi \u00a0W,\u00a0Kiertiburanakul \u00a0S,\u00a0Piyavong\u00a0B,\u00a0Chumpathat \u00a0N,\u00a0Chantratita \u00a0\nW.\u00a0Options\u00a0for\u00a0a\u00a0second\u2010line\u00a0antiretroviral \u00a0regimen\u00a0for\u00a0HIV\u00a0type\u00a01\u2010infected\u00a0patients\u00a0whose\u00a0\ninitial\u00a0regimen\u00a0of\u00a0a\u00a0fixed\u2010dose\u00a0combination \u00a0of\u00a0stavudine, \u00a0lamivudine, \u00a0and\u00a0nevirapine \u00a0fails.\u00a0\nClin\u00a0Infect\u00a0Dis\u00a02007;\u00a044(3):447 \u2010452.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 119 \n \u00a0 293.\u00a0\u00a0Lockman\u00a0S,\u00a0Shapiro\u00a0RL,\u00a0Smeaton\u00a0LM,\u00a0Wester\u00a0C,\u00a0Thior\u00a0I,\u00a0Stevens\u00a0L\u00a0et\u00a0al.\u00a0Response \u00a0to\u00a0antiretro\u2010\nviral\u00a0therapy\u00a0after\u00a0a\u00a0single,\u00a0peripartum \u00a0dose\u00a0of\u00a0nevirapine. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02007;\u00a0356(2):135 \u2010\n147.\u00a0\n\u00a0 294.\u00a0\u00a0Gupta\u00a0RK,\u00a0Hill\u00a0A,\u00a0Sawyer\u00a0AW,\u00a0Cozzi\u2010Lepri\u00a0A,\u00a0von\u00a0W,\u00a0V,\u00a0Yerly\u00a0S\u00a0et\u00a0al.\u00a0Virological \u00a0monitoring \u00a0and\u00a0\nresistance \u00a0to\u00a0first\u2010line\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0adults\u00a0infected\u00a0with\u00a0HIV\u20101\u00a0trea\u2010\nted\u00a0under\u00a0WHO\u00a0guidelines: \u00a0a\u00a0systematic \u00a0review\u00a0and\u00a0meta\u2010analysis.\u00a0Lancet\u00a0Infect\u00a0Dis\u00a02009;\u00a0\n9(7):409\u2010417.\u00a0\n\u00a0 295.\u00a0\u00a0Brenner\u00a0BG,\u00a0Oliveira\u00a0M,\u00a0Doualla\u2010Bell\u00a0F,\u00a0Moisi\u00a0DD,\u00a0Ntemgwa \u00a0M,\u00a0Frankel\u00a0F\u00a0et\u00a0al.\u00a0HIV\u20101\u00a0subtype\u00a0\nC\u00a0viruses\u00a0rapidly\u00a0develop\u00a0K65R\u00a0resistance \u00a0to\u00a0tenofovir\u00a0in\u00a0cell\u00a0culture.\u00a0AIDS\u00a02006;\u00a020(9):F9\u201013.\u00a0\n\u00a0 296.\u00a0\u00a0Poveda\u00a0E,\u00a0de\u00a0MC,\u00a0Parkin\u00a0N,\u00a0Choe\u00a0S,\u00a0Garcia\u2010Gasco\u00a0P,\u00a0Corral\u00a0A\u00a0et\u00a0al.\u00a0Evidence\u00a0for\u00a0different\u00a0sus\u2010\nceptibility \u00a0to\u00a0tipranavir \u00a0and\u00a0darunavir \u00a0in\u00a0patients\u00a0infected\u00a0with\u00a0distinct\u00a0HIV\u20101\u00a0subtypes. \u00a0AIDS\u00a0\n2008;\u00a022(5):611 \u2010616.\u00a0\n\u00a0 297.\u00a0\u00a0Smith\u00a0RA,\u00a0Anderson \u00a0DJ,\u00a0Pyrak\u00a0CL,\u00a0Preston\u00a0BD,\u00a0Gottlieb\u00a0GS.\u00a0Antiretroviral \u00a0drug\u00a0resistance \u00a0in\u00a0\nHIV\u20102:\u00a0three\u00a0amino\u00a0acid\u00a0changes\u00a0are\u00a0sufficient \u00a0for\u00a0classwide \u00a0nucleoside \u00a0analogue\u00a0resistance. \u00a0J\u00a0\nInfect\u00a0Dis\u00a02009;\u00a0199(9):1323 \u20101326.\u00a0\n\u00a0 298.\u00a0\u00a0Cohen\u00a0Stuart\u00a0JW,\u00a0Wensing\u00a0AM,\u00a0Kovacs\u00a0C,\u00a0Righart\u00a0M,\u00a0de\u00a0Jong\u00a0D,\u00a0Kaye\u00a0S\u00a0et\u00a0al.\u00a0Transient \u00a0relap\u2010\nses\u00a0(\"blips\")\u00a0of\u00a0plasma\u00a0HIV\u00a0RNA\u00a0levels\u00a0during\u00a0HAART\u00a0are\u00a0associated \u00a0with\u00a0drug\u00a0resistance. \u00a0J\u00a0\nAcquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02001;\u00a028(2):105 \u201013.\u00a0\n\u00a0 299.\u00a0\u00a0Sungkanuparph \u00a0S,\u00a0Overton\u00a0ET,\u00a0Seyfried\u00a0W,\u00a0Groger\u00a0RK,\u00a0Fraser\u00a0VJ,\u00a0Powderly \u00a0WG.\u00a0Intermittent \u00a0\nepisodes\u00a0of\u00a0detectable \u00a0HIV\u00a0viremia\u00a0in\u00a0patients\u00a0receiving\u00a0nonnucleoside \u00a0reverse\u2010transcriptase \u00a0\ninhibitor\u2010based\u00a0or\u00a0protease\u00a0inhibitor\u2010based\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0regimens\u00a0are\u00a0\nequivalent \u00a0in\u00a0incidence \u00a0and\u00a0prognosis. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02005;\u00a041(9):1326 \u20101332.\u00a0\n\u00a0 300.\u00a0\u00a0Tan\u00a0R,\u00a0Westfall\u00a0AO,\u00a0Willig\u00a0JH,\u00a0Mugavero \u00a0MJ,\u00a0Saag\u00a0MS,\u00a0Kaslow\u00a0RA\u00a0et\u00a0al.\u00a0Clinical\u00a0outcome\u00a0of\u00a0\nHIV\u2010infected\u00a0antiretroviral \u2010naive\u00a0patients\u00a0with\u00a0discordant \u00a0immunologic \u00a0and\u00a0virologic\u00a0respon\u2010\nses\u00a0to\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02008;\u00a047(5):553 \u2010558.\u00a0\n\u00a0 301.\u00a0\u00a0Berenguer \u00a0J,\u00a0Ribera\u00a0Santasusana \u00a0J,\u00a0Rubio\u00a0R,\u00a0Miralles\u00a0P,\u00a0Mahillo\u00a0B,\u00a0T\u00e9llez\u00a0M\u00a0et\u00a0al.\u00a0Characteris \u2010\ntics\u00a0and\u00a0outcome\u00a0of\u00a0AIDS\u2010related\u00a0non\u2010Hodgkin's \u00a0lymphoma \u00a0in\u00a0patients\u00a0treated\u00a0with\u00a0HAART.\u00a0\n13\u00a0th\u00a0Conference \u00a0on\u00a0Retrovirus \u00a0and\u00a0Opportunistic \u00a0Infection, \u00a0Denver,\u00a0February\u00a05\u20108,\u00a02006\u00a0Abs\u2010\ntract\u00a0829\u00a0\n\u00a0 302.\u00a0\u00a0Montaner \u00a0J,\u00a0Guimaraes \u00a0D,\u00a0Chung\u00a0J,\u00a0Gafoor\u00a0Z,\u00a0Salgo\u00a0M,\u00a0DeMasi\u00a0R.\u00a0Prognostic \u00a0staging\u00a0of\u00a0exten\u2010\nsively\u00a0pretreated \u00a0patients\u00a0with\u00a0advanced \u00a0HIV\u20101\u00a0disease.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02005;\u00a06(6):281\u2010290.\u00a0\n\u00a0 303.\u00a0\u00a0Latham\u00a0V,\u00a0Stebbing\u00a0J,\u00a0Mandalia \u00a0S,\u00a0Michailidis \u00a0C,\u00a0Davies\u00a0E,\u00a0Bower\u00a0M\u00a0et\u00a0al.\u00a0Adherence \u00a0to\u00a0trizivir\u00a0\nand\u00a0tenofovir\u00a0as\u00a0a\u00a0simplified \u00a0salvage\u00a0regimen\u00a0is\u00a0associated \u00a0with\u00a0suppression \u00a0of\u00a0viraemia\u00a0and\u00a0\na\u00a0decreased \u00a0cholesterol. \u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02005;\u00a056(1):186 \u2010189.\u00a0\n\u00a0 304.\u00a0\u00a0Elzi\u00a0L,\u00a0Hirsch\u00a0HH,\u00a0Battegay\u00a0M.\u00a0Once\u2010daily\u00a0directly\u00a0observed \u00a0therapy\u00a0lopinavir/ritonavir \u00a0plus\u00a0\nindinavir\u00a0as\u00a0a\u00a0protease\u00a0inhibitor\u2010only\u00a0salvage\u00a0therapy\u00a0in\u00a0heavily\u00a0pretreated \u00a0HIV\u20101\u2010infected\u00a0pa\u2010\ntients:\u00a0a\u00a0pilot\u00a0study.\u00a0AIDS\u00a02006;\u00a020(1):129 \u2010131.\u00a0\n\u00a0 305.\u00a0\u00a0Mitty\u00a0J,\u00a0Mwamburi \u00a0D,\u00a0Macalino\u00a0G,\u00a0Caliendo\u00a0A,\u00a0Bazerman \u00a0L,\u00a0Flanigan\u00a0T.\u00a0Improved \u00a0virologic\u00a0\noutcomes \u00a0and\u00a0less\u00a0HIV\u00a0resistance \u00a0for\u00a0HAART\u2010experienced \u00a0substance \u00a0users\u00a0receiving\u00a0modified\u00a0\ndirectly\u00a0observed \u00a0therapy:\u00a0results\u00a0from\u00a0a\u00a0randomized \u00a0controlled \u00a0trial.\u00a013th\u00a0Conference \u00a0on\u00a0Re\u2010\ntroviruses \u00a0and\u00a0Opportunistics \u00a0Infections \u00a02006,\u00a0Denver,\u00a0Colorado. \u00a0Abstract\u00a0622a.\u00a0\n\u00a0 306.\u00a0\u00a0Palella\u00a0F,\u00a0Armon\u00a0C,\u00a0Cmiel\u00a0J,\u00a0Buchacz\u00a0K,\u00a0Novak\u00a0R,\u00a0Moorman \u00a0A\u00a0et\u00a0al.\u00a0Enhanced \u00a0survival\u00a0associa\u2010\nted\u00a0with\u00a0use\u00a0of\u00a0HIV\u00a0susceptibility \u00a0testing\u00a0among\u00a0HAART\u2010experienced \u00a0patients\u00a0in\u00a0the\u00a0HIV\u00a0Out\u2010Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 120 \n patient\u00a0Study\u00a0(HOPS).\u00a013th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistics \u00a0Infections \u00a02006,\u00a0\nDenver,\u00a0Colorado\u00a0Abstract\u00a0654\u00a0\n\u00a0 307.\u00a0\u00a0Lawrence \u00a0J,\u00a0Huppler\u00a0HK,\u00a0Coakley\u00a0E,\u00a0Bates\u00a0M,\u00a0Weidler\u00a0J,\u00a0Lie\u00a0Y\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0phenotypic \u00a0\nsusceptibility \u00a0score\u00a0as\u00a0a\u00a0predictor \u00a0of\u00a0treatment \u00a0response\u00a0in\u00a0persons\u00a0with\u00a0multi\u2010drug\u2010resistant\u00a0\nHIV\u20101.\u00a013th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistics \u00a0Infections \u00a02006,\u00a0Denver,\u00a0Colora\u2010\ndo.\u00a0Abstract\u00a0n\u00ba\u00a0651\u00a0\n\u00a0 308.\u00a0\u00a0Snoeck\u00a0J,\u00a0Kantor\u00a0R,\u00a0Shafer\u00a0RW,\u00a0Van\u00a0LK,\u00a0Deforche\u00a0K,\u00a0Carvalho\u00a0AP\u00a0et\u00a0al.\u00a0Discordances \u00a0between\u00a0\ninterpretation \u00a0algorithms \u00a0for\u00a0genotypic \u00a0resistance \u00a0to\u00a0protease\u00a0and\u00a0reverse\u00a0transcriptase \u00a0in\u2010\nhibitors\u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0are\u00a0subtype\u00a0dependent. \u00a0Antimicrob \u00a0Agents\u00a0Che\u2010\nmother\u00a02006;\u00a050(2):694 \u2010701.\u00a0\n\u00a0 309.\u00a0\u00a0Vora\u00a0S,\u00a0Marcelin\u00a0AG,\u00a0Gunthard \u00a0HF,\u00a0Flandre\u00a0P,\u00a0Hirsch\u00a0HH,\u00a0Masquelier \u00a0B\u00a0et\u00a0al.\u00a0Clinical\u00a0validation \u00a0\nof\u00a0atazanavir/ritonavir \u00a0genotypic \u00a0resistance \u00a0score\u00a0in\u00a0protease\u00a0inhibitor\u2010experienced \u00a0patients.\u00a0\nAIDS\u00a02006;\u00a020(1):35\u201040.\u00a0\n\u00a0 310.\u00a0\u00a0Marcelin\u00a0AG,\u00a0Flandre\u00a0P,\u00a0de\u00a0MC,\u00a0Roquebert \u00a0B,\u00a0Peytavin\u00a0G,\u00a0Valer\u00a0L\u00a0et\u00a0al.\u00a0Clinical\u00a0validation \u00a0of\u00a0\nsaquinavir/ritonavir \u00a0genotypic \u00a0resistance \u00a0score\u00a0in\u00a0protease\u2010inhibitor\u2010experienced \u00a0patients.\u00a0\nAntivir\u00a0Ther\u00a02007;\u00a012(2):247 \u2010252.\u00a0\n\u00a0 311.\u00a0\u00a0King\u00a0MS,\u00a0Rode\u00a0R,\u00a0Cohen\u2010Codar\u00a0I,\u00a0Calvez\u00a0V,\u00a0Marcelin\u00a0AG,\u00a0Hanna\u00a0GJ\u00a0et\u00a0al.\u00a0Predictive \u00a0genotypic \u00a0\nalgorithm \u00a0for\u00a0virologic\u00a0response\u00a0to\u00a0lopinavir\u2010ritonavir\u00a0in\u00a0protease\u00a0inhibitor\u2010experienced \u00a0pa\u2010\ntients.\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02007;\u00a051(9):3067 \u20103074.\u00a0\n\u00a0 312.\u00a0\u00a0de\u00a0Mendoza \u00a0C.,\u00a0Anta\u00a0L,\u00a0Garcia\u00a0F,\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Gutierrez \u00a0F,\u00a0Llibre\u00a0JM\u00a0et\u00a0al.\u00a0HIV\u20101\u00a0genotypic \u00a0\ndrug\u00a0resistance \u00a0interpretation \u00a0rules\u00a0\u2010\u00a02009\u00a0Spanish\u00a0guidelines. \u00a0AIDS\u00a0Rev\u00a02009;\u00a011(1):39\u201051.\u00a0\n\u00a0 313.\u00a0\u00a0Scherer\u00a0J,\u00a0Schapiro\u00a0JM,\u00a0Maggiolo \u00a0F,\u00a0Perno\u00a0CF,\u00a0Boucher\u00a0CA,\u00a0Baxter\u00a0J\u00a0et\u00a0al.\u00a0Improved \u00a0tipranavir \u00a0\nweighted \u00a0score\u00a0predics\u00a0virologic\u00a0response\u00a0in\u00a0diverse\u00a0treatment \u2010experienced \u00a0patient\u00a0popula\u2010\ntion.\u00a07th\u00a0European \u00a0HIV\u00a0Drug\u00a0Resistance \u00a0Workshop \u00a0March\u00a02009,\u00a0Stockholm, \u00a0Sweden\u00a02009.\u00a0\n\u00a0 314.\u00a0\u00a0Barreiro\u00a0P,\u00a0Camino\u00a0N,\u00a0de\u00a0MC,\u00a0Valer\u00a0L,\u00a0Nunez\u00a0M,\u00a0Martin\u2010Carbonero \u00a0L\u00a0et\u00a0al.\u00a0Comparison \u00a0of\u00a0the\u00a0\nefficacy,\u00a0safety\u00a0and\u00a0predictive \u00a0value\u00a0of\u00a0HIV\u00a0genotyping \u00a0using\u00a0distinct\u00a0ritonavir\u2010boosted\u00a0pro\u2010\ntease\u00a0inhibitors. \u00a0Int\u00a0J\u00a0Antimicrob \u00a0Agents\u00a02002;\u00a020(6):438 \u2010443.\u00a0\n\u00a0 315.\u00a0\u00a0Gonzalez\u00a0de\u00a0RD,\u00a0Gallego\u00a0O,\u00a0Valer\u00a0L,\u00a0Jimenez\u2010Nacher\u00a0I,\u00a0Soriano\u00a0V.\u00a0Prediction \u00a0of\u00a0virological \u00a0\nresponse\u00a0to\u00a0lopinavir/ritonavir \u00a0using\u00a0the\u00a0genotypic \u00a0inhibitory \u00a0quotient.\u00a0AIDS\u00a0Res\u00a0Hum\u00a0Retro\u2010\nviruses\u00a02004;\u00a020(3):275 \u2010278.\u00a0\n\u00a0 316.\u00a0\u00a0Hoefnagel \u00a0JG,\u00a0Van\u00a0der\u00a0Lee\u00a0MJ,\u00a0Koopmans \u00a0PP,\u00a0Schuurman \u00a0R,\u00a0Jurriaans\u00a0S,\u00a0van\u00a0Sighem\u00a0AI\u00a0et\u00a0al.\u00a0\nThe\u00a0genotypic \u00a0inhibitory \u00a0quotient\u00a0and\u00a0the\u00a0(cumulative) \u00a0number\u00a0of\u00a0mutations \u00a0predict\u00a0the\u00a0res\u2010\nponse\u00a0to\u00a0lopinavir\u00a0therapy.\u00a0AIDS\u00a02006;\u00a020(7):1069 \u20101071.\u00a0\n\u00a0 317.\u00a0\u00a0Winston\u00a0A,\u00a0Hales\u00a0G,\u00a0Amin\u00a0J,\u00a0van\u00a0SE,\u00a0Cooper\u00a0DA,\u00a0Emery\u00a0S.\u00a0The\u00a0normalized \u00a0inhibitory \u00a0quotient\u00a0\nof\u00a0boosted\u00a0protease\u00a0inhibitors \u00a0is\u00a0predictive \u00a0of\u00a0viral\u00a0load\u00a0response\u00a0in\u00a0treatment \u2010experienced \u00a0\nHIV\u20101\u2010infected\u00a0individuals. \u00a0AIDS\u00a02005;\u00a019(13):1393 \u20101399.\u00a0\n\u00a0 318.\u00a0\u00a0Hernandez \u2010Novoa\u00a0B,\u00a0Page\u00a0C,\u00a0Gutierrez \u00a0C,\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Casado\u00a0JL,\u00a0Dronda\u00a0F\u00a0et\u00a0al.\u00a0Mutant\u00a0\nHIV\u00a0minority\u00a0variants\u00a0detected\u00a0by\u00a0ultradeep \u00a0sequencing \u00a0do\u00a0not\u00a0condition \u00a0virological \u00a0failure\u00a0in\u00a0\npatients\u00a0starting\u00a0ARV\u00a0therapy\u00a0including\u00a0low\u00a0genetic\u00a0barrier\u00a0drugs.\u00a05th\u00a0International \u00a0AIDS\u00a0So\u2010\nciety\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention \u00a0Cape\u00a0Town,\u00a0South\u00a0Africa\u00a0\nJuly\u00a019\u201022,\u00a02009\u00a02009;\u00a0Abstract\u00a0WEPEB208. \u00a0\n\u00a0 319.\u00a0\u00a0Boffito\u00a0M,\u00a0Arnaudo\u00a0I,\u00a0Raiteri\u00a0R,\u00a0Bonora\u00a0S,\u00a0Sinicco\u00a0A,\u00a0Di\u00a0Garbo\u00a0A\u00a0et\u00a0al.\u00a0Clinical\u00a0use\u00a0of\u00a0lopina\u2010\nvir/ritonavir \u00a0in\u00a0a\u00a0salvage\u00a0therapy\u00a0setting:\u00a0pharmacokinetics \u00a0and\u00a0pharmacodynamics. \u00a0AIDS\u00a0\n2002;\u00a016(15):2081 \u20103.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 121 \n \u00a0 320.\u00a0\u00a0Best\u00a0BM,\u00a0Goicoechea \u00a0M,\u00a0Witt\u00a0MD,\u00a0Miller\u00a0L,\u00a0Daar\u00a0ES,\u00a0Diamond\u00a0C\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0contro\u2010\nlled\u00a0trial\u00a0of\u00a0therapeutic \u00a0drug\u00a0monitoring \u00a0in\u00a0treatment \u2010naive\u00a0and\u00a0\u2010experienced \u00a0HIV\u20101\u2010infected\u00a0\npatients.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a046(4):433 \u2010442.\u00a0\n\u00a0 321.\u00a0\u00a0Wainberg \u00a0MA,\u00a0Turner\u00a0D.\u00a0Resistance \u00a0issues\u00a0with\u00a0new\u00a0nucleoside/nucleotide \u00a0backbone \u00a0op\u2010\ntions.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02004;\u00a037\u00a0Suppl\u00a01:S36\u2010S43.\u00a0\n\u00a0 322.\u00a0\u00a0Jemsek\u00a0J,\u00a0Hutcherson \u00a0P,\u00a0Harper\u00a0E.\u00a0Poor\u00a0virologic\u00a0responses \u00a0and\u00a0early\u00a0emergence \u00a0of\u00a0resistance \u00a0\nin\u00a0treatment \u00a0naive,\u00a0HIV\u2010infected\u00a0patients\u00a0receiving\u00a0a\u00a0once\u00a0daily\u00a0triple\u00a0nucleoside \u00a0regimen\u00a0of\u00a0\ndidanosine, \u00a0lamivudine, \u00a0and\u00a0tenofovir\u00a0DF.\u00a011th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunis \u2010\ntic\u00a0Infections, \u00a0San\u00a0Francisco, \u00a0CA,\u00a02004\u00a0[Abstract\u00a051]\u00a0\n\u00a0 323.\u00a0\u00a0Landman\u00a0R,\u00a0Peytavin\u00a0G,\u00a0Descamps \u00a0D,\u00a0Brun\u00a0Vezinet\u00a0F,\u00a0Benech\u00a0H,\u00a0Benalisherif \u00a0A\u00a0et\u00a0al.\u00a0Low\u00a0\ngenetic\u00a0barrier\u00a0to\u00a0resistance \u00a0is\u00a0a\u00a0possible\u00a0cause\u00a0of\u00a0early\u00a0virologic\u00a0failures\u00a0in\u00a0once\u2010daily\u00a0regi\u2010\nmen\u00a0of\u00a0abacavir,\u00a0lamivudine, \u00a0and\u00a0tenofovir: \u00a0The\u00a0Tonus\u00a0study.\u00a011th\u00a0Conference \u00a0on\u00a0Retroviru \u2010\nses\u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0CA,\u00a02004\u00a0[Abstract\u00a052]\u00a0\n\u00a0 324.\u00a0\u00a0Shafer\u00a0RW,\u00a0Stevenson \u00a0D,\u00a0Chan\u00a0B.\u00a0Human\u00a0Immunodeficiency \u00a0Virus\u00a0Reverse\u00a0Transcriptase \u00a0and\u00a0\nProtease\u00a0Sequence \u00a0Database. \u00a0Nucleic\u00a0Acids\u00a0Res\u00a01999;\u00a027(1):348 \u201052.\u00a0\n\u00a0 325.\u00a0\u00a0Gupta\u00a0R,\u00a0Hill\u00a0A,\u00a0Sawyer\u00a0AW,\u00a0Pillay\u00a0D.\u00a0Emergence \u00a0of\u00a0drug\u00a0resistance \u00a0in\u00a0HIV\u00a0type\u00a01\u2010infected\u00a0\npatients\u00a0after\u00a0receipt\u00a0of\u00a0first\u2010line\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy:\u00a0a\u00a0systematic \u00a0review\u00a0of\u00a0\nclinical\u00a0trials.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02008;\u00a047(5):712 \u2010722.\u00a0\n\u00a0 326.\u00a0\u00a0Woodfall\u00a0B,\u00a0Vingerhoets \u00a0J,\u00a0Peeters\u00a0M,\u00a0de\u00a0Smedlt\u00a0G,\u00a0Miralles\u00a0GD,\u00a0de\u00a0Pethune\u00a0MP.\u00a0Impact\u00a0of\u00a0\nNNRTI\u00a0and\u00a0NRTI\u00a0resistance \u00a0on\u00a0the\u00a0response\u00a0to\u00a0the\u00a0regimen\u00a0of\u00a0TMC125\u00a0plus\u00a0two\u00a0NRTIs\u00a0in\u00a0Stu\u2010\ndy\u00a0TMC125\u2010C227.\u00a08th\u00a0International \u00a0Congress\u00a0on\u00a0Drug\u00a0Therapy\u00a0in\u00a0HIV\u00a0Infection\u00a0Glasgow,\u00a0Sco\u2010\ntland,\u00a0November \u00a02006\u00a02006;\u00a0Abstract\u00a0PL5.6.\u00a0\n\u00a0 327.\u00a0\u00a0de\u00a0Mendoza \u00a0C.,\u00a0Valer\u00a0L,\u00a0Bacheler\u00a0L,\u00a0Pattery\u00a0T,\u00a0Corral\u00a0A,\u00a0Soriano\u00a0V.\u00a0Prevalence \u00a0of\u00a0the\u00a0HIV\u20101\u00a0\nprotease\u00a0mutation\u00a0I47A\u00a0in\u00a0clinical\u00a0practice\u00a0and\u00a0association \u00a0with\u00a0lopinavir\u00a0resistance. \u00a0AIDS\u00a0\n2006;\u00a020(7):1071 \u20101074.\u00a0\n\u00a0 328.\u00a0\u00a0Nijhuis\u00a0M,\u00a0Wensing\u00a0AM,\u00a0Bierman\u00a0WF,\u00a0de\u00a0JD,\u00a0Kagan\u00a0R,\u00a0Fun\u00a0A\u00a0et\u00a0al.\u00a0Failure\u00a0of\u00a0treatment \u00a0with\u00a0\nfirst\u2010line\u00a0lopinavir\u00a0boosted\u00a0with\u00a0ritonavir\u00a0can\u00a0be\u00a0explained \u00a0by\u00a0novel\u00a0resistance \u00a0pathways \u00a0with\u00a0\nprotease\u00a0mutation\u00a076V.\u00a0J\u00a0Infect\u00a0Dis\u00a02009;\u00a0200(5):698 \u2010709.\u00a0\n\u00a0 329.\u00a0\u00a0Turner\u00a0D,\u00a0Schapiro\u00a0JM,\u00a0Brenner\u00a0BG,\u00a0Wainberg \u00a0MA.\u00a0The\u00a0influence\u00a0of\u00a0protease\u00a0inhibitor\u00a0resis\u2010\ntance\u00a0profiles\u00a0on\u00a0selection\u00a0of\u00a0HIV\u00a0therapy\u00a0in\u00a0treatment \u2010naive\u00a0patients.\u00a0Antivir\u00a0Ther\u00a02004;\u00a0\n9(3):301\u2010314.\u00a0\n\u00a0 330.\u00a0\u00a0Colonno\u00a0R,\u00a0Rose\u00a0R,\u00a0McLaren\u00a0C,\u00a0Thiry\u00a0A,\u00a0Parkin\u00a0N,\u00a0Friborg\u00a0J.\u00a0Identification \u00a0of\u00a0I50L\u00a0as\u00a0the\u00a0signa\u2010\nture\u00a0atazanavir \u00a0(ATV)\u2010resistance \u00a0mutation\u00a0in\u00a0treatment \u2010naive\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0recei\u2010\nving\u00a0ATV\u2010containing \u00a0regimens. \u00a0J\u00a0Infect\u00a0Dis\u00a02004;\u00a0189(10):1802 \u20101810.\u00a0\n\u00a0 331.\u00a0\u00a0Johnson\u00a0VA,\u00a0Brun\u2010Vezinet\u00a0F,\u00a0Clotet\u00a0B,\u00a0Gunthard \u00a0HF,\u00a0Kuritzkes\u00a0DR,\u00a0Pillay\u00a0D\u00a0et\u00a0al.\u00a0Update\u00a0of\u00a0the\u00a0\nDrug\u00a0Resistance \u00a0Mutations \u00a0in\u00a0HIV\u20101:\u00a0Spring\u00a02008.\u00a0Top\u00a0HIV\u00a0Med\u00a02008;\u00a016(1):62\u201068.\u00a0\n\u00a0 332.\u00a0\u00a0Weinheimer \u00a0S,\u00a0Discotto\u00a0L,\u00a0Friborg\u00a0J,\u00a0Yang\u00a0H,\u00a0Colonno\u00a0R.\u00a0Atazanavir \u00a0signature \u00a0I50L\u00a0resistance \u00a0\nsubstitution \u00a0accounts\u00a0for\u00a0unique\u00a0phenotype \u00a0of\u00a0increased \u00a0susceptibility \u00a0to\u00a0other\u00a0protease\u00a0in\u2010\nhibitors\u00a0in\u00a0a\u00a0variety\u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0genetic\u00a0backbones. \u00a0Antimicrob \u00a0\nAgents\u00a0Chemother \u00a02005;\u00a049(9):3816 \u20103824.\u00a0\n\u00a0 333.\u00a0\u00a0DeJesus\u00a0E,\u00a0LaMarca\u00a0A,\u00a0Sension\u00a0M,\u00a0Beltran\u00a0C,\u00a0Yeni\u00a0P.\u00a0The\u00a0Context\u00a0Study:\u00a0Efficacy\u00a0and\u00a0Safety\u00a0of\u00a0\nGW433908/RTV \u00a0in\u00a0PI\u2010experienced \u00a0Subjects\u00a0with\u00a0Virological \u00a0Failure\u00a0(24\u00a0Week\u00a0Results).\u00a010th\u00a0\nConference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Boston,\u00a0MA,\u00a02003\u00a0(Abstract\u00a0178)\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 122 \n \u00a0 334.\u00a0\u00a0Elston\u00a0RC,\u00a0Yates\u00a0P,\u00a0Tisdale\u00a0M,\u00a0Richards\u00a0N,\u00a0White\u00a0S,\u00a0DeJesus\u00a0E.\u00a0GW433908/ritonavir: \u00a048\u00a0weeks\u00a0\nresults\u00a0in\u00a0PI\u2010experienced \u00a0subjects:\u00a0a\u00a0retrospective \u00a0analysis\u00a0of\u00a0virological \u00a0response\u00a0based\u00a0on\u00a0\nbaseline\u00a0genotype \u00a0and\u00a0phenotype. \u00a0XIV\u00a0International \u00a0AIDS\u00a0Conference, \u00a0Bangkok,\u00a0July\u00a011\u201016,\u00a0\n2004\u00a0Abstract\u00a0MoOrB1055. \u00a0\n\u00a0 335.\u00a0\u00a0Dragsted\u00a0UB,\u00a0Gerstoft\u00a0J,\u00a0Youle\u00a0M,\u00a0Fox\u00a0Z,\u00a0Losso\u00a0M,\u00a0Benetucci \u00a0J\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0trial\u00a0to\u00a0\nevaluate\u00a0lopinavir/ritonavir \u00a0versus\u00a0saquinavir/ritonavir \u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients:\u00a0the\u00a0\nMaxCmin2 \u00a0trial.\u00a0Antivir\u00a0Ther\u00a02005;\u00a010(6):735 \u2010743.\u00a0\n\u00a0 336.\u00a0\u00a0Johnson\u00a0M,\u00a0Grinsztejn \u00a0B,\u00a0Rodriguez \u00a0C,\u00a0Coco\u00a0J,\u00a0DeJesus\u00a0E,\u00a0Lazzarin\u00a0A\u00a0et\u00a0al.\u00a0Atazanavir \u00a0plus\u00a0\nritonavir\u00a0or\u00a0saquinavir, \u00a0and\u00a0lopinavir/ritonavir \u00a0in\u00a0patients\u00a0experiencing \u00a0multiple\u00a0virological \u00a0\nfailures.\u00a0AIDS\u00a02005;\u00a019(2):153 \u2010162.\u00a0\n\u00a0 337.\u00a0\u00a0Naeger\u00a0LK,\u00a0Struble\u00a0KA.\u00a0Effect\u00a0of\u00a0baseline\u00a0protease\u00a0genotype \u00a0and\u00a0phenotype \u00a0on\u00a0HIV\u00a0response\u00a0\nto\u00a0atazanavir/ritonavir \u00a0in\u00a0treatment \u2010experienced \u00a0patients.\u00a0AIDS\u00a02006;\u00a020(6):847 \u2010853.\u00a0\n\u00a0 338.\u00a0\u00a0Hicks\u00a0CB,\u00a0Cahn\u00a0P,\u00a0Cooper\u00a0DA,\u00a0Walmsley \u00a0SL,\u00a0Katlama\u00a0C,\u00a0Clotet\u00a0B\u00a0et\u00a0al.\u00a0Durable\u00a0efficacy\u00a0of\u00a0ti\u2010\npranavir\u2010ritonavir\u00a0in\u00a0combination \u00a0with\u00a0an\u00a0optimised \u00a0background \u00a0regimen\u00a0of\u00a0antiretroviral \u00a0\ndrugs\u00a0for\u00a0treatment \u2010experienced \u00a0HIV\u20101\u2010infected\u00a0patients\u00a0at\u00a048\u00a0weeks\u00a0in\u00a0the\u00a0Randomized \u00a0Eva\u2010\nluation\u00a0of\u00a0Strategic\u00a0Intervention \u00a0in\u00a0multi\u2010drug\u00a0reSistant\u00a0patients\u00a0with\u00a0Tipranavir \u00a0(RESIST)\u00a0stu\u2010\ndies:\u00a0an\u00a0analysis\u00a0of\u00a0combined \u00a0data\u00a0from\u00a0two\u00a0randomised \u00a0open\u2010label\u00a0trials.\u00a0Lancet\u00a02006;\u00a0\n368(9534):466 \u2010475.\u00a0\n\u00a0 339.\u00a0\u00a0Arasteh\u00a0K,\u00a0Clumeck\u00a0N,\u00a0Pozniak\u00a0A,\u00a0Lazzarin\u00a0A,\u00a0De\u00a0MS,\u00a0Muller\u00a0H\u00a0et\u00a0al.\u00a0TMC114/ritonavir \u00a0substi\u2010\ntution\u00a0for\u00a0protease\u00a0inhibitor(s) \u00a0in\u00a0a\u00a0non\u2010suppressive \u00a0antiretroviral \u00a0regimen:\u00a0a\u00a014\u2010day\u00a0proof\u2010\nof\u2010principle\u00a0trial.\u00a0AIDS\u00a02005;\u00a019(9):943 \u2010947.\u00a0\n\u00a0 340.\u00a0\u00a0de\u00a0Meyer\u00a0S.,\u00a0Azijn\u00a0H,\u00a0Surleraux \u00a0D,\u00a0Jochmans \u00a0D,\u00a0Tahri\u00a0A,\u00a0Pauwels\u00a0R\u00a0et\u00a0al.\u00a0TMC114,\u00a0a\u00a0novel\u00a0\nhuman\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0protease\u00a0inhibitor\u00a0active\u00a0against\u00a0protease\u00a0inhibitor\u2010\nresistant\u00a0viruses,\u00a0including\u00a0a\u00a0broad\u00a0range\u00a0of\u00a0clinical\u00a0isolates.\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a0\n2005;\u00a049(6):2314 \u20102321.\u00a0\n\u00a0 341.\u00a0\u00a0Clotet\u00a0B,\u00a0Bellos\u00a0N,\u00a0Molina\u00a0JM,\u00a0Cooper\u00a0D,\u00a0Goffard\u00a0JC,\u00a0Lazzarin\u00a0A\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0\ndarunavir \u2010ritonavir\u00a0at\u00a0week\u00a048\u00a0in\u00a0treatment \u2010experienced \u00a0patients\u00a0with\u00a0HIV\u20101\u00a0infection\u00a0in\u00a0\nPOWER\u00a01\u00a0and\u00a02:\u00a0a\u00a0pooled\u00a0subgroup \u00a0analysis\u00a0of\u00a0data\u00a0from\u00a0two\u00a0randomised \u00a0trials.\u00a0Lancet\u00a02007;\u00a0\n369(9568):1169 \u20101178.\u00a0\n\u00a0 342.\u00a0\u00a0Pozniak\u00a0A,\u00a0Jayaweera \u00a0D,\u00a0Hoy\u00a0J,\u00a0de\u00a0Meyer\u00a0S,\u00a0De\u00a0Paepe\u00a0E,\u00a0Tomaka\u00a0F\u00a0et\u00a0al.\u00a0Efficacy\u00a0of\u00a0daruna\u2010\nvir/ritonavir \u00a0in\u00a0treatment \u2010experienced \u00a0patients\u00a0at\u00a096\u00a0weeks\u00a0in\u00a0the\u00a0POWER\u00a01\u00a0and\u00a02\u00a0trials.\u00a011th\u00a0\nEuropean \u00a0Aids\u00a0Conference, \u00a0Madrid,\u00a02007\u00a0Abstract\u00a0P7.2/07\u00a0\n\u00a0 343.\u00a0\u00a0Saag\u00a0M,\u00a0Falcon\u00a0R,\u00a0Lefebre\u00a0E.\u00a0Efficacy\u00a0and\u00a0safety\u00a0results\u00a0of\u00a0darunavir/r \u00a0in\u00a0treatment \u2010\nexperienced \u00a0patients:\u00a0POWER\u00a03.\u00a044th\u00a0Annual\u00a0meeting\u00a0of\u00a0the\u00a0Infectious \u00a0Disease\u00a0Society\u00a0of\u00a0\nAmerica.2006.Toronto, \u00a0Canada\u00a0Abstract\u00a0957\u00a0\n\u00a0 344.\u00a0\u00a0Katlama\u00a0C,\u00a0Bellos\u00a0N,\u00a0Grinsztejn \u00a0B,\u00a0Lazzarin\u00a0A,\u00a0Pozniak\u00a0A,\u00a0De\u00a0Meyer\u00a0S\u00a0et\u00a0al.\u00a0Power\u00a01\u00a0and\u00a02:\u00a0\ncombined \u00a0final\u00a0144\u2010week\u00a0efficacy\u00a0and\u00a0safety\u00a0results\u00a0for\u00a0darunavir/ritonavir \u00a0600/100mg \u00a0bid\u00a0in\u00a0\ntreatment \u2010experienced \u00a0HIV\u00a0patients.\u00a09th\u00a0International \u00a0Congess\u00a0on\u00a0Drug\u00a0Therapy\u00a0in\u00a0HIV\u00a0Infec\u2010\ntion,\u00a0Glasgow,\u00a0UK,\u00a09\u201013\u00a0November, \u00a02008\u00a02008;\u00a0Abstract\u00a0S1\u2010P21.\u00a0\n\u00a0 345.\u00a0\u00a0Madruga\u00a0JV,\u00a0Berger\u00a0D,\u00a0McMurchie \u00a0M,\u00a0Suter\u00a0F,\u00a0Banhegyi\u00a0D,\u00a0Ruxrungtham \u00a0K\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0\nsafety\u00a0of\u00a0darunavir \u2010ritonavir\u00a0compared \u00a0with\u00a0that\u00a0of\u00a0lopinavir\u2010ritonavir\u00a0at\u00a048\u00a0weeks\u00a0in\u00a0treat\u2010\nment\u2010experienced, \u00a0HIV\u2010infected\u00a0patients\u00a0in\u00a0TITAN:\u00a0a\u00a0randomised \u00a0controlled \u00a0phase\u00a0III\u00a0trial.\u00a0\nLancet\u00a02007;\u00a0370(9581):49 \u201058.\u00a0\n\u00a0 346.\u00a0\u00a0Squires\u00a0KE,\u00a0Currier\u00a0J,\u00a0Bridge\u00a0D,\u00a0Hagins\u00a0D,\u00a0Zorrilla\u00a0C,\u00a0Ryan\u00a0R\u00a0et\u00a0al.\u00a0GRACE\u00a0(Gender,\u00a0Race\u00a0And\u00a0\nClinical\u00a0Experience): \u00a048\u2010week\u00a0results\u00a0of\u00a0darunavir/r \u2010based\u00a0therapy\u00a0in\u00a0the\u00a0largest\u00a0trial\u00a0in\u00a0North\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 123 \n America\u00a0focused\u00a0on\u00a0treatment \u2010experienced \u00a0women.\u00a05th\u00a0International \u00a0AIDS\u00a0Society\u00a0Confe\u2010\nrence\u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention \u00a0Cape\u00a0Town,\u00a0South\u00a0Africa\u00a0July\u00a019\u201022,\u00a0\n2009\u00a02009;\u00a0Abstract\u00a0MOPEB042. \u00a0\n\u00a0 347.\u00a0\u00a0De\u00a0Meyer\u00a0S,\u00a0Dierynck\u00a0I,\u00a0Lathouwers \u00a0E,\u00a0van\u00a0Baelen\u00a0B,\u00a0Vangeneugden \u00a0T,\u00a0Spinosa\u2010Guzman\u00a0S\u00a0et\u00a0\nal.\u00a0Phenotypic \u00a0and\u00a0genotypic \u00a0determinants \u00a0of\u00a0resistance \u00a0to\u00a0darunavir: \u00a0analysis\u00a0of\u00a0data\u00a0from\u00a0\ntreatment \u2010experienced \u00a0patients\u00a0in\u00a0POWER\u00a01,\u00a02,\u00a03\u00a0and\u00a0DUET\u20101\u00a0and\u00a0DUET\u20102.\u00a017th\u00a0HIV\u00a0Drug\u00a0Re\u2010\nsistance\u00a0Workshop, \u00a0Junio\u00a02008,\u00a0Sitges\u00a0Espa\u00f1a\u00a0Poster\u00a031\u00a0\n\u00a0 348.\u00a0\u00a0Lazzarin\u00a0A,\u00a0Campbell \u00a0T,\u00a0Clotet\u00a0B,\u00a0Johnson\u00a0M,\u00a0Katlama\u00a0C,\u00a0Moll\u00a0A\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0\nTMC125\u00a0(etravirine) \u00a0in\u00a0treatment \u2010experienced \u00a0HIV\u20101\u2010infected\u00a0patients\u00a0in\u00a0DUET\u20102:\u00a024\u2010week\u00a0\nresults\u00a0from\u00a0a\u00a0randomised, \u00a0double\u2010blind,\u00a0placebo\u2010controlled \u00a0trial.\u00a0Lancet\u00a02007;\u00a0370(9581):39 \u2010\n48.\u00a0\n\u00a0 349.\u00a0\u00a0Madruga\u00a0JV,\u00a0Cahn\u00a0P,\u00a0Grinsztejn \u00a0B,\u00a0Haubrich\u00a0R,\u00a0Lalezari\u00a0J,\u00a0Mills\u00a0A\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0\nTMC125\u00a0(etravirine) \u00a0in\u00a0treatment \u2010experienced \u00a0HIV\u20101\u2010infected\u00a0patients\u00a0in\u00a0DUET\u20101:\u00a024\u2010week\u00a0\nresults\u00a0from\u00a0a\u00a0randomised, \u00a0double\u2010blind,\u00a0placebo\u2010controlled \u00a0trial.\u00a0Lancet\u00a02007;\u00a0370(9581):29 \u2010\n38.\u00a0\n\u00a0 350.\u00a0\u00a0Cahn\u00a0P,\u00a0Molina\u00a0JM,\u00a0Towner\u00a0W,\u00a0Peeters\u00a0M,\u00a0Vingerhoets \u00a0J,\u00a0Beets\u00a0G.\u00a048\u2010week\u00a0pooled\u00a0analysis\u00a0of\u00a0\nDUET\u20101\u00a0and\u00a0DUET\u20102:\u00a0the\u00a0impact\u00a0of\u00a0baseline\u00a0characteristics \u00a0on\u00a0virological \u00a0response\u00a0to\u00a0etraviri\u2010\nne\u00a0(TMC125; \u00a0ETR).\u00a017th\u00a0International \u00a0AIDS\u00a0Conference; \u00a03\u20108\u00a0August,\u00a02008;\u00a0Mexico\u00a0DF.\u00a0Abs\u2010\ntract\u00a0TUPE0047 \u00a0\n\u00a0 351.\u00a0\u00a0Trottier\u00a0B,\u00a0Mills\u00a0A,\u00a0Cahn\u00a0P,\u00a0Clotet\u00a0B,\u00a0Grinsztejn \u00a0B,\u00a0Towner\u00a0W\u00a0et\u00a0al.\u00a0Durable\u00a0efficacy\u00a0and\u00a0safety\u00a0\nof\u00a0etravirine \u00a0in\u00a0treatment \u2010experienced, \u00a0HIV\u20101\u2010infected\u00a0patients:\u00a0pooled\u00a0week\u00a096\u00a0results\u00a0from\u00a0\nthe\u00a0Phase\u00a0III\u00a0DUET\u20101\u00a0and\u00a0DUET\u20102\u00a0trials.\u00a018th\u00a0Annual\u00a0Canadian \u00a0Conference \u00a0on\u00a0HIV/AIDS\u00a0Rese\u2010\narch,\u00a0Vancouver, \u00a0Canada\u00a0April\u00a023\u201026,\u00a02009\u00a02009;\u00a0Abstract\u00a0PI\u201048.\u00a0\n\u00a0 352.\u00a0\u00a0Eron\u00a0J,\u00a0Haubrich\u00a0R,\u00a0Reiss\u00a0P,\u00a0Thompson \u00a0M,\u00a0Weber\u00a0R,\u00a0Nijs\u00a0S\u00a0et\u00a0al.\u00a0Clinical\u00a0endpoints \u00a0reduced\u00a0\nthrough\u00a0etravirine \u00a0use\u00a0in\u00a0treatment \u2010experienced, \u00a0HIV\u2010infected\u00a0patients:\u00a0pooled\u00a096\u2010week\u00a0re\u2010\nsults\u00a0from\u00a0the\u00a0Phase\u00a0III\u00a0Duet\u00a0trials.\u00a05th\u00a0International \u00a0AIDS\u00a0Society\u00a0Conference \u00a0on\u00a0HIV\u00a0Pat\u2010\nhogenesis, \u00a0Treatment \u00a0and\u00a0Prevention \u00a0Cape\u00a0Town,\u00a0South\u00a0Africa\u00a0July\u00a019\u201022,\u00a02009\u00a02009;\u00a0Abs\u2010\ntract\u00a0MOPEB043. \u00a0\n\u00a0 353.\u00a0\u00a0Vingerhoets \u00a0J,\u00a0Peeters\u00a0M,\u00a0Azijn\u00a0H,\u00a0Tambuyzer \u00a0L,\u00a0Hoogstoal \u00a0A,\u00a0Nijs\u00a0S\u00a0et\u00a0al.\u00a0An\u00a0updated\u00a0of\u00a0the\u00a0\nlist\u00a0of\u00a0NNRTI\u00a0mutations \u00a0associated \u00a0with\u00a0decreased \u00a0virologic\u00a0response\u00a0to\u00a0etravirine: \u00a0multiva\u2010\nriate\u00a0analyses\u00a0of\u00a0the\u00a0pooled\u00a0DUET\u20101\u00a0and\u00a0DUET\u20102\u00a0clinical\u00a0trial\u00a0data.\u00a017th\u00a0HIV\u00a0Drug\u00a0Resistance \u00a0\nWorkshop, \u00a0Junio\u00a02008,\u00a0Sitges\u00a0Espa\u00f1a\u00a02009;\u00a0Abstract\u00a024.\u00a0\n\u00a0 354.\u00a0\u00a0Benhamida \u00a0J,\u00a0Chappey\u00a0C,\u00a0Coakley\u00a0E,\u00a0Parkin\u00a0NT.\u00a0Monogram \u00a0HIV\u20101\u00a0Genotype \u00a0Algorithms \u00a0for\u00a0\nPrediction \u00a0of\u00a0Etravirine \u00a0Susceptibility: \u00a0Novel\u00a0Mutations \u00a0and\u00a0Weighting \u00a0Factors\u00a0Identified \u00a0\nThrough\u00a0Correlations \u00a0to\u00a0Phenotype. \u00a017th\u00a0HIV\u00a0Drug\u00a0Resistance \u00a0Workshop, \u00a0Junio\u00a02008,\u00a0Sitges\u00a0\nEspa\u00f1a\u00a0Abstract\u00a0130\u00a0\n\u00a0 355.\u00a0\u00a0Lalezari\u00a0JP,\u00a0Henry\u00a0K,\u00a0O'Hearn\u00a0M,\u00a0Montaner \u00a0JS,\u00a0Piliero\u00a0PJ,\u00a0Trottier\u00a0B\u00a0et\u00a0al.\u00a0Enfuvirtide, \u00a0an\u00a0HIV\u20101\u00a0\nfusion\u00a0inhibitor,\u00a0for\u00a0drug\u2010resistant\u00a0HIV\u00a0infection\u00a0in\u00a0North\u00a0and\u00a0South\u00a0America.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a0\n2003;\u00a0348(22):2175 \u201085.\u00a0\n\u00a0 356.\u00a0\u00a0Lazzarin\u00a0A,\u00a0Clotet\u00a0B,\u00a0Cooper\u00a0D,\u00a0Reynes\u00a0J,\u00a0Arasteh\u00a0K,\u00a0Nelson\u00a0M\u00a0et\u00a0al.\u00a0Efficacy\u00a0of\u00a0enfuvirtide \u00a0in\u00a0\npatients\u00a0infected\u00a0with\u00a0drug\u2010resistant\u00a0HIV\u20101\u00a0in\u00a0Europe\u00a0and\u00a0Australia. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02003;\u00a0\n348(22):2186 \u201095.\u00a0\n\u00a0 357.\u00a0\u00a0Katlama\u00a0C,\u00a0Arasteh\u00a0K,\u00a0Clotet\u00a0B.\u00a0Enfuvirtide \u00a0TORO\u00a0studies:\u00a048\u00a0week\u00a0results\u00a0confirm\u00a024\u00a0week\u00a0\nfindings.\u00a02nd\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis \u00a0and\u00a0Treatment, \u00a0Paris,\u00a02003\u00a0[Abstract\u00a0LB2]\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 124 \n \u00a0 358.\u00a0\u00a0Nelson\u00a0M,\u00a0Arasteh\u00a0K,\u00a0Clotet\u00a0B,\u00a0Cooper\u00a0DA,\u00a0Henry\u00a0K,\u00a0Katlama\u00a0C\u00a0et\u00a0al.\u00a0Durable\u00a0efficacy\u00a0of\u00a0enfu\u2010\nvirtide\u00a0over\u00a048\u00a0weeks\u00a0in\u00a0heavily\u00a0treatment \u2010experienced \u00a0HIV\u20101\u2010infected\u00a0patients\u00a0in\u00a0the\u00a0T\u201020\u00a0\nversus\u00a0optimized \u00a0background \u00a0regimen\u00a0only\u00a01\u00a0and\u00a02\u00a0clinical\u00a0trials.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0\nSyndr\u00a02005;\u00a040(4):404 \u2010412.\u00a0\n\u00a0 359.\u00a0\u00a0Ribera\u00a0E,\u00a0Moreno\u00a0S,\u00a0Viciana\u00a0P,\u00a0Echevarria \u00a0S,\u00a0Flores\u00a0J,\u00a0Frances\u00a0A\u00a0et\u00a0al.\u00a0Recomendaciones \u00a0espa\u2010\n\u00f1olas\u00a0para\u00a0el\u00a0uso\u00a0adecuado \u00a0de\u00a0la\u00a0enfuvirtida. \u00a0Enferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a02007;\u00a025(2):131 \u2010\n142.\u00a0\n\u00a0 360.\u00a0\u00a0Dorr\u00a0P,\u00a0Westby\u00a0M,\u00a0Dobbs\u00a0S,\u00a0Griffin\u00a0P,\u00a0Irvine\u00a0B,\u00a0Macartney \u00a0M\u00a0et\u00a0al.\u00a0Maraviroc \u00a0(UK\u2010427,857), \u00a0a\u00a0\npotent,\u00a0orally\u00a0bioavailable, \u00a0and\u00a0selective\u00a0small\u2010molecule\u00a0inhibitor\u00a0of\u00a0chemokine \u00a0receptor\u00a0\nCCR5\u00a0with\u00a0broad\u2010spectrum \u00a0anti\u2010human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0activity.\u00a0Antimicrob \u00a0\nAgents\u00a0Chemother \u00a02005;\u00a049(11):4721 \u20104732.\u00a0\n\u00a0 361.\u00a0\u00a0Gulick\u00a0RM,\u00a0Lalezari\u00a0J,\u00a0Goodrich\u00a0J,\u00a0Clumeck\u00a0N,\u00a0DeJesus\u00a0E,\u00a0Horban\u00a0A\u00a0et\u00a0al.\u00a0Maraviroc \u00a0for\u00a0Pre\u2010\nviously\u00a0Treated\u00a0Patients\u00a0with\u00a0R5\u00a0HIV\u20101\u00a0Infection. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02008;\u00a0359(14):1429 \u20101441.\u00a0\n\u00a0 362.\u00a0\u00a0Ashmuth\u00a0D,\u00a0Goodrich\u00a0J,\u00a0Cooper\u00a0D,\u00a0et\u00a0al.\u00a0CD4+\u00a0cell\u00a0restoration \u00a0after\u00a048\u00a0weeks\u00a0in\u00a0the\u00a0maraviroc \u00a0\ntreatment \u2010experienced \u00a0trials\u00a0MOTIVATE \u00a01\u00a0and\u00a02.\u00a017th\u00a0International \u00a0AIDS\u00a0Conference; \u00a03\u20108\u00a0\nAugust,\u00a02008;\u00a0Mexico\u00a0DF.\u00a0(Abstract\u00a0TUPE0050) \u00a0\n\u00a0 363.\u00a0\u00a0Fatkenheuer \u00a0G,\u00a0Nelson\u00a0M,\u00a0Lazzarin\u00a0A,\u00a0Konourina \u00a0I,\u00a0Hoepelman \u00a0AIM,\u00a0Lampiris\u00a0H\u00a0et\u00a0al.\u00a0Sub\u2010\ngroup\u00a0Analyses\u00a0of\u00a0Maraviroc \u00a0in\u00a0Previously \u00a0Treated\u00a0R5\u00a0HIV\u20101\u00a0Infection. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02008;\u00a0\n359(14):1442 \u20101455.\u00a0\n\u00a0 364.\u00a0\u00a0Hardy\u00a0WD,\u00a0Gulick\u00a0R,\u00a0Mayer\u00a0H,\u00a0F\u00e4lkenheuer \u00a0G,\u00a0Nelson\u00a0M,\u00a0Heera\u00a0J\u00a0et\u00a0al.\u00a0Efficay\u00a0and\u00a0safety\u00a0of\u00a0\nMaraviroc \u00a0in\u00a0treatment \u2010experienced \u00a0patients\u00a0infected\u00a0with\u00a0R5\u00a0HIV\u20101:\u00a096\u00a0week\u00a0combined \u00a0an\u00e1\u2010\nlisis\u00a0of\u00a0the\u00a0MOTIVATE \u00a01\u00a0and\u00a02\u00a0Studies.\u00a09th\u00a0International \u00a0Congess\u00a0on\u00a0Drug\u00a0Therapy\u00a0in\u00a0HIV\u00a0In\u2010\nfection,\u00a0Glasgow,\u00a0UK,\u00a09\u201013\u00a0November, \u00a02008\u00a02009;\u00a0Abstract\u00a0425.\u00a0\n\u00a0 365.\u00a0\u00a0Ayoub\u00a0A,\u00a0Goodrich\u00a0J,\u00a0Tressler\u00a0R,\u00a0van\u00a0der\u00a0Ryst\u00a0E,\u00a0Rajicic\u00a0N,\u00a0Butelli\u00a0S\u00a0et\u00a0al.\u00a0Incidence \u00a0of\u00a0infec\u2010\ntions\u00a0in\u00a0treatment \u2010experienced \u00a0patients\u00a0infected\u00a0with\u00a0R5\u00a0HIV\u20101\u00a0in\u00a0the\u00a0MOTIVATE \u00a0stuides\u00a0of\u00a0\nmaraviroc \u00a0in\u00a0combination \u00a0with\u00a0optimized \u00a0background \u00a0therapy.\u00a09th\u00a0International \u00a0Congess\u00a0on\u00a0\nDrug\u00a0Therapy\u00a0in\u00a0HIV\u00a0Infection, \u00a0Glasgow,\u00a0UK,\u00a09\u201013\u00a0November, \u00a02008\u00a02008;\u00a0Abstract\u00a0154.\u00a0\n\u00a0 366.\u00a0\u00a0Ayoub\u00a0A,\u00a0Walmsley \u00a0S,\u00a0Campo\u00a0R,\u00a0Goodrich\u00a0J,\u00a0Heera\u00a0J,\u00a0Valdez\u00a0H\u00a0et\u00a0al.\u00a0Incidence \u00a0and\u00a0risk\u00a0factors\u00a0\nfor\u00a0malignancies \u00a0in\u00a0treatment \u2010experienced \u00a0patients\u00a0in\u00a0the\u00a0MOTIVATE \u00a0Studies\u00a0of\u00a0Maraviroc \u00a0+\u00a0\noptimized \u00a0background \u00a0therapy:\u00a096\u2010week\u00a0follow\u2010up.\u00a05th\u00a0International \u00a0AIDS\u00a0Society\u00a0Conferen\u2010\nce\u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention \u00a0Cape\u00a0Town,\u00a0South\u00a0Africa\u00a0July\u00a019\u201022,\u00a02009\u00a0\n2009;\u00a0Abstract\u00a0WEPEB255. \u00a0\n\u00a0 367.\u00a0\u00a0Van\u00a0der\u00a0Ryst\u00a0E,\u00a0Westby\u00a0M.\u00a0Changes\u00a0in\u00a0HIV\u20101\u00a0co\u2010receptor\u00a0tropism\u00a0for\u00a0patients\u00a0participating \u00a0in\u00a0\nthe\u00a0maraviroc \u00a0MOTIVATE \u00a01\u00a0and\u00a02\u00a0clinical\u00a0trials.\u00a047th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicro \u2010\nbial\u00a0Agents\u00a0and\u00a0Chemotherapy.Chicago, \u00a02007\u00a0Abstract\u00a0H\u2010715\u00a0\n\u00a0 368.\u00a0\u00a0Cahn\u00a0P,\u00a0Sued\u00a0O.\u00a0Raltegravir: \u00a0a\u00a0new\u00a0antiretroviral \u00a0class\u00a0for\u00a0salvage\u00a0therapy.\u00a0Lancet\u00a02007;\u00a0\n369(9569):1235 \u20101236.\u00a0\n\u00a0 369.\u00a0\u00a0Steigbigel \u00a0RT,\u00a0Cooper\u00a0DA,\u00a0Kumar\u00a0PN,\u00a0Eron\u00a0JE,\u00a0Schechter \u00a0M,\u00a0Markowitz \u00a0M\u00a0et\u00a0al.\u00a0Raltegravir \u00a0\nwith\u00a0optimized \u00a0background \u00a0therapy\u00a0for\u00a0resistant\u00a0HIV\u20101\u00a0infection. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02008;\u00a0\n359(4):339 \u2010354.\u00a0\n\u00a0 370.\u00a0\u00a0Cooper\u00a0DA,\u00a0Steigbigel \u00a0RT,\u00a0Gatell\u00a0JM,\u00a0Rockstroh \u00a0JK,\u00a0Katlama\u00a0C,\u00a0Yeni\u00a0P\u00a0et\u00a0al.\u00a0Subgroup \u00a0and\u00a0resis\u2010\ntance\u00a0analyses\u00a0of\u00a0raltegravir \u00a0for\u00a0resistant\u00a0HIV\u20101\u00a0infection. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02008;\u00a0359(4):355 \u2010365.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 125 \n \u00a0 371.\u00a0\u00a0Cooper\u00a0D,\u00a0Steigbigel \u00a0R,\u00a0Lennox\u00a0J,\u00a0Grinsztejn \u00a0B,\u00a0Markowitz \u00a0M,\u00a0Sklar\u00a0P\u00a0et\u00a0al.\u00a0Review\u00a0of\u00a0cancer\u00a0\nincidence \u00a0in\u00a0raltegravir \u00a0clinical\u00a0trials.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0In\u2010\nfections;\u00a0February\u00a02009;\u00a0Montreal \u00a02009;\u00a0Abstract\u00a0859.\u00a0\n\u00a0 372.\u00a0\u00a0Steigbigel \u00a0R,\u00a0Cooper\u00a0D,\u00a0Eron\u00a0J,\u00a0Gatell\u00a0J,\u00a0Kumar\u00a0P,\u00a0Rockstroh \u00a0J\u00a0et\u00a0al.\u00a096\u2010week\u00a0results\u00a0from\u00a0\nBENCHMRK \u00a01\u00a0and\u00a02,\u00a0phase\u00a0III\u00a0studies\u00a0of\u00a0raltegravir \u00a0in\u00a0patients\u00a0failing\u00a0ART\u00a0with\u00a0triple\u2010class\u2010\nresistant\u00a0HIV.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a02009;\u00a0\nMontreal \u00a02009;\u00a0\u00a0Abstract\u00a0571b.\u00a0\n\u00a0 373.\u00a0\u00a0Fagard\u00a0C,\u00a0Descapms \u00a0D,\u00a0Dubar\u00a0V,\u00a0Colin\u00a0C,\u00a0Taburet\u00a0AM,\u00a0Roquebert \u00a0B\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0\nraltegravir \u00a0plus\u00a0etravirine \u00a0and\u00a0darunavir/ritonavir \u00a0in\u00a0treatment \u2010experienced \u00a0patients\u00a0with\u00a0\nmultidrug \u2010resistant\u00a0virus:\u00a048\u2010week\u00a0results\u00a0from\u00a0the\u00a0ANRS\u00a0139\u00a0TRIO\u00a0trial.\u00a05th\u00a0International \u00a0\nAIDS\u00a0Society\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention \u00a0Cape\u00a0Town,\u00a0South\u00a0\nAfrica\u00a0July\u00a019\u201022,\u00a02009\u00a02009;\u00a0Abstract\u00a0TUPDB204. \u00a0\n\u00a0 374.\u00a0\u00a0Grabar\u00a0S,\u00a0Le\u00a0Moing\u00a0V,\u00a0Goujard\u00a0C,\u00a0Leport\u00a0C,\u00a0Kazatchkine \u00a0MD,\u00a0Costagliola \u00a0D\u00a0et\u00a0al.\u00a0Clinical\u00a0out\u2010\ncome\u00a0of\u00a0patients\u00a0with\u00a0HIV\u20101\u00a0infection\u00a0according \u00a0to\u00a0immunologic \u00a0and\u00a0virologic\u00a0response\u00a0after\u00a0\n6\u00a0months\u00a0of\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0Ann\u00a0Intern\u00a0Med\u00a02000;\u00a0133(6):401 \u201010.\u00a0\n\u00a0 375.\u00a0\u00a0Ledergerber \u00a0B,\u00a0Egger\u00a0M,\u00a0Opravil\u00a0M,\u00a0Telenti\u00a0A,\u00a0Hirschel\u00a0B,\u00a0Battegay\u00a0M\u00a0et\u00a0al.\u00a0Clinical\u00a0progres\u2010\nsion\u00a0and\u00a0virological \u00a0failure\u00a0on\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0HIV\u20101\u00a0patients:\u00a0a\u00a0prospec\u2010\ntive\u00a0cohort\u00a0study.\u00a0Swiss\u00a0HIV\u00a0Cohort\u00a0Study.\u00a0Lancet\u00a01999;\u00a0353(9156):863 \u20108.\u00a0\n\u00a0 376.\u00a0\u00a0Deeks\u00a0SG,\u00a0Barbour\u00a0JD,\u00a0Grant\u00a0RM,\u00a0Martin\u00a0JN.\u00a0Duration\u00a0and\u00a0predictors \u00a0of\u00a0CD4\u00a0T\u2010cell\u00a0gains\u00a0in\u00a0\npatients\u00a0who\u00a0continue\u00a0combination \u00a0therapy\u00a0despite\u00a0detectable \u00a0plasma\u00a0viremia.\u00a0AIDS\u00a02002;\u00a0\n16(2):201 \u20107.\u00a0\n\u00a0 377.\u00a0\u00a0Lawrence \u00a0J,\u00a0Mayers\u00a0DL,\u00a0Hullsiek\u00a0KH,\u00a0Collins\u00a0G,\u00a0Abrams\u00a0DI,\u00a0Reisler\u00a0RB\u00a0et\u00a0al.\u00a0Structured \u00a0treat\u2010\nment\u00a0interruption \u00a0in\u00a0patients\u00a0with\u00a0multidrug \u2010resistant\u00a0human\u00a0immunodeficiency \u00a0virus.\u00a0N\u00a0Engl\u00a0\nJ\u00a0Med\u00a02003;\u00a0349(9):837 \u2010846.\u00a0\n\u00a0 378.\u00a0\u00a0Deeks\u00a0SG,\u00a0Wrin\u00a0T,\u00a0Liegler\u00a0T,\u00a0Hoh\u00a0R,\u00a0Hayden\u00a0M,\u00a0Barbour\u00a0JD\u00a0et\u00a0al.\u00a0Virologic\u00a0and\u00a0immunologic \u00a0\nconsequences \u00a0of\u00a0discontinuing \u00a0combination \u00a0antiretroviral \u2010drug\u00a0therapy\u00a0in\u00a0HIV\u2010infected\u00a0pa\u2010\ntients\u00a0with\u00a0detectable \u00a0viremia.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02001;\u00a0344(7):472 \u201080.\u00a0\n\u00a0 379.\u00a0\u00a0Gandhi\u00a0T,\u00a0Wei\u00a0W,\u00a0Amin\u00a0K,\u00a0Kazanjian \u00a0P.\u00a0Effect\u00a0of\u00a0maintaining \u00a0highly\u00a0active\u00a0antiretroviral \u00a0the\u2010\nrapy\u00a0on\u00a0AIDS\u00a0events\u00a0among\u00a0patients\u00a0with\u00a0late\u2010stage\u00a0HIV\u00a0infection\u00a0and\u00a0inadequate \u00a0response\u00a0\nto\u00a0therapy.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02006;\u00a042(6):878 \u2010884.\u00a0\n\u00a0 380.\u00a0\u00a0Kousignian \u00a0I,\u00a0Abgrall\u00a0S,\u00a0Grabar\u00a0S,\u00a0Mahamat \u00a0A,\u00a0Teicher\u00a0E,\u00a0Rouveix\u00a0E\u00a0et\u00a0al.\u00a0Maintaining \u00a0antire\u2010\ntroviral\u00a0therapy\u00a0reduces\u00a0the\u00a0risk\u00a0of\u00a0AIDS\u2010defining\u00a0events\u00a0in\u00a0patients\u00a0with\u00a0uncontrolled \u00a0viral\u00a0\nreplication \u00a0and\u00a0profound \u00a0immunodeficiency. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02008;\u00a046(2):296 \u2010304.\u00a0\n\u00a0 381.\u00a0\u00a0Deeks\u00a0SG,\u00a0Hoh\u00a0R,\u00a0Neilands\u00a0TB,\u00a0Liegler\u00a0T,\u00a0Aweeka\u00a0F,\u00a0Petropoulos \u00a0CJ\u00a0et\u00a0al.\u00a0Interruption \u00a0of\u00a0tre\u2010\natment\u00a0with\u00a0individual \u00a0therapeutic \u00a0drug\u00a0classes\u00a0in\u00a0adults\u00a0with\u00a0multidrug \u2010resistant\u00a0HIV\u20101\u00a0in\u2010\nfection.\u00a0J\u00a0Infect\u00a0Dis\u00a02005;\u00a0192(9):1537 \u20101544.\u00a0\n\u00a0 382.\u00a0\u00a0Castagna\u00a0A,\u00a0Danise\u00a0A,\u00a0Menzo\u00a0S,\u00a0Galli\u00a0L,\u00a0Gianotti\u00a0N,\u00a0Carini\u00a0E\u00a0et\u00a0al.\u00a0Lamivudine \u00a0monotherapy \u00a0in\u00a0\nHIV\u20101\u2010infected\u00a0patients\u00a0harbouring \u00a0a\u00a0lamivudine \u2010resistant\u00a0virus:\u00a0a\u00a0randomized \u00a0pilot\u00a0study\u00a0(E\u2010\n184V\u00a0study).\u00a0AIDS\u00a02006;\u00a020(6):795 \u2010803.\u00a0\n\u00a0 383.\u00a0\u00a0Anderson \u00a0AM,\u00a0Bartlett\u00a0JA.\u00a0Changing \u00a0antiretroviral \u00a0therapy\u00a0in\u00a0the\u00a0setting\u00a0of\u00a0virologic\u00a0relapse:\u00a0\nreview\u00a0of\u00a0the\u00a0current\u00a0literature. \u00a0Curr\u00a0HIV/AIDS\u00a0Rep\u00a02006;\u00a03(2):79\u201085.\u00a0\n\u00a0 384.\u00a0\u00a0Chaix\u00a0ML,\u00a0Sahali\u00a0S,\u00a0Pallier\u00a0C,\u00a0Barrail\u2010Tran\u00a0A,\u00a0Delfraissy \u00a0JF,\u00a0Ghosn\u00a0J.\u00a0Switching \u00a0to\u00a0daruna\u2010\nvir/ritonavir \u00a0achieves\u00a0viral\u00a0suppression \u00a0in\u00a0patients\u00a0with\u00a0persistent \u00a0low\u00a0replication \u00a0on\u00a0first\u2010line\u00a0\nlopinavir/ritonavir. \u00a0AIDS\u00a02008;\u00a022(17):2405 \u20102407.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 126 \n \u00a0 385.\u00a0\u00a0Verhofstede \u00a0C,\u00a0Van\u00a0WF,\u00a0Van\u00a0Der\u00a0GB,\u00a0Pelgrom\u00a0J,\u00a0Vandekerckhove \u00a0L,\u00a0Plum\u00a0J\u00a0et\u00a0al.\u00a0Detection \u00a0of\u00a0\ndrug\u00a0resistance \u00a0mutations \u00a0as\u00a0a\u00a0predictor \u00a0of\u00a0subsequent \u00a0virological \u00a0failure\u00a0in\u00a0patients\u00a0with\u00a0\nHIV\u20101\u00a0viral\u00a0rebounds \u00a0of\u00a0less\u00a0than\u00a01,000\u00a0RNA\u00a0copies/ml. \u00a0J\u00a0Med\u00a0Virol\u00a02007;\u00a079(9):1254 \u20101260.\u00a0\n\u00a0 386.\u00a0\u00a0Parra\u2010Ruiz\u00a0J,\u00a0Alvarez\u00a0M,\u00a0Chueca\u00a0N,\u00a0Pena\u00a0A,\u00a0Pasquau\u00a0J,\u00a0Lopez\u2010Ruz\u00a0MA\u00a0et\u00a0al.\u00a0Resistencias \u00a0ge\u2010\nnot\u00edpicas\u00a0en\u00a0pacientes \u00a0con\u00a0VIH\u20101\u00a0y\u00a0grados\u00a0de\u00a0viremia\u00a0persistentemente \u00a0bajos.\u00a0Enferm\u00a0Infecc\u00a0\nMicrobiol \u00a0Clin\u00a02009;\u00a027(2):75\u201080.\u00a0\n\u00a0 387.\u00a0\u00a0Neely\u00a0MN,\u00a0Benning\u00a0L,\u00a0Xu\u00a0J,\u00a0Strickler\u00a0HD,\u00a0Greenblatt \u00a0RM,\u00a0Minkoff\u00a0H\u00a0et\u00a0al.\u00a0Cervical\u00a0shedding\u00a0of\u00a0\nHIV\u20101\u00a0RNA\u00a0among\u00a0women\u00a0with\u00a0low\u00a0levels\u00a0of\u00a0viremia\u00a0while\u00a0receiving\u00a0highly\u00a0active\u00a0antiretrovi \u2010\nral\u00a0therapy.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a044(1):38\u201042.\u00a0\n\u00a0 388.\u00a0\u00a0Arribas\u00a0JR,\u00a0Pulido\u00a0F,\u00a0Delgado\u00a0R,\u00a0Lorenzo\u00a0A,\u00a0Miralles\u00a0P,\u00a0Arranz\u00a0A\u00a0et\u00a0al.\u00a0Lopinavir/ritonavir \u00a0as\u00a0\nsingle\u2010drug\u00a0therapy\u00a0for\u00a0maintenance \u00a0of\u00a0HIV\u20101\u00a0viral\u00a0suppression: \u00a048\u2010week\u00a0results\u00a0of\u00a0a\u00a0rando\u2010\nmized,\u00a0controlled, \u00a0open\u2010label,\u00a0proof\u2010of\u2010concept\u00a0pilot\u00a0clinical\u00a0trial\u00a0(OK\u00a0Study).\u00a0J\u00a0Acquir\u00a0Immu\u2010\nne\u00a0Defic\u00a0Syndr\u00a02005;\u00a040(3):280 \u2010287.\u00a0\n\u00a0 389.\u00a0\u00a0Pulido\u00a0F,\u00a0Arribas\u00a0JR,\u00a0Delgado\u00a0R,\u00a0Pa\u00f1o\u00a0JR,\u00a0Lorenzo\u00a0A,\u00a0Arranz\u00a0A\u00a0et\u00a0al.\u00a0Lopinavir/ritonavir \u00a0as\u00a0sin\u2010\ngle\u2010drug\u00a0therapy\u00a0for\u00a0maintenance \u00a0of\u00a0HIV\u20101\u00a0viral\u00a0suppression, \u00a0a\u00a0randomized, \u00a0controlled, \u00a0open\u00a0\nlabel,\u00a0pilot,\u00a0clinical\u00a0trial\u00a0(OK\u00a0study):\u00a072\u00a0weeks\u00a0analysis.\u00a010th\u00a0European \u00a0AIDS\u00a0Conference \u00a0\n(EACS),\u00a0Dublin,\u00a0Ireland\u00a0,\u00a017\u201020\u00a0Nov.2005. \u00a0PE7.5/5\u00a0\n\u00a0 390.\u00a0\u00a0Arribas\u00a0J,\u00a0Pulido\u00a0F,\u00a0Delgado\u00a0R,\u00a0Gonzalez\u2010Garcia\u00a0J,\u00a0P\u00e9rez\u2010Elias\u00a0MJ,\u00a0et\u00a0al.\u00a0Lopinavir/ritonavir \u00a0\nmonotherapy \u00a0vs\u00a0Lopinavir/ritonavir \u00a0and\u00a0two\u00a0nucleosides \u00a0for\u00a0maintenance \u00a0therapy\u00a0of\u00a0HIV.\u00a0Ni\u2010\nnety\u00a0six\u00a0week\u00a0results\u00a0of\u00a0a\u00a0randomized, \u00a0controlled, \u00a0open\u00a0label\u00a0clinical\u00a0trial\u00a0(OK04\u00a0study).\u00a011th\u00a0\nEuropean \u00a0AIDS\u00a0Conference/ \u00a0EACS.October \u00a024\u201027,\u00a02007.Madrid, \u00a0Spain.\u00a0PS\u00a03/1\u00a0\n\u00a0 391.\u00a0\u00a0Pulido\u00a0F,\u00a0Arribas\u00a0JR,\u00a0Delgado\u00a0R,\u00a0Cabrero\u00a0E,\u00a0Gonzalez\u2010Garcia\u00a0J,\u00a0Perez\u2010Elias\u00a0MJ\u00a0et\u00a0al.\u00a0Lopinavir\u2010\nritonavir\u00a0monotherapy \u00a0versus\u00a0lopinavir\u2010ritonavir\u00a0and\u00a0two\u00a0nucleosides \u00a0for\u00a0maintenance \u00a0the\u2010\nrapy\u00a0of\u00a0HIV.\u00a0AIDS\u00a02008;\u00a022(2):F1\u2010F9.\u00a0\n\u00a0 392.\u00a0\u00a0Pulido\u00a0F,\u00a0Arribas\u00a0J,\u00a0Gonzalez\u2010Garcia\u00a0J,\u00a0L\u00f3pez\u00a0Aldeguer\u00a0J,\u00a0Domingo\u00a0P,\u00a0Estrada\u00a0V\u00a0et\u00a0al.\u00a0Risk\u00a0fac\u2010\ntors\u00a0for\u00a0loss\u00a0of\u00a0virological \u00a0supression \u00a0at\u00a048\u00a0weeks\u00a0in\u00a0patients\u00a0receiving\u00a0Lopinavir/ritonavir \u00a0\nmonotherapy \u00a0in\u00a02\u00a0clinical\u00a0trials\u00a0comparing \u00a0LPV/r\u00a0monotherapy \u00a0vs\u00a0triple\u00a0therapy\u00a0with\u00a0LPV/r\u00a0\n(OK\u00a0and\u00a0OK04\u00a0trials).\u00a014th\u00a0Conference \u00a0on\u00a0Retrovirus \u00a0and\u00a0Opportunistic \u00a0Infections.Los \u00a0Angeles\u00a0\n2007\u00a0Abstract\u00a0513\u00a0\n\u00a0 393.\u00a0\u00a0Cameron\u00a0DW,\u00a0da\u00a0Silva\u00a0BA,\u00a0Arribas\u00a0JR,\u00a0Myers\u00a0RA,\u00a0Bellos\u00a0NC,\u00a0Gilmore\u00a0N\u00a0et\u00a0al.\u00a0A\u00a096\u2010week\u00a0com\u2010\nparison\u00a0of\u00a0lopinavir\u2010ritonavir\u00a0combination \u00a0therapy\u00a0followed\u00a0by\u00a0lopinavir\u2010ritonavir\u00a0monot\u2010\nherapy\u00a0versus\u00a0efavirenz\u00a0combination \u00a0therapy.\u00a0J\u00a0Infect\u00a0Dis\u00a02008;\u00a0198(2):234 \u2010240.\u00a0\n\u00a0 394.\u00a0\u00a0Wilkin\u00a0TJ,\u00a0McKinnon \u00a0JE,\u00a0DiRienzo\u00a0AG,\u00a0Mollan\u00a0K,\u00a0Fletcher\u00a0CV,\u00a0Margolis\u00a0DM\u00a0et\u00a0al.\u00a0Regimen\u00a0sim\u2010\nplification \u00a0to\u00a0atazanavir \u2010ritonavir\u00a0alone\u00a0as\u00a0maintenance \u00a0antiretroviral \u00a0therapy:\u00a0final\u00a048\u2010week\u00a0\nclinical\u00a0and\u00a0virologic\u00a0outcomes. \u00a0J\u00a0Infect\u00a0Dis\u00a02009;\u00a0199(6):866 \u2010871.\u00a0\n\u00a0 395.\u00a0\u00a0Arribas\u00a0JR,\u00a0Horban\u00a0A,\u00a0Gerstoft\u00a0J,\u00a0F\u00e4lkenheuer \u00a0G,\u00a0Nelson\u00a0M,\u00a0Clumeck\u00a0N\u00a0et\u00a0al.\u00a0The\u00a0MONET\u00a0trial:\u00a0\ndarunavir/ritonavir \u00a0monotherapy \u00a0shows\u00a0non\u2010inferior\u00a0efficacy\u00a0to\u00a0standard\u00a0HAART,\u00a0for\u00a0patients\u00a0\nwith\u00a0HIV\u00a0RNA\u00a0<50\u00a0copies/mL \u00a0at\u00a0baseline.\u00a05th\u00a0International \u00a0AIDS\u00a0Society\u00a0Conference \u00a0on\u00a0HIV\u00a0\nPathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention \u00a0Cape\u00a0Town,\u00a0South\u00a0Africa\u00a0July\u00a019\u201022,\u00a02009\u00a02009;\u00a0\nAbastract \u00a0TUAB106 \u2010LB.\u00a0\n\u00a0 396.\u00a0\u00a0Katlama\u00a0C,\u00a0Valantin\u00a0MA,\u00a0Algarte\u2010Genin\u00a0M,\u00a0Duvivier\u00a0C,\u00a0Lambert\u2010Niclot\u00a0S,\u00a0Girard\u00a0PM\u00a0et\u00a0al.\u00a0MO\u2010\nNOI\u00a0ANRS\u00a0136A\u00a0randomized \u00a0multicenter \u00a0study\u00a0to\u00a0compare\u00a0the\u00a0efficacy\u00a0of\u00a0a\u00a0\u00a0monotherapy \u00a0of\u00a0\u00a0\ndarunavir \u00a0to\u00a0a\u00a0triple\u00a0therapy\u00a0with\u00a0\u00a02\u00a0nucleosides \u00a0analogues \u00a0combined \u00a0to\u00a0darunavir/r \u00a0in\u00a0HIV\u00a0in\u2010\nfected\u00a0patients\u00a0with\u00a0full\u00a0viral\u00a0suppression. \u00a05th\u00a0International \u00a0AIDS\u00a0Society\u00a0Conference \u00a0on\u00a0HIV\u00a0\nPathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention \u00a0Cape\u00a0Town,\u00a0South\u00a0Africa\u00a0July\u00a019\u201022,\u00a02009\u00a02009;\u00a0\nAbstract\u00a0WELBB102. \u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 127 \n \u00a0 397.\u00a0\u00a0Pulido\u00a0F,\u00a0Serrano\u00a0O,\u00a0Rivero\u00a0A,\u00a0Montes\u00a0ML,\u00a0Rubio\u00a0R,\u00a0L\u00f3pez\u00a0Bernaldo\u00a0de\u00a0Quir\u00f3s\u00a0JC\u00a0et\u00a0al.\u00a0Ataza\u2010\nnavir/ritonavir \u00a0en\u00a0monoterapia \u00a0como\u00a0mantenimiento \u00a0en\u00a0pacientes \u00a0con\u00a0supresi\u00f3n \u00a0virol\u00f3gica: \u00a0\nAn\u00e1lisis\u00a0primario\u00a0a\u00a0las\u00a048\u00a0semanas\u00a0del\u00a0estudio\u00a0OREY.\u00a0Primer\u00a0Congreso \u00a0Nacional\u00a0de\u00a0Gesida,\u00a0\nMadrid,\u00a021\u201024\u00a0octubre,\u00a02009\u00a02009;\u00a0PO\u201070.\u00a0\n\u00a0 398.\u00a0\u00a0Delfraissy \u00a0JF,\u00a0Moreno\u00a0S,\u00a0Sanz\u2010Moreno\u00a0J,\u00a0Carosi\u00a0G,\u00a0Pokrovsky \u00a0V,\u00a0Lazzarin\u00a0A\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0\nsafety\u00a0of\u00a048\u2010week\u00a0maintenance \u00a0with\u00a0QD\u00a0ATV\u00a0vs\u00a0ATV/r\u00a0(both\u00a0+\u00a02NRTIs)\u00a0in\u00a0patients\u00a0with\u00a0VL\u00a0<50\u00a0\nc/mL\u00a0after\u00a0induction \u00a0with\u00a0ATV/r\u00a0+\u00a02NRTIs:\u00a0study\u00a0AI424136. \u00a09th\u00a0International \u00a0Congess\u00a0on\u00a0Drug\u00a0\nTherapy\u00a0in\u00a0HIV\u00a0Infection, \u00a0Glasgow,\u00a0UK,\u00a09\u201013\u00a0November, \u00a02008\u00a02009;\u00a0Abstract\u00a0O42.\u00a0\n\u00a0 399.\u00a0\u00a0Squires\u00a0KE,\u00a0Young\u00a0B,\u00a0DeJesus\u00a0E,\u00a0Bellos\u00a0N,\u00a0Murphy\u00a0D,\u00a0Sutherland \u2010Phillips\u00a0D\u00a0et\u00a0al.\u00a0Similar\u00a0effica\u2010\ncy\u00a0and\u00a0tolerability \u00a0of\u00a0atazanavir \u00a0compared \u00a0to\u00a0ATV/ritonavir, \u00a0each\u00a0in\u00a0combination \u00a0with\u00a0abaca\u2010\nvir/lamivudine, \u00a0after\u00a0initial\u00a0supression \u00a0with\u00a0ABC/3TC\u00a0+\u00a0ATV/r\u00a0in\u00a0HIV\u20101\u00a0infected\u00a0patients:\u00a084\u00a0\nweek\u00a0results\u00a0of\u00a0the\u00a0ARIES\u00a0trial.\u00a05th\u00a0International \u00a0AIDS\u00a0Society\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogene \u2010\nsis,\u00a0Treatment \u00a0and\u00a0Prevention \u00a0Cape\u00a0Town,\u00a0South\u00a0Africa\u00a0July\u00a019\u201022,\u00a02009\u00a02009;\u00a0Abstract\u00a0\nWELBB103. \u00a0\n\u00a0 400.\u00a0\u00a0Becker\u00a0S,\u00a0Rachlis\u00a0A,\u00a0Gill\u00a0J,\u00a0DeJesus\u00a0E,\u00a0Pierone\u00a0G,\u00a0Kirkland\u00a0L\u00a0et\u00a0al.\u00a0Successful \u00a0substitution \u00a0of\u00a0\nprotease\u00a0inhibitors \u00a0with\u00a0efavirenz\u00a0in\u00a0patients\u00a0with\u00a0undetectable \u00a0viral\u00a0loads:\u00a0A\u00a0prospective, \u00a0\nrandomized, \u00a0multicenter, \u00a0open\u2010label\u00a0study\u00a0(DMP\u00a0049).\u00a08th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections, \u00a0Chicago,\u00a0IL,\u00a02001\u00a0[Abstract\u00a020]\u00a0\n\u00a0 401.\u00a0\u00a0Katlama\u00a0C,\u00a0Stazewsky \u00a0S,\u00a0Clumeck\u00a0N,\u00a0Arasteh\u00a0K,\u00a0Dellamonica \u00a0P,\u00a0Molina\u00a0JM\u00a0et\u00a0al.\u00a0Successful \u00a0\nsubstitution \u00a0of\u00a0protease\u00a0inhibitors \u00a0with\u00a0Sustiva\u00a0(efavirenz) \u00a0in\u00a0patients\u00a0with\u00a0undetectable \u00a0\nplasma\u00a0HIV\u20101\u00a0RNA:\u00a0results\u00a0of\u00a0a\u00a0prospective, \u00a0randomized, \u00a0multicenter, \u00a0open\u2010label\u00a0study\u00a0(DMP\u00a0\n006\u2010027).\u00a0XIII\u00a0International \u00a0AIDS\u00a0Conference, \u00a0Durban,\u00a0South\u00a0Africa,\u00a02000\u00a0[Abstract\u00a0\nLbPeB7044] \u00a0\n\u00a0 402.\u00a0\u00a0Negredo\u00a0E,\u00a0Cruz\u00a0L,\u00a0Paredes\u00a0R,\u00a0Ruiz\u00a0L,\u00a0Fumaz\u00a0CR,\u00a0Bonjoch\u00a0A\u00a0et\u00a0al.\u00a0Virological, \u00a0immunological, \u00a0\nand\u00a0clinical\u00a0impact\u00a0of\u00a0switching \u00a0from\u00a0protease\u00a0inhibitors \u00a0to\u00a0nevirapine \u00a0or\u00a0to\u00a0efavirenz\u00a0in\u00a0pa\u2010\ntients\u00a0with\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0infection\u00a0and\u00a0long\u2010lasting\u00a0viral\u00a0suppression. \u00a0Clin\u00a0\nInfect\u00a0Dis\u00a02002;\u00a034(4):504 \u201010.\u00a0\n\u00a0 403.\u00a0\u00a0Maggiolo \u00a0F,\u00a0Ripamonti \u00a0D,\u00a0Ravasio\u00a0L,\u00a0Gregis\u00a0G,\u00a0Quinzan\u00a0G,\u00a0Callegaro \u00a0A\u00a0et\u00a0al.\u00a0Outcome \u00a0of\u00a02\u00a0\nsimplification \u00a0strategies \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0infection. \u00a0\nClin\u00a0Infect\u00a0Dis\u00a02003;\u00a037(1):41\u201049.\u00a0\n\u00a0 404.\u00a0\u00a0Ruiz\u00a0L,\u00a0Negredo\u00a0E,\u00a0Domingo\u00a0P,\u00a0Paredes\u00a0R,\u00a0Francia\u00a0E,\u00a0Balague\u00a0M\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0treatment \u00a0\nsimplification \u00a0with\u00a0nevirapine \u00a0in\u00a0protease\u00a0inhibitor\u2010experienced \u00a0patients\u00a0with\u00a0hiv\u2010associated \u00a0\nlipodystrophy: \u00a01\u2010year\u00a0prospective \u00a0follow\u2010up\u00a0of\u00a0a\u00a0multicenter, \u00a0randomized, \u00a0controlled \u00a0study.\u00a0J\u00a0\nAcquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02001;\u00a027(3):229 \u201036.\u00a0\n\u00a0 405.\u00a0\u00a0Negredo\u00a0E,\u00a0Ribalta\u00a0J,\u00a0Paredes\u00a0R,\u00a0Ferre\u00a0R,\u00a0Sirera\u00a0G,\u00a0Ruiz\u00a0L\u00a0et\u00a0al.\u00a0Reversal\u00a0of\u00a0atherogenic \u00a0lipopro\u2010\ntein\u00a0profile\u00a0in\u00a0HIV\u20101\u00a0infected\u00a0patients\u00a0with\u00a0lipodystrophy \u00a0after\u00a0replacing\u00a0protease\u00a0inhibitors \u00a0\nby\u00a0nevirapine. \u00a0AIDS\u00a02002;\u00a016(10):1383 \u20101389.\u00a0\n\u00a0 406.\u00a0\u00a0Arranz\u00a0Caso\u00a0JA,\u00a0Lopez\u00a0JC,\u00a0Santos\u00a0I,\u00a0Estrada\u00a0V,\u00a0Castilla\u00a0V,\u00a0Sanz\u00a0J\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0controlled \u00a0\ntrial\u00a0investigating \u00a0the\u00a0efficacy\u00a0and\u00a0safety\u00a0of\u00a0switching \u00a0from\u00a0a\u00a0protease\u00a0inhibitor\u00a0to\u00a0nevirapine \u00a0\nin\u00a0patients\u00a0with\u00a0undetectable \u00a0viral\u00a0load.\u00a0HIV\u00a0Med\u00a02005;\u00a06(5):353\u2010359.\u00a0\n\u00a0 407.\u00a0\u00a0Barreiro\u00a0P,\u00a0Soriano\u00a0V,\u00a0Blanco\u00a0F,\u00a0Casimiro\u00a0C,\u00a0de\u00a0la\u00a0Cruz\u00a0JJ,\u00a0Gonzalez\u2010Lahoz\u00a0J.\u00a0Risks\u00a0and\u00a0benefits\u00a0\nof\u00a0replacing\u00a0protease\u00a0inhibitors \u00a0by\u00a0nevirapine \u00a0in\u00a0HIV\u2010infected\u00a0subjects\u00a0under\u00a0long\u2010term\u00a0suc\u2010\ncessful\u00a0triple\u00a0combination \u00a0therapy.\u00a0AIDS\u00a02000;\u00a014(7):807 \u201012.\u00a0\n\u00a0 408.\u00a0\u00a0Dieleman \u00a0JP,\u00a0Sturkenboom \u00a0MC,\u00a0Wit\u00a0FW,\u00a0Jambroes \u00a0M,\u00a0Mulder\u00a0JW,\u00a0Ten\u00a0Veen\u00a0JH\u00a0et\u00a0al.\u00a0Low\u00a0risk\u00a0\nof\u00a0treatment \u00a0failure\u00a0after\u00a0substitution \u00a0of\u00a0nevirapine \u00a0for\u00a0protease\u00a0inhibitors \u00a0among\u00a0human\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 128 \n immunodeficiency \u00a0virus\u2010infected\u00a0patients\u00a0with\u00a0virus\u00a0suppression. \u00a0J\u00a0Infect\u00a0Dis\u00a02002;\u00a0\n185(9):1261 \u20101268.\u00a0\n\u00a0 409.\u00a0\u00a0Negredo\u00a0E,\u00a0Miro\u00a0O,\u00a0Rodriguez \u2010Santiago\u00a0B,\u00a0Garrabou \u00a0G,\u00a0Estany\u00a0C,\u00a0Masabeu\u00a0A\u00a0et\u00a0al.\u00a0Improve\u2010\nment\u00a0of\u00a0mitochondrial \u00a0toxicity\u00a0in\u00a0patients\u00a0receiving\u00a0a\u00a0nucleoside \u00a0reverse\u2010transcriptase \u00a0inhibi\u2010\ntor\u2010sparing\u00a0strategy:\u00a0results\u00a0from\u00a0the\u00a0Multicenter \u00a0Study\u00a0with\u00a0Nevirapine \u00a0and\u00a0Kaletra\u00a0(MULTI\u2010\nNEKA).\u00a0Clin\u00a0Infect\u00a0Dis\u00a02009;\u00a049(6):892 \u2010900.\u00a0\n\u00a0 410.\u00a0\u00a0Mocroft\u00a0A,\u00a0Staszewski \u00a0S,\u00a0Weber\u00a0R,\u00a0Gatell\u00a0J,\u00a0Rockstroh \u00a0J,\u00a0Gasiorowski \u00a0J\u00a0et\u00a0al.\u00a0Risk\u00a0of\u00a0disconti\u2010\nnuation\u00a0of\u00a0nevirapine \u00a0due\u00a0to\u00a0toxicities\u00a0in\u00a0antiretroviral \u2010naive\u00a0and\u00a0\u2010experienced \u00a0HIV\u2010infected\u00a0\npatients\u00a0with\u00a0high\u00a0and\u00a0low\u00a0CD4+\u00a0T\u2010cell\u00a0counts.\u00a0Antivir\u00a0Ther\u00a02007;\u00a012(3):325 \u2010333.\u00a0\n\u00a0 411.\u00a0\u00a0Manfredi \u00a0R,\u00a0Calza\u00a0L.\u00a0Nevirapine \u00a0versus\u00a0efavirenz\u00a0in\u00a0742\u00a0patients:\u00a0no\u00a0link\u00a0of\u00a0liver\u00a0toxicity\u00a0with\u00a0\nfemale\u00a0sex,\u00a0and\u00a0a\u00a0baseline\u00a0CD4\u00a0cell\u00a0count\u00a0greater\u00a0than\u00a0250\u00a0cells/microl. \u00a0AIDS\u00a02006;\u00a0\n20(17):2233 \u20102236.\u00a0\n\u00a0 412.\u00a0\u00a0Clumeck\u00a0N,\u00a0Goebel\u00a0F,\u00a0Rozenbaum \u00a0W,\u00a0Gerstoft\u00a0J,\u00a0Staszewski \u00a0S,\u00a0Montaner \u00a0J\u00a0et\u00a0al.\u00a0Simplification \u00a0\nwith\u00a0abacavir\u2010based\u00a0triple\u00a0nucleoside \u00a0therapy\u00a0versus\u00a0continued \u00a0protease\u00a0inhibitor\u2010based\u00a0\nhighly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0with\u00a0undetectable \u00a0plasma\u00a0HIV\u20101\u00a0\nRNA.\u00a0AIDS\u00a02001;\u00a015(12):1517 \u201026.\u00a0\n\u00a0 413.\u00a0\u00a0de\u00a0Lazzari\u00a0E,\u00a0Leon\u00a0A,\u00a0Arnaiz\u00a0JA,\u00a0Martinez\u00a0E,\u00a0Knobel\u00a0H,\u00a0Negredo\u00a0E\u00a0et\u00a0al.\u00a0Hepatotoxicity \u00a0of\u00a0nevi\u2010\nrapine\u00a0in\u00a0virologically \u00a0suppressed \u00a0patients\u00a0according \u00a0to\u00a0gender\u00a0and\u00a0CD4\u00a0cell\u00a0counts.\u00a0HIV\u00a0Med\u00a0\n2008;\u00a09(4):221\u2010226.\u00a0\n\u00a0 414.\u00a0\u00a0Kesselring \u00a0AM,\u00a0Wit\u00a0FW,\u00a0Sabin\u00a0CA,\u00a0Lundgren \u00a0JD,\u00a0Gill\u00a0MJ,\u00a0Gatell\u00a0JM\u00a0et\u00a0al.\u00a0Risk\u00a0factors\u00a0for\u00a0treat\u2010\nment\u2010limiting\u00a0toxicities\u00a0in\u00a0patients\u00a0starting\u00a0nevirapine \u2010containing \u00a0antiretroviral \u00a0therapy.\u00a0AIDS\u00a0\n2009;\u00a023(13):1689 \u20101699.\u00a0\n\u00a0 415.\u00a0\u00a0Wolf\u00a0E,\u00a0Koegl\u00a0C,\u00a0Theobald \u00a0T,\u00a0jaegel\u2010Guedes\u00a0E,\u00a0Jaeger\u00a0H.\u00a0Nevirapine \u2010associated \u00a0hepatotoxicity: \u00a0\nno\u00a0increased \u00a0risk\u00a0for\u00a0females\u00a0or\u00a0high\u00a0CD4\u00a0count\u00a0in\u00a0a\u00a0single\u2010centre\u00a0HIV\u00a0cohort.\u00a046th\u00a0Interscien \u2010\nce\u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy.San \u00a0Francisco, \u00a0September \u00a02\u201030,\u00a0\n2006\u00a0H\u20101063\u00a0\n\u00a0 416.\u00a0\u00a0Katlama\u00a0C,\u00a0Fenske\u00a0S,\u00a0Gazzard\u00a0B,\u00a0Lazzarin\u00a0A,\u00a0Clumeck\u00a0N,\u00a0Mallolas\u00a0J\u00a0et\u00a0al.\u00a0TRIZAL\u00a0study:\u00a0swit\u2010\nching\u00a0from\u00a0successful \u00a0HAART\u00a0to\u00a0Trizivir\u00a0(abacavir\u2010lamivudine \u2010zidovudine \u00a0combination \u00a0tablet):\u00a0\n48\u00a0weeks\u00a0efficacy,\u00a0safety\u00a0and\u00a0adherence \u00a0results.\u00a0HIV\u00a0Med\u00a02003;\u00a04(2):79\u201086.\u00a0\n\u00a0 417.\u00a0\u00a0Opravil\u00a0M,\u00a0Hirschel\u00a0B,\u00a0Lazzarin\u00a0A,\u00a0Furrer\u00a0H,\u00a0Chave\u00a0JP,\u00a0Yerly\u00a0S\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0trial\u00a0of\u00a0sim\u2010\nplified\u00a0maintenance \u00a0therapy\u00a0with\u00a0abacavir,\u00a0lamivudine, \u00a0and\u00a0zidovudine \u00a0in\u00a0human\u00a0immunode \u2010\nficiency\u00a0virus\u00a0infection. \u00a0J\u00a0Infect\u00a0Dis\u00a02002;\u00a0185(9):1251 \u20101260.\u00a0\n\u00a0 418.\u00a0\u00a0Pulvirenti \u00a0J,\u00a0Goodwin\u00a0D,\u00a0Slater\u00a0L.\u00a0Simplification \u00a0of\u00a0protease\u00a0inhibitor\u2010\u00a0containing \u00a0HAART\u00a0regi\u2010\nmens\u00a0with\u00a0abacavir\u00a0maintains \u00a0viral\u00a0suppression \u00a0and\u00a0favourable \u00a0adherence \u00a0in\u00a0HIV\u20101\u00a0infected\u00a0\nadults\u00a0(COLA30305). \u00a039th\u00a0Annual\u00a0Meeting\u00a0of\u00a0the\u00a0Infectious \u00a0Disease\u00a0Society\u00a0of\u00a0America,\u00a0San\u00a0\nFrancisco, \u00a0CA,\u00a02001\u00a0\u00a0\n\u00a0 419.\u00a0\u00a0Mallolas\u00a0J,\u00a0Pich\u00a0J,\u00a0Penaranda \u00a0M,\u00a0Domingo\u00a0P,\u00a0Knobel\u00a0H,\u00a0Pedrol\u00a0E\u00a0et\u00a0al.\u00a0Induction \u00a0therapy\u00a0with\u00a0\ntrizivir\u00a0plus\u00a0efavirenz\u00a0or\u00a0lopinavir/ritonavir \u00a0followed\u00a0by\u00a0trizivir\u00a0alone\u00a0in\u00a0naive\u00a0HIV\u20101\u2010infected\u00a0\nadults.\u00a0AIDS\u00a02008;\u00a022(3):377 \u2010384.\u00a0\n\u00a0 420.\u00a0\u00a0d'Ettorre\u00a0G,\u00a0Zaffiri\u00a0L,\u00a0Ceccarelli \u00a0G,\u00a0Andreotti \u00a0M,\u00a0Massetti\u00a0AP,\u00a0Vella\u00a0S\u00a0et\u00a0al.\u00a0Simplified \u00a0mainte\u2010\nnance\u00a0therapy\u00a0with\u00a0abacavir/lamivudine/zidovudine \u00a0plus\u00a0tenofovir\u00a0after\u00a0sustained \u00a0HIV\u00a0load\u00a0\nsuppression: \u00a0four\u00a0years\u00a0of\u00a0follow\u2010up.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02007;\u00a08(3):182\u2010188.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 129 \n \u00a0 421.\u00a0\u00a0Hoogewerf \u00a0M,\u00a0Regez\u00a0RM,\u00a0Schouten \u00a0WE,\u00a0Weigel\u00a0HM,\u00a0Frissen\u00a0PH,\u00a0Brinkman \u00a0K.\u00a0Change\u00a0to\u00a0aba\u2010\ncavir\u2010lamivudine \u2010tenofovir\u00a0combination \u00a0treatment \u00a0in\u00a0patients\u00a0with\u00a0HIV\u20101\u00a0who\u00a0had\u00a0complete \u00a0\nvirological \u00a0suppression. \u00a0Lancet\u00a02003;\u00a0362(9400):1979 \u20101980.\u00a0\n\u00a0 422.\u00a0\u00a0Martinez\u00a0E,\u00a0Arnaiz\u00a0JA,\u00a0Podzamczer \u00a0D,\u00a0Dalmau\u00a0D,\u00a0Ribera\u00a0E,\u00a0Domingo\u00a0P\u00a0et\u00a0al.\u00a0Substitution \u00a0of\u00a0\nnevirapine, \u00a0efavirenz, \u00a0or\u00a0abacavir\u00a0for\u00a0protease\u00a0inhibitors \u00a0in\u00a0patients\u00a0with\u00a0human\u00a0immunode \u2010\nficiency\u00a0virus\u00a0infection. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02003;\u00a0349(11):1036 \u20101046.\u00a0\n\u00a0 423.\u00a0\u00a0Martinez\u00a0E,\u00a0Arnaiz\u00a0JA,\u00a0Podzamczer \u00a0D,\u00a0Dalmau\u00a0D,\u00a0Ribera\u00a0E,\u00a0Domingo\u00a0P\u00a0et\u00a0al.\u00a0Three\u2010year\u00a0follow\u2010\nup\u00a0of\u00a0protease\u00a0inhibitor\u2010based\u00a0regimen\u00a0simplification \u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0AIDS\u00a02007;\u00a0\n21(3):367 \u2010369.\u00a0\n\u00a0 424.\u00a0\u00a0Ochoa\u00a0de\u00a0EA,\u00a0Arnedo\u00a0M,\u00a0Xercavins \u00a0M,\u00a0Martinez\u00a0E,\u00a0Roson\u00a0B,\u00a0Ribera\u00a0E\u00a0et\u00a0al.\u00a0Genotypic \u00a0and\u00a0\nphenotypic \u00a0resistance \u00a0patterns\u00a0at\u00a0virological \u00a0failure\u00a0in\u00a0a\u00a0simplification \u00a0trial\u00a0with\u00a0nevirapine, \u00a0\nefavirenz\u00a0or\u00a0abacavir.\u00a0AIDS\u00a02005;\u00a019(13):1385 \u20101391.\u00a0\n\u00a0 425.\u00a0\u00a0Fisac\u00a0C,\u00a0Fumero\u00a0E,\u00a0Crespo\u00a0M,\u00a0Roson\u00a0B,\u00a0Ferrer\u00a0E,\u00a0Virgili\u00a0N\u00a0et\u00a0al.\u00a0Metabolic \u00a0benefits\u00a024\u00a0months\u00a0\nafter\u00a0replacing\u00a0a\u00a0protease\u00a0inhibitor\u00a0with\u00a0abacavir,\u00a0efavirenz\u00a0or\u00a0nevirapine. \u00a0AIDS\u00a02005;\u00a0\n19(9):917 \u2010925.\u00a0\n\u00a0 426.\u00a0\u00a0Martinez\u00a0E,\u00a0Gatell\u00a0JM.\u00a0Considerations \u00a0on\u00a0the\u00a0effectiveness \u00a0of\u00a0nevirapine \u00a0in\u00a0protease\u00a0inhibi\u2010\ntor\u2010based\u00a0regimen\u00a0simplification. \u00a0AIDS\u00a02007;\u00a021(13):1829 \u20101830.\u00a0\n\u00a0 427.\u00a0\u00a0Abgrall\u00a0S,\u00a0Yeni\u00a0PG,\u00a0Bouchaud \u00a0O,\u00a0Costagliola \u00a0D.\u00a0Switch\u00a0from\u00a0a\u00a0first\u00a0virologically \u00a0effective\u00a0pro\u2010\ntease\u00a0inhibitor\u2010containing \u00a0regimen\u00a0to\u00a0a\u00a0regimen\u00a0containing \u00a0efavirenz, \u00a0nevirapine \u00a0or\u00a0abacavir.\u00a0\nAIDS\u00a02006;\u00a020(16):2099 \u20102106.\u00a0\n\u00a0 428.\u00a0\u00a0Bonjoch\u00a0A,\u00a0Paredes\u00a0R,\u00a0Galvez\u00a0J,\u00a0Miralles\u00a0C,\u00a0Videla\u00a0S,\u00a0Martinez\u00a0E\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0treatment \u00a0\nsimplification \u00a0with\u00a03\u00a0NRTIs\u00a0or\u00a02\u00a0NRTIs\u00a0plus\u00a0nevirapine \u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0treated\u00a0with\u00a0\nsuccessful \u00a0first\u2010line\u00a0HAART.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02005;\u00a039(3):313 \u2010316.\u00a0\n\u00a0 429.\u00a0\u00a0Gatell\u00a0J,\u00a0Salmon\u2010Ceron\u00a0D,\u00a0Lazzarin\u00a0A,\u00a0van\u00a0WE,\u00a0Antunes\u00a0F,\u00a0Leen\u00a0C\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0\natazanavir \u2010based\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0patients\u00a0with\u00a0virologic\u00a0suppression \u00a0\nswitched\u00a0from\u00a0a\u00a0stable,\u00a0boosted\u00a0or\u00a0unboosted \u00a0protease\u00a0inhibitor\u00a0treatment \u00a0regimen:\u00a0the\u00a0\nSWAN\u00a0Study\u00a0(AI424\u2010097)\u00a048\u2010week\u00a0results.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02007;\u00a044(11):1484 \u20101492.\u00a0\n\u00a0 430.\u00a0\u00a0Mallolas\u00a0J,\u00a0Podzamczer \u00a0D,\u00a0Milinkovic \u00a0A,\u00a0Domingo\u00a0P,\u00a0Clotet\u00a0B,\u00a0Ribera\u00a0E\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safe\u2010\nty\u00a0of\u00a0switching \u00a0from\u00a0boosted\u00a0lopinavir\u00a0to\u00a0boosted\u00a0atazanavir \u00a0in\u00a0patients\u00a0with\u00a0virological \u00a0sup\u2010\npression\u00a0receiving\u00a0a\u00a0LPV/r\u2010containing \u00a0HAART:\u00a0the\u00a0ATAZIP\u00a0study.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a0\n2009;\u00a051(1):29\u201036.\u00a0\n\u00a0 431.\u00a0\u00a0Rubio\u00a0R,\u00a0Carmena\u00a0J,\u00a0Asensi\u00a0V,\u00a0Echevarria \u00a0S,\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0simplification \u00a0from\u00a0protease\u00a0inhibi\u2010\ntors\u00a0to\u00a0boosted\u00a0atazanavir \u00a0based\u00a0regimens\u00a0in\u00a0real\u00a0life\u00a0conditions: \u00a0final\u00a01\u00a0year\u00a0results\u00a0of\u00a0GESI\u2010\nDA\u00a044/04\u00a0SIMPATAZ \u00a0study.\u00a017th\u00a0International \u00a0AIDS\u00a0Conference; \u00a03\u20108\u00a0August,\u00a02008;\u00a0Mexico\u00a0DF.\u00a0\n(Abstract\u00a0TUPE0111) \u00a0\n\u00a0 432.\u00a0\u00a0Moyle\u00a0G,\u00a0Girard\u00a0JM,\u00a0Andrade\u00a0J,\u00a0et\u00a0al.\u00a0Continuation \u00a0of\u00a0BID\u00a0boosted\u00a0PI\u00a0vs\u00a0switch\u00a0to\u00a0once\u2010daily\u00a0\nATV/RTV\u00a0for\u00a0the\u00a0management \u00a0of\u00a0lipodystrophy: \u00a048\u00a0week\u00a0primary\u00a0analysis\u00a0of\u00a0the\u00a096\u00a0week\u00a0\nmulticenter, \u00a0open\u2010label,\u00a0randomized, \u00a0prospective \u00a0ReAL\u00a0study.\u00a017th\u00a0International \u00a0AIDS\u00a0Confe\u2010\nrence;\u00a03\u20108\u00a0August,\u00a02008;\u00a0Mexico\u00a0DF.\u00a0(Abstract\u00a0no:\u00a0A\u2010072\u20100080\u201004171)\u00a0\n\u00a0 433.\u00a0\u00a0Sension\u00a0M,\u00a0ndrade\u00a0Neto\u00a0JL,\u00a0Grinsztejn \u00a0B,\u00a0Molina\u00a0JM,\u00a0Zavala\u00a0I,\u00a0Gonzalez\u2010Garcia\u00a0J\u00a0et\u00a0al.\u00a0Impro\u2010\nvement\u00a0in\u00a0lipid\u00a0profiles\u00a0in\u00a0antiretroviral \u2010experienced \u00a0HIV\u2010positive\u00a0patients\u00a0with\u00a0hyperlipide \u2010\nmia\u00a0after\u00a0a\u00a0switch\u00a0to\u00a0unboosted \u00a0atazanavir. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(2):153 \u2010\n162.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 130 \n \u00a0 434.\u00a0\u00a0Molina\u00a0JM,\u00a0Journot\u00a0V,\u00a0Morand\u2010Joubert\u00a0L,\u00a0Yeni\u00a0P,\u00a0Rozenbaum \u00a0W,\u00a0Rancinan\u00a0C\u00a0et\u00a0al.\u00a0Simplifica \u2010\ntion\u00a0therapy\u00a0with\u00a0once\u2010daily\u00a0emtricitabine, \u00a0didanosine, \u00a0and\u00a0efavirenz\u00a0in\u00a0HIV\u20101\u2010infected\u00a0adults\u00a0\nwith\u00a0viral\u00a0suppression \u00a0receiving\u00a0a\u00a0protease\u00a0inhibitor\u2010based\u00a0regimen:\u00a0a\u00a0randomized \u00a0trial.\u00a0J\u00a0In\u2010\nfect\u00a0Dis\u00a02005;\u00a0191(6):830 \u2010839.\u00a0\n\u00a0 435.\u00a0\u00a0Negredo\u00a0E,\u00a0Molto\u00a0J,\u00a0Munoz\u2010Moreno\u00a0JA,\u00a0Pedrol\u00a0E,\u00a0Ribera\u00a0E,\u00a0Viciana\u00a0P\u00a0et\u00a0al.\u00a0Safety\u00a0and\u00a0efficacy\u00a0\nof\u00a0once\u2010daily\u00a0didanosine, \u00a0tenofovir\u00a0and\u00a0nevirapine \u00a0as\u00a0a\u00a0simplification \u00a0antiretroviral \u00a0approach. \u00a0\nAntivir\u00a0Ther\u00a02004;\u00a09(3):335\u2010342.\u00a0\n\u00a0 436.\u00a0\u00a0Barrios\u00a0A,\u00a0Rendon\u00a0A,\u00a0Negredo\u00a0E,\u00a0Barreiro\u00a0P,\u00a0Garcia\u2010Benayas\u00a0T,\u00a0Labarga\u00a0P\u00a0et\u00a0al.\u00a0Paradoxical \u00a0\nCD4+\u00a0T\u2010cell\u00a0decline\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0complete \u00a0virus\u00a0suppression \u00a0taking\u00a0tenofovir\u00a0\nand\u00a0didanosine. \u00a0AIDS\u00a02005;\u00a019(6):569 \u2010575.\u00a0\n\u00a0 437.\u00a0\u00a0Fisher\u00a0M,\u00a0Moyle\u00a0GJ,\u00a0Shahmanesh \u00a0M,\u00a0Orkin\u00a0C,\u00a0Kingston\u00a0M,\u00a0Wilkins\u00a0E\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0com\u2010\nparative\u00a0trial\u00a0of\u00a0continued \u00a0zidovudine/lamivudine \u00a0or\u00a0replacement \u00a0with\u00a0tenofovir\u00a0disoproxil \u00a0\nfumarate/emtricitabine \u00a0in\u00a0efavirenz\u2010treated\u00a0HIV\u20101\u2010infected\u00a0individuals. \u00a0J\u00a0Acquir\u00a0Immune\u00a0De\u2010\nfic\u00a0Syndr\u00a02009;\u00a051(5):562 \u2010568.\u00a0\n\u00a0 438.\u00a0\u00a0Mart\u00ednez\u00a0E,\u00a0Ribera\u00a0E,\u00a0Pulido\u00a0F,\u00a0Rubio\u00a0R,\u00a0Negredo\u00a0E,\u00a0Sanz\u00a0J\u00a0et\u00a0al.\u00a0Early\u00a0improvement \u00a0of\u00a0limb\u00a0fat\u00a0\ncontent\u00a0in\u00a0patients\u00a0switching \u00a0from\u00a0AZT/3TC\u00a0to\u00a0FTC/TDF\u00a0(TVD):\u00a0a\u00a024\u00a0week\u00a0interim\u00a0analysis\u00a0of\u00a0\nthe\u00a0RECOMB\u00a0Trial.\u00a017th\u00a0International \u00a0AIDS\u00a0Conference; \u00a03\u20108\u00a0August,\u00a02008;\u00a0Mexico\u00a0DF.\u00a0Abs\u2010\ntract\u00a0MOPDB102 \u00a0\n\u00a0 439.\u00a0\u00a0Ribera\u00a0E,\u00a0Martinez\u00a0E,\u00a0Clotet\u00a0B,\u00a0Estrada\u00a0V,\u00a0Sanz\u00a0J,\u00a0Berenguer \u00a0J\u00a0et\u00a0al.\u00a072\u00a0week\u00a0outcomes \u00a0follo\u2010\nwing\u00a0switch\u00a0from\u00a0AZT/3TC\u00a0to\u00a0FTC/TDF\u00a0(TVD)\u00a0vs\u00a0continuing \u00a0on\u00a0AZT/3TC.\u00a0Final\u00a0results\u00a0of\u00a0the\u00a0\nRECOMB\u00a0trial.\u00a05th\u00a0International \u00a0AIDS\u00a0Society\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0\nand\u00a0Prevention \u00a0Cape\u00a0Town,\u00a0South\u00a0Africa\u00a0July\u00a019\u201022,\u00a02009\u00a02009;\u00a0Abstract\u00a0CDB091.\u00a0\n\u00a0 440.\u00a0\u00a0Valantin\u00a0MA,\u00a0de\u00a0truchis\u00a0P,\u00a0Bittar\u00a0R,\u00a0et\u00a0al.\u00a0Switching \u00a0NRTI\u00a0backbone \u00a0to\u00a0tenofovir\u00a0plus\u00a0emtrici\u2010\ntabine\u00a0(Truvada\u00a0TVD)\u00a0promptly\u00a0improves \u00a0triglycerides \u00a0and\u00a0LDL\u2010cholesterol \u00a0levels\u00a0in\u00a0dyslipi\u2010\ndemic\u00a0HIV\u00a0patients:\u00a0The\u00a0TOTEM\u00a0randomised \u00a0study.\u00a017th\u00a0International \u00a0AIDS\u00a0Conference; \u00a03\u20108\u00a0\nAugust,\u00a02008;\u00a0Mexico\u00a0DF.\u00a0(Abstract\u00a0THPE0156) \u00a0\n\u00a0 441.\u00a0\u00a0Martinez\u00a0E,\u00a0Arranz\u00a0JA,\u00a0Podzamczer \u00a0D,\u00a0Lonca\u00a0M,\u00a0Sanz\u00a0J,\u00a0Barragan\u00a0P\u00a0et\u00a0al.\u00a0A\u00a0simplification \u00a0trial\u00a0\nswitching \u00a0from\u00a0nucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitors \u00a0to\u00a0once\u2010daily\u00a0fixed\u2010dose\u00a0abaca\u2010\nvir/lamivudine \u00a0or\u00a0tenofovir/emtricitabine \u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0with\u00a0virological \u00a0suppres\u2010\nsion.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(3):290 \u2010297.\u00a0\n\u00a0 442.\u00a0\u00a0DeJesus\u00a0E,\u00a0Young\u00a0B,\u00a0Morales\u2010Ramirez\u00a0JO,\u00a0Sloan\u00a0L,\u00a0Ward\u00a0DJ,\u00a0Flaherty\u00a0JF\u00a0et\u00a0al.\u00a0Simplification \u00a0of\u00a0\nantiretroviral \u00a0therapy\u00a0to\u00a0a\u00a0single\u2010tablet\u00a0regimen\u00a0consisting \u00a0of\u00a0efavirenz, \u00a0emtricitabine, \u00a0and\u00a0\ntenofovir\u00a0disoproxil \u00a0fumarate \u00a0versus\u00a0unmodified \u00a0antiretroviral \u00a0therapy\u00a0in\u00a0virologically \u00a0sup\u2010\npressed\u00a0HIV\u20101\u2010infected\u00a0patients.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(2):163 \u2010174.\u00a0\n\u00a0 443.\u00a0\u00a0Hodder\u00a0S,\u00a0Mounzer\u00a0K,\u00a0DeJesus\u00a0E,\u00a0Maa\u00a0JF,\u00a0Ebrahimi\u00a0R,\u00a0Grimm\u00a0K\u00a0et\u00a0al.\u00a0Patients\u2010reported\u00a0out\u2010\ncomes\u00a0after\u00a0simplification \u00a0to\u00a0a\u00a0single\u00a0tablet\u00a0regimen\u00a0of\u00a0Efavirenz/emtricitabine/Tenofovir \u00a0DF.\u00a0\n9th\u00a0International \u00a0Congess\u00a0on\u00a0Drug\u00a0Therapy\u00a0in\u00a0HIV\u00a0Infection, \u00a0Glasgow,\u00a0UK,\u00a09\u201013\u00a0November, \u00a0\n2008\u00a02009;\u00a0Abstrac\u00a0P63.\u00a0\n\u00a0 444.\u00a0\u00a0Pollard\u00a0RB.\u00a0Can\u00a0HIV\u00a0infection\u00a0be\u00a0treated\u00a0successfully \u00a0with\u00a0a\u00a0once\u2010daily\u00a0regimen? \u00a0AIDS\u00a0Read\u00a0\n2002;\u00a012(11):489 \u20108,\u00a0500,\u00a0508.\u00a0\n\u00a0 445.\u00a0\u00a0Towner\u00a0W,\u00a0Klein\u00a0D,\u00a0Kerrigan\u00a0HL,\u00a0Follansbee \u00a0S,\u00a0Yu\u00a0K,\u00a0Horberg\u00a0M.\u00a0Virologic\u00a0outcomes \u00a0of\u00a0chan\u2010\nging\u00a0enfuvirtide \u00a0to\u00a0raltegravir \u00a0in\u00a0HIV\u20101\u00a0patients\u00a0well\u00a0controlled \u00a0on\u00a0an\u00a0enfuvirtide \u00a0based\u00a0regi\u2010\nmen:\u00a024\u2010week\u00a0results\u00a0of\u00a0the\u00a0CHEER\u00a0study.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(4):367 \u2010373.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 131 \n \u00a0 446.\u00a0\u00a0Harris\u00a0M,\u00a0Larsen\u00a0G,\u00a0Montaner \u00a0JSG.\u00a0Outcomes \u00a0of\u00a0patients\u00a0switched\u00a0from\u00a0Raltegravir \u00a0within\u00a0a\u00a0\nvirologocally \u00a0suppressive \u00a0regimen.\u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infec\u2010\ntions;\u00a0February\u00a02008;\u00a0Boston,\u00a0Massachusetts \u00a02009;\u00a0Abstract\u00a0799.\u00a0\n\u00a0 447.\u00a0\u00a0De\u00a0Castro\u00a0N,\u00a0Braun\u00a0J,\u00a0Charreau\u00a0I,\u00a0Pialoux\u00a0G,\u00a0Cotte\u00a0L,\u00a0Katlama\u00a0C\u00a0et\u00a0al.\u00a0Switch\u00a0from\u00a0Enfuvirtide \u00a0\nto\u00a0Raltegravir \u00a0in\u00a0highly\u00a0treatment \u2010experienced \u00a0patients:\u00a0a\u00a0randomized \u00a0open\u00a0label\u00a0non\u2010\ninferiority \u00a0trial,\u00a0Easier\u2010ANRS\u00a0138.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infec\u2010\ntions;\u00a0February\u00a02009;\u00a0Montreal \u00a02009;\u00a0Abstract\u00a0572.\u00a0\n\u00a0 448.\u00a0\u00a0Gatti\u00a0F,\u00a0Matti\u00a0A,\u00a0Nasta\u00a0P,\u00a0Cologni\u00a0G,\u00a0Costarelli \u00a0S,\u00a0Carosi\u00a0G.\u00a0Switch\u00a0from\u00a0enfuvirtide \u00a0to\u00a0raltegra\u2010\nvir:\u00a0a\u00a0simplification \u00a0option\u00a0for\u00a0heavily\u00a0pretreated \u00a0patients.\u00a09th\u00a0International \u00a0congress\u00a0on\u00a0Drug\u00a0\nTherapy\u00a0in\u00a0HIV\u00a0Infection\u00a0Glasgow,\u00a0UK\u00a0November \u00a09\u201013,\u00a02008\u00a02009;\u00a0Abstract\u00a0P52.\u00a0\n\u00a0 449.\u00a0\u00a0Santos\u00a0JR,\u00a0Llibre\u00a0JM,\u00a0Molto\u00a0J,\u00a0Perez\u00a0N,\u00a0Garcia\u00a0MC,\u00a0Clotet\u00a0B.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0switching \u00a0\nenfuvirtide \u00a0to\u00a0raltegravir \u00a0in\u00a0patients\u00a0with\u00a0viral\u00a0supression. \u00a09th\u00a0International \u00a0congress\u00a0on\u00a0Drug\u00a0\nTherapy\u00a0in\u00a0HIV\u00a0Infection\u00a0Glasgow,\u00a0UK\u00a0November \u00a09\u201013,\u00a02008\u00a02009;\u00a0Abstract\u00a0P58.\u00a0\n\u00a0 450.\u00a0\u00a0Talbot\u00a0A,\u00a0Machouf\u00a0N,\u00a0Thomas\u00a0R,\u00a0Marcotte \u00a0S,\u00a0Therrien\u00a0R,\u00a0Lessard\u00a0B\u00a0et\u00a0al.\u00a0Switch\u00a0from\u00a0enfuvir\u2010\ntide\u00a0to\u00a0raltegravir \u00a0in\u00a0patients\u00a0with\u00a0undetectable \u00a0viral\u00a0load:\u00a0efficacy\u00a0and\u00a0safety\u00a0at\u00a024\u00a0weeks\u00a0in\u00a0\na\u00a0Montreal \u00a0cohort.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(3):362 \u2010364.\u00a0\n\u00a0 451.\u00a0\u00a0Eron\u00a0J,\u00a0Andrade\u00a0J,\u00a0Zajdenverg \u00a0R,\u00a0Workman \u00a0C,\u00a0Cooper\u00a0D,\u00a0Young\u00a0B\u00a0et\u00a0al.\u00a0Switching \u00a0from\u00a0stable\u00a0\nLopinavir/ritonavir \u2010based\u00a0to\u00a0Raltegravir \u2010based\u00a0combination \u00a0ART\u00a0resulted\u00a0in\u00a0a\u00a0superior\u00a0lipid\u00a0\nprofile\u00a0at\u00a0week\u00a012\u00a0but\u00a0did\u00a0not\u00a0demonstrate \u00a0non\u2010inferior\u00a0virologic\u00a0efficacy\u00a0at\u00a0week\u00a024.\u00a016th\u00a0\nConference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a02009;\u00a0Montreal \u00a02009;\u00a0\nAbstract\u00a070aLB.\u00a0\n\u00a0 452.\u00a0\u00a0Arribas\u00a0JR,\u00a0Delgado\u00a0R,\u00a0Arranz\u00a0A,\u00a0Munoz\u00a0R,\u00a0Portilla\u00a0J,\u00a0Pasquau\u00a0J\u00a0et\u00a0al.\u00a0Lopinavir\u2010ritonavir\u00a0mo\u2010\nnotherapy \u00a0versus\u00a0lopinavir\u2010ritonavir\u00a0and\u00a02\u00a0nucleosides \u00a0for\u00a0maintenance \u00a0therapy\u00a0of\u00a0HIV:\u00a096\u2010\nweek\u00a0analysis.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(2):147 \u2010152.\u00a0\n\u00a0 453.\u00a0\u00a0Barrios\u00a0A,\u00a0Negredo\u00a0E,\u00a0Domingo\u00a0P,\u00a0Estrada\u00a0V,\u00a0Labarga\u00a0P,\u00a0Asensi\u00a0V\u00a0et\u00a0al.\u00a0Simplification \u00a0therapy\u00a0\nwith\u00a0once\u2010daily\u00a0didanosine, \u00a0tenofovir\u00a0and\u00a0efavirenz\u00a0in\u00a0HIV\u20101\u2010infected\u00a0adults\u00a0with\u00a0viral\u00a0sup\u2010\npression\u00a0receiving\u00a0a\u00a0more\u00a0complex\u00a0antiretroviral \u00a0regimen:\u00a0final\u00a0results\u00a0of\u00a0the\u00a0EFADITE\u00a0trial.\u00a0\nAntivir\u00a0Ther\u00a02005;\u00a010(7):825 \u2010832.\u00a0\n\u00a0 454.\u00a0\u00a0Gatell\u00a0JM,\u00a0Salmon\u2010Ceron\u00a0D,\u00a0Lalezzari\u00a0A,\u00a0Van\u00a0Wijngaerden \u00a0E,\u00a0Antunes\u00a0F,\u00a0Leen\u00a0C\u00a0et\u00a0al.\u00a0Efficacy\u00a0\nand\u00a0safety\u00a0of\u00a0atazanavir \u00a0based\u00a0HAART\u00a0in\u00a0patients\u00a0switching \u00a0from\u00a0a\u00a0stable\u00a0boosted/unboosted \u00a0\nprotease\u00a0inhibitor\u00a0treatment: \u00a0the\u00a0SWAN\u00a0Study.\u00a010th\u00a0European \u00a0AIDS\u00a0Conference.November \u00a0\n17\u201020,\u00a02005.Dublin. \u00a0Abstract\u00a0PS1/1\u00a0\n\u00a0 455.\u00a0\u00a0Nieuwkerk \u00a0PT,\u00a0Oort\u00a0FJ.\u00a0Self\u2010reported\u00a0adherence \u00a0to\u00a0antiretroviral \u00a0therapy\u00a0for\u00a0HIV\u20101\u00a0infection\u00a0\nand\u00a0virologic\u00a0treatment \u00a0response: \u00a0a\u00a0meta\u2010analysis.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02005;\u00a0\n38(4):445 \u2010448.\u00a0\n\u00a0 456.\u00a0\u00a0Wood\u00a0E,\u00a0Hogg\u00a0RS,\u00a0Yip\u00a0B,\u00a0Harrigan\u00a0PR,\u00a0O'Shaughnessy \u00a0MV,\u00a0Montaner \u00a0JS.\u00a0The\u00a0impact\u00a0of\u00a0ad\u2010\nherence\u00a0on\u00a0CD4\u00a0cell\u00a0count\u00a0responses \u00a0among\u00a0HIV\u2010infected\u00a0patients.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0\nSyndr\u00a02004;\u00a035(3):261 \u2010268.\u00a0\n\u00a0 457.\u00a0\u00a0Hogg\u00a0RS,\u00a0Heath\u00a0K,\u00a0Bangsberg \u00a0D,\u00a0Yip\u00a0B,\u00a0Press\u00a0N,\u00a0O'Shaughnessy \u00a0MV\u00a0et\u00a0al.\u00a0Intermittent \u00a0use\u00a0of\u00a0\ntriple\u2010combination \u00a0therapy\u00a0is\u00a0predictive \u00a0of\u00a0mortality\u00a0at\u00a0baseline\u00a0and\u00a0after\u00a01\u00a0year\u00a0of\u00a0follow\u2010up.\u00a0\nAIDS\u00a02002;\u00a016(7):1051 \u20101058.\u00a0\n\u00a0 458.\u00a0\u00a0Garcia\u00a0de\u00a0Olalla\u00a0P,\u00a0Knobel\u00a0H,\u00a0Carmona\u00a0A,\u00a0Guelar\u00a0A,\u00a0Lopez\u2010Colomes\u00a0JL,\u00a0Cayla\u00a0JA.\u00a0Impact\u00a0of\u00a0\nadherence \u00a0and\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0on\u00a0survival\u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0J\u00a0Ac\u2010\nquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02002;\u00a030(1):105 \u2010110.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 132 \n \u00a0 459.\u00a0\u00a0Rueda\u00a0S,\u00a0Park\u2010Wyllie\u00a0LY,\u00a0Bayoumi\u00a0AM,\u00a0Tynan\u00a0AM,\u00a0Antoniou \u00a0TA,\u00a0Rourke\u00a0SB\u00a0et\u00a0al.\u00a0Patient\u00a0sup\u2010\nport\u00a0and\u00a0education \u00a0for\u00a0promoting \u00a0adherence \u00a0to\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0for\u00a0\nHIV/AIDS. \u00a0Cochrane \u00a0Database \u00a0of\u00a0Systematic \u00a0Reviews\u00a02006\u00a0Issue\u00a03.\u00a0Art.\u00a0No.:\u00a0CD001442. \u00a0DOI:\u00a0\n10.1002/14651858.CD001442.pub2. \u00a0\n\u00a0 460.\u00a0\u00a0Mills\u00a0EJ,\u00a0Nachega\u00a0JB,\u00a0Bangsberg \u00a0DR,\u00a0Singh\u00a0S,\u00a0Rachlis\u00a0B,\u00a0Wu\u00a0P\u00a0et\u00a0al.\u00a0Adherence \u00a0to\u00a0HAART:\u00a0a\u00a0\nsystematic \u00a0review\u00a0of\u00a0developed \u00a0and\u00a0developing \u00a0nation\u00a0patient\u2010reported\u00a0barriers\u00a0and\u00a0facilita\u2010\ntors.\u00a0PLoS\u00a0Med\u00a02006;\u00a03(11):e438. \u00a0\n\u00a0 461.\u00a0\u00a0Glass\u00a0TR,\u00a0De\u00a0GS,\u00a0Weber\u00a0R,\u00a0Vernazza\u00a0PL,\u00a0Rickenbach \u00a0M,\u00a0Furrer\u00a0H\u00a0et\u00a0al.\u00a0Correlates \u00a0of\u00a0self\u2010\nreported\u00a0nonadherence \u00a0to\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0HIV\u2010infected\u00a0patients:\u00a0the\u00a0Swiss\u00a0HIV\u00a0Co\u2010\nhort\u00a0Study.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02006;\u00a041(3):385 \u2010392.\u00a0\n\u00a0 462.\u00a0\u00a0Pardi\u00a0GR,\u00a0Nunes\u00a0MA,\u00a0Preto\u00a0R,\u00a0Canassa\u00a0PG,\u00a0Correia\u00a0D.\u00a0Profile\u00a0of\u00a0adherence \u00a0to\u00a0highly\u00a0active\u00a0\nantiretroviral \u00a0therapy\u00a0of\u00a0patients\u00a0older\u00a0than\u00a050\u00a0years\u00a0old.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Synd\u00a02009;\u00a0\n52(2):301 \u2010303.\u00a0\n\u00a0 463.\u00a0\u00a0Ettenhofer \u00a0ML,\u00a0Hinkin\u00a0CH,\u00a0Castellon\u00a0SA,\u00a0Durvasula \u00a0R,\u00a0Ullman\u00a0J,\u00a0Lam\u00a0M\u00a0et\u00a0al.\u00a0Aging,\u00a0neurocog \u2010\nnition,\u00a0and\u00a0medication \u00a0adherence \u00a0in\u00a0HIV\u00a0infection. \u00a0Am\u00a0J\u00a0Geriatr\u00a0Psychiatry \u00a02009;\u00a017(4):281 \u2010\n290.\u00a0\n\u00a0 464.\u00a0\u00a0Stone\u00a0VE.\u00a0Strategies \u00a0for\u00a0optimizing \u00a0adherence \u00a0to\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy:\u00a0lessons\u00a0\nfrom\u00a0research\u00a0and\u00a0clinical\u00a0practice.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02001;\u00a033(6):865 \u201072.\u00a0\n\u00a0 465.\u00a0\u00a0Mu\u00f1oz\u2010Moreno\u00a0JA,\u00a0Fumaz\u00a0CR,\u00a0Ferrer\u00a0MJ,\u00a0Tuldra\u00a0A,\u00a0Rovira\u00a0T,\u00a0Viladrich\u00a0C\u00a0et\u00a0al.\u00a0Assessing \u00a0self\u2010\nreported\u00a0adherence \u00a0to\u00a0HIV\u00a0therapy\u00a0by\u00a0questionnaire: \u00a0the\u00a0SERAD\u00a0(Self\u2010Reported \u00a0Adherence) \u00a0\nStudy.\u00a0AIDS\u00a0Res\u00a0Hum\u00a0Retroviruses \u00a02007;\u00a023(10):1166 \u20101175.\u00a0\n\u00a0 466.\u00a0\u00a0Knobel\u00a0H,\u00a0Alonso\u00a0J,\u00a0Casado\u00a0JL,\u00a0Collazos\u00a0J,\u00a0Gonzalez\u00a0J,\u00a0Ruiz\u00a0I\u00a0et\u00a0al.\u00a0Validation \u00a0of\u00a0a\u00a0simplified \u00a0\nmedication \u00a0adherence \u00a0questionnaire \u00a0in\u00a0a\u00a0large\u00a0cohort\u00a0of\u00a0HIV\u2010infected\u00a0patients:\u00a0the\u00a0GEEMA\u00a0\nStudy.\u00a0AIDS\u00a02002;\u00a016(4):605 \u2010613.\u00a0\n\u00a0 467.\u00a0\u00a0Duong\u00a0M,\u00a0Golzi\u00a0A,\u00a0Peytavin\u00a0G,\u00a0Piroth\u00a0L,\u00a0Froidure\u00a0M,\u00a0Grappin\u00a0M\u00a0et\u00a0al.\u00a0Usefulness \u00a0of\u00a0therapeu\u2010\ntic\u00a0drug\u00a0monitoring \u00a0of\u00a0antiretrovirals \u00a0in\u00a0routine\u00a0clinical\u00a0practice.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02004;\u00a0\n5(4):216\u2010223.\u00a0\n\u00a0 468.\u00a0\u00a0Deschamps \u00a0AE,\u00a0Graeve\u00a0VD,\u00a0van\u00a0WE,\u00a0De\u00a0S,\u00a0V,\u00a0Vandamme \u00a0AM,\u00a0van\u00a0VK\u00a0et\u00a0al.\u00a0Prevalence \u00a0and\u00a0\ncorrelates \u00a0of\u00a0nonadherence \u00a0to\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0a\u00a0population \u00a0of\u00a0HIV\u00a0patients\u00a0using\u00a0\nMedication \u00a0Event\u00a0Monitoring \u00a0System.\u00a0AIDS\u00a0Patient\u00a0Care\u00a0STDS\u00a02004;\u00a018(11):644 \u2010657.\u00a0\n\u00a0 469.\u00a0\u00a0Bangsberg \u00a0DR.\u00a0Less\u00a0than\u00a095%\u00a0adherence \u00a0to\u00a0nonnucleoside \u00a0reverse\u2010transcriptase \u00a0inhibitor\u00a0\ntherapy\u00a0can\u00a0lead\u00a0to\u00a0viral\u00a0suppression. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02006;\u00a043(7):939 \u2010941.\u00a0\n\u00a0 470.\u00a0\u00a0Maggiolo \u00a0F,\u00a0Ravasio\u00a0L,\u00a0Ripamonti \u00a0D,\u00a0Gregis\u00a0G,\u00a0Quinzan\u00a0G,\u00a0Arici\u00a0C\u00a0et\u00a0al.\u00a0Similar\u00a0adherence \u00a0rates\u00a0\nfavor\u00a0different\u00a0virologic\u00a0outcomes \u00a0for\u00a0patients\u00a0treated\u00a0with\u00a0nonnucleoside \u00a0analogues \u00a0or\u00a0pro\u2010\ntease\u00a0inhibitors. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02005;\u00a040(1):158 \u2010163.\u00a0\n\u00a0 471.\u00a0\u00a0Knobel\u00a0H,\u00a0Urbina\u00a0O,\u00a0Gonzalez\u00a0A,\u00a0Sorli\u00a0ML,\u00a0Montero\u00a0M,\u00a0Carmona\u00a0A\u00a0et\u00a0al.\u00a0Impact\u00a0of\u00a0different\u00a0\npatterns\u00a0of\u00a0nonadherence \u00a0on\u00a0the\u00a0outcome\u00a0of\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0patients\u00a0\nwith\u00a0long\u2010term\u00a0follow\u2010up.\u00a0HIV\u00a0Med\u00a02009;\u00a010(6):364 \u2010369.\u00a0\n\u00a0 472.\u00a0\u00a0Nachega\u00a0JB,\u00a0Hislop\u00a0M,\u00a0Dowdy\u00a0DW,\u00a0Chaisson\u00a0RE,\u00a0Regensberg \u00a0L,\u00a0Maartens \u00a0G.\u00a0Adherence \u00a0to\u00a0\nnonnucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitor\u2010based\u00a0HIV\u00a0therapy\u00a0and\u00a0virologic\u00a0outcomes. \u00a0Ann\u00a0\nIntern\u00a0Med\u00a02007;\u00a0146(8):564 \u2010573.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 133 \n \u00a0 473.\u00a0\u00a0Parienti\u00a0JJ,\u00a0Das\u2010Douglas\u00a0M,\u00a0Massari\u00a0V,\u00a0Guzman\u00a0D,\u00a0Deeks\u00a0SG,\u00a0Verdon\u00a0R\u00a0et\u00a0al.\u00a0Not\u00a0all\u00a0missed\u00a0\ndoses\u00a0are\u00a0the\u00a0same:\u00a0sustained \u00a0NNRTI\u00a0treatment \u00a0interruptions \u00a0predict\u00a0HIV\u00a0rebound\u00a0at\u00a0low\u2010to\u2010\nmoderate \u00a0adherence \u00a0levels.\u00a0PLoS\u00a0ONE\u00a02008;\u00a03(7):e2783. \u00a0\n\u00a0 474.\u00a0\u00a0Bangsberg \u00a0DR,\u00a0Kroetz\u00a0DL,\u00a0Deeks\u00a0SG.\u00a0Adherence \u2010resistance \u00a0relationships \u00a0to\u00a0combination \u00a0HIV\u00a0\nantiretroviral \u00a0therapy.\u00a0Curr\u00a0HIV/AIDS\u00a0Rep\u00a02007;\u00a04(2):65\u201072.\u00a0\n\u00a0 475.\u00a0\u00a0Maggiolo \u00a0F,\u00a0Airoldi\u00a0M,\u00a0Kleinloog\u00a0HD,\u00a0Callegaro \u00a0A,\u00a0Ravasio\u00a0V,\u00a0Arici\u00a0C\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0adherence \u00a0\nto\u00a0HAART\u00a0on\u00a0virologic\u00a0outcome\u00a0and\u00a0on\u00a0the\u00a0selection\u00a0of\u00a0resistance \u2010conferring \u00a0mutations \u00a0in\u00a0N.\u00a0\nHIV\u00a0Clin\u00a0Trials\u00a02007;\u00a08(5):282\u2010292.\u00a0\n\u00a0 476.\u00a0\u00a0Bangsberg \u00a0DR.\u00a0Preventing \u00a0HIV\u00a0antiretroviral \u00a0resistance \u00a0through\u00a0better\u00a0monitoring \u00a0of\u00a0treat\u2010\nment\u00a0adherence. \u00a0J\u00a0Infect\u00a0Dis\u00a02008;\u00a0197\u00a0Suppl\u00a03:S272\u2010S278.\u00a0\n\u00a0 477.\u00a0\u00a0Gardner\u00a0EM,\u00a0Sharma\u00a0S,\u00a0Peng\u00a0G,\u00a0Hullsiek\u00a0KH,\u00a0Burman\u00a0WJ,\u00a0MacArthur \u00a0RD\u00a0et\u00a0al.\u00a0Differential \u00a0\nadherence \u00a0to\u00a0combination \u00a0antiretroviral \u00a0therapy\u00a0is\u00a0associated \u00a0with\u00a0virological \u00a0failure\u00a0with\u00a0re\u2010\nsistance.\u00a0AIDS\u00a02008;\u00a022(1):75\u201082.\u00a0\n\u00a0 478.\u00a0\u00a0Golin\u00a0CE,\u00a0Earp\u00a0J,\u00a0Tien\u00a0HC,\u00a0Stewart\u00a0P,\u00a0Porter\u00a0C,\u00a0Howie\u00a0L.\u00a0A\u00a02\u2010arm,\u00a0randomized, \u00a0controlled \u00a0trial\u00a0\nof\u00a0a\u00a0motivational \u00a0interviewing \u2010based\u00a0intervention \u00a0to\u00a0improve\u00a0adherence \u00a0to\u00a0antiretroviral \u00a0the\u2010\nrapy\u00a0(ART)\u00a0among\u00a0patients\u00a0failing\u00a0or\u00a0initiating\u00a0ART.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02006;\u00a0\n42(1):42\u201051.\u00a0\n\u00a0 479.\u00a0\u00a0Amico\u00a0KR,\u00a0Harman\u00a0JJ,\u00a0Johnson\u00a0BT.\u00a0Efficacy\u00a0of\u00a0antiretroviral \u00a0therapy\u00a0adherence \u00a0interventions: \u00a0\na\u00a0research\u00a0synthesis\u00a0of\u00a0trials,\u00a01996\u00a0to\u00a02004.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02006;\u00a041(3):285 \u2010\n297.\u00a0\n\u00a0 480.\u00a0\u00a0Wohl\u00a0AR,\u00a0Garland\u00a0WH,\u00a0Valencia\u00a0R,\u00a0Squires\u00a0K,\u00a0Witt\u00a0MD,\u00a0Kovacs\u00a0A\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0trial\u00a0of\u00a0\ndirectly\u00a0administered \u00a0antiretroviral \u00a0therapy\u00a0and\u00a0adherence \u00a0case\u00a0management \u00a0intervention. \u00a0\nClin\u00a0Infect\u00a0Dis\u00a02006;\u00a042(11):1619 \u20101627.\u00a0\n\u00a0 481.\u00a0\u00a0Gross\u00a0R,\u00a0Tierney\u00a0C,\u00a0Andrade\u00a0A,\u00a0Lalama\u00a0C,\u00a0Rosenkranz \u00a0S,\u00a0Eshleman \u00a0SH\u00a0et\u00a0al.\u00a0Modified\u00a0directly\u00a0\nobserved \u00a0antiretroviral \u00a0therapy\u00a0compared \u00a0with\u00a0self\u2010administered \u00a0therapy\u00a0in\u00a0treatment \u2010naive\u00a0\nHIV\u20101\u2010infected\u00a0patients:\u00a0a\u00a0randomized \u00a0trial.\u00a0Arch\u00a0Intern\u00a0Med\u00a02009;\u00a0169(13):1224 \u20101232.\u00a0\n\u00a0 482.\u00a0\u00a0Kleeberger \u00a0CA,\u00a0Buechner \u00a0J,\u00a0Palella\u00a0F,\u00a0Detels\u00a0R,\u00a0Riddler\u00a0S,\u00a0Godfrey\u00a0R\u00a0et\u00a0al.\u00a0Changes\u00a0in\u00a0adheren\u2010\nce\u00a0to\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0medications \u00a0in\u00a0the\u00a0Multicenter \u00a0AIDS\u00a0Cohort\u00a0Study.\u00a0\nAIDS\u00a02004;\u00a018(4):683 \u2010688.\u00a0\n\u00a0 483.\u00a0\u00a0Falco\u00a0V,\u00a0Rodriguez \u00a0D,\u00a0Ribera\u00a0E,\u00a0Martinez\u00a0E,\u00a0Miro\u00a0JM,\u00a0Domingo\u00a0P\u00a0et\u00a0al.\u00a0Severe\u00a0nucleoside \u2010\nassociated \u00a0lactic\u00a0acidosis\u00a0in\u00a0human\u00a0immunodeficiency \u00a0virus\u2010infected\u00a0patients:\u00a0report\u00a0of\u00a012\u00a0\ncases\u00a0and\u00a0review\u00a0of\u00a0the\u00a0literature. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02002;\u00a034(6):838 \u201046.\u00a0\n\u00a0 484.\u00a0\u00a0Waters\u00a0L,\u00a0Nelson\u00a0M.\u00a0Long\u2010term\u00a0complications \u00a0of\u00a0antiretroviral \u00a0therapy:\u00a0lipoatrophy. \u00a0Int\u00a0J\u00a0Clin\u00a0\nPract\u00a02007;\u00a061(6):999 \u20101014.\u00a0\n\u00a0 485.\u00a0\u00a0Hetherington \u00a0S,\u00a0McGuirk\u00a0S,\u00a0Powell\u00a0G,\u00a0Cutrell\u00a0A,\u00a0Naderer\u00a0O,\u00a0Spreen\u00a0B\u00a0et\u00a0al.\u00a0Hypersensitivity \u00a0\nreactions \u00a0during\u00a0therapy\u00a0with\u00a0the\u00a0nucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitor\u00a0abacavir.\u00a0Clin\u00a0\nTher\u00a02001;\u00a023(10):1603 \u20101614.\u00a0\n\u00a0 486.\u00a0\u00a0Dear\u00a0Health\u00a0Care\u00a0Professional \u00a0Letter.\u00a0Clarification \u00a0of\u00a0risk\u00a0factors\u00a0for\u00a0severe,\u00a0life\u2010threatening \u00a0\nand\u00a0fatal\u00a0hepatotoxicity \u00a0with\u00a0VIRAMUNE\u00ae \u00a0(nevirapine). \u00a0Boehringer \u00a0Ingelheim, \u00a0February\u00a02004\u00a0\u00a0\n\u00a0 487.\u00a0\u00a0Kesselring \u00a0A,\u00a0Wit\u00a0F,\u00a0Gras\u00a0L,\u00a0et\u00a0al.\u00a0Incidence \u00a0of\u00a0nevirapine \u2010associated \u00a0hypersensitivity \u00a0reactions \u00a0\nis\u00a0different\u00a0in\u00a0patients\u00a0with\u00a0prior\u00a0treatment \u00a0experience \u00a0compared \u00a0to\u00a0treatment \u2010na\u00efve\u00a0pa\u2010\ntients\u00a0The\u00a0ATHENA\u00a0cohort\u00a0study.\u00a04th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0\nPrevention, \u00a0Sydney,\u00a02007\u00a0MOPEB008 \u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 134 \n \u00a0 488.\u00a0\u00a0Sulkowski \u00a0MS.\u00a0Drug\u2010induced\u00a0liver\u00a0injury\u00a0associated \u00a0with\u00a0antiretroviral \u00a0therapy\u00a0that\u00a0includes\u00a0\nHIV\u20101\u00a0protease\u00a0inhibitors. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02004;\u00a038\u00a0Suppl\u00a02:S90\u2010S97.\u00a0\n\u00a0 489.\u00a0\u00a0Pineda\u00a0JA,\u00a0Palacios\u00a0R,\u00a0Rivero\u00a0A,\u00a0bdel\u2010Kader\u00a0L,\u00a0Marquez\u00a0M,\u00a0Cano\u00a0P\u00a0et\u00a0al.\u00a0Low\u00a0incidence \u00a0of\u00a0se\u2010\nvere\u00a0liver\u00a0toxicity\u00a0in\u00a0patients\u00a0receiving\u00a0antiretroviral \u00a0combinations \u00a0including\u00a0atazanavir. \u00a0J\u00a0An\u2010\ntimicrob\u00a0Chemother \u00a02006;\u00a057(5):1016 \u20101017.\u00a0\n\u00a0 490.\u00a0\u00a0Palacios\u00a0R,\u00a0Vergara\u00a0S,\u00a0Rivero\u00a0A,\u00a0Aguilar\u00a0I,\u00a0Macias\u00a0J,\u00a0Camacho \u00a0A\u00a0et\u00a0al.\u00a0Low\u00a0incidence \u00a0of\u00a0severe\u00a0\nliver\u00a0events\u00a0in\u00a0HIV\u00a0patients\u00a0with\u00a0and\u00a0without\u00a0hepatitis\u00a0C\u00a0or\u00a0B\u00a0coinfection \u00a0receiving\u00a0lopina\u2010\nvir/ritonavir. \u00a0HIV\u00a0Clin\u00a0Trials\u00a02006;\u00a07(6):319\u2010323.\u00a0\n\u00a0 491.\u00a0\u00a0Clifford\u00a0DB,\u00a0Evans\u00a0S,\u00a0Yang\u00a0Y,\u00a0Acosta\u00a0EP,\u00a0Goodkin\u00a0K,\u00a0Tashima\u00a0K\u00a0et\u00a0al.\u00a0Impact\u00a0of\u00a0efavirenz\u00a0on\u00a0\nneuropsychological \u00a0performance \u00a0and\u00a0symptoms \u00a0in\u00a0HIV\u2010infected\u00a0individuals. \u00a0Ann\u00a0Intern\u00a0Med\u00a0\n2005;\u00a0143(10):714 \u2010721.\u00a0\n\u00a0 492.\u00a0\u00a0Blanch\u00a0J,\u00a0Martinez\u00a0E,\u00a0Rousaud\u00a0A,\u00a0Blanco\u00a0JL,\u00a0Garcia\u2010Viejo\u00a0MA,\u00a0Peri\u00a0JM\u00a0et\u00a0al.\u00a0Preliminary \u00a0data\u00a0of\u00a0\na\u00a0prospective \u00a0study\u00a0on\u00a0neuropsychiatric \u00a0side\u00a0effects\u00a0after\u00a0initiation\u00a0of\u00a0efavirenz. \u00a0J\u00a0Acquir\u00a0Im\u2010\nmune\u00a0Defic\u00a0Syndr\u00a02001;\u00a027(4):336 \u201043.\u00a0\n\u00a0 493.\u00a0\u00a0Journot\u00a0V,\u00a0Chene\u00a0G,\u00a0De\u00a0CN,\u00a0Rancinan\u00a0C,\u00a0Cassuto\u00a0JP,\u00a0Allard\u00a0C\u00a0et\u00a0al.\u00a0Use\u00a0of\u00a0efavirenz\u00a0is\u00a0not\u00a0as\u2010\nsociated\u00a0with\u00a0a\u00a0higher\u00a0risk\u00a0of\u00a0depressive \u00a0disorders: \u00a0a\u00a0substudy\u00a0of\u00a0the\u00a0randomized \u00a0clinical\u00a0trial\u00a0\nALIZE\u2010ANRS\u00a0099.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02006;\u00a042(12):1790 \u20101799.\u00a0\n\u00a0 494.\u00a0\u00a0Gallant\u00a0JE,\u00a0Parish\u00a0MA,\u00a0Keruly\u00a0JC,\u00a0Moore\u00a0RD.\u00a0Changes\u00a0in\u00a0renal\u00a0function\u00a0associated \u00a0with\u00a0teno\u2010\nfovir\u00a0disoproxil \u00a0fumarate \u00a0treatment, \u00a0compared \u00a0with\u00a0nucleoside \u00a0reverse\u2010transcriptase \u00a0inhibi\u2010\ntor\u00a0treatment. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02005;\u00a040(8):1194 \u20101198.\u00a0\n\u00a0 495.\u00a0\u00a0Nelson\u00a0MR,\u00a0Katlama\u00a0C,\u00a0Montaner \u00a0JS,\u00a0Cooper\u00a0DA,\u00a0Gazzard\u00a0B,\u00a0Clotet\u00a0B\u00a0et\u00a0al.\u00a0The\u00a0safety\u00a0of\u00a0teno\u2010\nfovir\u00a0disoproxil \u00a0fumarate \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0HIV\u00a0infection\u00a0in\u00a0adults:\u00a0the\u00a0first\u00a04\u00a0years.\u00a0AIDS\u00a0\n2007;\u00a021(10):1273 \u20101281.\u00a0\n\u00a0 496.\u00a0\u00a0Arribas\u00a0JR,\u00a0Pozniak\u00a0AL,\u00a0Gallant\u00a0JE,\u00a0DeJesus\u00a0E,\u00a0Gazzard\u00a0B,\u00a0Campo\u00a0RE\u00a0et\u00a0al.\u00a0Tenofovir \u00a0disoproxil \u00a0\nfumarate, \u00a0emtricitabine, \u00a0and\u00a0efavirenz\u00a0compared \u00a0with\u00a0zidovudine/lamivudine \u00a0and\u00a0efavirenz\u00a0\nin\u00a0treatment \u2010naive\u00a0patients:\u00a0144\u2010week\u00a0analysis.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02008;\u00a047(1):74\u2010\n78.\u00a0\n\u00a0 497.\u00a0\u00a0Cassetti\u00a0I,\u00a0Madruga\u00a0JV,\u00a0Suleiman\u00a0JM,\u00a0Etzel\u00a0A,\u00a0Zhong\u00a0L,\u00a0Cheng\u00a0AK\u00a0et\u00a0al.\u00a0The\u00a0safety\u00a0and\u00a0efficacy\u00a0\nof\u00a0tenofovir\u00a0DF\u00a0in\u00a0combination \u00a0with\u00a0lamivudine \u00a0and\u00a0efavirenz\u00a0through\u00a06\u00a0years\u00a0in\u00a0antiretrovi \u2010\nral\u2010naive\u00a0HIV\u20101\u2010infected\u00a0patients.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02007;\u00a08(3):164\u2010172.\u00a0\n\u00a0 498.\u00a0\u00a0Gupta\u00a0SK.\u00a0Tenofovir \u2010associated \u00a0Fanconi\u00a0syndrome: \u00a0review\u00a0of\u00a0the\u00a0FDA\u00a0adverse\u00a0event\u00a0repor\u2010\nting\u00a0system.\u00a0AIDS\u00a0Patient\u00a0Care\u00a0STDS\u00a02008;\u00a022(2):99\u2010103.\u00a0\n\u00a0 499.\u00a0\u00a0Moyle\u00a0GJ,\u00a0Sabin\u00a0CA,\u00a0Cartledge \u00a0J,\u00a0Johnson\u00a0M,\u00a0Wilkins\u00a0E,\u00a0Churchill\u00a0D\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0com\u2010\nparative\u00a0trial\u00a0of\u00a0tenofovir\u00a0DF\u00a0or\u00a0abacavir\u00a0as\u00a0replacement \u00a0for\u00a0a\u00a0thymidine \u00a0analogue\u00a0in\u00a0persons\u00a0\nwith\u00a0lipoatrophy. \u00a0AIDS\u00a02006;\u00a020(16):2043 \u20102050.\u00a0\n\u00a0 500.\u00a0\u00a0Hicks\u00a0C,\u00a0Cahn\u00a0P,\u00a0Ward\u00a0D,\u00a0Lazzarin\u00a0A,\u00a0Jelaska\u00a0A,\u00a0Drulak\u00a0M\u00a0et\u00a0al.\u00a0Tripranavir/r \u00a0mantains \u00a0long\u00a0\nterm\u00a0virological \u00a0suppression \u00a0in\u00a0highly\u00a0treatment \u00a0experienced \u00a0patients\u00a0\u2013Three\u00a0year\u00a0follow\u2010up\u00a0\nRESIST.\u00a011th\u00a0European \u00a0Aids\u00a0Conference, \u00a0Madrid,\u00a02007\u00a0Abstract\u00a0P7.3/25\u00a0\n\u00a0 501.\u00a0\u00a0Moyle\u00a0G.\u00a0Metabolic \u00a0issues\u00a0associated \u00a0with\u00a0protease\u00a0inhibitors. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a0\n2007;\u00a045\u00a0Suppl\u00a01:S19\u2010S26.\u00a0\n\u00a0 502.\u00a0\u00a0Smith\u00a0KY,\u00a0Weinberg \u00a0WG,\u00a0DeJesus\u00a0E,\u00a0Fischl\u00a0MA,\u00a0Liao\u00a0Q,\u00a0Ross\u00a0LL\u00a0et\u00a0al.\u00a0Fosamprenavir \u00a0or\u00a0ataza\u2010\nnavir\u00a0once\u00a0daily\u00a0boosted\u00a0with\u00a0ritonavir\u00a0100\u00a0mg,\u00a0plus\u00a0tenofovir/emtricitabine, \u00a0for\u00a0the\u00a0initial\u00a0\ntreatment \u00a0of\u00a0HIV\u00a0infection: \u00a048\u2010week\u00a0results\u00a0of\u00a0ALERT.\u00a0AIDS\u00a0Res\u00a0Ther\u00a02008;\u00a05:5.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 135 \n \u00a0 503.\u00a0\u00a0Mallolas\u00a0J,\u00a0Podzamczer \u00a0D,\u00a0Domingo\u00a0P,\u00a0Clotet\u00a0B,\u00a0Ribera\u00a0E,\u00a0Guti\u00e9rrez \u00a0F.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0\nswitching \u00a0from\u00a0boosted\u00a0lopinavir\u00a0(LPV/r)\u00a0to\u00a0boosted\u00a0atazanavir \u00a0(ATV/r)\u00a0in\u00a0patients\u00a0with\u00a0viro\u2010\nlogic\u00a0suppression \u00a0receiving\u00a0a\u00a0LPV/r\u2010containing \u00a0HAART:\u00a0the\u00a0AZATIP\u00a0study.\u00a04th\u00a0IAS\u00a0Conference \u00a0\non\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Sydney,\u00a02007\u00a0Abstract\u00a0WEPEB117LB \u00a0\n\u00a0 504.\u00a0\u00a0Martinez\u00a0E,\u00a0Arranz\u00a0JA,\u00a0Podzamczer \u00a0D,\u00a0Ribera\u00a0E,\u00a0Roca\u00a0V,\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0NRTI's\u00a0\nswitch\u00a0to\u00a0tenofovir\u00a0plus\u00a0emtricitabine \u00a0(Truvada) \u00a0vs.\u00a0abacavir\u00a0plus\u00a0lamivudine \u00a0(Kivexa)\u00a0in\u00a0pa\u2010\ntients\u00a0with\u00a0virologic\u00a0suppression \u00a0receiving\u00a0a\u00a0lamivudine \u00a0containing \u00a0HAART:\u00a0The\u00a0BICOMBO \u00a0\nstudy.\u00a04th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Sydney,\u00a02007\u00a0\nAbstract\u00a0WESS102. \u00a0\n\u00a0 505.\u00a0\u00a0Tomaka\u00a0F,\u00a0Lefebvre\u00a0E,\u00a0Sekar\u00a0V,\u00a0Van\u00a0BB,\u00a0Vangeneugden \u00a0T,\u00a0Vandevoorde \u00a0A\u00a0et\u00a0al.\u00a0Effects\u00a0of\u00a0\nritonavir\u2010boosted\u00a0darunavir \u00a0vs.\u00a0ritonavir\u2010boosted\u00a0atazanavir \u00a0on\u00a0lipid\u00a0and\u00a0glucose\u00a0parameters \u00a0\nin\u00a0HIV\u2010negative,\u00a0healthy\u00a0volunteers. \u00a0HIV\u00a0Med\u00a02009;\u00a010(5):318 \u2010327.\u00a0\n\u00a0 506.\u00a0\u00a0Lundgren \u00a0JD,\u00a0Battegay\u00a0M,\u00a0Behrens\u00a0G,\u00a0De\u00a0WS,\u00a0Guaraldi\u00a0G,\u00a0Katlama\u00a0C\u00a0et\u00a0al.\u00a0European \u00a0AIDS\u00a0\nClinical\u00a0Society\u00a0(EACS)\u00a0guidelines \u00a0on\u00a0the\u00a0prevention \u00a0and\u00a0management \u00a0of\u00a0metabolic \u00a0diseases\u00a0\nin\u00a0HIV.\u00a0HIV\u00a0Med\u00a02008;\u00a09(2):72\u201081.\u00a0\n\u00a0 507.\u00a0\u00a0Polo\u00a0R,\u00a0Galindo\u00a0MJ,\u00a0Martinez\u00a0E,\u00a0Alvarez\u00a0J,\u00a0Arevalo\u00a0JM,\u00a0Asensi\u00a0V\u00a0et\u00a0al.\u00a0Recomendaciones \u00a0de\u00a0\nGEAM/SPNS \u00a0sobre\u00a0el\u00a0tratamiento \u00a0de\u00a0las\u00a0alteraciones \u00a0metab\u00f3licas \u00a0y\u00a0morfol\u00f3gicas \u00a0en\u00a0el\u00a0pa\u2010\nciente\u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0VIH.\u00a0Enferm\u00a0Infecc\u00a0Microbiol \u00a0Clin\u00a02006;\u00a024(2):96\u2010117.\u00a0\n\u00a0 508.\u00a0\u00a0Llibre\u00a0JM,\u00a0Domingo\u00a0P,\u00a0Palacios\u00a0R,\u00a0Santos\u00a0J,\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Sanchez\u2010de\u00a0la\u00a0RR\u00a0et\u00a0al.\u00a0Sustained \u00a0\nimprovement \u00a0of\u00a0dyslipidaemia \u00a0in\u00a0HAART\u2010treated\u00a0patients\u00a0replacing\u00a0stavudine \u00a0with\u00a0tenofovir. \u00a0\nAIDS\u00a02006;\u00a020(10):1407 \u20101414.\u00a0\n\u00a0 509.\u00a0\u00a0Madruga\u00a0JR,\u00a0Cassetti\u00a0I,\u00a0Suleiman\u00a0JM,\u00a0Etzel\u00a0A,\u00a0Zhong\u00a0L,\u00a0Holmes\u00a0CB\u00a0et\u00a0al.\u00a0The\u00a0safety\u00a0and\u00a0efficacy\u00a0\nof\u00a0switching \u00a0stavudine \u00a0to\u00a0tenofovir\u00a0DF\u00a0in\u00a0combination \u00a0with\u00a0lamivudine \u00a0and\u00a0efavirenz\u00a0in\u00a0hiv\u20101\u2010\ninfected\u00a0patients:\u00a0three\u2010year\u00a0follow\u2010up\u00a0after\u00a0switching \u00a0therapy.\u00a0HIV\u00a0Clin\u00a0Trials\u00a02007;\u00a08(6):381\u2010\n390.\u00a0\n\u00a0 510.\u00a0\u00a0Moyle\u00a0G,\u00a0Fisher\u00a0M,\u00a0and\u00a0the\u00a0SWEET\u00a0study\u00a0group.\u00a0Switching \u00a0from\u00a0Combivir\u00a0to\u00a0Truvada\u00a0preser\u2010\nved\u00a0limb\u00a0fat:\u00a0results\u00a0of\u00a0a\u00a0DEXA\u00a0sub\u2010study\u00a0of\u00a0a\u00a048\u2010week\u00a0randomized \u00a0study.\u00a015th\u00a0Conference \u00a0on\u00a0\nRetroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a02008;\u00a0Boston,\u00a0Massachusetts \u00a0(Abstract\u00a0\n938)\u00a0\n\u00a0 511.\u00a0\u00a0Blumer\u00a0RM,\u00a0van\u00a0Vonderen \u00a0MG,\u00a0Sutinen\u00a0J,\u00a0Hassink\u00a0E,\u00a0Ackermans \u00a0M,\u00a0van\u00a0Agtmael\u00a0MA\u00a0et\u00a0al.\u00a0\nZidovudine/lamivudine \u00a0contributes \u00a0to\u00a0insulin\u00a0resistance \u00a0within\u00a03\u00a0months\u00a0of\u00a0starting\u00a0combina\u2010\ntion\u00a0antiretroviral \u00a0therapy.\u00a0AIDS\u00a02008;\u00a022(2):227 \u2010236.\u00a0\n\u00a0 512.\u00a0\u00a0Carr\u00a0A,\u00a0Ritzhaupt \u00a0A,\u00a0Zhang\u00a0W,\u00a0Zajdenverg \u00a0R,\u00a0Workman \u00a0C,\u00a0Gatell\u00a0JM\u00a0et\u00a0al.\u00a0Effects\u00a0of\u00a0boosted\u00a0\ntipranavir \u00a0and\u00a0lopinavir\u00a0on\u00a0body\u00a0composition, \u00a0insulin\u00a0sensitivity \u00a0and\u00a0adipocytokines \u00a0in\u00a0antire\u2010\ntroviral\u2010naive\u00a0adults.\u00a0AIDS\u00a02008;\u00a022(17):2313 \u20102321.\u00a0\n\u00a0 513.\u00a0\u00a0Brown\u00a0TT,\u00a0Li\u00a0X,\u00a0Cole\u00a0SR,\u00a0Kingsley\u00a0LA,\u00a0Palella\u00a0FJ,\u00a0Riddler\u00a0SA\u00a0et\u00a0al.\u00a0Cumulative \u00a0exposure\u00a0to\u00a0nu\u2010\ncleoside\u00a0analogue\u00a0reverse\u00a0transcriptase \u00a0inhibitors \u00a0is\u00a0associated \u00a0with\u00a0insulin\u00a0resistance \u00a0mar\u2010\nkers\u00a0in\u00a0the\u00a0Multicenter \u00a0AIDS\u00a0Cohort\u00a0Study.\u00a0AIDS\u00a02005;\u00a019(13):1375 \u20101383.\u00a0\n\u00a0 514.\u00a0\u00a0De\u00a0Wit\u00a0S.,\u00a0Sabin\u00a0CA,\u00a0Weber\u00a0R,\u00a0Worm\u00a0SW,\u00a0Reiss\u00a0P,\u00a0Cazanave \u00a0C\u00a0et\u00a0al.\u00a0Incidence \u00a0and\u00a0risk\u00a0factors\u00a0\nfor\u00a0new\u2010onset\u00a0diabetes\u00a0in\u00a0HIV\u2010infected\u00a0patients:\u00a0the\u00a0Data\u00a0Collection \u00a0on\u00a0Adverse\u00a0Events\u00a0of\u00a0An\u2010\nti\u2010HIV\u00a0Drugs\u00a0(D:A:D)\u00a0study.\u00a0Diabetes\u00a0Care\u00a02008;\u00a031(6):1224 \u20101229.\u00a0\n\u00a0 515.\u00a0\u00a0Ledergerber \u00a0B,\u00a0Furrer\u00a0H,\u00a0Rickenbach \u00a0M,\u00a0Lehmann \u00a0R,\u00a0Elzi\u00a0L,\u00a0Hirschel\u00a0B\u00a0et\u00a0al.\u00a0Factors\u00a0associated \u00a0\nwith\u00a0the\u00a0incidence \u00a0of\u00a0type\u00a02\u00a0diabetes\u00a0mellitus\u00a0in\u00a0HIV\u2010infected\u00a0participants \u00a0in\u00a0the\u00a0Swiss\u00a0HIV\u00a0\nCohort\u00a0Study.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02007;\u00a045(1):111 \u2010119.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 136 \n \u00a0 516.\u00a0\u00a0Fleischman \u00a0A,\u00a0Johnsen\u00a0S,\u00a0Systrom\u00a0DM,\u00a0Hrovat\u00a0M,\u00a0Farrar\u00a0CT,\u00a0Frontera\u00a0W\u00a0et\u00a0al.\u00a0Effects\u00a0of\u00a0a\u00a0\nnucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitor,\u00a0stavudine, \u00a0on\u00a0glucose\u00a0disposal\u00a0and\u00a0mitochondrial \u00a0\nfunction\u00a0in\u00a0muscle\u00a0of\u00a0healthy\u00a0adults.\u00a0Am\u00a0J\u00a0Physiol\u00a0Endocrinol \u00a0Metab\u00a02007;\u00a0292(6):E1666 \u2010\nE1673.\u00a0\n\u00a0 517.\u00a0\u00a0Lennox\u00a0J,\u00a0DeJesus\u00a0E,\u00a0Lazzarin\u00a0A,\u00a0Pollard\u00a0R,\u00a0Madruga\u00a0J,\u00a0Zhao\u00a0J\u00a0et\u00a0al.\u00a0Safety\u00a0and\u00a0efficacy\u00a0of\u00a0ralte\u2010\ngravir\u2010based\u00a0versus\u00a0efavirenz\u2010based\u00a0combination \u00a0therapy\u00a0in\u00a0treatment \u2010na\u00efve\u00a0HIV\u20101\u2010infected\u00a0\npatients.\u00a048th\u00a0Annual\u00a0ICCAC/IDSA \u00a046th\u00a0Annual\u00a0Meeting;\u00a0October\u00a025\u201028,\u00a02008;\u00a0Washington, \u00a0\nDC\u00a02009;\u00a0Abstract\u00a0H\u2010896a.\u00a0\n\u00a0 518.\u00a0\u00a0Heera\u00a0J,\u00a0Ive\u00a0P,\u00a0Botes\u00a0M,\u00a0DeJesus\u00a0E,\u00a0Mayer\u00a0H,\u00a0Goodrich\u00a0J\u00a0et\u00a0al.\u00a0The\u00a0MERIT\u00a0study\u00a0of\u00a0Maraviroc \u00a0\nin\u00a0antiretroviral \u2010na\u00efve\u00a0patients\u00a0with\u00a0R5\u00a0HIV\u20101:\u00a096\u2010week\u00a0results.\u00a05th\u00a0International \u00a0AIDS\u00a0Society\u00a0\nConference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention \u00a0Cape\u00a0Town,\u00a0South\u00a0Africa\u00a0July\u00a019\u2010\n22,\u00a02009\u00a02009;\u00a0Abstract\u00a0TuAB103. \u00a0\n\u00a0 519.\u00a0\u00a0Randell\u00a0P,\u00a0Jackson\u00a0A,\u00a0Taylor\u00a0J,\u00a0Moyle\u00a0G.\u00a0The\u00a0impact\u00a0of\u00a0maraviroc \u00a0on\u00a0insulin\u00a0sensitivity, \u00a0lipids\u00a0\nand\u00a0aipokines \u00a0after\u00a02\u00a0weeks\u00a0in\u00a0HIV\u2010negative\u00a0males\u00a0volunteers. \u00a011th\u00a0International \u00a0workshop \u00a0\non\u00a0adverse\u00a0drug\u00a0reactions\u00a0and\u00a0co\u2010morbidities \u00a0in\u00a0HIV,\u00a0Philadelphia, \u00a0octubre\u00a02009\u00a02009;\u00a0Abs\u2010\ntract\u00a0P18.\u00a0\n\u00a0 520.\u00a0\u00a0Randell\u00a0P,\u00a0Jackson\u00a0A,\u00a0Mandalia \u00a0S,\u00a0Taylor\u00a0J,\u00a0Moyle\u00a0G.\u00a0The\u00a0impact\u00a0of\u00a0raltegravir \u00a0and\u00a0lopina\u2010\nvir/ritonaviron \u00a0lipids,\u00a0adiponectin \u00a0and\u00a0periferal\u00a0glucose\u00a0disposal\u00a0in\u00a0HIV\u00a0negative\u00a0subjects.\u00a05th\u00a0\nInternational \u00a0AIDS\u00a0Society\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention \u00a0Cape\u00a0\nTown,\u00a0South\u00a0Africa\u00a0July\u00a019\u201022,\u00a02009\u00a02009;\u00a0Abstract\u00a0TUPEB171. \u00a0\n\u00a0 521.\u00a0\u00a0Bozzette\u00a0SA,\u00a0Ake\u00a0CF,\u00a0Tam\u00a0HK,\u00a0Phippard\u00a0A,\u00a0Cohen\u00a0D,\u00a0Scharfstein \u00a0DO\u00a0et\u00a0al.\u00a0Long\u2010term\u00a0survival\u00a0\nand\u00a0serious\u00a0cardiovascular \u00a0events\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0treated\u00a0with\u00a0highly\u00a0active\u00a0antire\u2010\ntroviral\u00a0therapy.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02008;\u00a047(3):338 \u2010341.\u00a0\n\u00a0 522.\u00a0\u00a0Holmberg \u00a0SD,\u00a0Moorman \u00a0AC,\u00a0Williamson \u00a0JM,\u00a0Tong\u00a0TC,\u00a0Ward\u00a0DJ,\u00a0Wood\u00a0KC\u00a0et\u00a0al.\u00a0Protease\u00a0in\u2010\nhibitors\u00a0and\u00a0cardiovascular \u00a0outcomes \u00a0in\u00a0patients\u00a0with\u00a0HIV\u20101.\u00a0Lancet\u00a02002;\u00a0360(9347):1747 \u2010\n1748.\u00a0\n\u00a0 523.\u00a0\u00a0Mary\u2010Krause\u00a0M,\u00a0Cotte\u00a0L,\u00a0Simon\u00a0A,\u00a0Partisani\u00a0M,\u00a0Costagliola \u00a0D,\u00a0Clinical\u00a0Epidemiology \u00a0Group\u00a0\nfrom\u00a0the\u00a0French\u00a0Hospital\u00a0Database. \u00a0Increased \u00a0risk\u00a0of\u00a0myocardial \u00a0infarction \u00a0with\u00a0duration\u00a0of\u00a0\nprotease\u00a0inhibitor\u00a0therapy\u00a0in\u00a0HIV\u2010infected\u00a0men.\u00a0AIDS\u00a02003;\u00a017:2479\u20102486.\u00a0\n\u00a0 524.\u00a0\u00a0Bongiovanni \u00a0M,\u00a0Casana\u00a0M,\u00a0Cicconi\u00a0P,\u00a0Pisacreta\u00a0M,\u00a0Codemo\u00a0R,\u00a0Pelucchi\u00a0M\u00a0et\u00a0al.\u00a0Predictive \u00a0\nfactors\u00a0of\u00a0vascular\u00a0intima\u00a0media\u00a0thickness \u00a0in\u00a0HIV\u2010positive\u00a0subjects.\u00a0J\u00a0Antimicrob \u00a0Chemother \u00a0\n2008;\u00a061(1):195 \u2010199.\u00a0\n\u00a0 525.\u00a0\u00a0Currier\u00a0JS,\u00a0Kendall\u00a0MA,\u00a0Henry\u00a0WK,\u00a0ston\u2010Smith\u00a0B,\u00a0Torriani\u00a0FJ,\u00a0Tebas\u00a0P\u00a0et\u00a0al.\u00a0Progression \u00a0of\u00a0\ncarotid\u00a0artery\u00a0intima\u2010media\u00a0thickening \u00a0in\u00a0HIV\u2010infected\u00a0and\u00a0uninfected \u00a0adults.\u00a0AIDS\u00a02007;\u00a0\n21(9):1137 \u20101145.\u00a0\n\u00a0 526.\u00a0\u00a0Currier\u00a0JS,\u00a0Lundgren \u00a0JD,\u00a0Carr\u00a0A,\u00a0Klein\u00a0D,\u00a0Sabin\u00a0CA,\u00a0Sax\u00a0PE\u00a0et\u00a0al.\u00a0Epidemiological \u00a0evidence\u00a0for\u00a0\ncardiovascular \u00a0disease\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0and\u00a0relationship \u00a0to\u00a0highly\u00a0active\u00a0antiretroviral \u00a0\ntherapy.\u00a0Circulation \u00a02008;\u00a0118(2):e29 \u2010e35.\u00a0\n\u00a0 527.\u00a0\u00a0Lundgren \u00a0JD,\u00a0Reiss\u00a0P,\u00a0Worms\u00a0S,\u00a0Weber\u00a0R,\u00a0El\u2010Sadr\u00a0W,\u00a0De\u00a0Wit\u00a0S\u00a0et\u00a0al.\u00a0Risk\u00a0of\u00a0myocardial \u00a0infarc\u2010\ntion\u00a0with\u00a0exposure\u00a0to\u00a0specific\u00a0ARV\u00a0from\u00a0the\u00a0PI,\u00a0NNRTI,\u00a0and\u00a0NRTI\u00a0classes:\u00a0The\u00a0D:A:D\u00a0study.\u00a0\n16th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a02009;\u00a0Montreal \u00a0\n2009;\u00a0\u00a0Abstract\u00a044LB.\u00a0\n\u00a0 528.\u00a0\u00a0Lang\u00a0S,\u00a0Mary\u2010Krause\u00a0M,\u00a0Cotte\u00a0L,\u00a0Gilquin\u00a0J,\u00a0Partisani\u00a0M,\u00a0Simon\u00a0A\u00a0et\u00a0al.\u00a0Impact\u00a0of\u00a0specific\u00a0NRTI\u00a0\nand\u00a0PI\u00a0exposure\u00a0on\u00a0the\u00a0risk\u00a0of\u00a0myocardial \u00a0infarction: \u00a0a\u00a0cese\u2010control\u00a0stydy\u00a0nested\u00a0with\u00a0FHDH\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 137 \n ANRS\u00a0CO4.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a02009;\u00a0\nMontreal \u00a02009;\u00a0Abstract\u00a043LB.\u00a0\n\u00a0 529.\u00a0\u00a0Durand\u00a0M,\u00a0Sheehy\u00a0O,\u00a0Baril\u00a0JG,\u00a0Lelonier\u00a0J,\u00a0Tremblay \u00a0C.\u00a0Relation\u00a0between\u00a0use\u00a0of\u00a0nucleosidic \u00a0\nreverse\u00a0transcriptase \u00a0inhibitors \u00a0and\u00a0risk\u00a0of\u00a0myocardial \u00a0infarction: \u00a0a\u00a0nested\u00a0case\u00a0control\u00a0study\u00a0\nusing\u00a0Quebec's\u00a0Public\u00a0Health\u00a0Insurance \u00a0Database. \u00a05th\u00a0International \u00a0AIDS\u00a0Society\u00a0Conference \u00a0\non\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention \u00a0Cape\u00a0Town,\u00a0South\u00a0Africa\u00a0July\u00a019\u201022,\u00a02009\u00a0\n2009;\u00a0Abstract\u00a0TuPEB175. \u00a0\n\u00a0 530.\u00a0\u00a0Brothers\u00a0CH,\u00a0Hernandez \u00a0JE,\u00a0Cutrell\u00a0AG,\u00a0Curtis\u00a0L,\u00a0it\u2010Khaled\u00a0M,\u00a0Bowlin\u00a0SJ\u00a0et\u00a0al.\u00a0Risk\u00a0of\u00a0myocar\u2010\ndial\u00a0infarction \u00a0and\u00a0abacavir\u00a0therapy:\u00a0no\u00a0increased \u00a0risk\u00a0across\u00a052\u00a0GlaxoSmithKline \u2010sponsored \u00a0\nclinical\u00a0trials\u00a0in\u00a0adult\u00a0subjects.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(1):20\u201028.\u00a0\n\u00a0 531.\u00a0\u00a0Lichtenstein \u00a0K,\u00a0Buckner\u00a0K,\u00a0Armon\u00a0C,\u00a0Tedalti\u00a0E,\u00a0Chmiel\u00a0J,\u00a0Wood\u00a0K\u00a0et\u00a0al.\u00a0Low\u00a0CD4\u00a0count\u00a0is\u00a0an\u00a0\nimportant \u00a0risk\u00a0factor\u00a0for\u00a0cardiovascular \u00a0disease\u00a0in\u00a0the\u00a0HIV\u00a0Outpatient \u00a0Study\u00a0(HOPS)\u00a0in\u00a0U.S.\u00a0\n17th\u00a0International \u00a0AIDS\u00a0Conference; \u00a03\u20108\u00a0August,\u00a02008;\u00a0Mexico\u00a0DF.\u00a0(Abstract\u00a0THPE0236) \u00a0\n\u00a0 532.\u00a0\u00a0Benson\u00a0C,\u00a0Ribaudo\u00a0H,\u00a0Zheng\u00a0E,\u00a0Koletar\u00a0S,\u00a0Smurzynski \u00a0M,\u00a0Bosch\u00a0R\u00a0et\u00a0al.\u00a0No\u00a0association \u00a0of\u00a0aba\u2010\ncavir\u00a0use\u00a0with\u00a0risk\u00a0of\u00a0myocardial \u00a0infarction \u00a0or\u00a0severe\u00a0cardiovascular \u00a0disease\u00a0events:\u00a0results\u00a0\nfrom\u00a0ACTG\u00a0A5001.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a0\n2009;\u00a0Montreal \u00a02009;\u00a0Abstract\u00a0721.\u00a0\n\u00a0 533.\u00a0\u00a0Bedimo\u00a0R,\u00a0Westfall\u00a0A,\u00a0Drechsler, \u00a0H,\u00a0Tebas\u00a0P.\u00a0Abacavir\u00a0use\u00a0and\u00a0risk\u00a0of\u00a0acute\u00a0myocardial \u00a0infarc\u2010\ntion\u00a0and\u00a0cerebrovascular \u00a0disease\u00a0in\u00a0the\u00a0HAART\u00a0era.\u00a05th\u00a0International \u00a0AIDS\u00a0Society\u00a0Conferen\u2010\nce\u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention \u00a0Cape\u00a0Town,\u00a0South\u00a0Africa\u00a0July\u00a019\u201022,\u00a02009\u00a0\n2009;\u00a0Abstract\u00a0MoAb202. \u00a0\n\u00a0 534.\u00a0\u00a0McComsey \u00a0G,\u00a0Smith\u00a0KY,\u00a0Patel\u00a0P,\u00a0Bellos\u00a0NC,\u00a0Sloan\u00a0L,\u00a0Lackey\u00a0P\u00a0et\u00a0al.\u00a0Similar\u00a0reductions \u00a0in\u00a0mar\u2010\nkers\u00a0of\u00a0inflammation \u00a0and\u00a0endothelial \u00a0activation \u00a0after\u00a0initiation\u00a0of\u00a0abacavir/lamivudine \u00a0\n(ABC/3TC) \u00a0or\u00a0tenofovir/emtricitabine \u00a0(TDF/FTC) \u00a0in\u00a0the\u00a0HEAT\u00a0study.\u00a016th\u00a0Conference \u00a0on\u00a0Re\u2010\ntroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a02009;\u00a0Montreal \u00a02009;\u00a0Abstract\u00a0732.\u00a0\n\u00a0 535.\u00a0\u00a0Martinez\u00a0E,\u00a0Larrousse \u00a0M,\u00a0Perez\u00a0I,\u00a0Lonca\u00a0M,\u00a0Podzamczer \u00a0D,\u00a0Gutierez\u00a0F\u00a0et\u00a0al.\u00a0No\u00a0evidence\u00a0for\u00a0\nrecent\u00a0abacavir/ \u00a0lamivudine \u00a0use\u00a0in\u00a0promoting \u00a0inflammation, \u00a0endothelial \u00a0dysfunction, \u00a0hyper\u2010\ncoagulability, \u00a0or\u00a0insulin\u00a0resistance \u00a0in\u00a0virologically \u00a0suppressed \u00a0HIV\u2010infected\u00a0patients:\u00a0a\u00a0substu\u2010\ndy\u00a0of\u00a0the\u00a0BICOMBO \u00a0randomized \u00a0clinical\u00a0trial\u00a0(ISRCTN\u00a06189).\u00a05th\u00a0International \u00a0AIDS\u00a0Society\u00a0\nConference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention \u00a0Cape\u00a0Town,\u00a0South\u00a0Africa\u00a0July\u00a019\u2010\n22,\u00a02009\u00a02009;\u00a0Abstract\u00a0MoAb203. \u00a0\n\u00a0 536.\u00a0\u00a0Haubrich\u00a0RH,\u00a0Riddler\u00a0SA,\u00a0DiRienzo\u00a0AG,\u00a0Komarow \u00a0L,\u00a0Powderly \u00a0WG,\u00a0Klingman \u00a0K\u00a0et\u00a0al.\u00a0Metabolic \u00a0\noutcomes \u00a0in\u00a0a\u00a0randomized \u00a0trial\u00a0of\u00a0nucleoside, \u00a0nonnucleoside \u00a0and\u00a0protease\u00a0inhibitor\u2010sparing\u00a0\nregimens \u00a0for\u00a0initial\u00a0HIV\u00a0treatment. \u00a0AIDS\u00a02009;\u00a023(9):1109 \u20101118.\u00a0\n\u00a0 537.\u00a0\u00a0Falutz\u00a0J,\u00a0Allas\u00a0S,\u00a0Mamputu \u00a0JC,\u00a0Potvin\u00a0D,\u00a0Kotler\u00a0D,\u00a0Somero\u00a0M\u00a0et\u00a0al.\u00a0Long\u2010term\u00a0safety\u00a0and\u00a0ef\u2010\nfects\u00a0of\u00a0tesamorelin, \u00a0a\u00a0growth\u00a0hormone\u2010releasing\u00a0factor\u00a0analogue, \u00a0in\u00a0HIV\u00a0patients\u00a0with\u00a0ab\u2010\ndominal\u00a0fat\u00a0accumulation. \u00a0AIDS\u00a02008;\u00a022(14):1719 \u20101728.\u00a0\n\u00a0 538.\u00a0\u00a0Guaraldi\u00a0G,\u00a0Orlando\u00a0G,\u00a0De\u00a0FD,\u00a0De\u00a0L,\u00a0I,\u00a0Rottino\u00a0A,\u00a0De\u00a0SG\u00a0et\u00a0al.\u00a0Comparison \u00a0of\u00a0three\u00a0different\u00a0\ninterventions \u00a0for\u00a0the\u00a0correction \u00a0of\u00a0HIV\u2010associated \u00a0facial\u00a0lipoatrophy: \u00a0a\u00a0prospective \u00a0study.\u00a0An\u2010\ntivir\u00a0Ther\u00a02005;\u00a010(6):753 \u2010759.\u00a0\n\u00a0 539.\u00a0\u00a0Lo\u00a0J,\u00a0You\u00a0SM,\u00a0Canavan\u00a0B,\u00a0Liebau\u00a0J,\u00a0Beltrani\u00a0G,\u00a0Koutkia\u00a0P\u00a0et\u00a0al.\u00a0Low\u2010dose\u00a0physiological \u00a0growth\u00a0\nhormone\u00a0in\u00a0patients\u00a0with\u00a0HIV\u00a0and\u00a0abdominal \u00a0fat\u00a0accumulation: \u00a0a\u00a0randomized \u00a0controlled \u00a0trial.\u00a0\nJama\u00a02008;\u00a0300(5):509 \u2010519.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 138 \n \u00a0 540.\u00a0\u00a0Moyle\u00a0GJ,\u00a0Lysakova\u00a0L,\u00a0Brown\u00a0S,\u00a0Sibtain\u00a0N,\u00a0Healy\u00a0J,\u00a0Priest\u00a0C\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0open\u2010label\u00a0\nstudy\u00a0of\u00a0immediate \u00a0versus\u00a0delayed\u00a0polylactic \u00a0acid\u00a0injections \u00a0for\u00a0the\u00a0cosmetic\u00a0management \u00a0of\u00a0\nfacial\u00a0lipoatrophy \u00a0in\u00a0persons\u00a0with\u00a0HIV\u00a0infection. \u00a0HIV\u00a0Med\u00a02004;\u00a05(2):82\u201087.\u00a0\n\u00a0 541.\u00a0\u00a0Amorosa\u00a0V,\u00a0Tebas\u00a0P.\u00a0Bone\u00a0disease\u00a0and\u00a0HIV\u00a0infection. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02006;\u00a042(1):108 \u2010114.\u00a0\n\u00a0 542.\u00a0\u00a0Gutierrez \u00a0F,\u00a0Padilla\u00a0S,\u00a0Masia\u00a0M,\u00a0Flores\u00a0J,\u00a0Boix\u00a0V,\u00a0Merino\u00a0E\u00a0et\u00a0al.\u00a0Osteonecrosis \u00a0in\u00a0patients\u00a0\ninfected\u00a0with\u00a0HIV:\u00a0clinical\u00a0epidemiology \u00a0and\u00a0natural\u00a0history\u00a0in\u00a0a\u00a0large\u00a0case\u00a0series\u00a0from\u00a0Spain.\u00a0J\u00a0\nAcquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02006;\u00a042(3):286 \u2010292.\u00a0\n\u00a0 543.\u00a0\u00a0Dear\u00a0Health\u00a0Care\u00a0Provider.\u00a0Important \u00a0Change\u00a0in\u00a0SUSTIVA\u00ae \u00a0(efavirenz) \u00a0Package\u00a0Insert\u00a0.\u00a0Chan\u2010\nge\u00a0from\u00a0Pregnancy \u00a0Category\u00a0C\u00a0to\u00a0D.\u00a0Bristol\u2010Myers\u00a0Squibb\u00a0Company.March \u00a02005\u00a0\u00a0\n\u00a0 544.\u00a0\u00a0Stein\u00a0JH.\u00a0Managing \u00a0cardiovascular \u00a0risk\u00a0in\u00a0patients\u00a0with\u00a0HIV\u00a0infection. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0\nSyndr\u00a02005;\u00a038(2):115 \u2010123.\u00a0\n\u00a0 545.\u00a0\u00a0Gupta\u00a0SK,\u00a0Eustace\u00a0JA,\u00a0Winston\u00a0JA,\u00a0Boydstun \u00a0II,\u00a0Ahuja\u00a0TS,\u00a0Rodriguez \u00a0RA\u00a0et\u00a0al.\u00a0Guidelines \u00a0for\u00a0\nthe\u00a0management \u00a0of\u00a0chronic\u00a0kidney\u00a0disease\u00a0in\u00a0HIV\u2010infected\u00a0patients:\u00a0recommendations \u00a0of\u00a0the\u00a0\nHIV\u00a0Medicine \u00a0Association \u00a0of\u00a0the\u00a0Infectious \u00a0Diseases\u00a0Society\u00a0of\u00a0America.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02005;\u00a0\n40(11):1559 \u20101585.\u00a0\n\u00a0 546.\u00a0\u00a0Panel\u00a0de\u00a0GESIDA\u00a0y\u00a0Plan\u00a0Nacional\u00a0del\u00a0Sida.\u00a0Recomendaciones \u00a0de\u00a0GESIDA/SPNS \u00a0para\u00a0la\u00a0evalua\u2010\nci\u00f3n\u00a0y\u00a0el\u00a0tratamiento \u00a0de\u00a0las\u00a0alteraciones \u00a0renales\u00a0en\u00a0pacientes \u00a0con\u00a0infecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0(2009).\u00a0\nDisponible \u00a0en:\u00a0www\u00a0gesida\u00a0seimc\u00a0org/pcientifica/dcconsensos \u00a02009.\u00a0\n\u00a0 547.\u00a0\u00a0Hsu\u00a0A,\u00a0Granneman \u00a0R,\u00a0Bertz\u00a0R.\u00a0Ritonavir. \u00a0Clinical\u00a0pharmacokinetics \u00a0and\u00a0interactions \u00a0with\u00a0other\u00a0\nanti\u2010HIV\u00a0agents.\u00a0Clin\u00a0Pharmacokinet \u00a01998;\u00a035:275\u2010291.\u00a0\n\u00a0 548.\u00a0\u00a0Clumeck\u00a0N,\u00a0Pozniak\u00a0A,\u00a0Raffi\u00a0F.\u00a0European \u00a0AIDS\u00a0Clinical\u00a0Society\u00a0(EACS)\u00a0guidelines \u00a0for\u00a0the\u00a0clinical\u00a0\nmanagement \u00a0and\u00a0treatment \u00a0of\u00a0HIV\u2010infected\u00a0adults.\u00a0HIV\u00a0Med\u00a02008;\u00a09(2):65\u201071.\u00a0\n\u00a0 549.\u00a0\u00a0Scholler\u2010Gyure\u00a0M,\u00a0Kakuda\u00a0TN,\u00a0Raoof\u00a0A,\u00a0de\u00a0SG,\u00a0Hoetelmans \u00a0RM.\u00a0Clinical\u00a0pharmacokinetics \u00a0and\u00a0\npharmacodynamics \u00a0of\u00a0etravirine. \u00a0Clin\u00a0Pharmacokinet \u00a02009;\u00a048(9):561 \u2010574.\u00a0\n\u00a0 550.\u00a0\u00a0Sch\u00f6ller\u2010Gy\u00fcre\u00a0M,\u00a0Kakuda\u00a0TN,\u00a0Stevens\u00a0T,\u00a0Aharchi\u00a0F,\u00a0de\u00a0Smedlt\u00a0G,\u00a0Peeters\u00a0M\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0\netravirine \u00a0on\u00a0cytochrome \u00a0P450\u00a0isozymes\u00a0assessed\u00a0by\u00a0the\u00a0Cooperstown \u00a05+1\u00a0cocktail.\u00a048th\u00a0An\u2010\nnual\u00a0ICCAC/IDSA \u00a046th\u00a0Annual\u00a0Meeting;\u00a0October\u00a025\u201028,\u00a02008;\u00a0Washington, \u00a0DC\u00a02009;\u00a0Abstract\u00a0\nA\u2010955.\u00a0\n\u00a0 551.\u00a0\u00a0Yeh\u00a0RF,\u00a0Gaver\u00a0VE,\u00a0Patterson \u00a0KB,\u00a0Rezk\u00a0NL,\u00a0Baxter\u2010Meheux\u00a0F,\u00a0Blake\u00a0MJ\u00a0et\u00a0al.\u00a0Lopinavir/ritonavir \u00a0\ninduces\u00a0the\u00a0hepatic\u00a0activity\u00a0of\u00a0cytochrome \u00a0P450\u00a0enzymes\u00a0CYP2C9,\u00a0CYP2C19, \u00a0and\u00a0CYP1A2\u00a0but\u00a0\ninhibits\u00a0the\u00a0hepatic\u00a0and\u00a0intestinal \u00a0activity\u00a0of\u00a0CYP3A\u00a0as\u00a0measured \u00a0by\u00a0a\u00a0phenotyping \u00a0drug\u00a0cock\u2010\ntail\u00a0in\u00a0healthy\u00a0volunteers. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02006;\u00a042(1):52\u201060.\u00a0\n\u00a0 552.\u00a0\u00a0Vourvahis \u00a0M,\u00a0Dumond\u00a0J,\u00a0Patterson \u00a0K,\u00a0Rezk\u00a0N,\u00a0Tien\u00a0H,\u00a0Li\u00a0J\u00a0et\u00a0al.\u00a0Effects\u00a0of\u00a0tipranavir/ritonavir \u00a0\n(TPV/r)\u00a0on\u00a0the\u00a0activity\u00a0of\u00a0cytochrome \u00a0p450\u00a0(CYP)\u00a0enzymes\u00a01A2,\u00a02C9,\u00a0and\u00a02D6\u00a0in\u00a0healthy\u00a0vo\u2010\nlunteers.\u00a08th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy.Budapest, \u00a0\nHungary,\u00a016\u201018\u00a0April,\u00a02007\u00a0[abstract\u00a052]\u00a0\n\u00a0 553.\u00a0\u00a0Celsentri\u00ae \u00a0(Maraviroc). \u00a0Pfizer\u00a0Limited.\u00a0Sandwich, \u00a0Kent,\u00a0Reino\u00a0Unido.\u00a0Septiembre \u00a02007.\u00a0Dis\u2010\nponible\u00a0en:\u00a0http://www.emea.europa.eu/humandocs/PDFs/EPAR/celsentri/emea \u2010combined \u2010\nh811es.pdf \u00a0(Acceso:\u00a08.12.09)\u00a0\n\u00a0 554.\u00a0\u00a0Carter\u00a0NJ,\u00a0Keating\u00a0GM.\u00a0Maraviroc. \u00a0Drugs\u00a02007;\u00a067(15):2277 \u20102288.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 139 \n \u00a0 555.\u00a0\u00a0Raltegravir. \u00a0Merck\u00a0Sharp\u00a0&\u00a0Dohme\u00a0Ltd.\u00a0Hertfordshire, \u00a0Reino\u00a0Unido.\u00a0Diciembre \u00a02007.\u00a0Dispo\u2010\nnible\u00a0en:\u00a0http://www.emea.europa.eu/huma ndocs/PDFs/EPAR/isentress/emea \u2010combined \u2010\nh860es.pdf \u00a0(Acceso\u00a08.12.09)\u00a0\u00a0\n\u00a0 556.\u00a0\u00a0Croxtall\u00a0JD,\u00a0Lyseng\u2010Williamson \u00a0KA,\u00a0Perry\u00a0CM.\u00a0Raltegravir. \u00a0Drugs\u00a02008;\u00a068(1):131 \u2010138.\u00a0\n\u00a0 557.\u00a0\u00a0Evering\u00a0TH,\u00a0Markowitz \u00a0M.\u00a0Raltegravir \u00a0(MK\u20100518):\u00a0an\u00a0integrase \u00a0inhibitor\u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0\nHIV\u20101.\u00a0Drugs\u00a0Today\u00a0(Barc\u00a0)\u00a02007;\u00a043(12):865 \u2010877.\u00a0\n\u00a0 558.\u00a0\u00a0Hyland\u00a0R,\u00a0Dickins\u00a0M,\u00a0Collins\u00a0C,\u00a0Jones\u00a0H,\u00a0Jones\u00a0B.\u00a0Maraviroc: \u00a0in\u00a0vitro\u00a0assessment \u00a0of\u00a0drug\u2010drug\u00a0\ninteraction \u00a0potential. \u00a0Br\u00a0J\u00a0Clin\u00a0Pharmacol \u00a02008;\u00a066(4):498 \u2010507.\u00a0\n\u00a0 559.\u00a0\u00a0Colombo\u00a0S,\u00a0Buclin\u00a0T,\u00a0Franc\u00a0C,\u00a0Guignard\u00a0N,\u00a0Khonkarly \u00a0M,\u00a0Tarr\u00a0PE\u00a0et\u00a0al.\u00a0Ritonavir\u2010boosted\u00a0ata\u2010\nzanavir\u2010lopinavir\u00a0combination: \u00a0a\u00a0pharmacokinetic \u00a0interaction \u00a0study\u00a0of\u00a0total,\u00a0unbound\u00a0plasma\u00a0\nand\u00a0cellular\u00a0exposures. \u00a0Antivir\u00a0Ther\u00a02006;\u00a011(1):53\u201062.\u00a0\n\u00a0 560.\u00a0\u00a0Abel\u00a0S,\u00a0Ridgway\u00a0C,\u00a0Hamlin\u00a0J,\u00a0Davis\u00a0J,\u00a0Mack\u00a0R,\u00a0Sekar\u00a0V.\u00a0An\u00a0open,\u00a0randomised, \u00a02\u2010way\u00a0crossover \u00a0\nstudy\u00a0to\u00a0investigate \u00a0the\u00a0effect\u00a0of\u00a0darunavir/ritonavir \u00a0on\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0maraviroc \u00a0in\u00a0\nhealthy\u00a0subjects.\u00a08th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Thera\u2010\npy.Budapest, \u00a0Hungary,\u00a016\u201018\u00a0April,\u00a02007\u00a0[abstract\u00a055]\u00a0\n\u00a0 561.\u00a0\u00a0Anderson \u00a0MS,\u00a0Kakuda\u00a0NT,\u00a0Miller\u00a0JL,\u00a0Simonts\u00a0M,\u00a0Miller\u00a0D,\u00a0Hanley\u00a0W\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0\nevaluation \u00a0of\u00a0non\u2010nucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitor\u00a0TMC125\u00a0and\u00a0integrase \u00a0inhibitor\u00a0\nraltegravir \u00a0in\u00a0healthy\u00a0subjects.\u00a04th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Pre\u2010\nvention,\u00a0Sydney,\u00a02007\u00a0Abstract\u00a0TUPDB02 \u00a0\n\u00a0 562.\u00a0\u00a0Iwamoto\u00a0M,\u00a0Wenning\u00a0LA,\u00a0Mistry\u00a0GC,\u00a0Petry\u00a0AS,\u00a0Liou\u00a0SY,\u00a0Ghosh\u00a0K\u00a0et\u00a0al.\u00a0Atazanavir \u00a0modestly\u00a0\nincreases \u00a0plasma\u00a0levels\u00a0of\u00a0raltegravir \u00a0in\u00a0healthy\u00a0subjects.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02008;\u00a047(1):137 \u2010140.\u00a0\n\u00a0 563.\u00a0\u00a0King\u00a0JR,\u00a0Kakuda\u00a0TN,\u00a0Paul\u00a0S,\u00a0Tse\u00a0MM,\u00a0Acosta\u00a0EP,\u00a0Becker\u00a0SL.\u00a0Pharmacokinetics \u00a0of\u00a0saquinavir \u00a0\nwith\u00a0atazanavir \u00a0or\u00a0low\u2010dose\u00a0ritonavir\u00a0administered \u00a0once\u00a0daily\u00a0(ASPIRE\u00a0I)\u00a0or\u00a0twice\u00a0daily\u00a0(ASPI\u2010\nRE\u00a0II)\u00a0in\u00a0seronegative \u00a0volunteers. \u00a0J\u00a0Clin\u00a0Pharmacol \u00a02007;\u00a047(2):201 \u2010208.\u00a0\n\u00a0 564.\u00a0\u00a0Ofotokun \u00a0I,\u00a0Acosta\u00a0EP,\u00a0Lennox\u00a0JL,\u00a0Pan\u00a0Y,\u00a0Easley\u00a0KA.\u00a0Pharmacokinetics \u00a0of\u00a0an\u00a0indinavir\u2010ritonavir\u2010\nfosamprenavir \u00a0regimen\u00a0in\u00a0patients\u00a0with\u00a0human\u00a0immunodeficiency \u00a0virus.\u00a0Pharmacotherapy \u00a0\n2008;\u00a028(1):74\u201081.\u00a0\n\u00a0 565.\u00a0\u00a0Pham\u00a0PA,\u00a0Flexner\u00a0C,\u00a0Parsons\u00a0T,\u00a0Vasist\u00a0L,\u00a0Fuchs\u00a0E,\u00a0Carson\u00a0K\u00a0et\u00a0al.\u00a0Beneficial \u00a0pharmacokinetic \u00a0\ninteraction \u00a0between\u00a0atazanavir \u00a0and\u00a0lopinavir/ritonavir. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a0\n45(2):201 \u2010205.\u00a0\n\u00a0 566.\u00a0\u00a0Sekar\u00a0VJ,\u00a0De\u00a0PM,\u00a0Marien\u00a0K,\u00a0Peeters\u00a0M,\u00a0Lefebvre\u00a0E,\u00a0Hoetelmans \u00a0RM.\u00a0Pharmacokinetic \u00a0interac\u2010\ntion\u00a0between\u00a0TMC114/r \u00a0and\u00a0efavirenz\u00a0in\u00a0healthy\u00a0volunteers. \u00a0Antivir\u00a0Ther\u00a02007;\u00a012(4):509 \u2010\n514.\u00a0\n\u00a0 567.\u00a0\u00a0Winston\u00a0A,\u00a0Mallon\u00a0PW,\u00a0Satchell\u00a0C,\u00a0MacRae\u00a0K,\u00a0Williams\u00a0KM,\u00a0Schutz\u00a0M\u00a0et\u00a0al.\u00a0The\u00a0safety,\u00a0effica\u2010\ncy,\u00a0and\u00a0pharmacokinetic \u00a0profile\u00a0of\u00a0a\u00a0switch\u00a0in\u00a0antiretroviral \u00a0therapy\u00a0to\u00a0saquinavir, \u00a0ritonavir,\u00a0\nand\u00a0atazanavir \u00a0alone\u00a0for\u00a048\u00a0weeks\u00a0and\u00a0a\u00a0switch\u00a0in\u00a0the\u00a0saquinavir \u00a0formulation. \u00a0Clin\u00a0Infect\u00a0Dis\u00a0\n2007;\u00a044(11):1475 \u20101483.\u00a0\n\u00a0 568.\u00a0\u00a0Raffi\u00a0F,\u00a0Battegay\u00a0M,\u00a0Rusconi\u00a0S,\u00a0Opravil\u00a0M,\u00a0Blick\u00a0G,\u00a0Steigbigel \u00a0RT\u00a0et\u00a0al.\u00a0Combined \u00a0tipranavir \u00a0and\u00a0\nenfuvirtide \u00a0use\u00a0associated \u00a0with\u00a0higher\u00a0plasma\u00a0tipranavir \u00a0concentrations \u00a0but\u00a0not\u00a0with\u00a0increa\u2010\nsed\u00a0hepatotoxicity: \u00a0sub\u2010analysis\u00a0from\u00a0RESIST.\u00a0AIDS\u00a02007;\u00a021(14):1977 \u20101980.\u00a0\n\u00a0 569.\u00a0\u00a0Kurowski\u00a0M,\u00a0Walli\u00a0RK,\u00a0Breske\u00a0A,\u00a0Kruse\u00a0G,\u00a0Stocker\u00a0H,\u00a0Banik\u00a0N\u00a0et\u00a0al.\u00a0Fosamprenavir/ritonavir \u00a0\nplus\u00a0tenofovir\u00a0does\u00a0not\u00a0affect\u00a0amprenavir \u00a0pharmacokinetics: \u00a0no\u00a0effect\u00a0of\u00a0tenofovir. \u00a0AIDS\u00a0\n2007;\u00a021(10):1368 \u20101370.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 140 \n \u00a0 570.\u00a0\u00a0Sekar\u00a0VJ,\u00a0Lefebvre\u00a0E,\u00a0Marien\u00a0K,\u00a0De\u00a0PM,\u00a0Vangeneugden \u00a0T,\u00a0Hoetelmans \u00a0RM.\u00a0Pharmacokinetic \u00a0\ninteraction \u00a0between\u00a0darunavir \u00a0and\u00a0saquinavir \u00a0in\u00a0HIV\u2010negative\u00a0volunteers. \u00a0Ther\u00a0Drug\u00a0Monit\u00a0\n2007;\u00a029(6):795 \u2010801.\u00a0\n\u00a0 571.\u00a0\u00a0Peytavin\u00a0G,\u00a0Chazallon \u00a0C,\u00a0Descamps \u00a0D,\u00a0Capitant\u00a0C,\u00a0Katlama\u00a0C,\u00a0Pialoux\u00a0G\u00a0et\u00a0al.\u00a0Pharmacokinetic, \u00a0\nsafety\u00a0and\u00a0efficacy\u00a0of\u00a0two\u00a0dual\u00a0PI\u00a0regimens \u00a0(FPV/r\u00a0bid/ATV\u00a0qd\u00a0and\u00a0SQV/ATV/r \u00a0qd)\u00a0for\u00a0the\u00a0tre\u2010\natment\u00a0of\u00a0antiretroviral \u2010na\u00efve\u00a0HIV\u20101\u00a0subjects:\u00a0a\u00a0randomized \u00a0pilot\u00a0study\u00a0(ANRS\u00a0127).\u00a09th\u00a0In\u2010\nternational \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy.New \u00a0Orleans,\u00a0LA,\u00a02008\u00a0[Abs\u2010\ntract\u00a0P39]\u00a0\n\u00a0 572.\u00a0\u00a0Molt\u00f3\u00a0J,\u00a0Llibre\u00a0JM,\u00a0Valle\u00a0M,\u00a0Miranda\u00a0C,\u00a0Cede\u00f1o\u00a0S,\u00a0P\u00e9rez\u00a0Alvarez\u00a0N\u00a0et\u00a0al.\u00a0The\u00a0effect\u00a0of\u00a0nevira\u2010\npine\u00a0on\u00a0the\u00a0steady\u2010state\u00a0through\u00a0concentrations \u00a0of\u00a0atazanavir/ritonavir. \u00a09th\u00a0International \u00a0\nWorkshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy.New \u00a0Orleans,\u00a0LA,\u00a02008\u00a0[Abstract\u00a0P20]\u00a0\n\u00a0 573.\u00a0\u00a0Rhame\u00a0F,\u00a0Long\u00a0M,\u00a0Acosta\u00a0E.\u00a0RAL\u2010KAL:\u00a0Pharmacokinetics \u00a0of\u00a0coadministered \u00a0Raltegravir \u00a0and\u00a0\nLopinavir\u2010Ritonavir\u00a0in\u00a0healthy\u00a0adults.\u00a09th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0\nHIV\u00a0Therapy.New \u00a0Orleans,\u00a0LA,\u00a02008\u00a0\u00a0\n\u00a0 574.\u00a0\u00a0Ng\u00a0J,\u00a0Klein\u00a0C,\u00a0Xiong\u00a0J,\u00a0Chiu\u00a0YL,\u00a0Doan\u00a0T,\u00a0Rolle\u00a0C\u00a0et\u00a0al.\u00a0Lopinavir/Ritonavir \u00a0500/125\u00a0mg\u00a0Twice\u2010\ndaily\u00a0+\u00a0Efavirenz\u00a0Approximate \u00a0the\u00a0Pharmacokinetic \u00a0Exposure\u00a0of\u00a0LPV/r\u00a0400/100\u00a0mg\u00a0Twice\u2010\ndaily\u00a0Administered \u00a0Alone\u00a0in\u00a0Healthy\u00a0Adult\u00a0Subjects.\u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections; \u00a0February\u00a02008;\u00a0Boston,\u00a0Massachusetts \u00a0[abstract\u00a0765]\u00a0\n\u00a0 575.\u00a0\u00a0Khanlou\u00a0H,\u00a0Allavena\u00a0C,\u00a0Billaud\u00a0E,\u00a0McKellar\u00a0M,\u00a0Reliquet\u00a0V.\u00a0Development \u00a0of\u00a0hepatic\u00a0cytolysis\u00a0\nalter\u00a0switching \u00a0from\u00a0enfuvirtide \u00a0to\u00a0raltegravir \u00a0in\u00a0virologically \u00a0suppressed \u00a0patients\u00a0treated\u00a0\nwith\u00a0tipranavir/ritonavir. \u00a017th\u00a0International \u00a0AIDS\u00a0Conference; \u00a03\u20108\u00a0August,\u00a02008;\u00a0Mexico\u00a0DF.\u00a0\n(Abstract\u00a0A\u2010072\u20100082\u201007276)\u00a0\n\u00a0 576.\u00a0\u00a0Kumar\u00a0PN,\u00a0Cooper\u00a0DA,\u00a0Steigbigel \u00a0R,\u00a0Zhao\u00a0J,\u00a0Teppler\u00a0H,\u00a0Nguyen\u00a0BY\u00a0et\u00a0al.\u00a0Efficacy\u00a0of\u00a0Raltegravir, \u00a0\nan\u00a0HIV\u00a0Integrase \u00a0Inhibitor,\u00a0in\u00a0Combination \u00a0with\u00a0Regimens \u00a0Containing \u00a0Enfuvirtide, \u00a0Darunavir, \u00a0\nor\u00a0Tipranavir \u00a0in\u00a0Patients\u00a0with\u00a0Triple\u2010class\u00a0Resistant\u00a0Virus:\u00a0Combined \u00a0Results\u00a0from\u00a0\nBENCHMRK \u20101\u00a0and\u00a0BENCHMRK \u20102.\u00a011th\u00a0European \u00a0AIDS\u00a0Conference \u00a0/EACS.Madrid, \u00a0Spain,\u00a0Oc\u2010\ntober\u00a024\u201027,\u00a02007\u00a0(abstract\u00a0P7.2/06)\u00a0\n\u00a0 577.\u00a0\u00a0Hicks\u00a0C,\u00a0DeJesus\u00a0E,\u00a0Wohl\u00a0D,\u00a0Liao\u00a0Q,\u00a0Pappa\u00a0K,\u00a0Lancaster \u00a0T.\u00a0Once\u2010Daily\u00a0Fosamprenavir \u00a0Boosted\u00a0\nwith\u00a0Either\u00a0100mg\u00a0or\u00a0200mg\u00a0of\u00a0Ritonavir\u00a0and\u00a0Combined \u00a0with\u00a0Abacavir/Lamivudine: \u00a048\u2010Week\u00a0\nSafety\u00a0and\u00a0Efficacy\u00a0Results\u00a0from\u00a0COL100758. \u00a011th\u00a0European \u00a0AIDS\u00a0Conference \u00a0/EACS.Madrid, \u00a0\nSpain,\u00a0October\u00a024\u201027,\u00a02007\u00a0(abstract\u00a0P5.7/01)\u00a0\n\u00a0 578.\u00a0\u00a0Davis\u00a0Jr\u00a0C,\u00a0Giliam\u00a0b,\u00a0Amoroso\u00a0A,\u00a0Redfield\u00a0R,\u00a0Piliero\u00a0P,\u00a0MacGregor \u00a0T.\u00a0Lack\u00a0of\u00a0Pharmacokinetic \u00a0\nInteraction \u00a0of\u00a0Tenofovir \u00a0and\u00a0Emtricitabine \u00a0on\u00a0Nevirapine. \u00a011th\u00a0European \u00a0AIDS\u00a0Conference \u00a0\n/EACS.Madrid, \u00a0Spain,\u00a0October\u00a024\u201027,\u00a02007\u00a0(abstract\u00a0P4.1/03)\u00a0\n\u00a0 579.\u00a0\u00a0Davis\u00a0J,\u00a0Sch\u00f6ller\u2010Gy\u00fcre\u00a0M,\u00a0Kakuda\u00a0NT,\u00a0Ridgway\u00a0C,\u00a0Tweedy\u00a0S,\u00a0Ndongo\u00a0N\u00a0et\u00a0al.\u00a0An\u00a0Open,\u00a0Ran\u2010\ndomized,\u00a0Two\u00a0Period,\u00a0Crossover \u00a0Study\u00a0in\u00a02\u00a0Cohorts\u00a0to\u00a0Investigate \u00a0the\u00a0Effect\u00a0of\u00a0Steady\u00a0State\u00a0\nTMC125\u00a0and\u00a0the\u00a0Combination \u00a0of\u00a0TMC125\u00a0/\u00a0Darunavir \u00a0/\u00a0Ritonavir\u00a0on\u00a0the\u00a0Steady\u00a0State\u00a0Phar\u2010\nmacokinetics \u00a0of\u00a0Oral\u00a0Maraviroc \u00a0in\u00a0Healthy\u00a0Subjects.\u00a011th\u00a0European \u00a0AIDS\u00a0Conference \u00a0\n/EACS.Madrid, \u00a0Spain,\u00a0October\u00a024\u201027,\u00a02007\u00a0(abstract\u00a0P4.3/02)\u00a0\n\u00a0 580.\u00a0\u00a0Curran\u00a0A,\u00a0L\u00f3pez\u00a0R,\u00a0Deig\u00a0E,\u00a0Falc\u00f3\u00a0V,\u00a0Crespo\u00a0M,\u00a0Villar\u00a0del\u00a0Saz\u00a0S\u00a0et\u00a0al.\u00a0Saquinavir/ritonavir \u00a0\n1500/100: \u00a0A\u00a0Good\u00a0Option\u00a0for\u00a0a\u00a0Once\u2010Daily\u00a0Treatment. \u00a011th\u00a0European \u00a0AIDS\u00a0Conference \u00a0\n/EACS.Madrid, \u00a0Spain,\u00a0October\u00a024\u201027,\u00a02007\u00a0(abstract\u00a0P4.1/11)\u00a0\n\u00a0 581.\u00a0\u00a0Hanley\u00a0WD,\u00a0Wenning\u00a0LA,\u00a0Moreau\u00a0A,\u00a0Kost\u00a0JT,\u00a0Mangin\u00a0E,\u00a0Shamp\u00a0T\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0tipranavir \u2010\nritonavir\u00a0on\u00a0pharmacokinetics \u00a0of\u00a0raltegravir. \u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02009;\u00a053(7):2752 \u2010\n2755.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 141 \n \u00a0 582.\u00a0\u00a0Haas\u00a0D,\u00a0Koletar\u00a0S,\u00a0Laughlin\u00a0L,\u00a0Kendall\u00a0M,\u00a0Suckow\u00a0C,\u00a0Gerber\u00a0J\u00a0et\u00a0al.\u00a0Hepatic\u00a0Transaminase \u00a0Ele\u2010\nvations\u00a0and\u00a0Gastrointestinal \u00a0Intolerance \u00a0when\u00a0HIV\u2010negative\u00a0Healthy\u00a0Volunteers \u00a0on\u00a0Rifampin\u00a0\nadd\u00a0Twice\u2010daily\u00a0Atazanavir \u00a0(300\u00a0mg)/Ritonavir \u00a0(100\u00a0mg):\u00a0ACTG\u00a0Protocol\u00a0A5213.\u00a015th\u00a0Confe\u2010\nrence\u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a02008;\u00a0Boston,\u00a0Massachusetts \u00a0\n[abstract\u00a0766b]\u00a0\n\u00a0 583.\u00a0\u00a0Tansuphasawadikul \u00a0S,\u00a0Saito\u00a0W,\u00a0Kim\u00a0J,\u00a0Phonrat\u00a0B,\u00a0Dhitavat\u00a0J,\u00a0Chamnachanan \u00a0S\u00a0et\u00a0al.\u00a0Outcomes \u00a0\nin\u00a0HIV\u2010infected\u00a0patients\u00a0on\u00a0antiretroviral \u00a0therapy\u00a0with\u00a0tuberculosis. \u00a0Southeast \u00a0Asian\u00a0J\u00a0Trop\u00a0\nMed\u00a0Public\u00a0Health\u00a02007;\u00a038(6):1053 \u20101060.\u00a0\n\u00a0 584.\u00a0\u00a0Nijland\u00a0HM,\u00a0L'homme \u00a0RF,\u00a0Rongen\u00a0GA,\u00a0van\u00a0UP,\u00a0van\u00a0CR,\u00a0Boeree\u00a0MJ\u00a0et\u00a0al.\u00a0High\u00a0incidence \u00a0of\u00a0\nadverse\u00a0events\u00a0in\u00a0healthy\u00a0volunteers \u00a0receiving\u00a0rifampicin \u00a0and\u00a0adjusted\u00a0doses\u00a0of\u00a0lopina\u2010\nvir/ritonavir \u00a0tablets.\u00a0AIDS\u00a02008;\u00a022(8):931 \u2010935.\u00a0\n\u00a0 585.\u00a0\u00a0Mallolas\u00a0J,\u00a0Sarasa\u00a0M,\u00a0Nomdedeu \u00a0M,\u00a0Soriano\u00a0A,\u00a0Lopez\u2010Pua\u00a0Y,\u00a0Blanco\u00a0JL\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0\ninteraction \u00a0between\u00a0rifampicin \u00a0and\u00a0ritonavir\u2010boosted\u00a0atazanavir \u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0HIV\u00a0\nMed\u00a02007;\u00a08(2):131\u2010134.\u00a0\n\u00a0 586.\u00a0\u00a0CDC.\u00a0Managing \u00a0Drug\u00a0Interactions \u00a0in\u00a0the\u00a0Treatment \u00a0of\u00a0HIV\u2010Related\u00a0Tuberculosis \u00a0(2007).\u00a0Dis\u2010\nponible\u00a0en:\u00a0http://www.cdc.gov/tb/publications/g uidelines/TB_HIV_Drugs/default.htm \u00a0(Ac\u2010\nceso\u00a08.12.09)\u00a0\u00a0\n\u00a0 587.\u00a0\u00a0Patel\u00a0K,\u00a0Patel\u00a0A,\u00a0Naik\u00a0E,\u00a0Ranjan\u00a0R,\u00a0Patel\u00a0J,\u00a0Tash\u00a0K\u00a0et\u00a0al.\u00a0TB\u00a0co\u2010infection\u00a0treated\u00a0at\u00a0onset\u00a0of\u00a0\ntherapy\u00a0does\u00a0not\u00a0affect\u00a0long\u2010term\u00a0risk\u00a0of\u00a0treatment \u00a0failure\u00a0among\u00a0HIV\u20101\u00a0patients\u00a0initiating\u00a0\nefavirenz\u2010based\u00a0combination \u00a0antiretroviral \u00a0treatment. \u00a04th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogene \u2010\nsis,\u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Sydney,\u00a02007\u00a0Abstract\u00a0MOAB103 \u00a0\n\u00a0 588.\u00a0\u00a0Wenning\u00a0LA,\u00a0Hanley\u00a0WD,\u00a0Brainard\u00a0DM,\u00a0Petry\u00a0AS,\u00a0Ghosh\u00a0K,\u00a0Jin\u00a0B\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0rifampin,\u00a0a\u00a0\npotent\u00a0inducer\u00a0of\u00a0drug\u2010metabolizing \u00a0enzymes, \u00a0on\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0raltegravir. \u00a0Anti\u2010\nmicrob\u00a0Agents\u00a0Chemother \u00a02009;\u00a053(7):2852 \u20102856.\u00a0\n\u00a0 589.\u00a0\u00a0Andrews\u00a0E,\u00a0Glue\u00a0P,\u00a0Labadie\u00a0R,\u00a0Crownover \u00a0P,\u00a0Tressler\u00a0R,\u00a0Damle\u00a0B\u00a0et\u00a0al.\u00a0A\u00a0pharmacokinetic \u00a0\nstudy\u00a0to\u00a0evaluate\u00a0an\u00a0interaction \u00a0bewteen\u00a0maraviroc \u00a0and\u00a0raltegravir \u00a0in\u00a0healthy\u00a0adults\u00a0[.\u00a048th\u00a0\nAnnual\u00a0ICCAC/IDSA \u00a046th\u00a0Annual\u00a0Meeting;\u00a0October\u00a025\u201028,\u00a02008;\u00a0Washington, \u00a0DC\u00a02009;\u00a0Abs\u2010\ntract\u00a0H\u20104055.\u00a0\n\u00a0 590.\u00a0\u00a0Fux\u00a0C,\u00a0Opravil\u00a0M,\u00a0Cavassini\u00a0M,\u00a0Calmy\u00a0A,\u00a0Flepp\u00a0M,\u00a0Gurtner\u2010Delafuente \u00a0V\u00a0et\u00a0al.\u00a0Tenofovir \u00a0and\u00a0PI\u00a0\nuse\u00a0are\u00a0associated \u00a0with\u00a0an\u00a0increased \u00a0prevalence \u00a0of\u00a0proximal\u00a0renal\u00a0tubular\u00a0dysfunction \u00a0in\u00a0the\u00a0\nSwiss\u00a0HIV\u00a0cohort\u00a0study.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0Fe\u2010\nbruary\u00a02009;\u00a0Montreal \u00a02009;\u00a0Abstract\u00a0743.\u00a0\n\u00a0 591.\u00a0\u00a0Luber\u00a0A,\u00a0Condoluci \u00a0D,\u00a0Slowinski \u00a0P,\u00a0Loui\u00a0S,\u00a0Morwinkin \u00a0N,\u00a0Pappa\u00a0K\u00a0et\u00a0al.\u00a0Steady\u2010state\u00a0pharma\u2010\ncokinetics \u00a0of\u00a0maraviroc \u00a0and\u00a0amprenavir \u00a0alone\u00a0and\u00a0in\u00a0combination \u00a0after\u00a0maraviroc \u00a0is\u00a0given\u00a0\nBID\u00a0with\u00a0unboosted \u00a0or\u00a0ritonavir\u00a0boosted\u00a0fosamprenavir \u00a0once\u2010\u00a0or\u00a0twice\u2010daily\u00a0in\u00a0fasted\u00a0healthy\u00a0\nvolunteers. \u00a010th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy\u00a0Amster\u2010\ndam,\u00a0The\u00a0Netherlands, \u00a0April\u00a015\u201017,\u00a02009\u00a02009;\u00a0Abstract\u00a0P\u201031.\u00a0\n\u00a0 592.\u00a0\u00a0Lee\u00a0LS,\u00a0Soon\u00a0GH,\u00a0Shen\u00a0P,\u00a0Flexner\u00a0C,\u00a0Pham\u00a0P.\u00a0Pharmacokinetics \u00a0of\u00a0darunavir \u00a0900\u00a0mg\u00a0and\u00a0rito\u2010\nnavir\u00a0100\u00a0mg\u00a0(DRV/RTV) \u00a0once\u00a0daily\u00a0when\u00a0co\u2010administered \u00a0with\u00a0efavirenz\u00a0600\u00a0mg\u00a0once\u00a0daily\u00a0\nin\u00a0healthy\u00a0adult\u00a0volunteers. \u00a010th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0\nTherapy\u00a0Amsterdam, \u00a0The\u00a0Netherlands, \u00a0April\u00a015\u201017,\u00a02009\u00a02009;\u00a0Abstract\u00a0P\u201029.\u00a0\n\u00a0 593.\u00a0\u00a0Sch\u00f6ller\u2010Gyure\u00a0M,\u00a0Kakuda\u00a0NT,\u00a0Akuma\u00a0SH,\u00a0DeClerq\u00a0I,\u00a0De\u00a0Smedt\u00a0G,\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0inte\u2010\nraction\u00a0between\u00a0etravirine \u00a0and\u00a0lopinavir/ritonavir. \u00a049th\u00a0ICAAC\u00a0San\u00a0Francisco, \u00a0CA\u00a0,\u00a0September \u00a0\n12\u201015,\u00a02009\u00a02009;\u00a0Abstract\u00a0A1\u20101298.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 142 \n \u00a0 594.\u00a0\u00a0Luber\u00a0A,\u00a0Slovinski\u00a0D,\u00a0Acosta\u00a0E,\u00a0Pakes\u00a0G,\u00a0Pappa\u00a0K,\u00a0Condoluci \u00a0D\u00a0et\u00a0al.\u00a0Steady\u2010state\u00a0pharmacoki \u2010\nnetics\u00a0of\u00a0fosamprenavir \u00a0and\u00a0raltegravir \u00a0alone\u00a0and\u00a0combined \u00a0with\u00a0unboosted \u00a0and\u00a0ritonavir\u2010\nboosted\u00a0fosamprenavir. \u00a049th\u00a0ICAAC\u00a0San\u00a0Francisco, \u00a0CA\u00a0,\u00a0September \u00a012\u201015,\u00a02009\u00a02009;\u00a0Abs\u2010\ntract\u00a0A1\u20101297.\u00a0\n\u00a0 595.\u00a0\u00a0Wittkop\u00a0L,\u00a0Breilh\u00a0D,\u00a0Da\u00a0SD,\u00a0Duffau\u00a0P,\u00a0Mercie\u00a0P,\u00a0Raymond \u00a0I\u00a0et\u00a0al.\u00a0Virological \u00a0and\u00a0immunologi \u2010\ncal\u00a0response\u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0with\u00a0multiple\u00a0treatment \u00a0failures\u00a0receiving\u00a0raltegravir \u00a0\nand\u00a0optimized \u00a0background \u00a0therapy,\u00a0ANRS\u00a0CO3\u00a0Aquitaine \u00a0Cohort.\u00a0J\u00a0Antimicrob \u00a0Chemother \u00a0\n2009;\u00a063(6):1251 \u20101255.\u00a0\n\u00a0 596.\u00a0\u00a0Sekar\u00a0V,\u00a0Lefebvre\u00a0E,\u00a0Marien\u00a0K,\u00a0De\u00a0PM,\u00a0Vangeneugden \u00a0T,\u00a0Pozniak\u00a0A\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0\ninteraction \u00a0between\u00a0nevirapine \u00a0and\u00a0darunavir \u00a0with\u00a0low\u2010dose\u00a0ritonavir\u00a0in\u00a0HIV\u20101\u2010infected\u00a0pa\u2010\ntients.\u00a0Br\u00a0J\u00a0Clin\u00a0Pharmacol \u00a02009;\u00a068(1):116 \u2010119.\u00a0\n\u00a0 597.\u00a0\u00a0Scholler\u2010Gyure\u00a0M,\u00a0van\u00a0den\u00a0BW,\u00a0Kakuda\u00a0TN,\u00a0Woodfall\u00a0B,\u00a0de\u00a0SG,\u00a0Vanaken\u00a0H\u00a0et\u00a0al.\u00a0Pharmacoki \u2010\nnetic\u00a0and\u00a0pharmacodynamic \u00a0study\u00a0of\u00a0the\u00a0concomitant \u00a0administration \u00a0of\u00a0methadone \u00a0and\u00a0\nTMC125\u00a0in\u00a0HIV\u2010negative\u00a0volunteers. \u00a0J\u00a0Clin\u00a0Pharmacol \u00a02008;\u00a048(3):322 \u2010329.\u00a0\n\u00a0 598.\u00a0\u00a0Khachi\u00a0H,\u00a0O'Connell \u00a0R,\u00a0Ladenheim \u00a0D,\u00a0Orkin\u00a0C.\u00a0Pharmacokinetic \u00a0interactions \u00a0between\u00a0rifabutin\u00a0\nand\u00a0lopinavir/ritonavir \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0mycobacterial \u00a0co\u2010infection. \u00a0J\u00a0Antimicrob \u00a0\nChemother \u00a02009;\u00a064(4):871 \u2010873.\u00a0\n\u00a0 599.\u00a0\u00a0Brainard\u00a0DM,\u00a0Petry\u00a0AS,\u00a0Hanley\u00a0WD,\u00a0Wenning\u00a0LA,\u00a0Jin\u00a0B,\u00a0Breidinger \u00a0S\u00a0et\u00a0al.\u00a0Doubling\u00a0the\u00a0dose\u00a0\nof\u00a0raltegravir \u00a0does\u00a0not\u00a0increase\u00a0trough\u00a0levels\u00a0in\u00a0the\u00a0presence\u00a0of\u00a0rifampin.\u00a048th\u00a0Annual\u00a0IC\u2010\nCAC/IDSA \u00a046th\u00a0Annual\u00a0Meeting;\u00a0October\u00a025\u201028,\u00a02008;\u00a0Washington, \u00a0DC\u00a02009;\u00a0Abstract\u00a0A\u2010964.\u00a0\n\u00a0 600.\u00a0\u00a0Swaminathan \u00a0S,\u00a0Padmapriyadarsini \u00a0C,\u00a0Venkatesan \u00a0P,\u00a0Narendran \u00a0G,\u00a0Kumar\u00a0R,\u00a0Iliayas\u00a0S\u00a0et\u00a0al.\u00a0\nOnce\u2010daily\u00a0nevirapine \u00a0vs\u00a0efavirenz\u00a0in\u00a0the\u00a0treatment \u00a0of\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0TB:\u00a0A\u00a0ran\u2010\ndomized\u00a0clinical\u00a0trial.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0Februa\u2010\nry\u00a02009;\u00a0Montreal \u00a02009;\u00a0Abstract\u00a035.\u00a0\n\u00a0 601.\u00a0\u00a0Ello\u00a0F,\u00a0Bissagnene \u00a0E,\u00a0Eholi\u00e9\u00a0S,\u00a0Polneau\u00a0S,\u00a0Moutom\u00e9 \u00a0K,\u00a0Tanon\u00a0A\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0clinical\u00a0\ntrial\u00a0of\u00a0efavirenz\u00a0600mg/day \u00a0versus\u00a0800mg/day \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0tuberculosis \u00a0re\u2010\nceiving\u00a0rifampicin \u00a0in\u00a0Abidjan\u00a0(Cote\u00a0d'Ivoire).\u00a05th\u00a0International \u00a0AIDS\u00a0Society\u00a0Conference \u00a0on\u00a0HIV\u00a0\nPathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention \u00a0Cape\u00a0Town,\u00a0South\u00a0Africa\u00a0July\u00a019\u201022,\u00a02009\u00a02009;\u00a0\nAbstract\u00a0TUPEB142. \u00a0\n\u00a0 602.\u00a0\u00a0Boulle\u00a0A,\u00a0van\u00a0CG,\u00a0Cohen\u00a0K,\u00a0Hilderbrand \u00a0K,\u00a0Mathee\u00a0S,\u00a0Abrahams \u00a0M\u00a0et\u00a0al.\u00a0Outcomes \u00a0of\u00a0nevira\u2010\npine\u2010\u00a0and\u00a0efavirenz\u2010based\u00a0antiretroviral \u00a0therapy\u00a0when\u00a0coadministered \u00a0with\u00a0rifampicin \u2010based\u00a0\nantitubercular \u00a0therapy.\u00a0Jama\u00a02008;\u00a0300(5):530 \u2010539.\u00a0\n\u00a0 603.\u00a0\u00a0Brainard\u00a0DM,\u00a0Petry\u00a0AS,\u00a0Fang\u00a0L,\u00a0Lui\u00a0C,\u00a0Breidinger \u00a0SA,\u00a0Denoia\u00a0EP\u00a0et\u00a0al.\u00a0Lack\u00a0of\u00a0a\u00a0clinically\u00a0impor\u2010\ntant\u00a0effect\u00a0of\u00a0rifabutin\u00a0on\u00a0raltegravir \u00a0pharmacokinetics. \u00a049th\u00a0ICAAC\u00a0San\u00a0Francisco, \u00a0CA\u00a0,\u00a0Sep\u2010\ntember\u00a012\u201015,\u00a02009\u00a02009;\u00a0Abstract\u00a0A1\u20101296.\u00a0\n\u00a0 604.\u00a0\u00a0Jenny\u2010Avital\u00a0ER,\u00a0Joseph\u00a0K.\u00a0Rifamycin \u2010resistant\u00a0Mycobacterium \u00a0tuberculosis \u00a0in\u00a0the\u00a0highly\u00a0acti\u2010\nve\u00a0antiretroviral \u00a0therapy\u00a0era:\u00a0a\u00a0report\u00a0of\u00a03\u00a0relapses\u00a0with\u00a0acquired\u00a0rifampin\u00a0resistance \u00a0follo\u2010\nwing\u00a0alternate\u2010day\u00a0rifabutin\u00a0and\u00a0boosted\u00a0protease\u00a0inhibitor\u00a0therapy.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02009;\u00a0\n48(10):1471 \u20101474.\u00a0\n\u00a0 605.\u00a0\u00a0van\u00a0Heeswijk\u00a0R,\u00a0Hoetelmans \u00a0R,\u00a0Aharchi\u00a0F,\u00a0Stevens\u00a0M,\u00a0Peeters\u00a0M,\u00a0Williams\u00a0P\u00a0et\u00a0al.\u00a0The\u00a0Phar\u2010\nmacokinetic \u00a0Interaction \u00a0between\u00a0Atorvastatin \u00a0and\u00a0TMC278,\u00a0a\u00a0Next\u00a0Generation \u00a0Non\u2010\nnucleoside \u00a0Reverse\u00a0Transcriptase \u00a0Inhibitor\u00a0(NNRTI),\u00a0in\u00a0HIV\u2010negative\u00a0Volunteers. \u00a011th\u00a0Europe\u2010\nan\u00a0AIDS\u00a0Conference \u00a0/EACS.Madrid, \u00a0Spain,\u00a0October\u00a024\u201027,\u00a02007\u00a0[abstract\u00a0P4.3/04]\u00a0\n\u00a0 606.\u00a0\u00a0Sch\u00f6ller\u2010Gy\u00fcre\u00a0M,\u00a0Kakuda\u00a0NT,\u00a0De\u00a0Smedt\u00a0G,\u00a0Woodfall\u00a0B,\u00a0Bollen\u00a0S,\u00a0Peeters\u00a0M\u00a0et\u00a0al.\u00a0Pharmaco \u2010\nkinetic\u00a0interaction \u00a0between\u00a0the\u00a0non\u2010nucleoside \u00a0reverse\u00a0transcriptase \u00a0inhibitor\u00a0TMC125\u00a0and\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 143 \n atorvastatin \u00a0in\u00a0HIV\u2010negative\u00a0volunteers. \u00a04th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0\nand\u00a0Prevention.Sydney, \u00a0Australia, \u00a022\u201025\u00a0July,\u00a02007\u00a0Abstract\u00a0WEPEA106 \u00a0\n\u00a0 607.\u00a0\u00a0Gallagher \u00a0DP,\u00a0Kieran\u00a0J,\u00a0Sheehan\u00a0G,\u00a0Lambert\u00a0J,\u00a0Mahon\u00a0N,\u00a0Mallon\u00a0PW.\u00a0Ritonavir\u2010boosted\u00a0ata\u2010\nzanavir,\u00a0methadone, \u00a0and\u00a0ventricular \u00a0tachycardia: \u00a02\u00a0case\u00a0reports.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02008;\u00a0\n47(3):e36 \u2010e38.\u00a0\n\u00a0 608.\u00a0\u00a0Bruce\u00a0R,\u00a0Altice\u00a0F,\u00a0Moody\u00a0D,\u00a0Lin\u00a0S,\u00a0Fanf\u00a0W,\u00a0Sabo\u00a0JS\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0interactions \u00a0betwe\u2010\nen\u00a0buprenorphine/naloxone \u00a0and\u00a0tipranavir/ritonavir \u00a0in\u00a0HIV\u2010negative\u00a0subjects\u00a0chronically \u00a0re\u2010\nceiving\u00a0buprenorphine/naloxone \u00a0[a].\u00a048th\u00a0Annual\u00a0ICCAC/IDSA \u00a046th\u00a0Annual\u00a0Meeting;\u00a0October\u00a0\n25\u201028,\u00a02008;\u00a0Washington, \u00a0DC\u00a02008;\u00a0Abstract\u00a0A\u2010967a.\u00a0\n\u00a0 609.\u00a0\u00a0Sekar\u00a0VJ,\u00a0Tomaka\u00a0F,\u00a0Meyvisch \u00a0P,\u00a0De\u00a0Pauw\u00a0M,\u00a0Spinosa\u2010Guzman\u00a0S,\u00a0Vangeneugden \u00a0T\u00a0et\u00a0al.\u00a0\nPharmacokinetic \u00a0interaction \u00a0between\u00a0darunavir \u00a0in\u00a0combination \u00a0with\u00a0low\u2010dose\u00a0ritonavir\u00a0and\u00a0\nbuprenorphine/naloxone. \u00a049th\u00a0ICAAC\u00a0San\u00a0Francisco, \u00a0CA\u00a0,\u00a0September \u00a012\u201015,\u00a02009\u00a02009;\u00a0\u00a0Abs\u2010\ntract\u00a0H\u2010232.\u00a0\n\u00a0 610.\u00a0\u00a0Baker\u00a0J,\u00a0Gruber\u00a0VA,\u00a0Moody\u00a0DE,\u00a0Morse\u00a0GD,\u00a0Ma\u00a0Q,\u00a0Arenander \u00a0JN\u00a0et\u00a0al.\u00a0Interactions \u00a0between\u00a0\nbuprenorphine \u00a0and\u00a0antiretrovirals: \u00a0Nucleos(t)ide \u00a0reverse\u00a0transcriptase \u00a0inhibitors \u00a0didanosine, \u00a0\nlamivudine \u00a0and\u00a0tenofovir. \u00a049th\u00a0ICAAC\u00a0San\u00a0Francisco, \u00a0CA\u00a0,\u00a0September \u00a012\u201015,\u00a02009\u00a02009;\u00a0Abs\u2010\ntract\u00a0A1\u20101306.\u00a0\n\u00a0 611.\u00a0\u00a0Anderson \u00a0MS,\u00a0Luk\u00a0JM,\u00a0Hanley\u00a0WD,\u00a0Jin\u00a0B,\u00a0Reisenberg \u00a0RA,\u00a0Wenning\u00a0LA\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0raltegra\u2010\nvir\u00a0on\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0methadone. \u00a049th\u00a0ICAAC\u00a0San\u00a0Francisco, \u00a0CA\u00a0,\u00a0September \u00a012\u201015,\u00a0\n2009\u00a02009;\u00a0Abstract\u00a0A1\u20101295.\u00a0\n\u00a0 612.\u00a0\u00a0Guaraldi\u00a0G,\u00a0Cocchi\u00a0S,\u00a0Motta\u00a0A,\u00a0Ciaffi\u00a0S,\u00a0Conti\u00a0C,\u00a0Codeluppi \u00a0M\u00a0et\u00a0al.\u00a0Differential \u00a0dose\u00a0adjust\u2010\nments\u00a0of\u00a0immunosuppressants \u00a0after\u00a0resuming \u00a0boosted\u00a0versus\u00a0unboosted \u00a0HIV\u2010protease\u00a0in\u2010\nhibitors\u00a0postliver\u00a0transplant. \u00a0Am\u00a0J\u00a0Transplant \u00a02009;\u00a09(10):2429 \u20102434.\u00a0\n\u00a0 613.\u00a0\u00a0Krishna\u00a0G,\u00a0Moton\u00a0A,\u00a0Ma\u00a0L,\u00a0Martinho \u00a0M,\u00a0Seiberling \u00a0M,\u00a0McLeod\u00a0J.\u00a0Effects\u00a0of\u00a0oral\u00a0posaconazole \u00a0\non\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0atazanavir \u00a0alone\u00a0and\u00a0with\u00a0ritonavir\u00a0or\u00a0with\u00a0efavirenz\u00a0in\u00a0healthy\u00a0\nadult\u00a0volunteers. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(4):437 \u2010444.\u00a0\n\u00a0 614.\u00a0\u00a0Sekar\u00a0VJ,\u00a0Lefebvre\u00a0E,\u00a0De\u00a0PE,\u00a0De\u00a0MT,\u00a0De\u00a0PM,\u00a0Parys\u00a0W\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0interaction \u00a0bet\u2010\nween\u00a0darunavir \u00a0boosted\u00a0with\u00a0ritonavir\u00a0and\u00a0omeprazole \u00a0or\u00a0ranitidine \u00a0in\u00a0human\u00a0immunodefi \u2010\nciency\u00a0virus\u2010negative\u00a0healthy\u00a0volunteers. \u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02007;\u00a051(3):958 \u2010961.\u00a0\n\u00a0 615.\u00a0\u00a0Sekar\u00a0V,\u00a0Kestens\u00a0D,\u00a0Spinosa\u2010Guzman\u00a0S,\u00a0De\u00a0PM,\u00a0De\u00a0PE,\u00a0Vangeneugden \u00a0T\u00a0et\u00a0al.\u00a0The\u00a0effect\u00a0of\u00a0\ndifferent\u00a0meal\u00a0types\u00a0on\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0darunavir \u00a0(TMC114)/ritonavir \u00a0in\u00a0HIV\u2010\nnegative\u00a0healthy\u00a0volunteers. \u00a0J\u00a0Clin\u00a0Pharmacol \u00a02007;\u00a047(4):479 \u2010484.\u00a0\n\u00a0 616.\u00a0\u00a0Sekar\u00a0VJ,\u00a0Lefebvre\u00a0E,\u00a0De\u00a0MT,\u00a0Spinosa\u2010Guzman\u00a0S,\u00a0De\u00a0PM,\u00a0De\u00a0PE\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0of\u00a0\ndarunavir \u00a0(TMC114) \u00a0and\u00a0atazanavir \u00a0during\u00a0coadministration \u00a0in\u00a0HIV\u2010negative,\u00a0healthy\u00a0volun\u2010\nteers.\u00a0Drugs\u00a0R\u00a0D\u00a02007;\u00a08(4):241\u2010248.\u00a0\n\u00a0 617.\u00a0\u00a0Hoetelmans \u00a0RM,\u00a0Marien\u00a0K,\u00a0De\u00a0PM,\u00a0Hill\u00a0A,\u00a0Peeters\u00a0M,\u00a0Sekar\u00a0V\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0interac\u2010\ntion\u00a0between\u00a0TMC114/ritonavir \u00a0and\u00a0tenofovir\u00a0disoproxil \u00a0fumarate \u00a0in\u00a0healthy\u00a0volunteers. \u00a0Br\u00a0J\u00a0\nClin\u00a0Pharmacol \u00a02007;\u00a064(5):655 \u2010661.\u00a0\n\u00a0 618.\u00a0\u00a0Scholler\u2010Gyure\u00a0M,\u00a0Kakuda\u00a0TN,\u00a0Sekar\u00a0V,\u00a0Woodfall\u00a0B,\u00a0de\u00a0SG,\u00a0Lefebvre\u00a0E\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0\nof\u00a0darunavir/ritonavir \u00a0and\u00a0TMC125\u00a0alone\u00a0and\u00a0coadministered \u00a0in\u00a0HIV\u2010negative\u00a0volunteers. \u00a0An\u2010\ntivir\u00a0Ther\u00a02007;\u00a012(5):789 \u2010796.\u00a0\n\u00a0 619.\u00a0\u00a0Sekar\u00a0VJ,\u00a0Spinosa\u2010Guzman\u00a0S,\u00a0De\u00a0PE,\u00a0De\u00a0PM,\u00a0Vangeneugden \u00a0T,\u00a0Lefebvre\u00a0E\u00a0et\u00a0al.\u00a0Daruna\u2010\nvir/ritonavir \u00a0pharmacokinetics \u00a0following \u00a0coadministration \u00a0with\u00a0clarithromycin \u00a0in\u00a0healthy\u00a0vo\u2010\nlunteers.\u00a0J\u00a0Clin\u00a0Pharmacol \u00a02008;\u00a048(1):60\u201065.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 144 \n \u00a0 620.\u00a0\u00a0Sekar\u00a0VJ,\u00a0Lefebvre\u00a0E,\u00a0De\u00a0PM,\u00a0Vangeneugden \u00a0T,\u00a0Hoetelmans \u00a0RM.\u00a0Pharmacokinetics \u00a0of\u00a0daruna\u2010\nvir/ritonavir \u00a0and\u00a0ketoconazole \u00a0following \u00a0co\u2010administration \u00a0in\u00a0HIV\u2010healthy\u00a0volunteers. \u00a0Br\u00a0J\u00a0Clin\u00a0\nPharmacol \u00a02008;\u00a066(2):215 \u2010221.\u00a0\n\u00a0 621.\u00a0\u00a0Sekar\u00a0V,\u00a0Lefebvre\u00a0E,\u00a0De\u00a0MT,\u00a0De\u00a0PM,\u00a0De\u00a0PE,\u00a0Vangeneugden \u00a0T\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0repeated\u00a0doses\u00a0of\u00a0\ndarunavir \u00a0plus\u00a0low\u2010dose\u00a0ritonavir\u00a0on\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0sildenafil\u00a0in\u00a0healthy\u00a0male\u00a0sub\u2010\njects:\u00a0phase\u00a0I\u00a0randomized, \u00a0open\u2010label,\u00a0two\u2010way\u00a0crossover \u00a0study.\u00a0Clin\u00a0Drug\u00a0Investig\u00a02008;\u00a0\n28(8):479 \u2010485.\u00a0\n\u00a0 622.\u00a0\u00a0Sekar\u00a0VJ,\u00a0Lefebvre\u00a0E,\u00a0Guzman\u00a0SS,\u00a0Felicione\u00a0E,\u00a0De\u00a0PM,\u00a0Vangeneugden \u00a0T\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0\ninteraction \u00a0between\u00a0ethinyl\u00a0estradiol, \u00a0norethindrone \u00a0and\u00a0darunavir \u00a0with\u00a0low\u2010dose\u00a0ritonavir\u00a0\nin\u00a0healthy\u00a0women.\u00a0Antivir\u00a0Ther\u00a02008;\u00a013(4):563 \u2010569.\u00a0\n\u00a0 623.\u00a0\u00a0Corona\u00a0G,\u00a0Vaccher\u00a0E,\u00a0Sandron\u00a0S,\u00a0Sartor\u00a0I,\u00a0Tirelli\u00a0U,\u00a0Innocenti \u00a0F\u00a0et\u00a0al.\u00a0Lopinavir\u2010ritonavir\u00a0dra\u2010\nmatically\u00a0affects\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0irinotecan \u00a0in\u00a0HIV\u00a0patients\u00a0with\u00a0Kaposi's\u00a0sarcoma.\u00a0\nClin\u00a0Pharmacol \u00a0Ther\u00a02008;\u00a083(4):601 \u2010606.\u00a0\n\u00a0 624.\u00a0\u00a0Hogeland \u00a0GW,\u00a0Swindells \u00a0S,\u00a0McNabb\u00a0JC,\u00a0Kashuba\u00a0AD,\u00a0Yee\u00a0GC,\u00a0Lindley\u00a0CM.\u00a0Lopinavir/ritonavir \u00a0\nreduces\u00a0bupropion \u00a0plasma\u00a0concentrations \u00a0in\u00a0healthy\u00a0subjects.\u00a0Clin\u00a0Pharmacol \u00a0Ther\u00a02007;\u00a0\n81(1):69\u201075.\u00a0\n\u00a0 625.\u00a0\u00a0Bhumbra\u00a0NA,\u00a0Sahloff\u00a0EG,\u00a0Oehrtman \u00a0SJ,\u00a0Horner\u00a0JM.\u00a0Exogenous \u00a0Cushing\u00a0syndrome \u00a0with\u00a0in\u2010\nhaled\u00a0fluticasone \u00a0in\u00a0a\u00a0child\u00a0receiving\u00a0lopinavir/ritonavir. \u00a0Ann\u00a0Pharmacother \u00a02007;\u00a041(7):1306 \u2010\n1309.\u00a0\n\u00a0 626.\u00a0\u00a0Pessanha \u00a0TM,\u00a0Campos\u00a0JM,\u00a0Barros\u00a0AC,\u00a0Pone\u00a0MV,\u00a0Garrido\u00a0JR,\u00a0Pone\u00a0SM.\u00a0Iatrogenic \u00a0Cushing's \u00a0\nsyndrome \u00a0in\u00a0a\u00a0adolescent \u00a0with\u00a0AIDSs\u00a0on\u00a0ritonavir\u00a0and\u00a0inhaled\u00a0fluticasone. \u00a0Case\u00a0report\u00a0and\u00a0li\u2010\nterature\u00a0review.\u00a0AIDS\u00a02007;\u00a021(4):529 \u2010532.\u00a0\n\u00a0 627.\u00a0\u00a0Bonora\u00a0S,\u00a0Calcagno\u00a0A,\u00a0Fontana\u00a0S,\u00a0D'Avolio\u00a0A,\u00a0Siccardi\u00a0M,\u00a0Gobbi\u00a0F\u00a0et\u00a0al.\u00a0Clinically\u00a0significant \u00a0\ndrug\u00a0interaction \u00a0between\u00a0tipranavir \u2010ritonavir\u00a0and\u00a0phenobarbital \u00a0in\u00a0an\u00a0HIV\u2010infected\u00a0subject.\u00a0\nClin\u00a0Infect\u00a0Dis\u00a02007;\u00a045(12):1654 \u20101655.\u00a0\n\u00a0 628.\u00a0\u00a0Spak\u00a0CW,\u00a0Dhanireddy \u00a0S,\u00a0Kosel\u00a0BW.\u00a0Clinical\u00a0interaction \u00a0between\u00a0efavirenz\u00a0and\u00a0phenytoin. \u00a0\nAIDS\u00a02008;\u00a022(1):164 \u2010165.\u00a0\n\u00a0 629.\u00a0\u00a0Tappouni \u00a0HL,\u00a0Rublein\u00a0JC,\u00a0Donovan\u00a0BJ,\u00a0Hollowell \u00a0SB,\u00a0Tien\u00a0HC,\u00a0Min\u00a0SS\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0omeprazo \u2010\nle\u00a0on\u00a0the\u00a0plasma\u00a0concentrations \u00a0of\u00a0indinavir\u00a0when\u00a0administered \u00a0alone\u00a0and\u00a0in\u00a0combination \u00a0\nwith\u00a0ritonavir.\u00a0Am\u00a0J\u00a0Health\u00a0Syst\u00a0Pharm\u00a02008;\u00a065(5):422 \u2010428.\u00a0\n\u00a0 630.\u00a0\u00a0Moreno\u00a0A,\u00a0Barcena\u00a0R,\u00a0Quereda\u00a0C,\u00a0Casado\u00a0JL,\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Fortun\u00a0J\u00a0et\u00a0al.\u00a0Safe\u00a0use\u00a0of\u00a0ralte\u2010\ngravir\u00a0and\u00a0sirolimus\u00a0in\u00a0an\u00a0HIV\u2010infected\u00a0patient\u00a0with\u00a0renal\u00a0impairment \u00a0after\u00a0orthotopic \u00a0liver\u00a0\ntransplantation. \u00a0AIDS\u00a02008;\u00a022(4):547 \u2010548.\u00a0\n\u00a0 631.\u00a0\u00a0Sekar\u00a0V,\u00a0Tomaka\u00a0F,\u00a0Lavreys\u00a0L,\u00a0Meyvisch \u00a0P,\u00a0Bleys\u00a0C,\u00a0Da\u00a0Pawn\u00a0M\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0interac\u2010\ntion\u00a0between\u00a0darunavir \u00a0in\u00a0combination \u00a0with\u00a0low\u2010dose\u00a0ritonavir\u00a0(DRV/r)\u00a0and\u00a0carbamazepine. \u00a0\n17th\u00a0International \u00a0AIDS\u00a0Conference; \u00a03\u20108\u00a0August,\u00a02008;\u00a0Mexico\u00a0DF.\u00a0(Abstract\u00a0A\u2010072\u20100082\u2010\n08423)\u00a0\n\u00a0 632.\u00a0\u00a0Sch\u00f6ller\u2010Gy\u00fcre\u00a0M,\u00a0Kakuda\u00a0NT,\u00a0Van\u00a0Solingen\u2010Ristea\u00a0RM,\u00a0Onkelinx\u00a0J,\u00a0De\u00a0Smedt\u00a0G,\u00a0Peeters\u00a0M\u00a0et\u00a0\nal.\u00a0No\u00a0clinically\u00a0relevant\u00a0effect\u00a0of\u00a0etravirine \u00a0on\u00a0digoxin\u00a0pharmacokinetics \u00a0in\u00a0HIV\u2010negative\u00a0vo\u2010\nlunteers.\u00a09th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy.New \u00a0Orleans,\u00a0\nLA,\u00a02008\u00a0[Abstract\u00a0P22]\u00a0\n\u00a0 633.\u00a0\u00a0Vfend\u00ae\u00a0(voriconazol). \u00a0Informaci\u00f3n \u00a0t\u00e9cnica\u00a0del\u00a0producto. \u00a0Agencia\u00a0Europea\u00a0del\u00a0Medicamento \u00a0\n(EMEA).\u00a0Revisado: \u00a026/10/2006. \u00a0Disponible \u00a0en:\u00a0\nhttp://www.emea.europa.eu/humando cs/PDFs/EPAR/vfe nd/404901es1.pdf \u00a0(Acceso\u00a08.12.09)\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 145 \n \u00a0 634.\u00a0\u00a0Ciraci\u00a0E,\u00a0Villani\u00a0P,\u00a0Stano\u00a0F,\u00a0Cusato\u00a0M,\u00a0Heichen\u00a0M,\u00a0Monno\u00a0L\u00a0et\u00a0al.\u00a0Efficacy\u00a0and\u00a0safety\u00a0of\u00a0TDM\u2010\nassisted\u00a0combination \u00a0therapy\u00a0with\u00a0voriconazole \u00a0plus\u00a0efavirenz\u00a0in\u00a0AIDS\u00a0patients\u00a0with\u00a0crypto\u2010\ncoccosis.\u00a09th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy.New \u00a0Orleans,\u00a0\nLA,\u00a02008\u00a0[Abstract\u00a0\u00a0P18]\u00a0\n\u00a0 635.\u00a0\u00a0Sch\u00f6ller\u2010Gy\u00fcre\u00a0M,\u00a0Kakuda\u00a0NT,\u00a0Bollen\u00a0S,\u00a0De\u00a0Smedt\u00a0G,\u00a0Woodfall\u00a0B,\u00a0Peeters\u00a0et\u00a0al.\u00a0No\u00a0Pharmaco \u2010\nkinetic\u00a0Interaction \u00a0between\u00a0TMC125\u00a0and\u00a0Paroxetine \u00a0in\u00a0HIV\u2010negative\u00a0Volunteers. \u00a011th\u00a0Euro\u2010\npean\u00a0AIDS\u00a0Conference \u00a0/EACS.Madrid, \u00a0Spain,\u00a0October\u00a024\u201027,\u00a02007\u00a0[abstract\u00a0P4.3/01]\u00a0\n\u00a0 636.\u00a0\u00a0Moton\u00a0A,\u00a0Ma\u00a0L,\u00a0Krishna\u00a0G,\u00a0Martinho \u00a0M,\u00a0Seigberling \u00a0M,\u00a0McLeod\u00a0J.\u00a0Pharmacokinetics \u00a0of\u00a0the\u00a0\nAntifungal \u00a0Triazole\u00a0Posaconazole \u00a0and\u00a0the\u00a0NRTI\u00a0Efavirenz\u00a0when\u00a0Coadministered \u00a0in\u00a0Healthy\u00a0\nAdult\u00a0Volunteers. \u00a011th\u00a0European \u00a0AIDS\u00a0Conference \u00a0/EACS.Madrid, \u00a0Spain,\u00a0October\u00a024\u201027,\u00a02007\u00a0\n[abstract\u00a0P4.3/05]\u00a0\n\u00a0 637.\u00a0\u00a0Moreno\u00a0A,\u00a0Quereda\u00a0C,\u00a0Muriel\u00a0A,\u00a0P\u00e9rez\u2010Elias\u00a0M,\u00a0Casado\u00a0J,\u00a0Dronda\u00a0F\u00a0et\u00a0al.\u00a0Does\u00a0the\u00a0Choice\u00a0of\u00a0\nNRTI\u00a0Have\u00a0a\u00a0Significant \u00a0Influence \u00a0on\u00a0the\u00a0Outcome \u00a0of\u00a0pegIFN\u00a0plus\u00a0Ribavirin\u00a0among\u00a0HIV/HCV\u2010\nco\u2010infected\u00a0Patients? \u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0Februa\u2010\nry\u00a02008;\u00a0Boston,\u00a0Massachusetts \u00a0[abstract\u00a01075]\u00a0\n\u00a0 638.\u00a0\u00a0Mira\u00a0J,\u00a0L\u00f3pez\u2010Cort\u00e9s\u00a0L,\u00a0Barreiro\u00a0P,\u00a0Tural\u00a0C,\u00a0Torres\u2010Tortosa\u00a0M,\u00a0de\u00a0los\u00a0Santos\u00a0Gil\u00a0I\u00a0et\u00a0al.\u00a0Efficacy\u00a0\nof\u00a0Pegylated \u00a0Interferon \u00a0+\u00a0Ribavirin\u00a0Treatment \u00a0in\u00a0HIV/HCV\u2010co\u2010infected\u00a0Patients\u00a0Receiving \u00a0Aba\u2010\ncavir\u00a0+\u00a0Lamivudine \u00a0or\u00a0Tenofovir \u00a0+\u00a0either\u00a0Lamivudine \u00a0or\u00a0Emtricitabine \u00a0as\u00a0Nucleoside \u00a0Analogue \u00a0\nBackbone. \u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a02008;\u00a0\nBoston,\u00a0Massachusetts \u00a0(abstract\u00a01074)\u00a0\n\u00a0 639.\u00a0\u00a0Goanz\u00e1lez \u2010Garc\u00eda\u00a0JJ,\u00a0Berenguer \u00a0J,\u00a0Condes\u00a0E,\u00a0Quereda\u00a0C,\u00a0Labarga\u00a0P,\u00a0Laguno\u00a0M\u00a0et\u00a0al.\u00a0The\u00a0Use\u00a0of\u00a0\nTDF+\u00a03TC/\u00a0FTC\u00a0Is\u00a0Associated \u00a0with\u00a0an\u00a0Improved \u00a0Response \u00a0to\u00a0Pegylated \u00a0Interferon \u00a0+\u00a0Ribavirin\u00a0\nin\u00a0HIV/HCV\u2010co\u2010infected\u00a0Patients\u00a0Receiving \u00a0HAART:\u00a0The\u00a0Gesida\u00a050/06\u00a0Study.\u00a015th\u00a0Conference \u00a0\non\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a02008;\u00a0Boston,\u00a0Massachusetts \u00a0[abs\u2010\ntract\u00a01076]\u00a0\n\u00a0 640.\u00a0\u00a0Koo\u00a0HL,\u00a0Hamill\u00a0RJ,\u00a0Andrade\u00a0RA.\u00a0Drug\u2010drug\u00a0interaction \u00a0between\u00a0itraconazole \u00a0and\u00a0efavirenz\u00a0in\u00a0\na\u00a0patient\u00a0with\u00a0AIDS\u00a0and\u00a0disseminated \u00a0histoplasmosis. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02007;\u00a045(6):e77 \u2010e79.\u00a0\n\u00a0 641.\u00a0\u00a0Back\u00a0D,\u00a0Sekar\u00a0V,\u00a0Hoetelmans \u00a0RM.\u00a0Darunavir: \u00a0pharmacokinetics \u00a0and\u00a0drug\u00a0interactions. \u00a0Antivir\u00a0\nTher\u00a02008;\u00a013(1):1\u201013.\u00a0\n\u00a0 642.\u00a0\u00a0Iwamoto\u00a0M,\u00a0Kassahun \u00a0K,\u00a0Troyer\u00a0MD,\u00a0Hanley\u00a0WD,\u00a0Lu\u00a0P,\u00a0Rhoton\u00a0A\u00a0et\u00a0al.\u00a0Lack\u00a0of\u00a0a\u00a0pharmacoki \u2010\nnetic\u00a0effect\u00a0of\u00a0raltegravir \u00a0on\u00a0midazolam: \u00a0in\u00a0vitro/in\u00a0vivo\u00a0correlation. \u00a0J\u00a0Clin\u00a0Pharmacol \u00a02008;\u00a0\n48(2):209 \u2010214.\u00a0\n\u00a0 643.\u00a0\u00a0Knoll\u00a0BM,\u00a0Vento\u00a0S,\u00a0Temesgen \u00a0Z.\u00a0Etravirine. \u00a0Drugs\u00a0Today\u00a0(Barc\u00a0)\u00a02008;\u00a044(1):23\u201033.\u00a0\n\u00a0 644.\u00a0\u00a0Ji\u00a0P,\u00a0Damle\u00a0B,\u00a0Xie\u00a0J,\u00a0Unger\u00a0SE,\u00a0Grasela\u00a0DM,\u00a0Kaul\u00a0S.\u00a0Pharmacokinetic \u00a0interaction \u00a0between\u00a0efavi\u2010\nrenz\u00a0and\u00a0carbamazepine \u00a0after\u00a0multiple\u2010dose\u00a0administration \u00a0in\u00a0healthy\u00a0subjects.\u00a0J\u00a0Clin\u00a0Phar\u2010\nmacol\u00a02008;\u00a048(8):948 \u2010956.\u00a0\n\u00a0 645.\u00a0\u00a0Chiu\u00a0YL,\u00a0Klein\u00a0CE,\u00a0Woodward \u00a0WC,\u00a0King\u00a0KR,\u00a0Naylor\u00a0C,\u00a0Awni\u00a0W\u00a0et\u00a0al.\u00a0Lack\u00a0of\u00a0effect\u00a0of\u00a0gastric\u00a0\nacid\u2010reducing\u00a0agents\u00a0on\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0lopinavir/ritonavir \u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0\nAIDS\u00a0Patient\u00a0Care\u00a0STDS\u00a02007;\u00a021(4):247 \u2010251.\u00a0\n\u00a0 646.\u00a0\u00a0Luber\u00a0AD,\u00a0Brower\u00a0R,\u00a0Kim\u00a0D,\u00a0Silverman \u00a0R,\u00a0Peloquin\u00a0CA,\u00a0Frank\u00a0I.\u00a0Steady\u2010state\u00a0pharmacokinetics \u00a0\nof\u00a0once\u2010daily\u00a0fosamprenavir/ritonavir \u00a0and\u00a0atazanavir/ritonavir \u00a0alone\u00a0and\u00a0in\u00a0combination \u00a0with\u00a0\n20\u00a0mg\u00a0omeprazole \u00a0in\u00a0healthy\u00a0volunteers. \u00a0HIV\u00a0Med\u00a02007;\u00a08(7):457\u2010464.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 146 \n \u00a0 647.\u00a0\u00a0Van\u00a0der\u00a0Lee\u00a0MJ,\u00a0Blenke\u00a0AA,\u00a0Rongen\u00a0GA,\u00a0Verwey\u2010van\u00a0Wissen\u00a0CP,\u00a0Koopmans \u00a0PP,\u00a0Pharo\u00a0C\u00a0et\u00a0al.\u00a0\nInteraction \u00a0study\u00a0of\u00a0the\u00a0combined \u00a0use\u00a0of\u00a0paroxetine \u00a0and\u00a0fosamprenavir \u2010ritonavir\u00a0in\u00a0healthy\u00a0\nsubjects.\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02007;\u00a051(11):4098 \u20104104.\u00a0\n\u00a0 648.\u00a0\u00a0Cance\u2010Katz\u00a0EF,\u00a0Moody\u00a0DE,\u00a0Morse\u00a0GD,\u00a0Ma\u00a0Q,\u00a0DiFrancesco \u00a0R,\u00a0Friedland \u00a0G\u00a0et\u00a0al.\u00a0Interaction \u00a0\nbetween\u00a0buprenorphine \u00a0and\u00a0atazanavir \u00a0or\u00a0atazanavir/ritonavir. \u00a0Drug\u00a0Alcohol\u00a0Depend\u00a02007;\u00a0\n91(2\u20103):269\u2010278.\u00a0\n\u00a0 649.\u00a0\u00a0Fang\u00a0AF,\u00a0Damle\u00a0BD,\u00a0LaBadie\u00a0RR,\u00a0Crownover \u00a0PH,\u00a0Hewlett\u00a0D,\u00a0Jr.,\u00a0Glue\u00a0PW.\u00a0Significant \u00a0decrease\u00a0\nin\u00a0nelfinavir \u00a0systemic\u00a0exposure\u00a0after\u00a0omeprazole \u00a0coadministration \u00a0in\u00a0healthy\u00a0subjects.\u00a0Phar\u2010\nmacotherapy \u00a02008;\u00a028(1):42\u201050.\u00a0\n\u00a0 650.\u00a0\u00a0Anderson \u00a0MS,\u00a0Wenning\u00a0LA,\u00a0Moreau\u00a0A,\u00a0Kost\u00a0JT,\u00a0Bieberdorf \u00a0FA,\u00a0Stone\u00a0JA\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0ralte\u2010\ngravir\u00a0on\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0oral\u00a0contraceptives. \u00a047th\u00a0Interscience \u00a0Conference \u00a0on\u00a0An\u2010\ntimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy.Chicago, \u00a02007\u00a0abstract\u00a0A\u20101425\u00a0\n\u00a0 651.\u00a0\u00a0Zhang\u00a0J,\u00a0Chung\u00a0E,\u00a0Eley\u00a0T,\u00a0Yones\u00a0C,\u00a0Persson\u00a0A,\u00a0Xu\u00a0X\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0atazanavir/ritonavir \u00a0on\u00a0the\u00a0\npharmacokinetics \u00a0of\u00a0ethinyl\u00a0estradiol\u00a0and\u00a017\u2010deacetyl\u00a0norgestimate \u00a0in\u00a0healthy\u00a0female\u00a0sub\u2010\njects.\u00a047th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy.Chicago, \u00a0\n2007\u00a0abstract\u00a0A\u20101415\u00a0\n\u00a0 652.\u00a0\u00a0Kaeser\u00a0B,\u00a0Zandt\u00a0H,\u00a0Deraet\u00a0M,\u00a0Bour\u00a0F,\u00a0Laudamy\u00a0A,\u00a0Schmitt\u00a0C\u00a0et\u00a0al.\u00a0Ritonavir\u00a0boosted\u00a0saquina\u2010\nvir\u2010ketoconazole \u00a0drug\u2010drug\u00a0interaction. \u00a047th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0\nAgents\u00a0and\u00a0Chemotherapy.Chicago, \u00a02007\u00a0abstract\u00a0A\u20101426\u00a0\n\u00a0 653.\u00a0\u00a0Durant\u00a0J,\u00a0Dellamonica \u00a0P,\u00a0Garraffo\u00a0R,\u00a0Baakili\u00a0A,\u00a0Rouyrre\u00a0N,\u00a0MacGregor \u00a0T\u00a0et\u00a0al.\u00a0The\u00a0effect\u00a0of\u00a0\nTipranavir/Ritonavir \u00a0on\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0Tadalafil\u00a0in\u00a0healthy\u00a0volunteers. \u00a08th\u00a0Interna\u2010\ntional\u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy.Budapest, \u00a0Hungary,\u00a016\u201018\u00a0April,\u00a0\n2007\u00a0abstract\u00a061\u00a0\n\u00a0 654.\u00a0\u00a0Sch\u00f6ller\u2010Gy\u00fcre\u00a0M,\u00a0Debroye\u00a0C,\u00a0Aharchi\u00a0F,\u00a0Woodfall\u00a0B,\u00a0Peeters\u00a0M,\u00a0Vandermeulen \u00a0K\u00a0et\u00a0al.\u00a0No\u00a0\neffect\u00a0of\u00a0TMC125\u00a0on\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0oral\u00a0contraceptives. \u00a08th\u00a0International \u00a0Congress\u00a0\non\u00a0Drug\u00a0Therapy\u00a0in\u00a0HIV\u00a0Infection, \u00a0Glasgow,\u00a02006.\u00a0abstract\u00a0P277\u00a0\n\u00a0 655.\u00a0\u00a0Abel\u00a0S,\u00a0Ridgway\u00a0C,\u00a0Hamlin\u00a0J,\u00a0Davis\u00a0J.\u00a0An\u00a0open,\u00a0parallel\u00a0group\u00a0study\u00a0to\u00a0compare\u00a0the\u00a0pharmaco \u2010\nkinetics,\u00a0safety\u00a0and\u00a0toleration \u00a0of\u00a0a\u00a0single\u00a0oral\u00a0dose\u00a0of\u00a0Maraviroc \u00a0in\u00a0subjects\u00a0with\u00a0mild\u00a0and\u00a0\nmoderate \u00a0hepatic\u00a0impairment \u00a0with\u00a0subjects\u00a0with\u00a0normal\u00a0hepatic\u00a0function.\u00a08th\u00a0International \u00a0\nWorkshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy.Budapest, \u00a0Hungary,\u00a016\u201018\u00a0April,\u00a02007\u00a0\nabstract\u00a08\u00a0\n\u00a0 656.\u00a0\u00a0Agarwala \u00a0S,\u00a0Eley\u00a0T,\u00a0Child\u00a0M,\u00a0Wang\u00a0Y,\u00a0Persson\u00a0A,\u00a0Filoramo\u00a0D\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0of\u00a0Ataza\u2010\nnavir\u00a0in\u00a0severely\u00a0renally\u00a0impaired\u00a0subjects\u00a0including\u00a0those\u00a0on\u00a0hemodialysis. \u00a08th\u00a0International \u00a0\nWorkshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy.Budapest, \u00a0Hungary,\u00a016\u201018\u00a0April,\u00a02007\u00a0\nabstract\u00a02\u00a0\n\u00a0 657.\u00a0\u00a0Barreiro\u00a0P,\u00a0Rodriguez \u2010Novoa\u00a0S,\u00a0Labarga\u00a0P,\u00a0Ruiz\u00a0A,\u00a0Jimenez\u2010Nacher\u00a0I,\u00a0Martin\u2010Carbonero \u00a0L\u00a0et\u00a0al.\u00a0\nInfluence \u00a0of\u00a0liver\u00a0fibrosis\u00a0stage\u00a0on\u00a0plasma\u00a0levels\u00a0of\u00a0antiretroviral \u00a0drugs\u00a0in\u00a0HIV\u2010infected\u00a0pa\u2010\ntients\u00a0with\u00a0chronic\u00a0hepatitis\u00a0C.\u00a0J\u00a0Infect\u00a0Dis\u00a02007;\u00a0195(7):973 \u2010979.\u00a0\n\u00a0 658.\u00a0\u00a0Bossi\u00a0P,\u00a0Peytavin\u00a0G,\u00a0Lamotte\u00a0C,\u00a0Calvez\u00a0V,\u00a0Bricaire\u00a0F,\u00a0Costagliola \u00a0D\u00a0et\u00a0al.\u00a0High\u00a0indinavir\u00a0plasma\u00a0\nconcentrations \u00a0in\u00a0HIV\u2010positive\u00a0patients\u00a0co\u2010infected\u00a0with\u00a0hepatitis\u00a0B\u00a0or\u00a0C\u00a0virus\u00a0treated\u00a0with\u00a0\nlow\u00a0doses\u00a0of\u00a0indinavir\u00a0and\u00a0ritonavir\u00a0(400/100\u00a0mg\u00a0twice\u00a0a\u00a0day)\u00a0plus\u00a0two\u00a0nucleoside \u00a0reverse\u00a0\ntranscriptase \u00a0inhibitors. \u00a0AIDS\u00a02003;\u00a017(7):1108 \u20101110.\u00a0\n\u00a0 659.\u00a0\u00a0Breilh\u00a0D,\u00a0Guinguene \u00a0S,\u00a0de\u00a0Ledinghen \u00a0V,\u00a0Toutain\u00a0J,\u00a0Pellegrin\u00a0JL,\u00a0Trimoulet \u00a0P\u00a0et\u00a0al.\u00a0Pharmacoki \u2010\nnetics\u00a0of\u00a0Boosted\u00a0PI\u00a0and\u00a0NNRTI\u00a0in\u00a0HCV/HIV\u2010co\u2010infected\u00a0Patients.\u00a014th\u00a0Conference \u00a0on\u00a0retrovi\u2010\nrus\u00a0and\u00a0opportunistic \u00a0infections.Los \u00a0Angeles,\u00a02007\u00a0abstract\u00a0946]\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 147 \n \u00a0 660.\u00a0\u00a0Chen\u00a0L,\u00a0Sabo\u00a0JP,\u00a0Philip\u00a0E,\u00a0Mao\u00a0Y,\u00a0Norris\u00a0SH,\u00a0MacGregor \u00a0TR\u00a0et\u00a0al.\u00a0Steady\u2010state\u00a0disposition \u00a0of\u00a0\nthe\u00a0nonpeptidic \u00a0protease\u00a0inhibitor\u00a0tipranavir \u00a0when\u00a0coadministered \u00a0with\u00a0ritonavir.\u00a0Antimicrob \u00a0\nAgents\u00a0Chemother \u00a02007;\u00a051(7):2436 \u20102444.\u00a0\n\u00a0 661.\u00a0\u00a0Damle\u00a0B,\u00a0Hewlett\u00a0D,\u00a0Jr.,\u00a0Hsyu\u00a0PH,\u00a0Becker\u00a0M,\u00a0Petersen\u00a0A.\u00a0Pharmacokinetics \u00a0of\u00a0nelfinavir \u00a0in\u00a0\nsubjects\u00a0with\u00a0hepatic\u00a0impairment. \u00a0J\u00a0Clin\u00a0Pharmacol \u00a02006;\u00a046(11):1241 \u20101249.\u00a0\n\u00a0 662.\u00a0\u00a0Dominguez \u00a0S,\u00a0Benhamou \u00a0Y,\u00a0Katlama\u00a0C,\u00a0Peytavin\u00a0G.\u00a0Nevirapine \u00a0plasma\u00a0concentrations \u00a0in\u00a0\nHIV/HCV\u00a0and\u00a0HIV\u00a0infected\u00a0patients,\u00a0a\u00a0case\u00a0control\u00a0study:\u00a0NEVADOSE. \u00a07th\u00a0International \u00a0\nWorkshop \u00a0of\u00a0Clinical\u00a0Pharmacology.Lisbon, \u00a0Portugal,\u00a0April\u00a020\u201022,\u00a02006.\u00a0Abstract\u00a021\u00a0\n\u00a0 663.\u00a0\u00a0Dragovic\u00a0G,\u00a0Smith\u00a0CJ,\u00a0Jevtovic\u00a0D,\u00a0Grbovic\u00a0L,\u00a0Ypole\u00a0M.\u00a0The\u00a0impact\u00a0of\u00a0HCV/HIV\u00a0co\u2010infection\u00a0on\u00a0\nnevirapine \u00a0plasma\u00a0concentration \u00a0in\u00a0a\u00a0cohort\u00a0of\u00a0patients\u00a0in\u00a0Belgrade. \u00a08th\u00a0International \u00a0\nWorkshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy.Budapest, \u00a0Hungary,\u00a016\u201018\u00a0April,\u00a02007\u00a0\nabstract\u00a04\u00a0\n\u00a0 664.\u00a0\u00a0Gatti\u00a0F,\u00a0Nasta\u00a0P,\u00a0Matti\u00a0A,\u00a0Loregian\u00a0A,\u00a0Pagni\u00a0S,\u00a0Prestini\u00a0K\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0of\u00a0atazanavir \u00a0\nin\u00a0HIV\u20101\u2010HCV\u00a0co\u2010infected\u00a0patients.\u00a04th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0\nPrevention, \u00a0Sydney,\u00a02007\u00a0Abstract\u00a0WEPEB008 \u00a0\n\u00a0 665.\u00a0\u00a0Gatti\u00a0F,\u00a0Pagni\u00a0S,\u00a0Nasta\u00a0P,\u00a0Boldrin\u00a0C,\u00a0Matti\u00a0A,\u00a0Loregian\u00a0A\u00a0et\u00a0al.\u00a0Potential\u00a0role\u00a0of\u00a0TDM\u00a0in\u00a0dosing\u00a0\nprotease\u00a0inhibitors \u00a0in\u00a0HIV\u2010HCV\u00a0co\u2010infected\u00a0patients\u00a0with\u00a0or\u00a0without\u00a0cirrhosis.\u00a025th\u00a0Interna\u2010\ntional\u00a0Congress\u00a0of\u00a0Chemotherapy.Munich, \u00a0March\u00a031\u00a0\u2010\u00a0April\u00a03,\u00a02007.\u00a0Abstact\u00a0N\u00fam.\u00a0\n\u00a0 666.\u00a0\u00a0Gill\u00a0MJ,\u00a0Ostrop\u00a0NJ,\u00a0Fiske\u00a0WD,\u00a0Brennan\u00a0JM.\u00a0Efavirenz\u00a0dosing\u00a0in\u00a0patients\u00a0receiving\u00a0continuous \u00a0\nambulatory \u00a0peritoneal \u00a0dialysis.\u00a0AIDS\u00a02000;\u00a014(8):1062 \u20101064.\u00a0\n\u00a0 667.\u00a0\u00a0Guaraldi\u00a0G,\u00a0Cocchi\u00a0S,\u00a0Motta\u00a0A,\u00a0Ciaffi\u00a0S,\u00a0Codeluppi \u00a0M,\u00a0Bonora\u00a0S\u00a0et\u00a0al.\u00a0A\u00a0pilot\u00a0study\u00a0on\u00a0the\u00a0effi\u2010\ncacy,\u00a0pharmacokinetics \u00a0and\u00a0safety\u00a0of\u00a0atazanavir \u00a0in\u00a0patients\u00a0with\u00a0end\u2010stage\u00a0liver\u00a0disease.\u00a0J\u00a0An\u2010\ntimicrob\u00a0Chemother \u00a02008.\u00a0\n\u00a0 668.\u00a0\u00a0Gupta\u00a0SK,\u00a0Rosenkranz \u00a0SL,\u00a0Cramer\u00a0YS,\u00a0Koletar\u00a0SL,\u00a0Szczech\u00a0LA,\u00a0Amorosa\u00a0V\u00a0et\u00a0al.\u00a0The\u00a0pharmaco \u2010\nkinetics\u00a0and\u00a0pharmacogenomics \u00a0of\u00a0efavirenz\u00a0and\u00a0lopinavir/ritonavir \u00a0in\u00a0HIV\u2010infected\u00a0persons\u00a0\nrequiring\u00a0hemodialysis. \u00a0AIDS\u00a02008;\u00a022(15):1919 \u20101927.\u00a0\n\u00a0 669.\u00a0\u00a0Hermida\u00a0Donate\u00a0JM,\u00a0Quereda\u00a0C,\u00a0Moreno\u00a0A,\u00a0Hernandez \u00a0B,\u00a0Rodriguez \u00a0MA,\u00a0Dronda\u00a0F\u00a0et\u00a0al.\u00a0\nEfficacy\u00a0and\u00a0safety\u00a0of\u00a0atazanavir \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0liver\u00a0cirrhosis.\u00a04th\u00a0IAS\u00a0Confe\u2010\nrence\u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Sydney,\u00a02007\u00a0Abstract\u00a0MOPEB060 \u00a0\n\u00a0 670.\u00a0\u00a0Izzedine\u00a0H,\u00a0Launay\u2010Vacher\u00a0V,\u00a0Jullien\u00a0V,\u00a0Aymard\u00a0G,\u00a0Duvivier\u00a0C,\u00a0Deray\u00a0G.\u00a0Pharmacokinetics \u00a0of\u00a0\ntenofovir\u00a0in\u00a0haemodialysis. \u00a0Nephrol\u00a0Dial\u00a0Transplant \u00a02003;\u00a018(9):1931 \u20101933.\u00a0\n\u00a0 671.\u00a0\u00a0Jayasekara \u00a0D,\u00a0Aweeka\u00a0FT,\u00a0Rodriguez \u00a0R,\u00a0Kalayjian\u00a0RC,\u00a0Humphreys \u00a0MH,\u00a0Gambertoglio \u00a0JG.\u00a0Anti\u2010\nviral\u00a0therapy\u00a0for\u00a0HIV\u00a0patients\u00a0with\u00a0renal\u00a0insufficiency. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a01999;\u00a0\n21(5):384 \u201095.\u00a0\n\u00a0 672.\u00a0\u00a0Katsounas \u00a0A,\u00a0Frank\u00a0A,\u00a0Klinker\u00a0H,\u00a0Langmann \u00a0P.\u00a0Efavirenz\u2010therapy\u00a0in\u00a0HIV\u2010patients\u00a0with\u00a0underl\u2010\nying\u00a0liver\u00a0disease:\u00a0importance \u00a0of\u00a0continuous \u00a0TDM\u00a0of\u00a0EFV.\u00a0Eur\u00a0J\u00a0Med\u00a0Res\u00a02007;\u00a012(8):331 \u2010336.\u00a0\n\u00a0 673.\u00a0\u00a0Kearney\u00a0BP,\u00a0Yale\u00a0K,\u00a0Shah\u00a0J,\u00a0Zhong\u00a0L,\u00a0Flaherty\u00a0JF.\u00a0Pharmacokinetics \u00a0and\u00a0dosing\u00a0recommenda \u2010\ntions\u00a0of\u00a0tenofovir\u00a0disoproxil \u00a0fumarate \u00a0in\u00a0hepatic\u00a0or\u00a0renal\u00a0impairment. \u00a0Clin\u00a0Pharmacokinet \u00a0\n2006;\u00a045(11):1115 \u20101124.\u00a0\n\u00a0 674.\u00a0\u00a0King\u00a0JR,\u00a0Acosta\u00a0EP.\u00a0Tipranavir: \u00a0a\u00a0novel\u00a0nonpeptidic \u00a0protease\u00a0inhibitor\u00a0of\u00a0HIV.\u00a0Clin\u00a0Pharmaco \u2010\nkinet\u00a02006;\u00a045(7):665 \u2010682.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 148 \n \u00a0 675.\u00a0\u00a0Mallolas\u00a0J,\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Ortega\u00a0E,\u00a0Guti\u00e9rrez \u00a0F,\u00a0Felizarta\u00a0F,\u00a0Bleiber\u00a0G\u00a0et\u00a0al.\u00a0Fosamprenavir \u00a0/\u00a0\nritonavir\u00a0dose\u00a0adjustment \u00a0for\u00a0patients\u00a0with\u00a0mild\u00a0and\u00a0moderate \u00a0hepatic\u00a0impairment \u00a0\n(APV10017). \u00a08th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy.Budapest, \u00a0\nHungary,\u00a016\u201018\u00a0April,\u00a02007\u00a0abstract\u00a01\u00a0\n\u00a0 676.\u00a0\u00a0Micheli\u00a0V,\u00a0Regazzi\u00a0M,\u00a0Dickinson \u00a0L,\u00a0Meraviglia \u00a0P,\u00a0Villani\u00a0P,\u00a0Khoo\u00a0SH\u00a0et\u00a0al.\u00a0Lopinavir/ritonavir \u00a0\npharmacokinetics \u00a0in\u00a0HIV/HCV\u2010coinfected \u00a0patients\u00a0with\u00a0or\u00a0without\u00a0cirrhosis.\u00a0Ther\u00a0Drug\u00a0Monit\u00a0\n2008;\u00a030(3):306 \u2010313.\u00a0\n\u00a0 677.\u00a0\u00a0Molto\u00a0J,\u00a0Valle\u00a0M,\u00a0Blanco\u00a0A,\u00a0Negredo\u00a0E,\u00a0Delavarga \u00a0M,\u00a0Miranda\u00a0C\u00a0et\u00a0al.\u00a0Lopinavir/ritonavir \u00a0\npharmacokinetics \u00a0in\u00a0HIV\u00a0and\u00a0hepatitis\u00a0C\u00a0virus\u00a0co\u2010infected\u00a0patients\u00a0without\u00a0liver\u00a0function\u00a0im\u2010\npairment: \u00a0influence \u00a0of\u00a0liver\u00a0fibrosis.\u00a0Clin\u00a0Pharmacokinet \u00a02007;\u00a046(1):85\u201092.\u00a0\n\u00a0 678.\u00a0\u00a0Molto\u00a0J,\u00a0Negredo\u00a0E,\u00a0Kaeser\u00a0B,\u00a0Gel\u00a0S,\u00a0Abt\u00a0M,\u00a0Becker\u00a0M\u00a0et\u00a0al.\u00a0Nelfinavir \u00a0pharmacokinetics \u00a0in\u00a0\npatients\u00a0with\u00a0HIV\u00a0mono\u2010\u00a0and\u00a0HIV\u2010HCV\u00a0co\u2010infection. \u00a08th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0\nPharmacology \u00a0of\u00a0HIV\u00a0Therapy.Budapest, \u00a0Hungary,\u00a016\u201018\u00a0April,\u00a02007\u00a0abstract\u00a09\u00a0\n\u00a0 679.\u00a0\u00a0Morello\u00a0J,\u00a0Garc\u00eda\u2010Gasc\u00f3\u00a0P,\u00a0Blanco\u00a0F,\u00a0Rodriguez \u2010Novoa\u00a0S,\u00a0Barreiro\u00a0P,\u00a0Maida\u00a0I\u00a0et\u00a0al.\u00a0Higher\u00a0\nplasma\u00a0levels\u00a0of\u00a0Tipranavir \u00a0in\u00a0patients\u00a0with\u00a0more\u00a0significant \u00a0liver\u00a0fibrosis\u00a0and\u00a0risk\u00a0of\u00a0liver\u00a0toxi\u2010\ncity.\u00a08th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy.Budapest, \u00a0Hunga\u2010\nry,\u00a016\u201018\u00a0April,\u00a02007\u00a0abstract\u00a035\u00a0\n\u00a0 680.\u00a0\u00a0Paci\u2010Bonaventure \u00a0S,\u00a0Hafi\u00a0A,\u00a0Vincent\u00a0I,\u00a0Quertainmont \u00a0Y,\u00a0Goujard\u00a0C,\u00a0Charpentier \u00a0B\u00a0et\u00a0al.\u00a0Lack\u00a0of\u00a0\nremoval\u00a0of\u00a0nelfinavir \u00a0during\u00a0a\u00a0haemodialysis \u00a0session\u00a0in\u00a0an\u00a0HIV\u20101\u00a0infected\u00a0patient\u00a0with\u00a0hepatic\u00a0\nand\u00a0renal\u00a0insufficiency. \u00a0Nephrol\u00a0Dial\u00a0Transplant \u00a02001;\u00a016:642\u2010643.\u00a0\n\u00a0 681.\u00a0\u00a0Peng\u00a0JZ,\u00a0Pulido\u00a0F,\u00a0Causemaker \u00a0SJ,\u00a0Li\u00a0J,\u00a0Lorenzo\u00a0A,\u00a0Cepeda\u00a0C\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0of\u00a0lopina\u2010\nvir/ritonavir \u00a0in\u00a0HIV/hepatitis \u00a0C\u00a0virus\u2010coinfected \u00a0subjects\u00a0with\u00a0hepatic\u00a0impairment. \u00a0J\u00a0Clin\u00a0\nPharmacol \u00a02006;\u00a046(3):265 \u2010274.\u00a0\n\u00a0 682.\u00a0\u00a0Pereira\u00a0SA,\u00a0Caixas\u00a0U,\u00a0Branco\u00a0T,\u00a0Germano \u00a0I,\u00a0Lampreia \u00a0F,\u00a0Papoila\u00a0AL\u00a0et\u00a0al.\u00a0Efavirenz\u00a0concentra \u2010\ntions\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0and\u00a0without\u00a0viral\u00a0hepatitis. \u00a0Br\u00a0J\u00a0Clin\u00a0Pharmacol \u00a02008.\u00a0\n\u00a0 683.\u00a0\u00a0Pineda\u00a0JA,\u00a0Santos\u00a0J,\u00a0Rivero\u00a0A,\u00a0bdel\u2010Kader\u00a0L,\u00a0Palacios\u00a0R,\u00a0Camacho \u00a0A\u00a0et\u00a0al.\u00a0Liver\u00a0toxicity\u00a0of\u00a0anti\u2010\nretroviral \u00a0combinations \u00a0including\u00a0atazanavir/ritonavir \u00a0in\u00a0patients\u00a0co\u2010infected\u00a0with\u00a0HIV\u00a0and\u00a0\nhepatitis\u00a0viruses:\u00a0impact\u00a0of\u00a0pre\u2010existing\u00a0liver\u00a0fibrosis.\u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02008;\u00a0\n61(4):925 \u2010932.\u00a0\n\u00a0 684.\u00a0\u00a0Regazzi\u00a0M,\u00a0Tinelli\u00a0C,\u00a0Villani\u00a0P,\u00a0Cusato\u00a0M,\u00a0De\u00a0Silvestri\u00a0A,\u00a0Zucchi\u00a0P\u00a0et\u00a0al.\u00a0Predictability \u00a0of\u00a0indivi\u2010\ndual\u00a0Nelfinavir \u00a0concentrations \u00a0at\u00a0different\u00a0time\u00a0points\u00a0for\u00a0total\u00a0systemic\u00a0exposure\u00a0in\u00a0HIV\u00a0and\u00a0\nHIV/HCV\u00a0co\u2010infected\u00a0patients,\u00a0with\u00a0and\u00a0without\u00a0cirrhosis.\u00a06th\u00a0International \u00a0Workshop \u00a0on\u00a0Cli\u2010\nnical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy.Quebec, \u00a0Canada,\u00a0April\u00a028\u201030,\u00a02005.\u00a0Abstract\u00a061\u00a0\n\u00a0 685.\u00a0\u00a0Sch\u00f6ller\u2010Gy\u00fcre\u00a0M,\u00a0Kakuda\u00a0NT,\u00a0De\u00a0Smedt\u00a0G,\u00a0Woodfall\u00a0B,\u00a0Berckmans \u00a0C,\u00a0Peeters\u00a0M\u00a0et\u00a0al.\u00a0Phar\u2010\nmacokinetics \u00a0of\u00a0TMC125\u00a0in\u00a0HIV\u2010negative\u00a0volunteers \u00a0with\u00a0mild\u00a0and\u00a0moderate \u00a0hepatic\u00a0impair\u2010\nment.\u00a047th\u00a0Interscience \u00a0Conference \u00a0on\u00a0Antimicrobial \u00a0Agents\u00a0and\u00a0Chemotherapy.Chicago, \u00a0\n2007\u00a0Abstract\u00a0A\u20101428\u00a0\n\u00a0 686.\u00a0\u00a0Sekar\u00a0VJ,\u00a0Spinosa\u2010Guzman\u00a0S,\u00a0De\u00a0Paepe\u00a0E,\u00a0Stevens\u00a0T,\u00a0Tomaka\u00a0F,\u00a0De\u00a0Pauw\u00a0M\u00a0et\u00a0al.\u00a0Pharmacoki \u2010\nnetics\u00a0of\u00a0multiple\u2010dose\u00a0darunavir \u00a0in\u00a0combination \u00a0with\u00a0low\u2010dose\u00a0ritonavir\u00a0in\u00a0individuals \u00a0with\u00a0\nimpaired\u00a0hepatic\u00a0function.\u00a04th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Preven\u2010\ntion,\u00a0Sydney,\u00a02007\u00a0Abstract\u00a0TUPDB05 \u00a0\n\u00a0 687.\u00a0\u00a0Spagnuolo \u00a0V,\u00a0Gentilini\u00a0G,\u00a0De\u00a0BA,\u00a0Galli\u00a0L,\u00a0Uberti\u2010Foppa\u00a0C,\u00a0Soldarini\u00a0A\u00a0et\u00a0al.\u00a0Liver\u00a0function\u00a0pa\u2010\nrameters\u00a0in\u00a0HIV/HCV\u00a0co\u2010infected\u00a0patients\u00a0treated\u00a0with\u00a0amprenavir \u00a0and\u00a0ritonavir\u00a0and\u00a0correla\u2010\ntion\u00a0with\u00a0plasma\u00a0levels.\u00a0New\u00a0Microbiol \u00a02007;\u00a030(3):279 \u2010282.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 149 \n \u00a0 688.\u00a0\u00a0Taburet\u00a0AM,\u00a0Naveau\u00a0S,\u00a0Zorza\u00a0G,\u00a0Colin\u00a0JN,\u00a0Delfraissy \u00a0JF,\u00a0Chaput\u00a0JC\u00a0et\u00a0al.\u00a0Pharmacokinetics \u00a0of\u00a0\nzidovudine \u00a0in\u00a0patients\u00a0with\u00a0liver\u00a0cirrhosis.\u00a0Clin\u00a0Pharmacol \u00a0Ther\u00a01990;\u00a047(6):731 \u20109.\u00a0\n\u00a0 689.\u00a0\u00a0Tebas\u00a0P,\u00a0Bellos\u00a0N,\u00a0Lucasti\u00a0C,\u00a0Richmond \u00a0G,\u00a0Godofsky \u00a0E,\u00a0Patel\u00a0I\u00a0et\u00a0al.\u00a0Enfuvirtide \u00a0does\u00a0not\u00a0requi\u2010\nre\u00a0dose\u2010adjustment \u00a0in\u00a0patients\u00a0with\u00a0chronic\u00a0renal\u00a0failure:\u00a0the\u00a0results\u00a0of\u00a0a\u00a0pharmacokinetic \u00a0\nstudy\u00a0on\u00a0enfuvirtide \u00a0in\u00a0HIV\u20101\u2010infected\u00a0patients\u00a0with\u00a0inpaired\u00a0renal\u00a0function\u00a0(NP17586). \u00a014th\u00a0\nConference \u00a0on\u00a0retrovirus \u00a0and\u00a0opportunistic \u00a0infections.Los \u00a0Angeles,\u00a02007\u00a0Abstract\u00a0n\u00fam\u00a0\n\u00a0 690.\u00a0\u00a0Veronese \u00a0L,\u00a0Rautaureau \u00a0J,\u00a0Sadler\u00a0BM,\u00a0Gillotin\u00a0C,\u00a0Petite\u00a0JP,\u00a0Pillegand\u00a0B\u00a0et\u00a0al.\u00a0Single\u2010dose\u00a0phar\u2010\nmacokinetics \u00a0of\u00a0amprenavir, \u00a0a\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0protease\u00a0inhibitor,\u00a0in\u00a0\nsubjects\u00a0with\u00a0normal\u00a0or\u00a0impaired\u00a0hepatic\u00a0function.\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02000;\u00a0\n44(4):821 \u20106.\u00a0\n\u00a0 691.\u00a0\u00a0Wyles\u00a0DL,\u00a0Gerber\u00a0JG.\u00a0Antiretroviral \u00a0drug\u00a0pharmacokinetics \u00a0in\u00a0hepatitis\u00a0with\u00a0hepatic\u00a0dysfunc\u2010\ntion.\u00a0Clin\u00a0Infect\u00a0Dis\u00a02005;\u00a040(1):174 \u2010181.\u00a0\n\u00a0 692.\u00a0\u00a0Busti\u00a0AJ,\u00a0Bain\u00a0AM,\u00a0Hall\u00a0RG,\u00a0Bedimo\u00a0RG,\u00a0Leff\u00a0RD,\u00a0Meek\u00a0C\u00a0et\u00a0al.\u00a0Effects\u00a0of\u00a0atazanavir/ritonavir \u00a0\nor\u00a0fosamprenavir/ritonavir \u00a0on\u00a0the\u00a0pharmacokinetics \u00a0of\u00a0rosuvastatin. \u00a0J\u00a0Cardiovasc \u00a0Pharmacol \u00a0\n2008;\u00a051(6):605 \u2010610.\u00a0\n\u00a0 693.\u00a0\u00a0Pham\u00a0P,\u00a0Lee\u00a0L,\u00a0Fuchs\u00a0E,\u00a0Barditch\u2010Crovo\u00a0P,\u00a0Carson\u00a0K,\u00a0Radebaugh \u00a0C\u00a0et\u00a0al.\u00a0Pharmacokinetic \u00a0inte\u2010\nraction\u00a0between\u00a0tipranavir/ritonavir \u00a0and\u00a0rosuvastatin. \u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections; \u00a0February\u00a02008;\u00a0Boston,\u00a0Massachusetts \u00a02008;\u00a0Abstract\u00a0767.\u00a0\n\u00a0 694.\u00a0\u00a0van\u00a0der\u00a0LM,\u00a0Sankatsing \u00a0R,\u00a0Schippers \u00a0E,\u00a0Vogel\u00a0M,\u00a0Fatkenheuer \u00a0G,\u00a0van\u00a0d,\u00a0V\u00a0et\u00a0al.\u00a0Pharmacokine \u2010\ntics\u00a0and\u00a0pharmacodynamics \u00a0of\u00a0combined \u00a0use\u00a0of\u00a0lopinavir/ritonavir \u00a0and\u00a0rosuvastatin \u00a0in\u00a0HIV\u2010\ninfected\u00a0patients.\u00a0Antivir\u00a0Ther\u00a02007;\u00a012(7):1127 \u20101132.\u00a0\n\u00a0 695.\u00a0\u00a0Kiser\u00a0JJ,\u00a0Gerber\u00a0JG,\u00a0Predhomme \u00a0JA,\u00a0Wolfe\u00a0P,\u00a0Flynn\u00a0DM,\u00a0Hoody\u00a0DW.\u00a0Drug/Drug \u00a0interaction \u00a0\nbetween\u00a0lopinavir/ritonavir \u00a0and\u00a0rosuvastatin \u00a0in\u00a0healthy\u00a0volunteers. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0\nSyndr\u00a02008;\u00a047(5):570 \u2010578.\u00a0\n\u00a0 696.\u00a0\u00a0Busse\u00a0K,\u00a0PenzaK\u00a0SR,\u00a0Formentini \u00a0E,\u00a0Chairez\u00a0C,\u00a0Alfaro\u00a0R,\u00a0Kovacs\u00a0JA\u00a0et\u00a0al.\u00a0Lopinavir/ritonavir \u00a0\nsignificantly \u00a0decreases \u00a0gemfibrozil \u00a0plasma\u00a0concentrations \u00a0in\u00a0healthy\u00a0volunteers. \u00a048th\u00a0Annual\u00a0\nICCAC/IDSA \u00a046th\u00a0Annual\u00a0Meeting;\u00a0October\u00a025\u201028,\u00a02008;\u00a0Washington, \u00a0DC\u00a02009;\u00a0Abstract\u00a0A\u2010\n959.\u00a0\n\u00a0 697.\u00a0\u00a0Jackson\u00a0A,\u00a0Moyle\u00a0G,\u00a0Watson\u00a0V,\u00a0Back\u00a0D,\u00a0Khoo\u00a0S,\u00a0Higgs\u00a0C\u00a0et\u00a0al.\u00a0Variability \u00a0in\u00a0steady\u00a0state\u00a0ralte\u2010\ngravir\u00a0pharmacokinetics, \u00a0impact\u00a0of\u00a0ezetimibe? \u00a010th\u00a0International \u00a0Workshop \u00a0on\u00a0Clinical\u00a0\nPharmacology \u00a0of\u00a0HIV\u00a0Therapy\u00a0Amsterdam, \u00a0The\u00a0Netherlands, \u00a0April\u00a015\u201017,\u00a02009\u00a02009;\u00a0Abstract\u00a0\nP\u201025.\u00a0\n\u00a0 698.\u00a0\u00a0Crespo\u00a0M,\u00a0Pou\u00a0L,\u00a0Esteban\u00a0JI,\u00a0Falco\u00a0V,\u00a0Ribera\u00a0E,\u00a0L\u00f3pez\u00a0R\u00a0et\u00a0al.\u00a0Early\u00a0monitoring \u00a0of\u00a0ribavirin\u00a0\nserum\u00a0concentration \u00a0is\u00a0not\u00a0useful\u00a0to\u00a0optimize\u00a0hepatitis\u00a0C\u00a0virus\u00a0treatment \u00a0in\u00a0HIV\u2010coinfected \u00a0\npatients.\u00a0Antiviral\u00a0Ther\u00a02007;\u00a012(8):1217 \u20101223.\u00a0\n\u00a0 699.\u00a0\u00a0Fleischer\u00a0R,\u00a0Boxwell\u00a0D,\u00a0Sherman\u00a0KE.\u00a0Nucleoside \u00a0analogues \u00a0and\u00a0mitochondrial \u00a0toxicity.\u00a0Clin\u00a0\nInfect\u00a0Dis\u00a02004;\u00a038(8):e79 \u2010e80.\u00a0\n\u00a0 700.\u00a0\u00a0Hoggard\u00a0PG,\u00a0Sales\u00a0SD,\u00a0Kewn\u00a0S,\u00a0Sunderland \u00a0D,\u00a0Khoo\u00a0SH,\u00a0Hart\u00a0CA\u00a0et\u00a0al.\u00a0Correlation \u00a0between\u00a0\nintracellular \u00a0pharmacological \u00a0activation \u00a0of\u00a0nucleoside \u00a0analogues \u00a0and\u00a0HIV\u00a0suppression \u00a0in\u00a0vitro.\u00a0\nAntivir\u00a0Chem\u00a0Chemother \u00a02000;\u00a011(6):353 \u20108.\u00a0\n\u00a0 701.\u00a0\u00a0Kharasch\u00a0ED,\u00a0Mitchell\u00a0D,\u00a0Coles\u00a0R,\u00a0Blanco\u00a0R.\u00a0Rapid\u00a0clinical\u00a0induction \u00a0of\u00a0hepatic\u00a0cytochrome \u00a0\nP4502B6\u00a0activity\u00a0by\u00a0ritonavir.\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02008;\u00a052(5):1663 \u20101669.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 150 \n \u00a0 702.\u00a0\u00a0Vispo\u00a0E,\u00a0Barreiro\u00a0P,\u00a0Pineda\u00a0JA,\u00a0Mira\u00a0JA,\u00a0Gir\u00f3n\u00a0JA.\u00a0Higher\u00a0rate\u00a0of\u00a0failure\u00a0to\u00a0pegylated \u2010interferon \u00a0\nplus\u00a0ribavirin\u00a0in\u00a0HIV+\u00a0patients\u00a0with\u00a0chronic\u00a0hepatitis\u00a0C\u00a0receiving\u00a0abacavir.\u00a0Antivir\u00a0Ther\u00a02008;\u00a0\n13:428\u2010437.\u00a0\n\u00a0 703.\u00a0\u00a0Brown\u00a0KC,\u00a0Paul\u00a0S,\u00a0Kashuba\u00a0AD.\u00a0Drug\u00a0interactions \u00a0with\u00a0new\u00a0and\u00a0investigational \u00a0antiretrovirals. \u00a0\nClin\u00a0Pharmacokinet \u00a02009;\u00a048(4):211 \u2010241.\u00a0\n\u00a0 704.\u00a0\u00a0Robertson \u00a0SM,\u00a0Davey\u00a0RT,\u00a0Voell\u00a0J,\u00a0Formentini \u00a0E,\u00a0Alfaro\u00a0RM,\u00a0Penzak\u00a0SR.\u00a0Effect\u00a0of\u00a0Ginkgo\u00a0biloba\u00a0\nextract\u00a0on\u00a0lopinavir, \u00a0midazolam \u00a0and\u00a0fexofenadine \u00a0pharmacokinetics \u00a0in\u00a0healthy\u00a0subjects.\u00a0Curr\u00a0\nMed\u00a0Res\u00a0Opin\u00a02008;\u00a024(2):591 \u2010599.\u00a0\n\u00a0 705.\u00a0\u00a0Malati\u00a0CY,\u00a0Robertson \u00a0SM,\u00a0Hunt\u00a0JD,\u00a0Chairez\u00a0C,\u00a0Alfaro\u00a0RA,\u00a0Kovacs\u00a0JA\u00a0et\u00a0al.\u00a0Echinacea \u00a0purpurea\u00a0\ndoes\u00a0not\u00a0alter\u00a0the\u00a0steady\u00a0state\u00a0pharmacokinetics \u00a0of\u00a0lopinavir\u00a0or\u00a0ritonavir\u00a0in\u00a0healthy\u00a0human\u00a0\nvolunteers. \u00a049th\u00a0ICAAC\u00a0San\u00a0Francisco, \u00a0CA\u00a0,\u00a0September \u00a012\u201015,\u00a02009\u00a02009;\u00a0Abstract\u00a0A1\u20101307.\u00a0\n\u00a0 706.\u00a0\u00a0Foisy\u00a0MM,\u00a0Yakiwchuk \u00a0EM,\u00a0Chiu\u00a0I,\u00a0Singh\u00a0AE.\u00a0Adrenal\u00a0suppression \u00a0and\u00a0Cushing's \u00a0syndrome \u00a0\nsecondary \u00a0to\u00a0an\u00a0interaction \u00a0between\u00a0ritonavir\u00a0and\u00a0fluticasone: \u00a0a\u00a0review\u00a0of\u00a0the\u00a0literature. \u00a0HIV\u00a0\nMed\u00a02008;\u00a09(6):389\u2010396.\u00a0\n\u00a0 707.\u00a0\u00a0Sabo\u00a0JP,\u00a0Cong\u00a0XJ,\u00a0Haas\u00a0D,\u00a0Eskoetter \u00a0H,\u00a0Kraft\u00a0M,\u00a0Mauss\u00a0S.\u00a0Lack\u00a0of\u00a0a\u00a0pharmacokinetic \u00a0effect\u00a0\nbetween\u00a0steady\u2010state\u00a0tipranavir/ritonavir \u00a0and\u00a0single\u2010dose\u00a0valacyclovir \u00a0in\u00a0healthy\u00a0volunteers. \u00a0\n48th\u00a0Annual\u00a0ICCAC/IDSA \u00a046th\u00a0Annual\u00a0Meeting;\u00a0October\u00a025\u201028,\u00a02008;\u00a0Washington, \u00a0DC\u00a02009;\u00a0\nAbstract\u00a0A\u2010967.\u00a0\n\u00a0 708.\u00a0\u00a0Oostendorp \u00a0RL,\u00a0Huitema\u00a0A,\u00a0Rosing\u00a0H,\u00a0Jansen\u00a0RS,\u00a0Ter\u00a0HR,\u00a0Keessen\u00a0M\u00a0et\u00a0al.\u00a0Coadministration \u00a0of\u00a0\nritonavir\u00a0strongly\u00a0enhances \u00a0the\u00a0apparent\u00a0oral\u00a0bioavailability \u00a0of\u00a0docetaxel \u00a0in\u00a0patients\u00a0with\u00a0so\u2010\nlid\u00a0tumors.\u00a0Clin\u00a0Cancer\u00a0Res\u00a02009;\u00a015(12):4228 \u20104233.\u00a0\n\u00a0 709.\u00a0\u00a0Bonora\u00a0S,\u00a0Di\u00a0PG.\u00a0Interactions \u00a0between\u00a0antiretroviral \u00a0agents\u00a0and\u00a0those\u00a0used\u00a0to\u00a0treat\u00a0tubercu\u2010\nlosis.\u00a0Curr\u00a0Opin\u00a0HIV\u00a0AIDS\u00a02008;\u00a03(3):306\u2010312.\u00a0\n\u00a0 710.\u00a0\u00a0German\u00a0P,\u00a0Parikh\u00a0S,\u00a0Lawrence \u00a0J,\u00a0Dorsey\u00a0G,\u00a0Rosenthal \u00a0PJ,\u00a0Havlir\u00a0D\u00a0et\u00a0al.\u00a0Lopinavir/ritonavir \u00a0\naffects\u00a0pharmacokinetic \u00a0exposure\u00a0of\u00a0artemether/lumefantrine \u00a0in\u00a0HIV\u2010uninfected \u00a0healthy\u00a0vo\u2010\nlunteers.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02009;\u00a051(4):424 \u2010429.\u00a0\n\u00a0 711.\u00a0\u00a0Soyinka\u00a0JO,\u00a0Onyeji\u00a0CO,\u00a0Owolabi\u00a0AR,\u00a0Sarma\u00a0PVVS,\u00a0Cook\u00a0JM.\u00a0Pharmacokinetic \u00a0interaction \u00a0bet\u2010\nween\u00a0ritonavir\u00a0and\u00a0quinine.\u00a048th\u00a0Annual\u00a0ICCAC/IDSA \u00a046th\u00a0Annual\u00a0Meeting;\u00a0October\u00a025\u201028,\u00a0\n2008;\u00a0Washington, \u00a0DC\u00a02009;\u00a0Abstract\u00a0A\u2010965.\u00a0\n\u00a0 712.\u00a0\u00a0Van\u00a0Luin\u00a0M,\u00a0Van\u00a0Der\u00a0Ende\u00a0ME,\u00a0Richter\u00a0C,\u00a0Visser\u00a0M,\u00a0Farag\u00a0D,\u00a0Van\u00a0der\u00a0Ven\u00a0A\u00a0et\u00a0al.\u00a0Drug\u00a0interac\u2010\ntions\u00a0between\u00a0atovaquone/proguanil \u00a0and\u00a0antiretroviral \u00a0agents.\u00a010th\u00a0International \u00a0Workshop \u00a0\non\u00a0Clinical\u00a0Pharmacology \u00a0of\u00a0HIV\u00a0Therapy\u00a0Amsterdam, \u00a0The\u00a0Netherlands, \u00a0April\u00a015\u201017,\u00a02009\u00a0\n2009;\u00a0Abstract\u00a0O\u201019.\u00a0\n\u00a0 713.\u00a0\u00a0Burger\u00a0DM,\u00a0Huisman\u00a0A,\u00a0Van\u00a0EN,\u00a0Neisingh\u00a0H,\u00a0van\u00a0UP,\u00a0Rongen\u00a0GA\u00a0et\u00a0al.\u00a0The\u00a0effect\u00a0of\u00a0atazanavir \u00a0\nand\u00a0atazanavir/ritonavir \u00a0on\u00a0UDP\u2010glucuronosyltransferase \u00a0using\u00a0lamotrigine \u00a0as\u00a0a\u00a0phenotypic \u00a0\nprobe.\u00a0Clin\u00a0Pharmacol \u00a0Ther\u00a02008;\u00a084(6):698 \u2010703.\u00a0\n\u00a0 714.\u00a0\u00a0Van\u00a0Luin\u00a0M,\u00a0Colbers\u00a0A,\u00a0Van\u00a0Ewijk\u2010Beneken\u00a0Kolmer\u00a0E,\u00a0Verweij\u2010Van\u00a0Wissen\u00a0C,\u00a0Van\u00a0der\u00a0Kolk\u00a0M,\u00a0\nHoitsma\u00a0A\u00a0et\u00a0al.\u00a0Raltegravir \u00a0has\u00a0no\u00a0influence\u00a0on\u00a0UGT1A4/2B7 \u00a0when\u00a0using\u00a0lamotrigine \u00a0as\u00a0a\u00a0\nphenotypic \u00a0probe.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a0\n2009;\u00a0Montreal \u00a02009;\u00a0Abstract\u00a0693.\u00a0\n\u00a0 715.\u00a0\u00a0Iwamoto\u00a0M,\u00a0Wenning\u00a0LA,\u00a0Moreau\u00a0AR,\u00a0Hanley\u00a0WD,\u00a0Jin\u00a0B,\u00a0Breidinger \u00a0SA\u00a0et\u00a0al.\u00a0Omeprazole \u00a0\nincreases \u00a0plasma\u00a0levels\u00a0of\u00a0raltegravir \u00a0in\u00a0healthy\u00a0subjects.\u00a048th\u00a0Annual\u00a0ICCAC/IDSA \u00a046th\u00a0An\u2010\nnual\u00a0Meeting;\u00a0October\u00a025\u201028,\u00a02008;\u00a0Washington, \u00a0DC\u00a02008;\u00a0Abstract\u00a0A\u2010963.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 151 \n \u00a0 716.\u00a0\u00a0Mertz\u00a0D,\u00a0Battegay\u00a0M,\u00a0Marzolini \u00a0C,\u00a0Mayr\u00a0M.\u00a0Drug\u2010drug\u00a0interaction \u00a0in\u00a0a\u00a0kidney\u00a0transplant \u00a0reci\u2010\npient\u00a0receiving\u00a0HIV\u00a0salvage\u00a0therapy\u00a0and\u00a0tacrolimus. \u00a0Am\u00a0J\u00a0Kidney\u00a0Dis\u00a02009;\u00a054(1):e1\u2010e4.\u00a0\n\u00a0 717.\u00a0\u00a0Tricot\u00a0L,\u00a0Teicher\u00a0E,\u00a0Peytavin\u00a0G,\u00a0Zucman\u00a0D,\u00a0Conti\u00a0F,\u00a0Calmus\u00a0Y\u00a0et\u00a0al.\u00a0Safety\u00a0and\u00a0efficacy\u00a0of\u00a0ralte\u2010\ngravir\u00a0in\u00a0HIV\u2010infected\u00a0transplant \u00a0patients\u00a0cotreated \u00a0with\u00a0immunosuppressive \u00a0drugs.\u00a0Am\u00a0J\u00a0\nTransplant \u00a02009;\u00a09(8):1946 \u20101952.\u00a0\n\u00a0 718.\u00a0\u00a0Di\u00a0Biagio\u00a0A.,\u00a0Rosso\u00a0R,\u00a0Siccardi\u00a0M,\u00a0D'Avolio\u00a0A,\u00a0Bonora\u00a0S,\u00a0Viscoli\u00a0C.\u00a0Lack\u00a0of\u00a0interaction \u00a0between\u00a0\nraltegravir \u00a0and\u00a0cyclosporin \u00a0in\u00a0an\u00a0HIV\u2010infected\u00a0liver\u00a0transplant \u00a0recipient. \u00a0J\u00a0Antimicrob \u00a0Che\u2010\nmother\u00a02009;\u00a064(4):874 \u2010875.\u00a0\n\u00a0 719.\u00a0\u00a0Moreno\u00a0A,\u00a0Perez\u2010Elias\u00a0MJ,\u00a0Casado\u00a0JL,\u00a0Fortun\u00a0J,\u00a0Quereda\u00a0C,\u00a0B\u00e1rcena\u00a0R\u00a0et\u00a0al.\u00a0Safety\u00a0and\u00a0effecti\u2010\nveness\u00a0of\u00a0raltegravir \u2010based\u00a0HAART\u00a0in\u00a0HIV\u2010subjects\u00a0after\u00a0solid\u00a0organ\u00a0transplantation. \u00a049th\u00a0\nICAAC\u00a0San\u00a0Francisco, \u00a0CA\u00a0,\u00a0September \u00a012\u201015,\u00a02009\u00a02009;\u00a0Abstract\u00a0H\u2010913.\u00a0\n\u00a0 720.\u00a0\u00a0Sch\u00f6ller\u2010Gy\u00fcre\u00a0M,\u00a0Kakuda\u00a0NT,\u00a0Van\u00a0Solingen\u2010Ristea\u00a0RM,\u00a0Aharchi\u00a0F,\u00a0De\u00a0Smedt\u00a0G,\u00a0Witek\u00a0J\u00a0et\u00a0al.\u00a0\nPharmacokinetic \u00a0interaction \u00a0between\u00a0etravirine \u00a0and\u00a0lluconazole \u00a0or\u00a0voriconazole \u00a0in\u00a0HIV\u2010\nnegative\u00a0volunteers. \u00a049th\u00a0ICAAC\u00a0San\u00a0Francisco, \u00a0CA\u00a0,\u00a0September \u00a012\u201015,\u00a02009\u00a02009;\u00a0Abstract\u00a0\nA1\u20101299.\u00a0\n\u00a0 721.\u00a0\u00a0van\u00a0Heeswijk\u00a0R,\u00a0Gysen\u00a0V,\u00a0Boogaerts \u00a0G,\u00a0De\u00a0Paepe\u00a0E,\u00a0Vangeneugden \u00a0T,\u00a0De\u00a0Backer\u00a0K\u00a0et\u00a0al.\u00a0The\u00a0\npharmacokinetic \u00a0interaction \u00a0between\u00a0tenofovir\u00a0disoproxil \u00a0fumarate \u00a0and\u00a0the\u00a0investigational \u00a0\nHCV\u00a0protease\u00a0inhibitor\u00a0telaprevir. \u00a048th\u00a0Annual\u00a0ICCAC/IDSA \u00a046th\u00a0Annual\u00a0Meeting;\u00a0October\u00a025\u2010\n28,\u00a02008;\u00a0Washington, \u00a0DC\u00a02009;\u00a0Abstract\u00a0A\u2010966.\u00a0\n\u00a0 722.\u00a0\u00a0Amorosa\u00a0V,\u00a0Slim\u00a0J,\u00a0Mounzer\u00a0K,\u00a0Bruno\u00a0C,\u00a0Hoffman\u2010Terry\u00a0M,\u00a0Dorey\u2010Stein\u00a0Z\u00a0et\u00a0al.\u00a0Abacavir\u00a0use\u00a0is\u00a0\nnot\u00a0associated \u00a0with\u00a0lack\u00a0of\u00a0virologic\u00a0response\u00a0in\u00a0ARV\u2010treated\u00a0HIV/HCV\u2010co\u2010infected\u00a0patients\u00a0\nreceiving\u00a0pegylated \u00a0interferon \u00a0and\u00a0ribavirin.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportu\u2010\nnistic\u00a0Infections; \u00a0February\u00a02009;\u00a0Montreal \u00a02009;\u00a0Abstract\u00a0850.\u00a0\n\u00a0 723.\u00a0\u00a0University \u00a0of\u00a0Liverpool\u00a0website.\u00a0Disponible \u00a0en:\u00a0www\u00a0hiv\u2010druginteractions \u00a0org\u00a0(\u00faltimo\u00a0acceso\u00a0\n20\u00a010\u00a009)\u00a02009.\u00a0\n\u00a0 724.\u00a0\u00a0Tuyama\u00a0A,\u00a0Hong\u00a0F,\u00a0Mosoian\u00a0A,\u00a0Chen\u00a0P,\u00a0Chen\u00a0B,\u00a0Fiel\u00a0I\u00a0et\u00a0al.\u00a0HIV\u00a0Entry\u00a0and\u00a0Replication \u00a0in\u00a0Stella\u2010\nte\u00a0Cells\u00a0Promotes \u00a0Cellular\u00a0Activation \u00a0and\u00a0Fibrogenesis: \u00a0Implications \u00a0for\u00a0Hepatic\u00a0Fibrosis\u00a0in\u00a0\nHIV/HCV\u00a0Co\u2010infection. \u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0Fe\u2010\nbruary\u00a02008;\u00a0Boston,\u00a0Massachusetts \u00a0(Abstract\u00a057)\u00a0\n\u00a0 725.\u00a0\u00a0Bonacini\u00a0M,\u00a0Louie\u00a0S,\u00a0Bzowej\u00a0N,\u00a0Wohl\u00a0AR.\u00a0Survival\u00a0in\u00a0patients\u00a0with\u00a0HIV\u00a0infection\u00a0and\u00a0viral\u00a0\nhepatitis\u00a0B\u00a0or\u00a0C:\u00a0a\u00a0cohort\u00a0study.\u00a0AIDS\u00a02004;\u00a018(15):2039 \u20102045.\u00a0\n\u00a0 726.\u00a0\u00a0Garc\u00eda\u00a0Garc\u00eda\u00a0JA,\u00a0Aguilar\u2010Guisado\u00a0M,\u00a0Rivero\u00a0A,\u00a0Gir\u00f3n\u00a0Gonz\u00e1lez\u00a0J,\u00a0Gonz\u00e1lez\u00a0Serrano\u00a0M,\u00a0Merino\u00a0\nD\u00a0et\u00a0al.\u00a0Natural\u00a0History\u00a0of\u00a0Compensated \u00a0Hepatitis\u00a0C\u00a0Virus\u2010related\u00a0Cirrhosis\u00a0in\u00a0HIV\u2010infected\u00a0Pa\u2010\ntients.\u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a02008;\u00a0Boston,\u00a0\nMassachusetts \u00a0(Abstrac\u00a01059)\u00a0\n\u00a0 727.\u00a0\u00a0Lopez\u2010Dieguez,\u00a0Gesida\u00a037/03\u2010FIPSE\u00a036465/03 \u00a0Study\u00a0Group.\u00a0Factors\u00a0Associated \u00a0with\u00a0Survival\u00a0\nand\u00a0First\u00a0Hepatic\u00a0Decompensation \u00a0in\u00a0a\u00a0Large\u00a0Prospective \u00a0Cohort\u00a0of\u00a0HIV/HCV\u2010co\u2010infected\u00a0Pa\u2010\ntients\u00a0with\u00a0Liver\u00a0Cirrhosis. \u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0Fe\u2010\nbruary\u00a02008;\u00a0Boston,\u00a0Massachusetts \u00a0(Abstract\u00a01057)\u00a0\n\u00a0 728.\u00a0\u00a0Macias\u00a0J,\u00a0Mira\u00a0JA,\u00a0Lopez\u2010Cortes\u00a0LF,\u00a0Santos\u00a0I,\u00a0Giron\u2010Gonzalez\u00a0JA,\u00a0Gonzalez\u2010Serrano\u00a0M\u00a0et\u00a0al.\u00a0\nAntiretroviral \u00a0therapy\u00a0based\u00a0on\u00a0protease\u00a0inhibitors \u00a0as\u00a0a\u00a0protective \u00a0factor\u00a0against\u00a0liver\u00a0fibrosis\u00a0\nprogression \u00a0in\u00a0patients\u00a0with\u00a0chronic\u00a0hepatitis\u00a0C.\u00a0Antivir\u00a0Ther\u00a02006;\u00a011(7):839 \u2010846.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 152 \n \u00a0 729.\u00a0\u00a0Merchante \u00a0N,\u00a0Giron\u2010Gonzalez\u00a0JA,\u00a0Gonzalez\u2010Serrano\u00a0M,\u00a0Torre\u2010Cisneros\u00a0J,\u00a0Garcia\u2010Garcia\u00a0JA,\u00a0\nArizcorreta \u00a0A\u00a0et\u00a0al.\u00a0Survival\u00a0and\u00a0prognostic \u00a0factors\u00a0of\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0HCV\u2010related\u00a0\nend\u2010stage\u00a0liver\u00a0disease.\u00a0AIDS\u00a02006;\u00a020(1):49\u201057.\u00a0\n\u00a0 730.\u00a0\u00a0Qurishi\u00a0N,\u00a0Kreuzberg \u00a0C,\u00a0Luchters\u00a0G,\u00a0Effenberger \u00a0W,\u00a0Kupfer\u00a0B,\u00a0Sauerbruch \u00a0T\u00a0et\u00a0al.\u00a0Effect\u00a0of\u00a0\nantiretroviral \u00a0therapy\u00a0on\u00a0liver\u2010related\u00a0mortality\u00a0in\u00a0patients\u00a0with\u00a0HIV\u00a0and\u00a0hepatitis\u00a0C\u00a0virus\u00a0\ncoinfection. \u00a0Lancet\u00a02003;\u00a0362(9397):1708 \u20101713.\u00a0\n\u00a0 731.\u00a0\u00a0Pineda\u00a0JA,\u00a0Garcia\u2010Garcia\u00a0JA,\u00a0guilar\u2010Guisado\u00a0M,\u00a0Rios\u2010Villegas\u00a0MJ,\u00a0Ruiz\u2010Morales\u00a0J,\u00a0Rivero\u00a0A\u00a0et\u00a0al.\u00a0\nClinical\u00a0progression \u00a0of\u00a0hepatitis\u00a0C\u00a0virus\u2010related\u00a0chronic\u00a0liver\u00a0disease\u00a0in\u00a0human\u00a0immunodefi \u2010\nciency\u00a0virus\u2010infected\u00a0patients\u00a0undergoing \u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy.\u00a0Hepatology \u00a0\n2007;\u00a046(3):622 \u2010630.\u00a0\n\u00a0 732.\u00a0\u00a0Soriano\u00a0V,\u00a0Puoti\u00a0M,\u00a0Peters\u00a0M,\u00a0Benhamou \u00a0Y,\u00a0Sulkowski \u00a0M,\u00a0Zoulim\u00a0F\u00a0et\u00a0al.\u00a0Care\u00a0of\u00a0HIV\u00a0patients\u00a0\nwith\u00a0chronic\u00a0hepatitis\u00a0B:\u00a0updated\u00a0recommendations \u00a0from\u00a0the\u00a0HIV\u2010Hepatitis\u00a0B\u00a0Virus\u00a0Interna\u2010\ntional\u00a0Panel.\u00a0AIDS\u00a02008;\u00a022(12):1399 \u20101410.\u00a0\n\u00a0 733.\u00a0\u00a0Reisler\u00a0RB,\u00a0Han\u00a0C,\u00a0Burman\u00a0WJ,\u00a0Tedaldi\u00a0EM,\u00a0Neaton\u00a0JD.\u00a0Grade\u00a04\u00a0events\u00a0are\u00a0as\u00a0important \u00a0as\u00a0\nAIDS\u00a0events\u00a0in\u00a0the\u00a0era\u00a0of\u00a0HAART.\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02003;\u00a034(4):379 \u2010386.\u00a0\n\u00a0 734.\u00a0\u00a0Rivero\u00a0A,\u00a0Mira\u00a0JA,\u00a0Pineda\u00a0JA.\u00a0Liver\u00a0toxicity\u00a0induced\u00a0by\u00a0non\u2010nucleoside \u00a0reverse\u00a0transcriptase \u00a0\ninhibitors. \u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02007;\u00a059(3):342 \u2010346.\u00a0\n\u00a0 735.\u00a0\u00a0Nunez\u00a0M.\u00a0Hepatotoxicity \u00a0of\u00a0antiretrovirals: \u00a0incidence, \u00a0mechanisms \u00a0and\u00a0management. \u00a0J\u00a0Hepa\u2010\ntol\u00a02006;\u00a044(1\u00a0Suppl):S132 \u2010S139.\u00a0\n\u00a0 736.\u00a0\u00a0Sabin\u00a0CA.\u00a0Pitfalls\u00a0of\u00a0assessing \u00a0hepatotoxicity \u00a0in\u00a0trials\u00a0and\u00a0observational \u00a0cohorts.\u00a0Clin\u00a0Infect\u00a0Dis\u00a0\n2004;\u00a038\u00a0Suppl\u00a02:S56\u2010S64.\u00a0\n\u00a0 737.\u00a0\u00a0AIDS\u00a0Clinical\u00a0Trials\u00a0Group.\u00a0Table\u00a0of\u00a0grading\u00a0severity\u00a0of\u00a0adult\u00a0adverse\u00a0experiences. \u00a0Rockville, \u00a0\nMD:\u00a0US\u00a0Division\u00a0of\u00a0AIDS,\u00a0National\u00a0Institute\u00a0of\u00a0Allergy\u00a0and\u00a0Infectious \u00a0Diseases,\u00a0Bethesda, \u00a0\n1996.\u00a0\u00a0\n\u00a0 738.\u00a0\u00a0Sulkowski \u00a0MS,\u00a0Thomas\u00a0DL,\u00a0Chaisson\u00a0RE,\u00a0Moore\u00a0RD.\u00a0Hepatotoxicity \u00a0associated \u00a0with\u00a0antiretro\u2010\nviral\u00a0therapy\u00a0in\u00a0adults\u00a0infected\u00a0with\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0and\u00a0the\u00a0role\u00a0of\u00a0hepatitis\u00a0\nC\u00a0or\u00a0B\u00a0virus\u00a0infection. \u00a0Jama\u00a02000;\u00a0283(1):74 \u201080.\u00a0\n\u00a0 739.\u00a0\u00a0Saves\u00a0M,\u00a0Raffi\u00a0F,\u00a0Clevenbergh \u00a0P,\u00a0Marchou\u00a0B,\u00a0Waldner\u2010Combernoux \u00a0A,\u00a0Morlat\u00a0P.\u00a0Hepatitis\u00a0B\u00a0or\u00a0\nhepatitis\u00a0C\u00a0virus\u00a0infection\u00a0is\u00a0a\u00a0risk\u00a0factor\u00a0for\u00a0severe\u00a0hepatic\u00a0cytolysis\u00a0after\u00a0initiation\u00a0of\u00a0protea\u2010\nse\u00a0inhibitor\u00a0containing \u00a0antiretroviral \u00a0regimen\u00a0in\u00a0human\u00a0immunodeficiency \u00a0virus\u2010infected\u00a0pa\u2010\ntients.\u00a044:3451\u20103455.\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a02000;\u00a044:3451\u20103455.\u00a0\n\u00a0 740.\u00a0\u00a0Sulkowski \u00a0MS,\u00a0Thomas\u00a0DL,\u00a0Mehta\u00a0SH,\u00a0Chaisson\u00a0RE,\u00a0Moore\u00a0RD.\u00a0Hepatotoxicity \u00a0associated \u00a0with\u00a0\nnevirapine \u00a0or\u00a0efavirenz\u2010containing \u00a0antiretroviral \u00a0therapy:\u00a0role\u00a0of\u00a0hepatitis\u00a0C\u00a0and\u00a0B\u00a0infections. \u00a0\nHepatology \u00a02002;\u00a035(1):182 \u20109.\u00a0\n\u00a0 741.\u00a0\u00a0Aranzabal \u00a0L,\u00a0Casado\u00a0JL,\u00a0Moya\u00a0J,\u00a0Quereda\u00a0C,\u00a0Diz\u00a0S,\u00a0Moreno\u00a0A\u00a0et\u00a0al.\u00a0Influence \u00a0of\u00a0liver\u00a0fibrosis\u00a0on\u00a0\nhighly\u00a0active\u00a0antiretroviral \u00a0therapy\u2010associated \u00a0hepatotoxicity \u00a0in\u00a0patients\u00a0with\u00a0HIV\u00a0and\u00a0hepati\u2010\ntis\u00a0C\u00a0virus\u00a0coinfection. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02005;\u00a040(4):588 \u2010593.\u00a0\n\u00a0 742.\u00a0\u00a0McGovern \u00a0BH,\u00a0Birch\u00a0C,\u00a0Zaman\u00a0MT,\u00a0Bica\u00a0I,\u00a0Stone\u00a0D,\u00a0Quirk\u00a0JR\u00a0et\u00a0al.\u00a0Managing \u00a0symptomatic \u00a0\ndrug\u2010induced\u00a0liver\u00a0injury\u00a0in\u00a0HIV\u2010hepatitis\u00a0C\u00a0virus\u2010coinfected \u00a0patients:\u00a0a\u00a0role\u00a0for\u00a0interferon. \u00a0\nClin\u00a0Infect\u00a0Dis\u00a02007;\u00a045(10):1386 \u20101392.\u00a0\n\u00a0 743.\u00a0\u00a0Labarga\u00a0P,\u00a0Soriano\u00a0V,\u00a0Vispo\u00a0ME,\u00a0Pinilla\u00a0J,\u00a0Martin\u2010Carbonero \u00a0L,\u00a0Castellares \u00a0C\u00a0et\u00a0al.\u00a0Hepatotoxi \u2010\ncity\u00a0of\u00a0antiretroviral \u00a0drugs\u00a0is\u00a0reduced\u00a0after\u00a0successful \u00a0treatment \u00a0of\u00a0chronic\u00a0hepatitis\u00a0C\u00a0in\u00a0HIV\u2010\ninfected\u00a0patients.\u00a0J\u00a0Infect\u00a0Dis\u00a02007;\u00a0196(5):670 \u2010676.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 153 \n \u00a0 744.\u00a0\u00a0Moore\u00a0KH,\u00a0Raasch\u00a0RH,\u00a0Brouwer\u00a0KL,\u00a0Opheim\u00a0K,\u00a0Cheeseman \u00a0SH,\u00a0Eyster\u00a0E\u00a0et\u00a0al.\u00a0Pharmacokine \u2010\ntics\u00a0and\u00a0bioavailability \u00a0of\u00a0zidovudine \u00a0and\u00a0its\u00a0glucuronidated \u00a0metabolite \u00a0in\u00a0patients\u00a0with\u00a0\nhuman\u00a0immunodeficiency \u00a0virus\u00a0infection\u00a0and\u00a0hepatic\u00a0disease\u00a0(AIDS\u00a0Clinical\u00a0Trials\u00a0Group\u00a0pro\u2010\ntocol\u00a0062).\u00a0Antimicrob \u00a0Agents\u00a0Chemother \u00a01995;\u00a039(12):2732 \u20107.\u00a0\n\u00a0 745.\u00a0\u00a0Johnson\u00a0MA,\u00a0Horak\u00a0J,\u00a0Breuel\u00a0P.\u00a0The\u00a0pharmacokinetics \u00a0of\u00a0lamivudine \u00a0in\u00a0patients\u00a0with\u00a0impaired\u00a0\nhepatic\u00a0function.\u00a0Eur\u00a0J\u00a0Clin\u00a0Pharmacol \u00a01998;\u00a054(4):363 \u20106.\u00a0\n\u00a0 746.\u00a0\u00a0Schaad\u00a0HJ,\u00a0Petty\u00a0BG,\u00a0Grasela\u00a0DM,\u00a0Christofalo \u00a0B,\u00a0Raymond \u00a0R,\u00a0Stewart\u00a0M.\u00a0Pharmacokinetics \u00a0\nand\u00a0safety\u00a0of\u00a0a\u00a0single\u00a0dose\u00a0of\u00a0stavudine \u00a0(d4T)\u00a0in\u00a0patients\u00a0with\u00a0severe\u00a0hepatic\u00a0impairment. \u00a0An\u2010\ntimicrob\u00a0Agents\u00a0Chemother \u00a01997;\u00a041(12):2793 \u20106.\u00a0\n\u00a0 747.\u00a0\u00a0Khaliq\u00a0Y,\u00a0Gallicano\u00a0K,\u00a0Seguin\u00a0I,\u00a0Fyke\u00a0K,\u00a0Carignan\u00a0G,\u00a0Bulman\u00a0D\u00a0et\u00a0al.\u00a0Single\u00a0and\u00a0multiple\u00a0dose\u00a0\npharmacokinetics \u00a0of\u00a0nelfinavir \u00a0and\u00a0CYP2C19\u00a0activity\u00a0in\u00a0human\u00a0immunodeficiency \u00a0virus\u2010\ninfected\u00a0patients\u00a0with\u00a0chronic\u00a0liver\u00a0disease.\u00a0Br\u00a0J\u00a0Clin\u00a0Pharmacol \u00a02000;\u00a050(2):108 \u201015.\u00a0\n\u00a0 748.\u00a0\u00a0Arribas\u00a0J,\u00a0Pulido\u00a0F,\u00a0Peng\u00a0JZ,\u00a0Kemmis\u00a0S,\u00a0Li\u00a0JL,\u00a0Lorenzo\u00a0A.\u00a0Evaluation \u00a0of\u00a0the\u00a0multiple\u2010dose\u00a0phar\u2010\nmacokinetics \u00a0of\u00a0lopinavir/ritonavir \u00a0(LPV/R)\u00a0in\u00a0HIV\u00a0and\u00a0HCV\u00a0co\u2010infected\u00a0subjects\u00a0with\u00a0mild\u00a0or\u00a0\nmoderate \u00a0hepatic\u00a0insufficiency. \u00a09th\u00a0European \u00a0AIDS\u00a0Conference \u00a0(EACS).1st \u00a0EACS\u00a0resistance \u00a0&\u00a0\npharmacology \u00a0workshop.Warsaw, \u00a0Poland,\u00a0October\u00a025\u00a0\u2010\u00a029,\u00a02003.\u00a0[Abstract\u00a0F2/6]\u00a0\n\u00a0 749.\u00a0\u00a0Torriani\u00a0FJ,\u00a0Rodriguez \u2010Torres\u00a0M,\u00a0Rockstroh \u00a0JK,\u00a0Lissen\u00a0E,\u00a0Gonzalez\u2010Garcia\u00a0J,\u00a0Lazzarin\u00a0A\u00a0et\u00a0al.\u00a0\nPeginterferon \u00a0Alfa\u20102a\u00a0plus\u00a0ribavirin\u00a0for\u00a0chronic\u00a0hepatitis\u00a0C\u00a0virus\u00a0infection\u00a0in\u00a0HIV\u2010infected\u00a0pa\u2010\ntients.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02004;\u00a0351(5):438 \u2010450.\u00a0\n\u00a0 750.\u00a0\u00a0Torriani\u00a0FJ,\u00a0Rockstroh \u00a0J,\u00a0Rodriguez \u2010Torres\u00a0M,\u00a0Lissen\u00a0E,\u00a0Gonzalez\u00a0J,\u00a0Lazzarin\u00a0A\u00a0et\u00a0al.\u00a0Final\u00a0re\u2010\nsults\u00a0of\u00a0APRICOT: \u00a0A\u00a0randomized, \u00a0partially\u00a0blinded,\u00a0international \u00a0trial\u00a0evaluating \u00a0peginterfe \u2010\nron\u2010alfa\u20102a\u00a0+\u00a0ribavirin\u00a0vs\u00a0interferon \u2010alfa\u20102a\u00a0+\u00a0ribavirin\u00a0in\u00a0the\u00a0treatment \u00a0of\u00a0HCV\u00a0in\u00a0HIV/HCV\u00a0co\u2010\ninfection. \u00a011th\u00a0Conference \u00a0on\u00a0Retrovirus \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0Februa\u2010\nry\u00a08\u2010\u201011,\u00a02004\u00a0[Abstract\u00a0112]\u00a0\n\u00a0 751.\u00a0\u00a0Perronne \u00a0C,\u00a0Carrat\u00a0F,\u00a0Bani\u2010Sadr\u00a0F,\u00a0Pol\u00a0S,\u00a0Rosenthal \u00a0E,\u00a0Lunel\u00a0F\u00a0et\u00a0al.\u00a0Final\u00a0results\u00a0of\u00a0ANRS\u00a0HC02\u2010\nRIBAVIC:\u00a0A\u00a0randomized \u00a0controlled \u00a0trial\u00a0of\u00a0pegylated \u2010Interferon \u2010alfa\u20102b\u00a0plus\u00a0ribavirin\u00a0vs\u00a0inter\u2010\nferon\u2010alfa\u20102b\u00a0plus\u00a0ribavirin\u00a0for\u00a0the\u00a0initial\u00a0treatment \u00a0of\u00a0chronic\u00a0hepatitis\u00a0C\u00a0in\u00a0HIV\u00a0co\u2010infected\u00a0\npatients.\u00a011th\u00a0Conference \u00a0on\u00a0Retrovirus \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0Februa\u2010\nry\u00a08\u2010\u201011,\u00a02004\u00a0[Abstract\u00a0117LB]\u00a0\n\u00a0 752.\u00a0\u00a0Perez\u2010Olmeda\u00a0M,\u00a0Soriano\u00a0V,\u00a0Asensi\u00a0V,\u00a0Morales\u00a0D,\u00a0Romero\u00a0M,\u00a0Ochoa\u00a0A\u00a0et\u00a0al.\u00a0Treatment \u00a0of\u00a0\nchronic\u00a0hepatitis\u00a0C\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0interferon \u00a0alpha\u20102b\u00a0plus\u00a0ribavirin.\u00a0AIDS\u00a0Res\u00a0\nHum\u00a0Retroviruses \u00a02003;\u00a019(12):1083 \u20101089.\u00a0\n\u00a0 753.\u00a0\u00a0Perez\u2010Olmeda\u00a0M,\u00a0Nunez\u00a0M,\u00a0Romero\u00a0M,\u00a0Gonzalez\u00a0J,\u00a0Castro\u00a0A,\u00a0Arribas\u00a0JR\u00a0et\u00a0al.\u00a0Pegylated \u00a0IFN\u2010\nalpha2b\u00a0plus\u00a0ribavirin\u00a0as\u00a0therapy\u00a0for\u00a0chronic\u00a0hepatitis\u00a0C\u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0AIDS\u00a02003;\u00a0\n17(7):1023 \u20101028.\u00a0\n\u00a0 754.\u00a0\u00a0Laguno\u00a0M,\u00a0Murillas\u00a0J,\u00a0Blanco\u00a0JL,\u00a0Martinez\u00a0E,\u00a0Miquel\u00a0R,\u00a0Sanchez\u2010Tapias\u00a0JM\u00a0et\u00a0al.\u00a0Peginterferon \u00a0\nalfa\u20102b\u00a0plus\u00a0ribavirin\u00a0compared \u00a0with\u00a0interferon \u00a0alfa\u20102b\u00a0plus\u00a0ribavirin\u00a0for\u00a0treatment \u00a0of\u00a0\nHIV/HCV\u00a0co\u2010infected\u00a0patients.\u00a0AIDS\u00a02004;\u00a018(13):F27 \u2010F36.\u00a0\n\u00a0 755.\u00a0\u00a0Chung\u00a0RT,\u00a0Andersen \u00a0J,\u00a0Volberding \u00a0P,\u00a0Robbins\u00a0GK,\u00a0Liu\u00a0T,\u00a0Sherman\u00a0KE\u00a0et\u00a0al.\u00a0Peginterferon \u00a0Alfa\u2010\n2a\u00a0plus\u00a0ribavirin\u00a0versus\u00a0interferon \u00a0alfa\u20102a\u00a0plus\u00a0ribavirin\u00a0for\u00a0chronic\u00a0hepatitis\u00a0C\u00a0in\u00a0HIV\u2010\ncoinfected \u00a0persons.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02004;\u00a0351(5):451 \u2010459.\u00a0\n\u00a0 756.\u00a0\u00a0Chung\u00a0R,\u00a0Andersen \u00a0J,\u00a0Volberding \u00a0P,\u00a0Robbins\u00a0G,\u00a0Liu\u00a0T,\u00a0Sherman\u00a0K\u00a0et\u00a0al.\u00a0A\u00a0Randomized, \u00a0Contro\u2010\nlled\u00a0Trial\u00a0of\u00a0PEG\u2010Interferon \u2010alfa\u20102a\u00a0plus\u00a0Ribavirin\u00a0vs\u00a0Interferon \u2010alfa\u20102a\u00a0plus\u00a0Ribavirin\u00a0for\u00a0Chro\u2010\nnic\u00a0Hepatitis\u00a0C\u00a0Virus\u00a0Infection\u00a0in\u00a0HIV\u2010co\u2010infected\u00a0Persons:\u00a0Follow\u2010up\u00a0Results\u00a0of\u00a0ACTG\u00a0A5071.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 154 \n 11th\u00a0Conference \u00a0on\u00a0Retrovirus \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a08\u2010\u201011,\u00a0\n2004\u00a0[Abstract\u00a0110]\u00a0\n\u00a0 757.\u00a0\u00a0Carrat\u00a0F,\u00a0Bani\u2010Sadr\u00a0F,\u00a0Pol\u00a0S,\u00a0Rosenthal \u00a0E,\u00a0Lunel\u2010Fabiani\u00a0F,\u00a0Benzekri\u00a0A\u00a0et\u00a0al.\u00a0Pegylated \u00a0interfe\u2010\nron\u00a0alfa\u20102b\u00a0vs\u00a0standard\u00a0interferon \u00a0alfa\u20102b,\u00a0plus\u00a0ribavirin,\u00a0for\u00a0chronic\u00a0hepatitis\u00a0C\u00a0in\u00a0HIV\u2010\ninfected\u00a0patients:\u00a0a\u00a0randomized \u00a0controlled \u00a0trial.\u00a0Jama\u00a02004;\u00a0292(23):2839 \u20102848.\u00a0\n\u00a0 758.\u00a0\u00a0Soriano\u00a0V,\u00a0Mocroft\u00a0A,\u00a0Rockstroh \u00a0J,\u00a0Ledergerber \u00a0B,\u00a0Knysz\u00a0B,\u00a0Chaplinskas \u00a0S\u00a0et\u00a0al.\u00a0Spontaneous \u00a0\nviral\u00a0clearance, \u00a0viral\u00a0load,\u00a0and\u00a0genotype \u00a0distribution \u00a0of\u00a0hepatitis\u00a0C\u00a0virus\u00a0(HCV)\u00a0in\u00a0HIV\u2010infected\u00a0\npatients\u00a0with\u00a0anti\u2010HCV\u00a0antibodies \u00a0in\u00a0Europe.\u00a0J\u00a0Infect\u00a0Dis\u00a02008;\u00a0198(9):1337 \u20101344.\u00a0\n\u00a0 759.\u00a0\u00a0Shores\u00a0NJ,\u00a0Maida\u00a0I,\u00a0Soriano\u00a0V,\u00a0Nunez\u00a0M.\u00a0Sexual\u00a0transmission \u00a0is\u00a0associated \u00a0with\u00a0spontaneous \u00a0\nHCV\u00a0clearance \u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0J\u00a0Hepatol\u00a02008;\u00a049(3):323 \u2010328.\u00a0\n\u00a0 760.\u00a0\u00a0Serpaggi\u00a0J,\u00a0Chaix\u00a0ML,\u00a0Batisse\u00a0D,\u00a0Dupont\u00a0C,\u00a0Vallet\u2010Pichard\u00a0A,\u00a0Fontaine\u00a0H\u00a0et\u00a0al.\u00a0Sexually\u00a0trans\u2010\nmitted\u00a0acute\u00a0infection\u00a0with\u00a0a\u00a0clustered \u00a0genotype \u00a04\u00a0hepatitis\u00a0C\u00a0virus\u00a0in\u00a0HIV\u20101\u2010infected\u00a0men\u00a0\nand\u00a0inefficacy \u00a0of\u00a0early\u00a0antiviral\u00a0therapy.\u00a0AIDS\u00a02006;\u00a020(2):233 \u2010240.\u00a0\n\u00a0 761.\u00a0\u00a0Gotz\u00a0HM,\u00a0van\u00a0DG,\u00a0Niesters\u00a0HG,\u00a0den\u00a0Hollander \u00a0JG,\u00a0Thio\u00a0HB,\u00a0de\u00a0ZO.\u00a0A\u00a0cluster\u00a0of\u00a0acute\u00a0hepatitis\u00a0\nC\u00a0virus\u00a0infection\u00a0among\u00a0men\u00a0who\u00a0have\u00a0sex\u00a0with\u00a0men\u2010\u2010results\u00a0from\u00a0contact\u00a0tracing\u00a0and\u00a0public\u00a0\nhealth\u00a0implications. \u00a0AIDS\u00a02005;\u00a019(9):969 \u2010974.\u00a0\n\u00a0 762.\u00a0\u00a0Jaeckel\u00a0E,\u00a0Cornberg \u00a0M,\u00a0Wedemeyer \u00a0H,\u00a0Santantonio \u00a0T,\u00a0Mayer\u00a0J,\u00a0Zankel\u00a0M\u00a0et\u00a0al.\u00a0Treatment \u00a0of\u00a0\nacute\u00a0hepatitis\u00a0C\u00a0with\u00a0interferon \u00a0alfa\u20102b.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02001;\u00a0345(20):1452 \u20101457.\u00a0\n\u00a0 763.\u00a0\u00a0Santantonio \u00a0T,\u00a0Fasano\u00a0M.\u00a0Therapy\u00a0of\u00a0acute\u00a0hepatitis\u00a0C:\u00a0a\u00a0review\u00a0of\u00a0literature. \u00a0Curr\u00a0Pharm\u00a0Des\u00a0\n2008;\u00a014(17):1686 \u20101689.\u00a0\n\u00a0 764.\u00a0\u00a0Soriano\u00a0V,\u00a0Puoti\u00a0M,\u00a0Sulkowski \u00a0M,\u00a0Cargnel\u00a0A,\u00a0Benhamou \u00a0Y,\u00a0Peters\u00a0M\u00a0et\u00a0al.\u00a0Care\u00a0of\u00a0patients\u00a0\ncoinfected \u00a0with\u00a0HIV\u00a0and\u00a0hepatitis\u00a0C\u00a0virus:\u00a02007\u00a0updated\u00a0recommendations \u00a0from\u00a0the\u00a0HCV\u2010HIV\u00a0\nInternational \u00a0Panel.\u00a0AIDS\u00a02007;\u00a021(9):1073 \u20101089.\u00a0\n\u00a0 765.\u00a0\u00a0Vogel\u00a0M,\u00a0Nattermann \u00a0J,\u00a0Baumgarten \u00a0A,\u00a0Klausen\u00a0G,\u00a0Bieniek\u00a0B,\u00a0Schewe\u00a0K\u00a0et\u00a0al.\u00a0Pegylated \u00a0inter\u2010\nferon\u2010alpha\u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0sexually\u00a0transmitted \u00a0acute\u00a0hepatitis\u00a0C\u00a0in\u00a0HIV\u2010infected\u00a0indivi\u2010\nduals.\u00a0Antivir\u00a0Ther\u00a02006;\u00a011(8):1097 \u20101101.\u00a0\n\u00a0 766.\u00a0\u00a0Glue\u00a0P.\u00a0The\u00a0clinical\u00a0pharmacology \u00a0of\u00a0ribavirin.\u00a0Semin\u00a0Liver\u00a0Dis\u00a01999;\u00a019\u00a0Suppl\u00a01:17\u201024.\u00a0\n\u00a0 767.\u00a0\u00a0Japour\u00a0AJ,\u00a0Lertora\u00a0JJ,\u00a0Meehan\u00a0PM,\u00a0Erice\u00a0A,\u00a0Connor\u00a0JD,\u00a0Griffith\u00a0BP\u00a0et\u00a0al.\u00a0A\u00a0phase\u2010I\u00a0study\u00a0of\u00a0the\u00a0\nsafety,\u00a0pharmacokinetics, \u00a0and\u00a0antiviral\u00a0activity\u00a0of\u00a0combination \u00a0didanosine \u00a0and\u00a0ribavirin\u00a0in\u00a0pa\u2010\ntients\u00a0with\u00a0HIV\u20101\u00a0disease.\u00a0AIDS\u00a0Clinical\u00a0Trials\u00a0Group\u00a0231\u00a0Protocol\u00a0Team.\u00a0J\u00a0Acquir\u00a0Immune\u00a0De\u2010\nfic\u00a0Syndr\u00a0Hum\u00a0Retrovirol \u00a01996;\u00a013(3):235 \u201046.\u00a0\n\u00a0 768.\u00a0\u00a0Mira\u00a0JA,\u00a0Lopez\u2010Cortes\u00a0LF,\u00a0Barreiro\u00a0P,\u00a0Tural\u00a0C,\u00a0Torres\u2010Tortosa\u00a0M,\u00a0de\u00a0Los\u00a0SG,\u00a0I\u00a0et\u00a0al.\u00a0Efficacy\u00a0of\u00a0\npegylated \u00a0interferon \u00a0plus\u00a0ribavirin\u00a0treatment \u00a0in\u00a0HIV/hepatitis \u00a0C\u00a0virus\u00a0co\u2010infected\u00a0patients\u00a0re\u2010\nceiving\u00a0abacavir\u00a0plus\u00a0lamivudine \u00a0or\u00a0tenofovir\u00a0plus\u00a0either\u00a0lamivudine \u00a0or\u00a0emtricitabine \u00a0as\u00a0nu\u2010\ncleoside\u00a0analogue\u00a0backbone. \u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02008;\u00a062(6):1365 \u20101373.\u00a0\n\u00a0 769.\u00a0\u00a0Bani\u2010Sadr\u00a0F,\u00a0Denoeud\u00a0L,\u00a0Morand\u00a0P,\u00a0Lunel\u2010Fabiani\u00a0F,\u00a0Pol\u00a0S,\u00a0Cacoub\u00a0P\u00a0et\u00a0al.\u00a0Early\u00a0virologic\u00a0failu\u2010\nre\u00a0in\u00a0HIV\u2010coinfected \u00a0hepatitis\u00a0C\u00a0patients\u00a0treated\u00a0with\u00a0the\u00a0peginterferon \u2010ribavirin\u00a0combina\u2010\ntion:\u00a0does\u00a0abacavir\u00a0play\u00a0a\u00a0role?\u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a045(1):123 \u2010125.\u00a0\n\u00a0 770.\u00a0\u00a0Laguno\u00a0M,\u00a0Cifuentes \u00a0C,\u00a0Murillas\u00a0J,\u00a0Veloso\u00a0S,\u00a0Larrousse \u00a0M,\u00a0Payeras\u00a0A\u00a0et\u00a0al.\u00a0Randomized \u00a0trial\u00a0\ncomparing \u00a0pegylated \u00a0interferon \u00a0alpha\u20102b\u00a0versus\u00a0pegylated \u00a0interferon \u00a0alpha\u20102a,\u00a0both\u00a0plus\u00a0ri\u2010\nbavirin,\u00a0to\u00a0treat\u00a0chronic\u00a0hepatitis\u00a0C\u00a0in\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0patients.\u00a0Hepatology \u00a0\n2009;\u00a049(1):22\u201031.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 155 \n \u00a0 771.\u00a0\u00a0Laufer\u00a0N,\u00a0Laguno\u00a0M,\u00a0Perez\u00a0I,\u00a0Cifuentes \u00a0C,\u00a0Murillas\u00a0J,\u00a0Vidal\u00a0F\u00a0et\u00a0al.\u00a0Abacavir\u00a0does\u00a0not\u00a0influence\u00a0\nthe\u00a0rate\u00a0of\u00a0virological \u00a0response\u00a0in\u00a0HIV\u2010HCV\u2010coinfected \u00a0patients\u00a0treated\u00a0with\u00a0pegylated \u00a0inter\u2010\nferon\u00a0and\u00a0weight\u2010adjusted\u00a0ribavirin.\u00a0Antivir\u00a0Ther\u00a02008;\u00a013(7):953 \u2010957.\u00a0\n\u00a0 772.\u00a0\u00a0Meynard\u00a0JL,\u00a0Lacombe\u00a0K,\u00a0Poirier\u00a0JM,\u00a0Legrand\u00a0J,\u00a0Morand\u2010Joubert\u00a0L,\u00a0Girard\u00a0PM.\u00a0Influence \u00a0of\u00a0\nliver\u00a0fibrosis\u00a0stage\u00a0on\u00a0plasma\u00a0levels\u00a0of\u00a0efavirenz\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0chronic\u00a0hepati\u2010\ntis\u00a0B\u00a0or\u00a0C.\u00a0J\u00a0Antimicrob \u00a0Chemother \u00a02009;\u00a063(3):579 \u2010584.\u00a0\n\u00a0 773.\u00a0\u00a0Rodriguez \u2010Novoa\u00a0S,\u00a0Morello\u00a0J,\u00a0Gonzalez\u00a0M,\u00a0Vispo\u00a0E,\u00a0Barreiro\u00a0P,\u00a0Gonzalez\u2010Pardo\u00a0G\u00a0et\u00a0al.\u00a0In\u2010\ncrease\u00a0in\u00a0serum\u00a0bilirubin\u00a0in\u00a0HIV/hepatitis \u2010C\u00a0virus\u2010coinfected \u00a0patients\u00a0on\u00a0atazanavir \u00a0therapy\u00a0\nfollowing \u00a0initiation\u00a0of\u00a0pegylated \u2010interferon \u00a0and\u00a0ribavirin.\u00a0AIDS\u00a02008;\u00a022(18):2535 \u20102537.\u00a0\n\u00a0 774.\u00a0\u00a0van\u00a0Bommel\u00a0F.,\u00a0Wunsche \u00a0T,\u00a0Mauss\u00a0S,\u00a0Reinke\u00a0P,\u00a0Bergk\u00a0A,\u00a0Schurmann \u00a0D\u00a0et\u00a0al.\u00a0Comparison \u00a0of\u00a0\nadefovir\u00a0and\u00a0tenofovir\u00a0in\u00a0the\u00a0treatment \u00a0of\u00a0lamivudine \u2010resistant\u00a0hepatitis\u00a0B\u00a0virus\u00a0infection. \u00a0\nHepatology \u00a02004;\u00a040(6):1421 \u20101425.\u00a0\n\u00a0 775.\u00a0\u00a0Dore\u00a0GJ,\u00a0Cooper\u00a0DA,\u00a0Pozniak\u00a0AL,\u00a0DeJesus\u00a0E,\u00a0Zhong\u00a0L,\u00a0Miller\u00a0MD\u00a0et\u00a0al.\u00a0Efficacy\u00a0of\u00a0tenofovir\u00a0\ndisoproxil \u00a0fumarate \u00a0in\u00a0antiretroviral \u00a0therapy\u2010naive\u00a0and\u00a0\u2010experienced \u00a0patients\u00a0coinfected \u00a0with\u00a0\nHIV\u20101\u00a0and\u00a0hepatitis\u00a0B\u00a0virus.\u00a0J\u00a0Infect\u00a0Dis\u00a02004;\u00a0189(7):1185 \u20101192.\u00a0\n\u00a0 776.\u00a0\u00a0Schildgen \u00a0O,\u00a0Schewe\u00a0CK,\u00a0Vogel\u00a0M,\u00a0Daumer\u00a0M,\u00a0Kaiser\u00a0R,\u00a0Weitner\u00a0L\u00a0et\u00a0al.\u00a0Successful \u00a0therapy\u00a0of\u00a0\nhepatitis\u00a0B\u00a0with\u00a0tenofovir\u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0failing\u00a0previous\u00a0adefovir\u00a0and\u00a0lamivudine \u00a0\ntreatment. \u00a0AIDS\u00a02004;\u00a018(17):2325 \u20102327.\u00a0\n\u00a0 777.\u00a0\u00a0Lim\u00a0SG,\u00a0Ng\u00a0TM,\u00a0Kung\u00a0N,\u00a0Krastev\u00a0Z,\u00a0Volfova\u00a0M,\u00a0Husa\u00a0P\u00a0et\u00a0al.\u00a0A\u00a0double\u2010blind\u00a0placebo\u2010controlled \u00a0\nstudy\u00a0of\u00a0emtricitabine \u00a0in\u00a0chronic\u00a0hepatitis\u00a0B.\u00a0Arch\u00a0Intern\u00a0Med\u00a02006;\u00a0166(1):49 \u201056.\u00a0\n\u00a0 778.\u00a0\u00a0Bang\u00a0LM,\u00a0Scott\u00a0LJ.\u00a0Emtricitabine: \u00a0an\u00a0antiretroviral \u00a0agent\u00a0for\u00a0HIV\u00a0infection. \u00a0Drugs\u00a02003;\u00a0\n63(22):2413 \u20102424.\u00a0\n\u00a0 779.\u00a0\u00a0Thio\u00a0CL,\u00a0Locarnini\u00a0S.\u00a0Treatment \u00a0of\u00a0HIV/HBV\u00a0coinfection: \u00a0clinical\u00a0and\u00a0virologic\u00a0issues.\u00a0AIDS\u00a0Rev\u00a0\n2007;\u00a09(1):40\u201053.\u00a0\n\u00a0 780.\u00a0\u00a0Ramos\u00a0B,\u00a0Nunez\u00a0M,\u00a0Martin\u2010Carbonero \u00a0L,\u00a0Sheldon\u00a0J,\u00a0Rios\u00a0P,\u00a0Labarga\u00a0P\u00a0et\u00a0al.\u00a0Hepatitis\u00a0B\u00a0virus\u00a0\ngenotypes \u00a0and\u00a0lamivudine \u00a0resistance \u00a0mutations \u00a0in\u00a0HIV/hepatitis \u00a0B\u00a0virus\u2010coinfected \u00a0patients.\u00a0J\u00a0\nAcquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02007;\u00a044(5):557 \u2010561.\u00a0\n\u00a0 781.\u00a0\u00a0Matthews \u00a0GV,\u00a0Bartholomeusz \u00a0A,\u00a0Locarnini\u00a0S,\u00a0Ayres\u00a0A,\u00a0Sasaduesz \u00a0J,\u00a0Seaberg\u00a0E\u00a0et\u00a0al.\u00a0Characte\u2010\nristics\u00a0of\u00a0drug\u00a0resistant\u00a0HBV\u00a0in\u00a0an\u00a0international \u00a0collaborative \u00a0study\u00a0of\u00a0HIV\u2010HBV\u2010infected\u00a0indi\u2010\nviduals\u00a0on\u00a0extended \u00a0lamivudine \u00a0therapy.\u00a0AIDS\u00a02006;\u00a020(6):863 \u2010870.\u00a0\n\u00a0 782.\u00a0\u00a0Suzuki\u00a0F,\u00a0Tsubota\u00a0A,\u00a0Arase\u00a0Y,\u00a0Suzuki\u00a0Y,\u00a0Akuta\u00a0N,\u00a0Hosaka\u00a0T\u00a0et\u00a0al.\u00a0Efficacy\u00a0of\u00a0lamivudine \u00a0therapy\u00a0\nand\u00a0factors\u00a0associated \u00a0with\u00a0emergence \u00a0of\u00a0resistance \u00a0in\u00a0chronic\u00a0hepatitis\u00a0B\u00a0virus\u00a0infection\u00a0in\u00a0\nJapan.\u00a0Intervirology \u00a02003;\u00a046(3):182 \u2010189.\u00a0\n\u00a0 783.\u00a0\u00a0Bessesen\u00a0M,\u00a0Ives\u00a0D,\u00a0Condreay \u00a0L,\u00a0Lawrence \u00a0S,\u00a0Sherman\u00a0KE.\u00a0Chronic\u00a0active\u00a0hepatitis\u00a0B\u00a0exacer\u2010\nbations\u00a0in\u00a0human\u00a0immunodeficiency \u00a0virus\u2010infected\u00a0patients\u00a0following \u00a0development \u00a0of\u00a0resis\u2010\ntance\u00a0to\u00a0or\u00a0withdrawal \u00a0of\u00a0lamivudine. \u00a0Clin\u00a0Infect\u00a0Dis\u00a01999;\u00a028(5):1032 \u20105.\u00a0\n\u00a0 784.\u00a0\u00a0Polo\u00a0R,\u00a0Iribarren\u00a0JA,\u00a0de\u00a0Jos\u00e9\u00a0MI,\u00a0Mu\u00f1oz\u00a0G\u00e1lligo\u00a0E,\u00a0(Coordinadores). \u00a0Recomendaciones \u00a0de\u00a0la\u00a0\nSecretar\u00eda \u00a0del\u00a0Plan\u00a0Nacional\u00a0sobre\u00a0el\u00a0Sida,\u00a0el\u00a0Grupo\u00a0de\u00a0estudio\u00a0de\u00a0Sida,\u00a0la\u00a0Sociedad\u00a0Espa\u00f1ola\u00a0\nde\u00a0Ginecolog\u00eda \u00a0y\u00a0Obstetricia \u00a0y\u00a0la\u00a0Asociaci\u00f3n \u00a0Espa\u00f1ola\u00a0de\u00a0Pediatr\u00eda\u00a0para\u00a0el\u00a0seguimiento \u00a0de\u00a0la\u00a0\ninfecci\u00f3n\u00a0por\u00a0el\u00a0VIH\u00a0con\u00a0relaci\u00f3n\u00a0a\u00a0la\u00a0reproducci\u00f3n, \u00a0el\u00a0embarazo \u00a0y\u00a0la\u00a0prevenci\u00f3n \u00a0de\u00a0la\u00a0trans\u2010\nmisi\u00f3n\u00a0vertical\u00a0(diciembre \u00a02007).\u00a0Accesible \u00a0en:\u00a0http://www.gesida.seimc.org/ \u00a0(Acceso\u00a0\n8.12.09)\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 156 \n \u00a0 785.\u00a0\u00a0Public\u00a0Health\u00a0Service\u00a0Task\u00a0Force.\u00a0Recommendations \u00a0for\u00a0the\u00a0Use\u00a0of\u00a0Antiretroviral \u00a0Drugs\u00a0in\u00a0\nPregnant\u00a0HIV\u2010Infected\u00a0Women\u00a0for\u00a0Maternal\u00a0Health\u00a0and\u00a0Interventions \u00a0to\u00a0Reduce\u00a0Perinatal\u00a0\nHIV\u00a0Transmission \u00a0in\u00a0the\u00a0United\u00a0States,\u00a0April\u00a029,\u00a02009.\u00a0Disponible \u00a0en:\u00a0\nhttp://aidsinfo.nih.gov/con tentfiles/PerinatalGL.pdf \u00a0(Acceso\u00a08.12.09)\u00a0\u00a0\n\u00a0 786.\u00a0\u00a0Ioannidis\u00a0JP,\u00a0Abrams\u00a0EJ,\u00a0Ammann\u00a0A,\u00a0Bulterys\u00a0M,\u00a0Goedert\u00a0JJ,\u00a0Gray\u00a0L\u00a0et\u00a0al.\u00a0Perinatal\u00a0transmis\u2010\nsion\u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0by\u00a0pregnant\u00a0women\u00a0with\u00a0RNA\u00a0virus\u00a0loads\u00a0\n<1000\u00a0copies/ml. \u00a0J\u00a0Infect\u00a0Dis\u00a02001;\u00a0183(4):539 \u201045.\u00a0\n\u00a0 787.\u00a0\u00a0Watts\u00a0DH.\u00a0Management \u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0infection\u00a0in\u00a0pregnancy. \u00a0N\u00a0Engl\u00a0J\u00a0\nMed\u00a02002;\u00a0346(24):1879 \u20101891.\u00a0\n\u00a0 788.\u00a0\u00a0Riley\u00a0LE,\u00a0Yawetz\u00a0S.\u00a0Case\u00a0records\u00a0of\u00a0the\u00a0Massachusetts \u00a0General\u00a0Hospital.\u00a0Case\u00a032\u20102005.\u00a0A\u00a034\u2010\nyear\u2010old\u00a0HIV\u2010positive\u00a0woman\u00a0who\u00a0desired\u00a0to\u00a0become\u00a0pregnant. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02005;\u00a0\n353(16):1725 \u20101732.\u00a0\n\u00a0 789.\u00a0\u00a0Connor\u00a0EM,\u00a0Sperling\u00a0RS,\u00a0Gelber\u00a0R,\u00a0Kiselev\u00a0P,\u00a0Scott\u00a0G,\u00a0O'Sullivan \u00a0MJ\u00a0et\u00a0al.\u00a0Reduction \u00a0of\u00a0mater\u2010\nnal\u2010infant\u00a0transmission \u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0with\u00a0zidovudine \u00a0treatment. \u00a0\nPediatric\u00a0AIDS\u00a0Clinical\u00a0Trials\u00a0Group\u00a0Protocol\u00a0076\u00a0Study\u00a0Group.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a01994;\u00a0\n331(18):1173 \u201080.\u00a0\n\u00a0 790.\u00a0\u00a0Sperling\u00a0RS,\u00a0Shapiro\u00a0DE,\u00a0Coombs\u00a0RW,\u00a0Todd\u00a0JA,\u00a0Herman\u00a0SA,\u00a0McSherry \u00a0GD\u00a0et\u00a0al.\u00a0Maternal\u00a0viral\u00a0\nload,\u00a0zidovudine \u00a0treatment, \u00a0and\u00a0the\u00a0risk\u00a0of\u00a0transmission \u00a0of\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0\ntype\u00a01\u00a0from\u00a0mother\u00a0to\u00a0infant.\u00a0Pediatric\u00a0AIDS\u00a0Clinical\u00a0Trials\u00a0Group\u00a0Protocol\u00a0076\u00a0Study\u00a0Group.\u00a0\nN\u00a0Engl\u00a0J\u00a0Med\u00a01996;\u00a0335(22):1621 \u20109.\u00a0\n\u00a0 791.\u00a0\u00a0Jackson\u00a0JB,\u00a0Musoke\u00a0P,\u00a0Fleming\u00a0T,\u00a0Guay\u00a0LA,\u00a0Bagenda\u00a0D,\u00a0Allen\u00a0M\u00a0et\u00a0al.\u00a0Intrapartum \u00a0and\u00a0neona\u2010\ntal\u00a0single\u2010dose\u00a0nevirapine \u00a0compared \u00a0with\u00a0zidovudine \u00a0for\u00a0prevention \u00a0of\u00a0mother\u2010to\u2010child\u00a0\ntransmission \u00a0of\u00a0HIV\u20101\u00a0in\u00a0Kampala, \u00a0Uganda:\u00a018\u2010month\u00a0follow\u2010up\u00a0of\u00a0the\u00a0HIVNET\u00a0012\u00a0randomi\u2010\nsed\u00a0trial.\u00a0Lancet\u00a02003;\u00a0362(9387):859 \u2010868.\u00a0\n\u00a0 792.\u00a0\u00a0Johnson\u00a0JA,\u00a0Li\u00a0JF,\u00a0Morris\u00a0L,\u00a0Martinson \u00a0N,\u00a0Gray\u00a0G,\u00a0McIntyre\u00a0J\u00a0et\u00a0al.\u00a0Emergence \u00a0of\u00a0drug\u2010resistant\u00a0\nHIV\u20101\u00a0after\u00a0intrapartum \u00a0administration \u00a0of\u00a0single\u2010dose\u00a0nevirapine \u00a0is\u00a0substantially \u00a0underesti \u2010\nmated.\u00a0J\u00a0Infect\u00a0Dis\u00a02005;\u00a0192(1):16 \u201023.\u00a0\n\u00a0 793.\u00a0\u00a0Cunningham \u00a0CK,\u00a0Chaix\u00a0ML,\u00a0Rekacewicz \u00a0C,\u00a0Britto\u00a0P,\u00a0Rouzioux\u00a0C,\u00a0Gelber\u00a0RD\u00a0et\u00a0al.\u00a0Development \u00a0\nof\u00a0resistance \u00a0mutations \u00a0in\u00a0women\u00a0receiving\u00a0standard\u00a0antiretroviral \u00a0therapy\u00a0who\u00a0received\u00a0in\u2010\ntrapartum \u00a0nevirapine \u00a0to\u00a0prevent\u00a0perinatal\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0type\u00a01\u00a0transmis\u2010\nsion:\u00a0a\u00a0substudy\u00a0of\u00a0pediatric\u00a0AIDS\u00a0clinical\u00a0trials\u00a0group\u00a0protocol\u00a0316.\u00a0J\u00a0Infect\u00a0Dis\u00a02002;\u00a0\n186(2):181 \u2010188.\u00a0\n\u00a0 794.\u00a0\u00a0Mandelbrot \u00a0L,\u00a0Landreau \u2010Mascaro\u00a0A,\u00a0Rekacewicz \u00a0C,\u00a0Berrebi\u00a0A,\u00a0Benifla\u00a0JL,\u00a0Burgard\u00a0M\u00a0et\u00a0al.\u00a0\nLamivudine \u2010zidovudine \u00a0combination \u00a0for\u00a0prevention \u00a0of\u00a0maternal\u2010infant\u00a0transmission \u00a0of\u00a0HIV\u20101.\u00a0\nJama\u00a02001;\u00a0285(16):2083 \u20102093.\u00a0\n\u00a0 795.\u00a0\u00a0Apil\u00e1nez\u00a0M,\u00a0Iribarren\u00a0JA,\u00a0Echeverr\u00eda \u00a0J,\u00a0Landa\u00a0J,\u00a0Arrizabalaga \u00a0J,\u00a0Larraz\u00a0J\u00a0et\u00a0al.\u00a0Evoluci\u00f3n \u00a0de\u00a0la\u00a0\ntransmisi\u00f3n \u00a0vertical\u00a0del\u00a0VIH\u00a0en\u00a0Gipuzkoa: \u00a0la\u00a0experiencia \u00a0de\u00a020\u00a0a\u00f1os.\u00a0XI\u00a0Congreso \u00a0de\u00a0la\u00a0SEIMC,\u00a0\nBilbao,\u00a016\u201019\u00a0de\u00a0mayo\u00a0de\u00a02004\u00a0[Abstract\u00a026]\u00a0\n\u00a0 796.\u00a0\u00a0Shapiro\u00a0D,\u00a0Tuomala\u00a0R,\u00a0Pollack\u00a0H,\u00a0Burchett\u00a0S,\u00a0Read\u00a0J,\u00a0Cababasi\u00a0M\u00a0et\u00a0al.\u00a0Mother\u2010to\u2010child\u00a0HIV\u00a0\ntransmission \u00a0risk\u00a0according \u00a0to\u00a0antiretroviral \u00a0therapy,\u00a0mode\u00a0of\u00a0delivery,\u00a0and\u00a0viral\u00a0load\u00a0in\u00a02895\u00a0\nU.S.\u00a0women\u00a0(PACTG\u00a0367).\u00a011th\u00a0Conference \u00a0on\u00a0Retrovirus \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0\nFrancisco, \u00a0February\u00a08\u2010\u201011,\u00a02004\u00a0[Abstract\u00a099]\u00a0\n\u00a0 797.\u00a0\u00a0Cooper\u00a0ER,\u00a0Charurat\u00a0M,\u00a0Mofenson \u00a0L,\u00a0Hanson\u00a0IC,\u00a0Pitt\u00a0J,\u00a0Diaz\u00a0C\u00a0et\u00a0al.\u00a0Combination \u00a0antiretroviral \u00a0\nstrategies \u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0pregnant\u00a0HIV\u20101\u2010infected\u00a0women\u00a0and\u00a0prevention \u00a0of\u00a0perinatal\u00a0\nHIV\u20101\u00a0transmission. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02002;\u00a029(5):484 \u2010494.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 157 \n \u00a0 798.\u00a0\u00a0Morris\u00a0AB,\u00a0Dobles\u00a0AR,\u00a0Cu\u2010Uvin\u00a0S,\u00a0Zorrilla\u00a0C,\u00a0Anderson \u00a0J,\u00a0Harwell\u00a0JI\u00a0et\u00a0al.\u00a0Protease\u00a0inhibitor\u00a0use\u00a0\nin\u00a0233\u00a0pregnancies. \u00a0J\u00a0Acquir\u00a0Immune\u00a0Defic\u00a0Syndr\u00a02005;\u00a040(1):30\u201033.\u00a0\n\u00a0 799.\u00a0\u00a0Warszawski \u00a0J,\u00a0Tubiana\u00a0R,\u00a0Le\u00a0CJ,\u00a0Blanche\u00a0S,\u00a0Teglas\u00a0JP,\u00a0Dollfus\u00a0C\u00a0et\u00a0al.\u00a0Mother\u2010to\u2010child\u00a0HIV\u00a0\ntransmission \u00a0despite\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0the\u00a0ANRS\u00a0French\u00a0Perinatal\u00a0Cohort.\u00a0AIDS\u00a02008;\u00a0\n22(2):289 \u2010299.\u00a0\n\u00a0 800.\u00a0\u00a0Tuomala\u00a0RE,\u00a0Shapiro\u00a0DE,\u00a0Mofenson \u00a0LM,\u00a0Bryson\u00a0Y,\u00a0Culnane\u00a0M,\u00a0Hughes\u00a0MD\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0\ntherapy\u00a0during\u00a0pregnancy \u00a0and\u00a0the\u00a0risk\u00a0of\u00a0an\u00a0adverse\u00a0outcome. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02002;\u00a0\n346(24):1863 \u20101870.\u00a0\n\u00a0 801.\u00a0\u00a0Cotter\u00a0AM,\u00a0Garcia\u00a0AG,\u00a0Duthely\u00a0ML,\u00a0Luke\u00a0B,\u00a0O'Sullivan \u00a0MJ.\u00a0Is\u00a0antiretroviral \u00a0therapy\u00a0during\u00a0\npregnancy \u00a0associated \u00a0with\u00a0an\u00a0increased \u00a0risk\u00a0of\u00a0preterm\u00a0delivery,\u00a0low\u00a0birth\u00a0weight,\u00a0or\u00a0still\u2010\nbirth?\u00a0J\u00a0Infect\u00a0Dis\u00a02006;\u00a0193(9):1195 \u20101201.\u00a0\n\u00a0 802.\u00a0\u00a0Antiretroviral \u00a0Pregnancy \u00a0Registry\u00a0Steering\u00a0Committee. \u00a0Antiretroviral \u00a0pregnancy \u00a0registry\u00a0in\u2010\nternational \u00a0interim\u00a0report\u00a0for\u00a01\u00a0January\u00a01989\u00a0through\u00a031\u00a0January\u00a02008.\u00a0Accesible \u00a0\nen:www.apregistry.com .\u00a0\u00a0\n\u00a0 803.\u00a0\u00a0Sarner\u00a0L,\u00a0Fakoya\u00a0A.\u00a0Acute\u00a0onset\u00a0lactic\u00a0acidosis\u00a0and\u00a0pancreatitis \u00a0in\u00a0the\u00a0third\u00a0trimester \u00a0of\u00a0preg\u2010\nnancy\u00a0in\u00a0HIV\u20101\u00a0positive\u00a0women\u00a0taking\u00a0antiretroviral \u00a0medication. \u00a0Sex\u00a0Transm\u00a0Infect\u00a02002;\u00a0\n78(1):58\u201059.\u00a0\n\u00a0 804.\u00a0\u00a0Aaron\u00a0E,\u00a0Levine\u00a0AB,\u00a0Monahan \u00a0K,\u00a0Biondo\u00a0CP.\u00a0A\u00a0rapid\u00a0HIV\u00a0testing\u00a0program\u00a0for\u00a0labor\u00a0and\u00a0delive\u2010\nry\u00a0in\u00a0an\u00a0inner\u2010city\u00a0teaching\u00a0hospital.\u00a0AIDS\u00a0Read\u00a02006;\u00a016(1):22\u20109,\u00a037.\u00a0\n\u00a0 805.\u00a0\u00a0Fiore\u00a0S,\u00a0Newell\u00a0ML,\u00a0Thorne\u00a0C.\u00a0Higher\u00a0rates\u00a0of\u00a0post\u2010partum\u00a0complications \u00a0in\u00a0HIV\u2010infected\u00a0than\u00a0\nin\u00a0uninfected \u00a0women\u00a0irrespective \u00a0of\u00a0mode\u00a0of\u00a0delivery.\u00a0AIDS\u00a02004;\u00a018(6):933 \u2010938.\u00a0\n\u00a0 806.\u00a0\u00a0Achievements \u00a0in\u00a0public\u00a0health.\u00a0Reduction \u00a0in\u00a0perinatal\u00a0transmission \u00a0of\u00a0HIV\u00a0infection\u2010\u2010United\u00a0\nStates,\u00a01985\u20102005.\u00a0MMWR\u00a0Morb\u00a0Mortal\u00a0Wkly\u00a0Rep\u00a02006;\u00a055(21):592 \u2010597.\u00a0\n\u00a0 807.\u00a0\u00a0Baggaley\u00a0RF,\u00a0Boily\u00a0MC,\u00a0White\u00a0RG,\u00a0Alary\u00a0M.\u00a0Risk\u00a0of\u00a0HIV\u20101\u00a0transmission \u00a0for\u00a0parenteral \u00a0exposure\u00a0\nand\u00a0blood\u00a0transfusion: \u00a0a\u00a0systematic \u00a0review\u00a0and\u00a0meta\u2010analysis.\u00a0AIDS\u00a02006;\u00a020(6):805 \u2010812.\u00a0\n\u00a0 808.\u00a0\u00a0Cardo\u00a0DM,\u00a0Culver\u00a0DH,\u00a0Ciesielski\u00a0CA,\u00a0Srivastava \u00a0PU,\u00a0Marcus\u00a0R,\u00a0Abiteboul \u00a0D\u00a0et\u00a0al.\u00a0A\u00a0case\u2010control\u00a0\nstudy\u00a0of\u00a0HIV\u00a0seroconversion \u00a0in\u00a0health\u00a0care\u00a0workers\u00a0after\u00a0percutaneous \u00a0exposure. \u00a0Centers\u00a0for\u00a0\nDisease\u00a0Control\u00a0and\u00a0Prevention \u00a0Needlestick \u00a0Surveillance \u00a0Group.\u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a01997;\u00a0\n337(21):1485 \u201090.\u00a0\n\u00a0 809.\u00a0\u00a0Grob\u00a0PM,\u00a0Cao\u00a0Y,\u00a0Muchmore \u00a0E,\u00a0Ho\u00a0DD,\u00a0Norris\u00a0S,\u00a0Pav\u00a0JW\u00a0et\u00a0al.\u00a0Prophylaxis \u00a0against\u00a0HIV\u20101\u00a0infec\u2010\ntion\u00a0in\u00a0chimpanzees \u00a0by\u00a0nevirapine, \u00a0a\u00a0nonnucleoside \u00a0inhibitor\u00a0of\u00a0reverse\u00a0transcriptase. \u00a0Nat\u00a0\nMed\u00a01997;\u00a03(6):665\u201070.\u00a0\n\u00a0 810.\u00a0\u00a0Centers\u00a0for\u00a0Disease\u00a0Control\u00a0and\u00a0Prevention. \u00a0Serious\u00a0adverse\u00a0events\u00a0attributed \u00a0to\u00a0nevirapine \u00a0\nregimens \u00a0for\u00a0postexposure \u00a0prophylaxis \u00a0after\u00a0HIV\u00a0exposures \u2010\u2010worldwide, \u00a01997\u20102000.\u00a0MMWR\u00a0\nMorb\u00a0Mortal\u00a0Wkly\u00a0Rep\u00a02001;\u00a049(51\u201052):1153\u20106.\u00a0\n\u00a0 811.\u00a0\u00a0Moyle\u00a0G,\u00a0Higgs\u00a0C,\u00a0Teague\u00a0A,\u00a0Mandalia \u00a0S,\u00a0Nelson\u00a0M,\u00a0Johnson\u00a0M\u00a0et\u00a0al.\u00a0An\u00a0open\u2010label,\u00a0randomi\u2010\nzed\u00a0comparative \u00a0pilot\u00a0study\u00a0of\u00a0a\u00a0single\u2010class\u00a0quadruple \u00a0therapy\u00a0regimen\u00a0versus\u00a0a\u00a02\u2010class\u00a0tri\u2010\nple\u00a0therapy\u00a0regimen\u00a0for\u00a0individuals \u00a0initiating\u00a0antiretroviral \u00a0therapy.\u00a0Antivir\u00a0Ther\u00a02006;\u00a0\n11(1):73\u201078.\u00a0\n\u00a0 812.\u00a0\u00a0Dumond\u00a0JB,\u00a0Yeh\u00a0RF,\u00a0Patterson \u00a0KB,\u00a0Corbett\u00a0AH,\u00a0Jung\u00a0BH,\u00a0Rezk\u00a0NL\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0drug\u00a0\nexposure\u00a0in\u00a0the\u00a0female\u00a0genital\u00a0tract:\u00a0implications \u00a0for\u00a0oral\u00a0pre\u2010\u00a0and\u00a0post\u2010exposure\u00a0prophylaxis. \u00a0\nAIDS\u00a02007;\u00a021(14):1899 \u20101907.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 158 \n \u00a0 813.\u00a0\u00a0Beltrami\u00a0EM,\u00a0Cheingsong \u00a0R,\u00a0Heneine\u00a0WM,\u00a0Respess\u00a0RA,\u00a0Orelien\u00a0JG,\u00a0Mendelson \u00a0MH\u00a0et\u00a0al.\u00a0Anti\u2010\nretroviral \u00a0drug\u00a0resistance \u00a0in\u00a0human\u00a0immunodeficiency \u00a0virus\u2010infected\u00a0source\u00a0patients\u00a0for\u00a0oc\u2010\ncupational \u00a0exposures \u00a0to\u00a0healthcare \u00a0workers.\u00a0Infect\u00a0Control\u00a0Hosp\u00a0Epidemiol \u00a02003;\u00a024(10):724 \u2010\n730.\u00a0\n\u00a0 814.\u00a0\u00a0Polo\u00a0R,\u00a0Aguirrebengoa \u00a0K,\u00a0Vives\u00a0N,\u00a0(Coordinadores). \u00a0Recomendaciones \u00a0del\u00a0SPNS,\u00a0Gesida,\u00a0CE\u2010\nESCAT,\u00a0SEIP\u00a0y\u00a0AEP\u00a0sobre\u00a0profilaxis\u00a0postexposici\u00f3n \u00a0frente\u00a0al\u00a0VIH,\u00a0VHB\u00a0y\u00a0VHC\u00a0en\u00a0adultos\u00a0y\u00a0ni\u00f1os.\u00a0\nMinisterio \u00a0Sanidad\u00a0y\u00a0Consumo \u00a02008\u00a0\n\u00a0 815.\u00a0\u00a0Smith\u00a0DK,\u00a0Grohskopf \u00a0LA,\u00a0Black\u00a0RJ,\u00a0Auerbach \u00a0JD,\u00a0Veronese \u00a0F,\u00a0Struble\u00a0KA\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0\npostexposure \u00a0prophylaxis \u00a0after\u00a0sexual,\u00a0injection\u2010drug\u00a0use,\u00a0or\u00a0other\u00a0nonoccupational \u00a0exposu\u2010\nre\u00a0to\u00a0HIV\u00a0in\u00a0the\u00a0United\u00a0States:\u00a0recommendations \u00a0from\u00a0the\u00a0U.S.\u00a0Department \u00a0of\u00a0Health\u00a0and\u00a0\nHuman\u00a0Services.\u00a0MMWR\u00a0Recomm\u00a0Rep\u00a02005;\u00a054(RR\u20102):1\u201020.\u00a0\n\u00a0 816.\u00a0\u00a0van\u00a0der\u00a0Straten\u00a0A,\u00a0Gomez\u00a0CA,\u00a0Saul\u00a0J,\u00a0Quan\u00a0J,\u00a0Padian\u00a0N.\u00a0Sexual\u00a0risk\u00a0behaviors \u00a0among\u00a0hetero\u2010\nsexual\u00a0HIV\u00a0serodiscordant \u00a0couples\u00a0in\u00a0the\u00a0era\u00a0of\u00a0post\u2010exposure\u00a0prevention \u00a0and\u00a0viral\u00a0suppressi \u2010\nve\u00a0therapy.\u00a0AIDS\u00a02000;\u00a014(4):47\u201054.\u00a0\n\u00a0 817.\u00a0\u00a0Martin\u00a0JN,\u00a0Roland\u00a0ME,\u00a0Neilands\u00a0TB,\u00a0Krone\u00a0MR,\u00a0Bamberger \u00a0JD,\u00a0Kohn\u00a0RP\u00a0et\u00a0al.\u00a0Use\u00a0of\u00a0postex\u2010\nposure\u00a0prophylaxis \u00a0against\u00a0HIV\u00a0infection\u00a0following \u00a0sexual\u00a0exposure\u00a0does\u00a0not\u00a0lead\u00a0to\u00a0increases \u00a0\nin\u00a0high\u2010risk\u00a0behavior. \u00a0AIDS\u00a02004;\u00a018(5):787 \u2010792.\u00a0\n\u00a0 818.\u00a0\u00a0Rabaud\u00a0C,\u00a0Bevilacqua \u00a0S,\u00a0Beguinot\u00a0I,\u00a0Dorvaux\u00a0V,\u00a0Schuhmacher \u00a0H,\u00a0May\u00a0T\u00a0et\u00a0al.\u00a0Tolerability \u00a0of\u00a0\npostexposure \u00a0prophylaxis \u00a0with\u00a0zidovudine, \u00a0lamivudine, \u00a0and\u00a0nelfinavir \u00a0for\u00a0human\u00a0immunode \u2010\nficiency\u00a0virus\u00a0infection. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02001;\u00a032(10):1494 \u20105.\u00a0\n\u00a0 819.\u00a0\u00a0Guinot\u00a0D,\u00a0Ho\u00a0MT,\u00a0Poynten\u00a0IM,\u00a0McAllister \u00a0J,\u00a0Pierce\u00a0A,\u00a0Pell\u00a0C\u00a0et\u00a0al.\u00a0Cost\u2010effectiveness \u00a0of\u00a0HIV\u00a0\nnonoccupational \u00a0post\u2010exposure\u00a0prophylaxis \u00a0in\u00a0Australia. \u00a0HIV\u00a0Med\u00a02009;\u00a010(4):199 \u2010208.\u00a0\n\u00a0 820.\u00a0\u00a0Dybul\u00a0M,\u00a0Chun\u00a0TW,\u00a0Yoder\u00a0C,\u00a0Hidalgo\u00a0B,\u00a0Belson\u00a0M,\u00a0Hertogs\u00a0K\u00a0et\u00a0al.\u00a0Short\u2010cycle\u00a0structured \u00a0\nintermittent \u00a0treatment \u00a0of\u00a0chronic\u00a0HIV\u00a0infection\u00a0with\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy:\u00a0ef\u2010\nfects\u00a0on\u00a0virologic,\u00a0immunologic, \u00a0and\u00a0toxicity\u00a0parameters. \u00a0Proc\u00a0Natl\u00a0Acad\u00a0Sci\u00a0U\u00a0S\u00a0A\u00a02001;\u00a0\n98(26):15161 \u20106.\u00a0\n\u00a0 821.\u00a0\u00a0Garcia\u00a0F,\u00a0Plana\u00a0M,\u00a0Ortiz\u00a0GM,\u00a0Bonhoeffer \u00a0S,\u00a0Soriano\u00a0A,\u00a0Vidal\u00a0C\u00a0et\u00a0al.\u00a0The\u00a0virological \u00a0and\u00a0immu\u2010\nnological\u00a0consequences \u00a0of\u00a0structured \u00a0treatment \u00a0interruptions \u00a0in\u00a0chronic\u00a0HIV\u20101\u00a0infection. \u00a0\u00a0\nAIDS\u00a02001;\u00a015:F29\u201040.\u00a0\n\u00a0 822.\u00a0\u00a0Ruiz\u00a0L,\u00a0Carcelain\u00a0G,\u00a0Martinez\u2010Picado\u00a0J,\u00a0Frost\u00a0S,\u00a0Marfil\u00a0S,\u00a0Paredes\u00a0R\u00a0et\u00a0al.\u00a0HIV\u00a0dynamics \u00a0and\u00a0\nTcell\u00a0immunity \u00a0after\u00a0three\u00a0structured \u00a0treatment \u00a0interruptions \u00a0in\u00a0chronic\u00a0HIV\u20101\u00a0infection. \u00a0\u00a0\nAIDS\u00a02001;\u00a015:F19\u201027.\u00a0\n\u00a0 823.\u00a0\u00a0Fagard\u00a0C,\u00a0Oxenius\u00a0A,\u00a0Gunthard \u00a0H,\u00a0Garcia\u00a0F,\u00a0Le\u00a0Braz\u00a0M,\u00a0Mestre\u00a0G\u00a0et\u00a0al.\u00a0A\u00a0prospective \u00a0trial\u00a0of\u00a0\nstructured \u00a0treatment \u00a0interruptions \u00a0in\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0infection. \u00a0Arch\u00a0Intern\u00a0\nMed\u00a02003;\u00a0163:1220 \u20101226.\u00a0\n\u00a0 824.\u00a0\u00a0Miller\u00a0V,\u00a0Sabin\u00a0C,\u00a0Hertogs\u00a0K,\u00a0Bloor\u00a0S,\u00a0Martinez\u2010Picado\u00a0J,\u00a0D'Aquila\u00a0R\u00a0et\u00a0al.\u00a0Virological \u00a0and\u00a0im\u2010\nmunological \u00a0effects\u00a0of\u00a0treatment \u00a0interruptions \u00a0in\u00a0HIV\u20101\u00a0infected\u00a0patients\u00a0with\u00a0treatment \u00a0fai\u2010\nlure.\u00a0AIDS\u00a02000;\u00a014(18):2857 \u201067.\u00a0\n\u00a0 825.\u00a0\u00a0Walmsley \u00a0SL,\u00a0Thorne\u00a0A,\u00a0Loutfy\u00a0MR,\u00a0LaPierre\u00a0N,\u00a0MacLeod\u00a0J,\u00a0Harrigan\u00a0R\u00a0et\u00a0al.\u00a0A\u00a0prospective \u00a0\nrandomized \u00a0controlled \u00a0trial\u00a0of\u00a0structured \u00a0treatment \u00a0interruption \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0fai\u2010\nling\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy\u00a0(Canadian \u00a0HIV\u00a0Trials\u00a0Network\u00a0Study\u00a0164).\u00a0J\u00a0Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr\u00a02007;\u00a045(4):418 \u2010425.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 159 \n \u00a0 826.\u00a0\u00a0Ruiz\u00a0L,\u00a0Ribera\u00a0E,\u00a0Bonjoch\u00a0A,\u00a0Romeu\u00a0J,\u00a0Martinez\u2010Picado\u00a0J,\u00a0Paredes\u00a0R\u00a0et\u00a0al.\u00a0Role\u00a0of\u00a0structured \u00a0\ntreatment \u00a0interruption \u00a0before\u00a0a\u00a05\u2010drug\u00a0salvage\u00a0antiretroviral \u00a0regimen:\u00a0the\u00a0Retrogene \u00a0Study.\u00a0J\u00a0\nInfect\u00a0Dis\u00a02003;\u00a0188:977\u2010985.\u00a0\n\u00a0 827.\u00a0\u00a0Deeks\u00a0SG,\u00a0Hoh\u00a0R,\u00a0Grant\u00a0RM,\u00a0Wrin\u00a0T,\u00a0Barbour\u00a0JD,\u00a0Narvaez\u00a0A\u00a0et\u00a0al.\u00a0CD4+\u00a0T\u00a0Cell\u00a0Kinetics\u00a0and\u00a0\nActivation \u00a0in\u00a0Human\u00a0Immunodeficiency \u00a0Virus\u2010Infected\u00a0Patients\u00a0Who\u00a0Remain\u00a0Viremic\u00a0Despite\u00a0\nLong\u2010Term\u00a0Treatment \u00a0with\u00a0Protease\u00a0Inhibitor\u2010Based\u00a0Therapy.\u00a0J\u00a0Infect\u00a0Dis\u00a02002;\u00a0185(3):315 \u2010\n23.\u00a0\n\u00a0 828.\u00a0\u00a0Ananworanich \u00a0J,\u00a0Hirschel\u00a0B.\u00a0Intermittent \u00a0therapy\u00a0for\u00a0the\u00a0treatment \u00a0of\u00a0chronic\u00a0HIV\u00a0infection. \u00a0\nAIDS\u00a02007;\u00a021(2):123 \u2010134.\u00a0\n\u00a0 829.\u00a0\u00a0Arnedo\u2010Valero\u00a0M,\u00a0Garc\u00eda\u00a0F,\u00a0Gil\u00a0C,\u00a0Castro\u00a0P,\u00a0Blanco\u00a0JL,\u00a0Miro\u00a0JM\u00a0et\u00a0al.\u00a0Risk\u00a0of\u00a0developing \u00a0selec\u2010\nted\u00a0de\u00a0novo\u00a0resistance \u00a0mutations \u00a0during\u00a0structured \u00a0therapy\u00a0interruption \u00a0in\u00a0chronic\u00a0HIV\u20101\u00a0in\u2010\nfection.\u00a011th\u00a0Conference \u00a0on\u00a0Retrovirus \u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0San\u00a0Francisco, \u00a0February\u00a0\n8\u2010\u201011,\u00a02004\u00a0[Abstract\u00a0668]\u00a0\n\u00a0 830.\u00a0\u00a0Cardiello\u00a0PG,\u00a0Hassink\u00a0E,\u00a0Ananworanich \u00a0J,\u00a0Srasuebkul \u00a0P,\u00a0Samor\u00a0T,\u00a0Mahanontharit \u00a0A\u00a0et\u00a0al.\u00a0A\u00a0\nprospective, \u00a0randomized \u00a0trial\u00a0of\u00a0structured \u00a0treatment \u00a0interruption \u00a0for\u00a0patients\u00a0with\u00a0chronic\u00a0\nHIV\u00a0type\u00a01\u00a0infection. \u00a0Clin\u00a0Infect\u00a0Dis\u00a02005;\u00a040(4):594 \u2010600.\u00a0\n\u00a0 831.\u00a0\u00a0Danel\u00a0C,\u00a0Moh\u00a0R,\u00a0Minga\u00a0A,\u00a0Anzian\u00a0A,\u00a0Ba\u2010Gomis\u00a0O,\u00a0Kanga\u00a0C\u00a0et\u00a0al.\u00a0CD4\u2010guided\u00a0structured \u00a0antire\u2010\ntroviral\u00a0treatment \u00a0interruption \u00a0strategy\u00a0in\u00a0HIV\u2010infected\u00a0adults\u00a0in\u00a0west\u00a0Africa\u00a0(Trivacan\u00a0ANRS\u00a0\n1269\u00a0trial):\u00a0a\u00a0randomised \u00a0trial.\u00a0Lancet\u00a02006;\u00a0367(9527):1981 \u20101989.\u00a0\n\u00a0 832.\u00a0\u00a0Jacobson\u00a0JM,\u00a0Turner\u00a0BJ,\u00a0Abrutyn\u00a0E.\u00a0Trials\u00a0that\u00a0matter:\u00a0CD4+\u00a0T\u2010lymphocyte \u00a0count\u2010guided\u00a0inte\u2010\nrruption\u00a0of\u00a0antiretroviral \u00a0therapy\u00a0in\u00a0HIV\u2010infected\u00a0patients.\u00a0Ann\u00a0Intern\u00a0Med\u00a02007;\u00a0146(9):682 \u2010\n683.\u00a0\n\u00a0 833.\u00a0\u00a0Marchou\u00a0B,\u00a0Tangre\u00a0P,\u00a0Charreau\u00a0I,\u00a0Izopet\u00a0J,\u00a0Girard\u00a0PM,\u00a0May\u00a0T\u00a0et\u00a0al.\u00a0Structured \u00a0treatment \u00a0inte\u2010\nrruptions \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0high\u00a0CD4\u00a0cell\u00a0counts\u00a0and\u00a0virologic\u00a0suppression: \u00a0Results\u00a0\nof\u00a0a\u00a0prospective, \u00a0randomized, \u00a0open\u2010label\u00a0trial\u00a0(Window\u00a0\u2010\u00a0ANRS\u00a0106).\u00a013th\u00a0Conference \u00a0on\u00a0Re\u2010\ntrovirus\u00a0and\u00a0Opportunistic \u00a0Infections, \u00a0Denver,\u00a0February\u00a05\u20108,\u00a02006\u00a0Abstract\u00a0104\u00a0\n\u00a0 834.\u00a0\u00a0Olmo\u00a0M,\u00a0Podzamczer \u00a0D,\u00a0Pe\u00f1aranda \u00a0M,\u00a0Guti\u00e9rrez \u00a0F,\u00a0Nubi\u00f3\u00a0J,\u00a0Romeu\u00a0J\u00a0et\u00a0al.\u00a0A\u00a0randomized \u00a0trial\u00a0\nof\u00a0CD4\u2010guided\u00a0haart\u00a0interruption \u00a0in\u00a0patients\u00a0receiving\u00a0mostly\u00a0NRTI\u2010based\u00a0regimens: \u00a096\u2010week\u00a0\nresults.\u00a011th\u00a0European \u00a0Aids\u00a0Conference, \u00a0Madrid,\u00a02007\u00a0(Abstract\u00a0P7.6/02)\u00a0\n\u00a0 835.\u00a0\u00a0Olmo\u00a0M,\u00a0Podzamczer \u00a0D,\u00a0Pe\u00f1aranda \u00a0M,\u00a0Guti\u00e9rrez \u00a0F,\u00a0Nubi\u00f3\u00a0J,\u00a0Romeu\u00a0J\u00a0et\u00a0al.\u00a0PBMC\u00a0and\u00a0plasma\u00a0\ngenotypic \u00a0resistance \u00a0during\u00a0a\u00a0CD4\u2010guided\u00a0HAART\u00a0interruption \u00a0randomized \u00a0study.\u00a096\u2010week\u00a0fo\u2010\nllow\u2010up.\u00a011th\u00a0European \u00a0Aids\u00a0Conference, \u00a0Madrid,\u00a02007\u00a0(abstract\u00a0P3.4/04)\u00a0\n\u00a0 836.\u00a0\u00a0Pogany\u00a0K,\u00a0van\u00a0V,\u00a0I,\u00a0Prins\u00a0JM,\u00a0Nieuwkerk \u00a0PT,\u00a0van\u00a0dE,\u00a0I,\u00a0Kauffmann \u00a0RH\u00a0et\u00a0al.\u00a0Effects\u00a0of\u00a0active\u00a0\ntreatment \u00a0discontinuation \u00a0in\u00a0patients\u00a0with\u00a0a\u00a0CD4+\u00a0T\u2010cell\u00a0nadir\u00a0greater\u00a0than\u00a0350\u00a0cells/mm3: \u00a0\n48\u2010week\u00a0Treatment \u00a0Interruption \u00a0in\u00a0Early\u00a0Starters\u00a0Netherlands \u00a0Study\u00a0(TRIESTAN). \u00a0J\u00a0Acquir\u00a0\nImmune\u00a0Defic\u00a0Syndr\u00a02007;\u00a044(4):395 \u2010400.\u00a0\n\u00a0 837.\u00a0\u00a0Ruiz\u00a0L,\u00a0Paredes\u00a0R,\u00a0Gomez\u00a0G,\u00a0Romeu\u00a0J,\u00a0Domingo\u00a0P,\u00a0Perez\u2010Alvarez\u00a0N\u00a0et\u00a0al.\u00a0Antiretroviral \u00a0thera\u2010\npy\u00a0interruption \u00a0guided\u00a0by\u00a0CD4\u00a0cell\u00a0counts\u00a0and\u00a0plasma\u00a0HIV\u20101\u00a0RNA\u00a0levels\u00a0in\u00a0chronically \u00a0HIV\u20101\u2010\ninfected\u00a0patients.\u00a0AIDS\u00a02007;\u00a021(2):169 \u2010178.\u00a0\n\u00a0 838.\u00a0\u00a0Skiest\u00a0DJ,\u00a0Su\u00a0Z,\u00a0Havlir\u00a0DV,\u00a0Robertson \u00a0KR,\u00a0Coombs\u00a0RW,\u00a0Cain\u00a0P\u00a0et\u00a0al.\u00a0Interruption \u00a0of\u00a0antiretrovi \u2010\nral\u00a0treatment \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0preserved \u00a0immune\u00a0function\u00a0is\u00a0associated \u00a0with\u00a0a\u00a0\nlow\u00a0rate\u00a0of\u00a0clinical\u00a0progression: \u00a0a\u00a0prospective \u00a0study\u00a0by\u00a0AIDS\u00a0Clinical\u00a0Trials\u00a0Group\u00a05170.\u00a0J\u00a0In\u2010\nfect\u00a0Dis\u00a02007;\u00a0195(10):1426 \u20101436.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 160 \n \u00a0 839.\u00a0\u00a0Ananworanich \u00a0J,\u00a0Gayet\u2010Ageron\u00a0A,\u00a0Le\u00a0BM,\u00a0Prasithsirikul \u00a0W,\u00a0Chetchotisakd \u00a0P,\u00a0Kiertiburanakul \u00a0S\u00a0\net\u00a0al.\u00a0CD4\u2010guided\u00a0scheduled \u00a0treatment \u00a0interruptions \u00a0compared \u00a0with\u00a0continuous \u00a0therapy\u00a0for\u00a0\npatients\u00a0infected\u00a0with\u00a0HIV\u20101:\u00a0results\u00a0of\u00a0the\u00a0Staccato\u00a0randomised \u00a0trial.\u00a0Lancet\u00a02006;\u00a0\n368(9534):459 \u2010465.\u00a0\n\u00a0 840.\u00a0\u00a0Kuller\u00a0L,\u00a0SMART\u00a0Study\u00a0Group.\u00a0Elevated\u00a0levels\u00a0of\u00a0interleukin \u20106\u00a0and\u00a0D\u2010dimer\u00a0are\u00a0associated \u00a0\nwith\u00a0an\u00a0increased \u00a0risk\u00a0of\u00a0death\u00a0in\u00a0patients\u00a0with\u00a0HIV.\u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections; \u00a0February\u00a02008;\u00a0Boston,\u00a0Massachusetts \u00a0(Abstract\u00a0139)\u00a0\n\u00a0 841.\u00a0\u00a0Calmy\u00a0A,\u00a0Nguyen\u00a0A,\u00a0Montecucco \u00a0F,\u00a0Gayet\u2010Ageron\u00a0A,\u00a0Burger\u00a0F,\u00a0Mach\u00a0F\u00a0et\u00a0al.\u00a0HIV\u00a0activates\u00a0\nmarkers\u00a0of\u00a0cardiovascular \u00a0risk\u00a0in\u00a0a\u00a0randomized \u00a0treatment \u00a0interruption \u00a0trial:\u00a0STACCATO. \u00a015th\u00a0\nConference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Opportunistic \u00a0Infections; \u00a0February\u00a02008;\u00a0Boston,\u00a0Massachu \u2010\nsetts\u00a0(Abstract\u00a0140)\u00a0\n\u00a0 842.\u00a0\u00a0Olmo\u00a0M,\u00a0Alonso\u00a0Villaverde \u00a0C,\u00a0Penaranda \u00a0M,\u00a0Gutierrez \u00a0F,\u00a0Romeu\u00a0J,\u00a0Larrousse \u00a0M\u00a0et\u00a0al.\u00a0Impact\u00a0\nof\u00a0HAART\u00a0interruption \u00a0on\u00a0plasma\u00a0inflammatory \u00a0markers\u00a0associated \u00a0with\u00a0cardiovascular \u00a0di\u2010\nsease.\u00a024\u2010month\u00a0results\u00a0from\u00a0a\u00a0randomized \u00a0study.\u00a016th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0Op\u2010\nportunistic \u00a0Infections; \u00a0February\u00a02009;\u00a0Montreal \u00a02009;\u00a0(Abstract\u00a0738).\u00a0\n\u00a0 843.\u00a0\u00a0Davey\u00a0RT,\u00a0Jr.,\u00a0Murphy\u00a0RL,\u00a0Graziano\u00a0FM,\u00a0Boswell\u00a0SL,\u00a0Pavia\u00a0AT,\u00a0Cancio\u00a0M\u00a0et\u00a0al.\u00a0Immunologic \u00a0\nand\u00a0virologic\u00a0effects\u00a0of\u00a0subcutaneous \u00a0interleukin \u00a02\u00a0in\u00a0combination \u00a0with\u00a0antiretroviral \u00a0thera\u2010\npy:\u00a0A\u00a0randomized \u00a0controlled \u00a0trial.\u00a0Jama\u00a02000;\u00a0284(2):183 \u20109.\u00a0\n\u00a0 844.\u00a0\u00a0Emery\u00a0S,\u00a0Capra\u00a0WB,\u00a0Cooper\u00a0DA,\u00a0Mitsuyasu \u00a0RT,\u00a0Kovacs\u00a0JA,\u00a0Vig\u00a0P\u00a0et\u00a0al.\u00a0Pooled\u00a0analysis\u00a0of\u00a03\u00a0\nrandomized, \u00a0controlled \u00a0trials\u00a0of\u00a0interleukin \u20102\u00a0therapy\u00a0in\u00a0adult\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0\ntype\u00a01\u00a0disease.\u00a0J\u00a0Infect\u00a0Dis\u00a02000;\u00a0182(2):428 \u201034.\u00a0\n\u00a0 845.\u00a0\u00a0Katlama\u00a0C,\u00a0Carcelain\u00a0G,\u00a0Duvivier\u00a0C,\u00a0Chouquet \u00a0C,\u00a0Tubiana\u00a0R,\u00a0De\u00a0Sa\u00a0M\u00a0et\u00a0al.\u00a0Interleukin \u00a0\u20102\u00a0acce\u2010\nlerates\u00a0CD4\u00a0cell\u00a0reconstitution \u00a0in\u00a0HIV\u2010infected\u00a0patients\u00a0with\u00a0severe\u00a0immunosuppression \u00a0des\u2010\npite\u00a0highly\u00a0active\u00a0antiretroviral \u00a0therapy:\u00a0the\u00a0ILSTIM\u00a0study\u2010\u2010ANRS\u00a0082.\u00a0AIDS\u00a02002;\u00a016:2027\u2010\n2034.\u00a0\n\u00a0 846.\u00a0\u00a0The\u00a0INSIGHT\u2010ESPRIT\u00a0Study\u00a0Group\u00a0and\u00a0SILCAAT\u00a0Scientific\u00a0Committee. \u00a0Interleukin \u20102\u00a0Therapy\u00a0in\u00a0\nPatients\u00a0with\u00a0HIV\u00a0Infection. \u00a0N\u00a0Engl\u00a0J\u00a0Med\u00a02009;\u00a0361(16):1548 \u20101559.\u00a0\n\u00a0 847.\u00a0\u00a0Kahn\u00a0JO,\u00a0Cherng\u00a0DW,\u00a0Mayer\u00a0K,\u00a0Murray\u00a0H,\u00a0Lagakos\u00a0S.\u00a0Evaluation \u00a0of\u00a0HIV\u20101\u00a0immunogen, \u00a0an\u00a0\nimmunologic \u00a0modifier,\u00a0administered \u00a0to\u00a0patients\u00a0infected\u00a0with\u00a0HIV\u00a0having\u00a0300\u00a0to\u00a0549\u00a0x\u00a0\n10(6)/L\u00a0CD4\u00a0cell\u00a0counts:\u00a0A\u00a0randomized \u00a0controlled \u00a0trial.\u00a0Jama\u00a02000;\u00a0284(17):2193 \u2010202.\u00a0\n\u00a0 848.\u00a0\u00a0Garcia\u00a0F,\u00a0Lejeune\u00a0M,\u00a0Climent\u00a0N,\u00a0Gil\u00a0C,\u00a0Alcami\u00a0J,\u00a0Morente\u00a0V\u00a0et\u00a0al.\u00a0Therapeutic \u00a0immunization \u00a0\nwith\u00a0dendritic\u00a0cells\u00a0loaded\u00a0with\u00a0heat\u2010inactivated \u00a0autologous \u00a0HIV\u20101\u00a0in\u00a0patients\u00a0with\u00a0chronic\u00a0\nHIV\u20101\u00a0infection. \u00a0J\u00a0Infect\u00a0Dis\u00a02005;\u00a0191(10):1680 \u20101685.\u00a0\n\u00a0 849.\u00a0\u00a0Fernandez \u2010Cruz\u00a0E,\u00a0Moreno\u00a0S,\u00a0Navarro\u00a0J,\u00a0Clotet\u00a0B,\u00a0Bouza\u00a0E,\u00a0Carbone\u00a0J\u00a0et\u00a0al.\u00a0Therapeutic \u00a0im\u2010\nmunization \u00a0with\u00a0an\u00a0inactivated \u00a0HIV\u20101\u00a0Immunogen \u00a0plus\u00a0antiretrovirals \u00a0versus\u00a0antiretroviral \u00a0\ntherapy\u00a0alone\u00a0in\u00a0asymptomatic \u00a0HIV\u2010infected\u00a0subjects.\u00a0Vaccine\u00a02004;\u00a022(23\u201024):2966\u20102973.\u00a0\n\u00a0 850.\u00a0\u00a0Pozniak\u00a0A,\u00a0Morales\u2010Ramirez\u00a0J,\u00a0Mohap\u00a0L,\u00a0et\u00a0al.\u00a048\u2010week\u00a0primary\u00a0analysis\u00a0of\u00a0trial\u00a0TMC278\u2010\nC204:\u00a0TMC278\u00a0demonstrates \u00a0potent\u00a0and\u00a0sustained \u00a0efficacy\u00a0in\u00a0ART\u2010na\u00efve\u00a0patients.\u00a014th\u00a0Con\u2010\nference\u00a0on\u00a0retrovirus \u00a0and\u00a0opportunistic \u00a0infections.Los \u00a0Angeles,\u00a02007\u00a0(abstract\u00a0144LB)\u00a0\n\u00a0 851.\u00a0\u00a0Shimura\u00a0K,\u00a0Kodama\u00a0E,\u00a0Sakagami \u00a0Y,\u00a0Matsuzaki \u00a0Y,\u00a0Watanabe \u00a0W,\u00a0Yamataka \u00a0K\u00a0et\u00a0al.\u00a0Broad\u00a0antire\u2010\ntroviral\u00a0activity\u00a0and\u00a0resistance \u00a0profile\u00a0of\u00a0the\u00a0novel\u00a0human\u00a0immunodeficiency \u00a0virus\u00a0integrase \u00a0\ninhibitor\u00a0elvitegravir \u00a0(JTK\u2010303/GS\u20109137).\u00a0J\u00a0Virol\u00a02008;\u00a082(2):764 \u2010774.\u00a0Documento \u00a0de\u00a0consenso\u00a0\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 161 \n \u00a0 852.\u00a0\u00a0Zolopa\u00a0A,\u00a0Mullen\u00a0M,\u00a0Berger\u00a0D,\u00a0Ruane\u00a0P,\u00a0Hawkins\u00a0T,\u00a0Zhong\u00a0L\u00a0et\u00a0al.\u00a0The\u00a0HIV\u00a0Integrase \u00a0Inhibitor\u00a0\nGS\u20109137\u00a0Demonstrates \u00a0Potent\u00a0Antiretroviral \u00a0Activity\u00a0in\u00a0Treatment \u2010experienced \u00a0Patients.\u00a014th\u00a0\nConference \u00a0on\u00a0retrovirus \u00a0and\u00a0opportunistic \u00a0infections.Los \u00a0Angeles,\u00a02007\u00a0(Abstract\u00a0143LB)\u00a0\n\u00a0 853.\u00a0\u00a0Underwood \u00a0M,\u00a0Johns\u00a0B,\u00a0Sato\u00a0A,\u00a0Fujiwara\u00a0T,\u00a0Spreen\u00a0W.\u00a0S/GSK1349572: \u00a0a\u00a0next\u00a0generation \u00a0\nintegrase \u00a0inhibitor\u00a0with\u00a0activity\u00a0against\u00a0integrase \u00a0inhibitor\u00a0clinical\u00a0isolates\u00a0from\u00a0patients\u00a0ex\u2010\nperiencing \u00a0virologic\u00a0failure\u00a0while\u00a0on\u00a0raltegravir \u00a0therapy.\u00a05th\u00a0International \u00a0AIDS\u00a0Society\u00a0Confe\u2010\nrence\u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention \u00a0Cape\u00a0Town,\u00a0South\u00a0Africa\u00a0July\u00a019\u201022,\u00a0\n2009\u00a02009;\u00a0Abstract\u00a0WePeAO98. \u00a0\n\u00a0 854.\u00a0\u00a0Gulick\u00a0RM,\u00a0Su\u00a0Z,\u00a0Flexner\u00a0C,\u00a0Hughes\u00a0MD,\u00a0Skolnik\u00a0PR,\u00a0Wilkin\u00a0TJ\u00a0et\u00a0al.\u00a0Phase\u00a02\u00a0study\u00a0of\u00a0the\u00a0safety\u00a0\nand\u00a0efficacy\u00a0of\u00a0vicriviroc, \u00a0a\u00a0CCR5\u00a0inhibitor,\u00a0in\u00a0HIV\u20101\u2010Infected,\u00a0treatment \u2010experienced \u00a0patients:\u00a0\nAIDS\u00a0clinical\u00a0trials\u00a0group\u00a05211.\u00a0J\u00a0Infect\u00a0Dis\u00a02007;\u00a0196(2):304 \u2010312.\u00a0\n\u00a0 855.\u00a0\u00a0Greaves\u00a0W,\u00a0Landovitz \u00a0R,\u00a0Fatkenheuer \u00a0G,\u00a0Hoffmann \u00a0C,\u00a0Antunes\u00a0F,\u00a0Angel\u00a0J\u00a0et\u00a0al.\u00a0Late\u00a0virologic\u00a0\nbreakthrough \u00a0in\u00a0treatment \u2010naive\u00a0patients\u00a0on\u00a0a\u00a0regimen\u00a0of\u00a0Combivir\u00a0+\u00a0Vicriviroc. \u00a013\u00a0th\u00a0Confe\u2010\nrence\u00a0on\u00a0Retrovirus \u00a0and\u00a0Opportunistic \u00a0Infection, \u00a0Denver,\u00a0February\u00a05\u20108,\u00a02006\u00a0Abstract\u00a0161LB\u00a0\n\u00a0 856.\u00a0\u00a0Zingman\u00a0B,\u00a0Suleiman\u00a0J,\u00a0DeJesus\u00a0E,\u00a0Slim\u00a0J,\u00a0McCarthy \u00a0M,\u00a0Lee\u00a0E\u00a0et\u00a0al.\u00a0Vicriviroc, \u00a0a\u00a0Next\u00a0Genera\u2010\ntion\u00a0CCR5\u00a0Antagonist, \u00a0Exhibits\u00a0Potent,\u00a0Sustained \u00a0Suppression \u00a0of\u00a0Viral\u00a0Replication \u00a0in\u00a0Treat\u2010\nment\u2010experienced \u00a0Adults:\u00a0VICTOR\u2010E1\u00a048\u2010week\u00a0Results.\u00a015th\u00a0Conference \u00a0on\u00a0Retroviruses \u00a0and\u00a0\nOpportunistic \u00a0Infections; \u00a0February\u00a02008;\u00a0Boston,\u00a0Massachusetts \u00a0(Abstract\u00a039LB)\u00a0\n\u00a0 857.\u00a0\u00a0McCallister \u00a0S,\u00a0Doto\u00a0J,\u00a0Allaway\u00a0G,\u00a0Martin\u00a0DE.\u00a0Multiple\u00a0dosing\u00a0of\u00a0the\u00a0novel\u00a0HIV\u20101\u00a0maturation \u00a0\ninhibitor\u00a0bevirimat: \u00a0aggregate \u00a0adverse\u00a0event\u00a0(AE)\u00a0and\u00a0laboratory \u00a0data\u00a0from\u00a0four\u00a0short\u2010term\u00a0\nstudies.\u00a04th\u00a0IAS\u00a0Conference \u00a0on\u00a0HIV\u00a0Pathogenesis, \u00a0Treatment \u00a0and\u00a0Prevention, \u00a0Sydney,\u00a02007\u00a0\n(abstract\u00a0WEPEA110) \u00a0\n\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 162\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\nTablas\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \u00a0\n\u00a0\nTabla\u00a01.\u00a0Exploraciones \u00a0complementarias \u00a0en\u00a0la\u00a0valoraci\u00f3n \u00a0y\u00a0seguimiento \u00a0de\u00a0los\u00a0\npacientes \u00a0con\u00a0infecci\u00f3n \u00a0por\u00a0el\u00a0VIH\u00a0\n\u00a0\n\u00a0\n\u2022 Valoraci\u00f3n \u00a0inicial\u00a0\nExploraci\u00f3n \u00a0f\u00edsica\u00a0completa \u00a0\n\u00a0Medidas\u00a0antropom\u00e9tricas \u00a0(talla,\u00a0peso\u00a0y\u00a0cintura)\u00a0\nHematimetr\u00eda \u00a0\u00a0\nBioqu\u00edmica \u00a0(incluyendo \u00a0glucemia, \u00a0perfil\u00a0hep\u00e1tico\u00a0y\u00a0lip\u00eddico)\u00a0\nSerolog\u00eda: \u00a0VHB,\u00a0VHC,\u00a0VHA,\u00a0L\u00faes,\u00a0CMV\u00a0y\u00a0Toxoplasma \u00a0\u00a0\nEstudio\u00a0de\u00a0poblaciones \u00a0linfoides\u00a0\nCarga\u00a0viral\u00a0VIH\u00a0\u00a0\nEstudio\u00a0genot\u00edpico \u00a0de\u00a0resistencias \u00a0\nHLA\u00a0B*5701\u00a0\nMantoux\u00a0(o\u00a0quantifer\u00f3n) \u00a0y\u00a0radiograf\u00eda \u00a0de\u00a0t\u00f3rax\u00a0\u00a0\nValoraci\u00f3n \u00a0de\u00a0la\u00a0fibrosis\u00a0hep\u00e1tica* \u00a0\n\u2022 Previo\u00a0al\u00a0inicio\u00a0del\u00a0TARV\u00a0\nEstudio\u00a0de\u00a0resistencias \u00a0\n\u2022 Seguimiento \u00a0(4\u00a0semanas\u00a0post\u00a0inicio\u00a0y\u00a0c/3\u20106\u00a0meses)\u00a0\nHematimetr\u00eda \u00a0y\u00a0bioqu\u00edmica \u00a0de\u00a0rutina\u00a0(con\u00a0perfil\u00a0lip\u00eddico)\u00a0\nCarga\u00a0viral\u00a0VIH\u00a0y\u00a0estudio\u00a0de\u00a0poblaciones \u00a0linfoides\u00a0\nEstudio\u00a0de\u00a0resistencias, \u00a0si\u00a0fracaso\u00a0virol\u00f3gico \u00a0\nTropismo \u00a0viral\u00a0(si\u00a0fracaso\u00a0virol\u00f3gico) \u00a0\n\u00a0\n*Si\u00a0hepatitis\u00a0cr\u00f3nica\u00a0(optativo) \u00a0\n\u00a0\n Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \u00a0\n\u00a0\nTabla\u00a02.\u00a0Indicaciones \u00a0de\u00a0las\u00a0pruebas\u00a0de\u00a0resistencia \u00a0en\u00a0la\u00a0pr\u00e1ctica\u00a0cl\u00ednica\u00a0\n\u00a0\n\u00a0\n\u2022 En\u00a0el\u00a0momento \u00a0del\u00a0diagn\u00f3stico \u00a0de\u00a0la\u00a0infecci\u00f3n\u00a0por\u00a0VIH*\u00a0\n\u2022 Inicio\u00a0del\u00a0TARV*\u00a0\n\u2022 Mujeres\u00a0embarazadas \u00a0\u00a0\n\u2022 En\u00a0cada\u00a0fracaso\u00a0del\u00a0TARV\u00a0\n\u2022 Profilaxis\u00a0post\u2010exposici\u00f3n \u00a0(caso\u00a0fuente)\u00a0\n\u00a0\n*Todos\u00a0los\u00a0pacientes \u00a0debieran\u00a0tener\u00a0un\u00a0estudio\u00a0de\u00a0resistencias \u00a0genot\u00edpicas \u00a0en\u00a0el\u00a0momento \u00a0del\u00a0\ndiagn\u00f3stico \u00a0y\u00a0antes\u00a0de\u00a0iniciar\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0si\u00a0se\u00a0difiere\u00a0\u00a0\n\u00a0\n Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \u00a0\n\u00a0\nTabla\u00a03.\u00a0Indicaciones \u00a0de\u00a0TARV\u00a0en\u00a0pacientes \u00a0asintom\u00e1ticos \u00a0con\u00a0infecci\u00f3n \u00a0cr\u00f3nica\u00a0por\u00a0VIH\u00a0\n\u00a0\nLinfocitos \u00a0CD4\u00a0 Pacientes \u00a0asintom\u00e1ticos \u00a0 Nivel\u00a0evidencia \u00a0\n\u2264350\u00a0 Recomendar \u00a0 A*,\u00a0B**\u00a0\n350\u2010500\u00a0 Recomendar \u00a0\u00a0en\u00a0determinadas \u00a0ocasiones*** \u00a0 B\u00a0\n>500\u00a0Diferir\u00a0en\u00a0general.\u00a0Considerar \u00a0en\u00a0\ndeterminadas \u00a0ocasiones*** \u00a0B\u00a0\n*\u00a0<\u00a0200\u00a0\n**\u00a0200\u2010350\u00a0\n***\u00a0Cirrosis\u00a0hep\u00e1tica,\u00a0hepatitis\u00a0cr\u00f3nica\u00a0por\u00a0VHC;\u00a0CVP\u00a0>\u00a0105\u00a0copias/ml; \u00a0proporci\u00f3n \u00a0de\u00a0CD4\u00a0<14%;\u00a0edad\u00a0\n>55\u00a0a\u00f1os;\u00a0riesgo\u00a0cardiovascular \u00a0elevado;\u00a0nefropat\u00eda \u00a0VIH.\u00a0Si\u00a0hepatitis\u00a0B\u00a0que\u00a0requiere\u00a0tratamiento, \u00a0se\u00a0\nrecomienda \u00a0iniciar\u00a0el\u00a0TARV\u00a0\u00a0\n***Considerar \u00a0el\u00a0tratamiento \u00a0en\u00a0parejas\u00a0serodiscordantes \u00a0con\u00a0alto\u00a0riesgo\u00a0de\u00a0transmisi\u00f3n \u00a0(Nivel\u00a0B)\u00a0\n\u00a0\u00a0\nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0\n\u00a0Tabla\u00a04.\u00a0Combinaciones \u00a0de\u00a0tratamiento \u00a0antirretroviral \u00a0en\u00a0pacientes \u00a0sin\u00a0terapia\u00a0previa\u00a0\u00a0\n\u00a0\nCOMBINACIONES \u00a0\nPOSIBLES \u00a0PAUTAS\u00a0\nPAUTAS\u00a0PREFERENTES\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nPAUTAS\u00a0ALTERNATIVAS \u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nPAUTA\u00a0EN\u00a0CASO\u00a0DE\u00a0NO\u00a0\nPODER\u00a0USAR\u00a0LAS\u00a0PREVIAS\u00a0\n\u00a0\nPAUTAS\u00a0\nCONTRAINDICADAS \u00a0Un\u00a0f\u00e1rmaco\u00a0de\u00a0columna\u00a0A\u00a0+\u00a0uno\u00a0de\u00a0columna\u00a0B\u00a0+\u00a0uno\u00a0de\u00a0columna\u00a0C\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nA1B1C2\u00a0\nTenofovir \u00a0(TDF)\nAbacavir\u00a0(ABC)3\u00a0Emtricitabina \u00a0(FTC)\nLamivudina \u00a0(3TC)\u00a0\n\u00a0Efavirenz\u00a0\nNevirapina4\u00a0\n\u00a0Atazanavir/r \u00a0QD\u00a0\nDarunavir/r \u00a0QD\u00a0\nFosamprenavir/r \u00a0BID\u00a0\nLopinavir/r \u00a0QD\u00a0\u00f3\u00a0BID\u00a0\nSaquinavir/r \u00a0BID\u00a0\n\u00a0\nRaltegravir5\u00a0\nZidovudina \u00a0(AZT)\nDidanosina \u00a0(ddI)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0Atazanavir \u00a0\u00a0\nFosamprenavir \u00a0BID\u00a0\nFosamprenavir/r \u00a0QD\u00a0\n\u00a0\nMaraviroc6\u00a0\nAZT+3TC+ABC C/s\u00a0TDF\nCombinaciones de\u00a0AN:\u00a0AZT+d4T, \u00a03TC+FTC\nABC+\u00a03TC+TDF\u00a0\nddI+3TC+TDF \u00a0\u00a0\nd4T+ddI+ABC \u00a0\n\u00a0\n1. Las\u00a0combinaciones \u00a0de\u00a0AN\u00a0de\u00a0elecci\u00f3n\u00a0en\u00a0los\u00a0reg\u00edmenes \u00a0triples\u00a0de\u00a0inicio\u00a0son\u00a0TDF+FTC\u00a0(o\u00a03TC)\u00a0y\u00a0ABC+3TC\u00a0(o\u00a0FTC).\u00a0La\u00a0elecci\u00f3n\u00a0\nde\u00a0una\u00a0de\u00a0ellas\u00a0depender\u00e1 \u00a0del\u00a0tercer\u00a0f\u00e1rmaco\u00a0elegido\u00a0y\u00a0del\u00a0perfil\u00a0de\u00a0seguridad. \u00a0Aunque\u00a03TC\u00a0y\u00a0FTC\u00a0son\u00a0f\u00e1rmacos \u00a0que\u00a0se\u00a0\npueden\u00a0utilizar\u00a0indistintamente, \u00a0se\u00a0recomienda \u00a0utilizar\u00a0las\u00a0coformulaciones \u00a0ABC/3TC\u00a0y\u00a0TDF/FTC\u00a0(nivel\u00a0C).\u00a0Antes\u00a0de\u00a0iniciar\u00a0\ntratamiento \u00a0con\u00a0ABC\u00a0se\u00a0debe\u00a0realizar\u00a0una\u00a0prueba\u00a0de\u00a0genotipificaci\u00f3n \u00a0de\u00a0HLA\u2010B5701\u00a0y\u00a0si\u00a0el\u00a0resultado \u00a0es\u00a0positivo\u00a0el\u00a0ABC\u00a0est\u00e1\u00a0\ncontraindicado \u00a0(nivel\u00a0A).\u00a0Seg\u00fan\u00a0el\u00a0tercer\u00a0f\u00e1rmaco,\u00a0no\u00a0hay\u00a0experiencia \u00a0con\u00a0algunas\u00a0combinaciones \u00a0de\u00a0AN\u00a0de\u00a0elecci\u00f3n\u00a0como\u00a0\nABC+3TC+NVP. \u00a0\u00a0No\u00a0hay\u00a0experiencia \u00a0de\u00a0TDF+3TC\u00a0con\u00a0un\u00a0IP\u00a0como\u00a0tratamiento \u00a0inicial,\u00a0pero\u00a0s\u00ed\u00a0de\u00a0TDF+FTC\u00a0(con\u00a0LPV/r,\u00a0DRV/r\u00a0y\u00a0\nSQV/r).\u00a0Las\u00a0combinaciones \u00a0AZT+3TC\u00a0o\u00a0DDI+3TC\u00a0causan\u00a0m\u00e1s\u00a0lipoatrofia \u00a0que\u00a0TDF+FTC\u00a0o\u00a0ABC+3TC. \u00a0\n2. En\u00a0las\u00a0pautas\u00a0preferentes \u00a0de\u00a0la\u00a0columna\u00a0C\u00a0se\u00a0incluyen\u00a0f\u00e1rmacos \u00a0de\u00a0tres\u00a0familias.\u00a0Se\u00a0considera \u00a0que\u00a0entre\u00a0los\u00a0NN\u00a0el\u00a0balance\u00a0\nglobal\u00a0de\u00a0riesgo/beneficio \u00a0favorece\u00a0a\u00a0EFV\u00a0frente\u00a0a\u00a0NVP\u00a0(Nivel\u00a0C).\u00a0EFV\u00a0ha\u00a0demostrado \u00a0mayor\u00a0eficacia\u00a0virol\u00f3gica \u00a0que\u00a0LPV/r\u00a0\n(nivel\u00a0A).\u00a0Ning\u00fan\u00a0otro\u00a0IP\u00a0se\u00a0ha\u00a0comparado \u00a0con\u00a0EFV.\u00a0Los\u00a0IP\u00a0est\u00e1n\u00a0en\u00a0orden\u00a0alfab\u00e9tico. \u00a0DRV/r\u00a0y\u00a0ATV/r\u00a0han\u00a0demostrado \u00a0mayor\u00a0\neficacia\u00a0y\u00a0menor\u00a0toxicidad\u00a0que\u00a0LPV/r,\u00a0mientras\u00a0que\u00a0FPV/r\u00a0y\u00a0SQV/r\u00a0han\u00a0demostrado \u00a0no\u00a0ser\u00a0inferiores \u00a0a\u00a0LPV/r.\u00a0\u00a0\n3. Los\u00a0estudios\u00a0que\u00a0demuestran \u00a0la\u00a0eficacia\u00a0similar\u00a0entre\u00a0ABC\u00a0y\u00a0TDF\u00a0en\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0se\u00a0han\u00a0generado \u00a0con\u00a0\u00a0un\u00a0\nIP/r\u00a0como\u00a0tercer\u00a0f\u00e1rmaco.\u00a0ABC\u20103TC\u00a0ha\u00a0presentado \u00a0un\u00a0mayor\u00a0riesgo\u00a0de\u00a0fracaso\u00a0virol\u00f3gico \u00a0que\u00a0TDF/FTC\u00a0en\u00a0pacientes \u00a0con\u00a0\ncargas\u00a0virales\u00a0altas\u00a0(>100.000 \u00a0copias/mL). \u00a0Con\u00a0respecto\u00a0a\u00a0la\u00a0asociaci\u00f3n \u00a0entre\u00a0ABC\u00a0y\u00a0riesgo\u00a0cardiovascular, \u00a0no\u00a0hay\u00a0datos\u00a0\nsuficientes \u00a0para\u00a0tomar\u00a0decisiones \u00a0cl\u00ednicas,\u00a0pero\u00a0se\u00a0debiera\u00a0usar\u00a0con\u00a0precauci\u00f3n \u00a0en\u00a0pacientes \u00a0con\u00a0riesgo\u00a0cardiovascular \u00a0\nelevado.\u00a0\u00a0\n4. NVP\u00a0ha\u00a0demostrado \u00a0no\u00a0inferioridad \u00a0con\u00a0respecto\u00a0a\u00a0ATV/r\u00a0(ambos\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0TDF+FTC). \u00a0NVP\u00a0no\u00a0debe\u00a0administrarse \u00a0\n(como\u00a0tratamiento \u00a0de\u00a0inicio)\u00a0a\u00a0mujeres\u00a0con\u00a0>250\u00a0CD4/\u00b5L\u00a0o\u00a0a\u00a0varones\u00a0con\u00a0>400\u00a0CD4/\u00b5L\u00a0\u00a0\n5. RAL\u00a0ha\u00a0demostrado \u00a0no\u00a0inferioridad \u00a0frente\u00a0a\u00a0EFV.\u00a0Este\u00a0comit\u00e9\u00a0considera \u00a0que\u00a0RAL\u00a0s\u00f3lo\u00a0debe\u00a0utilizarse\u00a0en\u00a0caso\u00a0de\u00a0no\u00a0poder\u00a0usar\u00a0\nNN\u00a0o\u00a0IP\u00a0por\u00a0razones\u00a0de\u00a0coste.\u00a0\n6. MVC\u00a0no\u00a0est\u00e1\u00a0aprobado \u00a0por\u00a0la\u00a0EMEA\u00a0como\u00a0tratamiento \u00a0de\u00a0inicio.\u00a0MVC\u00a0s\u00f3lo\u00a0debe\u00a0emplearse \u00a0como\u00a0primer\u00a0tratamiento \u00a0\u00a0en\u00a0\npacientes \u00a0\u00a0que\u00a0est\u00e9n\u00a0infectados \u00a0por\u00a0virus\u00a0R5\u00a0tr\u00f3pico\u00a0cuando\u00a0no\u00a0sea\u00a0posible\u00a0usar\u00a0las\u00a0pautas\u00a0preferentes. \u00a0\n\u00a0\nNota:\u00a0Para\u00a0una\u00a0mejor\u00a0interpretaci\u00f3n \u00a0de\u00a0la\u00a0tabla,\u00a0se\u00a0recomienda \u00a0consultar \u00a0el\u00a0texto\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 1 Tabla\u00a05.\u00a0Inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3sido \u00a0y\u00a0\u00a0de\u00a0nucle\u00f3tido \u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico Zidovudina \u00a0\nAZT\u00a0Didanosina\nddI\u00a0Estavudina\nd4T\u00a0Lamivudina\n3TC\u00a0Emtricitabina\nFTC\u00a0Abacavir\nABC\u00a0Tenofovir\nTDF\u00a0\n\u00a0\nNombre\u00a0\ncomercial \u00a0Retrovir\u00ae\u00a0\nZidovudinaCom \u00a0\nbinopharm\u00ae\u00a0\n*Combivir\u00ae\u00a0\n**Trizivir\u00ae\u00a0\u00a0\nVidex\u00ae\u00a0 Zerit\u00ae\u00a0 Epivir\u00ae\u00a0\n*Combivir\u00ae\u00a0\n**Trizivir\u00ae\u00a0\n***Kivexa\u00ae \u00a0\u00a0\nEmtriva\u00ae\u00a0\n****Truvada\u00ae \u00a0\n*****\u00a0Atripla\u00ae\u00a0Ziagen\u00ae\u00a0\n**Trizivir\u00ae\u00a0\n***Kivexa\u00ae \u00a0Viread\u00ae\u00a0\n****Truvada\u00ae \u00a0\n*****\u00a0Atripla\u00ae\u00a0\n\u00a0\nDosis\u00a0\nrecomendada \u00a0250\u2010300\u00a0mg\u00a0BID\u00a0<60\u00a0Kg.:\n250\u00a0mg\u00a0QD\u00a0\u00f3\u00a0\n125\u00a0mg\u00a0BID\u00a0\n>60\u00a0Kg:\u00a0\u00a0\n400\u00a0mg\u00a0QD\u00a0\u00f3\u00a0\n\u00a0200\u00a0mg\u00a0BID\u00a0<60\u00a0Kg:\n30\u00a0mg\u00a0BID\u00a0\n>60\u00a0mg:\u00a0\n40\u00a0mg\u00a0BID\u00a0150\u00a0mg\u00a0BID\u00a0\n300\u00a0mg\u00a0QD\u00a0\u00a0\n200\u00a0mg\u00a0QD\u00a0 300\u00a0mg\u00a0BID\u00a0\n600\u00a0mg\u00a0QD\u00a0300\u00a0mg\u00a0QD\u00a0\n\u00a0\nPresentaciones \u00a0\ncomerciales \u00a0caps.\u00a0100,\u00a0250\u00a0\nmg\u00a0y\u00a0comp\u00a0300\u00a0\nmg.\u00a0\nsol.\u00a0oral\u00a010\u00a0\nmg/ml\u00a0\nvial\u00a0\u00a0i.v.\u00a0(10\u00a0\nmg/ml)\u00a0comp\u00a025,\u00a050,100,\u00a0\n150\u00a0y\u00a0200\u00a0mg.\u00a0\nc\u00e1ps\u00a0ent\u00e9ricas\u00a0de\u00a0\n125,\u00a0200,\u00a0250\u00a0y\u00a0\n400\u00a0mg.\u00a0\nsol.\u00a0oral\u00a05\u00a0y\u00a010\u00a0\nmg/ml\u00a0caps.\u00a015,\u00a020,\u00a030\u00a0y\u00a0\n40\u00a0mg\u00a0\nsol.\u00a0oral\u00a01mg/ml\u00a0comp.\u00a0150\u00a0mg\u00a0\ncomp.\u00a0300\u00a0mg\u00a0\nsol.\u00a0oral\u00a010\u00a0\nmg/ml\u00a0\u00a0\u00a0\nc\u00e1ps\u00a0200\u00a0mg\u00a0\nsol.\u00a0oral\u00a010mg/ml\n\u00a0comp.\u00a0300\u00a0mg\u00a0\nsol.\u00a0oral\u00a020\u00a0\nmg/ml\u00a0\u00a0comp.\u00a0300\u00a0mg\u00a0\u00a0\n\u00a0\nBiodisponibilid. \u00a0\noral\u00a0\n\u00a060\u201070%\u00a0 30\u201040%\u00a0 85%\u00a0 85%\u00a0\u00a0\n93%\u00a0(c\u00e1ps)\u00a0\n75%\u00a0(sol\u00a0oral)\u00a083%\u00a0 40%\u00a0(prof\u00e1rmaco \u00a0\ncon\u00a0alimentos) \u00a0\n\u00a0\nVida\u00a0media\u00a0\u00a0\nSuero\u00a01,1\u00a0horas\u00a0 1,6\u00a0horas\u00a0 1\u00a0hora\u00a0 5\u20107horas\u00a0\u00a0\n10\u00a0horas\u00a0 1,5\u00a0horas\u00a010\u201014\u00a0horas\u00a0\n(prof\u00e1rmaco \u00a0con\u00a0\nalimentos) \u00a0\n\u00a0\nVida\u00a0media\u00a0\nintracelular \u00a0\n\u00a03\u00a0horas\u00a0\u00a0 25\u00a0horas\u00a0 3,5\u00a0horas\u00a0\n\u00a0\n\u00a016\u201019\u00a0horas\u00a0\u00a0\n39\u00a0horas\u00a0 20,6\u00a0horas\u00a0\n(carbovir\u00a0\ntrifosfato) \u00a012\u201015\u00a0horas\u00a0(en\u00a0\nlinfocitos\u00a0\nactivados) \u00a0\n33\u201050\u00a0horas\u00a0(en\u00a0el\u00a0\nresto\u00a0de\u00a0linfocitos) \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 2 \u00a0\nNombre\u00a0gen\u00e9rico Zidovudina \u00a0\nAZT\u00a0Didanosina\nddI\u00a0Estavudina\nd4T\u00a0Lamivudina\n3TC\u00a0Emtricitabina\nFTC\u00a0Abacavir\nABC\u00a0Tenofovir\nTDF\u00a0\n\u00a0\nCmax\u00a0 1,8\u03bcg/ml\u00a0\u00a0\n\u00a0(6,7\u00a0\u03bcM)\u00a0\n\u00a0\u00a00,9\u00a0\u03bcg/ml\u00a0\n\u00a0(3,8\u00a0\u03bcM)\u00a0\u00a00,85\u00a0\u03bcg/ml\u00a0\n\u00a0(3,79\u00a0\u03bcM)\u00a0\u00a01,5\u00a0\u03bcg/ml\u00a0\n\u00a0(6,54\u00a0\u03bcM)\u00a0\u00a0\n1,8\u03bcg/ml\u00a0\n(7,8\u03bcM)\u00a0\u00a03.0\u00a0\u03bcg/ml\u00a0\n\u00a0(10.7\u00a0\u03bcM)\u00a0\u00a0362\u00a0ng/ml\u00a0\u00a0\n(1.2\u00a0\u03bcM)\u00a0\n\u00a0\nCI50\u00a0\n\u00a0\u00a00.061\u03bcg/ml\u00a0\n\u00a0(0,23\u00a0\u03bcM)\u00a0\n\u00a0\u00a00.116\u00a0\u03bcg/ml\u00a0\n\u00a0(0,49\u00a0\u03bcM)\u00a0\u00a00,002\u20100,9\u00a0\u03bcg/ml\u00a0\n\u00a0(0.0089\u20104\u03bcM)\u00a0\u00a00,002\u20100,3\u00a0\u03bcg/ml\u00a0\n\u00a0(0.0087\u20101.308\u00a0\n\u03bcM)\u00a0\u00a0\n0,00032\u20100,124\u00a0\n\u03bcg/ml\u00a0\n(0,0013\u20100,5\u00a0\u03bcM)\u00a00.07\u20101.04\u00a0\u03bcg/ml\u00a0\n(0,26\u20103.7\u00a0\u03bcM)\u00a0<3\u00a0ng/ml\u00a0\u00a0\n(<0,01\u00a0\u03bcM)\u00a0\n\u00a0\nPenetraci\u00f3n \u00a0en\u00a0\nLCR\u00a050\u201085%\u00a0\u00a0 20%\u00a0\u00a0 40%\u00a0 10%\u00a0\u00a0\nNo\u00a0se\u00a0dispone\u00a0de\u00a0\ndatos\u00a027\u201033%\u00a0 5%\u00a0\n\u00a0\nActividad \u00a0\n\u00a0VIH\u20101,2\u00a0 VIH\u20101,2\u00a0 VIH\u20101,2\u00a0 VIH\u20101,2\u00a0\nVHB\u00a0\u00a0\nVIH\u20101,2\u00a0\nVHB\u00a0VIH\u20101,2\u00a0\n\u00a0VIH\u20101,2\u00a0\nVHB\u00a0\n\u00a0\nRestricci\u00f3n \u00a0\u00a0\ndiet\u00e9tica\u00a0\n\u00a0\u00a0No\u00a0 Administrar \u00a0en\u00a0\nayunas,\u00a0aunque\u00a0\nestudios\u00a0reci\u00e9n\u2010\ntes\u00a0muestran \u00a0que\u00a0\npuede\u00a0tambi\u00e9n\u00a0\nadministrarse \u00a0\ncon\u00a0alimentos. \u00a0\u00a0No\u00a0\u00a0 No\u00a0\u00a0\nNo\u00a0\u00a0 No\u00a0 Administrar \u00a0con\u00a0\nalimentos \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 3 \u00a0\nNombre\u00a0gen\u00e9rico Zidovudina \u00a0\nAZT\u00a0Didanosina\nddI\u00a0Estavudina\nd4T\u00a0Lamivudina\n3TC\u00a0Emtricitabina\nFTC\u00a0Abacavir\nABC\u00a0Tenofovir\nTDF\u00a0\n\u00a0\nMetabolizaci\u00f3n \u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\nExcreci\u00f3n \u00a0\u00a0\nGlucuronidaci\u00f3n \u00a0\nhep\u00e1tica\u00a0\n\u00a0\u00a0\u00a0\nRenal\u00a0(15%\u00a0\ninalterado) \u00a0Hep\u00e1tica\u00a050%\u00a0\nRenal\u00a0(50%\u00a0\ninalterado) \u00a0\u00a0\nHep\u00e1tica\u00a050%\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\nRenal\u00a0(50%\u00a0\ninalterado) \u00a0\u00a0\nHep\u00e1tica\u00a05\u201010%\u00a0\n\u00a0\u00a0\n\u00a0\nRenal\u00a0(70%\u00a0\ninalterado) \u00a0\u00a0\nHep\u00e1tica\u00a013%\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0\nRenal\u00a0\u00a086%\u00a0\u00a0\nGlucuronidaci\u00f3n \u00a0\nhep\u00e1tica\u00a0\nAlcohol\u00a0\ndeshidrogenasa \u00a0\n\u00a0Renal\u00a083%\u00a0(2%\u00a0\ninalterado \u00a0y\u00a081%\u00a0\nmetabolitos) \u00a0\u00a0\nEl\u00a0TDF\u00a0(pro\u00a0\nf\u00e1rmaco)\u00a0es\u00a0\nr\u00e1pidamente \u00a0\nhidrolizado \u00a0a\u00a0\ntenofovir\u00a0por\u00a0las\u00a0\nesterasas \u00a0\nplasm\u00e1ticas. \u00a0\u00a0\n70\u201080%\u00a0renal\u00a0\ninalterado \u00a0\n\u00a0\nEfectos\u00a0adversos\u00a0Mielosupresi\u00f3n: \u00a0\nanemia\u00a0y/o\u00a0\nneutropenia \u00a0a\u00a0\ndosis\u00a0elevadas\u00a0\nCefalea\u00a0\nMareo\u00a0\nIntolerancia \u00a0\ngastrointestinal. \u00a0\nLipodistrofia \u00a0\nAcidosis\u00a0l\u00e1ctica\u00a0\u00a0\ncon\u00a0esteatosis \u00a0\nhep\u00e1tica1\u00a0Pancreatitis \u00a0\nHiperuricemia \u00a0\nNeuropat\u00eda \u00a0\nperif\u00e9rica \u00a0\nDiarrea\u00a0\nN\u00e1useas\u00a0\nLipodistrofia \u00a0\nAcidosis\u00a0l\u00e1ctica\u00a0\ncon\u00a0esteatosis \u00a0\nhep\u00e1tica1\u00a0Neuropat\u00eda \u00a0\nperif\u00e9rica \u00a0\u00a0\nPancreatitis \u00a0\nLipodistrofia \u00a0\nAcidosis\u00a0l\u00e1ctica\u00a0\ncon\u00a0esteatosis \u00a0\nhep\u00e1tica1\u00a0Intolerancia \u00a0\ndigestiva\u00a0\nCefalea\u00a0\nFatiga\u00a0\nDolor\u00a0abdominal \u00a0\nLipodistrofia \u00a0\nAcidosis\u00a0l\u00e1ctica\u00a0\ncon\u00a0esteatosis \u00a0\nhep\u00e1tica1 \u00a0Cefalea\u00a0\nIntolerancia \u00a0\ndigestiva\u00a0\nExantema \u00a0\ncut\u00e1neo\u00a0\nElevaci\u00f3n \u00a0CPK\u00a0\nAnemia/neutrop\nenia\u00a0\nLipodistrofia \u00a0\nAcidosis\u00a0l\u00e1ctica\u00a0\ncon\u00a0esteatosis \u00a0\nhep\u00e1tica1\u00a0Hipersensibilidad \u00a0\n(5\u20108%)\u00a0\nLipodistrofia \u00a0\nAcidosis\u00a0l\u00e1ctica\u00a0\ncon\u00a0esteatosis \u00a0\nhep\u00e1tica1\u00a0Intolerancia \u00a0\ndigestiva\u00a0\nCefalea\u00a0\nFatiga\u00a0\nDolor\u00a0abdominal \u00a0\nProteinuria \u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 4 \u00a0\nNombre\u00a0gen\u00e9rico Zidovudina \u00a0\nAZT\u00a0Didanosina\nddI\u00a0Estavudina\nd4T\u00a0Lamivudina\n3tC\u00a0Emtricitabina\nFTC\u00a0Abacavir\nABC\u00a0Tenofovir \u00a0\nTDF3\u00a0\n\u00a0\nInteracciones \u00a0\u00a0\n\u00a0\nAsociaciones \u00a0no\u00a0\nrecomendables \u00a0o\ncontraindicadas \u00a0D4T\nPrecauci\u00f3n \u00a0en\u00a0la\u00a0\nasociaci\u00f3n \u00a0con\u00a0\nTPV/r\u00a0por\u00a0\ndisminuci\u00f3n \u00a0de\u00a0\nlos\u00a0niveles\u00a0de\u00a0\nzidovudina \u00a0\n\u00a0ddC\nRibavirina \u00a0\nd4T\u00a0\n\u00a0\nTDF\u00a0(ajustar\u00a0dosis\u00a0de\u00a0\nddI)\u00a0AZT\nddI\u00a0ddC\u00a0\nFTC\u00a0\nCotrimoxazol \u00a0(dosis\u00a0\naltas;\u00a0a\u00a0dosis\u00a0\nprofil\u00e1cticas \u00a0NRAD)\u00a03TC\nddC\u00a0Precauci\u00f3n \u00a0en\u00a0\u00a0la\u00a0\nasociaci\u00f3n \u00a0con\u00a0\nTPV/r\u00a0por\u00a0\ndisminuci\u00f3n \u00a0de\u00a0\nlos\u00a0niveles\u00a0de\u00a0\nabacavir\u00a0\n\u00a0ATV\u00a0no\u00a0\npotenciado \u00a0\n\u00a0ddI\u00a0(ajustar\u00a0dosis\u00a0\nde\u00a0ddI)\u00a0\nInmunosupreso r\nes\u00a0In\u00a0vitro ,\u00a0el\u00a0\u00e1cido\u00a0micofen\u00f3lico \u00a0aument\u00f3\u00a0el\u00a0efecto\u00a0antirretroviral \u00a0de\u00a0ABC,\u00a0ddI\u00a0y\u00a0TDF\u00a0de\u00a0forma\u00a0dosis\u2010dependiente. \u00a0En\u00a0cambio,\u00a0el\u00a0\u00e1cido\u00a0micofen\u00f3lico \u00a0mostr\u00f3\u00a0\nantagonismo \u00a0in\u00a0vitro\u00a0con\u00a0AZT\u00a0y\u00a0d4T.\u00a0Se\u00a0desconoce \u00a0su\u00a0significado \u00a0cl\u00ednico.\u00a0Posible\u00a0aumento\u00a0nefrotoxicidad \u00a0con\u00a0la\u00a0asociaci\u00f3n \u00a0de\u00a0TDF\u00a0a\u00a0ciclosporina \u00a0\u00f3\u00a0\ntacrolimus. \u00a0\nInterferon /\nRibavirina \u00a0Se\u00a0recomienda \u00a0evitar\u00a0la\u00a0asociaci\u00f3n \u00a0de\u00a0ddI\u00a0y\u00a0ribavirina, \u00a0ya\u00a0que\u00a0se\u00a0ha\u00a0descrito\u00a0aumento\u00a0de\u00a0toxicidad\u00a0mitocondrial \u00a0y\u00a0pancreatitis. \u00a0Ribavirina2ha\u00a0mostrado \u00a0\ninhibir\u00a0in\u00a0vitro\u00a0la\u00a0fosforilaci\u00f3n \u00a0intracelular \u00a0de\u00a0AZT\u00a0y\u00a0d4T.\u00a0Sin\u00a0embargo, \u00a0en\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0VIH\u00a0y\u00a0VHC\u00a0no\u00a0se\u00a0ha\u00a0observado \u00a0esta\u00a0interacci\u00f3n \u00a0\nnegativa\u00a0entre\u00a0ribavirina \u00a0y\u00a0AZT,\u00a0d4T\u00a0\u00f3\u00a03TC\u00a0(subestudio \u00a0del\u00a0APRICOT). \u00a0Se\u00a0evitar\u00e1\u00a0en\u00a0la\u00a0medida\u00a0de\u00a0lo\u00a0posible\u00a0el\u00a0uso\u00a0simult\u00e1neo \u00a0de\u00a0ribavirina \u00a0con\u00a0ZDV\u00a0por\u00a0\nriesgo\u00a0de\u00a0anemia.\u00a0Sobre\u00a0la\u00a0posible\u00a0interacci\u00f3n \u00a0entre\u00a0ABC\u00a0\u00a0y\u00a0ribavirina, \u00a0los\u00a0resultados \u00a0son\u00a0contradictorios: \u00a0si\u00a0bien\u00a0algunos\u00a0estudios\u00a0han\u00a0sugerido\u00a0que\u00a0ABC\u00a0\npodr\u00eda\u00a0reducir\u00a0la\u00a0eficacia\u00a0de\u00a0ribavirina, \u00a0en\u00a0la\u00a0mayor\u00eda\u00a0\u00a0de\u00a0estudios\u00a0no\u00a0se\u00a0ha\u00a0observado \u00a0esta\u00a0interacci\u00f3n, \u00a0especialmente \u00a0cuando\u00a0la\u00a0dosis\u00a0de\u00a0ribavirina \u00a0se\u00a0\najustaba\u00a0a\u00a0peso.\u00a0Con\u00a0el\u00a0interfer\u00f3n \u00a0beta\u00a0(Avonex\u00ae, \u00a0Rebif\u00ae,\u00a0Betaferon\u00ae) \u00a0se\u00a0han\u00a0descrito\u00a0aumentos \u00a0de\u00a0la\u00a0vida\u00a0media\u00a0AZT\u00a0hasta\u00a03\u00a0veces\u00a0y\u00a0con\u00a0interfer\u00f3n \u00a0alfa\u00a0\n(Intron\u00ae,PegIntron\u00ae, \u00a0Roferon\u00a0A\u00ae,\u00a0Wellferon\u00ae) \u00a0\u219136%\u00a0AUC\u00a0AZT\u00a0(\u2191\u00a0riesgo\u00a0toxicidad\u00a0hematol\u00f3gica). \u00a0Algunos\u00a0autores\u00a0recomiendan \u00a0reducir\u00a0la\u00a0dosis\u00a0de\u00a0AZT\u00a0un\u00a0\n50\u201075%\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0interferon \u00a0beta.\u00a0\u00a0\n\u00a0\nMetadona \u00a0(MT)\u00a0\ny\u00a0otros\u00a0opi\u00e1ceos\u00a0Puede\u2191Cp\u00a0AZT\u00a0MT:\u00a0Interacci\u00f3n \u00a0poco\u00a0\nprobable\u00a0\u00a0\nBuprenorfina: \u00a0No\u00a0\ninteracci\u00f3n \u00a0\u00a0\nNRAD\u00a0(\u219327%\u00a0AUC\u00a0d4T)\u00a0MT:\u00a0Interacci\u00f3n \u00a0poco\u00a0\nprobable\u00a0\u00a0\nBuprenorfina: \u00a0No\u00a0\ninteracci\u00f3n \u00a0Interacci\u00f3n \u00a0poco\u00a0\nprobable\u00a0Puede\u00a0requerir\u00a0\nun\u00a0ligero\u00a0\u2191\u00a0MT\u00a0\n\u00a0MT: Interacci\u00f3n \u00a0\npoco\u00a0probable\u00a0\u00a0\nBuprenorfina: \u00a0No\u00a0\ninteracci\u00f3n \u00a0\nF\u00e1rmacos \u00a0\nempleados \u00a0para\u00a0\ntratar\u00a0la\u00a0\ninfluenza \u00a0Una\u00a0interacci\u00f3n \u00a0con\u00a0zanamivir \u00a0se\u00a0considera \u00a0poco\u00a0probable, \u00a0dada\u00a0su\u00a0escasa\u00a0absorci\u00f3n. \u00a0\nOseltamivir \u00a0y\u00a0amantadina \u00a0se\u00a0eliminan\u00a0por\u00a0v\u00eda\u00a0renal.\u00a0Oseltamivir \u00a0mediante \u00a0filtraci\u00f3n\u00a0glomerular \u00a0y\u00a0secreci\u00f3n \u00a0tubular.\u00a0Se\u00a0ha\u00a0observado \u00a0un\u00a0aumento\u00a0del\u00a0doble\u00a0\nen\u00a0sus\u00a0Cp\u00a0al\u00a0asociarlo\u00a0con\u00a0probenecid, \u00a0f\u00e1rmaco\u00a0inhibidor\u00a0de\u00a0la\u00a0secreci\u00f3n \u00a0tubular.\u00a0Es\u00a0probable\u00a0que\u00a0en\u00a0la\u00a0eliminaci\u00f3n \u00a0de\u00a0amantadina \u00a0intervenga \u00a0tambi\u00e9n\u00a0la\u00a0\nsecreci\u00f3n \u00a0tubular.\u00a0No\u00a0puede\u00a0descartarse \u00a0una\u00a0interacci\u00f3n \u00a0con\u00a0otros\u00a0f\u00e1rmacos\u00a0eliminados \u00a0mediante \u00a0esta\u00a0v\u00eda\u00a0como\u00a0lamivudina, \u00a0emtricitabina \u00a0y\u00a0tenofovir, \u00a0\naunque\u00a0no\u00a0se\u00a0dispone\u00a0de\u00a0informaci\u00f3n \u00a0espec\u00edfica \u00a0al\u00a0respecto. \u00a0Se\u00a0recomienda \u00a0precauci\u00f3n \u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0funci\u00f3n\u00a0renal\u00a0alterada\u00a0que\u00a0deban\u00a0recibir\u00a0\noseltamivir \u00a0u\u00a0amantadina \u00a0junto\u00a0con\u00a0estos\u00a0ARV.\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 5 \u00a0\nNombre\u00a0gen\u00e9rico Zidovudina \u00a0\nAZT\u00a0Didanosina\nddI\u00a0Estavudina\nd4T\u00a0Lamivudina\n3tC\u00a0Emtricitabina\nFTC\u00a0Abacavir\nABC\u00a0Tenofovir\nTDF3\u00a0\n\u00a0\nOtros\u00a0 Ganciclovir: \u00a0\n\u2191riesgo\u00a0\ntoxicidad\u00a0\nhematol\u00f3gica. \u00a0\u00a0\n\u00a0\nProbenecid: \u00a0\nevitar\u00a0\u00f3\u00a0reducir\u00a0\n50%\u00a0AZT\u00a0\u00a0\nTDF:\u00a0evitar\u00a0la\u00a0\nasociaci\u00f3n, \u00a0por\u00a0\naumento\u00a0del\u00a0riesgo\u00a0\nde\u00a0fracaso\u00a0\nterap\u00e9utico. \u00a0En\u00a0\ncaso\u00a0necesario, \u00a0\najustar\u00a0dosis.\u00a0(\u219140%\u00a0\nAUC\u00a0ddI).\u00a0Sin\u00a0\ncambios\u00a0TDF.\u00a0Ajuste\u00a0\nde\u00a0dosis\u00a0ddI:\u00a0\u226560\u00a0\nkg:\u00a0250\u00a0mg/d\u00eda;\u00a0<60\u00a0\nkg:\u00a0200\u00a0mg/d\u00eda\u00a0(en\u00a0\neste\u00a0caso\u00a0ddI\u00a0se\u00a0\npueden\u00a0administrar \u00a0\njuntos\u00a0c/s\u00a0comida\u00a0\nligera).\u00a0\n\u00a0Con\u00a0alopurinol, \u00a0\nreducir\u00a0la\u00a0dosis\u00a0de\u00a0\nddI\u00a0a\u00a0la\u00a0mitad\u00a0\n\u00a0\u00a0\nDoxorrubicina \u00a0in\u00a0\nvitro\u00a0interfiere \u00a0la\u00a0\nfosforilaci\u00f3n \u00a0de\u00a0\nd4T.\u00a0Se\u00a0\ndesconoce \u00a0la\u00a0\nimportancia \u00a0\ncl\u00ednica,\u00a0pero\u00a0se\u00a0\nrecomienda \u00a0un\u00a0\ncontrol\u00a0estrecho\u00a0\nde\u00a0la\u00a0carga\u00a0viral.\u00a0Nefrot\u00f3xicos: \u00a0\nposible\u00a0\u2191Cp\u00a03TC\u00a0\nPrecauci\u00f3n \u00a0con\u00a0\nf\u00e1rmacos\u00a0que\u00a0se\u00a0\neliminen\u00a0por\u00a0v\u00eda\u00a0\nrenal\u00a0(secreci\u00f3n \u00a0\nactiva\u00a0por\u00a0el\u00a0\nsistema\u00a0de\u00a0\ntransporte \u00a0\ncati\u00f3nico\u00a0\norg\u00e1nico): \u00a0riesgo\u00a0\nde\u00a0ac\u00famulo\u00a0de\u00a0\nambos.\u00a0\u00a0\nNefrot\u00f3xicos: \u00a0posible\u00a0\n\u2191Cp\u00a0FTC\u00a0precauci\u00f3n \u00a0con\u00a0\nf\u00e1rmacos\u00a0que\u00a0se\u00a0\neliminen\u00a0por\u00a0v\u00eda\u00a0renal\u00a0\n(secreci\u00f3n \u00a0tubular\u00a0\nactiva):\u00a0riesgo\u00a0de\u00a0\nac\u00famulo\u00a0de\u00a0ambos.\u00a0FTC\u00a0\nno\u00a0ha\u00a0mostrado \u00a0efecto\u00a0\ninhibidor\u00a0sobre\u00a0las\u00a0\nprincipales \u00a0isoenzimas \u00a0\ndel\u00a0citocromo \u00a0P450\u00a0ni\u00a0\nsobre\u00a0la\u00a0\nglucuronidaci\u00f3n, \u00a0por\u00a0lo\u00a0\nque\u00a0no\u00a0es\u00a0de\u00a0esperar\u00a0\nque\u00a0se\u00a0produzcan \u00a0\ninteracciones \u00a0\nmetab\u00f3licas \u00a0\nimportantes \u00a0a\u00a0este\u00a0\nnivel.\u00a0Clorpromacina, \u00a0\ndisulfiram \u00a0e\u00a0\nisoniacida \u00a0\u2191\u00a0Cp\u00a0de\u00a0\nambos.\u00a0\nSe\u00a0ha\u00a0\u00a0descrito\u00a0un\u00a0\ncaso\u00a0de\u00a0\nrabdomiolisis \u00a0grave\u00a0\nen\u00a0un\u00a0paciente\u00a0que\u00a0\npresent\u00f3\u00a0\nhipersensibilidad \u00a0a\u00a0\nABC\u00a0y\u00a0\u00a0recib\u00eda\u00a0\ntratamiento \u00a0con\u00a0\nfibratos\u00a0(ciprofibrato \u00a0\n100\u00a0mg/24\u00a0horas).\u00a0ddI:evitar\u00a0la\u00a0asociaci\u00f3n. \u00a0En\u00a0\ncaso\u00a0necesario, \u00a0ajustar\u00a0\ndosis:\u00a0\u00a0Sin\u00a0cambios\u00a0TDF.\u00a0\nAjuste\u00a0de\u00a0ddI:\u00a0\u226560\u00a0kg:\u00a0250\u00a0\nmg/d\u00eda;\u00a0<60\u00a0kg:\u00a0200\u00a0mg/d\u00eda\u00a0\n(pueden\u00a0administrarse \u00a0\njuntos\u00a0c/s\u00a0comida)\u00a0\nCon\u00a0ATV\u00a0utilizar\u00a0ATV/r\u00a0\u00a0\n300/100\u00a0mg\u00a0c/24h.\u00a0\nTelaprevir: \u00a0NRAD\u00a0\nNefrot\u00f3xicos \u00a0,\u00a0inhibidores \u00a0o\u00a0\ncompetidores \u00a0por\u00a0la\u00a0\nsecreci\u00f3n \u00a0tubular\u00a0renal\u00a0\npodr\u00edan\u00a0aumentar \u00a0la\u00a0\ntoxicidad\u00a0de\u00a0ambos.\u00a0\nAumento \u00a0de\u00a0riesgo\u00a0de\u00a0\ntoxicidad\u00a0renal\u00a0con\u00a0IP.\u00a0\nProbenecid \u00a0podr\u00eda\u00a0\naumentar \u00a0las\u00a0\nconcentraciones \u00a0\nplasm\u00e1ticas \u00a0de\u00a0TDF.\u00a0\n\u00a0\nAUC\u00a0:\u00a0Area\u00a0bajo\u00a0la\u00a0curva;\u00a0BID:\u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda;\u00a0Cp:\u00a0Concentraci\u00f3n \u00a0plasm\u00e1tica; \u00a0NRAD :\u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis;\u00a0QD:\u00a0una\u00a0vez\u00a0al\u00a0d\u00eda;\u00a0TID:\u00a0tres\u00a0veces\u00a0al\u00a0d\u00eda.\u00a0*Combivir \u00ae:\u00a0asociaci\u00f3n \u00a0a\u00a0\ndosis\u00a0fijas\u00a0de\u00a0AZT\u00a0300\u00a0mg\u00a0y\u00a03TC\u00a0150\u00a0mg.**Trizivir\u00ae\u00a0:\u00a0asociaci\u00f3n \u00a0a\u00a0dosis\u00a0fijas\u00a0de\u00a0AZT\u00a0300\u00a0mg,\u00a03TC\u00a0150\u00a0mg\u00a0y\u00a0abacavir\u00a0300\u00a0mg.\u00a0***Kivexa\u00ae: \u00a0asociaci\u00f3n \u00a0a\u00a0dosis\u00a0fijas\u00a0de\u00a03TC\u00a0300\u00a0mg\u00a0y\u00a0\nabacavir\u00a0600\u00a0mg;\u00a0****Truvada\u00ae: \u00a0\u00a0asociaci\u00f3n \u00a0a\u00a0dosis\u00a0fijas\u00a0de\u00a0tenofovir\u00a0300\u00a0mg\u00a0y\u00a0emtricitabina \u00a0200\u00a0mg.\u00a0*****Atripla\u00ae: \u00a0\u00a0asociaci\u00f3n \u00a0a\u00a0dosis\u00a0fijas\u00a0de\u00a0tenofovir\u00a0300\u00a0mg,\u00a0emtricitabina \u00a0200\u00a0\nmg\u00a0y\u00a0efavirenz\u00a0600\u00a0mg.\u00a0\n\u00a0\n1\u00a0Reacci\u00f3n\u00a0poco\u00a0frecuente \u00a0aunque\u00a0potencialmente \u00a0muy\u00a0grave.\u00a0\n2cabe\u00a0recordar\u00a0que\u00a0cualquier \u00a0posible\u00a0interacci\u00f3n \u00a0con\u00a0ribavirina \u00a0puede\u00a0persistir\u00a0hasta\u00a02\u00a0meses\u00a0despu\u00e9s\u00a0de\u00a0interrumpir \u00a0el\u00a0tratamiento \u00a0con\u00a0Rebetol\u00ae\u00a0debido\u00a0a\u00a0la\u00a0larga\u00a0vida\u00a0\nmedia\u00a0de\u00a0este\u00a0f\u00e1rmaco.\u00a0\n3Tenofovir \u00a0se\u00a0elimina\u00a0mayoritariamente \u00a0por\u00a0v\u00eda\u00a0renal\u00a0y\u00a0no\u00a0act\u00faa\u00a0como\u00a0substrato, \u00a0inductor\u00a0\u00f3\u00a0inhibidor\u00a0del\u00a0citocromo \u00a0P\u2010450,\u00a0por\u00a0lo\u00a0que\u00a0no\u00a0se\u00a0espera\u00a0que\u00a0tenga\u00a0\ninteracciones \u00a0relevantes \u00a0de\u00a0car\u00e1cter\u00a0metab\u00f3lico. \u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 6 NOTA:\u00a0debido\u00a0a\u00a0que\u00a0la\u00a0informaci\u00f3n \u00a0cient\u00edfica\u00a0relacionada \u00a0con\u00a0los\u00a0f\u00e1rmacos\u00a0antirretrovirales \u00a0se\u00a0renueva\u00a0constantemente, \u00a0se\u00a0recomienda \u00a0consultar \u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0de\u00a0los\u00a0\nf\u00e1rmacos\u00a0y\u00a0la\u00a0informaci\u00f3n \u00a0actualizada \u00a0ofrecida\u00a0por\u00a0las\u00a0distintas\u00a0compa\u00f1\u00edas \u00a0farmac\u00e9uticas \u00a0y\u00a0las\u00a0autoridades \u00a0sanitarias. \u00a0\n\u00a0\n\u00a0\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 1 Tabla\u00a06.\u00a0Inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0nucle\u00f3sidos \u00a0\n\u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\n\u00a0Nevirapina \u00a0(NVP)\u00a0 Efavirenz \u00a0(EFV)\u00a0 Etravirina \u00a0(ETR)\u00a0\n\u00a0\nNombre\u00a0comercial \u00a0Viramune\u00ae\u00a0Sustiva\u00ae\u00a0\n*Atripla\u00ae  Intelence\u00ae\u00a0\nDosis\u00a0recomendada \u00a0\n\u00a0200\u00a0mg\u00a0QD\u00a0x\u00a014\u00a0d\u00edas\u00a0\nseguidas\u00a0de\u00a0200\u00a0mg\u00a0BID\u00a0600\u00a0mg\u00a0QD\u00a0 200\u00a0mg\u00a0BID\u00a0(dispersable \u00a0en\u00a0agua)\u00a0\nPresentaciones \u00a0\ncomerciales \u00a0comprimidos \u00a0200\u00a0mg\u00a0 c\u00e1psulas\u00a050,\u00a0100\u00a0y\u00a0200\u00a0mg\u00a0y\u00a0600\u00a0mg\u00a0 comprimidos \u00a0100\u00a0mg\u00a0\nBiodisponibilidad \u00a0oral\u00a0\n\u00a0>\u00a090%\u00a0 66%\u00a0(aumenta \u00a0con\u00a0comida\u00a0con\u00a0contenido \u00a0graso)\u00a0\u00a0\nCmax\u00a0\n\u00a0200mg/24h \u00a0:\u00a03,6\u03bcg/ml\u00a0\u00a0(13,51\u00a0\u03bcM)\u00a0\n400\u00a0mg/24h:\u00a04,5\u03bcg/ml\u00a0\u00a0(17\u00a0\u03bcM)\u00a04,07\u00a0\u03bcg/ml\u00a0\u00a0\n(12,9\u00a0\u03bcM)\u00a04,51\u00a0\u03bcg/ml\u00a0\n\u00a0\nCmin\u00a0\n\u00a01,9\u00a0\u03bcg/ml\u00a0\u00a0\n(7,13\u00a0\u03bcM)\u00a01,77\u00a0\u03bcg/ml\u00a0\n(5,6\u00a0\u03bcM)\u00a01,85\u00a0\u03bcg/ml\u00a0\nCI\u00a050\u00a0\n\u00a00.0026\u20100.026\u00a0\u03bcg/ml\u00a0\u00a0\n(0.01\u20100.1\u00a0\u03bcM)\u00a0\n\u00a0(CI\u00a090\u201095)\u00a0:\u00a0\u00a0\n\u00a00.00014\u20100.0021\u00a0\u03bcg/ml\u00a0\u00a0\n\u00a0(0,00046\u20100.0068\u00a0\u03bcM)\u00a0(0,0014\u20100.0048\u00a0\u03bcM)\u00a0\nActividad \u00a0 VIH\u20101\u00a0 VIH\u20101\u00a0 VIH\u20101\u00a0\n\u00a0\nNiveles\u00a0de\u00a0LCR\u00a0\u00a0\n45%\u00a0\u00a0\n69%\u00a0No\u00a0disponible \u00a0\nSemivida \u00a0de\u00a0elimin.\u00a0\nplasm\u00e1tica \u00a0\u00a0\n25\u201030\u00a0horas\u00a0\u00a0\n40\u201050\u00a0horas\u00a035\u201040\u00a0h\u00a0\n\u00a0\nRestricci\u00f3n \u00a0diet\u00e9tica\u00a0\u00a0\nCon\u00a0o\u00a0sin\u00a0alimentos \u00a0\u00a0\nCon\u00a0o\u00a0sin\u00a0alimentos \u00a0\u00a0\nCon\u00a0alimentos \u00a0o\u00a0bebida\u00a0energ\u00e9tica \u00a0\nMetabolizaci\u00f3n \u00a0\n\u00a0\u00a0Excreci\u00f3n \u00a0\n\u00a0\u00a0\nHep\u00e1tica\u00a0CYP3A4\u00a0\n(Inducci\u00f3n) \u00a0\n\u00a0Renal\u00a080%\u00a0\nHeces\u00a010%\u00a0\u00a0\nHep\u00e1tica\u00a0CYP3A4\u00a0\n(inducci\u00f3n \u2010inhibici\u00f3n) \u00a0\n\u00a0Renal\u00a034%\u00a0\nHeces\u00a016\u201061%\u00a0Hep\u00e1tica: \u00a0\n\u2010\u00a0inducci\u00f3n \u00a0de\u00a0CYP3A4;\u00a0\n\u2010\u00a0Inhibici\u00f3n: \u00a02C9,\u00a02C19\u00a0\n\u2010\u00a0glucuronidaci\u00f3n \u00a0\n\u00a0\nRenal:\u00a0<\u00a01,2\u00a0%\u00a0\nExcrecci\u00f3n \u00a0fundamentalmente \u00a0por\u00a0heces\u00a0\nEfectos\u00a0adversos\u00a0\n\u00a0Exantema \u00a0\nAumento \u00a0de\u00a0transaminasas \u00a0y\u00a0\nHepatitis\u00a0aguda\u00a0Exantema \u00a0\nS\u00edntomas \u00a0neuropsiqui\u00e1tricos \u00a0\nAumento \u00a0de\u00a0las\u00a0transaminasas \u00a0\nTeratogenicidad \u00a0en\u00a0monos\u00a0Exantema \u00a0\nN\u00e1useas\u00a0\nDiarrea\u00a0\n\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 2 Nombre\u00a0gen\u00e9rico\u00a0 Nevirapina \u00a0 Efavirenz \u00a0 Etravirina \u00a0(ETR)\u00a0\nInteracciones \u00a0\n\u00a0\nAsociaciones \u00a0\ncontraindicadas \u00a0\n\u00a0\u00a0\nAnticonceptivos \u00a0orales\u00a0\nEtravirina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0Juan)\u00a0\nKetoconazol \u00a0\nItraconazol \u00a0\nRifampicina \u00a0\nSaquinavir1\u00a0\nVoriconazol\u00a0\u00a0 \nAnticonceptivos orales  \nAstemizol \nCarbamacepina Cisaprida \nClaritromicina \nDeriv. Ergotamina Etravirina \nHipericum (hierba de S. Juan) Itraconazol \nMidazolam \nPimozida Posaconazol  \nSaquinavir (como \u00fanico IP) \nTerfenadina \nTriazolam \nVoriconazol (evitar/ajustar dosis)  Carbamacepina \u00a0\nEFV\u00a0\nFenitoina \u00a0\nFenobarbital \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0Juan)\u00a0\nNVP\u00a0\nRifampicina \u00a0\nTPV/r\u00a0\nIP\u00a0no\u00a0potenciado \u00a0\nAnti\u00e1cidos No\u00a0se\u00a0ha\u00a0observado \u00a0interacci\u00f3n \u00a0significativa No se ha observado interacci\u00f3n \nsignificativa Te\u00f3ricamente \u00a0no\u00a0es\u00a0de\u00a0esperar\u00a0una\u00a0\ninteracci\u00f3n \u00a0significativa \u00a0\nInhibidores \u00a0de\u00a0la\u00a0\nbomba\u00a0de\u00a0protones\u00a0\n\u00a0Te\u00f3ricamente \u00a0no\u00a0es\u00a0de\u00a0esperar\u00a0una\u00a0interacci\u00f3n \u00a0\nsignificativa \u00a0Ausencia de interacci\u00f3n. NRAD\u00a0(\u219141%\u00a0AUC\u00a0ETR)\u00a0\nAntihistam\u00ednicos \u00a0H2 Te\u00f3ricamente \u00a0no\u00a0es\u00a0de\u00a0esperar\u00a0una\u00a0interacci\u00f3n \u00a0\nsignificativa \u00a0Ausencia\u00a0de\u00a0interacci\u00f3n. \u00a0 NRAD\u00a0(\u219314%\u00a0AUC\u00a0ETR)\u00a0\nAntimicobacterianos :\n\u00a0\n\u2010 Rifampicina \u00a0\n\u00a0\u2193Cm\u00edn\u00a0y\u00a0AUC\u00a0NVP\u00a0del\u00a035\u00a0a\u00a0m\u00e1s\u00a0del\u00a050%.\u00a0\nResultados \u00a0cl\u00ednicos\u00a0discordantes. \u00a0No\u00a0aumentar \u00a0\nla\u00a0dosis\u00a0de\u00a0NVP\u00a0por\u00a0mayor\u00a0toxicidad. \u00a0No\u00a0\nemplear\u00a0pautas\u00a0de\u00a0NVP\u00a0QD\u00a0con\u00a0rifampicina. \u00a0\nPrecauci\u00f3n \u2010monitorizar \u00a0estrechamente \u00a0eficacia.\u00a0NRAD\u00a0(\u219325%\u00a0AUC\u00a0EFV)\u00a0\u00a0\u00a0\n\u00a0No\u00a0hay\u00a0datos.\u00a0No\u00a0se\u00a0recomienda \u00a0dado\u00a0que\u00a0se\u00a0\nprev\u00e9\u00a0una\u00a0importante \u00a0reducci\u00f3n \u00a0de\u00a0las\u00a0\nconcentraciones \u00a0de\u00a0ETR\u00a0\n\u2010 Rifabutina\n\u00a0NRAD\u00a0 450\u2010600\u00a0mg/d\u00eda\u00a0rifabutina \u00a0\u00f3\u00a0450\u2010600\u00a0mg\u00a0\n3veces\u00a0/semana\u00a0NRAD\u00a0(\u219337%\u00a0AUC\u00a0ETR)\u00a0\n\u2010 Claritromicina\n\u00a0NRAD\u00a0 \u219339%\u00a0AUC\u00a0claritromicina \u00a0\nBuscar\u00a0alternativa \u00a0(azitromicina) \u00a0para\u00a0el\u00a0\ntratamiento \u00a0de\u00a0MAC\u00a0\u219339%\u00a0AUC\u00a0claritro,\u00a0\u219142%\u00a0AUC\u00a0ETR\u00a0\nBuscar\u00a0alternativa \u00a0(azitromicina) \u00a0para\u00a0el\u00a0\ntratamiento \u00a0de\u00a0MAC\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 3 \u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\n\u00a0Nevirapina \u00a0 Efavirenz \u00a0 Etravirina \u00a0(ETR)\u00a0\nAntiepil\u00e9pticos :\n\u00a0\u2010 Carbamazepina, \u00a0\u00a0\n\u2010 fenito\u00edna, \u00a0\nfenobarbital \u00a0\u00a0\nPrecauci\u00f3n. \u00a0Monitorizar \u00a0niveles\u00a0de\u00a0ambos\u00a0\nf\u00e1rmacos\u00a0Precauci\u00f3n. \u00a0Monitorizar \u00a0niveles\u00a0de\u00a0antiepil\u00e9ptico. \u00a0\nCarbamacepina: \u00a0no\u00a0recomendado \u00a0(\u219347%\u00a0Cmin\u00a0EFV\u00a0\ncon\u00a0400\u00a0mg\u00a0c/24h\u00a0de\u00a0CBZ;\u00a0\u219335%\u00a0Cmin\u00a0CBZ).\u00a0\nFenito\u00edna: \u00a0algun\u00a0caso\u00a0descrito\u00a0de\u00a0\u2191\u00a0fenito\u00edna\u00a0y\u00a0\u2193\u00a0\nEFV\u00a0a\u00a0niveles\u00a0indetectables \u00a0(evitar\u00a0o\u00a0monitorizar \u00a0\nniveles\u00a0de\n\u00a0ambos).\u00a0No\u00a0hay\u00a0datos\u00a0\nAnticoagulantes \u00a0orales\u00a0Te\u00f3ricamente \u00a0NVP\u00a0podr\u00eda\u00a0aumentar \u00a0o\u00a0reducir\u00a0\nel\u00a0INR.\u00a0Monitorizar \u00a0estrechamente \u00a0Te\u00f3ricamente \u00a0NVP\u00a0podr\u00eda\u00a0aumentar \u00a0o\u00a0reducir\u00a0el\u00a0INR\u00a0\n(un\u00a0caso\u00a0descrito\u00a0que\u00a0requiri\u00f3\u00a0reducir\u00a0dosis\u00a0de\u00a0\nwarfarina). \u00a0Monitorizar \u00a0estrechamente \u00a0Te\u00f3ricamente \u00a0NVP\u00a0podr\u00eda\u00a0aumentar \u00a0o\u00a0\nreducir\u00a0el\u00a0INR.\u00a0Monitorizar \u00a0\nestrechamente \u00a0\nAnticonceptivos\norales :\u00a0\u219319%\u00a0AUC\u00a0etinilestradiol. \u00a0Utilizar\u00a0m\u00e9todos\u00a0\nalternativos \u00a0\u219137%\u00a0AUC\u00a0etinilestradiol \u00a0(no\u00a0hay\u00a0datos\u00a0con\u00a0dosis\u00a0\nm\u00faltiples). \u00a0Utilizar\u00a0m\u00e9todos\u00a0alternativos \u00a0Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0\n\u00a0\nAntif\u00fangicos \u00a0\u00a0Anfotericina \u00a0B:\u00a0NRAD.\n\u00a0\nCaspofungina: \u00a0considerar \u00a0un\u00a0aumento\u00a0de\u00a0la\u00a0\ndosis\u00a0de\u00a0mantenimiento \u00a0de\u00a0caspofungina \u00a0a\u00a070\u00a0\nmg/d.\u00a0\n\u00a0\nFluconazol: \u00a0No\u00a0recomendable \u00a0(\u2191100%\u00a0AUC\u00a0\nNVP\u00a0con\u00a0toxicidad). \u00a0\n\u00a0\nItraconazol, \u00a0ketoconazol \u00a0y\u00a0voriconazol: \u00a0\nContraindicados. \u00a0Anfotericina \u00a0B:\u00a0NRAD.\u00a0\nCaspofungina: \u00a0considerar \u00a0un\u00a0aumento\u00a0de\u00a0la\u00a0dosis\u00a0de\u00a0\nmantenimiento \u00a0de\u00a0caspofungina \u00a0a\u00a070\u00a0mg/d.\u00a0\nFluconazol: \u00a0NRAD.\u00a0\nItraconazol: \u00a0No\u00a0recomendable \u00a0(s\u00f3lo\u00a0con\u00a0\nmonitorizaci\u00f3n \u00a0de\u00a0niveles\u00a0de\u00a0ambos\u00a0f\u00e1rmacos; \u00a0un\u00a0\ncaso\u00a0de\u00a0histoplasmosis \u00a0tratada\u00a0con\u00a0\u00e9xito\u00a0con\u00a0TDM\u00a0y\u00a0\najuste\u00a0a\u00a0800\u00a0mg/d\u00a0de\u00a0itraconazol \u00a0y\u00a0400\u00a0mg/d\u00a0de\u00a0\nEFV)\u00a0\nPosaconazol: \u00a0contraindicado \u00a0(\u2193\u00a050%\u00a0AUC\u00a0posacon)\u00a0\nVoriconazol \u00a0:\u00a0No\u00a0recomendable \u00a0(solo\u00a0con\u00a0monitori\u2010\nzaci\u00f3n\u00a0de\u00a0niveles\u00a0de\u00a0ambos\u00a0f\u00e1rmacos)(aumentar \u00a0\ndosis\u00a0de\u00a0voriconazol \u00a0a\u00a0400mg/12 \u00a0y\u00a0posible\u00a0\ndisminuci\u00f3n \u00a0de\u00a0EFV\u00a0a\u00a0300\u00a0mg/d)\u00a0\u00a0Anfotericina \u00a0B:\u00a0NRAD.\u00a0\nLos\u00a0antif\u00fangicos \u00a0imidaz\u00f3licos \u00a0pueden\u00a0\naumentar \u00a0las\u00a0concentraciones \u00a0\nplasm\u00e1ticas \u00a0de\u00a0etravirina. \u00a0Etravirina \u00a0\npodr\u00eda\u00a0reducir\u00a0las\u00a0concentraciones \u00a0\nplasm\u00e1ticas \u00a0de\u00a0itraconazol \u00a0y\u00a0ketoconazol \u00a0\npor\u00a0aumento\u00a0de\u00a0su\u00a0metabolismo \u00a0a\u00a0trav\u00e9s\u00a0\ndel\u00a0CYP3A4.\u00a0\u00a0\nFluconazol: \u00a0NRAD\u00a0(AUC\u00a0de\u00a0fluconazol \u00a0sin\u00a0\ncambios;\u00a0\u2191\u00a086%\u00a0AUC\u00a0ETR\u00a0\nVoriconazol: \u00a0\u2191\u00a036%\u00a0AUC\u00a0voriconazol; \u00a0\n\u219114%\u00a0AUC\u00a0ETR\u00a0\n\u00a0\nEstatinas: \u00a0 \u00a0\nCon\u00a0atorvastatina, \u00a0lovastatina \u00a0y\u00a0simvastatina, \u00a0\nmonitorizar \u00a0eficacia\u00a0estatina.\u00a0Con\u00a0fluvastatina \u00a0\ny\u00a0pravastatina \u00a0interacci\u00f3n \u00a0poco\u00a0probable\u00a0Se\u00a0han\u00a0descrito\u00a0reducciones \u00a0del\u00a058%\u00a0en\u00a0el\u00a0AUC\u00a0de\u00a0\nsimvastatina, \u00a0del\u00a043%\u00a0en\u00a0el\u00a0AUC\u00a0de\u00a0atorvastatina \u00a0y\u00a0\ndel\u00a040%\u00a0en\u00a0el\u00a0AUC\u00a0de\u00a0pravastatina. \u00a0No\u00a0hay\u00a0datos\u00a0\npara\u00a0lovastatina \u00a0y\u00a0fluvastatina. \u00a0Algunos\u00a0pacientes \u00a0\npueden\u00a0requerir\u00a0aumento\u00a0de\u00a0dosis,\u00a0que\u00a0debe\u00a0\nrealizarse \u00a0de\u00a0forma\u00a0gradual.\u00a0\u00a0NRAD\u00a0(\u219337%\u00a0AUC\u00a0de\u00a0atorvastatina, \u00a0\n\u219127%\u00a0AUC\u00a02\u2010OH\u2010atorvastatina \u00a0).\u00a0\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 4 \u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\n\u00a0Nevirapina \u00a0 Efavirenz \u00a0 Etravirina \u00a0(ETR)\u00a0\nF\u00e1rmacos \u00a0empleados \u00a0\npara\u00a0tratar\u00a0la\u00a0\ninfluenza \u00a0Amantadina \u00a0/\u00a0oseltamivir \u00a0/\u00a0zanamivir: \u00a0te\u00f3ricamente \u00a0no\u00a0deben\u00a0esperarse \u00a0interacciones \u00a0\n\u00a0 \u00a0\nNo\u00a0hay\u00a0datos.\u00a0ETR\u00a0podr\u00eda\u00a0reducir\u00a0la\u00a0Cp\u00a0de\u00a0\nciclosporina, \u00a0tacrolimus \u00a0y\u00a0sirolimus\u00a0\n(monitorizar) \u00a0Inmunosupresores: Posible\u00a0\u2193Cp\u00a0ciclosporina, \u00a0prednisona, \u00a0\ntacrolimus \u00a0y\u00a0sirolimus. \u00a0Monitorizar \u00a0\nniveles/eficacia \u00a0del\u00a0inmunosupresor. \u00a0La\u00a0dosis\u00a0\nde\u00a0ciclosporina \u00a0y\u00a0tacrolimus, \u00a0una\u00a0vez\u00a0ajustada,\u00a0\nse\u00a0mantiene \u00a0m\u00e1s\u00a0o\u00a0menos\u00a0constante \u00a0a\u00a0lo\u00a0largo\u00a0\ndel\u00a0tiempo.\u00a0En\u00a0pacientes \u00a0con\u00a0TOH,\u00a0la\u00a0dosis\u00a0de\u00a0\ntacrolimus \u00a0requerida \u00a0en\u00a0pacientes \u00a0tratados\u00a0\ncon\u00a0NVP\u00a0fue\u00a0similar\u00a0a\u00a0la\u00a0utilizada\u00a0en\u00a0VIH\u00a0\nnegativos. \u00a0Con\u00a0ciclosporina \u00a0una\u00a0vez\u00a0ajustada\u00a0la\u00a0dosis,\u00a0\u00e9sta\u00a0se\u00a0\nmantiene \u00a0m\u00e1s\u00a0o\u00a0menos\u00a0constante \u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0\ntiempo.\u00a0Sin\u00a0embargo, \u00a0EFV\u00a0\u00a0redujo\u00a0de\u00a0forma\u00a0\nimportante \u00a0los\u00a0niveles\u00a0de\u00a0tacrolimus \u00a0en\u00a0pacientes \u00a0\ncon\u00a0TOH.\u00a0Con\u00a0el\u00a0resto,\u00a0te\u00f3ricamente \u00a0posible\u00a0\u2193Cp\u00a0\n(aunque\u00a0tambi\u00e9n\u00a0podr\u00eda\u00a0\u2191Cp)\u00a0de\u00a0prednisona \u00a0y\u00a0\nsirolimus. \u00a0Monitorizar \u00a0niveles/eficacia \u2010toxicidad\u00a0del\u00a0\ninmunosupresor. \u00a0\nInterfer\u00f3n/ \u00a0Ribavirina Ribavirina: \u00a0no\u00a0existe\u00a0evidencia \u00a0de\u00a0interacci\u00f3n \u00a0con\u00a0los\u00a0no\u00a0nucle\u00f3sidos. \u00a0Interfer\u00f3n: \u00a0su\u00a0v\u00eda\u00a0de\u00a0\neliminaci\u00f3n \u00a0no\u00a0est\u00e1\u00a0claramente \u00a0establecida \u00a0as\u00ed\u00a0como\u00a0tampoco\u00a0su\u00a0posible\u00a0efecto\u00a0inhibidor\u00a0sobre\u00a0el\u00a0\ncitocromo \u00a0P\u2010450\u00a0(ha\u00a0mostrado \u00a0p.\u00a0ej.\u00a0\u2191Cp\u00a0de\u00a0teofilina\u00a0y\u00a0barbit\u00faricos). \u00a0No\u00a0hay\u00a0datos\u00a0con\u00a0respecto\u00a0a\u00a0\nposibles\u00a0interacciones \u00a0con\u00a0los\u00a0no\u00a0nucle\u00f3sidos. \u00a0Se\u00a0recomienda \u00a0una\u00a0monitorizaci\u00f3n \u00a0m\u00e1s\u00a0estrecha\u00a0de\u00a0\nlos\u00a0efectos\u00a0secundarios \u00a0a\u00a0nivel\u00a0de\u00a0SNC\u00a0con\u00a0la\u00a0combinaci\u00f3n \u00a0de\u00a0efavirenz\u00a0\u00a0e\u00a0interfer\u00f3n. \u00a0\u00a0No\u00a0hay\u00a0datos.\u00a0Te\u00f3ricamente \u00a0no\u00a0es\u00a0de\u00a0\nesperar\u00a0una\u00a0interacci\u00f3n \u00a0significativa \u00a0\nMetadona\n\u00a0Posible\u00a0s\u00edndrome \u00a0abstinencia\nPuede\u00a0requerir\u00a0\u2191\u00a0dosis\u00a0MT\u00a0del\u00a08\u00ba\u201010\u00ba\u00a0d\u00eda.\u00a0Posible\u00a0s\u00edndrome \u00a0abstinencia\nPuede\u00a0requerir\u00a0\u2191\u00a0dosis\u00a0MT\u00a0del\u00a08\u00ba\u201010\u00ba\u00a0d\u00eda.\u00a0\nBuprenorfina \u00a0podr\u00eda\u00a0ser\u00a0una\u00a0alternativa \u00a0con\u00a0menor\u00a0\nriesgo\u00a0de\u00a0sd.\u00a0abstinencia \u00a0(datos\u00a0limitados). \u00a0\u00a0Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 5 \u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\n\u00a0Nevirapina \u00a0 Efavirenz \u00a0 Etravirina \u00a0(ETR)\u00a0\nAntirretrovirales \u00a0IP\u00a0\n\u00a0\n\u2010 IDV\u00a0\u219330%\u00a0AUC\u00a0IDV.\u00a0Valorar\u00a0\u2191\u00a01000\u00a0mg\u00a0c/8h\u00a0IDV\u00a0en\u00a0\nfunci\u00f3n\u00a0de\u00a0sus\u00a0Cp\u00a0(elevada\u00a0variabilidad \u00a0\ninterindividual) \u00a0\u00f3\u00a0usar\u00a0IDV/r\u00a0800/100\u00a0mg\u00a0c/12h.\u00a0\nNRAD\u00a0NVP\u00a0\u219331%\u00a0AUC\u00a0IDV\u00a0con\u00a0200\u00a0mg/d\u00eda\u00a0de\u00a0EFV.\u00a0\u00a0\u2191\u00a01000\u00a0\nmg\u00a0c/8h\u00a0IDV\u00a0\u00f3\u00a0usar\u00a0IDV/r\u00a0800/100\u00a0mg\u00a0c/12h.\u00a0\nNRAD\u00a0EFV\u00a0Evitar\u00a0el\u00a0uso\u00a0de\u00a0IDV\u00a0no\u00a0potenciado \u00a0con\u00a0\nTMC125.\u00a0No\u00a0hay\u00a0estudios\u00a0con\u00a0IDV/r.\u00a0\n\u00a0\n\u2010 RTV\u00a0\u00a0\nNRAD\u00a0 NRAD\u00a0(\u219118%\u00a0AUC\u00a0RTV)\u00a0NRAD\u00a0en\u00a0dosis\u00a0potenciaci\u00f3n.\nContraindicado \u00a0con\u00a0RTV\u00a0a\u00a0dosis\u00a0plenas\u00a0\n(\u219346%\u00a0AUC\u00a0ETV)\u00a0\u00a0\n\u2010 SQV\u00a0 No\u00a0recomendado \u00a0con\u00a0SQV\u00a0no\u00a0potenciado( \u219327%\u00a0\nAUC\u00a0SQV)1.\u00a0\u00a0\nNRAD\u00a0NVP\u00a0No\u00a0recomendado \u00a0con\u00a0SQV\u00a0no\u00a0potenciado \u00a0(\u219362%\u00a0\nAUC\u00a0SQV)2\u00a0NRAD\u00a0con\u00a0SQV\u00a0potenciado\n\u00a0\n\u2010 NFV\u00a0\u00a0\nNRAD\u00a0Si\u00a0bien\u00a0los\u00a0estudios\u00a0en\u00a0voluntarios \u00a0sanos\u00a0no\u00a0\nmostraron \u00a0interacci\u00f3n, \u00a0un\u00a0estudio\u00a0en\u00a0pacientes \u00a0\nnaive\u00a0mostr\u00f3\u00a0a\u00a0las\u00a032\u00a0semanas\u00a0una\u00a0tendencia \u00a0no\u00a0\nsignificativa \u00a0a\u00a0\u2193Cm\u00e1x\u00a0y\u00a0AUC\u00a0NFV\u00a0\u00a0y\u00a0\u2193Cmin\u00a0NFV\u00a0\nsignificativa. \u00a0\u00a0No\u00a0hay\u00a0datos.\u00a0Asociaci\u00f3n \u00a0no\u00a0recomendada \u00a0\n\u2010 FPV\u00a0 \u00a0\nNRAD\u00a0(FPV/r\u00a0700/100\u00a0mg\u00a0c/12h)\u00a0\u00a0\nValorar\u00a0aumento\u00a0de\u00a0dosis\u00a0de\u00a0RTV\u00a0en\u00a0QD\u00a0(300\u00a0mg)NRAD\u00a0(FPV/r\u00a0700/100\u00a0mg\u00a0c/12h)\u00a0\nValorar\u00a0aumento\u00a0de\u00a0dosis\u00a0de\u00a0RTV\u00a0en\u00a0QD\u00a0(300\u00a0mg)ETR\u00a0sin\u00a0cambios.\u00a0\u219169%\u00a0AUC\u00a0FPV\u00a0/r\u00a0\n(700/100\u00a0mg/12\u00a0h)(contrariamente \u00a0a\u00a0lo\u00a0\nesperado). \u00a0Considerar \u00a0reducci\u00f3n \u00a0de\u00a0dosis\u00a0\nde\u00a0FPV\u00a0(no\u00a0hay\u00a0informaci\u00f3n \u00a0suficiente \u00a0para\u00a0\nrecomendar \u00a0un\u00a0ajuste\u00a0de\u00a0dosis).\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 6 \u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Nevirapina \u00a0 Efavirenz \u00a0 Etravirina \u00a0(ETR)\u00a0\n\u2010 LPV/ r \u219322%\u00a0AUC/\u219355%\u00a0Cmin\u00a0LPV.\u00a0Valorar\u00a0600/150\u00a0mg\u00a0\nc/12h\u00a0(variabilidad \u00a0interindividual \u00a0elevada.\u00a0Si\u00a0es\u00a0\nposible,\u00a0determinar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0LPV).\u00a0\u00a0\nNRAD\u00a0NVP\u00a0\n\u00a0\u219320\u201025%\u00a0AUC\u00a0LPV.\u00a0Valorar\u00a0600/150\u00a0mg\u00a0c/12h.\u00a0\n(variabilidad \u00a0interindividual \u00a0elevada.\u00a0Si\u00a0es\u00a0posible,\u00a0\ndeterminar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0LPV).\u00a0\u00a0\nNRAD\u00a0EFV\u00a0Formulaci\u00f3n \u00a0meltrex\u00a0de\u00a0LPV/r:\u00a0NRAD\u00a0\n(LPV\u00a0sin\u00a0cambios,\u00a0\u219335%\u00a0AUC\u00a0de\u00a0ETR)\u00a0\n\u2010 ATV/r \u219333%\u00a0Cmin,\u00a0\u219360%\u00a0AUC\u00a0ATV.\u00a0No\u00a0se\u00a0recomienda \u00a0en\u00a0\npacientes \u00a0pretratados. \u00a0Ajuste\u00a0de\u00a0dosis\u00a0de\u00a0\u00a0ATV/r\u00a0en\u00a0\npacientes \u00a0naive\u00a0a\u00a0400/100\u00a0mg\u00a0c/24h.\u00a0Se\u00a0recomienda \u00a0\nmonitorizar \u00a0niveles\u00a0de\u00a0ATV.\u00a0\u219342%\u00a0Cmin\u00a0ATV.\u00a0No\u00a0se\u00a0recomienda \u00a0en\u00a0pacientes \u00a0\npretratados. \u00a0Ajuste\u00a0de\u00a0dosis\u00a0ATV/r\u00a0\u00a0en\u00a0pacientes \u00a0\nnaive\u00a0a\u00a0400/100\u00a0mg\u00a0/24h.\u00a0Se\u00a0recomienda \u00a0\nmonitorizar \u00a0niveles\u00a0de\u00a0ATV.\u00a0Utilizar\u00a0ATV/r\u00a0(\u219130%\u00a0AUC\u00a0ETR\u00a0y\u00a0\u219317%\u00a0\u00a0\nAUC\u00a0ATV.\u00a0\n\u2010 TPV/ r\nNRAD\u00a0 NRAD\u00a0 Asociaci\u00f3n \u00a0contraindicada \u00a0\u00a0(\u219376%\u00a0AUC\u00a0\nETR\u00a0y\u00a0\u219118%\u00a0el\u00a0AUC\u00a0de\u00a0TPV)\u00a0\n\u2010 Darunavir/ \u00a0\nritonavir\u00a0NRAD\u00a0 NRAD\u00a0(\u219121%\u00a0AUC\u00a0EFV\u00a0y\u00a0\u219313%\u00a0\u00a0AUC\u00a0DRV)\u00a0 NRAD\u00a0(\u219337%\u00a0AUC\u00a0ETR\u00a0y\u00a0\u21916%\u00a0\u00a0AUC\u00a0DRV)\u00a0\n\u00a0\nInhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0\n\u2010 RTG\u00a0 NRAD\u00a0 NRAD\u00a0(\u219336%\u00a0AUC\u00a0RAL)\u00a0 NRAD\u00a0(\u219310%\u00a0AUC\u00a0RAL,\u00a0\u2193\u00a034%\u00a0Cmin\u00a0de\u00a0\nRAL).\u00a0Debido\u00a0a\u00a0la\u00a0amplia\u00a0variabilidad \u00a0de\u00a0\nla\u00a0PK\u00a0de\u00a0RAL\u00a0se\u00a0han\u00a0descrito\u00a0Cmin\u00a0<CI 95\u00a0\n(14,6\u00a0ng/mL)\u00a0en\u00a0algunos\u00a0pacientes. \u00a0\nSignificado \u00a0cl\u00ednico\u00a0incierto\u00a0\n\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 7 \u00a0\nNombre\u00a0gen\u00e9rico Nevirapina \u00a0 Efavirenz \u00a0 Etravirina \u00a0(ETR)\u00a0\n\u00a0\nInhibidores \u00a0del\u00a0correceptor \u00a0CCR5\u00a0\n\u00a0\nMVC\u00a0 NRAD En ausencia de inhibidores enzim\u00e1ticos potentes \ndebe aumentarse la dosis de MVC a 600 mg c/12h. Si se coadministran inhibdores (ej. IP/r) la \ndosis de MVC ser\u00e1 de 150 mg/12h \n3. En ausencia de inhibidores enzim\u00e1ticos \npotentes debe aumentarse la dosis de MVC a 600 mg c/12h. Si se \ncoadministran inhibdores (ej. IP/r) la dosis de MVC ser\u00e1 de 150 mg/12h \n3. \n\u00a0\n\u2010 Otros\u00a0\n\u00a0\n\u00a0 \nPuede \u2193 Cp de los f\u00e1rmacos metabolizados \na trav\u00e9s del CYP3A44.   \nAtovacuona / proguanilo: \u2193 68% AUC atovacuona \ny \u2193 58% AUC de proguanilo. Valorar aumento de \ndosis (datos limitados procedentes de la \ncomparaci\u00f3n de datos de pacientes con datos \nhist\u00f3ricos de voluntarios sanos sin TARV \nPuede \u2191 Cp de los f\u00e1rmacos metabolizados a \ntrav\u00e9s del CYP3A44 aunque es m\u00e1s probable \nque las \u2193.  Puede \u2191 Cp de los f\u00e1rmacos \nmetabolizados a trav\u00e9s del CYP3A44 \naunque es m\u00e1s probable que las \u2193.  \nSildenafilo: ( \u219341\u201357% AUC sildenafilo) \n(puede requerir aumento de dosis) Paroxetina: ausencia de interacci\u00f3n. \nDigoxina: ausencia de interacciones \n\u00a0\nAUC\u00a0:\u00a0\u00e1rea\u00a0bajo\u00a0la\u00a0curva\u00a0de\u00a0concentraciones \u00a0plasm\u00e1ticas \u00a0frente\u00a0al\u00a0tiempo\u00a0(exposici\u00f3n \u00a0al\u00a0f\u00e1rmaco); \u00a0BID:\u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda;\u00a0Cp:\u00a0concentraci\u00f3n \u00a0\n\u00a0plasm\u00e1tica; \u00a0NRAD :\u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis;\u00a0QD:\u00a0una\u00a0vez\u00a0al\u00a0d\u00eda;\u00a0TDM:\u00a0monitorizaci\u00f3n \u00a0de\u00a0niveles\u00a0plasm\u00e1ticos; \u00a0TID:\u00a0tres\u00a0veces\u00a0al\u00a0d\u00eda.\u00a0\n*\u00a0Atripla\u00ae:\u00a0\u00a0asociaci\u00f3n \u00a0a\u00a0dosis\u00a0fijas\u00a0de\u00a0tenofovir\u00a0300\u00a0mg,\u00a0emtricitabina \u00a0200\u00a0mg\u00a0y\u00a0efavirenz\u00a0600\u00a0mg.\u00a0\n1\u00a0Saquinavir \u00a0en\u00a0c\u00e1psulas\u00a0duras\u00a0(Invirase\u00ae) \u00a0puede\u00a0asociarse \u00a0con\u00a0nevirapina \u00a0si\u00a0se\u00a0combina\u00a0con\u00a0ritonavir\u00a0(SQV/RTV \u00a01000/100 \u00a0mg\u00a0c/12h),\u00a0en\u00a0cuyo\u00a0caso\u00a0\u00a0\n\u00a0\u00a0datos\u00a0preliminares \u00a0han\u00a0mostrado \u00a0buenos\u00a0resultados. \u00a0\u00a0\n2\u00a0Saquinavir \u00a0puede\u00a0asociarse \u00a0con\u00a0la\u00a0dosis\u00a0habitual\u00a0de\u00a0efavirenz\u00a0si\u00a0se\u00a0combina\u00a0con\u00a0ritonavir\u00a0(1000/100 \u2010200\u00a0mg\u00a0c/12h).\u00a0\n3En\u00a0presencia \u00a0de\u00a0inhibidores \u00a0enzim\u00e1ticos \u00a0potentes\u00a0como\u00a0los\u00a0IP\u00a0(excepto\u00a0TPV/r\u00a0y\u00a0FPV/r),\u00a0antif\u00fangicos \u00a0imidaz\u00f3licos \u00a0(ketoconazol, \u00a0itraconazol), \u00a0macr\u00f3lidos \u00a0(eritromicina, \u00a0\nclaritromicina), \u00a0nefazodona \u00a0\u00f3\u00a0telitromicina \u00a0el\u00a0efecto\u00a0inhibidor\u00a0predomina \u00a0sobre\u00a0el\u00a0efecto\u00a0inductor\u00a0enzim\u00e1tico \u00a0y\u00a0por\u00a0lo\u00a0tanto,\u00a0se\u00a0recomienda \u00a0reducir\u00a0la\u00a0dosis\u00a0de\u00a0maraviroc \u00a0\na\u00a0150\u00a0mg\u00a0c/12h.\u00a0Maraviroc \u00a0no\u00a0debe\u00a0combinarse \u00a0con\u00a0dos\u00a0inductores \u00a0potentes\u00a0p.\u00a0ej.\u00a0rifampicina \u00a0+\u00a0efavrienz. \u00a0\n4\u00a0Principales \u00a0f\u00e1rmacos\u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP3A4:\u00a0alprazolam, \u00a0amiodarona, \u00a0amlodipino, \u00a0amprenavir, \u00a0ciclofosfamida, \u00a0\u00a0\nciclosporina, \u00a0clonacepam, \u00a0\u00a0\u00a0cloracepato, \u00a0dexametasona, \u00a0diazepam, \u00a0disopiramida, \u00a0estazolam, \u00a0etionamida, \u00a0fentanilo, \u00a0finasterida, \u00a0\n\u00a0fluracepam, \u00a0glipizida,\u00a0itraconazol, \u00a0lacidipino, \u00a0lidoca\u00edna, \u00a0loratadina, \u00a0meperidina, \u00a0nicardipino, \u00a0nifedipino, \u00a0nimodipino, \u00a0nitrendipino, \u00a0\u00a0\nprednisona, \u00a0quinidina, \u00a0sertralina, \u00a0sildenafilo \u00a0(Viagra\u00ae),\u00a0vardenafilo, \u00a0tadalafilo, \u00a0tacrolimus, \u00a0vincristina \u00a0y\u00a0\u00a0\u00a0zolpidem. \u00a0\nCategorias \u00a0seguridad \u00a0embarazo \u00a0(FDA):\u00a0A=\u00a0ausencia\u00a0de\u00a0riesgos\u00a0para\u00a0el\u00a0feto;\u00a0B=\u00a0no\u00a0teratogenicidad \u00a0en\u00a0animales, \u00a0falta\u00a0de\u00a0estudios\u00a0en\u00a0humanos; \u00a0C=\u00a0no\u00a0datos\u00a0de\u00a0seguridad \u00a0\n\u00a0en\u00a0embarazadas \u00a0y\u00a0los\u00a0estudios\u00a0en\u00a0animales\u00a0muestran \u00a0toxicidad\u00a0fetal\u00a0o\u00a0no\u00a0se\u00a0han\u00a0realizado\u00a0y\u00a0no\u00a0deben\u00a0utilizarse\u00a0dichos\u00a0f\u00e1rmacos, \u00a0a\u00a0menos\u00a0que\u00a0el\u00a0beneficio\u00a0potencial \u00a0supere\u00a0\u00a0\n\u00a0\u00a0el\u00a0posible\u00a0riesgo\u00a0fetal.\u00a0\n\u00a0NOTA:\u00a0debido\u00a0a\u00a0\u00a0que\u00a0la\u00a0informaci\u00f3n \u00a0cient\u00edfica\u00a0relacionada \u00a0con\u00a0los\u00a0f\u00e1rmacos\u00a0antirretrovirales \u00a0se\u00a0renueva\u00a0constantemente, \u00a0se\u00a0recomienda \u00a0consultar \u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0de\u00a0los\u00a0\nf\u00e1rmacos\u00a0y\u00a0la\u00a0informaci\u00f3n \u00a0actualizada \u00a0ofrecida\u00a0por\u00a0las\u00a0distintas\u00a0compa\u00f1\u00edas \u00a0farmac\u00e9uticas \u00a0y\u00a0las\u00a0autoridades \u00a0sanitarias.\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 1 Tabla\u00a07.\u00a0Inhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0(1\u00aa\u00a0parte):\u00a0indinavir, \u00a0ritonavir, \u00a0saquinavir, \u00a0nelfinavir \u00a0y\u00a0fosamprenavir \u00a0\n\u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\u00a0\nIndinavir\u00a0\u00a0\nRitonavir \u00a0\u00a0\nSaquinavir \u00a0\u00a0\nNelfinavir \u00a0\u00a0\nFosamprenavir \u00a0\n\u00a0\nNombre\u00a0comercial \u00a0\n\u00a0Crixivan\u00ae\u00a0 Norvir\u00ae\u00a0\u00a0\nInvirase\u00ae\u00a0\n\u00a0Viracept\u00ae\u00a0 Telzir\u00ae\u00a0\n\u00a0\nDosis\u00a0\u00a0\n\u00a0\u00a0\nRecomendaci\u00f3n \u00a0\n\u00a0\u00a0\n800\u00a0mg\u00a0TID\u00a0\nIDV/r\u00a0800/100\u00a0BID\u00a0\n\u00a0\nRestricci\u00f3n \u00a0diet\u00e9tica\u00a0\n\u00a0Ingesta\u00a0abundante \u00a0de\u00a0\nl\u00edquidos\u00a0no\u00a0carb\u00f3nicos \u00a0\n\u00a0\u00a0\nComo\u00a0potenciador \u00a0de\u00a0\notros\u00a0IP\u00a0:\u00a0100\u00a0\u00f3\u00a0200\u00a0mg\u00a0\ncon\u00a0cada\u00a0dosis\u00a0de\u00a0IP\u00a0\nComo\u00a0IP\u00a0(600\u00a0mg\u00a0BID)\u00a0se\u00a0\ndesaconseja \u00a0\n\u00a0\u00a0\u00a0\u00a0\nSQV/r\u00a01000/100 \u00a0BID\u00a0\n\u00a0Tomar\u00a0con\u00a0comida\u00a0grasa.\u00a0\u00a0\u00a0\n750\n\u00a0mg\u00a0TID\u00a0\u00f3\u00a0\n1250\u00a0mg\u00a0BID\u00a0\n\u00a0\nTomar\u00a0con\u00a0comida\u00a0grasa\u00a0\u00a0\u00a0\nFPV/r\u00a0\u00a0700/100\u00a0mg\u00a0c/12h\u00a0\n\u00a0Con\u00a0\u00f3\u00a0sin\u00a0alimentos \u00a0\nPresentaci\u00f3n \u00a0comercial \u00a0 c\u00e1ps.\u00a0200\u00a0y\u00a0400\u00a0mg\u00a0 sol.\u00a0oral\u00a080\u00a0mg/ml\u00a0\nc\u00e1ps.\u00a0100\u00a0mg\u00a0\u00a0comp\u00a0200\u00a0mg\u00a0\ncomp\u00a0500\u00a0mg\u00a0\n\u00a0comp\u00a0250\u00a0mg\u00a0\npolvo\u00a0(1\u00a0cuch\u00a01g\u00a0=50\u00a0mg\u00a0\nde\u00a0NFV)\u00a0comp\u00a0700\u00a0mg\u00a0\n\u00a0\nBiodisponibilidad \u00a0Oral\u00a0\n\u00a030\u2010\u00a060%\u00a0 80%\u00a0 4\u20108%\u00a0\n\u00a020\u201080%\u00a0 No\u00a0hay\u00a0datos\u00a0\nSemivida \u00a0de\u00a0eliminaci\u00f3n \u00a0\nplasm\u00e1tica \u00a0\u00a0\n1,5\u20102\u00a0horas\u00a0\u00a0\n3\u20105\u00a0horas\u00a0\u00a0\n1\u20102\u00a0horas\u00a0\u00a0\n3,5\u20105\u00a0horas\u00a09\u00a0horas\u00a0\n\u00a0\nCmax\u00a0\n\u00a0\n\u00a0\u00a0\n\u00a08\u00a0\u03bcg/ml\u00a0\u00a0\n(12,6\u00a0\u03bcM)\u00a0\n\u00a011,2\u00a0\n\u03bcg/ml\u00a0\u00a0\n(15,54\u00a0\u03bcM)\u00a0\n\u00a0\u00a00,243\u00a0\u03bcg/ml\u00a0\n(0,32\u00a0\u03bcM)\u00a0\u00a0\n\u00a03\u00a0\u03bcg/ml\u00a0\u00a0\n4,52\u03bcM)\u00a0\n\u00a0\u00a0\nFPV/r\u00a0700/100\u00a0mg\u00a0\nc/12h:\u00a06,08\u03bcg/ml\u00a0\n\u00a0FPV/r\u00a01400/200 \u00a0mg\u00a0\nc/24h:\u00a07,24\u03bcg/ml\u00a0\n\u00a0\nCmin\u00a0\n\u00a0\n\u00a00,15\u00a0\u03bcg/ml\u00a0\u00a0\n(0,25\u00a0\u03bcM)\u00a03,7\u00a0\u03bcg/ml\u00a0(5,13\u03bcM)\u00a0\u00a075\u00a0ng/ml\u00a0\n\u00a01,2\u00a0\u03bcg/ml\u00a0(1,81\u03bcM)\u00a0\u00a0\nFPV/r\u00a0700/100\u00a0mg\u00a0\nc/12h:\u00a02,12\u03bcg/ml\u00a0\n\u00a0FPV/r\u00a01400/200 \u00a0mg\u00a0\nc/24h:\u00a01,45\u03bcg/ml\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 2 \u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\u00a0\nIndinavir\u00a0\u00a0\nRitonavir \u00a0\u00a0\nSaquinavir \u00a0\u00a0\nNelfinavir \u00a0\u00a0\nFosamprenavir \u00a0\n\u00a0\nConcentraci\u00f3n \u00a0inhibitoria \u00a0\n\u00a0\u00a0\nCI90 :\u00a0<0,07\u00a0\u03bcg/ml\u00a0\u00a0\n(<0.098\u00a0\u03bcM)\u00a0\n\u00a0\u00a0\nCI90 :\u00a0<0,1\u00a0\u03bcg/ml\u00a0\u00a0\n(<0.138\u00a0\u03bcM)\u00a0\n\u00a0\u00a0\nCI90 :\u00a00,1\u00a0\u03bcg/ml\u00a0\u00a0\n(0.13\u00a0\u03bcM)\u00a0\n\u00a0\u00a0\nCI95 :\u00a00.0046\u20100.13\u00a0\u03bcg/ml\u00a0\n(0.007\u20100.196\u00a0\u03bcM)\u00a0\u00a0\nCI50 :\u00a00.006\u00a0\u03bcg/ml\u00a0\n(0,012\u00a0\u03bcM)\u00a0\n\u00a0\nActividad \u00a0\n\u00a0\u00a0\nVIH\u20101.2\u00a0\u00a0\nVIH\u20101,2\u00a0\u00a0\nVIH\u20101,2\u00a0\u00a0\nVIH\u20101,2\u00a0\u00a0\nVIH\u20101,2\u00a0\n\u00a0\nMetabolizaci\u00f3n \u00a0\n\u00a0\u00a0\nCYP3A4\u00a0\u00a0\nCYP3A4\u00a0\u00a0\nCYP3A4\u00a0\u00a0\nCYP3A4\u00a0\u00a0\nCYP3A4\u00a0\n\u00a0\nEfectos\u00a0\nAdversos \u00a0\u00a0\nNefrolitiasis \u00a0\n\u00a0\u00a0Intolerancia \u00a0G\u2010I.\u00a0\n\u00a0\nHiperbilirrubinemia \u00a0\n\u00a0Hiperglucemia \u00a0\n\u00a0Dislipemia \u00a0\n\u00a0Lipodistrofia \u00a0\n\u00a0Posible\u00a0aumento\u00a0del\u00a0\nsangrado\u00a0en\u00a0hemof\u00edlicos \u00a0\u00a0\n(En\u00a0dosis\u00a0reducidas \u00a0la\u00a0\nprevalencia \u00a0de\u00a0los\u00a0\nefectos\u00a0adversos\u00a0es\u00a0muy\u00a0\nbaja)\u00a0\n\u00a0\nIntolerancia \u00a0G\u2010I\u00a0\n(v\u00f3mitos, \u00a0diarrea)\u00a0\nParestesias \u00a0orales\u00a0\nHepatitis\u00a0\nHiperglucemia \u00a0\nDislipemia \u00a0\nLipodistrofia \u00a0\nPosible\u00a0aumento\u00a0del\u00a0\nsangrado \u00a0en\u00a0hemof\u00edlicos \u00a0\n\u00a0\n\u00a0\u00a0\nIntolerancia \u00a0G\n\u2010I\u00a0\n(diarrea)\u00a0\n\u00a0\u00a0Cefalea\u00a0\n\u00a0\n\u2191\u00a0transaminasas \u00a0\n\u00a0Hiperglucemia \u00a0\n\u00a0Dislipemia \u00a0\n\u00a0Lipodistrofia \u00a0\n\u00a0Posible\u00a0aumento\u00a0del\u00a0\nsangrado\u00a0en\u00a0hemof\u00edlicos \u00a0\u00a0\nDiarrea\u00a0\n\u00a0Hiperglucemia \u00a0\n\u00a0Dislipemia \u00a0\n\u00a0\nLipodistrofia \u00a0\n\u00a0Posible\u00a0aumento\u00a0del\u00a0\nsangrado\u00a0en\u00a0hemof\u00edlicos \u00a0Intolerancia \u00a0G\u2010I\u00a0\n(diarrea)\u00a0\n\u00a0Exantema \u00a0\n\u00a0Cefalea\u00a0\n\u00a0\nHiperglucemia \u00a0\n\u00a0Dislipemia \u00a0\n\u00a0Lipodistrofia \u00a0\n\u00a0Posible\u00a0aumento\u00a0del\u00a0\nsangrado \u00a0en\u00a0hemof\u00edlicos \u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 3 \u00a0\n\u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\u00a0\nIndinavir\u00a0\u00a0\nRitonavir \u00a0\u00a0\nSaquinavir \u00a0\u00a0\nNelfinavir \u00a0\u00a0\nFosamprenavir \u00a0\n\u00a0\nInteracciones \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\nAsociaciones \u00a0\ncontraindicadas \u00a0Amiodarona \u00a0\nAstemizol \u00a0\nAtazanavir \u00a0\nEstatinas\u00a0(excepto\u00a0\natorvastatina, \u00a0\nfluvastatina \u00a0y\u00a0\npravastatina) \u00a0\u00a0\nCisaprida\u00a0\nDeriv.\u00a0Ergotamina \u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0\nSan\u00a0Juan)\u00a0\nLumefantrina \u00a0\nMidazolam \u00a0oral10\u00a0\nPimozida\u00a0\nRifampicina \u00a0\nTerfenadina \u00a0\u00a0\nTriazolam \u00a0\n\u00a0Alfuzosina \u00a0\nAmiodarona \u00a0\nAnticonceptivos \u00a0orales\u00a0\nAstemizol \u00a0\nCisaprida\u00a0\nCloracepato \u00a0\nClozapina \u00a0\nDextropropoxif. \u00a0\nDiacepam \u00a0\nDeriv.\u00a0ergotamina \u00a0\nDisulfiram \u00a0\nEncainida \u00a0\nEstatinas\u00a0(excepto\u00a0\npravastatina) \u00a0\nEstazolam, \u00a0\u00a0\n\u00c9xtasis\u00a0\u00a0\nFlecainida \u00a0\nFluracepam \u00a0\nFluticasona \u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0\nSan\u00a0Juan)\u00a0\nLumefantrina \u00a0\nMeperidina \u00a0\nMetanfetamina \u00a0\nMidazolam \u00a0oral10\u00a0\nPimozida\u00a0\nPiroxicam \u00a0\nPropafenona \u00a0\nQuinidina \u00a0\u00a0\nTerfenadina \u00a0\nTriazolam \u00a0\u00a0\u00a0\nVoriconazol \u00a0\nZolpidem \u00a0Ajo,\u00a0suplementos \u00a0\n(utilizar\u00a0SQV/r)\u00a0\nAstemizol \u00a0\nEstatinas\u00a0(excepto\u00a0\natorvastatina, \u00a0\nfluvastatina \u00a0y\u00a0\npravastatina) \u00a0\u00a0\nCarbamacepina \u00a0\nCisaprida\u00a0\nDexametasona \u00a0\nDeriv.\u00a0ergotamina \u00a0\nEfavirenz\u00a0\u00a0\nFenito\u00edna \u00a0\nFenobarbital \u00a0\nFluticasona \u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0\nSan\u00a0Juan)\u00a0\nLumefantrina \u00a0\nMidazolam \u00a0oral10\u00a0\nNevirapina \u00a0\nPimozida\u00a0\nRifampicina \u00a0\nTerfenadina \u00a0\u00a0\nTriazolam. \u00a0\n\u00a0Anticonceptivos \u00a0orales\u00a0\nAstemizol \u00a0\nBupropion \u00a0\nEstatinas\u00a0(excepto\u00a0\natorvastatina, \u00a0\nfluvastatina \u00a0y\u00a0\npravastatina) \u00a0\u00a0\nCisaprida\u00a0\nDeriv.\u00a0Ergotamina \u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0\nSan\u00a0Juan)\u00a0\nLumefantrina \u00a0\nMidazolam \u00a0oral10\u00a0\nOmeprazol \u00a0y\u00a0afines\u00a0\nPimozida\u00a0\nRifampicina \u00a0\nTerfenadina \u00a0\u00a0\nTriazolam \u00a0Anticonceptivos \u00a0orales\u00a0\nAstemizol \u00a0\nCisaprida\u00a0\nDeriv.\u00a0ergotamina \u00a0\u00a0\nEstatinas\u00a0(excepto\u00a0\natorvastatina, \u00a0\nfluvastatina \u00a0y\u00a0\npravastatina) \u00a0\u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0\nSan\u00a0Juan)\u00a0\nLumefantrina \u00a0\nLopinavir/ritonavir \u00a0\nMidazolam \u00a0oral10\u00a0\nPimozida\u00a0\u00a0\nRifampicina \u00a0\nTerfenadina \u00a0\nTriazolam \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 4 \u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\n\u00a0Indinavir\u00a0 Ritonavir \u00a0 Saquinavir \u00a0 Nelfinavir \u00a0 Fosamprenavir \u00a0\nAnti\u00e1cidos \u00a0 Espaciarlos \u00a01h\u00a0 No\u00a0hay\u00a0datos\u00a0 No\u00a0hay\u00a0datos\u00a0 No\u00a0hay\u00a0datos\u00a0 Ausencia\u00a0de\u00a0\ninteracciones  \u00a0\nInhibidores \u00a0de\u00a0la\u00a0\nbomba\u00a0de\u00a0protones\u00a0\n\u00a0Utilizar\u00a0IDV/r\u00a0(\u219347%\u00a0AUC\u00a0\nIDV)\u00a0No\u00a0hay\u00a0datos\u00a0 NRAD\u00a0(omeprazol \u00a040\u00a0\nmg/d\u00a0\u219180%\u00a0AUC\u00a0SQV\u00a0sin\u00a0\ntoxicidad) \u00a0Contraindicado \u00a0(\u219336%\u00a0\nAUc\u00a0NFV)\u00a0NRAD\u00a0(\u2193Cmax,\u00a0pero\u00a0AUC\u00a0\ny\u00a0Cmin\u00a0FPV\u00a0sin\u00a0cambios).\nAntihistam\u00ednicos \u00a0H2\u00a0 No\u00a0hay\u00a0datos.\u00a0 No\u00a0hay\u00a0datos\u00a0 NRAD\u00a0 No\u00a0hay\u00a0datos\u00a0 NRAD\u00a0(\u219330%\u00a0AUC,\u00a0pero\u00a0\nCmin\u00a0sin\u00a0cambios)\u00a0\nAntimicobact. \u00a0\n\u2010\u00a0Rifampicina \u00a0 Contraindicado \u00a0tanto\u00a0\ncon\u00a0IDV\u00a0como\u00a0con\u00a0IDV/r\u00a0\u219335%\u00a0AUC\u00a0RTV.\u00a0NRAD\u00a0\n(RTV\u00a0a\u00a0dosis\u00a0plenas).\u00a0\nMonitorizar \u00a0toxicidad\u00a0\nhep\u00e1tica\u00a0Contraindicado9\u00a0\u00a0 Contraindicado \u00a0 Contraindicado \u00a0\n\u2010\u00a0Rifabutina \u00a0(RFB)0\u00a0 1000\u00a0mg\u00a0c/8h\u00a0IDV.\u00a0\nRFB\u00a0150\u00a0mg\u00a0c/24h\u00a0\u00f3\u00a0300\u00a0\nmg\u00a03veces/semana0.\u00a0\u00a0RFB\u00a0150\u00a0mg\u00a0\u00a0\u00a03veces\u00a0\n/semana0\u00a0\u00a0Contraindicado \u00a0como\u00a0\n\u00fanico\u00a0IP\u00a00,2\u00a01000\u00a0mg\u00a0c/8h\u00a0\u00f3\u00a01250\u00a0mg\u00a0\nc/12h\u00a0NFV.\u00a0\nRFB\u00a0150\u00a0mg\u00a0c/24h\u00a0\u00f3\u00a0300\u00a0\nmg\u00a0\u00a03veces\u00a0/semana0.\u00a0NRAD\u00a0FPV/r\u00a0\u00a0\u00a0\u00a0RFB\u00a0150\u00a0\nmg\u00a0\u00a03veces\u00a0/semana0\u00a0\n\u00a0\n\u2010\u00a0Claritromicina \u00a0\u00a0\nNRAD\u00a0\nConsiderar \u00a0tratamientos \u00a0\nalternativos \u00a0para\u00a0\nindicaciones \u00a0diferentes \u00a0\nde\u00a0MAC\u00a0\nEn\u00a0presencia \u00a0de\u00a0RTV,\u00a0\najustar\u00a0dosis\u00a0de\u00a0claritro\u00a0\nsi\u00a0funci\u00f3n\u00a0renal\u00a0alterada1\u00a0\nConsiderar \u00a0tratamientos \u00a0\nalternativos \u00a0para\u00a0\nindicaciones \u00a0diferentes \u00a0\nde\u00a0MAC\u00a0(100%\u00a0AUC\u00a014\u2010\nOH\u2010claritromicina) \u00a0\nAjustar\u00a0dosis\u00a0claritro\u00a0si\u00a0\nfunc.\u00a0renal\u00a0alterada1.\u00a0\u00a0\nNRAD\u00a0\nDado\u00a0que\u00a0se\u00a0administra \u00a0\ncon\u00a0RTV,\u00a0considerar \u00a0\ntratamientos \u00a0\nalternativos \u00a0para\u00a0\nindicaciones \u00a0diferentes \u00a0\nde\u00a0MAC\u00a0\n\u00a0\u00a0\nNRAD\u00a0FPV\u00a0no\u00a0potenciado: \u00a0\nNRAD\u00a0\nFPV/r:\u00a0Considerar \u00a0\ntratamientos \u00a0\nalternativos \u00a0para\u00a0\nindicaciones \u00a0diferentes \u00a0\nde\u00a0MAC\u00a0\nAjustar\u00a0dosis\u00a0claritro\u00a0si\u00a0\nfunc.\u00a0renal\u00a0alterada1.\u00a0\nAntiepil\u00e9pticos :\u00a0\n\u00a0\n\u2010 Carbamacepina, \u00a0\nfenito\u00edna, \u00a0\nfenobarbital \u00a0Posible\u00a0\u2193Cp\u00a0IDV.\u00a0\nMonitorizar \u00a0Cp\u00a0\nantiepil\u00e9ptico \u00a0y\u00a0ARV.\u00a0\nCon\u00a0carbamacepina \u00a0\u2193Cp\u00a0\nIDV\u00a0importantes. \u00a0Evitar\u00a0\nasociarlos \u00a0Monitorizar \u00a0Cp\u00a0\nantiepil\u00e9ptico \u00a0y\u00a0ARV.\u00a0\nRTV\u00a0puede\u00a0\u2193Cp\u00a0de\u00a0\nfenito\u00edna\u00a0y\u00a0lamotrigina. \u00a0\nDatos\u00a0iniciales\u00a0indican\u00a0\nque\u00a0tambi\u00e9n\u00a0podr\u00eda\u00a0\u2193Cp\u00a0\nde\u00a0valproico. \u00a0\nVarios\u00a0casos\u00a0descritos\u00a0de\u00a0\ntoxicidad\u00a0por\u00a0\ncarbamacepina. \u00a0\u00a0\nNo\u00a0hay\u00a0datos.\u00a0Evitar\u00a0la\u00a0\ncombinaci\u00f3n \u00a0o\u00a0monito\u2010\nrizar\u00a0estrechamente \u00a0los\u00a0\nniveles\u00a0de\u00a0ambos.\u00a0Posible\u00a0\u2193Cp\u00a0NFV.\u00a0\nMonitorizar \u00a0Cp\u00a0\nantiepil\u00e9ptico \u00a0y\u00a0ARV.\u00a0\nAlg\u00fan\u00a0caso\u00a0descrito\u00a0de\u00a0\ntoxicidad\u00a0por\u00a0\ncarbamacepina. \u00a0Posible\u00a0\u2193Cp\u00a0APV.\u00a0\nMonitorizar \u00a0Cp\u00a0\nantiepil\u00e9ptico \u00a0y\u00a0ARV.\u00a0\nAnticoagulantes \u00a0orales\u00a0\n\u00a0Los\u00a0IP\u00a0pueden\u00a0alterar\u00a0las\u00a0Cp\u00a0de\u00a0los\u00a0anticoagulantes. \u00a0Existen\u00a0casos\u00a0descritos\u00a0de\u00a0reducci\u00f3n \u00a0del\u00a0efecto\u00a0anticoagulante \u00a0con\u00a0requerimiento \u00a0\nde\u00a0aumento\u00a0de\u00a0dosis\u00a0de\u00a0acenocumarol \u00a0y\u00a0warfarina \u00a0al\u00a0asociarlos \u00a0a\u00a0RTV\u00a0\u00f3\u00a0IDV.\u00a0Monitorizar \u00a0estrictamente \u00a0el\u00a0tiempo\u00a0de\u00a0protrombina. \u00a0\nAnticonceptivos \u00a0orales :\u00a0 NRAD\u00a0 \u219340%\u00a0AUC\u00a0\netinilestradiol. \u00a0Usar\u00a0\nm\u00e9todos\u00a0alternativos \u00a0No\u00a0hay\u00a0datos\u00a0 \u219347%\u00a0AUC\u00a0\netinilestradiol. \u00a0Usar\u00a0\nm\u00e9todos\u00a0alternativos \u00a0Usar\u00a0m\u00e9todos\u00a0\nalternativos \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 5 \u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\n\u00a0\u00a0\nIndinavir\u00a0\u00a0\nRitonavir\u00a0\u00a0\nSaquinavir \u00a0\u00a0\nNelfinavir \u00a0\u00a0\nFosamprenavir \u00a0\nAntif\u00fangicos \u00a0imidaz\u00f3licos \u00a0Con\u00a0fluconazol \u00a0NRAD.\u00a0\n\u00a0\nCon\u00a0ketoconazol \u00a0\u2193IDV\u00a0\n600\u00a0mg\u00a0c/8h.\u00a0\n\u00a0Con\u00a0itraconazol \u00a0posible\u00a0\n\u2191Cp\u00a0IDV.\u00a0\u00a0\n\u00a0Con\u00a0fluconazol \u00a0NRAD\u00a0de\u00a0\nninguno.\u00a0\n\u00a0\nCon\u00a0voriconazol \u00a0+\u00a0IDV\u00a0\n800\u00a0mg\u00a0c/8h:\u00a0NRAD.Con \u00a0\nIDV/r\u00a0no\u00a0hay\u00a0datos\u00a0(RTV\u00a0\n400\u00a0mg\u00a0c/12h\u00a0\u00a0\ncontraindicado; \u00a0RTV\u00a0100\u00a0\nmg\u00a0c/12h:\u00a0evitar\u00a0a\u00a0\nmenos\u00a0que\u00a0el\u00a0balance\u00a0\nriesgo/beneficio \u00a0\njustifique \u00a0\nsu\u00a0uso.\u00a0Ver\u00a0\nRTV).\u00a0Monitorizar \u00a0\nestrechamente. \u00a0M\u00e1x\u00a0200\u00a0mg/d\u00eda\u00a0de\u00a0\nketoconazol \u00a0e\u00a0\nitraconazol. \u00a0\u00a0\n\u00a0Con\u00a0fluconazol \u00a0NRAD\u00a0de\u00a0\nninguno.\u00a0\n\u00a0Voriconazol \u00a0\ncontraindicado \u00a0(estudio\u00a0\ncon\u00a0400\u00a0mg\u00a0c/12h\u00a0de\u00a0\nRTV:\u00a0\u219382%\u00a0AUC\u00a0\nvoriconazol, \u00a0AUC\u00a0RTV\u00a0sin\u00a0\ncambios;\u00a0estudio\u00a0con\u00a0\n100\u00a0mg\u00a0c/12h\u00a0de\u00a0RTV:\u00a0\n\u219339%\u00a0AUC\u00a0voriconazol, \u00a0\nAUC\u00a0RTV\u00a0sin\u00a0cambios\u00a0\nimportantes). \u00a0\u00a0\u00a0\nFluconazol: \u00a0NRAD\u00a0\n\u00a0Voriconazol \u00a0y\u00a0SQV+/\u2010\nRTV:\u00a0no\u00a0hay\u00a0datos\u00a0(RTV\u00a0\n400\u00a0mg\u00a0c/12h\u00a0\u00a0\ncontraindicado; \u00a0RTV\u00a0100\u00a0\nmg\u00a0c/12h:\u00a0evitar\u00a0a\u00a0\nmenos\u00a0que\u00a0el\u00a0balance\u00a0\nriesgo/beneficio \u00a0\njustifique \u00a0su\u00a0uso.\u00a0Ver\u00a0\nRitonavir). \u00a0Se\u00a0\nrecomienda \u00a0monitorizar \u00a0\nestrechamente. \u00a0\n\u00a0ketoconazol \u00a0e\u00a0\nitraconazol \u00a0m\u00e1x\u00a0200\u00a0\nmg/d\u00eda.\u00a0No\u00a0se\u00a0han\u00a0descrito\u00a0\ninteracciones \u00a0\ncl\u00ednicamente \u00a0\nimportantes \u00a0con\u00a0\nfluconazol, \u00a0itraconazol, \u00a0\nketoconazol\n\u00a0\u00a0o\u00a0\ncaspofungina. \u00a0\n\u00a0\nCon\u00a0Voriconazol: \u00a0no\u00a0hay\u00a0\ndatos.\u00a0Se\u00a0recomienda \u00a0\nmonitorizar \u00a0\nestrechamente \u00a0(podr\u00eda\u00a0\naumentar \u00a0la\u00a0toxicidad\u00a0de\u00a0\nambos).\u00a0Con\u00a0FPV/r\u00a0no\u00a0sobrepasar \u00a0\n200\u00a0mg/d\u00eda\u00a0de\u00a0\nketoconazol \u00a0e\u00a0\nitraconazol. \u00a0\n\u00a0Con\u00a0voriconazol \u00a0y\u00a0FPV+/\u2010\u00a0\nRTV\u00a0no\u00a0hay\u00a0datos\u00a0(RTV\u00a0\n400\u00a0mg\u00a0c/12h\u00a0\u00a0\ncontraindicado; \u00a0RTV\u00a0100\u00a0\nmg\u00a0c/12h:\u00a0evitar\u00a0a\u00a0\nmenos\u00a0que\u00a0el\u00a0balance\n\u00a0\nriesgo/beneficio \u00a0\njustifique \u00a0su\u00a0uso.\u00a0Ver\u00a0\nRitonavir). \u00a0Se\u00a0\nrecomienda \u00a0monitorizar \u00a0\nestrechamente. \u00a0\u00a0\nEstatinas: \u00a0 Lovastatina \u00a0y\u00a0\nsimvastatina \u00a0\ncontraindicadas. \u00a0Con\u00a0\nfluvastatina \u00a0y\u00a0\npravastatina \u00a0interacci\u00f3n \u00a0\npoco\u00a0probable. \u00a0\nAtorvastatina: \u00a0asociar\u00a0\ncon\u00a0precauci\u00f3n \u00a0(iniciar\u00a0\ncon\u00a0dosis\u00a0bajas\u00a0m\u00e1ximo\u00a0\n10\u00a0mg/d\u00eda).\u00a0Atorvastatina, \u00a0\nfluvastatina \u00a0lovastatina \u00a0y\u00a0\nsimvastatina \u00a0\ncontraindicadas. \u00a0Con\u00a0\npravastatina \u00a0interacci\u00f3n \u00a0\npoco\u00a0probable. \u00a0\u00a0\u00a0\u00a0\nSQV/RTV\u00a0400/400\u00a0mg\u00a0\nc/12h\u00a0\u219350%\u00a0pravastatina \u00a0\n(probablemente \u00a0NRAD)\u00a0y\u00a0\n\u2191x4.5\u00a0AUC\u00a0atorvastatina \u00a0\n(iniciar\u00a0con\u00a0dosis\u00a0bajas\u00a0\nm\u00e1ximo\u00a010\u00a0mg/d\u00eda).\u00a0Lovastatina \u00a0y\u00a0\nsimvastatina \u00a0\ncontraindicadas. \u00a0Con\u00a0\nfluvastatina \u00a0interac\u00a0poco\u00a0\nprobable. \u00a0Atorvastatina: \u00a0\nasociar\u00a0con\u00a0precauci\u00f3n \u00a0\n(iniciar\u00a0con\u00a0dosis\u00a0bajas\u00a0\nm\u00e1ximo\u00a010\u00a0mg/d\u00eda).\u00a0Con\u00a0\nSQV/RTV\u00a0400/400\u00a0mg\u00a0\nc/12h\u00a0\u219350%\u00a0pravastatina \u00a0\n(probablem \u00a0NRAD)\u00a0y\u00a0\n\u2191x4.5\u00a0AUC\u00a0atorvastatina \u00a0\u00a0\n(iniciar\u00a0con\u00a0dosis\u00a0bajas\u00a0\nm\u00e1ximo\u00a010\u00a0mg/d\u00eda).\u00a0Lovastatina \u00a0y\u00a0\nsimvastatina \u00a0\ncontraindicadas. \u00a0Con\u00a0\nfluvastatina \u00a0interacci\u00f3n \u00a0\npoco\u00a0probable. \u00a0\nPravastatina \u00a0es\u00a0segura\u00a0\npero\u00a0probablemente \u00a0\nrequiera\u00a0aumento\u00a0de\u00a0\ndosis\u00a0(\u219347%\u00a0AUC).\u00a0\nAtorvastatina: \u00a0Asociar\u00a0\ncon\u00a0precauci\u00f3n \u00a0(iniciar\u00a0\ncon\u00a0dosis\u00a0bajas\u00a0m\u00e1ximo\u00a0\n10\u00a0mg/d\u00eda).). \u00a0Lovastatina \u00a0y\u00a0\nsimvastatina \u00a0\ncontraindicadas. \u00a0Con\u00a0\nfluvastatina \u00a0y\u00a0\npravastatina \u00a0interacci\u00f3n \u00a0\npoco\u00a0probable. \u00a0FPV\u00a0\naument\u00f3\u00a02,3\u00a0veces\u00a0el\u00a0\nAUC\u00a0de\u00a0atorvastatina \u00a0(10\u00a0\nmg/d\u00eda):\u00a0asociar\u00a0con\u00a0\nprecauci\u00f3n \u00a0(iniciar\u00a0con\u00a0\ndosis\u00a0bajas\u00a0m\u00e1ximo\u00a010\u00a0\nmg/d\u00eda).\u00a0\nEtanol:\u00a0 El\u00a0uso\u00a0agudo\u00a0o\u00a0cr\u00f3nico\u00a0de\u00a0etanol\u00a0alter\u00f3\u00a0m\u00ednimamente \u00a0la\u00a0farmacocin\u00e9tica \u00a0de\u00a0los\u00a0IP.\u00a0\nAntabus:\u00a0algunos\u00a0IP\u00a0podr\u00edan\u00a0dar\u00a0lugar\u00a0a\u00a0una\u00a0reacci\u00f3n\u00a0de\u00a0tipo\u00a0disulfiram \u00a0por\u00a0su\u00a0contenido \u00a0en\u00a0etanol:\u00a0Norvir\u00ae\u00a0soluci\u00f3n\u00a0oral\u00a0(43%\u00a0v/v);\u00a0Norvir\u00a0c\u00e1psulas\u00a0\n(12%\u00a0p/p);\u00a0Kaletra\u00ae\u00a0soluci\u00f3n\u00a0oral\u00a0(42%);\u00a0Aptivus\u00a0c\u00e1psulas\u00a0(7%\u00a0p/p\u00a0=100\u00a0mg/c\u00e1ps). \u00a0Kaletra\u00ae\u00a0en\u00a0comprimidos \u00a0no\u00a0contiene\u00a0alcohol.\u00a0Agenerase\u00ae \u00a0en\u00a0\nsoluci\u00f3n\u00a0tiene\u00a0un\u00a0elevado\u00a0contenido \u00a0de\u00a0propilenglicol \u00a0(550\u00a0mg/mL),\u00a0que\u00a0se\u00a0metaboliza \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0alcohol\u00a0deshidrogenasa, \u00a0por\u00a0lo\u00a0que\u00a0el\u00a0consumo\u00a0de\u00a0\netanol\u00a0junto\u00a0con\u00a0estos\u00a0IPs\u00a0podr\u00eda\u00a0producir\u00a0toxicidad. \u00a0Kaletra\u00ae\u00a0en\u00a0c\u00e1psulas\u00a0y\u00a0Agenerase\u00ae \u00a0en\u00a0c\u00e1psulas\u00a0tambi\u00e9n\u00a0contienen \u00a0propilenglicol, \u00a0pero\u00a0en\u00a0menor\u00a0\ncantidad. \u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 6 \u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\n\u00a0\u00a0\nIndinavir\u00a0\u00a0\nRitonavir\u00a0\u00a0\nSaquinavir \u00a0\u00a0\nNelfinavir \u00a0\u00a0\nFosamprenavir \u00a0\nF\u00e1rmacos \u00a0empleados \u00a0\npara\u00a0tratar\u00a0la\u00a0influenza \u00a0Zanamivir/amantadina: \u00a0una\u00a0interacci\u00f3n \u00a0con\u00a0los\u00a0IPs\u00a0se\u00a0considera \u00a0poco\u00a0probable. \u00a0\nOseltamivir \u00a0se\u00a0ha\u00a0relacionado \u00a0con\u00a0efectos\u00a0adversos\u00a0neuropsiqui\u00e1tricos, \u00a0aunque\u00a0no\u00a0se\u00a0puede\u00a0descartar \u00a0que\u00a0\u00e9stos\u00a0sean\u00a0debidos,\u00a0al\u00a0\nmenos\u00a0en\u00a0parte,\u00a0a\u00a0la\u00a0propia\u00a0enfermedad. \u00a0Los\u00a0IPs\u00a0al\u00a0bloquear\u00a0la\u00a0glicoprote\u00edna \u2010P\u00a0podr\u00edan\u00a0aumentar \u00a0la\u00a0penetraci\u00f3n \u00a0de\u00a0oseltamivir \u00a0en\u00a0el\u00a0\nSNC\u00a0y\u00a0empeorar \u00a0sus\u00a0efectos\u00a0adversos. \u00a0Se\u00a0recomienda \u00a0asociarlos \u00a0con\u00a0pecauci\u00f3n \u00a0hasta\u00a0que\u00a0no\u00a0se\u00a0disponga\u00a0de\u00a0m\u00e1s\u00a0datos.\u00a0\u00a0\nInmunosupresores :\u00a0\n\u00a0\u00a0\n\u00a0\n\u00a0Posible\u00a0\u2191Cp\u00a0ciclosporina, \u00a0\nprednisona, \u00a0tacrolimus \u00a0y\u00a0\nsirolimus. \u00a0Monitorizar \u00a0\nniveles/toxicidad \u00a0del\u00a0\ninmunosupresor. \u00a0RTV\u00a0puede\u00a0aumentar \u00a0\nhasta\u00a03\u00a0veces\u00a0Cp\u00a0\nciclosporina \u00a0y\u00a0\ntacrolimus. \u00a0\u00a0\n\u219130%\u00a0AUC\u00a0de\u00a0\nprednisolona \u00a0tras\u00a0la\u00a0\nadministraci\u00f3n \u00a0de\u00a0\nprednisona. \u00a0\nPosible\u00a0\u2191Cp\u00a0sirolimus. \u00a0\nMonitorizar \u00a0\nniveles/toxicidad \u00a0\ninmunosupresor. \u00a0\nMicofenolato \u00a0se\u00a0\nglucuronida \u00a0por\u00a0lo\u00a0que\u00a0\nRTV\u00a0podr\u00eda\u00a0\u2193\u00a0sus\u00a0Cp.\n\u00a0\nMonitorizar \u00a0\nniveles/eficacia.Posible\u00a0\u2191Cp\u00a0ciclosporina, \u00a0\u00a0\nprednisona, \u00a0tacrolimus \u00a0y\u00a0\nsirolimus. \u00a0Monitorizar \u00a0\nniveles/toxicidad \u00a0del\u00a0\ninmunosupresor. \u00a0Posible\u00a0\u2191Cp\u00a0ciclosporina, \u00a0\nprednisona, \u00a0tacrolimus \u00a0y\u00a0\nsirolimus. \u00a0Monitorizar \u00a0\nniveles/toxicidad \u00a0del\u00a0\ninmunosupresor. \u00a0Un\u00a0\npaciente\u00a0con\u00a0trasplante \u00a0\nde\u00a0h\u00edgado\u00a0requiri\u00f3\u00a0una\u00a0\nreducci\u00f3n \u00a0muy\u00a0\nimportante \u00a0en\u00a0la\u00a0dosis\u00a0\nde\u00a0tacrolimus. \u00a0Las\u00a0Cp\u00a0\nNFV\u00a0no\u00a0se\u00a0alteraron. \u00a0\nMicofenolato \u00a0se\u00a0\nglucuronida \u00a0por\u00a0lo\u00a0que\u00a0\nNFV\u00a0podr\u00eda\u00a0\u2193\u00a0sus\u00a0Cp.\u00a0\nMonitorizar \u00a0\nniveles/eficacia. \u00a0Posible\u00a0\u2191Cp\u00a0ciclosporina, \u00a0\u00a0\nprednisona, \u00a0tacrolimus \u00a0y\u00a0\nsirolimus. \u00a0Monitorizar \u00a0\nniveles/toxicidad \u00a0del\u00a0\ninmunosupresor. \u00a0\nInmunosupresores :\u00a0 La\u00a0dosis\u00a0de\u00a0ciclosporina \u00a0inicial\u00a0debe\u00a0ser\u00a0aprox\u00a01/10\u00a0de\u00a0la\u00a0habitual\u00a0y\u00a0puede\u00a0requerir\u00a0reducciones \u00a0progresivas \u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0tiempo.\u00a0En\u00a0\nalgunos\u00a0casos\u00a0la\u00a0dosis\u00a0al\u00a0cabo\u00a0de\u00a02\u00a0a\u00f1os\u00a0es\u00a0tan\u00a0s\u00f3lo\u00a0un\u00a025%\u00a0de\u00a0la\u00a0inicial\u00a0(probablemente \u00a0por\u00a0aumento\u00a0de\u00a0la\u00a0absorci\u00f3n \u00a0intestinal \u00a0a\u00a0lo\u00a0\nlargo\u00a0del\u00a0tiempo).\u00a0\nTacrolimus: \u00a0se\u00a0ha\u00a0descrito\u00a0una\u00a0interacci\u00f3n \u00a0muy\u00a0importante \u00a0con\u00a0LPV/r\u00a0(pueden\u00a0ser\u00a0necesarios \u00a0menos\u00a0de\u00a01mg\u00a0de\u00a0tacrolimus \u00a0a\u00a0la\u00a0\nsemana\u00a0y\u00a0puede\u00a0ser\u00a0necesario \u00a0esperar\u00a0de\u00a03\u00a0a\u00a05\u00a0semanas\u00a0(seg\u00fan\u00a0funci\u00f3n\u00a0hep\u00e1tica) \u00a0antes\u00a0de\u00a0administrar \u00a0otra\u00a0dosis\u00a0de\u00a0tacrolimus \u00a0al\u00a0\niniciar\u00a0LPV/r.\u00a0Tambi\u00e9n\u00a0se\u00a0ha\u00a0descrito\u00a0interacci\u00f3n \u00a0con\u00a0otros\u00a0IP\u00a0(p.\u00a0ej\u00a0.\u00a0mayor\u00a0con\u00a0NFV\u00a0que\u00a0con\u00a0IDV,\u00a0requiri\u00e9ndose \u00a0en\u00a0un\u00a0estudio\u00a0unos\u00a0\n0,6\u00a0mg\u00a0diarios\u00a0de\u00a0tacrolimus \u00a0con\u00a0estos\u00a0IP.\u00a0Tras\u00a0el\u00a0cambio\u00a0de\u00a0NFV\u00a0por\u00a0FPV\u00a0no\u00a0potenciado \u00a0pueden\u00a0requerirse \u00a0aumentos \u00a0de\u00a0dosis\u00a0(se\u00a0han\u00a0\ndescrito\u00a0reducciones \u00a0del\u00a050%\u00a0de\u00a0sus\u00a0Cp)\nInterfer\u00f3n/ \u00a0\nRibavirina \u00a0Ribavirina: \u00a0no\u00a0existe\u00a0evidencia \u00a0de\u00a0interacci\u00f3n \u00a0con\u00a0los\u00a0IP.\u00a0Interfer\u00f3n: \u00a0su\u00a0v\u00eda\u00a0de\u00a0eliminaci\u00f3n \u00a0no\u00a0est\u00e1\u00a0claramente \u00a0establecida \u00a0as\u00ed\u00a0como\u00a0\ntampoco\u00a0su\u00a0posible\u00a0efecto\u00a0inhibidor\u00a0sobre\u00a0el\u00a0citocromo \u00a0P\u2010450\u00a0(ha\u00a0mostrado \u00a0p.\u00a0ej.\u00a0\u2191Cp\u00a0de\u00a0teofilina\u00a0y\u00a0barbituratos). \u00a0No\u00a0hay\u00a0datos\u00a0con\u00a0\nrespecto\u00a0a\u00a0posibles\u00a0interacciones \u00a0con\u00a0los\u00a0IP\u00a0\nMetadona(MT) \u00a0 in\u00a0vitro\u00a0\u219130%\u00a0AUC\u00a0MT.\u00a0\nProbablemente \u00a0\u00a0NRAD\u00a0in\u00a0vitro\u00a0x2\u00a0AUC\u00a0MT\u00a0\nin\u00a0vivo\u00a0\u219336%\u00a0AUC\u00a0MT.\u00a0\n\u2191dosis\u00a0MT.\u00a0NRAD\u00a0 \u219340\u201050%\u00a0Cp\u00a0MT\u00a0en\u00a0\nalgunos\u00a0pacientes. \u00a0\nSolo\u00a0requiere\u00a0peque\u00f1os \u00a0\n\u2191dosis.\u00a0Algunos\u00a0pacientes \u00a0\npueden\u00a0requerir\u00a0\naumento\u00a0de\u00a0dosis\u00a0de\u00a0MT.\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 7 \u00a0\n\u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0\u00a0\nIndinavir\u00a0\u00a0\nRitonavir \u00a0\u00a0\nSaquinavir \u00a0\u00a0\nNelfinavir \u00a0\u00a0\nFosamprenavir \u00a0\n\u00a0\nOtros\u00a0f\u00e1rmacos \u00a0\u00a0\nFluticasona \u00a0inh.:\u00a0en\u00a0un\u00a0\nestudio\u00a0caso\u2010control,\u00a0\nuna\u00a0elevada\u00a0proporci\u00f3n \u00a0\nde\u00a0los\u00a0pacientes \u00a0\nexpuestos \u00a0a\u00a0\nRTV+fluticasona \u00a0(7/8;\u00a0\n88%)\u00a0presentaron \u00a0\nsupresi\u00f3n \u00a0adrenal,\u00a0que\u00a0\nfue\u00a0sintom\u00e1tica \u00a0en\u00a0un\u00a0\n57%\u00a0de\u00a0los\u00a0casos.\u00a0\nAlg\u00fan\u00a0caso\u00a0descrito\u00a0de\u00a0\nreducci\u00f3n \u00a0de\u00a0eficacia\u00a0de\u00a0\nL\u2010tiroxina.\u00a0\nIDV\u00a0\u00a0puede\u00a0aumentar \u00a04.4\u00a0\nveces\u00a0AUC\u00a0sildenafilo \u00a0\n(max\u00a025\u00a0mg\u00a0en\u00a0un\u00a0\nperiodo\u00a0de\u00a048h).\u00a0Esta\u00a0\ninteracci\u00f3n \u00a0tambi\u00e9n\u00a0se\u00a0\nproduce\u00a0con\u00a0vardenafilo \u00a0\n(m\u00e1x\u00a02,5\u00a0mg\u00a0c/72h\u00a0si\u00a0\nasociado\u00a0a\u00a0RTV)\u00a0y\u00a0con\u00a0\ntadalafilo \u00a0(iniciar\u00a0con\u00a05\u00a0\nmg\u00a0y\u00a0no\u00a0exceder\u00a010\u00a0mg\u00a0\nc/72h).\u00a0\nCon\u00a0omeprazol \u00a0espaciar\u00a0\n1h\u00a0(ausencia \u00a0de\u00a0\ninteracci\u00f3n \u00a0con\u00a0IDV/r)\u00a0\nPuede\u00a0\u2191\u00a0Cp\u00a0de\u00a0los\u00a0\nf\u00e1rmacos \u00a0que\u00a0se\u00a0\nmetabolizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\u00a0\nCYP3A43.\u00a0Bupropi\u00f3n :\u00a0RTV\u00a0puede\u00a0\n\u2193Cp\u00a0bupropion. \u00a0\nFluticasona \u00a0inh.:\u00a0en\u00a0un\u00a0\nestudio\u00a0caso\u2010control,\u00a0\nuna\u00a0elevada\u00a0proporci\u00f3n \u00a0\nde\u00a0los\u00a0pacientes \u00a0\nexpuestos \u00a0a\u00a0\nRTV+fluticasona \u00a0(7/8;\u00a0\n88%)\u00a0presentaron \u00a0\nsupresi\u00f3n \u00a0adrenal,\u00a0que\u00a0\nfue\u00a0sintom\u00e1tica \u00a0en\u00a0un\u00a0\n57%\u00a0de\u00a0los\u00a0casos.\u00a0\nFluoxetina :\u00a0se\u00a0han\u00a0\ndescrito\u00a03\u00a0casos\u00a0de\u00a0\ns\u00edndrome \u00a0\nserotonin\u00e9rgico. \u00a0\nAlg\u00fan\u00a0caso\u00a0descrito\u00a0de\u00a0\nreducci\u00f3n \u00a0de\u00a0eficacia\u00a0de\u00a0\nL\u2010tiroxina.\u00a0\nQuinina:\u00a0\u2191\u00a0x4\u00a0AUC\u00a0\nquinina.\u00a0Reducir\u00a0dosis\u00a0\nRTV\u00a0puede\u00a0aumentar \u00a011\u00a0\nveces\u00a0AUC\u00a0sildenafilo \u00a0\n(max\u00a025\u00a0mg\u00a0en\u00a0un\u00a0\nperiodo\u00a0de\u00a048h).\u00a0Esta\u00a0\ninteracci\u00f3n \u00a0tambi\u00e9n\u00a0se\u00a0\nproduce\u00a0con\u00a0vardenafilo \u00a0\n(m\u00e1x\u00a02,5\u00a0mg\u00a0c/72h)\u00a0y\u00a0\ncon\u00a0tadalafilo \u00a0(iniciar\u00a0con\u00a0\n5\u00a0mg\u00a0y\u00a0no\u00a0exceder\u00a010\u00a0mg\u00a0\nc/72h).\u00a0\n\u00a0\nPuede\u00a0\u2191\u00a0Cp\u00a0de\u00a0los\u00a0\nf\u00e1rmacos \u00a0que\u00a0se\u00a0\nmetabolizan \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0\nlos\u00a0\u00a0CYP3A44>2D65,\u00a0\u2191\u00f3\u2193\u00a0\nCp\u00a0si\u00a02C96\u00a0y\u00a0\u2193\u00a0Cp\u00a0si\u00a0\nCYP1A27\u00a0y\u00a0\nglucuronidaci\u00f3n8.\u00a0\u00a0\nFluticasona \u00a0inh.:\u00a0en\u00a0un\u00a0\nestudio\u00a0caso\u2010control,\u00a0\nuna\u00a0elevada\u00a0proporci\u00f3n \u00a0\nde\u00a0los\u00a0pacientes \u00a0\nexpuestos \u00a0a\u00a0\nRTV+fluticasona \u00a0(7/8;\u00a0\n88%)\u00a0presentaron \u00a0\nsupresi\u00f3n \u00a0adrenal,\u00a0que\u00a0\nfue\u00a0sintom\u00e1tica \u00a0en\u00a0un\u00a0\n57%\u00a0de\u00a0los\u00a0casos.\u00a0\nDigoxina :\u00a0\u219149%AUC\u00a0de\u00a0\ndigoxina:\u00a0Monitorizar \u00a0\ndigoxinemia. \u00a0\u00a0\nSQV\u00a0\u00a0puede\u00a0aumentar \u00a0\n3.1\u00a0veces\u00a0AUC\u00a0sildenafilo \u00a0\n(max\u00a025\u00a0mg\u00a0en\u00a0un\u00a0\nperiodo\u00a0de\u00a048h).\u00a0Esta\u00a0\ninteracci\u00f3n \u00a0tambi\u00e9n\u00a0se\u00a0\nproduce\u00a0con\u00a0vardenafilo \u00a0\n(m\u00e1x\u00a02,5\u00a0mg\u00a0c/24h\u00a0y\u00a02,5\u00a0\nmg\u00a0c/72h\u00a0si\u00a0asociado\u00a0a\u00a0\nRTV)\u00a0y\u00a0con\u00a0tadalafilo \u00a0\n(iniciar\u00a0con\u00a05\u00a0mg\u00a0y\u00a0no\u00a0\nexceder\u00a010\u00a0mg\u00a0c/72h).\u00a0\u00a0\n\u00a0\nEl\u00a0zumo\u00a0de\u00a0pomelo\u00a0\naumenta\u00a0los\u00a0niveles\u00a0de\u00a0\nsaquinavir. \u00a0\n\u00a0\nPuede\u00a0\u2191\u00a0Cp\u00a0de\u00a0los\u00a0\nf\u00e1rmacos \u00a0que\u00a0se\u00a0\nmetabolizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\u00a0\nCYP3A43\u00a0\u00a0\nFelodipino :\u00a0un\u00a0caso\u00a0\ndescrito\u00a0de\u00a0interacci\u00f3n \u00a0\n(edema,\u00a0mareo,\u00a0\nhipotensi\u00f3n) \u00a0en\u00a0una\u00a0\nmujer\u00a0que\u00a0recib\u00eda\u00a050\u00a0\nmg/d\u00eda\u00a0de\u00a0metoprolol \u00a0y\u00a0\n5\u00a0mg/d\u00eda\u00a0de\u00a0felodipino. \u00a0\nPosible\u00a0aumento\u00a0Cp\u00a0\nsildenafilo \u00a0(max\u00a025\u00a0mg\u00a0\nen\u00a0un\u00a0periodo\u00a0de\u00a048h).\u00a0\nEsta\u00a0interacci\u00f3n \u00a0tambi\u00e9n\u00a0\nse\u00a0produce\u00a0con\u00a0\nvardenafilo \u00a0(m\u00e1x\u00a02,5\u00a0mg\u00a0\nc/24h)\u00a0y\u00a0con\u00a0tadalafilo \u00a0\n(iniciar\u00a0con\u00a05\u00a0mg\u00a0y\u00a0no\u00a0\nexceder\u00a010\u00a0mg\u00a0c/72h).\u00a0\n\u00a0\nPuede\u00a0\u2191\u00a0Cp\u00a0de\u00a0los\u00a0\nf\u00e1rmacos \u00a0que\u00a0se\u00a0\nmetabolizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\u00a0\nCYP3A43\u00a0\u00a0\u2193\u00a0Cp\u00a0de\u00a0los\u00a0que\u00a0\nsufren\u00a0glucuronidaci\u00f3n8\u00a0\n\u00a0\u00a0\nFluticasona \u00a0inh.:\u00a0en\u00a0un\u00a0\nestudio\u00a0caso\u2010control,\u00a0una\u00a0\nelevada\u00a0proporci\u00f3n \u00a0de\u00a0\nlos\u00a0pacientes \u00a0expuestos \u00a0a\u00a0\nRTV+fluticasona \u00a0(7/8;\u00a0\n88%)\u00a0presentaron \u00a0\nsupresi\u00f3n \u00a0adrenal,\u00a0que\u00a0\nfue\u00a0sintom\u00e1tica \u00a0en\u00a0un\u00a0\n57%\u00a0de\u00a0los\u00a0casos.\u00a0\n\u00a0Posible\u00a0aumento\u00a0Cp\u00a0\nsildenafilo\n\u00a0(max\u00a025\u00a0mg\u00a0\nen\u00a0un\u00a0periodo\u00a0de\u00a048h).\u00a0\nEsta\u00a0interacci\u00f3n \u00a0tambi\u00e9n\u00a0\nse\u00a0produce\u00a0con\u00a0\nvardenafilo \u00a0(m\u00e1x\u00a02,5\u00a0mg\u00a0\nc/24h\u00a0y\u00a02,5\u00a0mg\u00a0c/72h\u00a0si\u00a0\nasociado\u00a0a\u00a0RTV)\u00a0y\u00a0con\u00a0\ntadalafilo \u00a0(iniciar\u00a0con\u00a05\u00a0\nmg\u00a0y\u00a0no\u00a0exceder\u00a010\u00a0mg\u00a0\nc/72h).\u00a0\n\u00a0\nCon\u00a0FPV/r\u00a0700/100\u00a0mg\u00a0\nc/12h\u00a0se\u00a0redujo\u00a0aprox\u00a0un\u00a0\n50%\u00a0el\u00a0AUC\u00a0de\u00a0\nparoxetina \u00a0(20\u00a0mg/d\u00eda).\u00a0\u00a0\n\u00a0\nPuede\u00a0\u2191\u00a0\u00f3\u00a0\u2193\u00a0Cp\u00a0de\u00a0los\u00a0\nf\u00e1rmacos \u00a0que\u00a0se\u00a0\nmetabolizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\u00a0\nCYP3A43,\u00a0ya\u00a0que\u00a0es\u00a0un\u00a0\ninhibidor\u00a0de\u00a0este\u00a0\nisoenzima \u00a0pero\u00a0los\u00a0datos\u00a0\ntambi\u00e9n\u00a0sugieren\u00a0que\u00a0\npuede\u00a0inducirlo. \u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 8 \u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Indinavir\u00a0 Ritonavir \u00a0 Saquinavir \u00a0 Nelfinavir \u00a0 Fosamprenavir \u00a0\n\u00a0NN\u00a0 (ver\u00a0la\u00a0tabla\u00a0\nNN)\u00a0\u00a0\u00a0 \u00a0 \u00a0\n\u00a0IP\u00a0 \u00a0\u00a0 \u00a0 \u00a0 \u00a0\n\u00a0\n\u2010\u00a0IDV\u00a0\u00a0 IDV/r:\u00a0800/100\u2010200\u00a0mg\u00a0\nc/12h.\u00a0\nEn\u00a0investigaci\u00f3n \u00a0pauta\u00a0\nIDV/r:\u00a01200/200 \u00a0mg\u00a0c/24\u00a0h.\u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0\ny\u00a0seguridad \u00a0a\u00a0largo\u00a0plazo\u00a0\u2191x4\u20108\u00a0AUC\u00a0SQV.\u00a0Sin\u00a0cambios\u00a0\nAUC\u00a0IDV.\u00a0No\u00a0hay\u00a0datos\u00a0sobre\u00a0\najuste\u00a0de\u00a0dosis\u00a0(antagonismo \u00a0\nin\u00a0vitro\u00a0y\u00a0complicado \u00a0de\u00a0\ndosificar). \u00a0NFV/IDV: \u00a01250/\u00a01200\u00a0mg\u00a0\nc/12h.\u00a0\n(datos\u00a0limitados) \u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0\neficacia\u00a0y\u00a0seguridad \u00a0a\u00a0largo\u00a0\nplazo\u00a0No\u00a0hay\u00a0datos\u00a0suficientes \u00a0\nsobre\u00a0ajuste\u00a0de\u00a0dosis.\u00a0\n\u00a0\n\u2010\u00a0RTV\u00a0\u00a0\n\u00a0\u00a0 SQV/r:\u00a0400mg/400 \u00a0mg\u00a0BID\u00a0\nSQV/r:\u00a01000/100 \u00a0mg/12\u00a0h.\u00a0\u00a0\nEn\u00a0investigaci\u00f3n \u00a0en\u00a0pacientes \u00a0\nnaive\u00a0SQV/r\u00a01500/100 \u2010200\u00a0\nmg/24\u00a0h\u00a0(preferiblemente \u00a0en\u00a0\nel\u00a0desayuno). \u00a0RTV\u00a0100\u00a0\u00f3\u00a0200\u00a0mg\u00a0c/12h:\u00a0\n\u219130%\u00a0AUC\u00a0NFV.\u00a0\nSe\u00a0desaconseja \u00a0esta\u00a0\nasociaci\u00f3n. \u00a0FPV/r\u00a0700/100\u00a0mg\u00a0c/12h\u00a0\u00a0\u00a0\n(En\u00a0pacientes \u00a0naive\u00a0puede\u00a0\nadministrarse \u00a0una\u00a0vez\u00a0al\u00a0\nd\u00eda:\u00a0FPV/r\u00a01400/100 \u2010200\u00a0\nmg\u00a0c/24h.\u00a0No\u00a0se\u00a0\nrecomienda \u00a0en\u00a0pacientes \u00a0\npretratados). \u00a0\n\u00a0\n\u2010\u00a0SQV\u00a0\u00a0 \u00a0 \u00a0 Se\u00a0desaconseja \u00a0esta\u00a0\nasociaci\u00f3n \u00a0Datos\u00a0iniciales\u00a0sobre\u00a0\najuste\u00a0de\u00a0dosis:\u00a0SQV\u2010\nCGD/FPV/RTV \u00a0\n1000/700/200 \u00a0mg\u00a0c/12h\u00a0\n(Se\u00a0recomienda \u00a0\nmonitorizar \u00a0niveles\u00a0\nplasm\u00e1ticos). \u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0\neficacia\u00a0y\u00a0seguridad \u00a0a\u00a0\nlargo\u00a0plazo\u00a0\n\u2010\u00a0NFV\u00a0\u00a0 \u00a0 \u00a0 \u00a0 No\u00a0hay\u00a0datos\u00a0\n\u00a0\nAUC:\u00a0\u00e1rea\u00a0bajo\u00a0la\u00a0curva;\u00a0BID:\u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda;\u00a0Cp:\u00a0concentraciones \u00a0plasm\u00e1ticas; \u00a0\u00a0IT:\u00a0interacci\u00f3n; \u00a0NRAD :\u00a0no\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis;\u00a0NS:\u00a0no\u00a0significativa; \u00a0QD:una\u00a0vez\u00a0al\u00a0d\u00eda.\u00a0\n\u00a0\n0\u00a0En\u00a0pacientes \u00a0coinfectados \u00a0con\u00a0VIH\u00a0y\u00a0tuberculosis \u00a0con\u00a0inmunosupresi\u00f3n \u00a0avanzada \u00a0(CD4\u00a0<100\u00a0c\u00e9l/mm3) \u00a0en\u00a0tratamiento \u00a0con\u00a0rifampicina \u00a0\u00f3\u00a0rifabutina \u00a02\u00a0veces\u00a0por\u00a0semana\u00a0se\u00a0ha\u00a0descrito\u00a0la\u00a0\naparici\u00f3n \u00a0de\u00a0\u00a0resistencia \u00a0a\u00a0rifamicinas. \u00a0Tambi\u00e9n\u00a0se\u00a0han\u00a0descrito\u00a0fracasos\u00a0de\u00a0tratamiento \u00a0antituberculosos \u00a0con\u00a0aparici\u00f3n \u00a0de\u00a0resistencias \u00a0en\u00a0pacientes \u00a0con\u00a0imnonosupresi\u00f3n \u00a0avanzada \u00a0tratados\u00a0\ncon\u00a0IP/r\u00a0y\u00a0rifabutina \u00a0150\u00a0mg\u00a0c/48\u00a0horas\u00a0o\u00a0tres\u00a0veces\u00a0por\u00a0semana.\u00a0En\u00a0estos\u00a0casos\u00a0valorar\u00a0dosis\u00a0mayores: \u00a0rifabutina \u00a0300\u00a0mg\u00a0tres\u00a0veces\u00a0semana.\u00a0\n1\u00a0ClCr\u00a030\u201060\u00a0ml/min:\u00a0reducir\u00a0un\u00a050%,\u00a0ClCr\u00a0<30\u00a0ml/min:\u00a0reducir\u00a0un\u00a075%\u00a0(m\u00e1x.\u00a01g/d\u00eda).\u00a0\u00a0\n2\u00a0\u00a0SQV\u00a0junto\u00a0con\u00a0RTV\u00a0(400/400\u00a0mg\u00a0c/12h\u00a0\u00f3\u00a01000/100 \u00a0mg\u00a0c/12h)\u00a0pueden\u00a0administrarse \u00a0con\u00a0dosis\u00a0reducidas \u00a0de\u00a0rifabutina \u00a0(150\u00a0mg\u00a0\u00a03veces\u00a0/semana)(experiencia \u00a0limitada). \u00a0\u00a0\n3\u00a0Principales \u00a0f\u00e1rmacos\u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP3A4:\u00a0alprazolam, \u00a0amiodarona, \u00a0amlodipino, \u00a0ciclofosfamida, \u00a0ciclosporina, \u00a0clonacepam, \u00a0cloracepato, \u00a0dextropropoxifeno, \u00a0diazepam, \u00a0\ndiltiazem, \u00a0disopiramida, \u00a0estazolam, \u00a0etionamida, \u00a0etosuximida, \u00a0felodipino, \u00a0fentanilo, \u00a0finasterida, \u00a0flunaricina, \u00a0fluracepam, \u00a0lacidipino, \u00a0lidoca\u00edna, \u00a0loratadina, \u00a0meperidina, \u00a0nicardipino, \u00a0nifedipino, \u00a0\nnimodipino, \u00a0nitrendipino, \u00a0prednisona, \u00a0quinidina, \u00a0quinina,\u00a0sertralina, \u00a0sildenafilo \u00a0(Viagra\u00ae),\u00a0vardenafilo, \u00a0tadalafilo, \u00a0tacrolimus, \u00a0verapamilo, \u00a0vincristina \u00a0y\u00a0zolpidem. \u00a0\n4\u00a0RTV\u00a0pueder\u00a0aumentar \u00a0hasta\u00a03\u00a0veces\u00a0el\u00a0AUC\u00a0de\u00a0los\u00a0siguiente\u00a0f\u00e1rmacos \u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP3A:\u00a0alfentanilo, \u00a0antagonistas \u00a0del\u00a0calcio\u00a0(amlodipino, \u00a0diltiazem, \u00a0felodipino, \u00a0nicardipino, \u00a0\nnifedipino, \u00a0nisoldipino, \u00a0verapamilo), \u00a0carbamacepina, \u00a0ciclosporina, \u00a0citost\u00e1ticos \u00a0(etop\u00f3sido, \u00a0docetaxel, \u00a0paclitaxel, \u00a0tamoxifeno, \u00a0vinblastina \u00a0y\u00a0vincristina), \u00a0clonacepam, \u00a0dexametasona, \u00a0\ndisopiramida, \u00a0eritromicina, \u00a0etosuximida, \u00a0fentanilo, \u00a0lidoca\u00edna, \u00a0loratadina, \u00a0nefazodona, \u00a0ondansetron, \u00a0prednisona, \u00a0quinina,\u00a0rifampicina, \u00a0sertralina, \u00a0tacrolimus, \u00a0taxol\u00a0\u00a0y\u00a0trazodona, \u00a0entre\u00a0otros.\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 9 5\u00a0Aumento \u00a0de\u00a01.5\u00a0a\u00a03\u00a0veces\u00a0en\u00a0el\u00a0AUC\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP2D6:\u00a0amitriptilina, \u00a0clomipramina, \u00a0clorpromacina, \u00a0desipramina, \u00a0fluoxetina, \u00a0haloperidol, \u00a0imipramina, \u00a0\nmaprotilina, \u00a0metoprolol, \u00a0mexiletina, \u00a0nortriptilina, \u00a0paroxetina, \u00a0perfenazina, \u00a0pindolol,\u00a0propranolol, \u00a0risperidona, \u00a0timolol,\u00a0tioridacina, \u00a0tramadol\u00a0y\u00a0venlafaxina. \u00a0\n6\u00a0F\u00e1rmacos \u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP2C9/19: \u00a0diclofenac, \u00a0ibuprofeno, \u00a0indometacina, \u00a0fenito\u00edna, \u00a0gliburida, \u00a0glipizida,\u00a0\u00a0lansoprazol, \u00a0losartan,\u00a0omeprazol, \u00a0proguanilo \u00a0y\u00a0tolbutamida. \u00a0\n7teofilina,\u00a0tacrina,\u00a0clozapina, \u00a0tacrina.\u00a0\n8\u00a0atovaquona, \u00a0clofibrato, \u00a0code\u00edna,\u00a0difenoxilato, \u00a0ketoprofeno, \u00a0ketorolaco, \u00a0lamotrigina, \u00a0loracepam, \u00a0metoclopramida, \u00a0morfina,\u00a0naproxeno, \u00a0oxacepam, \u00a0propofol, \u00a0temacepam \u00a0y\u00a0valproico. \u00a0\u00a0\n9\u00a0En\u00a0un\u00a0estudio\u00a0en\u00a0voluntarios \u00a0sanos\u00a0se\u00a0observ\u00f3\u00a0una\u00a0elevada\u00a0incidencia \u00a0de\u00a0hepatotoxicidad \u00a0con\u00a0esta\u00a0combinaci\u00f3n \u00a0(rifampicina \u00a0600\u00a0mg\u00a0c/24h\u00a0+\u00a0SQV/r\u00a01000/100 \u00a0mg\u00a0c/12h).\u00a0\u00a0\n10\u00a0Seg\u00fan\u00a0datos\u00a0iniciales\u00a0el\u00a0midazolam \u00a0intravenoso \u00a0podr\u00eda\u00a0administrarse \u00a0junto\u00a0con\u00a0los\u00a0inhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0reduciendo \u00a0la\u00a0dosis\u00a0y\u00a0bajo\u00a0estrecha\u00a0monitorizaci\u00f3n \u00a0cl\u00ednica\u00a0(UCI\u00a0o\u00a0similar).\u00a0\u00a0Sin\u00a0\nembargo, \u00a0el\u00a0midazolam \u00a0oral\u00a0est\u00e1\u00a0contraindicado. \u00a0\n\u00a0\u00a0NOTA:\u00a0debido\u00a0a\u00a0\u00a0que\u00a0la\u00a0informaci\u00f3n \u00a0cient\u00edfica\u00a0relacionada \u00a0con\u00a0los\u00a0f\u00e1rmacos\u00a0antirretrovirales \u00a0se\u00a0renueva\u00a0constantemente, \u00a0se\u00a0recomienda \u00a0\nconsultar \u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0y\u00a0la\u00a0\ninformaci\u00f3n \u00a0actualizada \u00a0ofrecida\u00a0por\u00a0las\u00a0distintas\u00a0compa\u00f1\u00edas \u00a0farmac\u00e9uticas \u00a0y\u00a0las\u00a0autoridades \u00a0sanitarias. \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 10Tabla\u00a07.\u00a0Inhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0(2\u00aa\u00a0parte):\u00a0lopinavir/ritonavir, \u00a0atazanavir, \u00a0tipranavir \u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0 Lopinavir/r \u00a0 Atazanavir \u00a0\u00a0\nDarunavir/r \u00a0 Tipranavir/r \u00a0\n\u00a0\nNombre\u00a0comercial \u00a0\n\u00a0\u00a0\nKaletra\u00ae\u00a0\u00a0\nReyataz\u00ae\u00a0\u00a0\nPrezista\u00ae\u00a0\u00a0\nAptivus\u00ae\u00a0\n\u00a0\nDosis\u00a0\u00a0\n\u00a0Recomendaci\u00f3n \u00a0\n\u00a0\u00a0\n400/100\u00a0mg\u00a0c/12h\u00a0\n800/200\u00a0mg\u00a0/24\u00a0h\u00a0\n\u00a0Tomar\u00a0con\u00a0o\u00a0sin\u00a0comida\u00a0\u00a0\n300/100\u00a0mg\u00a0r/24\u00a0h\u00a0\u00f3\u00a0400\u00a0mg\u00a0c/24h\u00a0\nNota:\u00a0En\u00a0un\u00a0estudio\u00a0se\u00a0observ\u00f3\u00a0que\u00a0tan\u00a0\ns\u00f3lo\u00a0un\u00a038%\u00a0de\u00a0los\u00a0pacientes \u00a0tratados\u00a0\ncon\u00a0ATV\u00a0no\u00a0potenciado \u00a0alcanzaron \u00a0una\u00a0\nCmin>150 \u00a0ng/mL.\u00a0\u00a0\u00a0\n\u00a0\nTomar\u00a0con\u00a0comida\u00a0\u00a0\n600/100\u00a0mg\u00a0c/12h\u00a0(en\u00a0pacientes \u00a0\npretratados). \u00a0\u00a0\n800/100\u00a0QD\u00a0(en\u00a0pacientes \u00a0sin\u00a0\ntratamiento \u00a0previo\u00a0\n\u00a0\nTomar\u00a0con\u00a0comida\u00a0\n\u00a0\u00a0\nTPV/r\u00a0500/200\u00a0mg\u00a0c/12h\u00a0\n\u00a0Tomar\u00a0con\u00a0comida\u00a0\n\u00a0\nPresentaci\u00f3n \u00a0\ncomercial \u00a0\u00a0\ncomp\u00a0200/100\u00a0mg\u00a0\ncomp\u00a0100/25\u00a0mg\u00a0\nsol.\u00a0oral\u00a080/20\u00a0mg/ml\u00a0\u00a0\u00a0\nc\u00e1ps\u00a0100,\u00a0150,\u00a0200\u00a0y\u00a0300\u00a0mg\u00a0\u00a0\u00a0\nComp\u00a0300,\u00a0400\u00a0y\u00a0600\u00a0\u00a0mg\u00a0\u00a0\nc\u00e1ps\u00a0250\u00a0mg\u00a0\n\u00a0\nBiodisponibilidad \u00a0\nOral\u00a0\n\u00a0\u00a0\n70%\u00a0\u00a0\nLos\u00a0alimentos \u00a0aumentan \u00a0entre\u00a0un\u00a035\u00a0y\u00a0\nun\u00a070%\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos. \u00a0\u00a0\n82%\u00a0en\u00a0presencia \u00a0de\u00a0100\u00a0mg\u00a0de\u00a0ritonavir\nadministrados \u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda.\u00a0\u00a0\nLos\u00a0alimentos \u00a0aumentan \u00a0dos\u00a0veces\u00a0el\u00a0AUC\u00a0\nde\u00a0TPV.\u00a0\nSemivida \u00a0de\u00a0\neliminaci\u00f3n \u00a0\nplasm\u00e1tica \u00a0\u00a0\n5\u20106\u00a0horas\u00a0\u00a0\n5\u20108\u00a0horas\u00a0\u00a0\n15\u00a0\u00a0horas\u00a0\u00a0\n6\u00a0horas\u00a0\n\u00a0\nCmax\u00a0\n\u00a0\u00a0\u00a0\n10\u00a0\u03bcg/ml\u00a0ABT\u2010378\u00a0\n(15.9\u00a0\u03bcM)\u00a0\u00a0\n\u00a0\u00a0\u2010\u2010\u2010\u00a0\u00a0\n6890\u00a0ng/mL\u00a0\u00a0\n\u2010\u2010\u2010\u00a0\n\u00a0C\nmin\u00a0\n\u00a0\u00a0\u00a0\n5,16\u00a0\u03bcg/ml\u00a0ABT\u2010378\u00a0(8.2\u00a0\u03bcM)\u00a0\u00a0\u00a0\n\u00a0\u00a0\u2010\u2010\u2010\u00a0\u00a0\n3578\u00a0ng/mL\u00a0\u00a0\n32\u00a0\u03bcM\u00a0(TPV/r\u00a0500/200\u00a0mg\u00a0c/12h).\u00a0\n67\u00a0\u03bcM\u00a0(TPV/r\u00a01200/200 \u00a0mg\u00a0c/12h).\u00a0\n\u00a0\nConcentraci\u00f3n \u00a0\ninhibitoria \u00a0\n\u00a0\u00a0\n50:0.062\u00a0\u03bcg/ml\u00a0\n(0.1\u03bcM)\u00a0\u00a0\n50:0.002\u20100.004\u03bcg/ml\u00a0\n(2.6\u00a0\u2010\u00a05.3\u00a0nM)\u00a0\n90:\u00a00.007\u20100.012\u03bcg/ml\u00a0\n\u00a0(9\u201015\u00a0nM)\u00a0\u00a0\nEC50\u00a0=\u00a00.7\u00a0a\u00a05.0\u00a0ng/mL\u00a0\u00a0\n0,16\u20100,2\u00a0\u03bcM\u00a0(aunque,\u00a0debido\u00a0a\u00a0su\u00a0elevada\u00a0\nuni\u00f3n\u00a0a\u00a0prot\u00a0plasm\u00e1ticas, \u00a0deber\u00eda\u00a0alcanzar\u00a0\nentre\u00a00,5\u00a0y\u00a01\u00a0\u03bcM\u00a0para\u00a0mostrar\u00a0actividad\u00a0\nantiviral). \u00a0\n\u00a0\nActividad \u00a0\n\u00a0\u00a0\nVIH\u20101,2\u00a0\u00a0\nVIH\u20101\u00a0\u00a0\nVIH\u20101,2\u00a0\u00a0\nVIH\u20101,2\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 11\u00a0\nNombre\u00a0gen\u00e9rico\u00a0 Lopinavir/r \u00a0 Atazanavir \u00a0 Darunavir/r \u00a0 Tipranavir/r \u00a0\n\u00a0\nMetabolizaci\u00f3n \u00a0\n\u00a0\u00a0\nCYP3A4\u00a0\u00a0\nCYP3A4\u00a0\u00a0\nCYP3A4\u00a0\u00a0\nCYP3A4\u00a0\n\u00a0\nEfectos\u00a0\nAdversos \u00a0\u00a0\nIntolerancia \u00a0G\u2010I\u00a0\n(v\u00f3mitos, \u00a0diarrea)\u00a0\nCefalea\u00a0\nAstenia\u00a0\nHiperglicemia \u00a0\nDislipemia \u00a0\nLipodistrofia \u00a0\nPosible\u00a0aumento\u00a0del\u00a0sangrado\u00a0\nen\u00a0hemof\u00edlicos \u00a0\u00a0\nHiperbilirrubinemia \u00a0\nIntolerancia \u00a0GI\u00a0(diarrea)\u00a0\nCefalea\u00a0\nLos\u00a0estudios\u00a0disponibles \u00a0a\u00a0las\u00a048\u00a0\nsemanas\u00a0no\u00a0muestran \u00a0alteraciones \u00a0\nlip\u00eddicas\u00a0relevantes \u00a0\nATV/r:\u00a0Dislipemia \u00a0leve\u00a0\nPosible\u00a0aumento\u00a0del\u00a0sangrado \u00a0en\u00a0\nhemof\u00edlicos \u00a0\u00a0\nIntolerancia \u00a0G\u2010I\u00a0(v\u00f3mitos, \u00a0diarrea)\u00a0\nCefalea\u00a0\nAstenia\u00a0\nDislipemia \u00a0leve\u00a0\nErupci\u00f3n\u00a0cut\u00e1nea,\u00a0que\u00a0suele\u00a0ser\u00a0\nmoderada \u00a0y\u00a0autolimitada. \u00a0\u00a0\nPosible\u00a0aumento\u00a0del\u00a0sangrado\u00a0en\u00a0\nhemof\u00edlicos \u00a0\u00a0\u00a0\nIntolerancia \u00a0GI\u00a0(diarrea)\u00a0\nAlteraciones \u00a0SNC\u00a0(v\u00e9rtigo,\u00a0dificultad \u00a0de\u00a0\nconcentraci\u00f3n, \u00a0enlentecimiento, \u00a0cambios\u00a0de\u00a0\nhumor).\u00a0\nEn\u00a0combinaci\u00f3n \u00a0con\u00a0RTV,\u00a0aumento\u00a0de\u00a0\ntriglic\u00e9ridos \u00a0y\u00a0transaminasas. \u00a0\nSe\u00a0han\u00a0descrito\u00a014\u00a0casos\u00a0de\u00a0hemorragia \u00a0\nintracraneal, \u00a08\u00a0de\u00a0los\u00a0cuales\u00a0fueron\u00a0mortales, \u00a0\nentre\u00a06840\u00a0pacientes \u00a0incluidos\u00a0en\u00a0ensayos\u00a0\ncl\u00ednicos.\u00a0La\u00a0mayor\u00eda\u00a0ten\u00edan\u00a0factores\u00a0de\u00a0riesgo.\u00a0\n\u00a0\nAsociaciones \u00a0\ncontraindicadas \u00a0Anticonceptivos \u00a0orales\u00a0\nAstemizol \u00a0\nCisaprida\u00a0\nDeriv.\u00a0ergotamina \u00a0\nEncainida \u00a0\nEstatinas\u00a0(excepto\u00a0atorvastatina, \u00a0\nfluvastatina \u00a0y\u00a0pravastatina) \u00a0\n\u00c9xtasis\u00a0\u00a0\nFluticasona \u00a0inh.\u00a0\nFosamprenavir \u00a0\nFlecainida \u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0Juan)\u00a0\nLumefantrina \u00a0\nMetanfetamina \u00a0\nMidazolam \u00a0oral\u00a010\u00a0\nPimozida\u00a0\nPropafenona \u00a0\nQuinidina \u00a0\u00a0\nRifampicina \u00a0\nTerfenadina \u00a0\nTriazolam \u00a0\u00a0\u00a0\n\u00a0Astemizol \u00a0\nEstatinas\u00a0(excepto\u00a0fluvastatina \u00a0y\u00a0\npravastatina) \u00a0\u00a0\nCisaprida\u00a0\nDeriv.\u00a0Ergotamina \u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0Juan)\u00a0\nLumefantrina \u00a0\nIndinavir\u00a0\nIrinotecan \u00a0\nMidazolam \u00a0oral\u00a010\u00a0\nOmeprazol \u00a0y\u00a0afines\u00a09\u00a0\nPimozida\u00a0\nRifampicina \u00a0\nTerfenadina \u00a0\u00a0\nTriazolam \u00a0Amiodarona \u00a0\nAstemizol \u00a0\nCisaprida\u00a0\u00a0\nDeriv.\u00a0Ergotamina \u00a0\u00a0\nEstatinas\u00a0(simvastatina \u00a0y\u00a0lovastatina) \u00a0\nExtasis\u00a0\nFenobarbital \u00a0\nfenitoina\u00a0\nFluticasona \u00a0inh.\u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0Juan)\u00a0\nLidoca\u00edna \u00a0sist\u00e9mica \u00a0\nMetanfetamina \u00a0\nMidazolam \u00a0oral\u00a010\u00a0\nPimozida\u00a0\u00a0\nQuinidina \u00a0\u00a0\nRifampicina \u00a0\nSertindol\u00a0\nTerfenadina \u00a0\nTriazolam \u00a0\u00a0\u00a0Astemizol \u00a0\nCisaprida\u00a0\nDeriv.\u00a0ergotamina \u00a0\nEncainida \u00a0\nEstatinas\u00a0(excepto\u00a0atorvastatina, \u00a0fluvastatina \u00a0\ny\u00a0pravastatina) \u00a0\nEtravirina \u00a0\n\u00c9xtasis\u00a0\u00a0\nFlecainida \u00a0\nFluticasona \u00a0inh\u00a0\nHalofantrina \u00a0\nHypericum \u00a0(Hierba\u00a0de\u00a0San\u00a0Juan)\u00a0\nLumefantrina \u00a0\nMetanfetamina \u00a0\nMidazolam \u00a0oral\u00a010\u00a0\nPimozida\u00a0\nPropafenona \u00a0\nQuinidina \u00a0\u00a0\nRifampicina \u00a0\nSaquinavir \u00a0\nTerfenadina \u00a0\nTriazolam \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 12\u00a0\nNombre\u00a0gen\u00e9rico\u00a0 Lopinavir/r \u00a0 Atazanavir \u00a0 Darunavir/r \u00a0 Tipranavir/r \u00a0\nAnti\u00e1cidos \u00a0\u00a0 Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0\u00a0 Espaciar\u00a01\u20102h\u00a0(primero\u00a0ATV)\u00a0\u00a0 Espaciar\u00a01\u20102h\u00a0(\u219325\u201029%\u00a0AUC\u00a0TPV)\u00a0\nInh.\u00a0bomba\u00a0protones Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0 Contraindicado \u00a011\u00a0 Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0 Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0\nAntihist.\u00a0H2\u00a0 Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0 Ensayado \u00a0con\u00a0famotidina12\u00a0 Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0 No\u00a0hay\u00a0datos:\u00a0probablemente \u00a0ausencia\u00a0de\u00a0\ninteracci\u00f3n \u00a0\nAntimicobact. \u00a0\u00a0\u00a0 \u00a0 \u00a0\n\u2010\u00a0Rifampicina \u00a0 Contraindicado \u00a0 Contraindicado \u00a0 Contraindicado \u00a0 Contraindicado \u00a0(no\u00a0hay\u00a0datos)\u00a0\n\u2010\u00a0Rifabutina \u00a0(RFB)\u00a0 RFB\u00a0150\u00a0mg\u00a0\u00a03veces\u00a0/semana0\u00a0 NRAD\u00a0atazanavir \u00a0\n\u00a0RFB\u00a0150\u00a0mg\u00a03veces\u00a0/semana. \u00a0NRAD\u00a0darunavir/ritonavir \u00a0\n\u00a0RFB\u00a0150\u00a0mg\u00a03veces\u00a0/semana0\u00a0RFB\u00a0150\u00a0mg\u00a0\u00a03veces\u00a0/semana0\u00a0\n\u00a0\n\u2010\u00a0Claritromicina \u00a0 Considerar \u00a0tratamientos \u00a0\nalternativos \u00a0para\u00a0indicaciones \u00a0\ndiferentes \u00a0de\u00a0MAC.\u00a0Ajustar\u00a0dosis\u00a0\nclaritro\u00a0si\u00a0func.\u00a0renal\u00a0alterada1.\u00a0Reducir\u00a050%\u00a0la\u00a0dosis\u00a0de\u00a0claritro.\u00a0Se\u00a0\nreducen\u00a0las\u00a0concentraciones \u00a0de\u00a0su\u00a0\nmetabolito \u00a05\u2010hidroxi\u2010.\u00a0Considerar \u00a0\ntratamientos \u00a0alternativos \u00a0para\u00a0\nindicaciones \u00a0diferentes \u00a0de\u00a0MAC.\u00a0Considerar \u00a0tratamientos \u00a0alternativos \u00a0\npara\u00a0indicaciones \u00a0diferentes \u00a0de\u00a0MAC\u00a0\n(niveles\u00a0de\u00a014\u2010OH\u2010claritromicina \u00a0\ninferiores \u00a0al\u00a0l\u00edmite\u00a0de\u00a0cuantificaci\u00f3n). \u00a0\nAjustar\u00a0dosis\u00a0claritro\u00a0si\u00a0func.\u00a0renal\u00a0\nalterada1.\u00a0Considerar \u00a0tratamientos \u00a0alternativos \u00a0para\u00a0\nindicaciones \u00a0diferentes \u00a0de\u00a0MAC.\u00a0\nTPV:\u219160%\u00a0AUC,\u00a0x2\u00a0Cm\u00edn;\u00a0Claritro:\u00a0\u219119%\u00a0AUC,\u00a0\n\u219168%\u00a0Cmin,\u00a0\u2193>95%\u00a014\u2010OH\u2010claritromicina. \u00a0\n\u00a0\nAntiepil\u00e9pticos :\u00a0\n\u00a0Carbamazepina, \u00a0\nfenito\u00edna, \u00a0\nfenobarbital, \u00a0\nlamotrigina \u00a0Un\u00a0caso\u00a0descrito\u00a0de\u00a0intoxicaci\u00f3n \u00a0\ncon\u00a0carbamacepina \u00a0(tambien\u00a0\npodr\u00edan\u00a0\u2193Cp\u00a0LPV:\u00a0monitorizar \u00a0\nniveles\u00a0de\u00a0ambos).\u00a0\nCon\u00a0fenito\u00edna ,\u00a0se\u00a0han\u00a0descrito\u00a0\n\u219330%\u00a0en\u00a0el\u00a0AUC\u00a0de\u00a0fenito\u00edna, \u00a0\nLPV\u00a0y\u00a0RTV\u00a0y\u00a0\u2193\u00a0\u2245\u00a050%\u00a0Cmin\u00a0LPV\u00a0y\u00a0\nRTV.\u00a0Posible\u00a0repercusi\u00f3n \u00a0cl\u00ednica.\u00a0\nMonitorizar \u00a0Cp\u00a0de\u00a0ambos\u00a0\nf\u00e1rmacos. \u00a0\nCon\u00a0lamotrigina :\u00a0se\u00a0recomienda \u00a0\nduplicar\u00a0la\u00a0dosis\u00a0de\u00a0lamotrigina. \u00a0\nCon\u00a0\u00e1c\u00a0valproico :\u00a0datos\u00a0\ncontradictorios \u00a0(\u219348%\u00a0niveles\u00a0\nvalproico\u00a0en\u00a0un\u00a0paciente\u00a0versus\u00a0\nsin\u00a0cambios\u00a0en\u00a0otro\u00a0estudio\u00a0en\u00a0\nque\u00a0se\u00a0compar\u00f3\u00a0niv.\u00a0de\u00a0\nvalproico\u00a0con\u00a0datos\u00a0hist\u00f3ricos). \u00a0\nPrecauci\u00f3n. \u00a0\u00a0Posible\u00a0\u2193Cp\u00a0ATV.\u00a0Se\u00a0recomienda \u00a0\nmonitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0\nantirretroviral \u00a0y\u00a0antiepil\u00e9ptico. \u00a0\n\u00a0\nLamotrigina: \u00a0con\u00a0ATV\u00a0nopotenciado \u00a0\n\u219312%\u00a0AUC\u00a0lamotrigina; \u00a0con\u00a0ATV/r\u00a0\u219332%\u00a0\nAUC\u00a0lamotrigina. \u00a0\n\u00a0Carbamazepina \u00a0(200\u00a0mg/12h): \u00a0\u219145%\u00a0\nAUC\u00a0CBZ,\u00a0DRV\u00a0sin\u00a0cambios.\u00a0Valorar\u00a0\nreduccion \u00a0de\u00a0dosis\u00a0de\u00a0carbamazepina \u00a0\ndel\u00a025\u201050%.\u00a0Se\u00a0recomienda \u00a0\nmonitorizar \u00a0niveles\u00a0de\u00a0carbamazepina.\nFenobarbital \u00a0y\u00a0fenito\u00edna :\u00a0\ncontraindicados \u00a0por\u00a0riesgo\u00a0de\u00a0\nreducci\u00f3n \u00a0de\u00a0las\u00a0Cp\u00a0de\u00a0DRV.\u00a0\n\u00a0\u00a0\nSe\u00a0recomienda \u00a0monitorizar \u00a0niveles\u00a0\nplasm\u00e1ticos \u00a0de\u00a0antirretroviral \u00a0y\u00a0antiepil\u00e9ptico. \u00a0\n\u00a0\nUn\u00a0caso\u00a0de\u00a0reducci\u00f3n \u00a0del\u00a050%\u00a0en\u00a0las\u00a0Cp\u00a0de\u00a0\nfenobarbital .\u00a0\nAnticoagulantes \u00a0\norales\u00a0\n\u00a0Los\u00a0IP\u00a0pueden\u00a0alterar\u00a0las\u00a0Cp\u00a0de\u00a0los\u00a0anticoagulantes. \u00a0Existen\u00a0casos\u00a0descritos\u00a0de\u00a0reducci\u00f3n \u00a0del\u00a0efecto\u00a0anticoagulante \u00a0con\u00a0requerimiento \u00a0de\u00a0aumento\u00a0de\u00a0dosis\u00a0de\u00a0\nacenocumarol \u00a0y\u00a0warfarina \u00a0al\u00a0asociarlos \u00a0a\u00a0RTV,\u00a0LPV/r\u00a0\u00f3\u00a0IDV.\u00a0Monitorizar \u00a0estrictamente \u00a0el\u00a0tiempo\u00a0de\u00a0protrombina. \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 13\u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0Lopinavir/r \u00a0 Atazanavir \u00a0 Darunavir/r \u00a0 Tipranavir/r \u00a0\nAnticonceptivos \u00a0\norales :\u00a0\u219342%\u00a0AUC\u00a0etinilestradiol. \u00a0Usar\u00a0\nm\u00e9todos\u00a0alternativos \u00a0Posible\u00a0\u2193Cp\u00a0ATV.\u00a0Se\u00a0recomienda \u00a0\nmonitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0\nantirretroviral \u00a0y\u00a0antiepil\u00e9ptico. \u00a0\n\u00a0\nLamotrigina: \u00a0con\u00a0ATV\u00a0nopotenciado \u00a0\n\u219312%\u00a0AUC\u00a0lamotrigina; \u00a0con\u00a0ATV/r\u00a0\u219332%\u00a0\nAUC\u00a0lamotrigina. \u00a0\n\u00a0Carbamazepina \u00a0(200\u00a0mg/12h): \u00a0\u219145%\u00a0\nAUC\u00a0CBZ,\u00a0DRV\u00a0sin\u00a0cambios.\u00a0Valorar\u00a0\nreduccion \u00a0de\u00a0dosis\u00a0de\u00a0carbamazepina \u00a0\ndel\u00a025\u201050%.\u00a0Se\u00a0recomienda \u00a0\nmonitorizar \u00a0niveles\u00a0de\u00a0carbamazepina.\nFenobarbital \u00a0y\u00a0fenito\u00edna :\u00a0\ncontraindicados \u00a0por\u00a0riesgo\u00a0de\u00a0\nreducci\u00f3n \u00a0de\u00a0las\u00a0Cp\u00a0de\u00a0DRV.\u00a0\n\u00a0\u00a0\nSe\u00a0recomienda \u00a0monitorizar \u00a0\nniveles\u00a0plasm\u00e1ticos \u00a0de\u00a0\nantirretroviral \u00a0y\u00a0\nantiepil\u00e9ptico. \u00a0\n\u00a0\nUn\u00a0caso\u00a0de\u00a0reducci\u00f3n \u00a0del\u00a0\n50%\u00a0en\u00a0las\u00a0Cp\u00a0de\u00a0\nfenobarbital .\u00a0\nAntif\u00fangicos \u00a0\nimidaz\u00f3licos \u00a0No\u00a0se\u00a0han\u00a0descrito\u00a0interacciones \u00a0\ncl\u00ednicamente \u00a0importantes \u00a0con\u00a0\nfluconazol .\u00a0M\u00e1x\u00a0200\u00a0mg/d\u00eda\u00a0de\u00a0\nitraconazol \u00a0y\u00a0de\u00a0ketoconazol .\u00a0\nCon\u00a0voriconazol \u00a0y\u00a0LPV/r\u00a0no\u00a0hay\u00a0\ndatos\u00a0(RTV\u00a0400\u00a0mg\u00a0c/12h\u00a0\u00a0\ncontraindicado; \u00a0RTV\u00a0100\u00a0mg\u00a0\nc/12h:\u00a0evitar\u00a0a\u00a0menos\u00a0que\u00a0el\u00a0\nbalance\u00a0riesgo/beneficio \u00a0\njustifique \u00a0su\u00a0uso.\u00a0Ver\u00a0Ritonavir). \u00a0\nMonitorizar \u00a0estrechamente. \u00a0\n\u00a0\u00a0Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0con\u00a0fluconazol\n.\u00a0\nPuede\u00a0administrarse \u00a0atazanavir \u00a0no\u00a0\npotenciado \u00a0con\u00a0ketoconazol \u00a0junto\u00a0con\u00a0\nuna\u00a0comida\u00a0ligera\u00a0sin\u00a0que\u00a0se\u00a0requiera\u00a0\najuste\u00a0de\u00a0dosis.\u00a0Con\u00a0ATV/r\u00a0no\u00a0exceder\u00a0\n200\u00a0mg/d\u00eda\u00a0de\u00a0ketoconazol. \u00a0\n\u00a0Con\u00a0voriconazol\n\u00a0y\u00a0ATV+/\u2010\u00a0RTV:\u00a0no\u00a0hay\u00a0\ndatos\u00a0(RTV\u00a0400\u00a0mg\u00a0c/12h\u00a0\u00a0\ncontraindicado; \u00a0RTV\u00a0100\u00a0mg\u00a0c/12h:\u00a0\nevitar\u00a0a\u00a0menos\u00a0que\u00a0el\u00a0balance\u00a0\nriesgo/beneficio \u00a0justifique \u00a0su\u00a0uso.\u00a0Ver\u00a0\nRitonavir). \u00a0Monitorizar \u00a0estrechamente. \u00a0\n\u00a0Posaconazol \u00a0(400\u00a0mg/12h)\u00a0en\u00a0\nvoluntarios \u00a0sanos\u00a0aument\u00f3\u00a03,7\u00a0veces\u00a0el\u00a0\nAUC\u00a0de\u00a0ATV\u00a0no\u00a0potenciado \u00a0y\u00a02,5\u00a0veces\u00a0\nel\u00a0AUC\u00a0de\u00a0\nATV/r.\u00a0Se\u00a0observaron \u00a0\naumentos \u00a0de\u00a0los\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0\nbilirrubina. \u00a0Ketoconazol: \u00a0+\u00a042%\u00a0AUC\u00a0darunavir; \u00a0\nAUC\u00a0de\u00a0ketoconazol \u00a02\u00a0veces\u00a0mayor:\u00a0\ndosis\u00a0m\u00e1xima\u00a0de\u00a0ketoconazol \u00a0200\u00a0\nmg/d\u00eda.\u00a0\u00a0\nItraconazol: \u00a0dosis\u00a0m\u00e1xima\u00a0de\u00a0\nitraconazol \u00a0200\u00a0mg/d\u00eda.\u00a0\nLa\u00a0coadministraci\u00f3n \u00a0de\u00a0voriconazol \u00a0y\u00a0\ndarunavir/ritonavir \u00a0no\u00a0ha\u00a0sido\u00a0\nestudiada \u00a0(RTV\u00a0400\u00a0mg\u00a0c/12h\u00a0\u00a0\ncontraindicado; \u00a0RTV\u00a0100\u00a0mg\u00a0c/12h:\u00a0\nevitar\u00a0a\u00a0menos\u00a0que\u00a0el\u00a0balance\u00a0\nriesgo/beneficio \u00a0justifique \u00a0su\u00a0uso.\u00a0Ver\u00a0\nRitonavir). \u00a0Monitorizar \u00a0\nestrechamente. \u00a0Con\u00a0fluconazol \u00a0(100\u00a0mg\u00a0\nc/24h),\u00a0posible\u00a0aumento\u00a0de\u00a0\nlos\u00a0niveles\u00a0plasm\u00e1ticos \u00a0de\u00a0\nTPV\u00a0(datos\u00a0limitados). \u00a0\nMonitorizar \u00a0toxicidad. \u00a0\nNo\u00a0se\u00a0recomienda \u00a0\nsobrepasar \u00a0los\u00a0200\u00a0mg/d\u00eda\u00a0\nde\u00a0fluconazol, \u00a0itraconazol \u00a0y\u00a0\nketoconazol. \u00a0\n\u00a0Con\u00a0voriconazol \u00a0\ny\u00a0TPV+/\u2010\u00a0\nRTV:\u00a0no\u00a0hay\u00a0datos\u00a0(RTV\u00a0400\u00a0\nmg\u00a0c/12h\u00a0\u00a0contraindicado; \u00a0\nRTV\u00a0100\u00a0mg\u00a0c/12h:\u00a0evitar\u00a0a\u00a0\nmenos\u00a0que\u00a0el\u00a0balance\u00a0\nriesgo/beneficio \u00a0justifique \u00a0su\u00a0\nuso.\u00a0Ver\u00a0Ritonavir). \u00a0\nMonitorizar \u00a0estrechamente. \u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 14\u00a0\nNombre\u00a0gen\u00e9rico\u00a0Lopinavir/r \u00a0 Atazanavir \u00a0 Darunavir/r \u00a0 Tipranavir/r \u00a0\nEstatinas: \u00a0 Lovastatina, \u00a0simvastatina \u00a0y\u00a0\nfluvastatina \u00a0contraindicadas. \u00a0\u00a0\nPravastatina: \u00a0NRAD\u00a0\nAtorvastatina: \u00a0asociar\u00a0con\u00a0\nprecauci\u00f3n \u00a0(iniciar\u00a0con\u00a0m\u00e1ximo\u00a0\n10\u00a0mg/d\u00eda).\u00a0Lovastatina \u00a0y\u00a0simvastatina \u00a0\ncontraindicadas. \u00a0\u00a0\nFuvastatina \u00a0y\u00a0pravastatina \u00a0interacci\u00f3n \u00a0\npoco\u00a0probable. \u00a0\u00a0\nAtorvastatina: \u00a0asociar\u00a0con\u00a0precauci\u00f3n \u00a0\n(iniciar\u00a0con\u00a0m\u00e1ximo\u00a010\u00a0mg/d\u00eda).\u00a0Lovastatina, \u00a0simvastatina \u00a0y\u00a0\nfluvastatina \u00a0contraindicadas. \u00a0\nAtorvastatina \u00a0(\u2191x4\u00a0AUC\u00a0\natorvastatina): \u00a0se\u00a0recomienda \u00a0\nempezar\u00a0con\u00a0una\u00a0dosis\u00a0de\u00a0\natorvastatina \u00a0de\u00a010\u00a0mg\u00a0al\u00a0d\u00eda\u00a0y\u00a0\naumentar \u00a0progresivamente \u00a0en\u00a0funci\u00f3n\u00a0\nde\u00a0la\u00a0respuesta \u00a0cl\u00ednica.\u00a0\nPravastatina: \u00a0\u00a0DRV/r\u00a0no\u00a0aument\u00f3\u00a0la\u00a0\nexposici\u00f3n \u00a0a\u00a0una\u00a0dosis\u00a0\u00fanica\u00a0de\u00a0\npravastatina, \u00a0en\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0sujetos,\u00a0\naunque\u00a0\u00e9sta\u00a0se\u00a0multiplic\u00f3 \u00a05\u00a0veces\u00a0s\u00f3lo\u00a0\nen\u00a0un\u00a0subgrupo \u00a0de\u00a0sujetos.\u00a0Se\u00a0\nrecomienda \u00a0iniciar\u00a0con\u00a0dosis\u00a0bajas\u00a0de\u00a0\npravastatina \u00a0e\u00a0incrementarlas \u00a0\ngradualmente \u00a0\u00a0hasta\u00a0conseguir \u00a0el\u00a0\nefecto\u00a0cl\u00ednico\u00a0deseado\u00a0Lovastatina, \u00a0simvastatina \u00a0y\u00a0\nfluvastatina \u00a0contraindicadas. \u00a0\nTPV/r\u00a0aument\u00f3\u00a09\u00a0veces\u00a0el\u00a0\nAUC\u00a0de\u00a0atorvastatina. \u00a0\u00a0\nUtilizar\u00a0preferiblemente \u00a0\npravastatina \u00a0(interacci\u00f3n \u00a0\npoco\u00a0probable). \u00a0\nEtanol:\u00a0 El\u00a0uso\u00a0agudo\u00a0o\u00a0cr\u00f3nico\u00a0de\u00a0etanol\u00a0alter\u00f3\u00a0m\u00ednimamente \u00a0la\u00a0farmacocin\u00e9tica \u00a0de\u00a0los\u00a0IP.\u00a0\nAntabus:\u00a0algunos\u00a0IP\u00a0podr\u00edan\u00a0dar\u00a0lugar\u00a0a\u00a0una\u00a0reacci\u00f3n\u00a0de\u00a0tipo\u00a0disulfiram \u00a0por\u00a0su\u00a0contenido \u00a0en\u00a0etanol:\u00a0Norvir\u00ae\u00a0soluci\u00f3n\u00a0oral\u00a0(43%\u00a0v/v);\u00a0Norvir\u00a0c\u00e1psulas\u00a0\n(12%\u00a0p/p);\u00a0Kaletra\u00ae\u00a0soluci\u00f3n\u00a0oral\u00a0(42%);\u00a0Aptivus\u00a0c\u00e1psulas\u00a0(7%\u00a0p/p\u00a0=100\u00a0mg/c\u00e1ps). \u00a0Kaletra\u00ae\u00a0en\u00a0comprimidos \u00a0no\u00a0contiene\u00a0alcohol.\u00a0Agenerase\u00ae \u00a0en\u00a0\nsoluci\u00f3n\u00a0tiene\u00a0un\u00a0elevado\u00a0contenido \u00a0de\u00a0propilenglicol \u00a0(550\u00a0mg/mL),\u00a0que\u00a0se\u00a0metaboliza \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0alcohol\u00a0deshidrogenasa, \u00a0por\u00a0lo\u00a0que\u00a0el\u00a0\nconsumo\u00a0de\u00a0etanol\u00a0junto\u00a0con\u00a0estos\u00a0IPs\u00a0podr\u00eda\u00a0producir\u00a0toxicidad. \u00a0Kaletra\u00ae\u00a0en\u00a0c\u00e1psulas\u00a0y\u00a0Agenerase\u00ae \u00a0en\u00a0c\u00e1psulas\u00a0tambi\u00e9n\u00a0contienen \u00a0propilenglicol, \u00a0\npero\u00a0en\u00a0menor\u00a0cantidad. \u00a0\nF\u00e1rmacos \u00a0\nempleados \u00a0para\u00a0\ntratar\u00a0la\u00a0influenza \u00a0Zanamivir/amantadina: \u00a0una\u00a0interacci\u00f3n \u00a0con\u00a0los\u00a0IPs\u00a0se\u00a0considera \u00a0poco\u00a0probable. \u00a0\nOseltamivir \u00a0se\u00a0ha\u00a0relacionado \u00a0con\u00a0efectos\u00a0adversos\u00a0neuropsiqui\u00e1tricos, \u00a0aunque\u00a0no\u00a0se\u00a0puede\u00a0descartar \u00a0que\u00a0\u00e9stos\u00a0sean\u00a0debidos,\u00a0al\u00a0menos\u00a0en\u00a0parte,\u00a0a\u00a0\nla\u00a0propia\u00a0enfermedad. \u00a0Los\u00a0IPs\u00a0al\u00a0bloquear\u00a0la\u00a0glicoprote\u00edna \u2010P\u00a0podr\u00edan\u00a0aumentar \u00a0la\u00a0penetraci\u00f3n \u00a0de\u00a0oseltamivir \u00a0en\u00a0el\u00a0SNC\u00a0y\u00a0empeorar \u00a0sus\u00a0efectos\u00a0\nadversos. \u00a0Se\u00a0recomienda \u00a0asociarlos \u00a0con\u00a0precauci\u00f3n \u00a0hasta\u00a0que\u00a0no\u00a0se\u00a0disponga\u00a0de\u00a0m\u00e1s\u00a0datos.\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 15\u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0Lopinavir/r \u00a0 Atazanavir \u00a0 Darunavir/r \u00a0 Tipranavir/r \u00a0\nInmunosupresores :\u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0Posible\u00a0\u2191Cp\u00a0ciclosporina, \u00a0\u00a0\nprednisona, \u00a0tacrolimus \u00a0y\u00a0\nsirolimus. \u00a0Monitorizar \u00a0\nniveles/toxicidad \u00a0del\u00a0\ninmunosupresor. \u00a0Micofenolato \u00a0\nse\u00a0glucuronida \u00a0por\u00a0lo\u00a0que\u00a0RTV\u00a0\npodr\u00eda\u00a0\u2193\u00a0sus\u00a0Cp.\u00a0Monitorizar \u00a0\nniveles/eficacia. \u00a0En\u00a0un\u00a0paciente, \u00a0\nlas\u00a0dosis\u00a0de\u00a0ciclosporina \u00a0tuvo\u00a0\nque\u00a0reducirse \u00a0a\u00a01/20\u00a0parte\u00a0al\u00a0\na\u00f1adir\u00a0LPV/r.\u00a0\n\u00a0Posible\u00a0\u2191Cp\u00a0ciclosporina, \u00a0prednisona, \u00a0\ntacrolimus \u00a0y\u00a0sirolimus. \u00a0Monitorizar \u00a0\nniveles/toxicidad \u00a0del\u00a0inmunosupresor. \u00a0\n\u00a0Posible\u00a0\u2191Cp\u00a0ciclosporina, \u00a0\nprednisona, \u00a0tacrolimus \u00a0y\u00a0sirolimus. \u00a0\nMonitorizar \u00a0niveles/toxicidad \u00a0del\u00a0\ninmunosupresor. \u00a0\nTacrolimus: \u00a0un\u00a0caso\u00a0descrito\u00a0de\u00a0\najuste\u00a0hasta\u00a00,5\u00a0mg/semana. \u00a0No\u00a0hay\u00a0datos.\u00a0Se\u00a0recomienda \u00a0\nmonitorizar \u00a0estrechamente \u00a0los\u00a0\nniveles\u00a0plasm\u00e1ticos \u00a0de\u00a0\ninmunosupresor. \u00a0\n\u00a0\u00a0\nLa\u00a0dosis\u00a0de\u00a0ciclosporina \u00a0inicial\u00a0debe\u00a0ser\u00a0aprox\u00a01/10\u00a0de\u00a0la\u00a0habitual\u00a0y\u00a0puede\u00a0requerir\u00a0reducciones \u00a0progresivas \u00a0a\u00a0lo\u00a0\nlargo\u00a0del\u00a0tiempo.\u00a0En\u00a0algunos\u00a0casos\u00a0la\u00a0dosis\u00a0al\u00a0cabo\u00a0de\u00a02\u00a0a\u00f1os\u00a0es\u00a0tan\u00a0s\u00f3lo\u00a0un\u00a025%\u00a0de\u00a0la\u00a0inicial\u00a0(probablemente \u00a0por\u00a0\naumento\u00a0de\u00a0la\u00a0absorci\u00f3n \u00a0intestinal \u00a0a\u00a0lo\u00a0largo\u00a0del\u00a0tiempo).\u00a0\u00a0\nTacrolimus: \u00a0se\u00a0ha\u00a0descrito\u00a0una\u00a0interacci\u00f3n \u00a0muy\u00a0importante \u00a0con\u00a0LPV/r\u00a0(pueden\u00a0ser\u00a0necesarios \u00a0menos\u00a0de\u00a01mg\u00a0de\u00a0\ntacrolimus \u00a0a\u00a0la\u00a0semana\u00a0y\u00a0puede\u00a0ser\u00a0necesario \u00a0esperar\u00a0de\u00a03\u00a0a\u00a05\u00a0semanas\u00a0(seg\u00fan\u00a0funci\u00f3n\u00a0hep\u00e1tica) \u00a0antes\u00a0de\u00a0\nadministrar \u00a0otra\u00a0dosis\u00a0de\u00a0tacrolimus \u00a0al\u00a0iniciar\u00a0LPV/r.\u00a0Tambi\u00e9n\u00a0se\u00a0ha\u00a0descrito\u00a0interacci\u00f3n \u00a0con\u00a0otros\u00a0IP\u00a0(p.\u00a0ej\u00a0.\u00a0\nmayor\u00a0con\u00a0NFV\u00a0que\u00a0con\u00a0IDV,\u00a0requiri\u00e9ndose \u00a0en\u00a0un\u00a0estudio\u00a0unos\u00a00,6\u00a0mg\u00a0diarios\u00a0de\u00a0tacrolimus \u00a0con\u00a0estos\u00a0IP.\u00a0\u00a0\nInterfer\u00f3n/ \u00a0\nRibavirina \u00a0Ribavirina: \u00a0no\u00a0existe\u00a0evidencia \u00a0de\u00a0interacci\u00f3n \u00a0con\u00a0los\u00a0IP.\u00a0\u00a0\nInterfer\u00f3n: \u00a0su\u00a0v\u00eda\u00a0de\u00a0eliminaci\u00f3n \u00a0no\u00a0est\u00e1\u00a0claramente \u00a0establecida \u00a0as\u00ed\u00a0como\u00a0tampoco\u00a0su\u00a0posible\u00a0efecto\u00a0inhibidor\u00a0sobre\u00a0el\u00a0citocromo \u00a0P\u2010450\u00a0(ha\u00a0\nmostrado \u00a0p.\u00a0ej.\u00a0\u2191Cp\u00a0de\u00a0teofilina\u00a0y\u00a0barbituratos). \u00a0No\u00a0hay\u00a0datos\u00a0con\u00a0respecto\u00a0a\u00a0posibles\u00a0interacciones \u00a0con\u00a0IP.\u00a0\nEn\u00a0pacientes \u00a0tratados\u00a0con\u00a0ATV\u00a0se\u00a0han\u00a0descrito\u00a0\u2191x2\u00a0bilirrubina. \u00a0\nMetadona(MT) \u00a0y\u00a0otros\u00a0\nopi\u00e1ceos\u00a0\u219353%\u00a0AUC\u00a0MT.\u00a0Habitualmente \u00a0\nNRAD\u00a0de\u00a0metadona \u00a0Metadona: \u00a0Probablemente \u00a0NRAD.\u00a0\nAusencia\u00a0de\u00a0interacci\u00f3n \u00a0farmacocin\u00e9tica \u00a0\ncon\u00a0ATV\u00a0400mg/d\u00eda. \u00a0Seg\u00fan\u00a0datos\u00a0\niniciales\u00a0con\u00a0ATV/r\u00a0300/100\u00a0mg\u00a0c/24h\u00a0\nlos\u00a0ajustes\u00a0de\u00a0dosis\u00a0de\u00a0MT,\u00a0si\u00a0se\u00a0\nrequieren, \u00a0son\u00a0m\u00ednimos. \u00a0\nAlgunos\u00a0casos\u00a0descritos\u00a0de\u00a0intoxicaci\u00f3n \u00a0\nopi\u00e1cea\u00a0en\u00a0pacientes \u00a0tratados\u00a0con\u00a0ATV/r\u00a0\ny\u00a0buprenorfina, \u00a0resuelta\u00a0tras\u00a0reducir\u00a0la\u00a0\ndosis\u00a0del\u00a0opi\u00e1ceo.\u00a0Metadona: \u00a0no\u00a0se\u00a0requiere\u00a0ajustes\u00a0\ninicialmente. \u00a0Monitorizaci\u00f3n \u00a0\ncl\u00ednica\u00a0y\u00a0ajustar\u00a0dosis\u00a0\nposteriormente \u00a0en\u00a0caso\u00a0necesario, \u00a0\naunque\u00a0habitualmente \u00a0no\u00a0se\u00a0\nrequiere.\u00a0\nBuprenorfina/naloxona: \u00a0\nbuprenorfina \u00a0sin\u00a0cambios,\u00a0\u219146%\u00a0\nAUC\u00a0norbuprenorfina. \u00a0S\u00edntomas\u00a0\nleves\u00a0de\u00a0exceso\u00a0de\u00a0opi\u00e1ceos\u00a0en\u00a0\nalgunos\u00a0pacientes \u00a0sin\u00a0requerir\u00a0\n\u2193dosis.\u00a0Metadona: \u00a0\u219348%\u00a0is\u00f3mero\u00a0\nactivo\u00a0R\u2010metadona: \u00a0puede\u00a0\nrequerir\u00a0aumento\u00a0de\u00a0dosis.\u00a0\u00a0\n\u00a0Loperamida: \u00a0a\u00a0pesar\u00a0de\u00a0que\u00a0\nTPV/r\u00a0act\u00faa\u00a0como\u00a0inhibidor\u00a0de\u00a0la\u00a0\nglicoprote\u00edna \u2010P,\u00a0no\u00a0se\u00a0observ\u00f3\u00a0\naumento\u00a0de\u00a0los\u00a0efectos\u00a0en\u00a0SNC\u00a0\nde\u00a0loperamida \u00a0(16\u00a0mg).\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 16\u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0Lopinavir/r \u00a0 Atazanavir \u00a0 Darunavir/r \u00a0 Tipranavir/r \u00a0\nOtros\u00a0f\u00e1rmacos \u00a0 \u00a0\nArtemeter/lumefantrina :\u00a0\u00a0\n\u2191\u00a0x2\u20103\u00a0AUC\u00a0lumefantrina, \u00a0\n\u219335%\u00a0%AUC\u00a0artemeter, \u00a0\u00a0LPV\u00a0sin\u00a0\ncambios.\u00a0\u00a0NRAD\u00a0monitorizar \u00a0\ntoxicidad. \u00a0\nAtovaquona/proguanilo: \u00a0\u00a0\n\u219365%\u00a0AUC\u00a0atovaquona, \u00a0\u00a0\n\u219368%\u00a0AUC\u00a0proguanilo \u00a0(datos\u00a0\nlimitados\u00a0\u00a0procedentes \u00a0de\u00a0\ncomparar \u00a0niveles\u00a0de\u00a0pacientes \u00a0\ncon\u00a0voluntarios \u00a0sanos\u00a0sin\u00a0TARV).\u00a0\nValorar\u00a0aumento\u00a0de\u00a0dosis.\u00a0\nBupropi\u00f3n: \u00a0LPV/r\u00a0\u00a0\u219357%\u00a0AUCde\u00a0\nbupropi\u00f3n. \u00a0\nDigoxina :\u00a0\u219181%AUC\u00a0(0\u201012h)\u00a0de\u00a0\nuna\u00a0dosis\u00a0\u00fanica\u00a0de\u00a00,5\u00a0mg\u00a0de\u00a0\ndigoxina,\u00a0posiblemente \u00a0por\u00a0\ninteracci\u00f3n \u00a0con\u00a0Pgp\u00a0intestinal. \u00a0\nPrecauci\u00f3n \u00a0con\u00a0otros\u00a0f\u00e1rmacos \u00a0\nsubstrato \u00a0de\u00a0Pgp:\u00a0verapamilo, \u00a0\ndoxorrubicina. \u00a0\nEzetimiba \u00a0no\u00a0modific\u00f3\u00a0de\u00a0forma\u00a0\nsignificativa \u00a0la\u00a0farmacocin\u00e9tica \u00a0\nde\u00a0LPV/r\u00a0(no\u00a0se\u00a0evalu\u00f3\u00a0la\u00a0posible\u00a0\ninteracci\u00f3n \u00a0en\u00a0el\u00a0sentido\u00a0\ncontrario, \u00a0aunque\u00a0no\u00a0parece\u00a0\nprobable\u00a0una\u00a0interacci\u00f3n \u00a0\nimportante). \u00a0\u00a0\nGemfibrozilo: \u00a0\u219341%\u00a0AUC\u00a0de\u00a0\ngemfibrozilo. \u00a0\n\u00a0\n(sigue)\u00a0\u00a0\nAtovaquona/proguanilo :\u00a0\u00a0\n\u219333%\u00a0AUC\u00a0atovaquona, \u00a0\u00a0\n\u219374%\u00a0AUC\u00a0proguanilo \u00a0(datos\u00a0limitados\u00a0\u00a0\nprocedentes \u00a0de\u00a0comparar \u00a0niveles\u00a0de\u00a0\npacientes \u00a0con\u00a0voluntarios \u00a0sanos\u00a0sin\u00a0\nTARV).\u00a0\n\u00a0Con\u00a0TDF\n:\u00a0utilizar\u00a0ATV/r\u00a0300/100\u00a0mg\u00a0\nc/24h.\u00a0\nReducir\u00a0dosis\u00a0de\u00a0diltiazem\u00a0a\u00a0la\u00a0mitad.\u00a0\nPosible\u00a0aumento\u00a0Cp\u00a0sildenafilo \u00a0(max\u00a025\u00a0\nmg\u00a0en\u00a0un\u00a0periodo\u00a0de\u00a048h),\u00a0vardenafilo \u00a0\n(m\u00e1x\u00a02,5\u00a0mg\u00a0c/72h\u00a0si\u00a0asociado\u00a0a\u00a0RTV)\u00a0y\u00a0\ntadalafilo \u00a0(iniciar\u00a0con\u00a05\u00a0mg\u00a0y\u00a0no\u00a0exceder\u00a0\n10\u00a0mg\u00a0c/72h).\u00a0\n\u00a0\u00a0Fluticasona \u00a0inh\n.:\u00a0en\u00a0un\u00a0estudio\u00a0caso\u2010\ncontrol,\u00a0una\u00a0elevada\u00a0proporci\u00f3n \u00a0de\u00a0los\u00a0\npacientes \u00a0expuestos \u00a0a\u00a0RTV+fluticasona \u00a0\n(7/8;\u00a088%)\u00a0presentaron \u00a0supresi\u00f3n \u00a0\nadrenal,\u00a0que\u00a0fue\u00a0sintom\u00e1tica \u00a0en\u00a0un\u00a057%\u00a0\nde\u00a0los\u00a0casos.\u00a0\n\u00a0\nPuede\u00a0\u2191\u00a0Cp\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0que\u00a0se\u00a0\nmetabolizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\u00a0CYP3A43\u00a0y\u00a0\u00a0\nUDP\u2010glucuroniltransferasa \u00a01A1.\u00a0\n\u00a0Digoxina :\u00a0Darunavir/ritonavir \u00a0\naumenta\u00a0las\u00a0concentraciones \u00a0\nplasm\u00e1ticas \u00a0de\u00a0digoxina.\u00a0\n\u00a0Fluticasona \u00a0inh\n.:\u00a0en\u00a0un\u00a0estudio\u00a0\ncaso\u2010control,\u00a0una\u00a0elevada\u00a0\nproporci\u00f3n \u00a0de\u00a0los\u00a0pacientes \u00a0\nexpuestos \u00a0a\u00a0RTV+fluticasona \u00a0(7/8;\u00a0\n88%)\u00a0presentaron \u00a0supresi\u00f3n \u00a0\nadrenal,\u00a0que\u00a0fue\u00a0sintom\u00e1tica \u00a0en\u00a0un\u00a0\n57%\u00a0de\u00a0los\u00a0casos.\u00a0\n\u00a0Inhibidores \u00a0de\u00a0la\u00a0recaptaci\u00f3n \u00a0de\u00a0\nserotonina :\u00a0las\u00a0AUC\u00a0sertralina \u00a0(50\u00a0\nmg/d\u00eda)\u00a0y\u00a0de\u00a0paroxetina \u00a0(20\u00a0\nmg/d\u00eda)\u00a0se\u00a0redujeron \u00a0aprox.\u00a0un\u00a0\n50%\u00a0y\u00a040%,\u00a0respectivamente, \u00a0tras\u00a0\n7\u00a0d\u00edas\u00a0de\u00a0coadministraci\u00f3n \u00a0con\u00a0\nDRV/r.\u00a0\n\u00a0Sildenafilo\n:\u00a0el\u00a0AUC\u00a0de\u00a0sildenafilo \u00a0\nse\u00a0multiplica \u00a0por\u00a04.\u00a0\u00a0Dosis\u00a0inicial:\u00a0\nno\u00a0exceder\u00a025\u00a0mg\u00a0en\u00a0un\u00a0periodo\u00a0\nde\u00a048h\u00a0para\u00a0sildenafilo, \u00a02,5\u00a0mg\u00a0en\u00a0\n72h\u00a0para\u00a0vardenafilo \u00a0y\u00a010\u00a0mg\u00a0en\u00a0\n72h\u00a0para\u00a0tadalafilo. \u00a0\n\u00a0\u00a0\u00a0\u00a0\n(sigue)\u00a0\u00a0\n\u00a0Bupropi\u00f3n\n:\u00a0se\u00a0reducen\u00a0las\u00a0\nconcentraciones \u00a0a\u00a0la\u00a0mitad\u00a0en\u00a0\npresencia \u00a0de\u00a0TPV/r.\u00a0\n\u00a0\nFluticasona \u00a0inh.:\u00a0en\u00a0un\u00a0estudio\u00a0\ncaso\u2010control,\u00a0una\u00a0elevada\u00a0\nproporci\u00f3n \u00a0de\u00a0los\u00a0pacientes \u00a0\nexpuestos \u00a0a\u00a0RTV+fluticasona \u00a0\n(7/8;\u00a088%)\u00a0presentaron \u00a0\nsupresi\u00f3n \u00a0adrenal,\u00a0que\u00a0fue\u00a0\nsintom\u00e1tica \u00a0en\u00a0un\u00a057%\u00a0de\u00a0los\u00a0\ncasos.\u00a0\n\u00a0\nTadalafilo :\u00a0m\u00ednima\u00a0dosis\u00a0cuando\u00a0\nse\u00a0utiliza\u00a0los\u00a0primeros\u00a0d\u00edas\u00a0del\u00a0\ntratamiento \u00a0con\u00a0TPV/r.\u00a0\u00a0Despu\u00e9s\u00a0\nde\u00a07\u201010\u00a0d\u00edas\u00a0de\u00a0tratamiento \u00a0con\u00a0\nTPV/r,\u00a0no\u00a0es\u00a0necesario \u00a0ajustar\u00a0la\u00a0\ndosis\u00a0de\u00a0tadalafilo. \u00a0\n\u00a0\nValaciclovir: \u00a0ausencia\u00a0de\u00a0\ninteracci\u00f3n. \u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\n(sigue)\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 17 \n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0Lopinavir/r \u00a0 Atazanavir \u00a0 Darunavir/r \u00a0 Tipranavir/r \u00a0\n\u00a0Fluticasona \u00a0inh.:\u00a0en\u00a0un\u00a0estudio\u00a0\ncaso\u2010control,\u00a0una\u00a0elevada\u00a0\nproporci\u00f3n \u00a0de\u00a0los\u00a0pacientes \u00a0\nexpuestos \u00a0a\u00a0RTV+fluticasona \u00a0\n(7/8;\u00a088%)\u00a0presentaron \u00a0\nsupresi\u00f3n \u00a0adrenal,\u00a0que\u00a0fue\u00a0\nsintom\u00e1tica \u00a0en\u00a0un\u00a057%\u00a0\u00a0\nde\u00a0los\u00a0casos.\u00a0\u00a0\nAlg\u00fan\u00a0caso\u00a0descrito\u00a0de\u00a0reducci\u00f3n \u00a0\nde\u00a0eficacia\u00a0de\u00a0L\u2010tiroxina .\u00a0\nPosible\u00a0aumento\u00a0Cp\u00a0sildenafilo \u00a0\n(max\u00a025\u00a0mg\u00a0en\u00a0un\u00a0periodo\u00a0de\u00a0\n48h),\u00a0vardenafilo \u00a0(m\u00e1x\u00a02,5\u00a0mg\u00a0\nc/72h)\u00a0y\u00a0\u00a0tadalafilo \u00a0(iniciar\u00a0con\u00a05\u00a0\nmg\u00a0y\u00a0no\u00a0exceder\u00a010\u00a0mg\u00a0c/72h).\u00a0\nVinblastina :\u00a0un\u00a0caso\u00a0de\u00a0\ninteracci\u00f3n \u00a0grave\u00a0con\u00a0LPV/r:\u00a0tras\u00a0\nuna\u00a0dosis\u00a0de\u00a06\u00a0mg/m2\u00a0de\u00a0\nvinblastina \u00a0el\u00a0paciente\u00a0\ndesarroll\u00f3 \u00a0pancitopenia \u00a0de\u00a0\ngrado\u00a04.\u00a0Se\u00a0resolvi\u00f3\u00a0reduciendo \u00a0\nla\u00a0dosis\u00a0a\u00a0la\u00a0mitad.\u00a0\nProductos \u00a0naturales: \u00a0ausencia\u00a0\nde\u00a0interacci\u00f3n \u00a0PK\u00a0con\u00a0Ginkgo\u00a0\nbiloba\u00a0y\u00a0Echinacea \u00a0purpurea .\u00a0\u00a0\n\u00a0\nPuede\u00a0\u2191\u00a0Cp\u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0que\u00a0\nse\u00a0metabolizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\u00a0\nCYP3A43.\u00a0\nPodr\u00eda\u00a0tambi\u00e9n\u00a0\u2191Cp\u00a0(aumento \u00a0\nmucho\u00a0menor)\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0\nque\u00a0se\u00a0metabolizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\n2D6.5\u00a0\u00a0\nPuede\u00a0\u2193Cp\u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0que\u00a0\nse\u00a0metabolizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0\nCYP2C9/19 \u00a06\u00a0\u00f3\u00a0sufren\u00a0\nglucuronidaci\u00f3n.8\u00a0\n\u00a0\u00a0En\u00a0general\u00a0DRV/r\u00a0puede\u00a0aumentar \u00a0\nlas\u00a0concentraciones \u00a0plasm\u00e1ticas \u00a0\nde\u00a0los\u00a0f\u00e1rmacos \u00a0que\u00a0se\u00a0\nmetabolizan \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP3A43\u00a0\n\u00a0Aunque\u00a0con\u00a0TPV/r\u00a0se\u00a0ha\u00a0visto\u00a0\nque\u00a0predomina \u00a0el\u00a0efecto\u00a0\ninhibidor\u00a0enzim\u00e1tico \u00a0de\u00a0RTV,\u00a0se\u00a0\nrecomienda \u00a0mucha\u00a0precauci\u00f3n, \u00a0\nya\u00a0que\u00a0TPV\u00a0ha\u00a0reducido\u00a0los\u00a0\nniveles\u00a0plasm\u00e1ticos \u00a0de\u00a0varios\u00a0IP\u00a0\na\u00fan\u00a0en\u00a0presencia \u00a0de\u00a0RTV.\u00a0\n((\u219368%\u00a0AUC\u00a0ATV,\u00a0\u219370%\u00a0AUC\u00a0de\u00a0\nSQV,\u00a0\u2193\u00a045%\u00a0el\u00a0AUC\u00a0de\u00a0APV,\u00a0y\u00a0\u2193\u00a0\n49%\u00a0el\u00a0AUC\u00a0de\u00a0LPV).\u00a0\u00a0Podr\u00eda\u00a0\nocurrir\u00a0tambi\u00e9n\u00a0con\u00a0otros\u00a0\nf\u00e1rmacos. \u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 18\u00a0\n\u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Lopinavir/r \u00a0 Atazanavir \u00a0 Darunavir/r \u00a0 Tipranavir/r \u00a0\n\u00a0AN\u00a0\u00a0 (ver\u00a0tabla\u00a0AN)\u00a0\n\u00a0NN\u00a0\u00a0 (ver\u00a0tabla\u00a0NN)\u00a0\nIP\u00a0 \u00a0\u00a0 \u00a0 \u00a0\n\u00a0\n\u2010\u00a0IDV\u00a0Datos\u00a0farmacocin\u00e9ticos \u00a0iniciales:\u00a0IDV\u00a0600\u2010\n800\u00a0mg\u00a0c/12h\u00a0\nLPV/r\u00a0NRAD\u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0y\u00a0seguridad \u00a0a\u00a0\nlargo\u00a0plazo\u00a0Al\u00a0igual\u00a0que\u00a0atazanavir, \u00a0indinavir\u00a0se\u00a0ha\u00a0\nasociado\u00a0a\u00a0hiperbilirrubinemia \u00a0(aumento \u00a0\nde\u00a0la\u00a0Bi\u00a0indirecta) \u00a0por\u00a0lo\u00a0que\u00a0no\u00a0se\u00a0\nrecomienda \u00a0asociar\u00a0ambos\u00a0IPs.\u00a0DRV/r\u00a0600/100\u00a0mg\u00a0c/12h.\u00a0\nIDV:\u00a0800\u00a0g\u00a0c/12h\u00a0(600\u00a0mg\u00a0c/12h\u00a0en\u00a0\ncaso\u00a0de\u00a0intolerancia). \u00a0No\u00a0se\u00a0recomienda: \u00a0la\u00a0adici\u00f3n\u00a0de\u00a0TPV\u00a0puede\u00a0\nreducir\u00a0de\u00a0forma\u00a0importante \u00a0los\u00a0niveles\u00a0\nplasm\u00e1ticos \u00a0de\u00a0otros\u00a0IP\u00a0potenciados \u00a0con\u00a0RTV.\u00a0\u00a0\n\u00a0\n\u2010\u00a0RTV\u00a0LPV/r\u00a0400/100\u00a0mg\u00a0c/12h.\u00a0\u00a0\nUna\u00a0dosis\u00a0adicional\u00a0de\u00a0RTV\u00a0100\u00a0mg\u00a0c/12h:\u00a0\n\u219146%\u00a0AUC\u00a0LPV\u00a0y\u00a0x2\u00a0Cmin\u00a0LPV.\u00a0Con\u00a0LPV/r,\u00a0\nlas\u00a0Cmin\u00a0RTV\u00a0son\u00a03\u00a0veces\u00a0menores\u00a0que\u00a0con\u00a0\n100\u00a0mg\u00a0RTV\u00a0c/12h\u00a0asociado\u00a0a\u00a0IDV\u00a0\u00f3\u00a0SQV\u00a0\u00a0ATV/r\u00a0300/100\u00a0mg\u00a0c/24h\u00a0\n\u00a0\u2191\u00a014\u00a0veces\u00a0AUC\u00a0DRV.\u00a0DRV\u00a0esta\u00a0\nindicado\u00a0solamente \u00a0en\u00a0\ncombinaci\u00f3n \u00a0con\u00a0RTV.\u00a0Dosis\u00a0de\u00a0\nDRV/r\u00a0600/100\u00a0mg\u00a0c/12h\u00a0en\u00a0\npacientes \u00a0pretratados \u00a0y\u00a0800/100\u00a0\nmg\u00a0c/24h\u00a0en\u00a0pacientes \u00a0naive.\u00a0TPV/r\u00a0500/200\u00a0mg\u00a0c/12h.\u00a0\n\u00a0\n\u2010\u00a0SQV\u00a0SQV\u00a01000\u00a0mg\u00a0c/12h\u00a0+\u00a0LPV/R\u00a0dosis\u00a0habitual\u00a0\n.\u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0y\u00a0seguridad \u00a0a\u00a0\nlargo\u00a0plazo\u00a0Con\u00a0una\u00a0dosificaci\u00f3n \u00a0de\u00a0SQV/RTV/ATV \u00a0\n1500/100/300 \u00a0mg\u00a0c/24h\u00a0se\u00a0ha\u00a0observado \u00a0\nque\u00a0algunos\u00a0pacientes \u00a0no\u00a0alcanzan\u00a0una\u00a0\nCmin\u00a0adecuada \u00a0de\u00a0SQV,\u00a0por\u00a0lo\u00a0que\u00a0se\u00a0\nrecomienda \u00a0restringir\u00a0su\u00a0uso\u00a0a\u00a0pacientes \u00a0\nnaive\u00a0a\u00a0IP\u00a0con\u00a0CV\u00a0baja\u00a0a\u00a0intermedia. \u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0y\u00a0seguridad \u00a0\na\u00a0largo\u00a0plazo\u00a0No\u00a0recomendado \u00a0(SQV\u00a0sin\u00a0\ncambios;\u00a0\u219326%\u00a0AUC\u00a0de\u00a0darunavir). \u00a0No\u00a0se\u00a0recomienda: \u00a0la\u00a0adici\u00f3n\u00a0de\u00a0TPV\u00a0puede\u00a0\nreducir\u00a0de\u00a0forma\u00a0importante \u00a0los\u00a0niveles\u00a0\nplasm\u00e1ticos \u00a0de\u00a0otros\u00a0IP\u00a0potenciados \u00a0con\u00a0RTV\u00a0\u00a0\n(\u219370%\u00a0AUC\u00a0SQV).\u00a0\n\u2010\u00a0NFV\u00a0 NFV:\u00a01000\u20101250\u00a0mg\u00a0c/12h.\u00a0LPV/r :\u00a0\npacientes \u00a0con\u00a0susceptibilidad \u00a0reducida\u00a0o\u00a0\nexperiencia \u00a0previa\u00a0a\u00a0IP\u00a0pueden\u00a0requerir\u00a0\naumento\u00a0de\u00a0dosis.\u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0y\u00a0seguridad \u00a0a\u00a0\nlargo\u00a0plazo\u00a0\u00a0\nNo\u00a0hay\u00a0datos\u00a0\u00a0\nNo\u00a0hay\u00a0datos\u00a0No\u00a0se\u00a0recomienda: \u00a0la\u00a0adici\u00f3n\u00a0de\u00a0TPV\u00a0puede\u00a0\nreducir\u00a0de\u00a0forma\u00a0importante \u00a0los\u00a0niveles\u00a0\nplasm\u00e1ticos \u00a0de\u00a0otros\u00a0IP.\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 19\u00a0\n\u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Lopinavir/r \u00a0 Atazanavir \u00a0 Darunavir/r \u00a0 Tipranavir/r \u00a0\n\u2010FPV\u00a0 Si\u00a0se\u00a0requiere\u00a0usar\u00a0esta\u00a0combinaci\u00f3n, \u00a0se\u00a0\nrecomienda \u00a0monitorizar \u00a0niveles\u00a0\nplasm\u00e1ticos \u00a0(como\u00a0dosis\u00a0inicial\u00a0puede\u00a0\nemplearse \u00a01400\u00a0mg\u00a0c/12h\u00a0de\u00a0FOS\u2010APV\u00a0con\u00a0\n600/150\u00a0mg\u00a0c/12h\u00a0de\u00a0LPV/r.\u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0y\u00a0seguridad \u00a0a\u00a0\nlargo\u00a0plazo\u00a0ATV\u00a0300\u2010400\u00a0mg\u00a0c/24h\u00a0(\u00f3\u00a0repartidos \u00a0\nc/12h)\u00a0+\u00a0FPV/r\u00a0700/100\u00a0mg\u00a0c/12h\u00a0\u00f3\u00a0\n1400/100 \u2010200\u00a0mg\u00a0c/24h\u00a0(datos\u00a0\nfarmacocin\u00e9ticos \u00a0\u00a0iniciales). \u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0y\u00a0seguridad \u00a0\na\u00a0largo\u00a0plazo\u00a0\u00a0\nNo\u00a0hay\u00a0datos\u00a0No\u00a0se\u00a0recomienda: \u00a0la\u00a0adici\u00f3n\u00a0de\u00a0TPV\u00a0puede\u00a0\nreducir\u00a0de\u00a0forma\u00a0importante \u00a0los\u00a0niveles\u00a0\nplasm\u00e1ticos \u00a0de\u00a0otros\u00a0IP\u00a0potenciados \u00a0con\u00a0RTV.\u00a0\n(Algunos\u00a0autores\u00a0han\u00a0logrado\u00a0niveles\u00a0\nadecuados \u00a0monitorizando \u00a0y\u00a0aumentando \u00a0la\u00a0\ndosis\u00a0de\u00a0FPV/r\u00a0a\u00a0\u00a01400/200 \u00a0mg\u00a0c/12h\u00a0en\u00a0\ncombinaci\u00f3n \u00a0con\u00a0TPV\u00a0(500\u00a0mg\u00a0c/12h).\u00a0Sin\u00a0\nembargo, \u00a0dada\u00a0la\u00a0elevada\u00a0variabilidad \u00a0\ninterindividual, \u00a0algunos\u00a0pacientes \u00a0podr\u00edan\u00a0no\u00a0\nalcanzar\u00a0niveles\u00a0adecuados. \u00a0Experiencia \u00a0\nlimitada). \u00a0\n\u2010\u00a0LPV/r\u00a0\u00a0 Datos\u00a0farmacocin\u00e9ticos \u00a0iniciales:\u00a0ATV\u00a0\n300\u00a0mg\u00a0c/24h\u00a0+\u00a0LPV/r\u00a0400/100\u00a0mg\u00a0\nc/12h.\u00a0\nNo\u00a0existen\u00a0datos\u00a0de\u00a0eficacia\u00a0y\u00a0seguridad \u00a0\na\u00a0largo\u00a0plazo\u00a0Contraindicado \u00a0(\u219340%\u00a0AUC\u00a0DRV).\u00a0No\u00a0se\u00a0recomienda: \u00a0la\u00a0adici\u00f3n\u00a0de\u00a0TPV\u00a0puede\u00a0\nreducir\u00a0de\u00a0forma\u00a0importante \u00a0los\u00a0niveles\u00a0\nplasm\u00e1ticos \u00a0de\u00a0otros\u00a0IP\u00a0potenciados \u00a0con\u00a0RTV\u00a0\n(\u219349%\u00a0AUC\u00a0LPV).\u00a0\u00a0\n(Algunos\u00a0autores\u00a0han\u00a0logrado\u00a0niveles\u00a0\nadecuados \u00a0monitorizando \u00a0y\u00a0aumentando \u00a0la\u00a0\ndosis\u00a0de\u00a0LPV/r\u00a0a\u00a0\u00a0400/300\u00a0mg\u00a0c/12h\u00a0\u00f3\u00a0533/233\u00a0\nmg\u00a0c/12h\u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0TPV\u00a0(500\u00a0mg\u00a0\nc/12h).\u00a0Sin\u00a0embargo, \u00a0dada\u00a0la\u00a0elevada\u00a0\nvariabilidad \u00a0interindividual, \u00a0algunos\u00a0pacientes \u00a0\npodr\u00edan\u00a0no\u00a0alcanzar\u00a0niveles\u00a0adecuados. \u00a0\nExperiencia \u00a0limitada). \u00a0\n\u2010\u00a0ATV\u00a0\u00a0 \u00a0 NRAD\u00a0 No\u00a0se\u00a0recomienda: \u00a0la\u00a0adici\u00f3n\u00a0de\u00a0TPV\u00a0puede\u00a0\nreducir\u00a0de\u00a0forma\u00a0importante \u00a0los\u00a0niveles\u00a0\nplasm\u00e1ticos \u00a0de\u00a0otros\u00a0IP\u00a0potenciados \u00a0con\u00a0RTV\u00a0\n(\u219368%\u00a0AUC\u00a0ATV)\u00a0\n\u00a0\n\u2010\u00a0DRV/r\u00a0\u00a0 \u00a0 \u00a0 No\u00a0hay\u00a0datos\u00a0\n\u00a0\nAUC:\u00a0\u00e1rea\u00a0bajo\u00a0la\u00a0curva;\u00a0BID:\u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda;\u00a0Cp:\u00a0concentraciones \u00a0plasm\u00e1ticas; \u00a0I:\u00a0Invirase\u00ae; \u00a0IT:\u00a0interacci\u00f3n; \u00a0NRAD :\u00a0no\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis;\u00a0NS:\u00a0no\u00a0significativa; \u00a0QD:una\u00a0vez\u00a0al\u00a0d\u00eda.\u00a0\n\u00a0\n0\u00a0En\u00a0pacientes \u00a0coinfectados \u00a0con\u00a0VIH\u00a0y\u00a0tuberculosis \u00a0con\u00a0inmunosupresi\u00f3n \u00a0avanzada \u00a0(CD4\u00a0<100\u00a0c\u00e9l/mm3) \u00a0en\u00a0tratamiento \u00a0con\u00a0rifampicina \u00a0\u00f3\u00a0rifabutina \u00a02\u00a0veces\u00a0por\u00a0semana\u00a0se\u00a0ha\u00a0descrito\u00a0la\u00a0\napareci\u00f3n \u00a0de\u00a0\u00a0resistencia \u00a0a\u00a0rifamicinas. \u00a0Tambi\u00e9n\u00a0se\u00a0han\u00a0descrito\u00a0varios\u00a0casos\u00a0de\u00a0fracaso\u00a0del\u00a0tratamiento \u00a0antituberculoso \u00a0con\u00a0aparici\u00f3n \u00a0de\u00a0resistencias \u00a0en\u00a0pacientes \u00a0con\u00a0inmunosupresi\u00f3n \u00a0\navanzada \u00a0tratados\u00a0con\u00a0IPs\u00a0\u00a0potenciados \u00a0y\u00a0rifabutina \u00a0150\u00a0mg\u00a0c/48h\u00a0\u00f3\u00a0tres\u00a0veces\u00a0por\u00a0semana.\u00a0En\u00a0estos\u00a0pacientes \u00a0valorar\u00a0dosis\u00a0mayores: \u00a0300\u00a0mg\u00a0rifabutina \u00a0tres\u00a0veces\u00a0por\u00a0semana.\u00a0\n1\u00a0ClCr\u00a030\u201060\u00a0ml/min:\u00a0reducir\u00a0un\u00a050%,\u00a0ClCr\u00a0<30\u00a0ml/min:\u00a0reducir\u00a0un\u00a075%\u00a0(m\u00e1x.\u00a01g/d\u00eda).\u00a0\u00a0\n2\u00a0SQV\u00a0(I\u00a0\u00f3\u00a0F)\u00a0junto\u00a0con\u00a0RTV\u00a0(400/400\u00a0mg\u00a0c/12h\u00a0\u00f3\u00a01000/100 \u00a0mg\u00a0c/12h)\u00a0pueden\u00a0administrarse \u00a0con\u00a0la\u00a0dosis\u00a0habitual\u00a0de\u00a0rifampicina \u00a0o\u00a0dosis\u00a0reducidas \u00a0de\u00a0rifabutina \u00a0(150\u00a0mg\u00a0\u00a03veces\u00a0\n/semana)(experiencia \u00a0limitada\u00a0\n3\u00a0Principales \u00a0f\u00e1rmacos\u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP3A4:\u00a0alprazolam, \u00a0amiodarona, \u00a0amlodipino, \u00a0ciclofosfamida, \u00a0ciclosporina, \u00a0clonacepam, \u00a0cloracepato, \u00a0dextropropoxifeno, \u00a0diazepam, \u00a0\ndiltiazem, \u00a0disopiramida, \u00a0estazolam, \u00a0etionamida, \u00a0etosuximida, \u00a0felodipino, \u00a0fentanilo, \u00a0finasterida, \u00a0flunaricina, \u00a0fluracepam, \u00a0lacidipino, \u00a0lidoca\u00edna, \u00a0loratadina, \u00a0meperidina, \u00a0nicardipino, \u00a0nifedipino, \u00a0\nnimodipino, \u00a0nitrendipino, \u00a0prednisona, \u00a0quinidina, \u00a0quinina,\u00a0sertralina, \u00a0sildenafilo \u00a0(Viagra\u00ae),\u00a0vardenafilo, \u00a0tadalafilo, \u00a0tacrolimus, \u00a0verapamilo, \u00a0vincristina \u00a0y\u00a0zolpidem. \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 204\u00a0RTV\u00a0pueder\u00a0aumentar \u00a0hasta\u00a03\u00a0veces\u00a0el\u00a0AUC\u00a0de\u00a0los\u00a0siguiente\u00a0f\u00e1rmacos \u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP3A:\u00a0alfentanilo, \u00a0antagonistas \u00a0del\u00a0calcio\u00a0(amlodipino, \u00a0diltiazem, \u00a0felodipino, \u00a0nicardipino, \u00a0\nnifedipino, \u00a0nisoldipino, \u00a0verapamilo), \u00a0carbamacepina, \u00a0ciclosporina, \u00a0citost\u00e1ticos \u00a0(etop\u00f3sido, \u00a0paclitaxel, \u00a0tamoxifeno, \u00a0vinblastina \u00a0y\u00a0vincristina), \u00a0clonacepam, \u00a0dexametasona, \u00a0disopiramida, \u00a0\neritromicina, \u00a0etosuximida, \u00a0fentanilo, \u00a0lidoca\u00edna, \u00a0loratadina, \u00a0nefazodona, \u00a0ondansetron, \u00a0prednisona, \u00a0quinina,\u00a0rifampicina, \u00a0sertralina, \u00a0sildenafilo, \u00a0tacrolimus, \u00a0taxol\u00a0y\u00a0trazodona, \u00a0entre\u00a0otros.\u00a0\n5\u00a0Aumento \u00a0de\u00a01.5\u00a0a\u00a03\u00a0veces\u00a0en\u00a0el\u00a0AUC\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP2D6:\u00a0amitriptilina, \u00a0clomipramina, \u00a0clorpromacina, \u00a0desipramina, \u00a0fluoxetina, \u00a0haloperidol, \u00a0imipramina, \u00a0\nmaprotilina, \u00a0metoprolol, \u00a0mexiletina, \u00a0nortriptilina, \u00a0paroxetina, \u00a0perfenazina, \u00a0pindolol,\u00a0propranolol, \u00a0risperidona, \u00a0timolol,\u00a0tioridacina, \u00a0tramadol\u00a0y\u00a0venlafaxina. \u00a0\n6\u00a0F\u00e1rmacos \u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP2C9/19: \u00a0diclofenac, \u00a0ibuprofeno, \u00a0indometacina, \u00a0fenito\u00edna, \u00a0gliburida, \u00a0glipizida,\u00a0\u00a0lansoprazol, \u00a0losartan,\u00a0omeprazol, \u00a0proguanilo \u00a0y\u00a0tolbutamida. \u00a0\n7teofilina,\u00a0tacrina,\u00a0clozapina, \u00a0tacrina.\u00a0\n8\u00a0atovaquona, \u00a0clofibrato, \u00a0code\u00edna,\u00a0difenoxilato, \u00a0ketoprofeno, \u00a0ketorolaco, \u00a0lamotrigina, \u00a0loracepam, \u00a0metoclopramida, \u00a0morfina,\u00a0naproxeno, \u00a0oxacepam, \u00a0propofol, \u00a0temacepam \u00a0y\u00a0valproico. \u00a0\u00a0\na.\u00a0La\u00a0EMEA\u00a0ha\u00a0emitido\u00a0la\u00a0autorizaci\u00f3n \u00a0de\u00a0este\u00a0f\u00e1rmaco\u00a0s\u00f3lo\u00a0para\u00a0pacientes \u00a0pretratados, \u00a0a\u00a0la\u00a0dosis\u00a0de\u00a0300mg\u00a0ATV/100\u00a0mg\u00a0de\u00a0ritonavir.\u00a0\n9\u00a0Atazanavir/ritonavir \u00a0puede\u00a0administrarse \u00a0junto\u00a0con\u00a0antihistam\u00ednicos \u00a0H2\u00a0(estudio\u00a0realizado\u00a0con\u00a0famotidina) \u00a0sin\u00a0que\u00a0se\u00a0requiera\u00a0espaciarlos. \u00a0Si\u00a0el\u00a0atazanavir \u00a0no\u00a0se\u00a0potencia\u00a0con\u00a0ritonavir,\u00a0se\u00a0\nrecomienda \u00a0administrarlo \u00a02h\u00a0antes\u00a0del\u00a0antihistam\u00ednico \u00a0H2.\u00a0\u00a0\u00a0\n10\u00a0Seg\u00fan\u00a0datos\u00a0iniciales\u00a0el\u00a0midazolam \u00a0intravenoso \u00a0podr\u00eda\u00a0administrarse \u00a0junto\u00a0con\u00a0los\u00a0inhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0reduciendo \u00a0la\u00a0dosis\u00a0y\u00a0bajo\u00a0estrecha\u00a0monitorizaci\u00f3n \u00a0cl\u00ednica\u00a0(UCI\u00a0o\u00a0similar).\u00a0\u00a0Sin\u00a0\nembargo, \u00a0el\u00a0midazolam \u00a0oral\u00a0est\u00e1\u00a0contraindicado. \u00a0\n11\u00a0ATV\u00a0no\u00a0potenciado \u00a0nunca\u00a0debe\u00a0asociarse \u00a0a\u00a0IBP.\u00a0ATV/r\u00a0no\u00a0debe\u00a0asociarse \u00a0a\u00a0IBP\u00a0en\u00a0pacientes \u00a0pretratados. \u00a0En\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0podr\u00eda\u00a0emplearse \u00a0un\u00a0m\u00e1ximo\u00a0de\u00a020\u00a0mg\u00a0de\u00a0\nomeprazol \u00a0junto\u00a0con\u00a0ATV/r,\u00a0espaci\u00e1ndolos \u00a012\u00a0horas.\u00a0En\u00a0cualquier \u00a0caso\u00a0se\u00a0evitar\u00e1\u00a0la\u00a0administraci\u00f3n \u00a0de\u00a0ATV\u00a0en\u00a0las\u00a0primeras\u00a0horas\u00a0tras\u00a0administrar \u00a0un\u00a0IBP.\u00a0\n12\u00a0Con\u00a0ATV/r,\u00a0puede\u00a0emplearse \u00a0una\u00a0dosis\u00a0m\u00e1xima\u00a0de\u00a0famotidina \u00a0de\u00a040\u00a0mg\u00a0c/12h\u00a0en\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0\u00f3\u00a0de\u00a020\u00a0mg\u00a0c/12h\u00a0en\u00a0pacientes \u00a0pretratados \u00a0(el\u00a0ARV\u00a0se\u00a0administrar\u00e1 \u00a0\nsimult\u00e1neamente \u00a0a\u00a0fin\u00a0de\u00a0que\u00a0el\u00a0ATV/r\u00a0se\u00a0haya\u00a0absorbido \u00a0cuando\u00a0act\u00fae\u00a0el\u00a0anti\u2010H2,\u00a0o\u00a010\u00a0h\u00a0despu\u00e9s\u00a0del\u00a0anti\u2010H2).\u00a0Cuando\u00a0deba\u00a0emplearse \u00a0un\u00a0anti\u2010H2\u00a0junto\u00a0con\u00a0TDF\u00a0y\u00a0ATV/r\u00a0se\u00a0aumentar\u00e1 \u00a0la\u00a0\ndosis\u00a0de\u00a0ATV/r\u00a0a\u00a0400/100\u00a0mg\u00a0c/24h.\u00a0En\u00a0tratamiento \u00a0inicial,\u00a0si\u00a0s\u00f3lo\u00a0puede\u00a0emplearse \u00a0ATV\u00a0no\u00a0potenciado, \u00a0se\u00a0utilizar\u00e1\u00a0una\u00a0dosis\u00a0m\u00e1xima\u00a0de\u00a020\u00a0mg\u00a0en\u00a0una\u00a0toma\u00a0y\u00a020\u00a0mg\u00a0c/12h\u00a0en\u00a0total\u00a0de\u00a0\nfamotidina \u00a0(ATV\u00a0se\u00a0administrar\u00e1 \u00a0en\u00a0este\u00a0caso\u00a02\u00a0horas\u00a0antes,\u00a0para\u00a0asegurar\u00a0su\u00a0absorci\u00f3n \u00a0en\u00a0ausencia\u00a0de\u00a0RTV,\u00a0\u00a0\u00f3\u00a010h\u00a0despu\u00e9s\u00a0del\u00a0anti\u2010H2).\u00a0En\u00a0cualquier \u00a0caso,\u00a0se\u00a0evitar\u00e1\u00a0la\u00a0administraci\u00f3n \u00a0del\u00a0\nATV\u00a0dentro\u00a0de\u00a0las\u00a0primeras\u00a0horas\u00a0tras\u00a0la\u00a0administraci\u00f3n \u00a0de\u00a0un\u00a0anti\u2010H2.\u00a0\n\u00a0NOTA:\u00a0debido\u00a0a\u00a0\u00a0que\u00a0la\u00a0informaci\u00f3n \u00a0cient\u00edfica\u00a0relacionada \u00a0con\u00a0los\u00a0f\u00e1rmacos\u00a0antirretrovirales \u00a0se\u00a0renueva\u00a0constantemente, \u00a0se\u00a0recomienda \u00a0consultar \u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0y\u00a0la\u00a0\ninformaci\u00f3n \u00a0actualizada \u00a0ofrecida\u00a0por\u00a0las\u00a0distintas\u00a0compa\u00f1\u00edas \u00a0farmac\u00e9uticas \u00a0y\u00a0las\u00a0autoridades \u00a0sanitarias.\n\u00a0\n\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n 1\u00a0\n\u00a0\n\u00a0\nTabla\u00a08.\u00a0Antagonistas \u00a0del\u00a0correceptor \u00a0CCR5\u00a0e\u00a0inhibidores \u00a0integrasa \u00a0\n\u00a0\nGrupo\u00a0terap\u00e9utico \u00a0 Antagonistas correceptor \u00a0CCR5 Inhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0\nNombre\u00a0gen\u00e9rico\u00a0 Maraviroc \u00a01\u00a0Raltegravir \u00a0\n\u00a0\nNombre\u00a0comercial \u00a0\n\u00a0Celsentri\u00ae \u00a0 Isentress\u00ae \u00a0\nDosis\u00a0\u00a0\n\u00a0\u00a0\n\u00a0\nRecomendaci\u00f3n \u00a0150,\u00a0300\u00a0\u00f3\u00a0600\u00a0mg\u00a0BID\u00a0dependiendo \u00a0de\u00a0las\u00a0\ninteracciones \u00a0con\u00a0otros\u00a0f\u00e1rmacos. \u00a0300\u00a0mg\u00a0BID\u00a0en\u00a0\nausencia\u00a0de\u00a0inhibidores \u00a0o\u00a0inductores \u00a0de\u00a0CYP3A4.\u00a0\nPuede\u00a0tomarse\u00a0con\u00a0o\u00a0sin\u00a0alimentos. \u00a0400\u00a0mg\u00a0BID\u00a0\n\u00a0\n\u00a0\nPuede\u00a0tomarse\u00a0con\u00a0o\u00a0sin\u00a0alimentos. \u00a0\nPresentaci\u00f3n \u00a0comercial \u00a0 compr\u00a0de\u00a0150\u00a0y\u00a0de\u00a0300\u00a0mg compr\u00a0de\u00a0400\u00a0mg\u00a0\n\u00a0\nBiodisponibilidad \u00a0Oral\u00a0\n\u00a023\u201033%\u00a0 86%\u00a0\nSemivida \u00a0de\u00a0eliminaci\u00f3n \u00a0\nplasm\u00e1tica \u00a014\u201018\u00a0horas\u00a0 9\u00a0horas\u00a0\nCmax\u00a0 0,618\u00a0\u03bcg/mL\u00a0 4,5\u00a0\u03bcM\u00a0\nCmin\u00a0 0,034\u00a0\u03bcg/mL\u00a0 142\u00a0nM\u00a0\nConcentraci\u00f3n \u00a0inhibitoria \u00a0 CI90:\u00a02\u00a0nM/mL\u00a0 CI95:\u00a031\u00a0nM/mL\u00a0\n\u00a0\nActividad \u00a0\n\u00a0VIH\u20101\u00a0tropismo\u00a0R5\u00a0 VIH\u20101\u00a0y\u00a0VIH\u20102,\u00a0tropismo\u00a0R5,\u00a0X4\u00a0y\u00a0dual\u00a0\nRestricci\u00f3n \u00a0diet\u00e9tica\u00a0\u00a0 Con\u00a0o\u00a0sin\u00a0alimentos Con\u00a0o\u00a0sin\u00a0alimentos \u00a0\n\u00a0\nMetabolizaci\u00f3n \u00a0\n\u00a0CYP3A4\u00a0\n(No\u00a0inductor,\u00a0ni\u00a0inhibidor) \u00a0Glucuronidaci\u00f3n \u00a0(UGT1A1) \u00a0\n(No\u00a0inductor,\u00a0ni\u00a0inhibidor\u00a0de\u00a0CYP3A4\u00a0ni\u00a0\nde\u00a0UGT1A1)\u00a0\nEfectos\u00a0\nAdversos \u00a0N\u00e1useas,\u00a0v\u00f3mitos,\u00a0flatulencia, \u00a0dolor\u00a0abdominal\nParestesia, \u00a0disgeusia. \u00a0\nErupci\u00f3n\u00a0cut\u00e1nea.\u00a0\nAstenia.\u00a0Diarrea,\u00a0nauseas.\u00a0\nCefalea\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n 2\u00a0\nNombre\u00a0gen\u00e9rico\u00a0 Maraviroc \u00a0\u00a0\u00a0\nRaltegravir \u00a0\n\u00a0\nInteracciones \u00a0\u00a0\n\u00a0\nAsociaciones \u00a0contraindicadas \u00a0Hypericum \u00a0perforatum (Hierba\u00a0de\u00a0San\u00a0Juan) No\u00a0se\u00a0han\u00a0descrito.\u00a0\nAnti\u00e1cidos \u00a0\n\u00a0\nAntihistam\u00ednicos \u00a0H2\u00a0\n\u00a0\nInhibidores \u00a0Bomba\u00a0protones \u00a0\n\u00a0\n\u00a0No\u00a0hay\u00a0datos\u00a0\n\u00a0\nNo\u00a0hay\u00a0datos\u00a0\n\u00a0\nNo\u00a0hay\u00a0datos\u00a0Anti\u00e1cidos \u00a0y\u00a0anti\u2010H2:\u00a0No\u00a0hay\u00a0datos\u00a0\n\u00a0\nIBP:\u00a0en\u00a0voluntarios \u00a0sanos\u00a0\u2191x3\u00a0AUC,\u00a0\u2191\u00a046%\u00a0\nCmin\u00a0RAL.\u00a0Datos\u00a0en\u00a0pacientes \u00a0evidencian \u00a0un\u00a0\nmenor\u00a0grado\u00a0de\u00a0interacci\u00f3n \u00a0(\u2191\u00a021%\u00a0Cmin\u00a0de\u00a0\nRAL),\u00a0sin\u00a0que\u00a0se\u00a0observe\u00a0aumento\u00a0de\u00a0efectos\u00a0\nadversos. \u00a0Probablemente \u00a0escasa\u00a0\nrepercusi\u00f3n \u00a0cl\u00ednica\u00a0en\u00a0la\u00a0mayor\u00eda\u00a0de\u00a0los\u00a0\npacientes \u00a0\n\u00a0\nAntimicobact. \u00a0\u00a0\n\u2010\u00a0Rifampicina \u00a0 Dosis\u00a0de\u00a0maraviroc \u00a0600\u00a0mg\u00a0c/12h\u00a0en\u00a0ausencia\u00a0de\u00a0\ninhibidores \u00a0enzim\u00e1ticos \u00a0potentes. \u00a01\u00a0Rifampicina \u00a0redujo\u00a0un\u00a061%\u00a0la\u00a0Cmin\u00a0de\u00a0\nraltegravir \u00a0y\u00a0un\u00a040%\u00a0el\u00a0AUC.\u00a0Valorar\u00a0\naumento\u00a0de\u00a0dosis\u00a0de\u00a0raltegravir \u00a0a\u00a0800\u00a0mg\u00a0\nc/12h.\u00a0\n\u2010\u00a0Rifabutina \u00a0(RFB)\u00a0 No\u00a0hay\u00a0datos\u00a0 NRAD\n\u00a0\n\u2010\u00a0Claritromicina \u00a0 Dosis\u00a0de\u00a0maraviroc \u00a0a\u00a0150\u00a0mg\u00a0c/12h\u00a0en\u00a0combinaci\u00f3n \u00a0\ncon\u00a0claritromicina \u00a0o\u00a0eritromicina. \u00a0\nAntiepil\u00e9pticos :\u00a0\n\u00a0\u2010 Carbamazepina, \u00a0fenito\u00edna, \u00a0\nfenobarbital, \u00a0lamotrigina \u00a0\u00a0\nDosis\u00a0de\u00a0maraviroc \u00a0600\u00a0mg\u00a0c/12h\u00a0en\u00a0ausencia\u00a0de\u00a0\ninhibidores \u00a0enzim\u00e1ticos \u00a0potentes. \u00a01\u00a0Carbamacepina, \u00a0fenito\u00edna, \u00a0fenobarbital:\nValorar\u00a0aumento\u00a0de\u00a0dosis\u00a0de\u00a0raltegravir \u00a0a\u00a0\n800\u00a0mg\u00a0c/12h\u00a0(no\u00a0es\u00a0una\u00a0recomendaci\u00f3n \u00a0\nformal\u00a0del\u00a0laboratorio). \u00a0\nLamotrigina: \u00a0ausencia\u00a0de\u00a0interacci\u00f3n \u00a0PK\u00a0\nAnticoagulantes \u00a0orales\u00a0\n\u00a0No\u00a0hay\u00a0datos\u00a0 No\u00a0hay\u00a0datos\nAnticonceptivos \u00a0orales :\u00a0 Ausencia\u00a0de\u00a0interacci\u00f3n Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0\nAntif\u00fangicos \u00a0imidaz\u00f3licos \u00a0 Itraconazol \u00a0y\u00a0ketoconazol: \u00a0se\u00a0recomienda \u00a0reducir\u00a0la\u00a0\ndosis\u00a0de\u00a0maraviroc \u00a0a\u00a0150\u00a0mg\u00a0c/12h.\u00a0\nFluconazol: \u00a0los\u00a0estudios\u00a0farmacocin\u00e9ticos \u00a0\npoblacionales \u00a0sugieren\u00a0que\u00a0no\u00a0se\u00a0requiere\u00a0ajuste\u00a0de\u00a0\ndosis\u00a0de\u00a0maraviroc. \u00a0Sin\u00a0embargo, \u00a0maraviroc \u00a0300\u00a0mg\u00a0\nc/12h\u00a0debe\u00a0administrarse \u00a0con\u00a0precauci\u00f3n \u00a0cuando\u00a0se\u00a0\nadministre \u00a0con\u00a0fluconazol \u00a0hasta\u00a0disponer\u00a0de\u00a0m\u00e1s\u00a0\ndatos.\u00a0No\u00a0es\u00a0de\u00a0esperar\u00a0que\u00a0raltegravir \u00a0presente\u00a0\ninteracci\u00f3n \u00a0importante \u00a0con\u00a0los\u00a0antif\u00fangicos \u00a0\nimidaz\u00f3licos. \u00a0\nEstatinas: \u00a0 No\u00a0es\u00a0de\u00a0esperar\u00a0que\u00a0maraviroc \u00a0presente\u00a0interacci\u00f3n \u00a0\nimportante \u00a0con\u00a0las\u00a0estatinas. \u00a0No\u00a0es\u00a0de\u00a0esperar\u00a0que\u00a0raltegravir \u00a0presente\u00a0\ninteracci\u00f3n \u00a0importante \u00a0con\u00a0las\u00a0estatinas. \u00a0\nF\u00e1rmacos \u00a0empleados \u00a0para\u00a0\ntratar\u00a0la\u00a0influenza \u00a0Amantadina \u00a0/\u00a0oseltamivir \u00a0/zanamivir: \u00a0Te\u00f3ricamente \u00a0no\u00a0deben\u00a0esperarse \u00a0interacciones \u00a0\nInmunosupresores :\u00a0\n\u00a0No\u00a0hay\u00a0datos\u00a0 Te\u00f3ricamente \u00a0con\u00a0RAL\u00a0no\u00a0caben\u00a0esperar\u00a0\ninteracciones. \u00a0Datos\u00a0iniciales\u00a0sobre\u00a0el\u00a0uso\u00a0\nseguro\u00a0de\u00a0RAL\u00a0con\u00a0sirolimus, \u00a0tacrolimus \u00a0y\u00a0\nciclosporina. \u00a0\nInterfer\u00f3n/ \u00a0\nRibavirina \u00a0No\u00a0es\u00a0de\u00a0esperar\u00a0que\u00a0maraviroc \u00a0presente\u00a0interacci\u00f3n \u00a0\nimportante \u00a0con\u00a0interferon \u00a0alfa\u00a0ni\u00a0con\u00a0ribavirina. \u00a0Te\u00f3ricamente \u00a0RAL\u00a0no\u00a0caben\u00a0esperar\u00a0\ninteracciones \u00a0\nMetadona(MT) \u00a0y\u00a0otros\u00a0opi\u00e1ceos\u00a0No\u00a0es\u00a0de\u00a0esperar\u00a0que\u00a0maraviroc \u00a0presente\u00a0interacci\u00f3n \u00a0\nimportante \u00a0con\u00a0la\u00a0metadona. \u00a0RAL\u00a0no\u00a0modifica\u00a0las\u00a0concentraciones \u00a0de\u00a0\nmetadona \u00a0\nOtros\u00a0f\u00e1rmacos \u00a0 Cotrimoxazol: \u00a0ausencia\u00a0de\u00a0interacci\u00f3n \u00a0Midazolam: \u00a0\nausencia\u00a0de\u00a0interacci\u00f3n \u00a0\nNefazodona: \u00a0debido\u00a0al\u00a0efecto\u00a0inhibidor\u00a0enzim\u00e1tico \u00a0\npotente\u00a0de\u00a0nefazodona, \u00a0se\u00a0recomienda \u00a0reducir\u00a0la\u00a0\ndosis\u00a0de\u00a0maraviroc \u00a0a\u00a0la\u00a0mitad\u00a0\u00a0(150\u00a0mg\u00a0c/12h)\u00a0Ezetimiba: \u00a0NRAD\u00a0\nMidazolam: \u00a0ausencia\u00a0de\u00a0interacci\u00f3n. \u00a0\u00a0\nUna\u00a0interacci\u00f3n \u00a0con\u00a0los\u00a0f\u00e1rmacos \u00a0utilizados \u00a0\npara\u00a0la\u00a0disfunci\u00f3n \u00a0er\u00e9ctil\u00a0(sildenafilo, \u00a0\nvardenafilo \u00a0o\u00a0tadalafilo) \u00a0es\u00a0poco\u00a0probable. \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n 3\u00a0\nNombre\u00a0gen\u00e9rico\u00a0 Maraviroc \u00a0\u00a0Raltegravir \u00a0\n\u00a0AN\u00a0\u00a0 (ver\u00a0tabla\u00a0AN)\u00a0 (ver\u00a0tabla\u00a0AN)\u00a0\n\u00a0NN\u00a0\u00a0 (ver\u00a0tabla\u00a0NN)\u00a0 (ver\u00a0tabla\u00a0NN)\u00a0\nIP\u00a0 \u00a0\n\u2010\u00a0RTV\u00a0 Reducir\u00a0la\u00a0dosis\u00a0de\u00a0maraviroc \u00a0a\u00a0la\u00a0mitad\u00a0\u00a0(150\u00a0mg\u00a0\nc/12h)\u00a0Ausencia\u00a0de\u00a0interacci\u00f3n \u00a0o\u00a0cl\u00ednicamente \u00a0no\u00a0\nsignificativa \u00a0\n\u2010\u00a0IDV\u00a0 Reducir\u00a0la\u00a0dosis\u00a0de\u00a0maraviroc \u00a0a\u00a0la\u00a0mitad\u00a0(150\u00a0mg\u00a0\nc/12h)\u00a0Te\u00f3ricamente, \u00a0no\u00a0es\u00a0de\u00a0esperar\u00a0una\u00a0interacci\u00f3n \u00a0\nimportante. \u00a0\n\u2010\u00a0SQV\u00a0 Reducir\u00a0la\u00a0dosis\u00a0de\u00a0maraviroc \u00a0a\u00a0la\u00a0mitad\u00a0\u00a0(150\u00a0mg\u00a0\nc/12h)\u00a0Te\u00f3ricamente, \u00a0no\u00a0es\u00a0de\u00a0esperar\u00a0una\u00a0interacci\u00f3n \u00a0\nimportante. \u00a0\n\u2010\u00a0NFV\u00a0 Reducir\u00a0la\u00a0dosis\u00a0de\u00a0maraviroc \u00a0a\u00a0la\u00a0mitad\u00a0\u00a0(150\u00a0mg\u00a0\nc/12h)\u00a0No\u00a0hay\u00a0datos\n\u2010FPV\u00a0 No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis. Un\u00a0estudio\u00a0en\u00a0voluntarios \u00a0sanos\u00a0ha\u00a0demostrado \u00a0\nuna\u00a0reducci\u00f3n \u00a0de\u00a0Cp\u00a0de\u00a0ambos\u00a0(RAL:\u00a0\u2193\u00a015\u201055%\u00a0\nAUC,\u00a0\u219325\u201068%\u00a0Cmin;\u00a0FPV:\u00a0\u2193\u00a00\u201036%\u00a0AUC,\u00a0\u2193\u00a017\u2010\n50%\u00a0Cmin).\u00a0Los\u00a0niveles\u00a0resultantes \u00a0fueron\u00a0\nsuperiores \u00a0a\u00a0x2\u00a0veces\u00a0la\u00a0IC90\u00a0para\u00a0ambos\u00a0\nf\u00e1rmacos, \u00a0pero\u00a0podr\u00eda\u00a0tener\u00a0importancia \u00a0en\u00a0\npretratados. \u00a0\n\u2010\u00a0LPV/r\u00a0 Reducir\u00a0la\u00a0dosis\u00a0de\u00a0maraviroc \u00a0a\u00a0la\u00a0mitad\u00a0\u00a0(150\u00a0mg\u00a0\nc/12h)\u00a0NRAD\n\u2010\u00a0ATV\u00a0 Reducir\u00a0la\u00a0dosis\u00a0de\u00a0maraviroc \u00a0a\u00a0la\u00a0mitad\u00a0\u00a0(150\u00a0mg\u00a0\nc/12h)\u00a0NRAD\u00a0(Con\u00a0ATV/r\u00a0300/100\u00a0mg/24h\u00a0\u219141%\u00a0AUC\u00a0RAL\u00a0\nsin\u00a0toxicidad). \u00a0\u00a0\n\u2010TPV/r\u00a0 No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis.\u00a0Monitorizar \u00a0transaminasas NRAD\u00a0(\u2193\u00a024%\u00a0AUC\u00a0y\u00a055%\u00a0Cmin\u00a0RAL,\u00a0pero\u00a0en\u00a0los\u00a0\nestudios\u00a0BENCHMRK \u00a0no\u00a0disminuy\u00f3 \u00a0la\u00a0eficacia)\u00a0\n\u2010DRV/r\u00a0 Reducir\u00a0la\u00a0dosis\u00a0de\u00a0maraviroc \u00a0a\u00a0la\u00a0mitad\u00a0\u00a0(150\u00a0mg\u00a0\nc/12h)\u00a0No\u00a0es\u00a0de\u00a0esperar\u00a0una\u00a0interacci\u00f3n \u00a0importante.\n\u00a0\nAUC :\u00a0\u00e1rea\u00a0bajo\u00a0la\u00a0curva;\u00a0BID:\u00a0dos\u00a0veces\u00a0al\u00a0d\u00eda;\u00a0Cp:\u00a0concentraciones \u00a0plasm\u00e1ticas; \u00a0F:\u00a0Fortovase\u00ae; \u00a0I:\u00a0Invirase\u00ae; \u00a0IT:\u00a0interacci\u00f3n; \u00a0NRAD :\u00a0no\u00a0\nrequiere\u00a0ajuste\u00a0de\u00a0dosis;\u00a0NS:\u00a0no\u00a0significativa; \u00a0QD:una\u00a0vez\u00a0al\u00a0d\u00eda.\u00a0\n\u00a0\n1En\u00a0presencia \u00a0de\u00a0inhibidores \u00a0enzim\u00e1ticos \u00a0potentes\u00a0como\u00a0los\u00a0IP\u00a0(excepto\u00a0TPV/r\u00a0y\u00a0FPV/r),\u00a0antif\u00fangicos \u00a0imidaz\u00f3licos \u00a0(ketoconazol, \u00a0\nitraconazol), \u00a0macr\u00f3lidos \u00a0(eritromicina, \u00a0claritromicina), \u00a0nefazodona \u00a0\u00f3\u00a0telitromicina \u00a0el\u00a0efecto\u00a0inhibidor\u00a0predomina \u00a0sobre\u00a0el\u00a0efecto\u00a0inductor\u00a0\nenzim\u00e1tico \u00a0y\u00a0por\u00a0lo\u00a0tanto,\u00a0se\u00a0recomienda \u00a0reducir\u00a0la\u00a0dosis\u00a0de\u00a0maraviroc \u00a0a\u00a0150\u00a0mg\u00a0c/12h.\u00a0\u00a0\n\u00a0\n2F\u00e1rmacos \u00a0metabolizados \u00a0a\u00a0trav\u00e9s\u00a0del\u00a0CYP3A:\u00a0alfentanilo, \u00a0antagonistas \u00a0del\u00a0calcio\u00a0(amlodipino, \u00a0diltiazem, \u00a0felodipino, \u00a0nicardipino, \u00a0\nnifedipino, \u00a0nisoldipino, \u00a0verapamilo), \u00a0carbamacepina, \u00a0ciclosporina, \u00a0citost\u00e1ticos \u00a0(etop\u00f3sido, \u00a0paclitaxel, \u00a0tamoxifeno, \u00a0vinblastina \u00a0y\u00a0\nvincristina), \u00a0clonacepam, \u00a0dexametasona, \u00a0disopiramida, \u00a0eritromicina, \u00a0etosuximida, \u00a0fentanilo, \u00a0lidoca\u00edna, \u00a0loratadina, \u00a0nefazodona, \u00a0\nondansetron, \u00a0prednisona, \u00a0quinina,\u00a0rifampicina, \u00a0sertralina, \u00a0sildenafilo, \u00a0tacrolimus \u00a0y\u00a0trazodona, \u00a0entre\u00a0otros.\u00a0\n\u00a0\nNOTA:\u00a0debido\u00a0a\u00a0\u00a0que\u00a0la\u00a0informaci\u00f3n \u00a0cient\u00edfica\u00a0relacionada \u00a0con\u00a0los\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0se\u00a0renueva\u00a0constantemente, \u00a0se\u00a0recomienda \u00a0\nconsultar \u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0de\u00a0los\u00a0f\u00e1rmacos \u00a0y\u00a0la\u00a0informaci\u00f3n \u00a0actualizada \u00a0ofrecida\u00a0por\u00a0las\u00a0distintas\u00a0compa\u00f1\u00edas \u00a0farmac\u00e9uticas \u00a0y\u00a0las\u00a0\nautoridades \u00a0sanitarias. \u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 1 Tabla\u00a09.\u00a0Inhibidores \u00a0de\u00a0la\u00a0fusi\u00f3n\u00a0\n\u00a0\nNombre\u00a0gen\u00e9rico\u00a0 Enfuvirtida \u00a0(T\u201020)\u00a0\nNombre\u00a0comercial \u00a0 Fuzeon\u00ae\u00a0\u00a0\nDosis\u00a0recomendada \u00a0 90\u00a0mg\u00a0c/12h\u00a0s.c.\u00a0\nPresentaciones\ncomerciales \u00a0vial\u00a0de\u00a090\u00a0mg\u00a0\nCmax\u00a0 4.59\u00a0mcg/mL\u00a0\nCmin\u00a0 2,6\u00a0\u2013\u00a03,4\u00a0mcg/mL\u00a0\nCI\u00a050\u00a0 0,259\u00a0mcg/mL\u00a0\nActividad \u00a0 VIH\u20101\u00a0\nBiodisponibilidad \u00a0\u00a0 80%\u00a0(v\u00eda\u00a0s.c.)\u00a0\nVida\u00a0media\u00a0plasm\u00e1tica \u00a0 3.8h\u00a0\nMetabolizaci\u00f3n\nExcreci\u00f3n \u00a0Catabolismo \u00a0en\u00a0sus\u00a0amino\u00e1cidos \u00a0constituyentes\nNo\u00a0hay\u00a0datos\u00a0\nEfectos\u00a0adversos\u00a0 Reacciones \u00a0locales\u00a0leve\u2010moderadas \u00a0en\u00a0el\u00a0punto\u00a0de\u00a0inyecci\u00f3n, \u00a0dolor\u00a0de\u00a0cabeza\u00a0y\u00a0fiebre.\u00a0\nInteracciones \u00a0Escaso\u00a0riesgo\u00a0de\u00a0interacci\u00f3n \u00a0metab\u00f3lica. \u00a0Se\u00a0ha\u00a0observado \u00a0in\u00a0vitro\u00a0un\u00a0efecto\u00a0sin\u00e9gico\u00a0intenso\u00a0de\u00a0enfuvirtide \u00a0con\u00a0elvitegravir, \u00a0lopinavir\u00a0y\u00a0\ndarunavir \u00a0y\u00a0un\u00a0efecto\u00a0sin\u00e9rgico\u00a0moderado \u00a0con\u00a0efavirenz. \u00a0Estudios\u00a0in\u00a0vitro\u00a0e\u00a0in\u00a0vivo\u00a0con\u00a0una\u00a0amplia\u00a0variedad\u00a0de\u00a0isoenzimas \u00a0hep\u00e1ticos \u00a0no\u00a0\nhan\u00a0mostrado \u00a0efecto\u00a0inhibitorio \u00a0de\u00a0T\u201020\u00a0sobre\u00a0los\u00a0mismos.\u00a0Estudios\u00a0en\u00a0pacientes \u00a0no\u00a0se\u00a0ha\u00a0encontrado \u00a0interacci\u00f3n \u00a0de\u00a0T\u201020\u00a0con\u00a0\nrifampicina, \u00a0ETR,\u00a0RTV\u00a0y\u00a0SQV/r.\u00a0Tampoco \u00a0se\u00a0ha\u00a0observado \u00a0interacci\u00f3n \u00a0farmacocin\u00e9tica \u00a0de\u00a0T\u201020\u00a0con\u00a0tacrolimus \u00a0ni\u00a0con\u00a0DRV.\u00a0En\u00a0un\u00a0estudio\u00a0\nse\u00a0observ\u00f3\u00a0un\u00a0aumento\u00a0de\u00a0las\u00a0concentraciones \u00a0de\u00a0TPV\u00a0(\u219150%\u00a0Cmin)\u00a0y\u00a0de\u00a0RTV\u00a0(\u2191\u00a0volumen\u00a0de\u00a0distribuci\u00f3n \u00a0y\u00a0semivida\u00a0de\u00a0eliminaci\u00f3n \u00a0de\u00a0\nambos)\u00a0en\u00a0presencia \u00a0de\u00a0enfuvurtida, \u00a0aunque\u00a0estos\u00a0resultados \u00a0no\u00a0han\u00a0podido\u00a0corroborarse \u00a0en\u00a0otro\u00a0estudio.\u00a0Seg\u00fan\u00a0un\u00a0suban\u00e1lisis \u00a0del\u00a0\nestudio\u00a0RESIST,\u00a0no\u00a0parece\u00a0que\u00a0el\u00a0aumento\u00a0en\u00a0las\u00a0concentraciones \u00a0plasm\u00e1ticas \u00a0de\u00a0TPV\u00a0se\u00a0relacione\u00a0con\u00a0un\u00a0aumento\u00a0del\u00a0riesgo\u00a0de\u00a0\nhepatotoxicidad. \u00a0\u00a0\n\u00a0\nNOTA:\u00a0debido\u00a0a\u00a0\u00a0que\u00a0la\u00a0informaci\u00f3n \u00a0cient\u00edfica\u00a0relacionada \u00a0con\u00a0los\u00a0f\u00e1rmacos\u00a0antirretrovirales \u00a0se\u00a0renueva\u00a0constantemente, \u00a0se\u00a0recomienda \u00a0consultar \u00a0la\u00a0ficha\u00a0t\u00e9cnica\u00a0de\u00a0los\u00a0f\u00e1rmacos\u00a0y\u00a0la\u00a0\ninformaci\u00f3n \u00a0actualizada \u00a0ofrecida\u00a0por\u00a0las\u00a0distintas\u00a0compa\u00f1\u00edas \u00a0farmac\u00e9uticas \u00a0y\u00a0las\u00a0autoridades \u00a0sanitarias. \u00a0\n\u00a0\n\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n \u00a0\n\u00a0\n\u00a0\n\u00a0\n\u00a0\nTabla\u00a010.\u00a0Causas\u00a0de\u00a0adherencia \u00a0incorrecta \u00a0\u00a0y\u00a0posibles\u00a0estrategias \u00a0de\u00a0intervenci\u00f3n \u00a0\n\u00a0\n\u00a0 Causas\u00a0potenciales \u00a0de\u00a0incumplimiento Posibles\u00a0intervenciones \u00a0\nFactores\u00a0\nsociales,\u00a0\necon\u00f3micos, \u00a0\neducativos. \u00a0Falta\u00a0de\u00a0apoyo\u00a0social\u00a0y/o\u00a0familiar.\u00a0\nEscasos\u00a0recursos.\u00a0\u00a0Bajo\u00a0nivel\u00a0\neducativo \u00a0Buscar\u00a0alianza\u00a0con\u00a0familia\u00a0y\u00a0allegados. \u00a0Conocer\u00a0\nnecesidades \u00a0sociales.\u00a0Reclutar\u00a0organizaciones \u00a0\ncomunitarias. \u00a0Educaci\u00f3n \u00a0intensiva, \u00a0explicaciones \u00a0\nclaras\u00a0y\u00a0comprensibles \u00a0y\u00a0adaptadas \u00a0\nFactores\u00a0del\u00a0\nequipo\u00a0\nasistencial \u00a0Falta\u00a0de\u00a0recursos.\u00a0Atenci\u00f3n\u00a0masificada \u00a0\ne\u00a0impersonal. \u00a0Ausencia\u00a0de\u00a0\ncoordinaci\u00f3n \u00a0entre\u00a0diferentes \u00a0\nservicios\u00a0de\u00a0apoyo\u00a0a\u00a0la\u00a0asistencia. \u00a0\nInsuficiente \u00a0formaci\u00f3n \u00a0en\u00a0terapia\u00a0\nantirretroviral. \u00a0Falta\u00a0de\u00a0accesibilidad. \u00a0\nDeficiente \u00a0formaci\u00f3n \u00a0en\u00a0relaci\u00f3n\u00a0\npersonal\u00a0sanitario\u2010paciente. \u00a0Accesibilidad \u00a0y\u00a0continuidad \u00a0de\u00a0la\u00a0asistencia. \u00a0\nEquipo\u00a0multidisciplinar. \u00a0Recursos\u00a0materiales \u00a0y\u00a0\nhumanos \u00a0suficientes \u00a0y\u00a0coordinados. \u00a0\u00a0\nFormaci\u00f3n \u00a0s\u00f3lida\u00a0en\u00a0terapia\u00a0antirretroviral \u00a0y\u00a0en\u00a0\natenci\u00f3n\u00a0al\u00a0paciente. \u00a0\nPlantear\u00a0terapia\u00a0directamente \u00a0observada \u00a0en\u00a0\ndeterminados \u00a0\u00e1mbitos\u00a0asistenciales. \u00a0\nFactores\u00a0\nrelacionados \u00a0\ncon\u00a0el\u00a0\ntratamiento \u00a0Efectos\u00a0adversos, \u00a0tama\u00f1o\u00a0y\u00a0\npalatabilidad \u00a0de\u00a0las\u00a0unidades\u00a0\ngal\u00e9nicas, \u00a0n\u00famero\u00a0de\u00a0dosis\u00a0diarias.\u00a0\nIntrusi\u00f3n\u00a0en\u00a0la\u00a0vida\u00a0del\u00a0paciente. \u00a0Falta\u00a0\nde\u00a0adaptaci\u00f3n \u00a0a\u00a0las\u00a0preferencias \u00a0y\u00a0\nnecesidades \u00a0del\u00a0paciente. \u00a0Simplificar \u00a0el\u00a0r\u00e9gimen\u00a0terap\u00e9utico. \u00a0Pautas\u00a0\nconvenientes \u00a0en\u00a0n\u00famero\u00a0y\u00a0dosificaci\u00f3n \u00a0de\u00a0\ncomprimidos, \u00a0emplear\u00a0f\u00e1rmacos\u00a0co\u2010formulados \u00a0\nIndividualizar \u00a0tratamiento: \u00a0Resistencias, \u00a0\ncomorbilidad, \u00a0preferencias, \u00a0interacciones. \u00a0\u00a0\nT\u00e9cnicas\u00a0especiales \u00a0para\u00a0la\u00a0toma\u00a0de\u00a0la\u00a0\nmedicaci\u00f3n. \u00a0Ayudar\u00a0a\u00a0desarrollar \u00a0mecanismos \u00a0de\u00a0\nreacci\u00f3n\u00a0(p.e.\u00a0anticipaci\u00f3n \u00a0y\u00a0manejo\u00a0de\u00a0efectos\u00a0\nadversos) \u00a0\nFactores\u00a0\nrelacionados \u00a0\ncon\u00a0el\u00a0paciente\u00a0No\u00a0aceptaci\u00f3n. \u00a0Rechazo\u00a0del\u00a0\ndiagn\u00f3stico. \u00a0Rechazo\u00a0del\u00a0tratamiento \u00a0\n(creencias \u00a0y\u00a0actitudes) \u00a0\nOlvidos\u00a0y\u00a0barreras.\u00a0Insuficiente \u00a0\ncomprensi\u00f3n \u00a0de\u00a0la\u00a0enfermedad \u00a0y\u00a0su\u00a0\ntratamiento. \u00a0Insuficiente \u00a0\nentendimiento \u00a0de\u00a0la\u00a0relaci\u00f3n\u00a0\nriesgo/beneficio. \u00a0\nMotivos\u00a0de\u00a0dosificaci\u00f3n \u00a0y\u00a0\ncumplimiento. \u00a0\nComorbilidad \u00a0psiqui\u00e1trica. \u00a0\nUso\u00a0y\u00a0abuso\u00a0de\u00a0drogas\u00a0Negociar\u00a0y\u00a0consensuar \u00a0el\u00a0plan\u00a0terap\u00e9utico. \u00a0\nFomentar \u00a0la\u00a0percepci\u00f3n \u00a0de\u00a0indicadores \u00a0de\u00a0la\u00a0\nnecesidad \u00a0de\u00a0\u00a0tratamiento. \u00a0Informar\u00a0sobre\u00a0\u00a0\nriesgos\u00a0y\u00a0beneficios \u00a0del\u00a0tratamiento. \u00a0Asociar\u00a0cada\u00a0\ntoma\u00a0con\u00a0actividades \u00a0cotidianas. \u00a0T\u00e9cnicas\u00a0\nespeciales \u00a0y\u00a0ayudas\u00a0para\u00a0el\u00a0cumplimiento \u00a0(diarios\u00a0\nde\u00a0medicaci\u00f3n, \u00a0alarmas,\u00a0tel\u00e9fonos, \u00a0etc).\u00a0Mejorar\u00a0\nla\u00a0comunicaci\u00f3n \u00a0paciente\u00a0\u2013\u00a0profesional \u00a0sanitario. \u00a0\nInformaci\u00f3n \u00a0referente \u00a0a\u00a0la\u00a0enfermedad \u00a0y\u00a0el\u00a0\ntratamiento, \u00a0motivo\u00a0de\u00a0la\u00a0dosificaci\u00f3n, \u00a0riesgo\u00a0del\u00a0\nincumplimiento. \u00a0Informaci\u00f3n \u00a0oral\u00a0y\u00a0escrita.\u00a0\nVerificar\u00a0comprensi\u00f3n. \u00a0Derivar\u00a0para\u00a0intervenci\u00f3n \u00a0\npsicol\u00f3gica \u00a0en\u00a0\u00a0\u00e1reas\u00a0disfuncionales \u00a0o\u00a0\nintervenci\u00f3n \u00a0psiqui\u00e1trica \u00a0si\u00a0se\u00a0detecta\u00a0patolog\u00eda \u00a0\npsiqui\u00e1trica. \u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 1Tabla\u00a011.\u00a0Toxicidad \u00a0de\u00a0cada\u00a0familia\u00a0de\u00a0f\u00e1rmacos \u00a0antirretrovirales \u00a0\n\u00a0\nFamilia\u00a0 Toxicidad \u00a0 Prevalencia \u00a0 Cl\u00ednica\u00a0\nInhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0\ninversa\u00a0nucle\u00f3sidos \u00a0o\u00a0\nnucle\u00f3tidos1\u00a0Toxicidad \u00a0mitocondrial \u00a0 20\u201040%\u00a0 Neuropat\u00eda \u00a0perif\u00e9rica \u00a0\nMiopat\u00eda\u00a0\nCardiomiopat\u00eda \u00a0\nPancreatitis \u00a0\nHepatomegalia \u00a0\nEsteatosis \u00a0hep\u00e1tica\u00a0\nHepatitis\u00a0\nAcidosis\u00a0l\u00e1ctica\u00a0\nMielotoxicidad \u00a0\nAlteraci\u00f3n \u00a0tubular\u00a0proximal\u00a0renal\u00a0\nLipoatrofia \u00a0\nHiperlipemia \u00a0y\u00a0resistencia \u00a0insul\u00ednica \u00a0\nInhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0\ninversa\u00a0no\u00a0nucle\u00f3sidos2\u00a0Hipersensibilidad \u00a0 15\u201030%\u00a0 Exantema \u00a0(extensi\u00f3n \u00a0y\u00a0gravedad \u00a0variable)\u00a0\nAfectaci\u00f3n \u00a0multiorg\u00e1nica \u00a0\nFiebre\u00a0\nInhibidores \u00a0de\u00a0la\u00a0proteasa3\u00a0 Hiperlipemia \u00a0\u00a0\nResistencia \u00a0a\u00a0la\u00a0insulina\u00a0(IP\u00a0cl\u00e1sicos;\u00a0dif\u00edcil\u00a0\nde\u00a0separar\u00a0de\u00a0los\u00a0efectos\u00a0de\u00a0an\u00e1logos\u00a0de\u00a0\ntimidina)\u00a0y\u00a0lipodistrofia \u00a025\u201050%\u00a0 Hipertrigliceridemia \u00a0(especialmente) \u00a0\nHipercolesterolemia \u00a0\nDiabetes\u00a0mellitus\u00a0\nLipoacumulaci\u00f3n \u00a0intraabdominal \u00a0\nInhibidores \u00a0de\u00a0la\u00a0fusi\u00f3n4\u00a0 Inflamaci\u00f3n \u00a0d\u00e9rmica\u00a0local\u00a0 60\u201070%\u00a0 Dolor\u00a0\nTumoraci\u00f3n \u00a0\nLas\u00a0distintas\u00a0manifestaciones \u00a0de\u00a0la\u00a0toxicidad\u00a0se\u00a0suelen\u00a0presentar \u00a0de\u00a0forma\u00a0aislada.\u00a0Aparecen \u00a0generalmente \u00a0en\u00a0los\u00a0tres\u00a0primeros\u00a0meses\u00a0de\u00a0tratamiento, \u00a0\naunque\u00a0algunas\u00a0expresiones \u00a0de\u00a0la\u00a0toxicidad\u00a0mitocondrial \u00a0(neuropat\u00eda, \u00a0miopat\u00eda, \u00a0acidosis\u00a0l\u00e1ctica\u00a0o\u00a0lipoatrofia) \u00a0suelen\u00a0aparecer\u00a0de\u00a0forma\u00a0tard\u00eda\u00a0(meses\u00a0o\u00a0\na\u00f1os).\u00a0\n1.\u00a0ABC\u00a0constituye \u00a0una\u00a0excepci\u00f3n, \u00a0pues\u00a0su\u00a0toxicidad\u00a0est\u00e1\u00a0mediada\u00a0por\u00a0hipersensibilidad. \u00a0TDF\u00a0puede\u00a0inducir\u00a0nefrotoxicidad. \u00a0\n2.\u00a0Efavirenz\u00a0puede\u00a0inducir\u00a0toxicidad\u00a0neurops\u00edqui\u00e1trica \u00a0como\u00a0efecto\u00a0adverso\u00a0singular.\u00a0\n3.\u00a0Indinavir\u00a0puede\u00a0causar\u00a0nefrolitiasis \u00a0e\u00a0insuficiencia \u00a0renal\u00a0como\u00a0efectos\u00a0adversos\u00a0singulares. \u00a0Atazanavir \u00a0no\u00a0comporta \u00a0el\u00a0riesgo\u00a0de\u00a0alteraciones \u00a0\nmetab\u00f3licas, \u00a0como\u00a0otros\u00a0IP,\u00a0pero\u00a0puede\u00a0producir\u00a0hiperbilirrubinemia \u00a0y\u00a0nefrolitiasis \u00a0como\u00a0efectos\u00a0adversos\u00a0singulares. \u00a0\n4.\u00a0La\u00a0enfuvirtida \u00a0(T\u201020),\u00a0\u00fanico\u00a0representante \u00a0de\u00a0esta\u00a0familia\u00a0disponible \u00a0en\u00a0la\u00a0actualidad, \u00a0se\u00a0administra \u00a0por\u00a0v\u00eda\u00a0subcut\u00e1nea.   \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 1Tabla\u00a012.\u00a0Toxicidad \u00a0de\u00a0los\u00a0antirretrovirales \u00a0por\u00a0\u00f3rganos\u00a0y\u00a0aparatos\u00a0\n\u00a0\n \nToxicidad \u00a0 F\u00e1rmaco/s \u00a0 Diagn\u00f3stico \u00a0 Patogenia \u00a0 Actitud\u00a0\nAnemia\u00a0 AZT\u00a0(dosis\u2010dependiente) \u00a0 S\u00edntomas\u00a0cl\u00ednicos\u00a0de\u00a0anemia\u00a0 Inhibici\u00f3n \u00a0de\u00a0la\u00a0proliferaci\u00f3n \u00a0de\u00a0\nlas\u00a0c\u00e9lulas\u00a0progenitoras \u00a0eritroidesSuspensi\u00f3n \u00a0de\u00a0AZT\u00a0\nTransfusi\u00f3n \u00a0de\u00a0hemat\u00edes \u00a0(si\u00a0hemoglobina \u00a0<8g/dL\u00a0\u00f3\u00a0hay\u00a0s\u00edntomas\u00a0de\u00a0\nanemia)\u00a0\nMiopat\u00eda\u00a0 AZT\u00a0(dosis\u2010dependiente) \u00a0 Despu\u00e9s\u00a0del\u00a0primer\u00a0semestre \u00a0\u00a0de\u00a0\ntratamiento \u00a0\nS\u00edntomas: \u00a0mialgias\u00a0o\u00a0debilidad \u00a0\nmuscular\u00a0proximal\u00a0y\u00a0elevaci\u00f3n \u00a0de\u00a0\nenzimas\u00a0musculares \u00a0(CPK,\u00a0LDH,\u00a0\u00a0\naldolasa)\u00a0Toxicidad \u00a0mitocondrial \u00a0 Suspensi\u00f3n \u00a0de\u00a0AZT\u00a0\nSi\u00a0cl\u00ednica\u00a0importante, \u00a0prednisona \u00a01\u20102\u00a0mg/kg/d\u00eda \u00a0\nNeuropat\u00eda \u00a0perif\u00e9rica \u00a0ddI\u00a0(13\u201034%)\u00a0\nd4T\u00a0(15\u201020%)\u00a0\n(dosis\u2010dependiente) \u00a0\n\u00a0Hipoestesia, \u00a0parestesia \u00a0o\u00a0dolor\u00a0\nen\u00a0zona\u00a0distal\u00a0de\u00a0extremidades \u00a0\n(especialmente \u00a0pies)\u00a0\nDiagn\u00f3stico \u00a0diferencial \u00a0con\u00a0la\u00a0\nneuropat\u00eda \u00a0por\u00a0el\u00a0propio\u00a0VIH\u00a0\n(aparece\u00a0en\u00a0pacientes \u00a0sin\u00a0\ntratamiento \u00a0e\u00a0inmunodepresi\u00f3n \u00a0\ngrave)\u00a0Interacci\u00f3n \u00a0entre\u00a0citoquinas \u00a0y\u00a0\nfactores\u00a0de\u00a0crecimiento \u00a0neuronal\u00a0\nFavorecida \u00a0por\u00a0neuropat\u00eda \u00a0previa\u00a0\ny\u00a0\u00a0factores\u00a0predisponentes \u00a0\n(enolismo, \u00a0desnutrici\u00f3n, \u00a0\ndiabetes,\u00a0etc)\u00a0Evitar\u00a0asociaciones \u00a0de\u00a0f\u00e1rmacos\u00a0neurot\u00f3xicos \u00a0\nValorar\u00a0mantener \u00a0f\u00e1rmacos \u00a0potencialmente \u00a0implicados \u00a0si\u00a0la\u00a0cl\u00ednica\u00a0no\u00a0es\u00a0\ngrave\u00a0y\u00a0no\u00a0hay\u00a0alternativas \u00a0razonables \u00a0\nSuspender \u00a0los\u00a0f\u00e1rmacos\u00a0implicados \u00a0si\u00a0cl\u00ednica\u00a0progresiva \u00a0o\u00a0invalidante. \u00a0La\u00a0\nrecuperaci\u00f3n \u00a0es\u00a0lenta\u00a0(meses\u00a0o\u00a0a\u00f1os).\u00a0\nSi\u00a0dolor\u00a0leve:\u00a0analg\u00e9sicos \u00a0habituales. \u00a0\nSi\u00a0dolor\u00a0moderado \u2010intenso:\u00a0gabapentina, \u00a0\u00a0pregabalina \u00a0o\u00a0lamotrigina \u00a0con\u00a0\no\u00a0sin\u00a0benzodiacepinas; \u00a0si\u00a0no\u00a0eficacia,\u00a0valorar\u00a0carbamacepina \u00a0y/o\u00a0\namitriptilina \u00a0(producen \u00a0efectos\u00a0colin\u00e9rgicos) \u00a0\nSi\u00a0dolor\u00a0muy\u00a0intenso\u00a0o\u00a0refractario: \u00a0opi\u00e1ceos\u00a0\nToxicidad \u00a0\nneurops\u00edquica \u00a0EFV\u00a0(20\u201050%)\u00a0\u00a0\n(dosis\u2010dependiente; \u00a0m\u00e1s\u00a0\nprevalente \u00a0si\u00a0administraci\u00f3n \u00a0\ncon\u00a0alimentos) \u00a0Durante\u00a0el\u00a0primer\u00a0mes\u00a0de\u00a0\ntratamiento, \u00a0tras\u00a0lo\u00a0cual\u00a0\ndisminuye \u00a0o\u00a0desaparece. \u00a0\nEspectro\u00a0cl\u00ednico\u00a0variado:\u00a0mareo,\u00a0\nansiedad, \u00a0somnolencia, \u00a0\ntrastornos \u00a0del\u00a0sue\u00f1o,\u00a0\nagravamiento \u00a0de\u00a0problemas \u00a0\nps\u00edquicos \u00a0subyacentes, \u00a0y\u00a0\nalteraciones \u00a0motoras.\u00a0Desconocida. \u00a0 Evitar\u00a0en\u00a0pacientes \u00a0con\u00a0trastornos \u00a0psiqui\u00e1tricos \u00a0mayores. \u00a0\nValorar\u00a0individualmente \u00a0el\u00a0estilo\u00a0de\u00a0vida\u00a0y\u00a0la\u00a0actividad\u00a0del\u00a0paciente\u00a0antes\u00a0\nde\u00a0prescribirlo. \u00a0\nGeneralmente \u00a0no\u00a0es\u00a0necesaria \u00a0la\u00a0suspensi\u00f3n \u00a0de\u00a0efavirenz. \u00a0\nSuspender \u00a0en\u00a0casos\u00a0de\u00a0manifestaciones \u00a0graves\u00a0o\u00a0invalidantes. \u00a0\nAdministraci\u00f3n \u00a0por\u00a0la\u00a0noche,\u00a0al\u00a0menos\u00a01\u20102\u00a0horas\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0cena.\u00a0\nValorar\u00a0benzodiacepinas \u00a0o\u00a0neurol\u00e9pticos \u00a0si\u00a0alteraciones \u00a0del\u00a0sue\u00f1o\u00a0\npersistentes. \u00a0\nPuede\u00a0intentarse \u00a0ajuste\u00a0de\u00a0dosis\u00a0si\u00a0hay\u00a0posibilidad \u00a0de\u00a0estudio\u00a0\nfarmacocin\u00e9tico, \u00a0aunque\u00a0no\u00a0est\u00e1\u00a0definitivamente \u00a0probado\u00a0\n\u00a0\u00a0 \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 2Toxicidad \u00a0 F\u00e1rmaco/s \u00a0 Diagn\u00f3stico \u00a0 Patogenia \u00a0 Actitud\u00a0\nExantema \u00a0y/o\u00a0\nhipersensibilidad \u00a0No\u2010nucle\u00f3sidos \u00a0(m\u00e1s\u00a0\nfrecuente \u00a0NVP\u00a0y\u00a0ETV)\u00a0\n(<20%)\u00a0\u00a0\nInhibidores \u00a0de\u00a0proteasa\u00a0\n(m\u00e1s\u00a0frecuente \u00a0TPV\u00a0\u00a0(8\u2010\n14%),\u00a0DRV\u00a0y\u00a0FPV\u00a0(3\u20105%)\u00a0\nNucle\u00f3sidos \u00a0(m\u00e1s\u00a0frecuente \u00a0\nABC,\u00a05\u20108%)\u00a0\n\u00a0Durante\u00a0los\u00a0primeros\u00a0dos\u00a0meses\u00a0\nde\u00a0tratamiento \u00a0\nExantema \u00a0maculo\u2010papular\u00a0(casos\u00a0\nleves).\u00a0\nFiebre,\u00a0afectaci\u00f3n \u00a0mucosa,\u00a0\npulmonar, \u00a0hep\u00e1tica\u00a0o\u00a0\nhematol\u00f3gica \u00a0(casos\u00a0graves)\u00a0\nLa\u00a0hipersensibilidad \u00a0se\u00a0manifiesta \u00a0\npor\u00a0afectaci\u00f3n \u00a0multi\u00f3rganica, \u00a0a\u00a0\nveces\u00a0con\u00a0escaso\u00a0o\u00a0nulo\u00a0\nexantema, \u00a0y\u00a0puede\u00a0haber\u00a0\neosinofilia. \u00a0Desconocida. \u00a0\nSe\u00a0ha\u00a0sugerido\u00a0una\u00a0reacci\u00f3n\u00a0\nant\u00edgeno\u2010anticuerpo \u00a0similar\u00a0a\u00a0la\u00a0\u00a0\nenfermedad \u00a0del\u00a0suero\u00a0o\u00a0una\u00a0\ntoxicidad\u00a0directa\u00a0por\u00a0metabolitos \u00a0\nintermediarios. \u00a0\nIdentificaci\u00f3n \u00a0de\u00a0pacientes \u00a0con\u00a0\nriesgo\u00a0gen\u00e9tico\u00a0elevado\u00a0de\u00a0\nhipersensibilidad \u00a0a\u00a0abacavir\u00a0(HLA\u2010\nB*5701)\u00a0Comienzo \u00a0escalonado \u00a0de\u00a0dosis\u00a0de\u00a0nevirapina. \u00a0No\u00a0dar\u00a0corticoides \u00a0\nprofil\u00e1cticos \u00a0(no\u00a0evitan\u00a0el\u00a0riesgo\u00a0e\u00a0incluso\u00a0lo\u00a0pueden\u00a0aumentar) \u00a0ni\u00a0\nantihistam\u00ednicos \u00a0\nSi\u00a0exantema \u00a0leve\u00a0sin\u00a0cl\u00ednica\u00a0de\u00a0hipersensibilidad \u00a0acompa\u00f1ante, \u00a0se\u00a0puede\u00a0\nmantener \u00a0el\u00a0tratamiento \u00a0y\u00a0realizar\u00a0una\u00a0vigilancia \u00a0estrecha. \u00a0\nEl\u00a0exantema \u00a0por\u00a0ETV,\u00a0\u00a0aunque\u00a0puede\u00a0ser\u00a0grave,\u00a0raramente \u00a0obliga\u00a0a\u00a0\nretirar\u00a0el\u00a0f\u00e1rmaco\u00a0\nSi\u00a0exantema \u00a0grave\u00a0o\u00a0cl\u00ednica\u00a0de\u00a0hipersensibilidad, \u00a0interrupci\u00f3n \u00a0\npermanente \u00a0del\u00a0f\u00e1rmaco.\u00a0\u00a0\nEn\u00a0los\u00a0casos\u00a0donde\u00a0pueda\u00a0estar\u00a0implicado \u00a0ABC\u00a0\u00a0y\u00a0la\u00a0cl\u00ednica\u00a0no\u00a0sea\u00a0clara,\u00a0\npuede\u00a0ser\u00a0razonable \u00a0mantener \u00a0el\u00a0tratamiento \u00a0durante\u00a024\u00a0horas\u00a0m\u00e1s\u00a0con\u00a0\nuna\u00a0vigilancia \u00a0estrecha\u00a0y\u00a0valorar\u00a0evoluci\u00f3n \u00a0antes\u00a0de\u00a0retirar\u00a0ABC.\u00a0\nTratamiento \u00a0sintom\u00e1tico \u00a0con\u00a0antihistam\u00ednicos \u00a0y/o\u00a0corticoides \u00a0una\u00a0vez\u00a0\ninterrumpido \u00a0el\u00a0f\u00e1rmaco\u00a0sospechoso \u00a0\nTratamiento \u00a0de\u00a0soporte\u00a0hemodin\u00e1mico, \u00a0o\u00a0respiratorio \u00a0en\u00a0casos\u00a0graves\u00a0\nque\u00a0lo\u00a0requieran \u00a0\nNO\u00a0REINTRODUCIR \u00a0NUNCA\u00a0UN\u00a0F\u00c1RMACO \u00a0RETIRADO \u00a0POR\u00a0SOSPECHA \u00a0DE\u00a0\nHIPERSENSIBILIDAD \u00a0\nHepatitis\u00a0 Nucle\u00f3sidos \u00a0(m\u00e1s\u00a0frecuente \u00a0\nAZT,\u00a0ddI\u00a0y\u00a0d4T).\u00a0No\u00a0\nnucle\u00f3sidos \u00a0(m\u00e1s\u00a0frecuente \u00a0\nNVP)\u00a0\nInhibidores \u00a0de\u00a0proteasa\u00a0\n(m\u00e1s\u00a0frecuente \u00a0RTV)\u00a0\n\u00a0\u00a0El\u00a050%\u00a0de\u00a0los\u00a0casos\u00a0aparece\u00a0en\u00a0el\u00a0\nprimer\u00a0semestre. \u00a0\nAumento \u00a0de\u00a0transaminasas \u00a0sin\u00a0\ncl\u00ednica\u00a0(10\u201015%\u00a0de\u00a0pacientes). \u00a0\nHepatitis\u00a0cl\u00ednica\u00a0(<1%).\u00a0\nFactores\u00a0de\u00a0riesgo:\u00a0infecci\u00f3n\u00a0por\u00a0\nvirus\u00a0de\u00a0hepatitis\u00a0B\u00a0\ny\u00a0C\u00a0\u00a0Multifactorial: \u00a0toxicidad\u00a0\nmitocondrial \u00a0(nucle\u00f3sidos), \u00a0\nefecto\u00a0t\u00f3xico\u2010inmunol\u00f3gico \u00a0(no\u00a0\nnucle\u00f3sidos); \u00a0si\u00a0IP\u00a0efecto\u00a0mixto\u00a0\n(toxicidad \u00a0directa,\u00a0recuperaci\u00f3n \u00a0\ninmune\u00a0si\u00a0VHB\u00a0o\u00a0VHC),\u00a0rebrote\u00a0de\u00a0\nvirus\u00a0B\u00a0tras\u00a0suspender \u00a0TARV\u00a0con\u00a0\nefecto\u00a0anti\u2010VHB\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0Considerar \u00a0vigilancia \u00a0estrecha\u00a0y\u00a0potencial \u00a0suspensi\u00f3n \u00a0si\u00a0transaminasas \u00a0>5\u00a0\nveces\u00a0l\u00edmite\u00a0superior\u00a0de\u00a0normalidad. \u00a0\nInterrumpir \u00a0\nsi\u00a0transaminasas \u00a0>10\u00a0veces\u00a0l\u00edmite\u00a0superior\u00a0de\u00a0normalidad, \u00a0\nmanifestaciones \u00a0cl\u00ednicas\u00a0de\u00a0hipersensibilidad \u00a0(fiebre\u00a0o\u00a0exantema), \u00a0de\u00a0\nfallo\u00a0hep\u00e1tico\u00a0(ictericia, \u00a0encefalopat\u00eda, \u00a0o\u00a0hemorragia) \u00a0o\u00a0acidosis\u00a0l\u00e1ctica.\u00a0\n  \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 3 \n   \nToxicidad \u00a0 F\u00e1rmaco/s \u00a0 Diagn\u00f3stico \u00a0 Patogenia \u00a0 Actitud\u00a0\nToxicidad \u00a0\ngastrointestinal \u00a0Inhibidores \u00a0de\u00a0proteasa\u00a0\nsobre\u00a0todo\u00a0RTV\u00a0(a\u00a0dosis\u00a0\nplenas),\u00a0\u00a040%;\u00a0IDV,\u00a025%;\u00a0\u00a0\nNFV,\u00a025%\u00a0;\u00a0LPV/r,\u00a025%;\u00a0\u00a0\nSQV,\u00a05%\u00a0\nNucle\u00f3sidos \u00a0con\u00a0menor\u00a0\nfrecuencia \u00a0que\u00a0IP\u00a0\n(particularmente \u00a0AZT\u00a0y\u00a0TDF)\u00a0\n\u00a0Sabor\u00a0desagradable \u00a0(RTV\u00a0\nsuspensi\u00f3n) \u00a0\nMolestias \u00a0digestivas \u00a0altas\u00a0(IDV\u00a0y\u00a0\nAPV)\u00a0\nDiarrea\u00a0(NFV\u00a0y\u00a0LPV/r)\u00a0Multifactorial. \u00a0\nInhibici\u00f3n \u00a0de\u00a0enzimas\u00a0\npancre\u00e1ticas \u00a0(inhibidores \u00a0de\u00a0\nproteasa). \u00a0\nIntolerancia \u00a0a\u00a0la\u00a0lactosa\u00a0que\u00a0\ncontienen \u00a0como\u00a0excipiente \u00a0\n(todos\u00a0los\u00a0antirretrovirales). \u00a0Raramente \u00a0grave,\u00a0pero\u00a0por\u00a0su\u00a0frecuencia \u00a0e\u00a0incomodidad \u00a0puede\u00a0limitar\u00a0la\u00a0\nadherencia \u00a0al\u00a0TAR.\u00a0\nPara\u00a0la\u00a0diarrea,\u00a0dietas\u00a0rica\u00a0en\u00a0alimentos \u00a0astringentes \u00a0o\u00a0f\u00e1rmacos \u00a0\ninhibidores \u00a0de\u00a0la\u00a0motilidad \u00a0intestinal \u00a0(loperamida). \u00a0\nSuspensi\u00f3n \u00a0del\u00a0f\u00e1rmaco\u00a0si\u00a0molestias \u00a0persistentes \u00a0o\u00a0intensas.\u00a0\nPancreatitis \u00a0 Nucle\u00f3sidos \u00a0(m\u00e1s\u00a0frecuente \u00a0\nddI\u00a0y\u00a0d4T).\u00a0\nAumento \u00a0de\u00a0riesgo\u00a0cuando\u00a0\nse\u00a0administra \u00a0hidroxiurea, \u00a0o\u00a0\nTDF\u00a0con\u00a0ddI.\u00a0\n\u00a0Generalmente, \u00a0asintom\u00e1tica. \u00a0\nPuede\u00a0haber\u00a0manifestaciones \u00a0\ncl\u00ednicas\u00a0de\u00a0dolor\u00a0abdominal \u00a0y\u00a0\ndiarrea.\u00a0Toxicidad \u00a0mitocondrial \u00a0 Retirar\u00a0el\u00a0f\u00e1rmaco\u00a0potencialmente \u00a0implicado. \u00a0\n\u00a0\u00a0\nInsuficiencia \u00a0renal\u00a0y\u00a0\ntubulopat\u00eda \u00a0TDF\u00a0\nIDV\u00a0\n\u00a0Elevaci\u00f3n \u00a0leve\u00a0o\u00a0moderada \u00a0de\u00a0la\u00a0\ncreatinina \u00a0con/sin\u00a0anomal\u00edas \u00a0\nanal\u00edticas \u00a0de\u00a0disfunci\u00f3n \u00a0tubular.\u00a0\u00a0\nNo\u00a0suele\u00a0acompa\u00f1arse \u00a0de\u00a0cl\u00ednica.\u00a0Alteraci\u00f3n \u00a0tubular\u00a0proximal\u00a0\u00a0\n(TDF)\u00a0\u00a0\nNefritis\u00a0intersticial \u00a0por\u00a0cristales\u00a0\n(IDV)\u00a0\n\u00a0Evitar\u00a0en\u00a0pacientes \u00a0con\u00a0insuficiencia \u00a0renal.\u00a0Evitar\u00a0en\u00a0lo\u00a0posible\u00a0\ncoadministraci\u00f3n \u00a0con\u00a0otros\u00a0f\u00e1rmacos \u00a0potencialmente \u00a0nefrot\u00f3xicos. \u00a0\nHidrataci\u00f3n \u00a0adecuada \u00a0para\u00a0prevenir\u00a0o\u00a0mejorar\u00a0la\u00a0elevaci\u00f3n \u00a0de\u00a0creatinina. \u00a0\u00a0\nSuspensi\u00f3n \u00a0del\u00a0f\u00e1rmaco\u00a0si\u00a0el\u00a0filtrado\u00a0glomerular \u00a0es\u00a0<50\u00a0mL/min\u00a0\u00a0\nNefrolitiasis \u00a0 IDV\u00a0\nATV\u00a0\u00a0\n\u00a0Dolor\u00a0c\u00f3lico\u00a0lumbar.\u00a0\u00a0Hematuria \u00a0\nmicrosc\u00f3pica \u00a0y\u00a0ocasionalmente \u00a0\nmacrosc\u00f3pica. \u00a0Ocasionalmente, \u00a0\nfiebre\u00a0(diagn\u00f3stico \u00a0diferencial \u00a0\ncon\u00a0pielonefritis) \u00a0\nM\u00e1s\u00a0frecuente \u00a0en\u00a0ambientes \u00a0\ncalurosos \u00a0Precipitaci\u00f3n \u00a0de\u00a0indinavir\u00a0en\u00a0\norina\u00a0concentrada \u00a0(densidad \u00a0\n>1020)\u00a0\u00a0y\u00a0pH\u00a0b\u00e1sico\u00a0(>5).\u00a0Prevenci\u00f3n \u00a0mediante \u00a0ingesta\u00a0adecuada \u00a0de\u00a0l\u00edquido\u00a0(1500\u00a0ml\u00a0de\u00a0agua\u00a0al\u00a0\nd\u00eda\u00a0o\u00a0m\u00e1s\u00a0si\u00a0ambiente \u00a0caluroso\u00a0o\u00a0p\u00e9rdidas\u00a0extraordinarias \u00a0de\u00a0l\u00edquidos). \u00a0\nEvitar\u00a0bebidas\u00a0carb\u00f3nicas. \u00a0\nAnti\u2010inflamatorios \u00a0no\u00a0esteroideos \u00a0para\u00a0el\u00a0dolor.\u00a0\nSuspensi\u00f3n \u00a0transitoria \u00a0del\u00a0f\u00e1rmaco\u00a0responsable \u00a0si\u00a0dolor\u00a0intenso.\u00a0\nSuspensi\u00f3n \u00a0definitiva \u00a0del\u00a0f\u00e1rmaco\u00a0responsable \u00a0si\u00a0episodios \u00a0repetidos \u00a0sin\u00a0\ndesencadenante \u00a0evidente. \u00a0\u00a0\nAjuste\u00a0de\u00a0dosis\u00a0si\u00a0posibilidad \u00a0de\u00a0estudio\u00a0farmacocin\u00e9tico. \u00a0\n\u00a0\n\u00a0\n  \nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 1\u00a0\n\u00a0\nTabla\u00a013.\u00a0Evaluaci\u00f3n \u00a0y\u00a0tratamiento \u00a0de\u00a0la\u00a0dislipemia \u00a0\n\u00a0\nEvaluaci\u00f3n \u00a0 Tratamiento \u00a0\nRealizar\u00a0anal\u00edtica\u00a0en\u00a0ayunas\u00a0\nDescartar \u00a0otras\u00a0causas\u00a0de\u00a0hiperlipemia \u00a0secundaria \u00a0\nTratamiento \u00a0encaminado \u00a0a\u00a0prevenir\u00a0la\u00a0enfermedad \u00a0\nateroscler\u00f3tica \u00a0y\u00a0a\u00a0evitar\u00a0las\u00a0complicaciones \u00a0inmediatas \u00a0\nde\u00a0la\u00a0hipertrigliceridemia \u00a0grave.\u00a0Objetivo\u00a0del\u00a0tratamiento: \u00a0\n\u2010 Concentraci\u00f3n \u00a0plasm\u00e1tica \u00a0de\u00a0colesterol \u00a0LDL,\u00a0seg\u00fan\u00a0los\u00a0factores\u00a0de\u00a0riesgo:\u00a0\nenfermedad \u00a0coronaria \u00a0o\u00a0riesgo\u00a0equivalente, \u00a0<100\u00a0mg/dL;\u00a02\u00a0\u00f3\u00a0m\u00e1s\u00a0factores\u00a0de\u00a0\nriesgo,\u00a0<\u00a0130\u00a0mg/dL;\u00a0y,\u00a00\u20101\u00a0factor\u00a0de\u00a0riesgo,\u00a0\u00a0<\u00a0160\u00a0mg/dL\u00a0\u00a0(JAMA\u00a02001;\u00a0285:\u00a0\n2486\u20102497).\u00a0\u00a0\n\u2010 Si\u00a0triglic\u00e9ridos \u00a0>500mg/dL, \u00a0se\u00a0tratar\u00e1\u00a0la\u00a0hipertrigliceridemia \u00a0\nindependientemente \u00a0la\u00a0concentraci\u00f3n \u00a0de\u00a0colesterol \u2010LDL\u00a0\nTratamiento: \u00a0\nEn\u00a0primer\u00a0lugar,\u00a0medidas\u00a0generales: \u00a0dieta\u00a0(consulta \u00a0a\u00a0experto\u00a0en\u00a0nutrici\u00f3n), \u00a0\nejercicio\u00a0f\u00edsico,\u00a0abstinencia \u00a0de\u00a0tabaco,\u00a0y\u00a0sobre\u00a0todo\u00a0valoraci\u00f3n \u00a0individualizada \u00a0de\u00a0la\u00a0\nretirada\u00a0de\u00a0IP\u00a0y/o\u00a0de\u00a0los\u00a0an\u00e1logos\u00a0de\u00a0la\u00a0timidina .\u00a0\nTratamiento \u00a0farmacol\u00f3gico \u00a0(si\u00a0medidas\u00a0previas\u00a0no\u00a0son\u00a0eficaces): \u00a0\u00a0\n\u2010 Estatinas. \u00a0Utilizar\u00a0preferentemente \u00a0atorvastatina. \u00a0En\u00a0caso\u00a0de\u00a0valores\u00a0de\u00a0\ncolesterol \u2010LDL\u00a0persistentemente \u00a0por\u00a0encima\u00a0del\u00a0objetivo\u00a0terap\u00e9utico, \u00a0valorar\u00a0\nla\u00a0adici\u00f3n\u00a0de\u00a0ezetimiba. \u00a0\n\u2010 Fibratos\u00a0si\u00a0hipertrigliceridemia \u00a0aislada\u00a0o\u00a0junto\u00a0a\u00a0elevaci\u00f3n \u00a0moderada \u00a0de\u00a0\ncolesterol \u2010LDL.\u00a0En\u00a0caso\u00a0de\u00a0hipertrigliceridemia \u00a0intensa\u00a0y\u00a0refractaria \u00a0puede\u00a0\na\u00f1adirse\u00a0\u00e1cidos\u00a0grasos\u00a0omega\u20103.\u00a0\n\u2010 Precauci\u00f3n \u00a0con\u00a0la\u00a0coadministraci\u00f3n \u00a0de\u00a0fibratos\u00a0y\u00a0estatinas\u00a0(mayor\u00a0riesgo\u00a0de\u00a0\ntoxicidad\u00a0muscular) \u00a0\n\u00a0\u00a0\n Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 1Tabla\u00a014.\u00a0Evaluaci\u00f3n \u00a0y\u00a0tratamiento \u00a0de\u00a0la\u00a0diabetes\u00a0mellitus\u00a0\n\u00a0\n\u00a0\nEvaluaci\u00f3n \u00a0 Tratamiento \u00a0\nRealizar\u00a0anal\u00edtica\u00a0en\u00a0ayunas\u00a0\nPrueba\u00a0de\u00a0tolerancia \u00a0oral\u00a0a\u00a0la\u00a0glucosa\u00a0(si\u00a0glucosa\u00a0\nbasal\u00a0alterada)\u00a0\nTratamiento \u00a0encaminado \u00a0a\u00a0evitar\u00a0las\u00a0\ncomplicaciones \u00a0metab\u00f3licas \u00a0a\u00a0corto\u00a0plazo\u00a0\n(hipoglucemia, \u00a0cetosis,\u00a0cetoacidosis, \u00a0y\u00a0estado\u00a0\nhiperosmolar) \u00a0y\u00a0las\u00a0complicaciones \u00a0micro\u00a0y\u00a0macro\u2010\nvasculares \u00a0a\u00a0largo\u00a0plazo\u00a0Valorar\u00a0individualizadamente \u00a0la\u00a0sustituci\u00f3n \u00a0de\u00a0an\u00e1logos\u00a0de\u00a0la\u00a0\ntimidina\u00a0y\u00a0otros\u00a0f\u00e1rmacos\u00a0no\u00a0antirretrovirales \u00a0que\u00a0pudieran\u00a0estar\u00a0\nimplicados \u00a0\nObjetivo\u00a0terap\u00e9utico \u00a0guiado\u00a0por\u00a0hemoglobina \u00a0glicosilada \u00a0(HbA1c)\u00a0\n<7%\u00a0\nConsulta\u00a0con\u00a0endocrin\u00f3logo \u00a0\nAntidiab\u00e9ticos \u00a0orales.\u00a0Metformina, \u00a0si\u00a0sobrepeso \u00a0u\u00a0obesidad\u00a0\nabdominal, \u00a0o\u00a0sulfonilureas. \u00a0Pioglitazona \u00a0si\u00a0lipoatrofia \u00a0\nInsulina\u00a0en\u00a0los\u00a0pacientes \u00a0con\u00a0diabetes\u00a0de\u00a0inicio\u00a0e\u00a0insulinopenia \u00a0\n(cetosis\u00a0o\u00a0cetoacidosis), \u00a0p\u00e9rdida\u00a0de\u00a0peso\u00a0y\u00a0cuando\u00a0no\u00a0sea\u00a0posible\u00a0\nconseguir \u00a0el\u00a0objetivo\u00a0de\u00a0HbA1c\u00a0<\u00a07%\u00a0con\u00a0antidiab\u00e9ticos \u00a0orales.\u00a0\nDeber\u00eda\u00a0considerarse \u00a0la\u00a0administraci\u00f3n \u00a0de\u00a075\u2010150\u00a0mg/d\u00eda\u00a0de\u00a0AAS\u00a0\na\u00a0todos\u00a0los\u00a0pacientes \u00a0con\u00a0diabetes.\u00a0\n\u00a0\n\u00a0\n Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 1\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 Tabla\u00a015.\u00a0Impacto\u00a0metab\u00f3lico \u00a0(lip\u00eddico\u00a0e\u00a0hidrocarbonado) \u00a0del\u00a0TARV.\u00a0\u00a0\n\u00a0Familias\u00a0y\u00a0f\u00e1rmacos \u00a0individuales \u00a0\n \n \n\u00a0\u00a0\nNN\u00a0 AN\u00a0 IP\u00a0\nNVP\u00a03TC\u00a0/\u00a0FTC\u00a0\nTDF\u00a0\u00a0\n\u00a0ATV\u00a0\u00a0\nFPV\u00a0\n\u00a0\nETR\u00a0\nEFV\u00a0ABC\u00a0\n\u00a0ATV/r\u00a0\nDRV/r\u00a0\u00a0\nSQV/r\u00a0\n\u00a0ZDV\u00a0\u00a0\nddI\u00a0LPV/r\u00a0\nFPV/r\u00a0\n\u00a0\n\u00a0 D4T\u00a0IDV/r\u00a0\nTPV/r\u00a0\nRTV\u00a0(dosis\u00a0plenas)\u00a0\nLos\u00a0datos\u00a0disponibles \u00a0de\u00a0los\u00a0inhibidores \u00a0de\u00a0la\u00a0fusi\u00f3n\u00a0(enfuvirtida), \u00a0inhibidores \u00a0de\u00a0la\u00a0\nintegrasa \u00a0(raltegravir) \u00a0y\u00a0del\u00a0correceptor \u00a0CCR5\u00a0(maraviroc) \u00a0sugieren\u00a0que\u00a0estos\u00a0\nf\u00e1rmacos \u00a0tienen\u00a0escaso\u00a0impacto\u00a0metab\u00f3lico \u00a0\n M\u00e1s\u00a0 Menos\nM\u00e1s\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n 1\u00a0\n\u00a0\nTabla\u00a016.\u00a0\u00a0Evaluaci\u00f3n \u00a0y\u00a0tratamiento \u00a0de\u00a0la\u00a0alteraci\u00f3n \u00a0de\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0grasa\u00a0corporal* \u00a0\n\u00a0\nEvaluaci\u00f3n \u00a0 Tratamiento \u00a0\nDiagn\u00f3stico \u00a0cl\u00ednico\u00a0\nSer\u00eda\u00a0deseable\u00a0la\u00a0realizaci\u00f3n \u00a0peri\u00f3dica \u00a0de\u00a0alguna\u00a0\nmedida\u00a0objetiva\u00a0de\u00a0la\u00a0composici\u00f3n \u00a0corporal\u00a0(seg\u00fan\u00a0\ndisponibilidad \u00a0y\u00a0posibilidades \u00a0econ\u00f3micas \u00a0de\u00a0cada\u00a0\ncentro)\u00a0\n\u00a0No\u00a0hay\u00a0ninguna\u00a0medida\u00a0que\u00a0haya\u00a0demostrado \u00a0resolver\u00a0satisfactoriamente \u00a0los\u00a0\ncambios\u00a0corporales. \u00a0Las\u00a0que\u00a0a\u00a0continuaci\u00f3n \u00a0se\u00a0describen \u00a0han\u00a0mostrado, \u00a0en\u00a0el\u00a0\nmejor\u00a0de\u00a0los\u00a0casos,\u00a0una\u00a0eficacia\u00a0parcial\u00a0y\u00a0algunas\u00a0de\u00a0ellas\u00a0no\u00a0est\u00e1n\u00a0exentas\u00a0de\u00a0\nriesgos:\u00a0\n\u2022 medidas\u00a0generales \u00a0(dieta,\u00a0ejercicio\u00a0f\u00edsico):\u00a0evitar\u00a0modificaciones \u00a0de\u00a0peso\u00a0>5%\u00a0\ndel\u00a0peso\u00a0ideal\u00a0;\u00a0el\u00a0ejercicio\u00a0f\u00edsico\u00a0aer\u00f3bico\u00a0mejora\u00a0las\u00a0alteraciones \u00a0metab\u00f3licas \u00a0\ny\u00a0la\u00a0lipoacumulaci\u00f3n \u00a0intraabdominal \u00a0\n\u2022 sustituci\u00f3n \u00a0de\u00a0FAR\u00a0(IP,\u00a0AN):\u00a0la\u00a0retirada\u00a0de\u00a0los\u00a0IP\u00a0cl\u00e1sicos\u00a0puede\u00a0mejorar\u00a0las\u00a0\nalteraciones \u00a0metab\u00f3licas \u00a0y\u00a0la\u00a0lipoacumulaci\u00f3n \u00a0intraabdominal; \u00a0la\u00a0retirada\u00a0de\u00a0\nan\u00e1logos\u00a0de\u00a0timidina\u00a0mejora\u00a0la\u00a0lipoatrofia \u00a0(existen\u00a0m\u00e1s\u00a0estudios\u00a0con\u00a0d4T\u00a0que\u00a0\ncon\u00a0AZT)\u00a0\u00a0\n\u2022 f\u00e1rmacos \u00a0con\u00a0efectos\u00a0metab\u00f3licos \u00a0(metformina, \u00a0glitazonas, \u00a0hormona\u00a0del\u00a0\ncrecimiento). \u00a0La\u00a0hormona\u00a0del\u00a0crecimiento \u00a0puede\u00a0disminuir \u00a0la\u00a0lipoacumulaci\u00f3n \u00a0\nintraabdominal \u00a0pero\u00a0provoca\u00a0hiperglucemia \u00a0y\u00a0otros\u00a0efectos\u00a0secundarios. \u00a0Se\u00a0\nhan\u00a0comunicado \u00a0buenos\u00a0resultados \u00a0en\u00a0la\u00a0lipoacumulaci\u00f3n \u00a0visceral\u00a0con\u00a0\ntesamorelina \u00a0(an\u00e1logo\u00a0del\u00a0factor\u00a0estimulante \u00a0de\u00a0la\u00a0hormona\u00a0de\u00a0crecimiento). \u00a0\nLos\u00a0efectos\u00a0de\u00a0todos\u00a0estos\u00a0f\u00e1rmacos \u00a0revierten\u00a0con\u00a0el\u00a0cese\u00a0del\u00a0mismo\u00a0y\u00a0ninguno\u00a0\nde\u00a0ellos\u00a0tiene\u00a0indicaci\u00f3n \u00a0para\u00a0el\u00a0tratamiento \u00a0de\u00a0la\u00a0lipodistrofia. \u00a0\n\u2022 cirug\u00eda\u00a0pl\u00e1stica\u00a0(relleno\u00a0facial\u00a0en\u00a0lipoatrofia, \u00a0cirug\u00eda\u00a0reductora \u00a0en\u00a0lipoac\u00famulos \u00a0\naccesibles): \u00a0es\u00a0el\u00a0\u00fanico\u00a0tratamiento \u00a0actual\u00a0con\u00a0resultados \u00a0inmediatos .\u00a0\n\u00a0\n*\u00a0La\u00a0alteraci\u00f3n \u00a0de\u00a0la\u00a0distribuci\u00f3n \u00a0de\u00a0la\u00a0grasa\u00a0corporal\u00a0es\u00a0una\u00a0complicaci\u00f3n \u00a0prevalente \u00a0y\u00a0limitante\u00a0de\u00a0la\u00a0calidad\u00a0de\u00a0vida\u00a0de\u00a0los\u00a0pacientes \u00a0que\u00a0\nreciben\u00a0TARV\u00a0\n Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n 1 Tabla\u00a017.\u00a0Ajuste\u00a0de\u00a0dosis\u00a0en\u00a0insuficiencia \u00a0renal\u00a0y\u00a0hep\u00e1tica\u00a0\nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0 Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0\n(HD/CAPD) \u00a0Insuficiencia \u00a0hep\u00e1tica\u00a0\n(IH)\u00a0\nInhibidores \u00a0TI,\u00a0an\u00e1logos\u00a0nucle\u00f3sido \u00a0\nABC\u00a0(abacavir) \u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\nNo\u00a0administrar \u00a0Combivir\u00ae\u00a0y\u00a0Trizivir\u00ae\u00a0en\u00a0\npacientes \u00a0con\u00a0Cl\u00a0<50\u00a0mL/min\u00a0\u00a0(por\u00a0\nseparado, \u00a0ajustar\u00a0dosis\u00a0\nadecuadamente) \u00a0Dosis\u00a0habitual.\u00a0\nHD:\u00a0administrar \u00a0independientemente \u00a0de\u00a0la\u00a0\nsesi\u00f3n\u00a0de\u00a0HD,\u00a0ya\u00a0que\u00a0se\u00a0elimina\u00a0m\u00ednimamente. \u00a0IH\u00a0leve\u00a0(Child\u2010Pugh\u00a05\u00a0a\u00a06):\u00a0200\u00a0mg\u00a0c/12h.\u00a0Utilizar\u00a0\u00a0la\u00a0\nsoluci\u00f3n\u00a0oral\u00a0de\u00a0Ziagen\u00ae\u00a0(10\u00a0mL\u00a0c/12h).\u00a0\n\u00a0\nIH\u00a0moderada \u2010grave:\u00a0la\u00a0seguridad, \u00a0eficacia\u00a0y\u00a0propiedades \u00a0\nfarmacocin\u00e9ticas \u00a0no\u00a0han\u00a0sido\u00a0evaluadas. \u00a0Evitar\u00a0en\u00a0lo\u00a0\nposible\u00a0su\u00a0uso.\u00a0\n\u00a0\nddI\u00a0\u00a0(didanosina, \u00a0\nc\u00e1psulas\u00a0ent\u00e9ricas) \u00a0\u2265\u00a060\u00a0Kg\u00a0\u00a0\u00a0\u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nCl\u00a0\u226560:\u00a0400\u00a0mg\u00a0c/24h\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nCl\u00a030\u201059:\u00a0200\u00a0mg\u00a0c/24h\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nCl\u00a010\u201029:\u00a0125\u00a0mg\u00a0c/24h\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\nCl\u00a0<10:\u00a0125\u00a0mg\u00a0c/24h\u00a0HD/CAPD: \u00a0125\u00a0mg\u00a0c/24h;\u00a0los\u00a0d\u00edas\u00a0de\u00a0HD\u00a0\nadministrar \u00a0post\u2010HD/CAPD \u00a0(no\u00a0requiere\u00a0\nsuplemento). \u00a0Riesgo\u00a0elevado\u00a0de\u00a0toxicidad\u00a0hep\u00e1tica\u00a0y\u00a0descompensaci\u00f3n. \u00a0\u00a0\nSu\u00a0uso\u00a0prolongado \u00a0se\u00a0ha\u00a0asociado\u00a0a\u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0\nhipertensi\u00f3n \u00a0portal\u00a0en\u00a0pacientes \u00a0no\u00a0cirr\u00f3ticos. \u00a0\nEn\u00a0pacientes \u00a0cirr\u00f3ticos, \u00a0no\u00a0se\u00a0recomienda \u00a0el\u00a0uso\u00a0de\u00a0\ndidanosina. \u00a0\n\u00a0\nEn\u00a0pacientes \u00a0en\u00a0tratamiento \u00a0del\u00a0VHC\u00a0didanosina \u00a0no\u00a0debe\u00a0\nadministrarse \u00a0conjuntamente \u00a0con\u00a0ribavirina. \u00a0\n\u00a0<60\u00a0kg\u00a0\n\u00a0\nCl\u00a0\u226560:\u00a0250\u00a0mg\u00a0c/24h\u00a0\nCl\u00a030\u201059:\u00a0125\u00a0mg\u00a0c/24h\u00a0\nCl\u00a010\u201029:\u00a0125\u00a0mg\u00a0c/24h\u00a0\nCl\u00a0<10:\u00a0no\u00a0existen\u00a0presentaciones \u00a0\nadecuadas. \u00a0Utilizar\u00a0los\u00a0comprimidos. \u00a0HD/CAPD: \u00a0no\u00a0existen\u00a0presentaciones \u00a0\nadecuadas. \u00a0Utilizar\u00a0los\u00a0comprimidos \u00a0\ntamponados. \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n 2 \u00a0\nAntirretrovirales \u00a0Insuficiencia \u00a0renal\u00a0Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0\n(HD/CAPD) \u00a0Insuficiencia \u00a0hep\u00e1tica\u00a0\n(IH)\u00a0\nFTC\u00a0(emtricitabina) \u00a0En\u00a0comprimidos: \u00a0\nCl\u00a0\u226550:\u00a0200\u00a0mg\u00a0c/24h\u00a0\u00a0\nCl\u00a030\u201049:\u00a0200\u00a0mg\u00a0c/48h\u00a0\nCl\u00a015\u201029:\u00a0200\u00a0mg\u00a0c/72h\u00a0\nCl\u00a0<15:\u00a0200\u00a0mg\u00a0c/96h\u00a0\u00a0\n\u00a0\nEn\u00a0soluci\u00f3n:\u00a0\nCl\u00a0\u226550:\u00a0240\u00a0mg\u00a0(24\u00a0ml)\u00a0c/24h\u00a0\u00a0\nCl\u00a030\u201049:\u00a0120\u00a0mg\u00a0(12\u00a0ml)\u00a0c/24h\u00a0\nCl\u00a015\u201029:\u00a080\u00a0mg\u00a0(8\u00a0ml)\u00a0c/24h\u00a0\nCl\u00a0<15:\u00a060\u00a0mg\u00a0(6\u00a0ml)\u00a0c/24h\u00a0\u00a0\n\u00a0\nTruvada\u00ae:\u00a0no\u00a0administrar \u00a0a\u00a0pacientes \u00a0\ncon\u00a0Cl\u00a0<\u00a030\u00a0mL/min\u00a0HD:\u00a0200\u00a0mg\u00a0c/96h\u00a0en\u00a0compr\u00a0o\u00a060\u00a0mg\u00a0(6\u00a0\nml)\u00a0en\u00a0soluci\u00f3n\u00a0oral;\u00a0los\u00a0d\u00edas\u00a0de\u00a0HD\u00a0\nadministrar \u00a0post\u2010HD\u00a0\nNo\u00a0se\u00a0ha\u00a0estudiado \u00a0en\u00a0di\u00e1lisis\u00a0\nperitoneal. \u00a0\nTruvada\u00ae:\u00a0no\u00a0administrar \u00a0a\u00a0pacientes \u00a0\nen\u00a0HD\u00a0(administrar \u00a0los\u00a0componentes \u00a0\npor\u00a0separado, \u00a0ajustando \u00a0dosis\u00a0\nadecuadamente) \u00a0Dosis\u00a0habitual\u00a0(no\u00a0hay\u00a0datos,\u00a0pero\u00a0en\u00a0base\u00a0a\u00a0su\u00a0m\u00ednimo\u00a0\nmetabolismo \u00a0hep\u00e1tico, \u00a0es\u00a0poco\u00a0probable\u00a0que\u00a0requiera\u00a0ajuste\u00a0de\u00a0\ndosis).\u00a0\n\u00a0\n\u00a0\nd4T\u00a0(didanosina) \u00a0\u2265\u00a060\u00a0Kg\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n\u00a0\u00a0\nCl\u00a0\u226550:\u00a040\u00a0mg\u00a0c/12h\u00a0\u00a0\u00a0\u00a0\nCl\u00a026\u201049:\u00a020\u00a0mg\u00a0c/12h\u00a0\u00a0\u00a0\u00a0\nCl\u00a0<\u00a025:\u00a020\u00a0mg\u00a0c/24h\u00a0\u00a0\u00a0\u00a0HD:\u00a0\u00a020\u00a0mg\u00a0c/24h;\u00a0los\u00a0d\u00edas\u00a0de\u00a0HD\u00a0\nadministrar \u00a0post\u2010HD\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\nDosis\u00a0habitual.\u00a0\u00a0Utilizar\u00a0con\u00a0precauci\u00f3n \u00a0por\u00a0el\u00a0riesgo\u00a0de\u00a0toxicidad\u00a0\nmitocondrial \u00a0y\u00a0esteatosis \u00a0hep\u00e1tica.\u00a0\n<60\u00a0kg\u00a0\n\u00a0\nCl\u00a0\u226550:\u00a030\u00a0mg\u00a0c/12h\u00a0\nCl\u00a026\u201049:\u00a015\u00a0mg\u00a0c/12h\u00a0\nCl\u00a0<\u00a025:\u00a015\u00a0mg\u00a0c/24h\u00a0HD:\u00a0\u00a015\u00a0mg\u00a0c/24h;\u00a0los\u00a0d\u00edas\u00a0de\u00a0HD\u00a0\nadministrar \u00a0post\u2010HD\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n 3 Antirretrovirales \u00a0Insuficiencia \u00a0renal\u00a0 Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0\n(HD/CAPD) \u00a0\n\u00a0Insuficiencia \u00a0hep\u00e1tica\u00a0\n(IH)\u00a0\n3TC\u00a0(lamivudina) \u00a0\n\u00a0Cl\u00a0\u2265\u00a050:\u00a0150\u00a0mg\u00a0c/12h\u00a0\u00f3\u00a0300\u00a0mg\u00a0c/24h\u00a0\nCl\u00a030\u201049:\u00a0150\u00a0mg\u00a0c/24h\u00a0(primera\u00a0dosis\u00a0de\u00a0150\u00a0mg)\u00a0\nCl\u00a015\u201029:\u00a0100\u00a0mg\u00a0c/24h\u00a0(primera\u00a0dosis\u00a0150\u00a0mg)\u00a0\nCl\u00a05\u201014:\u00a050\u00a0mg\u00a0c/24h\u00a0(primera\u00a0dosis\u00a0150\u00a0mg)\u00a0\nCl\u00a0<5:\u00a025\u00a0mg\u00a0c/24h\u00a0(primera\u00a0dosis\u00a050\u00a0mg)\u00a0\nNo\u00a0administrar \u00a0Combivir\u00ae\u00a0y\u00a0Trizivir\u00ae\u00a0si\u00a0\u00a0Cl\u00a0<50\u00a0mL/min\u00a0\u00a0\n(administrar \u00a0los\u00a0componentes \u00a0por\u00a0separado, \u00a0ajustando \u00a0\ndosis\u00a0adecuadamente) \u00a0HD:\u00a025\u00a0mg\u00a0c/24h\u00a0(primera\u00a0dosis\u00a050\u00a0mg)\u00a0Los\u00a0\nd\u00edas\u00a0de\u00a0la\u00a0HD,\u00a0administrar \u00a0post\u2010HD.\u00a0\n\u00a0\u00a0Dosis\u00a0habitual\u00a0\n\u00a0\nZDV\u00a0(zidovudina) \u00a0Puede\u00a0acumularse \u00a0el\u00a0metabolito \u00a0glucur\u00f3nido \u00a0(GAZT)\u00a0\n\u00a0\nCl\u00a010\u201050:\u00a0250\u2010300\u00a0mg\u00a0c/12h.\u00a0\nCl\u00a0<10:\u00a0250\u2010300\u00a0mg\u00a0c/24h.\u00a0\u00a0\n\u00a0\nNo\u00a0administrar \u00a0Combivir\u00ae\u00a0y\u00a0Trizivir\u00ae\u00a0en\u00a0pacientes \u00a0con\u00a0Cl\u00a0\n<50\u00a0mL/min\u00a0\u00a0(administrar \u00a0los\u00a0componentes \u00a0por\u00a0\nseparado, \u00a0ajustando \u00a0dosis\u00a0adecuadamente) \u00a0\n\u00a0300\u00a0mg\u00a0c/24h.\u00a0\nHD/CAPD: \u00a0no\u00a0afecta\u00a0la\u00a0eliminaci\u00f3n \u00a0de\u00a0AZT\u00a0y\u00a0\naumenta\u00a0la\u00a0eliminaci\u00f3n \u00a0de\u00a0GAZT.\u00a0Por\u00a0\nprecauci\u00f3n, \u00a0se\u00a0recomienda \u00a0administrar \u00a0la\u00a0dosis\u00a0\ndiaria\u00a0post\u2010HD/CAPD. \u00a0Se\u00a0ha\u00a0observado \u00a0una\u00a0reducci\u00f3n \u00a0del\u00a0\naclaramiento \u00a0oral\u00a0de\u00a0zidovudina \u00a0el\u00a032%,\u00a0\n63%\u00a0\u00a0y\u00a070%,\u00a0respectivamente, \u00a0en\u00a0\npacientes \u00a0con\u00a0IH\u00a0leve,\u00a0moderada \u2010grave\u00a0\n\u00f3\u00a0cirrosis\u00a0comprobada \u00a0por\u00a0biopsia,\u00a0en\u00a0\ncomparaci\u00f3n \u00a0con\u00a0sujetos\u00a0sin\u00a0alteraci\u00f3n \u00a0\nhep\u00e1tica.\u00a0\u00a0\n\u00a0\nAlgunos\u00a0autores\u00a0sugieren\u00a0reducir\u00a0la\u00a0\ndosis\u00a0a\u00a0200\u00a0mg\u00a0c/12h\u00a0en\u00a0pacientes \u00a0con\u00a0\nIH\u00a0grave.\u00a0Se\u00a0recomienda \u00a0monitorizar \u00a0\nestrechamente \u00a0la\u00a0aparici\u00f3n \u00a0de\u00a0toxicidad\u00a0\nhematol\u00f3gica. \u00a0\u00a0\n\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n 4  \nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0 Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0\n(HD/CAPD) \u00a0Insuficiencia \u00a0hep\u00e1tica\u00a0\n(IH)\u00a0\nInhibidores \u00a0TI,\u00a0an\u00e1logos\u00a0nucle\u00f3tido \u00a0\nTDF\u00a0(tenofovir) \u00a0Cl\u00a0\u2265\u00a050:\u00a0no\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\nCl\u00a030\u201049:\u00a0300\u00a0mg\u00a0c/48h\u00a0\nCl\u00a010\u201029:\u00a0300\u00a0mg\u00a0c/72\u00a0a\u00a096h\u00a0\nNo\u00a0hay\u00a0recomendaciones \u00a0disponibles \u00a0\npara\u00a0pacientes \u00a0con\u00a0Cl\u00a0<10\u00a0sin\u00a0HD\u00a0\n\u00a0HD:\u00a0habitualmente \u00a0300\u00a0mg\u00a0una\u00a0vez\u00a0por\u00a0\nsemana,\u00a0despu\u00e9s\u00a0de\u00a0una\u00a0de\u00a0las\u00a0sesiones\u00a0\n(asumiendo \u00a03\u00a0sesiones\u00a0de\u00a0di\u00e1lisis\u00a0\nsemanales \u00a0de\u00a04h)\u00a0Dosis\u00a0habitual\u00a0\nInhibidores \u00a0de\u00a0la\u00a0TI,\u00a0no\u00a0an\u00e1logos\u00a0\nEFV\u00a0(efavirenz) \u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis.\u00a0\n\u00a0\nAtripla\u00ae:\u00a0en\u00a0pacientes \u00a0con\u00a0Cl\u00a0<50\u00a0\nml/min,\u00a0utilizar\u00a0los\u00a0principios \u00a0activos\u00a0\npor\u00a0separado. \u00a0\u00a0HD:\u00a0no\u00a0parece\u00a0necesario \u00a0ajustar\u00a0la\u00a0\ndosis.\u00a0Sin\u00a0embargo, \u00a0por\u00a0la\u00a0elevada\u00a0\nvariabilidad \u00a0interindividual, \u00a0se\u00a0\nrecomienda \u00a0monitorizar \u00a0niveles\u00a0\nplasm\u00e1ticos. \u00a0\u00a0\n\u00a0\nCAPD:\u00a0un\u00a0estudio\u00a0farmacocin\u00e9tico \u00a0\npreliminar \u00a0indica\u00a0que\u00a0no\u00a0se\u00a0requiere\u00a0\najuste\u00a0de\u00a0dosis\u00a0(datos\u00a0de\u00a0un\u00a0solo\u00a0\npaciente). \u00a0IH\u00a0leve\u00a0a\u00a0moderada: \u00a0dosis\u00a0habitual.\u00a0Dada\u00a0la\u00a0elevada\u00a0variabilidad \u00a0\ninterindividual, \u00a0se\u00a0recomienda \u00a0monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0y\u00a0\naparici\u00f3n \u00a0de\u00a0efectos\u00a0adversos, \u00a0especialmente \u00a0a\u00a0nivel\u00a0de\u00a0SNC.\u00a0\u00a0\n\u00a0\nIH\u00a0grave:\u00a0datos\u00a0escasos.\u00a0Evitar\u00a0en\u00a0lo\u00a0posible\u00a0su\u00a0uso/\u00a0monitorizar \u00a0\nniveles\u00a0plasm\u00e1ticos. \u00a0En\u00a0un\u00a0paciente\u00a0con\u00a0Child\u00a0Pugh\u00a0grado\u00a0C,\u00a0la\u00a0\nsemivida\u00a0de\u00a0EFV\u00a0se\u00a0duplic\u00f3.\u00a0En\u00a0dos\u00a0pacientes \u00a0con\u00a0IH\u00a0(uno\u00a0de\u00a0\nellos\u00a0con\u00a0cirrosis)\u00a0el\u00a0AUC\u00a0de\u00a0EFV\u00a0aument\u00f3\u00a04\u00a0veces.\u00a0\u00a0En\u00a03\u00a0\npacientes \u00a0con\u00a0fibrosis\u00a0>12\u00a0kPa\u00a0(Fibroscan\u00ae) \u00a0la\u00a0Cmin\u00a0fue\u00a02,5\u00a0veces\u00a0\nsuperior\u00a0a\u00a0la\u00a0obtenida\u00a0en\u00a015\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0VHC\u00a0con\u00a0\nfibrosis\u00a0<12kPa.\u00a0\u00a0\nEn\u00a0otro\u00a0estudio\u00a0el\u00a031%\u00a0de\u00a0los\u00a0pacientes \u00a0cirr\u00f3ticos \u00a0presentaron \u00a0\nunas\u00a0concentraciones \u00a0>\u00a04000\u00a0ng/mL,\u00a0en\u00a0comparaci\u00f3n \u00a0con\u00a0un\u00a03%\u00a0\nen\u00a0los\u00a0coinfectados \u00a0no\u00a0cirr\u00f3ticos. \u00a0\n\u00a0\n\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n 5 \u00a0\nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0\n(HD/CAPD) \u00a0Insuficiencia \u00a0hep\u00e1tica\u00a0\n(IH)\u00a0\nNVP\u00a0(nevirapina) \u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis.\u00a0 HD:\u00a0los\u00a0d\u00edas\u00a0de\u00a0HD,\u00a0se\u00a0recomienda \u00a0\nadministrar \u00a0la\u00a0dosis\u00a0despu\u00e9s\u00a0de\u00a0la\u00a0\nHD\u00a0\u00f3\u00a0un\u00a0suplemento \u00a0de\u00a0200\u00a0mg\u00a0\npost\u2010hemodi\u00e1lisis. \u00a0\u00a0IH\u00a0leve\u00a0a\u00a0moderada \u00a0(Child\u2010Pugh\u00a0\u22647):\u00a0dosis\u00a0habitual.\u00a0Sin\u00a0embargo, \u00a0en\u00a0\npacientes \u00a0con\u00a0IH\u00a0moderada, \u00a0se\u00a0recomienda \u00a0monitorizar \u00a0\nestrechamente \u00a0niveles\u00a0plasm\u00e1ticos \u00a0y\u00a0aparici\u00f3n \u00a0de\u00a0efectos\u00a0adversos. \u00a0\nEn\u00a0un\u00a0estudio\u00a0en\u00a04\u00a0pacientes \u00a0con\u00a0\u00a0IH\u00a0moderada \u00a0(Child\u2010Pugh\u00a0B),\u00a0el\u00a0\nAUC\u00a0de\u00a0NVP\u00a0aument\u00f3\u00a041%.\u00a0\u00a0\n\u00a0\nIH\u00a0grave:\u00a0Evitar\u00a0en\u00a0lo\u00a0posible\u00a0su\u00a0uso\u00a0(hepatotoxicidad). \u00a0\u00a0\u00a0\u00a0\n\u00a0\nEn\u00a0el\u00a0estudio\u00a0NEVADOSE \u00a066%\u00a0de\u00a0los\u00a0pacientes \u00a0con\u00a0un\u00a0mayor\u00a0grado\u00a0\nde\u00a0fibrosis\u00a0(F4;\u00a0Fibroscan\u00ae) \u00a0presentaron \u00a0una\u00a0Cmin\u00a0de\u00a0NVP\u00a0por\u00a0\nencima\u00a0del\u00a0l\u00edmite\u00a0superior\u00a0de\u00a0normalidad \u00a0(>6000\u00a0ng/mL).\u00a0En\u00a0otro\u00a0\nestudio\u00a0el\u00a050%\u00a0de\u00a0los\u00a0pacientes \u00a0cirr\u00f3ticos \u00a0presentaron \u00a0unas\u00a0\nconcentraciones \u00a0>\u00a08000\u00a0ng/mL,\u00a0en\u00a0comparaci\u00f3n \u00a0con\u00a0un\u00a027%\u00a0en\u00a0los\u00a0\ncoinfectados \u00a0no\u00a0cirr\u00f3ticos. \u00a0\n\u00a0\nSe\u00a0ha\u00a0observado \u00a0un\u00a0aumento\u00a0de\u00a0riesgo\u00a0de\u00a0hepatotoxicidad \u00a0en\u00a0\npacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0con\u00a0CD4\u00a0>250\u00a0c\u00e9ls/\u00b5L\u00a0(mujeres) \u00a0o\u00a0\u00a0\n>400\u00a0c\u00e9ls/\u00b5L\u00a0(hombres) \u00a0\n\u00a0\nETR\u00a0(etravirina) \u00a0NRAD\u00a0 HD/CAPD: \u00a0por\u00a0su\u00a0elevada\u00a0uni\u00f3n\u00a0a\u00a0\nprote\u00ednas \u00a0plasm\u00e1ticas, \u00a0no\u00a0es\u00a0de\u00a0\nesperar\u00a0que\u00a0se\u00a0elimine\u00a0en\u00a0las\u00a0\nsesiones\u00a0de\u00a0HD/CAPD. \u00a0\n\u00a0IH\u00a0leve\u00a0o\u00a0moderada: \u00a0no\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\n\u00a0\nIH\u00a0grave:\u00a0no\u00a0hay\u00a0datos;\u00a0evitar\u00a0en\u00a0lo\u00a0posible\u00a0su\u00a0uso.\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n 6 \u00a0\nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0\n(HD/CAPD) \u00a0Insuficiencia \u00a0hep\u00e1tica\u00a0\n(IH)\u00a0\nInhibidores \u00a0de\u00a0la\u00a0\u00a0proteasa\u00a0\nATV\u00a0(atazanavir) \u00a0 No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0HD/CAPD: \u00a0por\u00a0su\u00a0elevada\u00a0uni\u00f3n\u00a0a\u00a0\nprote\u00ednas \u00a0plasm\u00e1ticas, \u00a0no\u00a0es\u00a0de\u00a0\nesperar\u00a0que\u00a0se\u00a0elimine\u00a0en\u00a0las\u00a0\nsesiones\u00a0de\u00a0HD/CAPD. \u00a0\n\u00a0\nHD:\u00a0se\u00a0recomienda \u00a0su\u00a0uso\u00a0\npotenciado \u00a0(\u00a0ATV/r\u00a0300/100)\u00a0para\u00a0\ncompensar \u00a0el\u00a0descenso \u00a0de\u00a0\nconcentraci\u00f3n \u00a0de\u00a0ATV\u00a0(reducci\u00f3n \u00a0\ndel\u00a028%\u00a0en\u00a0el\u00a0AUC\u00a0de\u00a0ATV;\u00a0la\u00a0\neliminaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0la\u00a0HD\u00a0es\u00a0de\u00a0\ns\u00f3lo\u00a0el\u00a02%).\u00a0Monitorizar \u00a0niveles\u00a0\nplasm\u00e1ticos \u00a0cuando\u00a0sea\u00a0posible\u00a0IH\u00a0moderada \u00a0(Child\u2010Pugh\u00a0B\u00a07\u20109):\u00a0seg\u00fan\u00a0un\u00a0estudio\u00a0en\u00a0pacientes \u00a0\ncoinfectados \u00a0con\u00a0VHC\u00a0con\u00a0IH\u00a0leve\u00a0a\u00a0moderada, \u00a0el\u00a0ATV\u00a0no\u00a0potenciado \u00a0\n(400\u00a0mg/24h)\u00a0puede\u00a0no\u00a0llegar\u00a0a\u00a0alcanzar\u00a0la\u00a0Cm\u00edn\u00a0deseada\u00a0(6/9\u00a0\npacientes \u00a0con\u00a0niveles\u00a0subterap\u00e9uticos). \u00a0\u00a0\n\u00a0\nIH\u00a0grave:\u00a0Datos\u00a0limitados\u00a0apoyan\u00a0el\u00a0uso\u00a0de\u00a0ATV\u00a0no\u00a0potenciado \u00a0(400\u00a0\nmg/24\u00a0h)\u00a0en\u00a0pacientes \u00a0en\u00a0insuficiencia \u00a0hep\u00e1tica\u00a0en\u00a0fase\u00a0terminal\u00a0pre\u00a0\ntrasplante. \u00a0\n\u00a0\nEn\u00a09\u00a0pacientes \u00a0con\u00a0fibrosis\u00a0>12\u00a0kPa\u00a0(Fibroscan\u00ae) \u00a0que\u00a0recibieron \u00a0\nATV/r,\u00a0la\u00a0Cmin\u00a0fue\u00a0comparable \u00a0a\u00a0la\u00a0obtenida\u00a0en\u00a026\u00a0pacientes \u00a0\ncoinfectados \u00a0por\u00a0VHC\u00a0con\u00a0fibrosis<12 \u00a0kPa.\u00a0Un\u00a0\u00a0estudio\u00a0en\u00a012\u00a0\npacientes \u00a0coinfectados \u00a0por\u00a0VHC\u00a0tratados\u00a0con\u00a0ATV/r,\u00a0el\u00a0AUC\u00a0fue\u00a0solo\u00a0\nun\u00a036%\u00a0superior\u00a0en\u00a0los\u00a0pacientes \u00a0cirr\u00f3ticos \u00a0(n=7)\u00a0\u00a0\n\u00a0\nMonitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0cuando\u00a0sea\u00a0posible.\u00a0\n\u00a0\nDRV\u00a0(darunavir) \u00a0IR\u00a0leve\u00a0o\u00a0moderada: \u00a0no\u00a0requiere\u00a0ajuste\u00a0\nde\u00a0dosis\u00a0\n\u00a0\nIR\u00a0grave\u00a0o\u00a0en\u00a0estado\u00a0terminal:\u00a0no\u00a0hay\u00a0\ndatos.\u00a0Sin\u00a0embargo, \u00a0debido\u00a0a\u00a0su\u00a0\nlimitada\u00a0eliminaci\u00f3n \u00a0renal,\u00a0no\u00a0es\u00a0de\u00a0\nesperar\u00a0que\u00a0el\u00a0aclaramiento \u00a0total\u00a0\ndisminuya \u00a0en\u00a0pacientes \u00a0con\u00a0IR.\u00a0\u00a0HD/CAPD: \u00a0debido\u00a0a\u00a0la\u00a0elevada\u00a0uni\u00f3n\u00a0\na\u00a0prote\u00ednas \u00a0plasm\u00e1ticas, \u00a0no\u00a0es\u00a0de\u00a0\nesperar\u00a0que\u00a0se\u00a0elimine\u00a0en\u00a0las\u00a0\nsesiones\u00a0de\u00a0HD/CAPD. \u00a0IH\u00a0leve\u00a0o\u00a0moderada: \u00a0no\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\u00a0\n\u00a0\nIH\u00a0grave:\u00a0no\u00a0hay\u00a0datos;\u00a0evitar\u00a0en\u00a0lo\u00a0posible\u00a0su\u00a0uso.\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n 7  \nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0\n(HD/CAPD) \u00a0Insuficiencia \u00a0hep\u00e1tica\u00a0\n(IH)\u00a0\nFPV\u00a0(fosamprenavir) \u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0\ndosis\u00a0\u00a0\nHD/CAPD: \u00a0debido\u00a0a\u00a0su\u00a0elevada\u00a0uni\u00f3n\u00a0\na\u00a0prote\u00ednas \u00a0plasm\u00e1ticas, \u00a0no\u00a0es\u00a0de\u00a0\nesperar\u00a0que\u00a0se\u00a0elimine\u00a0en\u00a0las\u00a0sesiones\u00a0\nde\u00a0HD/CAPD. \u00a0FPV\u00a0\u00a0(no\u00a0potenciado): Utilizar\u00a0solamente \u00a0en\u00a0pacientes \u00a0sin\u00a0tratamiento \u00a0previo\u00a0\nIH\u00a0leve\u00a0a\u00a0moderada \u00a0(Child\u2010Pugh\u00a05\u20108):\u00a0700\u00a0mg\u00a0c/12h\u00a0\u00a0\nIH\u00a0grave\u00a0(Child\u2010Pugh\u00a0>9):\u00a0350\u00a0mg/12\u00a0horas\u00a0\nUtilizar\u00a0con\u00a0precauci\u00f3n. \u00a0Se\u00a0recomienda \u00a0la\u00a0monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0\ncuando\u00a0sea\u00a0posible.\u00a0\n\u00a0\nFPV/r\u00a0\u00a0en\u00a0pacientes \u00a0con\u00a0o\u00a0sin\u00a0tratamiento \u00a0previo :\u00a0\nIH\u00a0leve\u00a0(Child\u2010Pugh\u00a05\u20106):\u00a0700\u00a0mg\u00a0c/12h\u00a0+\u00a0RTV\u00a0100\u00a0mg/24\u00a0horas\u00a0\u00a0\nIH\u00a0moderada \u00a0(Child\u2010Pugh\u00a07\u20109):\u00a0450\u00a0mg\u00a0c/12h\u00a0+\u00a0RTV\u00a0100\u00a0mg/24\u00a0horas\u00a0\u00a0\nIH\u00a0grave\u00a0(Child\u2010Pugh\u00a0>9):\u00a0300\u00a0mg\u00a0c/12h\u00a0+\u00a0RTV\u00a0100\u00a0mg/24\u00a0horas\u00a0\nUtilizar\u00a0con\u00a0precauci\u00f3n. \u00a0Se\u00a0recomienda \u00a0la\u00a0monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0\ncuando\u00a0sea\u00a0posible.\u00a0\nIDV\u00a0(indinavir) \u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0\ndosis\u00a0HD:\u00a0probablemente \u00a0no\u00a0requiera\u00a0\najuste\u00a0de\u00a0dosis\u00a0si\u00a0funci\u00f3n\u00a0hep\u00e1tica\u00a0\nconservada \u00a0(datos\u00a0de\u00a0un\u00a0solo\u00a0\npaciente). \u00a0Se\u00a0elimina\u00a0m\u00ednimamente \u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0la\u00a0HD.\u00a0IDV\u00a0(no\u00a0potenciado):\nIH\u00a0leve\u00a0a\u00a0moderada: \u00a0600\u00a0mg\u00a0c/8h.\u00a0\u00a0\nIH\u00a0grave:\u00a0no\u00a0hay\u00a0datos.\u00a0\u00a0\nSe\u00a0recomienda \u00a0monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0cuando\u00a0sea\u00a0posible.\u00a0\u00a0\n\u00a0\nIDV/r :\u00a0\u00a0\nAlgunos\u00a0pacientes \u00a0coinfectados \u00a0con\u00a0VHC\u00a0pueden\u00a0requerir\u00a0reducci\u00f3n \u00a0de\u00a0dosis,\u00a0\nhabitualmente \u00a0IDV/r\u00a0\u00a0400/100\u00a0mg\u00a0C/12h\u00a0o,\u00a0incluso\u00a0IDV/r\u00a0200/100\u00a0mg\u00a0c/12h.\u00a0\u00a0\u00a0\nSe\u00a0recomienda \u00a0monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0cuando\u00a0sea\u00a0posible.\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n 8 \u00a0\nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0\n(HD/CAPD) \u00a0Insuficiencia \u00a0hep\u00e1tica\u00a0\n(IH)\u00a0\nLPV/r\u00a0(lopinavir/r) \u00a0 No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0HD:\u00a0El\u00a0AUC\u00a0de\u00a0LPV/r\u00a0en\u00a013\u00a0pacientes \u00a0\nen\u00a0HD\u00a0fue\u00a0equivalente \u00a0a\u00a0la\u00a0de\u00a0\npacientes \u00a0con\u00a0funci\u00f3n\u00a0renal\u00a0normal.\u00a0\nNo\u00a0ajuste\u00a0de\u00a0dosis.\u00a0\u00a0\n\u00a0\nCAPD:\u00a0no\u00a0hay\u00a0datos.\u00a0Debido\u00a0a\u00a0la\u00a0\nelevada\u00a0uni\u00f3n\u00a0a\u00a0prote\u00ednas \u00a0\nplasm\u00e1ticas \u00a0de\u00a0lopinavir\u00a0y\u00a0ritonavir,\u00a0\nno\u00a0es\u00a0de\u00a0esperar\u00a0que\u00a0se\u00a0elimine\u00a0en\u00a0\nlas\u00a0sesiones\u00a0de\u00a0CAPD.\u00a0\n\u00a0Diferentes \u00a0estudios\u00a0indican\u00a0que\u00a0la\u00a0farmacocin\u00e9tica \u00a0de\u00a0LPV/r\u00a0no\u00a0se\u00a0\nmodifica\u00a0de\u00a0modo\u00a0importante \u00a0en\u00a0presencia \u00a0de\u00a0insuficiencia \u00a0\nhep\u00e1tica,\u00a0aunque\u00a0las\u00a0concentraciones \u00a0de\u00a0RTV\u00a0son\u00a0algo\u00a0mayores.\u00a0\n\u00a0\nEn\u00a0un\u00a0estudio\u00a011\u00a0pacientes \u00a0con\u00a0fibrosis\u00a0>12\u00a0kPa\u00a0(Fibroscan\u00ae) \u00a0la\u00a0Cmin\u00a0\nfue\u00a0comparable \u00a0a\u00a0la\u00a0obtenida\u00a0en\u00a028\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0VHC\u00a0\ncon\u00a0fibrosis<12 \u00a0kPa.\u00a0\u00a0\n\u00a0\u00a0\nSe\u00a0recomienda \u00a0monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0cuando\u00a0sea\u00a0posible.\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n 9 \u00a0\nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0\n(HD/CAPD) \u00a0Insuficiencia \u00a0hep\u00e1tica\u00a0\n(IH)\u00a0\nNFV\u00a0(nelfinavir) \u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\u00a0HD:\u00a0no\u00a0es\u00a0probable\u00a0que\u00a0NFV\u00a0se\u00a0\nelimine\u00a0significativamente \u00a0a\u00a0trav\u00e9s\u00a0\nde\u00a0la\u00a0HD.\u00a0Datos\u00a0de\u00a0un\u00a0paciente\u00a0con\u00a0\nIH\u00a0mostraron \u00a0la\u00a0ausencia\u00a0de\u00a0\neliminaci\u00f3n \u00a0de\u00a0NFV\u00a0durante\u00a0una\u00a0\nsesi\u00f3n\u00a0de\u00a0HD\u00a0de\u00a04\u00a0horas.\u00a0\u00a0\n\u00a0\nCAPD:\u00a0no\u00a0es\u00a0probable\u00a0que\u00a0NFV\u00a0se\u00a0\nelimine\u00a0significativamente \u00a0a\u00a0trav\u00e9s\u00a0\nde\u00a0la\u00a0CAPD.\u00a0En\u00a0un\u00a0paciente\u00a0tratado\u00a0\ncon\u00a01250\u00a0mg\u00a0c/12h\u00a0de\u00a0NFV,\u00a0las\u00a0\nconcentraciones \u00a0en\u00a0el\u00a0l\u00edquido\u00a0de\u00a0\ndi\u00e1lisis\u00a0fueron\u00a0inferiores \u00a0al\u00a0l\u00edmite\u00a0de\u00a0\ndetecci\u00f3n. \u00a0\n\u00a0Dosis\u00a0habitual\u00a0\u00a0\n(aunque\u00a0en\u00a0presencia \u00a0de\u00a0IH\u00a0aumenta\u00a0el\u00a0AUC\u00a0de\u00a0NFV\u00a0entre\u00a0un\u00a049\u00a0%\u00a0y\u00a0\nun\u00a069\u00a0%,\u00a0los\u00a0datos\u00a0no\u00a0parecen\u00a0indicar\u00a0que\u00a0se\u00a0produzca\u00a0un\u00a0aumento\u00a0\nde\u00a0toxicidad). \u00a0\u00a0\u00a0\n\u00a0\nSe\u00a0recomienda \u00a0monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0cuando\u00a0sea\u00a0posible.\u00a0\n\u00a0\nRTV\u00a0(ritonavir) \u00a0 No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\n\u00a0HD/CAPD: \u00a0debido\u00a0a\u00a0la\u00a0elevada\u00a0uni\u00f3n\u00a0\na\u00a0prote\u00ednas \u00a0plasm\u00e1ticas \u00a0de\u00a0ritonavir,\u00a0\nno\u00a0es\u00a0de\u00a0esperar\u00a0que\u00a0se\u00a0elimine\u00a0en\u00a0\nlas\u00a0sesiones\u00a0de\u00a0HD/CAPD \u00a0\n\u00a0No\u00a0usar\u00a0RTV\u00a0a\u00a0dosis\u00a0plenas\u00a0por\u00a0el\u00a0riesgo\u00a0de\u00a0hepatotoxicidad. \u00a0\n\u00a0\nRitonavir\u00a0como\u00a0potenciador \u00a0farmacocin\u00e9tico: \u00a0\u00a0\nIH\u00a0leve\u00a0a\u00a0moderada: \u00a0dosis\u00a0habitual.\u00a0\nIH\u00a0grave:\u00a0no\u00a0hay\u00a0datos.\u00a0Evitar\u00a0en\u00a0lo\u00a0posible\u00a0su\u00a0uso.\u00a0\n\u00a0\n\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n 10\u00a0\nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0\n(HD/CAPD) \u00a0Insuficiencia \u00a0hep\u00e1tica\u00a0\n(IH)\u00a0\nSQV\u00a0(saquinavir) \u00a0\u00a0\nNo\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis.\u00a0\u00a0\n\u00a0\n\u00a0HD/CAPD: \u00a0debido\u00a0a\u00a0la\u00a0elevada\u00a0uni\u00f3n\u00a0\na\u00a0prote\u00ednas \u00a0plasm\u00e1ticas \u00a0de\u00a0ritonavir,\u00a0\nno\u00a0es\u00a0de\u00a0esperar\u00a0que\u00a0se\u00a0elimine\u00a0en\u00a0\nlas\u00a0sesiones\u00a0de\u00a0HD/CAPD. \u00a0Datos\u00a0de\u00a0\nun\u00a0paciente\u00a0indican\u00a0escasa\u00a0\neliminaci\u00f3n \u00a0a\u00a0trav\u00e9s\u00a0de\u00a0HD.\u00a0\n\u00a0IH\u00a0leve\u00a0(SQV/r):\u00a0dosis\u00a0habitual.\u00a0\n\u00a0\nIH\u00a0moderada \u00a0(SQV+/\u2010RTV):\u00a0no\u00a0hay\u00a0datos.\u00a0Utilizar\u00a0con\u00a0precauci\u00f3n. \u00a0\u00a0Se\u00a0\nrecomienda \u00a0monitorizar \u00a0niveles\u00a0plasm\u00e1ticos \u00a0cuando\u00a0sea\u00a0posible.\u00a0\n\u00a0\nIH\u00a0grave:\u00a0no\u00a0hay\u00a0datos.\u00a0Evitar\u00a0en\u00a0lo\u00a0posible\u00a0su\u00a0uso\u00a0(contraindicado \u00a0\nen\u00a0insuficiencia \u00a0hep\u00e1tica\u00a0descompensada). \u00a0\n\u00a0\nTPV\u00a0(tipranavir) \u00a0 No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis.\u00a0\u00a0\n\u00a0HD/CAPD: \u00a0debido\u00a0a\u00a0la\u00a0elevada\u00a0uni\u00f3n\u00a0\na\u00a0prote\u00ednas \u00a0plasm\u00e1ticas \u00a0de\u00a0TPV/RTV, \u00a0\nno\u00a0es\u00a0de\u00a0esperar\u00a0que\u00a0se\u00a0eliminen\u00a0en\u00a0\nlas\u00a0sesiones\u00a0de\u00a0HD/CAPD. \u00a0\n\u00a0Datos\u00a0limitados. \u00a0Elevado\u00a0riesgo\u00a0de\u00a0toxicidad\u00a0hep\u00e1tica: \u00a0TPV/r\u00a0se\u00a0ha\u00a0\nrelacionado \u00a0con\u00a0casos\u00a0de\u00a0hepatitis\u00a0cl\u00ednica\u00a0y\u00a0descompensaci\u00f3n \u00a0\nhep\u00e1tica,\u00a0incluyendo\n\u00a0algunos\u00a0casos\u00a0mortales. \u00a0Se\u00a0recomienda \u00a0un\u00a0\nestrecho\u00a0seguimiento \u00a0de\u00a0los\u00a0pacientes \u00a0coinfectados \u00a0por\u00a0VHB\u00a0\u00f3\u00a0VHC,\u00a0\npor\u00a0el\u00a0aumento\u00a0de\u00a0riesgo\u00a0de\u00a0hepatotoxicidad \u00a0que\u00a0presentan. \u00a0\u00a0\n\u00a0\nIH\u00a0leve\u00a0(Child\u2010Pugh\u00a0A):\u00a0\u00a0dosis\u00a0habitual.\u00a0\u00a0\nIH\u00a0moderada \u00a0o\u00a0grave\u00a0(Child\u2010Pugh\u00a0B\u00a0y\u00a0C):\u00a0contraindicado. \u00a0\u00a0\n\u00a0\nInhibidores \u00a0de\u00a0la\u00a0fusi\u00f3n\u00a0\nEnfuvirtide \u00a0(T\u201020)\u00a0 No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis.\u00a0 HD:\u00a0No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\n(datos\u00a0limitados) \u00a0No\u00a0hay\u00a0datos.\u00a0Algunos\u00a0autores\u00a0recomiendan \u00a0utilizar\u00a0la\u00a0dosis\u00a0\nhabitual.\u00a0\u00a0\u00a0\n\u00a0\n\u00a0\n\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n 11\u00a0\n\u00a0\n\u00a0\nAntirretrovirales \u00a0 Insuficiencia \u00a0renal\u00a0Hemodi\u00e1lisis/di\u00e1lisis \u00a0peritoneal \u00a0\n(HD/CAPD) \u00a0Insuficiencia \u00a0hep\u00e1tica\u00a0\n(IH)\u00a0\nInhibidores \u00a0correceptor \u00a0CCR5\u00a0\nMVR\u00a0(maraviroc) \u00a0En\u00a0ausencia\u00a0de\u00a0inhibidores \u00a0potentes\u00a0del\u00a0\nCYP3A4\u00a0probablemente \u00a0no\u00a0requiera\u00a0\najuste\u00a0de\u00a0dosis.\u00a0\nS\u00f3lo\u00a0se\u00a0recomienda \u00a0un\u00a0ajuste\u00a0de\u00a0dosis\u00a0\nen\u00a0pacientes \u00a0con\u00a0Cl\u00a0<80\u00a0ml/min\u00a0y\u00a0que\u00a0\nest\u00e1n\u00a0recibiendo \u00a0inhibidores \u00a0potentes\u00a0\ndel\u00a0CYP3A4,\u00a0como\u00a0los\u00a0IPs\u00a0\u00a0(excepto\u00a0\nTPV/r),\u00a0ketoconazol, \u00a0itraconazol, \u00a0\nclaritromicina \u00a0o\u00a0telitromicina: \u00a0en\u00a0estos\u00a0\ncasos\u00a0administrar \u00a0c/24h.\u00a0\nEn\u00a0combinaci\u00f3n \u00a0con\u00a0SQV/r\u00a0reducir\u00a0el\u00a0\nintervalo\u00a0a\u00a0c/24h\u00a0\u00a0si\u00a0Cl\u00a0entre\u00a080\u00a0y\u00a050\u00a0\nml/min,\u00a0c/48h\u00a0si\u00a0Cl\u00a0<50\u201030\u00a0ml/min\u00a0y\u00a0\nc/72h\u00a0si\u00a0Cl\u00a0<30\u00a0ml\u00a0/min.\u00a0(Estos\u00a0ajustes\u00a0\nde\u00a0dosis\u00a0se\u00a0recomiendan \u00a0bas\u00e1ndose \u00a0en\u00a0\nsimulaciones \u00a0farmacocin\u00e9ticas, \u00a0sin\u00a0que\u00a0\nsu\u00a0seguridad \u00a0y\u00a0eficacia\u00a0hayan\u00a0sido\u00a0\nevaluadas \u00a0cl\u00ednicamente, \u00a0por\u00a0lo\u00a0que\u00a0se\u00a0\nrecomienda \u00a0una\u00a0estrecha\u00a0\nmonitorizaci\u00f3n). \u00a0No\u00a0hay\u00a0datos\u00a0 Datos\u00a0de\u00a0un\u00a0estudio\u00a0con\u00a0dosis\u00a0\u00fanicas\u00a0de\u00a0300\u00a0mg\u00a0MVR.\u00a0En\u00a0\ncomparaci\u00f3n \u00a0con\u00a0los\u00a0voluntarios \u00a0con\u00a0funci\u00f3n\u00a0hep\u00e1tica\u00a0normal:\u00a0\nIH\u00a0leve:\u00a0+25%\u00a0AUC\u00a0\nIH\u00a0moderada: \u00a0+45%\u00a0AUC\u00a0\nSe\u00a0desconoce \u00a0la\u00a0importancia \u00a0cl\u00ednica\u00a0que\u00a0estos\u00a0aumentos \u00a0pueden\u00a0\nsuponer.\u00a0\u00a0\n\u00a0\nSe\u00a0han\u00a0descrito\u00a0casos\u00a0de\u00a0hepatotoxicidad \u00a0precedidos \u00a0de\u00a0una\u00a0\nreacci\u00f3n\u00a0al\u00e9rgica\u00a0sist\u00e9mica. \u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n 12\u00a0\nInhibidores \u00a0de\u00a0la\u00a0Integrasa \u00a0\nRTG\u00a0(raltegravir) \u00a0 No\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis\u00a0\u00a0No\u00a0hay\u00a0datos.\u00a0Dado\u00a0que\u00a0se\u00a0\ndesconoce \u00a0su\u00a0posible\u00a0eliminaci\u00f3n \u00a0a\u00a0\ntrav\u00e9s\u00a0de\u00a0la\u00a0HD,\u00a0se\u00a0recomienda \u00a0\ndosificar\u00a0post\u2010\u00a0HD.\u00a0IH\u00a0leve\u2010moderada: \u00a0no\u00a0requiere\u00a0ajuste\u00a0de\u00a0dosis.\u00a0\nIH\u00a0grave:\u00a0no\u00a0hay\u00a0estudios.\u00a0Utilizar\u00a0con\u00a0precauci\u00f3n. \u00a0\n\u00a0\nAN:\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3sidos; \u00a0ANt:\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3tidos, \u00a0CH:\u00a0cirrosis\u00a0hep\u00e1tica; \u00a0Cl:\u00a0aclaramiento \u00a0de\u00a0creatinina \u00a0en\u00a0ml/min;\u00a0ERCA:\u00a0enfermedad \u00a0renal\u00a0cr\u00f3nica\u00a0avanzada, \u00a0HD:\u00a0\nhemodi\u00e1lisis; \u00a0IH:\u00a0insuficiencia \u00a0hep\u00e1tica; \u00a0IP:\u00a0inhibidores \u00a0de\u00a0la\u00a0proteasa; \u00a0IR:\u00a0insuficiencia \u00a0renal;\u00a0NN:\u00a0inhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0an\u00e1logos\u00a0de\u00a0nucle\u00f3sidos. \u00a0\n\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0 \u00a0 \u00a0 \u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0 \u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n Tabla\u00a018.\u00a0Seguridad \u00a0de\u00a0los\u00a0antirretrovirales \u00a0en\u00a0el\u00a0embarazo \u00a0\n\u00a0\nF\u00e1rmaco\u00a0 FDA*\u00a0Paso\u00a0a\u00a0trav\u00e9s\u00a0de\u00a0placenta\u00a0\n(Cociente \u00a0RN/madre) \u00a0Carcinogenicidad \u00a0\n(animales) \u00a0Teratogenicidad \u00a0\n(animales) \u00a0\nZidovudina \u00a0 C\u00a0 0,85\u00a0 S\u00ed\u00a0 Si\u00a0\nDidanosina \u00a0 B\u00a0 0,5\u00a0 No\u00a0 No\u00a0\nEstavudina \u00a0 C\u00a0 0,76\u00a0 S\u00ed\u00a0 No\u00a0\nLamivudina \u00a0 C\u00a0 1\u00a0 No\u00a0 No\u00a0\nAbacavir\u00a0 C\u00a0 Si\u00a0(ratas)\u00a0 S\u00ed\u00a0 Si\u00a0\nTenofovir \u00a0 B\u00a0 0,95\u20100\u201099\u00a0 S\u00ed\u00a0 No\u00a0\nEmtricitabina \u00a0 B\u00a0 0,4\u20100,5\u00a0 No\u00a0 No\u00a0\nSaquinavir \u00a0 B\u00a0 M\u00ednimo\u00a0 No\u00a0 No\u00a0\nIndinavir\u00a0 C\u00a0 M\u00ednimo\u00a0 S\u00ed\u00a0 No\u00a0\nRitonavir\u00a0 B\u00a0 M\u00ednimo\u00a0 S\u00ed\u00a0 Si\u00a0\nNelfinavir \u00a0 B\u00a0 M\u00ednimo/Variable \u00a0 S\u00ed\u00a0 No\u00a0\nFosamprenavir \u00a0 C\u00a0 \u00bf?\u00a0 S\u00ed\u00a0 No\u00a0\nLopinavir\u00a0 C\u00a0 0,2+/\u20100,13\u00a0 S\u00ed\u00a0 Si\u00a0\nAtazanavir \u00a0 B\u00a0 M\u00ednimo/Variable \u00a0 S\u00ed\u00a0 No\u00a0\nTipranavir \u00a0 C\u00a0 \u00bf?\u00a0 No\u00a0completado \u00a0 No\u00a0\nDarunavir \u00a0 B\u00a0 \u00bf?\u00a0 S\u00ed\u00a0 No\u00a0\nNevirapina \u00a0 B\u00a0 1\u00a0 S\u00ed\u00a0 No\u00a0\nEfavirenz\u00a0 D\u00a0 1\u00a0 S\u00ed\u00a0 Si\u00a0\nEtravirina \u00a0 B\u00a0 \u00bf?\u00a0 No\u00a0completado \u00a0 No\u00a0\nEnfuvirtida \u00a0 B\u00a0No\u00a0(basado\u00a0en\u00a0muy\u00a0pocos\u00a0\ndatos)\u00a0No\u00a0realizado\u00a0 No\u00a0\nMaraviroc \u00a0 B\u00a0 \u00bf?\u00a0 No\u00a0 No\u00a0\nRaltegravir \u00a0 C\u00a0Ratas\u00a0(1,5\u20102,5)\u00a0\nConejos\u00a0(0,02)\u00a0No\u00a0completado \u00a0 No\u00a0\n\u00a0\n Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n Tabla\u00a019.\u00a0Recomendaciones \u00a0de\u00a0profilaxis \u00a0postexposici\u00f3n \u00a0\u00a0\n \n\u00a0PPE\u00a0recomendada \u00a0si:\u00a0\nExposici\u00f3n \u00a0a:\u00a0Tipo\u00a0exposici\u00f3n \u00a0 Fuente\u00a0\nSangre\u00a0u\u00a0otros\u00a0\nfluidos\u00a0\npotencialmente \u00a0\ninfectivos \u00a0Penetraci\u00f3n \u00a0SC\u00a0o\u00a0IM\u00a0con\u00a0aguja\u00a0IM/IV\u00a0o\u00a0sistema\u00a0IV\u00a0 VIH+,\u00a0o\u00a0desconocido \u00a0pero\u00a0con\u00a0factores\u00a0de\u00a0riesgo\u00a0\nAccidente \u00a0percut\u00e1neo \u00a0con\u00a0instrumento \u00a0cortante\u00a0o\u00a0aguja\u00a0\nIM/SC\u00a0o\u00a0sutura\u00a0\nContacto\u00a0>\u00a015min\u00a0con\u00a0mucosas\u00a0o\u00a0piel\u00a0no\u00a0intacta.\u00a0VIH+\u00a0\nSecreciones \u00a0\nGenitales \u00a0Sexo\u00a0anal\u00a0o\u00a0vaginal\u00a0 VIH+,\u00a0o\u00a0desconocido \u00a0pero\u00a0con\u00a0factores\u00a0de\u00a0riesgo\u00a0\nSexo\u00a0oral\u00a0receptivo \u00a0con\u00a0eyaculaci\u00f3n \u00a0 VIH+\u00a0\nUDVP\u00a0Intercambio \u00a0de\u00a0jeringuilla \u00a0o\u00a0\u00a0agujas\u00a0 VIH+\u00a0\nR\u00e9gimen\u00a0terap\u00e9utico: \u00a0\nTDF/FTC\u00a0oAZT+3TC\u00a0+\u00a0IP/r\u00a0\nAlternativas*: \u00a0\nTDF/FTC\u00a0o\u00a0AZT+3TC\u00a0+\u00a0EFV\u00a0\n\u00a0AZT+3TC+TDF\n*\u00a0En\u00a0casos\u00a0de\u00a0intolerancia \u00a0o\u00a0imposibilidad \u00a0de\u00a0usar\u00a0TARV\u00a0basados\u00a0en\u00a0IP/r\u00a0\n Tabla\u00a0/\u00a0Figura\u00a020\u00a0a.\u00a0Coste\u00a0mensual\u00a0de\u00a0los\u00a0tratamientos \u00a0preferentes \u00a0(seg\u00fan\u00a0Tabla\u00a04)\n1400\n1212,161292,44\n12001400\n725 67 732 6 746,05785,78812,88 826,33 837,42 847,18866,06917,7 927,6\n8001000\n577,52645,39 657,8725,67 732,6746,05\n600800\n200400\nDocumento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n \u00a0\nTabla\u00a020.\u00a0Coste\u00a0mensual\u00a0(PVL+IVA, \u00a0en\u00a0\u20ac)\u00a0de\u00a0los\u00a0antirretrovirales \u00a0de\u00a0uso\u00a0m\u00e1s\u00a0frecuente \u00a0\n\u00a0\n\u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Nombre\u00a0comercial \u00a0 Presentaci\u00f3n \u00a0Coste\u00a0\n(PVL+4%\u00a0\nIVA)\u00a0Coste/\u00a0\nunidad\u00a0Unidades/\nmes\u00a0Coste/\u00a0\nmes\u00a0Coste/\u00a0\nmes\u00a0RTVCoste\u00a0total\u00a0\nmensual\u00a0de\u00a0\nla\u00a0pauta\u00a0Pauta\u00a0\nAn\u00e1logos \u00a0de\u00a0nucle\u00f3sido \u00a0y\u00a0nucle\u00f3tido \u00a0\nAbacavir\u00a0 ZIAGEN\u00a0 300\u00a0MG\u00a060\u00a0COMP\u00a0 234,72 3,91 60 234,72 234,72 ABC\u00a0300\u00a0mg/12h\u00a0\nDidanosina \u00a0 VIDEX\u00a0 400\u00a0MG\u00a030\u00a0CAPS\u00a0 160,56 5,35 30 160,56 \u00a0 160,56 ddI\u00a0400\u00a0mg/24h\u00a0\nDidanosina \u00a0 VIDEX\u00a0 250\u00a0MG\u00a030\u00a0CAPS\u00a0 100,34 3,34 30 100,34 100,34 ddI\u00a0250\u00a0mg/24h\u00a0\nEmtricitabina \u00a0EMTRIVA \u00a0 200\u00a0MG\u00a030\u00a0CAPS\u00a0 153,24 5,11 30 153,24 153,24 FTC\u00a0200\u00a0mg/24h\u00a0\nEstavudina \u00a0 ZERIT\u00a0 40\u00a0MG\u00a0448\u00a0CAPS\u00a0 1213,84 2,71 60 162,57 162,57 d4T\u00a040\u00a0mg/12h\u00a0\nEstavudina \u00a0 ZERIT\u00a0 30\u00a0MG\u00a0448\u00a0CAPS\u00a0 1174,65 2,62 60 157,32 \u00a0 157,32 d4T\u00a030\u00a0mg/12h\u00a0\nLamivudina \u00a0 EPIVIR\u00a0 300\u00a0MG\u00a030\u00a0COMP\u00a0 153,24 5,11 30 153,24 153,24 3TC\u00a0300\u00a0mg/24h\u00a0\nTenofovir \u00a0 VIREAD\u00a0 245\u00a0MG\u00a030\u00a0COMP\u00a0 300,25 10,00 30 300,25 300,25 TDF\u00a0300\u00a0mg/24h\u00a0\nZidovudina \u00a0 RETROVIR \u00a0 300\u00a0MG\u00a060\u00a0COMP\u00a0 171,12 2,85 60 171,12 171,12 AZT\u00a0300\u00a0mg/12h\u00a0\nZidovudina \u00a0ZIDOVUDINA \u00a0\nCOMBINOPHARM \u00a0300\u00a0MG\u00a0300\u00a0CAPS\u00a0 615,18 2,05 60 123,04 123,04 AZT\u00a0300\u00a0mg/12h\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n \u00a0\nNombre\u00a0\ngen\u00e9rico\u00a0Nombre\u00a0comercial \u00a0 Presentaci\u00f3n \u00a0Coste\u00a0\n(PVL+4%\u00a0\nIVA)\u00a0Coste/\u00a0\nunidad\u00a0Unidades/\nmes\u00a0Coste/\u00a0\nmes\u00a0Coste/\u00a0\nmes\u00a0RTVCoste\u00a0total\u00a0\nmensual\u00a0de\u00a0\nla\u00a0pauta\u00a0Pauta\u00a0\nAn\u00e1logos \u00a0de\u00a0nucle\u00f3sido \u00a0y\u00a0nucle\u00f3tido \u00a0en\u00a0combinaci\u00f3n \u00a0\nAbacavir+ \u00a0\nLamivudina \u00a0KIVEXA\u00a0600/300\u00a0MG\u00a0\u00a0\n30\u00a0COMP\u00a0369,76 12,33 30 369,77 369,76 Kivexa\u00a01c/24h\u00a0\nEmtricitabina+ \u00a0\nTenofovir \u00a0TRUVADA \u00a0200/245\u00a0MG\u00a0\n30\u00a0COMP\u00a0450,04 15,00 30 450,04 450,04 Truvada\u00a01c/24h\u00a0\nZidovudina+ \u00a0\nLamivudina \u00a0COMBIVIR \u00a0150/300\u00a0MG\u00a0\u00a0\n60\u00a0COMP\u00a0302,03 5,03 60 302,03 302,03 Combivir\u00a01c/12h\u00a0\nZidovudina+ \u00a0\nLamivudina+ \u00a0\nAbacavir\u00a0TRIZIVIR\u00a0300/150/300 \u00a0MG\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\n60\u00a0COMP\u00a0509,93 8,50 60 509,93 509,93 TZV\u00a01c/12h\u00a0\nInhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0nucle\u00f3sidos \u00a0\nEfavirenz\u00a0 SUSTIVA\u00a0 600\u00a0MG\u00a030\u00a0COMP\u00a0 275,63 9,19 30 275,63 \u00a0 275,63 EFV\u00a0600\u00a0mg/24h\u00a0\nNevirapina \u00a0 VIRAMUNE \u00a0 200\u00a0MG\u00a060\u00a0COMP\u00a0 207,68 3,46 60 207,68 207,68 NVP\u00a0200\u00a0mg/12h\u00a0\nEtravirina \u00a0 INTELENCE \u00a0 100\u00a0MG\u00a0120\u00a0COMP\u00a0 468,00 3,9 120 468,00 468,00 ETR\u00a0200\u00a0MG/12\u00a0H\u00a0\nInhibidores \u00a0de\u00a0la\u00a0transcriptasa \u00a0inversa\u00a0no\u00a0nucle\u00f3sidos \u00a0en\u00a0combinaci\u00f3n \u00a0con\u00a0an\u00e1logos \u00a0de\u00a0nucle\u00f3sidos \u00a0y\u00a0nucle\u00f3tidos \u00a0\nEfavirenz\u00a0+\u00a0\nEmtricitabina+ \u00a0\nTenofovir \u00a0ATRIPLA\u00a0600\u00a0MG\u00a0\n200\u00a0MG\u00a0\n245\u00a0MG\u00a0COMP\u00a0729,12 24.30 30 729,12 729,12 Atripla\u00a01c/24h\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n  \nNombre\u00a0\ngen\u00e9rico\u00a0Nombre\u00a0comercial \u00a0 Presentaci\u00f3n \u00a0Coste\u00a0\n(PVL+4%\u00a0\nIVA)\u00a0Coste/\u00a0\nunidad\u00a0Unidades/\nmes\u00a0Coste/\u00a0\nmes\u00a0Coste/\u00a0\nmes\u00a0RTVCoste\u00a0total\u00a0\nmensual\u00a0de\u00a0\nla\u00a0pauta\u00a0Pauta\u00a0\nInhibidores \u00a0de\u00a0la\u00a0proteasa\u00a0\nAtazanavir \u00a0 REYATAZ\u00a0 200\u00a0MG\u00a060\u00a0CAPS\u00a0 454,05 7,57 60 454,05 454,05 ATV\u00a0400\u00a0mg/24h\u00a0\nAtazanavir \u00a0 REYATAZ\u00a0 150\u00a0MG\u00a060\u00a0CAPS\u00a0 454,05 7,57 60 454,05 23,36 477,42 ATV/r\u00a0300/100\u00a0mg/24h\u00a0\nAtazanavir \u00a0 REYATAZ\u00a0 300\u00a0MG\u00a030\u00a0CAPS\u00a0 454,05 7,57 60 454,05 23,36 477,42 ATV/r\u00a0300/100\u00a0mg/24h\u00a0\nDarunavir \u00a0 PREZISTA \u00a0 300\u00a0MG\u00a0120\u00a0COMP\u00a0 666,40 5,55 120 666,40 46,72 713,17 DRV/r\u00a0600/100\u00a0mg/12h\u00a0\nDarunavir \u00a0 PREZISTA \u00a0 600\u00a0MG\u00a060\u00a0COMP\u00a0 666,40 11,11 60 666,40 46,72 713,17 DRV/r\u00a0600/100\u00a0mg/12h\u00a0\nDarunavir \u00a0 PREZISTA \u00a0 400\u00a0MG\u00a060\u00a0COMP\u00a0 444,30 7,40 60 444,30 46,72 467,66 DRV/r\u00a0800/100\u00a0mg/24h\u00a0\nFosamprenavir \u00a0TELZIR\u00a0 700\u00a0MG\u00a060\u00a0COMP\u00a0 329,57 5,49 60 329,57 46,72 376,29 FPV/r\u00a0700/100\u00a0mg/12h\u00a0\nIndinavir\u00a0 CRIXIVAN \u00a0 400\u00a0MG\u00a0180\u00a0CAPS\u00a0 272,22 1,51 120 181,48 46,72 228,20 IDV/r\u00a0800/100\u00a0mg/12h\u00a0\nLopinavir+ \u00a0\nRitonavir\u00a0comp\u00a0KALETRA\u00a0 120\u00a0COMP\u00a0 416,02 3,47 120 416,02 416,02 LPV/r\u00a02\u00a0comp/12h \u00a0\nNelfinavir \u00a0 VIRACEPT \u00a0 250\u00a0MG\u00a0270\u00a0COMP\u00a0 306,91 1,14 300 341,02 \u00a0 341,02 NFV\u00a01250\u00a0mg/12h\u00a0\nSaquinavir \u00a0 INVIRASE \u00a0 500\u00a0MG\u00a0120\u00a0COMP\u00a0 316,11 2,63 120 316,12 46,72 362,84SQV/r\u00a01000/100 \u00a0\nmg/12h\u00a0\nRitonavir\u00a0 NORVIR\u00a0 100\u00a0MG\u00a0336\u00a0CAPS\u00a0 261,65 0,78 60 46,72 46,72 46,72 RTV\u00a0100\u00a0mg/12h\u00a0\nTipranavir \u00a0 APTIVUS\u00a0 250\u00a0MG\u00a0120\u00a0CAPS\u00a0 733,20 6,11 120 733,20 93,44 826,64 TPV/r\u00a0500/200\u00a0mg/12h\u00a0Documento \u00a0de\u00a0consenso\u00a0de\u00a0Gesida\u00a0y\u00a0PNS\u00a0sobre\u00a0el\u00a0tratamiento \u00a0antirretroviral \u00a0del\u00a0adulto\u00a0(enero\u00a02010)\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0\u00a0  \n \n  \nNombre\u00a0\ngen\u00e9rico\u00a0Nombre\u00a0comercial \u00a0 Presentaci\u00f3n \u00a0Coste\u00a0\n(PVL+4%\u00a0\nIVA)\u00a0Coste/\u00a0\nunidad\u00a0Unidades/\nmes\u00a0Coste/\u00a0\nmes\u00a0Coste/\u00a0\nmes\u00a0RTVCoste\u00a0total\u00a0\nmensual\u00a0de\u00a0\nla\u00a0pauta\u00a0Pauta\u00a0\nInhibidores \u00a0de\u00a0la\u00a0fusi\u00f3n\u00a0\nEnfuvirtida \u00a0 FUZEON\u00a090\u00a0MG/ML\u00a0\u00a0\n60\u00a0VIALES\u00a01586,38 26,44 60 1586,37 1586,37 T20\u00a090\u00a0mg/12h\u00a0\nInhibidores \u00a0de\u00a0la\u00a0uni\u00f3n\u00a0\nMaraviroc \u00a0 CELSENTRI \u00a0150\u00a0Y\u00a0300\u00a0MG\u00a0\nCOMP\u00a0816,\u00a000 13.6 60 816 816MVC\u00a0300\u00a0(\u00f3\u00a0150)\u00a0\nmg/12\u00a0h\u00a0\nInhibidores \u00a0de\u00a0la\u00a0integrasa \u00a0\nRaltegravir \u00a0\u00a0 ISENTRESS \u00a0 400\u00a0MG\u00a060\u00a0COMP\u00a0 842,40 14,04 60 842,40 842,40 RAL\u00a0400\u00a0mg/12h\u00a0\n\u00a0\n ", "language": "PDF", "image": "PDF", "pagetype": "PDF", "links": "PDF"}